PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Wang, LF; Liu, YS; Yang, B; Li, P; Cheng, XS; Xiao, CX; Liu, JJ; Li, S; Ren, JL; Guleng, B				Wang, L-F; Liu, Y-S; Yang, B.; Li, P.; Cheng, X-S; Xiao, C-X; Liu, J-J; Li, S.; Ren, J-L; Guleng, B.			The extracellular matrix protein mindin attenuates colon cancer progression by blocking angiogenesis via Egr-1-mediated regulation	ONCOGENE			English	Article							PATTERN-RECOGNITION MOLECULE; TRANSCRIPTION FACTOR EGR-1; THYROID-HORMONE; BREAST-CANCER; CELLS; EXPRESSION; GROWTH; SPONDIN-2; INJURY; IDENTIFICATION	Mindin, a secreted, highly conserved extracellular matrix (ECM) protein, exerts a broad spectrum of effects on the innate immune system. However, its function in colorectal cancer (CRC) progression is not well established, and its upstream regulation mechanisms remain unclear. Contrary to previous reports, this study used two different enzyme-linked immunosorbent assay (ELISA) kits to show that the serum level of mindin was significantly decreased in CRC patients and that this decreased level is more significantly associated with the early stages of the disease. To explore the regulation of mindin, we used a bioinformatics approach to predict potential transcription factors and determined that early growth response factor (Egr)-1 directly regulates mindin expression at the transcriptional level using dual luciferase, chromatin immunoprecipitation (ChIP) DNA and electrophoretic mobility shift assay (EMSA) methods. Egr-1 regulates mindin mRNA and protein expression in CRC cells, and the protein expression of both Egr-1 and mindin was significantly decreased in tumor lesions of patients compared with adjacent control tissues. Mindin is essential for Egr-1-mediated inhibition of endothelial cell tube formation, and mindin inhibits endotheliocyte proliferation, migration and angiogenic sprouts in vitro. Overexpression of mindin suppressed xenograft tumor growth by blocking angiogenesis instead of directly suppressing CRC cell proliferation. Mechanically, mindin inhibits the hypoxia-induced HIF-1a and VEGFA protein expression in CRC cells and the phosphorylation of VEGFR-2 in endothelial cells. The results suggest that the serum level of mindin can be used as a novel biomarker for early detection of CRC and that the Egr-1/mindin axis is a potential therapeutic target for the inhibition of angiogenesis in CRC development.	[Wang, L-F; Liu, Y-S; Yang, B.; Li, P.; Cheng, X-S; Xiao, C-X; Liu, J-J; Ren, J-L; Guleng, B.] Xiamen Univ, Dept Gastroenterol, Zhongshan Hosp, 201 Hubin South Rd, Xiamen 361004, Fujian, Peoples R China; [Li, P.] Zhejiang Univ, Childrens Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Li, S.] Tsinghua Univ, MOE Key Lab Bioinformat, Beijing, Peoples R China; [Guleng, B.] Xiamen Univ, Fac Clin Med, Med Coll, 168 Univ Rd, Xiamen 361005, Fujian, Peoples R China; [Guleng, B.] Xiamen Univ, State Key Lab Cellular Stress Biol, 168 Univ Rd, Xiamen 361005, Fujian, Peoples R China	Xiamen University; Zhejiang University; Tsinghua University; Xiamen University; Xiamen University	Guleng, B (corresponding author), Xiamen Univ, Dept Gastroenterol, Zhongshan Hosp, 201 Hubin South Rd, Xiamen 361004, Fujian, Peoples R China.; Guleng, B (corresponding author), Xiamen Univ, Fac Clin Med, Med Coll, 168 Univ Rd, Xiamen 361005, Fujian, Peoples R China.; Guleng, B (corresponding author), Xiamen Univ, State Key Lab Cellular Stress Biol, 168 Univ Rd, Xiamen 361005, Fujian, Peoples R China.	bayasi@xmu.edu.cn	Li, Shao/GPX-5473-2022	Guleng, Bayasi/0000-0003-1106-5304; Li, Shao/0000-0002-8709-9167	National Natural Science Foundation of China [81570496, 81370505, 81370591, 91229201]; 973 programs in China [2015CB553800]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 973 programs in China(National Basic Research Program of China)	The National Natural Science Foundation of China (No. 81570496, 81370505, 81370591 and 91229201) and 973 programs (2015CB553800) in China supported this study.	Adams JC, 2000, DEV DYNAM, V218, P280; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Bergers G, 1998, INT J DEV BIOL, V42, P995; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Cai H, 2017, ONCOGENE, V36, P318, DOI 10.1038/onc.2016.212; Chen WQ, 2017, CANCER LETT, V401, P63, DOI 10.1016/j.canlet.2017.04.024; Chen WQ, 2015, CHINESE J CANCER RES, V27, P2, DOI 10.3978/j.issn.1000-9604.2015.01.06; Duclot F, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00035; Feinstein Y, 2004, INT J BIOCHEM CELL B, V36, P975, DOI 10.1016/j.biocel.2004.01.002; Ferraro B, 2005, J CLIN ONCOL, V23, P1921, DOI 10.1200/JCO.2005.08.127; Folkman J, 2000, ACAD RADIOL, V7, P783, DOI 10.1016/S1076-6332(00)80625-X; Folkman J, 1997, NAT BIOTECHNOL, V15, P510, DOI 10.1038/nbt0697-510; Fontao L, 1999, EXP CELL RES, V250, P298, DOI 10.1006/excr.1999.4549; Fournier ML, 2010, MOL CELL PROTEOMICS, V9, P271, DOI 10.1074/mcp.M900415-MCP200; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Guleng B, 2010, WORLD J GASTROENTERO, V16, P1070, DOI 10.3748/wjg.v16.i9.1070; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He YW, 2004, NAT IMMUNOL, V5, P88, DOI 10.1038/ni1021; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jia W, 2005, BLOOD, V106, P3854, DOI 10.1182/blood-2005-04-1658; Jia W, 2008, J IMMUNOL, V180, P6255, DOI 10.4049/jimmunol.180.9.6255; Jing FY, 2014, TUMOR BIOL, V35, P9233, DOI 10.1007/s13277-014-2197-1; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Li DP, 2013, ONCOTARGET, V4, P1373, DOI 10.18632/oncotarget.1165; Liao CH, 2010, ENDOCR-RELAT CANCER, V17, P99, DOI 10.1677/ERC-09-0050; Liu Jingbo, 2007, Cancer Genomics & Proteomics, V4, P377; Liu MJ, 2014, BMC MOL BIOL, V15, DOI 10.1186/1471-2199-15-14; Liu Y, 2007, VISION RES, V47, P2314, DOI 10.1016/j.visres.2007.04.023; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Munkley J, 2016, ONCOTARGET, V7, P35478, DOI 10.18632/oncotarget.8155; Murakoshi M, 2011, NEPHROL DIAL TRANSPL, V26, P2153, DOI 10.1093/ndt/gfq708; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Nie L, 2014, SMALL, V10, P1441; Parry R, 2005, CANCER RES, V65, P8397, DOI 10.1158/0008-5472.CAN-05-1203; Pusztai L, 2004, CYTOKINE, V25, P94, DOI 10.1016/j.cyto.2003.10.004; Qian XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037225; Qin M, 2015, INT J COLORECTAL DIS, V30, P353, DOI 10.1007/s00384-014-2090-9; Quante M, 2013, GASTROENTEROLOGY, V145, P63, DOI 10.1053/j.gastro.2013.03.052; Romanuik TL, 2009, AM J PATHOL, V175, P2264, DOI 10.2353/ajpath.2009.080868; Santiago FS, 1999, AM J PATHOL, V155, P897, DOI 10.1016/S0002-9440(10)65189-9; Scharnhorst V, 2000, ONCOGENE, V19, P791, DOI 10.1038/sj.onc.1203390; Schmid F, 2016, ONCOGENE, V35, P5942, DOI 10.1038/onc.2015.451; Shin SY, 2010, MOL CANCER RES, V8, P507, DOI 10.1158/1541-7786.MCR-09-0454; Simon I, 2007, GYNECOL ONCOL, V106, P112, DOI 10.1016/j.ygyno.2007.03.007; Sobolewski C, 2015, BIOMOLECULES, V5, P2035, DOI 10.3390/biom5032035; Tan K, 2011, BMC STRUCT BIOL, V11, DOI 10.1186/1472-6807-11-22; Villani F, 2008, TUMORI J, V94, P803; Wirth M, 2014, NUCLEIC ACIDS RES, V42, P10433, DOI 10.1093/nar/gku763; Zhang M, 2014, WORLD J GASTROENTERO, V20, P5082, DOI 10.3748/wjg.v20.i17.5082; Zhang Q, 2015, ONCOTARGET, V6, P15095, DOI 10.18632/oncotarget.3822; Zhu LH, 2015, CLIN SCI, V129, P129, DOI 10.1042/CS20140679; Zhu LH, 2014, J HEPATOL, V60, P1046, DOI 10.1016/j.jhep.2014.01.011; Zwang Y, 2012, CANCER RES, V72, P1051, DOI 10.1158/0008-5472.CAN-11-3382	56	34	35	3	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					601	615		10.1038/onc.2017.359	http://dx.doi.org/10.1038/onc.2017.359			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	28991232				2022-12-17	WOS:000423812200006
J	Feng, GX; Li, J; Yang, Z; Zhang, SQ; Liu, YX; Zhang, WY; Ye, LH; Zhang, XD				Feng, G. X.; Li, J.; Yang, Z.; Zhang, S. Q.; Liu, Y. X.; Zhang, W. Y.; Ye, L. H.; Zhang, X. D.			Hepatitis B virus X protein promotes the development of liver fibrosis and hepatoma through downregulation of miR-30e targeting P4HA2 mRNA	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; EXTRACELLULAR-MATRIX; CELL-CELL; EXPRESSION; MICRORNAS; PROLIFERATION; BIOMARKERS; METASTASIS; CIRRHOSIS; ENHANCE	Hepatitis B virus (HBV)-induced liver necrosis takes great part in liver cirrhosis progression. However, less is known about whether hepatitis B virus X protein (HBx) has effect on liver fibrosis. Here, we report that HBV leads to liver fibrosis and hepatocarcinogenesis through miR-30e targeting P4HA2. HBV transgenic mouse was treated by CCl4 to generate a model of liver fibrosis. A crucial enzyme catalyzing collagen formation, prolyl 4-hydroxylase subunit alpha 2 (P4HA2) was evaluated by immunohistochemistry, western blotting or quantitative reverse transcription-PCR analysis. The function of HBV-modulated P4HA2 in hepatoma cell growth in vitro and in vivo was analyzed by EdU, MTT, colony-forming assay and animal transplantation assay. HBV transgenic mice exhibited more collagen deposition in liver after intraperitoneal injection of CCl4. P4HA2 was dramatically augmented in liver samples of HBV transgenic mice, clinical liver cirrhosis and liver cancer patients. Mechanistically, HBx was capable of inducing P4HA2 through suppressing miR-30e, in which miR-30e could target P4HA2 mRNA 3' untranslated region in liver cancer cells. HBx inhibited the miR-30e expression through increasing methylation of CpG islands in its promoter mediated by EZH2-formed complexes. Functionally, HBx-elevated P4HA2 enhanced the collagen deposition in the liver in vivo and in vitro, leading to liver fibrosis and liver cancer progression. In conclusion, HBx promotes the development of liver fibrosis and hepatocellular carcinoma through miR-30e targeting P4HA2 mRNA. We provide novel perspective on how HBx induces liver fibrosis.	[Feng, G. X.; Li, J.; Yang, Z.; Zhang, S. Q.; Liu, Y. X.; Zhang, W. Y.; Zhang, X. D.] Nankai Univ, Dept Canc Res, Coll Life Sci, State Key Lab Med Chem Biol, Tianjin, Peoples R China; [Ye, L. H.] Nankai Univ, Dept Biochem, Coll Life Sci, State Key Lab Med Chem Biol, Tianjin, Peoples R China	Nankai University; Nankai University	Zhang, WY; Zhang, XD (corresponding author), Nankai Univ, Dept Canc Res, Coll Life Sci, Tianjin 300071, Peoples R China.; Ye, LH (corresponding author), Nankai Univ, Dept Biochem, Coll Life Sci, Tianjin 300071, Peoples R China.	zhwybao@nankai.edu.cn; yelihong@nankai.edu.cn; zhangxd@nankai.edu.cn	Feng, Guoxing/AAD-6163-2019		National Natural Science Foundation of China [81372186, 31470756, 31670769, 31670771]; National Basic Research Program of China (973 Program) [2015CB553905, 2015CB553703]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China (973 Program)(National Basic Research Program of China)	This work was supported by the grants of National Natural Science Foundation of China (No. 81372186, 31470756, 31670769, 31670771) and National Basic Research Program of China (973 Program, No. 2015CB553905, 2015CB553703).	Bhattacharya S, 2016, AM J PATHOL, V186, P242, DOI 10.1016/j.ajpath.2015.10.003; Chakravarthi BVSK, 2014, ONCOTARGET, V5, P6654, DOI 10.18632/oncotarget.2208; Chang KP, 2011, J PROTEOME RES, V10, P4935, DOI 10.1021/pr200311p; Chen RJ, 2015, NEUROSCIENCE, V305, P36, DOI 10.1016/j.neuroscience.2015.07.045; Cushing L, 2015, BIOCHEM CELL BIOL, V93, P109, DOI 10.1139/bcb-2014-0095; de Martel C, 2015, HEPATOLOGY, V62, P1190, DOI 10.1002/hep.27969; Feng GL, 2016, PROCEEDINGS 2016 FIRST INTERNATIONAL CONFERENCE ON MULTIMEDIA AND IMAGE PROCESSING (ICMIP 2016), P1, DOI 10.1109/ICMIP.2016.13; Gilkes DM, 2013, J BIOL CHEM, V288, P10819, DOI 10.1074/jbc.M112.442939; Haflidadottir BS, 2015, EUR UROL, V67, P42, DOI 10.1016/j.eururo.2014.08.067; Jarzab B, 2005, CANCER RES, V65, P1587, DOI 10.1158/0008-5472.CAN-04-3078; Jin ZX, 2011, HEPATOLOGY, V53, P219, DOI 10.1002/hep.23983; Joo SH, 2015, SCI REP-UK, V5, DOI 10.1038/srep09660; Karsdal MA, 2016, J HEPATOL, V64, P103, DOI 10.1016/j.jhep.2015.08.014; Kayashima H, 2015, SURGERY, V158, P1670, DOI 10.1016/j.surg.2015.06.001; Kriegel AJ, 2015, HYPERTENSION, V66, P793, DOI 10.1161/HYPERTENSIONAHA.115.05645; Li J, 2013, J HEPATOL, V58, P522, DOI 10.1016/j.jhep.2012.11.011; Lin Cong, 2013, Zhongguo Shengwu Huaxue yu Fenzi Shengwu Xuebao, V29, P704; McMillen P, 2015, CURR OPIN CELL BIOL, V36, P48, DOI 10.1016/j.ceb.2015.07.002; Park ES, 2013, HEPATOLOGY, V58, P762, DOI 10.1002/hep.26379; Park IY, 2007, GASTROENTEROLOGY, V132, P1476, DOI 10.1053/j.gastro.2007.01.034; PIHLAJANIEMI T, 1991, J HEPATOL, V13, pS2, DOI 10.1016/0168-8278(91)90002-S; Pungpapong S, 2007, MAYO CLIN PROC, V82, P967, DOI 10.4065/82.8.967; Shan CL, 2011, CARCINOGENESIS, V32, P1190, DOI 10.1093/carcin/bgr106; Shi Xiao-Yan, 2011, Chin J Cancer, V30, P273; Sim JY, 2015, MOL BIOL CELL, V26, P2456, DOI 10.1091/mbc.E14-12-1618; Sinn DH, 2015, HEPATOLOGY, V62, P694, DOI 10.1002/hep.27889; Song K, 2013, HEPATOLOGY, V58, P1681, DOI 10.1002/hep.26514; Su XQ, 2013, CHINESE J CANCER RES, V25, P235, DOI 10.3978/j.issn.1000-9604.2013.03.08; Sze KMF, 2013, HEPATOLOGY, V57, P131, DOI 10.1002/hep.25979; Tameda M, 2014, INT J ONCOL, V45, P541, DOI 10.3892/ijo.2014.2445; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wang YH, 2016, ONCOL LETT, V11, P801, DOI 10.3892/ol.2015.3976; Wells RG, 2008, CLIN LIVER DIS, V12, P759, DOI 10.1016/j.cld.2008.07.008; Wong CM, 2012, HEPATOLOGY, V55, P1453, DOI 10.1002/hep.25512; Xiong GF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-1; Xu C, 2014, CANCER LETT, V345, P216, DOI 10.1016/j.canlet.2013.08.035; Yang SL, 2016, J GASTROENTEROL, V51, P722, DOI 10.1007/s00535-015-1146-0; Yi T, 2017, SCI REP, V7, P1; You X, 2014, ONCOGENE, V33, P449, DOI 10.1038/onc.2012.618; You XN, 2013, CARCINOGENESIS, V34, P1644, DOI 10.1093/carcin/bgt089; Zanotti S, 2015, BBA-MOL BASIS DIS, V1852, P1451, DOI 10.1016/j.bbadis.2015.04.013; Zhang R, 2015, INT J CORROS, V2015, DOI 10.1155/2015/823172; Zhang S, 2013, FEBS LETT, V587, P645, DOI 10.1016/j.febslet.2013.01.019; Zhang T, 2013, NEOPLASIA, V15, P1282, DOI 10.1593/neo.131362; Zhang W, 2014, MOL CANCER, V13, P1; Zhang Xiao-Dong, 2014, Cancer Biology Medicine, V11, P182, DOI 10.7497/j.issn.2095-3941.2014.03.004; Zhang Y, 2012, HEPATOLOGY, V56, p617A; Zhu MY, 2015, ONCOTARGET, V6, P12196, DOI 10.18632/oncotarget.2906	48	34	37	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2017	36	50					6895	6905		10.1038/onc.2017.291	http://dx.doi.org/10.1038/onc.2017.291			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FQ0JM	28846110				2022-12-17	WOS:000418041800006
J	Kitamura, H; Onodera, Y; Murakami, S; Suzuki, T; Motohashi, H				Kitamura, H.; Onodera, Y.; Murakami, S.; Suzuki, T.; Motohashi, H.			IL-11 contribution to tumorigenesis in an NRF2 addiction cancer model	ONCOGENE			English	Article							INTERLEUKIN-11; RESISTANCE; EXPRESSION; CELLS; MICROENVIRONMENT; RECOGNITION; SENSITIVITY; P62/SQSTM1; PROGNOSIS; CARCINOMA	The interaction between cancer cells and their microenvironment is an important determinant of the pathological nature of cancers, particularly their tumorigenic abilities. The KEAP1-NRF2 system, originally identified as a critical defense mechanism against oxidative stress, is often dysregulated in various human cancers forming solid tumors, resulting in the aberrant activation of NRF2. Increased accumulation of NRF2 in cancers is strongly associated with the poor prognoses of cancer patients, including those with lung and breast cancers. Multiple lines of evidence suggest that aberrantly activated NRF2 in cancer cells drives their malignant progression and that the cancer cells consequently develop 'NRF2 addiction.' Although the downstream effectors of NRF2 that are responsible for cancer malignancy have been extensively studied, mechanisms of how NRF2 activation contributes to the aggressive tumorigenesis remains to be elucidated. In this study, we found a significant correlation between NRF2 and IL-11 status in breast cancer patients. Based on a recent report demonstrating that IL-11 is induced downstream of NRF2, we examined the significance of IL-11 in NRF2-driven tumorigenesis with a newly established NRF2 addiction cancer model. Expression of Il11 was elevated during the tumorigenesis of the NRF2 addiction cancer model, but intriguingly, it was hardly detected when the cancer model cells were cultured in vitro. These results imply that a signal originating from the microenvironment cooperates with NRF2 to activate Il11. To the best of our knowledge, this is the first report showing the influence of the microenvironment on the NRF2 pathway in cancer cells and the contribution of NRF2 to the secretory phenotypes of cancers. Disruption of Il11 in the NRF2 addiction cancer model remarkably inhibited the tumorigenesis, suggesting an essential role of IL-11 in NRF2-driven tumorigenesis. Thus, this study suggests that IL-11 is a potential therapeutic target for NRF2-addicted breast cancers.	[Kitamura, H.; Murakami, S.; Motohashi, H.] Tohoku Univ, Inst Dev Aging & Canc, Dept Gene Express Regulat, Sendai, Miyagi, Japan; [Onodera, Y.] Tohoku Univ, Grad Sch Med, Dept Anat Pathol, Sendai, Miyagi, Japan; [Suzuki, T.] Tohoku Univ, Grad Sch Med, Dept Pathol & Histotechnol, Sendai, Miyagi, Japan	Tohoku University; Tohoku University; Tohoku University	Kitamura, H (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Gene Express Regulat, Sendai, Miyagi, Japan.; Kitamura, H (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Gene Express Regulat, Aoba Ku, 4-1 Seiryo Cho, Sendai, Miyagi 9808575, Japan.	hozumim@med.tohoku.ac.jp	Motohashi, Hozumi/AAZ-2628-2020; Murakami, Shohei/GPW-9730-2022	Murakami, Shohei/0000-0002-2555-1568	JSPS KAKENHI [JP26860180, 15H04692, 16K15228]; Daiichi Sankyo Foundation of Life Science; Uehara Memorial Foundation; Mitsubishi Foundation; Naito Foundation; Princess Takamatsu Cancer Research Fund [15-24728]; Grants-in-Aid for Scientific Research [15H04692] Funding Source: KAKEN	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Daiichi Sankyo Foundation of Life Science; Uehara Memorial Foundation(Uehara Memorial Foundation); Mitsubishi Foundation; Naito Foundation(Naito Memorial Foundation); Princess Takamatsu Cancer Research Fund; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Keiko Nakayama for providing a mutant HRAS-expression vector, pMX-puro- HRASG12V, Drs. Norio Suzuki and Masayuki Yamamoto for providing SV40 T antigen expressing vectors, HA-KEAP1 cDNA and intensive discussion, and Drs Tomohiro Nakamura and Atsushi Hozawa for checking the quality of quantitative data and the adequacy of their presentation. We also thank Ms Nao Ohta for technical assistance and the Biomedical Research Core of Tohoku University Graduate School of Medicine for technical support. This work was supported by JSPS KAKENHI Grant Numbers JP26860180 (HK), 15H04692 (HM) and 16K15228 (HM), Daiichi Sankyo Foundation of Life Science (HM), the Uehara Memorial Foundation (HM), the Mitsubishi Foundation (HM), the Naito Foundation (HM), and the Princess Takamatsu Cancer Research Fund 15-24728 (HM). The funders had no role in the design of the study, data collection and analysis, decision to publish or preparation of the manuscript.	Bockhorn J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2393; Bockhorn J, 2013, BREAST CANCER RES TR, V137, P373, DOI 10.1007/s10549-012-2346-4; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chowdhry S, 2013, ONCOGENE, V32, P3765, DOI 10.1038/onc.2012.388; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; DeNicola GM, 2015, NAT GENET, V47, P1475, DOI 10.1038/ng.3421; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Ernst M, 2014, CLIN CANCER RES, V20, P5579, DOI 10.1158/1078-0432.CCR-13-2492; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goto M, 2015, GENES CELLS, V20, P464, DOI 10.1111/gtc.12237; Grivennikov SI, 2013, CANCER CELL, V24, P145, DOI 10.1016/j.ccr.2013.07.018; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanavadi S, 2006, ANN SURG ONCOL, V13, P802, DOI 10.1245/ASO.2006.05.028; Homma S, 2009, CLIN CANCER RES, V15, P3423, DOI 10.1158/1078-0432.CCR-08-2822; Inoue D, 2012, CANCER SCI, V103, P760, DOI 10.1111/j.1349-7006.2012.02216.x; Johnstone CN, 2015, CYTOKINE GROWTH F R, V26, P489, DOI 10.1016/j.cytogfr.2015.07.015; Kanamori M, 2015, NEURO-ONCOLOGY, V17, P555, DOI 10.1093/neuonc/nou282; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mitsuishi Y, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00200; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Nakayama T, 2007, INT J ONCOL, V30, P825; Nishina T, 2017, J BIOL CHEM, V292, P205, DOI 10.1074/jbc.M116.744755; Nishina T, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002056; Ohkoshi A, 2013, CANCER PREV RES, V6, P149, DOI 10.1158/1940-6207.CAPR-12-0401-T; Okawa H, 2006, BIOCHEM BIOPH RES CO, V339, P79, DOI 10.1016/j.bbrc.2005.10.185; Onodera Y, 2014, ENDOCR-RELAT CANCER, V21, P241, DOI 10.1530/ERC-13-0234; Putoczki TL, 2013, CANCER CELL, V24, P257, DOI 10.1016/j.ccr.2013.06.017; Rada P, 2011, MOL CELL BIOL, V31, P1121, DOI 10.1128/MCB.01204-10; Saito T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12030; Satoh H, 2016, CANCER RES, V76, P3088, DOI 10.1158/0008-5472.CAN-15-1584; Satoh H, 2010, CARCINOGENESIS, V31, P1833, DOI 10.1093/carcin/bgq105; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Shin SY, 2012, CARCINOGENESIS, V33, P2467, DOI 10.1093/carcin/bgs297; Shirasaki K, 2014, HEPATOLOGY, V59, P2371, DOI 10.1002/hep.27020; Singh A, 2016, ACS CHEM BIOL, V11, P3214, DOI 10.1021/acschembio.6b00651; Singh A, 2013, J CLIN INVEST, V123, P2921, DOI 10.1172/JCI66353; Singh A, 2010, ANTIOXID REDOX SIGN, V13, P1627, DOI 10.1089/ars.2010.3219; Solimini NL, 2007, CELL, V130, P986, DOI 10.1016/j.cell.2007.09.007; Suzuki T, 2013, TRENDS PHARMACOL SCI, V34, P340, DOI 10.1016/j.tips.2013.04.005; Taguchi K, 2010, MOL CELL BIOL, V30, P3016, DOI 10.1128/MCB.01591-09; Tsuchida K, 2017, FREE RADICAL BIO MED, V103, P236, DOI 10.1016/j.freeradbiomed.2016.12.041; Uruno A, 2011, NITRIC OXIDE-BIOL CH, V25, P153, DOI 10.1016/j.niox.2011.02.007; Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Wang XJ, 2008, CARCINOGENESIS, V29, P1235, DOI 10.1093/carcin/bgn095; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Zelenay S, 2015, CELL, V162, P1257, DOI 10.1016/j.cell.2015.08.015	52	34	35	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6315	6324		10.1038/onc.2017.236	http://dx.doi.org/10.1038/onc.2017.236			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28714957				2022-12-17	WOS:000414774800010
J	Khan, KA; Naylor, AJ; Khan, A; Noy, PJ; Mambretti, M; Lodhia, P; Athwal, J; Korzystka, A; Buckley, CD; Willcox, BE; Mohammed, F; Bicknell, R				Khan, K. A.; Naylor, A. J.; Khan, A.; Noy, P. J.; Mambretti, M.; Lodhia, P.; Athwal, J.; Korzystka, A.; Buckley, C. D.; Willcox, B. E.; Mohammed, F.; Bicknell, R.			Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface	ONCOGENE			English	Article							TUMOR ANGIOGENESIS; MOLECULAR CHARACTERIZATION; SPROUTING ANGIOGENESIS; ELEVATED EXPRESSION; COLORECTAL-CANCER; IN-VITRO; ENDOSIALIN; MARKER; GROWTH; RECEPTOR	The C-type lectin domain containing group 14 family members CLEC14A and CD93 are proteins expressed by endothelium and are implicated in tumour angiogenesis. CD248 (alternatively known as endosialin or tumour endothelial marker-1) is also a member of this family and is expressed by tumour-associated fibroblasts and pericytes. Multimerin-2 (MMRN2) is a unique endothelial specific extracellular matrix protein that has been implicated in angiogenesis and tumour progression. We show that the group 14 C-type lectins CLEC14A, CD93 and CD248 directly bind to MMRN2 and only thrombomodulin of the family does not. Binding to MMRN2 is dependent on a predicted long-loop region in the C-type lectin domain and is abrogated by mutation within the domain. CLEC14A and CD93 bind to the same non-glycosylated coiled-coil region of MMRN2, but the binding of CD248 occurs on a distinct non-competing region. CLEC14A and CD248 can bind MMRN2 simultaneously and this occurs at the interface between endothelium and pericytes in human pancreatic cancer. A recombinant peptide of MMRN2 spanning the CLEC14A and CD93 binding region blocks CLEC14A extracellular domain binding to the endothelial cell surface as well as increasing adherence of human umbilical vein endothelial cells to the active peptide. This MMRN2 peptide is anti-angiogenic in vitro and reduces tumour growth in mouse models. These findings identify novel protein interactions involving CLEC14A, CD93 and CD248 with MMRN2 as targetable components of vessel formation.	[Khan, K. A.; Khan, A.; Noy, P. J.; Mambretti, M.; Lodhia, P.; Athwal, J.; Korzystka, A.; Bicknell, R.] Univ Birmingham, Inst Biomed Res & Cardiovasc Sci, Coll Med & Dent Sci, Mol Angiogenesis Lab, Birmingham B15 2TT, W Midlands, England; [Naylor, A. J.; Buckley, C. D.] Univ Birmingham, Inst Inflammat & Ageing, Rheumatol Res Grp, Birmingham, W Midlands, England; [Willcox, B. E.; Mohammed, F.] Univ Birmingham, Inst Immunol & Immunotherapy, Canc Immunol & Immunotherapy Ctr, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham	Bicknell, R (corresponding author), Univ Birmingham, Inst Biomed Res & Cardiovasc Sci, Coll Med & Dent Sci, Mol Angiogenesis Lab, Birmingham B15 2TT, W Midlands, England.	r.bicknell@bham.ac.uk	Buckley, Christopher/AAN-6378-2021; Khan, Kabir/U-8350-2018	Buckley, Christopher/0000-0001-6924-6402; Khan, Kabir/0000-0001-8453-3485; Noy, Peter/0000-0001-6142-8957; Khan, Abdullah/0000-0003-0825-3179; Bicknell, Roy/0000-0002-0941-8919; Mambretti, Marco/0000-0003-2765-3805; Naylor, Amy/0000-0001-8384-8215	UoB; MRC [GBT1465]; Versus Arthritis [19791] Funding Source: researchfish	UoB; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Versus Arthritis(Versus Arthritis)	We thank the University of Birmingham (UoB) Protein expression facility for use of CD248-ECD-Fc; Raj Mehta and Tassos Konstantinou from Cancer Research Technologies for useful discussions. This work was funded by UoB and MRC grant GBT1465.	Aricescu AR, 2006, ACTA CRYSTALLOGR D, V62, P1243, DOI 10.1107/S0907444906029799; Bao LL, 2016, BIOCHEM BIOPH RES CO, V476, P467, DOI 10.1016/j.bbrc.2016.05.146; Bohlson SS, 2005, J IMMUNOL, V175, P1239, DOI 10.4049/jimmunol.175.2.1239; Brady J, 2004, J NEUROPATH EXP NEUR, V63, P1274, DOI 10.1093/jnen/63.12.1274; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Christian S, 2001, J BIOL CHEM, V276, P48588, DOI 10.1074/jbc.M106152200; Colladel R, 2016, ONCOTARGET, V7, P2022, DOI 10.18632/oncotarget.6515; Diaz LA, 2015, CLIN CANCER RES, V21, P1281, DOI 10.1158/1078-0432.CCR-14-1829; Donovan D., 2001, Angiogenesis, V4, P113, DOI 10.1023/A:1012218401036; GUAN E, 1991, J BIOL CHEM, V266, P20345; Huber MA, 2006, J CUTAN PATHOL, V33, P145, DOI 10.1111/j.0303-6987.2006.00446.x; Kastrup JS, 1998, ACTA CRYSTALLOGR D, V54, P757, DOI 10.1107/S0907444997016806; Kaur S, 2011, ARTERIOSCL THROM VAS, V31, P657, DOI 10.1161/ATVBAHA.110.216341; Ki MK, 2013, ONCOGENE, V32, P5449, DOI 10.1038/onc.2013.156; Kontsekova S, 2016, NEOPLASMA, V63, P183, DOI 10.4149/202_15090N474; Langenkamp E, 2015, CANCER RES, V75, P4504, DOI 10.1158/0008-5472.CAN-14-3636; Lee SM, 2013, Publication number, Patent No. [WO2013187724 A1, 2013187724]; Lorenzon E, 2012, ONCOGENE, V31, P3136, DOI 10.1038/onc.2011.487; Masiero M, 2013, CANCER CELL, V24, P229, DOI 10.1016/j.ccr.2013.06.004; McGreal EP, 2002, J IMMUNOL, V168, P5222, DOI 10.4049/jimmunol.168.10.5222; Naylor AJ, 2012, ARTHRITIS RHEUM-US, V64, P3334, DOI 10.1002/art.34556; Nepomuceno RR, 1998, J IMMUNOL, V160, P1929; Noy PJ, 2015, ONCOGENE, V34, P5821, DOI 10.1038/onc.2015.34; Noy PJ, 2016, FASEB J, V30, P2311, DOI 10.1096/fj.201500122R; O'Callaghan CA, 1999, ANAL BIOCHEM, V266, P9, DOI 10.1006/abio.1998.2930; Olsen RS, 2015, INT J COLORECTAL DIS, V30, P883, DOI 10.1007/s00384-015-2247-1; Opavsky R, 2001, J BIOL CHEM, V276, P38795, DOI 10.1074/jbc.M105241200; Petrenko O, 1999, IMMUNITY, V10, P691, DOI 10.1016/S1074-7613(00)80068-0; Rho SS, 2011, BIOCHEM BIOPH RES CO, V404, P103, DOI 10.1016/j.bbrc.2010.11.075; Rmali KA, 2005, WORLD J GASTROENTERO, V11, P1283, DOI 10.3748/wjg.v11.i9.1283; Simonavicius N, 2008, MODERN PATHOL, V21, P308, DOI 10.1038/modpathol.3801006; Simonavicius N, 2012, BLOOD, V120, P1516, DOI 10.1182/blood-2011-01-332338; Simossis VA, 2005, NUCLEIC ACIDS RES, V33, pW289, DOI 10.1093/nar/gki390; Tomkowicz B, 2007, P NATL ACAD SCI USA, V104, P17965, DOI 10.1073/pnas.0705647104; Wilson E, 2014, J CELL SCI, V127, P3039, DOI 10.1242/jcs.140434; Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213; Zanivan S, 2013, MOL CELL PROTEOMICS, V12, P3599, DOI 10.1074/mcp.M113.031344; Zelensky AN, 2005, FEBS J, V272, P6179, DOI 10.1111/j.1742-4658.2005.05031.x	38	34	35	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6097	6108		10.1038/onc.2017.214	http://dx.doi.org/10.1038/onc.2017.214			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28671670	Green Published, hybrid			2022-12-17	WOS:000414249800004
J	Chi, HC; Chen, SL; Lin, SL; Tsai, CY; Chuang, WY; Lin, YH; Huang, YH; Tsai, MM; Yeh, CT; Lin, KH				Chi, H-C; Chen, S-L; Lin, S-L; Tsai, C-Y; Chuang, W-Y; Lin, Y-H; Huang, Y-H; Tsai, M-M; Yeh, C-T; Lin, K-H			Thyroid hormone protects hepatocytes from HBx-induced carcinogenesis by enhancing mitochondrial turnover	ONCOGENE			English	Article							VIRUS-X-PROTEIN; HEPATITIS-B; HEPATOCELLULAR-CARCINOMA; CELL-PROLIFERATION; REDUCTIVE STRESS; LIVER; METASTASIS; ACTIVATION; DEATH; HYPOTHYROIDISM	Infection by hepatitis B virus (HBV) accounts for 50-80% of hepatocellular carcinoma (HCC) development worldwide, in which the HBV-encoded X protein (HBx) has critical role in the induction of carcinogenesis. Several studies have shown that thyroid hormone (TH) suppresses HCC development and protects hepatocytes from HBx-induced damage, thus it is of interest to examine whether TH can protect hepatocytes from HBx-induced carcinogenesis. By treating HBx-transgenic mice with or without TH, we confirmed the protective effects of TH on HBx-induced hepatocarcinogenesis, which was achieved via reduction of reactive oxygen species (ROS) inflicted DNA damage. We further found that TH induced biogenesis of mitochondria (MITO) and autophagy of HBx-targeted MITO simultaneously, consequently leading to suppression of HBx-promoted ROS and carcinogenesis. Using microarray data analysis, this protective effect of TH was found to be mediated via activation of PTEN-induced kinase 1 (PINK1) in hepatocytes. PINK1, in turn, activated and recruited Parkin, an E3 ligase, to ubiquitinate MITO-associated HBx protein and trigger selective mitophagy. The pathological significance of the TH/PINK1 pathway in liver protection was confirmed by the concomitant decrease in expression of both TR and PINK1 in matched HCC tumor tissues and negatively correlated with aggressive progression of cancer and poor prognosis. Our data indicate that TH/PINK1/Parkin pathway has a critical role in protecting hepatocytes from HBx-induced carcinogenesis. Notably, several liver-targeting therapeutic derivatives of TH facilitating prevention or therapy of steatosis have been identified. Furthermore, our proof-of-concept experiments suggest that application of T3 constitutes an effective novel therapeutic or preventive option for HCC. Thus, the utilization of the agonists of TRs could be the meaningful strategy in liver relative diseases, ranging from simple hepatic steatosis to HCC.	[Chi, H-C; Lin, S-L; Lin, Y-H; Lin, K-H] Chang Gung Univ, Dept Biochem, Coll Med, Taoyuan, Taiwan; [Chen, S-L] Natl Cent Univ, Dept Life Sci, Jhongli, Taiwan; [Tsai, C-Y] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Kidney Res Ctr, Taoyuan, Taiwan; [Tsai, C-Y] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Dept Nephrol,Chang Gung Immunol Consortium, Taoyuan, Taiwan; [Chuang, W-Y] Chang Gung Mem Hosp, Dept Pathol, Taoyuan, Taiwan; [Chuang, W-Y] Chang Gung Univ, Coll Med, Taoyuan, Taiwan; [Huang, Y-H; Yeh, C-T; Lin, K-H] Chang Gung Mem Hosp, Dept Hepatogastroenterol, Liver Res Ctr, Taoyuan, Taiwan; [Tsai, M-M] Chang Gung Univ Sci & Technol, Dept Nursing, Taoyuan, Taiwan; [Tsai, M-M] Chang Gung Mem Hosp, Dept Gen Surg, Chiayi, Taiwan; [Lin, K-H] Chang Gung Univ Sci & Technol, Coll Human Ecol, Res Ctr Chinese Herbal Med, Taoyuan, Taiwan	Chang Gung University; National Central University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University of Science & Technology; Chang Gung Memorial Hospital; Chang Gung University of Science & Technology	Lin, KH (corresponding author), Chang Gung Univ, Dept Biochem, 259 Wen Hwa 1 Rd, Taoyuan, Taiwan.	khlin@mail.cgu.edu.tw	Chuang, Wen-Yu/I-8013-2019	Chuang, Wen-Yu/0000-0002-3729-073X	Chang Gung Memorial Hospital, Taoyuan, Taiwan [CRRPD1F0011, CRRPD1F0012]; Ministry of Science and Technology of the Republic of China [MOST 103-2320-B-182-018-MY3, 103-2320-B-182-017-MY3, 105-2811-B-182-018, 105-2321-B-182-002-MY3]	Chang Gung Memorial Hospital, Taoyuan, Taiwan(Chang Gung Memorial Hospital); Ministry of Science and Technology of the Republic of China(Ministry of Science and Technology, Taiwan)	This work was supported by grants from Chang Gung Memorial Hospital, Taoyuan, Taiwan (CRRPD1F0011, CRRPD1F0012) and from the Ministry of Science and Technology of the Republic of China (MOST 103-2320-B-182-018-MY3, 103-2320-B-182-017-MY3, 105-2811-B-182-018, 105-2321-B-182-002-MY3). Accession number of transcript profiling: GEO accession: GSE14520.	BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; Calvisi DF, 2006, GASTROENTEROLOGY, V130, P1117, DOI 10.1053/j.gastro.2006.01.006; Cheng SY, 2010, ENDOCR REV, V31, P139, DOI 10.1210/er.2009-0007; Chi HC, 2012, CELL DEATH DIFFER, V19, P1802, DOI 10.1038/cdd.2012.58; Chi HC, 2016, AUTOPHAGY, V12, P2271, DOI 10.1080/15548627.2016.1230583; Clippinger AJ, 2008, J VIROL, V82, P6798, DOI 10.1128/JVI.00154-08; Columbano A, 1996, FASEB J, V10, P1118, DOI 10.1096/fasebj.10.10.8751714; DAWSON TL, 1993, AM J PHYSIOL, V264, pC961, DOI 10.1152/ajpcell.1993.264.4.C961; Dias V, 2013, J PARKINSON DIS, V3, P461, DOI 10.3233/JPD-130230; FARBER E, 1991, DIGEST DIS SCI, V36, P973, DOI 10.1007/BF01297150; Frau C, 2015, HEPATOLOGY, V61, P249, DOI 10.1002/hep.27399; Gentric G, 2012, INT J HEPATOL, V2012, DOI 10.1155/2012/282430; GORES GJ, 1989, AM J PHYSIOL, V257, pC347, DOI 10.1152/ajpcell.1989.257.2.C347; GROSS NJ, 1971, J CELL BIOL, V48, P29, DOI 10.1083/jcb.48.1.29; Harper ME, 2008, THYROID, V18, P145, DOI 10.1089/thy.2007.0250; Hassan MM, 2009, HEPATOLOGY, V49, P1563, DOI 10.1002/hep.22793; Hunter J, 1996, MOL CELL ENDOCRINOL, V116, P213, DOI 10.1016/0303-7207(95)03717-9; Jiang TY, 2016, P NATL ACAD SCI USA, V113, P2074, DOI 10.1073/pnas.1525616113; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; Kim HJ, 2008, IUBMB LIFE, V60, P473, DOI 10.1002/iub.68; Kim SJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003722; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Kremsdorf D, 2006, ONCOGENE, V25, P3823, DOI 10.1038/sj.onc.1209559; Ledda-Columbano GM, 2000, CANCER RES, V60, P603; Ledda-Columbano GM, 1999, CARCINOGENESIS, V20, P2299, DOI 10.1093/carcin/20.12.2299; Lee S, 2014, TOX RESEARCH, V30, P243, DOI 10.5487/TR.2014.30.4.243; Lee YI, 2004, J BIOL CHEM, V279, P15460, DOI 10.1074/jbc.M309280200; Lin YH, 2013, ONCOGENE, V32, P3904, DOI 10.1038/onc.2013.5; Ma NF, 2008, CLIN CANCER RES, V14, P5061, DOI 10.1158/1078-0432.CCR-07-5082; Malhi H, 2008, GASTROENTEROLOGY, V134, P1641, DOI 10.1053/j.gastro.2008.03.002; Mansour-Ghanaei F, 2012, ANN HEPATOL, V11, P667, DOI 10.1016/S1665-2681(19)31440-1; Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140; Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298; Nguyen VTT, 2009, J VIRAL HEPATITIS, V16, P453, DOI 10.1111/j.1365-2893.2009.01117.x; Perra A, 2008, FASEB J, V22, P2981, DOI 10.1096/fj.08-108464; Perra A, 2009, HEPATOLOGY, V49, P1287, DOI 10.1002/hep.22750; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Seo AY, 2010, J CELL SCI, V123, P2533, DOI 10.1242/jcs.070490; Shirakata Y, 2003, J BIOL CHEM, V278, P22071, DOI 10.1074/jbc.M301606200; Sinha RA, 2015, AUTOPHAGY, V11, P1341, DOI 10.1080/15548627.2015.1061849; Sinha RA, 2012, J CLIN INVEST, V122, P2428, DOI 10.1172/JCI60580; Sullivan LB, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-17; Sze KMF, 2013, HEPATOLOGY, V57, P131, DOI 10.1002/hep.25979; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; Terradillos O, 2002, ONCOGENE, V21, P377, DOI 10.1038/sj.onc.1205110; Tseng YH, 2014, AUTOPHAGY, V10, P20, DOI 10.4161/auto.26126; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107; Waris G, 2001, MOL CELL BIOL, V21, P7721, DOI 10.1128/MCB.21.22.7721-7730.2001; Weitzel JM, 2011, MOL CELL ENDOCRINOL, V342, P1, DOI 10.1016/j.mce.2011.05.009; Wu BK, 2006, BIOCHEM BIOPH RES CO, V340, P916, DOI 10.1016/j.bbrc.2005.12.089; Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028	56	34	36	3	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2017	36	37					5274	5284		10.1038/onc.2017.136	http://dx.doi.org/10.1038/onc.2017.136			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FG8HT	28504722				2022-12-17	WOS:000410671700006
J	Luo, S; Li, Y; Ma, R; Liu, J; Xu, P; Zhang, H; Tang, K; Ma, J; Liu, N; Zhang, Y; Sun, Y; Ji, T; Liang, X; Yin, X; Liu, Y; Tong, W; Niu, Y; Wang, N; Wang, X; Huang, B				Luo, S.; Li, Y.; Ma, R.; Liu, J.; Xu, P.; Zhang, H.; Tang, K.; Ma, J.; Liu, N.; Zhang, Y.; Sun, Y.; Ji, T.; Liang, X.; Yin, X.; Liu, Y.; Tong, W.; Niu, Y.; Wang, N.; Wang, X.; Huang, B.			Downregulation of PCK2 remodels tricarboxylic acid cycle in tumor-repopulating cells of melanoma	ONCOGENE			English	Article							CYTOSOLIC PHOSPHOENOLPYRUVATE CARBOXYKINASE; ATP-CITRATE LYASE; CANCER; GROWTH; INHIBITION; ADAPTATION; EXPRESSION; SUCCINATE; FUMARATE; FH	For cancer cells to proliferate, a balance must be built between biomass-forming, glucose-metabolized intermediates and ATP production. How intrinsic glucose carbon flow regulates this balance remains unclear. Here we show that mitochondrial phosphoenolpyruvate carboxykinase (PCK2), the hub molecule linking tricarboxylic acid (TCA) cycle, glycolysis and gluconeogenesis by conversion of mitochondrial oxaloacetate (OAA) to phosphoenolpyruvate, regulates glucose carbon flow direction in stem-like cells that repopulate tumors (tumor-repopulating cells (TRCs)). PCK2 downregulation accelerated biosynthesis and transportation of citrate from mitochondria to the cytosol, leading to cytosolic glucose carbon flow via OAA-malate-pyruvate and acetyl-CoA-fatty acid pathways in TRCs. On the other hand, downregulating PCK2 hindered fumarate carbon flows in TCA cycle, leading to attenuated oxidative phosphorylation. In pathological terms, PCK2 overexpression slowed TRC growth in vitro and impeded tumorigenesis in vivo. Overall, our work unveiled unexpected glucose carbon flows of TRCs in melanoma that have implications for targeting metabolic aspects of melanoma.	[Luo, S.; Li, Y.; Ma, R.; Liu, J.; Xu, P.; Tang, K.; Ma, J.; Liu, N.; Zhang, Y.; Sun, Y.; Ji, T.; Huang, B.] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Biochem & Mol Biol, Wuhan, Peoples R China; [Zhang, H.; Liang, X.; Yin, X.; Liu, Y.; Wang, X.; Huang, B.] Chinese Acad Med Sci, Inst Basic Med Sci, State Key Lab Med Mol Biol, Beijing, Peoples R China; [Zhang, H.; Liang, X.; Yin, X.; Liu, Y.; Huang, B.] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Immunol, Dong Dan San Tiao 5, Beijing 100005, Peoples R China; [Zhang, H.; Liang, X.; Yin, X.; Liu, Y.; Tong, W.; Niu, Y.; Wang, X.; Huang, B.] Peking Union Med Coll, Dong Dan San Tiao 5, Beijing 100005, Peoples R China; [Tong, W.; Niu, Y.] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Pathol, Beijing, Peoples R China; [Wang, N.] Huazhong Univ Sci & Technol, Sch Life Sci & Technol, Lab Cell Biomech & Regenerat Med, Wuhan, Peoples R China; [Wang, N.] Univ Illinois, Dept Mech Sci & Engn, Urbana, IL USA	Huazhong University of Science & Technology; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Huazhong University of Science & Technology; University of Illinois System; University of Illinois Urbana-Champaign	Huang, B (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Dept Immunol, Dong Dan San Tiao 5, Beijing 100005, Peoples R China.; Huang, B (corresponding author), Peking Union Med Coll, Dong Dan San Tiao 5, Beijing 100005, Peoples R China.	tjhuangbo@hotmail.com	Ma, Ruihua/K-2183-2019	Li, Yong/0000-0001-8265-577X; Liu, Na/0000-0001-9903-1314; luo, shunqun/0000-0002-5728-2112	National Basic Research Program of China [2014CB542100]; National Natural Science Foundation of China [81472653, 81530080, 81661128007]; CAMS Initiative for Innovative Medicine [2016-I2M-1-007]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Initiative for Innovative Medicine	This work was supported by National Basic Research Program of China (2014CB542100), National Natural Science Foundation of China (81472653, 81530080, 81661128007) and CAMS Initiative for Innovative Medicine (2016-I2M-1-007).	Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Burgess SC, 2007, CELL METAB, V5, P313, DOI 10.1016/j.cmet.2007.03.004; Cairns RA, 2006, NAT REV CANCER, V11, P85; Chowdhury F, 2010, NAT MATER, V9, P82, DOI [10.1038/NMAT2563, 10.1038/nmat2563]; Costello LC, 2005, MOL CELL BIOCHEM, V280, P1, DOI 10.1007/s11010-005-8841-8; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Klein WM, 2007, MODERN PATHOL, V20, P102, DOI 10.1038/modpathol.3800720; Kolukula VK, 2014, ONCOTARGET, V5, P1212, DOI 10.18632/oncotarget.1831; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Leithner K, 2015, ONCOGENE, V34, P1044, DOI 10.1038/onc.2014.47; Li Y, 2015, CANCER RES, V75, P1191, DOI 10.1158/0008-5472.CAN-14-2615; Liu J, 2012, NAT MATER, V11, P734, DOI [10.1038/NMAT3361, 10.1038/nmat3361]; Mendez-Lucas A, 2014, J BIOL CHEM, V289, P22090, DOI 10.1074/jbc.M114.566927; Montal ED, 2015, MOL CELL, V60, P571, DOI 10.1016/j.molcel.2015.09.025; Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Sudarshan S, 2009, MOL CELL BIOL, V29, P4080, DOI 10.1128/MCB.00483-09; Vincent EE, 2015, MOL CELL, V60, P195, DOI 10.1016/j.molcel.2015.08.013; Xiao MT, 2012, GENE DEV, V26, P1326, DOI 10.1101/gad.191056.112; Yang H, 2015, EMBO J, V34, P1110, DOI 10.15252/embj.201591041; Zaidi N, 2012, CANCER RES, V72, P3709, DOI 10.1158/0008-5472.CAN-11-4112; Zelle RM, 2008, APPL ENVIRON MICROB, V74, P2766, DOI 10.1128/AEM.02591-07	27	34	37	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3609	3617		10.1038/onc.2016.520	http://dx.doi.org/10.1038/onc.2016.520			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28166201				2022-12-17	WOS:000403878600010
J	Amit, M; Na'ara, S; Leider-Trejo, L; Binenbaum, Y; Kulish, N; Fridman, E; Shabtai-Orbach, A; Wong, RJ; Gil, Z				Amit, M.; Na'ara, S.; Leider-Trejo, L.; Binenbaum, Y.; Kulish, N.; Fridman, E.; Shabtai-Orbach, A.; Wong, R. J.; Gil, Z.			Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; CANCER CELL INVASION; NEUROTROPHIC FACTOR; NEURAL INVASION; NEURONAL PLASTICITY; LIGAND COMPLEXES; NEUROPATHIC PAIN; TYROSINE KINASE; CARCINOMA CELLS; BREAST-CANCER	Tumor spread along nerves, a phenomenon known as perineurial invasion, is common in various cancers including pancreatic ductal adenocarcinoma PDAC). Neural invasion is associated with poor outcome, yet its mechanism remains unclear. Using the transgenic Pdx1- Cre/KrasG12D/p53R172H (KPC) mouse model, we investigated the mechanism of neural invasion in PDAC. To detect tissue-specific factors that influence neural invasion by cancer cells, we characterized the perineurial microenvironment using a series of bone marrow transplantation (BMT) experiments in transgenic mice expressing single mutations in the Cx3cr1, GDNF and CCR2 genes. Immunolabeling of tumors in KPC mice of different ages and analysis of human cancer specimens revealed that RET expression is upregulated during PDAC tumorigenesis. BMT experiments revealed that BM-derived macrophages expressing the RET ligand GDNF are highly abundant around nerves invaded by cancer. Inhibition of perineurial macrophage recruitment, using the CSF-1R antagonist GW2580 or BMT from CCR2-deficient donors, reduced perineurial invasion. Deletion of GDNF expression by perineurial macrophages, or inhibition of RET with shRNA or a small-molecule inhibitor, reduced perineurial invasion in KPC mice with PDAC. Taken together, our findings show that RET is upregulated during pancreas tumorigenesis and its activation induces cancer perineurial invasion. Trafficking of BM-derived macrophages to the perineurial microenvironment and secretion of GDNF are essential for pancreatic cancer neural spread.	[Amit, M.] Univ Texas MD Anderson Canc Ctr, Head & Neck Surg Dept, Houston, TX 77030 USA; [Amit, M.; Na'ara, S.; Binenbaum, Y.; Kulish, N.; Fridman, E.; Shabtai-Orbach, A.; Gil, Z.] Technion Israel Inst Technol, Rappaport Inst Med & Res, Clin Res Inst Rambam, Lab Appl Canc Res, Haifa, Israel; [Amit, M.; Na'ara, S.; Fridman, E.; Gil, Z.] Technion Israel Inst Technol, Dept Otolaryngol Head & Neck Surg,Head & Neck Ctr, Rappaport Inst Med & Res,Rambam Med Ctr, Rambam Healthcare Campus,Clin Res Inst Rambam, 8 HaAliya St,POB 9602, IL-31096 Haifa, Israel; [Leider-Trejo, L.] Tel Aviv Med Ctr & Sch Med, Dept Pathol, Tel Aviv, Israel; [Wong, R. J.] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA	University of Texas System; UTMD Anderson Cancer Center; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Tel Aviv University; Sackler Faculty of Medicine; Memorial Sloan Kettering Cancer Center	Gil, Z (corresponding author), Technion Israel Inst Technol, Dept Otolaryngol Head & Neck Surg,Head & Neck Ctr, Rappaport Inst Med & Res,Rambam Med Ctr, Rambam Healthcare Campus,Clin Res Inst Rambam, 8 HaAliya St,POB 9602, IL-31096 Haifa, Israel.	ziv@baseofskull.org			Israeli Science Foundation; Binational US-Israel Science Foundation; Barbara S Goodman ICRF grant; Israel Cancer Association; Rappaport Research Institute; Clinical Research Institute	Israeli Science Foundation(Israel Science Foundation); Binational US-Israel Science Foundation(US-Israel Binational Science Foundation); Barbara S Goodman ICRF grant; Israel Cancer Association; Rappaport Research Institute; Clinical Research Institute	We thank Cindy Cohen for her editorial assistance. We also thank Dr Inna Narodezky for her assistance in reviewing pathological specimens. This study was supported by grants from the Israeli Science Foundation, Binational US-Israel Science Foundation, Barbara S Goodman ICRF grant, Israel Cancer Association, the Rappaport Research Institute and the Clinical Research Institute at Rambam.	Amit M, 2016, NAT REV CANCER, V16, P399, DOI 10.1038/nrc.2016.38; Amit M, 2013, CANCER MED-US, V2, P155, DOI 10.1002/cam4.45; Beatty GL, 2015, GASTROENTEROLOGY, V149, P201, DOI 10.1053/j.gastro.2015.04.010; Ben QW, 2010, ANN SURG ONCOL, V17, P2213, DOI 10.1245/s10434-010-0955-x; Cavel O, 2012, CANCER RES, V72, P5733, DOI 10.1158/0008-5472.CAN-12-0764; Ceyhan GO, 2010, ANN SURG, V251, P923, DOI 10.1097/SLA.0b013e3181d974d4; Ceyhan GO, 2009, GASTROENTEROLOGY, V136, P177, DOI 10.1053/j.gastro.2008.09.029; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Conway JG, 2005, P NATL ACAD SCI USA, V102, P16078, DOI 10.1073/pnas.0502000102; Cullen-McEwen LA, 2001, KIDNEY INT, V60, P31, DOI 10.1046/j.1523-1755.2001.00767.x; Demir IE, 2010, NEUROGASTROENT MOTIL, V22, P480, DOI 10.1111/j.1365-2982.2009.01428.x; Demir IE, 2016, GUT, V65, P1001, DOI 10.1136/gutjnl-2015-309784; Demir IE, 2015, NAT REV GASTRO HEPAT, V12, P649, DOI 10.1038/nrgastro.2015.166; Demir IE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060529; Demir Ihsan Ekin, 2010, Cancers (Basel), V2, P1513, DOI 10.3390/cancers2031513; Edstrom E, 2000, INT J MOL MED, V6, P469; Esseghir S, 2007, CANCER RES, V67, P11732, DOI 10.1158/0008-5472.CAN-07-2343; Frisk T, 2000, EUR J ENDOCRINOL, V142, P643, DOI 10.1530/eje.0.1420643; Fukuda T, 2002, J BIOL CHEM, V277, P19114, DOI 10.1074/jbc.M200643200; Giehl K, 2000, ONCOGENE, V19, P2930, DOI 10.1038/sj.onc.1203612; Gil Z, 2010, J NATL CANCER I, V102, P107, DOI 10.1093/jnci/djp456; Gil Z, 2009, ARCH OTOLARYNGOL, V135, P173, DOI 10.1001/archoto.2008.525; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; He SZ, 2015, MOL CANCER RES, V13, P380, DOI 10.1158/1541-7786.MCR-14-0303; Jamieson NB, 2012, ANN SURG ONCOL, V19, P3581, DOI 10.1245/s10434-012-2370-y; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kang J, 2009, ONCOGENE, V28, P2034, DOI 10.1038/onc.2009.66; Kelly DJ, 2005, J AM SOC NEPHROL, V16, P1654, DOI 10.1681/ASN.2004070578; Kelly K, 2008, FASEB J, V22, P1839, DOI 10.1096/fj.07-097808; Kieseier BC, 2006, CURR OPIN NEUROL, V19, P437, DOI 10.1097/01.wco.0000245365.51823.72; Kim-Fuchs C, 2014, BRAIN BEHAV IMMUN, V40, P40, DOI 10.1016/j.bbi.2014.02.019; Liebl F, 2014, ANN SURG, V260, P900, DOI 10.1097/SLA.0000000000000968; Liebl F, 2013, CLIN CANCER RES, V19, P50, DOI 10.1158/1078-0432.CCR-12-2392; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008-5472.CAN-12-2731; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Pahler J, 2008, NEOPLASIA, V10, P329, DOI 10.1593/neo.07871; Patwardhan PP, 2014, CLIN CANCER RES, V20, P3146, DOI 10.1158/1078-0432.CCR-13-2576; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Qian BZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006562; Qiao S, 2009, CLIN NEUROPATHOL, V28, P105; Ruffell B, 2012, TRENDS IMMUNOL, V33, P119, DOI 10.1016/j.it.2011.12.001; Sawai H, 2005, CANCER RES, V65, P11536, DOI 10.1158/0008-5472.CAN-05-2843; Stahle M, 2003, J CELL SCI, V116, P3835, DOI 10.1242/jcs.00679; Tang MJ, 1998, J CELL BIOL, V142, P1337, DOI 10.1083/jcb.142.5.1337; Torres MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080580; Veit C, 2004, CANCER RES, V64, P5291, DOI 10.1158/0008-5472.CAN-04-1112; Wang K, 2014, CARCINOGENESIS, V35, P103, DOI 10.1093/carcin/bgt312; Yamaguchi R, 2002, BRIT J SURG, V89, P1130, DOI 10.1046/j.1365-2168.2002.02184.x; Yoshikawa K, 2012, CANCER SCI, V103, P2012, DOI 10.1111/j.1349-7006.2012.02411.x; Zeng LJ, 2014, J CANCER, V5, P754, DOI 10.7150/jca.10238; Zhang J, 2010, JNCI-J NATL CANCER I, V102, P522, DOI 10.1093/jnci/djq044	53	34	43	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3232	3239		10.1038/onc.2016.483	http://dx.doi.org/10.1038/onc.2016.483			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28092668				2022-12-17	WOS:000402869800003
J	Li, J; Xi, Y; Li, W; McCarthy, RL; Stratton, SA; Zou, W; Li, W; Dent, SY; Jain, AK; Barton, MC				Li, J.; Xi, Y.; Li, W.; McCarthy, R. L.; Stratton, S. A.; Zou, W.; Li, W.; Dent, S. Y.; Jain, A. K.; Barton, M. C.			TRIM28 interacts with EZH2 and SWI/SNF to activate genes that promote mammosphere formation	ONCOGENE			English	Article							EMBRYONIC STEM-CELLS; BREAST-CANCER CELLS; IN-VITRO PROPAGATION; EXPRESSION ANALYSIS; COMPLEX PRC2; PROTEIN EED; GENOME; METHYLATION; REPRESSION; BINDING	Histone methyl transferase EZH2 (Enhancer of Zeste Homolog 2) is generally associated with H3K27 methylation and gene silencing, as a member of the polycomb repressor 2 (PRC2) complex. Immunoprecipitation and mass spectrometry of the EZH2-protein interactome in estrogen receptor positive, breast cancer-derived MCF7 cells revealed EZH2 interactions with subunits of chromatin remodeler SWI/SNF complex and TRIM28, which formed a complex with EZH2 distinct from PRC2. Unexpectedly, transcriptome profiling showed that EZH2 primarily activates, rather than represses, transcription in MCF7 cells and with TRIM28 co-regulates a set of genes associated with stem cell maintenance and poor survival of breast cancer patients. TRIM28 depletion repressed EZH2 recruitment to chromatin and expression of this gene set, in parallel with decreased CD44(hi)/CD24(lo) mammosphere formation. Mammosphere formation, inhibited by EZH2 depletion, was rescued by ectopic expression of EZH2 but not by TRIM28 expression or by EZH2 mutated at the region (pre-SET domain) of TRIM28 interaction. These results support PRC2-independent functions of EZH2 and TRIM28 in activation of gene expression that promotes mammary stem cell enrichment and maintenance.	[Li, J.; Barton, M. C.] Univ Texas MD Anderson Canc Ctr, Univ Texas Grad Sch Biomed Sci Houston, Genes & Dev Grad Program, Houston, TX 77030 USA; [Li, J.; Li, W.; McCarthy, R. L.; Stratton, S. A.; Dent, S. Y.; Jain, A. K.; Barton, M. C.] Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Li, J.; Li, W.; McCarthy, R. L.; Stratton, S. A.; Dent, S. Y.; Jain, A. K.; Barton, M. C.] Univ Texas MD Anderson Canc Ctr, Ctr Canc Epigenet, Houston, TX 77030 USA; [Xi, Y.; Zou, W.] Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI USA; [Li, W.] Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Michigan System; University of Michigan; Baylor College of Medicine	Barton, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mbarton@mdanderson.org	Dent, Sharon YR/F-1746-2011	Dent, Sharon YR/0000-0002-4824-3269; Jain, Abhinav/0000-0003-3268-514X; Barton, Michelle/0000-0002-4042-1374	CPRIT [RP110471]; Gigli Family Endowed Scholarship of the UT-Graduate School of Biomedical Sciences at Houston, TX; Laura and John Arnold Foundation; Odyssey Program fellowship; CPRIT Core Facility Support [RP120348]; National Institutes of Health through MD Anderson's Cancer Center Support [CA016672]; NATIONAL CANCER INSTITUTE [R01CA190176, P30CA016672] Funding Source: NIH RePORTER	CPRIT; Gigli Family Endowed Scholarship of the UT-Graduate School of Biomedical Sciences at Houston, TX; Laura and John Arnold Foundation; Odyssey Program fellowship; CPRIT Core Facility Support; National Institutes of Health through MD Anderson's Cancer Center Support(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by CPRIT RP110471 to MCB, WL and SYD. JL received support by a Gigli Family Endowed Scholarship of the UT-Graduate School of Biomedical Sciences at Houston, TX. AKJ was supported by The Laura and John Arnold Foundation and Odyssey Program fellowship. We thank Dr M-C Hung for the Myc-EZH2 plasmid, Dr J-I Park for Flag-EZH2 plasmids and Dr PR Potts for HA-TRIM28, GST-TRIM28 full-length and RBCC only plasmids. This study used the Science Park NGS Core, supported by CPRIT Core Facility Support Grant RP120348, and the Flow Cytometry and Cellular Imaging Facility, which is supported in part by the National Institutes of Health through MD Anderson's Cancer Center Support Grant CA016672.	Addison J, 2014, CANCER RES, V75, P344; Akdemir KC, 2014, NUCLEIC ACIDS RES, V42, P205, DOI 10.1093/nar/gkt866; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Allton K, 2009, P NATL ACAD SCI USA, V106, P11612, DOI 10.1073/pnas.0813177106; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Bhatnagar S, 2014, NATURE, V516, P116, DOI 10.1038/nature13955; Braun P, 2002, P NATL ACAD SCI USA, V99, P2654, DOI 10.1073/pnas.042684199; Cama A, 2013, ACTA NEUROPATHOL, V126, P575, DOI 10.1007/s00401-013-1165-y; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Changchien YC, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-216; Cheung RK, 2011, NAT REV RHEUMATOL, V7, P502, DOI 10.1038/nrrheum.2011.110; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Doyle JM, 2010, MOL CELL, V39, P963, DOI 10.1016/j.molcel.2010.08.029; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Fienberg HG, 2012, CYTOM PART A, V81A, P467, DOI 10.1002/cyto.a.22067; Gonzalez ME, 2014, P NATL ACAD SCI USA, V111, P3098, DOI 10.1073/pnas.1308953111; Hansen KH, 2008, NAT CELL BIOL, V10, P1291, DOI 10.1038/ncb1787; Herquel B, 2011, P NATL ACAD SCI USA, V108, P8212, DOI 10.1073/pnas.1101544108; Hu G, 2009, GENE DEV, V23, P837, DOI 10.1101/gad.1769609; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Iyengar S, 2011, J BIOL CHEM, V286, P26267, DOI 10.1074/jbc.R111.252569; Jung HY, 2013, MOL CELL, V52, P193, DOI 10.1016/j.molcel.2013.08.028; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kim H, 2009, NUCLEIC ACIDS RES, V37, P2940, DOI 10.1093/nar/gkp149; Kim KH, 2015, NAT MED, V21, P1491, DOI 10.1038/nm.3968; Kim W, 2013, NAT CHEM BIOL, V9, P643, DOI [10.1038/NCHEMBIO.1331, 10.1038/nchembio.1331]; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Kryczek I, 2014, IMMUNITY, V40, P772, DOI 10.1016/j.immuni.2014.03.010; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011; Li G, 2010, GENE DEV, V24, P368, DOI 10.1101/gad.1886410; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Li X, 2009, AM J PATHOL, V175, P1246, DOI 10.2353/ajpath.2009.090042; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Margueron R, 2009, NATURE, V461, P762, DOI 10.1038/nature08398; Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Montgomery ND, 2005, CURR BIOL, V15, P942, DOI 10.1016/j.cub.2005.04.051; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Pasini D, 2010, NATURE, V464, P306, DOI 10.1038/nature08788; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Qi W, 2012, P NATL ACAD SCI USA, V109, P21360, DOI 10.1073/pnas.1210371110; Quenneville S, 2011, MOL CELL, V44, P361, DOI 10.1016/j.molcel.2011.08.032; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rowe HM, 2013, GENOME RES, V23, P452, DOI 10.1101/gr.147678.112; Sarma K, 2014, CELL, V159, P869, DOI 10.1016/j.cell.2014.10.019; Seki Y, 2010, P NATL ACAD SCI USA, V107, P10926, DOI 10.1073/pnas.0907601107; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07; Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Tsai WW, 2010, NATURE, V468, P927, DOI 10.1038/nature09542; Wolf D, 2007, CELL, V131, P46, DOI 10.1016/j.cell.2007.07.026; Wu RC, 2014, ELECTRON J QUAL THEO, P1; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110	66	34	34	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					2991	3001		10.1038/onc.2016.453	http://dx.doi.org/10.1038/onc.2016.453			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	28068325	Green Accepted			2022-12-17	WOS:000402000400007
J	Wilson, C; Qiu, L; Hong, Y; Karnik, T; Tadros, G; Mau, B; Ma, T; Mu, Y; New, J; Louie, RJ; Gunewardena, S; Godwin, AK; Tawfik, OW; Chien, J; Roby, KF; Krieg, AJ				Wilson, C.; Qiu, L.; Hong, Y.; Karnik, T.; Tadros, G.; Mau, B.; Ma, T.; Mu, Y.; New, J.; Louie, R. J.; Gunewardena, S.; Godwin, A. K.; Tawfik, O. W.; Chien, J.; Roby, K. F.; Krieg, A. J.			The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer	ONCOGENE			English	Article							LYSINE DEMETHYLASE; GENE-EXPRESSION; GROWTH-FACTOR; COPY GAIN; HYPOXIA; METASTASIS; TARGET; JMJD2B; CELLS; METHYLATION	Epithelial ovarian cancer (EOC) has poor prognosis and rapid recurrence because of widespread dissemination of peritoneal metastases at diagnosis. Multiple pathways contribute to the aggressiveness of ovarian cancer, including hypoxic signaling mechanisms. In this study, we have determined that the hypoxia-inducible histone demethylase KDM4B is expressed in similar to 60% of EOC tumors assayed, including primary and matched metastatic tumors. Expression of KDM4B in tumors is positively correlated with expression of the tumor hypoxia marker CA-IX, and is robustly induced in EOC cell lines exposed to hypoxia. KDM4B regulates expression of metastatic genes and pathways, and loss of KDM4B increases H3K9 trimethylation at the promoters of target genes like LOXL2, LCN2 and PDGFB. Suppressing KDM4B inhibits ovarian cancer cell invasion, migration and spheroid formation in vitro. KDM4B also regulates seeding and growth of peritoneal tumors in vivo, where its expression corresponds to hypoxic regions. This is the first demonstration that a Jumonji-domain histone demethylase regulates cellular processes required for peritoneal dissemination of cancer cells, one of the predominant factors affecting prognosis of EOC. The pathways regulated by KDM4B may present novel opportunities to develop combinatorial therapies to improve existing therapies for EOC patients.	[Wilson, C.; Qiu, L.; Hong, Y.; Mu, Y.; Krieg, A. J.] Univ Kansas, Med Ctr, Dept Obstet & Gynecol, Kansas City, KS 66103 USA; [Wilson, C.; Qiu, L.; Karnik, T.; Tadros, G.; Mau, B.; Ma, T.; Godwin, A. K.; Tawfik, O. W.; Krieg, A. J.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA; [New, J.] Univ Kansas, Med Ctr, Med Scholars Program, Kansas City, KS 66103 USA; [Louie, R. J.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA; [Gunewardena, S.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66103 USA; [Chien, J.] Univ Kansas, Med Ctr, Dept Canc Biol, Kansas City, KS 66103 USA; [Roby, K. F.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66103 USA; [Krieg, A. J.] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of California System; University of California San Francisco; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; Oregon Health & Science University	Krieg, AJ (corresponding author), Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Div Reprod & Dev Sci, Oregon Natl Primate Res Ctr, 505 NW 185th Ave,Mail Stop L584, Beaverton, OR 97006 USA.	kriega@ohsu.edu	Chien, Jeremy/AID-8939-2022	Krieg, Adam/0000-0002-3069-0378; New, Jacob/0000-0003-0707-9324; Chien, Jeremy/0000-0003-4744-8374	Institutional Development Award (IDeA) [P20GM104936]; American Cancer Society Institutional Research Grant [ACS IRG-09-062-04]; KUMC Department of OB/GYN start-up funds; KU Cancer Center's Cancer Center Support Grant [P30 CA168524]; NATIONAL CANCER INSTITUTE [P30CA168524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM104936] Funding Source: NIH RePORTER	Institutional Development Award (IDeA); American Cancer Society Institutional Research Grant(American Cancer Society); KUMC Department of OB/GYN start-up funds; KU Cancer Center's Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Research was supported by an Institutional Development Award (IDeA) P20GM104936 (to AJK and SG), an American Cancer Society Institutional Research Grant ACS IRG-09-062-04 (to AJK) and KUMC Department of OB/GYN start-up funds (to AJK). We thank the staff of the University of Kansas Cancer Center's Biospecimen Repository Core Facility staff for specimen collection (Colleen Reilly and Zaid Naima) and for excellent histological assistance in the creation of the TMAs (Dr Rashna Madan and Tara Meyer). We acknowledge the KU Cancer Center's Cancer Center Support Grant (P30 CA168524 to AJK, AKG, JC, KFR). Special appreciation is given to Dr Denise A Chan (UCSF), whose untimely passing in 2014 prevents inclusion as a co-author.	ACS, 2015, AM CANC SOC CANC FAC; Agger K, 2016, GENE DEV, V30, P1278, DOI 10.1101/gad.280495.116; Apte SM, 2004, GYNECOL ONCOL, V93, P78, DOI 10.1016/j.ygyno.2003.12.041; Barker HE, 2011, FUTURE ONCOL, V7, P707, DOI [10.2217/FON.11.46, 10.2217/fon.11.46]; Barker HE, 2011, CANCER RES, V71, P1561, DOI 10.1158/0008-5472.CAN-10-2868; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008-5472.CAN-12-4300; Beyer S, 2008, J BIOL CHEM, V283, P36542, DOI 10.1074/jbc.M804578200; Birner P, 2001, CLIN CANCER RES, V7, P1661; Black JC, 2015, GENE DEV, V29, P1018, DOI 10.1101/gad.259796.115; Black JC, 2013, CELL, V154, P541, DOI 10.1016/j.cell.2013.06.051; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Chi JT, 2006, PLOS MED, V3, P395, DOI 10.1371/journal.pmed.0030047; Coffey K, 2013, NUCLEIC ACIDS RES, V41, P4433, DOI 10.1093/nar/gkt106; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Goode EL, 2011, CANCER EPIDEM BIOMAR, V20, P1638, DOI 10.1158/1055-9965.EPI-11-0455; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Hojfeldt JW, 2013, NAT REV DRUG DISCOV, V12, P917, DOI 10.1038/nrd4154; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Iwamori N, 2011, BIOL REPROD, V84, P1225, DOI 10.1095/biolreprod.110.088955; Joberty G, 2016, ACS CHEM BIOL, V11, P2002, DOI 10.1021/acschembio.6b00080; Krieg AJ, 2010, MOL CELL BIOL, V30, P344, DOI 10.1128/MCB.00444-09; Kruidenier L, 2012, NATURE, V488, P404, DOI 10.1038/nature11262; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lu CH, 2010, CANCER BIOL THER, V9, P176, DOI 10.4161/cbt.9.3.10635; Maes C, 2012, NAT REV RHEUMATOL, V8, P358, DOI 10.1038/nrrheum.2012.36; Maes T, 2015, CURR OPIN PHARMACOL, V23, P52, DOI 10.1016/j.coph.2015.05.009; Mallette FA, 2012, EMBO J, V31, P1865, DOI 10.1038/emboj.2012.47; Mosammaparast N, 2010, ANNU REV BIOCHEM, V79, P155, DOI 10.1146/annurev.biochem.78.070907.103946; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Pack LR, 2016, J BIOL CHEM, V291, P6060, DOI 10.1074/jbc.M115.696864; Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238; Rai G., 2010, PROBE REPORTS NIH MO; Rankin EB, 2010, CANCER RES, V70, P7570, DOI 10.1158/0008-5472.CAN-10-1267; Sanchez-Fernandez EM, 2013, BIOCHEM J, V449, P491, DOI 10.1042/BJ20121155; Santin AD, 2004, INT J CANCER, V112, P14, DOI 10.1002/ijc.20408; Schito L, 2012, P NATL ACAD SCI USA, V109, pE2707, DOI 10.1073/pnas.1214019109; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108; Swenson-Fields KI, 2013, KIDNEY INT, V83, P855, DOI 10.1038/ki.2012.446; Thalhammer A, 2011, ORG BIOMOL CHEM, V9, P127, DOI 10.1039/c0ob00592d; Vang R, 2009, ADV ANAT PATHOL, V16, P267, DOI 10.1097/PAP.0b013e3181b4fffa; Vinci M, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-29; Welford SM, 2006, GENE DEV, V20, P3366, DOI 10.1101/gad.1471106; Wellmann S, 2008, BIOCHEM BIOPH RES CO, V372, P892, DOI 10.1016/j.bbrc.2008.05.150; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Xia XB, 2009, P NATL ACAD SCI USA, V106, P4260, DOI 10.1073/pnas.0810067106; Yang J, 2010, CANCER RES, V70, P6456, DOI 10.1158/0008-5472.CAN-10-0413; Yoneda J, 1998, JNCI-J NATL CANCER I, V90, P447, DOI 10.1093/jnci/90.6.447; Young LC, 2013, J BIOL CHEM, V288, P21376, DOI 10.1074/jbc.M113.491514; Zhao L, 2013, CLIN CANCER RES, V19, P6419, DOI 10.1158/1078-0432.CCR-13-0254	52	34	34	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2565	2576		10.1038/onc.2016.412	http://dx.doi.org/10.1038/onc.2016.412			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27869162	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000400597300007
J	Lu, W; Liu, S; Li, B; Xie, Y; Izban, MG; Ballard, BR; Sathyanarayana, SA; Adunyah, SE; Matusik, RJ; Chen, Z				Lu, W.; Liu, S.; Li, B.; Xie, Y.; Izban, M. G.; Ballard, B. R.; Sathyanarayana, S. A.; Adunyah, S. E.; Matusik, R. J.; Chen, Z.			SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer	ONCOGENE			English	Article							ANDROGEN RECEPTOR; MEDIATED DEGRADATION; CELLULAR SENESCENCE; PROTEIN STABILITY; GENE-EXPRESSION; DOWN-REGULATION; LIGASE; POLYCOMB; COMPLEX; KINASE	EZH2 is crucial for the progression of prostate cancer (PCa) and castration-resistant prostate cancer (CRPC) through upregulation and activation of progenitor genes, as well as androgen receptor (AR)-target genes. However, the mechanisms by which EZH2 is regulated in PCa and CRPC remain elusive. Here we report that EZH2 is post-transcriptionally regulated by SKP2 in vitro in cultured cells and in vivo in mouse models. We observed aberrant upregulation of Skp2, Ezh2 and histone H3 lysine 27 trimethylation (H3K27me3) in both Pten null mouse embryonic fibroblasts (MEFs) and Pten null mouse prostate tissues. Loss of Skp2 resulted in a striking decrease of Ezh2 levels in Pten/Trp53 double-null MEFs and in prostate tumors of Pten/Trp53 double-null mutant mice. SKP2 knockdown decreased EZH2 levels in human PCa cells through upregulation of TRAF6-mediated and lysine(K) 63-linked ubiquitination of EZH2 for degradation. Ectopic expression of TRAF6 promoted the K63-linked ubiquitination of EZH2 to decrease EZH2 and H3K27me3 levels in PCa cells. In contrast, TRAF6 knockdown resulted in a reduced EZH2 ubiquitination with an increase of EZH2 and H3K27me3 levels in PCa cells. Furthermore, the catalytically dead mutant TRAF6 C70A abolished the TRAF6-mediated polyubiquitination of recombinant human EZH2 in vitro. Most importantly, a concurrent elevation of Skp2 and Ezh2 was found in CRPC tumors of Pten/Trp53 mutant mice, and expression levels of SKP2 and EZH2 were positively correlated in human PCa specimens. Taken together, our findings revealed a novel mechanism on EZH2 ubiquitination and an important signaling network of SKP2-TRAF6-EZH2/H3K27me3, and targeting SKP2-EZH2 pathway may be a promising therapeutic strategy for CRPC treatment.	[Lu, W.; Liu, S.; Li, B.; Adunyah, S. E.; Chen, Z.] Meharry Med Coll, Dept Biochem & Canc Biol, 1005 Dr DB Todd Jr Blvd, Nashville, TN 37208 USA; [Xie, Y.] Nazarbayev Univ, Sch Sci & Technol, Dept Biol, Astana, Kazakhstan; [Izban, M. G.; Ballard, B. R.] Meharry Med Coll, Dept Pathol Anat & Cell Biol, Nashville, TN 37208 USA; [Sathyanarayana, S. A.] Meharry Med Coll, Dept Surg, Nashville, TN 37208 USA; [Matusik, R. J.] Vanderbilt Univ, Sch Med, Dept Urol Surg, Nashville, TN 37212 USA	Meharry Medical College; Nazarbayev University; Meharry Medical College; Meharry Medical College; Vanderbilt University	Chen, Z (corresponding author), Meharry Med Coll, Dept Biochem & Canc Biol, 1005 Dr DB Todd Jr Blvd, Nashville, TN 37208 USA.	zchen@mmc.edu		Matusik, Robert/0000-0003-2057-9892	NIH [MD004038, DK055748, CA163069, MD007593, MD007586, DA036420, S10RR0254970, UL1TR000445-06]; National Institute on Minority Health and Health Disparities [U54MD007593, G12MD007586, R01MD004038] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	We would like to thank Dr Jae-Il Park for Flag-EZH2 plasmid, Dr Paul Bates and Dr Zhaocai (Joe) Zhou for Myc-TRAF6 and Myc-TRAF6-C70A plasmids, Dr Edward W. Harhaj for ubiquitin and ubiquitin mutant plasmids, and Dr Hui-Kuan Lin for GST, GST-TRAF6 and GST-TRAF6-C70A plasmids. HA-tagged EZH2 is a gift from Kristian Helin (Addgene plasmid # 24230).<SUP>54</SUP> This work was supported in part by NIH grants MD004038, DK055748, CA163069, MD007593 and UL1TR000445-06. Human tissue staining, microscopy experiments and data analysis were performed through the Human Tissue & Pathology Core and Morphology Core of Meharry Medical College, supported in part by NIH grants MD007593, MD007586, DA036420 and S10RR0254970.	Bhatt KV, 2007, ONCOGENE, V26, P1056, DOI 10.1038/sj.onc.1209861; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chan CH, 2013, CELL, V154, P556, DOI 10.1016/j.cell.2013.06.048; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Chu CS, 2014, P NATL ACAD SCI USA, V111, P1355, DOI 10.1073/pnas.1323226111; Cocka LJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002931; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; Duncan LM, 2006, EMBO J, V25, P1635, DOI 10.1038/sj.emboj.7601056; Ellinger J, 2012, CANCER INVEST, V30, P92, DOI 10.3109/07357907.2011.636117; Ferreira JV, 2015, SCI REP-UK, V5, DOI 10.1038/srep10210; Gao DM, 2010, MOL CELL, V39, P797, DOI 10.1016/j.molcel.2010.08.016; Gao DM, 2009, NAT CELL BIOL, V11, P397, DOI 10.1038/ncb1847; Huang FT, 2013, P NATL ACAD SCI USA, V110, P15722, DOI 10.1073/pnas.1308014110; Jiao S, 2015, NAT IMMUNOL, V16, P246, DOI 10.1038/ni.3097; Jung HY, 2013, MOL CELL, V52, P193, DOI 10.1016/j.molcel.2013.08.028; Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Li B, 2014, PROSTATE, V74, P421, DOI 10.1002/pros.22763; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Lin TY, 2012, ONCOGENE, V31, P3287, DOI 10.1038/onc.2011.491; Lu WF, 2015, ONCOTARGET, V6, P771, DOI 10.18632/oncotarget.2718; Lu WF, 2013, MOL ENDOCRINOL, V27, P635, DOI 10.1210/me.2012-1294; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Ngollo M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-994; Qi JF, 2013, CANCER CELL, V23, P332, DOI 10.1016/j.ccr.2013.02.016; Sahasrabuddhe AA, 2015, ONCOGENE, V34, P445, DOI 10.1038/onc.2013.571; Shembade N, 2010, SCIENCE, V327, P1135, DOI 10.1126/science.1182364; Shen Z, 2013, BBA-MOL CELL RES, V1833, P2190, DOI 10.1016/j.bbamcr.2013.05.014; Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531; Sugeno N, 2014, J BIOL CHEM, V289, P18137, DOI 10.1074/jbc.M113.529461; Valdes-Mora F, 2015, ONCOGENE, V34, P1609, DOI 10.1038/onc.2014.111; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang ZW, 2012, BBA-REV CANCER, V1825, P11, DOI 10.1016/j.bbcan.2011.09.002; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yamaguchi H, 2014, CANCER RES TREAT, V46, P209, DOI 10.4143/crt.2014.46.3.209; Yang G, 2002, CLIN CANCER RES, V8, P3419; Yang WL, 2010, ONCOGENE, V29, P4493, DOI 10.1038/onc.2010.190; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Yu YL, 2013, EMBO MOL MED, V5, P531, DOI 10.1002/emmm.201201783; Zhang L, 2013, J LIPID RES, V54, P1410, DOI 10.1194/jlr.M035774; Zoabi M, 2011, BIOCHEM BIOPH RES CO, V408, P393, DOI 10.1016/j.bbrc.2011.04.025	54	34	37	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1364	1373		10.1038/onc.2016.300	http://dx.doi.org/10.1038/onc.2016.300			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27869166	Green Accepted			2022-12-17	WOS:000395862500005
J	Seviour, EG; Sehgal, V; Mishra, D; Rupaimoole, R; Rodriguez-Aguayo, C; Lopez-Berestein, G; Lee, JS; Sood, AK; Kim, MP; Mills, GB; Ram, PT				Seviour, E. G.; Sehgal, V.; Mishra, D.; Rupaimoole, R.; Rodriguez-Aguayo, C.; Lopez-Berestein, G.; Lee, J-S; Sood, A. K.; Kim, M. P.; Mills, G. B.; Ram, P. T.			Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p	ONCOGENE			English	Article							LUNG-CANCER; DNA METHYLATION; K-RAS; EXPRESSION; PATHWAYS; YAP	KRas is mutated in a significant number of human cancers and so there is an urgent therapeutic need to target KRas signalling. To target KRas in lung cancers we used a systems approach of integrating a genome-wide miRNA screen with patient-derived phospho-proteomic signatures of the KRas downstream pathway, and identified miR-193a-3p, which directly targets KRas. Unique aspects of miR-193a-3p biology include two functionally independent target sites in the KRas 3' UTR and clinically significant correlation between miR-193a-3p and KRas expression in patients. Rescue experiments with mutated KRas 3' UTR showed very significantly that the anti-tumour effect of miR-193a-3p is via specific direct targeting of KRas and not due to other targets. Ex vivo and in vivo studies utilizing nanoliposome packaged miR-193a-3p demonstrated significant inhibition of tumour growth, circulating tumour cell viability and decreased metastasis. These studies show the broader applicability of using miR-193a-3p as a therapeutic agent to target KRas-mutant cancer.	[Seviour, E. G.; Sehgal, V.; Lee, J-S; Mills, G. B.; Ram, P. T.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Mishra, D.; Kim, M. P.] Methodist Hosp, Res Inst, 6535 Fannin, Houston, TX 77030 USA; [Rupaimoole, R.; Sood, A. K.] UTMDACC, Dept Gynecol Oncol, Houston, TX USA; [Rodriguez-Aguayo, C.; Lopez-Berestein, G.] UTMDACC, Dept Expt Therapeut, Houston, TX USA; [Lopez-Berestein, G.; Lee, J-S; Sood, A. K.; Ram, P. T.] UTMDACC, Ctr RNA Interference & Noncoding RNA, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; The Methodist Hospital System; The Methodist Hospital - Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Ram, PT (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	pram@mdanderson.org	Sood, Anoop Kumar/A-7344-2013	Sood, Anoop Kumar/0000-0001-5702-4108; Mishra, Dhruva/0000-0001-8651-005X; Mills, Gordon/0000-0002-0144-9614; RODRIGUEZ-AGUAYO, CRISTIAN/0000-0002-7880-7723; Ram, Prahlad/0000-0003-4739-3166	NIH/NCI ICBP [U54-CA112970]; CCBTP training grant from the CPRIT; NIH [UH2 TR000943]; RGK Foundation; CPRIT [RP110595]; NATIONAL CANCER INSTITUTE [P30CA016672, U54CA112970] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UH2TR000943] Funding Source: NIH RePORTER	NIH/NCI ICBP; CCBTP training grant from the CPRIT; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RGK Foundation; CPRIT; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	All the data reported in the paper are presented. The microarray data are available from GEO under the accession number GSE73194. The work presented here was funded by NIH/NCI ICBP grant U54-CA112970 (Project 2 PI-JWG, Project 4 Co-PI's PTR and GBM), VS was funded by the CCBTP training grant from the CPRIT, and grants from the NIH (UH2 TR000943), the RGK Foundation, and CPRIT RP110595 (AKS).	Agarwal A, 2008, LEUKEMIA, V22, P2269, DOI 10.1038/leu.2008.124; Akbani R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4887; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; BOS JL, 1989, CANCER RES, V49, P4682; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; DER CJ, 1983, CELL, V32, P201, DOI 10.1016/0092-8674(83)90510-X; Grana TM, 2002, CANCER RES, V62, P4142; Grechukhina O, 2012, EMBO MOL MED, V4, P206, DOI 10.1002/emmm.201100200; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Heller G, 2012, CLIN CANCER RES, V18, P1619, DOI 10.1158/1078-0432.CCR-11-2450; Hong X, 2014, EMBO J, V33, P2447, DOI 10.15252/embj.201489385; Iliopoulos D, 2011, CANCER RES, V71, P5144, DOI 10.1158/0008-5472.CAN-11-0425; Jancik S, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/150960; Jiao LR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032068; Kalinichenko VV, 2015, EXPERT OPIN THER TAR, V19, P865, DOI 10.1517/14728222.2015.1042366; Katzel JA, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-2; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Komurov K, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-282; Komurov K, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000889; Li CX, 2006, CELL CYCLE, V5, P2103, DOI 10.4161/cc.5.18.3192; Li J, 2013, NAT METHODS, V10, P1046, DOI [10.1038/nmeth.2650, 10.1038/NMETH.2650]; Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906; Lv L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.367; Mishra DK, 2015, ANN THORAC SURG, V99, P1149, DOI 10.1016/j.athoracsur.2014.08.085; Mishra DK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045308; Mishra DK, 2012, ANN THORAC SURG, V93, P1075, DOI 10.1016/j.athoracsur.2012.01.011; Moss TJ, 2015, NPJ SYST BIOL APPL, V1, DOI 10.1038/npjsba.2015.1; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Rosell R, 1995, SEMIN ONCOL, V22, P12; Seviour EG, 2016, ONCOGENE, V35, P801, DOI 10.1038/onc.2015.177; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Uberall I, 2008, EXP MOL PATHOL, V84, P79, DOI 10.1016/j.yexmp.2007.12.002; Wu SY, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008362; Yang JH, 2011, NUCLEIC ACIDS RES, V39, pD202, DOI 10.1093/nar/gkq1056; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049	36	34	34	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1339	1350		10.1038/onc.2016.308	http://dx.doi.org/10.1038/onc.2016.308			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27669434	Green Accepted			2022-12-17	WOS:000395862500003
J	Kondo, S; Wakae, K; Wakisaka, N; Nakanishi, Y; Ishikawa, K; Komori, T; Moriyama-Kita, M; Endo, K; Murono, S; Wang, Z; Kitamura, K; Nishiyama, T; Yamaguchi, K; Shigenobu, S; Muramatsu, M; Yoshizaki, T				Kondo, S.; Wakae, K.; Wakisaka, N.; Nakanishi, Y.; Ishikawa, K.; Komori, T.; Moriyama-Kita, M.; Endo, K.; Murono, S.; Wang, Z.; Kitamura, K.; Nishiyama, T.; Yamaguchi, K.; Shigenobu, S.; Muramatsu, M.; Yoshizaki, T.			APOBEC3A associates with human papillomavirus genome integration in oropharyngeal cancers	ONCOGENE			English	Article							SIMPLEX-VIRUS 1; MUTATIONAL PROCESSES; CYTIDINE DEAMINASES; DNA; HYPERMUTATION; EXPRESSION; PATTERNS; TYPE-16; HEAD; RESTRICTION	The prevalence of human papillomavirus (HPV)-related oropharyngeal cancers has been increasing in developed countries. We recently demonstrated that members of the apolipoprotein B mRNA-editing catalytic polypeptide 3 (APOBEC3, A3) family, which are antiviral factors, can induce hypermutation of HPV DNA in vitro. In the present study, we found numerous C-to-T and G-to-A hypermutations in the HPV16 genome in oropharyngeal cancer (OPC) biopsy samples using differential DNA denaturation PCR and next-generation sequencing. A3s were more abundantly expressed in HPV16-positive OPCs than in HPV-negative, as assessed using immunohistochemistry and reverse transcription quantitative PCR. In addition, interferons upregulated A3s in an HPV16-positive OPC cell line. Furthermore, quantitative PCR analysis of HPV DNA suggests that APOBEC3A (A3A) expression is strongly correlated with the integration of HPV DNA. These results suggest that HPV16 infection may upregulate A3A expression, thereby increasing the chance of viral DNA integration. The role of A3A in HPV-induced carcinogenesis is discussed.	[Kondo, S.; Wakisaka, N.; Nakanishi, Y.; Ishikawa, K.; Komori, T.; Moriyama-Kita, M.; Endo, K.; Murono, S.; Yoshizaki, T.] Kanazawa Univ, Grad Sch Med Sci, Div Otolaryngol Head & Neck Surg, 13-1 Takara Machi, Kanazawa, Ishikawa 9208640, Japan; [Wakae, K.; Wang, Z.; Kitamura, K.; Muramatsu, M.] Kanazawa Univ, Grad Sch Med Sci, Dept Mol Genet, Kanazawa, Ishikawa, Japan; [Wang, Z.] Dalian Univ, Affiliated Zhongshan Hosp, Div Med Oncol, Dalian, Peoples R China; [Nishiyama, T.] Kanazawa Univ, Adv Sci Res Ctr, Kanazawa, Ishikawa, Japan; [Yamaguchi, K.; Shigenobu, S.] Natl Inst Basic Biol, Funct Genom Facil, Okazaki, Aichi, Japan	Kanazawa University; Kanazawa University; Dalian University; Kanazawa University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Kondo, S (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Div Otolaryngol Head & Neck Surg, 13-1 Takara Machi, Kanazawa, Ishikawa 9208640, Japan.	tomoy@med.kanazawa-u.ac.jp	Kitamura, Kouichi/L-3654-2015; Shigenobu, Shuji/B-6239-2011	Kitamura, Kouichi/0000-0001-9692-8724; Yamaguchi, Katsushi/0000-0001-6871-7882; Shigenobu, Shuji/0000-0003-4640-2323	Ministry of Education, Science, Sports, Culture and Technology of Japan [A24689064, B23390396]; Grants-in-Aid for Scientific Research [26460993] Funding Source: KAKEN	Ministry of Education, Science, Sports, Culture and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr H Joenje for providing the VU147T cell line. We thank Dr P Howley for providing p1203 PML2d HPV16 and p1321-HPV16 E6/E7. The authors would like to thank Ms A Akita and Ms M Koura for technical assistance. This study was supported by research grants from the Ministry of Education, Science, Sports, Culture and Technology of Japan (A24689064 for SK and B23390396 for TY).	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; [Anonymous], 2007, HUMAN PAPILLOMAVIRUS; Argyris EG, 2007, VIROLOGY, V367, P440, DOI 10.1016/j.virol.2007.06.010; Bodily J, 2011, TRENDS MICROBIOL, V19, P33, DOI 10.1016/j.tim.2010.10.002; Bonvin M, 2006, HEPATOLOGY, V43, P1364, DOI 10.1002/hep.21187; Bulliard Y, 2011, J VIROL, V85, P1765, DOI 10.1128/JVI.01651-10; Burns MB, 2013, NAT GENET, V45, P977, DOI 10.1038/ng.2701; Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881; Chaturvedi AK, 2013, J CLIN ONCOL, V31, P4550, DOI 10.1200/JCO.2013.50.3870; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Edge SB, 2009, CANC STAGING MANUAL; Gee P, 2011, J VIROL, V85, P9726, DOI 10.1128/JVI.05288-11; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Goila-Gaur R, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-51; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Harris RS, 2004, NAT REV IMMUNOL, V4, P868, DOI 10.1038/nri1489; Henderson S, 2014, CELL REP, V7, P1833, DOI 10.1016/j.celrep.2014.05.012; Hoopes JI, 2016, CELL REP, V14, P1273, DOI 10.1016/j.celrep.2016.01.021; Kim SH, 2007, INT J CANCER, V120, P1418, DOI 10.1002/ijc.22464; Kitamura K, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003361; Kondo S, 2011, J VIROL, V85, P11255, DOI 10.1128/JVI.00188-11; Koning FA, 2009, J VIROL, V83, P9474, DOI 10.1128/JVI.01089-09; Krokan HE, 2014, DNA REPAIR, V19, P38, DOI 10.1016/j.dnarep.2014.03.028; Landry S, 2011, EMBO REP, V12, P444, DOI 10.1038/embor.2011.46; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Liang GX, 2013, P NATL ACAD SCI USA, V110, P2246, DOI 10.1073/pnas.1221921110; Malim MH, 2009, PHILOS T R SOC B, V364, P675, DOI 10.1098/rstb.2008.0185; Mork J, 2001, NEW ENGL J MED, V344, P1125, DOI 10.1056/NEJM200104123441503; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Mussil B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073641; Nagao S, 2002, J CLIN MICROBIOL, V40, P863, DOI 10.1128/JCM.40.3.863-867.2002; Nakanishi Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062066; Nguyen DH, 2008, J VIROL, V82, P6852, DOI 10.1128/JVI.00465-08; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Noguchi C, 2007, J GEN VIROL, V88, P432, DOI 10.1099/vir.0.82319-0; Ohba K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097787; Okeoma CM, 2007, NATURE, V445, P927, DOI 10.1038/nature05540; Park IS, 2011, CANCER PREV RES, V4, P207, DOI 10.1158/1940-6207.CAPR-10-0147; Pett M, 2007, J PATHOL, V212, P356, DOI 10.1002/path.2192; Roberts I, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-57; Roberts SA, 2014, NAT REV CANCER, V14, P786, DOI 10.1038/nrc3816; Roberts SA, 2013, NAT GENET, V45, P970, DOI 10.1038/ng.2702; STEENBERGEN RDM, 1995, CANCER RES, V55, P5465; Stenglein MD, 2010, NAT STRUCT MOL BIOL, V17, P222, DOI 10.1038/nsmb.1744; Suspene R, 2005, P NATL ACAD SCI USA, V102, P8321, DOI 10.1073/pnas.0408223102; Suspene R, 2005, J GEN VIROL, V86, P125, DOI 10.1099/vir.0.80426-0; Suspene R, 2011, J VIROL, V85, P7594, DOI 10.1128/JVI.00290-11; Taylor BJM, 2013, ELIFE, V2, DOI 10.7554/eLife.00534; Vartanian JP, 2008, SCIENCE, V320, P230, DOI 10.1126/science.1153201; Wang Z, 2014, J VIROL, V88, P1308, DOI 10.1128/JVI.03091-13; Warren CJ, 2015, J VIROL, V89, P688, DOI 10.1128/JVI.02383-14; Wilczynski SP, 1998, AM J PATHOL, V152, P145; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	53	34	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1687	1697		10.1038/onc.2016.335	http://dx.doi.org/10.1038/onc.2016.335			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27694899				2022-12-17	WOS:000397460600008
J	Izrailit, J; Jaiswal, A; Zheng, W; Moran, MF; Reedijk, M				Izrailit, J.; Jaiswal, A.; Zheng, W.; Moran, M. F.; Reedijk, M.			Cellular stress induces TRB3/USP9x-dependent Notch activation in cancer	ONCOGENE			English	Article							E3 UBIQUITIN LIGASE; BREAST-CANCER; POOR-PROGNOSIS; BETA-CATENIN; MIND BOMB; ER STRESS; TRB3; PROTEIN; ENDOCYTOSIS; DEGRADATION	Expression of the Notch ligand JAG1 and Notch pathway activation promote poor prognosis, basal-like breast cancer. We have recently shown that the pseudokinase Tribbles homolog 3 (TRB3) regulates JAG1 expression in this malignancy. TRB3 is a stress and metabolic sensor, and here we show that nutrient deprivation or endoplasmic reticulum stress markedly upregulate TRB3, which serves as a scaffold for the deubiquitinase USP9x. USP9x in turn stimulates JAG1 activity through two mechanisms: (1) through TRB3 deubiquitination and stabilization, and (2) through deubiquitination and activation of Mind Bomb 1, an E3 ligase required for JAG1 ubiquitination-mediated endocytosis and Notch activation. These USP9x activities are confined to the signal-sending cell of a cell pair undergoing Notch signaling. We demonstrate that USP9x is required for TRB3 upregulation and Notch activation in response to cellular stress in basal-like breast cancer cells. These data suggest that TRB3 functions as a sensor of tumor microenvironmental stress and together with USP9x induces the cell survival and tumor-promoting activities of Notch. These findings identify a novel mechanism by which cancer cells survive in their hostile environment and provide potential therapeutic targets in breast cancer.	[Izrailit, J.; Jaiswal, A.; Zheng, W.; Reedijk, M.] Ontario Canc Inst, Campbell Family Inst Canc Res, Toronto, ON, Canada; [Izrailit, J.; Jaiswal, A.; Reedijk, M.] Univ Toronto, Princess Margaret Hosp, Ontario Canc Inst, Dept Med Biophys, Toronto, ON, Canada; [Moran, M. F.] Hosp Sick Children, Program Mol Struct & Funct, Toronto, ON, Canada; [Moran, M. F.] Univ Toronto, Dept Med Genet, Toronto, ON, Canada; [Reedijk, M.] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Surg Oncol, 610 Univ Ave,Suite 3-130, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Reedijk, M (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Dept Surg Oncol, 610 Univ Ave,Suite 3-130, Toronto, ON M5G 2M9, Canada.	michael.reedijk@uhn.ca	Moran, Michael/GYD-3631-2022		Canadian Breast Cancer Foundation; Ontario Ministry of Health and Long Term Care	Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Ontario Ministry of Health and Long Term Care(Ministry of Health and Long-Term Care, Ontario)	This study was supported by funds to MR from the Canadian Breast Cancer Foundation. This research was funded in part by the Ontario Ministry of Health and Long Term Care. The views expressed do not necessarily reflect those of the OMOHLTC. We thank J Tong for technical support, and B Martin and P Taylor for bioinformatic support.	Ackerman D, 2014, TRENDS CELL BIOL, V24, P472, DOI 10.1016/j.tcb.2014.06.001; Bowers AJ, 2003, ONCOGENE, V22, P2823, DOI 10.1038/sj.onc.1206367; Choe EA, 2007, J NEUROSCI, V27, P9503, DOI 10.1523/JNEUROSCI.1408-07.2007; Dobens LL, 2012, DEV DYNAM, V241, P1239, DOI 10.1002/dvdy.23822; Du KY, 2009, MOL ENDOCRINOL, V23, P475, DOI 10.1210/me.2008-0284; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Hansson EM, 2010, J CELL SCI, V123, P2931, DOI 10.1242/jcs.073239; Harris DR, 2012, CANCER BIOL THER, V13, P1319, DOI 10.4161/cbt.21792; Hua F, 2011, J CELL SCI, V124, P3235, DOI 10.1242/jcs.082875; Irshad K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118201; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Izrailit J, 2013, P NATL ACAD SCI USA, V110, P1714, DOI 10.1073/pnas.1214014110; Jin YJ, 2002, J BIOL CHEM, V277, P46980, DOI 10.1074/jbc.M208585200; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Koo BK, 2005, DEVELOPMENT, V132, P3459, DOI 10.1242/dev.01922; Koritzinsky M, 2013, J CELL BIOL, V203, P615, DOI 10.1083/jcb.201307185; Lai EC, 2001, DEV CELL, V1, P783, DOI 10.1016/S1534-5807(01)00092-2; Li D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00254; Li ST, 2011, IMMUNITY, V35, P426, DOI 10.1016/j.immuni.2011.06.014; Lohan F, 2013, BIOCHEM SOC T, V41, P1096, DOI 10.1042/BST20130105; Meloty-Kapella L, 2012, DEV CELL, V22, P1299, DOI 10.1016/j.devcel.2012.04.005; Mouchantaf R, 2006, J BIOL CHEM, V281, P38738, DOI 10.1074/jbc.M605959200; Murray RZ, 2004, MOL BIOL CELL, V15, P1591, DOI 10.1091/mbc.E03-08-0630; Nagelkerke A, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3373; Nichols JT, 2007, J CELL BIOL, V176, P445, DOI 10.1083/jcb.200609014; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Ord D, 2007, EXP CELL RES, V313, P3556, DOI 10.1016/j.yexcr.2007.07.017; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Ohoka N, 2010, BIOCHEM BIOPH RES CO, V392, P289, DOI 10.1016/j.bbrc.2009.12.175; Ossipova O, 2009, DEV CELL, V17, P222, DOI 10.1016/j.devcel.2009.06.010; Overstreet E, 2004, DEVELOPMENT, V131, P5355, DOI 10.1242/dev.01434; Pal A, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0461-3; Parks AL, 2000, DEVELOPMENT, V127, P1373; Qi L, 2006, SCIENCE, V312, P1763, DOI 10.1126/science.1123374; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Reedijk M, 2008, BREAST CANCER RES TR, V111, P439, DOI 10.1007/s10549-007-9805-3; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Schwarzer R, 2006, CELL SIGNAL, V18, P899, DOI 10.1016/j.cellsig.2005.08.002; Taya S, 1999, GENES CELLS, V4, P757, DOI 10.1046/j.1365-2443.1999.00297.x; Tong JF, 2014, MOL CELL PROTEOMICS, V13, P1644, DOI 10.1074/mcp.M114.038596; Tseng LC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093394; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vara D, 2011, CELL DEATH DIFFER, V18, P1099, DOI 10.1038/cdd.2011.32; Wang WD, 2004, DEVELOPMENT, V131, P5367, DOI 10.1242/dev.01413; Wang Y, 2015, J THORAC DIS, V7, P672, DOI 10.3978/j.issn.2072-1439.2015.04.28; Weinmaster G, 2011, DEV CELL, V21, P134, DOI 10.1016/j.devcel.2011.06.006; Wennemers M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2934; Xie Y, 2013, J BIOL CHEM, V288, P2976, DOI 10.1074/jbc.M112.430066; Zhou M, 2015, BIOCHEM BIOPH RES CO, V459, P333, DOI 10.1016/j.bbrc.2015.02.115; Zhou Y, 2008, CELL SIGNAL, V20, P942, DOI 10.1016/j.cellsig.2008.01.010	50	34	34	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1048	1057		10.1038/onc.2016.276	http://dx.doi.org/10.1038/onc.2016.276			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27593927				2022-12-17	WOS:000395371500003
J	Yu, J; Liang, Q; Wang, J; Wang, K; Gao, J; Zhang, J; Zeng, Y; Chiu, PWY; Ng, EKW; Sung, JJY				Yu, J.; Liang, Q.; Wang, J.; Wang, K.; Gao, J.; Zhang, J.; Zeng, Y.; Chiu, P. W. Y.; Ng, E. K. W.; Sung, J. J. Y.			REC8 functions as a tumor suppressor and is epigenetically downregulated in gastric cancer, especially in EBV-positive subtype	ONCOGENE			English	Article							PROMOTER HYPERMETHYLATION; CELL-PROLIFERATION; DNA METHYLATION; E-CADHERIN; EXPRESSION; CARCINOMA; PATHWAY; GENE; AGGRESSIVENESS; INHIBITION	REC8 meiotic recombination protein (REC8) was found to be preferentially methylated in gastric cancer (GC) using promoter methylation array. We aimed to elucidate the epigenetic alteration and biological function of REC8 in GC. REC8 was downregulated in 100% (3/3) of Epstein Barr virus (EBV)-positive and 80% (8/10) of EBV-negative GC cell lines by promoter methylation, but the expression could be restored through demethylation treatment. Protein expression of REC8 was significantly lower in human primary gastric tumors than in adjacent non-tumor tissues. A negative correlation between methylation and mRNA expression of REC8 was observed in 223 gastric samples of The Cancer Genome Atlas study (r= 0.7018, P < 0.001). The methylation level (%) of the REC8 promoter was significantly higher in EBV-positive gastric tumors than in EBV-negative gastric tumors, as shown by bisulfite genomic sequencing (77.6 (69.3-80.5) vs 51.4 (39.5-62.3), median (interquartile range); P < 0.001); methylation levels in both subtypes of tumors were significantly higher than in normal stomach tissues (14.8 (4.2-24.0)) (both P < 0.001). Multivariate analysis revealed that REC8 methylation was an independent factor for poor survival in GC patients (hazard ratio = 1.68, P < 0.05). REC8 expression significantly suppressed cell viability, clonogenicity and cell cycle progression; it induced apoptosis and inhibited migration of AGS-EBV (EBV-positive) and BGC823 (EBV-negative) GC cells, and it suppressed tumorigenicity in nude mice. In contrast, knockdown of REC8 in gastric epithelial immortalized GES-1 cells significantly increased cell viability, clonogenicity and migration ability. The tumor-suppressive effect of REC8 is mediated at least in part by the downregulation of genes involved in cell growth (G6PD, SLC2A1, NOL3, MCM2, SNAI7 and SNAI2), and the upregulation of apoptosis/migration inhibitors (GADD45G and LDHA) and tumor suppressors (PinX7, IGFBP3 and ETS2). In conclusion, REC8 is a novel tumor suppressor that is commonly downregulated by promoter methylation in GC, especially in the EBV-associated subtype. Promoter methylation of REC8 is an independent risk factor for the shortened survival of GC patients.	[Yu, J.; Liang, Q.; Wang, J.; Wang, K.; Zhang, J.; Zeng, Y.; Sung, J. J. Y.] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Yu, J.; Liang, Q.; Wang, J.; Wang, K.; Zhang, J.; Zeng, Y.; Sung, J. J. Y.] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Gao, J.] Peking Univ, Canc Hosp & Inst, Dept Gastrointestinal Oncol, Beijing, Peoples R China; [Chiu, P. W. Y.; Ng, E. K. W.] Chinese Univ Hong Kong, Dept Surg, State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Peking University; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Room 707A,7-F,Li Ka Shing Med Sci Bldg, Shatin, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Chiu, Philip/A-4019-2009; Chiu, Philip/ABB-1454-2020; Ng, Enders Kwok Wai/E-8276-2016; Sung, Joseph J. Y./R-3203-2018; ZHANG, Jingwan/AIC-2560-2022; WANG, JIA/A-2799-2019; Liang, Qiaoyi Jessie/G-9612-2019; Jun, Yu/D-8569-2015	Chiu, Philip/0000-0001-9292-112X; Chiu, Philip/0000-0001-9292-112X; Sung, Joseph J. Y./0000-0003-3125-5199; Liang, Qiaoyi Jessie/0000-0001-8496-3442; ZHANG, Jingwan/0000-0002-0344-3398; WANG, JIA/0000-0001-5339-8954; Jun, Yu/0000-0001-5008-2153	HMRF [11100022]; RGC-GRF Hong Kong [766613]; National Natural Science Foundation of China [81272304]; China 863 Program [2012AA02A504]; Shenzhen Municipal Science and Technology R D fund [JCYJ20130401151108652]; Shenzhen Virtual University Park Support Scheme	HMRF; RGC-GRF Hong Kong(Hong Kong Research Grants Council); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China 863 Program(National High Technology Research and Development Program of China); Shenzhen Municipal Science and Technology R D fund; Shenzhen Virtual University Park Support Scheme	This project was supported by research funds of HMRF (11100022), RGC-GRF Hong Kong (766613), National Natural Science Foundation of China (81272304), China 863 Program (2012AA02A504), Shenzhen Municipal Science and Technology R & D fund (JCYJ20130401151108652) and Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute. The results shown here are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/.	Arseneault R, 2013, CANCER LETT, V338, P255, DOI 10.1016/j.canlet.2013.03.034; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Camargo MC, 2014, GUT, V63, P236, DOI 10.1136/gutjnl-2013-304531; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Deep G, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-37; Du WJ, 2013, NAT CELL BIOL, V15, P991, DOI 10.1038/ncb2789; Feng WH, 2007, J VIROL, V81, P10113, DOI 10.1128/JVI.00692-07; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hino R, 2009, CANCER RES, V69, P2766, DOI 10.1158/0008-5472.CAN-08-3070; Kabbout M, 2013, CLIN CANCER RES, V19, P3383, DOI 10.1158/1078-0432.CCR-13-0341; Kim MO, 2012, BBA-GEN SUBJECTS, V1820, P1636, DOI 10.1016/j.bbagen.2012.05.008; Liang QY, 2014, GASTROENTEROLOGY, V147, P1350, DOI 10.1053/j.gastro.2014.08.036; Liu DX, 2015, ONCOTARGET, V6, P39211, DOI 10.18632/oncotarget.5391; Liu JY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-148; Medina-Ramirez CM, 2011, CANCER RES, V71, P7705, DOI 10.1158/0008-5472.CAN-11-2192; Mikeska T, 2010, EPIGENOMICS-UK, V2, P561, DOI 10.2217/EPI.10.32; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Okamoto Y, 2012, GUT, V61, P392, DOI 10.1136/gut.2011.241034; Pruitt SC, 2007, STEM CELLS, V25, P3121, DOI 10.1634/stemcells.2007-0483; Regel I, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-9; Sudo M, 2004, INT J CANCER, V109, P194, DOI 10.1002/ijc.11701; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang SY, 2013, GUT, V62, P833, DOI 10.1136/gutjnl-2011-301776; Wockner LF, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.177; Xu LX, 2012, GUT, V61, P977, DOI 10.1136/gutjnl-2011-300411; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yu J, 2013, ONCOGENE, V32, P307, DOI 10.1038/onc.2012.54; Yu J, 2002, BRIT J CANCER, V87, P91, DOI 10.1038/sj.bjc.6600421; Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050; Zhang Zhiqian, 2011, Genes Cancer, V2, P782, DOI 10.1177/1947601911429743; Zhao J, 2013, INT J DISTRIB SENS N, DOI 10.1155/2013/241913; Zhao JH, 2013, CANCER-AM CANCER SOC, V119, P304, DOI 10.1002/cncr.27724; Zhao JH, 2012, CANCER-AM CANCER SOC, V118, P924, DOI 10.1002/cncr.26184	34	34	37	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					182	193		10.1038/onc.2016.187	http://dx.doi.org/10.1038/onc.2016.187			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27212034	Green Published, hybrid			2022-12-17	WOS:000393938100004
J	Sanduja, S; Feng, Y; Mathis, RA; Sokol, ES; Reinhardt, F; Halaban, R; Gupta, PB				Sanduja, S.; Feng, Y.; Mathis, R. A.; Sokol, E. S.; Reinhardt, F.; Halaban, R.; Gupta, P. B.			AMPK promotes tolerance to Ras pathway inhibition by activating autophagy	ONCOGENE			English	Article							INITIATING KINASE ULK1; TUMOR-SUPPRESSOR LKB1; ADVANCED MELANOMA; BRAF; RESISTANCE; PROLIFERATION; BRAF(V600E); VEMURAFENIB; METABOLISM; SURVIVAL	Targeted inhibitors of oncogenic Ras (rat sarcoma viral oncogene)-Raf signaling have shown great promise in the clinic, but resistance remains a major challenge: 30% of tumors with pathway mutations do not respond to targeted inhibitors, and of the 70% that do respond, all eventually develop resistance. Before cancer cells acquire resistance, they respond to initial drug treatment either by undergoing apoptosis ('addiction') or by surviving treatment albeit with reduced growth ('tolerance'). As these drug-tolerant cells serve as a reservoir from which resistant cells eventually emerge, inhibiting the pathways that confer tolerance could potentially delay or even prevent recurrence. Here, we show that melanomas and other cancers acquire tolerance to Ras-Raf pathway inhibitors by activating autophagy, which is mediated by the cellular energy sensor AMP-activated protein kinase (AMPK). Blocking this AMPK-mediated autophagy sensitizes drug-tolerant melanomas to Ras-Raf pathway inhibitors. Conversely, activating AMPK signaling and autophagy enables melanomas that would otherwise be addicted to the Ras-Raf pathway to instead tolerate pathway inhibition. These findings identify a key mechanism of tolerance to Ras-Raf pathway inhibitors and suggest that blocking either AMPK or autophagy in combination with these targeted inhibitors could increase tumor regression and decrease the likelihood of eventual recurrence.	[Sanduja, S.; Feng, Y.; Mathis, R. A.; Sokol, E. S.; Reinhardt, F.; Gupta, P. B.] Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA; [Mathis, R. A.; Sokol, E. S.; Gupta, P. B.] MIT, Dept Biol, Cambridge, MA USA; [Halaban, R.] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA; [Gupta, P. B.] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Gupta, P. B.] Harvard Stem Cell Inst, Cambridge, MA USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Yale University; Massachusetts Institute of Technology (MIT); Harvard University	Gupta, PB (corresponding author), Whitehead Inst Biomed Res, Biol, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	pgupta@wi.mit.edu			Ellison Foundation; Melanoma Research Alliance [311800]; Yale SPORE in Skin Cancer - National Cancer Institute [1 P50 CA121974]; NSFGRFP [1122374]; NATIONAL CANCER INSTITUTE [P50CA121973, P50CA121974] Funding Source: NIH RePORTER	Ellison Foundation(Lawrence Ellison Foundation); Melanoma Research Alliance; Yale SPORE in Skin Cancer - National Cancer Institute; NSFGRFP(National Science Foundation (NSF)NSF - Office of the Director (OD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Tyler Jacks for providing us with mouse KRAS<SUP>mut</SUP>/p53<SUP>-/-</SUP> NSCLC line, the Whitehead flow cytometry facility, and Nicki Watson and Wendy Salmon at the Whitehead Keck Imaging Facility for microscopy services. We thank Dr David Pincus and Dr Luke Whitesell for critical reading of the manuscript. This research was supported by grants from the Ellison Foundation (PBG) and Melanoma Research Alliance (#311800; PBG), a Yale SPORE in Skin Cancer funded by the National Cancer Institute (#1 P50 CA121974; RH), and funds from the NSFGRFP (#1122374; ESS).	Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Cerezo M, 2013, MOL CANCER THER, V12, P1605, DOI 10.1158/1535-7163.MCT-12-1226-T; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Egan DF, 2011, AUTOPHAGY, V7, P645, DOI 10.4161/auto.7.6.15123; Flaherty KT, 2010, ANN INTERN MED, V153, P587, DOI 10.7326/0003-4819-153-9-201011020-00008; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; Gamrekelashvili J, 2007, J IMMUNOL, V178, P1573, DOI 10.4049/jimmunol.178.3.1573; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Halaban R, 2010, PIGM CELL MELANOMA R, V23, P190, DOI 10.1111/j.1755-148X.2010.00685.x; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kawada K, 2012, CLIN CANCER RES, V18, P1696, DOI 10.1158/1078-0432.CCR-11-1909; Kim J, 2011, CELL CYCLE, V10, P1337, DOI 10.4161/cc.10.9.15291; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Levy JMM, 2014, CANCER DISCOV, V4, P773, DOI 10.1158/2159-8290.CD-14-0049; Lock R, 2014, CANCER DISCOV, V4, P466, DOI 10.1158/2159-8290.CD-13-0841; Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660; Luo ZJ, 2010, FUTURE ONCOL, V6, P457, DOI [10.2217/fon.09.174, 10.2217/FON.09.174]; Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454; McArthur GA, 2012, J CLIN ONCOL, V30, P1628, DOI 10.1200/JCO.2011.39.1938; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Petti C, 2012, MELANOMA RES, V22, P341, DOI 10.1097/CMR.0b013e3283544929; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shi HB, 2011, CANCER RES, V71, P5067, DOI 10.1158/0008-5472.CAN-11-0140; Smalley KSM, 2010, CURR OPIN INVEST DR, V11, P699; Sondergaard JN, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-39; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Strohecker AM, 2014, AUTOPHAGY, V10, P384, DOI 10.4161/auto.27320; Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026	44	34	34	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5295	5303		10.1038/onc.2016.70	http://dx.doi.org/10.1038/onc.2016.70			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	27041569	Green Submitted, Green Accepted			2022-12-17	WOS:000386053000008
J	Black, SA; Nelson, AC; Gurule, NJ; Futscher, BW; Lyons, TR				Black, S. A.; Nelson, A. C.; Gurule, N. J.; Futscher, B. W.; Lyons, T. R.			Semaphorin 7a exerts pleiotropic effects to promote breast tumor progression	ONCOGENE			English	Article							CARCINOMA IN-SITU; MAMMARY-TUMOR; CANCER; EXPRESSION; MODEL; ARCHITECTURE; METASTASIS; SIGNATURE; RESPONSES; GUIDANCE	Understanding what drives breast tumor progression is of utmost importance for blocking tumor metastasis; we have identified that semaphorin 7a is a potent driver of ductal carcinoma in situ (DCIS) progression. Semaphorin 7a is a glycophosphatidylinositol membrane-anchored protein that promotes attachment and spreading in multiple cell types. Here, we show that increased expression of SEMA7A occurs in a large percentage of breast cancers and is associated with decreased overall and distant metastasis-free survival. In both in vitro and in vivo models, short hairpin-mediated silencing of SEMA7A reveals roles for semaphorin 7a in the promotion of DCIS growth, motility and invasion as well as lymphangiogenesis in the tumor microenvironment. Our studies also uncover a relationship between COX-2 and semaphorin 7a expression and suggest that semaphorin 7a promotes tumor cell invasion on collagen and lymphangiogenesis via activation of beta(1)-integrin receptor. Our results suggest that semaphorin 7a may be novel target for blocking breast tumor progression.	[Black, S. A.; Gurule, N. J.; Lyons, T. R.] Univ Colorado Anschutz Med Campus, Sch Med, Dept Med, Div Med Oncol, Aurora, CO USA; [Nelson, A. C.] Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; [Gurule, N. J.; Lyons, T. R.] Univ Colorado Anschutz Med Campus, Univ Colorado Canc Biol Grad Program, Aurora, CO USA; [Futscher, B. W.] Univ Arizona, Univ Arizona Canc Ctr, Tucson, AZ USA; [Futscher, B. W.] Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA; [Lyons, T. R.] Univ Colorado Anschutz Med Campus, Univ Colorado Canc Ctr, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Minnesota System; University of Minnesota Twin Cities; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Arizona; University of Arizona; University of Colorado System; University of Colorado Anschutz Medical Campus	Lyons, TR (corresponding author), Univ Colorado Anschutz Med Campus, Div Med Oncol, MS8117,L18-8103,12801 East 17th Ave, Aurora, CO 80045 USA.	Traci.Lyons@ucdenver.edu			Cancer League of Colorado CCTSI Mentored Career Development Award [1KL2TR001080-01]; CCTSI CO PILOT NIH/NCI [M-13-161, 1R21CA185226-01]; University of Colorado Cancer Center Summer Fellowship; Cancer League of Colorado;  [U01CA153086]; NATIONAL CANCER INSTITUTE [R21CA185226] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001080] Funding Source: NIH RePORTER	Cancer League of Colorado CCTSI Mentored Career Development Award; CCTSI CO PILOT NIH/NCI; University of Colorado Cancer Center Summer Fellowship; Cancer League of Colorado; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We gratefully acknowledge K Polyak and A Marusyk (Harvard Medical School) for providing MCF10DCIS parental cells and shCOX-2 derivatives; AC Tan, K Hunter (NCI), J Richer, T Rogers and M Gordon for advice on dataset analysis; L Crump, A Elder, M Kobritz, J Pruitt, A Pham, S Tarullo and V Wessells for technical support; V Borges and P Schedin for critical review of the manuscript and crucial advice. This work was supported by Cancer League of Colorado, 1KL2TR001080-01 CCTSI Mentored Career Development Award, CCTSI CO PILOT M-13-161 and 1R21CA185226-01 NIH/NCI to TL. University of Colorado Cancer Center Summer Fellowship and Cancer League of Colorado to SB and U01CA153086 to BF.	Adams RH, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001875; Allegra M, 2012, MOL BIOL CELL, V23, P3873, DOI 10.1091/mbc.E12-04-0276; ASLAKSON CJ, 1991, INT J CANCER, V47, P466, DOI 10.1002/ijc.2910470327; Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Czopik AK, 2006, IMMUNITY, V24, P591, DOI 10.1016/j.immuni.2006.03.013; Delorme G, 2005, BIOL CELL, V97, P589; Esserman L, 2015, JAMA ONCOL, V1, P881, DOI 10.1001/jamaoncol.2015.2607; Formolo CA, 2011, J PROTEOME RES, V10, P3149, DOI 10.1021/pr200210w; Garcia-Areas R, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00017; Gelfand MV, 2009, TRENDS CELL BIOL, V19, P99, DOI 10.1016/j.tcb.2009.01.001; Ghanem RC, 2011, CURR EYE RES, V36, P989, DOI 10.3109/02713683.2011.593730; Gu CH, 2013, EXP CELL RES, V319, P1306, DOI 10.1016/j.yexcr.2013.02.003; Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007; Hua M, 2009, P NATL ACAD SCI USA, V106, P3372, DOI 10.1073/pnas.0813306106; Koh JM, 2006, J HUM GENET, V51, P112, DOI 10.1007/s10038-005-0331-z; Lyons TR, 2014, J CLIN INVEST, V124, P3901, DOI 10.1172/JCI73777; Lyons TR, 2011, NAT MED, V17, P1109, DOI 10.1038/nm.2416; Maller O, 2013, J CELL SCI, V126, P4108, DOI 10.1242/jcs.121590; Maurin JC, 2005, MATRIX BIOL, V24, P232, DOI 10.1016/j.matbio.2005.03.005; Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A; Moserle L, 2012, EMBO MOL MED, V4, P168, DOI 10.1002/emmm.201200206; Narod SA, 2015, JAMA ONCOL, V1, P888, DOI 10.1001/jamaoncol.2015.2510; Pasterkamp RJ, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-98; Pasterkamp RJ, 2003, NATURE, V424, P398, DOI 10.1038/nature01790; Pasterkamp RJ, 2003, CURR OPIN NEUROBIOL, V13, P79, DOI 10.1016/S0959-4388(03)00003-5; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ringner M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911; Scott GA, 2008, J INVEST DERMATOL, V128, P151, DOI 10.1038/sj.jid.5700974; Stefanou D, 2004, HISTOL HISTOPATHOL, V19, P465, DOI 10.14670/HH-19.465; Suzuki K, 2007, NATURE, V446, P680, DOI 10.1038/nature05652; Tait LR, 2007, INT J CANCER, V120, P2127, DOI 10.1002/ijc.22572; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wang Xiaojuan, 2002, Breast Cancer, V9, P216, DOI 10.1007/BF02967592; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764	35	34	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5170	5178		10.1038/onc.2016.49	http://dx.doi.org/10.1038/onc.2016.49			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	27065336	Green Accepted			2022-12-17	WOS:000384433000008
J	Rice, MA; Ishteiwy, RA; Magani, F; Udayakumar, T; Reiner, T; Yates, TJ; Miller, P; Perez-Stable, C; Rai, P; Verdun, R; Dykxhoorn, DM; Burnstein, KL				Rice, M. A.; Ishteiwy, R. A.; Magani, F.; Udayakumar, T.; Reiner, T.; Yates, T. J.; Miller, P.; Perez-Stable, C.; Rai, P.; Verdun, R.; Dykxhoorn, D. M.; Burnstein, K. L.			The microRNA-23b/-27b cluster suppresses prostate cancer metastasis via Huntingtin-interacting protein 1-related	ONCOGENE			English	Article							MICRORNA EXPRESSION; MOLECULAR PATHWAYS; HIP1R; FAMILY; GROWTH; MODEL	Deregulation of microRNAs (miRs) contributes to progression and metastasis of prostate and other cancers. miR-23b and -27b, encoded in the same miR cluster (miR-23b/-27b), are downregulated in human metastatic prostate cancer compared with primary tumors and benign tissue. Expression of miR-23b/-27b decreases prostate cancer cell migration, invasion and results in anoikis resistance. Conversely, antagomiR-mediated miR-23b and -27b silencing produces the opposite result in a more indolent prostate cancer cell line. However, neither miR-23b/-27b expression or inhibition impacts prostate cancer cell proliferation suggesting that miR-23b/-27b selectively suppresses metastasis. To examine the effects of miR-23b/-27b on prostate cancer metastasis in vivo, orthotopic prostate xenografts were established using aggressive prostate cancer cells transduced with miR-23b/-27b or non-targeting control miRNA. Although primary tumor formation was similar between miR-23b/-27b-transduced cells and controls, miR-23b/-27b expression in prostate cancer cells decreased seminal vesicle invasion and distant metastases. Gene-expression profiling identified the endocytic adaptor, Huntingtin-interacting protein 1-related (HIP1R) as being downregulated by miR-23b/-27b. Increased HIP1R expression in prostate cancer cells inversely phenocopied the effects of miR-23b/-27b overexpression on migration, invasion and anchorage-independent growth. HIP1R rescued miR-23b/-27b-mediated repression of migration in prostate cancer cells. HIP1R mRNA levels were decreased in seminal vesicle tissue from mice bearing miR-23b/-27b-transduced prostate cancer cell xenografts compared with scrambled controls, suggesting HIP1R is a key functional target of miR-23b/-27b. In addition, depletion of HIP1R led to a more rounded, less mesenchymal-like cell morphology, consistent with decreased metastatic properties. Together, these data demonstrate that the miR-23b/-27b cluster functions as a metastasis-suppressor by decreasing HIP1R levels in pre-clinical models of prostate cancer.	[Rice, M. A.; Magani, F.; Yates, T. J.] Univ Miami, Miller Sch Med, Sheila & David Fuente Grad Program Canc Biol, Miami, FL 33136 USA; [Ishteiwy, R. A.; Burnstein, K. L.] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave,RMSB 6155,R-189, Miami, FL 33136 USA; [Udayakumar, T.] Univ Miami, Miller Sch Med, Dept Radiat Oncol, Miami, FL 33136 USA; [Reiner, T.; Perez-Stable, C.; Verdun, R.] Univ Miami, Miller Sch Med, Div Geriatr, Dept Med, Miami, FL 33136 USA; [Miller, P.; Perez-Stable, C.; Rai, P.; Verdun, R.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA; [Dykxhoorn, D. M.] Univ Miami, Miller Sch Med, Dept Human Genet, John T Macdonald Fdn, Miami, FL 33136 USA; [Dykxhoorn, D. M.] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA; [Dykxhoorn, D. M.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami; University of Miami; University of Miami; University of Miami; University of Miami; University of Miami	Burnstein, KL (corresponding author), Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave,RMSB 6155,R-189, Miami, FL 33136 USA.	KBurnstein@med.miami.edu	Rice, Meghan/AAH-3098-2019	Rai, Priyamvada/0000-0001-7822-7553; Rice, Meghan/0000-0003-4578-0461	DOD [W81XWH-11-1-0314]; NIH [R01CA132200]; Women's Cancer Association of the University of Miami; NATIONAL CANCER INSTITUTE [R01CA132200] Funding Source: NIH RePORTER	DOD(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Women's Cancer Association of the University of Miami; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funding provided by DOD pre-doctoral fellowship W81XWH-11-1-0314 (RAI/MAR), NIH R01CA132200 and Women's Cancer Association of the University of Miami (KLB). We thank UM investigators Drs Cale Fahrenholtz, Stephanie Peacock and Ning Zhao, as well as Annie Greene and Govindi Samaranayake for helpful technical assistance and guidance. Dr Michael Henry at the University of Iowa and Dr David Drubin at University of California at Berkeley generously provided the PQCXIN-luciferase and HIP1R-6myc constructs respectively.	Altuvia Y, 2005, NUCLEIC ACIDS RES, V33, P2697, DOI 10.1093/nar/gki567; Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Baines AT, 2011, FUTURE MED CHEM, V3, P1787, DOI [10.4155/FMC.11.121, 10.4155/fmc.11.121]; Boettner DR, 2012, NAT CELL BIOL, V14, P2, DOI 10.1038/ncb2403; Brett TJ, 2006, NAT STRUCT MOL BIOL, V13, P121, DOI 10.1038/nsmb1043; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Coppola V, 2010, ENDOCR-RELAT CANCER, V17, pF1, DOI 10.1677/ERC-09-0172; D'Ambrosio J, 2009, CLIN EXP METASTAS, V26, P955, DOI 10.1007/s10585-009-9286-3; Dalmay T, 2006, ONCOGENE, V25, P6170, DOI 10.1038/sj.onc.1209911; DAMICO AV, 1995, J UROLOGY, V154, P131, DOI 10.1016/S0022-5347(01)67248-3; Dykxhoorn DM, 2010, CANCER RES, V70, P6401, DOI 10.1158/0008-5472.CAN-10-1346; Engqvist-Goldstein AEY, 2004, MOL BIOL CELL, V15, P1666, DOI 10.1091/mbc.E03-09-0639; Engqvist-Goldstein AEY, 1999, J CELL BIOL, V147, P1503, DOI 10.1083/jcb.147.7.1503; Fuse M, 2012, J HUM GENET, V57, P691, DOI 10.1038/jhg.2012.95; Gandellini P, 2009, TRENDS MOL MED, V15, P381, DOI 10.1016/j.molmed.2009.07.004; Gottfried I, 2010, BIOCHEM SOC T, V38, P187, DOI 10.1042/BST0380187; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867; Hurst DR, 2009, CANCER RES, V69, P7495, DOI 10.1158/0008-5472.CAN-09-2111; Hyun TS, 2004, MOL CELL BIOL, V24, P4329, DOI 10.1128/MCB.24.10.4329-4340.2004; Hyun TS, 2004, J BIOL CHEM, V279, P14294, DOI 10.1074/jbc.M312645200; Ishteiwy RA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052106; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Liu W, 2014, CANCER MICROENVIRON, V7, P117, DOI 10.1007/s12307-014-0148-4; LOOP SM, 1993, PROSTATE, V22, P93, DOI 10.1002/pros.2990220202; Lyons LS, 2008, MOL ENDOCRINOL, V22, P597, DOI 10.1210/me.2007-0158; Martens-Uzunova ES, 2012, ONCOGENE, V31, P978, DOI 10.1038/onc.2011.304; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; O'Day E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2484; Peacock SO, 2012, MOL ENDOCRINOL, V26, P1967, DOI 10.1210/me.2012-1165; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Rao DS, 2002, J CLIN INVEST, V110, P351, DOI 10.1172/JCI200215529; Seki N, 1998, J HUM GENET, V43, P268, DOI 10.1007/s100380050087; Shi XB, 2008, J CELL MOL MED, V12, P1456, DOI 10.1111/j.1582-4934.2008.00420.x; STEPHENSON RA, 1992, J NATL CANCER I, V84, P951, DOI 10.1093/jnci/84.12.951; Sun T, 2012, PROSTATE, V72, P1093, DOI 10.1002/pros.22456; Sun T, 2009, CANCER RES, V69, P3356, DOI 10.1158/0008-5472.CAN-08-4112; Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299; Thomson DW, 2011, NUCLEIC ACIDS RES, V39, P6845, DOI 10.1093/nar/gkr330; Wang JH, 2008, NEOPLASIA, V10, P847, DOI 10.1593/neo.08450; WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432-0436.1991.tb00250.x; Wang YL, 2015, CLIN GENITOURIN CANC, V13, P261, DOI 10.1016/j.clgc.2015.01.003; Yates TJ, 2015, JNCI-J NATL CANCER I, V107, P7; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158	45	34	38	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4752	4761		10.1038/onc.2016.6	http://dx.doi.org/10.1038/onc.2016.6			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26898757	Green Accepted			2022-12-17	WOS:000383324700008
J	Duckworth, C; Zhang, L; Carroll, SL; Ethier, SP; Cheung, HW				Duckworth, C.; Zhang, L.; Carroll, S. L.; Ethier, S. P.; Cheung, H. W.			Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression	ONCOGENE			English	Article							BREAST-CANCER; EPITHELIAL OVARIAN; TUMORIGENESIS; INHIBITION; PROLIFERATION; MALIGNANCIES; METASTASIS; ACTIVATION; RESISTANCE; BLOCKADE	We previously found that the scaffold adapter GRB2-associated binding protein 2 (GAB2) is amplified and overexpressed in a subset of primary high-grade serous ovarian cancers and cell lines. Ovarian cancer cells overexpressing GAB2 are dependent on GAB2 for activation of the phosphatidylinositol 3-kinase (PI3K) pathway and are sensitive to PI3K inhibition. In this study, we show an important role of GAB2 overexpression in promoting tumor angiogenesis by upregulating expression of multiple chemokines. Specifically, we found that suppression of GAB2 by inducible small hairpin RNA in ovarian cancer cells inhibited tumor cell proliferation, angiogenesis and peritoneal tumor growth in immunodeficient mice. Overexpression of GAB2 upregulated the secretion of several chemokines from ovarian cancer cells, including CXCL1, CXCL2 and CXCL8. The secreted chemokines not only signal through endothelial CXCR2 receptor in a paracrine manner to promote endothelial tube formation, but also act as autocrine growth factors for GAB2-induced transformation of fallopian tube secretory epithelial cells and clonogenic growth of ovarian cancer cells overexpressing GAB2. Pharmacological inhibition of inhibitor of nuclear factor kappa-B kinase subunit beta (IKK beta), but not PI3K, mechanistic target of rapamycin (mTOR) or mitogen-activated protein kinase (MEK), could effectively suppress GAB2-induced chemokine expression. Inhibition of IKK beta augmented the efficacy of PI3K/mTOR inhibition in suppressing clonogenic growth of ovarian cancer cells with GAB2 overexpression. Taken together, these findings suggest that overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating expression of CXCL1, CXCL2 and CXCL8 that is IKK beta-dependent. Co-targeting IKK beta and PI3K pathways downstream of GAB2 might be a promising therapeutic strategy for ovarian cancer that overexpresses GAB2.	[Duckworth, C.; Zhang, L.; Carroll, S. L.; Ethier, S. P.; Cheung, H. W.] Med Univ South Carolina, Dept Pathol & Lab Med, 68 President St,Room BE413,MSC 908, Charleston, SC 29425 USA; [Duckworth, C.; Zhang, L.; Carroll, S. L.; Ethier, S. P.; Cheung, H. W.] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [Duckworth, C.; Zhang, L.; Carroll, S. L.; Ethier, S. P.; Cheung, H. W.] Med Univ South Carolina, Ctr Genom Med, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Cheung, HW (corresponding author), Med Univ South Carolina, Dept Pathol & Lab Med, 68 President St,Room BE413,MSC 908, Charleston, SC 29425 USA.	cheungh@musc.edu	Duckworth, Carrie/AAC-8361-2020; Duckworth, Carrie A/K-7302-2014	Duckworth, Carrie/0000-0001-9992-7540; Duckworth, Carrie A/0000-0001-9992-7540	Ovarian Cancer Research Fund [292377]; V Foundation for Cancer Research; Marsha Rivkin Center for Ovarian Cancer Research; American Cancer Society Institutional Research Grant [IRG-97-219-14]; Colleen's Dream Foundation; Cancer Center Support Grant [P30 CA139313]; NATIONAL CANCER INSTITUTE [R03CA139313] Funding Source: NIH RePORTER	Ovarian Cancer Research Fund; V Foundation for Cancer Research; Marsha Rivkin Center for Ovarian Cancer Research; American Cancer Society Institutional Research Grant(American Cancer Society); Colleen's Dream Foundation; Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by grants from the Ovarian Cancer Research Fund (292377) (HWC); the V Foundation for Cancer Research (HWC); the Marsha Rivkin Center for Ovarian Cancer Research (HWC); the American Cancer Society Institutional Research Grant #IRG-97-219-14 (HWC); Colleen's Dream Foundation (HWC); Department start-up fund (HWC). This research utilized the Cell & Molecular Imaging, and Genomics Shared Resources which were supported, in part, by Cancer Center Support Grant P30 CA139313 to the Hollings Cancer Center, Medical University of South Carolina. We thank Alfred Moore for assistance with bioluminescent imaging. We thank Dennis Watson, Patricia Watson, Bart Smits and Qi Wang for stimulating discussion.	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Adams SJ, 2012, MOL CANCER RES, V10, P1265, DOI 10.1158/1541-7786.MCR-12-0352; Allegretti M, 2012, IMMUNOL LETT, V145, P68, DOI 10.1016/j.imlet.2012.04.003; Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Behbakht K, 2011, GYNECOL ONCOL, V123, P19, DOI 10.1016/j.ygyno.2011.06.022; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Bolitho C, 2010, ENDOCR-RELAT CANCER, V17, P929, DOI 10.1677/ERC-10-0107; Britschgi A, 2012, CANCER CELL, V22, P796, DOI 10.1016/j.ccr.2012.10.023; Caino MC, 2015, P NATL ACAD SCI USA, V112, P8638, DOI 10.1073/pnas.1500722112; Charles KA, 2009, J CLIN INVEST, V119, P3011, DOI 10.1172/JCI39065; Cheung HW, 2011, CANCER DISCOV, V1, P608, DOI 10.1158/2159-8290.CD-11-0046; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; Cho KR, 2009, ANNU REV PATHOL-MECH, V4, P287, DOI 10.1146/annurev.pathol.4.110807.092246; Choi HJ, 2015, CANCER METAST REV, V34, P19, DOI 10.1007/s10555-014-9538-9; Davis SJ, 2015, MOL CANCER THER, V14, P1495, DOI 10.1158/1535-7163.MCT-15-0039; Dunn GP, 2014, P NATL ACAD SCI USA, V111, P1102, DOI 10.1073/pnas.1311909111; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Hernandez L, 2010, CANCER RES, V70, P4005, DOI 10.1158/0008-5472.CAN-09-3912; Huang J, 2011, GENE CHROMOSOME CANC, V50, P606, DOI 10.1002/gcc.20883; Janku F, 2012, J CLIN ONCOL, V30, P777, DOI 10.1200/JCO.2011.36.1196; Ke Y, 2007, ONCOGENE, V26, P4951, DOI 10.1038/sj.onc.1210315; Merritt WM, 2008, J NATL CANCER I, V100, P359, DOI 10.1093/jnci/djn024; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Schmitt J, 2012, CANCER TREAT REV, V38, P272, DOI 10.1016/j.ctrv.2011.06.004; Shih IM, 2004, AM J PATHOL, V164, P1511, DOI 10.1016/S0002-9440(10)63708-X; Wang Y, 2012, ONCOGENE, V31, P2512, DOI 10.1038/onc.2011.435; Wang Y, 2012, CYTOKINE, V59, P145, DOI 10.1016/j.cyto.2012.04.013; Wohrle FU, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-22; Yang G, 2006, P NATL ACAD SCI USA, V103, P16472, DOI 10.1073/pnas.0605752103; Yang G, 2010, CLIN CANCER RES, V16, P3875, DOI 10.1158/1078-0432.CCR-10-0483; Yang Y, 2013, ONCOGENE, V32, P3627, DOI 10.1038/onc.2012.367; Yuan TL, 2008, P NATL ACAD SCI USA, V105, P9739, DOI 10.1073/pnas.0804123105	34	34	37	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4036	4047		10.1038/onc.2015.472	http://dx.doi.org/10.1038/onc.2015.472			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26657155	Green Published, hybrid			2022-12-17	WOS:000381020900002
J	Ventura, S; Aryee, DNT; Felicetti, F; De Feo, A; Mancarella, C; Manara, MC; Picci, P; Colombo, MP; Kovar, H; Care, A; Scotlandi, K				Ventura, S.; Aryee, D. N. T.; Felicetti, F.; De Feo, A.; Mancarella, C.; Manara, M. C.; Picci, P.; Colombo, M. P.; Kovar, H.; Care, A.; Scotlandi, K.			CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-kappa B signaling	ONCOGENE			English	Article							MESENCHYMAL STEM-CELLS; PANCREATIC-CANCER CELLS; OSTEOGENIC DIFFERENTIATION; GENOMIC LANDSCAPE; DOWN-REGULATION; FAMILY TUMORS; GROWTH-FACTOR; IN-VITRO; EXPRESSION; PATHWAY	Sarcomas are mesenchymal tumors characterized by blocked differentiation process. In Ewing sarcoma (EWS) both CD99 and EWS-FLI1 concur to oncogenesis and inhibition of differentiation. Here, we demonstrate that uncoupling CD99 from EWS-FLI1 by silencing the former, nuclear factor-kappa B (NF-kappa B) signaling is inhibited and the neural differentiation program is re-established. NF-kappa B inhibition passes through miR-34a-mediated repression of Notch pathway. CD99 counteracts EWS-FLI1 in controlling NF-kappa B signaling through the miR-34a, which is increased and secreted into exosomes released by CD99-silenced EWS cells. Delivery of exosomes from CD99-silenced cells was sufficient to induce neural differentiation in recipient EWS cells through miR-34a inhibition of Notch-NF-kappa B signaling. Notably, even the partial delivery of CD99 small interfering RNA may have a broad effect on the entire tumor cell population owing to the spread operated by their miR-34a-enriched exosomes, a feature opening to a new therapeutic option.	[Ventura, S.; Mancarella, C.; Manara, M. C.; Picci, P.; Scotlandi, K.] Ist Ortoped Rizzoli, Expt Oncol Lab, CRS Dev Biomol Therapies, Via Barbiano 1-10, I-40136 Bologna, Italy; [Aryee, D. N. T.; Kovar, H.] St Anna Kinderkrebsforsch, Childrens Canc Res Inst, Vienna, Austria; [Aryee, D. N. T.; Kovar, H.] Med Univ, Dept Pediat, Vienna, Austria; [Felicetti, F.; De Feo, A.; Care, A.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, Rome, Italy; [Colombo, M. P.] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Mol Immunol Unit, Milan, Italy	IRCCS Istituto Ortopedico Rizzoli; Saint Anna Children's Hospital; Istituto Superiore di Sanita (ISS); Fondazione IRCCS Istituto Nazionale Tumori Milan	Scotlandi, K (corresponding author), Ist Ortoped Rizzoli, Expt Oncol Lab, CRS Dev Biomol Therapies, Via Barbiano 1-10, I-40136 Bologna, Italy.	katia.scotlandi@ior.it	Scotlandi, Katia/J-9009-2016; Mancarella, Caterina/C-7463-2019; Manara, Maria Cristina/K-3366-2018; Colombo, Mario P./V-7166-2017; De Feo, Alessandra/ABI-1458-2020; Felicetti, Federica/N-7077-2017; De Feo, Alessandra/C-7030-2019; Care, Alessandra/H-5090-2016	Scotlandi, Katia/0000-0001-6114-9499; Mancarella, Caterina/0000-0002-5778-4251; Manara, Maria Cristina/0000-0001-5686-720X; Colombo, Mario P./0000-0003-0042-7955; De Feo, Alessandra/0000-0002-9805-1361; Felicetti, Federica/0000-0003-4628-0696; De Feo, Alessandra/0000-0002-9805-1361; Kovar, Heinrich/0000-0001-6873-9109; Care, Alessandra/0000-0003-4106-3342	Italian Association for Cancer Research (AIRC project) [IG2013_14049, IG2012_13247]; Ministry of Education, Research and Universities (FIRB project) [RBAP11884 M_005]; Ministry of Health (PROVABES project) [PER-2011-2353839]; Austrian Science Fund [P24708-B21]; Austrian Science Fund (PROVABES project) [I-1225-B19]; fellowship 'Guglielmina Lucatello e Gino Mazzega' - Fondazione Italiana per la Ricerca sul Cancro (FIRC project) [13811]; Austrian Science Fund (FWF) [P 24708] Funding Source: researchfish	Italian Association for Cancer Research (AIRC project)(Fondazione AIRC per la ricerca sul cancro); Ministry of Education, Research and Universities (FIRB project); Ministry of Health (PROVABES project); Austrian Science Fund(Austrian Science Fund (FWF)); Austrian Science Fund (PROVABES project)(Austrian Science Fund (FWF)); fellowship 'Guglielmina Lucatello e Gino Mazzega' - Fondazione Italiana per la Ricerca sul Cancro (FIRC project); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We are indebted to Cristina Ghinelli for editing the manuscript. We wish to thank Dr Gianfranco Mattia for the assessment of immunofluorescence analysis on the exosome fusion. We are also grateful to Prof. Alain Israel and Dr Johannes Schmid for sharing NF-kappa B reporter and plasmids. This work was supported by grants from the Italian Association for Cancer Research (AIRC project: IG2013_14049 to KS; IG2012_13247 to AC), Ministry of Education, Research and Universities (FIRB project: RBAP11884 M_005 to KS), Ministry of Health (PROVABES project: PER-2011-2353839 to PP and KS), Austrian Science Fund (project: P24708-B21 and PROVABES project: I-1225-B19 to HK). Selena Ventura is in receipt of the fellowship 'Guglielmina Lucatello e Gino Mazzega' granted by Fondazione Italiana per la Ricerca sul Cancro (FIRC project code: 13811).	Ahmed AA, 2012, HUM PATHOL, V43, P1077, DOI 10.1016/j.humpath.2011.09.001; Alberti I, 2002, FASEB J, V16, P1946, DOI 10.1096/fj.02-0049fje; Armengol G, 1997, BRIT J CANCER, V75, P1403, DOI 10.1038/bjc.1997.242; Baliko F, 2007, AM J PATHOL, V170, P1686, DOI 10.2353/ajpath.2007.060971; Ban J, 2008, CANCER RES, V68, P7100, DOI 10.1158/0008-5472.CAN-07-6145; Bennani-Baiti IM, 2011, J PATHOL, V225, P353, DOI 10.1002/path.2966; Bernard G, 1997, J IMMUNOL, V158, P2543; Braicu C, 2015, CELL DEATH DIFFER, V22, P34, DOI 10.1038/cdd.2014.130; Brohl AS, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004475; Carrillo J, 2007, CLIN CANCER RES, V13, P2429, DOI 10.1158/1078-0432.CCR-06-1762; Charytonowicz E, 2012, J CLIN INVEST, V122, P886, DOI 10.1172/JCI60015; Cho HH, 2010, J CELL PHYSIOL, V223, P168, DOI 10.1002/jcp.22024; Crompton BD, 2014, CANCER DISCOV, V4, P1326, DOI 10.1158/2159-8290.CD-13-1037; De Molfetta GA, 2010, DIFFERENTIATION, V80, P195, DOI 10.1016/j.diff.2010.07.004; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Di Martino MT, 2012, CLIN CANCER RES, V18, P6260, DOI 10.1158/1078-0432.CCR-12-1708; Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200; Franzetti GA, 2013, ONCOGENE, V32, P3915, DOI 10.1038/onc.2012.403; Garofalo C, 2012, MOL ENDOCRINOL, V26, P1603, DOI 10.1210/me.2012-1142; GELIN C, 1989, EMBO J, V8, P3253, DOI 10.1002/j.1460-2075.1989.tb08485.x; Ginsberg JP, 2010, JNCI-J NATL CANCER I, V102, P1272, DOI 10.1093/jnci/djq278; Gonzalez I, 2007, J MOL MED, V85, P1015, DOI 10.1007/s00109-007-0202-5; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hayden MS, 2014, SEMIN IMMUNOL, V26, P253, DOI 10.1016/j.smim.2014.05.004; Hess K, 2009, BONE, V45, P367, DOI 10.1016/j.bone.2009.04.252; Hu-Lieskovan S, 2005, CANCER RES, V65, P4633, DOI 10.1158/0008-5472.CAN-04-2857; Huang HY, 2005, J CLIN ONCOL, V23, P548, DOI 10.1200/JCO.2005.02.081; Javelaud D, 2002, INT J CANCER, V98, P193, DOI 10.1002/ijc.10192; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Kok MGM, 2015, FASEB J, V29, P3853, DOI 10.1096/fj.15-271312; Lagirand-Cantaloube J, 2010, BIOCHEM BIOPH RES CO, V399, P705, DOI 10.1016/j.bbrc.2010.08.004; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; Lessnick SL, 2012, ANNU REV PATHOL-MECH, V7, P145, DOI 10.1146/annurev-pathol-011110-130237; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lopez-Guerrero JA, 2001, LAB INVEST, V81, P803, DOI 10.1038/labinvest.3780290; Magnan H, 2015, PEDIATR BLOOD CANCER, V62, P594, DOI 10.1002/pbc.25373; Maksimenko A, 2005, EXPERT OPIN THER TAR, V9, P825, DOI 10.1517/14728222.9.4.825; Marino MT, 2014, ANN ONCOL, V25, P2080, DOI 10.1093/annonc/mdu249; McDermott AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083718; Miyagawa Y, 2008, MOL CELL BIOL, V28, P2125, DOI 10.1128/MCB.00740-07; Nakatani F, 2012, J PATHOL, V226, P796, DOI 10.1002/path.3007; Nogueira L, 2011, ONCOGENE, V30, P3537, DOI 10.1038/onc.2011.74; Osipo C, 2008, LAB INVEST, V88, P11, DOI 10.1038/labinvest.3700700; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Ozeki A, 2012, NEUROREPORT, V23, P290, DOI 10.1097/WNR.0b013e3283509a79; Pang RTK, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-25; Pata Supansa, 2011, BMC Res Notes, V4, P293, DOI 10.1186/1756-0500-4-293; Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Rocchi A, 2010, J CLIN INVEST, V120, P668, DOI 10.1172/JCI36667; Rorie CJ, 2004, CANCER RES, V64, P1266, DOI 10.1158/0008-5472.CAN-03-3274; Sabolek M, 2006, NEUROREPORT, V17, P1719, DOI 10.1097/01.wnr.0000236862.08834.50; Sasaki CY, 2005, J BIOL CHEM, V280, P34538, DOI 10.1074/jbc.M504943200; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Sonnemann J, 2007, J CANCER RES CLIN, V133, P847, DOI 10.1007/s00432-007-0227-8; Sonnemann J, 2011, EUR J CANCER, V47, P1432, DOI 10.1016/j.ejca.2011.01.015; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Staudt LM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000109; Teitell MA, 1999, LAB INVEST, V79, P1535; Amaral AT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085814; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Tirode F, 2014, CANCER DISCOV, V4, P1342, DOI 10.1158/2159-8290.CD-14-0622; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Vaira S, 2008, P NATL ACAD SCI USA, V105, P3897, DOI 10.1073/pnas.0708576105; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; von Levetzow C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019305; Wang Y, 2004, P NATL ACAD SCI USA, V101, P9458, DOI 10.1073/pnas.0308126101; Wang ZW, 2006, CANCER RES, V66, P2778, DOI 10.1158/0008-5472.CAN-05-4281; Wang ZW, 2006, INT J CANCER, V118, P1930, DOI 10.1002/ijc.21589; Widera D, 2006, INT J DEV NEUROSCI, V24, P91, DOI 10.1016/j.ijdevneu.2005.11.017; Womer RB, 2012, J CLIN ONCOL, V30, P4148, DOI 10.1200/JCO.2011.41.5703; Yang CB, 2010, STEM CELLS, V28, P1970, DOI 10.1002/stem.528	72	34	38	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3944	3954		10.1038/onc.2015.463	http://dx.doi.org/10.1038/onc.2015.463			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26616853	Green Accepted			2022-12-17	WOS:000381013100006
J	Chen, CC; Kim, KH; Lau, LF				Chen, C-C; Kim, K-H; Lau, L. F.			The matricellular protein CCN1 suppresses hepato-carcinogenesis by inhibiting compensatory proliferation	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; TUMOR-SUPPRESSOR; LIVER FIBROSIS; MOUSE MODELS; IN-VIVO; CYR61; CANCER; P53; HEPATOCARCINOGENESIS; APOPTOSIS	Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide, and is on the rise in the United States. Previous studies showed that the matricellular protein CCN1 (CYR61) is induced during hepatic injuries and functions to restrict and resolve liver fibrosis. Here, we show that CCN1 suppresses hepatocarcinogenesis by inhibiting carcinogen-induced compensatory hepatocyte proliferation, thus limiting the expansion of damaged and potentially oncogenic hepatocytes. Consistent with tumor suppression, CCN1 expression is downregulated in human HCC. Ccn1(Delta Hep) mice with hepatocyte-specific deletion of Ccn1 suffer increased HCC tumor multiplicity induced by the hepatocarcinogen diethylnitrosamine (DEN). Knockin mice (Ccn1(dm/dm)) that express an integrin alpha(6)beta(1)-binding defective CCN1 phenocopied Ccn1(Delta Hep) mice, indicating that CCN1 acts through its alpha(6)beta(1) binding sites in this context. CCN1 effectively inhibits epidermal growth factor receptor (EGFR)-dependent hepatocyte proliferation through integrin alpha(6)-mediated accumulation of reactive oxygen species (ROS), thereby triggering p53 activation and cell cycle block. Consequently, Ccn1(dm/dm) mice exhibit diminished p53 activation and elevated compensatory hepatocyte proliferation, resulting in increased HCC. Furthermore, we show that a single dose of the EGFR inhibitor erlotinib delivered prior to DEN-induced injury was sufficient to block compensatory proliferation and annihilate development of HCC nodules observed 8 months later, suggesting potential chemoprevention by targeting CCN1-inhibitable EGFR-dependent hepatocyte proliferation. Together, these results show that CCN1 is an injury response protein that functions not only to restrict fibrosis in the liver, but also to suppress hepatocarcinogenesis by inhibiting EGFR-dependent hepatocyte compensatory proliferation.	[Chen, C-C; Kim, K-H; Lau, L. F.] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lau, LF (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, Coll Med, 900 S Ashland Ave, Chicago, IL 60607 USA.	LFLau@uic.edu		Kim, Ki-Hyun/0000-0001-8265-6609; Lau, Lester/0000-0002-4364-2914	NIH [R01GM78492]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR061791] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078492] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Seungwon Shin and Guoqiang Yan for technical assistance. This work was supported by a grant from the NIH (R01GM78492) to LFL.	Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Baffy G, 2012, J HEPATOL, V56, P1384, DOI 10.1016/j.jhep.2011.10.027; Bakiri L, 2013, MOL ONCOL, V7, P206, DOI 10.1016/j.molonc.2013.01.005; Chen CC, 2007, EMBO J, V26, P1257, DOI 10.1038/sj.emboj.7601596; Chen NY, 2004, J BIOL CHEM, V279, P44166, DOI 10.1074/jbc.M406813200; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Chien WW, 2004, J BIOL CHEM, V279, P53087, DOI 10.1074/jbc.M410254200; Choi JS, 2015, MUCOSAL IMMUNOL, V8, P1285, DOI 10.1038/mi.2015.19; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Feng P, 2008, INT J BIOCHEM CELL B, V40, P98, DOI 10.1016/j.biocel.2007.06.020; Fuchs BC, 2014, HEPATOLOGY, V59, P1577, DOI 10.1002/hep.26898; Gery S, 2005, CLIN CANCER RES, V11, P7243, DOI 10.1158/1078-0432.CCR-05-0231; Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Haque I, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-8; Hiotis SP, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-64; Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599; Jun JI, 2010, NAT CELL BIOL, V12, P676, DOI 10.1038/ncb2070; Juric V, 2009, MOL CELL BIOL, V29, P3266, DOI 10.1128/MCB.00064-09; Kang JS, 2007, CANCER RES, V67, P11141, DOI 10.1158/0008-5472.CAN-07-1369; Kardeh S, 2014, EUR J PHARMACOL, V735, P150, DOI 10.1016/j.ejphar.2014.04.023; Kim KH, 2015, J CLIN INVEST, V125, P1886, DOI 10.1172/JCI79327; Kim KH, 2013, MOL CELL BIOL, V33, P2078, DOI 10.1128/MCB.00049-13; Kuraishy A, 2011, IMMUNITY, V35, P467, DOI 10.1016/j.immuni.2011.09.006; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481; Li WC, 2010, METHODS MOL BIOL, V633, P185, DOI 10.1007/978-1-59745-019-5_13; Li ZY, 2012, COMPUT ENG APPL, V2012, P1, DOI DOI 10.1371/J0URNAL.P0NE.0040132; Liebermann DA, 2007, CELL CYCLE, V6, P166, DOI 10.4161/cc.6.2.3789; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Mas VR, 2009, MOL MED, V15, P85, DOI 10.2119/molmed.2008.00110; Mellert H, 2013, CELL REP, V3, P1335, DOI 10.1016/j.celrep.2013.05.011; Mo FE, 2006, CIRC RES, V99, P961, DOI 10.1161/01.RES.0000248426.35019.89; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; O'Connor S., 2010, Morbidity and Mortality Weekly Report, V59, P517; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; Sakurai T, 2013, CANCER RES, V73, P215, DOI 10.1158/0008-5472.CAN-12-1602; Schiffer E, 2005, HEPATOLOGY, V41, P307, DOI 10.1002/hep.20538; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Smith NF, 2008, BRIT J CANCER, V98, P1630, DOI 10.1038/sj.bjc.6604353; Stepniak E, 2006, GENE DEV, V20, P2306, DOI 10.1101/gad.390506; Sun BC, 2013, FRONT MED-PRC, V7, P242, DOI 10.1007/s11684-013-0256-4; Teoh N, 2010, GASTROENTEROLOGY, V138, P1155, DOI 10.1053/j.gastro.2009.11.008; Thomas MB, 2007, CANCER-AM CANCER SOC, V110, P1059, DOI 10.1002/cncr.22886; Todorovic V, 2005, J CELL BIOL, V171, P559, DOI 10.1083/jcb.200504015; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Verna L, 1996, PHARMACOL THERAPEUT, V71, P57, DOI 10.1016/0163-7258(96)00062-9; Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622; Xie D, 2004, CANCER RES, V64, P1987, DOI 10.1158/0008-5472.CAN-03-0666; Yan HX, 2013, ONCOGENE, V32, P4565, DOI 10.1038/onc.2012.451; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100	55	34	36	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1314	1323		10.1038/onc.2015.190	http://dx.doi.org/10.1038/onc.2015.190			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26028023	Green Accepted			2022-12-17	WOS:000371763100011
J	Castro-Vega, LJ; Lepoutre-Lussey, C; Gimenez-Roqueplo, AP; Favier, J				Castro-Vega, L. J.; Lepoutre-Lussey, C.; Gimenez-Roqueplo, A-P; Favier, J.			Rethinking pheochromocytomas and paragangliomas from a genomic perspective	ONCOGENE			English	Review							ISLAND METHYLATOR PHENOTYPE; GERMLINE SDHB MUTATIONS; TUMOR-SUPPRESSOR GENE; HIPPEL-LINDAU DISEASE; SPORADIC PHEOCHROMOCYTOMA; MALIGNANT PHEOCHROMOCYTOMAS; SUCCINATE-DEHYDROGENASE; SOMATIC MUTATIONS; ABDOMINAL PARAGANGLIOMAS; INTEGRATIVE ANALYSIS	Pheochromocytomas (PCC) and paragangliomas (PGL) are rare neuroendocrine tumors of neural crest origin. These tumors are caused by germline or somatic mutations in known susceptibility genes in up to 70% of cases. Over the past few years, the emergence of high-throughput technologies has enabled the unprecedented characterization of genomic alterations in PCC/PGL, and has improved our understanding of the molecular mechanisms that distinguish the different tumor subtypes. Integrated genomic analyses have shown that the mutation status of PCC/PGL susceptibility genes strongly correlates with multi-omics data. These observations not only emphasize the role of the long-standing susceptibility genes as the main drivers of PCC/PGL tumorigenesis, but also illustrate the functional interdependence between genomic and epigenomic alterations. In this review, we discuss the genomic landscape underlying PCC/PGL, its functional consequences for tumorigenesis and tumor progression, and the potential clinical relevance of this knowledge for the application of precision medicine for patients with PCC/PGL.	[Castro-Vega, L. J.; Lepoutre-Lussey, C.; Gimenez-Roqueplo, A-P; Favier, J.] Paris Cardiovasc Res Ctr, INSERM, UMR970, F-75015 Paris, France; [Castro-Vega, L. J.; Lepoutre-Lussey, C.; Gimenez-Roqueplo, A-P; Favier, J.] Univ Paris 05, Sorbonne Paris Cite, Fac Med, Paris, France; [Gimenez-Roqueplo, A-P] Hop Europeen Georges Pompidou, AP HP, Dept Genet, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Favier, J (corresponding author), Paris Cardiovasc Res Ctr, INSERM, UMR970, F-75015 Paris, France.	judith.favier@inserm.fr	Castro-Vega, Luis Jaime/L-5587-2019; Lussey-Lepoutre, Charlotte/AAO-7653-2020; Favier, Judith/M-7601-2017; GIMENEZ-ROQUEPLO, Anne-Paule/T-6752-2018; Castro-Vega, Luis Jaime/AAO-9988-2021	Lussey-Lepoutre, Charlotte/0000-0003-2228-0106; Favier, Judith/0000-0001-8190-5853; GIMENEZ-ROQUEPLO, Anne-Paule/0000-0002-4816-670X; Castro-Vega, Luis Jaime/0000-0002-7232-9871	Agence Nationale de la Recherche [ANR-2011-JCJC-00701 MODEO-MAPP]; European Union [259735]; Programme Hospitalier de Recherche Clinique [COMETE 3 AOM 06 179]; Plan Cancer Action (AAP Epigenetique et Cancer) [3.2 2009-2013, U970-C13089KS-INSERM PLAN CANCER]; Cancer Research for Personalized Medicine - CARPEM project (Site de Recherche Integre sur le Cancer - SIRIC)	Agence Nationale de la Recherche(French National Research Agency (ANR)); European Union(European Commission); Programme Hospitalier de Recherche Clinique; Plan Cancer Action (AAP Epigenetique et Cancer); Cancer Research for Personalized Medicine - CARPEM project (Site de Recherche Integre sur le Cancer - SIRIC)	We thank the Agence Nationale de la Recherche (ANR-2011-JCJC-00701 MODEO-MAPP), the European Union Seventh Framework Program FP7/2007-2013 (grant agreement no. 259735), the Programme Hospitalier de Recherche Clinique (COMETE 3 AOM 06 179) and the Plan Cancer Action no 3.2 2009-2013 (AAP Epigenetique et Cancer 2013, U970-C13089KS-INSERM PLAN CANCER) for financial support. CL-L received funding from the Cancer Research for Personalized Medicine - CARPEM project (Site de Recherche Integre sur le Cancer - SIRIC). We apologize to researchers in the field whose contributions were not cited because of space limitations.	Aarts M, 2006, GENE CHROMOSOME CANC, V45, P83, DOI 10.1002/gcc.20268; Abe M, 2005, CANCER RES, V65, P828; Abe M, 2007, CANCER LETT, V247, P253, DOI 10.1016/j.canlet.2006.05.001; Agrawal R, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-686; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Amar L, 2007, J CLIN ENDOCR METAB, V92, P3822, DOI 10.1210/jc.2007-0709; Assie G, 2014, NAT GENET, V46, P607, DOI 10.1038/ng.2953; Astuti D, 2001, LANCET, V357, P1181, DOI 10.1016/S0140-6736(00)04378-6; Astuti D, 2005, BRIT J CANCER, V92, P1574, DOI 10.1038/sj.bjc.6602478; August C, 2004, MODERN PATHOL, V17, P1119, DOI 10.1038/modpathol.3800160; Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095; Bayley JP, 2010, LANCET ONCOL, V11, P366, DOI 10.1016/S1470-2045(10)70007-3; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Blumenschein GR, 2012, J CLIN ONCOL, V30, P3287, DOI 10.1200/JCO.2011.40.3774; Brouwers FM, 2006, J CLIN ENDOCR METAB, V91, P4505, DOI 10.1210/jc.2006-0423; Burnichon N, 2012, HUM MOL GENET, V21, P5397, DOI 10.1093/hmg/dds374; Burnichon N, 2012, CLIN CANCER RES, V18, P2828, DOI 10.1158/1078-0432.CCR-12-0160; Burnichon N, 2011, HUM MOL GENET, V20, P3974, DOI 10.1093/hmg/ddr324; Burnichon N, 2011, EUR J ENDOCRINOL, V164, P141, DOI 10.1530/EJE-10-0758; Burnichon N, 2010, HUM MOL GENET, V19, P3011, DOI 10.1093/hmg/ddq206; Cancer Genome Atlas Research Network, 2013, Nat Genet, V45, P1113, DOI 10.1038/ng.2764; Cascon A, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv053; Castro-Vega LJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7044; Castro-Vega LJ, 2014, HUM MOL GENET, V23, P2440, DOI 10.1093/hmg/ddt639; Clark GR, 2014, J CLIN ENDOCR METAB; Comino-Mendez I, 2013, HUM MOL GENET, V22, P2169, DOI 10.1093/hmg/ddt069; Comino-Mendez I, 2011, NAT GENET, V43, P663, DOI 10.1038/ng.861; Crona J, 2013, J CLIN ENDOCR METAB, V98, pE1266, DOI 10.1210/jc.2012-4257; CROSSEY PA, 1995, J MED GENET, V32, P885, DOI 10.1136/jmg.32.11.885; Da Rocha ST, 2008, TRENDS GENET, V24, P306, DOI 10.1016/j.tig.2008.03.011; Dahia PLM, 2005, PLOS GENET, V1, P72, DOI 10.1371/journal.pgen.0010008; Dannenberg H, 2001, AM J PATHOL, V158, P1937, DOI 10.1016/S0002-9440(10)64662-7; de Cubas AA, 2013, ENDOCR-RELAT CANCER, V20, P477, DOI 10.1530/ERC-12-0183; DEANGELIS LM, 1987, NEUROLOGY, V37, P129, DOI 10.1212/WNL.37.1.129; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Edstrom E, 2000, AM J PATHOL, V156, P651, DOI 10.1016/S0002-9440(10)64769-4; Eisenhofer G, 2004, ENDOCR-RELAT CANCER, V11, P897, DOI 10.1677/erc.1.00838; Eisenhofer G, 2012, EUR J CANCER, V48, P1739, DOI 10.1016/j.ejca.2011.07.016; ENG C, 1995, J MED GENET, V32, P934, DOI 10.1136/jmg.32.12.934; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Favier J, 2015, NAT REV ENDOCRINOL, V11, P101, DOI 10.1038/nrendo.2014.188; Favier J, 2012, NEW ENGL J MED, V367, P2161, DOI 10.1056/NEJMc1211953; Favier J, 2010, BEST PRACT RES CL EN, V24, P957, DOI 10.1016/j.beem.2010.10.004; Favier J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007094; Feinberg AP, 2004, SEMIN CANCER BIOL, V14, P427, DOI 10.1016/j.semcancer.2004.06.005; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fishbein L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7140; Flynn A, 2015, J PATHOL, V236, P78, DOI 10.1002/path.4503; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Geli J, 2008, CLIN CANCER RES, V14, P2551, DOI 10.1158/1078-0432.CCR-07-1867; Gimenez-Roqueplo AP, 2003, CANCER RES, V63, P5615; GRIFFITHS DFR, 1987, Q J MED, V64, P769; Hadoux J, 2014, INT J CANCER, V135, P2711, DOI 10.1002/ijc.28913; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Herfarth KKF, 1997, GENE CHROMOSOME CANC, V20, P24, DOI 10.1002/(SICI)1098-2264(199709)20:1<24::AID-GCC4>3.3.CO;2-V; Huang X, 2009, MOL CELL, V35, P856, DOI 10.1016/j.molcel.2009.09.006; Huether R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4630; Igaz P, 2015, CELL MOL LIFE SCI, V72, P417, DOI 10.1007/s00018-014-1752-7; Janeway KA, 2011, P NATL ACAD SCI USA, V108, P314, DOI 10.1073/pnas.1009199108; Jarbo C, 2006, INT J CANCER, V118, P1159, DOI 10.1002/ijc.21385; Jones DTW, 2012, NATURE, V488, P100, DOI 10.1038/nature11284; KALFF V, 1982, ARCH INTERN MED, V142, P2092, DOI 10.1001/archinte.142.12.2092; Karpathakis A, 2013, ENDOCR-RELAT CANCER, V20, pR65, DOI 10.1530/ERC-12-0338; KHOSLA S, 1991, J CLIN INVEST, V87, P1691, DOI 10.1172/JCI115186; Killian JK, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009961; Killian JK, 2013, CANCER DISCOV, V3, P648, DOI 10.1158/2159-8290.CD-13-0092; Klein RD, 2008, DIAGN MOL PATHOL, V17, P94, DOI 10.1097/PDM.0b013e318150d67c; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kupka S, 2008, J CANCER RES CLIN, V134, P463, DOI 10.1007/s00432-007-0307-9; Laddha SV, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-10; Ladroue C, 2008, NEW ENGL J MED, V359, P2685, DOI 10.1056/NEJMoa0806277; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lenders JWM, 2014, J CLIN ENDOCR METAB, V99, P1915, DOI 10.1210/jc.2014-1498; Letouze E, 2013, CANCER CELL, V23, P739, DOI 10.1016/j.ccr.2013.04.018; Liu TT, 2014, ENDOCR-RELAT CANCER, V21, P427, DOI 10.1530/ERC-14-0016; Liu XD, 2010, TRENDS MOL MED, V16, P37, DOI 10.1016/j.molmed.2009.11.005; Loriot C, 2012, J CLIN ENDOCR METAB, V97, pE954, DOI 10.1210/jc.2011-3437; Luca R, 2013, EMBO MOL MED, V5, P1523, DOI 10.1002/emmm.201302847; Mack SC, 2014, NATURE, V506, P445, DOI 10.1038/nature13108; Meyer-Rochow GY, 2010, ENDOCR-RELAT CANCER, V17, P835, DOI 10.1677/ERC-10-0142; Milunsky JM, 2001, AM J MED GENET, V100, P311, DOI 10.1002/ajmg.1270; Modali SD, 2015, MOL ENDOCRINOL; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Noushmehr Houtan, 2010, Cancer Cell, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Oudijk L, 2014, J CLIN ENDOCR METAB, V99, pE1376, DOI 10.1210/jc.2013-3879; Papathomas TG, 2014, ENDOCR-RELAT CANCER, V21, P653, DOI 10.1530/ERC-13-0429; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Patterson E, 2012, ENDOCR-RELAT CANCER, V19, P157, DOI 10.1530/ERC-11-0308; Petri BJ, 2008, MODERN PATHOL, V21, P407, DOI 10.1038/modpathol.3801013; Powers JF, 2005, CANCER GENET CYTOGEN, V159, P27, DOI 10.1016/j.cancergencyto.2004.09.018; Pugh TJ, 2013, NAT GENET, V45, P279, DOI 10.1038/ng.2529; Qin Q, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-50; Qin YJ, 2010, NAT GENET, V42, P229, DOI 10.1038/ng.533; Ricketts C, 2008, J NATL CANCER I, V100, P1260, DOI 10.1093/jnci/djn254; Robinson CM, 2014, FEBS LETT, V588, P2704, DOI 10.1016/j.febslet.2014.02.026; SALDANA MJ, 1973, HUM PATHOL, V4, P251, DOI 10.1016/S0046-8177(73)80012-7; Sandgren J, 2010, ENDOCR-RELAT CANCER, V17, P561, DOI 10.1677/ERC-09-0310; Schlisio S, 2008, GENE DEV, V22, P884, DOI 10.1101/gad.1648608; Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Szabo PM, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-48; Tombol Z, 2010, MODERN PATHOL, V23, P1583, DOI 10.1038/modpathol.2010.164; van Nederveen FH, 2009, ENDOCR-RELAT CANCER, V16, P505, DOI 10.1677/ERC-08-0241; Vargas MP, 1997, HUM PATHOL, V28, P411, DOI 10.1016/S0046-8177(97)90028-9; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weeraratne SD, 2012, ACTA NEUROPATHOL, V123, P539, DOI 10.1007/s00401-012-0969-5; Weinhold N, 2014, NAT GENET, V46, P1160, DOI 10.1038/ng.3101; Welander J, 2012, HUM MOL GENET, V21, P5406, DOI 10.1093/hmg/dds402; Wheeler DA, 2013, GENOME RES, V23, P1054, DOI 10.1101/gr.157602.113; Wu G, 2014, NAT GENET, V46, P444, DOI 10.1038/ng.2938; Xiao MT, 2012, GENE DEV, V26, P1326, DOI 10.1101/gad.191056.112; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yang CZ, 2015, J MOL MED, V93, P93, DOI 10.1007/s00109-014-1205-7; Yao L, 2010, JAMA-J AM MED ASSOC, V304, P2611, DOI 10.1001/jama.2010.1830; Yeh IT, 2008, HUM GENET, V124, P279, DOI 10.1007/s00439-008-0553-1; Zhang QH, 2013, GENE, V527, P26, DOI 10.1016/j.gene.2013.06.006; Zhuang ZP, 2012, NEW ENGL J MED, V367, P922, DOI 10.1056/NEJMoa1205119	124	34	37	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1080	1089		10.1038/onc.2015.172	http://dx.doi.org/10.1038/onc.2015.172			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	26028031				2022-12-17	WOS:000371351700002
J	Scala, F; Brighenti, E; Govoni, M; Imbrogno, E; Fornari, F; Trere, D; Montanaro, L; Derenzini, M				Scala, F.; Brighenti, E.; Govoni, M.; Imbrogno, E.; Fornari, F.; Trere, D.; Montanaro, L.; Derenzini, M.			Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate	ONCOGENE			English	Article							POLYMERASE I; PROTEIN L11; DNA-DAMAGE; ACTIVATION; APOPTOSIS; CANCER; MDM2; PATHWAY; VIVO; 5-FLUOROURACIL	Many drugs currently used in chemotherapy work by hindering the process of ribosome biogenesis. In tumors with functional p53, the inhibition of ribosome biogenesis may contribute to the efficacy of this treatment by inducing p53 stabilization. As the level of stabilized p53 is critical for the induction of cytotoxic effects, it seems useful to highlight those cancer cell characteristics that can predict the degree of p53 stabilization following the treatment with inhibitors of ribosome biogenesis. In the present study we exposed a series of p53 wild-type human cancer cell lines to drugs such as actinomycin D (ActD), doxorubicin, 5-fluorouracil and CX-5461, which hinder ribosomal RNA (rRNA) synthesis. We found that the amount of stabilized p53 was directly related to the level of ribosome biogenesis in cells before the drug treatment. This was due to different levels of inactivation of the ribosomal proteins-MDM2 pathway of p53 digestion. Inhibition of rRNA synthesis always caused cell cycle arrest, independent of the ribosome biogenesis rate of the cells, whereas apoptosis occurred only in cells with a high rDNA transcription rate. The level of p53 stabilization induced by drugs acting in different ways from the inhibition of ribosome biogenesis, such as hydroxyurea (HU) and nutlin-3, was independent of the level of ribosome biogenesis in cells and always lower than that occurring after the inhibition of rRNA synthesis. Interestingly, in cells with a low ribosome biogenesis rate, the combined treatment with ActD and HU exerted an additive effect on p53 stabilization. These results indicated that (i) drugs inhibiting ribosome biogenesis may be highly effective in p53 wild-type cancers with a high ribosome biogenesis rate, as they induce apoptotic cell death, and (ii) the combination of drugs capable of stabilizing p53 through different mechanisms may be useful for treating cancers with a low ribosome biogenesis rate.	[Scala, F.; Brighenti, E.; Govoni, M.; Imbrogno, E.; Trere, D.; Montanaro, L.; Derenzini, M.] Univ Bologna, Dept Expt Diagnost & Specialty Med, Via Massarenti 9, I-40138 Bologna, Italy; [Fornari, F.] Azienda Osped Univ Bologna, Policlin S Orsola Malpighi, Biomed & Appl Res Ctr, Bologna, Italy	University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna	Derenzini, M (corresponding author), Univ Bologna, Dept Expt Diagnost & Specialty Med, Via Massarenti 9, I-40138 Bologna, Italy.	massimo.derenzini@unibo.it	Trere', Davide/AAC-4725-2021; Fornari, Francesca/K-6748-2016; Montanaro, Lorenzo/I-4236-2019; imbrogno, enrica/AAL-2342-2020	Trere', Davide/0000-0003-1127-1052; Montanaro, Lorenzo/0000-0001-9776-9518; Fornari, Francesca/0000-0002-4302-4411; govoni, marzia/0000-0003-1673-0107; IMBROGNO, ENRICA/0000-0002-6375-9343	Roberto and Cornelia Pallotti's Legacy for Cancer Research; Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG13480]	Roberto and Cornelia Pallotti's Legacy for Cancer Research; Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the Roberto and Cornelia Pallotti's Legacy for Cancer Research and Associazione Italiana per la Ricerca sul Cancro (AIRC, grant number IG13480).	Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Bland JM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3985; Burger K, 2010, J BIOL CHEM, V285, P12416, DOI 10.1074/jbc.M109.074211; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Deisenroth C, 2010, ONCOGENE, V29, P4253, DOI 10.1038/onc.2010.189; Derenzini M, 2005, J CELL PHYSIOL, V202, P483, DOI 10.1002/jcp.20144; Derenzini M, 2000, MICRON, V31, P117, DOI 10.1016/S0968-4328(99)00067-0; Derenzini M, 2009, HISTOPATHOLOGY, V54, P753, DOI 10.1111/j.1365-2559.2008.03168.x; Donati G, 2011, ONCOGENE, V30, P3274, DOI 10.1038/onc.2011.48; Drygin D, 2011, CANCER RES, V71, P1418, DOI 10.1158/0008-5472.CAN-10-1728; Drygin D, 2010, ANNU REV PHARMACOL, V50, P131, DOI 10.1146/annurev.pharmtox.010909.105844; Drygin D, 2009, CANCER RES, V69, P7653, DOI 10.1158/0008-5472.CAN-09-1304; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; Gajjar M, 2012, CANCER CELL, V21, P25, DOI 10.1016/j.ccr.2011.11.016; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hu Wenwei, 2012, Genes Cancer, V3, P199, DOI 10.1177/1947601912454734; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; Maggi LB, 2005, CANCER INVEST, V23, P599, DOI 10.1080/07357900500283085; Mayer C, 2005, CELL CYCLE, V4, P1036, DOI 10.4161/cc.4.8.1925; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Oskarsson T, 2005, NAT CELL BIOL, V7, P215, DOI 10.1038/ncb0305-215; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; Poortinga G, 2015, ONCOGENE, V34, P403, DOI 10.1038/onc.2014.13; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Sax Joanna K, 2003, Methods Mol Biol, V234, P65; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sun XX, 2008, J BIOL CHEM, V283, P12387, DOI 10.1074/jbc.M801387200; Sun XX, 2007, J BIOL CHEM, V282, P8052, DOI 10.1074/jbc.M610621200; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45; Yuan XJ, 2005, MOL CELL, V19, P77, DOI 10.1016/j.molcel.2005.05.023; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	55	34	36	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					977	989		10.1038/onc.2015.147	http://dx.doi.org/10.1038/onc.2015.147			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	25961931				2022-12-17	WOS:000370823300004
J	Haeger, SM; Thompson, JJ; Kalra, S; Cleaver, TG; Merrick, D; Wang, XJ; Malkoski, SP				Haeger, S. M.; Thompson, J. J.; Kalra, S.; Cleaver, T. G.; Merrick, D.; Wang, X-J; Malkoski, S. P.			Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; BASAL-CELLS; STEM-CELLS; REPAIR; ADENOCARCINOMA; MOUSE; EXPRESSION; PTEN; DISRUPTION; ACTIVATION	Non-small-cell lung cancer (NSCLC) is a common malignancy with a poor prognosis. Despite progress targeting oncogenic drivers, there are no therapies targeting tumor-suppressor loss. Smad4 is an established tumor suppressor in pancreatic and colon cancer; however, the consequences of Smad4 loss in lung cancer are largely unknown. We evaluated Smad4 expression in human NSCLC samples and examined Smad4 alterations in large NSCLC data sets and found that reduced Smad4 expression is common in human NSCLC and occurs through a variety of mechanisms, including mutation, homozygous deletion and heterozygous loss. We modeled Smad4 loss in lung cancer by deleting Smad4 in airway epithelial cells and found that Smad4 deletion both initiates and promotes lung tumor development. Interestingly, both Smad4(-/-) mouse tumors and human NSCLC samples with reduced Smad4 expression demonstrated increased DNA damage, whereas Smad4 knockdown in lung cancer cells reduced DNA repair and increased apoptosis after DNA damage. In addition, Smad4-deficient NSCLC cells demonstrated increased sensitivity to both chemotherapeutics that inhibit DNA topoisomerase and drugs that block double-strand DNA break repair by non-homologous end joining. In sum, these studies establish Smad4 as a lung tumor suppressor and suggest that the defective DNA repair phenotype of Smad4-deficient tumors can be exploited by specific therapeutic strategies.	[Haeger, S. M.; Thompson, J. J.; Kalra, S.; Cleaver, T. G.; Malkoski, S. P.] Univ Colorado, Div Pulm Sci & Crit Care Med, Denver Anschutz Med Campus,12700 E 19th Ave,RC2,R, Aurora, CO 80045 USA; [Merrick, D.; Wang, X-J; Malkoski, S. P.] Univ Colorado, Dept Pathol, Denver Anschutz Med Campus, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Malkoski, SP (corresponding author), Univ Colorado, Div Pulm Sci & Crit Care Med, Denver Anschutz Med Campus,12700 E 19th Ave,RC2,R, Aurora, CO 80045 USA.	Stephen.Malkoski@ucdenver.edu			NIH/NCI [K08 CA131483]; NIH/NIDCR [R01 DE015953]; National Lung Cancer Partnership; Colorado Lung Cancer SPORE [P50 CA058187]; American Cancer Society Institutional Research Grant [ACS IRG 57-001-53];  [P30 CA069533];  [P30 CA046934]; NATIONAL CANCER INSTITUTE [P30CA046934, P50CA058187, R21CA194662, K08CA131483, P30CA069533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007635] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); National Lung Cancer Partnership; Colorado Lung Cancer SPORE; American Cancer Society Institutional Research Grant(American Cancer Society); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the NIH/NCI (K08 CA131483 to SPM) and NIH/NIDCR (R01 DE015953 to XJW). SPM was also supported by the National Lung Cancer Partnership and a Career Development Award from the Colorado Lung Cancer SPORE (P50 CA058187) and an American Cancer Society Institutional Research Grant (ACS IRG 57-001-53). The OHSU BioLibrary is supported by P30 CA069533. The Colorado Lung Cancer SPORE Tissue Bank is supported by P30 CA046934 and P50 CA058187. We thank OHSU BioLibrary staff for their assistance with patient samples. We also thank Jerry Haney, Christina Nall, Marina Lewis and Wilbur Franklin at the Colorado Lung SPORE for assistance acquiring patient samples and data.	Achanta G, 2001, CANCER RES, V61, P8723; Adachi N, 2004, J BIOL CHEM, V279, P37343, DOI 10.1074/jbc.M313910200; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; Bargonetti J, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/698960; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Berton TR, 2000, GENESIS, V26, P160, DOI 10.1002/(SICI)1526-968X(200002)26:2<160::AID-GENE20>3.0.CO;2-#; Bornstein S, 2009, J CLIN INVEST, V119, P3408, DOI 10.1172/JCI38854; Caulin C, 2004, CANCER RES, V64, P5054, DOI 10.1158/0008-5472.CAN-04-1488; Crul M, 2003, BIOCHEM PHARMACOL, V65, P275, DOI 10.1016/S0006-2952(02)01508-3; Curtin NJ, 2012, NAT REV CANCER, V12, P801, DOI 10.1038/nrc3399; Gemma A, 2001, EUR J CANCER, V37, P1554, DOI 10.1016/S0959-8049(01)00154-X; Glick AB, 1997, CANCER RES, V57, P2079; Goldstraw P, 2011, LANCET, V378, P1727, DOI 10.1016/S0140-6736(10)62101-0; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hong KU, 2004, AM J PATHOL, V164, P577, DOI 10.1016/S0002-9440(10)63147-1; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Izeradjene K, 2007, CANCER CELL, V11, P229, DOI 10.1016/j.ccr.2007.01.017; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jalal S, CLIN CANC RES, V17, P6973; Jazag A, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni130; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jin SF, 1998, CARCINOGENESIS, V19, P965, DOI 10.1093/carcin/19.6.965; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kass EM, 2010, FEBS LETT, V584, P3703, DOI 10.1016/j.febslet.2010.07.057; Ke Z, 2008, NEOPLASMA, V55, P323; Kirshner J, 2006, CANCER RES, V66, P10861, DOI 10.1158/0008-5472.CAN-06-2565; Kojima K, 2007, CANCER RES, V67, P8121, DOI 10.1158/0008-5472.CAN-06-4167; Kumar PA, 2011, CELL, V147, P525, DOI 10.1016/j.cell.2011.10.001; Li WM, 2003, DEVELOPMENT, V130, P6143, DOI 10.1242/dev.00820; Malkoski SP, 2014, MOL CARCINOGEN, V53, P841, DOI 10.1002/mc.22030; Malkoski SP, 2012, FEBS LETT, V586, P1984, DOI 10.1016/j.febslet.2012.01.054; Malkoski SP, 2012, CLIN CANCER RES, V18, P2173, DOI 10.1158/1078-0432.CCR-11-2557; Malkoski SP, 2010, INT J BIOL SCI, V6, P68; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Nagatake M, 1996, CANCER RES, V56, P2718; Neal JA, 2011, MUTAT RES-FUND MOL M, V711, P73, DOI 10.1016/j.mrfmmm.2011.02.010; Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376; Papageorgis P, 2011, CANCER RES, V71, P998, DOI 10.1158/0008-5472.CAN-09-3269; Qiao W, 2006, ONCOGENE, V25, P207, DOI 10.1038/sj.onc.1209029; Rock JR, 2009, P NATL ACAD SCI USA, V106, P12771, DOI 10.1073/pnas.0906850106; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; Teng Y, 2006, CANCER RES, V66, P6972, DOI 10.1158/0008-5472.CAN-06-0507; Treszezamsky AD, 2007, CANCER RES, V67, P7078, DOI 10.1158/0008-5472.CAN-07-0601; Wachters FM, 2003, INT J RADIAT ONCOL, V57, P553, DOI 10.1016/s0360-3016(03)00503-0; Woods D, 2013, CANCER BIOL THER, V14, P379, DOI 10.4161/cbt.23761; Wunderlich FT, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.10.e47; Wyatt MD, 2009, CELL MOL LIFE SCI, V66, P788, DOI 10.1007/s00018-008-8557-5; Xu X, 2010, ONCOGENE, V29, P674, DOI 10.1038/onc.2009.375; Xu XL, 2006, J CLIN INVEST, V116, P1843, DOI 10.1172/JCI27282; Yanagisawa K, 2000, ONCOGENE, V19, P2305, DOI 10.1038/sj.onc.1203591; Yang LL, 2005, CANCER RES, V65, P8671, DOI 10.1158/0008-5472.CAN-05-0800; Yu SL, 2013, ONCOL REP, V30, P1293, DOI 10.3892/or.2013.2578	52	34	35	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					577	586		10.1038/onc.2015.112	http://dx.doi.org/10.1038/onc.2015.112			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25893305	Green Accepted			2022-12-17	WOS:000369548800005
J	Zunino, B; Rubio-Patino, C; Villa, E; Meynet, O; Proics, E; Cornille, A; Pommier, S; Mondragon, L; Chiche, J; Bereder, JM; Carles, M; Ricci, JE				Zunino, B.; Rubio-Patino, C.; Villa, E.; Meynet, O.; Proics, E.; Cornille, A.; Pommier, S.; Mondragon, L.; Chiche, J.; Bereder, J-M; Carles, M.; Ricci, J-E			Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90	ONCOGENE			English	Article							PERITONEAL CARCINOMATOSIS; CYTOREDUCTIVE SURGERY; DENDRITIC CELL; CANCER; TUMOR; HEAT-SHOCK-PROTEIN-90; IMMUNOSURVEILLANCE; INHIBITION; APOPTOSIS	The occurrence of peritoneal carcinomatosis is a major cause of treatment failure in colorectal cancer and is considered incurable. However, new therapeutic approaches have been proposed, including cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC). Although HIPEC has been effective in selected patients, it is not known how HIPEC prolongs a patient's lifespan. Here, we have demonstrated that HIPEC-treated tumor cells induce the activation of tumor-specific T cells and lead to vaccination against tumor cells in mice. We have established that this effect results from the HIPEC-mediated exposure of heat shock protein (HSP) 90 at the plasma membrane. Inhibition or blocking of HSP90, but not HSP70, prevented the HIPECmediated antitumoral vaccination. Our work raises the possibility that the HIPEC procedure not only kills tumor cells but also induces an efficient anticancer immune response, therefore opening new opportunities for cancer treatment.	[Zunino, B.; Rubio-Patino, C.; Villa, E.; Meynet, O.; Proics, E.; Cornille, A.; Pommier, S.; Mondragon, L.; Chiche, J.; Carles, M.; Ricci, J-E] Ctr Mediterraneen Med Mol C3M, INSERM, U1065, Equipe Controle Metab Morts Cellulaires, F-06204 Nice 03, France; [Zunino, B.; Rubio-Patino, C.; Villa, E.; Meynet, O.; Proics, E.; Cornille, A.; Pommier, S.; Mondragon, L.; Chiche, J.; Carles, M.; Ricci, J-E] Univ Nice Sophia Antipolis, Fac Med, F-06189 Nice, France; [Zunino, B.; Pommier, S.; Carles, M.; Ricci, J-E] CHU Nice, Dept Anesthesie Reanimat, F-06202 Nice, France; [Bereder, J-M] CHU Nice, Serv Chirurg Gen & Cancerol Digest, F-06202 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; CHU Nice	Ricci, JE (corresponding author), Ctr Mediterraneen Med Mol C3M, INSERM, U1065, Equipe Controle Metab Morts Cellulaires, 151 Route St Antoine de Ginestiere,BP 23194, F-06204 Nice 03, France.	ricci@unice.fr	Martinez, Laura Mondragon/P-1670-2018; Martinez, Laura Mondragon/X-1577-2019; Ricci, Jean Ehrland/I-7117-2016; Chiche, Johanna/P-6382-2016; Carles, Michel/CAH-0065-2022; RICCI, Jean Ehrland/AAS-4379-2020	Martinez, Laura Mondragon/0000-0002-3257-045X; Martinez, Laura Mondragon/0000-0002-3257-045X; Ricci, Jean Ehrland/0000-0003-1585-8117; Chiche, Johanna/0000-0001-5276-1125; RICCI, Jean Ehrland/0000-0003-1585-8117; CARLES, MICHEL/0000-0001-5485-1511; Rubio-Patino, Camila/0000-0002-0489-2419	Fondation ARC (Association pour la Recherche sur le Cancer); Agence Nationale de la Recherche (LABEX SIGNALIFE) [ANR-11-LABX-0028-01]; Fondation ARC; la Ville de Nice; Fondation pour la Recherche Medicale (FRM); la Fondation de France	Fondation ARC (Association pour la Recherche sur le Cancer)(Fondation ARC pour la Recherche sur le Cancer); Agence Nationale de la Recherche (LABEX SIGNALIFE)(French National Research Agency (ANR)); Fondation ARC; la Ville de Nice; Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); la Fondation de France(Fondation de France)	We gratefully acknowledge the Centre Mediterraneen de Medecine Moleculaire animal room and imaging facilities. We thank Jozef Bossowski, Drs Raucoules and Benchimol, Benjamin Lefebvre and all of the operating room and surgical digestive service nurses for their help. This work was supported by the Fondation ARC (Association pour la Recherche sur le Cancer), the Agence Nationale de la Recherche (LABEX SIGNALIFE ANR-11-LABX-0028-01). CRP is supported by the Fondation ARC, LM is supported by la Ville de Nice and by Fondation pour la Recherche Medicale (FRM) and JC is supported by la Fondation de France.	Bae J, 2007, J IMMUNOL, V178, P7730, DOI 10.4049/jimmunol.178.12.7730; Beneteau M, 2012, P NATL ACAD SCI USA, V109, P20071, DOI 10.1073/pnas.1206360109; Botzler C, 1998, CELL STRESS CHAPERON, V3, P6, DOI 10.1379/1466-1268(1998)003<0006:DOELEO>2.3.CO;2; Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957; Elias D, 2009, J CLIN ONCOL, V27, P681, DOI 10.1200/JCO.2008.19.7160; Garg AD, 2010, BBA-REV CANCER, V1805, P53, DOI 10.1016/j.bbcan.2009.08.003; John K, 2002, BIOPHYS J, V83, P3315, DOI 10.1016/S0006-3495(02)75332-0; Kepp O, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.955691; Kim YS, 2009, CURR TOP MED CHEM, V9, P1479, DOI 10.2174/156802609789895728; Klaver YLB, 2010, BRIT J SURG, V97, P1874, DOI 10.1002/bjs.7249; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Lanneau D, 2008, J CELL MOL MED, V12, P743, DOI 10.1111/j.1582-4934.2008.00273.x; Massey AJ, 2010, CANCER CHEMOTH PHARM, V66, P535, DOI 10.1007/s00280-009-1194-3; Murshid A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00063; Pelz JOW, 2013, ANN SURG ONCOL, V20, P1105, DOI 10.1245/s10434-012-2784-6; Pockley AG, 2003, LANCET, V362, P469, DOI 10.1016/S0140-6736(03)14075-5; Schmitt E, 2006, CANCER RES, V66, P4191, DOI 10.1158/0008-5472.CAN-05-3778; Senovilla L, 2012, SCIENCE, V337, P1678, DOI 10.1126/science.1224922; Spiliotis JD, 2010, HEPATO-GASTROENTEROL, V57, P1173; Spisek R, 2007, BLOOD, V109, P4839, DOI 10.1182/blood-2006-10-054221; Sugarbaker PH, 2012, GASTROENT RES PRACT, V2012, DOI 10.1155/2012/623417; Tsutsumi S, 2008, ONCOGENE, V27, P2478, DOI 10.1038/sj.onc.1210897; Tsvetkova NM, 2002, P NATL ACAD SCI USA, V99, P13504, DOI 10.1073/pnas.192468399; Wilke CM, 2010, INT J CANCER, V127, P748, DOI 10.1002/ijc.25464; Yang XJ, 2009, ANN SURG ONCOL, V16, P345, DOI 10.1245/s10434-008-0226-2; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	26	34	45	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					261	268		10.1038/onc.2015.82	http://dx.doi.org/10.1038/onc.2015.82			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25867070				2022-12-17	WOS:000368193900012
J	Wang, J; Tang, X; Weng, W; Qiao, Y; Lin, J; Liu, W; Liu, R; Ma, L; Yu, W; Yu, Y; Pan, Q; Sun, F				Wang, J.; Tang, X.; Weng, W.; Qiao, Y.; Lin, J.; Liu, W.; Liu, R.; Ma, L.; Yu, W.; Yu, Y.; Pan, Q.; Sun, F.			The membrane protein melanoma cell adhesion molecule (MCAM) is a novel tumor marker that stimulates tumorigenesis in hepatocellular carcinoma	ONCOGENE			English	Article							YES-ASSOCIATED PROTEIN; LONG NONCODING RNA; LIVER-CANCER CELLS; TRANSLATION INITIATION; MUTUAL INTERACTION; YAP; GROWTH; TRANSCRIPTION; ACTIVATION; INHIBITION	Yes-associated protein (YAP) is overexpressed and has an oncogenic role in hepatocellular carcinoma (HCC). However, whether membrane protein can serve not only as a tumor marker that reflects YAP function but also as a therapeutic target that stimulates tumorigenesis in HCC remains unknown. Here we report that the membrane protein melanoma cell adhesion molecule (MCAM) was under positive regulation by YAP and was highly elevated in HCC cells. Within the MCAM promoter, we found the presence of a cAMP Response Element (CRE; -32 to -25 nt), which is conserved among species and is essential for YAP-and CREB-dependent regulation. Moreover, the interaction between CREB and YAP at the CRE site was dependent on PTPIY-WW domain interactions. However, MCAM expression was low and could not be regulated by YAP in breast and colon cancer cells because of the low levels of the acetyltransferase p300. In HCC cells, high levels of p300 facilitated the binding of YAP to the MCAM promoter, which in turn enhanced histone acetylation and polymerase II recruitment through the dissociation of the deacetylase Sirt1. These results suggest that MCAM is an HCC-specific target of YAP. In clinical serum samples, we found that the serum levels of MCAM were highly elevated in patients with HCC compared with healthy controls and with patients with cirrhosis, hepatitis, colon cancer and breast cancer. MCAM levels were shown to be a slightly better indicator than serum alpha-fetoprotein for predicting HCC. We further demonstrated that MCAM is essential for the survival and transformation of HCC. Mechanistically, MCAM induced translation initiation and the transcriptional activities of c-Jun/c-Fos. In addition, AKT activation had an essential role in the MCAM-promoted binding of eukaryotic initiation factor 4E to c-Jun/c-Fos mRNA. In conclusion, we demonstrated that MCAM may be a potential tumor marker and therapeutic target for the diagnosis and treatment of HCC.	[Wang, J.; Tang, X.; Weng, W.; Liu, W.; Ma, L.; Yu, W.; Sun, F.] Tongji Univ, Shanghai Peoples Hosp 10, Dept Clin Lab Med, Shanghai 200072, Peoples R China; [Qiao, Y.] Shanghai Jiao Tong Univ, Sch Med, Sch Publ Hlth, Shanghai, Peoples R China; [Lin, J.] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Clin Lab Med, Shanghai, Peoples R China; [Liu, R.] Tongji Univ, Shanghai Peoples Hosp 10, Dept Sci & Res, Shanghai 200072, Peoples R China; [Yu, Y.] Shanghai TCM Univ, Shanghai Municipal Hosp Tradit Chinese Med, Shanghai, Peoples R China; [Pan, Q.] Tongji Univ, Shanghai Peoples Hosp 10, Dept Cent Lab, Shanghai 200072, Peoples R China	Tongji University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Tongji University; Tongji University	Sun, F (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Dept Clin Lab Med, 301 Middle Yanchang Rd, Shanghai 200072, Peoples R China.	panqiuhui@263.net; sunfenyong@126.com		Wang, Jiayi/0000-0003-1688-2864	China National 973 Project [2012CB966904, 20110402]; National Natural Science Foundation of China [81301689, 81201884]; Yangfan Project of the Shanghai Committee of Science and Technology [14YF1412300]; Outstanding Youth Training Program of Tongji University [1501219080]; Shanghai Tenth People's Hospital Climbing Training Program [04.01.13024]	China National 973 Project(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Yangfan Project of the Shanghai Committee of Science and Technology; Outstanding Youth Training Program of Tongji University; Shanghai Tenth People's Hospital Climbing Training Program	This work was supported by the China National 973 Project (2012CB966904 and 20110402), the National Natural Science Foundation of China (81301689 and 81201884), the Yangfan Project of the Shanghai Committee of Science and Technology (14YF1412300), the Outstanding Youth Training Program of Tongji University (1501219080) and the Shanghai Tenth People's Hospital Climbing Training Program (04.01.13024).	Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Bardin N, 1998, FEBS LETT, V421, P12, DOI 10.1016/S0014-5793(97)01455-5; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Fan R, 2013, P NATL ACAD SCI USA, V110, P2569, DOI 10.1073/pnas.1216462110; He L, 2006, J BIOL CHEM, V281, P11126, DOI 10.1074/jbc.M510724200; Iatropoulos MJ, 1996, EXP TOXICOL PATHOL, V48, P175, DOI 10.1016/S0940-2993(96)80039-X; LEHMANN JM, 1987, CANCER RES, V47, P841; Li G, 2003, ONCOGENE, V22, P6891, DOI 10.1038/sj.onc.1206819; Li H, 2012, LIVER INT, V32, P38, DOI 10.1111/j.1478-3231.2011.02646.x; Li LL, 2013, FEBS LETT, V587, P3921, DOI 10.1016/j.febslet.2013.10.042; Ma LF, 2014, J BIOL CHEM, V289, P6921, DOI 10.1074/jbc.M113.524819; Mills L, 2002, CANCER RES, V62, P5106; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Quan TH, 2010, J INVEST DERMATOL, V130, P1697, DOI 10.1038/jid.2010.29; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Servillo G, 2002, EXP CELL RES, V275, P143, DOI 10.1006/excr.2002.5491; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Sudol Marius, 2010, Genes Cancer, V1, P1115, DOI 10.1177/1947601911401911; Tschaharganeh DF, 2013, GASTROENTEROLOGY, V144, P1530, DOI 10.1053/j.gastro.2013.02.009; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Urtasun R, 2011, HEPATOLOGY, V54, P2149, DOI 10.1002/hep.24587; Wang JY, 2014, CELL SIGNAL, V26, P1048, DOI 10.1016/j.cellsig.2014.01.022; Wang JY, 2013, HEPATOLOGY, V58, P1011, DOI 10.1002/hep.26420; Wang JY, 2013, MOL CELL, V51, P211, DOI 10.1016/j.molcel.2013.05.013; Wang JY, 2011, NUCLEIC ACIDS RES, V39, P6440, DOI 10.1093/nar/gkr302; Wang JY, 2010, NUCLEIC ACIDS RES, V38, P5366, DOI 10.1093/nar/gkq285; Wang ZQ, 2013, CANCER LETT, V330, P150, DOI 10.1016/j.canlet.2012.11.049; Xiao WF, 2013, BIOCHEM BIOPH RES CO, V439, P167, DOI 10.1016/j.bbrc.2013.08.071; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Xue HP, 2011, INT J BIOCHEM CELL B, V43, P348, DOI 10.1016/j.biocel.2010.11.002; Yamaguchi K, 2005, J BIOL CHEM, V280, P32569, DOI 10.1074/jbc.M503201200; Yu WJ, 2014, CELL SIGNAL, V26, P2961, DOI 10.1016/j.cellsig.2014.09.011; Zhang H, 2012, CELL SIGNAL, V24, P224, DOI 10.1016/j.cellsig.2011.09.004; Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408	39	34	37	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2015	34	47					5781	5795		10.1038/onc.2015.36	http://dx.doi.org/10.1038/onc.2015.36			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW5KV	25728681				2022-12-17	WOS:000365035200002
J	Licciardello, MP; Mullner, MK; Durnberger, G; Kerzendorfer, C; Boidol, B; Trefzer, C; Sdelci, S; Berg, T; Penz, T; Schuster, M; Bock, C; Kralovics, R; Superti-Furga, G; Colinge, J; Nijman, SM; Kubicek, S				Licciardello, M. P.; Muellner, M. K.; Duernberger, G.; Kerzendorfer, C.; Boidol, B.; Trefzer, C.; Sdelci, S.; Berg, T.; Penz, T.; Schuster, M.; Bock, C.; Kralovics, R.; Superti-Furga, G.; Colinge, J.; Nijman, S. M.; Kubicek, S.			NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation	ONCOGENE			English	Article							PATHWAY; TUMORS; SUMO; UBC9; IDENTIFICATION; GENERATION; LEUKEMIA; EFFICACY; REVEALS; PROTEIN	Breast cancer is genetically heterogeneous, and recent studies have underlined a prominent contribution of epigenetics to the development of this disease. To uncover new synthetic lethalities with known breast cancer oncogenes, we screened an epigenome-focused short hairpin RNA library on a panel of engineered breast epithelial cell lines. Here we report a selective interaction between the NOTCH1 signaling pathway and the SUMOylation cascade. Knockdown of the E2-conjugating enzyme UBC9 (UBE2I) as well as inhibition of the E1-activating complex SAE1/UBA2 using ginkgolic acid impairs the growth of NOTCH1-activated breast epithelial cells. We show that upon inhibition of SUMOylation NOTCH1-activated cells proceed slower through the cell cycle and ultimately enter apoptosis. Mechanistically, activation of NOTCH1 signaling depletes the pool of unconjugated small ubiquitin-like modifier 1 (SUMO1) and SUMO2/3 leading to increased sensitivity to perturbation of the SUMOylation cascade. Depletion of unconjugated SUMO correlates with sensitivity to inhibition of SUMOylation also in patient-derived breast cancer cell lines with constitutive NOTCH pathway activation. Our investigation suggests that SUMOylation cascade inhibitors should be further explored as targeted treatment for NOTCH-driven breast cancer.	[Licciardello, M. P.; Muellner, M. K.; Duernberger, G.; Kerzendorfer, C.; Boidol, B.; Trefzer, C.; Sdelci, S.; Berg, T.; Penz, T.; Schuster, M.; Bock, C.; Kralovics, R.; Superti-Furga, G.; Colinge, J.; Nijman, S. M.; Kubicek, S.] Austrian Acad Sci, CeMM Res Ctr Mol Med, A-1090 Vienna, Austria; [Boidol, B.; Kubicek, S.] Austrian Acad Sci, CeMM Res Ctr Mol Med, Christian Doppler Lab Chem Epigenet & Antiinfect, A-1090 Vienna, Austria	Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences	Kubicek, S (corresponding author), Austrian Acad Sci, CeMM Res Ctr Mol Med, Lazarettgasse 14 AKH BT 25-3, A-1090 Vienna, Austria.	skubicek@cemm.oeaw.ac.at	Jessen-Trefzer, Claudia/E-3710-2019; sdelci, sara/S-2243-2018; Bock, Christoph/AAE-7618-2019; Kubicek, Stefan/C-2089-2017; Colinge, Jacques/Z-2613-2019; Colinge, Jacques/D-1578-2017; Superti-Furga, Giulio/AAE-5681-2019; Superti-Furga, Giulio/F-4755-2015	Jessen-Trefzer, Claudia/0000-0003-4216-8189; sdelci, sara/0000-0003-1330-4364; Bock, Christoph/0000-0001-6091-3088; Kubicek, Stefan/0000-0003-0855-8343; Colinge, Jacques/0000-0003-2466-4824; Colinge, Jacques/0000-0003-2466-4824; Licciardello, Marco/0000-0003-3197-4855; Schuster, Michael/0000-0003-2975-8969; Kralovics, Robert/0000-0002-6997-8539; Nijman, Sebastian/0000-0003-0464-6661; Superti-Furga, Giulio/0000-0002-0570-1768	Marie Curie Career Integration Grant; Austrian Federal Ministry of Science, Research and Economy; National Foundation for Research, Technology and Development	Marie Curie Career Integration Grant; Austrian Federal Ministry of Science, Research and Economy; National Foundation for Research, Technology and Development	We thank John Doench, Serena Silver and David E Root (Broad Institute of MIT and Harvard) for shRNA tools and screening protocols; Johannes Bigenzahn (CeMM) for providing the pMSCV-StrepHA-GW-hPGK-Bla vector; and Erika Schirghuber (CeMM) and Berend Snijder (CeMM) for critically reading the manuscript. SK acknowledges support by a Marie Curie Career Integration Grant, the Austrian Federal Ministry of Science, Research and Economy and the National Foundation for Research, Technology and Development.	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Al-Hussaini H, 2011, MOL CANCER THER, V10, P9, DOI 10.1158/1535-7163.MCT-10-0677; Andersson ER, 2014, NAT REV DRUG DISCOV, V13, P359, DOI 10.1038/nrd4252; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Falk R, 2012, METHODS, V58, P69, DOI 10.1016/j.ymeth.2012.07.008; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Fukuda I, 2009, CHEM BIOL, V16, P133, DOI 10.1016/j.chembiol.2009.01.009; Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Johnson DG, 2013, CELL, V152, P685, DOI 10.1016/j.cell.2013.01.017; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kessler JD, 2011, SCIENCE, V335, P348; Knipscheer P, 2008, MOL CELL, V31, P371, DOI 10.1016/j.molcel.2008.05.022; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lobry C, 2011, J EXP MED, V208, P1931, DOI 10.1084/jem.20111855; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Mair B, 2014, TRENDS PHARMACOL SCI, V35, P136, DOI 10.1016/j.tips.2014.01.001; Marcotte R, 2012, CANCER DISCOV, V2, P172, DOI 10.1158/2159-8290.CD-11-0224; Maxmen A, 2012, NATURE, V485, pS50, DOI 10.1038/485S50a; Mazzone M, 2010, P NATL ACAD SCI USA, V107, P5012, DOI 10.1073/pnas.1000896107; Mo YY, 2005, ONCOGENE, V24, P2677, DOI 10.1038/sj.onc.1208210; Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Moschos SJ, 2007, ONCOGENE, V26, P4216, DOI 10.1038/sj.onc.1210216; Muellner MK, 2011, NAT CHEM BIOL, V7, P787, DOI 10.1038/nchembio.695; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Nijman SMB, 2011, FEBS LETT, V585, P1, DOI 10.1016/j.febslet.2010.11.024; Pfander B, 2005, NATURE, V436, P428, DOI 10.1038/nature03665; Purow B, 2012, ADV EXP MED BIOL, V727, P305, DOI 10.1007/978-1-4614-0899-4_23; Radtke F, 2010, IMMUNITY, V32, P14, DOI 10.1016/j.immuni.2010.01.004; Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035; Rao SS, 2009, CANCER RES, V69, P3060, DOI 10.1158/0008-5472.CAN-08-4295; Robinson DR, 2011, NAT MED, V17, P1646, DOI 10.1038/nm.2580; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Sims D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-10-r104; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Whitfield ML, 2000, MOL CELL BIOL, V20, P4188, DOI 10.1128/MCB.20.12.4188-4198.2000	49	34	35	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3780	3790		10.1038/onc.2014.319	http://dx.doi.org/10.1038/onc.2014.319			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25263445				2022-12-17	WOS:000358001600004
J	Yang, YM; Lee, WH; Lee, CG; An, J; Kim, ES; Kim, SH; Lee, SK; Lee, CH; Dhanasekaran, DN; Moon, A; Hwang, S; Lee, SJ; Park, JW; Kim, KM; Kim, SG				Yang, Y. M.; Lee, W. H.; Lee, C. G.; An, J.; Kim, E-S; Kim, S. H.; Lee, S-K; Lee, C. H.; Dhanasekaran, D. N.; Moon, A.; Hwang, S.; Lee, S. J.; Park, J-W; Kim, K. M.; Kim, S. G.			G alpha(12) gep oncogene deregulation of p53-responsive microRNAs promotes epithelial-mesenchymal transition of hepatocellular carcinoma	ONCOGENE			English	Article							HETEROTRIMERIC G-PROTEINS; SPHINGOSINE 1-PHOSPHATE; P53-INDUCIBLE MICRORNAS; TARGETING ZEB1; MIR-200 FAMILY; TUMOR-GROWTH; G12 FAMILY; P53; INVASION; EXPRESSION	Hepatocellular carcinoma (HCC) has a poor prognosis owing to aggressive phenotype. G alpha(12) gep oncogene product couples to G-protein-coupled receptors, whose ligand levels are frequently increased in tumor microenvironments. Here, we report G alpha(12) overexpression in human HCC and the resultant induction of zinc-finger E-box-binding homeobox 1 (ZEB1) as mediated by microRNA deregulation. G alpha(12) expression was higher in HCC than surrounding non-tumorous tissue. Transfection of Huh7 cell with an activated mutant of G alpha(12) (G alpha(12)QL) deregulated microRNA (miRNA or miR)-200b/a/429, -194-2/192 and -194-1/215 clusters in the miRNome. cDNA microarray analyses disclosed the targets affected by G alpha(12) gene knockout. An integrative network of miRNAs and mRNA changes enabled us to predict ZEB1 as a key molecule governed by G alpha(12). Decreases of miR-200a/b, -192 and -215 by G alpha(12) caused ZEB1 induction. The ability of G alpha(12) to decrease p53 levels, as a result of activating protein-1 (AP-1)/c-Jun-mediated mouse double minute 2 homolog induction, contributed to transcriptional deregulation of the miRNAs. G alpha(12)QL induced ZEB1 and other epithelial-mesenchymal transition markers with fibroblastoid phenotype change. Consistently, transfection with miR-200b, -192 or -215 mimic prevented the ability of G alpha(12)QL to increase tumor cell migration/invasion. In xenograft studies, sustained knockdown of G alpha(12) decreased the overall growth rate and average volume of tumors derived from SK-Hep1 cell (mesenchymal-typed). In HCC patients, miR-192, -215 and/or -200a were deregulated with microvascular invasion or growth advantage. In the HCC samples with higher G alpha(12) level, a correlation existed in the comparison of relative changes of G alpha(12) and ZEB1. In conclusion, G alpha(12) overexpressed in HCC causes ZEB1 induction by deregulating p53-responsive miRNAs, which may facilitate epithelial-mesenchymal transition and growth of liver tumor. These findings highlight the significance of G alpha(12) upregulation in liver tumor progression, implicating G alpha(12) as an attractive therapeutic target.	[Yang, Y. M.; Lee, W. H.; Lee, C. G.; Kim, S. G.] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; [Yang, Y. M.; Lee, W. H.; Lee, C. G.; Kim, S. G.] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea; [An, J.; Kim, K. M.] Univ Ulsan, Coll Med, Asan Med Ctr, Asan Liver Ctr,Dept Internal Med, Seoul, South Korea; [Kim, E-S; Moon, A.] Duksung Womens Univ, Coll Pharm, Seoul, South Korea; [Kim, S. H.; Lee, C. H.; Hwang, S.] Hanyang Univ, Coll Med, Seoul 133791, South Korea; [Lee, S-K; Park, J-W] Natl Canc Ctr, Ctr Liver Canc, Goyang, South Korea; [Dhanasekaran, D. N.] Univ Oklahoma, Hlth Sci Ctr, OU Inst Canc, Dept Cell Biol, Oklahoma City, OK USA; [Lee, S. J.] Gachon Univ, Coll Pharm, Inchon, South Korea	Seoul National University (SNU); Seoul National University (SNU); University of Ulsan; Asan Medical Center; Duksung Women's University; Hanyang University; National Cancer Center - Korea (NCC); University of Oklahoma System; University of Oklahoma Health Sciences Center; Gachon University	Kim, SG (corresponding author), Seoul Natl Univ, Coll Pharm, 1 Gwanak Ro, Seoul 151742, South Korea.	sgk@snu.ac.kr		Yang, Yoon Mee/0000-0003-4281-9906; An, Jihyun/0000-0002-0110-0965; Lee, Seung Jin/0000-0003-0625-7774	National Research Foundation of Korea (NRF) grant - Korea government (MSIP) [2007-0056817]; World Class University project [R322012000100980]; National Cancer Center [1110050]	National Research Foundation of Korea (NRF) grant - Korea government (MSIP); World Class University project; National Cancer Center	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2007-0056817) and in part by the World Class University project (R322012000100980) and National Cancer Center (No. 1110050). We thank Prof Dr Soon-Sun Hong and Hee-Seung Lee for their indispensable support.	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chen XL, 2011, J HEPATOL, V55, P838, DOI 10.1016/j.jhep.2010.12.043; Dharel N, 2008, HEPATOLOGY, V47, P1136, DOI 10.1002/hep.22176; Di Como CJ, 1998, ONCOGENE, V16, P2527; Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005; Feng B, 2012, BIOMED PHARMACOTHER, V66, P397, DOI 10.1016/j.biopha.2012.06.002; Fornari F, 2009, CANCER RES, V69, P5761, DOI 10.1158/0008-5472.CAN-08-4797; Georges SA, 2008, CANCER RES, V68, P10105, DOI 10.1158/0008-5472.CAN-08-1846; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Grzelinski M, 2010, CLIN CANCER RES, V16, P1402, DOI 10.1158/1078-0432.CCR-09-1873; Gu JL, 2002, P NATL ACAD SCI USA, V99, P9352, DOI 10.1073/pnas.102291599; Hsieh JL, 2003, CLIN CANCER RES, V9, P338; Kang KW, 2003, J BIOL CHEM, V278, P17368, DOI 10.1074/jbc.M300471200; Kelly P, 2007, BIOCHEMISTRY-US, V46, P6677, DOI 10.1021/bi700235f; Kelly P, 2006, J BIOL CHEM, V281, P26483, DOI 10.1074/jbc.M604376200; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Ki SH, 2007, J BIOL CHEM, V282, P1938, DOI 10.1074/jbc.M606080200; Kim ES, 2011, J CELL SCI, V124, P2220, DOI 10.1242/jcs.076794; Kim MS, 2007, MOL CANCER RES, V5, P473, DOI 10.1158/1541-7786.MCR-06-0395; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Lee JM, 2012, INT J CANCER, V130, P716, DOI 10.1002/ijc.26075; Lee SJ, 2009, ONCOGENE, V28, P1230, DOI 10.1038/onc.2008.488; Lin F, 2009, J CELL BIOL, V184, P909, DOI 10.1083/jcb.200805148; Liu SC, 2009, CANCER RES, V69, P6122, DOI 10.1158/0008-5472.CAN-08-3435; Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58; Mazzocca A, 2011, HEPATOLOGY, V54, P920, DOI 10.1002/hep.24485; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pichiorri F, 2010, CANCER CELL, V18, P367, DOI 10.1016/j.ccr.2010.09.005; Poon RTP, 2000, ANN SURG, V232, P10, DOI 10.1097/00000658-200007000-00003; Riobo NA, 2005, TRENDS PHARMACOL SCI, V26, P146, DOI 10.1016/j.tips.2005.01.007; Sanchez-Tillo E, 2014, CELL DEATH DIFFER, V21, P247, DOI 10.1038/cdd.2013.123; Shin KJ, 2006, P NATL ACAD SCI USA, V103, P13759, DOI 10.1073/pnas.0606179103; Sumie S, 2008, ANN SURG ONCOL, V15, P1375, DOI 10.1245/s10434-008-9846-9; Wang B, 2010, DIABETES, V59, P1794, DOI 10.2337/db09-1736; Wang ZF, 2010, PROTEIN CELL, V1, P1063, DOI 10.1007/s13238-010-0140-9; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; Yang YM, 2012, HEPATOLOGY, V56, P2209, DOI 10.1002/hep.25912; Yang YM, 2010, CARCINOGENESIS, V31, P1230, DOI 10.1093/carcin/bgq097; Zhou YM, 2012, ANN SURG ONCOL, V19, P1700, DOI 10.1245/s10434-011-1772-6	46	34	34	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2910	2921		10.1038/onc.2014.218	http://dx.doi.org/10.1038/onc.2014.218			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25065598				2022-12-17	WOS:000355324300010
J	Oi, N; Yuan, J; Malakhova, M; Luo, K; Li, Y; Ryu, J; Zhang, L; Bode, AM; Xu, Z; Li, Y; Lou, Z; Dong, Z				Oi, N.; Yuan, J.; Malakhova, M.; Luo, K.; Li, Y.; Ryu, J.; Zhang, L.; Bode, A. M.; Xu, Z.; Li, Y.; Lou, Z.; Dong, Z.			Resveratrol induces apoptosis by directly targeting Ras-GTPase-activating protein SH3 domain-binding protein 1	ONCOGENE			English	Article							HUMAN-MALIGNANT MELANOMA; S-PHASE ARREST; RNASE ACTIVITY; CANCER CELLS; KAPPA-B; P53; G3BP; EXPRESSION; PHOSPHORYLATION; GROWTH	Resveratrol (trans-3,5,4'-truhydroxystilbene) possesses a strong anticancer activity exhibited as the induction of apoptosis through p53 activation. However, the molecular mechanism and direct target(s) of resveratrol-induced p53 activation remain elusive. Here, the Ras-GTPase-activating protein SH3 domain-binding protein 1 (G3BP1) was identified as a potential target of resveratrol, and in vitro binding assay results using resveratrol-conjugated Sepharose 4B beads confirmed their direct binding. Depletion of G3BP1 significantly diminishes resveratrol-induced p53 expression and apoptosis. We also found that G3BP1 negatively regulates p53 expression by interacting with ubiquitin-specific protease 10 (USP10), a deubiquitinating enzyme of p53. Disruption of the interaction of p53 with USP10 by G3BP1 interference leads to the suppression of p53 deubiquitination. Resveratrol, on the other hand, directly binds to G3BP1 and prevents the G3BP1/USP10 interaction, resulting in enhanced USP10-mediated deubiquitination of p53, and consequently increased p53 expression. These findings disclose a novel mechanism of resveratrol-induced p53 activation and resveratrol-induced apoptosis by direct targeting of G3BP1.	[Oi, N.; Malakhova, M.; Ryu, J.; Bode, A. M.; Li, Y.; Dong, Z.] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; [Yuan, J.; Luo, K.; Li, Y.; Xu, Z.] Tongji Univ, Res Ctr Translat Med, Sch Med, East Hosp, Shanghai 200092, Peoples R China; [Yuan, J.; Luo, K.; Li, Y.; Xu, Z.] Tongji Univ, Sch Med, East Hosp, Minist Educ China,Key Lab Arrhythmias, Shanghai 200092, Peoples R China; [Luo, K.; Li, Y.; Zhang, L.; Lou, Z.] Mayo Clin, Dept Oncol, Div Oncol Res, Rochester, MN 55902 USA	University of Minnesota System; Tongji University; Ministry of Education, China; Tongji University; Mayo Clinic	Lou, Z (corresponding author), Mayo Clin, Dept Oncol, Div Oncol Res, 200 1st St SW, Rochester, MN 55902 USA.	lou.zhenkun@mayo.edu; zgdong@hi.umn.edu			AgStar Minnesota; Hormel Foundation; National Institutes of Health Grants [CA111536, CA172457, CA166011, R37 CA081064, CA148940, CA108961]; National Basic Research Program of China (973 Program) [2013CB530700]; National Natural Science Foundation of China [81102011, 81222029, 31270806]; Kendall-Mayo Fellowship in Biochemistry, the Foundation for Innovative Research Groups of the National Natural Science Foundation of China [81221001]; Shanghai Science and Technology Committee Modernization of Traditional Chinese Medicine special [11DZ1973801]; NATIONAL CANCER INSTITUTE [R01CA166011, R37CA081064, P50CA108961, R01CA187027, R01CA129344, R21CA172457, R01CA130996, R01CA148940, P30CA015083, R01CA111536] Funding Source: NIH RePORTER	AgStar Minnesota; Hormel Foundation; National Institutes of Health Grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Kendall-Mayo Fellowship in Biochemistry, the Foundation for Innovative Research Groups of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Committee Modernization of Traditional Chinese Medicine special; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Yibin Deng (The Hormel Institute, University of Minnesota, Austin, MN, USA) for kindly providing the expression vectors of shRNA p53. This work was supported by AgStar Minnesota (to ZD), The Hormel Foundation (to ZD) and National Institutes of Health Grants CA111536 (to ZD), CA172457 (to ZD), CA166011 (to ZD), R37 CA081064 (to ZD), CA148940 (to ZL), CA108961 (to ZL), the National Basic Research Program of China (973 Program, Grant No. 2013CB530700), National Natural Science Foundation of China (81102011, 81222029 and 31270806) and Kendall-Mayo Fellowship in Biochemistry, the Foundation for Innovative Research Groups of the National Natural Science Foundation of China (81221001) and Shanghai Science and Technology Committee Modernization of Traditional Chinese Medicine special (11DZ1973801).	ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; Annibaldi A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029024; Barnes CJ, 2002, CANCER RES, V62, P1251; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; Celotti E, 1996, J CHROMATOGR A, V730, P47, DOI 10.1016/0021-9673(95)00962-0; Chen RS, 2002, J AGR FOOD CHEM, V50, P1665, DOI 10.1021/jf011134e; Chow SE, 2010, CANCER GENE THER, V17, P872, DOI 10.1038/cgt.2010.44; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; Estrov Z, 2003, BLOOD, V102, P987, DOI 10.1182/blood-2002-11-3550; French J, 2002, HISTOCHEM J, V34, P223, DOI 10.1023/A:1021737413055; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; Gautier-Bert K, 2003, MOL BIOL REP, V30, P1, DOI 10.1023/A:1022261925117; Gill C, 2007, PROSTATE, V67, P1641, DOI 10.1002/pros.20653; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Hartmann A, 1996, INT J CANCER, V67, P313, DOI 10.1002/(SICI)1097-0215(19960729)67:3<313::AID-IJC1>3.0.CO;2-U; Hsieh TC, 1999, CANCER RES, V59, P2596; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Joe AK, 2002, CLIN CANCER RES, V8, P893; Kim MM, 2007, ONCOGENE, V26, P4209, DOI 10.1038/sj.onc.1210212; Lev DC, 2003, MOL CANCER THER, V2, P753; Liu YX, 2001, CHINESE MED J-PEKING, V114, P35; Matsuki H, 2013, GENES CELLS, V18, P135, DOI 10.1111/gtc.12023; Niles RM, 2003, CANCER LETT, V190, P157, DOI 10.1016/S0304-3835(02)00676-6; Oi N, 2010, CANCER RES, V70, P9755, DOI 10.1158/0008-5472.CAN-10-2858; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Parker F, 1996, MOL CELL BIOL, V16, P2561; Pazman C, 2000, DEVELOPMENT, V127, P1715; Pervaiz S, 2003, FASEB J, V17, P1975, DOI 10.1096/fj.03-0168rev; Prigent M, 2000, J BIOL CHEM, V275, P36441, DOI 10.1074/jbc.M004751200; She QB, 2001, CANCER RES, V61, P1604; Sobolev VS, 1999, J AGR FOOD CHEM, V47, P1435, DOI 10.1021/jf9809885; Soncini C, 2001, ONCOGENE, V20, P3869, DOI 10.1038/sj.onc.1204553; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Takahashi M, 2013, MOL CELL BIOL, V33, P815, DOI 10.1128/MCB.00763-12; Tourriere H, 2001, MOL CELL BIOL, V21, P7747, DOI 10.1128/MCB.21.22.7747-7760.2001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032; Zannat MT, 2011, BIOCHEM BIOPH RES CO, V409, P171, DOI 10.1016/j.bbrc.2011.04.094; Zhang H, 2012, CANCER SCI, V103, P1848, DOI 10.1111/j.1349-7006.2012.02361.x; Zykova TA, 2008, MOL CARCINOGEN, V47, P797, DOI 10.1002/mc.20437	41	34	35	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2660	2671		10.1038/onc.2014.194	http://dx.doi.org/10.1038/onc.2014.194			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	24998844	Green Accepted			2022-12-17	WOS:000354541300012
J	Saqcena, M; Mukhopadhyay, S; Hosny, C; Alhamed, A; Chatterjee, A; Foster, DA				Saqcena, M.; Mukhopadhyay, S.; Hosny, C.; Alhamed, A.; Chatterjee, A.; Foster, D. A.			Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs	ONCOGENE			English	Article							PANCREATIC-CANCER; TRANSFORMED-CELLS; METABOLISM; GROWTH; MYC; P53; GLYCOLYSIS; ACTIVATION; HALLMARK; BIOLOGY	Cancer cells undergo a metabolic transformation that allows for increased anabolic demands, wherein glycolytic and tricarboxylic acid (TCA) cycle intermediates are shunted away for the synthesis of biological molecules required for cell growth and division. One of the key shunts is the exit of citrate from the mitochondria and the TCA cycle for the generation of cytosolic acetyl-coenzyme A that can be used for fatty acid and cholesterol biosynthesis. With the loss of mitochondrial citrate, cancer cells rely on the 'conditionally essential' amino acid glutamine (Q) as an anaplerotic carbon source for TCA cycle intermediates. Although Q deprivation causes G1 cell cycle arrest in non-transformed cells, its impact on the cancer cell cycle is not well characterized. We report here a correlation between bypass of the Q-dependent G1 checkpoint and cancer cells harboring K-Ras mutations. Instead of arresting in G1 in response to Q-deprivation, K-Ras-driven cancer cells arrest in either S-or G2/M-phase. Inhibition of K-Ras effector pathways was able to revert cells to G1 arrest upon Q deprivation. Blocking anaplerotic utilization of Q mimicked Q deprivation-causing S-and G2/M-phase arrest in K-Ras mutant cancer cells. Significantly, Q deprivation or suppression of anaplerotic Q utilization created synthetic lethality to the cell cycle phase-specific cytotoxic drugs, capecitabine and paclitaxel. These data suggest that disabling of the G1 Q checkpoint could represent a novel vulnerability of cancer cells harboring K-Ras and possibly other mutations that disable the Q-dependent checkpoint.	[Saqcena, M.; Mukhopadhyay, S.; Hosny, C.; Alhamed, A.; Chatterjee, A.; Foster, D. A.] CUNY, Hunter Coll, Dept Biol Sci, New York, NY 10065 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Foster, DA (corresponding author), CUNY, Hunter Coll, Dept Biol Sci, 695 Pk Ave,Room 927, New York, NY 10065 USA.	foster@genectr.hunter.cuny.edu	damiani, chiara/R-4256-2016; Saqcena, Mahesh/U-5973-2017; Mukhopadhyay, Suman/N-3556-2017	Saqcena, Mahesh/0000-0002-2210-3444; Mukhopadhyay, Suman/0000-0002-4658-1942	National Institute of Health [R01-CA046677]; National Center for Research Resources of the National Institute of Health [RP-03037]; Research Centers in Minority Institutions; NATIONAL CANCER INSTITUTE [R01CA046677, R01CA179542] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [G12MD007599] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources of the National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Research Centers in Minority Institutions(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This study was supported by the National Institute of Health grant R01-CA046677 and a pilot project award from the Research Centers in Minority Institutions award RP-03037 from the National Center for Research Resources of the National Institute of Health.	Baker NM, 2013, NATURE, V497, P577, DOI 10.1038/nature12248; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOS JL, 1989, CANCER RES, V49, P4682; Chen YH, 2005, ONCOGENE, V24, P672, DOI 10.1038/sj.onc.1208099; Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; DOTTO GP, 1985, NATURE, V318, P472; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Foster David A, 2010, Genes Cancer, V1, P1124, DOI 10.1177/1947601910392989; Gaglio D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004715; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Liu PD, 2014, NATURE, V508, P541, DOI 10.1038/nature13079; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Salloum D, 2014, MOL CANCER THER, V13, P733, DOI 10.1158/1535-7163.MCT-13-0762; Saqcena M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074157; Schneider G, 2005, GASTROENTEROLOGY, V128, P1606, DOI 10.1053/j.gastro.2005.04.001; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shanware NP, 2011, J MOL MED, V89, P229, DOI 10.1007/s00109-011-0731-9; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Thornburg JM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2154; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Walko CM, 2005, CLIN THER, V27, P23, DOI 10.1016/j.clinthera.2005.01.005; Wang XS, 2011, CANCER DISCOV, V1, P35, DOI 10.1158/2159-8274.CD-10-0022; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099	41	34	36	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2672	2680		10.1038/onc.2014.207	http://dx.doi.org/10.1038/onc.2014.207			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25023699	Green Accepted			2022-12-17	WOS:000354541300013
J	Honda, H; Nagamachi, A; Inaba, T				Honda, H.; Nagamachi, A.; Inaba, T.			-7/7q-syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity	ONCOGENE			English	Review							CHROMOSOME BAND 7Q22; JUVENILE MYELOMONOCYTIC LEUKEMIA; THERAPY-RELATED MYELODYSPLASIA; PROGNOSTIC SCORING SYSTEM; LOW-DOSE DECITABINE; METHYLTRANSFERASE GENE EZH2; COMMONLY DELETED SEGMENT; TUMOR-SUPPRESSOR LOCUS; ONE-STEP GENERATION; SOMATIC MUTATIONS	The recurrence of chromosomal abnormalities in a specific subtype of cancer strongly suggests that dysregulated gene expression in the corresponding region has a critical role in disease pathogenesis. - 7/7q -, defined as the entire loss of chromosome 7 and partial deletion of its long arm, is among the most frequently observed chromosomal aberrations in myeloid-lineage hematopoietic malignancies such as myelodysplastic syndrome and acute myeloid leukemia, particularly in patients treated with cytotoxic agents and/or irradiation. Tremendous efforts have been made to clarify the molecular mechanisms underlying the disease development, and several possible candidate genes have been cloned. However, the study is still underway, and the entire nature of this syndrome is not completely understood. In this review, we focus on the attempts to identify commonly deleted regions in patients with - 7/7q -; isolate the candidate genes responsible for disease development, cooperative genes and the factors affecting disease prognosis; and determine effective and potent therapeutic approaches. We also refer to the possibility that the accumulation of multiple gene haploinsufficiency, rather than the loss of a single tumor suppressor gene, may contribute to the development of diseases with large chromosomal deletions such as - 7/7q -.	[Honda, H.] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dis Model, Hiroshima, Japan; [Nagamachi, A.; Inaba, T.] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Oncol, Hiroshima, Japan; [Nagamachi, A.; Inaba, T.] Hiroshima Univ, Leukemia Program Project, Res Inst Radiat Biol & Med, Hiroshima, Japan	Hiroshima University; Hiroshima University; Hiroshima University	Honda, H (corresponding author), Res Inst Radiat Biol & Med, Dept Dis Model, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	hhonda@hiroshima-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan; Grants-in-Aid for Scientific Research [26293227] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was in part supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Alkelai A, 2012, INT J NEUROPSYCHOPH, V15, P459, DOI 10.1017/S1461145711000903; Ansari KI, 2010, FEBS J, V277, P1790, DOI 10.1111/j.1742-4658.2010.07606.x; Asou H, 2009, BIOCHEM BIOPH RES CO, V383, P245, DOI 10.1016/j.bbrc.2009.04.004; Au WY, 2003, BRIT J HAEMATOL, V120, P1062, DOI 10.1046/j.1365-2141.2003.04194.x; Balgobind BV, 2010, LEUKEMIA, V24, P942, DOI 10.1038/leu.2010.47; BARANGER L, 1990, LEUKEMIA, V4, P345; Barreyro L, 2012, BLOOD, V120, P1290, DOI 10.1182/blood-2012-01-404699; Bejar R, 2012, J CLIN ONCOL, V30, P3376, DOI 10.1200/JCO.2011.40.7379; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; Berger AH, 2011, NATURE, V476, P163, DOI 10.1038/nature10275; Bernstein R, 1984, CANCER GENET CYTOGEN, V11, P300; Bisen A, 2013, ADV EXP MED BIOL, V779, P179, DOI 10.1007/978-1-4614-6176-0_8; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Boultwood J, 2013, BLOOD, V121, P869, DOI 10.1182/blood-2012-12-473421; Boultwood J, 2010, BLOOD, V116, P5803, DOI 10.1182/blood-2010-04-273771; Brezinova J, 2007, CANCER GENET CYTOGEN, V173, P10, DOI 10.1016/j.cancergencyto.2006.09.003; Buonamici S, 2004, J CLIN INVEST, V114, P713, DOI 10.1172/JCI200421716; Cadieux C, 2006, CANCER RES, V66, P9492, DOI 10.1158/0008-5472.CAN-05-4230; Cadieux C, 2009, CANCER RES, V69, P7188, DOI 10.1158/0008-5472.CAN-08-4899; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cattaneo F, 2008, J CELL BIOCHEM, V105, P344, DOI 10.1002/jcb.21869; Chen CY, 2007, BRIT J HAEMATOL, V139, P405, DOI 10.1111/j.1365-2141.2007.06811.x; Chen C, 2014, CANCER CELL, V25, P652, DOI 10.1016/j.ccr.2014.03.016; Chen JJ, 2010, NAT REV CANCER, V10, P23, DOI 10.1038/nrc2765; Chen Z, 2005, CANCER GENET CYTOGEN, V162, P95, DOI 10.1016/j.cancergencyto.2005.03.017; Christiansen DH, 2007, GENE CHROMOSOME CANC, V46, P517, DOI 10.1002/gcc.20426; Christiansen DH, 2004, BLOOD, V104, P1474, DOI 10.1182/blood-2004-02-0754; Christiansen DH, 2003, LEUKEMIA, V17, P1813, DOI 10.1038/sj.leu.2403054; Claus R, 2003, ONCOGENE, V22, P6489, DOI 10.1038/sj.onc.1206814; Cordoba I, 2012, CANCER-AM CANCER SOC, V118, P127, DOI 10.1002/cncr.26279; Cortes J, 2012, BLOOD, V120, P1390, DOI 10.1182/blood-2012-03-378919; Cristobal I, 2010, BLOOD, V115, P615, DOI 10.1182/blood-2009-06-227363; Cuenco GM, 2004, ONCOGENE, V23, P569, DOI 10.1038/sj.onc.1207143; Curtiss NP, 2005, GENOMICS, V85, P600, DOI 10.1016/j.ygeno.2005.01.013; Czarnecka K, 2013, MOL BIOL REP, V40, P6671, DOI 10.1007/s11033-013-2782-1; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Damm F, 2013, LEUKEMIA, V27, P1401, DOI 10.1038/leu.2013.35; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; De Braekeleer E, 2011, FUTURE ONCOL, V7, P77, DOI 10.2217/FON.10.158; De Weer A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008676; Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417; Dohner K, 1998, BLOOD, V92, P4031, DOI 10.1182/blood.V92.11.4031.423k55_4031_4035; Dolnik A, 2012, BLOOD, V120, pE83, DOI 10.1182/blood-2011-12-401471; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Emerling BM, 2002, ONCOGENE, V21, P4849, DOI 10.1038/sj.onc.1205615; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Estey EH, 2013, LEUKEMIA, V27, P1803, DOI 10.1038/leu.2013.173; EVANS JPM, 1988, BRIT J HAEMATOL, V69, P41, DOI 10.1111/j.1365-2141.1988.tb07600.x; Fenaux P, 2010, BRIT J HAEMATOL, V149, P244, DOI 10.1111/j.1365-2141.2010.08082.x; Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8; Fischer K, 1997, BLOOD, V89, P2036, DOI 10.1182/blood.V89.6.2036; Freireich E, 1964, CLIN RES, V12, P284; Gaidzik VI, 2011, J CLIN ONCOL, V29, P1364, DOI 10.1200/JCO.2010.30.7926; Garcia-Manero G, 2006, BLOOD, V108, P3271, DOI 10.1182/blood-2006-03-009142; Germing U, 2005, LEUKEMIA, V19, P2223, DOI 10.1038/sj.leu.2403963; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Glass C, 2014, BLOOD CELL MOL DIS, V53, P67, DOI 10.1016/j.bcmd.2014.01.002; Glockner G, 1998, GENOME RES, V8, P1060; Gohring G, 2010, BLOOD, V116, P3766, DOI 10.1182/blood-2010-04-280313; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Greenberg PL, 2012, BLOOD, V120, P2454, DOI 10.1182/blood-2012-03-420489; Griffiths EA, 2013, ADV EXP MED BIOL, V754, P253, DOI 10.1007/978-1-4419-9967-2_13; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Grimwade D, 2010, BLOOD, V116, P354, DOI 10.1182/blood-2009-11-254441; Groschel S, 2010, J CLIN ONCOL, V28, P2101, DOI 10.1200/JCO.2009.26.0646; Groves MJ, 2011, CANCER GENET-NY, V204, P39, DOI 10.1016/j.cancergencyto.2010.08.017; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Haase D, 2007, BLOOD, V110, P4385, DOI 10.1182/blood-2007-03-082404; Hackanson B, 2005, ANN HEMATOL, V84, P32, DOI 10.1007/s00277-005-0004-1; Hasegawa D, 2009, PEDIATR BLOOD CANCER, V53, P1011, DOI 10.1002/pbc.22121; Hasle H, 1999, LEUKEMIA, V13, P376, DOI 10.1038/sj.leu.2401342; Hasle H, 2007, BLOOD, V109, P4641, DOI 10.1182/blood-2006-10-051342; HELLSTROMLINDBERG E, 1992, BRIT J HAEMATOL, V81, P503, DOI 10.1111/j.1365-2141.1992.tb02982.x; Herman JG, 1996, CANCER RES, V56, P722; Herrera-Merchan A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1623; Hershkovitz D, 2011, J INVEST DERMATOL, V131, P662, DOI 10.1038/jid.2010.387; Herz HM, 2014, MOL CELL, V53, P859, DOI 10.1016/j.molcel.2014.02.033; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Hirayama Y, 2003, BRIT J HAEMATOL, V121, P376, DOI 10.1046/j.1365-2141.2003.04279.x; Hodge JC, 2009, GENE CHROMOSOME CANC, V48, P865, DOI 10.1002/gcc.20692; Hosono N, 2014, LEUKEMIA, V28, P1348, DOI 10.1038/leu.2014.25; Hou HA, 2014, AM J HEMATOL, V89, P181, DOI 10.1002/ajh.23611; Howell VM, 2007, HUM MOL GENET, V16, P2506, DOI 10.1093/hmg/ddm206; Hulea L, 2012, GENE, V497, P18, DOI 10.1016/j.gene.2012.01.039; Hussain FTN, 2012, AM J HEMATOL, V87, P684, DOI 10.1002/ajh.23230; Ichikawa M, 2013, INT J HEMATOL, V97, P726, DOI 10.1007/s12185-013-1347-3; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Ito Y, 2008, ADV CANCER RES, V99, P33, DOI 10.1016/S0065-230X(07)99002-8; Itzykson R, 2014, LEUKEMIA, V28, P497, DOI 10.1038/leu.2013.343; Jerez A, 2012, BLOOD, V119, P6109, DOI 10.1182/blood-2011-12-397620; Johnson E, 1997, BLOOD REV, V11, P46, DOI 10.1016/S0268-960X(97)90006-0; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792; Kantarjian H, 2007, BLOOD, V109, P52, DOI 10.1182/blood-2006-05-021162; Kardos G, 2003, BLOOD, V102, P1997, DOI 10.1182/blood-2002-11-3444; Kawankar N, 2011, HEMATOLOGY, V16, P131, DOI 10.1179/102453311X12940641877966; KERE J, 1987, BLOOD, V70, P1349; Kim M, 2010, LEUKEMIA RES, V34, P718, DOI 10.1016/j.leukres.2009.09.007; Kiuru-Kuhlefelt S, 1997, LEUKEMIA, V11, P2097, DOI 10.1038/sj.leu.2400881; Kjeldsen E, 2013, CELL ONCOL, V36, P395, DOI 10.1007/s13402-013-0145-5; Klco JM, 2013, BLOOD, V121, P1633, DOI 10.1182/blood-2012-09-459313; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kratz CP, 2002, BLOOD, V99, P372, DOI 10.1182/blood.V99.1.372; Kratz CP, 2001, GENOMICS, V77, P171, DOI 10.1006/geno.2001.6636; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; Kuhn MWM, 2012, BLOOD, V119, pE67, DOI 10.1182/blood-2011-09-380444; Kunej T, 2011, MUTAT RES-FUND MOL M, V717, P77, DOI 10.1016/j.mrfmmm.2011.03.008; Largaespada DA, 2001, J EXP MED, V193, pF15, DOI 10.1084/jem.193.4.F15; Larsson N, 2010, CANCER GENET CYTOGEN, V199, P89, DOI 10.1016/j.cancergencyto.2010.02.005; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; LeBeau MM, 1996, BLOOD, V88, P1930; LEMIEUX N, 1994, GENOMICS, V24, P191, DOI 10.1006/geno.1994.1603; Lewis S, 1996, BRIT J HAEMATOL, V93, P75, DOI 10.1046/j.1365-2141.1996.4841025.x; Li CF, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-92; Li TT, 2013, J BIOL CHEM, V288, P4135, DOI 10.1074/jbc.M112.345942; Liang H, 1998, P NATL ACAD SCI USA, V95, P3781, DOI 10.1073/pnas.95.7.3781; Locatelli F, 2013, BLOOD, V122, P2135, DOI 10.1182/blood-2013-03-491589; Loh ML, 2004, BLOOD, V103, P2325, DOI 10.1182/blood-2003-09-3287; Lubbert M, 2011, J CLIN ONCOL, V29, P1987, DOI 10.1200/JCO.2010.30.9245; Lugthart S, 2010, J CLIN ONCOL, V28, P3890, DOI 10.1200/JCO.2010.29.2771; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Luna-Fineman S, 1999, BLOOD, V93, P459, DOI 10.1182/blood.V93.2.459.402k19_459_466; Madureira ABM, 2011, LEUKEMIA, V25, P449, DOI 10.1038/leu.2010.285; Maestrini E, 2010, MOL PSYCHIATR, V15, P954, DOI 10.1038/mp.2009.34; Makishima H, 2012, BLOOD, V119, P3203, DOI 10.1182/blood-2011-12-399774; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; McNerney ME, 2013, BLOOD, V121, P975, DOI 10.1182/blood-2012-04-426965; Meggendorfer M, 2013, LEUKEMIA, V27, P1852, DOI 10.1038/leu.2013.133; Michl P, 2005, CANCER CELL, V7, P521, DOI 10.1016/j.ccr.2005.05.018; Migas A, 2011, PEDIATR BLOOD CANCER, V57, P583, DOI 10.1002/pbc.22980; Mikhail FM, 2006, J CELL PHYSIOL, V207, P582, DOI 10.1002/jcp.20538; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Muto T, 2013, J EXP MED, V210, P2627, DOI 10.1084/jem.20131144; Nagamachi A, 2013, CANCER CELL, V24, P305, DOI 10.1016/j.ccr.2013.08.011; Nagasawa M, 2004, LEUKEMIA RES, V28, P315, DOI 10.1016/S0145-2126(03)00263-7; Navarro JT, 2007, AM J HEMATOL, V82, P849, DOI 10.1002/ajh.20859; NEUBAUER A, 1991, BLOOD, V77, P594; Neukirchen J, 2014, LEUKEMIA RES, V38, P57, DOI 10.1016/j.leukres.2013.10.013; Niimi H, 2006, LEUKEMIA, V20, P635, DOI 10.1038/sj.leu.2404136; Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620; Nucifora G, 2006, GENE, V368, P1, DOI 10.1016/j.gene.2005.09.020; O'Hare T, 2012, NAT REV CANCER, V12, P513, DOI 10.1038/nrc3317; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Olnes MJ, 2012, LEUKEMIA RES, V36, P982; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Osato M, 2004, ONCOGENE, V23, P4284, DOI 10.1038/sj.onc.1207779; Ozaki Y, 2012, MOL CELL, V47, P694, DOI 10.1016/j.molcel.2012.06.033; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; PASSMORE SJ, 1995, BLOOD, V85, P1742, DOI 10.1182/blood.V85.7.1742.bloodjournal8571742; Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304; Payne SR, 2005, CARCINOGENESIS, V26, P2031, DOI 10.1093/carcin/bgi223; Pedersen-Bjergaard J, 2008, LEUKEMIA, V22, P240, DOI 10.1038/sj.leu.2405078; Pellagatti A, 2010, LEUKEMIA, V24, P756, DOI 10.1038/leu.2010.31; Pozdnyakova O, 2008, CANCER-AM CANCER SOC, V113, P3331, DOI 10.1002/cncr.23977; Qian ZJ, 2010, CHEM-BIOL INTERACT, V184, P50, DOI 10.1016/j.cbi.2009.11.025; Quesnel B, 1998, BLOOD, V91, P2985, DOI 10.1182/blood.V91.8.2985.2985_2985_2990; QUESNEL B, 1995, BLOOD, V85, P657, DOI 10.1182/blood.V85.3.657.bloodjournal853657; Raj K, 2007, LEUKEMIA, V21, P1937, DOI 10.1038/sj.leu.2404796; Raj KK, 2005, BLOOD, V106, p710A; RAMBALDI A, 1991, BLOOD, V78, P3248; Ripka S, 2007, CARCINOGENESIS, V28, P1178, DOI 10.1093/carcin/bgl255; Roumier C, 2006, LEUKEMIA, V20, P433, DOI 10.1038/sj.leu.2404097; ROWLEY JD, 1966, BLOOD-J HEMATOL, V27, P782, DOI 10.1182/blood.V27.6.782.782; ROWLEY JD, 1973, LANCET, V2, P1385; Ruault M, 2002, GENE, V284, P73, DOI 10.1016/S0378-1119(02)00392-X; Ruckner FG, 2012, BLOOD, V119, P2114, DOI 10.1182/blood-2011-08-375758; Ruter B, 2007, BLOOD, V110, P1080, DOI 10.1182/blood-2007-03-080630; RUSSELL M, 1994, BLOOD, V84, P1243, DOI 10.1182/blood.V84.4.1243.bloodjournal8441243; Sansregret L, 2008, GENE, V412, P84, DOI 10.1016/j.gene.2008.01.017; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; SCHERER SW, 1993, GENOMICS, V15, P695, DOI 10.1006/geno.1993.1130; Seetharam M, 2012, LEUKEMIA RES, V36, P98; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Side LE, 2004, GENE CHROMOSOME CANC, V39, P217, DOI 10.1002/gcc.10320; Simon C, 2012, GENE DEV, V26, P651, DOI 10.1101/gad.186411.111; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Sinclair AM, 2001, BLOOD, V98, P3658, DOI 10.1182/blood.V98.13.3658; Singh H, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.16; Slovak ML, 2009, CANCER GENET CYTOGEN, V193, P78, DOI 10.1016/j.cancergencyto.2009.04.013; Slovak ML, 2000, BLOOD, V96, P4075, DOI 10.1182/blood.V96.13.4075; Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107; Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Soriano AO, 2007, BLOOD, V110, P2302, DOI 10.1182/blood-2007-03-078576; Spensberger D, 2008, FEBS LETT, V582, P2761, DOI 10.1016/j.febslet.2008.06.056; Steele M, 2005, PEDIATR BLOOD CANCER, V45, P212, DOI 10.1002/pbc.20332; Stein S, 2010, NAT MED, V16, P198, DOI 10.1038/nm.2088; Takaya A, 2007, MOL BIOL CELL, V18, P1850, DOI 10.1091/mbc.E06-08-0765; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Tien HF, 2001, BRIT J HAEMATOL, V112, P148, DOI 10.1046/j.1365-2141.2001.02496.x; Tong WG, 2012, CANCER-AM CANCER SOC, V118, P4462, DOI 10.1002/cncr.27420; Topaz O, 2006, AM J HUM GENET, V79, P759, DOI 10.1086/508069; Tosi S, 1999, GENE CHROMOSOME CANC, V25, P384, DOI 10.1002/(SICI)1098-2264(199908)25:4<384::AID-GCC11>3.0.CO;2-D; Tosi S, 1996, LEUKEMIA, V10, P644; Trobaugh-Lotrario AD, 2005, BONE MARROW TRANSPL, V35, P143, DOI 10.1038/sj.bmt.1704753; Uchida T, 1997, BLOOD, V90, P1403, DOI 10.1182/blood.V90.4.1403.1403_1403_1409; van Doorn-Khosrovani SBV, 2003, BLOOD, V101, P837, DOI 10.1182/blood-2002-05-1459; Voso MT, 2010, CHEM-BIOL INTERACT, V184, P46, DOI 10.1016/j.cbi.2009.10.013; Wang HY, 2013, CELL, V153, P910, DOI 10.1016/j.cell.2013.04.025; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wang XL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061341; Watanabe-Okochi N, 2008, BLOOD, V111, P4297, DOI 10.1182/blood-2007-01-068346; Webb DKH, 2002, BRIT J HAEMATOL, V117, P33, DOI 10.1046/j.1365-2141.2002.03369.x; Wieser R, 2007, GENE, V396, P346, DOI 10.1016/j.gene.2007.04.012; Wolff L, 2013, BLOOD CELL MOL DIS, V50, P227, DOI 10.1016/j.bcmd.2013.01.006; Wong CC, 2014, NAT GENET, V46, P33, DOI 10.1038/ng.2846; Wong IHN, 2000, BLOOD, V95, P1942, DOI 10.1182/blood.V95.6.1942; Wong JCY, 2010, BLOOD, V115, P4524, DOI 10.1182/blood-2009-07-232504; Xia JC, 2006, CANCER GENET CYTOGEN, V166, P166, DOI 10.1016/j.cancergencyto.2005.11.005; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7; Yang H, 2013, CELL, V154, P1370, DOI 10.1016/j.cell.2013.08.022; Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208; Yoshida K, 2011, NATURE, V478, P64, DOI 10.1038/nature10496; Yoshimi A, 2011, ONCOTARGET, V2, P575, DOI 10.18632/oncotarget.304; Yoshimi Ayami, 2014, Biol Blood Marrow Transplant, V20, P425, DOI 10.1016/j.bbmt.2013.11.031; Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246; Zeng WR, 1999, ONCOGENE, V18, P2015, DOI 10.1038/sj.onc.1202519; Zhou L, 2011, J BIOL CHEM, V286, P25211, DOI 10.1074/jbc.M111.235028; Zinzani PL, 2012, HEMATOL-AM SOC HEMAT, P426, DOI 10.1182/asheducation-2012.1.426; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	231	34	36	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2413	2425		10.1038/onc.2014.196	http://dx.doi.org/10.1038/onc.2014.196			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24998854				2022-12-17	WOS:000354190400001
J	Buss, MC; Remke, M; Lee, J; Gandhi, K; Schniederjan, MJ; Kool, M; Northcott, PA; Pfister, SM; Taylor, MD; Castellino, RC				Buss, M. C.; Remke, M.; Lee, J.; Gandhi, K.; Schniederjan, M. J.; Kool, M.; Northcott, P. A.; Pfister, S. M.; Taylor, M. D.; Castellino, R. C.			The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants	ONCOGENE			English	Article							CXCR4 ACTIVATION; P53 FUNCTION; CHK2 KINASE; PPM1D; PHOSPHATASE; PATHWAY; EXPRESSION; MUTATIONS; CHILDREN; SUBGROUP	Recent studies suggest that medulloblastoma, the most common malignant brain tumor of childhood, is comprised of four disease variants. The WIP1 oncogene is overexpressed in Group 3 and 4 tumors, which contain medulloblastomas with the most aggressive clinical behavior. Our data demonstrate increased WIP1 expression in metastatic medulloblastomas, and inferior progression-free and overall survival of patients with WIP1 high-expressing medulloblastoma. Microarray analysis identified upregulation of genes involved in tumor metastasis, including the G protein-coupled receptor CXCR4, in medulloblastoma cells with high WIP1 expression. Stimulation with the CXCR4 ligand SDF1a activated PI-3 kinase signaling, and promoted growth and invasion of WIP1 highexpressing medulloblastoma cells in a p53-dependent manner. When xenografted into the cerebellum of immunodeficient mice, medulloblastoma cells with stable or endogenous high WIP1 expression exhibited strong expression of CXCR4 and activated AKT in primary and invasive tumor cells. WIP1 or CXCR4 knockdown inhibited medulloblastoma growth and invasion. WIP1 knockdown also improved the survival of mice xenografted with WIP1 high-expressing medulloblastoma cells. WIP1 knockdown inhibited cell surface localization of CXCR4 by suppressing expression of the G protein receptor kinase 5, GRK5. Restoration of wild-type GRK5 promoted Ser339 phosphorylation of CXCR4 and inhibited the growth of WIP1-stable medulloblastoma cells. Conversely, GRK5 knockdown inhibited Ser339 phosphorylation of CXCR4, increased cell surface localization of CXCR4 and promoted the growth of medulloblastoma cells with low WIP1 expression. These results demonstrate crosstalk among WIP1, CXCR4 and GRK5, which may be important for the aggressive phenotype of a subclass of medulloblastomas in children.	[Buss, M. C.; Lee, J.; Castellino, R. C.] Emory Univ, Dept Pediat, Aflac Canc & Blood Disorders Ctr, Childrens Healthcare Atlanta, Atlanta, GA 30322 USA; [Remke, M.; Taylor, M. D.] Univ Toronto, Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Program Dev & Stem Cell Biol,Div Neurosurg, Toronto, ON M5G 1X8, Canada; [Gandhi, K.] Emory Univ, Dept Human Genet, Sch Med, Atlanta, GA 30322 USA; [Schniederjan, M. J.] Emory Univ, Childrens Healthcare Atlanta, Dept Pathol, Sch Med, Atlanta, GA 30322 USA; [Kool, M.; Northcott, P. A.; Pfister, S. M.] German Canc Res Ctr, Div Pediat Neurooncol, Heidelberg, Germany; [Pfister, S. M.] Univ Heidelberg Hosp, Dept Pediat Hematol Oncol & Immunol, Heidelberg, Germany	Children's Healthcare of Atlanta (CHOA); Emory University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Emory University; Children's Healthcare of Atlanta (CHOA); Emory University; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Castellino, RC (corresponding author), Emory Univ, Dept Pediat, Sch Med, 1760 Haygood Dr NE,Room E394, Atlanta, GA 30322 USA.	rccaste@emory.edu	Pfister, Stefan M/F-6860-2013; Northcott, Paul A/N-4022-2018; Castellino, Robert/GRF-7847-2022	Pfister, Stefan M/0000-0002-5447-5322; Northcott, Paul A/0000-0002-1220-5252; Remke, Marc/0000-0002-9404-9993; Taylor, Michael/0000-0001-7009-3466	NIH [1R01CA172392-01, CA159859]; St Baldrick's Foundation; CURE Childhood Cancer Foundation; Southeastern Brain Tumor Foundation; Emory Egleston Children's Research Center; Dr Mildred-Scheel Foundation; NIH/NCI [P30CA138292]; NATIONAL CANCER INSTITUTE [R01CA172392, P30CA138292, R01CA159859] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); St Baldrick's Foundation; CURE Childhood Cancer Foundation; Southeastern Brain Tumor Foundation; Emory Egleston Children's Research Center; Dr Mildred-Scheel Foundation(Deutsche Krebshilfe); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Jeffrey Benovic, Lawrence Donehower, H Trent Spencer, Laurent Brault, Jurg Schwaller and Rita Nahta for gene expression constructs, Gregory Doho for assistance with analysis of microarrays, and Dr Rita Nahta for editorial assistance. This work was supported by grants from the NIH (1R01CA172392-01, RCC; CA159859, MD Taylor), St Baldrick's Foundation (RCC), CURE Childhood Cancer Foundation (RCC), Southeastern Brain Tumor Foundation (RCC), the Emory Egleston Children's Research Center (RCC) and the Dr Mildred-Scheel Foundation (MR). Research reported in this publication was supported in part by the NIH/NCI under award number P30CA138292. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Barker BL, 2011, BIOCHEMISTRY-US, V50, P6933, DOI 10.1021/bi2005202; BELZA MG, 1991, J NEUROSURG, V75, P575, DOI 10.3171/jns.1991.75.4.0575; Bian XW, 2007, NEUROSURGERY, V61, P570, DOI 10.1227/01.NEU.0000290905.53685.A2; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Buss MC, 2012, NEURO-ONCOLOGY, V14, P440, DOI 10.1093/neuonc/nos001; Calatozzolo C, 2006, CANCER BIOL THER, V5, P827, DOI 10.4161/cbt.5.7.2838; Castellino RC, 2008, J NEURO-ONCOL, V86, P245, DOI 10.1007/s11060-007-9470-8; Castellino RC, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-127; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Clifford SC, 2006, CELL CYCLE, V5, P2666, DOI 10.4161/cc.5.22.3446; Demidov ON, 2007, ONCOGENE, V26, P2502, DOI 10.1038/sj.onc.1210032; Demidov ON, 2007, CELL STEM CELL, V1, P180, DOI 10.1016/j.stem.2007.05.020; Dhall G, 2009, J CHILD NEUROL, V24, P1418, DOI 10.1177/0883073809341668; Domanska UM, 2013, EUR J CANCER, V49, P219, DOI 10.1016/j.ejca.2012.05.005; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Dudgeon C, 2013, CELL CYCLE, V12, P2656, DOI 10.4161/cc.25694; Ellison DW, 2011, ACTA NEUROPATHOL, V121, P381, DOI 10.1007/s00401-011-0800-8; Ellison DW, 2011, J CLIN ONCOL, V29, P1400, DOI 10.1200/JCO.2010.30.2810; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Gajjar AJ, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.18_suppl.cra9501; Gajjar A, 2006, LANCET ONCOL, V7, P813, DOI 10.1016/S1470-2045(06)70867-1; Gessi M, 2012, J NEURO-ONCOL, V106, P135, DOI 10.1007/s11060-011-0648-8; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Grinkevich VV, 2009, CANCER CELL, V15, P441, DOI 10.1016/j.ccr.2009.03.021; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; Kleiblova P, 2013, J CELL BIOL, V201, P511, DOI 10.1083/jcb.201210031; Klein RS, 2001, DEVELOPMENT, V128, P1971; Kool M, 2012, ACTA NEUROPATHOL, V123, P473, DOI 10.1007/s00401-012-0958-8; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lamont JM, 2004, CLIN CANCER RES, V10, P5482, DOI 10.1158/1078-0432.CCR-03-0721; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Mabbott DJ, 2005, J CLIN ONCOL, V23, P2256, DOI 10.1200/JCO.2005.01.158; McNeil DE, 2002, MED PEDIATR ONCOL, V39, P190, DOI 10.1002/mpo.10121; Mendrzyk F, 2005, J CLIN ONCOL, V23, P8853, DOI 10.1200/JCO.2005.02.8589; Mumert M, 2012, CANCER RES, V72, P4944, DOI 10.1158/0008-5472.CAN-12-1629; Nannenga B, 2006, MOL CARCINOGEN, V45, P594, DOI 10.1002/mc.20195; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; Pan E, 2005, CLIN CANCER RES, V11, P4733; Pandolfi S, 2013, ONCOGENE, V32, P4737, DOI 10.1038/onc.2012.502; Pfister S, 2012, ACTA NEUROPATHOL, V123, P463, DOI 10.1007/s00401-012-0966-8; Pfister S, 2009, J CLIN ONCOL, V27, P1627, DOI 10.1200/JCO.2008.17.9432; Pugh TJ, 2012, NATURE, V488, P106, DOI 10.1038/nature11329; Rao G, 2003, NEOPLASIA, V5, P198, DOI 10.1016/S1476-5586(03)80052-0; Remke M, 2011, J CLIN ONCOL, V29, P3852, DOI 10.1200/JCO.2011.36.2798; Remke M, 2011, J CLIN ONCOL, V29, P2717, DOI 10.1200/JCO.2011.34.9373; Ruark E, 2013, NATURE, V493, P406, DOI 10.1038/nature11725; Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Sengupta R, 2012, CANCER RES, V72, P122, DOI 10.1158/0008-5472.CAN-11-1701; Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Siu IM, 2003, CANCER RES, V63, P4773; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; TORRES CF, 1994, NEW ENGL J MED, V330, P892, DOI 10.1056/NEJM199403313301303; Traenka C, 2010, CANCER RES, V70, P8003, DOI 10.1158/0008-5472.CAN-10-0592; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; von Hoff K, 2009, EUR J CANCER, V45, P1209, DOI 10.1016/j.ejca.2009.01.015; Wang Z, 2010, TRANSL ONCOL, V3, P1, DOI 10.1593/tlo.09250; Woerner BM, 2005, CANCER RES, V65, P11392, DOI 10.1158/0008-5472.CAN-05-0847; Wu X, 2012, NATURE, V482, P529, DOI 10.1038/nature10825; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386; Yoda A, 2006, J BIOL CHEM, V281, P24847, DOI 10.1074/jbc.M600403200	69	34	35	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1126	1140		10.1038/onc.2014.37	http://dx.doi.org/10.1038/onc.2014.37			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24632620	Green Accepted			2022-12-17	WOS:000350122100006
J	Adams, AK; Hallenbeck, GE; Casper, KA; Patil, YJ; Wilson, KM; Kimple, RJ; Lambert, PF; Witte, DP; Xiao, W; Gillison, ML; Wikenheiser-Brokamp, KA; Wise-Draper, TM; Wells, SI				Adams, A. K.; Hallenbeck, G. E.; Casper, K. A.; Patil, Y. J.; Wilson, K. M.; Kimple, R. J.; Lambert, P. F.; Witte, D. P.; Xiao, W.; Gillison, M. L.; Wikenheiser-Brokamp, K. A.; Wise-Draper, T. M.; Wells, S. I.			DEK promotes HPV-positive and -negative head and neck cancer cell proliferation	ONCOGENE			English	Article							HUMAN-PAPILLOMAVIRUS; EPIDERMAL MORPHOGENESIS; EPITHELIAL DEVELOPMENT; OROPHARYNGEAL CANCER; BREAST-CANCER; UNITED-STATES; E7 ONCOGENE; P63; EXPRESSION; CARCINOMA	Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide, and patient outcomes using current treatments remain poor. Tumor development is etiologically associated with tobacco or alcohol use and/or human papillomavirus (HPV) infection. HPV-positive HNSCCs, which frequently harbor wild-type p53, carry a more favorable prognosis and are a biologically distinct subgroup when compared with their HPV-negative counterparts. HPV E7 induces expression of the human DEK gene, both in vitro and in vivo. In keratinocytes, DEK overexpression is sufficient for causing oncogenic phenotypes in the absence of E7. Conversely, DEK loss results in cell death in HPV-positive cervical cancer cells at least in part through p53 activation, and Dek knockout mice are relatively resistant to the development of chemically induced skin papillomas. Despite the established oncogenic role of DEK in HPV-associated cervical cancer cell lines and keratinocytes, a functional role of DEK has not yet been explored in HNSCC. Using an established transgenic mouse model of HPV16 E7-induced HNSCC, we demonstrate that Dek is required for optimal proliferation of E7-transgenic epidermal cells and for the growth of HNSCC tumors. Importantly, these studies also demonstrate that DEK protein is universally upregulated in both HPV-positive and -negative human HNSCC tumors relative to adjacent normal tissue. Furthermore, DEK knockdown inhibited the proliferation of HPV-positive and -negative HNSCC cells, establishing a functional role for DEK in human disease. Mechanistic studies reveal that attenuated HNSCC cell growth in response to DEK loss was associated with reduced expression of the oncogenic p53 family member, Delta Np63. Exogenous Delta Np63 expression rescued the proliferative defect in the absence of DEK, thereby establishing a functional DEK-Delta Np63 oncogenic pathway that promotes HNSCC. Taken together, our data demonstrate that DEK stimulates HNSCC cellular growth and identify Delta Np63 as a novel DEK effector.	[Adams, A. K.; Hallenbeck, G. E.; Wise-Draper, T. M.; Wells, S. I.] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA; [Casper, K. A.; Patil, Y. J.; Wilson, K. M.] Univ Cincinnati, Dept Otolaryngol Head & Neck Surg, Cincinnati, OH 45267 USA; [Kimple, R. J.; Lambert, P. F.] Univ Wisconsin, Sch Med & Publ Hlth, McArdle Lab Canc Res, Madison, WI USA; [Witte, D. P.] Cincinnati Childrens Hosp Med Ctr, Div Pathol & Lab Med, Cincinnati, OH 45229 USA; [Xiao, W.; Gillison, M. L.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Wikenheiser-Brokamp, K. A.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Pathol & Lab Med & Pulm Biol, Cincinnati, OH 45267 USA; [Wise-Draper, T. M.] Univ Cincinnati, Univ Hosp, Div Hematol Oncol, Cincinnati, OH 45267 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Wisconsin System; University of Wisconsin Madison; Cincinnati Children's Hospital Medical Center; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Wise-Draper, TM (corresponding author), Univ Cincinnati, Dept Hematol Oncol, 231 Albert Sabin Way,ML 0562, Cincinnati, OH 45267 USA.	wiseth@uc.edu; Susanne.Wells@cchmc.org	Kimple, Randall/L-6460-2019	Kimple, Randall/0000-0001-8336-8000; Wise-Draper, Trisha/0000-0002-7279-4028	NIH [T32ES007250, R00 CA160639, AR-47363, DK78392, DK90971]; Clinical Scientist Training Program at the University of Cincinnati, Public Health Service from the NIH [R01 CA116316]; NATIONAL CANCER INSTITUTE [T32CA117846, R00CA160639, R01CA116316] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR047363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK090971, P30DK078392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007250] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Clinical Scientist Training Program at the University of Cincinnati, Public Health Service from the NIH; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by the Clinical Scientist Training Program at the University of Cincinnati (TWD), Public Health Service Grant R01 CA116316 from the NIH (SIW), NIH Training Grant T32ES007250 (AKA) and R00 CA160639 from the NIH (RJK). All flow cytometric data were acquired using equipment in the Research Flow Cytometry Core in the Division of Rheumatology at Cincinnati Children's Hospital Medical Center, supported in part by NIH AR-47363, NIH DK78392 and NIH DK90971. We would like to acknowledge the CCHMC pathology core with excellent technical support by Meredith Taylor for Ventana HPV in situ hybridization, Dr Madhavi Kadakia for providing the HA-Delta Np63 construct, Marie Matrka for providing protein lysates, and expert technical support by Dr Ronald Waclaw for use of his Leica microscope.	Alexandrova EM, 2013, CELL DEATH DIFFER, V20, P1698, DOI 10.1038/cdd.2013.122; Alexiadis V, 2000, GENE DEV, V14, P1308; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Bradford CR, 2003, HEAD NECK-J SCI SPEC, V25, P654, DOI 10.1002/hed.10274; Carro MS, 2006, CELL CYCLE, V5, P1202, DOI 10.4161/cc.5.11.2801; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; DeYoung MP, 2007, ONCOGENE, V26, P5169, DOI 10.1038/sj.onc.1210337; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Gupta S, 2009, INT J CANCER, V125, P2159, DOI 10.1002/ijc.24533; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Hoskins EE, 2009, ONCOGENE, V28, P674, DOI 10.1038/onc.2008.416; Jabbar S, 2010, VIROLOGY, V407, P60, DOI 10.1016/j.virol.2010.08.003; Kappes F, 2008, MOL CELL BIOL, V28, P3245, DOI 10.1128/MCB.01921-07; Khodadoust MS, 2009, CANCER RES, V69, P6405, DOI 10.1158/0008-5472.CAN-09-1063; Kimple RJ, 2013, CANCER RES, V73, P4791, DOI 10.1158/0008-5472.CAN-13-0587; Koster MI, 2007, P NATL ACAD SCI USA, V104, P3255, DOI 10.1073/pnas.0611376104; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Liu SP, 2012, PATHOL INT, V62, P176, DOI 10.1111/j.1440-1827.2011.02775.x; Lu ZL, 2005, WORLD J GASTROENTERO, V11, P3850; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moll UM, 2004, MOL CANCER RES, V2, P371; National Comprehensive Cancer Network, 2008, J Natl Compr Canc Netw, V6, P646; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pignon JC, 2013, P NATL ACAD SCI USA, V110, P8105, DOI 10.1073/pnas.1221216110; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Romano RA, 2012, DEVELOPMENT, V139, P772, DOI 10.1242/dev.071191; Sitwala KV, 2002, ONCOGENE, V21, P8862, DOI 10.1038/sj.onc.1206041; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Strati K, 2007, CANCER RES, V67, P11585, DOI 10.1158/0008-5472.CAN-07-3007; Strati K, 2006, P NATL ACAD SCI USA, V103, P14152, DOI 10.1073/pnas.0606698103; Su XH, 2013, NAT REV CANCER, V13, P136, DOI 10.1038/nrc3446; Truong AB, 2006, GENE DEV, V20, P3185, DOI 10.1101/gad.1463206; Vinnedge LMP, 2011, ONCOGENE, V30, P2741, DOI 10.1038/onc.2011.2; Vinnedge LMP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046985; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; Wise-Draper TM, 2005, J VIROL, V79, P14309, DOI 10.1128/JVI.79.22.14309-14317.2005; Wise-Draper TM, 2006, MOL CELL BIOL, V26, P7506, DOI 10.1128/MCB.00430-06; Wise-Draper TM, 2012, TRANSL RES, V160, P167, DOI 10.1016/j.trsl.2012.02.002; Wise-Draper TM, 2009, CANCER RES, V69, P1792, DOI 10.1158/0008-5472.CAN-08-2304; Wise-Draper TM, 2009, AM J PATHOL, V174, P71, DOI 10.2353/ajpath.2009.080330; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539	42	34	40	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					868	877		10.1038/onc.2014.15	http://dx.doi.org/10.1038/onc.2014.15			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24608431	Green Accepted			2022-12-17	WOS:000349472000007
J	Saxena, M; Dykes, SS; Malyarchuk, S; Wang, AE; Cardelli, JA; Pruitt, K				Saxena, M.; Dykes, S. S.; Malyarchuk, S.; Wang, A. E.; Cardelli, J. A.; Pruitt, K.			The sirtuins promote Dishevelled-1 scaffolding of TIAM1, Rac activation and cell migration	ONCOGENE			English	Article						SIRT1; SIRT2; TIAM1; Rac1-GTPase; Dishevelled; acetylation	NUCLEOTIDE EXCHANGE FACTOR; PREDICTS POOR-PROGNOSIS; HISTONE DEACETYLASE; BREAST-CANCER; HEPATOCELLULAR CARCINOMAS; COLORECTAL-CANCER; EPITHELIAL-CELLS; PROSTATE-CANCER; RHO GTPASES; SIRT1	Rac1-GTPases serve as intermediary cellular switches, which conduct transient and constitutive signals from upstream cues, including those from Ras oncoproteins. Although the sirtuin1 (SIRT1) deacetylase is overexpressed in several human cancers and has recently been linked to cancer cell motility as a context-dependent regulator of multiple pathways, its role in Rac1 activation has not been reported. Similarly, SIRT2 has been demonstrated to be upregulated in some cancers; however, studies have also reported its role in tumor suppression. Here, we demonstrate that SIRT1 and SIRT2 positively regulate the levels of Rac1-GTP and the activity of T-cell lymphoma invasion and metastasis 1 (TIAM1), a Rac guanine nucleotide exchange factor (GEF). Transient inhibition of SIRT1 and SIRT2 resulted in increased acetylation of TIAM1, whereas chronic SIRT2 knockdown resulted in enhanced acetylation of TIAM1. SIRT1 regulates Dishevelled (DVL) protein levels in cancer cells, and DVL along with TIAM1 are known to augment Rac activation; however, SIRT1 or 2 has not been previously linked with TIAM1. We found that diminished sirtuin activity led to the disruption of the DVL1-TIAM1 interaction. We hence propose a model for Rac activation where SIRT1/2 positively modulates the DVL/TIAM1/Rac axis and promotes sustained pathway activation.	[Saxena, M.; Malyarchuk, S.; Wang, A. E.; Pruitt, K.] LSU Hlth Shreveport, Dept Cellular & Mol Physiol, Shreveport, LA 71130 USA; [Dykes, S. S.; Cardelli, J. A.] LSU Hlth Shreveport, Dept Microbiol & Immunol, Shreveport, LA 71130 USA; [Cardelli, J. A.; Pruitt, K.] LSU Hlth Shreveport, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Pruitt, K (corresponding author), LSU Hlth Shreveport, Dept Cellular & Mol Physiol, BRI F4-26,1501 Kings Hwy, Shreveport, LA 71130 USA.	kpruit@lsuhsc.edu			Feist-Weiller Cancer Center Idea Award; Carroll-Feist Predoctoral Fellowship Award; NATIONAL CANCER INSTITUTE [R01CA155223] Funding Source: NIH RePORTER	Feist-Weiller Cancer Center Idea Award; Carroll-Feist Predoctoral Fellowship Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Channing Der at University of North Carolina and Dr Sharon Dent at University of Texas MD Anderson Cancer Center for providing the plasmids. The work described here is funded by a Feist-Weiller Cancer Center Idea Award to KP. MS is supported by the Carroll-Feist Predoctoral Fellowship Award.	Adam L, 2001, J BIOL CHEM, V276, P28443, DOI 10.1074/jbc.M009769200; Adams HC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2637; Allis CD, 2007, CELL, V131, P633, DOI 10.1016/j.cell.2007.10.039; Arthur WT, 2002, J BIOL CHEM, V277, P42964, DOI 10.1074/jbc.M207401200; Barrio-Real L, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003543; Bosco EE, 2009, CELL MOL LIFE SCI, V66, P370, DOI 10.1007/s00018-008-8552-x; Brooks CL, 2009, NAT REV CANCER, V9, P123, DOI 10.1038/nrc2562; Buongiorno P, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-73; Byles V, 2012, ONCOGENE, V31, P4619, DOI 10.1038/onc.2011.612; Byles V, 2010, INT J BIOL SCI, V6, P599; Cajanek L, 2013, MOL CELL BIOL, V33, P59, DOI 10.1128/MCB.00745-12; Chen J, 2013, HEPATOLOGY, V57, P2287, DOI 10.1002/hep.26278; Chen J, 2011, CANCER RES, V71, P4138, DOI 10.1158/0008-5472.CAN-10-4274; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Cook DR, 2014, ONCOGENE, V33, P4021, DOI 10.1038/onc.2013.362; Ding Y, 2009, INT J CANCER, V124, P653, DOI 10.1002/ijc.23954; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Gysin Stephan, 2011, Genes Cancer, V2, P359, DOI 10.1177/1947601911412376; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Heltweg B, 2006, CANCER RES, V66, P4368, DOI 10.1158/0008-5472.CAN-05-3617; Holloway KR, 2013, MOL ENDOCRINOL, V27, P480, DOI 10.1210/me.2012-1347; Holloway KR, 2010, P NATL ACAD SCI USA, V107, P9216, DOI 10.1073/pnas.0911325107; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Hornbeck PV, 2012, NUCLEIC ACIDS RES, V40, pD261, DOI 10.1093/nar/gkr1122; Hou HL, 2012, J CLIN PATHOL, V65, P1088, DOI 10.1136/jclinpath-2012-200940; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lee H, 2011, HUM PATHOL, V42, P204, DOI 10.1016/j.humpath.2010.05.023; Li Y, 2008, CELL METAB, V8, P38, DOI 10.1016/j.cmet.2008.05.004; Liu HM, 2011, ONCOL REP, V25, P841, DOI 10.3892/or.2010.1122; Liu PY, 2013, CELL DEATH DIFFER, V20, P503, DOI 10.1038/cdd.2012.147; Liu T, 2009, CANCER RES, V69, P1702, DOI 10.1158/0008-5472.CAN-08-3365; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Minard ME, 2005, ONCOGENE, V24, P2568, DOI 10.1038/sj.onc.1208503; Napper AD, 2005, J MED CHEM, V48, P8045, DOI 10.1021/jm050522v; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; North BJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000784; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; Pegtel DM, 2007, CURR BIOL, V17, P1623, DOI 10.1016/j.cub.2007.08.035; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706; Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960; Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4; Wang SJ, 2012, J CELL BIOL, V199, P331, DOI 10.1083/jcb.201202041; Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990; Woodcock SA, 2009, MOL CELL, V33, P639, DOI 10.1016/j.molcel.2009.02.012; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Yang MH, 2013, MOL CANCER RES, V11, P1072, DOI 10.1158/1541-7786.MCR-13-0040-T; Zhang Y, 2009, ONCOGENE, V28, P445, DOI 10.1038/onc.2008.388; Zhao G, 2011, GENE THER, V18, P920, DOI 10.1038/gt.2011.81	60	34	35	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					188	198		10.1038/onc.2013.549	http://dx.doi.org/10.1038/onc.2013.549			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24362520	Green Accepted			2022-12-17	WOS:000347790500006
J	Drake, CG; Sharma, P; Gerritsen, W				Drake, C. G.; Sharma, P.; Gerritsen, W.			Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy	ONCOGENE			English	Review						androgen ablation; chemotherapy; immunotherapy; post-docetaxel; prostate cancer; radiotherapy	T-CELL RESPONSES; IMMUNE-RESPONSE; CTLA-4 BLOCKADE; INCREASED SURVIVAL; RECENT SUCCESSES; CLINICAL-TRIALS; LOCAL RADIATION; TUMOR-CELLS; OPEN-LABEL; PHASE-II	For the past decade, docetaxel has remained the global standard of care for frontline treatment of metastatic castration-resistant prostate cancer (mCRPC). Until recently, there were limited options for patients with mCRPC following docetaxel failure or resistance, but now the approved treatment choices for these patients have expanded to include abiraterone acetate, cabazitaxel and enzalutamide. Additionally, the radioactive therapeutic agent radium-223 dichloride has been recently approved in patients with CRPC with bone metastases. Although each of these agents has been shown to convey significant survival benefit as a monotherapy, preclinical findings suggest that combining such innovative strategies with traditional treatments may achieve additive or synergistic effects, further augmenting patient benefit. This review will discuss the transformation of the post-docetaxel space in mCRPC, highlighting the spectrum of newly approved agents in this setting in the USA and the European Union, as well as summarizing treatments with non-chemotherapeutic mechanisms of action that have demonstrated promising results in recent phase 3 trials. Lastly, this review will address the potential of combinatorial regimens in mCRPC, including the pairing of novel immunotherapeutic approaches with chemotherapy, radiotherapy or androgen ablation.	[Drake, C. G.] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, 1650 Orleans St CRB 410, Baltimore, MD 21231 USA; [Sharma, P.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Gerritsen, W.] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6525 ED Nijmegen, Netherlands	Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; UTMD Anderson Cancer Center; Radboud University Nijmegen	Drake, CG (corresponding author), Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, 1650 Orleans St CRB 410, Baltimore, MD 21231 USA.	cdrake@jhmi.edu	Gerritsen, W.R./H-8031-2014		Bristol-Myers Squibb (BMS); NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER	Bristol-Myers Squibb (BMS)(Bristol-Myers Squibb); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Professional medical writing and editorial assistance was provided by Ami P. Modi, PhD, at StemScientific, and funded by Bristol-Myers Squibb (BMS).	Abdollah F, 2012, INT J UROL, V19, P836, DOI 10.1111/j.1442-2042.2012.03052.x; Angelergues A, 2013, J CLIN ONCOL, V31, p323s; [Anonymous], 2012, ZYT AB AC SUMM PROD; [Anonymous], 2013, US YERV IP PACK INS; [Anonymous], 2012, XTAND ENZ PACK INS; [Anonymous], PHAS 2 STUD AD PSA V; [Anonymous], 2012, ZYT AB AC PACK INS; [Anonymous], 2012, EU YERV IP PACK INS; [Anonymous], 2013, XOF RAD RA 223 DICHL; [Anonymous], 2013, XGEV DEN PACK INS; [Anonymous], 2011, PROV SIP T PACK INS; Antonarakis ES, 2012, CURR OPIN ONCOL, V24, P258, DOI 10.1097/CCO.0b013e32835205a0; Antonarakis ES, 2013, J CLIN ONCOL, V31, p312s; Aparicio A, 2012, CANC RES S8, V72; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Arlen PM, 2006, CLIN CANCER RES, V12, P1260, DOI 10.1158/1078-0432.CCR-05-2059; Berthold DR, 2008, J CLIN ONCOL, V26, P242, DOI 10.1200/JCO.2007.12.4008; Brown IE, 2006, J IMMUNOL, V177, P4521, DOI 10.4049/jimmunol.177.7.4521; Chakraborty M, 2004, CANCER RES, V64, P4328, DOI 10.1158/0008-5472.CAN-04-0073; Chakraborty M, 2003, J IMMUNOL, V170, P6338, DOI 10.4049/jimmunol.170.12.6338; *CLIN TRIALS, CONC VERS SEQ TREATM; *CLIN TRIALS, STUD DET SAF TOL ENZ; *CLIN TRIALS, SEQ SIP T ADT MEN NO; Clinical Trials.gov, PHAS 3 STUD IMM TREA; Clinical Trials.gov, STUD IMM TREAT ADV P; Clinical Trials.gov, IP ANDR DEPR THER; Clinical Trials.gov, IP COMB ANDR SUPPR T; Clinical Trials.gov, COMB IP AB ON AC PLU; Clinical Trials.gov NCT00450463, VACC THER PROSTVAC T; Clinical Trials.gov NCT01145508, DOC PREDN VACC THER; Clinical Trials.gov NCT01194271, NEOADJ IP PROST CANC; Clinical Trials.gov NCT01420965, SIP T CT 011 CYCL AD; Clinical Trials.gov NCT01436968, PHAS 3 STUD PROSTATA; Clinical Trials.gov NCT01696877, NEOADJ STUD ANDR ABL; Corn Paul G, 2012, Cancer Manag Res, V4, P183, DOI 10.2147/CMAR.S32839; Danila DC, 2011, CANCER J, V17, P438, DOI 10.1097/PPO.0b013e31823e69ac; Dayyani F, 2011, JNCI-J NATL CANCER I, V103, P1665, DOI 10.1093/jnci/djr362; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; Demaria S, 2005, CLIN CANCER RES, V11, P728; Dewan MZ, 2009, CLIN CANCER RES, V15, P5379, DOI 10.1158/1078-0432.CCR-09-0265; Dickinson M, 2010, INVEST NEW DRUG, V28, pS3, DOI 10.1007/s10637-010-9596-y; Drake CG, 2012, J CLIN ONCOL S, V30; Drake CG, 2010, NAT REV IMMUNOL, V10, P580, DOI 10.1038/nri2817; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; Gao J, 2012, CANC RES S8, V72; Garnett CT, 2008, CLIN CANCER RES, V14, P3536, DOI 10.1158/1078-0432.CCR-07-4025; Gulley JL, 2005, CLIN CANCER RES, V11, P3353, DOI 10.1158/1078-0432.CCR-04-2062; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris TJ, 2008, PROSTATE, V68, P1319, DOI 10.1002/pros.20794; Higano D, 2009, 2009 GEN CANC S ORL; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoos A, 2010, SEMIN ONCOL, V37, P533, DOI 10.1053/j.seminoncol.2010.09.015; Horwich A, 2010, ANN ONCOL, V21, pv129, DOI 10.1093/annonc/mdq174; Huang X, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-35; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jure-Kunkel MN, 2008, J CLIN ONCOL S, V26, p144s; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kodumudi KN, 2010, CLIN CANCER RES, V16, P4583, DOI 10.1158/1078-0432.CCR-10-0733; Kuroda K, 2009, PROSTATE, V69, P1579, DOI 10.1002/pros.21004; Lebbe C, 2012, ANN ONCOL, V23, P363; Lee Francis, 2011, Ther Adv Med Oncol, V3, P11, DOI 10.1177/1758834010386402; Levy MY, 2009, J PHARMACOL EXP THER, V330, P596, DOI 10.1124/jpet.109.152603; Lugade AA, 2005, J IMMUNOL, V174, P7516, DOI 10.4049/jimmunol.174.12.7516; Ma YT, 2011, CANCER METAST REV, V30, P71, DOI 10.1007/s10555-011-9283-2; Madan RA, 2008, CLIN CANCER RES, V14, P4526, DOI 10.1158/1078-0432.CCR-07-5048; Madan RA, 2012, LANCET ONCOL, V13, P501, DOI 10.1016/S1470-2045(12)70006-2; Maio M, 2012, ANN ONCOL, V23, P367; Maluf FC, 2012, CLINICS, V67, P389, DOI 10.6061/clinics/2012(04)13; Marin-Aguilera M, 2012, MOL CANCER THER, V11, P329, DOI 10.1158/1535-7163.MCT-11-0289; McCourt CM, 2013, J CLIN PATHOL, V66, P58, DOI 10.1136/jclinpath-2012-201140; McDonnell AM, 2011, SEMIN IMMUNOPATHOL, V33, P353, DOI 10.1007/s00281-011-0246-z; Mercader M, 2001, P NATL ACAD SCI USA, V98, P14565, DOI 10.1073/pnas.251140998; Mokyr MB, 1998, CANCER RES, V58, P5301; NCCN Clinical Practice Guidelines in Oncology, 2012, NCCN CLIN PRACT GUID; Nilsson S, 2013, J CLIN ONCOL, V31, p317s; Nowak AK, 2003, CANCER RES, V63, P4490; Parker C, 2012, 2012 AM SOC CLIN ONC; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Pilones KA, 2009, CLIN CANCER RES, V15, P597, DOI 10.1158/1078-0432.CCR-08-1277; Prieto PA, 2012, CLIN CANCER RES, V18, P2039, DOI 10.1158/1078-0432.CCR-11-1823; Rathkopf DE, 2013, J CLIN ONCOL, V31, p310s; Risk Michael, 2009, Rev Urol, V11, P16; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Ross RW, 2008, CANCER-AM CANCER SOC, V112, P1247, DOI 10.1002/cncr.23304; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Sanda MG, 1999, UROLOGY, V53, P260, DOI 10.1016/S0090-4295(98)00539-1; Scher HI, 2013, J CLIN ONCOL, V31; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Sharma P, 2011, NAT REV CANCER, V11, P805, DOI 10.1038/nrc3153; Sheikh NA, 2013, CANCER IMMUNOL IMMUN, V62, P137, DOI 10.1007/s00262-012-1317-2; Shen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030815; Slovin SF, 2013, ANN ONCOL, V24, P1813, DOI 10.1093/annonc/mdt107; Slovin SR, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00043; Small E, 2006, J CLIN ONCOL S18, V24, P4609; Small EJ, 2013, J CLIN ONCOL, V31, p319s; Stevenson R, 2013, J CLIN ONCOL, V31; Sutherland JS, 2005, J IMMUNOL, V175, P2741, DOI 10.4049/jimmunol.175.4.2741; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Terry S, 2009, BRIT J CANCER, V101, P951, DOI 10.1038/sj.bjc.6605245; Tollefson MK, 2010, AM SOC CLIN ONC 2010; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; van den Eertwegh AJM, 2012, LANCET ONCOL, V13, P509, DOI 10.1016/S1470-2045(12)70007-4; Vanneman M, 2012, NAT REV CANCER, V12, P237, DOI 10.1038/nrc3237; Vicari AP, 2009, CANCER IMMUNOL IMMUN, V58, P615, DOI 10.1007/s00262-008-0586-2; Vogelzang NJ, 2013, J CLIN ONCOL, V31, p324s; Yuan JD, 2011, P NATL ACAD SCI USA, V108, P16723, DOI 10.1073/pnas.1110814108; Zitvogel L, 2008, J CLIN INVEST, V118, P1991, DOI 10.1172/JCI35180; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	110	34	37	1	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2014	33	43					5053	5064		10.1038/onc.2013.497	http://dx.doi.org/10.1038/onc.2013.497			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OF	24276248	Green Accepted			2022-12-17	WOS:000343768400001
J	Xu, C; Lin, L; Cao, G; Chen, Q; Shou, P; Huang, Y; Han, Y; Wang, Y; Shi, Y				Xu, C.; Lin, L.; Cao, G.; Chen, Q.; Shou, P.; Huang, Y.; Han, Y.; Wang, Y.; Shi, Y.			Interferon-alpha-secreting mesenchymal stem cells exert potent antitumor effect in vivo	ONCOGENE			English	Article						mesenchymal stem cells; IFN alpha; NK cells; CD8(+) T cells; immune system; tumor	NATURAL-KILLER-CELLS; STROMAL CELLS; DELIVERY; TISSUE	Mesenchymal stem cells (MSCs) are a kind of adult stem cells that can be isolated easily from bone marrow, adipose tissue, umbilical cord and many other tissues. MSCs have been shown to specifically migrate to inflammatory sites, including tumors, and hold great promise as tumor-specific vectors to deliver antitumor agents. Interferon-alpha (IFN alpha) has been used in clinic to treat various types of tumors; however, because of its short half-life, significant therapeutic effects require high doses that often results in serious side effects. Here, we tested whether MSCs continuingly secreting IFN alpha can exert a persistent antitumor effect and eliminate the side effects associated with high clinical doses of recombinant IFN alpha. We found that even a small number of IFN alpha-secreting MSCs could potently halt B16 tumor growth in vivo. The antitumor activity of IFN alpha-secreting MSCs was largely abolished in immunodeficient mice, an effect largely attributed to natural killer cells and CD8(+) T cells. Therefore, IFNa-secreting MSCs provide an innovative strategy for tumor therapy.	[Xu, C.; Lin, L.; Cao, G.; Chen, Q.; Shou, P.; Huang, Y.; Han, Y.; Wang, Y.; Shi, Y.] Chinese Acad Sci, Shanghai Jiao Tong Univ, Shanghai Inst Biol Sci,Sch Med, Key Lab Stem Cell Biol,Inst Hlth Sci, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University	Shi, Y (corresponding author), Chinese Acad Sci, Shanghai Jiao Tong Univ, Shanghai Inst Biol Sci,Sch Med, Key Lab Stem Cell Biol,Inst Hlth Sci, 225 South Chongqing Rd,1 Bldg, Shanghai, Peoples R China.	yingwang@sibs.ac.cn; yufangshi@sibs.ac.cn	lin, liping/HGE-0871-2022; Xu, Chunliang/R-7065-2018; Shi, Yufang/AAE-4431-2020; Shou, Peishun/J-7985-2014; HUANG, YIN/AAH-6871-2020	Shi, Yufang/0000-0001-8964-319X; Shou, Peishun/0000-0001-7685-7471; HUANG, YIN/0000-0001-5602-9871; Chen, Qing/0000-0002-2088-0370; wang, ying/0000-0002-2571-9367	Scientific Innovation Project of the Chinese Academy of Science [XDA 01040107, XDA 01040110]; Ministry of Science and Technology of China [2010CB945600, 2011DFA30630]; National Science and Technology Project of China [31010103908, 81273316]; Shanghai Municipal Key Projects of Basic Research [12JC1409200]; Shanghai Municipal Natural Science Foundation [12ZR1452600]; Knowledge Innovation Program of Shanghai Institutes for Biological Sciences; Chinese Academy of Sciences [2012KIP202]	Scientific Innovation Project of the Chinese Academy of Science; Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Science and Technology Project of China; Shanghai Municipal Key Projects of Basic Research; Shanghai Municipal Natural Science Foundation; Knowledge Innovation Program of Shanghai Institutes for Biological Sciences(Knowledge Innovation Program of the Chinese Academy of Sciences); Chinese Academy of Sciences(Chinese Academy of Sciences)	This work was supported by grants from Scientific Innovation Project of the Chinese Academy of Science (XDA 01040107 and XDA 01040110), the Ministry of Science and Technology of China (2010CB945600 and 2011DFA30630), the National Science and Technology Project of China (31010103908 and 81273316), Shanghai Municipal Key Projects of Basic Research (12JC1409200), Shanghai Municipal Natural Science Foundation (12ZR1452600), the Knowledge Innovation Program of Shanghai Institutes for Biological Sciences and the Chinese Academy of Sciences (2012KIP202).	Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002; Bracarda S, 2010, EUR J CANCER, V46, P284, DOI 10.1016/j.ejca.2009.10.013; Cerwenka A, 2001, NAT REV IMMUNOL, V1, P41, DOI 10.1038/35095564; Elzaouk L, 2006, EXP DERMATOL, V15, P865, DOI 10.1111/j.1600-0625.2006.00479.x; Hainaut P, 2012, CURR OPIN ONCOL, V25, P50; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234; Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001; Keating A, 2012, CELL STEM CELL, V10, P709, DOI 10.1016/j.stem.2012.05.015; Kidd S, 2009, STEM CELLS, V27, P2614, DOI 10.1002/stem.187; Kim SM, 2008, CANCER RES, V68, P9614, DOI 10.1158/0008-5472.CAN-08-0451; Kolf CM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2116; Loebinger MR, 2009, CANCER RES, V69, P8862, DOI 10.1158/0008-5472.CAN-09-1912; Pestka S, 2003, CANCER CELL, V4, P85, DOI 10.1016/S1535-6108(03)00193-4; Pestka S, 2007, J BIOL CHEM, V282, P20047, DOI 10.1074/jbc.R700004200; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Ranganath SH, 2012, CELL STEM CELL, V10, P244, DOI 10.1016/j.stem.2012.02.005; Ren GW, 2012, CELL STEM CELL, V11, P812, DOI 10.1016/j.stem.2012.08.013; Ren GW, 2012, STEM CELL TRANSL MED, V1, P51, DOI 10.5966/sctm.2011-0019; Sensebe L, 2012, CELL STEM CELL, V10, P9, DOI 10.1016/j.stem.2011.12.005; Shi YF, 2010, CELL RES, V20, P510, DOI 10.1038/cr.2010.44; Studeny M, 2002, CANCER RES, V62, P3603; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; Vanneman M, 2012, NAT REV CANCER, V12, P237, DOI 10.1038/nrc3237; Vivier E, 2012, NAT REV IMMUNOL, V12, P239, DOI 10.1038/nri3174; Wang B, 2010, EXPERT OPIN DRUG DEL, V7, P1159, DOI 10.1517/17425247.2010.513968; Wang H, 2009, STEM CELLS, V27, P1548, DOI 10.1002/stem.81; Zou WB, 2012, CANCER RES, V72, P2980, DOI 10.1158/0008-5472.CAN-11-4216; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	29	34	36	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2014	33	42					5047	5052		10.1038/onc.2013.458	http://dx.doi.org/10.1038/onc.2013.458			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OB	24186200				2022-12-17	WOS:000343768000009
J	Banerjee, J; Mishra, R; Li, X; Jackson, RS; Sharma, A; Bhowmick, NA				Banerjee, J.; Mishra, R.; Li, X.; Jackson, R. S., II; Sharma, A.; Bhowmick, N. A.			A reciprocal role of prostate cancer on stromal DNA damage	ONCOGENE			English	Article						stromal coevolution; prostate cancer; TGF-beta; IL-6; DNA methylation	REACTIVE STROMA; TUMOR PROGRESSION; FIBROBLASTS; METHYLATION; GROWTH; TUMORIGENESIS; MECHANISMS; INDUCTION; PROMOTER; THERAPY	DNA damage found in prostate cancer-associated fibroblasts (CAF) promotes tumor progression. In the absence of somatic mutations in CAF, epigenetic changes dictate how stromal coevolution is mediated in tumors. Seventy percent of prostate cancer patients lose expression of transforming growth factor-beta type II receptor (TGFBR2) in the stromal compartment (n = 77, P-value = 0.0001), similar to the rate of glutathione S-transferase P1 (GSTP1) silencing. Xenografting of human prostate cancer epithelia, LNCaP, resulted in the epigenetic Tgfbr2 silencing of host mouse prostatic fibroblasts. Stromal Tgfbr2 promoter hypermethylation, initiated by LNCaP cells, was found to be dependent on interleukin 6 expression, based on neutralizing antibody studies. We further found that pharmacologic and transgenic knockout of TGF-beta responsiveness in prostatic fibroblasts induced Gstp1 promoter methylation. It is known that TGF-beta promotes DNA stability, however, the mechanism is not well understood. Both prostatic human CAF and mouse transgenic knockout of Tgbr2 had elevated DNA methyltransferase I (DNMT1) activity and histone H3 lysine 9 trimethylation (H3K9me3) to suggest greater promoter methylation. Interestingly, the conditional knockout of Tgfbr2 in mouse prostatic fibroblasts, in modeling epigenetic silencing of Tgfbr2, had greater epigenetic gene silencing of multiple DNA damage repair and oxidative stress response genes, based on promoter methylation array analysis. Homologous gene silencing was validated by reverse transcriptase (RT)-PCR in mouse and human prostatic CAF. Not surprisingly, DNA damage repair gene silencing in the prostatic stromal cells corresponded with the presence of DNA damage. Restoring the expression of the epigenetically silenced genes in wild-type fibroblasts with radiation-induced DNA damage reduced tumor progression. Tumor progression was inhibited even when epigenetic silencing was reversed in the Tgfbr2-knockout prostatic fibroblasts. Taken together, fibroblastic epigenetic changes causative of DNA damage, initiated by association with cancer epithelia, is a dominant mediator of tumor progression over TGF-beta responsiveness.	[Banerjee, J.; Li, X.; Jackson, R. S., II] Vanderbilt Univ, Dept Urol, Nashville, TN USA; [Mishra, R.; Bhowmick, N. A.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, Los Angeles, CA 90048 USA; [Jackson, R. S., II; Bhowmick, N. A.] Greater Los Angeles Vet Adm, Los Angeles, CA USA; [Sharma, A.] Univ Tennessee, Dept Mech Aerosp & Biomed Engn, Knoxville, TN USA	Vanderbilt University; Cedars Sinai Medical Center; University of Tennessee System; University of Tennessee Knoxville	Bhowmick, NA (corresponding author), Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, 8750 Beverly Blvd,Atrium 103, Los Angeles, CA 90048 USA.	bhowmickn@cshs.org	Mishra, Rajeev/AEX-2208-2022; Bhowmick, Neil/AAA-7302-2019; Mishra, Rajeev/T-4216-2017	Mishra, Rajeev/0000-0002-7411-4022; Bhowmick, Neil/0000-0001-8747-5989; , Xiaohong/0000-0001-5074-193X	National Cancer Institute [R01CA108646]; NATIONAL CANCER INSTITUTE [R01CA108646] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work was supported by R01CA108646 (to NAB) from the National Cancer Institute.	Ahles TA, 2007, NAT REV CANCER, V7, P192, DOI 10.1038/nrc2073; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Cahill DP, 1999, TRENDS BIOCHEM SCI, V24, pM57, DOI 10.1016/S0968-0004(99)01466-8; Campbell I, 2009, CANCER RES, V69, P6765, DOI 10.1158/0008-5472.CAN-08-4253; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Cunha G R, 1984, Prog Clin Biol Res, V145, P81; Dakhova O, 2009, CLIN CANCER RES, V15, P3979, DOI 10.1158/1078-0432.CCR-08-1899; Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462; Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Hodge David R., 2007, Cancer Genomics & Proteomics, V4, P387; Jackson RS, 2012, NEOPLASIA, V14, P656, DOI 10.1593/neo.12640; Jeronimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792; Kantarjian H, 2007, CANCER-AM CANCER SOC, V109, P1705, DOI 10.1002/cncr.22602; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Kiskowski MA, 2011, CANCER RES, V71, P3459, DOI 10.1158/0008-5472.CAN-10-2999; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Lee SO, 2003, CLIN CANCER RES, V9, P370; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li X, 2011, ONCOGENE, V30, P167, DOI 10.1038/onc.2010.400; Li X, 2008, ONCOGENE, V27, P7118, DOI 10.1038/onc.2008.293; Martinez-Ferrer M, 2010, AM J PATHOL, V176, P98, DOI 10.2353/ajpath.2010.090283; Maruyama R, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001369; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Ohuchida K, 2004, CANCER RES, V64, P3215, DOI 10.1158/0008-5472.CAN-03-2464; Olumi AF, 1999, CANCER RES, V59, P5002; Placencio VR, 2008, CANCER RES, V68, P4709, DOI 10.1158/0008-5472.CAN-07-6289; Placencio VR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012920; Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117; Shen H, 2012, CELL STEM CELL, V10, P353, DOI 10.1016/j.stem.2012.03.012; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Trobridge P, 2009, GASTROENTEROLOGY, V136, P1680, DOI 10.1053/j.gastro.2009.01.066; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; Tuxhorn JA, 2001, J UROLOGY, V166, P2472, DOI 10.1016/S0022-5347(05)65620-0; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598	39	34	34	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2014	33	41					4924	4931		10.1038/onc.2013.431	http://dx.doi.org/10.1038/onc.2013.431			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OA	24141771	Green Accepted			2022-12-17	WOS:000343767900005
J	Scortegagna, M; Ruller, C; Feng, Y; Lazova, R; Kluger, H; Li, JL; De, SK; Rickert, R; Pellecchia, M; Bosenberg, M; Ronai, ZA				Scortegagna, M.; Ruller, C.; Feng, Y.; Lazova, R.; Kluger, H.; Li, J-L; De, S. K.; Rickert, R.; Pellecchia, M.; Bosenberg, M.; Ronai, Z. A.			Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma	ONCOGENE			English	Article						PDK1; FOXO3a; melanoma; Braf; Pten; GSK2334470	AKT; DOWNSTREAM; MECHANISMS; RESISTANCE; MUTATIONS; SIZE; JNK	Phosphoinositide-dependent kinase-1 (PDK1) is a serine/threonine protein kinase that phosphorylates members of the conserved AGC kinase superfamily, including AKT and protein kinase C (PKC), and is implicated in important cellular processes including survival, metabolism and tumorigenesis. In large cohorts of nevi and melanoma samples, PDK1 expression was significantly higher in primary melanoma, compared with nevi, and was further increased in metastatic melanoma. PDK1 expression suffices for its activity, owing to auto-activation, or elevated phosphorylation by phosphoinositide 3'-OH-kinase (PI3K). Selective inactivation of Pdk1 in the melanocytes of Braf(V600E)::Pten(-/-) or Braf(V600E)::Cdkn2a(-/-)::Pten(-/-) mice delayed the development of pigmented lesions and melanoma induced by systemic or local administration of 4-hydroxytamoxifen. Melanoma invasion and metastasis were significantly reduced or completely prevented by Pdk1 deletion. Administration of the PDK1 inhibitor GSK2334470 (PDKi) effectively delayed melanomagenesis and metastasis in Braf(V600E)::Pten(-/-) mice. Pdk1(-/-) melanomas exhibit a marked decrease in the activity of AKT, P70S6K and PKC. Notably, PDKi was as effective in inhibiting AGC kinases and colony forming efficiency of melanoma with Pten wild-type (WT) genotypes. Gene expression analyses identified Pdk1-dependent changes in FOXO3a-regulated genes, and inhibition of FOXO3a restored proliferation and colony formation of Pdk1(-/-) melanoma cells. Our studies provide direct genetic evidence for the importance of PDK1, in part through FOXO3a-dependent pathway, in melanoma development and progression.	[Scortegagna, M.; Ruller, C.; Feng, Y.; Li, J-L; De, S. K.; Rickert, R.; Pellecchia, M.; Ronai, Z. A.] Sanford Burnham Med Res Inst, Ctr Canc, La Jolla, CA 92037 USA; [Lazova, R.; Kluger, H.; Bosenberg, M.] Yale Univ, Dept Dermatol Med & Pathol, New Haven, CT USA	Sanford Burnham Prebys Medical Discovery Institute; Yale University	Ronai, ZA (corresponding author), Sanford Burnham Med Res Inst, Ctr Canc, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ronai@sbmri.org	Li, J L/E-6100-2018; Li, Jian-Liang/AAE-9315-2019; Pellecchia, Maurizio/Y-7072-2018	Li, J L/0000-0002-6487-081X; Li, Jian-Liang/0000-0002-6487-081X; RONAI, ZEEV/0000-0002-3859-0400; De, SURYA/0000-0001-5014-0798	NIH [CA099961, CA128814]; Melanoma Research Alliance; NATIONAL CANCER INSTITUTE [R01CA179170, P30CA030199, R01CA099961, P01CA128814] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000142] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Melanoma Research Alliance; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This manuscript is dedicated in fond memory to Victor Fung, Ph.D., a former Program Officer at NCI and a former Scientific Review Officer of the Cancer Etiology study section of CSR, NIH, for his wisdom, compassion, integrity, his love of the sciences and the arts and his contributions to the career development of so many investigators during his own distinguished career. We thank Dario Alessi for providing the conditional Pdk1<SUP>-/-</SUP> mice, Vincent Hearing for the Tyrp1 antibody and Pedro Aza-Blanc for small interfering RNA library work. Support by NIH grants CA099961 (to ZR) and CA128814 (to ZR and MP) and a Melanoma Research Alliance grant (to ZR) is gratefully acknowledged.	Axten JM, 2011, CHEM COMPOUNDS; Aziz SA, 2009, CLIN CANCER RES, V15, P3029, DOI 10.1158/1078-0432.CCR-08-2768; Bagrodia S, 2012, PIGM CELL MELANOMA R, V25, P819, DOI 10.1111/pcmr.12007; Bayascas JR, 2005, CURR BIOL, V15, P1839, DOI 10.1016/j.cub.2005.08.066; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bosenberg M, 2006, GENESIS, V44, P262, DOI 10.1002/dvg.20205; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Choucair KA, 2012, TRANSL ONCOL, V5, P453, DOI 10.1593/tlo.12286; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Ellwood-Yen K, 2011, CANCER RES, V71, P3052, DOI 10.1158/0008-5472.CAN-10-2282; Eser S, 2013, CANCER CELL, V23, P406, DOI 10.1016/j.ccr.2013.01.023; Finlay DK, 2009, J EXP MED, V206, P2441, DOI 10.1084/jem.20090219; Gagliardi PA, 2012, NEOPLASIA, V14, P719, DOI 10.1593/neo.12856; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387; Lopez-Bergami P, 2005, MOL CELL, V19, P309, DOI 10.1016/j.molcel.2005.06.025; Lopez-Bergami P, 2007, CANCER CELL, V11, P447, DOI 10.1016/j.ccr.2007.03.009; Lopez-Bergami P, 2010, J BIOL CHEM, V285, P903, DOI 10.1074/jbc.M109.075630; Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820; Medina JR, 2011, J MED CHEM, V54, P1871, DOI 10.1021/jm101527u; Miao BC, 2010, P NATL ACAD SCI USA, V107, P20126, DOI 10.1073/pnas.1004522107; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Nagashima K, 2011, J BIOL CHEM, V286, P6433, DOI 10.1074/jbc.M110.156463; Najafov A, 2012, BIOCHEM J, V448, P285, DOI 10.1042/BJ20121287; Najafov A, 2011, BIOCHEM J, V433, P357, DOI 10.1042/BJ20101732; Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82_2010_43; Shen H, 2008, CANCER GENET CYTOGEN, V181, P100, DOI 10.1016/j.cancergencyto.2007.11.012; Shi W, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq871; Skurk C, 2005, J BIOL CHEM, V280, P20814, DOI 10.1074/jbc.M500528200; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Tsao H, 2012, GENE DEV, V26, P1131, DOI 10.1101/gad.191999.112; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Vultur A, 2009, PIGM CELL MELANOMA R, V22, P4, DOI 10.1111/j.1755-148X.2008.00527.x; You H, 2004, P NATL ACAD SCI USA, V101, P14057, DOI 10.1073/pnas.0406286101	35	34	34	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2014	33	34					4330	4339		10.1038/onc.2013.383	http://dx.doi.org/10.1038/onc.2013.383			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MK	24037523	Green Accepted			2022-12-17	WOS:000341156900006
J	Zhang, B; Chen, H; Zhang, L; Dakhova, O; Zhang, Y; Lewis, MT; Creighton, CJ; Ittmann, MM; Xin, L				Zhang, B.; Chen, H.; Zhang, L.; Dakhova, O.; Zhang, Y.; Lewis, M. T.; Creighton, C. J.; Ittmann, M. M.; Xin, L.			A dosage-dependent pleiotropic role of Dicer in prostate cancer growth and metastasis	ONCOGENE			English	Article						prostate cancer; Dicer; pten; senescence; apoptosis; invasiveness	MICRORNA EXPRESSION; ENZYME DICER; INTRAEPITHELIAL NEOPLASIA; CELL-PROLIFERATION; UP-REGULATION; DNA-DAMAGE; SENESCENCE; MOUSE; MORPHOGENESIS; DROSHA	Dicer is an RNase III enzyme essential for the maturation of the majority of microRNAs. Recent studies have revealed downregulation or hemizygous loss of Dicer in many tumor models and demonstrated that suppressing Dicer activity enhances tumorigenic activities of lung and breast cancer cells, which support Dicer as a haploinsufficient tumor suppressor in these cancer models. Surprisingly, we found that knocking down Dicer expression suppresses the growth and tumorigenic capacity of human prostate cancer cell lines, but enhances migratory capacities of some prostate cancer cell lines. Dicer is upregulated in human prostate cancer specimens, but lower Dicer expression portends a shorter time to recurrence. Complete ablation of Dicer activity in a Pten null mouse model for prostate cancer significantly halts tumor growth and progression, demonstrating that microRNAs have a critical role in maintaining cancer cell fitness. In comparison, hemizygous loss of Dicer in the same model also reduces primary tumor burden, but induces a more locally invasive phenotype and causes seminal vesicle obstruction at high penetrance. Disrupting Dicer activity leads to an increase in apoptosis and senescence in these models, presumably through upregulation of P16/INK4a and P27/Kip1. Collectively, these results highlight a pleotropic role of Dicer in tumorigenesis that is not only dosage-dependent but also tissue context-dependent.	[Zhang, B.; Chen, H.; Zhang, L.; Lewis, M. T.; Xin, L.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Dakhova, O.; Ittmann, M. M.; Xin, L.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Zhang, Y.; Lewis, M. T.; Creighton, C. J.; Ittmann, M. M.; Xin, L.] Dan L Duncan Canc Ctr, Houston, TX USA	Baylor College of Medicine; Baylor College of Medicine	Xin, L (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	xin@bcm.edu	Lewis, Michael T/A-9572-2009		NIH [R00 CA125937, U01 CA141497, P30 CA125123]; Cancer Prevention Research Institute of Texas [RP110005]; National Cancer Institute, Cancer Prevention and Research Institute of Texas; NATIONAL CANCER INSTITUTE [P30CA125123] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Research Institute of Texas; National Cancer Institute, Cancer Prevention and Research Institute of Texas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Lawrence Donehower and Jeffrey Rosen for critical comments, Dr Xiongbin Lu for sharing reagents. This work is supported by NIH R00 CA125937 (LX), Cancer Prevention Research Institute of Texas RP110005 (LX), NIH U01 CA141497 (MMI), and NIH P30 CA125123 (PI: Kent Osborne). This study was supported by National Cancer Institute, Cancer Prevention and Research Institute of Texas.	Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Andl T, 2006, CURR BIOL, V16, P1041, DOI 10.1016/j.cub.2006.04.005; Arrate MP, 2010, CANCER RES, V70, P6083, DOI 10.1158/0008-5472.CAN-09-4736; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chiosea S, 2007, CANCER RES, V67, P2345, DOI 10.1158/0008-5472.CAN-06-3533; Chiosea S, 2006, AM J PATHOL, V169, P1812, DOI 10.2353/ajpath.2006.060480; Faggad A, 2010, J PATHOL, V220, P382, DOI 10.1002/path.2658; Francia S, 2012, NATURE, V488, P231, DOI 10.1038/nature11179; Grelier G, 2009, BRIT J CANCER, V101, P673, DOI 10.1038/sj.bjc.6605193; Han L, 2010, INT J ONCOL, V37, P299, DOI 10.3892/ijo_00000678; Harfe BD, 2005, P NATL ACAD SCI USA, V102, P10898, DOI 10.1073/pnas.0504834102; Jafarnejad SM, 2013, ONCOGENE, V32, P2131, DOI 10.1038/onc.2012.239; Jin CL, 2003, PROSTATE, V57, P160, DOI 10.1002/pros.10283; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Karube Y, 2005, CANCER SCI, V96, P111, DOI 10.1111/j.1349-7006.2005.00015.x; Khoshnaw SM, 2012, BREAST CANCER RES TR, V135, P403, DOI 10.1007/s10549-012-2169-3; Kim J, 2012, P NATL ACAD SCI USA, V109, P3921, DOI 10.1073/pnas.1117135109; Koralov SB, 2008, CELL, V132, P860, DOI 10.1016/j.cell.2008.02.020; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Lambertz I, 2010, CELL DEATH DIFFER, V17, P633, DOI 10.1038/cdd.2009.202; Lin RJ, 2010, CANCER RES, V70, P7841, DOI 10.1158/0008-5472.CAN-10-0970; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Ma ZH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020494; Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Mudhasani R, 2008, J CELL BIOL, V181, P1055, DOI 10.1083/jcb.200802105; Nakagawa A, 2010, SCIENCE, V328, P327, DOI 10.1126/science.1182374; Narayanan R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013637; Nittner D, 2012, NAT CELL BIOL, V14, P958, DOI 10.1038/ncb2556; Noh Hyangsoon, 2011, Genes Cancer, V2, P140, DOI 10.1177/1947601911408888; O'Rourke JR, 2007, DEV BIOL, V311, P359, DOI 10.1016/j.ydbio.2007.08.032; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Park JH, 2002, AM J PATHOL, V161, P727, DOI 10.1016/S0002-9440(10)64228-9; Pastorelli LM, 2009, MAMM GENOME, V20, P140, DOI 10.1007/s00335-008-9169-y; Ravi A, 2012, CANCER CELL, V21, P848, DOI 10.1016/j.ccr.2012.04.037; Shlush LI, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-16; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Tang KF, 2008, J CELL BIOL, V182, P233, DOI 10.1083/jcb.200801169; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Ting AH, 2008, CANCER RES, V68, P2570, DOI 10.1158/0008-5472.CAN-07-6405; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wei W, 2012, CELL, V149, P101, DOI 10.1016/j.cell.2012.03.002; Xin L, 2003, P NATL ACAD SCI USA, V100, P11896, DOI 10.1073/pnas.1734139100; Xu SL, 2012, BLOOD, V119, P767, DOI 10.1182/blood-2011-05-355412; Yi R, 2006, NAT GENET, V38, P356, DOI 10.1038/ng1744; Yu JY, 2009, DEVELOPMENT, V136, P1497, DOI 10.1242/dev.025999; Zhang L, 2010, STEM CELLS, V28, P1260, DOI 10.1002/stem.455	51	34	34	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3099	3108		10.1038/onc.2013.281	http://dx.doi.org/10.1038/onc.2013.281			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23851498	Green Accepted			2022-12-17	WOS:000338410000003
J	Panupinthu, N; Yu, S; Zhang, D; Zhang, F; Gagea, M; Lu, Y; Grandis, JR; Dunn, SE; Lee, HY; Mills, GB				Panupinthu, N.; Yu, S.; Zhang, D.; Zhang, F.; Gagea, M.; Lu, Y.; Grandis, J. R.; Dunn, S. E.; Lee, H. Y.; Mills, G. B.			Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer	ONCOGENE			English	Article						autoregulation; crosstalk; feedback; G-protein-coupled receptor; receptor tyrosine kinase	GROWTH-FACTOR RECEPTOR; RIBOSOMAL S6 KINASE; LYSOPHOSPHATIDIC ACID PRODUCTION; ALLOSTERIC AKT INHIBITOR; BREAST-CANCER; NUCLEAR-LOCALIZATION; TUMOR-GROWTH; IN-VITRO; CELLS; YB-1	The Y-box binding protein-1 (YB-1) transcription factor is associated with unfavorable clinical outcomes. However, the mechanisms underlying this association remain to be fully elucidated. We demonstrate that YB-1 phosphorylation, indicative of YB-1 activation, is a powerful marker of outcomes for ovarian cancer patients. In ovarian cancer, YB-1 phosphorylation is induced by activation of the lysophosphatidic acid (LPA) receptor (LPAR) via SRC-dependent transactivation of the epidermal growth factor receptor (EGFR) that is coupled to MAPK/p90 ribosomal S6 kinase (p90RSK), but not phosphatidylinositol 3-kinase (PI3K)/AKT signaling. Activation of the LPAR/SRC/EGFR/MAPK/p90RSK/YB-1 axis leads to production of the EGFR ligand amphiregulin (AREG). AREG induces ongoing YB-1 phosphorylation as well as YB-1-dependent AREG expression, thus constituting an AREG/YB-1 self-reinforcing loop. Disruption of transactivation of the EGFR and the downstream self-reinforcing loop decreases invasiveness of ovarian cancer cells in vitro and limits ovarian cancer growth in xenograft models. These findings established the regulation and significance of YB-1 phosphorylation, therefore further exploration of this signaling axis as a therapeutic avenue in ovarian cancer is warranted.	[Panupinthu, N.; Yu, S.; Zhang, D.; Zhang, F.; Lu, Y.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Panupinthu, N.] Mahidol Univ, Fac Sci, Dept Physiol, Bangkok 10400, Thailand; [Gagea, M.] Univ Texas MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA; [Grandis, J. R.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA; [Grandis, J. R.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Dunn, S. E.] Univ British Columbia, Child & Family Res Inst, Dept Pediat, Vancouver, BC V5Z 1M9, Canada; [Dunn, S. E.] Univ British Columbia, Child & Family Res Inst, Dept Expt Med, Vancouver, BC V5Z 1M9, Canada; [Lee, H. Y.] Konyang Univ, Coll Med, Dept Pharmacol, Taejon, South Korea	University of Texas System; UTMD Anderson Cancer Center; Mahidol University; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Child & Family Research Institute; University of British Columbia; Child & Family Research Institute; University of British Columbia; Konyang University; Konyang University Hospital	Panupinthu, N (corresponding author), Mahidol Univ, Fac Sci, Dept Physiol, 272 Rama VI Rd, Bangkok 10400, Thailand.	nattapon.pan@mahidol.ac.th			NIH [R01CA92160, P01CA099031, R01CA098372]; Breast Cancer Research Foundation; National Research Foundation of Korea [2011-0015761]; Canadian Institutes of Health Research; SPORE in head-and-neck cancer [P50CA197190]; American Cancer Society; CCSG [CA16672]; NATIONAL CANCER INSTITUTE [P50CA083639, P50CA098258, P01CA099031, R01CA098372, R01CA092160, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE023685] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; National Research Foundation of Korea(National Research Foundation of Korea); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); SPORE in head-and-neck cancer; American Cancer Society(American Cancer Society); CCSG; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Drs Meng Gao and Zhiyong Ding at MD Anderson Cancer Center for authenticating the AKT1/AKT2 knockout cell lines.This work was supported by NIH grants R01CA92160 and P01CA099031 (to G.B.M.), and R01CA098372 (to J.R.G.), the Breast Cancer Research Foundation (to G.B.M.), the National Research Foundation of Korea 2011-0015761 (to H.Y.L.), Canadian Institutes of Health Research (to S.E.D.), the SPORE in head-and-neck cancer P50CA197190 (to J.R.G.), the American Cancer Society (to J.R.G.) and CCSG core grant CA16672 (to MD Anderson Cancer Center).	Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987; Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; Basaki Y, 2007, ONCOGENE, V26, P2736, DOI 10.1038/sj.onc.1210084; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bergmann S, 2005, CANCER RES, V65, P4078, DOI 10.1158/0008-5472.CAN-04-4056; Berquin IM, 2005, ONCOGENE, V24, P3177, DOI 10.1038/sj.onc.1208504; Berquin IM, 2001, ONCOGENE, V20, P4019, DOI 10.1038/sj.onc.1204537; Boerner JL, 2005, MOL CARCINOGEN, V44, P262, DOI 10.1002/mc.20138; Busser B, 2010, MOL THER, V18, P528, DOI 10.1038/mt.2009.226; Cherrin C, 2010, CANCER BIOL THER, V9, P493, DOI 10.4161/cbt.9.7.11100; Chetrit A, 2008, J CLIN ONCOL, V26, P20, DOI 10.1200/JCO.2007.11.6905; Clarke-Pearson DL, 2009, NEW ENGL J MED, V361, P170, DOI 10.1056/NEJMcp0901926; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; Eder AM, 2000, CLIN CANCER RES, V6, P2482; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ericson K, 2010, P NATL ACAD SCI USA, V107, P2598, DOI 10.1073/pnas.0914018107; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Fang XJ, 2004, J BIOL CHEM, V279, P9653, DOI 10.1074/jbc.M306662200; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Jeong KJ, 2013, MOL ONCOL, V7, P121, DOI 10.1016/j.molonc.2012.10.001; Jing JP, 2012, MOL CANCER THER, V11, P720, DOI 10.1158/1535-7163.MCT-11-0505; Jones S, 2012, J PATHOL, V226, P413, DOI 10.1002/path.3967; Jurchott K, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001231; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Lasham A, 2012, JNCI-J NATL CANCER I, V104, P133, DOI 10.1093/jnci/djr512; Law JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012661; Li C, 2009, ONCOGENE, V28, P3801, DOI 10.1038/onc.2009.234; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Lu Y, 2011, ONCOGENE, V30, P4567, DOI 10.1038/onc.2011.164; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; Okita M, 1997, INT J CANCER, V71, P31, DOI 10.1002/(SICI)1097-0215(19970328)71:1<31::AID-IJC7>3.0.CO;2-4; Panupinthu N, 2010, BRIT J CANCER, V102, P941, DOI 10.1038/sj.bjc.6605588; Rhodes N, 2008, CANCER RES, V68, P2366, DOI 10.1158/0008-5472.CAN-07-5783; Rodland KD, 2008, J BIOL CHEM, V283, P31477, DOI 10.1074/jbc.M800456200; Rusnak DW, 2001, MOL CANCER THER, V1, P85; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Siwak DR, 2010, J ONCOL, V2010, DOI 10.1155/2010/568938; Smith JA, 2005, CANCER RES, V65, P1027; Snider AJ, 2010, AM J PHYSIOL-CELL PH, V298, pC163, DOI 10.1152/ajpcell.00001.2009; Stratford AL, 2012, STEM CELLS, V30, P1338, DOI 10.1002/stem.1128; Stratford AL, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2202; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590; Tabchy A, 2011, NAT STRUCT MOL BIOL, V18, P117, DOI 10.1038/nsmb0211-117; Talavera A, 2009, CANCER RES, V69, P5851, DOI 10.1158/0008-5472.CAN-08-4518; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Wakeling AE, 2002, CANCER RES, V62, P5749; Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Yahata H, 2002, J CANCER RES CLIN, V128, P621, DOI 10.1007/s00432-002-0386-6; Yu SX, 2008, JNCI-J NATL CANCER I, V100, P1630, DOI 10.1093/jnci/djn378; Zhang L, 2009, BIOINFORMATICS, V25, P650, DOI 10.1093/bioinformatics/btn663; Zhang Q, 2006, P NATL ACAD SCI USA, V103, P6901, DOI 10.1073/pnas.0509719103; Zhang Q, 2007, MOL CANCER THER, V6, P1414, DOI 10.1158/1535-7163.MCT-06-0678	58	34	37	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2846	2856		10.1038/onc.2013.259	http://dx.doi.org/10.1038/onc.2013.259			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23851501	Green Accepted			2022-12-17	WOS:000337231800004
J	Sato, T; Tran, TH; Peck, AR; Girondo, MA; Liu, C; Goodman, CR; Neilson, LM; Freydin, B; Chervoneva, I; Hyslop, T; Kovatich, AJ; Hooke, JA; Shriver, CD; Fuchs, SY; Rui, H				Sato, T.; Tran, T. H.; Peck, A. R.; Girondo, M. A.; Liu, C.; Goodman, C. R.; Neilson, L. M.; Freydin, B.; Chervoneva, I.; Hyslop, T.; Kovatich, A. J.; Hooke, J. A.; Shriver, C. D.; Fuchs, S. Y.; Rui, H.			Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression	ONCOGENE			English	Article						breast cancer; CK5; BCL6; prolactin; progesterone; Stat5	SIGNAL TRANSDUCER; STEM-CELLS; TRANSCRIPTION FACTOR; GENE-REGULATION; IN-VITRO; STAT5; ACTIVATOR; HORMONE; RECEPTORS; PHOSPHORYLATION	Prolactin controls the development and function of milk-producing breast epithelia but also supports growth and differentiation of breast cancer, especially luminal subtypes. A principal signaling mediator of prolactin, Stat5, promotes cellular differentiation of breast cancer cells in vitro, and loss of active Stat5 in tumors is associated with antiestrogen therapy failure in patients. In luminal breast cancer, progesterone induces a cytokeratin-5 (CK5)-positive basal cell-like population. This population possesses characteristics of tumor stem cells including quiescence, therapy resistance and tumor-initiating capacity. Here we report that prolactin counteracts induction of the CK5-positive population by the synthetic progestin (Pg) R5020 in luminal breast cancer cells both in vitro and in vivo. CK5-positive cells were chemoresistant as determined by fourfold reduced rate of apoptosis following docetaxel exposure. Pg-induction of CK5 was preceded by marked upregulation of BCL6, an oncogene and transcriptional repressor critical for the maintenance of leukemia-initiating cells. Knockdown of BCL6 prevented induction of CK5-positive cell population by Pg. Prolactin suppressed Pg-induced BCL6 through Jak2-Stat5 but not Erk-or Akt-dependent pathways. In premenopausal but not postmenopausal patients with hormone receptor-positive breast cancer, tumor protein levels of CK5 correlated positively with BCL6, and high BCL6 or CK5-protein levels were associated with unfavorable clinical outcome. Suppression of Pg-induction of CK5positive cells represents a novel prodifferentiation effect of prolactin in breast cancer. The present progress may have direct implications for breast cancer progression and therapy as loss of prolactin receptor-Stat5 signaling occurs frequently and BCL6 inhibitors currently being evaluated for lymphomas may have value for breast cancer.	[Sato, T.; Tran, T. H.; Peck, A. R.; Girondo, M. A.; Liu, C.; Goodman, C. R.; Neilson, L. M.; Rui, H.] Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Freydin, B.; Chervoneva, I.; Hyslop, T.] Thomas Jefferson Univ, Div Biostat, Philadelphia, PA 19107 USA; [Kovatich, A. J.] MDR Global Syst LLC, Windber, PA USA; [Hooke, J. A.; Shriver, C. D.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [Fuchs, S. Y.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; [Fuchs, S. Y.] Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA	Jefferson University; Jefferson University; Walter Reed National Military Medical Center; University of Pennsylvania; University of Pennsylvania	Rui, H (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, 233S 10th St,BLSB 330, Philadelphia, PA 19107 USA.	hallgeir.rui@jefferson.edu		Goodman, Chelain/0000-0001-9083-3652; Kovatich, Albert/0000-0002-5169-4087	Komen for the Cure Promise Grant [KG091116]; NIH [CA101841, CA118740, CA092900]; NCI [1P30CA56036]; Commonwealth University Research Enhancement Program; Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE [R01CA101841, R01CA092900, R01CA142425, P30CA056036, R01CA118740] Funding Source: NIH RePORTER	Komen for the Cure Promise Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Commonwealth University Research Enhancement Program; Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Komen for the Cure Promise Grant KG091116 (HR, TH, JAH, AJK, CDS, TS, ARP, MAG, CL, BF, and IC), NIH grants CA101841 (HR), CA118740 (HR), CA092900 (SYF) and NCI Support Grant 1P30CA56036 to the Kimmel Cancer Center. The Project is funded, in part, under a Commonwealth University Research Enhancement Program grant with the Pennsylvania Department of Health (HR). The Department specifically disclaims responsibility for any analyses, interpretations or conclusions. The views expressed in this article are those of the authors and do not reflect the official policy of the Department of the Army, Department of Defense or US Government.	Aldaz CM, 1996, CARCINOGENESIS, V17, P2069, DOI 10.1093/carcin/17.9.2069; Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Cattoretti G, 2005, CANCER CELL, V7, P445, DOI 10.1016/j.ccr.2005.03.037; Cerchietti LC, 2010, CANCER CELL, V17, P400, DOI 10.1016/j.ccr.2009.12.050; Cerchietti LC, 2009, BLOOD, V113, P3397, DOI 10.1182/blood-2008-07-168773; Cotarla I, 2004, INT J CANCER, V108, P665, DOI 10.1002/ijc.11619; Dagvadorj A, 2008, CLIN CANCER RES, V14, P1317, DOI 10.1158/1078-0432.CCR-07-2024; Daniel AR, 2009, P NATL ACAD SCI USA, V106, P14287, DOI 10.1073/pnas.0905118106; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Duy C, 2011, NATURE, V473, P384, DOI 10.1038/nature09883; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Haughian JM, 2012, P NATL ACAD SCI USA, V109, P2742, DOI 10.1073/pnas.1106509108; Horwitz KB, 2008, J CLIN ENDOCR METAB, V93, P3295, DOI 10.1210/jc.2008-0938; Horwitzt KB, 2008, P NATL ACAD SCI USA, V105, P5774, DOI 10.1073/pnas.0706216105; Hurtz C, 2011, J EXP MED, V208, P2163, DOI 10.1084/jem.20110304; Jacobsen BM, 2005, MOL ENDOCRINOL, V19, P574, DOI 10.1210/me.2004-0287; Johnson KJ, 2010, AM J PATHOL, V177, P2971, DOI 10.2353/ajpath.2010.090399; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kabos P, 2011, BREAST CANCER RES TR, V128, P45, DOI 10.1007/s10549-010-1078-6; Keen JC, 2003, CANCER-AM CANCER SOC, V97, P825, DOI 10.1002/cncr.11126; Knutson TP, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3211; Lee HJ, 2012, MOL CELL ENDOCRINOL, V357, P101, DOI 10.1016/j.mce.2011.09.020; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Lim E, 2012, ONCOLOGY-NY, V26, P688; Liu R, 2011, MOL ENDOCRINOL, V25, P1137, DOI 10.1210/me.2010-0497; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Logarajah S, 2003, ONCOGENE, V22, P5572, DOI 10.1038/sj.onc.1206689; Neilson LM, 2007, MOL ENDOCRINOL, V21, P2218, DOI 10.1210/me.2007-0173; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Nouhi Z, 2006, CANCER RES, V66, P1824, DOI 10.1158/0008-5472.CAN-05-2292; Peck AR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3328; Peck AR, 2011, J CLIN ONCOL, V29, P2448, DOI 10.1200/JCO.2010.30.3552; Pierson-Mullany LK, 2004, MOL CELL BIOL, V24, P10542, DOI 10.1128/MCB.24.24.10542-10557.2004; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sartorius CA, 2005, CANCER RES, V65, P9779, DOI 10.1158/0008-5472.CAN-05-0505; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Sultan AS, 2008, CANCER SCI, V99, P272, DOI 10.1111/j.1349-7006.2007.00685.x; Sultan AS, 2005, ONCOGENE, V24, P746, DOI 10.1038/sj.onc.1208203; Tran TH, 2010, CANCER RES, V70, P1711, DOI 10.1158/0008-5472.CAN-09-2314; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; Tunyaplin C, 2004, J IMMUNOL, V173, P1158, DOI 10.4049/jimmunol.173.2.1158; Walker SR, 2009, MOL CANCER RES, V7, P966, DOI 10.1158/1541-7786.MCR-08-0238; Yamashita H, 2006, ENDOCR-RELAT CANCER, V13, P885, DOI 10.1677/erc.1.01095	47	34	36	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2215	2224		10.1038/onc.2013.172	http://dx.doi.org/10.1038/onc.2013.172			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23708665	Green Accepted			2022-12-17	WOS:000334996000007
J	Laval, S; Laklai, H; Fanjul, M; Pucelle, M; Laurell, H; Billon-Gales, A; Le Guellec, S; Delisle, MB; Sonnenberg, A; Susini, C; Pyronnet, S; Bousquet, C				Laval, S.; Laklai, H.; Fanjul, M.; Pucelle, M.; Laurell, H.; Billon-Gales, A.; Le Guellec, S.; Delisle, M-B; Sonnenberg, A.; Susini, C.; Pyronnet, S.; Bousquet, C.			Dual roles of hemidesmosomal proteins in the pancreatic epithelium: the phosphoinositide 3-kinase decides	ONCOGENE			English	Article						pancreatic ductal epithelium; hemidesmosome; phosphoinositide 3-kinase; cell migration and invasion; G protein-coupled somatostatin receptor	SST2 SOMATOSTATIN RECEPTOR; BETA-4 INTEGRIN; CANCER; PHOSPHORYLATION; ALPHA-6-BETA-4; PROGRESSION; EXPRESSION; CELLS; ADENOCARCINOMA; MIGRATION	Given the failure of chemo-and biotherapies to fight advanced pancreatic cancer, one major challenge is to identify critical events that initiate invasion. One priming step in epithelia carcinogenesis is the disruption of epithelial cell anchorage to the basement membrane which can be provided by hemidesmosomes (HDs). However, the existence of HDs in pancreatic ductal epithelium and their role in carcinogenesis remain unexplored. HDs have been explored in normal and cancer pancreatic cells, and patient samples. Unique cancer cell models where HD assembly can be pharmacologically manipulated by somatostatin/sst2 signaling have been then used to investigate the role and molecular mechanisms of dynamic HD during pancreatic carcinogenesis. We surprisingly report the presence of mature type-1 HDs comprising the integrin alpha 6 beta 4 and bullous pemphigoid antigen BP180 in the human pancreatic ductal epithelium. Importantly, HDs are shown to disassemble during pancreatic carcinogenesis. HD breakdown requires phosphoinositide 3-kinase (P13K)-dependent induction of the matrix-metalloprotease MMP-9, which cleaves BP180. Consequently, integrin alpha 6 beta 4 delocalizes to the cell-leading edges where it paradoxically promotes cell migration and invasion through S100A4 activation. As S100A4 in turn stimulates MMP-9 expression, a vicious cycle maintains BP180 cleavage. Inactivation of this P13K-MMP9- S100A4 signaling loop conversely blocks BP180 cleavage, induces HD reassembly and inhibits cell invasion. We conclude that mature type-1 HDs are critical anchoring structures for the pancreatic ductal epithelium whose disruption, upon P13K activation during carcinogenesis, provokes pancreatic cancer cell migration and invasion.	[Laval, S.; Laklai, H.; Fanjul, M.; Pucelle, M.; Laurell, H.; Billon-Gales, A.; Susini, C.; Pyronnet, S.; Bousquet, C.] CRCT, INSERM UMR 1037, Lab Excellence Toulouse Canc Labex TOUCAN, Equipe Labellisee Ligue Natl Contre Canc LNCC, Toulouse, France; [Laval, S.; Laklai, H.; Fanjul, M.; Laurell, H.; Billon-Gales, A.; Susini, C.; Pyronnet, S.; Bousquet, C.] Univ Toulouse 3, F-31062 Toulouse, France; [Le Guellec, S.; Delisle, M-B] Hop Rangueil, Serv Anat & Cytol Pathol, Toulouse, France; [Sonnenberg, A.] Netherlands Canc Inst, Dept Cell Biol, Amsterdam, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Netherlands Cancer Institute	Bousquet, C (corresponding author), CRCT, INSERM, UMR 1037, 1 Ave Jean Poulhes,BP84225, F-31432 Toulouse 4, France.	corinne.bousquet@inserm.fr	Pyronnet, Stéphane/P-2419-2014; Fanjul, Marjorie/G-2429-2017; Bousquet, Corinne/P-2917-2014	Bousquet, Corinne/0000-0002-2501-0593; Laurell, Henrik/0000-0001-7328-935X	ARC (Association pour la Recherche Contre le Cancer) [5000]; LNCC (Ligue Nationale Contre le Cancer) [RAB09006BBA]; Laboratoire d'Excellence Toulouse Cancer LABEX TOUCAN; Canceropole Grand Sud-Ouest [RMA04002BPA]; ANR (Agence Nationale pour la Recherche) [R06423BS]; University Paul Sabatier of Toulouse [CR27 A01BQR-2007]; INSERM-Region Midi-Pyrenees	ARC (Association pour la Recherche Contre le Cancer)(Fondation ARC pour la Recherche sur le Cancer); LNCC (Ligue Nationale Contre le Cancer); Laboratoire d'Excellence Toulouse Cancer LABEX TOUCAN; Canceropole Grand Sud-Ouest; ANR (Agence Nationale pour la Recherche)(French National Research Agency (ANR)); University Paul Sabatier of Toulouse; INSERM-Region Midi-Pyrenees(Region Occitanie)	This work was supported by ARC (grant no. 5000, Association pour la Recherche Contre le Cancer), LNCC (Ligue Nationale Contre le Cancer RAB09006BBA), the Laboratoire d'Excellence Toulouse Cancer LABEX TOUCAN, the Canceropole Grand Sud-Ouest (RMA04002BPA), the ANR (Agence Nationale pour la Recherche, project no. R06423BS) and the University Paul Sabatier of Toulouse (CR27 A01BQR-2007). SL was recipient of a fellowship from LNCC. HL was recipient of a fellowship from INSERM-Region Midi-Pyrenees. MP was contracted by the RTRS-RITC (Toulouse). We thank Dr K Owaribe (University of Nagoya, Japan) for providing antibodies to BP180, BP230 and plectin, and Dr Tsao, University of Toronto for providing HPV-16E6E7immortalized HPDE cells.	Bausch D, 2011, CLIN CANCER RES, V17, P302, DOI 10.1158/1078-0432.CCR-10-0999; BERGSTRAESSER LM, 1995, AM J PATHOL, V147, P1823; Bon G, 2009, CANCER RES, V69, P5978, DOI 10.1158/0008-5472.CAN-09-0244; Bousquet C, 2006, EMBO J, V25, P3943, DOI 10.1038/sj.emboj.7601279; Bruns Christiane J., 1999, Neoplasia (New York), V1, P50, DOI 10.1038/sj.neo.7900005; Buscail L, 1996, CANCER RES, V56, P1823; Chen M, 2009, J BIOL CHEM, V284, P1484, DOI 10.1074/jbc.M803997200; Cruz-Monserrate Z, 2007, MODERN PATHOL, V20, P656, DOI 10.1038/modpathol.3800782; de Pereda JM, 2009, EMBO J, V28, P1180, DOI 10.1038/emboj.2009.48; Durlik Marek, 2012, Pol Przegl Chir, V84, P377, DOI 10.2478/v10035-012-0064-6; Dutta U, 2008, CANCER RES, V68, P8779, DOI 10.1158/0008-5472.CAN-08-2125; Fontao L, 1999, EXP CELL RES, V250, P298, DOI 10.1006/excr.1999.4549; Franzke CW, 2009, J BIOL CHEM, V284, P23386, DOI 10.1074/jbc.M109.034090; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Frijns E, 2012, MOL BIOL CELL, V23, P1475, DOI 10.1091/mbc.E11-11-0957; Germain EC, 2009, MOL BIOL CELL, V20, P56, DOI 10.1091/mbc.E08-06-0646; Gleason B, 2005, J HISTOCHEM CYTOCHEM, V53, P799, DOI 10.1369/jhc.4B6522.2005; Hirako Y, 2003, J BIOCHEM, V133, P197, DOI 10.1093/jb/mvg024; Kelly KA, 2008, PLOS MED, V5, P657, DOI 10.1371/journal.pmed.0050085; Laklai H, 2009, P NATL ACAD SCI USA, V106, P17769, DOI 10.1073/pnas.0908674106; Margadant C, 2008, CURR OPIN CELL BIOL, V20, P589, DOI 10.1016/j.ceb.2008.05.001; Pal-Ghosh S, 2011, J CELL SCI, V124, P2666, DOI 10.1242/jcs.085480; Pyronnet S, 2008, MOL CELL ENDOCRINOL, V286, P230, DOI 10.1016/j.mce.2008.02.002; Radutovich N, 2008, METHOD ENZYMOL, V439, P1, DOI 10.1016/S0076-6879(07)00401-6; Shimanovich I, 2004, J PATHOL, V204, P519, DOI 10.1002/path.1674; Stathis A, 2010, NAT REV CLIN ONCOL, V7, P163, DOI 10.1038/nrclinonc.2009.236; Wilhelmsen K, 2006, MOL CELL BIOL, V26, P2877, DOI 10.1128/MCB.26.8.2877-2886.2006; Yu PT, 2012, INT J CANCER, V131, P1744, DOI 10.1002/ijc.27447	28	34	34	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1934	1944		10.1038/onc.2013.146	http://dx.doi.org/10.1038/onc.2013.146			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23624916				2022-12-17	WOS:000334346300006
J	Zucchini, C; Manara, MC; Pinca, RS; De Sanctis, P; Guerzoni, C; Sciandra, M; Lollini, PL; Cenacchi, G; Picci, P; Valvassori, L; Scotlandi, K				Zucchini, C.; Manara, M. C.; Pinca, R. S.; De Sanctis, P.; Guerzoni, C.; Sciandra, M.; Lollini, P-L; Cenacchi, G.; Picci, P.; Valvassori, L.; Scotlandi, K.			CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity	ONCOGENE			English	Article						CD99; osteosarcoma; cadherins; ezrin; ROCK2; ARP2/3	EWINGS-SARCOMA CELLS; RHO-KINASE-II; MOLECULAR-MECHANISMS; CANCER INVASION; ARP2/3 COMPLEX; IN-VIVO; C-SRC; EXPRESSION; ADHESION; EZRIN	CD99, a transmembrane protein encoded by MIC2 gene is involved in multiple cellular events including cell adhesion and migration, apoptosis, cell differentiation and regulation of protein trafficking either in physiological or pathological conditions. In osteosarcoma, CD99 is expressed at low levels and functions as a tumour suppressor. The full-length protein (CD99wt) and the short-form harbouring a deletion in the intracytoplasmic domain (CD99sh) have been associated with distinct functional outcomes with respect to tumour malignancy. In this study, we especially evaluated modulation of cell-cell contacts, reorganisation of the actin cytoskeleton and modulation of signalling pathways by comparing osteosarcoma cells characterised by different metastasis capabilities and CD99 expression, to identify molecular mechanisms responsible for metastasis. Our data indicate that forced expression of CD99wt induces recruitment of N-cadherin and beta-catenin to adherens junctions. In addition, transfection of CD99wt inhibits the expression of several molecules crucial to the remodelling of the actin cytoskeleton, such as ACTR2, ARPC1A, Rho-associated, coiled-coil containing protein kinase 2 (ROCK2) as well as ezrin, an ezrin/radixin/moesin family member that has been clearly associated with tumour progression and metastatic spread in osteosarcoma. Functional studies point to ROCK2 as a crucial intracellular mediator regulating osteosarcoma migration. By maintaining c-Src in an inactive conformation, CD99wt inhibits ROCK2 signalling and this leads to ezrin decrease at cell membrane while N-cadherin and b-catenin translocate to the plasma membrane and function as main molecular bridges for actin cytoskeleton. Taken together, we propose that the re-expression of CD99wt, which is generally present in osteoblasts but lost in osteosarcoma, through inhibition of c-Src and ROCK2 activity, manages to increase contact strength and reactivate stop-migration signals that counteract the otherwise dominant promigratory action of ezrin in osteosarcoma cells.	[Zucchini, C.; De Sanctis, P.; Lollini, P-L; Valvassori, L.] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy; [Manara, M. C.; Pinca, R. S.; Sciandra, M.; Scotlandi, K.] CRS Dev Biomol Therapies, Bologna, Italy; [Manara, M. C.; Pinca, R. S.; Guerzoni, C.; Picci, P.; Scotlandi, K.] Ist Ortoped Rizzoli, Expt Oncol Lab, I-40136 Bologna, Italy; [Guerzoni, C.; Scotlandi, K.] Ist Ortoped Rizzoli, RIT Dept, STB, PROMETEO Lab, I-40136 Bologna, Italy; [Cenacchi, G.] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy	University of Bologna; IRCCS Istituto Ortopedico Rizzoli; IRCCS Istituto Ortopedico Rizzoli; University of Bologna	Scotlandi, K (corresponding author), Ist Ortoped Rizzoli, CRS Dev Biomol Therapies, Via Barbiano 1-10, I-40136 Bologna, Italy.	katia.scotlandi@ior.it	Scotlandi, Katia/J-9009-2016; Manara, Maria Cristina/K-3366-2018; Sciandra, Marika/C-8724-2018; De Sanctis, Paola/HCI-1421-2022; Lollini, Pier Luigi/A-7644-2008; Picci, Piero/J-5979-2016	Scotlandi, Katia/0000-0001-6114-9499; Manara, Maria Cristina/0000-0001-5686-720X; Sciandra, Marika/0000-0001-7147-6960; Lollini, Pier Luigi/0000-0003-1702-4108; Picci, Piero/0000-0002-8519-4101; CENACCHI, GIOVANNA/0000-0001-5824-3118	Italian Association for Cancer Research (AIRC) [IG10452]; Liddy Shriver Sarcoma Initiative; Ricerca Fondamentale Orientata (RFO)	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Liddy Shriver Sarcoma Initiative; Ricerca Fondamentale Orientata (RFO)	We are in debt to Cristina Ghinelli for editing the manuscript and to Anming Meng, Department of Biological Sciences and Biotechnology, Tsinghua University, Beijing 100084, China, for kindly providing the plasmid pCMV5-HA3-ROCK2. This work was supported by the Italian Association for Cancer Research (AIRC; IG10452 to K Scotlandi), the Liddy Shriver Sarcoma Initiative (international grant to K Scotlandi) and Ricerca Fondamentale Orientata (RFO 2010 to C Zucchini). Rosa Simona Pinca is a recipient of a fellowship from the Associazione Onlus 'il Pensatore: Matteo Amitrano' and 'Liberi di Vivere Luca Righi.'	Alberti I, 2002, FASEB J, V16, P1946, DOI 10.1096/fj.02-0049fje; Bacci G, 2006, CANCER-AM CANCER SOC, V106, P1154, DOI 10.1002/cncr.21724; Bernard G, 2000, EUR J IMMUNOL, V30, P3061, DOI 10.1002/1521-4141(200010)30:10<3061::AID-IMMU3061>3.0.CO;2-M; Bernard G, 1997, J IMMUNOL, V158, P2543; BERNARD G, 1995, J IMMUNOL, V154, P26; Borensztajn K, 2010, THROMB RES, V125, pE323, DOI 10.1016/j.thromres.2010.02.018; Bruce B, 2007, CLIN EXP METASTAS, V24, P69, DOI 10.1007/s10585-006-9050-x; Bulut G, 2012, ONCOGENE, V31, P269, DOI 10.1038/onc.2011.245; Byun HJ, 2006, J BIOL CHEM, V281, P34833, DOI 10.1074/jbc.M605483200; Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628; Cerisano V, 2004, ONCOGENE, V23, P5664, DOI 10.1038/sj.onc.1207741; Croft DR, 2004, CANCER RES, V64, P8994, DOI 10.1158/0008-5472.CAN-04-2052; D'Souza-Schorey C, 2005, TRENDS CELL BIOL, V15, P19, DOI 10.1016/j.tcb.2004.11.002; Derycke LDM, 2004, INT J DEV BIOL, V48, P463, DOI 10.1387/ijdb.041793ld; Dworzak MN, 1999, BRIT J HAEMATOL, V105, P690, DOI 10.1046/j.1365-2141.1999.01426.x; Dworzak MN, 2004, LEUKEMIA, V18, P703, DOI 10.1038/sj.leu.2403303; Fievet BT, 2004, J CELL BIOL, V164, P653, DOI 10.1083/jcb.200307032; Hahn JH, 1997, J IMMUNOL, V159, P2250; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Husak Z, 2010, J LEUKOCYTE BIOL, V88, P405, DOI 10.1189/jlb.0210097; Imbert AM, 2006, BLOOD, V108, P2578, DOI 10.1182/blood-2005-12-010827; Jaganathan BG, 2007, STEM CELLS, V25, P1966, DOI 10.1634/stemcells.2007-0167; Jiao XM, 2008, MOL BIOL CELL, V19, P1378, DOI 10.1091/mbc.E07-08-0753; Jung KC, 2003, FEBS LETT, V554, P478, DOI 10.1016/S0014-5793(03)01224-9; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Kamai T, 2004, CLIN CANCER RES, V10, P4799, DOI 10.1158/1078-0432.CCR-0436-03; Kashima T, 2003, INT J CANCER, V104, P147, DOI 10.1002/ijc.10931; Kashima T, 1999, AM J PATHOL, V155, P1549, DOI 10.1016/S0002-9440(10)65471-5; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kim C, 2009, CANCER RES TREAT, V41, P138, DOI 10.4143/crt.2009.41.3.138; Kim SH, 2000, BLOOD, V95, P294; Laurila E, 2009, GENE CHROMOSOME CANC, V48, P330, DOI 10.1002/gcc.20643; Lee EJ, 2003, EXP MOL MED, V35, P438, DOI 10.1038/emm.2003.57; Lee HH, 2010, J CELL SCI, V123, P3368, DOI 10.1242/jcs.071555; LEVY R, 1979, P NATL ACAD SCI USA, V76, P6552, DOI 10.1073/pnas.76.12.6552; Lock FE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031423; Longhi A, 2006, CANCER TREAT REV, V32, P423, DOI 10.1016/j.ctrv.2006.05.005; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Manara MC, 2006, MOL BIOL CELL, V17, P1910, DOI 10.1091/mbc.E05-10-0971; Nakamura H, 1996, J BONE MINER RES, V11, P1715; Nurnberg A, 2011, NAT REV CANCER, V11, P177, DOI 10.1038/nrc3003; Otsubo T, 2004, MODERN PATHOL, V17, P461, DOI 10.1038/modpathol.3800062; Pankova K, 2010, CELL MOL LIFE SCI, V67, P63, DOI 10.1007/s00018-009-0132-1; Park HR, 2006, PATHOL RES PRACT, V202, P509, DOI 10.1016/j.prp.2006.01.015; Pettersen RD, 2001, J IMMUNOL, V166, P4931, DOI 10.4049/jimmunol.166.8.4931; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rivat C, 2004, ONCOGENE, V23, P3317, DOI 10.1038/sj.onc.1207437; Salhia B, 2005, CANCER RES, V65, P8792, DOI 10.1158/0008-5472.CAN-05-0160; Schenkel AR, 2007, CELL COMMUN ADHES, V14, P227, DOI 10.1080/15419060701755966; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Scotlandi K, 2007, ONCOGENE, V26, P6604, DOI 10.1038/sj.onc.1210481; Sohn HW, 1998, AM J PATHOL, V153, P1937, DOI 10.1016/S0002-9440(10)65707-0; Vishnubhotla R, 2007, LAB INVEST, V87, P1149, DOI 10.1038/labinvest.3700674; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Wong CCL, 2009, HEPATOLOGY, V49, P1583, DOI 10.1002/hep.22836; Yoneda A, 2005, J CELL BIOL, V170, P443, DOI 10.1083/jcb.200412043; Yoneda A, 2007, MOL BIOL CELL, V18, P66, DOI 10.1091/mbc.E06-08-0684; Yu HF, 2011, FRONT BIOSCI-LANDMRK, V16, P1536, DOI 10.2741/3803; Zhang XJ, 2011, CELL MOL BIOL LETT, V16, P279, DOI 10.2478/s11658-011-0006-z; Zhang Y, 2009, J CELL SCI, V122, P2197, DOI 10.1242/jcs.040659; Zheng SH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022439	63	34	34	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1912	1921		10.1038/onc.2013.152	http://dx.doi.org/10.1038/onc.2013.152			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23644663				2022-12-17	WOS:000334346300004
J	Rapino, F; Jung, M; Fulda, S				Rapino, F.; Jung, M.; Fulda, S.			BAG3 induction is required to mitigate proteotoxicity via selective autophagy following inhibition of constitutive protein degradation pathways	ONCOGENE			English	Article						BAG3; autophagy; proteasome inhibitor; HDAC6; cancer	QUALITY-CONTROL; AGGRESOME FORMATION; CO-CHAPERONES; CANCER CELLS; HEAT-STRESS; APOPTOSIS; MACROAUTOPHAGY; COMPLEX; TARGET; ACTIVATION	Simultaneous inhibition of the two major constitutive protein quality control (PQC) pathways, that is, the ubiquitin-proteasome system (UPS) and the aggresome-autophagy system, has been suggested as a promising strategy to trigger cell death in cancer cells. However, we observed that one third of rhabdomyosarcoma (RMS) cells survives parallel inhibition of the UPS by Bortezomib and the aggresome-autophagy pathway by the cytoplasmic histone deacetylase 6 inhibitor ST80, and is able to regrow upon drug removal, thus pointing to the induction of compensatory pathways. Here, we identify Bcl-2-associated athanogene 3 (BAG3) as a critical mediator of inducible resistance in surviving cells after concomitant blockage of constitutive PQC pathways by mitigating ST80/Bortezomib-triggered proteotoxicity via selective autophagy. ST80/Bortezomib cotreatment upregulates BAG3 mRNA and protein levels in surviving cells in addition to triggering the accumulation of insoluble protein aggregates. Intriguingly, knockdown of BAG3 by RNA interference severely impairs clearance of protein aggregates, significantly increases cell death and reduces long-term survival and clonogenic growth during recovery after ST80/Bortezomib cotreatment. Similarly, inhibition of autophagy by inducible autophagy-related protein 7 knockdown prevents removal of protein aggregates and cell regrowth during recovery after ST80/Bortezomib cotreatment. Also, the inhibition of lysosomal degradation using the V-ATPase pump inhibitor Bafilomycin A1 enhances accumulation of protein aggregates, and completely abolishes regrowth after Bortezomib/ST80-induced proteotoxic stress. By identifying BAG3 as a key mediator of inducible resistance by mitigating proteotoxicity via selective autophagy after inhibition of constitutive PQC systems, our study provides new insights into the regulation of PQC pathways in cancer cells and identifies new targets for therapeutic intervention.	[Rapino, F.; Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Germany; [Jung, M.] Univ Freiburg, Inst Pharmaceut Sci, D-79106 Freiburg, Germany	Goethe University Frankfurt; University of Freiburg	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Germany.	simone.fulda@kgu.de	Jung, Manfred/Q-8029-2016	Jung, Manfred/0000-0002-6361-7716; Fulda, Simone/0000-0002-0459-6417; Rapino, Francesca/0000-0002-4343-3805	Wilhelm-Sander Stiftung; Deutsche Krebshilfe; Bundesministerium fur Bildung und Forschung [01GM1104C]; Deutsche Forschungsgemeinschaft [JU 295/9-1, SPP1463, JU 295/10-2, CRU 201]	Wilhelm-Sander Stiftung; Deutsche Krebshilfe(Deutsche Krebshilfe); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank C Hugenberg for expert secretarial assistance. This work has been partially supported by grants from the Wilhelm-Sander Stiftung, the Deutsche Krebshilfe and the Bundesministerium fur Bildung und Forschung (01GM1104C) (to S F). Work on HDAC inhibitors in the Jung group is supported by the Deutsche Forschungsgemeinschaft (JU 295/9-1 within SPP1463, JU 295/10-2 within CRU 201).	Ammirante M, 2010, P NATL ACAD SCI USA, V107, P7497, DOI 10.1073/pnas.0907696107; Aveic S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026097; Basit F, 2012, J BIOL CHEM, V287, P38767, DOI 10.1074/jbc.M112.398966; Bazzaro M, 2008, CLIN CANCER RES, V14, P7340, DOI 10.1158/1078-0432.CCR-08-0642; Behl C, 2011, AUTOPHAGY, V7, P795, DOI 10.4161/auto.7.7.15844; Behrends Christian, 2012, Int J Cell Biol, V2012, P673290, DOI 10.1155/2012/673290; Bersani F, 2008, EUR J CANCER, V44, P876, DOI 10.1016/j.ejca.2008.02.022; Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x; Carra S, 2008, J BIOL CHEM, V283, P1437, DOI 10.1074/jbc.M706304200; Chiappetta G, 2007, J CLIN ENDOCR METAB, V92, P1159, DOI 10.1210/jc.2006-1712; Ding WX, 2008, AUTOPHAGY, V4, P141, DOI 10.4161/auto.5190; Du ZX, 2009, J CELL PHYSIOL, V218, P631, DOI 10.1002/jcp.21634; Festa M, 2011, AM J PATHOL, V178, P2504, DOI 10.1016/j.ajpath.2011.02.002; Frankland-Searby S, 2012, BBA-REV CANCER, V1825, P64, DOI 10.1016/j.bbcan.2011.10.003; Fulda S, 1997, CANCER RES, V57, P3823; Gamerdinger M, 2011, J MOL MED, V89, P1175, DOI 10.1007/s00109-011-0795-6; Gamerdinger M, 2011, EMBO REP, V12, P149, DOI 10.1038/embor.2010.203; Gamerdinger M, 2009, EMBO J, V28, P889, DOI 10.1038/emboj.2009.29; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Gonzalez P, 2012, CELL DEATH DIFFER, V19, P1337, DOI 10.1038/cdd.2012.10; Humphreys RC, 2008, ADV EXP MED BIOL, V615, P127, DOI 10.1007/978-1-4020-6554-5_7; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kubota H, 2009, J BIOCHEM, V146, P609, DOI 10.1093/jb/mvp139; Lamark Trond, 2012, Int J Cell Biol, V2012, P736905, DOI 10.1155/2012/736905; Lee JY, 2010, EMBO J, V29, P969, DOI 10.1038/emboj.2009.405; Liao Q, 2001, FEBS LETT, V503, P151, DOI 10.1016/S0014-5793(01)02728-4; Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839; Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708; Nivon M, 2012, J CELL SCI, V125, P1141, DOI 10.1242/jcs.091041; Rodriguez-Gonzalez A, 2008, CANCER RES, V68, P2557, DOI 10.1158/0008-5472.CAN-07-5989; Romano MF, 2003, CANCER BIOL THER, V2, P508, DOI 10.4161/cbt.2.5.524; Scott GK, 2008, MOL CANCER RES, V6, P1250, DOI 10.1158/1541-7786.MCR-07-2110; Seidel K, 2012, NEUROPATH APPL NEURO, V38, P39, DOI 10.1111/j.1365-2990.2011.01198.x; Tsukahara F, 2010, BLOOD, V116, P3582, DOI 10.1182/blood-2009-10-249623; Wang HQ, 2008, BIOCHEM BIOPH RES CO, V365, P381, DOI 10.1016/j.bbrc.2007.11.001; Wanker EE, 1999, METHOD ENZYMOL, V309, P375; Wu WKK, 2010, DRUG RESIST UPDATE, V13, P87, DOI 10.1016/j.drup.2010.04.003; Yao Tso-Pang, 2010, Genes Cancer, V1, P779; Zhang Y, 2012, ONCOL REP, V27, P109, DOI 10.3892/or.2011.1486; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	40	34	34	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1713	1724		10.1038/onc.2013.110	http://dx.doi.org/10.1038/onc.2013.110			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23644654	Green Published, Green Submitted			2022-12-17	WOS:000334344700011
J	Metcalf, JL; Bradshaw, PS; Komosa, M; Greer, SN; Meyn, MS; Ohh, M				Metcalf, J. L.; Bradshaw, P. S.; Komosa, M.; Greer, S. N.; Meyn, M. Stephen; Ohh, M.			K63-Ubiquitylation of VHL by SOCS1 mediates DNA double-strand break repair	ONCOGENE			English	Article						DNA repair; K63-ubiquitylation; RCC; SOCS1; VHL	TUMOR-SUPPRESSOR PROTEIN; HOMOLOGOUS RECOMBINATION; CYTOPLASMIC LOCALIZATION; ATM ACTIVATION; HIF-ALPHA; NUCLEAR; FIBRONECTIN; PATHWAY; COMPLEX; PHOSPHORYLATION	DNA repair is essential for maintaining genomic stability, and defects in this process significantly increase the risk of cancer. Clear-cell renal cell carcinoma (CCRCC) caused by inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene is characterized by high genomic instability. However, the molecular mechanism underlying the association between the loss of VHL and genomic instability remains unclear. Here, we show that suppressor of cytokine signaling 1 (SOCS1) promotes nuclear redistribution and K63-ubiquitylation of VHL in response to DNA double-strand breaks (DSBs). Loss of VHL or VHL mutations that compromise its K63-ubiquitylation attenuates the DNA-damage response (DDR), resulting in decreased homologous recombination repair and persistence of DSBs. These results identify VHL as a component of the DDR network, inactivation of which contributes to the genomic instability associated with CCRCC.	[Metcalf, J. L.; Greer, S. N.; Ohh, M.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; [Bradshaw, P. S.; Meyn, M. Stephen] Univ Toronto, Dept Mol Genet, Toronto, ON M5S 1A8, Canada; [Komosa, M.; Meyn, M. Stephen] Hosp Sick Children, Res Inst, Program Genet & Genome Biol, Toronto, ON M5G 1X8, Canada; [Meyn, M. Stephen] Hosp Sick Children, Dept Paediat, Toronto, ON M5G 1X8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Ohh, M (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Med Sci Bldg,Room 6306,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	michael.ohh@utoronto.ca			Canadian Institutes of Health Research [MOP77718]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by funds from the Canadian Institutes of Health Research (MOP77718).	Allen C, 2003, MOL CANCER RES, V1, P913; Arai E, 2011, INT J CLIN EXP PATHO, V4, P58; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Ben-Zvi T, 2006, J CELL SCI, V119, P380, DOI 10.1242/jcs.02740; Bluyssen HAR, 2004, FEBS LETT, V556, P137, DOI 10.1016/S0014-5793(03)01392-9; Cai QL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009720; Calabrese V, 2009, MOL CELL, V36, P754, DOI 10.1016/j.molcel.2009.09.044; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Christensen DE, 2007, NAT STRUCT MOL BIOL, V14, P941, DOI 10.1038/nsmb1295; Couedel C, 2004, GENE DEV, V18, P1293, DOI 10.1101/gad.1209204; Delacote F, 2002, NUCLEIC ACIDS RES, V30, P3454, DOI 10.1093/nar/gkf452; Evans AJ, 2007, MOL CELL BIOL, V27, P157, DOI 10.1128/MCB.00892-06; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Fukushima T, 2001, J BIOL CHEM, V276, P44413, DOI 10.1074/jbc.M106295200; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kim JS, 2005, J CELL BIOL, V170, P341, DOI 10.1083/jcb.200411083; Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015; Lavin MF, 2007, CELL CYCLE, V6, P931, DOI 10.4161/cc.6.8.4180; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lee S, 1999, MOL CELL BIOL, V19, P1486; Lewis MD, 2003, ONCOGENE, V22, P3992, DOI 10.1038/sj.onc.1206683; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; O'Donovan PJ, 2010, CARCINOGENESIS, V31, P961, DOI 10.1093/carcin/bgq069; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Panier S, 2009, DNA REPAIR, V8, P436, DOI 10.1016/j.dnarep.2009.01.013; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Plans V, 2006, J CELL BIOCHEM, V97, P572, DOI 10.1002/jcb.20587; Qi H, 2003, CANCER RES, V63, P7076; Rezvani HR, 2010, NUCLEIC ACIDS RES, V38, P797, DOI 10.1093/nar/gkp1072; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Roberts AM, 2009, CANCER RES, V69, P9056, DOI 10.1158/0008-5472.CAN-09-1770; Russell RC, 2011, NAT MED, V17, P845, DOI 10.1038/nm.2370; Schermer B, 2006, J CELL BIOL, V175, P547, DOI 10.1083/jcb.200605092; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Stewart GS, 2009, CELL, V136, P420, DOI 10.1016/j.cell.2008.12.042; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Wang Y, 2009, NAT MED, V15, P319, DOI 10.1038/nm.1922; Weinstock DM, 2006, METHOD ENZYMOL, V409, P524, DOI 10.1016/S0076-6879(05)09031-2; Yang H, 2007, MOL CELL, V28, P15, DOI 10.1016/j.molcel.2007.09.010; Young AP, 2008, NAT CELL BIOL, V10, P361, DOI 10.1038/ncb1699; Zhao GY, 2007, MOL CELL, V25, P663, DOI 10.1016/j.molcel.2007.01.029	53	34	34	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					1055	1065		10.1038/onc.2013.22	http://dx.doi.org/10.1038/onc.2013.22			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23455319				2022-12-17	WOS:000331933200013
J	Quail, DF; Zhang, G; Findlay, SD; Hess, DA; Postovit, LM				Quail, D. F.; Zhang, G.; Findlay, S. D.; Hess, D. A.; Postovit, L-M			Nodal promotes invasive phenotypes via a mitogen-activated protein kinase-dependent pathway	ONCOGENE			English	Article						Nodal; invasion; EMT; cancer; metastasis	EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR-BETA; BREAST-CANCER; MAP KINASE; TROPHOBLAST MIGRATION; STEM-CELLS; EXPRESSION; ALK7; PHOSPHORYLATION; PLASTICITY	The progression of cancer from localized to invasive disease is requisite for metastasis, and is often characterized by epithelial-to-mesenchymal transition (EMT) and alterations in cellular adhesion and migration. Studies have shown that this transition is associated with an upregulation of embryonic stem cell-associated genes, resulting in a dedifferentiated phenotype and poor patient prognosis. Nodal is an embryonic factor that plays a critical role in promoting early invasive events during development. Nodal is silenced as stem cells differentiate; however, it re-emerges in adult life during placentation and mammary gland development, and is aberrantly expressed in many cancers. Here, we show that Nodal overexpression, in poorly invasive breast cancer and choriocarcinoma cells, causes increased invasion and migration in vitro. Furthermore, we show that Nodal overexpression in these epithelial cancer types induces an EMT-like event concomitant with the internalization of E-Cadherin. This ability of Nodal to promote cellular invasion and EMT-like phenomena is dependent upon the phosphorylation of ERK1/2. As Nodal normally signals through SMADs, these findings lend insight into an alternative pathway that is hijacked by this protein in cancer. To evaluate the clinical implications of our results, we show that Nodal inhibition reduces liver tumor burden in a model of spontaneous breast cancer metastasis in vivo, and that Nodal loss-of-function in aggressive breast cancer lines results in a decrease in invasive phenotypes. Our results demonstrate that Nodal is involved in promoting invasion in multiple cellular contexts, and that Nodal inhibition may be useful as a therapeutic target for patients with progressive disease.	[Quail, D. F.; Zhang, G.; Findlay, S. D.; Postovit, L-M] Univ Western Ontario, Schulich Sch Med & Dent, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada; [Hess, D. A.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada; [Zhang, G.; Findlay, S. D.; Hess, D. A.; Postovit, L-M] Univ Western Ontario, Robarts Res Inst, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Postovit, LM (corresponding author), Univ Western Ontario, Schulich Sch Med & Dent, Dept Anat & Cell Biol, Med Sci Bldg,Room 438, London, ON N6A 5C1, Canada.	Lynne.Postovit@schulich.uwo.ca	Hess, David A/M-2828-2013; zhang, guihua/GVU-4494-2022; Findlay, Scott D/AAP-9554-2021	Findlay, Scott D/0000-0002-0393-1623; Postovit, Lynne-Marie/0000-0002-8088-4197	Canadian Institutes for Health Research [MOP 89714, MOP 119589, PLS 95381]; Cancer Research Society; Canadian Breast Cancer Foundation; CIHR; Premier New Investigator Award from the CIHR; new investigator award; MacDonald Scholarship; Alberta Innovates [201300495] Funding Source: researchfish	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Cancer Research Society; Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); CIHR(Canadian Institutes of Health Research (CIHR)); Premier New Investigator Award from the CIHR(Canadian Institutes of Health Research (CIHR)); new investigator award; MacDonald Scholarship; Alberta Innovates	We thank LA Walsh and SD Findlay for making the Nodal expression construct, and M Jewer and A Cloutier-Bosworth for assisting with tissue scoring. This work was supported by the Canadian Institutes for Health Research (MOP 89714, MOP 119589 and PLS 95381) and the Cancer Research Society to LMP. DQ is supported by fellowships from the Canadian Breast Cancer Foundation, and a CIHR training grant. LMP is the recipient of the Premier New Investigator Award from the CIHR. DAH is the recipient of a new investigator award and MacDonald Scholarship for the Canadian Heart and Stroke Foundation.	Beck S, 2002, NAT CELL BIOL, V4, P981, DOI 10.1038/ncb890; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bokobza SM, 2011, MOL CELL BIOCHEM, V349, P33, DOI 10.1007/s11010-010-0657-5; Cavallari C, 2013, ONCOGENE, V32, P819, DOI 10.1038/onc.2012.114; Chakraborty C, 2002, CAN J PHYSIOL PHARM, V80, P116, DOI 10.1139/Y02-016; CLEMENTS M, 2011, TLS TIMES LIT S 0325, P21; Davies M, 2005, J CELL BIOCHEM, V95, P918, DOI 10.1002/jcb.20458; Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293; Drasin DJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3037; Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Kannan S, 1997, J BIOL CHEM, V272, P3330, DOI 10.1074/jbc.272.6.3330; Kelber JA, 2009, ONCOGENE, V28, P2324, DOI 10.1038/onc.2009.97; Kolosova I, 2011, J CELL PHYSIOL, V226, P1248, DOI 10.1002/jcp.22448; Lawrence MG, 2011, PROSTATE, V71, P1198, DOI 10.1002/pros.21335; Lee CC, 2010, ONCOGENE, V29, P3110, DOI 10.1038/onc.2010.55; Lee MK, 2007, EMBO J, V26, P3957, DOI 10.1038/sj.emboj.7601818; Li QW, 2008, NEOPLASIA, V10, P1444, DOI 10.1593/neo.08968; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; Lu X, 2004, NEOPLASIA, V6, P603, DOI 10.1593/neo.04241; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Munir S, 2004, J BIOL CHEM, V279, P31277, DOI 10.1074/jbc.M400641200; Nadeem L, 2011, AM J PATHOL, V178, P1177, DOI 10.1016/j.ajpath.2010.11.066; Papageorgiou I, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-122; Postovit LM, 2008, PIGM CELL MELANOMA R, V21, P348, DOI 10.1111/j.1755-148X.2008.00463.x; Postovit LM, 2008, P NATL ACAD SCI USA, V105, P4329, DOI 10.1073/pnas.0800467105; Postovit LM, 2007, EXPERT OPIN THER TAR, V11, P497, DOI 10.1517/14728222.11.4.497; Quail DF, 2012, CANCER RES, V72, P3851, DOI 10.1158/0008-5472.CAN-11-3951; Quail DF, 2012, J BIOMOL SCREEN, V17, P1088, DOI 10.1177/1087057112449863; Quail DF, 2011, MOL BIOL CELL, V22, P4809, DOI 10.1091/mbc.E11-03-0263; Rangel MC, 2012, AM J PATHOL, V180, P2188, DOI 10.1016/j.ajpath.2012.02.031; Roberts HJ, 2003, BIOL REPROD, V68, P1719, DOI 10.1095/biolreprod.102.013045; Scherbakov AM, 2012, J CELL BIOCHEM, V113, P2147, DOI 10.1002/jcb.24087; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Schier AF, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003459; Strizzi L, 2004, J CELL PHYSIOL, V201, P266, DOI 10.1002/jcp.20062; Strizzi L, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3185; Strizzi L, 2011, LAB INVEST, V91, P819, DOI 10.1038/labinvest.2011.63; Strizzi Luigi, 2008, Breast Dis, V29, P91; Strizzi Luigi, 2009, Expert Rev Dermatol, V4, P67, DOI 10.1586/17469872.4.1.67; Tabaries S, 2011, ONCOGENE, V30, P1318, DOI 10.1038/onc.2010.518; Taylor MA, 2010, J MAMMARY GLAND BIOL, V15, P169, DOI 10.1007/s10911-010-9181-1; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448; Vicovac L, 1996, ACTA ANAT, V156, P202; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	47	34	36	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					461	473		10.1038/onc.2012.608	http://dx.doi.org/10.1038/onc.2012.608			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23334323	Green Accepted, Green Submitted			2022-12-17	WOS:000330214600007
J	Lang, UE; Kocabayoglu, P; Cheng, GZ; Ghiassi-Nejad, Z; Munoz, U; Vetter, D; Eckstein, DA; Hannivoort, RA; Walsh, MJ; Friedman, SL				Lang, U. E.; Kocabayoglu, P.; Cheng, G. Z.; Ghiassi-Nejad, Z.; Munoz, U.; Vetter, D.; Eckstein, D. A.; Hannivoort, R. A.; Walsh, M. J.; Friedman, S. L.			GSK3 beta phosphorylation of the KLF6 tumor suppressor promotes its transactivation of p21	ONCOGENE			English	Article						KLF6; GSK3 beta; p21; phosphorylation	BETA-CATENIN; TRANSCRIPTIONAL ACTIVATION; DOWN-REGULATION; GENE; DEGRADATION; FREQUENT; PROTEIN; TARGET; MOUSE	KLF6, a ubiquitously expressed Kruppel-like transcription factor, is frequently inactivated in human cancer and has significant roles in cellular proliferation, apoptosis, differentiation and development. A key mechanism of KLF6-mediated growth suppression is through p53-independent transactivation of p21. Several cancer-derived KLF6 mutants lead to the loss of p21-mediated growth suppression through an unknown mechanism. Because several colorectal cancer and hepatocellular carcinoma-derived KLF6 mutations affect a glycogen synthase kinase 3 beta (GSK3 beta) phosphorylation consensus site, we investigated the role of GSK3 beta in the regulation of KLF6 function. Based on transient transfection, GSK3 beta augments the transactivation of a p21 promoter luciferase by KLF6. Reciprocal co-immunoprecipitation of hemagglutinin (HA)-GSK3 beta and Flag-KLF6 validated the interaction between these two proteins. KLF6 phosphorylation is augmented in the presence of GSK3 beta based on in vitro and in vivo P-32 incorporation assays. Site-directed mutagenesis of the candidate phosphorylation sites to alanines ('KLF6-4A' phosphomutant) eliminated a higher molecular weight phosphorylated isoform of KLF6 based on western blot. GSK3 beta augmented the transactivation by wild-type KLF6, but not KLF6-4A, towards the p21 promoter, and increased p21 protein. Functionally, GSK3 beta enhanced KLF6-mediated growth suppression, which was abrogated by the KLF6-4A phosphomutant. These data establish that GSK3 beta directly phosphorylates KLF6, which augments its induction of p21 and resultant growth suppression. This interaction may account for the growth-promoting effects of cancer-derived KLF6 mutants that lack tumor suppressor activity.	[Lang, U. E.; Kocabayoglu, P.; Cheng, G. Z.; Ghiassi-Nejad, Z.; Munoz, U.; Vetter, D.; Eckstein, D. A.; Hannivoort, R. A.; Friedman, S. L.] Mt Sinai Sch Med, Div Liver Dis, New York, NY 10029 USA; [Walsh, M. J.] Mt Sinai Sch Med, Dept Struct & Chem Biol, New York, NY 10029 USA; [Walsh, M. J.] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; [Walsh, M. J.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Friedman, SL (corresponding author), Mt Sinai Sch Med, Dept Med, Div Liver Dis, 1425 Madison Ave,Room 11-70C,Box 1123, New York, NY 10029 USA.	scott.friedman@mssm.edu	De Cock, Martine/B-8567-2009; MUÑOZ MORON, URSULA/L-4561-2017	De Cock, Martine/0000-0001-7917-0771; MUÑOZ MORON, URSULA/0000-0001-6024-4697	NIH [RO1DK37340, RO1DK 56621, 1K05 AA018408, 1P20 AA017067, 1RO1CA154809-01, T32GM00728]; Deutsche Forschungsgemeinschaft (DFG); Graduate School for Drug Exploration (GUIDE) [KO 4086/11]; Stichting Nicholaas Muleriusfonds, Groningen; Netherlands; Ellison Medical Foundation Senior Scholar Award in Aging [SS-AG2482-1]; Swiss National Fund (SNF); Alonso Martin Escudero foundation; NATIONAL CANCER INSTITUTE [R01CA154809] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL103967] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340, R01DK056621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P20AA017067, K05AA018408] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Graduate School for Drug Exploration (GUIDE); Stichting Nicholaas Muleriusfonds, Groningen; Netherlands(Netherlands Government); Ellison Medical Foundation Senior Scholar Award in Aging(Lawrence Ellison Foundation); Swiss National Fund (SNF)(Swiss National Science Foundation (SNSF)); Alonso Martin Escudero foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	We thank Dr Ming-Ming Zhou at the Mount Sinai School of Medicine for his expert advice in protein purification of GST-KLF6. Dr Jin Q Cheng at H Lee Moffitt Cancer Center shared all GSK3b plasmids and contributed technical support for the in vivo kinase assays. We acknowledge funding support from the NIH (to SLF: RO1DK37340, RO1DK 56621, 1K05 AA018408, 1P20 AA017067; to MJW: 1RO1CA154809-01; to UEL and ZGN: T32GM00728), Deutsche Forschungsgemeinschaft (DFG) (to PK) KO 4086/11, Graduate School for Drug Exploration (GUIDE) and the Stichting Nicholaas Muleriusfonds, Groningen, the Netherlands (to RAH), the Ellison Medical Foundation Senior Scholar Award in Aging (SS-AG2482-1) (to MJW), the Swiss National Fund (SNF) (to DV) and the Alonso Martin Escudero foundation (to UM).	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Banck MS, 2006, FEBS LETT, V580, P6981, DOI 10.1016/j.febslet.2006.10.077; Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; Botella LM, 2002, BLOOD, V100, P4001, DOI 10.1182/blood.V100.12.4001; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Difeo A, 2006, ONCOGENE, V25, P6026, DOI 10.1038/sj.onc.1209611; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang HD, 2005, NUCLEIC ACIDS RES, V33, pW226, DOI 10.1093/nar/gki471; Kremer-Tal S, 2004, HEPATOLOGY, V40, P1047, DOI 10.1002/hep.20460; Kremer-Tal S, 2007, J HEPATOL, V46, P645, DOI 10.1016/j.jhep.2006.10.012; Lee UE, 2010, FEBS LETT, V584, P1006, DOI 10.1016/j.febslet.2010.01.049; Li D, 2005, J BIOL CHEM, V280, P26941, DOI 10.1074/jbc.M500463200; Li D, 2005, CANCER RES, V65, P9216, DOI 10.1158/0008-5472.CAN-05-1040; Li D, 2000, HEPATOLOGY, V32, p209A; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu N, 2010, J BIOL CHEM, V285, P18858, DOI 10.1074/jbc.M109.099440; Narla G, 2007, ONCOGENE, V26, P4428, DOI 10.1038/sj.onc.1210223; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Nejak-Bowen KN, 2011, SEMIN CANCER BIOL, V21, P44, DOI 10.1016/j.semcancer.2010.12.010; Pan Xiu-cheng, 2006, J Zhejiang Univ Sci B, V7, P830, DOI 10.1631/jzus.2006.B0830; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; Reeves HL, 2003, HEPATOLOGY, V2002; Rodriguez E, 2010, PLOS ONE, V5, P9; Slavin DA, 2004, ONCOGENE, V23, P8196, DOI 10.1038/sj.onc.1208020; Warke VG, 2003, J BIOL CHEM, V278, P14812, DOI 10.1074/jbc.M300787200; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100; Zeng CX, 2010, HEPATOLOGY, V52, P1702, DOI 10.1002/hep.23875	28	34	36	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4557	4564		10.1038/onc.2012.457	http://dx.doi.org/10.1038/onc.2012.457			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23085750	Green Accepted			2022-12-17	WOS:000324831300011
J	Kang, DW; Hwang, WC; Park, MH; Ko, GH; Ha, WS; Kim, KS; Lee, YC; Choi, KY; Min, DS				Kang, D. W.; Hwang, W. C.; Park, M. H.; Ko, G-H; Ha, W-S; Kim, K-S; Lee, Y-C; Choi, K-Y; Min, D. S.			Rebamipide abolishes Helicobacter pylori CagA-induced phospholipase D1 expression via inhibition of NF kappa B and suppresses invasion of gastric cancer cells	ONCOGENE			English	Article						phospholipase D1; Helicobacter pylori; CagA; gastric cancer; NF kappa B; rebamipide	TUMOR-SUPPRESSOR; EPITHELIAL-CELLS; C-MET; ACTIVATION; PATHWAY; SECRETION; PROTEIN; MATRIX-METALLOPROTEINASE-9; PROLIFERATION; MECHANISMS	Infection with cagA-positive Helicobacter pylori is a risk factor for the development of severe gastritis and gastric cancer (GC). CagA protein is injected into gastric epithelial cells and deregulates a variety of cellular signaling molecules. Phospholipase D (PLD) is elevated in many different types of human cancers and has been implicated as a critical factor in inflammation and carcinogenesis. In this study, we show that infection with cagA-positive H. pylori in GC cells significantly induces PLD1 expression via CagA-dependent activation of nuclear factor kappa B (NF kappa B). Interestingly, the level of PLD1 protein and I kappa B alpha phosphorylation is aberrantly upregulated in H. pylori-infected human GC tissues. Infection with cagA-positive H. pylori and expression of CagA enhanced the binding of NF kappa B to the PLD1 promoter, and two functional NF kappa B-binding sites were identified within the PLD1 promoter. Rebamipide, a mucosal-protective antiulcer agent, abolished H. pylori cagA-induced PLD1 expression via inhibition of binding of NF kappa B to the PLD1 promoter, and also inhibited PLD activity. Moreover, rebamipide suppressed H. pylori-induced matrix metalloproteinase-9, interleukin-8 and activation-induced cytidine deaminase expression as well as invasion of GC cells through downregulation of PLD1. Our data suggest that H. pylori cagA targets PLD1 for invasion of GC cells, and rebamipide might contribute to the antitumorigenic effect of GC cells via inhibition of the H. pylori cagA-NF kappa B-PLD1 signaling pathway.	[Kang, D. W.; Hwang, W. C.; Park, M. H.; Min, D. S.] Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea; [Ko, G-H] Gyeongsang Natl Univ, Sch Med, Dept Pathol, Jinju, Gyeongnam, South Korea; [Ha, W-S] Gyeongsang Natl Univ, Sch Med, Dept Surg, Jinju, Gyeongnam, South Korea; [Kim, K-S; Lee, Y-C] Dong A Univ, Dept Biotechnol, Pusan, South Korea; [Choi, K-Y; Min, D. S.] Yonsei Univ, Translat Res Ctr Prot Funct Control, Seoul 120749, South Korea; [Choi, K-Y; Min, D. S.] Yonsei Univ, Dept Biotechnol, Seoul 120749, South Korea	Pusan National University; Gyeongsang National University; Gyeongsang National University; Dong A University; Yonsei University; Yonsei University	Min, DS (corresponding author), Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea.	minds@pusan.ac.kr	Park, Min Hi/AAL-9880-2020		Translational Research Center for Protein Function Control, NSF, South Korea [2009-0092960]; National Research Foundation of Korea (NRF) grant; Korea government (MEST) [2012002009]; National R&D program for Cancer Control, Ministry for Health, Welfare and Family Affairs, Republic of Korea grant [0920050]	Translational Research Center for Protein Function Control, NSF, South Korea; National Research Foundation of Korea (NRF) grant(National Research Foundation of Korea); Korea government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government); National R&D program for Cancer Control, Ministry for Health, Welfare and Family Affairs, Republic of Korea grant	This work was supported by a grant from the Translational Research Center for Protein Function Control, NSF (2009-0092960), South Korea and a National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST; no. 2012002009) and by the National R&D program for Cancer Control, Ministry for Health, Welfare and Family Affairs, Republic of Korea grant 0920050. We are most grateful to Dr DaiHyun Yu (Otsuka Pharmaceutical Co. Ltd. Otsuka International Asia Arab Division, Korea) for his helpful suggestions and generous comments.	ARAKAWA T, 1995, DIGEST DIS SCI, V40, P2469, DOI 10.1007/BF02063257; Arakawa T, 2005, DIGEST DIS SCI, V50, pS3, DOI 10.1007/s10620-005-2800-9; Arakawa T, 1998, DIGEST DIS SCI, V43, p5S; BLASER MJ, 1995, CANCER RES, V55, P2111; Brandt S, 2005, P NATL ACAD SCI USA, V102, P9300, DOI 10.1073/pnas.0409873102; Buti L, 2011, P NATL ACAD SCI USA, V108, P9238, DOI 10.1073/pnas.1106200108; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Chen G, 1997, BIOCHEM BIOPH RES CO, V239, P626, DOI 10.1006/bbrc.1997.7485; Churin Y, 2003, J CELL BIOL, V161, P249, DOI 10.1083/jcb.200208039; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; COVER TL, 1990, INFECT IMMUN, V58, P603, DOI 10.1128/IAI.58.3.603-610.1990; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; Foryst-Ludwig A, 2000, J BIOL CHEM, V275, P39779, DOI 10.1074/jbc.M007617200; Gozgit JM, 2007, BRIT J CANCER, V97, P809, DOI 10.1038/sj.bjc.6603926; Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433; Hatakeyama M, 2008, ONCOGENE, V27, P7047, DOI 10.1038/onc.2008.353; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Huang JQ, 2003, GASTROENTEROLOGY, V125, P1636, DOI 10.1053/j.gastro.2003.08.033; Huang P, 2007, EXPERT OPIN THER TAR, V11, P707, DOI 10.1517/14728222.11.5.707; Jones NL, 1999, INFECT IMMUN, V67, P4237, DOI 10.1128/IAI.67.8.4237-4242.1999; Kang DW, 2008, J BIOL CHEM, V283, P4094, DOI 10.1074/jbc.M707416200; Kang DW, 2011, CANCER RES, V71, P293, DOI 10.1158/0008-5472.CAN-10-2463; Kang DW, 2011, INT J CANCER, V128, P805, DOI 10.1002/ijc.25402; Kang DW, 2010, EXP MOL MED, V42, P555, DOI 10.3858/emm.2010.42.8.056; Kang DW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012109; Kang DW, 2010, CANCER LETT, V294, P125, DOI 10.1016/j.canlet.2010.01.031; Kang DW, 2010, CANCER RES, V70, P4233, DOI 10.1158/0008-5472.CAN-09-3470; Kishimoto S, 2000, DIGEST DIS SCI, V45, P1608, DOI 10.1023/A:1005525313856; Knoepp SM, 2008, MOL PHARMACOL, V74, P574, DOI 10.1124/mol.107.040105; Lamb A, 2009, EMBO REP, V10, P1242, DOI 10.1038/embor.2009.210; Maeda S, 2000, GASTROENTEROLOGY, V119, P97, DOI 10.1053/gast.2000.8540; Matsumoto Y, 2007, NAT MED, V13, P470, DOI 10.1038/nm1566; Mimuro H, 2002, MOL CELL, V10, P745, DOI 10.1016/S1097-2765(02)00681-0; Min DS, 2001, CARCINOGENESIS, V22, P1641, DOI 10.1093/carcin/22.10.1641; Mori N, 2003, GASTROENTEROLOGY, V124, P983, DOI 10.1053/gast.2003.50152; Murata-Kamiya N, 2007, ONCOGENE, V26, P4617, DOI 10.1038/sj.onc.1210251; Ohnishi N, 2008, P NATL ACAD SCI USA, V105, P1003, DOI 10.1073/pnas.0711183105; Oliveira MJ, 2006, J BIOL CHEM, V281, P34888, DOI 10.1074/jbc.M607067200; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Peek Jr RM, 2005, SCI STKE, V2005, P14, DOI [10.1126/stke.2772005pe14, DOI 10.1126/STKE.2772005PE14]; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peek RM, 1999, CANCER RES, V59, P6124; Polk DB, 2010, NAT REV CANCER, V10, P403, DOI 10.1038/nrc2857; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; Rieder G, 2005, GASTROENTEROLOGY, V128, P1229, DOI 10.1053/j.gastro.2005.02.064; Rudi J, 1998, J CLIN INVEST, V102, P1506, DOI 10.1172/JCI2808; SHARMA SA, 1995, INFECT IMMUN, V63, P1681, DOI 10.1128/IAI.63.5.1681-1687.1995; Shibata W, 2006, J PATHOL, V210, P306, DOI 10.1002/path.2040; Sier CFM, 1996, BRIT J CANCER, V74, P413, DOI 10.1038/bjc.1996.374; Snider Jared L, 2009, J Carcinog, V8, P7, DOI 10.4103/1477-3163.50892; Su WJ, 2009, FUTURE ONCOL, V5, P1477, DOI [10.2217/fon.09.110, 10.2217/FON.09.110]; Suzuki M, 2009, CELL HOST MICROBE, V5, P23, DOI 10.1016/j.chom.2008.11.010; Tarnawski A, 2005, BIOCHEM BIOPH RES CO, V334, P207, DOI 10.1016/j.bbrc.2005.05.204; Wang HY, 2011, FEMS IMMUNOL MED MIC, V63, P82, DOI 10.1111/j.1574-695X.2011.00833.x; Wei JX, 2010, GASTROENTEROLOGY, V139, P1333, DOI 10.1053/j.gastro.2010.06.018; Yamane T, 1998, DIGEST DIS SCI, V43, p207S; Yoshida N, 1996, DIGEST DIS SCI, V41, P1139, DOI 10.1007/BF02088229; Zhang XY, 2002, DIAGN MOL PATHOL, V11, P135, DOI 10.1097/00019606-200209000-00002	58	34	34	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2013	32	30					3531	3542		10.1038/onc.2012.358	http://dx.doi.org/10.1038/onc.2012.358			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	188UQ	22890316				2022-12-17	WOS:000322220800006
J	Stebbing, J; Filipovic, A; Lit, LC; Blighe, K; Grothey, A; Xu, Y; Miki, Y; Chow, LW; Coombes, RC; Sasano, H; Shaw, JA; Giamas, G				Stebbing, J.; Filipovic, A.; Lit, L. C.; Blighe, K.; Grothey, A.; Xu, Y.; Miki, Y.; Chow, L. W.; Coombes, R. C.; Sasano, H.; Shaw, J. A.; Giamas, G.			LMTK3 is implicated in endocrine resistance via multiple signaling pathways	ONCOGENE			English	Article						LMTK3; breast cancer; estrogen receptor; endocrine resistance; HSPB8; oncogene	BREAST-CANCER CELLS; ESTROGEN-RECEPTOR-ALPHA; CYCLIN D1; IN-VITRO; EXPRESSION; KINASE; TUMORIGENESIS; RECURRENCE; ACTIVATION; TAMOXIFEN	Resistance to endocrine therapy in breast cancer is common. With the aim of discovering new molecular targets for breast cancer therapy, we have recently identified LMTK3 as a regulator of the estrogen receptor-alpha (ER alpha) and wished to understand its role in endocrine resistance. We find that inhibition of LMTK3 in a xenograft tamoxifen (Tam)-resistant (BT474) breast cancer mouse model results in re-sensitization to Tam as demonstrated by a reduction in tumor volume. A whole genome microarray analysis, using a BT474 cell line, reveals genes significantly modulated (positively or negatively) after LMTK3 silencing, including some that are known to be implicated in Tam resistance, notably c-MYC, HSPB8 and SIAH2. We show that LMTK3 is able to increase the levels of HSPB8 at a transcriptional and translational level thereby protecting MCF7 cells from Tam-induced cell death, by reducing autophagy. Finally, high LMTK3 levels at baseline in tumors are predictive for endocrine resistance; therapy does not lead to alteration in levels, whereas in patient's plasma samples, acquired LMTK3 gene amplification (copy number variation) was associated with relapse while receiving Tam. In aggregate, these data support a role for LMTK3 in both innate (intrinsic) and acquired (adaptive) endocrine resistance in breast cancer.	[Stebbing, J.; Filipovic, A.; Lit, L. C.; Grothey, A.; Xu, Y.; Coombes, R. C.; Giamas, G.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Div Canc, Hammersmith Hosp Campus, London W12 0NN, England; [Blighe, K.; Shaw, J. A.] Univ Leicester, Dept Canc Studies & Mol Med, Leicester, Leics, England; [Miki, Y.; Chow, L. W.; Sasano, H.] Tohoku Univ, Grad Sch Med, Dept Pathol, Sendai, Miyagi 980, Japan; [Chow, L. W.] Comprehens Ctr Breast Dis, UNIMED Med Inst, Hong Kong, Hong Kong, Peoples R China	Imperial College London; University of Leicester; Tohoku University	Giamas, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Hammersmith Hosp Campus, London W12 0NN, England.	g.giamas@imperial.ac.uk	LIT, LEI CHENG/B-8875-2010; Giamas, Georgios/AAP-3487-2021; Lit, Lei Cheng/AAS-9778-2021	LIT, LEI CHENG/0000-0002-3210-4491; Lit, Lei Cheng/0000-0002-3210-4491; Coombes, Raoul Charles/0000-0002-4811-1100; Blighe, Kevin/0000-0002-6322-6571; Shaw, Jacqui/0000-0003-4227-503X; Giamas, Georgios/0000-0002-4417-2707; Stebbing, Justin/0000-0002-1117-6947	Grants for Targets (G4T) program of Bayer Healthcare; Cancer Research UK; UICC Yamagiwa-Yoshida Memorial International Cancer Study Grant; R & E Girling and friends; Pink Ribbon Foundation; Imperial BRC; ECMC; MRC [MR/L000172/1] Funding Source: UKRI; Cancer Research UK [13462, 14549, 12011] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish	Grants for Targets (G4T) program of Bayer Healthcare; Cancer Research UK(Cancer Research UK); UICC Yamagiwa-Yoshida Memorial International Cancer Study Grant; R & E Girling and friends; Pink Ribbon Foundation; Imperial BRC; ECMC; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))	We would like to thank Champions Biotechnology, in particular David Sidransky and Elizabeth Bruckheimer for their expertise and help with the mouse xenograft model (Johns Hopkins, Baltimore, USA), P Trivedi for performing the immunohistochemistry staining (Imperial College) and Katsuhiko Ono for technical assistance (Tohoku University). We are grateful to Richard Szydlo (Imperial College) for statistical advice. We thank Martina Sperling for performing the Illumina microarray hybridizations. We thank Luisella Toschi, Anette Sommer, and Georg Beckmann (Bayer, Berlin, Germany) for their significant input in both the experimental design and analysis of the gene expression profiling experiments and the selection of cell lines, without which this work could not have been undertaken. The project was supported by a grant from the Grants for Targets (G4T) program of Bayer Healthcare. JS, JAS, RCC and GG are supported by grants from Cancer Research UK. This work has been supported by a UICC Yamagiwa-Yoshida Memorial International Cancer Study Grant to GG. We thank R & E Girling and friends, Cancer Research UK and the Pink Ribbon Foundation for their support. This work was also supported by the Imperial BRC and ECMC.	Agoulnik IU, 2011, ONCOTARGET, V2, P321; Al-Azawi D, 2008, ONCOGENE, V27, P3021, DOI 10.1038/sj.onc.1210964; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Chanplakorn N, BREAST CANC RES TREA, V120, P639; Chow LWC, 2008, J STEROID BIOCHEM, V111, P13, DOI 10.1016/j.jsbmb.2008.04.004; Cook KL, 2011, EXPERT REV ANTICANC, V11, P1283, DOI [10.1586/era.11.111, 10.1586/ERA.11.111]; Cordera F, 2006, SEMIN ONCOL, V33, P631, DOI 10.1053/j.seminoncol.2006.08.020; Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363; Dixon JM, 2005, CLIN EVID, p[13, 2226]; Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666; Fedele CG, 2010, P NATL ACAD SCI USA, V107, P22231, DOI 10.1073/pnas.1015245107; Giamas G, 2007, PHARMACOGENOMICS, V8, P1005, DOI 10.2217/14622416.8.8.1005; Giamas G, 2011, NAT MED, V17, P715, DOI 10.1038/nm.2351; Giamas G, 2010, CELL SIGNAL, V22, P984, DOI 10.1016/j.cellsig.2010.01.011; Gonzalez-Malerva L, 2011, P NATL ACAD SCI USA, V108, P2058, DOI 10.1073/pnas.1018157108; Guo SC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021467; Harrington WR, 2006, ENDOCRINOLOGY, V147, P3843, DOI 10.1210/en.2006-0358; Hu DG, 2009, MOL PHARMACOL, V76, P425, DOI 10.1124/mol.109.057380; Jansen MPHM, 2009, BREAST CANCER RES TR, V116, P263, DOI 10.1007/s10549-008-0125-z; Kappe G, 2003, CELL STRESS CHAPERON, V8, P53, DOI 10.1379/1466-1268(2003)8<53:THGECS>2.0.CO;2; Lange CA, 2011, ENDOCR-RELAT CANCER, V18, pC19, DOI 10.1530/ERC-11-0112; LASFARGUES EY, 1978, J NATL CANCER I, V61, P967; Li Y, 2010, NAT MED, V16, P214, DOI 10.1038/nm.2090; Liguori L, 2012, CELL CYCLE, V11, P569, DOI 10.4161/cc.11.3.19063; Miller TW, 2011, J CLIN ONCOL, V29, P4452, DOI 10.1200/JCO.2010.34.4879; Miller TW, CLIN CANC RES, V17, P2024; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Noetzel E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-154; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Oshima T, 2011, BIOL PHARM BULL, V34, P54, DOI 10.1248/bpb.34.54; Paroni G, 2011, ONCOGENE; Rizzo P, 2008, CANCER RES, V68, P5226, DOI 10.1158/0008-5472.CAN-07-5744; Schafer JM, 2006, METH MOLEC MED, V120, P453; Shaw JA, 2012, GENOME RES, V22, P220, DOI 10.1101/gr.123497.111; Stebbing J, 2007, CLIN EVID, V2007; Stebbing J, 2007, PHARMACOGENOMICS, V8, P1, DOI 10.2217/14622416.8.1.1; Stebbing J, 2012, BREAST CANCER RES TR, V132, P537, DOI 10.1007/s10549-011-1622-z; Stone James C, 2011, Genes Cancer, V2, P320, DOI 10.1177/1947601911408082; Sun X, 2007, CELL STRESS CHAPERON, V12, P307, DOI 10.1379/CSC-276.1; Tobin NP, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-417; Tomura H, 2005, CELL SIGNAL, V17, P1466, DOI 10.1016/j.cellsig.2005.06.002; Wang YZ, 2011, MOL ENDOCRINOL, V25, P72, DOI 10.1210/me.2010-0294; Wilson CG, 2011, FEBS LETT, V585, P2137, DOI 10.1016/j.febslet.2011.05.059; Xu J, 2012, BREAST CANC RES TREA; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Zhang Q, 2009, CANCER CELL, V16, P413, DOI 10.1016/j.ccr.2009.09.029	46	34	38	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2013	32	28					3371	3380		10.1038/onc.2012.343	http://dx.doi.org/10.1038/onc.2012.343			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	180TM	22869149				2022-12-17	WOS:000321620200007
J	Bagci-Onder, T; Agarwal, A; Flusberg, D; Wanningen, S; Sorger, P; Shah, K				Bagci-Onder, T.; Agarwal, A.; Flusberg, D.; Wanningen, S.; Sorger, P.; Shah, K.			Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors	ONCOGENE			English	Article						live-cell imaging; DR4/5; TRAIL; GBM; neural stem cell; dual luciferase imaging	PHASE-II TRIAL; CANCER-CELLS; INDUCED APOPTOSIS; UP-REGULATION; DOWN-REGULATION; STEM-CELLS; DR5; EXPRESSION; GLIOMA; INHIBITION	Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induces apoptosis specifically in tumor cells and its efficacy has been tested in pre-clinical models by delivering it systemically as a purified ligand or via engineered stem cells (SC). However, about 50% of tumor lines are resistant to TRAIL and overcoming TRAIL resistance in aggressive tumors, such as glioblastoma-multiforme (GBM), and understanding the molecular dynamics of TRAIL-based combination therapies are critical to broadly use TRAIL as a therapeutic agent. In this study, we developed death receptor (DR)4/5-reporters that offer an imaging-based platform to identify agents that act in concert with a potent, secretable variant of TRAIL (S-TRAIL) by monitoring changes in DR4/5 expression. Utilizing these reporters, we show a differential regulation of DR4/5 when exposed to a panel of clinically relevant agents. A histone deacetylase inhibitor, MS-275, resulted in upregulation of DR4/5 in all GBM cell lines, and these changes could be followed in real time both in vitro and in vivo in mice bearing tumors and they correlated with increased TRAIL sensitivity. To further assess the dynamics of combinatorial strategies that overcome resistance of tumors to SC released S-TRAIL, we also engineered tumor cells to express live-cell caspase-reporters and SCs to express S-TRAIL. Utilizing DR4/5 and caspase reporters in parallel, we show that MS-275 sensitizes TRAIL-resistant GBM cells to stem cell (SC) delivered S-TRAIL by changing the time-to-death in vitro and in vivo. This study demonstrates the effectiveness of a combination of real-time reporters of TRAIL-induced apoptosis pathway in evaluating the efficacy of SC-TRAIL-based therapeutics and may have implications in targeting a broad range of cancers.	[Bagci-Onder, T.; Agarwal, A.; Wanningen, S.; Shah, K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA 02114 USA; [Bagci-Onder, T.; Agarwal, A.; Wanningen, S.; Shah, K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA; [Flusberg, D.; Sorger, P.] Harvard Univ, Dept Syst Biol, Sch Med, Boston, MA 02114 USA; [Shah, K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA; [Shah, K.] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University	Shah, K (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA 02114 USA.	kshah@mgh.harvard.edu	Onder, Tugba Bagci/AAN-1392-2021	Flusberg, Deborah/0000-0001-9506-6990; Sorger, Peter/0000-0002-3364-1838; Bagci Onder, Tugba/0000-0003-3646-2613	American Cancer Society; NIH [CA138922, NS071197, CA139980]; James McDonnell Foundation; NATIONAL CANCER INSTITUTE [R01CA138922, P01CA139980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS071197] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James McDonnell Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr Shi-Yon Sun for providing pDR4 and pDR5 basic constructs; real-time PCR core facility of Neuroscience Department, Massachusetts General Hospital; flow cytometry core facility of Ragon Institute, Massachusetts General Hospital; and Nikon Imaging Center, Harvard Medical School for technical help and equipments. This work was supported by American Cancer Society (KS), NIH grants CA138922, NS071197 (KS), CA139980 (PKS) and the James McDonnell Foundation (KS). There are no competing financial interests to disclose.	Aguilera DG, 2009, J NEURO-ONCOL, V93, P303, DOI 10.1007/s11060-008-9788-x; Albeck JG, 2008, MOL CELL, V30, P11, DOI 10.1016/j.molcel.2008.02.012; Albeck JG, 2008, PLOS BIOL, V6, P2831, DOI 10.1371/journal.pbio.0060299; Ashkenazi A, 2008, J CLIN INVEST, V118, P1979, DOI 10.1172/JCI34359; Ashkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637; Bagci-Onder T, 2011, CANCER RES, V71, P154, DOI 10.1158/0008-5472.CAN-10-1601; Baritaki S, 2007, MOL CANCER THER, V6, P1387, DOI 10.1158/1535-7163.MCT-06-0521; Booth NL, 2009, CANCER IMMUNOL IMMUN, V58, P1229, DOI 10.1007/s00262-008-0637-8; Crosswell HE, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-411; Dhandapani L, 2011, CANCER RES, V71, P5245, DOI 10.1158/0008-5472.CAN-10-4180; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Finlay D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013375; Hingtgen S, 2008, MOL CANCER THER, V7, P3575, DOI 10.1158/1535-7163.MCT-08-0640; Hingtgen SD, 2010, STEM CELLS, V28, P832, DOI 10.1002/stem.313; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Kim MO, 2010, MOL CANCER THER, V9, P833, DOI 10.1158/1535-7163.MCT-09-0610; Kock N, 2007, NEOPLASIA, V9, P435, DOI 10.1593/neo.07223; Liu XG, 2007, CANCER RES, V67, P4981, DOI 10.1158/0008-5472.CAN-06-4274; McDermott U, 2010, CANCER RES, V70, P1625, DOI 10.1158/0008-5472.CAN-09-3620; Mrugala MM, 2008, NAT CLIN PRACT ONCOL, V5, P476, DOI 10.1038/ncponc1155; Nagane M, 2010, NEURO-ONCOLOGY, V12, P687, DOI 10.1093/neuonc/nop069; Nagar S, 2010, ADV EXP MED BIOL, V678, P124; Nakata S, 2004, ONCOGENE, V23, P6261, DOI 10.1038/sj.onc.1207830; Neyns B, 2009, ANN ONCOL, V20, P1596, DOI 10.1093/annonc/mdp032; Pennarun B, 2010, BBA-REV CANCER, V1805, P123, DOI 10.1016/j.bbcan.2009.11.004; Prasad S, 2010, MOL CANCER THER, V9, P856, DOI 10.1158/1535-7163.MCT-09-1113; Prince HM, 2009, CLIN CANCER RES, V15, P3958, DOI 10.1158/1078-0432.CCR-08-2785; Raizer JJ, 2010, NEURO-ONCOLOGY, V12, P95, DOI 10.1093/neuonc/nop015; Sasportas LS, 2009, P NATL ACAD SCI USA, V106, P4822, DOI 10.1073/pnas.0806647106; Shah K, 2005, ANN NEUROL, V57, P34, DOI 10.1002/ana.20306; Shah K, 2008, J NEUROSCI, V28, P4406, DOI 10.1523/JNEUROSCI.0296-08.2008; Singh TR, 2005, ONCOGENE, V24, P4609, DOI 10.1038/sj.onc.1208585; Song JH, 2008, J BIOL CHEM, V283, P25003, DOI 10.1074/jbc.M802511200; Spencer SL, 2009, NATURE, V459, P428, DOI 10.1038/nature08012; Sung B, 2010, J BIOL CHEM, V285, P11498, DOI 10.1074/jbc.M109.090209; Wiezorek J, 2010, CLIN CANCER RES, V16, P1701, DOI 10.1158/1078-0432.CCR-09-1692; Wood TE, 2010, MOL CANCER THER, V9, P246, DOI 10.1158/1535-7163.MCT-09-0495; Yang A, 2010, CURR OPIN CELL BIOL, V22, P837, DOI 10.1016/j.ceb.2010.08.001; Yoshida T, 2005, CANCER RES, V65, P5662, DOI 10.1158/0008-5472.CAN-05-0693	39	34	35	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2013	32	23					2818	2827		10.1038/onc.2012.304	http://dx.doi.org/10.1038/onc.2012.304			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WR	22824792	Green Accepted			2022-12-17	WOS:000320369100002
J	Lu, X; Liu, DP; Xu, Y				Lu, X.; Liu, D. P.; Xu, Y.			The gain of function of p53 cancer mutant in promoting mammary tumorigenesis	ONCOGENE			English	Article						p53 mutant; gain of function; genetic instability	BREAST-CANCER; GENETIC INSTABILITY; EPITHELIAL-CELLS; TRANSGENIC MICE; MOUSE MODEL; DNA-DAMAGE; STEM-CELL; ATM; CARCINOGENESIS; PROTEIN	Tumor suppressor p53 is critical for suppressing all types of human cancers, including breast cancer. The p53 gene is somatically mutated in over half of all human cancers. The majority of the p53 mutations are missense mutations, leading to the expression of the full-length p53 mutants. Several hotspot mutations, including R175H, are frequently detected in human breast cancer. P53 cancer mutants not only lose tumor suppression activity but, more problematically, also gain new oncogenic activities. Despite correlation of the expression of p53 cancer mutants and the poor prognosis of human breast cancer patients, the roles of p53 cancer mutants in promoting breast cancer remain unclear. We used the humanized p53 cancer mutant knock-in (R175H) mice and mouse mammary tumor virus (MMTV)-Wnt-1 transgenic (mWnt-1) mice to specifically address the gain of function of R175H in promoting breast cancer. Although both R175H/R175HmWnt-1(R175HmWnt-1) and p53(-/-) mWnt-1 mice died from mammary tumor at the same kinetics, which was much earlier than mWnt-1 mice, most of the R175HmWnt-1 mice developed multiple mammary tumors per mouse, whereas p53(-/-) mWnt-1 and mWnt-1 mice mostly developed one tumor per mouse. The multiple mammary tumors arose in the same R175HmWnt-1 mouse exhibited different histological characters. Moreover, R175H gain-of-function mutant expands the mammary epithelial stem cells (MESCs) that give rise to the mammary tumors. As ATM suppresses the expansion of MESCs, the inactivation of ATM by R175H in mammary epithelial cells (MECs) could contribute to the expansion of MESCs in R175HmWnt-1 mice. These findings provide the basis for R175H to promote the initiation of breast cancer by expanding MESCs.	[Lu, X.; Liu, D. P.; Xu, Y.] Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yangxu@ucsd.edu		Xu, Yang/0000-0001-5574-921X	NIH [R01 CA94254]; DOD Breast Cancer Research Program [W81XWH-08-1-0381]; NATIONAL CANCER INSTITUTE [R01CA094254] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD Breast Cancer Research Program(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Yi Li for the MMTV-Wnt-1 mice. This work was supported by grants from the NIH (R01 CA94254) and DOD Breast Cancer Research Program (W81XWH-08-1-0381) to YX.	Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Ayyanan A, 2006, P NATL ACAD SCI USA, V103, P3799, DOI 10.1073/pnas.0600065103; Bowen TJ, 2005, CANCER RES, V65, P8736, DOI 10.1158/0008-5472.CAN-05-1598; Cabioglu N, 2009, J AM COLL SURGEONS, V208, P67, DOI 10.1016/j.jamcollsurg.2008.09.001; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; ELLEDGE RM, 1994, BREAST CANCER RES TR, V32, P39, DOI 10.1007/BF00666204; Gallagher WM, 1999, ONCOGENE, V18, P3608, DOI 10.1038/sj.onc.1202937; Gasco M, 2002, BREAST CANCER RES, V4, P70, DOI 10.1186/bcr426; Haupt S, 2009, CANCER RES, V69, P4818, DOI 10.1158/0008-5472.CAN-08-4010; Hussain SP, 2000, MUTAT RES-REV MUTAT, V462, P311, DOI 10.1016/S1383-5742(00)00015-6; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Kalo E, 2007, MOL CELL BIOL, V27, P8228, DOI 10.1128/MCB.00374-07; Kitamura T, 2009, CANCER RES, V69, P7681, DOI 10.1158/0008-5472.CAN-09-2133; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; Lin SCJ, 2004, CANCER RES, V64, P3525, DOI 10.1158/0008-5472.CAN-03-3524; Liu DP, 2010, ONCOGENE, V29, P949, DOI 10.1038/onc.2009.376; Lu S, 2006, CARCINOGENESIS, V27, P848, DOI 10.1093/carcin/bgi302; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Reddy JP, 2010, P NATL ACAD SCI USA, V107, P3728, DOI 10.1073/pnas.0910665107; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Smalley MJ, 2010, METHODS MOL BIOL, V633, P139, DOI 10.1007/978-1-59745-019-5_11; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; Wang Y, 2011, ONCOGENE, V30, P1470, DOI 10.1038/onc.2010.531; Weissenbacher TM, 2010, BREAST CANCER RES TR, V122, P27, DOI 10.1007/s10549-010-0917-9; Weisz L, 2007, CANCER RES, V67, P2396, DOI 10.1158/0008-5472.CAN-06-2425; Xu Y, 2006, NAT REV IMMUNOL, V6, P261, DOI 10.1038/nri1804	36	34	35	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 6	2013	32	23					2900	2906		10.1038/onc.2012.299	http://dx.doi.org/10.1038/onc.2012.299			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WR	22824795	Green Accepted			2022-12-17	WOS:000320369100010
J	Asada, K; Ando, T; Niwa, T; Nanjo, S; Watanabe, N; Okochi-Takada, E; Yoshida, T; Miyamoto, K; Enomoto, S; Ichinose, M; Tsukamoto, T; Ito, S; Tatematsu, M; Sugiyama, T; Ushijima, T				Asada, K.; Ando, T.; Niwa, T.; Nanjo, S.; Watanabe, N.; Okochi-Takada, E.; Yoshida, T.; Miyamoto, K.; Enomoto, S.; Ichinose, M.; Tsukamoto, T.; Ito, S.; Tatematsu, M.; Sugiyama, T.; Ushijima, T.			FHL1 on chromosome X is a single-hit gastrointestinal tumor-suppressor gene and contributes to the formation of an epigenetic field defect	ONCOGENE			English	Article						field for cancerization; chromosome X; DNA methylation; gastrointestinal cancer; Helicobacter pylori	ABERRANT DNA METHYLATION; SQUAMOUS-CELL CARCINOMA; GASTRIC MUCOSAE; HELICOBACTER-PYLORI; SILENCED GENES; CANCER; HYPERMETHYLATION; EXPRESSION; BREAST; RISK	Tumor-suppressor genes on chromosome X can be inactivated by a single hit, any of the point mutations, chromosomal loss and aberrant DNA methylation. As aberrant DNA methylation can be induced frequently, we here aimed to identify a tumor-suppressor gene on chromosome X inactivated by promoter DNA methylation. Of 69 genes on chromosome X upregulated by treatment of a gastric cancer cell line with a DNA-demethylating agent, 5-aza-2'-deoxycytidine, 11 genes had low or no expression in the cell line and abundant expression in normal gastric mucosae. Among them, FHL1 was frequently methylation-silenced in gastric and colon cancer cell lines, and methylated in primary gastric (21/80) and colon (5/50) cancers. Knockdown of the endogenous FHL1 in two cell lines by two kinds of shRNAs significantly increased cell growth in vitro and sizes of xenografts in nude mice. Expression of exogenous FHL1 in a non-expressing cell line significantly reduced its migration, invasion and growth. Notably, a somatic mutation (G642T; Lys214Asn) was identified in one of 144 colon cancer specimens, and the mutant FHL1 was shown to lack its inhibitory effects on migration, invasion and growth. FHL1 methylation was associated with Helicobacter pylori infection and accumulated in normal-appearing gastric mucosae of gastric cancer patients. These data showed that FHL1 is a methylation-silenced tumor-suppressor gene on chromosome X in gastrointestinal cancers, and that its silencing contributes to the formation of an epigenetic field for cancerization. Oncogene (2013) 32, 2140-2149; doi:10.1038/onc.2012.228; published online 11 June 2012	[Asada, K.; Ando, T.; Niwa, T.; Nanjo, S.; Watanabe, N.; Okochi-Takada, E.; Yoshida, T.; Ushijima, T.] Natl Canc Ctr, Div Epigen, Tokyo 1040045, Japan; [Ando, T.; Sugiyama, T.] Toyama Univ, Dept Internal Med 3, Toyama 930, Japan; [Miyamoto, K.] Chugoku Canc Ctr, Natl Hosp Org Kure Med Ctr, Inst Clin Res, Hiroshima, Japan; [Miyamoto, K.] Chugoku Canc Ctr, Natl Hosp Org Kure Med Ctr, Dept Surg, Hiroshima, Japan; [Enomoto, S.; Ichinose, M.] Wakayama Med Univ, Dept Internal Med 2, Wakayama, Japan; [Tsukamoto, T.; Tatematsu, M.] Aichi Canc Ctr Res Inst, Div Oncol Pathol, Nagoya, Aichi, Japan; [Ito, S.] Aichi Canc Ctr Hosp, Dept Gastroenterol Surg, Nagoya, Aichi 464, Japan	National Cancer Center - Japan; University of Toyama; Wakayama Medical University; Aichi Cancer Center; Aichi Cancer Center	Ushijima, T (corresponding author), Natl Canc Ctr, Div Epigen, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tushijim@ncc.go.jp	Tsukamoto, Tetsuya/ABD-4397-2020; Asada, Kiyoshi/AFL-8696-2022; Ushijima, Toshikazu/AAP-5742-2021; Asada, Kiyoshi/GPW-7758-2022; Ichinose, Masao/HAB-1645-2022	Tsukamoto, Tetsuya/0000-0002-7502-8724; Asada, Kiyoshi/0000-0002-4515-6047; Ushijima, Toshikazu/0000-0003-3405-7817; 	Ministry of Health, Labour and Welfare, Japan; National Cancer Center Research and Development Fund; Foundation for Promotion of Cancer Research	Ministry of Health, Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); National Cancer Center Research and Development Fund(National Cancer Center - Japan); Foundation for Promotion of Cancer Research	We thank Dr Yanagihara and Dr Yasui for their kind gift of cell lines. This study was supported by a Grant-in-Aid for the Third-term Comprehensive Cancer Control Strategy from the Ministry of Health, Labour and Welfare, Japan, and by the National Cancer Center Research and Development Fund. TA is a recipient of the Research Resident Fellowship from the Foundation for Promotion of Cancer Research.	Achyut BR, 2011, GASTROENTEROLOGY, V141, P1167, DOI 10.1053/j.gastro.2011.07.048; Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219; Arai E, 2006, INT J CANCER, V119, P288, DOI 10.1002/ijc.21807; CHENG H, 1984, GASTROENTEROLOGY, V86, P78; Ding LH, 2011, J CELL MOL MED, V15, P72, DOI 10.1111/j.1582-4934.2009.00938.x; Ding LH, 2009, J CLIN INVEST, V119, P349, DOI 10.1172/JCI35930; Enomoto S, 2007, CANCER SCI, V98, P1853, DOI 10.1111/j.1349-7006.2007.00625.x; FUKAYAMA M, 1994, LAB INVEST, V71, P73; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hosoya K, 2009, CANCER LETT, V285, P182, DOI 10.1016/j.canlet.2009.05.016; Ishii T, 2007, GUT, V56, P13, DOI 10.1136/gut.2005.089813; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kaneda A, 2004, CANCER LETT, V212, P203, DOI 10.1016/j.canlet.2004.03.020; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lee YC, 2011, CANCER PREV RES, V4, P1982, DOI 10.1158/1940-6207.CAPR-11-0096; Li X, 2008, CANCER SCI, V99, P1326, DOI 10.1111/j.1349-7006.2008.00816.x; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Luo B, 2005, WORLD J GASTROENTERO, V11, P629, DOI 10.3748/wjg.v11.i5.629; Maekita T, 2006, CLIN CANCER RES, V12, P989, DOI 10.1158/1078-0432.CCR-05-2096; Matsumoto M, 2010, INT J MOL MED, V26, P241, DOI 10.3892/ijmm_00000458; Matsusaka K, 2011, CANCER RES, V71, P7187, DOI 10.1158/0008-5472.CAN-11-1349; Moriguchi K, 2007, CANCER LETT, V249, P178, DOI 10.1016/j.canlet.2006.08.014; Nakajima T, 2006, CANCER EPIDEM BIOMAR, V15, P2317, DOI 10.1158/1055-9965.EPI-06-0436; Niu C, 2012, INT J CANCER, V130, P2549, DOI 10.1002/ijc.26259; Niwa T, 2010, CANCER RES, V70, P1430, DOI 10.1158/0008-5472.CAN-09-2755; Oka D, 2009, CANCER-AM CANCER SOC, V115, P3412, DOI 10.1002/cncr.24394; Ota N, 2006, ANTICANCER RES, V26, P3729; Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1; Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509; Sakashita K, 2008, ANN SURG ONCOL, V15, P2293, DOI 10.1245/s10434-008-9904-3; Shathasivam T, 2010, J CELL MOL MED, V14, P2702, DOI 10.1111/j.1582-4934.2010.01176.x; Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275; Shen YQ, 2006, CANCER RES, V66, P1543, DOI 10.1158/0008-5472.CAN-05-3152; Ushijima T, 2005, CANCER RES, V65, P11; Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571; Ushijima T, 2007, J BIOCHEM MOL BIOL, V40, P142; Van Vlierberghe P, 2010, NAT GENET, V42, P338, DOI 10.1038/ng.542; Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016; Yamashita S, 2006, CANCER SCI, V97, P64, DOI 10.1111/j.1349-7006.2006.00136.x; Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467; Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034	43	34	35	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2140	2149		10.1038/onc.2012.228	http://dx.doi.org/10.1038/onc.2012.228			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22689052				2022-12-17	WOS:000318062800003
J	Perez-Benavente, B; Garcia, JL; Rodriguez, MS; Pineda-Lucena, A; Piechaczyk, M; de Mora, JF; Farras, R				Perez-Benavente, B.; Garcia, J. L.; Rodriguez, M. S.; Pineda-Lucena, A.; Piechaczyk, M.; Font de Mora, J.; Farras, R.			GSK3-SCFFBXW7 targets JunB for degradation in G2 to preserve chromatid cohesion before anaphase	ONCOGENE			English	Article						JunB; G2 phase; ubiquitin-proteasome; NPM-ALK; GSK3; DDX11	LARGE-CELL-LYMPHOMA; CHRONIC MYELOID-LEUKEMIA; C-JUN; PROFILING REVEALS; TUMOR-SUPPRESSOR; HODGKIN-LYMPHOMA; EXPRESSION; TRANSCRIPTION; KINASE; ALK	JunB, an activator protein-1 (AP-1) transcription factor component, acts either as a tumor suppressor or as an oncogene depending on the cell context. In particular, JunB is strongly upregulated in anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) where it enhances cell proliferation. Although its overexpression is linked to lymphomagenesis, the mechanisms whereby JunB promotes neoplastic growth are still largely obscure. Here, we show that JunB undergoes coordinated phosphorylation-dependent ubiquitylation during the G2 phase of the cell cycle. We characterized a critical consensus phosphodegron that controls JunB turnover and identified GSK3 and SCFFBXW7 as, respectively, the kinase and the E3 ubiquitin ligase responsible for its degradation in G2. Pharmacological or genetic inactivation of the GSK3-FBXW7-JunB axis induced accumulation of JunB in G2/M and entailed transcriptional repression of the DNA helicase DDX11, leading to premature sister chromatid separation. This abnormal phenotype due to dysregulation of the GSK3 beta/JunB/DDX11 pathway is phenocopied in ALK-positive ALCL. Thus, our results reveal a novel mechanism by which mitosis progression and chromatid cohesion are regulated through GSK3/SCFFBXW7-mediated proteolysis of JunB, and suggest that JunB proteolysis in G2 is an essential step in maintaining genetic fidelity during mitosis. Oncogene (2013) 32, 2189-2199; doi:10.1038/onc.2012.235; published online 18 June 2012	[Perez-Benavente, B.; Farras, R.] Ctr Invest Principe Felipe, Cytom Lab, Valencia 46012, Spain; [Garcia, J. L.] Univ Salamanca, Ctr Invest Canc, Hosp Univ Salamanca, Unidad Invest,IECSCYL,CSIC, E-37008 Salamanca, Spain; [Rodriguez, M. S.] CIC BioGUNE, Prote Unit, Bizkaia, Spain; [Pineda-Lucena, A.] Ctr Invest Principe Felipe, Struct Biochem Lab, Valencia 46012, Spain; [Piechaczyk, M.] Univ Montpellier I, Univ Montpellier 2, CNRS, UMR 5535,Inst Genet Mol Montpellier, Montpellier 2, France; [Font de Mora, J.] Ctr Invest Principe Felipe, Cellular & Mol Biol Lab, Valencia 46012, Spain	Prince Felipe Research Center; Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca; CIC bioGUNE; Prince Felipe Research Center; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Prince Felipe Research Center	Farras, R (corresponding author), Ctr Invest Principe Felipe, Cytom Lab, C EP Autopista del Saler 16, Valencia 46012, Spain.	rfarras@cipf.es	RODRIGUEZ, Manuel S./D-5439-2018; de Mora, Jaime Font/H-6304-2015; de Mora, Jaime Font/AAK-7591-2021; PIECHACZYK, Marc/E-7896-2013; Pineda-Lucena, Antonio/B-1320-2014; Farràs, Rosa/B-5180-2014	de Mora, Jaime Font/0000-0002-6816-2095; de Mora, Jaime Font/0000-0002-6816-2095; PIECHACZYK, Marc/0000-0003-1367-2597; Pineda-Lucena, Antonio/0000-0002-3532-8781; Farràs, Rosa/0000-0003-4931-1494; Perez-Benavente, Beatriz/0000-0001-9977-058X	Fondo de Investigaciones Sanitarias [PI08/1127]; Valencia's Regional Ministry of Health [AP007/11]; Spanish Ministry of Science and Innovation [SAF2009-08334]; Institute of Health Carlos III; Regional Ministry of Health; program 'Equipe Labellisee' of the French Ligue against Cancer	Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Valencia's Regional Ministry of Health; Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Institute of Health Carlos III(Instituto de Salud Carlos III); Regional Ministry of Health; program 'Equipe Labellisee' of the French Ligue against Cancer	We thank Sandra Gallach and Pablo Mateos for their excellent technical support and A Ferrando, TM Thomson, G Bossis and O Coux for fruitful discussions and critical reading of the manuscript. This research was supported by grants from the Fondo de Investigaciones Sanitarias (PI08/1127) and from Valencia's Regional Ministry of Health (AP007/11) to RF, from the Spanish Ministry of Science and Innovation (SAF2009-08334) to JFM. RF is supported by the Institute of Health Carlos III and by the Regional Ministry of Health. MP was supported by the program 'Equipe Labellisee' of the French Ligue against Cancer. We are grateful to B Vogelstein for providing DLD1 and DLD1<SUP>FBXW7-/-</SUP> cells, M Pagano for Flag-tagged SKP2, CDH1 and CDC20 constructs, O Sangfield for Flag-tagged FBXW7 alpha and FBXW7 gamma constructs, C Bonne-Andrea for Flag-tagged FBXW7 alpha(R465A), PK Vogt (Scripps Research Institute) for activated AKT and E Noguchi for DDX11.	Amin HM, 2007, BLOOD, V110, P2259, DOI 10.1182/blood-2007-04-060715; Andrecht S, 2002, J BIOL CHEM, V277, P35961, DOI 10.1074/jbc.M202847200; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Babaei-Jadidi R, 2011, J EXP MED, V208, P295, DOI 10.1084/jem.20100830; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Barber TD, 2008, P NATL ACAD SCI USA, V105, P3443, DOI 10.1073/pnas.0712384105; Bossis G, 2003, MOL CELL BIOL, V23, P7425, DOI 10.1128/MCB.23.20.7425-7436.2003; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; Bruchova H, 2002, LEUKEMIA LYMPHOMA, V43, P1289, DOI 10.1080/10428190290026358; Crusio KM, 2010, ONCOGENE, V29, P4865, DOI 10.1038/onc.2010.222; Dorsam ST, 2004, BLOOD, V103, P1676, DOI 10.1182/blood-2003-07-2202; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fadlelmola FM, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-2; Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763; Farina A, 2008, J BIOL CHEM, V283, P20925, DOI 10.1074/jbc.M802696200; Farras R, 2008, MOL CELL BIOL, V28, P4173, DOI 10.1128/MCB.01620-07; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Inoue A, 2007, CELL CYCLE, V6, P1646, DOI 10.4161/cc.6.13.4411; Inuzuka H, 2011, NATURE, V471, P104, DOI 10.1038/nature09732; Kang T, 2008, CANCER CELL, V13, P36, DOI 10.1016/j.ccr.2007.12.002; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Lopez-Bergami P, 2010, NAT REV CANCER, V10, P65, DOI 10.1038/nrc2681; Mao X, 2003, BLOOD, V101, P1513, DOI 10.1182/blood-2002-08-2434; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mussolin L, 2010, PEDIATR BLOOD CANCER, V55, P446, DOI 10.1002/pbc.22550; Nagel S, 2008, LEUKEMIA, V22, P387, DOI 10.1038/sj.leu.2405028; Palmer RH, 2009, BIOCHEM J, V420, P345, DOI 10.1042/BJ20090387; Parish JL, 2006, J CELL SCI, V119, P4857, DOI 10.1242/jcs.03262; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2004, CELL, V119, P431, DOI 10.1016/j.cell.2004.10.010; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; Peters JM, 2008, GENE DEV, V22, P3089, DOI 10.1101/gad.1724308; Piccaluga PP, 2010, ADV HEMATOL, DOI DOI 10.1155/2010/345053; Piechaczyk M, 2008, BIOCHEM SOC T, V36, P864, DOI 10.1042/BST0360864; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Rassidakis GZ, 2005, MODERN PATHOL, V18, P1365, DOI 10.1038/modpathol.3800419; Salaverria I, 2008, BRIT J HAEMATOL, V140, P516, DOI 10.1111/j.1365-2141.2007.06924.x; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Singh RR, 2009, CANCER RES, V69, P2550, DOI 10.1158/0008-5472.CAN-08-1808; Staber PB, 2007, BLOOD, V110, P3374, DOI 10.1182/blood-2007-02-071258; van der Lelij P, 2010, AM J HUM GENET, V86, P262, DOI 10.1016/j.ajhg.2010.01.008; Watanabe M, 2005, CANCER RES, V65, P7628, DOI 10.1158/0008-5472.CAN-05-0925; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Wertz IE, 2011, NATURE, V471, P110, DOI 10.1038/nature09779; Ye X, 2004, J BIOL CHEM, V279, P50110, DOI 10.1074/jbc.M409226200; Zettl A, 2004, AM J PATHOL, V164, P1837, DOI 10.1016/S0002-9440(10)63742-X	53	34	34	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2189	2199		10.1038/onc.2012.235	http://dx.doi.org/10.1038/onc.2012.235			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22710716				2022-12-17	WOS:000318062800008
J	Arabzadeh, A; Chan, C; Nouvion, AL; Breton, V; Benlolo, S; DeMarte, L; Turbide, C; Brodt, P; Ferri, L; Beauchemin, N				Arabzadeh, A.; Chan, C.; Nouvion, A-L; Breton, V.; Benlolo, S.; DeMarte, L.; Turbide, C.; Brodt, P.; Ferri, L.; Beauchemin, N.			Host-related carcinoembryonic antigen cell adhesion molecule 1 promotes metastasis of colorectal cancer	ONCOGENE			English	Article						CEACAM 1; metastasis; microenvironment; intravital microscopy; MDSC; colorectal cancer	BILIARY GLYCOPROTEIN; TUMOR PROGRESSION; PROSTATE-CANCER; POSSIBLE ROLES; CEACAM1; EXPRESSION; CD66A; ANGIOGENESIS; APOPTOSIS; INVASION	Liver metastasis is the predominant cause of colorectal cancer (CRC)-related mortality in developed countries. Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a cell adhesion molecule with reduced expression in early phases of CRC development and thus functions as a tumor growth inhibitor. However, CEACAM1 is upregulated in metastatic colon cancer, suggesting a bimodal role in CRC progression. To investigate the role of this protein in the host metastatic environment, Ceacam1(-/-) mice were injected intrasplenically with metastatic MC38 mouse CRC cells. A significant reduction in metastatic burden was observed in Ceacam1(-/-) compared with wild-type (WT) livers. Intravital microscopy showed decreased early survival of MC38 cells in Ceacam1(-/-) endothelial environment. Metastatic cell proliferation within the Ceacaml-i- livers was also diminished. Bone marrow-derived cell recruitment, attenuation of immune infiltrates and diminished CCL2, CCL3 and CCL5 chemokine production participated in the reduced Ceacam1(-/-) metastatic phenotype. Transplantations of WT bone marrow (BM) into Ceacam1(-/-) mice fully rescued metastatic development, whereas Ceacam1(-/-) BM transfer into WT mice showed reduced metastatic burden. Chimeric immune cell profiling revealed diminished recruitment of CD11b(+) Gr1(+) myeloid-derived suppressor cells (MDSCs) to Ceacam1(-/-)metastatic livers and adoptive transfer of MDSCs confirmed the involvement of these immune cells in reduction of liver metastasis. CEACAM1 may represent a novel metastatic CRC target for treatment. Oncogene (2013) 32, 849-860; doi:10.1038/onc.2012.112; published online 2 April 2012	[Arabzadeh, A.; Chan, C.; Nouvion, A-L; Breton, V.; Benlolo, S.; DeMarte, L.; Turbide, C.; Beauchemin, N.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3G 1Y6, Canada; [Chan, C.; Brodt, P.; Ferri, L.] McGill Univ, Dept Surg, Montreal, PQ H3G 1Y6, Canada; [Brodt, P.; Ferri, L.; Beauchemin, N.] McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; [Beauchemin, N.] McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; [Beauchemin, N.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University; McGill University; McGill University	Beauchemin, N (corresponding author), McGill Univ, Goodman Canc Res Ctr, Lab 708, McIntyre Bldg,3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	nicole.beauchemin@mcgill.ca		Chan, Carlos HF/0000-0003-3656-2470	Canadian Institutes for Health Research; Canadian Cancer Society Research Institute; Fonds de la Recherche en Sante du Quebec (FRSQ); McGill Integrated Cancer Research Training Program	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Fonds de la Recherche en Sante du Quebec (FRSQ)(Fonds de la Recherche en Sante du Quebec); McGill Integrated Cancer Research Training Program	We wish to thank Drs Janusz Rak, Peter Siegel and Julie St-Pierre (McGill University) for their helpful corrections and comments on the manuscript. We are also indebted to Dr Russell Jones (McGill University) for help with bone marrow transplantations and Dr Kathryn V Holmes (University of Colorado) for the monoclonal CC1 antibody. This work was supported by grants from the Canadian Institutes for Health Research (NB, LF and PB) and the Canadian Cancer Society Research Institute (LF). AA and ALN were recipients of post-doctoral fellowships from the Fonds de la Recherche en Sante du Quebec (FRSQ). AA and CC received post-doctoral awards from the McGill Integrated Cancer Research Training Program funded by the Canadian Institutes for Health Research and the Fonds de la Recherche en Sante du Quebec (FRSQ).	Bamberger AM, 1998, AM J PATHOL, V152, P1401; Beauchemin N, 1999, EXP CELL RES, V252, P243; Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218; Chen T, 2001, J LEUKOCYTE BIOL, V70, P335; Chen ZG, 2011, J EXP MED, V208, P2633, DOI 10.1084/jem.20102575; Dango S, 2008, LUNG CANCER, V60, P426, DOI 10.1016/j.lungcan.2007.11.015; Ebrahimnejad A, 2004, AM J PATHOL, V165, P1781, DOI 10.1016/S0002-9440(10)63433-5; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; GIAVAZZI R, 1986, CANCER RES, V46, P1928; Gout S, 2008, CANCER MICROENVIRON, V1, P69, DOI 10.1007/s12307-008-0007-2; Gray-Owen SD, 2006, NAT REV IMMUNOL, V6, P433, DOI 10.1038/nri1864; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hemmila E, 2004, J VIROL, V78, P10156, DOI 10.1128/JVI.78.18.10156-10165.2004; Horst AK, 2009, BLOOD, V113, P6726, DOI 10.1182/blood-2008-10-184556; Horst AK, 2006, J CLIN INVEST, V116, P1596, DOI 10.1172/JCI24340; Ieda J, 2011, INT J CANCER, V129, P1351, DOI 10.1002/ijc.26072; Kang WY, 2007, INT J COLORECTAL DIS, V22, P869, DOI 10.1007/s00384-006-0247-x; Kaplan RN, 2006, CANCER RES, V66, P11089, DOI 10.1158/0008-5472.CAN-06-2407; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Laurie NA, 2005, CANCER RES, V65, P11010, DOI 10.1158/0008-5472.CAN-04-2841; Leung N, 2008, ONCOGENE, V27, P4943, DOI 10.1038/onc.2008.136; Leung N, 2006, ONCOGENE, V25, P5527, DOI 10.1038/sj.onc.1209541; Liu W, 2007, ONCOGENE, V26, P2747, DOI 10.1038/sj.onc.1210077; Loberg RD, 2007, CANCER RES, V67, P9417, DOI 10.1158/0008-5472.CAN-07-1286; Ma G, 2011, IMMUNITY, V34, P385, DOI 10.1016/j.immuni.2011.02.004; Movahedi K, 2008, BLOOD, V111, P4233, DOI 10.1182/blood-2007-07-099226; Nagaishi T, 2006, IMMUNITY, V25, P769, DOI 10.1016/j.immuni.2006.08.026; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nittka S, 2004, ONCOGENE, V23, P9306, DOI 10.1038/sj.onc.1208259; Niwa Y, 2001, CLIN CANCER RES, V7, P285; Nollau P, 1997, AM J PATHOL, V151, P521; Nouvion AL, 2010, J CELL SCI, V123, P4221, DOI 10.1242/jcs.073635; Obrink B, 2008, LUNG CANCER, V60, P309, DOI 10.1016/j.lungcan.2008.03.020; Oliveira-Ferrer L, 2004, CANCER RES, V64, P8932, DOI 10.1158/0008-5472.CAN-04-0505; Pan H, 2010, IMMUNITY, V33, P620, DOI 10.1016/j.immuni.2010.10.009; Popivanova BK, 2009, CANCER RES, V69, P7884, DOI 10.1158/0008-5472.CAN-09-1451; Poy MN, 2002, NAT GENET, V30, P270, DOI 10.1038/ng840; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; ROSENBERG M, 1993, CANCER RES, V53, P4938; Serra S, 2009, APPL IMMUNOHISTO M M, V17, P286, DOI 10.1097/PAI.0b013e318196e13c; SKALLI O, 1989, J HISTOCHEM CYTOCHEM, V37, P315, DOI 10.1177/37.3.2918221; Song JH, 2011, PATHOL ONCOL RES, V17, P67, DOI 10.1007/s12253-010-9282-6; Starke RD, 2011, BLOOD, V117, P1071, DOI 10.1182/blood-2010-01-264507; Wu YJ, 2010, CANCER RES, V70, P57, DOI 10.1158/0008-5472.CAN-09-2472; Xu E, 2009, ENDOCRINOLOGY, V150, P3503, DOI 10.1210/en.2008-1439; Yeatman T J, 1997, J Gastrointest Surg, V1, P292, DOI 10.1016/S1091-255X(97)80123-0; Yoshidome H, 2009, INT J ONCOL, V34, P923, DOI 10.3892/ijo_00000218; Zhou CJ, 2009, PATHOL RES PRACT, V205, P483, DOI 10.1016/j.prp.2009.01.006	48	34	35	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2013	32	7					849	860		10.1038/onc.2012.112	http://dx.doi.org/10.1038/onc.2012.112			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22469976				2022-12-17	WOS:000316581100005
J	Jarde, T; Evans, RJ; McQuillan, KL; Parry, L; Feng, GJ; Alvares, B; Clarke, AR; Dale, TC				Jarde, T.; Evans, R. J.; McQuillan, K. L.; Parry, L.; Feng, G. J.; Alvares, B.; Clarke, A. R.; Dale, T. C.			In vivo and in vitro models for the therapeutic targeting of Wnt signaling using a Tet-O Delta N89 beta-catenin system	ONCOGENE			English	Article						Wnt pathway; reversal; colorectal cancer; crypt culture; organoids	SMALL-MOLECULE INHIBITORS; BETA-CATENIN; STEM-CELLS; WNT/BETA-CATENIN; TRANSGENIC MICE; SMALL-INTESTINE; CANCER; DIFFERENTIATION; EXPRESSION; APOPTOSIS	Although significant progress has been made in understanding the importance of Wnt signaling in the initiation of colorectal cancer, less is known about responses that accompany the reversal of oncogenic Wnt signaling. The aim of this study was to analyze in vivo and in vitro responses to an 'ideal' Wnt pathway inhibitor as a model for the therapeutic targeting of the pathway. A tetracycline-inducible transgenic mouse model expressing truncated beta-catenin (Delta N89 beta-catenin) that exhibited a strong intestinal hyperplasia was analyzed during the removal of oncogenic beta-catenin expression both in 3D 'crypt culture' and in vivo. Oncogenic Wnt signaling was rapidly and completely reversed. The strongest inhibition of Wnt target gene expression occurred within 24 h of doxycycline removal at which time the target genes Ascl2, Axin2 and C-myc were downregulated to levels below that in the control intestine. In vitro, the small molecule Wnt inhibitor CCT036477 induced a response within 4 h of treatment. By 7 days following doxycycline withdrawal, gene expression, cell proliferation and tissue morphology were undistinguishable from control animals.In conclusion, these results demonstrate that the reversal of Wnt signaling by inhibitors should ideally be studied within hours of treatment. The reversible system described, involving medium throughput in vitro approaches and rapid in vivo responses, should allow the rapid advance of early stage compounds into efficacy models that are more usually considered later in the drug discovery pipeline. Oncogene (2013) 32, 883-893; doi:10.1038/onc.2012.103; published online 2 April 2012	[Jarde, T.; Evans, R. J.; McQuillan, K. L.; Parry, L.; Feng, G. J.; Alvares, B.; Clarke, A. R.; Dale, T. C.] Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales	Cardiff University	Dale, TC (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Biomed Sci Bldg,Museum Ave, Cardiff CF10 3US, S Glam, Wales.	daletc@cardiff.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014; Jarde, Thierry/H-6781-2019; Parry, Lee/A-9623-2011; Dale, Trevor/D-3749-2009	Jarde, Thierry/0000-0001-7483-8672; Parry, Lee/0000-0002-4467-9196; Clarke, Alan/0000-0002-4281-426X; Dale, Trevor/0000-0002-4880-9963	Cancer Research UK; Breast Cancer Campaign; Biotechnology and Biological Sciences Research Council [BB/D00117X/1] Funding Source: researchfish; Cancer Research UK [15937] Funding Source: researchfish; BBSRC [BB/D00117X/1] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Breast Cancer Campaign; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by Cancer Research UK and the Breast Cancer Campaign. We thank C Beard and R Jaenisch (The Whitehead Institute for Biomedical Research, Massachusetts) for the embryonic stem cell lines and for technical advice; K Ewan, A Offergeld and S Braun (Cardiff School of Biosciences) for their assistance in tissue staining and cell counting; P Watson (Cardiff School of Biosciences) for his assistance in fluorescence microscopy; O Sansom and K Myant for their assistance in organoid culture; B Allen and O Asby for technical assistance in blastocyst injections and chimera crosses; and D Scarborough for help with histology.	Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Andreu P, 2005, DEVELOPMENT, V132, P1443, DOI 10.1242/dev.01700; Beard C, 2006, GENESIS, V44, P23, DOI 10.1002/gene.20180; Binnerts ME, 2007, P NATL ACAD SCI USA, V104, P14700, DOI 10.1073/pnas.0702305104; BOCKER R, 1981, ARZNEIMITTEL-FORSCH, V31-2, P2116; Buchert M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000816; Coste I, 2007, GASTROENTEROLOGY, V132, P1299, DOI 10.1053/j.gastro.2007.01.029; Ewan K, 2010, CANCER RES, V70, P5963, DOI 10.1158/0008-5472.CAN-10-1028; Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034-07; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gunther EJ, 2003, GENE DEV, V17, P488, DOI 10.1101/gad.1051603; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He B, 2004, NEOPLASIA, V6, P7, DOI 10.1016/S1476-5586(04)80048-4; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lucero OM, 2010, CURR ONCOL REP, V12, P314, DOI 10.1007/s11912-010-0114-3; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Minke KS, 2009, EUR J HAEMATOL, V82, P165, DOI 10.1111/j.1600-0609.2008.01188.x; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; Polakis P, 2000, GENE DEV, V14, P1837; Romagnolo B, 1999, CANCER RES, V59, P3875; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Scholer-Dahirel A, 2011, P NATL ACAD SCI USA, V108, P17135, DOI 10.1073/pnas.1104182108; Shorning BY, 2012, GUT, V61, P202, DOI 10.1136/gutjnl-2011-300046; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; van Amerongen R, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.135re9; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; van der Flier LG, 2009, ANNU REV PHYSIOL, V71, P241, DOI 10.1146/annurev.physiol.010908.163145; Wang YQ, 2009, MOL CANCER THER, V8, P2103, DOI 10.1158/1535-7163.MCT-09-0282; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Wutz A, 2000, MOL CELL, V5, P695, DOI 10.1016/S1097-2765(00)80248-8	38	34	35	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2013	32	7					883	893		10.1038/onc.2012.103	http://dx.doi.org/10.1038/onc.2012.103			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22469981	Green Accepted			2022-12-17	WOS:000316581100008
J	Keum, YS; Kim, HG; Bode, AM; Surh, YJ; Dong, Z				Keum, Y-S; Kim, H-G; Bode, A. M.; Surh, Y-J; Dong, Z.			UVB-induced COX-2 expression requires histone H3 phosphorylation at Ser10 and Ser28	ONCOGENE			English	Article						COX-2; UVB; histone H3; phosphorylation; Cdk9; RNA polymerase II	CHROMATIN MODIFICATIONS; RNA; METHYLATION; CYCLOOXYGENASE-2; ACETYLATION; SERINE-10; HUR	Cyclooxygenase-2 (COX-2) is an inducible enzyme that contributes to the generation of chronic inflammation in response to chemical carcinogens and environmental stresses, including ultraviolet B (UVB) irradiation. Although post-translational histone modifications are believed to have an important role in modulating transcriptional regulation of UVB-induced COX-2, the underlying biochemical mechanisms are completely unknown. Here, we show that UVB activates the p38 MAPK/MSK1 kinase cascade to phosphorylate histone H3 at Ser10 and Ser28, contributing to UVB-induced COX-2 expression. UVB has no effect on the global tri-methylation level of histone H3 (H3K4me3, H3K9me3, and H3K27me3). We observed that selected mammalian 14-3-3 proteins bind to UVB-induced phosphorylated histone H3 (Ser10 and Ser28). In particular, 14-3-3 epsilon is critical for recruiting MSK1 and Cdk9 to the chromatin and subsequently phosphorylating the C-terminal domain of RNA polymerase II in the cox-2 promoter. We propose that histone H3 phosphorylation at Ser10 and Ser28 serve as critical switches to promote cox-2 gene expression by facilitating the recruitment of MSK1 and Cdk9 to the cox-2 promoter, thereby promoting RNA polymerase II phosphorylation. Oncogene (2013) 32, 444-452; doi:10.1038/onc.2012.71; published online 5 March 2012	[Keum, Y-S; Kim, H-G; Bode, A. M.; Dong, Z.] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; [Surh, Y-J; Dong, Z.] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Chem, WCU Program, Seoul, South Korea; [Surh, Y-J; Dong, Z.] Seoul Natl Univ, Coll Med, Seoul, South Korea; [Keum, Y-S] Dongguk Univ, Coll Pharm, Dept Biochem, Goyang, South Korea	University of Minnesota System; Seoul National University (SNU); Seoul National University (SNU); Dongguk University	Dong, Z (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu			Hormel Foundation; National Institutes of Health [CA120388, R37 CA081064, ES016548]; Korea WCU project of the MEST [R31-2008-000-10103-0]; NRF; NATIONAL CANCER INSTITUTE [R01CA120388, R37CA081064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016548] Funding Source: NIH RePORTER	Hormel Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Korea WCU project of the MEST(Ministry of Education, Science & Technology (MEST), Republic of Korea); NRF; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by The Hormel Foundation and National Institutes of Health grants CA120388, R37 CA081064, ES016548 and Grant no. R31-2008-000-10103-0 from the Korea WCU project of the MEST and the NRF.	Allis CD, 2007, CELL, V131, P633, DOI 10.1016/j.cell.2007.10.039; Bachelor MA, 2005, MOL CANCER RES, V3, P90, DOI 10.1158/1541-7786.MCR-04-0065; Bernstein E, 2006, MOL CELL BIOL, V26, P2560, DOI 10.1128/MCB.26.7.2560-2569.2006; Bode Ann M, 2005, Sci STKE, V2005, pre4, DOI 10.1126/stke.2812005re4; Buratowski S, 2009, MOL CELL, V36, P541, DOI 10.1016/j.molcel.2009.10.019; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Egloff S, 2008, TRENDS GENET, V24, P280, DOI 10.1016/j.tig.2008.03.008; Fernau NS, 2010, J BIOL CHEM, V285, P3896, DOI 10.1074/jbc.M109.081430; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fischle W, 2005, NATURE, V438, P1116, DOI 10.1038/nature04219; Goto H, 2002, GENES CELLS, V7, P11, DOI 10.1046/j.1356-9597.2001.00498.x; Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254; Johansen KM, 2006, CHROMOSOME RES, V14, P393, DOI 10.1007/s10577-006-1063-4; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lomberk G, 2006, NAT CELL BIOL, V8, P407, DOI 10.1038/ncb1383; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MacDonald N, 2005, MOL CELL, V20, P199, DOI 10.1016/j.molcel.2005.08.032; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; Perez-Cadahia B, 2009, BIOCHEM CELL BIOL, V87, P695, DOI 10.1139/O09-053; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; Rundhaug JE, 2008, PHOTOCHEM PHOTOBIOL, V84, P322, DOI 10.1111/j.1751-1097.2007.00261.x; Rundhaug JE, 2007, MOL CARCINOGEN, V46, P692, DOI 10.1002/mc.20329; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Wang GG, 2007, TRENDS MOL MED, V13, P363, DOI 10.1016/j.molmed.2007.07.003; Winter S, 2008, CELL CYCLE, V7, P1336, DOI 10.4161/cc.7.10.5946; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Zhang J, 2008, MOL CARCINOGEN, V47, P974, DOI 10.1002/mc.20450; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200	32	34	34	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2013	32	4					444	452		10.1038/onc.2012.71	http://dx.doi.org/10.1038/onc.2012.71			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22391560	Green Accepted			2022-12-17	WOS:000315551300005
J	Sun, H; Jiang, L; Luo, X; Jin, W; He, Q; An, J; Lui, K; Shi, J; Rong, R; Su, W; Lucchesi, C; Liu, Y; Sheikh, MS; Huang, Y				Sun, H.; Jiang, L.; Luo, X.; Jin, W.; He, Q.; An, J.; Lui, K.; Shi, J.; Rong, R.; Su, W.; Lucchesi, C.; Liu, Y.; Sheikh, M. S.; Huang, Y.			Potential tumor-suppressive role of monoglyceride lipase in human colorectal cancer	ONCOGENE			English	Article						monoglyceride lipase; gene expression; Akt; phosphatidylinositides; colorectal cancer	COLON-CANCER; APOPTOSIS; GENETICS; PROTEIN; PATHWAY; CELLS	Human monoglyceride lipase (MGL) is a recently identified lipase and very little is known about its regulation and function in cellular regulatory processes, particularly in context to human malignancy. In this study, we investigated the regulation and function of MGL in human cancer(s) and report that MGL expression was either absent or reduced in the majority of primary colorectal cancers. Immunohistochemical studies showed that reduction of MGL expression in the colorectal tumor tissues predominantly occurred in the cancerous epithelial cells. MGL was found to reside in the core surface of a cellular organelle named 'lipid body'. Furthermore, it was found to interact selectively with a number of phospholipids, including phosphatidic acid and phosphoinositol(3,4,5)P3, phosphoinositol(3,5)P2, phosphoinositol(3,4)P2 and several other phosphoinositides, and among all phosphoinositides analyzed, its interaction with P1(3,4,5)P3 was found to be the strongest. In addition, overexpression of MGL suppressed colony formation in tumor cell lines and knockdown of MGL resulted in increased Akt phosphorylation. Taken together, our results suggest that MGL plays a negative regulatory role in phosphatidylinositol-3 kinase/Akt signaling and tumor cell growth. Oncogene (2013) 32, 234-241; doi:10.1038/onc.2012.34; published online 20 February 2012	[Sun, H.; Jiang, L.; Luo, X.; Jin, W.; He, Q.; An, J.; Lui, K.; Shi, J.; Rong, R.; Su, W.; Lucchesi, C.; Liu, Y.; Sheikh, M. S.; Huang, Y.] SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Huang, Y (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	huangy@upstate.edu		Lui, Ki/0000-0002-1690-4616; Liu, Yusen/0000-0002-0994-0109; Liu, Yuxin/0000-0002-0623-2561	NIH [DK062136, CA121850]; NATIONAL CANCER INSTITUTE [R01CA121850] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK062136] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH Grants DK062136 and CA121850 to YH.	Accioly MT, 2008, CANCER RES, V68, P1732, DOI 10.1158/0008-5472.CAN-07-1999; Duan RD, 2006, J FOOD NUTR S2, V50, P45; Dueck DA, 1996, MOL CELL BIOCHEM, V162, P97; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Huang Y, 2001, CANCER RES, V61, P6918; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Karakas B, 2006, BRIT J CANCER, V94, P455, DOI 10.1038/sj.bjc.6602970; Kennedy BP, 1998, CANCER RES, V58, P500; Li J, 2010, AM J PHYSIOL-CELL PH, V298, pC251, DOI 10.1152/ajpcell.00221.2009; LIU C, 2005, PATHOLOGIC BASIS DIS, P797; Nomura DK, 2010, CELL, V140, P49, DOI 10.1016/j.cell.2009.11.027; Prevost N, 2009, BLOOD, V113, P447, DOI 10.1182/blood-2008-06-162032; Rong R, 2005, ONCOGENE, V24, P4867, DOI 10.1038/sj.onc.1208660; Rustgi AK, 2007, GENE DEV, V21, P2525, DOI 10.1101/gad.1593107; Sheridan AM, 2001, MOL CELL BIOL, V21, P4470, DOI 10.1128/MCB.21.14.4470-4481.2001; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245	16	34	37	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2013	32	2					234	241		10.1038/onc.2012.34	http://dx.doi.org/10.1038/onc.2012.34			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22349814	Green Accepted			2022-12-17	WOS:000314075500011
J	Falco, A; Festa, M; Basile, A; Rosati, A; Pascale, M; Florenzano, F; Nori, SL; Nicolin, V; Di Benedetto, M; Vecchione, ML; Arra, C; Barbieri, A; De Laurenzi, V; Turco, MC				Falco, A.; Festa, M.; Basile, A.; Rosati, A.; Pascale, M.; Florenzano, F.; Nori, S. L.; Nicolin, V.; Di Benedetto, M.; Vecchione, M. L.; Arra, C.; Barbieri, A.; De Laurenzi, V.; Turco, M. C.			BAG3 controls angiogenesis through regulation of ERK phosphorylation	ONCOGENE			English	Article						BAG3; angiogenesis; tumour	HEAT-SHOCK FACTOR-1; CANCER-CELLS; NEUROBLASTOMA-CELLS; SIGNALING PATHWAY; INDUCED APOPTOSIS; GENE-EXPRESSION; PROTEIN; LEUKEMIA; STRESS; COMPLEX	BAG3 is a co-chaperone of the heat shock protein (Hsp) 70, is expressed in many cell types upon cell stress, however, its expression is constitutive in many tumours. We and others have previously shown that in neoplastic cells BAG3 exerts an antiapoptotic function thus favoring tumour progression. As a consequence we have proposed BAG3 as a target of antineoplastic therapies. Here we identify a novel role for BAG3 in regulation of neo-angiogenesis and show that its downregulation results in reduced angiogenesis therefore expanding the role of BAG3 as a therapeutical target. In brief we show that BAG3 is expressed in endothelial cells and is essential for the interaction between ERK and its phosphatase DUSP6, as a consequence its removal results in reduced binding of DUSP6 to ERK and sustained ERK phosphorylation that in turn determines increased levels of p21 and p15 and cell-cycle arrest in the G1 phase. Oncogene (2012) 31, 5153-5161; doi:10.1038/onc.2012.17; published online 6 February 2012	[Falco, A.; Festa, M.; Basile, A.; Rosati, A.; Pascale, M.; Nori, S. L.; Turco, M. C.] Univ Salerno, Dept Pharmaceut & Biomed Sci FARMABIOMED, I-84084 Fisciano, SA, Italy; [Falco, A.; Festa, M.; Basile, A.; Rosati, A.; Pascale, M.; De Laurenzi, V.; Turco, M. C.] Univ Salerno, BIOUNIVERSA Srl, I-84084 Fisciano, SA, Italy; [Florenzano, F.] IRCSS Fdn Santa Lucia, Rome, Italy; [Florenzano, F.] European Brain Res Inst Rita Levi Montalcini, Rome, Italy; [Nicolin, V.] Univ Trieste, Clin Dept Biomed, I-34127 Trieste, Italy; [Di Benedetto, M.; Vecchione, M. L.] Univ Naples Federico II, Clin & Expt Med Dept, Naples, Italy; [Arra, C.; Barbieri, A.] Pascale Tumor Inst, Anim Facil, Naples, Italy; [De Laurenzi, V.] Univ G dAnnunzio, Fdn G DAnnunzio, Dept Biomed Sci, Chieti, Italy; [De Laurenzi, V.] Ctr Studi Invecchiamento CeSI, Chieti, Italy	University of Salerno; University of Salerno; IRCCS Santa Lucia; University of Trieste; University of Naples Federico II; G d'Annunzio University of Chieti-Pescara	Turco, MC (corresponding author), Univ Salerno, Dept Pharmaceut & Biomed Sci FARMABIOMED, I-84084 Fisciano, SA, Italy.	mcturco@unisa.it	Barbieri, Antonio/AAG-8961-2019; TURCO, Maria Caterina/AAC-5282-2022; De Laurenzi, Vincenzo/K-7471-2016	Barbieri, Antonio/0000-0002-7788-6167; TURCO, Maria Caterina/0000-0002-7835-359X; Arra, Claudio/0000-0003-3162-2091; Basile, Anna/0000-0002-4523-8202; Rosati, Alessandra/0000-0001-6675-0857; Nicolin, Vanessa/0000-0002-5665-6493; De Laurenzi, Vincenzo/0000-0002-7506-1743	AIRC; Ministero Sanita' grant	AIRC(Fondazione AIRC per la ricerca sul cancro); Ministero Sanita' grant	This work was supported by AIRC and Ministero Sanita' grants to VDL.	Ammirante M, 2010, P NATL ACAD SCI USA, V107, P7497, DOI 10.1073/pnas.0907696107; Basile A, 2011, J MED CHEM, V54, P1391, DOI 10.1021/jm101435r; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Bodart JFL, 2010, J CELL BIOCHEM, V109, P850, DOI 10.1002/jcb.22477; Bonelli P, 2004, LEUKEMIA, V18, P358, DOI 10.1038/sj.leu.2403219; Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x; Canepa ET, 2007, IUBMB LIFE, V59, P419, DOI 10.1080/15216540701488358; Cesaro E, 2010, LEUKEMIA, V24, P1204, DOI 10.1038/leu.2010.68; Chiappetta G, 2007, J CLIN ENDOCR METAB, V92, P1159, DOI 10.1210/jc.2006-1712; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Doong H, 2003, J BIOL CHEM, V278, P28490, DOI 10.1074/jbc.M209682200; Doong H, 2000, ONCOGENE, V19, P4385, DOI 10.1038/sj.onc.1203797; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Festa M, 2011, AM J PATHOL, V178, P2504, DOI 10.1016/j.ajpath.2011.02.002; Franceschelli S, 2008, J CELL PHYSIOL, V215, P575, DOI 10.1002/jcp.21397; Gentilella A, 2008, ONCOGENE, V27, P5011, DOI 10.1038/onc.2008.142; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Guedez L, 2003, AM J PATHOL, V162, P1431, DOI 10.1016/S0002-9440(10)64276-9; Homma S, 2006, AM J PATHOL, V169, P761, DOI 10.2353/ajpath.2006.060250; Jacobs AT, 2009, J BIOL CHEM, V284, P9176, DOI 10.1074/jbc.M808656200; Jung SE, 2010, BRAIN RES, V1349, P1, DOI 10.1016/j.brainres.2010.06.043; Jurek A, 2009, J BIOL CHEM, V284, P4626, DOI 10.1074/jbc.M808490200; Katz M, 2007, BBA-MOL CELL RES, V1773, P1161, DOI 10.1016/j.bbamcr.2007.01.002; Liao Q, 2001, FEBS LETT, V503, P151, DOI 10.1016/S0014-5793(01)02728-4; Liu P, 2009, FEBS LETT, V583, P401, DOI 10.1016/j.febslet.2008.12.032; Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414; Norrby K, 2006, J CELL MOL MED, V10, P588, DOI 10.1111/j.1582-4934.2006.tb00423.x; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Patterson KI, 2009, BIOCHEM J, V418, P475, DOI 10.1042/BJ20082234; Ramos JW, 2008, INT J BIOCHEM CELL B, V40, P2707, DOI 10.1016/j.biocel.2008.04.009; Romano MF, 2003, CANCER BIOL THER, V2, P508, DOI 10.4161/cbt.2.5.524; Romano MF, 2003, CELL DEATH DIFFER, V10, P383, DOI 10.1038/sj.cdd.4401167; Rosati A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.24; Rosati A, 2009, LEUKEMIA, V23, P823, DOI 10.1038/leu.2009.23; Rosati A, 2007, INT J BIOCHEM CELL B, V39, P1337, DOI 10.1016/j.biocel.2007.03.007; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Tabuchi Y, 2007, CANCER LETT, V246, P149, DOI 10.1016/j.canlet.2006.02.011; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Valdez BC, 2008, LEUKEMIA RES, V32, P1684, DOI 10.1016/j.leukres.2008.01.016; Wainwright LJ, 2001, P NATL ACAD SCI USA, V98, P9396, DOI 10.1073/pnas.161288698; Wang HQ, 2009, BRIT J PHARMACOL, V158, P1405, DOI 10.1111/j.1476-5381.2009.00455.x	41	34	35	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2012	31	50					5153	5161		10.1038/onc.2012.17	http://dx.doi.org/10.1038/onc.2012.17			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055WY	22310281				2022-12-17	WOS:000312449800004
J	Carpenter, EL; Haglund, EA; Mace, EM; Deng, D; Martinez, D; Wood, AC; Chow, AK; Weiser, DA; Belcastro, LT; Winter, C; Bresler, SC; Asgharzadeh, S; Seeger, RC; Zhao, H; Guo, R; Christensen, JG; Orange, JS; Pawel, BR; Lemmon, MA; Mosse, YP				Carpenter, E. L.; Haglund, E. A.; Mace, E. M.; Deng, D.; Martinez, D.; Wood, A. C.; Chow, A. K.; Weiser, D. A.; Belcastro, L. T.; Winter, C.; Bresler, S. C.; Asgharzadeh, S.; Seeger, R. C.; Zhao, H.; Guo, R.; Christensen, J. G.; Orange, J. S.; Pawel, B. R.; Lemmon, M. A.; Mosse, Y. P.			Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma	ONCOGENE			English	Article						neuroblastoma; anaplastic lymphoma kinase; immunotherapy; receptor tyrosine kinase	RECEPTOR TYROSINE KINASE; ALK KINASE; MONOCLONAL-ANTIBODIES; ACTIVATING MUTATIONS; LAPATINIB GW572016; LUNG-CANCER; PHASE-I; INHIBITOR; IDENTIFICATION; RESISTANCE	Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase aberrantly expressed in neuroblastoma, a devastating pediatric cancer of the sympathetic nervous system. Germline and somatically acquired ALK aberrations induce increased autophosphorylation, constitutive ALK activation and increased downstream signaling. Thus, ALK is a tractable therapeutic target in neuroblastoma, likely to be susceptible to both small-molecule tyrosine kinase inhibitors and therapeutic antibodies-as has been shown for other receptor tyrosine kinases in malignancies such as breast and lung cancer. Small-molecule inhibitors of ALK are currently being studied in the clinic, but common ALK mutations in neuroblastoma appear to show de novo insensitivity, arguing that complementary therapeutic approaches must be developed. We therefore hypothesized that antibody targeting of ALK may be a relevant strategy for the majority of neuroblastoma patients likely to have ALK-positive tumors. We show here that an antagonistic ALK antibody inhibits cell growth and induces in vitro antibody-dependent cellular cytotoxicity of human neuroblastoma-derived cell lines. Cytotoxicity was induced in cell lines harboring either wild type or mutated forms of ALK. Treatment of neuroblastoma cells with the dual Met/ALK inhibitor crizotinib sensitized cells to antibody-induced growth inhibition by promoting cell surface accumulation of ALK and thus increasing the accessibility of antigen for antibody binding. These data support the concept of ALK-targeted immunotherapy as a highly promising therapeutic strategy for neuroblastomas with mutated or wild-type ALK.	[Mosse, Y. P.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med,Div Oncol, Ctr Childhood Canc Res,Dept Pediat, Philadelphia, PA 19104 USA; [Mace, E. M.; Lemmon, M. A.] Childrens Hosp Philadelphia, Res Inst, Philadelphia, PA 19104 USA; [Bresler, S. C.] Univ Penn, Perelman Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; [Asgharzadeh, S.; Seeger, R. C.] Univ So Calif, Childrens Hosp Angeles, Saban Res Inst, Div Hematol & Oncol, Los Angeles, CA USA; [Zhao, H.; Guo, R.] Childrens Hosp Philadelphia, Dept Pediat, Biostat & Data Management Core, Philadelphia, PA USA; [Christensen, J. G.] Pfizer Global Res & Dev, Dept Canc Biol, Jolla Labs, La Jolla, CA USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Children's Hospital Los Angeles; University of Southern California; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Pfizer	Mosse, YP (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med,Div Oncol, Ctr Childhood Canc Res,Dept Pediat, Colket Translat Res Bldg,3501 Civic Ctr Blvd,Off, Philadelphia, PA 19104 USA.	mosse@chop.edu	Weiser, Daniel A./B-6160-2016	Weiser, Daniel A./0000-0001-6673-5323; Lemmon, Mark/0000-0002-3379-5319; Belcastro, Lili/0000-0002-8666-2376; Mace, Emily/0000-0003-0226-7393; orange, jordan/0000-0001-7117-7725	NIH [R01-CA140198, 2R01 CA60104-16, 2R01 CA60104-16S1]; Children's Oncology Group; Carly Hillman Fund; NIH Training Grant in Structural Biology [T32-GM008275]; St Baldrick's Foundation; US Army Peer-Reviewed Medical Research Program [W81XWH-10-1-0212/3]; NATIONAL CANCER INSTITUTE [R01CA060104, T32CA009615, R01CA140198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008275] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Oncology Group; Carly Hillman Fund; NIH Training Grant in Structural Biology(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); St Baldrick's Foundation; US Army Peer-Reviewed Medical Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Pfizer for their gift of crizotinib, and Dr Marc Vigny for his gift of the ALK monoclonal antibodies 30, 49, 46 and 14. This work was supported in part by NIH Grants R01-CA140198 (YPM), 2R01 CA60104-16 (RCS), 2R01 CA60104-16S1 (RCS), the Children's Oncology Group, the Carly Hillman Fund (YPM), NIH Training Grant in Structural Biology T32-GM008275 (SCB), a fellowship grant from the St Baldrick's Foundation (ACW) and the US Army Peer-Reviewed Medical Research Program (W81XWH-10-1-0212/3 to MAL/YPM).	Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Bougherara H, 2009, MOL CANCER RES, V7, P1525, DOI 10.1158/1541-7786.MCR-09-0138; Bresler SC, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002950; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Choi YL, 2010, NEW ENGL J MED, V363, P1734, DOI 10.1056/NEJMoa1007478; De Brouwer S, 2010, CLIN CANCER RES, V16, P4353, DOI 10.1158/1078-0432.CCR-09-2660; Engelman JA, 2008, CURR OPIN GENET DEV, V18, P73, DOI 10.1016/j.gde.2008.01.004; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; George RE, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000255; Griffin CA, 1999, CANCER RES, V59, P2776; HANK JA, 1990, CANCER RES, V50, P5234; Haupt R, 2010, J CLIN ONCOL, V28, P2331, DOI 10.1200/JCO.2009.24.8351; Hobbie WL, 2008, PEDIATR BLOOD CANCER, V51, P679, DOI 10.1002/pbc.21683; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Hughes B, 2010, NAT REV DRUG DISCOV, V9, P665, DOI 10.1038/nrd3270; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Jazii FR, 2006, WORLD J GASTROENTERO, V12, P7104, DOI 10.3748/wjg.v12.i44.7104; Johns TG, 2003, P NATL ACAD SCI USA, V100, P15871, DOI 10.1073/pnas.2036503100; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Kurai J, 2007, CLIN CANCER RES, V13, P1552, DOI 10.1158/1078-0432.CCR-06-1726; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Matar P, 2004, CLIN CANCER RES, V10, P6487, DOI 10.1158/1078-0432.CCR-04-0870; Mazot P, 2011, ONCOGENE, V30, P2017, DOI 10.1038/onc.2010.595; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; Moog-Lutz C, 2005, J BIOL CHEM, V280, P26039, DOI 10.1074/jbc.M501972200; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Niwa R, 2005, CLIN CANCER RES, V11, P2327, DOI 10.1158/1078-0432.CCR-04-2263; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Osajima-Hakomori Y, 2005, AM J PATHOL, V167, P213, DOI 10.1016/S0002-9440(10)62966-5; Passoni L, 2009, CANCER RES, V69, P7338, DOI 10.1158/0008-5472.CAN-08-4419; Regales L, 2009, J CLIN INVEST, V119, P3000, DOI 10.1172/JCI38746; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Robert F, 2001, J CLIN ONCOL, V19, P3234, DOI 10.1200/JCO.2001.19.13.3234; Sasaki T, 2010, CANCER RES, V70, P10038, DOI 10.1158/0008-5472.CAN-10-2956; Scaltriti M, 2009, ONCOGENE, V28, P803, DOI 10.1038/onc.2008.432; Smith MA, 2010, J CLIN ONCOL, V28, P2625, DOI 10.1200/JCO.2009.27.0421; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Tabone-Eglinger S, 2008, CLIN CANCER RES, V14, P2285, DOI 10.1158/1078-0432.CCR-07-4102; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Weiner LM, 2010, NAT REV IMMUNOL, V10, P317, DOI 10.1038/nri2744; Xia WL, 2005, ONCOGENE, V24, P6213, DOI 10.1038/sj.onc.1208774; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu AL, 2010, NEW ENGL J MED, V363, P1324, DOI 10.1056/NEJMoa0911123; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559	49	34	38	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	46					4859	4867		10.1038/onc.2011.647	http://dx.doi.org/10.1038/onc.2011.647			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	038YT	22266870	Green Accepted			2022-12-17	WOS:000311210700006
J	Okubo, J; Takita, J; Chen, Y; Oki, K; Nishimura, R; Kato, M; Sanada, M; Hiwatari, M; Hayashi, Y; Igarashi, T; Ogawa, S				Okubo, J.; Takita, J.; Chen, Y.; Oki, K.; Nishimura, R.; Kato, M.; Sanada, M.; Hiwatari, M.; Hayashi, Y.; Igarashi, T.; Ogawa, S.			Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma	ONCOGENE			English	Article						neuroblastoma; ALK; truncated form ALK; amplification	RECEPTOR TYROSINE KINASE; ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL-GROWTH-FACTOR; EXPRESSION; GENE; IDENTIFICATION; MUTATIONS; CHEMOTHERAPY; DIAGNOSIS; VARIANTS	Anaplastic lymphoma kinase (ALK) was originally identified from a rare subtype of non-Hodgkin's lymphomas carrying t(2;5)(p23;q35) translocation, where ALK was constitutively activated as a result of a fusion with nucleophosmin (NPM). Aberrant ALK fusion proteins were also generated in inflammatory fibrosarcoma and a subset of non-small-cell lung cancers, and these proteins are implicated in their pathogenesis. Recently, ALK has been demonstrated to be constitutively activated by gene mutations and/or amplifications in sporadic as well as familial cases of neuroblastoma. Here we describe another mechanism of aberrant ALK activation observed in a neuroblastoma-derived cell line (NB-1), in which a short-form ALK protein (ALK(del2-3)) having a truncated extracellular domain is overexpressed because of amplification of an abnormal ALK gene that lacks exons 2 and 3. ALK(del2-3) was autophosphorylated in NB-1 cells as well as in ALK(del2-3)-transduced cells and exhibited enhanced in vitro kinase activity compared with the wild-type kinase. ALK(del2-3)-transduced NIH3T3 cells exhibited increased colony-forming capacity in soft agar and tumorigenicity in nude mice. RNAi-mediated ALK knockdown resulted in the growth suppression of ALK(del2-3)-expressing cells, arguing for the oncogenic role of this mutant. Our findings provide a novel insight into the mechanism of deregulation of the ALK kinase and its roles in neuroblastoma pathogenesis.	[Takita, J.] Univ Tokyo, Grad Sch Med, Cell Therapy & Transplantat Med, Bunkyo Ku, Tokyo 1138655, Japan; [Okubo, J.; Takita, J.; Chen, Y.; Oki, K.; Nishimura, R.; Kato, M.; Hiwatari, M.; Igarashi, T.] Univ Tokyo, Grad Sch Med, Dept Pediat, Tokyo 1138655, Japan; [Sanada, M.; Ogawa, S.] Univ Tokyo, Grad Sch Med, Canc Genom Project, Tokyo 1138655, Japan; [Hayashi, Y.] Gunma Childrens Med Ctr, Maebashi, Gunma, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Gunma Children's Medical Centre	Takita, J (corresponding author), Univ Tokyo, Grad Sch Med, Cell Therapy & Transplantat Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	jtakita-tky@umin.ac.jp	Chen, Yuyan/V-7279-2019; HIWATARI, Mitsuteru/HDM-0869-2022; Nishimura, Riki/K-1672-2019; Ogawa, Seishi/AAE-7088-2019	Chen, Yuyan/0000-0002-2894-1430; Kato, Motohiro/0000-0001-5145-1774; Hiwatari, Mitsuteru/0000-0003-3683-4472	Research on Measures for Intractable Diseases, Health and Labor Sciences Research Grants; Ministry of Health, Labor and Welfare, Research on Health Sciences focusing on Drug Innovation; Japan Health Sciences Foundation; Core Research for Evolutional Science and Technology, Japan Science and Technology Agency; Grants-in-Aid for Scientific Research [22591171, 22659196] Funding Source: KAKEN	Research on Measures for Intractable Diseases, Health and Labor Sciences Research Grants(Ministry of Health, Labour and Welfare, Japan); Ministry of Health, Labor and Welfare, Research on Health Sciences focusing on Drug Innovation; Japan Health Sciences Foundation; Core Research for Evolutional Science and Technology, Japan Science and Technology Agency(Japan Science & Technology Agency (JST)Core Research for Evolutional Science and Technology (CREST)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Mrs Matsumura, Mrs Hoshino, Mrs Yin, Miss Ogino and Mrs Saito for their excellent technical assistance. We would also thank Dr Tanaka, Dr Saito, Mr Shiosaka and Mrs Mori for useful advice concerning biological analysis; Dr AT Look, Harvard Medical University, and Dr A Inoue, St Jude Children's Research Hospital, for their generous gifts of neuroblastoma cell lines. This work was supported by Research on Measures for Intractable Diseases, Health and Labor Sciences Research Grants, Ministry of Health, Labor and Welfare, Research on Health Sciences focusing on Drug Innovation, the Japan Health Sciences Foundation and Core Research for Evolutional Science and Technology, Japan Science and Technology Agency.	BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Choudhary C, 2009, MOL CELL, V36, P326, DOI 10.1016/j.molcel.2009.09.019; De Bernardi B, 2003, J CLIN ONCOL, V21, P1592, DOI 10.1200/JCO.2003.05.191; Donella-Deana A, 2005, BIOCHEMISTRY-US, V44, P8533, DOI 10.1021/bi0472954; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Gan HK, 2009, J CLIN NEUROSCI, V16, P748, DOI 10.1016/j.jocn.2008.12.005; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Griffin CA, 1999, CANCER RES, V59, P2776; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Jazii FR, 2006, WORLD J GASTROENTERO, V12, P7104, DOI 10.3748/wjg.v12.i44.7104; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Loren CE, 2003, EMBO REP, V4, P781, DOI 10.1038/sj.embor.embor897; Lu Y, 2007, CANCER LETT, V257, P157, DOI 10.1016/j.canlet.2007.08.007; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Mazot P, 2011, ONCOGENE, V30, P2017, DOI 10.1038/onc.2010.595; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Palmer RH, 2009, BIOCHEM J, V420, P345, DOI 10.1042/BJ20090387; Pearson ADJ, 2008, LANCET ONCOL, V9, P247, DOI 10.1016/S1470-2045(08)70069-X; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; RONSIN C, 1993, ONCOGENE, V8, P1195; Schulte JH, 2011, CLIN CANCER RES, V17, P5082, DOI 10.1158/1078-0432.CCR-10-2809; SHIOTA M, 1995, BLOOD, V86, P1954, DOI 10.1182/blood.V86.5.1954.bloodjournal8651954; Smith JL, 2011, AM J PHYSIOL-CELL PH, V301, pC75, DOI 10.1152/ajpcell.00494.2010; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Takita J, 1998, ONCOGENE, V17, P3137, DOI 10.1038/sj.onc.1202232; Takita J, 2001, ONCOGENE, V20, P4424, DOI 10.1038/sj.onc.1204521; Wang MH, 2000, CARCINOGENESIS, V21, P1507, DOI 10.1093/carcin/21.8.1507; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075	37	34	35	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	44					4667	4676		10.1038/onc.2011.616	http://dx.doi.org/10.1038/onc.2011.616			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032MW	22249260				2022-12-17	WOS:000310724400002
J	Khanal, P; Yun, HJ; Lim, SC; Ahn, SG; Yoon, HE; Kang, KW; Hong, R; Choi, HS				Khanal, P.; Yun, H. J.; Lim, S. C.; Ahn, S. G.; Yoon, H. E.; Kang, K. W.; Hong, R.; Choi, H. S.			Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells	ONCOGENE			English	Article						Pin1; CDK10; ubiquitination; Raf-1; tamoxifen resistance	ESTROGEN-RECEPTOR; GROWTH-FACTOR; INDEPENDENT GROWTH; THERAPEUTIC TARGET; ENDOCRINE THERAPY; ALPHA EXPRESSION; RAF-1 KINASE; PHOSPHORYLATION; PATHWAY; IDENTIFICATION	Endocrine therapies that inhibit estrogen receptor (ER)-alpha signaling are the most common and effective treatment for ER-a-positive breast cancer. However, the use of these agents is limited by the frequent development of resistance. The aim of this study was to elucidate the mechanisms by which downregulation of CDK10 expression confers resistance to tamoxifen in breast cancer. Here, we show that peptidyl-prolyl isomerase Pin1 downregulates CDK10 protein as a result of its interaction with and ubiquitination of CDK10, thereby affecting CDK10-dependent Raf-1 phosphorylation (S338). Pin1(-/-) mouse embryonic fibroblasts (MEFs) show higher CDK10 expression than Pin1(+/+) MEFs, whereas CDK10 protein was downregulated in the rescued Pin1(-/-) MEFs after reexpression of Pin1. Pin1 silencing in SKBR-3 and MCF7 cells increased the CDK10 expression. In human tamoxifen-resistant breast cancer and tamoxifen-resistant MCF7 cells, immunohistochemical staining and immunoblotting analysis shows an inverse correlation between the expression of CDK10 and the degree of tamoxifen resistance. There was also a positive correlation between the high level of P-Raf-1 (Ser338) and Pin1 in human tamoxifen-resistant breast cancer and tamoxifen-resistant MCF7 (TAMR-MCF7) cells. Importantly, 4-OH tamoxifen (4-OHT), when used in combination with overexpressed CDK10 or Raf-1 inhibitor, increased cleaved PARP and DNA fragmentation to inhibit cologenic growth of MCF7 cells and Tamoxifen-resistant MCF7 cells, respectively. On the basis of these findings, we suggest that the Pin1-mediated CDK10 ubiquitination is a major regulator of tamoxifen-resistant breast cancer cell growth and survival. Oncogene (2012) 31, 3845-3856; doi:10.1038/onc.2011.548; published online 12 December 2011	[Khanal, P.; Yun, H. J.; Kang, K. W.; Choi, H. S.] Chosun Univ, Coll Pharm, Project Team BK21, Kwangju 501759, South Korea; [Lim, S. C.; Hong, R.] Chosun Univ, Sch Med, Dept Pathol, Kwangju 501759, South Korea; [Ahn, S. G.; Yoon, H. E.] Chosun Univ, Sch Dent, Dept Pathol, Kwangju 501759, South Korea	Chosun University; Chosun University; Chosun University	Choi, HS (corresponding author), Chosun Univ, Coll Pharm, Project Team BK21, Kwangju 501759, South Korea.	chs@chosun.ac.kr			Basic Science Research Program through the National Research Foundation of Korea (NRF); Ministry of Education, Science, and Technology [2009-0073468, 2010-0009728]	Basic Science Research Program through the National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science, and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (2009-0073468 and 2010-0009728).	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; BRAMBILLA R, 1994, ONCOGENE, V9, P3037; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; ElAshry D, 1997, ONCOGENE, V15, P423, DOI 10.1038/sj.onc.1201198; Finn G, 2008, CURR CANCER DRUG TAR, V8, P223, DOI 10.2174/156800908784293622; Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1; Heller G, 2009, ANTICANCER RES, V29, P3939; Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001; Lee M, 2003, CANCER LETT, V193, P57, DOI 10.1016/S0304-3835(02)00722-X; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LI S, 1995, CANCER RES, V55, P3992; Lu KP, 2003, CANCER CELL, V4, P175, DOI 10.1016/S1535-6108(03)00218-6; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2002, TRENDS CELL BIOL, V12, P164, DOI 10.1016/S0962-8924(02)02253-5; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; McGlynn LM, 2009, CLIN CANCER RES, V15, P1487, DOI 10.1158/1078-0432.CCR-07-4967; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Namgoong GM, 2010, J BIOL CHEM, V285, P23829, DOI 10.1074/jbc.M109.092874; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Oh AS, 2001, MOL ENDOCRINOL, V15, P1344, DOI 10.1210/me.15.8.1344; Osborne CK, 2005, CLIN CANCER RES, V11, p865S; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219; Ryo A, 2003, J CELL SCI, V116, P773, DOI 10.1242/jcs.00276; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Stanya KJ, 2008, J CELL BIOL, V183, P49, DOI 10.1083/jcb.200806172; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132; Valabrega G, 2011, BREAST CANCER RES TR, V130, P29, DOI 10.1007/s10549-010-1281-5; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wulf G, 2005, NAT CELL BIOL, V7, P435, DOI 10.1038/ncb0505-435; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yi P, 2005, MOL CELL BIOL, V25, P9687, DOI 10.1128/MCB.25.21.9687-9699.2005; Yoshiji H, 2004, HEPATOLOGY, V39, P1517, DOI 10.1002/hep.20218; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	39	34	36	6	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	34					3845	3856		10.1038/onc.2011.548	http://dx.doi.org/10.1038/onc.2011.548			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IV	22158035	Bronze			2022-12-17	WOS:000307925000002
J	Dittmann, LM; Danner, A; Gronych, J; Wolter, M; Stuhler, K; Grzendowski, M; Becker, N; Bageritz, J; Goidts, V; Toedt, G; Felsberg, J; Sabel, MC; Barbus, S; Reifenberger, G; Lichter, P; Tews, B				Dittmann, L. M.; Danner, A.; Gronych, J.; Wolter, M.; Stuehler, K.; Grzendowski, M.; Becker, N.; Bageritz, J.; Goidts, V.; Toedt, G.; Felsberg, J.; Sabel, M. C.; Barbus, S.; Reifenberger, G.; Lichter, P.; Tews, B.			Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitro	ONCOGENE			English	Article						chemosensitivity; oligodendroglioma; peroxiredoxin 1; promoter methylation; radiosensitivity; temozolomide	GENE-EXPRESSION; PEROXIREDOXIN-II; OXIDATIVE STRESS; CANCER-CELLS; MGMT GENE; 1P; TEMOZOLOMIDE; GRADE; CHEMOTHERAPY; IDENTIFICATION	Deletions of chromosomal arms 1p and 19q are frequent in oligodendroglial tumours and linked to radio- and chemotherapy response as well as longer survival. The molecular mechanisms underlying this clinically important association are as yet unknown. Here, we studied the peroxiredoxin 1 (PRDX1) gene at 1p34.1 for promoter methylation and expression in primary gliomas and investigated its role in radio- and chemosensitivity of glioma cells in vitro. In total, we screened primary glioma tissues from 93 patients for methylation of the 50-CpG island of PRDX1 by sodium bisulfite sequencing. PRDX1 mRNA and protein expression levels were determined in subsets of the tumours by quantitative PCR and western blot analysis, respectively. PRDX1 hypermethylation and reduced expression were frequently detected in oligodendroglial tumours and secondary glioblastomas, but not in primary glioblastomas. In oligodendroglial tumours, both PRDX1 hypermethylation and reduced mRNA expression were significantly associated with 1p/19q-deletion. Stable knockdown of PRDX1 by lentiviral transduction of short-hairpin (sh) RNA constructs significantly increased apoptosis and reduced cell viability of Hs683 glioma cells exposed to ionizing irradiation or temozolomide in vitro. Taken together, our findings indicate that epigenetic silencing of PRDX1 is frequent in 1p/19q-deleted oligodendroglial tumours and likely contributes to radio- and chemosensitivity of these tumours. Oncogene (2012) 31, 3409-3418; doi:10.1038/onc.2011.513; published online 12 December 2011	[Dittmann, L. M.; Danner, A.; Gronych, J.; Becker, N.; Bageritz, J.; Goidts, V.; Toedt, G.; Barbus, S.; Lichter, P.] German Canc Res Ctr, Div Mol Genet, D-6900 Heidelberg, Germany; [Wolter, M.; Felsberg, J.; Reifenberger, G.] Univ Dusseldorf, Dept Neuropathol, D-40225 Dusseldorf, Germany; [Stuehler, K.; Grzendowski, M.] Ruhr Univ Bochum, Med Proteom Ctr, Bochum, Germany; [Stuehler, K.] Univ Dusseldorf, Biol Med Forschungszentrum, Mol Prote Lab, D-40225 Dusseldorf, Germany; [Sabel, M. C.] Univ Dusseldorf, Dept Neurosurg, D-40225 Dusseldorf, Germany; [Tews, B.] Univ Zurich, Brain Res Inst, Zurich, Switzerland	Helmholtz Association; German Cancer Research Center (DKFZ); Heinrich Heine University Dusseldorf; Ruhr University Bochum; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; University of Zurich	Lichter, P (corresponding author), German Canc Res Ctr, Div Mol Genet, Neuenheimer Feld 280, D-69120 Heidelberg, Baden Wuerttemb, Germany.	m.macleod@dkfz.de	Gronych, Jan/G-9954-2013; Reifenberger, Guido/AAE-3599-2019	Bageritz, Josephine/0000-0002-9531-0452	German Federal Ministry of Education and Research (BMBF) within the National Genome Research Network NGFN2 [01GS0460, 01GS0462]; NGFN<SUP>plus</SUP> [01GS0883, 01GS0884, 01GS08186]; Ministry for Innovation, Science, Research and Technology (MIWFT) of Nordrhein Westfalen; Helmholtz international graduate school for cancer research	German Federal Ministry of Education and Research (BMBF) within the National Genome Research Network NGFN2(Federal Ministry of Education & Research (BMBF)); NGFN<SUP>plus</SUP>; Ministry for Innovation, Science, Research and Technology (MIWFT) of Nordrhein Westfalen; Helmholtz international graduate school for cancer research	The study was supported by the German Federal Ministry of Education and Research (BMBF) within the National Genome Research Network NGFN2 (01GS0460 to PL, 01GS0462 to GR), NGFN<SUP>plus</SUP> (01GS0883 to PL, 01GS0884 to GR and MW, 01GS08186 to KS) and the Ministry for Innovation, Science, Research and Technology (MIWFT) of Nordrhein Westfalen (MG). JG and JB were supported by scholarships from the Helmholtz international graduate school for cancer research.	Bae JY, 2007, J CELL BIOCHEM, V101, P1038, DOI 10.1002/jcb.21241; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Belot N, 2001, GLIA, V36, P375, DOI 10.1002/glia.1124; Bettegowda C, 2011, SCIENCE, V333, P1453, DOI 10.1126/science.1210557; Brada M, 2003, ANN ONCOL, V14, P1715, DOI 10.1093/annonc/mdg371; Branle F, 2002, CANCER-AM CANCER SOC, V95, P641, DOI 10.1002/cncr.10710; Cairncross G, 2006, J CLIN ONCOL, V24, P2707, DOI 10.1200/JCO.2005.04.3414; Camby I, 2000, BRAIN PATHOL, V10, P569; Cao JX, 2009, EMBO J, V28, P1505, DOI 10.1038/emboj.2009.101; Felsberg J, 2004, BRAIN PATHOL, V14, P121, DOI 10.1111/j.1750-3639.2004.tb00044.x; Felsberg J, 2010, ACTA NEUROPATHOL, V119, P501, DOI 10.1007/s00401-010-0647-4; Griffin CA, 2006, J NEUROPATH EXP NEUR, V65, P988, DOI 10.1097/01.jnen.0000235122.98052.8f; Grzenclowski M, 2010, NEURO-ONCOLOGY, V12, P243, DOI 10.1093/neuonc/nop025; Grzendowski M, 2009, PROTEOMICS, V9, P4985, DOI 10.1002/pmic.200800902; Hattori Fumiyuki, 2007, V44, P357; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hermisson M, 2006, J NEUROCHEM, V96, P766, DOI 10.1111/j.1471-4159.2005.03583.x; Hubstenberger A, 2008, EXP CELL RES, V314, P2870, DOI 10.1016/j.yexcr.2008.06.017; Immenschuh S, 2005, ANTIOXID REDOX SIGN, V7, P768, DOI 10.1089/ars.2005.7.768; Jenkins RB, 2006, CANCER RES, V66, P9852, DOI 10.1158/0008-5472.CAN-06-1796; Kim YJ, 2006, CANCER RES, V66, P7136, DOI 10.1158/0008-5472.CAN-05-4446; Korshunov A, 2003, AM J PATHOL, V163, P1721, DOI 10.1016/S0002-9440(10)63530-4; Kouwenhoven MCM, 2006, EUR J CANCER, V42, P2499, DOI 10.1016/j.ejca.2006.05.021; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Mates JM, 2008, ARCH TOXICOL, V82, P273, DOI 10.1007/s00204-008-0304-z; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Mollemann M, 2005, INT J CANCER, V113, P379, DOI 10.1002/ijc.20575; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Ohgaki H, 2009, CANCER SCI, V100, P2235, DOI 10.1111/j.1349-7006.2009.01308.x; Reifenberger G, 2003, J NEUROPATH EXP NEUR, V62, P111, DOI 10.1093/jnen/62.2.111; Riemenschneider MJ, 2009, CURR OPIN NEUROL, V22, P619, DOI 10.1097/WCO.0b013e32833245b0; Tews B, 2007, ONCOGENE, V26, P5010, DOI 10.1038/sj.onc.1210297; Tews B, 2006, INT J CANCER, V119, P792, DOI 10.1002/ijc.21901; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; van den Bent MJ, 2006, ANN ONCOL, V17, pX186, DOI 10.1093/annonc/mdl258; van den Bent MJ, 2005, LANCET, V366, P985, DOI 10.1016/S0140-6736(05)67070-5; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; Wang TL, 2005, CANCER RES, V65, P10338, DOI 10.1158/0008-5472.CAN-04-4614; Weller M, 2010, NAT REV NEUROL, V6, P39, DOI 10.1038/nrneurol.2009.197; Wick W, 2009, J CLIN ONCOL, V27, P5874, DOI 10.1200/JCO.2009.23.6497; Zhang B, 2008, BIOCHEM PHARMACOL, V75, P660, DOI 10.1016/j.bcp.2007.09.016	42	34	35	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	29					3409	3418		10.1038/onc.2011.513	http://dx.doi.org/10.1038/onc.2011.513			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	976FN	22158042				2022-12-17	WOS:000306566400002
J	Beekman, JM; Vervoort, SJ; Dekkers, F; van Vessem, ME; Vendelbosch, S; Brugulat-Panes, A; van Loosdregt, J; Braat, AK; Coffer, PJ				Beekman, J. M.; Vervoort, S. J.; Dekkers, F.; van Vessem, M. E.; Vendelbosch, S.; Brugulat-Panes, A.; van Loosdregt, J.; Braat, A. K.; Coffer, P. J.			Syntenin-mediated regulation of Sox4 proteasomal degradation modulates transcriptional output	ONCOGENE			English	Article						Sox4; syntenin; proteasomal degradation; metastasis	PROTEIN-DEGRADATION; CANCER METASTASIS; ADAPTER PROTEIN; KAPPA-B; CELLS; GENE; MDA-9/SYNTENIN; UBIQUITIN; MICE; DIFFERENTIATION	The transcription factor Sox4 is aberrantly expressed in many human tumors and can modulate tumorigenesis and metastases of murine tumors in vivo. However, mechanisms that control Sox4 function remain poorly defined. It has recently been observed that DNA damage increases Sox4 protein expression independently of Sox4 mRNA levels, suggesting an as yet undefined post-transcriptional mechanism regulating Sox4 expression and functionality. Here, we show that Sox4 protein is rapidly degraded by the proteasome as indicated by pharmacological inhibition with Mg132 and epoxymycin. Sox4 half-life was found to be less than 1 h as evident by inhibition of protein synthesis using cycloheximide. Ectopic expression of Sox4 deletion mutants revealed that the C-terminal 33 residues of Sox4 were critical in modulating its degradation in a polyubiquitin-independent manner. Syntenin, a Sox4 binding partner, associates with this domain and was found to stabilize Sox4 expression. Syntenin-induced stabilization of Sox4 correlated with Sox4-syntenin relocalization to the nucleus, where both proteins accumulate. Syntenin overexpression or knockdown in human tumor cell lines was found to reciprocally modulate Sox4 protein expression and transcriptional activity implicating its role as a regulator of Sox4. Taken together, our data demonstrate that the Sox4 C-terminal domain regulates polyubiquitin-independent proteasomal degradation of Sox4 that can be modulated by interaction with syntenin. As aberrant Sox4 expression has been found associated with many human cancers, modulation of Sox4 proteasomal degradation may impact oncogenesis and metastatic properties of tumors. Oncogene (2012) 31, 2668-2679; doi:10.1038/onc.2011.445; published online 10 October 2011	[Beekman, J. M.; van Vessem, M. E.; Vendelbosch, S.; Brugulat-Panes, A.; van Loosdregt, J.; Braat, A. K.; Coffer, P. J.] Univ Med Ctr Utrecht, Dept Immunol, NL-3584 EA Utrecht, Netherlands; [Beekman, J. M.; Vervoort, S. J.; Dekkers, F.; Coffer, P. J.] Univ Med Ctr Utrecht, Ctr Mol & Cellular Intervent, Wilhelmina Childrens Hosp, NL-3584 EA Utrecht, Netherlands; [Vervoort, S. J.; Coffer, P. J.] Univ Med Ctr Utrecht, Dept Cell Biol, NL-3584 EA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Utrecht University; Utrecht University Medical Center	Coffer, PJ (corresponding author), Univ Med Ctr Utrecht, Dept Immunol, KC 02-085-2,Lundlaan 6, NL-3584 EA Utrecht, Netherlands.	p.j.coffer@umcutrecht.nl	Coffer, Paul/AAF-7970-2020; Beekman, Jeffrey M/I-7781-2014; Vervoort, Stephin/AAP-7854-2020	Beekman, Jeffrey M/0000-0003-4886-3756; van Loosdregt, Jorg/0000-0003-1411-3754; Vervoort, Stephin/0000-0001-7459-126X; Brugulat Panes, Anna/0000-0003-4102-1417				Asher G, 2006, ISR MED ASSOC J, V8, P229; Asher G, 2006, BIOESSAYS, V28, P844, DOI 10.1002/bies.20447; Basbous J, 2008, BIOCHIMIE, V90, P296, DOI 10.1016/j.biochi.2007.07.016; Beekman JM, 2008, J CELL SCI, V121, P1349, DOI 10.1242/jcs.026401; Beekman JM, 2009, BLOOD, V114, P3917, DOI 10.1182/blood-2009-03-208850; Beekman JM, 2004, P NATL ACAD SCI USA, V101, P10392, DOI 10.1073/pnas.0401217101; Belizario JE, 2008, CURR PROTEIN PEPT SC, V9, P210, DOI 10.2174/138920308784534023; Bergsland M, 2006, GENE DEV, V20, P3475, DOI 10.1101/gad.403406; Bhattaram P, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1008; Boukerche H, 2010, ONCOGENE, V29, P3054, DOI 10.1038/onc.2010.65; Boukerche H, 2008, P NATL ACAD SCI USA, V105, P15914, DOI 10.1073/pnas.0808171105; Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883; Dy P, 2008, NUCLEIC ACIDS RES, V36, P3101, DOI 10.1093/nar/gkn162; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Fietta P, 2010, RIV BIOL-BIOL FORUM, V103, P29; Geijsen N, 2001, SCIENCE, V293, P1136, DOI 10.1126/science.1059157; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Hoser M, 2008, MOL CELL BIOL, V28, P4675, DOI 10.1128/MCB.00338-08; Hunt SMN, 1999, BIOL REPROD, V61, P476, DOI 10.1095/biolreprod61.2.476; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Kruger E, 2001, BIOCHIMIE, V83, P289, DOI 10.1016/S0300-9084(01)01241-X; Kwak J., 2010, BIOCHIM BIOPHYS ACTA, V1809, P88; Lambaerts K, 2009, CURR OPIN CELL BIOL, V21, P662, DOI 10.1016/j.ceb.2009.05.002; Lin JJ, 1998, GENE, V207, P105, DOI 10.1016/S0378-1119(97)00562-3; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Malki S, 2010, INT J BIOCHEM CELL B, V42, P411, DOI 10.1016/j.biocel.2009.09.020; Medina PP, 2009, HUM MOL GENET, V18, P1343, DOI 10.1093/hmg/ddp034; Nissen-Meyer LSH, 2007, J CELL SCI, V120, P2785, DOI 10.1242/jcs.003855; Pan X, 2009, P NATL ACAD SCI USA, V106, P3788, DOI 10.1073/pnas.0810147106; Penzo-Mendez AI, 2010, INT J BIOCHEM CELL B, V42, P425, DOI 10.1016/j.biocel.2009.07.018; Potzner MR, 2010, DEVELOPMENT, V137, P775, DOI 10.1242/dev.042101; Prakash S, 2004, NAT STRUCT MOL BIOL, V11, P830, DOI 10.1038/nsmb814; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Sarkar D, 2004, PHARMACOL THERAPEUT, V104, P101, DOI 10.1016/j.pharmthera.2004.08.004; Sarkar D, 2008, CANCER RES, V68, P3087, DOI 10.1158/0008-5472.CAN-07-6210; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; Schilham MW, 1997, EUR J IMMUNOL, V27, P1292, DOI 10.1002/eji.1830270534; Shin MS, 2004, CANCER RES, V64, P4419, DOI 10.1158/0008-5472.CAN-03-3885; Sinner D, 2007, MOL CELL BIOL, V27, P7802, DOI 10.1128/MCB.02179-06; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; van Loosdregt J, 2010, BLOOD, V115, P965, DOI 10.1182/blood-2009-02-207118; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; Wilson ME, 2005, DIABETES, V54, P3402, DOI 10.2337/diabetes.54.12.3402; Ziegler EC, 2005, SCI STKE, V2005, P1	50	34	36	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	21					2668	2679		10.1038/onc.2011.445	http://dx.doi.org/10.1038/onc.2011.445			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	948SS	21986941				2022-12-17	WOS:000304523500006
J	Thu, YM; Su, Y; Yang, J; Splittgerber, R; Na, S; Boyd, A; Mosse, C; Simons, C; Richmond, A				Thu, Y. M.; Su, Y.; Yang, J.; Splittgerber, R.; Na, S.; Boyd, A.; Mosse, C.; Simons, C.; Richmond, A.			NF-kappa B inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the beta-catenin pathway	ONCOGENE			English	Article						NIK; beta-catenin; melanoma; tumorigenesis; survival factors	INDUCED APOPTOSIS; TUMOR-GROWTH; C-MYC; ALPHA; TNF; ACTIVATION; CELLS; THERAPY; TARGET; INHIBITION	Nuclear factor-kappa B (NF-kappa B) inducing kinase (NIK) is a MAP3K that regulates the activation of NF-kappa B. NIK is often highly expressed in tumor cells, including melanoma, but the significance of this in melanoma progression has been unclear. Tissue microarray analysis of NIK expression reveals that dysplastic nevi (n = 22), primary (n = 15) and metastatic melanoma (n = 13) lesions showed a statistically significant elevation in NIK expression when compared with benign nevi (n = 30). Moreover, when short hairpin RNA techniques were used to knock-down NIK, the resultant NIK-depleted melanoma cell lines exhibited decreased proliferation, increased apoptosis, delayed cell cycle progression and reduced tumor growth in a mouse xenograft model. As expected, when NIK was depleted there was decreased activation of the non-canonical NF-kappa B pathway, whereas canonical NF-kappa B activation remained intact. NIK depletion also resulted in reduced expression of genes that contribute to tumor growth, including CXCR4, c-MYC and c-MET, and pro-survival factors such as BCL2 and survivin. These changes in gene expression are not fully explained by the attenuation of the non-canonical NF-kappa B pathway. Shown here for the first time is the demonstration that NIK modulates beta-catenin-mediated transcription to promote expression of survivin. NIK-depleted melanoma cells exhibited downregulation of survivin as well as other beta-catenin regulated genes including c-MYC, c-MET and CCND2. These data indicate that NIK mediates both beta-catenin and NF-kappa B regulated transcription to modulate melanoma survival and growth. Thus, NIK may be a promising therapeutic target for melanoma. Oncogene (2012) 31, 2580-2592; doi:10.1038/onc.2011.427; published online 3 October 2011	[Thu, Y. M.; Su, Y.; Yang, J.; Splittgerber, R.; Richmond, A.] Vanderbilt Univ, Dept Canc Biol, Sch Med, Nashville, TN 37232 USA; [Na, S.] Eli Lilly & Co, Oncol Res, Indianapolis, IN 46285 USA; [Boyd, A.] Vanderbilt Univ, Sch Med, Div Dermatol, Nashville, TN 37232 USA; [Mosse, C.; Simons, C.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Richmond, A.] Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; Eli Lilly; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Richmond, A (corresponding author), Vanderbilt Univ, Dept Canc Biol, Sch Med, 771 PRB,2220 Pierce Ave, Nashville, TN 37232 USA.	ann.richmond@vanderbilt.edu	Richmond, Ann/A-3048-2014	RICHMOND, ANN/0000-0002-9580-900X	NIH [CA 098807-01]; Department of Veterans Affairs; NATIONAL CANCER INSTITUTE [R01CA098807, R01CA116021, P30CA068485] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Dr Robert Schreiber (Washington University) for generously sharing Nik<SUP>-/-</SUP> MEFs, and Vanderbilt Functional Genomic Shared Resource Core, VA Flow Cytometry Core and Vanderbilt Immunohistochemistry Core for technical help. We thank Dr Joseph T Roland (Epithelial Biology Center) for assistance with the ariol scanning and quantitation of TMAs. We thank Dr Mark Kelly and Vanderbilt melanoma group for providing melanoma tissues and Dr Sara Kantrow for reviewing some of the TMA slides. We thank Dr Fiona Yull and Dr Punita Dhawan for thoughtful discussion and Vanderbilt Editor Club for careful reading of the manuscript. Grant Support: This work is supported by NIH, CA 098807-01 and the Department of Veterans Affairs, Career Scientist Award and Merit Award (to AR).	Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BALENTIEN E, 1991, ONCOGENE, V6, P1115; Boon EMJ, 2002, CANCER RES, V62, P5126; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chariot A, 2009, TRENDS CELL BIOL, V19, P404, DOI 10.1016/j.tcb.2009.05.006; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; Cole AM, 2010, CANCER RES, V70, P8149, DOI 10.1158/0008-5472.CAN-10-0315; Conze DB, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000518; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delmas V, 2007, GENE DEV, V21, P2923, DOI 10.1101/gad.450107; Demchenko YN, 2010, BLOOD, V115, P3541, DOI 10.1182/blood-2009-09-243535; Devalaraja MN, 1999, CANCER RES, V59, P1372; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Dhomen N, 2009, HEMATOL ONCOL CLIN N, V23, P529, DOI 10.1016/j.hoc.2009.04.001; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hilmi C, 2008, J INVEST DERMATOL, V128, P1499, DOI 10.1038/sj.jid.5701185; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Lai AZ, 2009, TRENDS CELL BIOL, V19, P542, DOI 10.1016/j.tcb.2009.07.002; Lecis D, 2010, BRIT J CANCER, V102, P1707, DOI 10.1038/sj.bjc.6605687; Lev DC, 2003, MOL CANCER THER, V2, P753; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Malbon Craig C, 2005, Sci STKE, V2005, ppe35, DOI 10.1126/stke.2922005pe35; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; McGary EC, 2002, CANCER BIOL THER, V1, P459, DOI 10.4161/cbt.1.5.158; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Moore SR, 2008, CLIN CANCER RES, V14, P2927, DOI 10.1158/1078-0432.CCR-07-4068; Neely RJ, 2011, ONCOGENE, V30, P87, DOI 10.1038/onc.2010.396; Ng KCP, 2004, J INVEST DERMATOL, V123, P1127, DOI 10.1111/j.0022-202X.2004.23467.x; Pastorino F, 2003, CLIN CANCER RES, V9, P4595; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Plenchette S, 2007, CURR OPIN INVEST DR, V8, P469; Puri N, 2007, CLIN CANCER RES, V13, P2246, DOI 10.1158/1078-0432.CCR-06-0776; Puzanov I, 2010, SEMIN CUTAN MED SURG, V29, P196, DOI 10.1016/j.sder.2010.06.005; Rosebeck S, 2011, SCIENCE, V331, P468, DOI 10.1126/science.1198946; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Ruggero D, 2009, CANCER RES, V69, P8839, DOI 10.1158/0008-5472.CAN-09-1970; Saitoh Y, 2008, BLOOD, V111, P5118, DOI 10.1182/blood-2007-09-110635; Saitoh Y, 2010, LUNG CANCER, V70, P263, DOI 10.1016/j.lungcan.2010.03.001; Scala S, 2006, CLIN CANCER RES, V12, P2427, DOI 10.1158/1078-0432.CCR-05-1940; Scala S, 2005, CLIN CANCER RES, V11, P1835, DOI 10.1158/1078-0432.CCR-04-1887; Sinnberg T, 2010, CANCER RES, V70, P6999, DOI 10.1158/0008-5472.CAN-10-0645; Smith C, 2001, J IMMUNOL, V167, P5895, DOI 10.4049/jimmunol.167.10.5895; Sullivan RJ, 2009, EXPERT REV ANTICANC, V9, P567, DOI [10.1586/era.09.20, 10.1586/ERA.09.20]; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang DZ, 2000, ONCOGENE, V19, P4647, DOI 10.1038/sj.onc.1203820; Yang JM, 2007, CANCER RES, V67, P3127, DOI 10.1158/0008-5472.CAN-06-3547; Yang JM, 2010, J CLIN INVEST, V120, P2563, DOI 10.1172/JCI42358; Yang JM, 2006, CLIN CANCER RES, V12, P950, DOI 10.1158/1078-0432.CCR-05-1220; Yang JM, 2001, CANCER RES, V61, P4901; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Zhang T, 2001, CANCER RES, V61, P8664	61	34	39	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	20					2580	2592		10.1038/onc.2011.427	http://dx.doi.org/10.1038/onc.2011.427			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	944ID	21963849	Green Accepted			2022-12-17	WOS:000304191800008
J	Dawson, JC; Timpson, P; Kalna, G; Machesky, LM				Dawson, J. C.; Timpson, P.; Kalna, G.; Machesky, L. M.			Mtss1 regulates epidermal growth factor signaling in head and neck squamous carcinoma cells	ONCOGENE			English	Article						Mtss1; HNSCC; epidermal growth factor receptor	HEDGEHOG-RESPONSIVE GENE; MISSING-IN-METASTASIS; SUPPRESSOR 1 MTSS1; FACTOR RECEPTOR; CANCER-CELLS; COPY NUMBER; DIFFERENTIAL REGULATION; ADHERENS JUNCTIONS; SURFACE DYNAMICS; DOWN-REGULATION	Mtss1 is located within chromosomal region 8q23-24, which is one of the three most commonly amplified regions in head and neck squamous cell carcinoma (HNSCC). Mtss1 is lost in metastatic cells, but confusingly is commonly overexpressed in primary tumors. Here we address possible reasons why Mtss1 is positively selected for in primary tumors. We find that Mtss1 enhances the localization of the epidermal growth factor (EGF) receptor to the plasma membrane, prolonging EGF signaling and resulting in enhanced proliferation in HNSCC. Depletion of Mtss1 results in decreased EGF receptor levels and decreased phosphorylation of Erk1/2 and Akt. However, when cells are at high density and adherent to each other, analogous to conditions in a solid tumor, Mtss1 does not confer any growth advantage, either in basal conditions or following EGF stimulation. This could indicate why Mtss1 might be lost in metastases, but preserved in early primary tumors. This is supported by an organotypic assay showing that Mtss1-expressing cells display a less proliferative more epithelial-like morphology on top of a collagen matrix. Furthermore, xenograft tumors expressing Mtss1 initially grow more rapidly, but later show less proliferation and more differentiation. Mtss1 positively modulates EGF signaling at low cell densities to promote proliferation and, therefore, may be beneficial for the early stages of primary HNSCC tumor growth. However, at high cell densities, Mtss1 impacts negatively on EGF signaling and this suggests why it inhibits metastasis. Oncogene (2012) 31, 1781-1793; doi: 10.1038/onc.2011.376; published online 19 September 2011	[Dawson, J. C.; Timpson, P.; Kalna, G.; Machesky, L. M.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Dawson, JC (corresponding author), Beatson Inst Canc Res, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	j.dawson@beatson.gla.ac.uk; l.machesky@beatson.gla.ac.uk	Timpson, Paul/A-9429-2016; Dawson, John/HDM-6702-2022; Machesky, Laura/Z-4554-2019	Machesky, Laura/0000-0002-7592-9856; Dawson, John/0000-0001-5713-1026; Timpson, Paul/0000-0002-5514-7080	AICR [07-0438]; MRC [G117/569]; CRUK; Cancer Research UK [15673] Funding Source: researchfish; Medical Research Council [G117/569] Funding Source: researchfish	AICR; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CRUK(Cancer Research UK); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	JD was funded by an AICR Grant to LMM (07-0438). LMM received funding from an MRC Senior Research fellowship (G117/569) and a CRUK core grant. We thank Roger Daly for HNSCC cell lines and Heather Spence for technical help.	Basu D, 2010, ONCOGENE, V29, P4170, DOI 10.1038/onc.2010.170; Bershteyn M, 2010, DEV CELL, V19, P270, DOI 10.1016/j.devcel.2010.07.009; Betson M, 2002, J BIOL CHEM, V277, P36962, DOI 10.1074/jbc.M207358200; Boissan M, 2010, CANCER RES, V70, P7710, DOI 10.1158/0008-5472.CAN-10-1887; Bompard G, 2005, J CELL SCI, V118, P5393, DOI 10.1242/jcs.02640; Bremm A, 2008, CANCER RES, V68, P707, DOI 10.1158/0008-5472.CAN-07-1588; Callahan CA, 2004, GENE DEV, V18, P2724, DOI 10.1101/gad.1221804; Canel M, 2006, CLIN CANCER RES, V12, P3272, DOI 10.1158/1078-0432.CCR-05-1583; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Chung CH, 2006, J CLIN ONCOL, V24, P4170, DOI 10.1200/JCO.2006.07.2587; Cooper JB, 2009, HEAD NECK-J SCI SPEC, V31, P1086, DOI 10.1002/hed.21109; Danglot L, 2010, J CELL SCI, V123, P723, DOI 10.1242/jcs.062497; Donev IS, 2011, CLIN CANCER RES, V17, P2260, DOI 10.1158/1078-0432.CCR-10-1993; Edward M, 2005, CARCINOGENESIS, V26, P1215, DOI 10.1093/carcin/bgi064; Gan Y, 2010, ONCOGENE, V29, P4947, DOI 10.1038/onc.2010.240; Goh LK, 2010, J CELL BIOL, V189, P871, DOI 10.1083/jcb.201001008; Gonzalez-Quevedo R, 2005, J CELL BIOL, V168, P453, DOI 10.1083/jcb.200409078; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Kelley LC, 2008, CLIN EXP METASTAS, V25, P289, DOI 10.1007/s10585-008-9154-6; Lee SH, 2007, STRUCTURE, V15, P145, DOI 10.1016/j.str.2006.12.005; Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231; Lin JX, 2005, ONCOGENE, V24, P2059, DOI 10.1038/sj.onc.1208412; Lin M, 2006, ONCOGENE, V25, P1424, DOI 10.1038/sj.onc.1209166; Liu K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-428; Loberg RD, 2005, INT J ONCOL, V26, P1699; Ma S, 2007, HUM PATHOL, V38, P1201, DOI 10.1016/j.humpath.2007.01.004; Machesky LM, 2007, J MOL MED-JMM, V85, P569, DOI 10.1007/s00109-007-0207-0; Mattila PK, 2007, J CELL BIOL, V176, P953, DOI 10.1083/jcb.200609176; Mattila PK, 2003, J BIOL CHEM, V278, P8452, DOI 10.1074/jbc.M212113200; Miranti CK, 2009, CELL SIGNAL, V21, P196, DOI 10.1016/j.cellsig.2008.08.023; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Parr C, 2009, EUR J CANCER, V45, P1673, DOI 10.1016/j.ejca.2009.02.019; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Quinones GA, 2010, J CELL BIOL, V189, P353, DOI 10.1083/jcb.200910136; Sigismund S, 2008, DEV CELL, V15, P209, DOI 10.1016/j.devcel.2008.06.012; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Thurlow JK, 2010, J CLIN ONCOL, V28, P2881, DOI 10.1200/JCO.2009.24.8724; Timpson P, 2005, CANCER RES, V65, P3273, DOI 10.1158/0008-5472.CAN-04-2118; Timpson P, 2007, CANCER RES, V67, P9304, DOI 10.1158/0008-5472.CAN-07-0798; Uhlenbrock K, 2004, J CELL SCI, V117, P4863, DOI 10.1242/jcs.01367; Woodcock SA, 2009, MOL CELL, V33, P639, DOI 10.1016/j.molcel.2009.02.012; Woodings JA, 2003, BIOCHEM J, V371, P463, DOI 10.1042/BJ20021962; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691	44	34	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	14					1781	1793		10.1038/onc.2011.376	http://dx.doi.org/10.1038/onc.2011.376			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21927027	Green Accepted			2022-12-17	WOS:000302785200004
J	Jones, TS; Holland, EC				Jones, T. S.; Holland, E. C.			Standard of care therapy for malignant glioma and its effect on tumor and stromal cells	ONCOGENE			English	Review						glioblastoma; temozolomide; radiation; tumor stroma; dexamethasone	GROWTH-FACTOR-RECEPTOR; REGULATORY T-CELLS; STEM-LIKE CELLS; NOTCH SIGNALING PATHWAY; BLOOD-VESSEL FORMATION; HUMAN-BRAIN-TUMORS; CHEMOKINE RECEPTOR; HUMAN GLIOBLASTOMA; NITRIC-OXIDE; TGF-BETA	Glioblastoma is the most common and deadly of the primary central nervous system tumors. Recent advances in molecular characterization have subdivided these tumors into at least three main groups. In addition, these tumors are cellularly complex with multiple stromal cell types contributing to the biology of the tumor and treatment response. Because essentially all glioma patients are treated with radiation, various chemotherapies and steroids, the tumor that finally kills them has been modified by these treatments. Most of the investigation of the effects of therapy on these tumors has focused on the glioma cells per se. However, despite the importance of the stromal cells in these tumors, little has been done to understand the effects of treatment on stromal cells and their contribution to disease. Understanding how current standard therapy affects the biology of the tumor and the tumor stroma may provide insight into the mechanisms that are important to the inhibition of tumor growth as well as the biology of recurrent tumors. Oncogene (2012) 31, 1995-2006; doi: 10.1038/onc.2011.398; published online 12 September 2011	[Jones, T. S.] Univ Tennessee, Hlth Sci Ctr, Dept Clin Pharm, Memphis, TN 38103 USA; [Jones, T. S.] Univ Tennessee, Hlth Sci Ctr, Dept Neurosurg, Memphis, TN 38103 USA; [Jones, T. S.] Univ Tennessee, Hlth Sci Ctr, Ctr Canc Res, Memphis, TN 38103 USA; [Holland, E. C.] Mem Sloan Kettering Canc Ctr, Dept Neurosurg, New York, NY 10065 USA; [Holland, E. C.] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10065 USA; [Holland, E. C.] Mem Sloan Kettering Canc Ctr, Brain Tumor Ctr, New York, NY 10065 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Jones, TS (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Clin Pharm, 19 S Manassas, Memphis, TN 38103 USA.	tjones@uthsc.edu; hollande@mskcc.org			NIH [RO1 CA100688, U54 CA126518-01, U01 CA141502-01, U54 CA143798]; NATIONAL CANCER INSTITUTE [U54CA126518, U01CA141502, U54CA143798, R01CA100688] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the NIH grants RO1 CA100688, U54 CA126518-01, U01 CA141502-01 and U54 CA143798.	ALTERMAN RL, 1994, MOL CHEM NEUROPATHOL, V21, P177, DOI 10.1007/BF02815350; Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023; [Anonymous], 2011, CBTRUS STAT REP PRIM; Arko L, 2010, PHARMACOL THERAPEUT, V128, P1, DOI 10.1016/j.pharmthera.2010.04.015; Bajetto A, 1999, J NEUROCHEM, V73, P2348, DOI 10.1046/j.1471-4159.1999.0732348.x; Bajetto A, 1999, ANN NY ACAD SCI, V876, P201, DOI 10.1111/j.1749-6632.1999.tb07640.x; Banissi C, 2009, CANCER IMMUNOL IMMUN, V58, P1627, DOI 10.1007/s00262-009-0671-1; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Barbero S, 2002, ANN NY ACAD SCI, V973, P60, DOI 10.1111/j.1749-6632.2002.tb04607.x; Baron M, 2003, SEMIN CELL DEV BIOL, V14, P113, DOI 10.1016/S1084-9521(02)00179-9; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Betsholtz C, 2004, CYTOKINE GROWTH F R, V15, P215, DOI 10.1016/j.cytogfr.2004.03.005; Bettinger I, 2002, ACTA NEUROPATHOL, V103, P351, DOI 10.1007/s00401-001-0472-x; Bhattacharya S, 2007, J CELL SCI, V120, P2652, DOI 10.1242/jcs.008417; Bjarnegard M, 2004, DEVELOPMENT, V131, P1847, DOI 10.1242/dev.01080; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Brennan C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007752; CAIRNCROSS JG, 1988, NEUROLOGY, V38, P724, DOI 10.1212/WNL.38.5.724; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Cavaliere R, 2005, LANCET NEUROL, V4, P760, DOI 10.1016/S1474-4422(05)70222-2; Chang JY, 2000, NEUROCHEM RES, V25, P903, DOI 10.1023/A:1007511221666; Charles N, 2009, EXPERT REV NEUROTHER, V9, P1447, DOI 10.1586/ERN.09.91; Charles N, 2010, CELL STEM CELL, V6, P141, DOI 10.1016/j.stem.2010.01.001; Charles NA, 2011, GLIA, V59, P1169, DOI 10.1002/glia.21136; CHIANG CS, 1991, BRAIN RES, V566, P265, DOI 10.1016/0006-8993(91)91707-8; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cleaver O, 2003, NAT MED, V9, P661, DOI 10.1038/nm0603-661; Daginakatte GC, 2007, HUM MOL GENET, V16, P1098, DOI 10.1093/hmg/ddm059; Diaz-Flores L, 2009, HISTOL HISTOPATHOL, V24, P909, DOI 10.14670/HH-24.909; Dix AR, 1999, J NEUROIMMUNOL, V100, P216, DOI 10.1016/S0165-5728(99)00203-9; Ehrenkranz JRL, 1980, ADRENOCORTICOSTEROID; EISENBERG HM, 1970, ARCH NEUROL-CHICAGO, V23, P18, DOI 10.1001/archneur.1970.00480250022004; El Andaloussi A, 2006, J NEUROSURG, V105, P430, DOI 10.3171/jns.2006.105.3.430; Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Frederick L, 2000, CANCER RES, V60, P1383; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; GALICICH JH, 1961, AM PRACT DIG TREAT, V12, P169; Gallagher PG, 2005, CANCER RES, V65, P4134, DOI 10.1158/0008-5472.CAN-04-0415; GANTER S, 1992, J NEUROSCI RES, V33, P218, DOI 10.1002/jnr.490330205; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; Goldstein LJ, 2005, SURGERY, V138, P439, DOI 10.1016/j.surg.2005.06.031; Gong X, 2011, NEUROLOGY, V76, P1126, DOI 10.1212/WNL.0b013e318212a89f; Graeber MB, 2002, GLIA, V40, P252, DOI 10.1002/glia.10147; Grauer OM, 2007, INT J CANCER, V121, P95, DOI 10.1002/ijc.22607; GREEN SB, 1983, CANCER TREAT REP, V67, P121; Gutin P H, 1975, Semin Oncol, V2, P49; Hambardzumyan D, 2008, GENE DEV, V22, P436, DOI 10.1101/gad.1627008; Hambardzumyan D, 2011, GLIA, V59, P1155, DOI 10.1002/glia.21142; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hellstrom NAK, 2011, MOL CELL NEUROSCI, V46, P710, DOI 10.1016/j.mcn.2011.02.001; Hoelzinger DB, 2007, J NATL CANCER I, V99, P1583, DOI 10.1093/jnci/djm187; Hong X, 2006, CANCER LETT, V236, P39, DOI 10.1016/j.canlet.2005.05.011; Huse JT, 2011, GLIA, V59, P1190, DOI 10.1002/glia.21165; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714; Hwang SY, 2006, NEUROBIOL DIS, V21, P457, DOI 10.1016/j.nbd.2005.08.006; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jones TS, 2011, TOXICOL PATHOL, V39, P158, DOI 10.1177/0192623310387617; Jordan JT, 2008, CANCER IMMUNOL IMMUN, V57, P123, DOI 10.1007/s00262-007-0336-x; Kalm M, 2009, RADIAT RES, V171, P66, DOI 10.1667/RR1269.1; Kaur B, 2005, NEURO-ONCOLOGY, V7, P134, DOI 10.1215/S1152851704001115; Keunen O, 2011, P NATL ACAD SCI USA, V108, P3749, DOI 10.1073/pnas.1014480108; KIEFER R, 1991, J NEUROIMMUNOL, V34, P99, DOI 10.1016/0165-5728(91)90119-R; Kim JH, 2006, J BIOCHEM MOL BIOL, V39, P339; Kim JH, 2010, J NEUROCHEM, V115, P1161, DOI 10.1111/j.1471-4159.2010.07004.x; Kim SH, 2002, J KOREAN MED SCI, V17, P242, DOI 10.3346/jkms.2002.17.2.242; KOFMAN S, 1957, JAMA-J AM MED ASSOC, V163, P1473, DOI 10.1001/jama.1957.02970510039008; KURESHI SA, 1994, NEUROSURGERY, V35, P822, DOI 10.1227/00006123-199411000-00004; Kyrkanides S, 1999, J NEUROIMMUNOL, V95, P95, DOI 10.1016/S0165-5728(98)00270-7; Lai A, 2011, J CLIN ONCOL, V29, P142, DOI 10.1200/JCO.2010.30.2729; Le DM, 2003, J NEUROSCI, V23, P4034; Leventhal C, 1999, MOL CELL NEUROSCI, V13, P450, DOI 10.1006/mcne.1999.0762; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Lohr J, 2011, CLIN CANCER RES, V17, P4296, DOI 10.1158/1078-0432.CCR-10-2557; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lu C, 2008, MOL CELL BIOCHEM, V312, P71, DOI 10.1007/s11010-008-9722-8; Markovic DS, 2009, P NATL ACAD SCI USA, V106, P12530, DOI 10.1073/pnas.0804273106; Markovic DS, 2005, J NEUROPATH EXP NEUR, V64, P754, DOI 10.1097/01.jnen.0000178445.33972.a9; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Okada M, 2009, INT J ONCOL, V34, P1621, DOI 10.3892/ijo_00000292; Ozerdem Ugur, 2004, Angiogenesis, V7, P269, DOI 10.1007/s10456-004-4182-6; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Platten M, 2003, ANN NEUROL, V54, P388, DOI 10.1002/ana.10679; Ramirez-Castillejo C, 2006, NAT NEUROSCI, V9, P331, DOI 10.1038/nn1657; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; Rempel SA, 2000, CLIN CANCER RES, V6, P102; Rong Y, 2006, J NEUROPATH EXP NEUR, V65, P529, DOI 10.1097/00005072-200606000-00001; ROVIT RL, 1968, J NEUROPATH EXP NEUR, V27, P277, DOI 10.1097/00005072-196804000-00007; Sameshima T, 2000, CANCER LETT, V157, P177, DOI 10.1016/S0304-3835(00)00485-7; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Sciuscio D, 2011, CLIN CANCER RES, V17, P255, DOI 10.1158/1078-0432.CCR-10-1931; Seidel S, 2010, BRAIN, V133, P983, DOI 10.1093/brain/awq042; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suzuki Y, 2008, BIOMED RES-TOKYO, V29, P77, DOI 10.2220/biomedres.29.77; SUZUMURA A, 1993, J IMMUNOL, V151, P2150; Vairano M, 2004, TOXICOL LETT, V148, P91, DOI 10.1016/j.toxlet.2003.12.058; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Verma S, 2006, BRAIN BEHAV IMMUN, V20, P449, DOI 10.1016/j.bbi.2005.10.005; Villeneuve J, 2008, BRAIN PATHOL, V18, P401, DOI 10.1111/j.1750-3639.2008.00139.x; Virrey JJ, 2009, J NEURO-ONCOL, V95, P13, DOI 10.1007/s11060-009-9891-7; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; WATLING CJ, 1994, J CLIN ONCOL, V12, P1886, DOI 10.1200/JCO.1994.12.9.1886; Weissenberger J, 2004, ONCOGENE, V23, P3308, DOI 10.1038/sj.onc.1207455; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wiesenhofer B, 2000, ANTISENSE NUCLEIC A, V10, P311, DOI 10.1089/oli.1.2000.10.311; Wilhelmsson U, 2006, P NATL ACAD SCI USA, V103, P17513, DOI 10.1073/pnas.0602841103; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Wu A, 2010, NEURO-ONCOLOGY, V12, P1113, DOI 10.1093/neuonc/noq082; Xu Q, 2007, CLIN EXP PHARMACOL P, V34, P624, DOI 10.1111/j.1440-1681.2007.04619.x; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yeh WL, 2011, J CELL PHYSL; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200; Zhu H, 2009, P NATL ACAD SCI USA, V106, P2712, DOI 10.1073/pnas.0813314106; Zuniga RM, 2009, J NEURO-ONCOL, V91, P329, DOI 10.1007/s11060-008-9718-y	122	34	37	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	16					1995	2006		10.1038/onc.2011.398	http://dx.doi.org/10.1038/onc.2011.398			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21909136				2022-12-17	WOS:000303008600001
J	Pradeep, CR; Kostler, WJ; Lauriola, M; Granit, RZ; Zhang, F; Jacob-Hirsch, J; Rechavi, G; Nair, HB; Hennessy, BT; Gonzalez-Angulo, AM; Tekmal, RR; Ben-Porath, I; Mills, GB; Domany, E; Yarden, Y				Pradeep, C-R; Koestler, W. J.; Lauriola, M.; Granit, R. Z.; Zhang, F.; Jacob-Hirsch, J.; Rechavi, G.; Nair, H. B.; Hennessy, B. T.; Gonzalez-Angulo, A. M.; Tekmal, R. R.; Ben-Porath, I.; Mills, G. B.; Domany, E.; Yarden, Y.			Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling	ONCOGENE			English	Article						breast cancer; DCIS; growth factor; spheroids; receptor tyrosine kinase; signal transduction	HUMAN-BREAST-CANCER; MAMMARY-GLAND DEVELOPMENT; STEM-CELL; 3-DIMENSIONAL CULTURES; MONOCLONAL-ANTIBODY; EPITHELIAL-CELLS; NEU ONCOGENE; NOTCH; ACTIVATION; OVEREXPRESSION	A large fraction of ductal carcinoma in situ ( DCIS), a non-invasive precursor lesion of invasive breast cancer, overexpresses the HER2/neu oncogene. The ducts of DCIS are abnormally filled with cells that evade apoptosis, but the underlying mechanisms remain incompletely understood. We overexpressed HER2 in mammary epithelial cells and observed growth factor-independent proliferation. When grown in extracellular matrix as three-dimensional spheroids, control cells developed a hollow lumen, but HER2-overexpressing cells populated the lumen by evading apoptosis. We demonstrate that HER2 overexpression in this cellular model of DCIS drives transcriptional upregulation of multiple components of the Notch survival pathway. Importantly, luminal filling required upregulation of a signaling pathway comprising Notch3, its cleaved intracellular domain and the transcriptional regulator HES1, resulting in elevated levels of c-MYC and cyclin D1. In line with HER2-Notch3 collaboration, drugs intercepting either arm reverted the DCIS-like phenotype. In addition, we report upregulation of Notch3 in hyperplastic lesions of HER2 transgenic animals, as well as an association between HER2 levels and expression levels of components of the Notch pathway in tumor specimens of breast cancer patients. Therefore, it is conceivable that the integration of the Notch and HER2 signaling pathways contributes to the pathophysiology of DCIS. Oncogene ( 2012) 31, 907-917; doi: 10.1038/onc.2011.279; published online 11 July 2011	[Pradeep, C-R; Koestler, W. J.; Lauriola, M.; Yarden, Y.] Weizmann Inst Sci, Dept Biol Regulat, IL-76100 Rehovot, Israel; [Granit, R. Z.; Ben-Porath, I.] Hebrew Univ Jerusalem, Hadassah Sch Med, Dept Dev Biol & Canc Res, Inst Med Res Israel Canada, Jerusalem, Israel; [Zhang, F.; Hennessy, B. T.; Gonzalez-Angulo, A. M.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Jacob-Hirsch, J.; Rechavi, G.] Chaim Sheba Med Ctr, Sheba Canc Res Ctr, IL-52621 Tel Hashomer, Israel; [Jacob-Hirsch, J.; Rechavi, G.] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Nair, H. B.] SW Natl Primate Res Ctr, San Antonio, TX USA; [Hennessy, B. T.] Beaumont Hosp, Dept Med Oncol, Dublin 9, Ireland; [Gonzalez-Angulo, A. M.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Tekmal, R. R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, San Antonio, TX 78229 USA; [Domany, E.] Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Hebrew University of Jerusalem; University of Texas System; UTMD Anderson Cancer Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Texas Biomedical Research Institute; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health San Antonio; Weizmann Institute of Science	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Biol Regulat, Candiotty Bldg,Room 302,1 Hertzl St, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	DOMANY, EYTAN/K-1560-2012; YARDEN, YOSEF/K-1467-2012; lauriola, mattia/N-6435-2014	Granit, Roy Zvi/0000-0002-6487-2559; Hennessy, Bryan/0000-0002-7871-6477; Bhaskaran Nair, Hareesh Babu/0000-0002-4309-9560; lauriola, mattia/0000-0002-7966-0065	National Cancer Institute [CA072981, CA121994-01, CA120248-01]; Israel Cancer Research Fund; Dr Miriam and Sheldon G Adelson Medical Research Foundation; Kekst Family Institute for Medical Genetics; Kirk Center for Childhood Cancer and Immunological Disorders; Bennett-Pritzker Endowment Fund; Marvelle Koffler Program for Breast Cancer Research; Leir Charitable Foundation; MD. Moross Institute for Cancer Research; Susan G Komen Foundation [FAS0703849]; Linda and Michael Jacobs Charitable Trust; NATIONAL CANCER INSTITUTE [P30CA016672, R21CA120248, K23CA121994, R01CA072981, R37CA072981] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Israel Cancer Research Fund; Dr Miriam and Sheldon G Adelson Medical Research Foundation; Kekst Family Institute for Medical Genetics; Kirk Center for Childhood Cancer and Immunological Disorders; Bennett-Pritzker Endowment Fund; Marvelle Koffler Program for Breast Cancer Research; Leir Charitable Foundation; MD. Moross Institute for Cancer Research; Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); Linda and Michael Jacobs Charitable Trust; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Amit Zeisel and Sara Lavi for help, Brenda Lilly for the Notch3 reporter, and Powel Brown, Corey Speers and the Kleberg Center for Molecular Markers at MD Anderson Cancer Center (CCSG grant NCI CA16672) for providing tumors for the RPPA analysis. We acknowledge research funding by the National Cancer Institute (CA072981, CA121994-01 and CA120248-01), the Israel Cancer Research Fund, Dr Miriam and Sheldon G Adelson Medical Research Foundation, Kekst Family Institute for Medical Genetics, Kirk Center for Childhood Cancer and Immunological Disorders, the Women's Health Research Center funded by Bennett-Pritzker Endowment Fund, Marvelle Koffler Program for Breast Cancer Research, Leir Charitable Foundation and the MD. Moross Institute for Cancer Research, the Susan G Komen Foundation (FAS0703849 to AMG, BTH and GBM), and a fellowship for PhD track for specialist medical doctors by the Linda and Michael Jacobs Charitable Trust (WJK). YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair and ED of the Henry J Leir Professorial Chair.	Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Chen YY, 1997, J BIOL CHEM, V272, P14110, DOI 10.1074/jbc.272.22.14110; Clemenz AZ, 2009, CANCER RES, V69, p362s; Cohen B, 2010, BREAST CANCER RES TR, V123, P113, DOI 10.1007/s10549-009-0621-9; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Hennessy Bryan T, 2010, Clin Proteomics, V6, P129, DOI 10.1007/s12014-010-9055-y; Howlin J, 2006, J MAMMARY GLAND BIOL, V11, P283, DOI 10.1007/s10911-006-9024-2; Hu CY, 2006, AM J PATHOL, V168, P973, DOI 10.2353/ajpath.2006.050416; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; Ignatiadis M, 2009, CLIN CANCER RES, V15, P1848, DOI 10.1158/1078-0432.CCR-08-1844; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Jechlinger M, 2009, GENE DEV, V23, P1677, DOI 10.1101/gad.1801809; Katz M, 2007, NAT CELL BIOL, V9, P961, DOI 10.1038/ncb1622; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Liu JN, 2010, CURR TOP DEV BIOL, V92, P367, DOI [10.1016/S0070-2153(10)91012-7, 10.1016/S0070-2153(10)92012-7]; LONARDO F, 1990, New Biologist, V2, P992; Magnifico A, 2009, CLIN CANCER RES, V15, P2010, DOI 10.1158/1078-0432.CCR-08-1327; Mazzone M, 2010, P NATL ACAD SCI USA, V107, P5012, DOI 10.1073/pnas.1000896107; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nakayama K, 2007, INT J CANCER, V120, P2613, DOI 10.1002/ijc.22609; Palomero T, 2008, CELL CYCLE, V7, P965, DOI 10.4161/cc.7.8.5753; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Simpson CD, 2008, CANCER LETT, V272, P177, DOI 10.1016/j.canlet.2008.05.029; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Speers C, 2009, CLIN CANCER RES, V15, P6327, DOI 10.1158/1078-0432.CCR-09-1107; Sriuranpong V, 2001, CANCER RES, V61, P3200; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Tekmal RR, 2007, J STEROID BIOCHEM, V106, P111, DOI 10.1016/j.jsbmb.2007.05.009; Ueda Y, 2004, J BIOL CHEM, V279, P24505, DOI 10.1074/jbc.M400081200; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Whelan JT, 2007, CELL CYCLE, V6, P80, DOI 10.4161/cc.6.1.3648; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yin L, 2010, BIOCHEM PHARMACOL, V80, P690, DOI 10.1016/j.bcp.2010.03.026; Zardawi SJ, 2010, HISTOPATHOLOGY, V56, P286, DOI 10.1111/j.1365-2559.2009.03475.x; Zhan LX, 2006, CANCER RES, V66, P5201, DOI 10.1158/0008-5472.CAN-05-4081	57	34	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	7					907	917		10.1038/onc.2011.279	http://dx.doi.org/10.1038/onc.2011.279			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21743488	Green Accepted, Bronze			2022-12-17	WOS:000300615800009
J	Rohlin, A; Engwall, Y; Fritzell, K; Goransson, K; Bergsten, A; Einbeigi, Z; Nilbert, M; Karlsson, P; Bjork, J; Nordling, M				Rohlin, A.; Engwall, Y.; Fritzell, K.; Goransson, K.; Bergsten, A.; Einbeigi, Z.; Nilbert, M.; Karlsson, P.; Bjork, J.; Nordling, M.			Inactivation of promoter 1B of APC causes partial gene silencing: evidence for a significant role of the promoter in regulation and causative of familial adenomatous polyposis	ONCOGENE			English	Article						familial adenomatous ployposis; APC; mutation; promoter; Q-PCR	GERM-LINE MUTATIONS; CLINICAL CHARACTERIZATION; TRUNCATING MUTATIONS; COLORECTAL-CANCER; BETA-CATENIN; COLI GENE; HYPERMETHYLATION; EXPRESSION; METHYLATION; REGION	Familial adenomatous polyposis (FAP) is caused by germline mutations in the adenomatous polyposis coli (APC) gene. Two promoters, 1A and 1B, have been recognized in APC, and 1B is thought to have a minor role in the regulation of the gene. We have identified a novel deletion encompassing half of this promoter in the largest family (Family 1) of the Swedish Polyposis Registry. The mutation leads to an imbalance in allele-specific expression of APC, and transcription from promoter 1B was highly impaired in both normal colorectal mucosa and blood from mutation carriers. To establish the significance of promoter 1B in normal colorectal mucosa (from controls), expression levels of specific transcripts from each of the promoters, 1A and 1B, were examined, and the expression from 1B was significantly higher compared with 1A. Significant amounts of transcripts generated from promoter 1B were also determined in a panel of 20 various normal tissues examined. In FAP-related tumors, the APC germline mutation is proposed to dictate the second hit. Mutations leaving two or three out of seven 20-amino-acid repeats in the central domain of APC intact seem to be required for tumorigenesis. We examined adenomas from mutation carriers in Family 1 for second hits in the entire gene without any findings, however, loss of the residual expression of the deleterious allele was observed. Three major conclusions of significant importance in relation to the function of APC can be drawn from this study; (i) germline inactivation of promoter 1B is disease causing in FAP; (ii) expression of transcripts from promoter 1B is generated at considerable higher levels compared with 1A, demonstrating a hitherto unknown importance of 1B; (iii) adenoma formation in FAP, caused by impaired function of promoter 1B, does not require homozygous inactivation of APC allowing for alternative genetic models as basis for adenoma formation. Oncogene (2011) 30, 4977-4989; doi:10.1038/onc.2011.201; published online 6 June 2011	[Rohlin, A.; Engwall, Y.; Bergsten, A.; Nordling, M.] Univ Gothenburg, Dept Clin Genet, Inst Biomed, Sahlgrens Univ Hosp,Sahlgrenska Acad, SE-41345 Gothenburg, Sweden; [Fritzell, K.; Goransson, K.; Bjork, J.] Karolinska Univ Hosp, Karolinska Inst, Dept Gastroenterol & Hepatol, Swedish Polyposis Registry, Stockholm, Sweden; [Einbeigi, Z.; Karlsson, P.] Univ Gothenburg, Dept Oncol, Sahlgrenska Acad, Sahlgrens Univ Hosp, SE-41345 Gothenburg, Sweden; [Nilbert, M.] Lund Univ, Dept Oncol, Lund, Sweden; [Nilbert, M.] Univ Copenhagen, Hvidovre Hosp, Clin Res Ctr, DK-2650 Hvidovre, Denmark	Sahlgrenska University Hospital; University of Gothenburg; Karolinska Institutet; Karolinska University Hospital; Sahlgrenska University Hospital; University of Gothenburg; Lund University; University of Copenhagen	Nordling, M (corresponding author), Univ Gothenburg, Dept Clin Genet, Inst Biomed, Sahlgrens Univ Hosp,Sahlgrenska Acad, Medicinargatan 3B, SE-41345 Gothenburg, Sweden.	margareta.nordling@gu.se		Fritzell, Kaisa/0000-0002-3554-074X; Nilbert, Mef/0000-0003-2717-1937	Swedish Cancer Society [ID CAN 2008/792]; Swedish state under the LUA/ALF agreement concerning research and education of doctors [76310]; Health and Medical Care Committee of the Region Vastra Gotaland [96750]; Laboratory division, Sahlgrenska University Hospital; Nilsson-Ehle Foundation; Assar Gabrielsson Foundation; Wilhelm and Martina Lundgren Research Foundation; Sahlgrenska University Hospital Foundation	Swedish Cancer Society(Swedish Cancer Society); Swedish state under the LUA/ALF agreement concerning research and education of doctors; Health and Medical Care Committee of the Region Vastra Gotaland; Laboratory division, Sahlgrenska University Hospital; Nilsson-Ehle Foundation; Assar Gabrielsson Foundation; Wilhelm and Martina Lundgren Research Foundation; Sahlgrenska University Hospital Foundation	The authors are grateful to the patients who participated in the study. This study was supported by grants from the Swedish Cancer Society (ID CAN 2008/792), the Swedish state under the LUA/ALF agreement concerning research and education of doctors, (ID no. 76310), the Health and Medical Care Committee of the Region Vastra Gotaland, (ID no. 96750), Project grant from the Laboratory division, Sahlgrenska University Hospital, the Nilsson-Ehle Foundation, the Assar Gabrielsson Foundation, the Wilhelm and Martina Lundgren Research Foundation and the Sahlgrenska University Hospital Foundation.	Amos-Landgraf JM, 2007, P NATL ACAD SCI USA, V104, P4036, DOI 10.1073/pnas.0611690104; Andreutti-Zaugg C, 1999, Hum Mutat, V13, P170, DOI 10.1002/(SICI)1098-1004(1999)13:2<170::AID-HUMU13>3.0.CO;2-4; BISGAARD ML, 1994, HUM MUTAT, V3, P121, DOI 10.1002/humu.1380030206; Blaker H, 2003, AM J CLIN PATHOL, V120, P418, DOI 10.1309/4E4WG3AYGJNCD11P; Castellsague E, 2010, GASTROENTEROLOGY, V139, P439, DOI 10.1053/j.gastro.2010.04.047; Charames GS, 2008, HUM GENET, V124, P535, DOI 10.1007/s00439-008-0579-4; Cowie S, 2004, HUM MUTAT, V24, P261, DOI 10.1002/humu.20078; De Rosa M, 2007, GENE, V395, P8, DOI 10.1016/j.gene.2006.10.027; Dobbie Z, 1996, J MED GENET, V33, P274, DOI 10.1136/jmg.33.4.274; Esteller M, 2000, CANCER RES, V60, P4366; Fiering S, 1999, METHOD ENZYMOL, V306, P42; FODDE R, 1992, GENOMICS, V13, P1162, DOI 10.1016/0888-7543(92)90032-N; GAYTHER SA, 1994, HUM MOL GENET, V3, P53, DOI 10.1093/hmg/3.1.53; Gismondi V, 1997, HUM MUTAT, V9, P370, DOI 10.1002/(SICI)1098-1004(1997)9:4<370::AID-HUMU14>3.3.CO;2-Z; Hamada F, 2004, DEV CELL, V7, P677, DOI 10.1016/j.devcel.2004.08.022; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; HORII A, 1993, HUM MOL GENET, V2, P283, DOI 10.1093/hmg/2.3.283; Hosoya K, 2009, CANCER LETT, V285, P182, DOI 10.1016/j.canlet.2009.05.016; Joensuu EI, 2008, CANCER RES, V68, P4597, DOI 10.1158/0008-5472.CAN-07-6645; JOHANNESSON T, 1991, HEREDITAS, V115, P295; Judson H, 2006, J PATHOL, V210, P344, DOI 10.1002/path.2044; Kanter-Smoler G, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-10; Kaufmann A, 2009, J MOL DIAGN, V11, P131, DOI 10.2353/jmoldx.2009.080129; Kawaji H, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-4-r40; Kohoutova M, 2002, HUM MUTAT, V19, DOI 10.1002/humu.9028; LAMBERTZ S, 1993, HUM GENET, V90, P650; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Moisio AL, 2002, GUT, V50, P845, DOI 10.1136/gut.50.6.845; Mutoh M, 2006, JPN J CLIN ONCOL, V36, P166, DOI 10.1093/jjco/hyi233; Nilbert M, 2000, SCAND J GASTROENTERO, V35, P1200; Palin K, 2006, NAT PROTOC, V1, P368, DOI 10.1038/nprot.2006.56; Phelps RA, 2009, CELL CYCLE, V8, P2549, DOI 10.4161/cc.8.16.9278; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Renkonen ET, 2005, J CLIN ONCOL, V23, P5651, DOI 10.1200/JCO.2005.14.712; Ripa R, 2002, EUR J HUM GENET, V10, P631, DOI 10.1038/sj.ejhg.5200853; Romero-Gimenez J, 2008, INT J CANCER, V122, P1422, DOI 10.1002/ijc.23247; Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; Segditsas S, 2008, EXP MOL PATHOL, V85, P201, DOI 10.1016/j.yexmp.2008.09.006; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; Stenson PD, 2009, GENOME MED, V1, DOI 10.1186/gm13; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Venesio T, 2003, LAB INVEST, V83, P1859, DOI 10.1097/01.LAB.0000106722.37873.8D; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799	45	34	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2011	30	50					4977	4989		10.1038/onc.2011.201	http://dx.doi.org/10.1038/onc.2011.201			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YJ	21643010	Green Published, hybrid			2022-12-17	WOS:000298346500006
J	Shouse, GP; Nobumori, Y; Panowicz, MJ; Liu, X				Shouse, G. P.; Nobumori, Y.; Panowicz, M. J.; Liu, X.			ATM-mediated phosphorylation activates the tumor-suppressive function of B56 gamma-PP2A	ONCOGENE			English	Article						ATM; PP2A; B56 gamma; MDM2; p53	PROTEIN PHOSPHATASE 2A; REGULATORY SUBUNIT; B56-DELTA SUBUNIT; C-MYC; PP2A; KINASE; IDENTIFICATION; PATHWAY; P53; TRANSFORMATION	Protein phosphatase 2A (PP2A) is a family of heterotrimeric protein phosphatases that has a multitude of functions inside the cell, acting through various substrate targets in cell-signaling pathways. Recent evidence suggests that a subset of PP2A holoenzymes function as tumor suppressors and one particular family of B subunits, B56, are implicated in this function. However, the regulatory mechanisms that govern activation of B56-PP2A tumor-suppressive function have not been elucidated. In the present study, we demonstrate that ataxia-telangiectasia mutated (ATM) directly phosphorylates and specifically regulates B56 gamma 3, B56 gamma 2 and B56 delta, after DNA damage. We further show that phosphorylation of B56 gamma 3 at Ser510 leads to an increase in B56 gamma 3-PP2A complexes, and direction of PP2A phosphatase activity toward the substrate p53, activating its tumor-suppressive functions. In addition, we found that under cell growth conditions B56 gamma 3 is kept at low levels through the actions of the E3 ubiquitin ligase MDM2, and, importantly, phosphorylation of B56 gamma 3 by ATM leads to upregulation of the protein by blocking MDM2-mediated B56 gamma 3 ubiquitination. Finally, we show that Ser510 phosphorylation significantly enhances the ability of B56 gamma 3 to inhibit cell proliferation and anchorage-independent growth. These results provide mechanistic insight into the regulation of PP2A tumor-suppressive function, and suggest a model for parallel regulation of p53 and B56 gamma 3. Oncogene (2011) 30, 3755-3765; doi:10.1038/onc.2011.95; published online 4 April 2011	[Shouse, G. P.; Nobumori, Y.; Panowicz, M. J.; Liu, X.] Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of California System; University of California Riverside	Liu, X (corresponding author), Univ Calif Riverside, Dept Biochem, 5414 Boyce Hall, Riverside, CA 92521 USA.	xuan.liu@ucr.edu		Shouse, Geoffrey/0000-0002-7917-5713	National Institute of Cancer [CA075180]; NATIONAL CANCER INSTITUTE [R29CA075180, R01CA075180] Funding Source: NIH RePORTER	National Institute of Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are very grateful to Dr D Virshup for providing B56 delta antibody, to Dr M Kastan for providing ATM plasmids, to Dr J Momand for providing SJSA-1 cells, and to Dr G Smith and Kudos Pharmaceuticals for providing the ATM inhibitor KU55933. We thank Drs E Lee, D Virshup, JA Traugh, and all members of our laboratory for the many helpful discussions. This work was supported by NIH grant CA075180 from the National Institute of Cancer.	Ahn JH, 2007, P NATL ACAD SCI USA, V104, P2979, DOI 10.1073/pnas.0611532104; Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Janssens V, 2008, TRENDS BIOCHEM SCI, V33, P113, DOI 10.1016/j.tibs.2007.12.004; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Li HH, 2007, EMBO J, V26, P402, DOI 10.1038/sj.emboj.7601519; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Margolis SS, 2006, CELL, V127, P759, DOI 10.1016/j.cell.2006.10.035; Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034; Muneer S, 2002, GENOMICS, V79, P344, DOI 10.1006/geno.2002.6721; Nousiainen M, 2006, P NATL ACAD SCI USA, V103, P5391, DOI 10.1073/pnas.0507066103; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Ortega-Lazaro JC, 2003, CYTOGENET GENOME RES, V103, P345, DOI 10.1159/000076823; Shouse GP, 2010, ONCOGENE, V29, P3933, DOI 10.1038/onc.2010.161; Shouse GP, 2008, MOL CELL BIOL, V28, P448, DOI 10.1128/MCB.00983-07; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Strack S, 2002, J BIOL CHEM, V277, P20750, DOI 10.1074/jbc.M202992200; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; Westermarck J, 2008, TRENDS MOL MED, V14, P152, DOI 10.1016/j.molmed.2008.02.001; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110	24	34	35	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	35					3755	3765		10.1038/onc.2011.95	http://dx.doi.org/10.1038/onc.2011.95			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814TZ	21460856				2022-12-17	WOS:000294481400003
J	Zheng, R; Bailey, E; Nguyen, B; Yang, X; Piloto, O; Levis, M; Small, D				Zheng, R.; Bailey, E.; Nguyen, B.; Yang, X.; Piloto, O.; Levis, M.; Small, D.			Further activation of FLT3 mutants by FLT3 ligand	ONCOGENE			English	Article						FLT3; tyrosine kinase receptor; FLT3 ligand; internal tandem duplication mutation; point mutation	ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; TYROSINE KINASE RECEPTOR; CONSTITUTIVE ACTIVATION; HEMATOPOIETIC-CELLS; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; C-KIT; EXPRESSION; GENE	Somatic mutations of FLT3 involving internal tandem duplication (ITD) of the juxtamembrane domain or point mutations in the tyrosine kinase domain (TKD) appear to activate FLT3 in a FLT3 ligand (FL)-independent manner. To determine whether or not FLT3 mutants respond to FL for their activation, a FL-deficient (FL-/-) murine embryo fibroblast (MEF) cell line was established. Expression of FLT3/ITD and FLT3/TKD mutations in FL-/- MEF cells resulted in low levels of constitutive phosphorylation of FLT3. However, a more than fourfold increase of FLT3 autophosphorylation was induced by exogenous FL. Rescue of endogenous FL expression in FL-/- MEF cells expressing FLT3 mutants led to more than a threefold increase of FLT3 phosphorylation. FL addition led to further activation of the FLT3 receptors and enhanced survival and/or decreased apoptosis in leukemia-derived cell lines and primary leukemic cells expressing FLT3 mutations. Functional studies revealed that exogenous FL promoted the colony-forming and recloning abilities of FLT3 mutant transduced primary bone marrow cells derived from FL-/- mice. Endogenous FL contributes in vivo to functional signaling through FLT3 as noted by the decreased survival of FL+/+ ITD+/+ mice compared with FL-/- ITD+/+ mice. These data suggest that FL leads to further activation of FLT3 mutants and is especially important in light of recent findings of elevated FL levels in acute myeloid leukemia patients in response to chemotherapy. Oncogene (2011) 30, 4004-4014; doi:10.1038/onc.2011.110; published online 25 April 2011	[Zheng, R.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA; [Bailey, E.; Nguyen, B.; Yang, X.; Piloto, O.; Levis, M.; Small, D.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21231 USA; [Small, D.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Small, D (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Pediat Oncol, CRB 251,1650 Orleans St, Baltimore, MD 21231 USA.	donsmall@jhmi.edu			Giant Food Pediatric Cancer Research Fund; NIH [CA90668, CA70970, CA095600-01]; Leukemia and Lymphoma Society; NCI (NCI Leukemia SPORE) [P50 CA100632-06, R01 CA128864]; American Society of Clinical Oncology; NATIONAL CANCER INSTITUTE [R01CA128864, R01CA090668, K08CA095600, P50CA100632] Funding Source: NIH RePORTER	Giant Food Pediatric Cancer Research Fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NCI (NCI Leukemia SPORE)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Society of Clinical Oncology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Katharine A Whartenby, Alan Friedman and Linzhao Cheng for their gift of reagents. DS is also supported by the Kyle Haydock Professorship in Oncology and the Giant Food Pediatric Cancer Research Fund. This work was supported by grants from the NIH (CA90668, CA70970 and CA095600-01) and the Leukemia and Lymphoma Society (DS). It was also supported by grants from the NCI (NCI Leukemia SPORE P50 CA100632-06, R01 CA128864) and the American Society of Clinical Oncology (ML). ML is a Clinical Scholar of the Leukemia and Lymphoma Society.	Abu-Duhier FM, 2001, BRIT J HAEMATOL, V113, P1076, DOI 10.1046/j.1365-2141.2001.02821.x; Bellamy WT, 2001, BLOOD, V97, P1427, DOI 10.1182/blood.V97.5.1427; BIRG F, 1992, BLOOD, V80, P2584; BRASEL K, 1995, LEUKEMIA, V9, P1212; Carow CE, 1996, BLOOD, V87, P1089, DOI 10.1182/blood.V87.3.1089.bloodjournal8731089; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; Drexler HG, 1996, LEUKEMIA, V10, P588; Fenski R, 2000, BRIT J HAEMATOL, V108, P322; FREEDMAN MH, 1993, BLOOD, V81, P3068; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Horiike S, 1997, LEUKEMIA, V11, P1442, DOI 10.1038/sj.leu.2400770; Iwai T, 1999, LEUKEMIA, V13, P38, DOI 10.1038/sj.leu.2401241; Kiyoi H, 1997, LEUKEMIA, V11, P1447, DOI 10.1038/sj.leu.2400756; Kiyoi H, 1999, BLOOD, V93, P3074; Kiyoi H, 1998, LEUKEMIA, V12, P1333, DOI 10.1038/sj.leu.2401130; Lavagna-Sevenier C, 1998, J BIOL CHEM, V273, P14962, DOI 10.1074/jbc.273.24.14962; Levis M, 2011, BLOOD, V117, P3294, DOI 10.1182/blood-2010-08-301796; Li L, 2008, BLOOD, V111, P3849, DOI 10.1182/blood-2007-08-109942; Li YW, 2004, BLOOD, V104, P1137, DOI 10.1182/blood-2003-07-2585; Lisovsky M, 1996, BLOOD, V88, P3987, DOI 10.1182/blood.V88.10.3987.bloodjournal88103987; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; Marchetto S, 1999, LEUKEMIA, V13, P1374, DOI 10.1038/sj.leu.2401527; MEIERHOFF G, 1995, LEUKEMIA, V9, P1368; Meshinchi S, 2001, BLOOD, V97, P89, DOI 10.1182/blood.V97.1.89; Nakao M, 1996, LEUKEMIA, V10, P1911; Pao W, 2005, J CLIN ONCOL, V23, P2556, DOI 10.1200/JCO.2005.07.799; PIETSCH T, 1993, NOUV REV FR HEMATOL, V35, P285; Piloto O, 2005, CANCER RES, V65, P1514, DOI 10.1158/0008-5472.CAN-04-3081; ROGERS SY, 1994, EXP HEMATOL, V22, P593; Rosnet O, 1996, ACTA HAEMATOL-BASEL, V95, P218; Sato T, 2011, BLOOD, V117, P3286, DOI 10.1182/blood-2010-01-266742; Stirewalt DL, 2001, BLOOD, V97, P3589, DOI 10.1182/blood.V97.11.3589; Tse KF, 2000, LEUKEMIA, V14, P1766, DOI 10.1038/sj.leu.2401905; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812; Zhang SL, 2000, BIOCHEM BIOPH RES CO, V277, P195, DOI 10.1006/bbrc.2000.3662; Zhang SL, 2000, J EXP MED, V192, P719, DOI 10.1084/jem.192.5.719; Zhang SL, 1999, J LEUKOCYTE BIOL, V65, P372, DOI 10.1002/jlb.65.3.372; Zheng R, 2004, BLOOD, V103, P267, DOI 10.1182/blood-2003-06-1969; Zheng R, 2002, BLOOD, V100, P4154, DOI 10.1182/blood-2002-03-0936	41	34	38	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	38					4004	4014		10.1038/onc.2011.110	http://dx.doi.org/10.1038/onc.2011.110			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823KR	21516120	Green Accepted			2022-12-17	WOS:000295121600002
J	Brem, R; Li, F; Montaner, B; Reelfs, O; Karran, P				Brem, R.; Li, F.; Montaner, B.; Reelfs, O.; Karran, P.			DNA breakage and cell cycle checkpoint abrogation induced by a therapeutic thiopurine and UVA radiation	ONCOGENE			English	Article						thiopurines; UVA; skin cancer; DNA breakage; cell cycle checkpoints	DOUBLE-STRAND BREAKS; TRANSPLANT RECIPIENTS; MEDIATED DAMAGE; REPAIR; AZATHIOPRINE; SKIN; MECHANISMS; PROTECTION; MUTATIONS; CANCERS	The frequency of squamous cell skin carcinoma in organ transplant patients is around 100-fold higher than normal. This dramatic example of therapy-related cancer reflects exposure to sunlight and to immunosuppressive drugs. Here, we show that the interaction between low doses of UVA, the major ultraviolet component of incident sunlight, and 6-TG, a UVA chromophore that is introduced into DNA by one of the most widely prescribed immunosuppressive drugs, causes DNA single- and double-strand breaks (DSB). S phase cells are particularly vulnerable to this DNA breakage and cells defective in rejoining of S-phase DSB are hypersensitive to the combination of low-dose UVA and DNA 6-TG. 6-TG/UVA-induced DNA lesions provoke canonical DNA damage responses involving activation of the ATM/Chk2 and ATR/Chk1 pathways and appropriate cell cycle checkpoints. Higher levels of photochemical DNA damage induce a proteasome-mediated degradation of Chk1 and checkpoint abrogation that is consistent with persistent unrepaired DNA damage. These findings indicate that the interaction between UVA and an immunosuppressant drug causes photochemical DNA lesions, including DNA breaks, and can compromise cell cycle checkpoints. These two properties could contribute to the high risk of sunlight-related skin cancer in long-term immunosuppressed patients. Oncogene (2010) 29, 3953-3963; doi:10.1038/onc.2010.140; published online 3 May 2010	[Brem, R.; Li, F.; Montaner, B.; Karran, P.] Canc Res UK London Res Inst, Mammalian DNA Repair Lab, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; [Reelfs, O.] Guys Hosp, Kings Coll Sch Med, St Johns Inst Dermatol, London SE1 9RT, England	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Karran, P (corresponding author), Canc Res UK London Res Inst, Mammalian DNA Repair Lab, Clare Hall Labs, Blanche Lane, S Mimms EN6 3LD, Herts, England.	peter.karran@cancer.org.uk	/AAD-1866-2020	Montaner, Beatriz/0000-0001-9877-7317	Cancer Research UK [A3558] Funding Source: Medline; Cancer Research UK [11584] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)		Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; Barnes DE, 2004, ANNU REV GENET, V38, P445, DOI 10.1146/annurev.genet.38.072902.092448; Bickers DR, 2006, J INVEST DERMATOL, V126, P2565, DOI 10.1038/sj.jid.5700340; Brem R, 2009, NUCLEIC ACIDS RES, V37, P1951, DOI 10.1093/nar/gkp070; Cadet J, 2005, MUTAT RES-FUND MOL M, V571, P3, DOI 10.1016/j.mrfmmm.2004.09.012; Cahill MA, 1996, BIOCHEM BIOPH RES CO, V229, P170, DOI 10.1006/bbrc.1996.1775; Caldecott KW, 2003, DNA REPAIR, V2, P955, DOI 10.1016/S1568-7864(03)00118-6; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; Cooke MS, 2008, DNA REPAIR, V7, P1982, DOI 10.1016/j.dnarep.2008.08.007; Daehn I, 2009, CANCER RES, V69, P2393, DOI 10.1158/0008-5472.CAN-08-4264; Davies MJ, 2004, PHOTOCH PHOTOBIO SCI, V3, P17, DOI 10.1039/b307576c; Demple B, 2002, ONCOGENE, V21, P8926, DOI 10.1038/sj.onc.1206178; Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Grosse Y, 2009, LANCET ONCOL, V10, P13, DOI 10.1016/S1470-2045(08)70286-9; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Karran P, 2008, NAT REV CANCER, V8, P24, DOI 10.1038/nrc2292; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; Kerzendorfer C, 2009, DNA REPAIR, V8, P1139, DOI 10.1016/j.dnarep.2009.04.018; Koniaras K, 2001, ONCOGENE, V20, P7453, DOI 10.1038/sj.onc.1204942; Kumar SS, 2000, MUTAT RES-GEN TOX EN, V469, P207, DOI 10.1016/S1383-5718(00)00074-7; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; LENNARD L, 1985, BRIT J DERMATOL, V113, P723, DOI 10.1111/j.1365-2133.1985.tb02408.x; LIMOLI CL, 1993, RADIAT RES, V134, P160, DOI 10.2307/3578455; LJUNGMAN M, 1992, MOL CARCINOGEN, V5, P264, DOI 10.1002/mc.2940050406; LJUNGMAN M, 1991, RADIAT RES, V127, P171, DOI 10.2307/3577962; Montaner B, 2007, EMBO REP, V8, P1074, DOI 10.1038/sj.embor.7401084; O'Donovan P, 2005, SCIENCE, V309, P1871, DOI 10.1126/science.1114233; ORMEROD MG, 2000, FLOW CYTOMETRY PRACT, P159; Penn I, 1994, Transplant Sci, V4, P23; Perrett CM, 2008, BRIT J DERMATOL, V159, P198, DOI 10.1111/j.1365-2133.2008.08610.x; Shiloh Y, 2001, BIOCHEM SOC T, V29, P661, DOI 10.1042/0300-5127:0290661; Smith CC, 1999, ENVIRON MOL MUTAGEN, V34, P131, DOI 10.1002/(SICI)1098-2280(1999)34:2/3<131::AID-EM12>3.3.CO;2-B; Toyooka T, 2006, ENVIRON MOL MUTAGEN, V47, P38, DOI 10.1002/em.20166; WARREN DJ, 1995, CANCER RES, V55, P1670; Yun MH, 2009, NATURE, V459, P460, DOI 10.1038/nature07955; Zhang XH, 2007, DNA REPAIR, V6, P344, DOI 10.1016/j.dnarep.2006.11.003; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019	39	34	34	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2010	29	27					3953	3963		10.1038/onc.2010.140	http://dx.doi.org/10.1038/onc.2010.140			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20440263	Green Accepted			2022-12-17	WOS:000279603200008
J	Hernandez, I; Moreno, JL; Zandueta, C; Montuenga, L; Lecanda, F				Hernandez, I.; Moreno, J. L.; Zandueta, C.; Montuenga, L.; Lecanda, F.			Novel alternatively spliced ADAM8 isoforms contribute to the aggressive bone metastatic phenotype of lung cancer	ONCOGENE			English	Article						microenvironment; tumor-stroma; splicing; osteolysis; colonization	METALLOPROTEASE-DISINTEGRIN ADAM8; OSTEOCLAST-STIMULATING FACTOR; RENAL-CELL CARCINOMA; INCREASED EXPRESSION; CATALYTIC-ACTIVITY; INTEGRIN; ADHESION; PROTEIN; FAMILY; INTERLEUKIN-8	ADAMs (a disintegrin and metalloprotease) are transmembrane proteins involved in a variety of physiological processes and tumorigenesis. Recently, ADAM8 has been associated with poor prognosis of lung cancer. However, its contribution to tumorigenesis in the context of lung cancer metastasis remains unknown. Native ADAM8 expression levels were lower in lung cancer cell lines. In contrast, we identified and characterized two novel spliced isoforms encoding truncated proteins, Delta 18a and Delta 14', which were present in several tumor cell lines and not in normal cells. Overexpression of Delta 18a protein resulted in enhanced invasive activity in vitro. ADAM8 and its Delta 14' isoform expression levels were markedly increased in lung cancer cells, in conditions mimicking tumor microenvironment. Moreover, addition of supernatants from Delta 14'-overexpressing cells resulted in a significant increase in tartrate-resistant acid phosphatase+ cells in osteoclast cultures in vitro. These findings were associated with increased pro-osteoclastogenic cytokines interleukin (IL)-8 and IL-6 protein levels. Furthermore, lung cancer cells overexpressing Delta 14' increased prometastatic activity with a high tumor burden and increased osteolysis in a murine model of bone metastasis. Thus, the expression of truncated forms of ADAM8 by the lung cancer cells may result in the specific upregulation of their invasive and osteoclastogenic activities in the bone microenvironment. These findings suggest a novel mechanism of tumor-induced osteolysis in metastatic bone colonization. Oncogene (2010) 29, 3758-3769; doi: 10.1038/onc.2010.130; published online 10 May 2010	[Hernandez, I.; Zandueta, C.; Lecanda, F.] Univ Navarra, Adhes & Metastasis Lab, Div Oncol, E-31080 Pamplona, Spain; [Moreno, J. L.] Univ Maryland, Sch Med, Dept Orthopaed, Baltimore, MD 21201 USA; [Montuenga, L.] Univ Navarra, Sch Med, Dept Histol & Pathol, E-31080 Pamplona, Spain; [Montuenga, L.] Univ Navarra, Biomarkers Lab, Ctr Appl Biomed Res CIMA, E-31080 Pamplona, Spain	University of Navarra; University System of Maryland; University of Maryland Baltimore; University of Navarra; University of Navarra	Lecanda, F (corresponding author), Univ Navarra, Adhes & Metastasis Lab, Div Oncol, Ctr Appl Biomed Res CIMA, Pio 12-55, Navarra 31080, Spain.	flecanda@unav.es	Montuenga, Luis M/AAF-7783-2020	Montuenga, Luis M/0000-0002-8739-1387; Zandueta Pascual, Carolina/0000-0002-7931-8649	'UTE project FIMA'; I3 Program; 'La Caixa Foundation'; Government of Navarra [67/2005];  [RTICCC C03/10];  [FIT-090100-2005-46];  [PI042284];  [PI070031];  [SAF-2009-11280]	'UTE project FIMA'; I3 Program; 'La Caixa Foundation'(La Caixa Foundation); Government of Navarra; ; ; ; ; 	We thank especially S Martinez and the members of the Morphology and Animal Core Facilities. C Berasain for critical reading of the article. This work was supported by 'UTE project FIMA' agreement, and RTICCC C03/10, FIT-090100-2005-46, PI042284, PI070031 and SAF-2009-11280 (to FL). FL is also supported by funds from the I3 Program, 'La Caixa Foundation', and is a recipient of the 'Ortiz de Landazuri' award (67/2005, Government of Navarra).	Amour A, 2002, FEBS LETT, V524, P154, DOI 10.1016/S0014-5793(02)03047-8; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Cao Y, 2001, BIOCHEM J, V357, P353, DOI 10.1042/0264-6021:3570353; Choi SJ, 2001, J BONE MINER RES, V16, P814, DOI 10.1359/jbmr.2001.16.5.814; Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G; De Larco JE, 2001, AM J PATHOL, V158, P639, DOI 10.1016/S0002-9440(10)64005-9; Foley SC, 2007, J ALLERGY CLIN IMMUN, V119, P863, DOI 10.1016/j.jaci.2006.12.665; Fourie AM, 2003, J BIOL CHEM, V278, P30469, DOI 10.1074/jbc.M213157200; Galliano MF, 2000, J BIOL CHEM, V275, P13933, DOI 10.1074/jbc.275.18.13933; Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200; Gee JMW, 2003, BREAST CANCER RES, V5, P223, DOI 10.1186/bcr637; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Gomez-Gaviro M, 2007, J IMMUNOL, V178, P8053, DOI 10.4049/jimmunol.178.12.8053; Gonzalez I, 2007, J MOL MED, V85, P1015, DOI 10.1007/s00109-007-0202-5; Haidl ID, 2002, GENE, V283, P163, DOI 10.1016/S0378-1119(01)00871-X; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Higashiyama S, 2005, BBA-PROTEINS PROTEOM, V1751, P110, DOI 10.1016/j.bbapap.2004.11.009; Hinkle CL, 2006, J NEUROBIOL, V66, P1378, DOI 10.1002/neu.20257; Hooper NM, 2005, ADAM FAMILY PROTEASE; Ishikawa N, 2004, CLIN CANCER RES, V10, P8363, DOI 10.1158/1078-0432.CCR-04-1436; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Karadag A, 2006, BLOOD, V107, P3271, DOI 10.1182/blood-2005-09-3830; Kelly K, 2005, DEV DYNAM, V232, P221, DOI 10.1002/dvdy.20221; Kim T, 2006, BIOL REPROD, V74, P744, DOI 10.1095/biolreprod.105.048892; King NE, 2004, AM J RESP CELL MOL, V31, P257, DOI 10.1165/rcmb.2004-0026OC; Kveiborg M, 2008, INT J BIOCHEM CELL B, V40, P1685, DOI 10.1016/j.biocel.2008.01.025; Lu X., 2007, Cardiovascular & Hematological Agents in Medicinal Chemistry, V5, P29; Mainiero F, 2000, IMMUNITY, V12, P7, DOI 10.1016/S1074-7613(00)80154-5; Mandelin J, 2003, J RHEUMATOL, V30, P2033; Matsuno O, 2006, IMMUNOL LETT, V102, P67, DOI 10.1016/j.imlet.2005.07.006; Matsuno O, 2007, INT ARCH ALLERGY IMM, V142, P285, DOI 10.1159/000097359; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Naus S, 2006, BIOL CHEM, V387, P337, DOI 10.1515/BC.2006.045; Naus S, 2004, J BIOL CHEM, V279, P16083, DOI 10.1074/jbc.M400560200; Ohtsu H, 2006, AM J PHYSIOL-CELL PH, V291, pC1, DOI 10.1152/ajpcell.00620.2005; Ohtsuka T, 2006, INT J CANCER, V118, P263, DOI 10.1002/ijc.21324; Rao HW, 2006, J BONE MINER RES, V21, P1657, DOI 10.1359/JBMR.060718; Reiss K, 2006, PHARMACOL THERAPEUT, V111, P985, DOI 10.1016/j.pharmthera.2006.02.009; Roemer A, 2004, J UROLOGY, V172, P2162, DOI 10.1097/01.ju.0000144602.01322.49; Roemer A, 2004, ONCOL REP, V11, P529; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Schlomann U, 2002, J BIOL CHEM, V277, P48210, DOI 10.1074/jbc.M203355200; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Stautz D, 2010, EXP CELL RES, V316, P55, DOI 10.1016/j.yexcr.2009.09.017; Takeda S, 2007, FEBS LETT, V581, P5859, DOI 10.1016/j.febslet.2007.11.062; Valkovskaya N, 2007, J CELL MOL MED, V11, P1162, DOI 10.1111/j.1582-4934.2007.00082.x; Verrier S, 2004, BONE, V35, P34, DOI 10.1016/j.bone.2003.12.029; Vicent S, 2008, CANCER RES, V68, P2275, DOI 10.1158/0008-5472.CAN-07-6493; Wildeboer D, 2006, J NEUROPATH EXP NEUR, V65, P516, DOI 10.1097/01.jnen.0000229240.51490.d3; YOSHIDA S, 1990, INT IMMUNOL, V2, P585, DOI 10.1093/intimm/2.6.585	50	34	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	2010	29	26					3758	3769		10.1038/onc.2010.130	http://dx.doi.org/10.1038/onc.2010.130			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20453887				2022-12-17	WOS:000279385200004
J	Kuzontkoski, PM; Mulligan-Kehoe, MJ; Harris, BT; Israel, MA				Kuzontkoski, P. M.; Mulligan-Kehoe, M. J.; Harris, B. T.; Israel, M. A.			Inhibitor of DNA binding-4 promotes angiogenesis and growth of glioblastoma multiforme by elevating matrix GLA levels	ONCOGENE			English	Article						ID4; MGP; angiogenesis; glioblastoma; vascularization	HUMAN-ENDOTHELIAL-CELLS; LOOP-HELIX PROTEINS; ID PROTEINS; TUMOR ANGIOGENESIS; ASTROCYTIC TUMORS; MESSENGER-RNA; BREAST-CANCER; IN-VITRO; EXPRESSION; DIFFERENTIATION	Inhibitor of differentiation-4 is highly expressed in glioblastoma multiforme (GBM). We report a novel pro-angiogenic function for inhibitor of differentiation-4 in the growth of glioblastoma xenografts. Tumor-derived cell cultures expressing elevated levels of ID4 produced enlarged xenografts in immunosuppressed mice that were better vascularized than corresponding control tumors and expressed elevated matrix GLA protein (MGP) that mediated enhanced tumor angiogenesis. Inhibition of MGP resulted in smaller and less vascularized xenografts. Our finding shows a novel function for ID4 in tumor angiogenesis, and identifies ID4 and MGP as possible therapeutic targets for GBM. Oncogene (2010) 29, 3793-3802; doi: 10.1038/onc.2010.147; published online 10 May 2010	[Kuzontkoski, P. M.; Israel, M. A.] Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Pediat, Lebanon, NH 03756 USA; [Kuzontkoski, P. M.; Israel, M. A.] Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Genet, Lebanon, NH 03756 USA; [Mulligan-Kehoe, M. J.] Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Surg, Vasc Sect, Lebanon, NH 03756 USA; [Harris, B. T.] Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Pathol, Lebanon, NH 03756 USA	Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center	Israel, MA (corresponding author), Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Pediat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	Mark.A.Israel@Dartmouth.edu			Theodora B. Betz Foundation; Jordan & Kyra Foundation	Theodora B. Betz Foundation; Jordan & Kyra Foundation	Many thanks to Dr Kristina I Bostrom for lending her expertise, sharing reagents, and fielding generously many questions about MGP. This work was supported by funding from the Theodora B. Betz Foundation (MAI) and the Jordan & Kyra Foundation (MAI).	AndresBarquin PJ, 1997, CANCER RES, V57, P215; Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130; Bellido M, 2003, HAEMATOLOGICA, V88, P994; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; Benezra R, 2001, TRENDS CARDIOVAS MED, V11, P237, DOI 10.1016/S1050-1738(01)00117-7; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bostrom K, 2004, J BIOL CHEM, V279, P52904, DOI 10.1074/jbc.M406868200; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Chan ASW, 2003, ONCOGENE, V22, P6946, DOI 10.1038/sj.onc.1206799; CHEN L, 1990, ONCOGENE, V5, P1391; de Candia P, 2006, HUM PATHOL, V37, P1032, DOI 10.1016/j.humpath.2006.03.004; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Fontemaggi G, 2009, NAT STRUCT MOL BIOL, V16, P1086, DOI 10.1038/nsmb.1669; Havrda MC, 2008, J NEUROSCI, V28, P14074, DOI 10.1523/JNEUROSCI.3188-08.2008; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Itahana Y, 2003, CANCER RES, V63, P7098; Jeon HM, 2008, GENE DEV, V22, P2028, DOI 10.1101/gad.1668708; Kargiotis O, 2006, J NEURO-ONCOL, V78, P281, DOI 10.1007/s11060-005-9097-6; Kleihues P., 1997, PATHOLOGY GENETICS T; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Lampugnani MG, 1999, METH MOL B, V96, P177; LEVEDAKOU EN, 1992, INT J CANCER, V52, P534, DOI 10.1002/ijc.2910520406; Liang Y, 2005, BMC CLIN PATHOL, V5, DOI 10.1186/1472-6890-5-6; Ling MT, 2005, CARCINOGENESIS, V26, P1668, DOI 10.1093/carcin/bgi128; Lofstedt T, 2004, J BIOL CHEM, V279, P39223, DOI 10.1074/jbc.M402904200; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Mikkola HKA, 2003, BLOOD, V101, P508, DOI 10.1182/blood-2002-06-1699; Newman B, 2001, J CELL BIOL, V154, P659, DOI 10.1083/jcb.200106040; Ozawa T, 1998, IN VIVO, V12, P369; Proudfoot D, 2006, NEPHROLOGY, V11, P455, DOI 10.1111/j.1440-1797.2006.00660.x; Russell RG, 2004, CANCER RES, V64, P7220, DOI 10.1158/0008-5472.CAN-04-2095; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Ruzinova MB, 2003, CANCER CELL, V4, P277, DOI 10.1016/S1535-6108(03)00240-X; Sakurai D, 2004, J IMMUNOL, V173, P5801, DOI 10.4049/jimmunol.173.9.5801; Shan L, 2003, AM J PATHOL, V163, P2495, DOI 10.1016/S0002-9440(10)63604-8; Sikder H, 2003, CANCER CELL, V4, P291, DOI 10.1016/S1535-6108(03)00245-9; St Croix B, 2000, SCIENCE, V289, P1197; Umetani N, 2004, CLIN CANCER RES, V10, P7475, DOI 10.1158/1078-0432.CCR-04-0689; Umetani N, 2005, ONCOGENE, V24, P4721, DOI 10.1038/sj.onc.1208538; Vandeputte DAA, 2002, GLIA, V38, P329, DOI 10.1002/glia.10076; VERMEER C, 2001, PATENT COOPERATION T, P1; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; Wu QO, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-16; Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521; Yun K, 2004, DEVELOPMENT, V131, P5441, DOI 10.1242/dev.01430	49	34	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	2010	29	26					3793	3802		10.1038/onc.2010.147	http://dx.doi.org/10.1038/onc.2010.147			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20453881				2022-12-17	WOS:000279385200007
J	Athineos, D; Sansom, OJ				Athineos, D.; Sansom, O. J.			Myc heterozygosity attenuates the phenotypes of APC deficiency in the small intestine	ONCOGENE			English	Article						APC; Myc; colorectal cancer	C-MYC; COLORECTAL-CANCER; IN-VIVO; ADENOMA FORMATION; IDENTIFICATION; PROLIFERATION; INHIBITION; ACTIVATION; RS6983267; TARGET	The adenomatous polyposis coli (APC) gene encodes APC tumour suppressor protein, germline mutation of which causes familial adenomatous polyposis, an autosomal intestinal cancer syndrome. We have previously demonstrated that the proto-oncogene c-Myc is essential for all the phenotypes that occur after APC loss in the murine small intestine. One caveat to this study is that it was performed in the complete absence of c-Myc. In this study, we show that heterozygosity for Myc reduces the phenotypes of APC loss and Wnt target gene expression and slows tumourigenesis. Crucially, the levels of Myc are twofold higher than wild-type levels showing that the level of Myc induced by Wnt signalling is absolutely vital for the fate of APC-deficient cells. Taken together, this suggests that c-Myc inhibition may be a viable chemoprevention strategy for colorectal cancer. Oncogene (2010) 29, 2585-2590; doi:10.1038/onc.2010.5; published online 8 February 2010	[Athineos, D.; Sansom, O. J.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Sansom, OJ (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	o.sansom@beatson.gla.ac.uk		Sansom, Owen J./0000-0001-9540-3010; Athineos, Dimitris/0000-0001-5298-7941	Cancer Research UK [12481] Funding Source: researchfish	Cancer Research UK(Cancer Research UK)		Andreu P, 2005, DEVELOPMENT, V132, P1443, DOI 10.1242/dev.01700; Baena E, 2005, P NATL ACAD SCI USA, V102, P7286, DOI 10.1073/pnas.0409260102; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bommer GT, 2007, CANCER CELL, V11, P391, DOI 10.1016/j.ccr.2007.04.015; Ciznadija D, 2009, CELL DEATH DIFFER, V16, P1530, DOI 10.1038/cdd.2009.94; Finch AJ, 2009, MOL CELL BIOL, V29, P5306, DOI 10.1128/MCB.01745-08; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ignatenko NA, 2006, CANCER BIOL THER, V5, P1658, DOI 10.4161/cbt.5.12.3376; Jubb AM, 2006, ONCOGENE, V25, P3445, DOI 10.1038/sj.onc.1209382; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Sansom OJ, 2006, P NATL ACAD SCI USA, V103, P14122, DOI 10.1073/pnas.0604130103; Shchors K, 2006, GENE DEV, V20, P2527, DOI 10.1101/gad.1455706; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Tuupanen S, 2009, NAT GENET, V41, P885, DOI 10.1038/ng.406; van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031; Wilkins JA, 2008, CANCER RES, V68, P4963, DOI 10.1158/0008-5472.CAN-07-5558; Yekkala K, 2007, MOL CANCER RES, V5, P1296, DOI 10.1158/1541-7786.MCR-07-0232	24	34	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2585	2590		10.1038/onc.2010.5	http://dx.doi.org/10.1038/onc.2010.5			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20140021				2022-12-17	WOS:000277169400013
J	Behren, A; Muhlen, S; Sanhueza, GAA; Schwager, C; Plinkert, PK; Huber, PE; Abdollahi, A; Simon, C				Behren, A.; Muehlen, S.; Sanhueza, G. A. Acuna; Schwager, C.; Plinkert, P. K.; Huber, P. E.; Abdollahi, A.; Simon, C.			Phenotype-assisted transcriptome analysis identifies FOXM1 downstream from Ras-MKK3-p38 to regulate in vitro cellular invasion	ONCOGENE			English	Article						MAPK; p38; ras; invasion; FOXM1; MKK3	ACTIVATED PROTEIN-KINASES; BREAST EPITHELIAL-CELLS; SIGNALING PATHWAYS; GENE-EXPRESSION; TRANSGENIC MICE; RAS; P38; CARCINOMA; FIBROBLASTS; SENESCENCE	The Ras oncogene is known to activate three major MAPK pathways, ERK, JNK, p38 and exert distinct cellular phenotypes, that is, apoptosis and invasion through the Ras-MKK3-p38-signaling cascade. We attempted to identify the molecular targets of this pathway that selectively govern the invasive phenotype. Stable transfection of NIH3T3 fibroblasts with MKK3(act) cDNA construct revealed similar p38-dependent in vitro characteristics observed in Ha-Ras(EJ)-transformed NIH3T3 cells, including enhanced invasiveness and anchorage-independent growth correlating with p38 phosphorylation status. To identify the consensus downstream targets of the Ras-MKK3-p38 cascade involved in invasion, in vitro invasion assays were used to isolate highly invasive cells from both, MKK3 and Ha-Ras(EJ) transgenic cell lines. Subsequently a genome-wide transcriptome analysis was employed to investigate differentially regulated genes in invasive Ha-Ras(EJ)- and MKK3(act)-transfected NIH3T3 fibroblasts. Using this phenotype-assisted approach combined with system level protein-interaction network analysis, we identified FOXM1, PLK1 and CDK1 to be differentially regulated in invasive Ha-Ras(EJ)- NIH3T3 and MKK3(act)-NIH3T3 cells. Finally, a FOXM1 RNA-knockdown approach revealed its requirement for both invasion and anchorage-independent growth of Ha-Ras(EJ)- and MKK3(act)-NIH3T3 cells. Together, we identified FOXM1 as a key downstream target of Ras and MKK3-induced cellular in vitro invasion and anchorage-independent growth signaling. Oncogene (2010) 29, 1519-1530; doi:10.1038/onc.2009.436; published online 21 December 2009	[Behren, A.] Ludwig Inst Canc Res Ltd, Melbourne Ctr Clin Sci, Canc Vaccine, Heidelberg, Vic, Australia; [Muehlen, S.] Univ Newcastle, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne, Tyne & Wear, England; [Behren, A.; Muehlen, S.; Plinkert, P. K.; Simon, C.] Univ Heidelberg Hosp, Dept Otolaryngol Head & Neck Surg, Heidelberg, Germany; [Sanhueza, G. A. Acuna] DKFZ, German Canc Res Ctr, Div Signal Transduct & Growth Control, Heidelberg, Germany; [Schwager, C.; Huber, P. E.; Abdollahi, A.] DKFZ, German Canc Res Ctr, Dept Radiat Oncol, Heidelberg, Germany; [Abdollahi, A.] Tufts Univ, Sch Med, Ctr Canc Syst Biol, Caritas St Elizabeths Med Ctr, Boston, MA 02111 USA; [Abdollahi, A.] Harvard Univ, Sch Med, Dept Surg, Karp Family Res Labs,Vasc Biol Program, Boston, MA 02115 USA	Ludwig Institute for Cancer Research; Newcastle University - UK; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); St. Elizabeth's Medical Center; Tufts University; Harvard University; Harvard Medical School	Simon, C (corresponding author), Univ Heidelberg, Dept Otolaryngol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	csimon1407@aol.com	Behren, Andreas/ABZ-2615-2022	Muehlen, Sabrina/0000-0001-7474-705X; Behren, Andreas/0000-0001-5329-280X	German Krebshilfe (Deutsche Krebshilfe) [107691]; NSCOR [NNJ04HJ12G]; DFG [SPP1190, Si634-5/1]	German Krebshilfe (Deutsche Krebshilfe)(Deutsche Krebshilfe); NSCOR; DFG(German Research Foundation (DFG))	We thank Thomas Regiert (DKFZ) for excellent technical assistance with microarray analysis. We also thank J Han (Scripps Research Institute) for providing us with the MKK3(b) expression construct and RH Medema (Laboratory of Experimental Oncology, University Medical Center Utrecht) for the FoxM1 promoter construct. This work was supported by the German Krebshilfe (Deutsche Krebshilfe, 107691, to CS, PH, PP and AA), NSCOR NNJ04HJ12G and DFG-SPP1190 (to AA and PH) and DFG-Si634-5/1 (to CS and PP).	Adam AP, 2009, CANCER RES, V69, P5664, DOI 10.1158/0008-5472.CAN-08-3820; Behren A, 2005, EXP CELL RES, V303, P321, DOI 10.1016/j.yexcr.2004.10.004; BRADLEY MO, 1986, P NATL ACAD SCI USA, V83, P5277, DOI 10.1073/pnas.83.14.5277; Demuth T, 2007, MOL CANCER THER, V6, P1212, DOI 10.1158/1535-7163.MCT-06-0711; Deng QD, 2004, J BIOL CHEM, V279, P1050, DOI 10.1074/jbc.M308644200; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Gemenetzidis E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004849; Gusarova GA, 2007, J CLIN INVEST, V117, P99, DOI 10.1172/JCI27527; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Haq R, 2002, CANCER RES, V62, P5076; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jin K, 2005, J BIOL CHEM, V280, P42097, DOI 10.1074/jbc.M507301200; Junttila MR, 2007, ONCOGENE, V26, P5267, DOI 10.1038/sj.onc.1210332; Kalin TV, 2006, CANCER RES, V66, P1712, DOI 10.1158/0008-5472.CAN-05-3138; Kalinina OA, 2003, ONCOGENE, V22, P6266, DOI 10.1038/sj.onc.1206640; Korver W, 1997, GENOMICS, V46, P435, DOI 10.1006/geno.1997.5065; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Moon A, 2006, ARCH PHARM RES, V29, P113, DOI 10.1007/BF02974271; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Park HJ, 2009, EMBO J, V28, P2908, DOI 10.1038/emboj.2009.239; Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277; Qi XM, 2006, CANCER RES, V66, P7540, DOI 10.1158/0008-5472.CAN-05-4639; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schwacke JH, 2007, J THEOR BIOL, V246, P604, DOI 10.1016/j.jtbi.2006.12.035; Shin I, 2005, J BIOL CHEM, V280, P14675, DOI 10.1074/jbc.M411625200; Song H, 2006, CANCER RES, V66, P10487, DOI 10.1158/0008-5472.CAN-06-1461; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Wierstra I, 2007, BIOL CHEM, V388, P1257, DOI 10.1515/BC.2007.159; Yoshida Y, 2007, GASTROENTEROLOGY, V132, P1420, DOI 10.1053/j.gastro.2007.01.036; ZHANG JY, 1992, CANCER RES, V52, P6682	39	34	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1519	1530		10.1038/onc.2009.436	http://dx.doi.org/10.1038/onc.2009.436			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	20023695				2022-12-17	WOS:000275392400010
J	Bommer, UA; Heng, C; Perrin, A; Dash, P; Lobov, S; Elia, A; Clemens, MJ				Bommer, U-A; Heng, C.; Perrin, A.; Dash, P.; Lobov, S.; Elia, A.; Clemens, M. J.			Roles of the translationally controlled tumour protein (TCTP) and the double-stranded RNA-dependent protein kinase, PKR, in cellular stress responses	ONCOGENE			English	Article						TCTP; PKR; p53; apoptosis; cell stress	MESSENGER-RNA; ALPHA-SUBUNIT; CALCIUM; ACTIVATION; APOPTOSIS; GENE; INITIATION; FORTILIN; TARGET; GROWTH	Translationally controlled tumour protein (TCTP) is a highly conserved protein present in all eukaryotic organisms. Various cellular functions and molecular interactions have been ascribed to this protein, many related to its growth-promoting and antiapoptotic properties. TCTP levels are highly regulated in response to various cellular stimuli and stresses. We have shown recently that the double-stranded RNA-dependent protein kinase, PKR, is involved in translational regulation of TCTP. Here we extend these studies by demonstrating that TCTP is downregulated in response to various proapoptotic treatments, in particular agents that induce Ca+ (+) stress, in a PKR-dependent manner. This regulation requires phosphorylation of protein synthesis factor eIF2 alpha. Since TCTP has been characterized as an antiapoptotic and Ca+ +- binding protein, we asked whether it is involved in protecting cells from Ca+ (+)- stress-induced apoptosis. Overexpression of TCTP partially protects cells against thapsigargin-induced apoptosis, as measured using caspase-3 activation assays, a nuclear fragmentation assay, using fluorescence-activated cell sorting analysis, and time-lapse video microscopy. TCTP also protects cells against the proapoptotic effects of tunicamycin and etoposide, but not against those of arsenite. Our results imply that cellular TCTP levels influence sensitivity to apoptosis and that PKR may exert its proapoptotic effects at least in part through downregulation of TCTP via eIF2 alpha phosphorylation. Oncogene (2010) 29, 763-773; doi: 10.1038/onc.2009.380; published online 9 November 2009	[Bommer, U-A; Heng, C.; Perrin, A.; Dash, P.; Lobov, S.; Elia, A.; Clemens, M. J.] Univ London, Div Basic Med Sci, London, England	University of London	Bommer, UA (corresponding author), Univ Wollongong, Grad Sch Med, Northfields Ave,Bldg 28, Wollongong, NSW 2522, Australia.	ubommer@uow.edu.au	Lobov, Sergei A/A-8803-2011; Elia, Androulla/AAE-6854-2021	Dash, Phil/0000-0002-6029-4560; Bommer, Ulrich/0000-0003-1110-7615	Wellcome Trust; Cancer Prevention Research Trust; Association for International Cancer Research	Wellcome Trust(Wellcome TrustEuropean Commission); Cancer Prevention Research Trust; Association for International Cancer Research	We thank Drs Charles Weissmann, Randy Kaufman and Donalyn Scheuner for cell lines; Mr Bill Newman for help in performing the initial fluorescence-activated cell sorting analysis experiments; Dr Constantina Constantinou for providing extracts from mouse erythroleukaemia cells and members of Dr Guy Whitley's laboratory for help with the cell-video microscopy facilities. This work was supported by The Wellcome Trust (UAB and MJC), the Cancer Prevention Research Trust (UAB) and the Association for International Cancer Research (MJC).	Barber GN, 2005, CELL DEATH DIFFER, V12, P563, DOI 10.1038/sj.cdd.4401643; Ben-Asouli Y, 2002, CELL, V108, P221, DOI 10.1016/S0092-8674(02)00616-5; Berkowitz O, 2008, PLANT CELL, V20, P3430, DOI 10.1105/tpc.108.061010; Bommer UA, 2002, RNA, V8, P478, DOI 10.1017/S1355838202022586; Bommer UA, 2004, INT J BIOCHEM CELL B, V36, P379, DOI 10.1016/S1357-2725(03)00213-9; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Cans C, 2003, P NATL ACAD SCI USA, V100, P13892, DOI 10.1073/pnas.2335950100; Chen SH, 2007, MOL BIOL CELL, V18, P2525, DOI 10.1091/mbc.e07-02-0188; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Constantinou C, 2007, CELL DEATH DIFFER, V14, P576, DOI 10.1038/sj.cdd.4402045; Davis S, 1996, P NATL ACAD SCI USA, V93, P508, DOI 10.1073/pnas.93.1.508; Efferth T, 2005, DRUG RESIST UPDATE, V8, P85, DOI 10.1016/j.drup.2005.04.003; Feng YG, 2007, ARCH BIOCHEM BIOPHYS, V467, P48, DOI 10.1016/j.abb.2007.08.021; Fritsch RM, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M702673200; Gachet Y, 1999, J CELL SCI, V112, P1257; Garcia MA, 2007, BIOCHIMIE, V89, P799, DOI 10.1016/j.biochi.2007.03.001; Garcia MA, 2006, MICROBIOL MOL BIOL R, V70, P1032, DOI 10.1128/MMBR.00027-06; Gnanasekar M, 2007, PARASITOL RES, V101, P1533, DOI 10.1007/s00436-007-0671-z; Gnanasekar M, 2009, INT J ONCOL, V34, P1241, DOI 10.3892/ijo_00000252; Graidist P, 2007, BIOCHEM J, V408, P181, DOI 10.1042/BJ20070679; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hsu YC, 2007, NATURE, V445, P785, DOI 10.1038/nature05528; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Jung J, 2004, J BIOL CHEM, V279, P49868, DOI 10.1074/jbc.M400895200; Kim JE, 2008, EXP MOL MED, V40, P709, DOI 10.3858/emm.2008.40.6.709; Kim M, 2000, ARCH PHARM RES, V23, P633, DOI 10.1007/BF02975253; Kim MJ, 2008, J MOL CELL CARDIOL, V44, P151, DOI 10.1016/j.yjmcc.2007.09.017; Koziol MJ, 2007, CURR BIOL, V17, P801, DOI 10.1016/j.cub.2007.03.062; Lee ES, 2007, FEBS LETT, V581, P4325, DOI 10.1016/j.febslet.2007.08.001; Li F, 2001, J BIOL CHEM, V276, P47542, DOI 10.1074/jbc.M108954200; Liu H, 2005, MOL CELL BIOL, V25, P3117, DOI 10.1128/MCB.25.8.3117-3126.2005; Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001; MA Q, 2009, J PROTEOME RES; Onuki R, 2004, EMBO J, V23, P959, DOI 10.1038/sj.emboj.7600049; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; Rehmann H, 2008, FEBS LETT, V582, P3005, DOI 10.1016/j.febslet.2008.07.057; Scheuner D, 2006, J BIOL CHEM, V281, P21458, DOI 10.1074/jbc.M603784200; Schmidt I, 2007, FEBS J, V274, P5416, DOI 10.1111/j.1742-4658.2007.06069.x; Singh M, 2009, J MOL BIOL, V385, P457, DOI 10.1016/j.jmb.2008.10.068; Slaby O, 2009, ONCOL REP, V21, P1235, DOI 10.3892/or_00000346; SPECTOR DL, 1998, CELLS LAB MANUAL, V1; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; Susini L, 2008, CELL DEATH DIFFER, V15, P1211, DOI 10.1038/cdd.2008.18; Tani T, 2007, CLONING STEM CELLS, V9, P267, DOI 10.1089/clo.2006.0072; Telerman A, 2009, NAT REV CANCER, V9, P206, DOI 10.1038/nrc2589; Tuynder M, 2004, P NATL ACAD SCI USA, V101, P15364, DOI 10.1073/pnas.0406776101; Tuynder M, 2002, P NATL ACAD SCI USA, V99, P14976, DOI 10.1073/pnas.222470799; van de Sande WWJ, 2006, J IMMUNOL, V177, P1997, DOI 10.4049/jimmunol.177.3.1997; Vonakis BM, 2008, BLOOD, V111, P1789, DOI 10.1182/blood-2007-07-104364; Wang XM, 2008, J BIOL CHEM, V283, P30482, DOI 10.1074/jbc.M803348200; Xiong ZY, 2009, ATHEROSCLEROSIS, V203, P401, DOI 10.1016/j.atherosclerosis.2008.07.041; Xu AM, 1999, BIOCHEM J, V342, P683, DOI 10.1042/0264-6021:3420683; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Yang Y, 2005, ONCOGENE, V24, P4778, DOI 10.1038/sj.onc.1208666; Yoon CH, 2009, P NATL ACAD SCI USA, V106, P7852, DOI 10.1073/pnas.0812148106; Zhang D, 2002, J BIOL CHEM, V277, P37430, DOI 10.1074/jbc.M207413200	58	34	40	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					763	773		10.1038/onc.2009.380	http://dx.doi.org/10.1038/onc.2009.380			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19901967				2022-12-17	WOS:000274223700012
J	Zhou, W; Tu, Y; Simpson, PJ; Kuhajda, FP				Zhou, W.; Tu, Y.; Simpson, P. J.; Kuhajda, F. P.			Malonyl-CoA decarboxylase inhibition is selectively cytotoxic to human breast cancer cells	ONCOGENE			English	Article						malonyl-CoA decarboxylase; apoptosis; fatty acid metabolism; malonyl-CoA; fatty acid synthase	FATTY-ACID SYNTHASE; 5-AMP-ACTIVATED PROTEIN-KINASE; COENZYME-A; ISCHEMIC-HEART; OXIDATION; APOPTOSIS; DEFICIENCY; EXPRESSION; TISSUE; PHASE	Fatty acid synthase (FAS) inhibition initiates selective apoptosis of cancer cells both in vivo and in vitro, which may involve malonyl-CoA metabolism. These findings have led to the exploration of malonyl-CoA decarboxylase (MCD) as a potential novel target for cancer treatment. MCD regulates the levels of cellular malonyl-CoA through the decarboxylation of malonyl-CoA to acetylCoA. Malonyl-CoA is both a substrate for FAS and an inhibitor of fatty acid oxidation acting as a metabolic switch between anabolic fatty acid synthesis and catabolic fatty acid oxidation. We now report that the treatment of human breast cancer (MCF7) cells with MCD small interference RNA (siRNA) reduces MCD expression and activity, reduces adenosine triphosphate levels, and is cytotoxic to MCF7 cells, but not to human fibroblasts. In addition, we synthesized a small-molecule inhibitor of MCD, 5-{(Morpholine-4-carbonyl)-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-amino}-pentanoic acid methyl ester (MPA). Similar to MCD siRNA, MPA inhibits MCD activity in MCF7 cells, increases cellular malonyl-CoA levels and is cytotoxic to a number of human breast cancer cell lines in vitro. Taken together, these data indicate that MCD-induced cytotoxicity is likely mediated through malonyl-CoA metabolism. These findings support the hypothesis that MCD is a potential therapeutic target for cancer therapy. Oncogene (2009) 28, 2979-2987; doi:10.1038/onc.2009.160; published online 22 June 2009	[Kuhajda, F. P.] Johns Hopkins Univ, Sch Med, Dept Pathol, Johns Hopkins Bayview Med Ctr, Baltimore, MD 21224 USA; [Tu, Y.; Simpson, P. J.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21224 USA; [Kuhajda, F. P.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21224 USA; [Kuhajda, F. P.] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Kuhajda, FP (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Johns Hopkins Bayview Med Ctr, UMB Res Pk,Bldg 1,4940 Eastern Ave, Baltimore, MD 21224 USA.	fkuhajda@jhmi.edu			Department of Defense Breast Cancer [BC050452]	Department of Defense Breast Cancer(United States Department of Defense)	This study was supported by a grant from the Department of Defense Breast Cancer Grant BC050452 to FPK. We thank FASgen Inc. for the generous gift of MPA.	Albayrak T, 2003, MOL BIOL CELL, V14, P3082, DOI 10.1091/mbc.e02-10-0631; Bandyopadhyay S, 2006, CANCER RES, V66, P5934, DOI 10.1158/0008-5472.CAN-05-3197; Cheng JF, 2006, J MED CHEM, V49, P1517, DOI 10.1021/jm050109n; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DEMOZ A, 1995, J CHROMATOGR B, V667, P148, DOI 10.1016/0378-4347(94)00595-V; Dyck JRB, 2004, CIRC RES, V94, pE78, DOI 10.1161/01.RES.0000129255.19569.8f; Dyck JRB, 2002, J MOL CELL CARDIOL, V34, P1099, DOI 10.1006/jmcc.2002.2060; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; FitzPatrick DR, 1999, AM J HUM GENET, V65, P318, DOI 10.1086/302492; FUNABASHI H, 1989, J BIOCHEM-TOKYO, V105, P751, DOI 10.1093/oxfordjournals.jbchem.a122739; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; Goodwin GW, 1999, AM J PHYSIOL-ENDOC M, V277, pE772, DOI 10.1152/ajpendo.1999.277.4.E772; KOEPPEN AH, 1987, J NEUROCHEM, V48, P1509, DOI 10.1111/j.1471-4159.1987.tb05693.x; Kuhajda FP, 2006, CANCER RES, V66, P5977, DOI 10.1158/0008-5472.CAN-05-4673; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Menendez JA, 2004, INT J ONCOL, V24, P591; Pegram MD, 2004, JNCI-J NATL CANCER I, V96, P739, DOI 10.1093/jnci/djh131; Pizer ES, 2000, CANCER RES, V60, P213; RILEY KM, 1991, NEUROCHEM RES, V16, P117, DOI 10.1007/BF00965698; Sacksteder KA, 1999, J BIOL CHEM, V274, P24461, DOI 10.1074/jbc.274.35.24461; Saha AK, 2003, MOL CELL BIOCHEM, V253, P65, DOI 10.1023/A:1026053302036; Shiu LY, 2008, CELL BIOL TOXICOL, V24, P1, DOI 10.1007/s10565-007-9010-5; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Tu YJ, 2005, ENDOCRINOLOGY, V146, P486, DOI 10.1210/en.2004-0976; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; Warburg O, 1924, BIOCHEM Z, V152, P319; WATKINS PA, 1991, ARCH BIOCHEM BIOPHYS, V289, P329, DOI 10.1016/0003-9861(91)90419-J; WITTERS LA, 1994, ARCH BIOCHEM BIOPHYS, V308, P413, DOI 10.1006/abbi.1994.1058; WITTERS LA, 1992, J BIOL CHEM, V267, P2864; WITTERS LA, 1994, INT J BIOCHEM, V26, P589, DOI 10.1016/0020-711X(94)90018-3; Zhou WB, 2003, CANCER RES, V63, P7330; Zhou WB, 2007, CANCER RES, V67, P2964, DOI 10.1158/0008-5472.CAN-06-3439	33	34	35	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2009	28	33					2979	2987		10.1038/onc.2009.160	http://dx.doi.org/10.1038/onc.2009.160			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485SA	19543323				2022-12-17	WOS:000269142800006
J	Pulukuri, SM; Gorantla, B; Knost, JA; Rao, JS				Pulukuri, S. M.; Gorantla, B.; Knost, J. A.; Rao, J. S.			Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer	ONCOGENE			English	Article						cystatins; cathepsins; invasion; histone modification; chromatin; prostate cancer	UROKINASE PLASMINOGEN-ACTIVATOR; HISTONE DEACETYLASE INHIBITION; CYSTEINE PROTEINASE-INHIBITOR; ABERRANT DNA METHYLATION; HUMAN GLIOBLASTOMA CELLS; TUMOR-SUPPRESSOR GENE; BREAST-CANCER; CATHEPSIN-B; EPIGENETIC INACTIVATION; INVASION	Cystatin E/M (CST6) is a natural inhibitor of lysosomal cysteine proteases. Recent studies have shown that experimental manipulation of CST6 expression alters the metastatic behavior of human breast cancer cells. However, the association of CST6 with prostate cancer invasion and progression remains unclear. Here, we show that CST6 is robustly expressed in normal human prostate epithelium, whereas its expression is downregulated in metastatic prostate cell lines and prostate tumor tissues. Treatment of metastatic prostate cell lines with the histone deacetylase inhibitor trichostatin A resulted in significant induction of CST6 mRNA levels and increased CST6 protein expression, indicating that epigenetic silencing may play a role in the loss of CST6 expression observed in prostate cancer. CST6 overexpression in human prostate cancer cells significantly reduced in vitro cell proliferation and matrigel invasion. Furthermore, the results from a bioluminescence tumor/metastasis model showed that the overexpression of CST6 significantly inhibits tumor growth and the incidence of lung metastasis. These results suggest that the downregulation of the CST6 gene is associated with promoter histone modi. cations and that this association plays an important role in prostate cancer progression during the invasive and metastatic stages of the disease. Oncogene (2009) 28, 2829-2838; doi:10.1038/onc.2009.134; published online 8 June 2009	[Pulukuri, S. M.; Gorantla, B.; Rao, J. S.] Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA; [Knost, J. A.] Illinois Canc Care, Peoria, IL USA; [Rao, J. S.] Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61605 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, 1 Illini Dr, Peoria, IL 61605 USA.	jsrao@uic.edu			National Cancer Institute [CA75557, CA92393, CA95058, CA116708, CA138409, NS47699, NS57529, NS61835]; Caterpillar Inc.,; NATIONAL CANCER INSTITUTE [R01CA092393, R01CA075557, R01CA138409, R01CA095058, R01CA116708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS057529, R01NS061835, R01NS047699] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Caterpillar Inc.,; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We are grateful to Dr Hnilica of the Department of Pathology at the University of Illinois College of Medicine ( Peoria) for kindly providing normal and tumor human prostate tissues. We thank Shellee Abraham for preparing the paper and Diana Meister and Sushma Jasti for paper review. We also thank Noorjehan Ali and Lavanya Talluri, for technical assistance. This research was supported by National Cancer Institute Grant CA75557, CA92393, CA95058, CA116708, CA138409, N. I. N. D. S. NS47699, NS57529 and NS61835 and Caterpillar Inc., OSF St Francis Inc. Peoria, IL ( to JSR). The contents are solely the responsibility of the authors and do not necessarily represent the official views of NIH.	ABRAHAMSON M, 1994, METHOD ENZYMOL, V244, P685; Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576; Alvarez-Fernandez M, 1999, J BIOL CHEM, V274, P19195, DOI 10.1074/jbc.274.27.19195; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Brunner N, 1994, Cancer Treat Res, V71, P299; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; DECLERCK YA, 1994, EUR J CANCER, V30A, P2170, DOI 10.1016/0959-8049(94)00460-M; Esteller M, 2001, CANCER RES, V61, P3225; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Keppler D, 1996, ENZYME PROTEIN, V49, P94, DOI 10.1159/000468619; Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552; Konduri SD, 2002, ONCOGENE, V21, P8705, DOI 10.1038/sj.onc.1205949; Krueger S, 2001, CANCER GENE THER, V8, P522, DOI 10.1038/sj.cgt.7700341; Marks PA, 2001, CLIN CANCER RES, V7, P759; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Ni J, 1997, J BIOL CHEM, V272, P10853; Pulukuri SM, 2007, ONCOGENE, V26, P5229, DOI 10.1038/sj.onc.1210329; Pulukuri SMK, 2007, J BIOL CHEM, V282, P35594, DOI 10.1074/jbc.M705867200; Pulukuri SMK, 2007, CANCER RES, V67, P6637, DOI 10.1158/0008-5472.CAN-07-0751; Qiu J, 2008, LAB INVEST, V88, P910, DOI 10.1038/labinvest.2008.66; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Roshy S, 2003, CANCER METAST REV, V22, P271, DOI 10.1023/A:1023007717757; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Schagdarsurengin U, 2007, ONCOGENE, V26, P3089, DOI 10.1038/sj.onc.1210107; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Shridhar R, 2004, ONCOGENE, V23, P2206, DOI 10.1038/sj.onc.1207340; Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; Veena MS, 2008, GENE CHROMOSOME CANC, V47, P740, DOI 10.1002/gcc.20576; Yanamandra N, 2004, ONCOGENE, V23, P2224, DOI 10.1038/sj.onc.1207338; Yoon SO, 2001, J BIOL CHEM, V276, P20085, DOI 10.1074/jbc.M101143200; Zhang J, 2004, CANCER RES, V64, P6957, DOI 10.1158/0008-5472.CAN-04-0819; Zhong S, 2007, ONCOGENE, V26, P2621, DOI 10.1038/sj.onc.1210041	34	34	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28	31					2829	2838		10.1038/onc.2009.134	http://dx.doi.org/10.1038/onc.2009.134			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479TS	19503093	Green Accepted			2022-12-17	WOS:000268684400006
J	Hagos, EG; Ghaleb, AM; Dalton, WB; Bialkowska, AB; Yang, VW				Hagos, E. G.; Ghaleb, A. M.; Dalton, W. B.; Bialkowska, A. B.; Yang, V. W.			Mouse embryonic fibroblasts null for the Kruppel-like factor 4 gene are genetically unstable	ONCOGENE			English	Article						aneuploidy; centrosome amplification; cell cycle; chromosome aberrations; gamma-H2AX; KLF4	GASTRIC-CANCER DEVELOPMENT; CENTROSOME AMPLIFICATION; CYCLIN-E; CHROMOSOMAL INSTABILITY; TRANSCRIPTION FACTORS; CELL-PROLIFERATION; TUMOR-SUPPRESSOR; DNA-DAMAGE; ANEUPLOIDY; P53	Kruppel-like factor 4 (KLF4) is a zinc-finger transcription factor with tumor suppressive activity in colorectal cancer. Here, we investigated whether KLF4 is involved in maintaining genetic stability in mouse embryonic fibroblasts (MEFs) isolated from mice wild type (+/+), heterozygous (+/-), or homozygous (-/-) for the Klf4 alleles. Compared to Klf4(+/+) and Klf4(+/-) MEFs, Klf4(-/-) MEFs had both a higher level of apoptosis and rate of proliferation. Quantification of chromosome numbers showed that Klf4(-/-) MEFs were aneuploid. A higher number of Klf4(-/-) MEFs exhibited gamma-H2AX foci and had higher amounts of gamma-H2AX compared to controls. Cytogenetic analysis demonstrated the presence of numerous chromosome aberrations including dicentric chromosomes, chromatid breaks, and double minute chromosomes in Klf4(-/-) cells but in few, if any, Klf4(+/+) or Klf4(+/-) MEFs. Approximately 25% of Klf4(-/-) MEFs exhibited centrosome amplification in contrast to the less than 5% of Klf4(+/+) or Klf4(+/-) MEFs. Finally, only Klf4(-/-) MEFs were capable of anchorage-independent growth. Taken together, these findings demonstrate that MEFs null for the Klf4 alleles are genetically unstable, as evidenced by the presence of aneuploidy, chromosome aberration and centrosome amplification. The results support a crucial role for KLF4 in maintaining genetic stability and as a tumor suppressor.	[Hagos, E. G.; Ghaleb, A. M.; Dalton, W. B.; Bialkowska, A. B.; Yang, V. W.] Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; [Yang, V. W.] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA	Emory University; Emory University	Yang, VW (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 201 Whitehead Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	vyang@emory.edu	, ehagos/AAY-8486-2020; Dalton, William/M-7944-2017	Dalton, William/0000-0002-1314-0534	National Institutes of Health [DK52230, DK64399, CA84197]; NIH National Research Service Award [CA130308]; Emory Biochemistry, Cell and Developmental Biology (BCDB) training grant; NATIONAL CANCER INSTITUTE [R01CA084197, F32CA130308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064399, R01DK052230] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Emory Biochemistry, Cell and Developmental Biology (BCDB) training grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Klaus Kaestner and Dr Jonathan Katz for providing the Klf4<SUP>+/-</SUP> mice. This work was in part supported by grants from the National Institutes of Health ( DK52230, DK64399, and CA84197). EGH was an Emory Fellowships in Research and Science Teaching ( FIRST) fellow. AMG was the recipient of a NIH National Research Service Award ( CA130308). WBD was supported in part by an Emory Biochemistry, Cell and Developmental Biology (BCDB) training grant.	Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Chen XM, 2003, J MOL BIOL, V326, P665, DOI 10.1016/S0022-2836(02)01449-3; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Chng WJ, 2008, BLOOD, V111, P1603, DOI 10.1182/blood-2007-06-097774; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Dalton WB, 2007, CANCER RES, V67, P11487, DOI 10.1158/0008-5472.CAN-07-5162; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Dang DT, 2000, FEBS LETT, V476, P203, DOI 10.1016/S0014-5793(00)01727-0; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Gartel AL, 2002, MOL CANCER THER, V1, P639; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Ghaleb AM, 2007, ONCOGENE, V26, P2365, DOI 10.1038/sj.onc.1210022; Ghaleb AM, 2005, CELL RES, V15, P92, DOI 10.1038/sj.cr.7290271; Ghaleb AM, 2007, CANCER RES, V67, P7147, DOI 10.1158/0008-5472.CAN-07-1302; Ghaleb AM, 2008, CURR COLORECT CANC R, V4, P59, DOI 10.1007/s11888-008-0011-4; Hanashiro K, 2008, ONCOGENE, V27, P5288, DOI 10.1038/onc.2008.161; HARVEY M, 1993, ONCOGENE, V8, P2457; Hinchcliffe EH, 2002, ONCOGENE, V21, P6154, DOI 10.1038/sj.onc.1205826; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kanai M, 2006, CLIN CANCER RES, V12, P6395, DOI 10.1158/1078-0432.CCR-06-1034; Katz JP, 2005, GASTROENTEROLOGY, V128, P935, DOI 10.1053/j.gastro.2005.02.022; Katz JP, 2002, DEVELOPMENT, V129, P2619; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KIRSCHNER MW, 1986, NATURE, V324, P621, DOI 10.1038/324621a0; LEE JJ, 1990, ANAL BIOCHEM, V189, P1, DOI 10.1016/0003-2697(90)90036-9; LEE JM, 1994, ONCOGENE, V9, P3731; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Mayer F, 2003, ONCOGENE, V22, P3859, DOI 10.1038/sj.onc.1206469; McConnell BB, 2007, BIOESSAYS, V29, P549, DOI 10.1002/bies.20581; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Salisbury JL, 2004, J MAMMARY GLAND BIOL, V9, P275, DOI 10.1023/B:JOMG.0000048774.27697.30; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Takada Y, 2007, ONCOGENE, V26, P1201, DOI 10.1038/sj.onc.1209906; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tarapore P, 2002, CELL CYCLE, V1, P75, DOI 10.4161/cc.1.1.103; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Weaver BAA, 2007, CANCER RES, V67, P10103, DOI 10.1158/0008-5472.CAN-07-2266; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002; Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619; Yoon HS, 2005, ONCOGENE, V24, P4017, DOI 10.1038/sj.onc.1208576; Yoon HS, 2004, J BIOL CHEM, V279, P5035, DOI 10.1074/jbc.M307631200; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	62	34	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1197	1205		10.1038/onc.2008.465	http://dx.doi.org/10.1038/onc.2008.465			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19137014	Green Accepted			2022-12-17	WOS:000263906200004
J	Min, SH; Kim, DM; Heo, YS; Kim, YI; Kim, HM; Kim, J; Han, YM; Kim, IC; Yoo, OJ				Min, S-H; Kim, D. M.; Heo, Y-S; Kim, Y-I; Kim, H. M.; Kim, J.; Han, Y-M; Kim, I-C; Yoo, O-J			New p53 target, phosphatase of regenerating liver 1 (PRL-1) downregulates p53	ONCOGENE			English	Article						p53 target; phosphatase of regenerating liver 1; PRL-1; EGR; PI3K	TUMOR-SUPPRESSOR PROTEIN; GENE-EXPRESSION; TYROSINE PHOSPHATASES; CANCER-CELLS; GROWTH; ACTIVATION; METASTASIS; INVASION; PHOSPHORYLATION; MDM2	Most of the p53 target genes, all except MDM2, COP1 and PIRH2, perform functions in apoptosis, differentiation and cell cycle arrest. The aforementioned oncogenes downregulate p53 through a negative feedback mechanism, and thus contribute to tumor development. In this study, we report a new p53 target, PRL-1, which is believed to be a significant regulator in the development and metastasis of a variety of cancer types. Phosphatase of regenerating liver 1 (PRL-1) overexpression reduced the levels of endogenous and exogenous p53 proteins, and inhibited p53-mediated apoptosis. On the other hand, the ablation of PRL-1 by small interfering RNA (siRNA) increased p53 protein levels. The p53 downregulation was mediated by p53 ubiquitination and subsequent proteasomal degradation. Furthermore, p53 ubiquitination by PRL-1 was achieved through two independent pathways, by inducing PIRH2 transcription and by inducing MDM2 phosphorylation through Akt signaling. In addition, we showed that the PRL-1 gene harbors a p53 response element in the first intron, and its transcription is regulated by the p53 protein. These findings imply that the new oncogenic p53 target, PRL-1, may contribute to tumor development by the downregulation of p53 by a negative feedback mechanism.	[Yoo, O-J] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Biomed Res Ctr, Dept Biol Sci, Taejon 305701, South Korea; [Kim, D. M.] Chonnam Natl Univ, Higher Educ Ctr Bioregulator Res BK21, Kwangju, South Korea; [Kim, I-C] Chonnam Natl Univ, Dept Biol, Kwangju, South Korea; [Yoo, O-J] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Biomed Res Ctr, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Chonnam National University; Chonnam National University; Korea Advanced Institute of Science & Technology (KAIST)	Yoo, OJ (corresponding author), Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Biomed Res Ctr, Dept Biol Sci, Taejon 305701, South Korea.	ojyoo@kaist.ac.kr	Kim, Ho Min/G-2712-2011; Yoo, Ook Joon/C-1860-2011		Ministry of Science and Technology of Korea [M1040101001-06N0101-00110]	Ministry of Science and Technology of Korea(Ministry of Science & Technology (MOST), Republic of Korea)	We thank Dr Sung Hyun Kang and Dr Kwang Hee Bae (KRIBB) for providing the FLAG-PRL-1. This work was supported by funding from the Ministry of Science and Technology of Korea (M1040101001-06N0101-00110).	Achiwa H, 2007, CANCER RES, V67, P643, DOI 10.1158/0008-5472.CAN-06-2436; Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Daoud SS, 2003, CANCER RES, V63, P2782; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Fiordalisi JJ, 2006, CANCER RES, V66, P3153, DOI 10.1158/0008-5472.CAN-05-3116; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; Huang JH, 1998, ONCOGENE, V17, P401, DOI 10.1038/sj.onc.1201951; Jeong SJ, 2005, ONCOGENE, V24, P6719, DOI 10.1038/sj.onc.1208825; Jung HY, 2007, J BIOL CHEM, V282, P35293, DOI 10.1074/jbc.M705181200; Kim SB, 2007, CELL DEATH DIFFER, V14, P982, DOI 10.1038/sj.cdd.4402083; Kobayashi D, 2002, ANTICANCER RES, V22, P3963; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Liang FB, 2007, J BIOL CHEM, V282, P5413, DOI 10.1074/jbc.M608940200; McMahon SB, 1996, J LEUKOCYTE BIOL, V60, P159, DOI 10.1002/jlb.60.2.159; Milne D, 2004, FEBS LETT, V577, P270, DOI 10.1016/j.febslet.2004.09.081; Miskad UA, 2004, PATHOBIOLOGY, V71, P176, DOI 10.1159/000078671; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; Parker BS, 2004, CANCER RES, V64, P7857, DOI 10.1158/0008-5472.CAN-04-1976; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Seong HA, 2007, J BIOL CHEM, V282, P12075, DOI 10.1074/jbc.M609832200; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Stephens BJ, 2005, MOL CANCER THER, V4, P1653, DOI 10.1158/1535-7163.MCT-05-0248; Wang HH, 2007, CANCER RES, V67, P2922, DOI 10.1158/0008-5472.CAN-06-3598; Wang Q, 2002, CANCER LETT, V175, P63, DOI 10.1016/S0304-3835(01)00703-0; Weizer-Stern O, 2007, BRIT J HAEMATOL, V138, P253, DOI 10.1111/j.1365-2141.2007.06638.x; Werner SR, 2003, CANCER LETT, V202, P201, DOI 10.1016/S0304-3835(03)00517-2; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wu XP, 2004, AM J PATHOL, V164, P2039, DOI 10.1016/S0002-9440(10)63763-7; Yoo YG, 2004, J BIOL CHEM, V279, P36242, DOI 10.1074/jbc.M401290200	36	34	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					545	554		10.1038/onc.2008.409	http://dx.doi.org/10.1038/onc.2008.409			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18997816				2022-12-17	WOS:000262866500008
J	Tamura, Y; Simizu, S; Muroi, M; Takagi, S; Kawatani, M; Watanabe, N; Osada, H				Tamura, Y.; Simizu, S.; Muroi, M.; Takagi, S.; Kawatani, M.; Watanabe, N.; Osada, H.			Polo-like kinase 1 phosphorylates and regulates Bcl-x(L) during pironetin-induced apoptosis	ONCOGENE			English	Article						apoptosis; Bcl-x(L); phosphorylation; Plk1; pironetin	BCL-2 FAMILY; SOMATIC WEE1; PROTEIN; IDENTIFICATION; INHIBITOR; DOMAIN; DEATH; GENE; ALPHA; PLK1	Bcl-x(L), an anti-apoptotic Bcl-2 family member protein, contributes to the resistance against chemotherapies such as tubulin-binder treatment in many human tumors. Although Bcl-x(L) is phosphorylated after tubulin-binder treatment, the role of the phosphorylation and its responsible kinase(s) are poorly understood. Here, we identified Plk1 (polo-like kinase 1) as a Bcl-x(L) kinase. Same location of Bcl-x(L) and Plk1 was revealed by immunocytochemical analyses at M-phase in situ. Plk1 phosphorylates Bcl-x(L) in vitro, and we identified Plk1 phosphorylation sites in Bcl-x(L). When all of these phosphorylation sites were substituted to alanines, the anti-apoptotic activity of the Bcl-x(L) mutant against the apoptosis induced by pironetin, but not against ultraviolet-induced apoptosis, was increased. These observations suggest that Plk1 is a regulator of Bcl-x(L) phosphorylation and controls the anti-apoptotic activity of Bcl-x(L) during pironetin-induced apoptosis.	[Tamura, Y.; Simizu, S.; Muroi, M.; Takagi, S.; Kawatani, M.; Watanabe, N.; Osada, H.] RIKEN, Antibiot Lab, Wako, Saitama 3510198, Japan; [Tamura, Y.; Simizu, S.; Muroi, M.; Takagi, S.; Kawatani, M.; Watanabe, N.; Osada, H.] RIKEN, Dept Biol Chem, Adv Sci Inst, Wako, Saitama 3510198, Japan; [Tamura, Y.; Takagi, S.; Osada, H.] Saitama Univ, Grad Sch Sci & Engn, Saitama 3388570, Japan	RIKEN; RIKEN; Saitama University	Osada, H (corresponding author), RIKEN, Antibiot Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	hisyo@riken.jp	Watanabe, Nobumoto/N-6959-2015; Muroi, Makoto/C-7430-2017; Osada, Hiroyuki/N-4305-2014; Osada, Hiroyuki/AAY-6254-2020	Watanabe, Nobumoto/0000-0002-2130-1334; Simizu, Siro/0000-0003-2949-2427; Kawatani, Makoto/0000-0002-9571-4916; MUROI, Makoto/0000-0002-4323-9527				Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Basu A, 2003, FEBS LETT, V538, P41, DOI 10.1016/S0014-5793(03)00131-5; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen J, 2006, FEBS LETT, V580, P3624, DOI 10.1016/j.febslet.2006.05.047; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cittelly DM, 2007, J NEUROSCI RES, V85, P1894, DOI 10.1002/jnr.21313; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Du LH, 2005, ONCOGENE, V24, P107, DOI 10.1038/sj.onc.1208189; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Feng Y, 1999, BIOCHEM J, V339, P435, DOI 10.1042/0264-6021:3390435; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kawatani M, 2003, J BIOL CHEM, V278, P19732, DOI 10.1074/jbc.M213038200; Kondoh M, 1999, BIOCHEM J, V340, P411, DOI 10.1042/0264-6021:3400411; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Ree AH, 2003, ONCOGENE, V22, P8952, DOI 10.1038/sj.onc.1207000; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Schinzel A, 2004, BBA-MOL CELL RES, V1644, P95, DOI 10.1016/j.bbamcr.2003.09.006; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; Simizu S, 2005, CANCER RES, V65, P7455, DOI 10.1158/0008-5472.CAN-04-4446; Simizu S, 2004, CANCER SCI, V95, P266, DOI 10.1111/j.1349-7006.2004.tb02214.x; Tamura Y, 2004, FEBS LETT, V569, P249, DOI 10.1016/j.febslet.2004.06.003; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Usui T, 2004, CHEM BIOL, V11, P799, DOI 10.1016/j.chembiol.2004.03.028; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zheng JY, 2008, BIOPHYS J, V94, P286, DOI 10.1529/biophysj.107.104323	37	34	34	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					107	116		10.1038/onc.2008.368	http://dx.doi.org/10.1038/onc.2008.368			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18820703				2022-12-17	WOS:000262294100011
J	Ametzazurra, A; Larrea, E; Civeira, MP; Prieto, J; Aldabe, R				Ametzazurra, A.; Larrea, E.; Civeira, M. P.; Prieto, J.; Aldabe, R.			Implication of human N-alpha-acetyltransferase 5 in cellular proliferation and carcinogenesis	ONCOGENE			English	Article						N-alpha-acetyltransferase; hNAT5/hNAT3; cellular proliferation; tumour progression	DIET-DEPENDENT CARCINOGENESIS; STRESS-INDUCED APOPTOSIS; TERMINAL ACETYLTRANSFERASES; RNA INTERFERENCE; TRANSGENIC MICE; P53; IDENTIFICATION; PROTEIN; GENES; YEAST	The N-alpha-acetyltransferase NatB, composed in Saccharomyces cerevisiae by the Nat3p and Mdm20p subunits, is an important factor for yeast growth and resistance to several stress agents. However, the expression and functional role of the mammalian counterpart has not yet been analysed. Here, we report the identification of Nat3p human homologue (hNAT5/hNAT3) and the characterization of its biological function. We found that hNAT5/hNAT3 silencing in HeLa cells results in inhibition of cell proliferation and increased sensitivity to the pro-apoptotic agent MG132. Moreover, inhibition of hNAT5/hNAT3 expression induces p53 activation and upregulation of the antiproliferative protein p21(WAF1/CIP1). The changes of the cellular transcriptome after hNAT5/hNAT3 knockdown confirmed the involvement of this protein in cell growth and survival processes. Among the genes differentially expressed, we observed upregulation of several p53-dependent antiproliferative and pro-apoptotic genes. In the c-myc transgenic mice, which is a model of inducible hepatocarcinoma, we found that hNAT5/hNAT3 was upregulated when the tumour was induced. In accordance with this observation, we noticed increased hNAT5/hNAT3 protein level in neoplastic versus non-neoplastic tissue in a high proportion of patients with hepatocellular carcinoma. Consequently, our results suggest that hNAT5/hNAT3 is required for cellular proliferation and can be implicated in tumour growth.	[Ametzazurra, A.; Larrea, E.; Prieto, J.; Aldabe, R.] Univ Navarra, CIMA, Div Gene Therapy & Hepatol, Pamplona 31008, Spain; [Civeira, M. P.; Prieto, J.] CIBER EHD, Clin Univ, Liver Unit, Pamplona, Spain	University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Navarra	Aldabe, R (corresponding author), Univ Navarra, CIMA, Div Gene Therapy & Hepatol, Ave Pio 12,55, Pamplona 31008, Spain.	raldabe@unav.es	Aldabe, Rafael/F-3112-2015; Larrea, Esther/L-7586-2014	Aldabe, Rafael/0000-0002-9461-020X; Larrea, Esther/0000-0002-1443-6513; Prieto, Jesus/0000-0002-1091-9593	FPU [AP2001-1567]; FIS; Instituto de Salud Carlos III; Ministerio de Sanidad y Consumo [02/3054]; Departamento de Educacion; Gobierno de Navarra (GNE-Enzima N); UTE	FPU(Spanish Government); FIS(Instituto de Salud Carlos III); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Ministerio de Sanidad y Consumo(Instituto de Salud Carlos III); Departamento de Educacion; Gobierno de Navarra (GNE-Enzima N); UTE	We thank Dr Christine Perret for the transgenic mice, Dr Carmen Berasain and Dr Maider Zabala for providing samples, Dr Francisco Borras-Cuesta and Virginia Belsue for peptides synthesis, Dr Victor Segura for bioinformatics assistance and Sandra Jusue, Maite Corres and Beatriz Carte for excellent technical assistance. AA was supported by an FPU training fellowship (AP2001-1567) and RA was supported by an FIS research contract. CIBEREHD is funded by Instituto de Salud Carlos III, and this research was partially supported by grants from Ministerio de Sanidad y Consumo (02/3054), Departamento de Educacion, Gobierno de Navarra (GNE-Enzima N) and UTE project CIMA.	Agarwal MK, 2006, P NATL ACAD SCI USA, V103, P16278, DOI 10.1073/pnas.0607210103; Arnesen T, 2006, ONCOGENE, V25, P4350, DOI 10.1038/sj.onc.1209469; Arnesen T, 2006, GENE, V371, P291, DOI 10.1016/j.gene.2005.12.008; Arnesen T, 2005, THYROID, V15, P1131, DOI 10.1089/thy.2005.15.1131; Arnesen T, 2005, BIOCHEM J, V386, P433, DOI 10.1042/BJ20041071; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; BORRASCUESTA F, 1991, BIOLOGICALS, V19, P187, DOI 10.1016/1045-1056(91)90033-G; Braun K, 1998, ONCOGENE, V17, P2259, DOI 10.1038/sj.onc.1202145; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Caesar R, 2006, EUKARYOT CELL, V5, P368, DOI 10.1128/EC.5.2.368-378.2006; CARTIER N, 1994, B ACAD NAT MED PARIS, V178, P23; CARTIER N, 1992, ONCOGENE, V7, P1413; CARTIER N, 1994, B ACAD NATL MED, V178, P32; Cheung PK, 2004, CANCER RES, V64, P5929, DOI 10.1158/0008-5472.CAN-04-1216; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Fisher TS, 2005, J BIOL CHEM, V280, P17749, DOI 10.1074/jbc.M412055200; Fluge O, 2002, ONCOGENE, V21, P5056, DOI 10.1038/sj.onc.1205687; Gautschi M, 2003, MOL CELL BIOL, V23, P7403, DOI 10.1128/MCB.23.20.7403-7414.2003; Gendron RL, 2000, DEV DYNAM, V218, P300, DOI 10.1002/(SICI)1097-0177(200006)218:2<300::AID-DVDY5>3.0.CO;2-K; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Joo HY, 2007, NATURE, V449, P1068, DOI 10.1038/nature06256; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lim JH, 2007, APOPTOSIS, V12, P411, DOI 10.1007/s10495-006-0576-9; Lim JH, 2006, CANCER RES, V66, P10677, DOI 10.1158/0008-5472.CAN-06-3171; Line A, 2002, BRIT J CANCER, V86, P1824, DOI 10.1038/sj.bjc.6600321; Liu G, 2005, CANCER CELL, V7, P113, DOI 10.1016/j.ccr.2005.01.019; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Polevoda B, 2003, J BIOL CHEM, V278, P30686, DOI 10.1074/jbc.M304690200; Polevoda B, 2003, J MOL BIOL, V325, P595, DOI 10.1016/S0022-2836(02)01269-X; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Polevoda B, 2008, J CELL BIOCHEM, V103, P492, DOI 10.1002/jcb.21418; Rellos P, 2007, J BIOL CHEM, V282, P6833, DOI 10.1074/jbc.M609721200; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Sim E, 2008, DRUG METAB REV, V40, P479, DOI [10.1080/03602530802186603, 10.1080/03602530802186603 ]; SIMON HU, 1994, BIOCHEM J, V297, P389, DOI 10.1042/bj2970389; Singer JM, 2003, P NATL ACAD SCI USA, V100, P7644, DOI 10.1073/pnas.1232343100; Spurgers KB, 2006, J BIOL CHEM, V281, P25134, DOI 10.1074/jbc.M513901200; STARHEIM KK, 2008, BIOCH J; Sugiura N, 2003, J BIOL CHEM, V278, P40113, DOI 10.1074/jbc.M301218200; Sugiura N, 2001, J BIOL CHEM, V276, P14257, DOI 10.1074/jbc.M100011200; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wise-Draper TM, 2006, MOL CELL BIOL, V26, P7506, DOI 10.1128/MCB.00430-06; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517	47	34	35	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	58					7296	7306		10.1038/onc.2008.332	http://dx.doi.org/10.1038/onc.2008.332			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382FI	18794801				2022-12-17	WOS:000261590300007
J	Meador, JA; Zhao, M; Su, Y; Narayan, G; Geard, CR; Balajee, AS				Meador, J. A.; Zhao, M.; Su, Y.; Narayan, G.; Geard, C. R.; Balajee, A. S.			Histone H2AX is a critical factor for cellular protection against DNA alkylating agents	ONCOGENE			English	Article						histone H2AX; poly(ADP) ribose polymerase 1; base excision repair; alkylation DNA damage; chromosomal instability; mitogen-activated protein kinase	DOUBLE-STRAND BREAKS; IONIZING-RADIATION; CYCLE ARREST; HUMAN-CELLS; POLY(ADP-RIBOSE) POLYMERASE-1; GENOMIC INSTABILITY; COMPLEX-FORMATION; DEPENDENT MANNER; GAMMA-H2AX FOCI; MISMATCH REPAIR	Histone H2A variant H2AX is a dose-dependent suppressor of oncogenic chromosome translocations. H2AX participates in DNA double-strand break repair, but its role in other DNA repair pathways is not known. In this study, role of H2AX in cellular response to alkylation DNA damage was investigated. Cellular sensitivity to two monofunctional alkylating agents (methyl methane sulfonate and N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)) was dependent on H2AX dosage, and H2AX null cells were more sensitive than heterozygous cells. In contrast to wild-type cells, H2AX-deficient cells displayed extensive apoptotic death due to a lack of cell-cycle arrest at G(2)/M phase. Lack of G(2)/M checkpoint in H2AX null cells correlated well with increased mitotic irregularities involving anaphase bridges and gross chromosomal instability. Observation of elevated poly(ADP) ribose polymerase 1 (PARP-1) cleavage suggests that MNNG-induced apoptosis occurs by PARP-1-dependent manner in H2AX-deficient cells. Consistent with this, increased activities of PARP and poly(ADP) ribose (PAR) polymer synthesis were detected in both H2AX heterozygous and null cells. Further, we demonstrate that the increased PAR synthesis and apoptotic death induced by MNNG in H2AX-deficient cells are due to impaired activation of mitogen-activated protein kinase pathway. Collectively, our novel study demonstrates that H2AX, similar to PARP-1, confers cellular protection against alkylation-induced DNA damage. Therefore, targeting either PARP-1 or histone H2AX may provide an effective way of maximizing the chemotherapeutic value of alkylating agents for cancer treatment.	[Meador, J. A.; Zhao, M.; Su, Y.; Narayan, G.; Geard, C. R.; Balajee, A. S.] Columbia Univ, Med Ctr, Dept Radiat Oncol, Coll Phys & Surg,Ctr Radiol Res, New York, NY 10032 USA	Columbia University	Balajee, AS (corresponding author), Columbia Univ, Med Ctr, Dept Radiat Oncol, Coll Phys & Surg,Ctr Radiol Res, VC 11,Room 239,168th St,630 West, New York, NY 10032 USA.	ab836@columbia.edu			US Department of Energy; Office of Sciences (BER) [DE-FG02-05ER64055]; CRG [DE-FG 02-05ER 64054]; NIH/NCI [5P01CA49062-16]; NATIONAL CANCER INSTITUTE [P01CA049062] Funding Source: NIH RePORTER	US Department of Energy(United States Department of Energy (DOE)); Office of Sciences (BER)(United States Department of Energy (DOE)); CRG; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge the generous gift of mouse ES cells proficient and deficient in H2AX from Dr CH Bassing and Dr FW Alt at the Department of Genetics, The CBR Institute for Biomedical Research, The Children's Hospital, Harvard Medical School, Boston, MA, USA. This study was partially supported by a research grant from US Department of Energy, Office of Sciences (BER) awarded to ASB (DE-FG02-05ER64055) and CRG (DE-FG 02-05ER 64054). ASB and CRG acknowledge the financial support received from NIH/NCI (5P01CA49062-16).	Aebi S, 1997, CLIN CANCER RES, V3, P1763; Balajee AS, 2004, EXP CELL RES, V300, P320, DOI 10.1016/j.yexcr.2004.07.022; Balajee AS, 2001, NUCLEIC ACIDS RES, V29, P1341, DOI 10.1093/nar/29.6.1341; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Beardsley DI, 2005, MOL PHARMACOL, V68, P1049, DOI 10.1124/mol.105.013888; BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chou YH, 2007, FOOD CHEM TOXICOL, V45, P1356, DOI 10.1016/j.fct.2007.01.012; Cohen-Armon M, 2007, MOL CELL, V25, P297, DOI 10.1016/j.molcel.2006.12.012; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Ethier C, 2007, APOPTOSIS, V12, P2037, DOI 10.1007/s10495-007-0127-z; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Horton JK, 2005, J BIOL CHEM, V280, P15773, DOI 10.1074/jbc.M413841200; Hurley LH, 2002, NAT REV CANCER, V2, P188, DOI 10.1038/nrc749; Ichijima Y, 2005, BIOCHEM BIOPH RES CO, V336, P807, DOI 10.1016/j.bbrc.2005.08.164; Karran P, 2003, BIOCHIMIE, V85, P1149, DOI 10.1016/j.biochi.2003.10.007; Kauppinen TM, 2006, P NATL ACAD SCI USA, V103, P7136, DOI 10.1073/pnas.0508606103; Lomax ME, 2004, BIOCHEMISTRY-US, V43, P11017, DOI 10.1021/bi049560r; McManus KJ, 2005, MOL BIOL CELL, V16, P5013, DOI 10.1091/mbc.E05-01-0065; Mischo HE, 2005, J BIOL CHEM, V280, P9586, DOI 10.1074/jbc.M411444200; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; Ochs K, 1999, CANCER RES, V59, P1544; Redon C, 2003, EMBO REP, V4, P678, DOI 10.1038/sj.embor.embor871; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Wang HY, 2005, J CELL PHYSIOL, V202, P492, DOI 10.1002/jcp.20141; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yan Y, 2007, ONCOGENE, V26, P4689, DOI 10.1038/sj.onc.1210268	42	34	35	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	43					5662	5671		10.1038/onc.2008.187	http://dx.doi.org/10.1038/onc.2008.187			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352HM	18542054				2022-12-17	WOS:000259487100002
J	Makkonen, H; Jaaskelainen, T; Pitkanen-Arsiola, T; Rytinki, M; Waltering, KK; Matto, M; Visakorpi, T; Palvimo, JJ				Makkonen, H.; Jaaskelainen, T.; Pitkanen-Arsiola, T.; Rytinki, M.; Waltering, K. K.; Matto, M.; Visakorpi, T.; Palvimo, J. J.			Identification of ETS-like transcription factor 4 as a novel androgen receptor target in prostate cancer cells	ONCOGENE			English	Article						androgen receptor; ETS transcription factor; prostate cancer; FoxA1	ETS TRANSCRIPTION FACTOR; GENE-EXPRESSION; REGULATED ACTIVITY; OVEREXPRESSION; AMPLIFICATION; MICROARRAYS; PROTEINS; MUTATION; DOMAIN; ROLES	Transcriptional control by androgens via androgen receptor (AR) is strongly involved in prostate cancer development, but the critical target genes have remained elusive. We have characterized E twenty-six-like transcription factor 4 (ELK4) ( also known as serum response factor accessory protein 1) as a novel AR target in human prostate cancer cells. In-silico screening identified three putative AR response elements (AREs) within -10 kb from the transcription start site of ELK4. Both ARE1 at -167/-153 and ARE2 at -481/-467 bound AR in vitro and mediated androgen induction as isolated elements in transcription assays in non-prostate cells. However, merely the ARE2 that cooperates with a proximal forkhead box A1-binding site was critical for the AR-dependent activation of ELK4 promoter in prostate cancer cells. Preferential loading of holo-AR onto the ARE2 and concomitant recruitment of RNA polymerase II onto the ELK4 promoter was conformed in prostate cancer cells by chromatin immunoprecipitation. Database searches indicated that the expression of ELK4 is markedly increased in prostate cancers relative to normal prostates. Moreover, prostate cancer tissue immunostainings showed that nuclear ELK4 levels are significantly increased in androgen-refractory prostate cancers compared to untreated tumours. Reduction of the amount of ELK4 in LNCaP cells by RNAi retarded cell growth. In conclusion, ELK4 is a direct AR target in prostate cancer cells. Androgens may thus contribute to the growth of prostate cancer via influencing ELK4 levels.	[Makkonen, H.; Jaaskelainen, T.; Pitkanen-Arsiola, T.; Rytinki, M.; Palvimo, J. J.] Univ Kuopio, Inst Biomed Med Biochem, FI-70211 Kuopio, Finland; [Waltering, K. K.; Visakorpi, T.] Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; [Waltering, K. K.; Visakorpi, T.] Tampere Univ Hosp, Tampere, Finland; [Matto, M.] Univ Kuopio, Inst Clin Med & Clin Microbiol, FI-70211 Kuopio, Finland	University of Eastern Finland; Tampere University; Tampere University; Tampere University Hospital; University of Eastern Finland	Palvimo, JJ (corresponding author), Univ Kuopio, Inst Biomed Med Biochem, POB 1627, FI-70211 Kuopio, Finland.	Jorma.Palvimo@uku.fi		Palvimo, Jorma/0000-0003-2373-0578; Visakorpi, Tapio/0000-0002-5004-0364	Academy of Finland; Association for International Cancer Research; Finnish Cancer Foundation; Sigrid Juselius Foundation; Kuopio Naturalists' Society; Helena Vuorenmies Foundation; Karjalan Sivistysseura; Finnish Union of Experts in Science	Academy of Finland(Academy of Finland); Association for International Cancer Research; Finnish Cancer Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Kuopio Naturalists' Society; Helena Vuorenmies Foundation; Karjalan Sivistysseura; Finnish Union of Experts in Science	This work was supported by grants from the Academy of Finland, Association for International Cancer Research, Finnish Cancer Foundation, Sigrid Juselius Foundation, Kuopio Naturalists' Society, Helena Vuorenmies Foundation, Karjalan Sivistysseura and Finnish Union of Experts in Science. We thank Merja Rasanen for skilful technical assistance.	Ayadi A, 2001, EMBO J, V20, P5139, DOI 10.1093/emboj/20.18.5139; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Cesari F, 2004, MOL CELL BIOL, V24, P294, DOI 10.1128/MCB.24.1.294-305.2004; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Costello PS, 2004, NAT IMMUNOL, V5, P289, DOI 10.1038/ni1038; Culig Z, 2004, J STEROID BIOCHEM, V92, P265, DOI 10.1016/j.jsbmb.2004.10.003; Culig Z, 2002, ENDOCR-RELAT CANCER, V9, P155, DOI 10.1677/erc.0.0090155; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Edwards S, 2005, BRIT J CANCER, V92, P376, DOI 10.1038/sj.bjc.6602261; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Gao N, 2003, MOL ENDOCRINOL, V17, P1484, DOI 10.1210/me.2003-0020; Gregory CW, 2001, CANCER RES, V61, P4315; Han GZ, 2005, P NATL ACAD SCI USA, V102, P1151, DOI 10.1073/pnas.0408925102; Heinlein CA, 2002, MOL ENDOCRINOL, V16, P2181, DOI 10.1210/me.2002-0070; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Huggins C, 1941, CANCER RES, V1, P293; Jackson AL, 2006, RNA, V12, P1197, DOI 10.1261/rna.30706; KALLIO PJ, 1994, J BIOL CHEM, V269, P11514; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Karvonen U, 2006, EXP CELL RES, V312, P3165, DOI 10.1016/j.yexcr.2006.06.018; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Linja MJ, 2004, CLIN CANCER RES, V10, P1032, DOI 10.1158/1078-0432.CCR-0990-3; Linja MJ, 2001, CANCER RES, V61, P3550; Luo J, 2001, CANCER RES, V61, P4683; Magee JA, 2001, CANCER RES, V61, P5692; Maroni Paul D, 2006, N C Med J, V67, P136; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; RIEGMAN PHJ, 1991, MOL CELL ENDOCRINOL, V76, P181, DOI 10.1016/0303-7207(91)90272-T; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaw PE, 2003, INT J BIOCHEM CELL B, V35, P1210, DOI 10.1016/S1357-2725(03)00031-1; Stewart Alistair B., 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P603, DOI 10.2174/156801105774574658; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Thompson J, 2001, MOL ENDOCRINOL, V15, P923, DOI 10.1210/me.15.6.923; Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Welsh JB, 2001, CANCER RES, V61, P5974; Xiao DM, 2002, REGUL PEPTIDES, V109, P141, DOI 10.1016/S0167-0115(02)00197-0; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zheng H, 2003, GENE DEV, V17, P2283, DOI 10.1101/gad.272503	46	34	45	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2008	27	36					4865	4876		10.1038/onc.2008.125	http://dx.doi.org/10.1038/onc.2008.125			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18469865				2022-12-17	WOS:000258596900001
J	Lakshmikuttyamma, A; Pastural, E; Takahashi, N; Sawada, K; Sheridan, DP; DeCoteau, JF; Geyer, CR				Lakshmikuttyamma, A.; Pastural, E.; Takahashi, N.; Sawada, K.; Sheridan, D. P.; DeCoteau, J. F.; Geyer, C. R.			Bcr-Abl induces autocrine IGF-1 signaling	ONCOGENE			English	Article						IGF-1; BCR-ABL; CML; autocrine signaling	GROWTH-FACTOR-I; CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE INHIBITOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; FACTOR 1 RECEPTOR; HEMATOPOIETIC-CELLS; BETA-CATENIN; PHILADELPHIA-CHROMOSOME	Bcr-Abl oncogene is responsible for the initial phase of chronic myelogenous leukemia (CML), which is effectively treated by the Bcr-Abl inhibitor imatinib. Over time patients become resistant to treatment and progress to blast crisis, an event that is driven by additional genetic and epigenetic aberrations. Recently, we showed that Riz1 expression decreases in blast crisis and that re-expression of Riz1 inhibits IGF-1 expression. IGF-1 signaling is required in many stages of hematopoiesis and inappropriate activation of autocrine IGF-1 signaling may facilitate transformation to blast crisis. We observed that in 8 out of 11 matched CML patient biopsies the IGF-1 expression is elevated in blast crisis. We examined mechanisms used by CML blast crisis cell lines to activate IGF-1 expression. We found that Bcr-Abl activates autocrine IGF- 1 signaling using Hck and Stat5b. Inhibition of these signaling components using small molecule drugs or shRNA decreases proliferation and enhances apoptosis. Together, our study suggests that aberrant IGF- 1 signaling is an important event in blast crisis transformation and it provides a mechanism to explain the activity of IGF-1R and Hck inhibitors in blocking CML blast crisis phenotypes.	[Lakshmikuttyamma, A.; Pastural, E.; Sheridan, D. P.; DeCoteau, J. F.; Geyer, C. R.] Univ Saskatchewan, Genom Med & Pathobiol Res Grp, Dept Biochem, Saskatoon, SK S7N 5E5, Canada; [Lakshmikuttyamma, A.; DeCoteau, J. F.] Univ Saskatchewan, Dept Pathol, Saskatoon, SK S7N 5E5, Canada; [Pastural, E.; Geyer, C. R.] Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada; [Sheridan, D. P.] Univ Saskatchewan, Dept Med, Saskatoon, SK S7N 5E5, Canada; [Takahashi, N.; Sawada, K.] Akita Univ, Sch Med, Akita 010, Japan	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan; University of Saskatchewan; Akita University	Geyer, CR (corresponding author), Univ Saskatchewan, Genom Med & Pathobiol Res Grp, Dept Biochem, Hlth Sci Bldg,107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	ron.geyer@usask.ca	Lakshmikuttyamma, Ashakumary/K-7164-2019	Lakshmikuttyamma, Ashakumary/0000-0001-8580-7855				AKAHANE K, 1987, EXP HEMATOL, V15, P797; Barnes DJ, 2002, ACTA HAEMATOL-BASEL, V108, P180, DOI 10.1159/000065655; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Chen J, 2005, J BIOL CHEM, V280, P29912, DOI 10.1074/jbc.M504516200; Coluccia AML, 2007, EMBO J, V26, P1456, DOI 10.1038/sj.emboj.7601485; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; Danielpour D, 2006, CYTOKINE GROWTH F R, V17, P59, DOI 10.1016/j.cytogfr.2005.09.007; Deutsch E, 2004, BRIT J CANCER, V91, P1735, DOI 10.1038/sj.bjc.6602190; DiNoto R, 1997, LEUKEMIA, V11, P1554; Doepfner KT, 2007, LEUKEMIA, V21, P1921, DOI 10.1038/sj.leu.2404813; Drexler HG, 1999, LEUKEMIA RES, V23, P207; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Guilhot F, 2007, BLOOD, V109, P4143, DOI 10.1182/blood-2006-09-046839; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; HIZUKA N, 1987, ENDOCRINOL JAPON, V34, P81; Hoelbl A, 2006, BLOOD, V107, P4898, DOI 10.1182/blood-2005-09-3596; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Hu YG, 2006, P NATL ACAD SCI USA, V103, P16870, DOI 10.1073/pnas.0606509103; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; JOHNSON EW, 1992, J IMMUNOL, V148, P63; Jones HE, 2006, ENDOCR-RELAT CANCER, V13, pS45, DOI 10.1677/erc.1.01275; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Kofoed EM, 2003, NEW ENGL J MED, V349, P1139, DOI 10.1056/NEJMoa022926; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; KURTZ A, 1988, P NATL ACAD SCI USA, V85, P7825, DOI 10.1073/pnas.85.20.7825; LEROITH D, 1991, TRENDS ENDOCRIN MET, V2, P134, DOI 10.1016/1043-2760(91)90003-6; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Majka M, 2001, BLOOD, V97, P3075, DOI 10.1182/blood.V97.10.3075; Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109; MERCHAV S, 1988, BRIT J HAEMATOL, V70, P267, DOI 10.1111/j.1365-2141.1988.tb02480.x; MERCHAV S, 1988, J CLIN INVEST, V81, P791, DOI 10.1172/JCI113385; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Mori N, 1998, BLOOD, V92, P3405, DOI 10.1182/blood.V92.9.3405.421k44_3405_3409; Nam S, 2007, MOL CANCER THER, V6, P1400, DOI 10.1158/1535-7163.MCT-06-0446; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Pastural E, 2007, ONCOGENE, V26, P1586, DOI 10.1038/sj.onc.1209959; PEPE MG, 1987, J CELL PHYSIOL, V133, P219, DOI 10.1002/jcp.1041330204; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535-7163.MCT-06-0080; SANDERS M, 1993, EXP HEMATOL, V21, P25; Scherr M, 2006, BLOOD, V107, P3279, DOI 10.1182/blood-2005-08-3087; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schwartz GN, 1996, STEM CELLS, V14, P337, DOI 10.1002/stem.140337; Scott SA, 2007, EXP HEMATOL, V35, P263, DOI 10.1016/j.exphem.2006.10.005; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHIMON I, 1995, LEUKEMIA RES, V19, P233, DOI 10.1016/0145-2126(94)00133-U; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; SPECCHIA G, 1992, BRIT J HAEMATOL, V80, P310, DOI 10.1111/j.1365-2141.1992.tb08138.x; Steller MA, 1996, CANCER RES, V56, P5087; Takahashi N, 2006, BLOOD, V108, p605A, DOI 10.1182/blood.V108.11.2134.2134; Tazzari PL, 2007, LEUKEMIA, V21, P886, DOI 10.1038/sj.leu.2404643; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Wang Y, 2005, J BIOL CHEM, V280, P10955, DOI 10.1074/jbc.M412808200; Wilson MB, 2002, ONCOGENE, V21, P8075, DOI 10.1038/sj.onc.1206008; Woelfle J, 2003, J BIOL CHEM, V278, P51261, DOI 10.1074/jbc.M309486200; ZADIK Z, 1993, J PEDIATR ENDOCRINOL, V6, P79; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829; Zhang ZH, 2006, MOL PHARMACOL, V69, P1510, DOI 10.1124/mol.106.023721; Zumkeller W, 1999, BLOOD, V94, P3653, DOI 10.1182/blood.V94.11.3653.423k42_3653_3657	72	34	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2008	27	27					3831	3844		10.1038/onc.2008.8	http://dx.doi.org/10.1038/onc.2008.8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18246120				2022-12-17	WOS:000256904700007
J	Lee, YJ; Lee, HJ; Lee, JS; Jeoung, D; Kang, CM; Bae, S; Lee, SJ; Kwon, SH; Kang, D; Lee, YS				Lee, Y. J.; Lee, H. J.; Lee, J. S.; Jeoung, D.; Kang, C. M.; Bae, S.; Lee, S. J.; Kwon, S. H.; Kang, D.; Lee, Y. S.			A novel function for HSF1-induced mitotic exit failure and genomic instability through direct interaction between HSF1 and Cdc20	ONCOGENE			English	Article						HSF1; interaction with Cdc20; mitotic arrest; aneuploidy; inhibition of APC activity	SHOCK; DEPHOSPHORYLATION; EXPRESSION; FACTOR-1; CANCERS; MITOSIS; ROLES; CELLS	Although heat-shock factor (HSF) 1 is a known transcriptional factor of heat-shock proteins, other pathwayslike production of aneuploidy and increased protein stability of cyclin B1 have been proposed. In the present study, the regulatory domain of HSF1 (amino-acid sequence 212-380) was found to interact directly with the amino-acid sequence 106-171 of Cdc20. The association between HSF1 and Cdc20 inhibited the interaction between Cdc27 and Cdc20, the phosphorylation of Cdc27 and the ubiquitination activity of anaphase-promoting complex (APC). The overexpression of HSF1 inhibited mitotic exit and the degradations of cyclin B1 and securin, which resulted in production of aneuploidy and multinucleated cells, but regulatory domain-deficient HSF1 did not. Moreover, HSF1-overexpressing cells showed elevated levels of micronuclei and genomic alteration. The depletion of HSF1 from cells highly expressing HSF1 reduced nocodazole-mediated aneuploidy in cells. These findingss suggest a novel function of HSF1 frequently overexpressed in cancer cells, to inhibit APC/C activity by interacting with Cdc20, and to result in aneuploidy development and genomic instability.	[Lee, Y. J.; Lee, H. J.; Kang, C. M.; Bae, S.; Lee, Y. S.] Korea Inst Radiol & Med Sci, Div Radiat Effect, Seoul 139706, South Korea; [Lee, J. S.; Lee, S. J.] Korea Inst Radiol & Med Sci, Div Radiat Canc Res, Seoul 139706, South Korea; [Jeoung, D.] Kangwon Natl Univ, Coll Nat Sci, Chunchon, South Korea; [Kwon, S. H.; Kang, D.] Korea basic Sci Inst, Chunchon Ctr, Chunchon, South Korea	Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Kangwon National University; Korea Basic Science Institute (KBSI)	Lee, YS (corresponding author), Korea Inst Radiol & Med Sci, Div Radiat Effect, 215-4 Gongneung Dong, Seoul 139706, South Korea.	yslee@kcch.re.kr	Lee, Yun-Sil/AAP-1378-2020	Lee, Yun-Sil/0000-0002-7538-8850				Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Cen H, 2004, WORLD J GASTROENTERO, V10, P3122; Cross FR, 2003, DEV CELL, V4, P741, DOI 10.1016/S1534-5807(03)00119-9; HAHN GM, 1988, CANCER RES, V48, P1803; Hida K, 2005, CANCER RES, V65, P2507, DOI 10.1158/0008-5472.CAN-05-0002; Hoang AT, 2000, AM J PATHOL, V156, P857, DOI 10.1016/S0002-9440(10)64954-1; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; Min JN, 2007, ONCOGENE, V26, P5086, DOI 10.1038/sj.onc.1210317; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Ricaniadis N, 2001, EUR J SURG ONCOL, V27, P88, DOI 10.1053/ejso.1999.1018; Seo HR, 2006, J BIOL CHEM, V281, P17220, DOI 10.1074/jbc.M600062200; SHIN CR, 2003, CANC LETT, V201, P203; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Su TT, 1998, GENE DEV, V12, P1495, DOI 10.1101/gad.12.10.1495; Wang YQ, 2004, J BIOL CHEM, V279, P32651, DOI 10.1074/jbc.M401475200	17	34	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2008	27	21					2999	3009		10.1038/sj.onc.1210966	http://dx.doi.org/10.1038/sj.onc.1210966			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18059335				2022-12-17	WOS:000255681700007
J	Shafiei, F; Rahnama, F; Pawella, L; Mitchell, MD; Gluckman, PD; Lobie, PE				Shafiei, F.; Rahnama, F.; Pawella, L.; Mitchell, M. D.; Gluckman, P. D.; Lobie, P. E.			DNMT3A and DNMT3B mediate autocrine hGH repression of plakoglobin gene transcription and consequent phenotypic conversion of mammary carcinoma cells	ONCOGENE			English	Article						DNA methylation; DNA methyltransferases; human growth hormone; plakoglobin; mammary carcinoma	HUMAN GROWTH-HORMONE; DNA METHYLTRANSFERASES DNMT3A; TUMOR-SUPPRESSOR GENES; GAMMA-CATENIN GENE; PROMOTER METHYLATION; COLON-CANCER; EXPRESSION; ACTIVATION; KINASE; IDENTIFICATION	Directed by microarray analyses, we report that autocrine human growth hormone (hGH) increased the mRNA and protein expression of DNA methyltransferase 1 (DNMT1), DNMT3A and DNMT3B in mammary carcinoma cells. Autocrine hGH stimulation of DNMT3A and DNMT3B expression was mediated by JAK2 and Src kinases, and treatment of mammary carcinoma cells with the DNMT inhibitor, 5'-aza-2'-deoxycytidine (AZA), abrogated autocrine hGH-stimulated cellular proliferation, apoptosis and anchorage-independent growth. AZA reversed the epitheliomesenchymal transition of mammary carcinoma cells induced by autocrine hGH, to an epithelioid morphology and abrogated cell migration stimulated by autocrine hGH. Autocrine hGH-stimulated hypermethylation of the first exon of the PLAKOGLOBIN gene and AZA abrogated the ability of autocrine hGH to repress plakoglobin gene transcription. Small interfering RNA (siRNA)-mediated depletion of the individual DNMT molecules did not release autocrine hGH repression of PLAKOGLOBIN promoter activity nor did individual DNMT depletion affect autocrine hGH-stimulated migration. However, concomitant siRNA-mediated depletion of both DNMT3A and DNMT3B abrogated hypermethylation of the PLAKOGLOBIN gene stimulated by autocrine hGH and subsequent repression of plakoglobin gene transcription and increased cell migration. Thus, the autocrine hGH-stimulated increases in DNMT3A and DNMT3B expression mediate repression of plakoglobin gene transcription by direct hypermethylation of its promoter and consequent phenotypic conversion of mammary carcinoma cells. Autocrine hGH, therefore, utilizes DNA methylation as a mechanism to exert its oncogenic effects in mammary carcinoma cells.	[Lobie, P. E.] Univ Auckland, Liggins Inst, Auckland 1, New Zealand; Univ Auckland, Natl Res Ctr Growth & Dev, Auckland 1, New Zealand	University of Auckland; University of Auckland	Lobie, PE (corresponding author), Univ Auckland, Liggins Inst, 2-6 Pk Ave, Auckland 1, New Zealand.	p.lobie@auckland.ac.nz	Mitchell, Murray/A-8639-2010	Mitchell, Murray/0000-0002-6167-7176				Bai SM, 2005, MOL CELL BIOL, V25, P751, DOI 10.1128/MCB.25.2.751-766.2005; Bartolomei MS, 1997, ANNU REV GENET, V31, P493, DOI 10.1146/annurev.genet.31.1.493; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Breault JE, 2005, CLIN CANCER RES, V11, P557; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Fukunaga Y, 2005, CELL STRUCT FUNCT, V30, P25, DOI 10.1247/csf.30.25; Hausherr A, 2007, ONCOGENE, V26, P4987, DOI 10.1038/sj.onc.1210306; Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138; Hodge DR, 2005, CANCER RES, V65, P4673, DOI 10.1158/0008-5472.CAN-04-3589; Hodge DR, 2001, J BIOL CHEM, V276, P39508, DOI 10.1074/jbc.C100343200; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jaenisch R, 1998, CIBA F SYMP, V214, P200; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Kaulsay KK, 1999, EXP CELL RES, V250, P35, DOI 10.1006/excr.1999.4492; Kaulsay KK, 2001, ENDOCRINOLOGY, V142, P767, DOI 10.1210/en.142.2.767; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Ling L, 2004, J BIOL CHEM, V279, P32737, DOI 10.1074/jbc.M400601200; Ling L, 2003, J BIOL CHEM, V278, P27301, DOI 10.1074/jbc.M302516200; MENG F, 2007, ONCOGENE        0709; Mertani HC, 2001, J BIOL CHEM, V276, P21464, DOI 10.1074/jbc.M100437200; Mukhina S, 2004, P NATL ACAD SCI USA, V101, P15166, DOI 10.1073/pnas.0405881101; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; Oka M, 2005, ONCOGENE, V24, P3091, DOI 10.1038/sj.onc.1208540; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Perry JK, 2006, GROWTH HORM IGF RES, V16, P277, DOI 10.1016/j.ghir.2006.09.006; Potter E, 2001, EUR J ENDOCRINOL, V145, P625, DOI 10.1530/eje.0.1450625; Rahnama F, 2006, ENDOCRINOLOGY, V147, P5275, DOI 10.1210/en.2006-0288; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; SERRANO J, 1993, J CHROMATOGR-BIOMED, V615, P203, DOI 10.1016/0378-4347(93)80334-Z; Shiina H, 2005, CANCER RES, V65, P2130, DOI 10.1158/0008-5472.CAN-04-3398; Sung J, 2005, CARCINOGENESIS, V26, P487, DOI 10.1093/carcin/bgh318; Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168; Waters MJ, 1999, CLIN EXP PHARMACOL P, V26, P760, DOI 10.1046/j.1440-1681.1999.03129.x; Wehbe H, 2006, CANCER RES, V66, P10517, DOI 10.1158/0008-5472.CAN-06-2130; Winn RA, 2002, ONCOGENE, V21, P7497, DOI 10.1038/sj.onc.1205963; Yanagisawa Y, 2002, BBA-GENE STRUCT EXPR, V1577, P457, DOI 10.1016/S0167-4781(02)00482-7; Zhang X, 2003, J BIOL CHEM, V278, P7580, DOI 10.1074/jbc.M212050200; Zhu T, 2005, CANCER RES, V65, P317; Zhu T, 2002, J BIOL CHEM, V277, P45592, DOI 10.1074/jbc.M201385200	44	34	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2008	27	18					2602	2612		10.1038/sj.onc.1210917	http://dx.doi.org/10.1038/sj.onc.1210917			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17998942				2022-12-17	WOS:000255057000010
J	Knoops, L; Hornakova, T; Royer, Y; Constantinescu, SN; Renauld, JC				Knoops, L.; Hornakova, T.; Royer, Y.; Constantinescu, S. N.; Renauld, J-C			JAK kinases overexpression promotes in vitro cell transformation	ONCOGENE			English	Article						interleukin-9; Janus kinases; transforming gene; overexpression	SURFACE EXPRESSION; POLYCYTHEMIA-VERA; MYELOPROLIFERATIVE DISORDERS; CONSTITUTIVE ACTIVATION; ERYTHROPOIETIN RECEPTOR; CYTOKINE RECEPTOR; HODGKINS LYMPHOMA; STAT PROTEINS; INTERLEUKIN-9; MUTATION	Constitutive activation of the JAK-STAT pathway is frequent in cancer and contributes to oncogenesis. Here, we took advantage of the Ba/F3 cell line, a murine proB cell line dependent on IL-3 for growth, to analyse mechanisms of constitutive STAT activation in vitro. Cytokine-independent and tumorigenic Ba/F3 cell lines were derived from a two-step selection process. Cells transfected with a defective IL-9 receptor acquire IL-9 responsiveness during a first step of selection, and progress after a second selection step to autonomously growing tumorigenic cells. Microarray analysis pointed to JAK1 overexpression as a key genetic event in this transformation. Overexpression of JAK1 not only increased the sensitivity to IL-9 but also allowed a second selection step toward cytokine-independent growth with constitutive STAT activation. This progression was dependent on a functional FERM and kinase JAK1 domain. Similar results were observed after JAK2, JAK3 and TYK2 overexpression. All autonomous cell lines showed an activation of STAT5, ERK1-2 and AKT but only TYK2-overexpressing cell lines showed a constitutive activation of STAT3. Thus, JAK overexpression can be considered as one of the oncogenic events leading to the constitutive activation of the JAK-STAT pathway.	[Knoops, L.; Hornakova, T.; Royer, Y.; Constantinescu, S. N.; Renauld, J-C] Univ Catholique Louvain, Ludwig Inst Canc Res, Brussels Branch, B-1200 Brussels, Belgium; [Knoops, L.; Hornakova, T.; Royer, Y.; Constantinescu, S. N.; Renauld, J-C] Univ Catholique Louvain, Duve Inst, B-1200 Brussels, Belgium; [Knoops, L.] Clin Univ St Luc, Div Hematol, B-1200 Brussels, Belgium	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Renauld, JC (corresponding author), Univ Catholique Louvain, Ludwig Inst Canc Res, Brussels Branch, Ave Hippocrate 74, B-1200 Brussels, Belgium.	renauld@bru.licr.org	Constantinescu, Stefan N/E-5277-2012; Renauld, Jean-Christophe/B-7268-2012	Renauld, Jean-Christophe/0000-0003-1736-2131; Constantinescu, Stefan N./0000-0002-8599-2699				Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Cochet O, 2006, CELL SIGNAL, V18, P449, DOI 10.1016/j.cellsig.2005.05.010; Demoulin JB, 2000, CANCER RES, V60, P3971; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; DRUEZ C, 1990, J IMMUNOL, V145, P2494; Fischer M, 2003, LEUKEMIA, V17, P2513, DOI 10.1038/sj.leu.2403123; Guiter C, 2004, BLOOD, V104, P543, DOI 10.1182/blood-2003-10-3545; Haan C, 2001, J BIOL CHEM, V276, P37451, DOI 10.1074/jbc.M106135200; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Joos S, 2000, CANCER RES, V60, P549; Joos S, 2003, INT J CANCER, V103, P489, DOI 10.1002/ijc.10845; KELLEHER K, 1991, BLOOD, V77, P1436; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Knoops L, 2004, GROWTH FACTORS, V22, P207, DOI 10.1080/08977190410001720879; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; Lu XH, 2005, P NATL ACAD SCI USA, V102, P18962, DOI 10.1073/pnas.0509714102; MERZ H, 1991, BLOOD, V78, P1311; Nagai H, 2003, J HUM GENET, V48, P65, DOI 10.1007/s100380300008; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; Rawat R, 2000, BLOOD, V96, P3514; Renauld J.-C., 2003, CYTOKINE HDB, P347; RENAULD JC, 1994, ONCOGENE, V9, P1327; RENAULD JC, 1995, J LEUKOCYTE BIOL, V57, P353, DOI 10.1002/jlb.57.3.353; Rucker FG, 2006, J CLIN ONCOL, V24, P3887, DOI 10.1200/JCO.2005.04.5450; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; Staerk J, 2005, J BIOL CHEM, V280, P41893, DOI 10.1074/jbc.C500358200; Trikha M, 2003, CLIN CANCER RES, V9, P4653; UYTTENHOVE C, 1991, J EXP MED, V173, P519, DOI 10.1084/jem.173.2.519; Zhou YJ, 2001, MOL CELL, V8, P959, DOI 10.1016/S1097-2765(01)00398-7	41	34	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1511	1519		10.1038/sj.onc.1210800	http://dx.doi.org/10.1038/sj.onc.1210800			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17873904				2022-12-17	WOS:000253815800002
J	Plans, V; Guerra-Rebollo, M; Thomson, TM				Plans, V.; Guerra-Rebollo, M.; Thomson, T. M.			Regulation of mitotic exit by the RNF8 ubiquitin ligase	ONCOGENE			English	Article						RNF8; ubiquitin ligase; cell cycle; mitosis	RING FINGER PROTEIN; CELL-CYCLE; CONJUGATING ENZYMES; CYTOKINESIS FAILURE; FHA DOMAIN; CHFR; CHECKPOINT; MECHANISMS; DMA1; LOCALIZATION	RNF8 is a ubiquitin ligase with a FHA domain near its N terminus, and a RING-finger domain at its C terminus, through which it recruits several ubiquitin-conjugating enzymes. In metazoans, only the mitotic checkpoint regulator CHFR shares this domain architecture. Here we show that RNF8 is a nuclear protein that follows a cell-cycle-dependent turnover, reaching its highest levels in mitosis, followed by a strong decline in late mitotic stages. Overexpression of RNF8 caused a delay in cytokinesis and the frequent appearance of aberrant mitotic figures. These effects were dependent on the ubiquitin ligase activity of RNF8, since they were significantly attenuated when a RING-finger mutant, inactive as an E3, was over-expressed. Depletion of RNF8 also caused a delay in the exit from the mitotic arrest induced by nocodazole, associated with a reduced turnover of the APC/C substrate cyclin B1. These observations suggest that RNF8 regulates the rate of exit from mitosis and cytokinesis.	[Plans, V.; Guerra-Rebollo, M.; Thomson, T. M.] CSIC, Inst Biol Mol Barcelona, Dept Mol & Cellular Biol, ES-08034 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Thomson, TM (corresponding author), CSIC, Inst Biol Mol Barcelona, Dept Mol & Cellular Biol, C Jordi Girona 18-26, ES-08034 Barcelona, Spain.	titbmc@cid.csic.es	Guerra-Rebollo, Marta/H-3199-2015; Thomson, Timothy/Z-6271-2019	Guerra-Rebollo, Marta/0000-0002-3731-4527; Thomson, Timothy/0000-0002-4670-9440				Bothos J, 2003, ONCOGENE, V22, P7101, DOI 10.1038/sj.onc.1206831; Chaturvedi P, 2002, CANCER RES, V62, P1797; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Fraschini R, 2004, MOL BIOL CELL, V15, P3796, DOI 10.1091/mbc.E04-02-0094; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Guertin DA, 2002, DEV CELL, V3, P779, DOI 10.1016/S1534-5807(02)00367-2; Guertin DA, 2002, MICROBIOL MOL BIOL R, V66, P155, DOI 10.1128/MMBR.66.2.155-178.2002; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Howell BJ, 2001, J CELL BIOL, V155, P1159, DOI 10.1083/jcb.200105093; Ito K, 2001, EUR J BIOCHEM, V268, P2725, DOI 10.1046/j.1432-1327.2001.02169.x; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Liao H, 1999, J MOL BIOL, V294, P1041, DOI 10.1006/jmbi.1999.3313; Mariatos G, 2003, CANCER RES, V63, P7185; Moore FL, 2003, P NATL ACAD SCI USA, V100, P538, DOI 10.1073/pnas.0234478100; Murone M, 1996, EMBO J, V15, P6605, DOI 10.1002/j.1460-2075.1996.tb01051.x; Passmore LA, 2004, BIOCHEM J, V379, P513, DOI 10.1042/BJ20040198; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Plans V, 2006, J CELL BIOCHEM, V97, P572, DOI 10.1002/jcb.20587; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; Satoh A, 2003, CANCER RES, V63, P8606; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Takano Y, 2004, J BIOL CHEM, V279, P18926, DOI 10.1074/jbc.M309148200; Trielli MO, 1996, J CELL BIOL, V135, P689, DOI 10.1083/jcb.135.3.689; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538	30	34	35	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2008	27	10					1355	1365		10.1038/sj.onc.1210782	http://dx.doi.org/10.1038/sj.onc.1210782			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17724460				2022-12-17	WOS:000253548200002
J	Chan, BL; Ching, AK; To, KF; Leung, JK; Chen, S; Li, Q; Lai, PS; Tang, NS; Shaw, PC; Chan, JH; James, A; Lai, KN; Lim, PL; Lee, KH; Chui, YL				Chan, BC-L; Ching, AK-K; To, K-F; Leung, JC-K; Chen, S.; Li, Q.; Lai, PB-S; Tang, NL-S; Shaw, P-C; Chan, JY-H; James, A. E.; Lai, K-N; Lim, P-L; Lee, KK-H; Chui, Y-L			BRE is an antiapoptotic protein in vivo and overexpressed in human hepatocellular carcinoma	ONCOGENE			English	Article						BRE; antiapoptosis; tumorigenesis; human hepatocellular carcinoma; BRE-specific monoclonal antibody; Fas-mediated acute liver failure	ANTI-FAS ANTIBODY; CELL-CYCLE ENTRY; TRANSGENIC MICE; HEPATIC CARCINOGENESIS; SIGNALING PATHWAYS; BCL-2 FAMILY; APOPTOSIS; DEATH; EXPRESSION; PROLIFERATION	BRE binds to the cytoplasmic domains of tumor necrosis factor receptor-1 and Fas, and in cell lines can attenuate death receptor-initiated apoptosis by inhibiting t-BID-induced activation of the mitochondrial apoptotic pathway. Overexpression of BRE by transfection can also attenuate intrinsic apoptosis and promote growth of the transfected Lewis lung carcinoma line in mice. There is, however, a complete lack of in vivo data about the protein. Here, we report that by using our BRE-specific monoclonal antibody on the immunohistochemistry of 123 specimens of human hepatocellular carcinoma (HCC), significant differences in BRE expression levels between the paired tumoral and non-tumoral regions (P<2.2e-16) were found. Marked overexpression of BRE was detected in majority of the tumors, whereas most non-tumoral regions expressed the same low level of the protein as in normal livers. To investigate whether BRE overexpression could promote cell survival in vivo, liver-specific transgenic BRE mice were generated and found to be significantly resistant to Fas-mediated lethal hepatic apoptosis. The transgenic model also revealed post-transcriptional regulation of Bre level in the liver, which was not observed in HCC and non-HCC cell lines. Indeed, all cell lines analysed express high levels of BRE. In conclusion, BRE is antiapoptotic in vivo, and may promote tumorigenesis when overexpressed.	[Chan, BC-L; Ching, AK-K; Chen, S.; Li, Q.; Lim, P-L; Chui, Y-L] Chinese Univ Hong Kong, Clin Immunol Unit, Hong Kong, Hong Kong, Peoples R China; [Chan, BC-L; Ching, AK-K; Chen, S.; Li, Q.; Lim, P-L; Chui, Y-L] Clin Immunol Unit, Hong Kong, Hong Kong, Peoples R China; [To, K-F] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, State Key Lab Oncol S China, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Leung, JC-K; Lai, K-N] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; [Lai, PB-S] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; [Tang, NL-S] Chinese Univ Hong Kong, Dept Chem Pathol, Hong Kong, Hong Kong, Peoples R China; [Shaw, P-C] Chinese Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; [Chan, JY-H] Univ Texas Houston, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; [James, A. E.] Chinese Univ Hong Kong, Lab Anim Serv Ctr, Hong Kong, Hong Kong, Peoples R China; [Lee, KK-H] Chinese Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; [Chui, Y-L] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Prince of Wales Hospital	Chui, YL (corresponding author), Chinese Univ Hong Kong, Clin Immunol Unit, Hong Kong, Hong Kong, Peoples R China.	yiuloonchui@cuhk.edu.hk	Lai, Paul BS/K-8556-2015; Lee, Kenneth Ka Ho/H-6698-2013; Lai, Kar Neng/C-4300-2009; Leung, Joseph Chi Kam/C-4338-2009; Tang, Nelson L/P-5018-2017	Lai, Paul BS/0000-0002-9469-6728; Lee, Kenneth Ka Ho/0000-0002-6520-304X; Tang, Nelson L/0000-0002-3607-5819; Chui, Yiu-Loon/0000-0002-3441-9729				Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Bai L, 2005, AM J PATHOL, V166, P1523, DOI 10.1016/S0002-9440(10)62368-1; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; Chan BCL, 2005, BIOCHEM BIOPH RES CO, V326, P268, DOI 10.1016/j.bbrc.2004.11.013; Chan BCL, 2002, INT J CANCER, V102, P492, DOI 10.1002/ijc.10773; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Ching AKK, 2000, INT IMMUNOL, V12, P1245, DOI 10.1093/intimm/12.9.1245; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; de la Coste A, 1999, CANCER RES, V59, P5017; De la Coste A, 1999, AM J PHYSIOL-GASTR L, V277, pG702, DOI 10.1152/ajpgi.1999.277.3.G702; Dive C, 1992, Semin Cancer Biol, V3, P417; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gu CH, 1998, FASEB J, V12, P1101, DOI 10.1096/fasebj.12.12.1101; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; KOHLER G, 1975, NATURE, V256, P497; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; LI L, 1995, BIOCHEM BIOPH RES CO, V206, P764, DOI 10.1006/bbrc.1995.1108; Li Q, 2004, J BIOL CHEM, V279, P52106, DOI 10.1074/jbc.M408678200; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Pierce RH, 2002, AM J PATHOL, V160, P1555, DOI 10.1016/S0002-9440(10)61101-7; Rausa FM, 2000, MOL CELL BIOL, V20, P8264, DOI 10.1128/MCB.20.21.8264-8282.2000; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Tang MK, 2006, PROTEOMICS, V6, P2376, DOI 10.1002/pmic.200500603; Vail ME, 2001, CANCER RES, V61, P594; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yu J, 2007, GUT, V56, P991, DOI 10.1136/gut.2006.097923; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zhivotovsky B, 2006, CARCINOGENESIS, V27, P1939, DOI 10.1093/carcin/bgl035	39	34	36	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1208	1217		10.1038/sj.onc.1210733	http://dx.doi.org/10.1038/sj.onc.1210733			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17704801				2022-12-17	WOS:000253407000003
J	Verbrugge, I; de Vries, E; Tait, SWG; Wissink, EHJ; Walczak, H; Verheij, M; Borst, J				Verbrugge, I.; de Vries, E.; Tait, S. W. G.; Wissink, E. H. J.; Walczak, H.; Verheij, M.; Borst, J.			Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway	ONCOGENE			English	Article						apoptosis; DISC; ionizing radiation; mitochondria; TRAIL	IRRADIATION-INDUCED APOPTOSIS; DNA-DAMAGE; CELL-DEATH; CHEMOTHERAPEUTIC DRUGS; CASPASE-8 RECRUITMENT; GAMMA-RADIATION; LIGAND TRAIL; IN-VIVO; ACTIVATION; CD95	In many tumor cell types, ionizing radiation (IR) or DNA-damaging anticancer drugs enhance sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, which is of great clinical interest. We have investigated the molecular mechanism underlying the response to combined modality treatment in p53-mutant Jurkat T leukemic cells overexpressing Bcl-2. These cells are largely resistant to individual treatment with TRAIL or IR, but sensitive to combined treatment, in vitro as well as in vivo. We demonstrate that IR and DNA-damaging anticancer drugs enable TRAIL receptor-2 and CD95/Fas to bypass the mitochondrial pathway for effector caspase activation. This was validated by RNA interference for Bax and Bak and by overexpression of dominant-negative Caspase-9. Improved effector caspase activation was neither caused by altered expression of proapoptotic components nor by impaired activity of inhibitor of apoptosis proteins or nuclear factor-kappa B signaling. Rather, we found that pretreatment of cells with IR caused quantitative and qualitative changes in death receptor signaling. It strongly improved the capacity of ligand-bound receptors to recruit FADD and activate Caspase-8 and -10 in the death-inducing signaling complex, while c-FLIPL levels were unaffected.	[Verbrugge, I.; de Vries, E.; Tait, S. W. G.; Wissink, E. H. J.; Borst, J.] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands; [Walczak, H.] German Canc Res Ctr, Div Apoptosis Regulat, D-6900 Heidelberg, Germany; [Verheij, M.] Netherlands Canc Inst, Div Radiotherapy, Amsterdam, Netherlands	Netherlands Cancer Institute; Helmholtz Association; German Cancer Research Center (DKFZ); Netherlands Cancer Institute	Borst, J (corresponding author), Netherlands Canc Inst, Div Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.borst@nki.nl	Verheij, Marcel/O-9652-2018; Walczak, Henning/AAV-2214-2020	Walczak, Henning/0000-0002-6312-4591; Tait, Stephen/0000-0001-7697-132X; Borst, Jannie/0000-0002-8043-5009				Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Broaddus VC, 2005, J BIOL CHEM, V280, P12486, DOI 10.1074/jbc.M408190200; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ganten TM, 2006, CLIN CANCER RES, V12, P2640, DOI 10.1158/1078-0432.CCR-05-2635; Ganten TM, 2004, CELL DEATH DIFFER, V11, pS86, DOI 10.1038/sj.cdd.4401437; Guan BX, 2001, J CELL PHYSIOL, V188, P98, DOI 10.1002/jcp.1101; Kim MR, 2001, FEBS LETT, V505, P179, DOI 10.1016/S0014-5793(01)02816-2; Kitamura T, 1998, INT J HEMATOL, V67, P351; Lacour S, 2003, ONCOGENE, V22, P1807, DOI 10.1038/sj.onc.1206127; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MARINI P, 2005, BMC CANC, V5; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Ramp U, 2003, BRIT J CANCER, V88, P1800, DOI 10.1038/sj.bjc.6600984; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Ravi R, 2002, CANCER RES, V62, P1583; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Singh TR, 2003, CANCER RES, V63, P5390; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Vivo C, 2003, J BIOL CHEM, V278, P25461, DOI 10.1074/jbc.M302161200; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang XD, 2001, GENE DEV, V15, P2922; Wendt J, 2005, ONCOGENE, V24, P4052, DOI 10.1038/sj.onc.1208580; Werner AB, 2004, J BIOL CHEM, V279, P28771, DOI 10.1074/jbc.M400268200; Wissink EHJ, 2006, RADIOTHER ONCOL, V80, P214, DOI 10.1016/j.radonc.2006.07.030; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141	42	34	36	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2008	27	5					574	584		10.1038/sj.onc.1210696	http://dx.doi.org/10.1038/sj.onc.1210696			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17684487				2022-12-17	WOS:000252674900002
J	Moussa, O; Riker, J; Klein, J; Fraig, M; Halushka, P; Watson, D				Moussa, O.; Riker, Jm; Klein, J.; Fraig, M.; Halushka, Pv; Watson, Dk			Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents	ONCOGENE			English	Article						bladder cancer; thromboxane synthase; chemosensitivity	INTRACELLULAR ACCUMULATION; LINES; CIS-DIAMMINEDICHLOROPLATINUM(II); CARCINOMA; CISPLATIN; APOPTOSIS; A(2); PACLITAXEL; RESISTANCE; MIGRATION	Recently, we reported prognostic significance of thromboxane synthase (TXAS) gene expression in invasive bladder cancer. The positive correlation between elevated TXAS expression and shorter patient survival supports a potential role for TXAS-regulated pathways in tumor metastases. In this study, using immunohistochemical analysis, we found an increased expression of TXAS protein in bladder cancer. Treatment of T24 and transitional cell carcinoma TCC-SUP bladder cancer cells with the TXAS inhibitors furegrelate or ozagrel induced an apoptotic effect measured as an increase in caspase-3 activation and cell death, and decreased survivin expression. Pharmacological inhibition of TXAS using the TXAS inhibitor furegrelate increased sensitivity to the chemotherapeutic agents cisplatin and paclitaxel. Molecular inhibition of TXAS expression by siRNA significantly decreased cell growth and migration. In concordance with the pharmacological data, siRNA-mediated reduction of TXAS expression increased sensitivity to cisplatin and paclitaxel in T24 and TCC-SUP cells. In summary, the data support a role for the thromboxane A(2) pathway in the pathogenesis of bladder cancer and the potential utility of modulation of this signaling pathway for cancer chemotherapy.	[Moussa, O.; Riker, Jm; Klein, J.; Watson, Dk] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [Moussa, O.; Riker, Jm; Klein, J.; Fraig, M.; Watson, Dk] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Halushka, Pv] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Halushka, Pv] Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA; [Halushka, Pv] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; [Watson, Dk] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Moussa, O (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Room 313,86 Jonathan Lucas St, Charleston, SC 29425 USA.	moussa@musc.edu	Fraig, Mostafa M/I-1670-2016	Fraig, Mostafa M/0000-0003-1119-3672				Bando T, 1997, ANTICANCER RES, V17, P3345; Bando T, 1998, ANTICANCER RES, V18, P1079; Bando T, 1998, ANTICANCER RES, V18, P1085; Bokemeyer C, 1998, WORLD J UROL, V16, P155, DOI 10.1007/s003450050044; Calabro Fabio, 2002, Curr Opin Urol, V12, P441, DOI 10.1097/00042307-200209000-00013; Giese A, 1999, Neuro Oncol, V1, P3, DOI 10.1093/neuonc/1.1.3; Hour TC, 2000, ANTICANCER RES, V20, P3221; Jantke J, 2004, ACTA NEUROCHIR, V146, P483, DOI 10.1007/s00701-004-0238-z; Jariyawat S, 1997, BIOCHEM MOL BIOL INT, V42, P113; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kamath K, 2005, J BIOL CHEM, V280, P12902, DOI 10.1074/jbc.M414477200; Kasahara K, 1996, BRIT J CANCER, V74, P1553, DOI 10.1038/bjc.1996.588; Kim E, 2003, ONCOGENE, V22, P7716, DOI 10.1038/sj.onc.1207155; Moussa O, 2005, CANCER RES, V65, P11581, DOI 10.1158/0008-5472.CAN-05-1622; MURPHY S, 1990, GLIA, V3, P205, DOI 10.1002/glia.440030307; Nie DT, 2004, AM J PATHOL, V164, P429, DOI 10.1016/S0002-9440(10)63133-1; PASCUAL J, 1988, PROSTAG LEUKOTR ESS, V33, P53, DOI 10.1016/0952-3278(88)90123-8; Pradono P, 2002, CANCER RES, V62, P63; Safirstein R, 1985, AM J PHYSIOL, V249, P490; Sakai H, 2006, FEBS LETT, V580, P3368, DOI 10.1016/j.febslet.2006.05.007; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Stein JP, 2001, J CLIN ONCOL, V19, P666, DOI 10.1200/JCO.2001.19.3.666; WALD M, 1989, BIOCHEM PHARMACOL, V38, P3347, DOI 10.1016/0006-2952(89)90633-3; Watkins Gareth, 2005, Int Semin Surg Oncol, V2, P23, DOI 10.1186/1477-7800-2-23; Yoshizato K, 2002, NEUROSURGERY, V50, P343, DOI 10.1097/00006123-200202000-00021	25	34	34	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2008	27	1					55	62		10.1038/sj.onc.1210629	http://dx.doi.org/10.1038/sj.onc.1210629			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17603559				2022-12-17	WOS:000252118700006
J	Schneider, L; Essmann, F; Kletke, A; Rio, P; Hanenberg, H; Schulze-Osthoff, K; Nurnberg, B; Piekorz, RP				Schneider, L.; Essmann, F.; Kletke, A.; Rio, P.; Hanenberg, H.; Schulze-Osthoff, K.; Nuernberg, B.; Piekorz, R. P.			TACC3 depletion sensitizes to paclitaxel-induced cell death and overrides p21(WAF)-mediated cell cycle arrest	ONCOGENE			English	Article						TACC3; paclitaxel; mitosis; apoptosis; p53; p21(WAF)	SPINDLE ASSEMBLY CHECKPOINT; SMOOTH-MUSCLE-CELLS; ACIDIC COILED-COIL; INDUCED APOPTOSIS; POLE ORGANIZATION; MITOTIC ARREST; CANCER-CELLS; P21; P53; D1	Regulators of the mitotic spindle apparatus are attractive cellular targets for antitumor therapy. The centrosomal protein transforming acidic coiled coil (TACC) 3 is required for spindle assembly and proper chromosome segregation. In this study, we employed an inducible RNA interference approach to downregulate TACC3 expression. We show that TACC3 knock-down in NIH3T3 fibroblasts caused aneuploidy, but failed to overtly impair mitotic progression. TACC3 depletion rather triggered a postmitotic p53-p21(WAF) pathway and led to a reversible cell cycle arrest. Similar effects were induced by low concentrations of paclitaxel, a spindle poison used in antitumor therapy. Interestingly, however, and unlike in TACC3-proficient cells, paclitaxel was able to induce strong polyploidy and subsequent apoptosis in TACC3-depleted cells. Even though paclitaxel treatment was associated with the activation of the survival kinase Akt and an antiapoptotic expression of cytoplasmic p21(WAF) and cyclin D1, this inhibition of cell death was abrogated by depletion of TACC3. Thus, our data identify TACC3 as a potential target to overcome p21(WAF)-associated protection of transformed cells against paclitaxel-induced cell death.	[Schneider, L.; Kletke, A.; Nuernberg, B.; Piekorz, R. P.] Univ Klinikum Dusseldorf, Inst Biochem & Molekularbiol 2, D-40225 Dusseldorf, Germany; [Essmann, F.; Schulze-Osthoff, K.] Univ Klinikum Dusseldorf, Inst Mol Med, Dusseldorf, Germany; [Rio, P.; Hanenberg, H.] Univ Klinikum Dusseldorf, Klin Kindeer Oncol Haematol, Dusseldorf, Germany; [Rio, P.; Hanenberg, H.] Univ Klinikum Dusseldorf, Klin Immunol, Dusseldorf, Germany; [Hanenberg, H.] Indiana Univ, Sch Med, Riley Hosp Children, Dept Pediat,Wells Ctr & Pediat Res, Indianapolis, IN 46204 USA	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	Piekorz, RP (corresponding author), Univ Klinikum Dusseldorf, Inst Biochem & Molekularbiol 2, D-40225 Dusseldorf, Germany.	roland.piekorz@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013; Essmann, Frank/ABG-7409-2020; Rio, Paula/G-8681-2015; Schneider, Leonid/H-3275-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Essmann, Frank/0000-0003-4369-8456; Rio, Paula/0000-0002-5424-5543; Schneider, Leonid/0000-0002-6204-9470; Nurnberg, Bernd/0000-0002-5995-6555				Abal M, 2003, CURR CANCER DRUG TAR, V3, P193, DOI 10.2174/1568009033481967; Andreassen PR, 2003, MUTAT RES-FUND MOL M, V532, P245, DOI 10.1016/j.mrfmmm.2003.08.020; Blagosklonny MV, 2006, CELL CYCLE, V5, P1574, DOI 10.4161/cc.5.14.3113; Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625; Blagosklonny MV, 2004, CELL CYCLE, V3, P1050; Blagosklonny MV, 2006, CELL CYCLE, V5, P971, DOI 10.4161/cc.5.9.2711; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Cassimeris L, 2004, MOL BIOL CELL, V15, P1580, DOI 10.1091/mbc.E03-07-0544; Chen JG, 2002, CANCER RES, V62, P1935; CHEN XB, 1995, CANCER RES, V55, P4257; Child ES, 2006, CELL CYCLE, V5, P1313, DOI 10.4161/cc.5.12.2863; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Cully M, 2005, CANCER RES, V65, P10363, DOI 10.1158/0008-5472.CAN-05-1633; DelSal G, 1996, ONCOGENE, V12, P177; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Gergely F, 2002, BIOESSAYS, V24, P915, DOI 10.1002/bies.10162; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Gladden AB, 2005, J CELL BIOCHEM, V96, P906, DOI 10.1002/jcb.20613; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; Han EKH, 1999, APOPTOSIS, V4, P213, DOI 10.1023/A:1009618824145; Heliez C, 2003, ONCOGENE, V22, P3260, DOI 10.1038/sj.onc.1206409; Ikui AE, 2005, CELL CYCLE, V4, P1385, DOI 10.4161/cc.4.10.2061; Janicke RU, 2007, CELL CYCLE, V6, P407; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Judson PL, 1999, CANCER RES, V59, P2425; Jung CK, 2006, PATHOL INT, V56, P503, DOI 10.1111/j.1440-1827.2006.01998.x; Kadura S, 2005, CELL MOTIL CYTOSKEL, V61, P145, DOI 10.1002/cm.20072; Lauffart Brenda, 2005, BMC Womens Health, V5, P8, DOI 10.1186/1472-6874-5-8; Leurs C, 2003, HUM GENE THER, V14, P509, DOI 10.1089/104303403764539305; Mikule K, 2007, NAT CELL BIOL, V9, P160, DOI 10.1038/ncb1529; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Olashaw N, 2004, CELL CYCLE, V3, P263; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; Sohn D, 2006, CANCER RES, V66, P11254, DOI 10.1158/0008-5472.CAN-06-1569; Srsen V, 2006, J CELL BIOL, V174, P625, DOI 10.1083/jcb.200606051; Stewart ZA, 1999, CANCER RES, V59, P3831; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; TAYLOR SL, 2001, FOOD ALLERGY INTOLER, V2, P53; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yao R, 2007, CANCER SCI, V98, P555, DOI 10.1111/j.1349-7006.2007.00433.x; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Zachos G, 2007, DEV CELL, V12, P247, DOI 10.1016/j.devcel.2007.01.003	47	34	35	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2008	27	1					116	125		10.1038/sj.onc.1210628	http://dx.doi.org/10.1038/sj.onc.1210628			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599038				2022-12-17	WOS:000252118700012
J	Chetty, C; Bhoopathi, P; Lakka, SS; Rao, JS				Chetty, C.; Bhoopathi, P.; Lakka, S. S.; Rao, J. S.			MMP-2 siRNA induced Fas/CD95-mediated extrinsic II apoptotic pathway in the A549 lung adenocarcinoma cell line	ONCOGENE			English	Article						CD95 (APO/Fas); Fas-L; cytochrome c; apoptosis; MMP-2; TIMP-3	TISSUE INHIBITOR; METALLOPROTEINASE INHIBITORS; ANTITUMOR-ACTIVITY; GASTRIC-CANCER; CYTOCHROME-C; DEATH DOMAIN; TUMOR-GROWTH; EXPRESSION; GENE; OVEREXPRESSION	We have previously reported that the downregulation of MMP-2 by adenovirus-mediated delivery of MMP-2 siRNA (Ad-MMP-2) reduced spheroid invasion and angiogenesis in vitro, and, metastasis and tumor growth in vivo. In this study, we investigated the mechanism of Ad-MMP-2-mediated growth inhibition in vitro and in vivo. Ad-MMP-2 infection led to the induction of apoptosis as determined by TUNEL assay, Annexin-V staining and PARP-1 cleavage in a dose-dependent manner in A549 cells. Ad-MMP-2 decreased the content of the antiapoptotic members of the Bcl-2 family proteins (Bcl-2 and Bcl-xL) and increased the content of the proapoptotic members of the Bcl-2 family (Bax and Bcl-xS) as determined by immunoblotting analysis. Furthermore, Ad-MMP-2-mediated apoptosis was accompanied by increase in truncated Bid, release of cytochrome c and the activation of caspase-8, - 9 and -3. Immunoblot analysis showed that Ad-MMP-2 infection caused upregulation of Fas/Fas-L and FADD, and Anti-Fas-L antibody reversed Ad-MMP-2-induced apoptosis. Tissue inhibitor of metalloproteinases ( TIMP)- 3, an endogenous inhibitor of MMP-2, which cleaves Fas-L and activates the Fas/Fas-L inducing apoptotic pathway, was increased in Ad-MMP-2-treated cells. Adenovirus-mediated expression of MMP-2 siRNA in human lung xenografts in vivo resulted in increased immunostaining of Fas, Fas-L, cleaved Bid and TIMP-3. This is the first report, to our knowledge, showing that MMP-2 inhibition upregulates TIMP-3 levels, which in turn, promotes apoptosis in lung cancer.	[Chetty, C.; Bhoopathi, P.; Lakka, S. S.; Rao, J. S.] Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Program Canc Biol, Peoria, IL 61656 USA; [Rao, J. S.] Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Program Canc Biol, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu	bhoopathi, praveen/A-9410-2010		NCI NIH HHS [R01 CA092393, R01 CA075557-09, CA92393, R01 CA095058, CA95058, CA116708, R01 CA095058-03, CA75557, R01 CA075557, R01 CA116708-02, R01 CA116708, R01 CA092393-04] Funding Source: Medline; NINDS NIH HHS [NS57529, R01 NS057529-01, R01 NS057529, R01 NS047699, NS47699, R01 NS047699-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA116708, R01CA092393, R01CA075557, R01CA095058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047699, R01NS057529] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahonen M, 2002, MOL THER, V5, P705, DOI 10.1006/mthe.2002.0606; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Bond M, 2002, J BIOL CHEM, V277, P13787, DOI 10.1074/jbc.M111507200; Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200; Bramhall SR, 2002, BRIT J CANCER, V86, P1864, DOI 10.1038/sj.bjc.6600310; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Brown PD, 1995, ANN ONCOL, V6, P967, DOI 10.1093/oxfordjournals.annonc.a059091; CAWSTON TE, 1995, BRIT MED BULL, V51, P385, DOI 10.1093/oxfordjournals.bmb.a072968; Chetty C, 2006, MOL CANCER THER, V5, P2289, DOI 10.1158/1535-7163.MCT-06-0169; CHINNAIYAN AM, 1995, CELL, V81, P512; Drynda A, 2005, J IMMUNOL, V174, P6524, DOI 10.4049/jimmunol.174.10.6524; Evans JD, 2001, BRIT J CANCER, V85, P1865, DOI 10.1054/bjoc.2001.2168; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI200113171; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Kang SH, 2000, INT J CANCER, V86, P632, DOI 10.1002/(SICI)1097-0215(20000601)86:5<632::AID-IJC5>3.0.CO;2-5; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li WQ, 1998, J IMMUNOL, V161, P5000; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; Mitsiades N, 2001, EXPERT OPIN INV DRUG, V10, P1075, DOI 10.1517/13543784.10.6.1075; Nyormoi O, 2003, CELL DEATH DIFFER, V10, P558, DOI 10.1038/sj.cdd.4401209; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Spurbeck WW, 2002, BLOOD, V100, P3361, DOI 10.1182/blood.V100.9.3361; Strand S, 2004, ONCOGENE, V23, P3732, DOI 10.1038/sj.onc.1207387; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Uramoto H, 1999, EUR J CANCER, V35, P1462, DOI 10.1016/S0959-8049(99)00157-4	32	34	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7675	7683		10.1038/sj.onc.1210584	http://dx.doi.org/10.1038/sj.onc.1210584			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17599056	Green Accepted			2022-12-17	WOS:000251537800009
J	Jie, X; Lang, C; Jian, Q; Chaoqun, L; Dehua, Y; Yu, S; Yanping, J; Luokun, X; Qiuping, Z; Hui, W; Feili, G; Boquan, J; Youxin, J; Jinquan, T				Jie, X.; Lang, C.; Jian, Q.; Chaoqun, L.; Dehua, Y.; Yu, S.; Yanping, J.; Luokun, X.; Qiuping, Z.; Hui, W.; Feili, G.; Boquan, J.; Youxin, J.; Jinquan, T.			RETRACTED: Androgen activates PEG10 to promote carcinogenesis in hepatic cancer cells (Retracted article. See vol. 30, pg. 2798, 2011)	ONCOGENE			English	Article; Retracted Publication						hepatocellular carcinoma; androgen; androgen; receptor; PEG10; apoptosis	HEPATOCELLULAR-CARCINOMA; IMPRINTED GENE; APOPTOSIS; EXPRESSION; INTERACTS; RECEPTOR; PROTEIN; RETROTRANSPOSON	The molecular mechanism of striking higher prevalence of hepatocellular carcinoma (HCC) in male subjects has not yet been fully elucidated. Here, we report that androgen receptor (AR) is differentially expressed in different HCC cell lines. AR agonist dihydrotestosterone (DHT) enhances HCC cell growth and apoptotic resistance. Antagonist flutamide (FLU) blocks the effects of DHT on the HCC cell lines. Paternally expressed gene 10 (PEGI10) is expressed in HCC cell lines at substantial high level. Using small interfering RNAs against AR and PEG10 in AR- and PEG10-expressing BEL-7404 hepatoma cells and HuH7 hepatoma cells (HuH7) cells, and AR-transfection technique in AR-lacking and PEG10-expressing HepG2 cells, we have confirmed that through upregulation and activation of PEG10, DHT enhances HCC cell growth and apoptotic resistance. We have further demonstrated that DHT upregulates expression of human telomerase reverse transcriptase (hTERT) in HCC cell lines in a PEG10-dependent manner. Moreover, AR directly interacts in vivo with androgen-responsive elements in the regions of promoter and exon 2 of PEG10 gene in HCC cell lines. DHT promotes the hepatoma formation in viro nude mice through PEG10 activation. AR antagonists (FLU and valproate) inhibit the hepatoma formation. These findings suggest that PEG10 plays an essential role in hepatocarcinogenesis. The PEG10 inhibition can be a novel approach for therapy of HCC.	Wuhan Univ, Sch Med, Dept Immunol, Wuhan 430071, Hubei, Peoples R China; Wuhan Univ, Sch Med, Inst Allergy & Immune Related Dis, Lab Allergy & Clin Immunol, Wuhan 430072, Peoples R China; Wuhan Univ, Sch Med, Med Res Ctr, Wuhan 430072, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai, Peoples R China; Shanghai Med Univ 2, Ruijin Hosp, Dept Infect Dis, Shanghai, Peoples R China; S China Normal Univ, Coll Life Sci, Guangzhou, Peoples R China; Wuhan Univ, Sch Med, Dept Pharmacol, Wuhan 430072, Peoples R China; Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Immunol, Wuhan 430074, Peoples R China; Fourth Mil Med Univ, Dept Immunol, Xian 710032, Peoples R China	Wuhan University; Wuhan University; Wuhan University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; South China Normal University; Wuhan University; Huazhong University of Science & Technology; Air Force Military Medical University	Jinquan, T (corresponding author), Wuhan Univ, Sch Med, Dept Immunol, Dong Hu Rd 115, Wuhan 430071, Hubei, Peoples R China.	jinquan_tan@hotmail.com						Death AK, 2005, STEROIDS, V70, P946, DOI 10.1016/j.steroids.2005.07.003; Greider CW, 1999, TRENDS GENET, V15, P109, DOI 10.1016/S0168-9525(98)01681-3; Hu CS, 2006, J IMMUNOL, V177, P6713, DOI 10.4049/jimmunol.177.10.6713; Huang RM, 2003, CANCER RES, V63, P3775; Kim DH, 2005, NAT BIOTECHNOL, V23, P222, DOI 10.1038/nbt1051; Komine F, 2000, J HEPATOL, V32, P235, DOI 10.1016/S0168-8278(00)80068-9; Li CM, 2006, CANCER RES, V66, P665, DOI 10.1158/0008-5472.CAN-05-1553; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Massari P, 2000, P NATL ACAD SCI USA, V97, P9070, DOI 10.1073/pnas.97.16.9070; NAGASUE N, 1995, BRIT J SURG, V82, P542, DOI 10.1002/bjs.1800820435; Okabe H, 2001, CANCER RES, V61, P2129; Okabe H, 2003, CANCER RES, V63, P3043; Ono R, 2006, NAT GENET, V38, P101, DOI 10.1038/ng1699; Ono R, 2001, GENOMICS, V73, P232, DOI 10.1006/geno.2001.6494; Ramirez R, 2003, J BIOL CHEM, V278, P836, DOI 10.1074/jbc.M206818200; Rokhlin OW, 2005, ONCOGENE, V24, P6773, DOI 10.1038/sj.onc.1208833; Sathya G, 2003, CANCER RES, V63, P8029; Shammas MA, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-24; Sica A, 1997, J EXP MED, V185, P969, DOI 10.1084/jem.185.5.969; Steplewski A, 1998, BIOCHEM BIOPH RES CO, V243, P295, DOI 10.1006/bbrc.1997.7821; Tan JQ, 2003, J IMMUNOL, V171, P1722, DOI 10.4049/jimmunol.171.4.1722; Tsou AP, 2003, J BIOMED SCI, V10, P625, DOI 10.1159/000073528; Youssef N, 2001, J PATHOL, V194, P459, DOI 10.1002/path.901; Yu MW, 2001, J NATL CANCER I, V93, P1644, DOI 10.1093/jnci/93.21.1644; Zhang DY, 2004, HEPATOLOGY, V39, P954, DOI 10.1002/hep.20135; Zhang YX, 2005, P NATL ACAD SCI USA, V102, P9890, DOI 10.1073/pnas.0503829102	26	34	38	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5741	5751		10.1038/sj.onc.1210362	http://dx.doi.org/10.1038/sj.onc.1210362			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17369855				2022-12-17	WOS:000248885100006
J	Trapp, C; Reite, K; Klungland, A; Epe, B				Trapp, C.; Reite, K.; Klungland, A.; Epe, B.			Deficiency of the Cockayne syndrome B (CSB) gene aggravates the genomic instability caused by endogenous oxidative DNA base damage in mice	ONCOGENE			English	Article						oxidative DNA damage; spontaneous mutations; DNA repair; OGG1	BIG BLUE(R); MAMMALIAN-CELLS; REPAIR; ACCUMULATION; MUTATIONS; TISSUE; AGE; 8-HYDROXYGUANINE; PREDISPOSITION; 8-OXOGUANINE	The Cockayne syndrome B protein ( CSB) has long been known to be involved in the repair of DNA modi. cations that block the RNA polymerase in transcribed DNA sequences ( transcription-coupled repair). Recent evidence suggests that it also has a more general role in the repair of oxidative DNA base modi. cations such as 7,8-dihydro-8-oxo-2'-deoxyguanosine ( 8-oxoG). In mammalian cells, 8-oxoG is a substrate of the repair glycosylase OGG1. Mice without this enzyme accumulate 8-oxoG in the genome and have elevated spontaneous mutation rates. To elucidate the role of CSB in the prevention of mutations by oxidative DNA base damage, we have generated mice that are deficient in Csb or Ogg1 or both genes and carry a non-transcribed bacterial lacI gene for mutation analysis ( Big Blue mice). Our results indicate that the overall spontaneous mutation frequencies in the livers of Csb(m/m)/Ogg1(-/-)-mice are elevated not only compared with heterozygous control mice ( factor 3.3), but also with Ogg1(-/-)-animals ( factor 1.6). Sequence analysis revealed that the additional mutations caused by CSB deficiency in an Ogg1(-/-) background are mostly G: C to T: A transversions and small deletions. For all mouse strains, the background levels of oxidative purine modi. cations in the livers correlate linearly with the numbers of G: C to T: A transversions observed. The data indicate that CSB is involved in the inhibition of mutations caused by spontaneous oxidative DNA base damage in a non-transcribed gene.	Johannes Gutenberg Univ Mainz, Inst Pharm, D-55099 Mainz, Germany; Rikshosp Radiumhosp, Ctr Mol Biol & Neurosci, Oslo, Norway; Rikshosp Radiumhosp, Inst Med Microbiol, Oslo, Norway	Johannes Gutenberg University of Mainz; University of Oslo; University of Oslo	Epe, B (corresponding author), Johannes Gutenberg Univ Mainz, Inst Pharm, Staudingerweg 5, D-55099 Mainz, Germany.	epe@uni-mainz.de	Klungland, Arne/X-1233-2019	Klungland, Arne/0000-0001-7274-3661				Bjelland S, 2003, MUTAT RES-FUND MOL M, V531, P37, DOI 10.1016/j.mrfmmm.2003.07.002; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CHENG KC, 1992, J BIOL CHEM, V267, P166; Collins A, 2003, FREE RADICAL BIO MED, V34, P1089, DOI 10.1016/s0891-5849(03)00041-8; Collins A, 2002, CARCINOGENESIS, V23, P2129, DOI 10.1093/carcin/23.12.2129; Dolle MET, 2006, MUTAT RES-FUND MOL M, V596, P22, DOI 10.1016/j.mrfmmm.2005.11.008; Flohr C, 2003, NUCLEIC ACIDS RES, V31, P5332, DOI 10.1093/nar/gkg715; Halangoda A, 2001, ENVIRON MOL MUTAGEN, V37, P311, DOI 10.1002/em.1038; Heinmoller PW, 2000, MUTAT RES-FUND MOL M, V453, P97, DOI 10.1016/S0027-5107(00)00091-9; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Hill KA, 2004, ENVIRON MOL MUTAGEN, V43, P110, DOI 10.1002/em.20004; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; KOHLER SW, 1991, ENVIRON MOL MUTAGEN, V18, P316, DOI 10.1002/em.2850180421; Licht CL, 2003, AM J HUM GENET, V73, P1217, DOI 10.1086/380399; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; Nishino H, 1996, MUTAT RES-FUND MOL M, V372, P97, DOI 10.1016/S0027-5107(96)00172-8; Osterod M, 2002, ONCOGENE, V21, P8232, DOI 10.1038/sj.onc.1206027; Osterod M, 2001, CARCINOGENESIS, V22, P1459, DOI 10.1093/carcin/22.9.1459; Pflaum M, 1997, CARCINOGENESIS, V18, P2225, DOI 10.1093/carcin/18.11.2225; PROVOST GS, 1994, P NATL ACAD SCI USA, V91, P6564, DOI 10.1073/pnas.91.14.6564; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; Xie YL, 2004, CANCER RES, V64, P3096, DOI 10.1158/0008-5472.CAN-03-3834; YOUNG RR, 1995, MUTAT RES-FUND MOL M, V327, P67, DOI 10.1016/0027-5107(94)00080-O	31	34	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					4044	4048		10.1038/sj.onc.1210167	http://dx.doi.org/10.1038/sj.onc.1210167			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213818				2022-12-17	WOS:000247144500016
J	Andersen, JB; Li, XL; Judge, CS; Zhou, A; Jha, BK; Shelby, S; Zhou, L; Silverman, RH; Hassel, BA				Andersen, J. B.; Li, X. L.; Judge, C. S.; Zhou, A.; Jha, B. K.; Shelby, S.; Zhou, L.; Silverman, R. H.; Hassel, B. A.			Role of 2-5A-dependent RNase-L in senescence and longevity	ONCOGENE			English	Article						RNase-L; senescence; apoptosis; 2 '-5 '-oligoadenylate; aging	CELLULAR SENESCENCE; SIGNALING PATHWAY; INTERFERON ACTION; L INHIBITOR; CANCER; ACTIVATION; APOPTOSIS; EXPRESSION; GENES; CELLS	Senescence is a permanent growth arrest that restricts the lifespan of primary cells in culture, and represents an in vitro model for aging. Senescence functions as a tumor suppressor mechanism that can be induced independent of replicative crisis by diverse stress stimuli. RNase-L mediates antiproliferative activities and functions as a tumor suppressor in prostate cancer, therefore, we examined a role for RNase-L in cellular senescence and aging. Ectopic expression of RNase-L induced a senescent morphology, a decrease in DNA synthesis, an increase in senescence-associated beta-galactosidase activity, and accelerated replicative senescence. In contrast, senescence was retarded in RNase-L-null fibroblasts compared with wildtype fibroblasts. Activation of endogenous RNase-L by 2-5A transfection induced distinct senescent and apoptotic responses in parental and Simian virus 40-transformed WI38 fibroblasts, respectively, demonstrating cell type specific differences in the antiproliferative response to RNase-L activation. Replicative senescence is a model for in vivo aging; therefore, genetic disruption of senescence effectors may impact lifespan. RNase-L-/- mice survived 31.7% ( P < 0.0001) longer than strain-matched RNase-L+/+ mice providing evidence for a physiological role for RNase-L in aging. These findings identify a novel role for RNase-L in senescence that may contribute to its tumor suppressive function and to the enhanced longevity of RNase-L-/- mice.	Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Program Mol & Cell Biol, College Pk, MD 20742 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; No Arizona Univ, Dept Chem & Biochem, Flagstaff, AZ 86011 USA; Univ Maryland, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland College Park; University System of Ohio; Cleveland State University; Cleveland Clinic Foundation; Northern Arizona University; University System of Maryland; University of Maryland Baltimore	Hassel, BA (corresponding author), Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, 655 W Baltimore St,9th Floor BRB, Baltimore, MD 21201 USA.	bhassel@som.umaryland.edu	jha, babal k/B-1803-2010	jha, babal k/0000-0002-7660-5255; Andersen, Jesper B/0000-0003-1760-5244	NATIONAL CANCER INSTITUTE [R01CA044059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG020355] Funding Source: NIH RePORTER; NCI NIH HHS [CA044059] Funding Source: Medline; NIA NIH HHS [AG20355] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BISBAL C, 1995, J BIOL CHEM, V270, P13308, DOI 10.1074/jbc.270.22.13308; Bisbal C, 2000, MOL CELL BIOL, V20, P4959, DOI 10.1128/MCB.20.14.4959-4969.2000; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; Casey G, 2002, NAT GENET, V32, P582, DOI 10.1038/ng1021; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; Chase BI, 2003, J INTERF CYTOK RES, V23, P565, DOI 10.1089/107999003322485062; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; DiazGuerra M, 1997, VIROLOGY, V236, P354, DOI 10.1006/viro.1997.8719; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; FLOYDSMITH G, 1988, P SOC EXP BIOL MED, V189, P329; Hardy K, 2005, MOL BIOL CELL, V16, P943, DOI 10.1091/mbc.E04-05-0392; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kubota K, 2004, J BIOL CHEM, V279, P37832, DOI 10.1074/jbc.M400089200; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; Leszczyniecka M, 2003, GENE, V316, P143, DOI 10.1016/S0378-1119(03)00752-2; Li GQ, 2004, J BIOL CHEM, V279, P1123, DOI 10.1074/jbc.M305893200; Malathi K, 2005, P NATL ACAD SCI USA, V102, P14533, DOI 10.1073/pnas.0507551102; Malathi K, 2004, CANCER RES, V64, P9144, DOI 10.1158/0008-5472.CAN-04-2226; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; QUARRIE JK, 2004, SCI AGING KNOWLEDGE, V31, pRE5; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Silverman RH, 2003, BIOCHEMISTRY-US, V42, P1805, DOI 10.1021/bi027147i; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TAHARA H, 1995, ONCOGENE, V11, P1125; Untergasser G, 2002, CANCER RES, V62, P6255; White MK, 2004, VIROLOGY, V324, P1, DOI 10.1016/j.virol.2004.03.025; Xin H, 2004, ONCOGENE, V23, P6209, DOI 10.1038/sj.onc.1207836; Yoon IK, 2004, EXP GERONTOL, V39, P1369, DOI 10.1016/j.exger.2004.07.002; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	41	34	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2007	26	21					3081	3088		10.1038/sj.onc.1210111	http://dx.doi.org/10.1038/sj.onc.1210111			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17130839	Green Submitted			2022-12-17	WOS:000246395400013
J	Lau, L; Hansford, LM; Cheng, LS; Hang, M; Baruchel, S; Kaplan, DR; Irwin, MS				Lau, L.; Hansford, L. M.; Cheng, L. S.; Hang, M.; Baruchel, S.; Kaplan, D. R.; Irwin, M. S.			Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma	ONCOGENE			English	Article						neuroblastoma; cyclooxygenase inhibitor; p53; HDM2; chemosensitivity	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SELECTIVE COX-2 INHIBITOR; P53 GENE-MUTATIONS; CANCER CELL-LINES; ANTICANCER AGENTS; NUCLEAR EXCLUSION; GROWTH-INHIBITION; NITRIC-OXIDE; MDM2; HDM2	Cyclooxygenase-2 (COX-2) is upregulated in many tumors including neuroblastoma, and its overexpression has been implicated in resistance to p53-dependent apoptosis. Although p53 is rarely mutated in neuroblastoma, the p53 protein is rendered inactive via several mechanisms including sequestration in the cytoplasm. Here, we show that COX inhibitors inhibit the growth of neuroblastoma and when combined with low doses of chemotherapy, exert synergistic effects on neuroblastoma cells. Following COX inhibitor treatment, HDM2, which targets p53 for ubiquitin-mediated degradation, is downregulated, resulting in an attenuation of p53 ubiquitination and an increase in p53 half-life. The level of HDM2 phosphorylation at ser166, which influences both HDM2 and p53 subcellular distribution, is markedly diminished in response to COX inhibitors and is associated with increased p53 nuclear localization. Combining COX inhibitors with low-dose chemotherapy potentiates apoptosis and p53 stability, nuclear localization, and activity. p53 knockdown by siRNA resulted in the rescue of COX-inhibitor-treated cells, indicating that COX inhibitor-induced apoptosis is, at least in part, p53-dependent. Taken together, these results provide the first evidence that COX inhibitors enhance chemosensitivity in neuroblastoma via downregulating HDM2 and augmenting p53 stability and nuclear accumulation.	Hosp Sick Children, Dept Pediat & Canc Res, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Res Inst, Canc Res Program, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Irwin, MS (corresponding author), Hosp Sick Children, Dept Pediat & Canc Res, Div Haematol Oncol, Black Wing 9th Floor,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	meredith.irwin@sickkids.ca	Lau, Loretta MS/B-1565-2008	Lau, Loretta MS/0000-0002-3172-0970				Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bianco R, 2005, CURR CANCER DRUG TAR, V5, P51, DOI 10.2174/1568009053332681; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Brooks CL, 2004, CELL CYCLE, V3, P895; Brown JR, 2005, J CLIN ONCOL, V23, P2840, DOI 10.1200/JCO.2005.09.051; Carr J, 2006, CANCER RES, V66, P2138, DOI 10.1158/0008-5472.CAN-05-2623; Choi EM, 2005, BIOCHEM BIOPH RES CO, V328, P1107, DOI 10.1016/j.bbrc.2005.01.072; CHOU TC, 1981, EUR J BIOCHEM, V115, P207, DOI 10.1111/j.1432-1033.1981.tb06218.x; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Corcoran CA, 2005, ONCOGENE, V24, P1634, DOI 10.1038/sj.onc.1208353; CORVI R, 1995, ONCOGENE, V10, P1081; Cui HJ, 2002, MOL CANCER THER, V1, P679; Dannenberg AJ, 2003, CANCER CELL, V4, P431, DOI 10.1016/S1535-6108(03)00310-6; Fischer PM, 2004, TRENDS PHARMACOL SCI, V25, P343, DOI 10.1016/j.tips.2004.04.011; Gasparini G, 2003, LANCET ONCOL, V4, P605, DOI 10.1016/S1470-2045(03)01220-8; Han C, 2004, CANCER RES, V64, P1369, DOI 10.1158/0008-5472.CAN-03-1086; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hida T, 2000, CLIN CANCER RES, V6, P2006; HOSOI G, 1994, CANCER, V73, P3087, DOI 10.1002/1097-0142(19940615)73:12<3087::AID-CNCR2820731230>3.0.CO;2-9; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; IMAMURA J, 1993, CANCER RES, V53, P4053; Inoue T, 2005, FEBS LETT, V579, P4978, DOI 10.1016/j.febslet.2005.08.006; Isaacs JS, 2001, J BIOL CHEM, V276, P18497, DOI 10.1074/jbc.M100638200; Johnsen JI, 2004, CANCER RES, V64, P7210, DOI 10.1158/0008-5472.CAN-04-1795; KOMURO H, 1993, CANCER RES, V53, P5284; Liu XH, 2005, J BIOL CHEM, V280, P3817, DOI 10.1074/jbc.M406577200; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; Lu WG, 2000, ONCOGENE, V19, P232, DOI 10.1038/sj.onc.1203262; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moos PJ, 2000, P NATL ACAD SCI USA, V97, P9215, DOI 10.1073/pnas.160241897; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Parashar B, 2005, J NEURO-ONCOL, V71, P141, DOI 10.1007/s11060-004-1721-3; Parashar B, 2006, J NEURO-ONCOL, V78, P129, DOI 10.1007/s11060-005-9079-8; Rodriguez-Lopez AM, 2001, MOL PHARMACOL, V59, P135, DOI 10.1124/mol.59.1.135; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Swamy MV, 2003, CANCER RES, V63, P5239; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Trifan OC, 2002, CANCER RES, V62, P5778; Tweddle DA, 2001, AM J PATHOL, V158, P2067, DOI 10.1016/S0002-9440(10)64678-0; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; VOGAN K, 1993, CANCER RES, V53, P5269; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang X, 2003, CELL DEATH DIFFER, V10, P468, DOI 10.1038/sj.cdd.4401181; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Waskewich C, 2002, CANCER RES, V62, P2029; Weber HO, 2005, ONCOGENE, V24, P1965, DOI 10.1038/sj.onc.1208389; Winters ME, 2005, CANCER RES, V65, P3853, DOI 10.1158/0008-5472.CAN-04-1989; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175	54	34	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1920	1931		10.1038/sj.onc.1209981	http://dx.doi.org/10.1038/sj.onc.1209981			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	16983334				2022-12-17	WOS:000245117700009
J	Lim, YP; Lim, TT; Chan, YL; Song, ACM; Yeo, BH; Vojtesek, B; Coomber, D; Rajagopal, G; Lane, D				Lim, Y. P.; Lim, T. T.; Chan, Y. L.; Song, A. C. M.; Yeo, B. H.; Vojtesek, B.; Coomber, D.; Rajagopal, G.; Lane, D.			The p53 knowledgebase: an integrated information resource for p53 research	ONCOGENE			English	Article						database; p53; web portal	CELL-CYCLE ARREST; NUCLEAR ACCUMULATION; PROTEIN; INDUCTION; SELECTION; DATABASE; ANTIGEN	The p53 tumor suppressor protein plays a central role in maintaining genomic integrity by occupying a nodal point in the DNA damage control pathway. Here it integrates a wide variety of signals, responding in one of several ways, that is, cell cycle arrest, senescence or programmed cell death (apoptosis). Mutations in the tumor suppressor gene tp53, which affects the key transcriptional regulatory processes in cell growth and death, occur frequently in cancer and helps explain why p53 has been called the guardian of the genome. There is a vast body of published knowledge on all aspects of p53's role in cancer. To facilitate research, it would be helpful if this information could be collected, curated and updated in a format that is easily accessible to the user community. To this end, we initiated the p53 knowledgebase project (http://p53.bii.a-star.edu.sg). The p53 knowledgebase is a user-friendly web portal incorporating visualization and analysis tools that integrates information from the published literature with other manually curated information to facilitate knowledge discovery. This includes curated information on sequence, structural, mutation, polymorphisms, protein-protein interactions, transcription factors, transcriptional targets, antibodies and post-translational modifications that involve p53. The goal is to collect and maintain all relevant data on p53 and present it in an easily accessible format that will be useful to researchers in the field.	Inst Mol & Cell Biol, Singapore 138673, Singapore; Matrix, Bioinformat Inst, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII)	Lane, D (corresponding author), Inst Mol & Cell Biol, 61 Biopolis St, Singapore 138673, Singapore.	d.p.lane@imcb.a-star.edu.sg	Lane, David P/C-4920-2008; Lim, Elaine/H-9032-2016	Rajagopal, Gunaretnam/0000-0003-0111-1936; Lane, David/0000-0003-0551-3545				Bader GD, 2001, NUCLEIC ACIDS RES, V29, P242, DOI 10.1093/nar/29.1.242; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Beroud C, 2003, HUM MUTAT, V21, P176, DOI 10.1002/humu.10187; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; FRITSCHE M, 1993, ONCOGENE, V8, P307; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; KASTAN MB, 1991, CANCER RES, V51, P6304; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; SUGANO T, 1995, JPN J CANCER RES, V86, P415, DOI 10.1111/j.1349-7006.1995.tb03072.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Williams AC, 1999, ONCOGENE, V18, P3199, DOI 10.1038/sj.onc.1202660; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Zhang K, 2005, BIOINFORMATICS, V21, P131, DOI 10.1093/bioinformatics/bth482; Zhao LL, 2005, J SOL-GEL SCI TECHN, V33, P103, DOI 10.1007/s10971-005-6708-9	25	34	35	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1517	1521		10.1038/sj.onc.1209952	http://dx.doi.org/10.1038/sj.onc.1209952			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16953220				2022-12-17	WOS:000244782500001
J	Furge, KA; Tan, MH; Dykema, K; Kort, E; Stadler, W; Yao, X; Zhou, M; Teh, BT				Furge, K. A.; Tan, M. H.; Dykema, K.; Kort, E.; Stadler, W.; Yao, X.; Zhou, M.; Teh, B. T.			Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling	ONCOGENE			English	Review						renal; cancer; pathways; GSEA; PGSEA; CGMA	SET ENRICHMENT; SIGNATURES; ANEUPLOIDY; PATTERNS	In this age of targeted therapy, identification of molecular pathways that are deregulated in cancer will not only elucidate underlying tumorigenic mechanisms, but may also help to determine the classes of drugs that are used for treatment. In kidney cancer, a spectrum of histological subtypes exists that are characterized both by distinct molecular signatures and increasingly by distinct molecular pathways that are deregulated in each subtype. For example, the VHL/hypoxia pathway is well-known to be deregulated in clear cell renal cell carcinoma (RCC) whereas in papillary RCC activation of the HGF/Met pathway has been implicated. Additional molecular pathways, many not yet identified, may also be involved in the development of the different histologic subtypes. Moreover, differences in pathway activation may reflect differences in tumor progression and response to treatment. In this article, we describe an oncogenomic approach, based on integrative analysis of gene expression pro. ling data. In this approach, gene expression data is used to identify both cytogenetic abnormalities and molecular pathways that are deregulated in RCC. Ideally, predicted pathway abnormalities can be linked to predicted cytogenetic abnormalities to identify likely candidate genes. Although further cellular and functional studies are warranted to validate the computational models, development of such models in RCC have the potential to open up new avenues of molecular research and may have significant diagnostic and therapeutic implications.	Van Andel Res Inst, Lab Computat Biol, Grand Rapids, MI 49503 USA; Natl Canc Ctr Singapore, Dept Med Oncol, Singapore, Singapore; Van Andel Res Inst, Canc Genet Lab, Grand Rapids, MI 49503 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Surg, Chicago, IL 60637 USA; Tianjin Canc Ctr, Dept Pelv & Urol Oncol, Tianjin, Peoples R China; Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA	Van Andel Institute; National Cancer Centre Singapore (NCCS); Van Andel Institute; University of Chicago; University of Chicago; Cleveland Clinic Foundation	Furge, KA (corresponding author), Van Andel Res Inst, Lab Computat Biol, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.	kyle.furge@vai.org; bin.teh@vai.org	Tan, Min Han/D-9205-2014	Tan, Min Han/0000-0002-0644-3457; Teh, Bin Tean/0000-0003-1514-1124	NCI NIH HHS [R33 CA 10113-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler AS, 2006, NAT GENET, V38, P421, DOI 10.1038/ng1752; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Chi JT, 2006, PLOS MED, V3, P395, DOI 10.1371/journal.pmed.0030047; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Crawley JJ, 2002, GENOME BIOL, V3; Desai KV, 2002, P NATL ACAD SCI USA, V99, P6967, DOI 10.1073/pnas.102172399; Dupont J, 2001, ENDOCRINOLOGY, V142, P4969, DOI 10.1210/en.142.11.4969; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Furge KA, 2004, CANCER RES, V64, P4117, DOI 10.1158/0008-5472.CAN-04-0534; Gerritsen ME, 2003, BRIT J PHARMACOL, V140, P595, DOI 10.1038/sj.bjp.0705494; Harding MA, 2002, CANCER RES, V62, P6981; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Hughes TR, 2000, NAT GENET, V25, P333, DOI 10.1038/77116; Kim SY, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-144; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Phillips JL, 2001, CANCER RES, V61, P8143; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Vanharanta S, 2006, HUM MOL GENET, V15, P97, DOI 10.1093/hmg/ddi431; Virtaneva K, 2001, P NATL ACAD SCI USA, V98, P1124, DOI 10.1073/pnas.98.3.1124; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398	23	34	34	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2007	26	9					1346	1350		10.1038/sj.onc.1210256	http://dx.doi.org/10.1038/sj.onc.1210256			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322920				2022-12-17	WOS:000244558700012
J	Cody, NAL; Ouellet, V; Manderson, EN; Quinn, MCJ; Filali-Mouhim, A; Tellis, P; Zietarska, M; Provencher, DM; Mes-Masson, AM; Chevrette, M; Tonin, PN				Cody, N. A. L.; Ouellet, V.; Manderson, E. N.; Quinn, M. C. J.; Filali-Mouhim, A.; Tellis, P.; Zietarska, M.; Provencher, D. M.; Mes-Masson, A-M; Chevrette, M.; Tonin, P. N.			Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p	ONCOGENE			English	Article						ovarian cancer; chromosome 3p; radiation hybrids; tumor suppressor gene	ENDOTHELIAL GROWTH-FACTOR; GENE-EXPRESSION; PRIMARY CULTURES; SOLID TUMORS; TRANSCRIPTION FACTORS; LOW-GRADE; CARCINOMA; HETEROZYGOSITY; LOCUS; ADENOCARCINOMA	Multiple chromosome 3p tumor suppressor genes (TSG) have been proposed in the pathogenesis of ovarian cancer based on complex patterns of 3p loss. To attain functional evidence in support of TSGs and identify candidate regions, we applied a chromosome transfer method involving cell fusions of the tumorigenic OV90 human ovarian cancer cell line, monoallelic for 3p and an irradiated mouse cell line containing a human chromosome 3 in order to derive OV90 hybrids containing normal 3p fragments. The resulting hybrids showed complete or incomplete suppression of tumorigenicity in nude mouse xenograft assays, and varied in their ability to form colonies in soft agarose and three-dimensional spheroids in a manner consistent with alteration of their in vivo tumorigenic phenotypes. Expression microarray analysis identified a set of common differentially expressed genes, such as SPARC, DAB2 and VEGF, some of which have been shown implicated in ovarian cancer. Genotyping assays revealed that they harbored normal 3p fragments, some of which overlapped candidate TSG regions (3p25p26, 3p24 and 3p14-pcen) identified previously in loss of heterozygosity analyses of ovarian cancers. However, only the 3p12-pcen region was acquired in common by all hybrids where expression microarray analysis identified differentially expressed genes. The correlation of 3p12peen transfer and tumor suppression with a concerted reprogramming of the cellular transcriptome suggest that the putative TSG may have affected key underlying events in ovarian cancer.	McGill Univ, Dept Human Genet, Montreal, PQ H3H 1P3, Canada; McGill Univ, Res Inst, Ctr Hlth, Montreal, PQ H3H 1P3, Canada; Univ Montreal, Inct Canc Montreal, Ctr Rech, Ctr Hosp, Montreal, PQ, Canada; Univ Montreal, Div Gynecol Oncol, Montreal, PQ, Canada; Univ Montreal, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Surg, Div Urol, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2T5, Canada	McGill University; McGill University; Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University; McGill University	Tonin, PN (corresponding author), Montreal Gen Hosp, Room L10-120,1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	patricia.tonin@mcgill.ca		Mes-Masson, Anne-Marie/0000-0002-6498-266X				Adams J, 2002, CURR OPIN CHEM BIOL, V6, P486, DOI 10.1016/S1367-5931(02)00357-5; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Akutagawa N, 2002, JPN J CANCER RES, V93, P644, DOI 10.1111/j.1349-7006.2002.tb01302.x; Arcand SL, 2004, MOL CARCINOGEN, V41, P17, DOI 10.1002/mc.20038; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Bayani J, 2002, CANCER RES, V62, P3466; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Chen HH, 2004, J BIOL CHEM, V279, P30800, DOI 10.1074/jbc.M400154200; Cheng N, 2002, MOL CANCER RES, V1, P2; Cheng N, 2003, NEOPLASIA, V5, P445, DOI 10.1016/S1476-5586(03)80047-7; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; Dallol A, 2002, ONCOGENE, V21, P3020, DOI 10.1038/sj.onc.1205421; Davidson B, 2003, CANCER METAST REV, V22, P103, DOI 10.1023/A:1022272204045; DODSON MK, 1993, CANCER RES, V53, P4456; Doherty AMO, 2003, MAMM GENOME, V14, P583, DOI 10.1007/s00335-003-4002-0; DORIN JR, 1992, HUM MOL GENET, V1, P53, DOI 10.1093/hmg/1.1.53; EHLEN T, 1990, ONCOGENE, V5, P219; Fullwood P, 1999, CANCER RES, V59, P4662; GENTLEMAN R, 2003, VISUALIZATION ANNOTA; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Hoglund M, 2001, GENE CHROMOSOME CANC, V31, P156; Hoglund M, 2003, CANCER RES, V63, P3378; Huebner K, 2001, P NATL ACAD SCI USA, V98, P14763, DOI 10.1073/pnas.261586598; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Kelm JM, 2003, BIOTECHNOL BIOENG, V83, P173, DOI 10.1002/bit.10655; KRUK PA, 1990, LAB INVEST, V63, P132; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; Lacerte A, 2004, MOL ENDOCRINOL, V18, P1558, DOI 10.1210/me.2003-0470; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; Lott ST, 1998, CANCER RES, V58, P3533; Lounis H, 1998, ONCOGENE, V17, P2359, DOI 10.1038/sj.onc.1202152; LOUNIS H, 1994, EXP CELL RES, V215, P303, DOI 10.1006/excr.1994.1346; Lovell M, 1999, CANCER RES, V59, P2182; Maeda T, 2002, J BIOL CHEM, V277, P48889, DOI 10.1074/jbc.M206858200; Manderson EN, 2002, MOL CARCINOGEN, V34, P78, DOI 10.1002/mc.10051; Manderson EN, 2002, GENOME RES, V12, P112, DOI 10.1101/gr.174202; Manning AP, 1999, MOL CARCINOGEN, V24, P218, DOI 10.1002/(SICI)1098-2744(199903)24:3<218::AID-MC8>3.0.CO;2-A; McMahon G, 2000, Oncologist, V5 Suppl 1, P3; Mertens F, 1997, CANCER RES, V57, P2765; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Mok SC, 1996, ONCOGENE, V12, P1895; Novak JP, 2002, GENOMICS, V79, P104, DOI 10.1006/geno.2001.6675; Paley PJ, 1997, CANCER, V80, P98, DOI 10.1002/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A; PEJOVIC T, 1992, GENE CHROMOSOME CANC, V4, P58, DOI 10.1002/gcc.2870040108; Petursdottir TE, 2004, GENE CHROMOSOME CANC, V41, P232, DOI 10.1002/gcc.20072; Presneau N, 2005, MOL CARCINOGEN, V43, P141, DOI 10.1002/mc.20096; Presneau N, 2003, ONCOGENE, V22, P1568, DOI 10.1038/sj.onc.1206219; Provencher DM, 2000, IN VITRO CELL DEV-AN, V36, P357; RIMESSI P, 1994, ONCOGENE, V9, P3467; SANCHEZ Y, 1994, P NATL ACAD SCI USA, V91, P3383, DOI 10.1073/pnas.91.8.3383; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; Simon R, 2000, GENE CHROMOSOME CANC, V28, P106, DOI 10.1002/(SICI)1098-2264(200005)28:1<106::AID-GCC13>3.3.CO;2-J; Speevak MD, 1996, MOL CELL BIOL, V16, P2214; SPEEVAK MD, 1995, CYTOGENET CELL GENET, V69, P63, DOI 10.1159/000133939; Taetle R, 1999, GENE CHROMOSOME CANC, V25, P290, DOI 10.1002/(SICI)1098-2264(199907)25:3<290::AID-GCC12>3.3.CO;2-7; Taetle R, 1999, GENE CHROMOSOME CANC, V25, P46, DOI 10.1002/(SICI)1098-2264(199905)25:1<46::AID-GCC7>3.3.CO;2-F; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Teodoridis JM, 2005, CANCER RES, V65, P8961, DOI 10.1158/0008-5472.CAN-05-1187; Tse C, 2002, CANCER RES, V62, P542; Wang L, 2000, GENE CHROMOSOME CANC, V27, P1, DOI 10.1002/(SICI)1098-2264(200001)27:1<1::AID-GCC1>3.0.CO;2-6; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V11, P91, DOI 10.1016/0165-4608(84)90102-X; Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098; Xiang RH, 2002, CANCER RES, V62, P2637; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4; Yoneda J, 1998, JNCI-J NATL CANCER I, V90, P447, DOI 10.1093/jnci/90.6.447; Yonescu R, 1996, CANCER GENET CYTOGEN, V87, P167, DOI 10.1016/0165-4608(95)00241-3; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104; ZHENG JP, 1991, CANCER RES, V51, P4045	70	34	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					618	632		10.1038/sj.onc.1209821	http://dx.doi.org/10.1038/sj.onc.1209821			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16909122				2022-12-17	WOS:000243731600014
J	de Nigris, F; Botti, C; Rossiello, R; Crimi, E; Sica, V; Napoli, C				de Nigris, F.; Botti, C.; Rossiello, R.; Crimi, E.; Sica, V.; Napoli, C.			Cooperation between Myc and YY1 provides novel silencing transcriptional targets of alpha 3 beta 1-integrin in tumour cells	ONCOGENE			English	Article						YY1; integrin; c-myc; tumours	C-MYC; IN-VIVO; OSTEOSARCOMA CELLS; SIGNALING PATHWAYS; OVER-EXPRESSION; INTEGRINS; CANCER; MECHANISMS; BETA-1-INTEGRIN; ACTIVATION	We show that human osteosarcoma cells (Saos-2) have downregulation of alpha 3 beta 1-integrin compared to normal bone cells; this was further described in human osteosarcomas and in a primary murine sarcoma. The alpha 3 gene was silenced in Saos-2 cells causing a low expression of alpha 3 beta 1-integrin and reduction in collagen attachment with increasing migratory capacity. Chromatin immunoprecipitation assay performed on alpha 3 promoter established that Myc and Yin Yang protein (YY1) cooperate in tandem to downregulate the alpha 3 gene. This silencing mechanism involves the binding of Myc and YY1 to DNA and formation of complexes among Myc/Max, YY1, CREB-binding protein and deacetylation activity. The promoter containing deletions of E-boxes or YY1 cassettes failed to downregulate the transcription of a reporter gene as well as the inhibition of deacetylation activity. Overexpression of both Myc and YY1 was necessary to determine the alpha 3-integrin promoter downregulation in normal osteoblasts. This downregulation of alpha 3 beta 1-integrin can contribute to the acquisition of a more aggressive phenotype. YY1 regulated negatively the Myc activity through a direct interaction with the Myc/Max and deacetylase complexes. This represents a novel silencing mechanism with broad implications in the transcription machinery of tumours.	Univ Naples 2, Sch Med 1, Dept Gen Pathol, Div Clin Pathol, I-80138 Naples, Italy; Univ Naples 2, Sch Med 2, Div Human Pathol, I-80138 Naples, Italy; Berkshire Med Ctr, Dept Internal Med, Pittsfield, MA USA	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli	Napoli, C (corresponding author), Univ Naples 2, Sch Med 1, Dept Gen Pathol, Div Clin Pathol, Via Luigi Crecchio 7,Complesso S Maria Dame, I-80138 Naples, Italy.	claudio.napoli@unina2.it		Napoli, Claudio/0000-0002-5455-555X				Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; Brockbank EC, 2005, BRIT J CANCER, V92, P102, DOI 10.1038/sj.bjc.6602255; Dang CV, 1997, J BIOMED SCI, V4, P269, DOI 10.1007/BF02258350; Davie JR, 1998, J CELL BIOCHEM, P203; de Nigris F, 2000, CIRCULATION, V102, P2111, DOI 10.1161/01.CIR.102.17.2111; de Nigris F, 2002, BRIT J CANCER, V87, P1479, DOI 10.1038/sj.bjc.6600636; de Nigris F, 2001, CANCER RES, V61, P2267; de Nigris F, 2003, CELL CYCLE, V2, P325, DOI 10.4161/cc.2.4.414; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Judware R, 1997, CLIN EXP METASTAS, V15, P228, DOI 10.1023/A:1018417330479; Judware R, 1995, ONCOGENE, V11, P2599; Kawashima A, 2001, CELL BIOL INT, V25, P319, DOI 10.1006/cbir.2000.0652; LEE TC, 1994, ONCOGENE, V9, P1047; Napoli C, 2000, FASEB J, V14, P1996, DOI 10.1096/fj.99-0986com; Napoli C, 2002, NEOPLASIA, V4, P185, DOI 10.1038/sj.neo.7900232; Parise LV, 2000, SEMIN CANCER BIOL, V10, P407, DOI 10.1006/scbi.2000.0337; PIGNATELLI M, 1991, J PATHOL, V165, P25, DOI 10.1002/path.1711650106; PULVERER BJ, 1994, ONCOGENE, V9, P59; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; Seales EC, 2005, CANCER RES, V65, P4645, DOI 10.1158/0008-5472.CAN-04-3117; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Ye JP, 1996, MOL CELL BIOL, V16, P4744	34	34	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					382	394		10.1038/sj.onc.1209804	http://dx.doi.org/10.1038/sj.onc.1209804			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16878156				2022-12-17	WOS:000243544000007
J	Hamai, A; Richon, C; Meslin, F; Faure, F; Kauffmann, A; Lecluse, Y; Jalil, A; Larue, L; Avril, MF; Chouaib, S; Mehrpour, M				Hamai, A.; Richon, C.; Meslin, F.; Faure, F.; Kauffmann, A.; Lecluse, Y.; Jalil, A.; Larue, L.; Avril, M. F.; Chouaib, S.; Mehrpour, M.			Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: relationship to Bcl-2 family and caspase activation	ONCOGENE			English	Article						human melanoma; metastasis; apoptosis; gene expression profiling; TRAIL; tyrosine kinase	TYROSINE KINASE INHIBITOR; IN-VIVO EFFICACY; INDUCED APOPTOSIS; BCR-ABL; LUNG-CANCER; LIGAND; PROTEIN; BAX; SENSITIZES; RECEPTORS	In order to de. ne genetic determinants of primary and metastatic melanoma cell susceptibility to tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL), we have applied oligonucleotide microarrays to TRAIL-sensitive primary T1 cells and TRAIL-resistant metastatic G1 cells treated or not with TRAIL. T1 and G1 cells are isogenic melanoma cell subclones. We examined 22 000 spots, 4.2% of which displayed differential expression in G1 and T1 cells. Cell susceptibility to TRAIL-mediated apoptosis was found to be correlated with gene expression signatures in this model. Some of the differentially expressed genes were identified as involved in ATP-binding and signaling pathways, based on previously published data. Further analysis provided evidences that c-kit was overexpressed in G1 cells while it was absent in T1 cells. The c-kit inhibitor, imatinib, did not restore TRAIL sensitivity, excluding a role for c-kit in TRAIL resistance in G1 cells. Surprisingly, imatinib inhibited cell proliferation and TRAIL-mediated apoptosis in melanoma cells. We investigated the possible involvement of several molecules, including c-ABL, platelet-derived growth factor receptor (PDGFR), cellular FADD-like interleukin-1 alpha-converting enzyme-like inhibitory protein (c-FLIP)(L/S), Fas-associated DD kinase, p53, p21(WAF1), proteins of B-cell leukemia/lymphoma 2 (Bcl-2) family and cytochrome c. Imatinib did not modulate the expression or activation of its own targets, such as c-ABL, PDGFR alpha and PDGFR beta, but it did affect the expression of c-FLIPL, BCL2-associated X protein (Bax) and Bcl-2. Moreover, c-FLIPL knockdown sensitized T1 cells to TRAIL-mediated apoptosis, with a sensitivity similar to that of cells previously treated with imatinib. More notably, we found that the resistance to TRAIL in G1 cells was correlated with constitutive c-FLIPL recruitment to the DISC and the inhibition of caspase 8, 3 and 9 processing. Moreover, c-FLIPL knockdown partly restored TRAIL sensitivity in G1 cells, indicating that the expression level of c-FLIPL and its interaction with TRAIL receptor2 play a crucial role in determining TRAIL resistance in metastatic melanoma cells. Our results also show that imatinib enhances TRAIL-induced cell death independently of BH3-interacting domain death agonist translocation, in a process involving the Bax: Bcl-X-L ratio, Bax: Bcl-X-L/Bcl-2 translocation, cytochrome c release and caspase activation. Our data indicate that imatinib sensitizes T1 cells by directly downregulating c-FLIPL, with the use of an alternative pathway for antitumor activity, because PDGFRa is not activated in T1 cells and these cells do not express c-kit, c-ABL or PDGFR beta. Caspase cascade activation and mitochondria also play a key role in the imatinib-mediated sensitization of melanoma cells to the proapoptotic action of TRAIL.	Inst Gustave Roussy, INSERM, U753, Labs Immunol Tumeurs Humaines,PRI, F-94805 Villejuif, France; Inst Curie, INSERM, U520, Lab Biol Cellulaire Immun Antitumorale, Paris, France; Inst Gustave Roussy, CNRS, UMR 8125, Lab Genet Oncol,PRI, F-94805 Villejuif, France; Inst Curie, CNRS, UMR 146, F-91405 Orsay, France; Chinese Acad Sci, Lab Apoptosis & Canc Biol, Natl Key Lab Biomembrane & Membrane Biotechnol, Inst Zool, Beijing, Peoples R China	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Chinese Academy of Sciences; Institute of Zoology, CAS	Mehrpour, M (corresponding author), Inst Gustave Roussy, INSERM, U753, Labs Immunol Tumeurs Humaines,PRI, Rue Camille Desmoulins, F-94805 Villejuif, France.	mehrpour@igr.fr	Larue, Lionel/F-7355-2013; Mehrpour, Maryam/D-8640-2017; Larue, Lionel/I-6532-2016; Chouaib, Salem/F-7939-2016; faure, florence/P-9064-2016	faure, florence/0000-0002-8359-4283; RICHON, Catherine/0000-0002-3556-3941; JALIL, Abdelali/0000-0003-2710-8735				Al-Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455; All-Ericsson C, 2004, INVEST OPHTH VIS SCI, V45, P2075, DOI 10.1167/iovs.03-1196; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Barnhart BC, 2003, ONCOGENE, V22, P8634, DOI 10.1038/sj.onc.1207103; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Carcelain G, 1997, INT J CANCER, V72, P241, DOI 10.1002/(SICI)1097-0215(19970717)72:2<241::AID-IJC7>3.0.CO;2-R; Carr KM, 2003, ONCOGENE, V22, P3076, DOI 10.1038/sj.onc.1206448; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cory GOC, 2002, NATURE, V418, P732, DOI 10.1038/418732a; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Decaudin D, 2005, INT J CANCER, V113, P849, DOI 10.1002/ijc.20652; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Diarra-Mehrpour M, 2004, CANCER RES, V64, P719, DOI 10.1158/0008-5472.CAN-03-1735; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Dufour E, 1997, J IMMUNOL, V158, P3787; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; Eriksson L, 2004, ANAL BIOANAL CHEM, V380, P419, DOI 10.1007/s00216-004-2783-y; Ganten TM, 2004, CELL DEATH DIFFER, V11, pS86, DOI 10.1038/sj.cdd.4401437; Hasegawa J, 1996, CANCER RES, V56, P1713; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Hersey P, 2001, NAT REV CANCER, V1, P142, DOI 10.1038/35101078; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Ivanov VN, 2005, ONCOGENE, V24, P616, DOI 10.1038/sj.onc.1208125; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Jin TG, 2004, J BIOL CHEM, V279, P55594, DOI 10.1074/jbc.M401056200; Johnston JB, 2003, ONCOGENE, V22, P8356, DOI 10.1038/sj.onc.1207004; Kelley SK, 2001, J PHARMACOL EXP THER, V299, P31; Kim KM, 2005, ONCOGENE, V24, P355, DOI 10.1038/sj.onc.1208213; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lefevre G, 2004, J BIOL CHEM, V279, P31769, DOI 10.1074/jbc.M403907200; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Leverkus M, 2000, CANCER RES, V60, P553; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Muhlethaler-Mottet A, 2004, ONCOGENE, V23, P5415, DOI 10.1038/sj.onc.1207704; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151; Nimmanapalli R, 2002, ONCOGENE, V21, P8584, DOI 10.1038/sj.onc.1206086; Pandiella A, 2003, BRIT J HAEMATOL, V123, P858, DOI 10.1046/j.1365-2141.2003.04706.x; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Sattler M, 2004, LEUKEMIA RES, V28, pS11, DOI 10.1016/j.leukres.2003.10.004; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Taylor JR, 2006, ONCOGENE, V25, P147, DOI 10.1038/sj.onc.1209007; Thomas WD, 1998, J IMMUNOL, V161, P2195; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Uziel O, 2005, BRIT J CANCER, V92, P1881, DOI 10.1038/sj.bjc.6602592; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Weeraratna AT, 2004, ONCOGENE, V23, P2264, DOI 10.1038/sj.onc.1207337; Wei MC, 2000, GENE DEV, V14, P2060; Wendt J, 2005, ONCOGENE, V24, P4052, DOI 10.1038/sj.onc.1208580; Wittnebel S, 2005, EUR CYTOKINE NETW, V16, P123; Yagita H, 2004, CANCER SCI, V95, P777, DOI 10.1111/j.1349-7006.2004.tb02181.x; Yamaguchi K, 2005, ONCOGENE, V24, P5868, DOI 10.1038/sj.onc.1208742	59	34	35	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7618	7634		10.1038/sj.onc.1209738	http://dx.doi.org/10.1038/sj.onc.1209738			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16983347				2022-12-17	WOS:000242655500007
J	Holcomb, VB; Vogel, H; Marple, T; Kornegay, RW; Hasty, P				Holcomb, V. B.; Vogel, H.; Marple, T.; Kornegay, R. W.; Hasty, P.			Ku80 and p53 suppress medulloblastoma that arise independent of Rag-1-induced DSBs	ONCOGENE			English	Article						Ku80; p53; nonhomologous end joining; Rag-1; medulloblastoma; DNA double-strand breaks	MAJOR BREAKPOINT REGION; END-JOINING PATHWAY; V(D)J RECOMBINATION; EMBRYONIC LETHALITY; DNA-REPAIR; GENOMIC STABILITY; MICE; DEFICIENT; CELLS; GENE	Ku80 maintains the genome by repairing DNA double-strand breaks (DSBs) through nonhomologous end joining (NHEJ), a pathway that repairs nonspecific DSBs and Rag-1 Rag-2 (Rag)-specific DSBs. As a result, Ku80 deletion results in phenotypes characteristic of defective repair for both nonspecific DSBs (c-radiation hypersensitivity and genomic instability) and Rag-specific DSBs (immunodeficiency). ku80(-/)-mice also exhibit neuronal apoptosis, but we do not know the type of DSBs responsible for this response. In spite of genomic instability and immunodeficiency, cancer incidence is not increased in ku80(-/-)mice. However, deletion of the tumor suppressor, p53 greatly increases pro-B-cell lymphoma in ku80(-/-)mice due to IgH/ c-Myc translocations suggesting that responses to Rag-specific DNA DSBs suppress cancer. Like suppression of pro-B-cell lymphoma, neuronal apoptosis requires p53 presenting the intriguing possibility that Rag-specific DSBs mediate neuronal development as they do lymphocyte development. Here we delete Rag-1 from ku80(-/)-p53(-/-)mice to differentiate the impact nonspecific vs Rag-specific DSBs have on ku80(-/-)mice. We find that deleting Rag-1 prevents pro-B cell lymphoma confirming Rag-induced DSBs induce this form of cancer. Both the triple mutant mice and the p53(-/-)rag-1(-/)-mice exhibit T-cell lymphoma and medulloblastoma; incidence of T-cell lymphoma is the same for both cohorts whereas incidence of medulloblastoma is higher for the triple-mutant cohort. Thus, p53-mediated neuronal apoptosis likely suppresses medulloblastoma in Ku80-deleted mice and Ku80 likely suppresses medulloblastoma by repairing nonspecific DNA DSBs instead of Rag-specific DSBs. Our observations are the first to show that Ku80 suppresses cancer caused by nonspecific DNA damage and we present a novel mouse model for medulloblastoma.	Univ Texas, Hlth Sci Ctr San Antonio, Dept Mol Med, Inst Biotechnol, 15355 Lambda Dr, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr San Antonio, Lab Anim Resources, San Antonio, TX 78245 USA; Stanford Univ, Med Ctr, Dept Pathol, Palo Alto, CA 94304 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Stanford University	Hasty, P (corresponding author), Univ Texas, Hlth Sci Ctr San Antonio, Dept Mol Med, Inst Biotechnol, 15355 Lambda Dr, San Antonio, TX 78245 USA.	hastye@uthscsa.edu		Hasty, Paul/0000-0003-3046-0131; Vogel, Otto Hannes/0000-0002-0960-3508	NATIONAL CANCER INSTITUTE [R01CA076317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG017242] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA76317-05A1] Funding Source: Medline; NIA NIH HHS [P01 AG17242] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; Difilippantonio MJ, 2002, J EXP MED, V196, P469, DOI 10.1084/jem.20020851; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Dolle MET, 2000, P NATL ACAD SCI USA, V97, P8403, DOI 10.1073/pnas.97.15.8403; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Gladdy RA, 2003, CANCER CELL, V3, P37, DOI 10.1016/S1535-6108(02)00236-2; Gu YS, 2000, P NATL ACAD SCI USA, V97, P2668, DOI 10.1073/pnas.97.6.2668; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Karanjawala ZE, 2002, DNA REPAIR, V1, P1017, DOI 10.1016/S1568-7864(02)00151-9; Lee CJ, 2005, J NEURO-ONCOL, V73, P101, DOI 10.1007/s11060-004-4598-2; Lee Y, 2002, CANCER RES, V62, P6395; Liao MJ, 1998, MOL CELL BIOL, V18, P3495, DOI 10.1128/MCB.18.6.3495; Lieber MR, 2004, DNA REPAIR, V3, P817, DOI 10.1016/j.dnarep.2004.03.015; Lim DS, 2000, MOL CELL BIOL, V20, P3772, DOI 10.1128/MCB.20.11.3772-3780.2000; Lin WS, 2004, J NEUROSCI, V24, P10074, DOI 10.1523/JNEUROSCI.2604-04.2004; Marino S, 2005, TRENDS MOL MED, V11, P17, DOI 10.1016/j.molmed.2004.11.008; Maser RS, 2003, CANCER CELL, V3, P4, DOI 10.1016/S1535-6108(02)00243-X; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Muotri AR, 2005, NATURE, V435, P903, DOI 10.1038/nature03663; Nacht M, 1998, CELL GROWTH DIFFER, V9, P131; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Raghavan SC, 2005, MOL CELL BIOL, V25, P6475, DOI 10.1128/MCB.25.15.6475-6484.2005; Raghavan SC, 2005, MOL CELL BIOL, V25, P5904, DOI 10.1128/MCB.25.14.5904-5919.2005; Raghavan SC, 2004, NATURE, V428, P88, DOI 10.1038/nature02355; Roth DB, 1998, CELL, V94, P411, DOI 10.1016/S0092-8674(00)81580-9; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Vanasse GJ, 1999, J CLIN INVEST, V103, P1669, DOI 10.1172/JCI6658; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	46	34	36	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7159	7165		10.1038/sj.onc.1209704	http://dx.doi.org/10.1038/sj.onc.1209704			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16751807				2022-12-17	WOS:000242046900005
J	Cruz-Munoz, W; Sanchez, OH; Di Grappa, M; English, JL; Hill, RP; Khokha, R				Cruz-Munoz, W.; Sanchez, O. H.; Di Grappa, M.; English, J. L.; Hill, R. P.; Khokha, R.			Enhanced metastatic dissemination to multiple organs by melanoma and lymphoma cells in timp-3(-/-) mice	ONCOGENE			English	Article						TIMP-3; metastasis; melanoma; lymphoma; deficient mice	TISSUE INHIBITOR; MATRIX METALLOPROTEINASE-2; LIVER METASTASIS; TUMOR INVASION; A MMP-2; EXPRESSION; PROGRESSION; CANCER; TIMP; LUNG	Identifying versatile inhibitors of metastasis that operate in multiple sites against distinct cancer cell types is important for designing novel therapeutics for metastasis. We show that multiple tissues of timp-3(-/-) mice are more susceptible to metastatic colonization. Overall, a 5-14-fold increase in liver and kidney colonization occurred by EL-4 lymphoma cells, and a twofold increase upon targeting B16F10 melanoma cells to the bone or lung of timp-3(-/-) mice. There was a general lack of macrophage or neutrophil localization to metastases in the liver, kidney and lung, and of osteoclasts to bone in both genotypes. Analysis of lung showed that proliferation or angiogenesis were unaltered within the metastatic colonies. Lung-trap assays revealed that initial tumor cell trapping was similar in the lung vasculature of timp-3(-/-) and wild-type mice. However, more tumor cells were found in timp-3(-/-) lungs at 48 and 96 h after tumor cell injection indicating more efficient extravasation and initial proliferation. Activation of pro-MMP-2 was greater in timp-3(-/-) lungs at these time points. These data demonstrate TIMP-3 functions to inhibit metastatic dissemination of diverse cancer cells to multiple organs. TIMP-3 regulates MMP-2 activation to limit tumor cell extravasation and subsequent colonization of the lung, without augmenting inflammatory cell response.	Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Ontario, Inst Technol, Oshawa, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Ontario Tech University	Khokha, R (corresponding author), Univ Toronto, Ontario Canc Inst, 610 Univ Ave,Room 10 328, Toronto, ON M5G 2M9, Canada.	rkhokha@uhnres.utoronto.ca		Hill, Richard Peter/0000-0001-5331-8045				Ahonen M, 1998, CANCER RES, V58, P2310; Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Banerji A, 2004, CANCER LETT, V211, P235, DOI 10.1016/j.canlet.2004.02.007; Cameron MD, 2000, CANCER RES, V60, P2541; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cruz-Munoz W, 2006, ONCOGENE, V25, P650, DOI 10.1038/sj.onc.1209104; De Larco JE, 2004, CLIN CANCER RES, V10, P4895, DOI 10.1158/1078-0432.CCR-03-0760; Ding L, 2001, BRIT J CANCER, V85, P431, DOI 10.1054/bjoc.2001.1911; English JL, 2006, J BIOL CHEM, V281, P10337, DOI 10.1074/jbc.M512009200; Gill SE, 2003, DEV BIOL, V261, P313, DOI 10.1016/S0012-1606(03)00318-X; Hofmann UB, 2000, J PATHOL, V191, P245; Hofmann UB, 2005, ARCH DERMATOL RES, V297, P154, DOI 10.1007/s00403-005-0588-2; Itoh T, 1998, CANCER RES, V58, P1048; Kassiri Z, 2005, CIRC RES, V97, P380, DOI 10.1161/01.RES.0000178789.16929.cf; Khatib AM, 1999, CANCER RES, V59, P1356; Kitakata H, 2002, CANCER RES, V62, P6682; Leco KJ, 2001, J CLIN INVEST, V108, P817, DOI 10.1172/JCI12067; LECO KJ, 1994, J BIOL CHEM, V269, P9352; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Miyazaki T, 2004, BRIT J CANCER, V91, P1556, DOI 10.1038/sj.bjc.6602185; Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Nuttall RK, 2004, FEBS LETT, V563, P129, DOI 10.1016/S0014-5793(04)00281-9; ORR FW, 1993, BREAST CANCER RES TR, V25, P151, DOI 10.1007/BF00662140; Pastorino U, 1997, J CLIN ONCOL, V15, P2858, DOI 10.1200/JCO.1997.15.8.2858; Perez M, 2001, EUR J CANCER, V37, P629, DOI 10.1016/S0959-8049(00)00436-6; Powe DG, 1997, BRIT J CANCER, V75, P1678, DOI 10.1038/bjc.1997.285; Rustgi A. K., 2003, GASTROINTESTINAL CAN, P69; Salmela MT, 2003, MODERN PATHOL, V16, P108, DOI 10.1097/01.MP.0000051681.43441.82; SanchezSweatman OH, 1997, EUR J CANCER, V33, P918, DOI 10.1016/S0959-8049(97)00513-3; Shamamian P, 2001, J CELL PHYSIOL, V189, P197, DOI 10.1002/jcp.10014; Soloway PD, 1996, ONCOGENE, V13, P2307; Spurbeck WW, 2002, BLOOD, V100, P3361, DOI 10.1182/blood.V100.9.3361; Urban BA, 2000, RADIOGRAPHICS, V20, P197, DOI 10.1148/radiographics.20.1.g00ja09197; Woessner JF, 2001, J CLIN INVEST, V108, P799, DOI 10.1172/JCI13709; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200; Zhang L, 2004, CANCER RES, V64, P4180, DOI 10.1158/0008-5472.CAN-03-3038	39	34	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2006	25	49					6489	6496		10.1038/sj.onc.1209663	http://dx.doi.org/10.1038/sj.onc.1209663			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16702949				2022-12-17	WOS:000241395100005
J	Cerveira, N; Correia, C; Bizarro, S; Pinto, C; Lisboa, S; Mariz, JM; Marques, M; Teixeira, MR				Cerveira, N.; Correia, C.; Bizarro, S.; Pinto, C.; Lisboa, S.; Mariz, J. M.; Marques, M.; Teixeira, M. R.			SEPT2 is a new fusion partner of MLL in acute myeloid leukemia with t(2 ; 11)(q37 ; q23)	ONCOGENE			English	Article						MLL-SEPT2; fusion oncogenes; t(2;11) (q37; q23); therapy-related AML	ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN INHERITED DISEASE; FUSES MLL; DROSOPHILA-TRITHORAX; FAMILY GENE; 11Q23; TRANSLOCATION; PROTEINS; DELETION; REARRANGEMENTS	We have identified a new mixed lineage leukemia (MLL) gene fusion partner in a patient with treatment-related acute myeloid leukemia (AML) presenting a t(2; 11)(q37; q23) as the only cytogenetic abnormality. Fluorescence in situ hybridization demonstrated a rearrangement of the MLL gene and molecular genetic analyses identified a septin family gene, SEPT2, located on chromosome 2q37, as the fusion partner of MLL. RNA and DNA analyses showed the existence of an in-frame fusion of MLL exon 7 with SEPT2 exon 3, with the genomic breakpoints located in intron 7 and 2 of MLL and SEPT2, respectively. Search for DNA sequence motifs revealed the existence of two sequences with 94.4% homology with the topoisomerase II consensus cleavage site in MLL intron 7 and SEPT2 intron 2. SEPT2 is the fifth septin family gene fused with MLL, making this gene family the most frequently involved in MLL-related AML (about 10% of all known fusion partners). The protein encoded by SEPT2 is highly homologous to septins 1, 4 and 5 and is involved in the coordination of several key steps of mitosis. Further studies are warranted to understand why the septin protein family is particularly involved in the pathogenesis of MLL-associated leukemia.	Portuguese Oncol Inst, Dept Genet, P-4200072 Oporto, Portugal; Portuguese Oncol Inst, Dept Oncohematol, Oporto, Portugal	Portuguese Institute of Oncology; Portuguese Institute of Oncology	Teixeira, MR (corresponding author), Portuguese Oncol Inst, Dept Genet, Rua Dr Antonio Bernardino Almeida, P-4200072 Oporto, Portugal.	mteixeir@ipoporto.min-saude.pt	Teixeira, Manuel AC/AAZ-7251-2020; Teixeira, Manuel António Rodrigues/E-4885-2011	Teixeira, Manuel AC/0000-0002-1959-0624; Teixeira, Manuel António Rodrigues/0000-0002-4896-5982; de Campos Bizarro, Susana/0000-0002-3495-2080; Lisboa, Susana/0000-0002-9773-331X; Pinto, Carla/0000-0001-8689-3388; Correia, Cecilia/0000-0002-4838-7756; Cerveira, Nuno/0000-0001-5098-3840				Abeysinghe SS, 2003, HUM MUTAT, V22, P229, DOI 10.1002/humu.10254; BERGER R, 1987, CANCER GENET CYTOGEN, V29, P9, DOI 10.1016/0165-4608(87)90026-4; Borkhardt A, 2000, P NATL ACAD SCI USA, V97, P9168, DOI 10.1073/pnas.150079597; Chinwalla V, 2003, ONCOGENE, V22, P1400, DOI 10.1038/sj.onc.1206273; Chuzhanova N, 2003, HUM MUTAT, V22, P245, DOI 10.1002/humu.10253; Daser A, 2005, SEMIN CANCER BIOL, V15, P175, DOI 10.1016/j.semcancer.2005.01.007; DELOZIERBLANCHET CD, 1985, CANCER GENET CYTOGEN, V16, P95, DOI 10.1016/0165-4608(85)90001-9; Fischer K, 1997, BLOOD, V89, P2036, DOI 10.1182/blood.V89.6.2036; Fuchs U, 2001, P NATL ACAD SCI USA, V98, P8756, DOI 10.1073/pnas.121433898; Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hall PA, 2004, J PATHOL, V204, P489, DOI 10.1002/path.1654; Harrison CJ, 1998, LEUKEMIA, V12, P811, DOI 10.1038/sj.leu.2401017; Hayette S, 2000, ONCOGENE, V19, P4446, DOI 10.1038/sj.onc.1203789; HURET JL, 2005, ATLAS GENETICS CYTOG; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Kojima K, 2004, LEUKEMIA, V18, P998, DOI 10.1038/sj.leu.2403334; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Li ZY, 2005, LEUKEMIA, V19, P183, DOI 10.1038/sj.leu.2403602; MAROSI C, 1992, CANCER GENET CYTOGEN, V61, P14, DOI 10.1016/0165-4608(92)90364-E; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Mitelman F., 1995, INT SYSTEM HUMAN CYT; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Ono R, 2005, J CLIN INVEST, V115, P919, DOI 10.1172/JCI200522725; Ono R, 2002, CANCER RES, V62, P333; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Poirel H, 1996, BLOOD, V87, P2496, DOI 10.1182/blood.V87.6.2496.bloodjournal8762496; Popovic R, 2005, J CELL BIOCHEM, V95, P234, DOI 10.1002/jcb.20430; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; Pui CH, 2000, BRIT J HAEMATOL, V109, P13, DOI 10.1046/j.1365-2141.2000.01843.x; RASMUSSEN SW, 2004, SEQ TOOLS VERSION 8; RUDIGER NS, 1995, NUCLEIC ACIDS RES, V23, P256, DOI 10.1093/nar/23.2.256; Russell SEH, 2005, BRIT J CANCER, V93, P499, DOI 10.1038/sj.bjc.6602753; Satake N, 1999, LEUKEMIA, V13, P1013, DOI 10.1038/sj.leu.2401439; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; Slany RK, 2005, HEMATOL ONCOL, V23, P1, DOI 10.1002/hon.739; SMIT AFA, 2004, REPEATMASKER OPE 3 0; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Spiliotis ET, 2005, SCIENCE, V307, P1781, DOI 10.1126/science.1106823; Strehl S, 2003, ONCOGENE, V22, P157, DOI 10.1038/sj.onc.1206042; Surka MC, 2002, MOL BIOL CELL, V13, P3532, DOI 10.1091/mbc.E02-01-0042; Taki T, 1999, P NATL ACAD SCI USA, V96, P14535, DOI 10.1073/pnas.96.25.14535; Taki T, 1999, CANCER RES, V59, P4261; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; von Bergh ARM, 2004, GENE CHROMOSOME CANC, V39, P324, DOI 10.1002/gcc.20004; WINICK NJ, 1993, J CLIN ONCOL, V11, P209, DOI 10.1200/JCO.1993.11.2.209; YAMAMOTO K, 1994, BLOOD, V83, P2912, DOI 10.1182/blood.V83.10.2912.2912	51	34	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6147	6152		10.1038/sj.onc.1209626	http://dx.doi.org/10.1038/sj.onc.1209626			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16682951				2022-12-17	WOS:000241101200013
J	Hemmati, PG; Guner, D; Gillissen, B; Wendt, J; von Haefen, C; Chinnadurai, G; Dorken, B; Daniel, PT				Hemmati, P. G.; Guener, D.; Gillissen, B.; Wendt, J.; von Haefen, C.; Chinnadurai, G.; Doerken, B.; Daniel, P. T.			Bak functionally complements for loss of Bax during p14(ARF)-induced mitochondrial apoptosis in human cancer cells	ONCOGENE			English	Article						p14(ARF); Bax; Bak; p53; apoptosis; mitochondria	NF-KAPPA-B; REGULATED FORM; CYCLE ARREST; P53; ARF; DEATH; BCL-2; P19(ARF); ACTIVATION; INDUCTION	In contrast to the initial notion that the biological activity of p14(ARF) strictly depends on a functional mdm-2/p53 signaling axis, we recently demonstrated that p14ARF mediates apoptosis in a p53/Bax-independent manner. Here, we show that p14ARF induces breakdown of the mitochondrial membrane potential and cytochrome c release before triggering caspase-9- and caspase-3/7-like activities in p53/Bax-deficient DU145 prostate cancer cells expressing wild-type Bak. Re-expression of Bax in these cells failed to further enhance p14(ARF)-induced apoptosis, suggesting that p14(ARF)-induced apoptosis primarily depends on Bak but not Bax in these cells. To further de. ne the role of Bak and Bax in p14(ARF)-induced mitochondrial apoptosis, we employed short interference RNA for the knockdown of bak in isogeneic, p53 wildtype HCT116 colon cancer cells either proefficient or deficient for Bax. There, combined loss of Bax and Bak attenuated p14(ARF)-induced apoptosis whereas single loss of Bax or Bak was only marginally effective, as in the case of DU145. Notably, HCT116 cells deficient for Bax and Bak failed to release cytochrome c and showed attenuated activation of caspase-9 (LEHDase) and caspase-3/caspase-7 (DEVDase) upon p14ARF expression. These data indicate that p14ARF triggers apoptosis via a Bax/Bak-dependent pathway in p53-proficient HCT116, whereas Bax is dispensable in p53-deficient DU145 cells. Nevertheless, a substantial proportion of p14(ARF)-induced cell death proceeds in a Bax/Bak-independent manner. This is also the case for inhibition of clonogenic growth that occurs, at least in part, through an entirely Bax/Bak-independent mechanism.	Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; St Louis Univ, Sch Med, Inst Mol Virol, St Louis, MO 63103 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Saint Louis University	Daniel, PT (corresponding author), Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de		Gillissen, Bernhard/0000-0002-1815-2091	NCI NIH HHS [R01 CA033616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Chandra D, 2005, J BIOL CHEM, V280, P19051, DOI 10.1074/jbc.M501391200; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Fatyol K, 2001, J BIOL CHEM, V276, P28421, DOI 10.1074/jbc.M102847200; Gelinas W, 2005, GENE DEV, V19, P1263, DOI 10.1101/gad.1326205; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Groth A, 2000, J BIOL CHEM, V275, P27473; Hemmati PG, 2005, ONCOGENE, V24, P4114, DOI 10.1038/sj.onc.1208579; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; MAO L, 1995, CANCER RES, V55, P2995; Normand G, 2005, J BIOL CHEM, V280, P7118, DOI 10.1074/jbc.M412330200; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; QUELLE DE, 1995, CELL, V83, P993; Rocha S, 2005, CELL CYCLE, V4, P756, DOI 10.4161/cc.4.6.1739; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Scholz C, 2005, ONCOGENE, V24, P7031, DOI 10.1038/sj.onc.1208868; Scholz C, 2005, ONCOGENE, V24, P1904, DOI 10.1038/sj.onc.1208233; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shmueli A, 2005, CELL, V121, P963, DOI 10.1016/j.cell.2005.06.018; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Suzuki H, 2003, BIOCHEM BIOPH RES CO, V312, P1273, DOI 10.1016/j.bbrc.2003.11.071; Theodorakis P, 2002, CANCER RES, V62, P3373; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wendt J, 2005, ONCOGENE, V24, P4052, DOI 10.1038/sj.onc.1208580; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200; Yarbrough WG, 2002, CANCER RES, V62, P1171; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	48	34	35	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6582	6594		10.1038/sj.onc.1209668	http://dx.doi.org/10.1038/sj.onc.1209668			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16847458				2022-12-17	WOS:000241569700003
J	Gonzalez, L; Freije, JMP; Cal, S; Lopez-Otin, C; Serrano, M; Palmero, I				Gonzalez, L.; Freije, J. M. P.; Cal, S.; Lopez-Otin, C.; Serrano, M.; Palmero, I.			A functional link between the tumour suppressors ARF and p33ING1	ONCOGENE			English	Article						ARF; p53; ING1; tumour suppressor	NF-KAPPA-B; ALTERNATIVE TRANSCRIPTS; PHD FINGER; ING FAMILY; P53; P19(ARF); PROTEINS; GENE; MDM2; ACTIVATION	The ARF tumour suppressor protein plays a critical role in the activation of p53 in response to oncogenic stress. ARF can activate p53 through nucleolar sequestration of Mdm2. However, several lines of evidence indicate that this is not the only way of action of ARF, and alternative mechanisms must exist. p33ING1 is a putative tumour suppresor, which induces cell-cycle arrest and apoptosis in a p53-dependent manner. Here, we describe that ARF and p33ING1 can interact in vivo. We also show that the subcellular localization of ING1 can be modulated by ARF protein levels, causing a displacement from nuclear to nucleolar localization. Finally, the ability of p33ING1 to cause cell-cycle arrest and induction of p21CIP1, or Mdm2, is impaired in ARF-deficient primary mouse fibroblasts. Based on these observations, we propose that the interaction with p33ING1 represents a novel mechanism for the tumour suppression function of ARF.	Univ Autonoma Madrid, CSIC, Inst Biomed Res, E-28029 Madrid, Spain; Univ Oviedo, Inst Oncol, Dept Biochem & Mol Biol, Oviedo, Spain; Spanish Natl Canc Ctr, CNIO, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); University of Oviedo; Centro Nacional de Investigaciones Oncologicas (CNIO)	Palmero, I (corresponding author), Univ Autonoma Madrid, CSIC, Inst Biomed Res, Arturo Duperier 4, E-28029 Madrid, Spain.	ipalmero@iib.uam.es	Serrano, Manuel/H-2634-2015; Freije, José M.P./A-6535-2008; López-Otín, Carlos/AAB-2106-2020; Palmero, Ignacio/B-4346-2013	Serrano, Manuel/0000-0001-7177-9312; Freije, José M.P./0000-0002-4688-8266; López-Otín, Carlos/0000-0001-6964-1904; 				Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Calabro V, 2004, MOL CELL BIOL, V24, P8529, DOI 10.1128/MCB.24.19.8529-8540.2004; Campos EI, 2004, CELL MOL LIFE SCI, V61, P2597, DOI 10.1007/s00018-004-4199-4; D'Amico M, 2004, CANCER RES, V64, P4122, DOI 10.1158/0008-5472.CAN-03-2519; Datta A, 2004, J BIOL CHEM, V279, P36698, DOI 10.1074/jbc.M312305200; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Feng XL, 2002, TRENDS CELL BIOL, V12, P532, DOI 10.1016/S0962-8924(02)02391-7; Goeman F, 2005, MOL CELL BIOL, V25, P422, DOI 10.1128/MCB.25.1.422-431.2005; Gong W, 2005, INT J BIOCHEM CELL B, V37, P1054, DOI 10.1016/j.biocel.2004.09.008; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Kuo ML, 2003, CANCER RES, V63, P1046; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Leung KM, 2002, CANCER RES, V62, P4890; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nouman GS, 2003, J CLIN PATHOL, V56, P491, DOI 10.1136/jcp.56.7.491; Nourani A, 2001, MOL CELL BIOL, V21, P7629, DOI 10.1128/MCB.21.22.7629-7640.2001; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Scott M, 2001, NUCLEIC ACIDS RES, V29, P2052, DOI 10.1093/nar/29.10.2052; Scott M, 2001, J CELL SCI, V114, P3455; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shimada H, 2002, ONCOGENE, V21, P1208, DOI 10.1038/sj.onc.1205176; Shinoura N, 1999, CANCER RES, V59, P5521; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Vieyra D, 2002, J BIOL CHEM, V277, P29832, DOI 10.1074/jbc.M200197200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Xin HW, 2004, J BIOL CHEM, V279, P9539, DOI 10.1074/jbc.M311587200; Yarbrough WG, 2002, CANCER RES, V62, P1171; Zeremski M, 1999, J BIOL CHEM, V274, P32172, DOI 10.1074/jbc.274.45.32172	45	34	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2006	25	37					5173	5179		10.1038/sj.onc.1209526	http://dx.doi.org/10.1038/sj.onc.1209526			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16607280				2022-12-17	WOS:000240063700010
J	Pulukuri, SM; Rao, JS				Pulukuri, S. M.; Rao, J. S.			CpG island promoter methylation and silencing of 14-3-3 sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2	ONCOGENE			English	Article						CpG methylation; 14-3-3 sigma; MBD2; prostate cancer	DNA METHYLATION; BREAST-CANCER; TRANSCRIPTIONAL REPRESSION; EPIGENETIC INACTIVATION; UPA PROMOTER; HYPERMETHYLATION; CARCINOMA; CHROMATIN; MECHANISM; GROWTH	14-3-3 sigma proteins regulate numerous cellular processes that are important to cancer development. One of its biological roles involves G2 cell-cycle arrest following DNA damage. It has also been reported that the loss of 14-3-3 sigma expression via CpG methylation may contribute to malignant transformation by impairing the G2 cell-cycle checkpoint function, thereby allowing an accumulation of genetic defects. However, how the CpG methylation-dependent silencing mechanism works in relation to promoter methylation associated with methyl-CpG-binding proteins (MeCPs) is still unclear. To better understand the mechanism, we first examined the methylation status of the 14-3-3 sigma promoter-associated CpG islands and 14-33 sigma gene expression in a subset of prostate cancer cell lines using methylation-specific PCR (MSP), an HhaI-based DNA methylation assay, and reverse transcription-PCR (RT-PCR). We found that the 14-3-3 sigma expression is lost in LNCaP and Tramp-Cl prostate cancer cell lines and that this expression is restored after treatment with epigenetic silencing modifiers 5-aza-2'-deoxycytidine (5-aza) and trichostatin A (TSA). These results imply transcriptional silencing via promoter-associated CpG methylation. Chromatin immunroprecipitation analysis revealed that methyl-CpG-binding protein 2 (MBD2) is associated preferentially to the methylated CpG island in the 14-3-3 sigma promoter in LNCaP and Tramp-Cl cells but not in 14-3-3 sigma-expressing PC3 and DU145 cells, which contain an unmethylated CpG island in the 14-3-3 sigma promoter region. The 14-3-3 sigma gene silencing because of CpG methylation correlates with binding of MBD2. In addition, the activation of 14-3-3 sigma gene expression by a combination of 5-aza and TSA also involves the release of the MBD2 from the 14-3-3 sigma promoter-methylated CpG island in LNCaP and Tramp-C1 cells. Furthermore, MBD2 knockdown by siRNA stimulated 14-3-3 sigma expression in LNCaP cells. We also investigated whether the loss of 14-3-3 sigma expression in LNCaP and Tramp-Cl cells affects cell proliferation by MTT assays. Interestingly, we observed that 14-3-3 sigma-inactivated LNCaP and Tramp-Cl cells had markedly decreased cell proliferation and protein expression of proliferation cell nuclear antigen (PCNA) after restoration of 14-3-3 sigma expression with 5-aza and TSA treatment. On the other hand, the same treatment did not significantly affect 14-3-3 sigma-active PC3 and DU145 cells, which normally express 14-3-3 sigma. Finally, 14-3-3 sigma knockdown by siRNA resulted in increased proliferation in PC3 and DU145 cells. These findings suggest that the transcriptional silencing of the 14-3-3 sigma gene is caused by promoter CpG island methylation associated with MBD2, and that this may play an important role in prostate cancer progression during the invasive and metastatic stages of the disease.	Univ Illinois, Coll Med, Program Canc Biol, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Program Canc Biol, Dept Biomed & Therapeut Sci, 1 Illini Dr,Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu			NCI NIH HHS [R01 CA095058, R01 CA092393, R01 CA116708, R01 CA075557, CA 75557, CA 116708, CA 95058, CA 92393] Funding Source: Medline; NINDS NIH HHS [NS 47699, R01 NS047699] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095058, R01CA092393, R01CA116708, R01CA075557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047699] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Cheng L, 2004, CLIN CANCER RES, V10, P3064, DOI 10.1158/1078-0432.CCR-03-0652; Darwanto A, 2003, CANCER SCI, V94, P442, DOI 10.1111/j.1349-7006.2003.tb01462.x; De Smet C, 2004, MOL CELL BIOL, V24, P4781, DOI 10.1128/MCB.24.11.4781-4790.2004; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; Ego T, 2005, ONCOGENE, V24, P1914, DOI 10.1038/sj.onc.1208394; Esteller M, 2001, CANCER RES, V61, P4689; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Galm O, 2005, ONCOGENE, V24, P4799, DOI 10.1038/sj.onc.1208599; Goodman PA, 2003, ONCOGENE, V22, P2504, DOI 10.1038/sj.onc.1206313; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaneuchi M, 2004, BIOCHEM BIOPH RES CO, V316, P1156, DOI 10.1016/j.bbrc.2004.02.171; Kitazawa S, 1999, J BIOL CHEM, V274, P28787, DOI 10.1074/jbc.274.40.28787; Konduri SD, 2003, ONCOGENE, V22, P4509, DOI 10.1038/sj.onc.1206695; Lin XH, 2003, CANCER RES, V63, P498; Lodygin D, 2004, ONCOGENE, V23, P9034, DOI 10.1038/sj.onc.1208004; Lodygin D, 2003, ONCOGENE, V22, P5519, DOI 10.1038/sj.onc.1206854; Lodygin D, 2005, CELL RES, V15, P237, DOI 10.1038/sj.cr.7290292; McKie AB, 2005, ONCOGENE, V24, P2166, DOI 10.1038/sj.onc.1208371; Mhawech P, 2005, CELL RES, V15, P228, DOI 10.1038/sj.cr.7290291; Mhawech P, 2005, MODERN PATHOL, V18, P340, DOI 10.1038/modpathol.3800240; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nakagawachi T, 2003, ONCOGENE, V22, P8835, DOI 10.1038/sj.onc.1207183; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303; Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200; Pakneshan P, 2003, FASEB J, V17, P1081, DOI 10.1096/fj.02-0973com; Park J, 2004, ONCOGENE, V23, P3474, DOI 10.1038/sj.onc.1207470; Patra SK, 2003, BIOCHEM BIOPH RES CO, V302, P759, DOI 10.1016/S0006-291X(03)00253-5; Relchelt J, 2002, J CELL SCI, V115, P2639; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; Singal R, 2001, CANCER RES, V61, P4820; Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690; Tanaka K, 2004, INT J ONCOL, V25, P1591; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Urano T, 2004, BIOCHEM BIOPH RES CO, V319, P795, DOI 10.1016/j.bbrc.2004.05.056; Woodcock JM, 2003, J BIOL CHEM, V278, P36323, DOI 10.1074/jbc.M304689200; Yatabe Y, 2002, ONCOGENE, V21, P8310, DOI 10.1038/sj.onc.1206014; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201; Zhang Y, 2004, J BIOL CHEM, V279, P34353, DOI 10.1074/jbc.M401300200	57	34	40	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2006	25	33					4559	4572		10.1038/sj.onc.1209462	http://dx.doi.org/10.1038/sj.onc.1209462			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16786000	Green Accepted			2022-12-17	WOS:000239457500006
J	Kreppel, M; Aryee, DNT; Schaefer, KL; Amann, G; Kofler, R; Poremba, C; Kovar, H				Kreppel, M; Aryee, DNT; Schaefer, KL; Amann, G; Kofler, R; Poremba, C; Kovar, H			Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells	ONCOGENE			English	Article						Ewing's sarcoma; EWS-FL11; CD99; migration; ion channels	PRIMITIVE NEUROECTODERMAL TUMORS; REED-STERNBERG PHENOTYPE; MIC2 EXPRESSION; PSEUDOAUTOSOMAL GENE; PERIPHERAL-BLOOD; DOWN-REGULATION; ENGAGEMENT; ADHESION; FAMILY; ACTIVATION	High CD99 expression levels and rearrangements of the EWS gene with ETS transcription factor genes characterize the Ewing's sarcoma family of tumors (ESFT). CD99 is a cell surface glycoprotein whose engagement has been implicated in cell proliferation as well as upregulation and transport of several transmembrane proteins in hematopoietic cells. In ESFT, antibody ligation of CD99 induces fast homotypic cell aggregation and cell death although its functional role in these processes remains largely unknown. Here, using an RNAi approach, we studied for the first time the consequences of modulated CD99 expression in six different ESFT cell lines, representing the most frequent variant forms of EWS gene rearrangement. CD99 suppression resulted in growth inhibition and reduced migration of ESFT cells. Among genes whose expression changes in response to CD99 modulation, the potassium-channel modulatory factor KCMF1 was consistently upregulated. In a series of 22 primary ESFT, KCMF1 expression levels inversely correlated with CD99 abundancy. Cells forced to express ectopic KCMF1 showed a similar reduction in migratory ability as CD99 silenced ESFT cells. Our results suggest that in ESFT, high CD99 expression levels contribute to the malignant properties of ESFT by promoting growth and migration of tumor cells and identify KCMF1 as a potential metastasis suppressor gene downregulated by high constitutive CD99 expression in ESFT.	Univ Dusseldorf, Inst Pathol, D-4000 Dusseldorf, Germany; Med Univ Vienna, Inst Pathol, Vienna, Austria; Tyrolean Canc Res Inst, Innsbruck, Austria	Heinrich Heine University Dusseldorf; Medical University of Vienna	Kovar, H (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.	heinrich.kovar@ccri.univie.ac.at		Kovar, Heinrich/0000-0001-6873-9109				Alberti I, 2002, FASEB J, V16, P1946, DOI 10.1096/fj.02-0049fje; AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Bernard G, 1997, J IMMUNOL, V158, P2543; BERNARD G, 1995, J IMMUNOL, V154, P26; Bertaux K, 2005, J BONE MINER METAB, V23, P114, DOI 10.1007/s00774-004-0549-4; Cerisano V, 2004, ONCOGENE, V23, P5664, DOI 10.1038/sj.onc.1207741; Choi FY, 1998, J IMMUNOL, V161, P749; Conti DJ, 2004, AM J TRANSPLANT, V4, P166; Dworzak MN, 1999, BRIT J HAEMATOL, V105, P690, DOI 10.1046/j.1365-2141.1999.01426.x; DWORZAK MN, 1994, BLOOD, V83, P415, DOI 10.1182/blood.V83.2.415.bloodjournal832415; FELLINGER EJ, 1991, AM J PATHOL, V139, P317; GELIN C, 1989, EMBO J, V8, P3253, DOI 10.1002/j.1460-2075.1989.tb08485.x; GOODFELLOW PN, 1988, PHILOS T ROY SOC B, V322, P145, DOI 10.1098/rstb.1988.0122; Hahn JH, 1997, J IMMUNOL, V159, P2250; Hahn MJ, 2000, FEBS LETT, V470, P350, DOI 10.1016/S0014-5793(00)01330-2; Hu-Lieskovan S, 2005, CANCER RES, V65, P4633, DOI 10.1158/0008-5472.CAN-04-2857; Jang JH, 2004, FEBS LETT, V578, P21, DOI 10.1016/j.febslet.2004.10.071; Kasinrerk W, 2000, IMMUNOL LETT, V71, P33, DOI 10.1016/S0165-2478(99)00165-0; Kim SH, 1998, BLOOD, V92, P4287, DOI 10.1182/blood.V92.11.4287.423k41_4287_4295; Kim SH, 2000, BLOOD, V95, P294; KOVAR H, 1990, ONCOGENE, V5, P1067; LEE YS, 1993, CELL SIGNAL, V5, P803, DOI 10.1016/0898-6568(93)90041-J; Li ZX, 2003, BIOCHEM BIOPH RES CO, V306, P623, DOI 10.1016/S0006-291X(03)00875-1; Park SH, 2005, GENE, V353, P177, DOI 10.1016/j.gene.2005.04.023; Rorie CJ, 2004, CANCER RES, V64, P1266, DOI 10.1158/0008-5472.CAN-03-3274; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Scotlandi K, 2000, CANCER RES, V60, P5134; Sohn HW, 1998, AM J PATHOL, V153, P1937, DOI 10.1016/S0002-9440(10)65707-0; Sohn HW, 2001, J IMMUNOL, V166, P787, DOI 10.4049/jimmunol.166.2.787; Waclavicek M, 1998, J IMMUNOL, V161, P4671	31	34	36	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2795	2800		10.1038/sj.onc.1209300	http://dx.doi.org/10.1038/sj.onc.1209300			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16314831				2022-12-17	WOS:000237272900010
J	Mai, RT; Yeh, TS; Kao, CF; Sun, SK; Huang, HH; Lee, YHW				Mai, RT; Yeh, TS; Kao, CF; Sun, SK; Huang, HH; Lee, YHW			Hepatitis C virus core protein recruits nucleolar phosphoprotein B23 and coactivator p300 to relieve the repression effect of transcriptional factor YY1 on B23 gene expression	ONCOGENE			English	Article						HCV core protein; B23; YY1; p300; B23 promoter	HISTONE ACETYLTRANSFERASE ACTIVITY; HEPATOCELLULAR-CARCINOMA; ADENOVIRUS E1A; RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; DNA-DAMAGE; NON-A; P53; ACTIVATION; NUCLEOPHOSMIN/B23	Hepatitis C virus (HCV) core has a pleiotropic effect on various promoters. In this study, we found that the expression of nucleolar phosphoprotein B23 was enhanced in HCV core-expressing cells and, moreover, HCV core interacts directly with the C-terminal end of B23. Using sucrose gradient centrifugation analysis and immunoprecipitation assays, HCV core was found in a large complex containing B23 and its interacting partner transcription factor YY1. Both B23 and HCV core associated with YY1 in the central GA/GK-rich and C-terminal zinc finger domain. These physical interactions between core, B23, and YY1 led to ternary complex formation that was bound to the YY1 response element. In a transient cotransfection experiment, relief of the transsuppression activity of YY1 on the YY1-response element-driven reporter by core and B23 was found. This is also true when examining the effects of these three constructs on the B23 promoter-driven reporter. Additionally, chromatin immunoprecipitation assays indicated that a transcriptional activation complex consisting of core, together with B23, p300, and YY1, was recruited to the YY1 response element of B23 promoter, and this probably occurred through complex formation between core and these three cellular transcription regulators. This is different from the situation in the absence of core, where YY1 and histone deacetylase 1, but not B23 and p300, were associated on the YY1 element as the transcription repression complex. Together, our results indicate that HCV core can recruit B23 and p300 to relieve the repression effect of YY1 on B23 promoter activity, a property that requires the intrinsic histone acetyltransferase activity of p300. Thus, because these three core-associated cellular transcription regulators have a multitude of cellular interacting proteins and are involved in a versatility of cellular processes, the complex formation described here may partially account for the pleiotropic effects of core protein on gene expression and cellular function in HCV-infected cells.	Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Lee, YHW (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, 155 Li Nog St Sect 2,Shih Pai, Taipei 112, Taiwan.	yhwulee@ym.edu.tw		Mai, Ru-Tsun/0000-0002-9935-4268; Lee Wu, Yan-Hwa/0000-0001-7299-7354				Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Brockmann D, 2001, GENE, V277, P111, DOI 10.1016/S0378-1119(01)00703-X; BRUIX J, 1989, LANCET, V2, P1004; Chan HM, 2001, J CELL SCI, V114, P2363; Chan PK, 1997, NUCLEIC ACIDS RES, V25, P1225, DOI 10.1093/nar/25.6.1225; Chang J, 1998, J VIROL, V72, P3060, DOI 10.1128/JVI.72.4.3060-3065.1998; Chen CM, 1997, J VIROL, V71, P9417, DOI 10.1128/JVI.71.12.9417-9426.1997; Chen SY, 2003, J BIOL CHEM, V278, P591, DOI 10.1074/jbc.M204241200; Cheng PL, 2004, ONCOGENE, V23, P7821, DOI 10.1038/sj.onc.1208066; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Dhar SK, 2004, J BIOL CHEM, V279, P28209, DOI 10.1074/jbc.M403553200; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Gomez-Gonzalo M, 2004, VIROLOGY, V328, P120, DOI 10.1016/j.virol.2004.06.044; Goodman RH, 2000, GENE DEV, V14, P1553; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; HSIEH CL, 1995, BIOCHEM BIOPH RES CO, V214, P910, DOI 10.1006/bbrc.1995.2373; Huang WH, 2001, J BIOL CHEM, V276, P25166, DOI 10.1074/jbc.M010087200; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kalkhoven E, 2004, BIOCHEM PHARMACOL, V68, P1145, DOI 10.1016/j.bcp.2004.03.045; Kao CF, 2004, ONCOGENE, V23, P2472, DOI 10.1038/sj.onc.1207368; Kao CF, 2004, J BIOMED SCI, V11, P72, DOI 10.1159/000075291; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Krippner-Heidenreich A, 2005, MOL CELL BIOL, V25, P3704, DOI 10.1128/MCB.25.9.3704-3714.2005; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Machida K, 2004, J VIROL, V78, P8835, DOI 10.1128/JVI.78.16.8835-8843.2004; Machida K, 2004, P NATL ACAD SCI USA, V101, P4262, DOI 10.1073/pnas.0303971101; Maiguel DA, 2004, MOL CELL BIOL, V24, P3703, DOI 10.1128/MCB.24.9.3703-3711.2004; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Moss T, 2002, CELL, V109, P545, DOI 10.1016/S0092-8674(02)00761-4; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Palko L, 2004, J CELL SCI, V117, P465, DOI 10.1242/jcs.00870; Petkova V, 2001, J BIOL CHEM, V276, P7932, DOI 10.1074/jbc.M007411200; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; Ray S, 2002, MOL ENDOCRINOL, V16, P824, DOI 10.1210/me.16.4.824; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; SHIH CM, 1995, J VIROL, V69, P1160, DOI 10.1128/JVI.69.2.1160-1171.1995; Song CZ, 2002, J BIOL CHEM, V277, P7029, DOI 10.1074/jbc.M108826200; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Sun HJ, 2004, MOL IMMUNOL, V41, P1241, DOI 10.1016/j.molimm.2004.05.013; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Takemura M, 2002, EXP CELL RES, V276, P233, DOI 10.1006/excr.2002.5523; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; van Pelt JF, 2004, CANCER LETT, V209, P197, DOI 10.1016/j.canlet.2003.11.035; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Watashi K, 2003, CANCER SCI, V94, P937, DOI 10.1111/j.1349-7006.2003.tb01381.x; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wu MH, 2002, CARCINOGENESIS, V23, P93, DOI 10.1093/carcin/23.1.93; Wu MH, 2002, J BIOL CHEM, V277, P48234, DOI 10.1074/jbc.M206550200; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Yuan ZM, 1999, ONCOGENE, V18, P5714, DOI 10.1038/sj.onc.1202930; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8	67	34	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					448	462		10.1038/sj.onc.1209052	http://dx.doi.org/10.1038/sj.onc.1209052			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16170350				2022-12-17	WOS:000234714100013
J	Tsai, MH; Chen, X; Chandramouli, GVR; Chen, Y; Yan, H; Zhao, S; Keng, P; Liber, HL; Coleman, CN; Mitchell, JB; Chuang, EY				Tsai, MH; Chen, X; Chandramouli, GVR; Chen, Y; Yan, H; Zhao, S; Keng, P; Liber, HL; Coleman, CN; Mitchell, JB; Chuang, EY			Transcriptional responses to ionizing radiation reveal that p53R2 protects against radiation-induced mutagenesis in human lymphoblastoid cells	ONCOGENE			English	Article						microarray; radiation; p53R2; TK6	NF-KAPPA-B; RIBONUCLEOTIDE REDUCTASE GENE; NUCLEOTIDE EXCISION-REPAIR; THYMIDINE KINASE LOCUS; DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; CYCLE CHECKPOINT; MAMMALIAN-CELLS; CANCER CELLS; APOPTOSIS	The p53 protein has been implicated in multiple cellular responses related to DNA damage. Alterations in any of these cellular responses could be related to increased genomic instability. Our previous study has shown that mutations in p53 lead to hypermutability to ionizing radiation. To investigate further how p53 is involved in regulating mutational processes, we used 8K cDNA microarrays to compare the patterns of gene expression among three closely related human cell lines with different p53 status including TK6 (wild-type p53), NH32 (p53null), and WTK1 (mutant p53). Total RNA samples were collected at 1, 3, 6, 9, and 24 h after 10 Gy gamma-irradiation. Template-based clustering analysis of the gene expression over the time course showed that 464 genes are either up or downregulated by at least twofold following radiation treatment. In addition, cluster analyses of gene expression profiles among these three cell lines revealed distinct patterns. In TK6, 165 genes were upregulated, while 36 genes were downregulated. In contrast, in WTK1 75 genes were upregulated and 12 genes were downregulated. In NH32, only 54 genes were upregulated. Furthermore, we found several genes associated with DNA repair namely p53R2, DDB2, XPC, PCNA, BTG2, and MSH2 that were highly induced in TK6 compared to WTK1 and NH32. p53R2, which is regulated by the tumor suppressor p53, is a small subunit of ribonucleotide reductase. To determine whether it is involved in radiation-induced mutagenesis, p53R2 protein was inhibited by siRNA in TK6 cells and followed by 2Gy radiation. The background mutation frequencies at the TK locus of siRNA-transfected TK6 cells were about three times higher than those seen in TK6 cells. The mutation frequencies of siRNA-transfected TK6 cells after 2 Gy radiation were significantly higher than the irradiated TK6 cells without p53R2 knock down. These results indicate that p53R2 was induced by p53 protein and is involved in protecting against radiation-induced mutagenesis.	NCI, Radiat Biol Branch, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NCI, Oncol Branch, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NCI, Ctr Adv Technol, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Univ Rochester, Sch Med & Dent, Rochester, NY 14627 USA; Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA; Natl Taiwan Univ, Dept Elect Engn, Taipei 10764, Taiwan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Rochester; Colorado State University; National Taiwan University	Chuang, EY (corresponding author), NCI, Radiat Biol Branch, Canc Res Ctr, NIH, Bldg 10,Room B3-B69, Bethesda, MD 20892 USA.	chuange@mail.nih.gov		TSAI, MONG-HSUN/0000-0001-8777-5818				Amundson SA, 2000, RADIAT RES, V154, P342, DOI 10.1667/0033-7587(2000)154[0342:IOPMBI]2.0.CO;2; Backlund MG, 2001, CANCER RES, V61, P6577; BARCELLOS CK, 1994, BRAZ J MED BIOL RES, V27, P1111; BENJAMIN MB, 1991, P NATL ACAD SCI USA, V88, P6652, DOI 10.1073/pnas.88.15.6652; Chen XF, 2002, CANCER RES, V62, P1213; Chuang YYE, 1999, CANCER RES, V59, P3073; Chuang YYE, 2002, CANCER RES, V62, P6246; Coelho D, 2002, RADIAT RES, V157, P446, DOI 10.1667/0033-7587(2002)157[0446:IOTIAI]2.0.CO;2; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Evans E, 2000, MOL CELL, V5, P789, DOI 10.1016/S1097-2765(00)80319-6; Ewan KB, 2002, CANCER RES, V62, P5627; Fitch ME, 2003, DNA REPAIR, V2, P819, DOI 10.1016/S1568-7864(03)00066-1; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; Geffrotin C, 1998, RADIAT RES, V149, P472, DOI 10.2307/3579787; Gong BD, 2000, CANCER RES, V60, P5754; Guittet O, 2001, J BIOL CHEM, V276, P40647, DOI 10.1074/jbc.M106088200; Holbrook N J, 1996, EXS, V77, P273; Kawai H, 1999, CANCER RES, V59, P6038; Kimura T, 2003, NAT GENET, V34, P440, DOI 10.1038/ng1212; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lin ZP, 2004, J BIOL CHEM, V279, P27030, DOI 10.1074/jbc.M402056200; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Peng YL, 2002, CANCER RES, V62, P6400; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SKOPEK TR, 1978, BIOCHEM BIOPH RES CO, V84, P411, DOI 10.1016/0006-291X(78)90185-7; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; Sugasawa K, 2001, GENE DEV, V15, P507, DOI 10.1101/gad.866301; Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Won KA, 1998, MOL CELL BIOL, V18, P7584, DOI 10.1128/MCB.18.12.7584; XIA F, 1995, CANCER RES, V55, P12; Xue LJ, 2003, CANCER RES, V63, P980; Yamaguchi T, 2001, CANCER RES, V61, P8256; Yang CR, 2000, FASEB J, V14, P379, DOI 10.1096/fasebj.14.2.379; Yang O, 2004, ONCOGENE, V23, P3749, DOI 10.1038/sj.onc.1207462; Yu YJ, 1997, ONCOGENE, V14, P1661, DOI 10.1038/sj.onc.1201026; Yu YJ, 1998, CANCER RES, V58, P4277; Zhao WL, 2001, CANCER RES, V61, P5537	48	34	34	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					622	632		10.1038/sj.onc.1209082	http://dx.doi.org/10.1038/sj.onc.1209082			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16247478	Green Submitted			2022-12-17	WOS:000234897400013
J	Lievre, A; Landi, B; Cote, JF; Veyrie, N; Zucman-Rossi, J; Berger, A; Laurent-Puig, P				Lievre, A; Landi, B; Cote, JF; Veyrie, N; Zucman-Rossi, J; Berger, A; Laurent-Puig, P			Absence of mutation in the putative tumor-suppressor gene KLF6 in colorectal cancers	ONCOGENE			English	Article						colorectal cancer; KLF6; mutation	PROSTATE-CANCER; MICROSATELLITE INSTABILITY; P53 MUTATIONS; DNA-SYNTHESIS; KIRSTEN-RAS; CELL-LINES; SURVIVAL; GLIOBLASTOMAS; POLYMERASES; CARCINOMA	The KLF6 gene encodes the Kruppel-like factor 6, a transcription factor that has been individualized as a tumor-suppressor gene involved in the regulation of cell proliferation and differentiation. Recently, high frequency (42%) of KLF6 mutations have been reported in colorectal cancers (CRC) as in prostate cancers, astrocytic gliomas and hepatocellular carcinomas. The aims of the study was to confirm the frequency of KLF6 mutations in a larger series of CRC than that previously published by using DNA extracted from frozen tissue samples, which have been proved to generate less mutational artefact than that extracted from formalin-fixed paraffin-embedded tissue samples, in order to compare KLF6 mutation frequency with that of other common genetic alterations and to determine genotype-phenotype correlations. Amplification and direct sequencing of KLF6 exon 2 of 76 CRC and matched normal frozen tissues was performed. Polymorphisms were observed in 14 cases, among which two (T35T and S116S) had not already been reported. No KLF6 somatic mutation was observed. Our data suggest a minor role of KLF6 mutation in colorectal carcinogenesis and underline the fact that the validity of sequence informations obtained from DNA extracted from formalin-fixed tissues may be limited.	Univ Paris 05, INSERM, UMR, U490,Lab Toxicol Mol S490, F-75006 Paris, France; Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, Serv Gastroenterol, F-75015 Paris, France; INSERM, U674 Genom Tumeurs Solides, F-75010 Paris, France; Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, Serv Chirurg Gen Digest & Oncol, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite	Laurent-Puig, P (corresponding author), Univ Paris 05, INSERM, UMR, U490,Lab Toxicol Mol S490, 45 Rue St Peres, F-75006 Paris, France.	pierre.laurent-puig@univ-paris5.fr	j, zucman-rossi/AAV-3594-2021; Laurent-Puig, Pierre/K-3641-2019; laurent-puig, pierre/B-2226-2013; zucman-rossi, Jessica/B-5098-2009	j, zucman-rossi/0000-0002-5687-0334; Laurent-Puig, Pierre/0000-0001-8475-5459; laurent-puig, pierre/0000-0001-8475-5459; zucman-rossi, Jessica/0000-0002-5687-0334				Andreyev HJN, 1998, J NATL CANCER I, V90, P675, DOI 10.1093/jnci/90.9.675; Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Boyault S, 2005, HEPATOLOGY, V41, P681, DOI 10.1002/hep.20588; Chen Han-kui, 2002, Ai Zheng, V21, P1047; CHO YG, 2005, ONCOGENE        0411; Choi SW, 2002, CLIN CANCER RES, V8, P2311; Duarte V, 2000, NUCLEIC ACIDS RES, V28, P1555, DOI 10.1093/nar/28.7.1555; Feldman M Y, 1973, Prog Nucleic Acid Res Mol Biol, V13, P1, DOI 10.1016/S0079-6603(08)60099-9; Ferraz JM, 2004, INT J CANCER, V110, P183, DOI 10.1002/ijc.20124; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Halling KC, 1999, JNCI-J NATL CANCER I, V91, P1295, DOI 10.1093/jnci/91.15.1295; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; Jeng YM, 2003, INT J CANCER, V105, P625, DOI 10.1002/ijc.11123; Kohler B, 2004, INT J CANCER, V111, P644, DOI 10.1002/ijc.20302; Koivisto PA, 2004, INT J CANCER, V111, P642, DOI 10.1002/ijc.20301; Koivisto PA, 2004, J UROLOGY, V172, P506, DOI 10.1097/01.ju.0000129242.88182.e1; Kremer-Tal S, 2004, HEPATOLOGY, V40, P1047, DOI 10.1002/hep.20460; Montanini L, 2004, INT J CANCER, V111, P640, DOI 10.1002/ijc.20303; Muhlbauer KR, 2003, BRIT J CANCER, V89, P687, DOI 10.1038/sj.bjc.6601164; Narla G, 2005, CANCER RES, V65, P1213, DOI 10.1158/0008-5472.CAN-04-4249; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Quach Nancy, 2004, BMC Clin Pathol, V4, P1, DOI 10.1186/1472-6890-4-1; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; Smith CA, 1998, J BIOL CHEM, V273, P21933, DOI 10.1074/jbc.273.34.21933; Smith G, 2002, P NATL ACAD SCI USA, V99, P9433, DOI 10.1073/pnas.122612899; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Williams C, 1999, AM J PATHOL, V155, P1467, DOI 10.1016/S0002-9440(10)65461-2; Wong C, 1998, CANCER GENET CYTOGEN, V107, P21, DOI 10.1016/S0165-4608(98)00079-X; Yngveson A, 1999, CANCER EPIDEM BIOMAR, V8, P433; Zhou CZ, 2002, WORLD J GASTROENTERO, V8, P668, DOI 10.3748/wjg.v8.i4.668	34	34	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7253	7256		10.1038/sj.onc.1208867	http://dx.doi.org/10.1038/sj.onc.1208867			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16044160				2022-12-17	WOS:000232990100014
J	Frigola, J; Munoz, M; Clark, SJ; Moreno, V; Capella, G; Peinado, MA				Frigola, J; Munoz, M; Clark, SJ; Moreno, V; Capella, G; Peinado, MA			Hypermethylation of the prostacyclin synthase (PTGIS) promoter is a frequent event in colorectal cancer and associated with aneuploidy	ONCOGENE			English	Article						colorectal cancer; tumor progression; cancer marker; cancer epigenetics; genetic instability	HISTONE DEACETYLASE INHIBITION; GENE; CELLS; ACTIVATION; GROWTH	Inactivation of specific tumor suppressor genes by transcriptional silencing associated with hypermethylation of the promoter is a common event in cancer. We have applied the amplification of intermethylated sites (AIMS) technique to a 100 human colorectal cancers and seven cell lines to identify recurrent alterations that may unveil silenced tumor suppressor genes. Bisulfite sequencing was used to con. firm differential DNA methylation results. Gene expression analysis was performed by real-time RT-PCR. An AIMS band recurrently displayed in tumors but not in normal tissues was isolated and identified as part of the CpG island of the prostacyclin synthase (PTGIS) gene promoter. PTGIS promoter was hypermethylated in 43 out of 100 colorectal cancers and in all cell lines. Bisulfite sequencing and clonal analysis confirmed the results obtained by AIMS and demonstrated biallelic hypermethylation of PTGIS promoter. Hypermethylation of the PTGIS promoter was associated with diminished gene expression, that was restored after treatment with demethylating and histone deacetylases inhibitor agents. PTGIS hypermethylation was associated with aneuploidy and p53 mutations. In the adjusted model, PTGIS methylation, but not p53 mutation, maintained the association with aneuploidy. We conclude that epigenetic inactivation of the PTGIS gene is a recurrent alteration in colorectal carcinogenesis.	Hosp Duran & Reynals, Inst Recerca Oncol, IDIBELL, Barcelona 08907, Spain; Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia; IDIBELL, Inst Catala Oncol, Barcelona, Spain; Univ Autonoma Barcelona, Fac Med, Lab Bioestadistica & Epidemiol, E-08193 Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Garvan Institute of Medical Research; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Autonomous University of Barcelona; University of Barcelona	Peinado, MA (corresponding author), Hosp Duran & Reynals, Inst Recerca Oncol, IDIBELL, Gran Via Km 2-7, Barcelona 08907, Spain.	mpeinado@iro.es	Clark, Susan J/U-7365-2019; Capella, Gabriel/I-1879-2015; Clark, Susan J/B-2272-2008; Frigola, Jordi/N-4602-2015; Peinado, Miguel A./A-5591-2008; Moreno, Victor/A-1697-2010	Clark, Susan J/0000-0001-5925-5030; Capella, Gabriel/0000-0002-4669-7320; Clark, Susan J/0000-0001-5925-5030; Frigola, Jordi/0000-0002-7231-3853; Peinado, Miguel A./0000-0002-4090-793X; Moreno, Victor/0000-0002-2818-5487				Amano S, 2004, RESPIROLOGY, V9, P184, DOI 10.1111/j.1440-1843.2004.00568.x; Brown JR, 2005, J CLIN ONCOL, V23, P2840, DOI 10.1200/JCO.2005.09.051; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cutler NS, 2003, CANCER RES, V63, P1748; Frigola J, 2005, HUM MOL GENET, V14, P319, DOI 10.1093/hmg/ddi028; Frigola J, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.7.e28; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; Gupta RA, 2004, NAT MED, V10, P245, DOI 10.1038/nm993; Hatae T, 2001, J BIOL CHEM, V276, P46260, DOI 10.1074/jbc.M107180200; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Keith RL, 2004, CANCER RES, V64, P5897, DOI 10.1158/0008-5472.CAN-04-1070; Keith RL, 2002, CANCER RES, V62, P734; Lim H, 2002, ENDOCRINOLOGY, V143, P3207, DOI 10.1210/en.2002-220159; Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226; Pradono P, 2002, CANCER RES, V62, P63; Risques RA, 2001, LAB INVEST, V81, P307, DOI 10.1038/labinvest.3780239; Sadikovic B, 2004, BREAST CANCER RES, V6, pR329, DOI 10.1186/bcr799; Tortola S, 1999, J CLIN ONCOL, V17, P1375, DOI 10.1200/JCO.1999.17.5.1375; Yang XW, 2001, CANCER RES, V61, P7025; Yokoyama C, 1996, GENOMICS, V36, P296, DOI 10.1006/geno.1996.0465	22	34	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7320	7326		10.1038/sj.onc.1208883	http://dx.doi.org/10.1038/sj.onc.1208883			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16007128				2022-12-17	WOS:000233142100008
J	Oppermann, M; Geilen, CC; Fecker, LF; Gillissen, B; Daniel, PT; Eberle, J				Oppermann, M; Geilen, CC; Fecker, LF; Gillissen, B; Daniel, PT; Eberle, J			Caspase-independent induction of apoptosis in human melanoma cells by the proapoptotic Bcl-2-related protein Nbk/Bik	ONCOGENE			English	Article						Nbk/Bik; BH3-only; melanoma; apoptosis	CERAMIDE-MEDIATED APOPTOSIS; BCL-2 FAMILY-MEMBERS; CONDITIONAL EXPRESSION; ENDOPLASMIC-RETICULUM; MALIGNANT-MELANOMA; IN-VITRO; DEATH; BIK; RESISTANCE; CATHEPSIN	The proapoptotic BH3-only protein natural born killer/Bcl-2 interacting killer (Nbk/Bik) has been described to inhibit Bcl-2 and Bcl-x(L), thereby supporting the death promoting ability of Bax. In order to evaluate its function in melanoma, we investigated the response after Nbk/Bik overexpression in cultured human melanoma cells and in a melanoma mouse model. Untransfected melanoma cell lines expressed Nbk/Bik only weakly at the mRNA and protein level. Conditional expression of Nbk/Bik by applying the inducible tetracycline-responsive expression system triggered apoptosis and enhanced sensitivity to proapoptotic stimuli as to agonistic CD95 activation and to chemotherapeutics etoposide, doxorubicin and pamidronate. For investigating the effects of Nbk/Bik in vivo, stably transfected melanoma cells were subcutaneously injected into nude mice. Signifi. cantly delayed tumor growth was the result when mice received doxycycline for induction of Nbk/Bik expression. By investigating the mechanism of Nbk/Bik-induced cell death, typical hallmarks of apoptosis such as DNA fragmentation and chromatin condensation were seen after induction. Interestingly, no indications for cytochrome c release and caspase processing were found, and selective caspase inhibition remained without effect. These data indicate the high potential of Nbk/Bik in regulating apoptosis in melanoma by a caspase-independent pathway and may corroborate the potency of novel antimelanoma strategies based on activation of BH3-only proteins such as Nbk/Bik.	Univ Med Berlin, Skin Canc Ctr, Dept Dermatol & Allergy, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Eberle, J (corresponding author), Univ Med Berlin, Skin Canc Ctr, Dept Dermatol & Allergy, Charite Campus Benjamin Franklin, D-14195 Berlin, Germany.	juergen.eberle@charite.de		Eberle, Jurgen/0000-0001-8533-1519; Gillissen, Bernhard/0000-0002-1815-2091				Bang B, 2004, ARCH DERMATOL RES, V296, P67, DOI 10.1007/s00403-004-0473-4; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Bouillet P, 2001, DEV CELL, V1, P645, DOI 10.1016/S1534-5807(01)00083-1; BOYD JM, 1995, ONCOGENE, V11, P1921; Broker LE, 2004, CANCER RES, V64, P27, DOI 10.1158/0008-5472.CAN-03-3060; BRUGGEN J, 1981, J CANCER RES CLIN, V102, P141, DOI 10.1007/BF00410665; CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; Coultas L, 2004, MOL CELL BIOL, V24, P1570, DOI 10.1128/MCB.24.4.1570-1581.2004; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Daniel PT, 1999, BLOOD, V94, P1100, DOI 10.1182/blood.V94.3.1100.415a16_1100_1107; Eberle J, 1999, J INVEST DERMATOL, V112, P925, DOI 10.1046/j.1523-1747.1999.00598.x; Eberle J, 2003, ONCOGENE, V22, P9131, DOI 10.1038/sj.onc.1207228; Eberle J, 2002, BRIT J CANCER, V86, P1957, DOI 10.1038/sj.bjc.6600351; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Fecker LF, 2005, J INVEST DERMATOL, V124, P221, DOI 10.1111/j.0022-202X.2004.23572.x; Festjens N, 2003, ACTA HAEMATOL-BASEL, V111, P7, DOI 10.1159/000074483; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; FISCHER U, 2005, IN PRESS CELL DEATH; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Garbe C, 2001, SKIN PHARMACOL APPL, V14, P280, DOI 10.1159/000056358; Germain M, 2002, J BIOL CHEM, V277, P18053, DOI 10.1074/jbc.M201235200; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Guner Dilek, 2003, Curr Med Chem Anticancer Agents, V3, P319, DOI 10.2174/1568011033482369; Han J, 1996, MOL CELL BIOL, V16, P5857; Hossini AM, 2003, FEBS LETT, V553, P250, DOI 10.1016/S0014-5793(03)01017-2; Hur JY, 2004, P NATL ACAD SCI USA, V101, P2351, DOI 10.1073/pnas.0307337101; Hussein MR, 2003, J PATHOL, V199, P275, DOI 10.1002/path.1300; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jiang AM, 2001, J IMMUNOL, V166, P6025, DOI 10.4049/jimmunol.166.10.6025; Juin P, 2004, BBA-MOL CELL RES, V1644, P251, DOI 10.1016/j.bbamcr.2003.10.010; LOCKSHIN A, 1985, CANCER RES, V45, P345; Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340; Naumann U, 2003, HUM GENE THER, V14, P1235, DOI 10.1089/104303403767740777; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Orth R, 1997, J BIOL CHEM, V272, P8841; Paquet C, 2004, APOPTOSIS, V9, P815, DOI 10.1023/B:APPT.0000045791.55282.91; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Reed J. C., 2004, SCI STKE, V2004, pre9, DOI DOI 10.1126/STKE.2392004RE9; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Scholz C, 2005, ONCOGENE, V24, P1904, DOI 10.1038/sj.onc.1208233; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Suzuki M, 2003, INFECT IMMUN, V71, P3503, DOI 10.1128/IAI.71.6.3503-3511.2003; Theodorakis P, 2002, CANCER RES, V62, P3373; Tong Y, 2001, MOL CANCER THER, V1, P95; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025	52	34	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7369	7380		10.1038/sj.onc.1208890	http://dx.doi.org/10.1038/sj.onc.1208890			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16007125				2022-12-17	WOS:000233142100013
J	Tahmatzopoulos, A; Sheng, SJ; Kyprianou, N				Tahmatzopoulos, A; Sheng, SJ; Kyprianou, N			Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis	ONCOGENE			English	Article						prostate cancer; alpha-blockers; apoptosis	ALPHA-1-ADRENOCEPTOR ANTAGONISTS; GROWTH-FACTOR; TUMOR-SUPPRESSOR; CARCINOMA CELLS; INDUCTION; ANGIOGENESIS; METASTASIS; EXPRESSION; INVASION; TERAZOSIN	Maspin is a mammary serine protease inhibitor or serpin with tumor suppressive and antiangiogenic activity that inhibits tumor motility, invasion and metastasis, at least by its actions on cell membrane and extracellular matrix (ECM) proteins. Previous studies documented that the quinazoline-derived alpha 1-adrenoceptor antagonist doxazosin affects the attachment and migration of prostate cancer cells. In this study, we investigated the effect of maspin overexpression on the apoptotic/antiadhesion response of prostate cancer cells to doxazosin. The response of maspin-overexpressing clones of human prostate cancer cells DU-145 to doxazosin was evaluated by determining cell viability, apoptosis and cell proliferation on the basis of the trypan blue exclusion assay/methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay, Hoechst staining and caspase-3 activation, and [H-3] thymidine incorporation assay. Vascular endothelial growth factor (VEGF), transforming growth factor beta RII (TGF beta RII), Smad4 (a TGF beta intracellular effector) and bax expression was evaluated at the mRNA and protein level using reverse transcriptase-polymerase chain reaction and Western blotting, respectively. The effect of doxazosin on cell attachment of maspin-expressing prostate cancer cells was evaluated on collagen- and fibronectin-coated plates. Cell migration was assessed using the wounding assay. In response to tumor necrosis factor-related apoptosis-inducing ligand, DU-145-maspin expressing cells undergo apoptosis, via poly(ADP-ribose) polymerasecleavage and caspase-3 activation. DU-145-maspin cells exhibited higher sensitivity to doxazosin and an earlier temporal activation of caspase-3. The number of apoptotic cells detected in response to doxazosin was significantly higher compared to the neo control (P < 0.0001). Doxazosin resulted in dramatic downregulation of the 189 isoform of VEGF in maspin transfectants, while a fivefold induction of Smad4 mRNA expression was detected in those cells after 24 h of treatment. Maspin overexpression in prostate cancer cells resulted in an increased ability to attach to ECM-coated plates, and doxazosin treatment considerably antagonized this effect by decreasing the attachment potential to collagen and fibronectin. The present study supports the ability of maspin to enhance the apoptotic threshold of prostate cancer cells to the quinazoline-based alpha 1-adrenoceptor antagonist doxazosin. These findings may have therapeutic significance in the development of antiangiogenic targeting by doxazosin and derivative agents for advanced prostate cancer.	Univ Kentucky, Med Ctr, Dept Surg, Div Oncol, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Mol & Cellular Biochem, Lexington, KY USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Univ Kentucky, Coll Med, Dept Pathol, Lexington, KY USA	University of Kentucky; University of Kentucky; Wayne State University; University of Kentucky	Kyprianou, N (corresponding author), Univ Kentucky, Med Ctr, Dept Surg, Div Oncol, 800 Rose St,MS-283, Lexington, KY 40536 USA.	nkypr2@uky.edu			NATIONAL CANCER INSTITUTE [R01CA107575] Funding Source: NIH RePORTER; NCI NIH HHS [CA10757-01, R01 CA107575, R01 CA107575-02, R01 CA107575-03, R01 CA107575-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham S, 2003, J UROLOGY, V169, P1157, DOI 10.1097/01.ju.0000040245.70349.37; Bare R L, 1998, Cancer Treat Res, V94, P69; Benning CM, 2002, CANCER RES, V62, P597; BILIRAN JH, 2001, CANCER RES, V61, P676; Blacque OE, 2002, J BIOL CHEM, V277, P10783, DOI 10.1074/jbc.M110992200; Bruckheimer EM, 2000, CELL TISSUE RES, V301, P153, DOI 10.1007/s004410000196; Burchardt M, 1999, BIOL REPROD, V60, P398, DOI 10.1095/biolreprod60.2.398; Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Guo YP, 1998, CELL GROWTH DIFFER, V9, P185; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jiang N, 2002, ONCOGENE, V21, P4089, DOI 10.1038/sj.onc.1205507; Keledjian K, 2005, J CELL BIOCHEM, V94, P374, DOI 10.1002/jcb.20240; Keledjian K, 2003, J UROLOGY, V169, P1150, DOI 10.1097/01.ju.0000042453.12079.77; Keledjian K, 2001, PROSTATE, V48, P71, DOI 10.1002/pros.1083; Kyprianou N, 2000, CANCER RES, V60, P4550; Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568; Oades G M, 2000, Curr Urol Rep, V1, P97, DOI 10.1007/s11934-000-0043-z; Partin JV, 2003, BRIT J CANCER, V88, P1615, DOI 10.1038/sj.bjc.6600961; Raghavan D, 1997, EUR J CANCER, V33, P566, DOI 10.1016/S0959-8049(96)00510-2; Schaefer JS, 2003, CURR MOL MED, V3, P653, DOI 10.2174/1566524033479519; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Shi HY, 2001, CANCER RES, V61, P6945; Sternberg CN, 2003, EUR J CANCER, V39, P136, DOI 10.1016/S0959-8049(02)00665-2; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; Yang G, 1997, PROSTATE, V33, P157; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	29	34	38	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5375	5383		10.1038/sj.onc.1208684	http://dx.doi.org/10.1038/sj.onc.1208684			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007219	Green Accepted			2022-12-17	WOS:000231158500011
J	Abraham, N; Ma, MC; Snow, JW; Miners, MJ; Herndier, BG; Goldsmith, MA				Abraham, N; Ma, MC; Snow, JW; Miners, MJ; Herndier, BG; Goldsmith, MA			Haploinsufficiency identifies STAT5 as a modifier of IL-7-induced lymphomas	ONCOGENE			English	Article						cytokine; cytokine receptors; transcription factors; haploinsufficiency; lymphoma development	SEVERE COMBINED IMMUNODEFICIENCY; LYMPHOBLASTIC-LEUKEMIA CELLS; HEMATOPOIETIC STEM-CELLS; INTERLEUKIN-7 RECEPTOR; T-CELLS; IN-VIVO; CYCLE PROGRESSION; SEXUAL-DIMORPHISM; GENE-EXPRESSION; TRANSGENIC MICE	The requirement for receptor components and the signalling effector, signal transducer and activator of transcription (STAT) 5A/5B, was assessed genetically in a lymphoma development model induced by interleukin-7 (IL-7). This growth factor for T- and B-cell progenitors and mature lymphocytes activates survival and proliferative pathways including Bcl-2, phosphatidylinositol-3 kinase and STAT5. Overexpression of IL-7 in vivo causes early mortality from lymphoma development. Mice overexpressing IL-7 that were heterozygous for the IL-7R alpha subunit showed improved survival compared to wild-type mice. In addition, STAT5A/5B(+/-) compound heterozygous mice with one targeted allele each of STAT5A and STAT5B showed striking amelioration of IL-7-induced mortality and disease development. STAT5A/5B(+/-) compound heterozygous mice were otherwise normal in stem cell and lymphocyte development and cellularity. Lower STAT5 protein levels accompanied the reduction in STAT5A/5B copy number, which suggests that STAT5 haploinsufficiency is a modifier of IL-7 signal strength.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94141 USA; Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA	University of British Columbia; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Diego; University of California System; University of California San Francisco	Abraham, N (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 300-6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	ninan@interchange.ubc.ca	Abraham, Ninan/K-5572-2012	Abraham, Ninan/0000-0002-2747-1246	NIGMS NIH HHS [R01 GM54351] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054351] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENJAMIN D, 1994, J IMMUNOL, V152, P4749; Bradley HL, 2002, BLOOD, V100, P3983, DOI 10.1182/blood-2002-05-1602; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; Cai ZL, 2000, IMMUNITY, V13, P423, DOI 10.1016/S1074-7613(00)00042-X; CHAZEN GD, 1989, P NATL ACAD SCI USA, V86, P5923, DOI 10.1073/pnas.86.15.5923; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; DADI HK, 1993, J CLIN INVEST, V92, P1559, DOI 10.1172/JCI116736; DALLOUL A, 1992, J CLIN INVEST, V90, P1054, DOI 10.1172/JCI115920; Danilovich N, 2002, BIOL REPROD, V67, P361, DOI 10.1095/biolreprod67.2.361; DIBIRDIK I, 1991, BLOOD, V78, P564, DOI 10.1182/blood.V78.3.564.bloodjournal783564; FISHER AG, 1993, LEUKEMIA, V7, pS66; FRISHMAN J, 1993, J EXP MED, V177, P955, DOI 10.1084/jem.177.4.955; GRABSTEIN KH, 1993, J EXP MED, V178, P257, DOI 10.1084/jem.178.1.257; Hofmeister R, 1999, CYTOKINE GROWTH F R, V10, P41, DOI 10.1016/S1359-6101(98)00025-2; Jegalian AG, 2002, BLOOD, V99, P2603, DOI 10.1182/blood.V99.7.2603; Kang JS, 2004, J IMMUNOL, V173, P2307, DOI 10.4049/jimmunol.173.4.2307; Kemkemer R, 2002, P NATL ACAD SCI USA, V99, P13783, DOI 10.1073/pnas.212386999; Kieslinger M, 2000, GENE DEV, V14, P232; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Lin JX, 2000, ONCOGENE, V19, P2566, DOI 10.1038/sj.onc.1203523; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Qin JZ, 2001, J INVEST DERMATOL, V117, P583, DOI 10.1046/j.0022-202x.2001.01436.x; Qin JZ, 2001, BLOOD, V98, P2778, DOI 10.1182/blood.V98.9.2778; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Ren SX, 2002, ONCOGENE, V21, P4335, DOI 10.1038/sj.onc.1205484; RICH BE, 1993, J EXP MED, V177, P305, DOI 10.1084/jem.177.2.305; SAMARIDIS J, 1991, EUR J IMMUNOL, V21, P453, DOI 10.1002/eji.1830210230; Saxton TM, 2001, CURR BIOL, V11, P662, DOI 10.1016/S0960-9822(01)00198-1; Schluns KS, 2000, NAT IMMUNOL, V1, P426, DOI 10.1038/80868; Seidman JG, 2002, J CLIN INVEST, V109, P451, DOI 10.1172/JC1200215043; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shelburne CP, 2002, MOL IMMUNOL, V38, P1187, DOI 10.1016/S0161-5890(02)00061-5; Snow JW, 2002, BLOOD, V99, P95, DOI 10.1182/blood.V99.1.95; Socolovsky M, 1998, P NATL ACAD SCI USA, V95, P6573, DOI 10.1073/pnas.95.12.6573; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; TRUMPER L, 1994, ANN ONCOL, V5, pS93, DOI 10.1093/annonc/5.suppl_1.S93; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; UEHIRA M, 1993, INT IMMUNOL, V5, P1619, DOI 10.1093/intimm/5.12.1619; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; vanderPlas DC, 1996, LEUKEMIA, V10, P1317; VENKITARAMAN AR, 1994, EUR J IMMUNOL, V24, P2168, DOI 10.1002/eji.1830240935; Williams IR, 1997, J IMMUNOL, V159, P3044; Zamorano J, 1998, J IMMUNOL, V160, P3502	53	34	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5252	5257		10.1038/sj.onc.1208726	http://dx.doi.org/10.1038/sj.onc.1208726			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15870688				2022-12-17	WOS:000230964600012
J	De Servi, B; Hermani, A; Medunjanin, S; Mayer, D				De Servi, B; Hermani, A; Medunjanin, S; Mayer, D			Impact of PKC delta on estrogen receptor localization and activity in breast cancer cells	ONCOGENE			English	Article						PKC delta; phorbol ester; estrogen receptor; GSK3; breast cancer	PROTEIN-KINASE-C; PHORBOL ESTER; CARCINOMA-CELLS; DOWN-REGULATION; MESSENGER-RNA; ESTRADIOL; MCF-7; ACTIVATION; PHOSPHORYLATION; ALPHA	Regulation of estrogen receptor (ER) function in breast cancer cells is a complex process involving different signalling mechanisms. One signal transduction component that appears to influence ER signalling is protein kinase C (PKC). PKC delta is a particular isoenzyme of the novel PKC subfamily that plays a role in growth control, differentiation and apoptosis. The aim of the present study was to investigate the impact of PKC delta on the regulation of the transcriptional activity of the human ER alpha. By using 12-O-tetradecanoylphorbol- 13-acetate (TPA), Bryostatin1 and Rottlerin, we show that active PKC delta is a proproliferative factor in estrogen-dependent breast cancer cells. Furthermore, activation of PKC delta by TPA resulted in activation and nuclear translocation of ER alpha and in an increase of ER-dependent reporter gene expression. Transfection and expression of the regulatory domain RD delta of PKC delta, which is inhibitory to PKC delta, inhibited the TPA-induced ER alpha activation and translocation. ER alpha was not phosphorylated by PKC delta; however, glycogen synthase kinase-3 (GSK3) was identified as a substrate of PKC delta. The expression of RD delta resulted in a decrease of TPA-induced GSK3 phosphorylation and translocation into the nucleus. We suggest that GSK3 plays a role in the PKC delta-related nuclear translocation of ER alpha.	Deutsch Krebsforschungszentrum, Hormones & Signal Transduct, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Mayer, D (corresponding author), Deutsch Krebsforschungszentrum, Hormones & Signal Transduct, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	d.mayer@dkfz-heidelberg.de						BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; DAUVOIS S, 1993, J CELL SCI, V106, P1377; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; Kiley SC, 1999, CANCER RES, V59, P3230; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lahooti H, 1998, J MOL ENDOCRINOL, V20, P245, DOI 10.1677/jme.0.0200245; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Le Bail JC, 1998, STEROIDS, V63, P678, DOI 10.1016/S0039-128X(98)00078-6; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Longo M, 2004, BONE, V34, P100, DOI 10.1016/j.bone.2003.09.007; Lorenzo PS, 1999, CANCER RES, V59, P6137; Maizels ET, 1996, MOL CELL ENDOCRINOL, V122, P213, DOI 10.1016/0303-7207(96)03885-3; Marino M, 2001, J CELL PHYSIOL, V188, P170, DOI 10.1002/jcp.1105; MARTIN MB, 1995, J BIOL CHEM, V270, P25244, DOI 10.1074/jbc.270.42.25244; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; McCracken MA, 2003, MOL CANCER THER, V2, P273; MIGLIACCIO A, 1993, ONCOGENE, V8, P2183; MIGLIACCIO A, 1986, EMBO J, V5, P2867, DOI 10.1002/j.1460-2075.1986.tb04581.x; Mochly-Rosen D, 1998, FASEB J, V12, P35; PARKER MG, 1993, ANN NY ACAD SCI, V684, P119, DOI 10.1111/j.1749-6632.1993.tb32276.x; REE AH, 1991, ENDOCRINOLOGY, V129, P339, DOI 10.1210/endo-129-1-339; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; SACEDA M, 1991, J BIOL CHEM, V266, P17809; Shanmugam M, 1999, MOL CELL ENDOCRINOL, V148, P109, DOI 10.1016/S0303-7207(98)00229-9; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; Tonetti DA, 2000, BRIT J CANCER, V83, P782, DOI 10.1054/bjoc.2000.1326; Tsujio I, 2000, FEBS LETT, V469, P111, DOI 10.1016/S0014-5793(00)01234-5; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; VALETTE A, 1987, CANCER RES, V47, P1615	47	34	34	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4946	4955		10.1038/sj.onc.1208676	http://dx.doi.org/10.1038/sj.onc.1208676			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15824731				2022-12-17	WOS:000230646500007
J	Yanagida, M; Osato, M; Yamashita, N; Huang, LQ; Jacob, B; Wu, F; Cao, XM; Nakamura, T; Yokomizo, T; Takahashi, S; Yamamoto, M; Shigesada, K; Ito, Y				Yanagida, M; Osato, M; Yamashita, N; Huang, LQ; Jacob, B; Wu, F; Cao, XM; Nakamura, T; Yokomizo, T; Takahashi, S; Yamamoto, M; Shigesada, K; Ito, Y			Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice	ONCOGENE			English	Article						Runx; GATA-1; CBF; down syndrome; megakaryoblastic leukemia	ACUTE MYELOGENOUS LEUKEMIA; DOWN-SYNDROME; CELL-CYCLE; MEGAKARYOBLASTIC LEUKEMIA; GENE; MECHANISMS; TRANSCRIPTION; EXPRESSION; MUTATIONS; GATA-1	The RUNX1/AML1 gene on chromosome 21 is most frequently inactivated in human leukemias. In addition, an increased dose of RUNX1 is suggested as a basis for several kinds of leukemias. Amplifications of chromosome 21 or the RUNX1 gene are shown to be associated with leukemias with lymphoid lineage, whereas its involvement in myeloid lineage remains unclear. In this study, we generated GATA-1 promoter-driven Runx1 transgenic (Tg) mice, which showed a transient mild increase of megakaryocyte marker-positive myeloid cells but no spontaneous leukemia. These mice were then crossed with BXH2 mice, which have a replication-competent retrovirus in the mouse and develop myeloid leukemia due to insertional mutagenesis by random integration of the virus. Overexpressed Runx1 transgene in BXH2 mice resulted in shortening of the latency of leukemia with increased frequency of megakaryoblastic leukemia, suggesting that increased Runx1 dosage is leukemogenic in myeloid lineage. Identifications of retroviral integration sites revealed the genetic alterations that may cooperate with Runx1 overdose in myeloid leukemogenesis. This mouse model may be useful for analysing the pathogenesis of myeloid leukemias with RUNX1 overdose, especially to examine whether an extra-copy of RUNX1 by trisomy 21 is causally related to Down's syndrome-related acute megakaryoblastic leukemia (DS-AMKL).	Inst Mol & Cell Biol, Singapore 138673, Singapore; Natl Univ Singapore, Oncol Res Inst, Singapore 117548, Singapore; Kyoto Univ, Inst Virus Res, Kyoto 606, Japan; Japanese Fdn Canc Res, Inst Canc, Tokyo 170, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 305, Japan	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Kyoto University; Japanese Foundation for Cancer Research; University of Tsukuba; University of Tsukuba	Ito, Y (corresponding author), Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore.	itoy@imcb.a-star.edu.sg	Osato, Motomi/N-5056-2014; Yamamoto, Masayuki/A-4873-2010	Osato, Motomi/0000-0003-3982-9054; Yamamoto, Masayuki/0000-0002-9073-9436; Yanagida, Masatoshi/0000-0002-4407-8120				Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Antonarakis SE, 1998, GENOMICS, V51, P1, DOI 10.1006/geno.1998.5335; Bernardin-Fried F, 2004, J BIOL CHEM, V279, P15678, DOI 10.1074/jbc.M310023200; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; DUFRESNEZACHARIA MC, 1994, GENOMICS, V19, P462, DOI 10.1006/geno.1994.1095; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; Fagerlund R, 2002, J BIOL CHEM, V277, P30072, DOI 10.1074/jbc.M202943200; Gjertson C, 1999, CLIN IMMUNOL, V91, P50, DOI 10.1006/clim.1998.4685; Gurbuxani S, 2004, BLOOD, V103, P399, DOI 10.1182/blood-2003-05-1556; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Kirito K, 2002, BLOOD, V99, P3220, DOI 10.1182/blood.V99.9.3220; Kobayashi M, 2001, DEVELOPMENT, V128, P2341; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; McElwaine S, 2004, BRIT J HAEMATOL, V125, P729, DOI 10.1111/j.1365-2141.2004.04982.x; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Niini T, 2000, HAEMATOLOGICA, V85, P362; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Reeves RH, 2001, TRENDS GENET, V17, P83, DOI 10.1016/S0168-9525(00)02172-7; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; Saleque S, 2002, GENE DEV, V16, P301, DOI 10.1101/gad.959102; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Sui XW, 1999, BLOOD, V93, P2525, DOI 10.1182/blood.V93.8.2525.408k11_2525_2532; Tassone F, 1999, J NEURAL TRANSM-SUPP, P179; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; Wotton S, 2002, CANCER RES, V62, P7181; Zhang Y, 2004, BLOOD, V103, P3717, DOI 10.1182/blood-2003-09-3365; Zimmet J, 2000, EXP HEMATOL, V28, P3, DOI 10.1016/S0301-472X(99)00124-1; Zimmet JM, 1997, MOL CELL BIOL, V17, P7248, DOI 10.1128/MCB.17.12.7248	37	34	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4477	4485		10.1038/sj.onc.1208675	http://dx.doi.org/10.1038/sj.onc.1208675			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856017				2022-12-17	WOS:000230157100001
J	Cairo, S; De Falco, F; Pizzo, M; Salomoni, P; Pandolfi, PP; Meroni, G				Cairo, S; De Falco, F; Pizzo, M; Salomoni, P; Pandolfi, PP; Meroni, G			PML interacts with Myc, and Myc target gene expression is altered in PML-null fibroblasts	ONCOGENE			English	Article						Myc; PML; G1 phase; gene expression	ACUTE PROMYELOCYTIC LEUKEMIA; MEDIATED TRANSCRIPTIONAL REPRESSION; RECURRING CHROMOSOMAL-ABNORMALITIES; C-MYC; TRANSGENIC MICE; NUCLEAR-BODIES; PREMATURE SENESCENCE; PROTEIN STABILITY; CELL-GROWTH; RAR-ALPHA	c-myc is a well-known proto-oncogene encoding for a transcription factor that needs to be tightly regulated in order to preserve cell homeostasis. The Promyelocytic Leukaemia gene product PML plays an important role in cell growth and survival, and resides in discrete subnuclear structures called Nuclear Bodies ( NB). We performed comparative analysis of the expression of 40 Myc target genes and of Myc binding to their regulatory regions both in wild-type and PML knockout cells. We demonstrate that if PML is absent, despite Myc binding to the DNA regulatory sequences is unchanged, the expression pro. le of several Myc target genes is altered. PML is largely involved in gene regulation, via recruitment of several transcription factors and cofactors to the NB. Consistently, we show that Myc partially localizes to the NB and physically interacts with PML, and that this localization depends on Myc expression levels. As deregulation occurs to both activated and repressed Myc target genes, we propose that PML influences Myc transcriptional activity through a mechanism that involves the control of Myc post-translational modifications.	TIGEM, I-80131 Naples, Italy; Cornell Univ, Mem Sloan Kettering Canc Ctr, Mol Biol Program, New York, NY 10021 USA; Cornell Univ, Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Meroni, G (corresponding author), TIGEM, Via P Castellino, I-80131 Naples, Italy.	meroni@tigem.it	Cairo, Stefano/O-2831-2016	Cairo, Stefano/0000-0002-4725-5970	Telethon [TGM03Z05, TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Arabi A, 2003, J CELL SCI, V116, P1707, DOI 10.1242/jcs.00370; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Chiang YC, 2003, J BIOL CHEM, V278, P19286, DOI 10.1074/jbc.M212043200; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Le Beau MM, 2003, BLOOD, V102, P1072, DOI 10.1182/blood-2003-01-0155; Le Beau MM, 2002, BLOOD, V99, P2985, DOI 10.1182/blood.V99.8.2985; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Moller A, 2003, CANCER RES, V63, P4310; Naka K, 2002, BIOCHEM BIOPH RES CO, V299, P863, DOI 10.1016/S0006-291X(02)02755-9; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nikiforov MA, 2003, J BIOL CHEM, V278, P11094, DOI 10.1074/jbc.M212298200; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang ZG, 1998, SCIENCE, V279, P1547; Yin XY, 2001, ONCOGENE, V20, P4650, DOI 10.1038/sj.onc.1204606; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zimonjic DB, 2000, P NATL ACAD SCI USA, V97, P13306, DOI 10.1073/pnas.97.24.13306; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	43	34	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2195	2203		10.1038/sj.onc.1208338	http://dx.doi.org/10.1038/sj.onc.1208338			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735755				2022-12-17	WOS:000227857900007
J	von Wichert, T; Haeussler, U; Greten, FR; Kliche, S; Dralle, H; Bohm, BO; Adler, G; Seufferlein, T				von Wichert, T; Haeussler, U; Greten, FR; Kliche, S; Dralle, H; Bohm, BO; Adler, G; Seufferlein, T			Regulation of cyclin D1 expression by autocrine IGF-I in human BON neuroendocrine tumour cells	ONCOGENE			English	Article						IGF-I; cyclin D1; PI3-kinase; neuroendocrine tumours; NF kappa B	GROWTH-FACTOR-I; NF-KAPPA-B; CARCINOID-TUMORS; CANCER-CELLS; ANTISENSE; PATHWAYS; PROMOTER; KINASE	Constitutive expression of cyclin D1 is a frequent abnormality in human cancer and sustains the transformed phenotype. We have previously demonstrated that cyclin D1 is constitutively expressed in human BON neuroendocrine tumour cells due to an autocrine insulin-like growth factor-I (IGF-I) loop. Here we examine the regulation of cyclin D1 expression by endogenously released IGF-I in BON cells. Cyclin D1 expression in these cells was found to be dependent on phosphatidylinositol 3-kinase (PI3-K), but independent of the extracellular signal-regulated kinase cascade. Ras- and Rac-GTPases were found to be upstream activators of cyclin D1 expression, whereas protein kinase B/AKT and nuclear factor kappa B (NFkappaB) could be established as downstream mediators of cyclin D1 transcription in response to endogenously released IGF-I in these cells. In addition, the Ras/PI3-K/AKT/Rac/NFkappaB/ cyclin D1 signaling cascade triggered by endogenously released IGF-I is sufficient to sustain Rb phosphorylation and cdk4 kinase activity in BON cells. In conclusion, our data provide the first comprehensive map of the signaling events elicited by endogenously released IGF-I leading to constitutive cyclin D1 expression in human neuroendocrine tumour cells.	Univ Ulm, Med Klin, Innere Med Abt 1, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Ulm, Dept Internal Med 2, D-89081 Ulm, Germany; Univ Halle Wittenberg, Dept Surg, D-06099 Halle Saale, Germany	Ulm University; Ulm University; Martin Luther University Halle Wittenberg	Seufferlein, T (corresponding author), Univ Ulm, Med Klin, Innere Med Abt 1, Dept Internal Med 1, Robert Koch Str 8, D-89081 Ulm, Germany.	thomas.seufferlein@medizin.uni-ulm.de	Seufferlein, Thomas TW/P-7147-2018; Greten, Florian R/AAF-5196-2020; Boehm, Bernhard Otto/F-8750-2015	Greten, Florian R/0000-0002-3928-6080; 				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Arber N, 1997, CANCER RES, V57, P1569; Cheng HL, 2000, J BIOL CHEM, V275, P27197; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; EVERS BM, 1994, ANN NY ACAD SCI, V733, P393, DOI 10.1111/j.1749-6632.1994.tb17289.x; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Guillemot L, 2000, J BIOL CHEM, V275, P26349, DOI 10.1074/jbc.M001614200; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Kuemmerle JF, 2004, AM J PHYSIOL-GASTR L, V286, pG412, DOI 10.1152/ajpgi.00403.2003; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Oberg K, 2002, CURR OPIN ONCOL, V14, P38, DOI 10.1097/00001622-200201000-00008; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; von Wichert G, 2000, CANCER RES, V60, P4573; Weinstein IB, 2000, CARCINOGENESIS, V21, P857, DOI 10.1093/carcin/21.5.857; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023; ZHOU P, 1995, ONCOGENE, V11, P571	20	34	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1284	1289		10.1038/sj.onc.1208264	http://dx.doi.org/10.1038/sj.onc.1208264			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15580291				2022-12-17	WOS:000226898700016
J	Sakamoto, N; Terai, T; Ajioka, Y; Abe, S; Kobayasi, O; Hirai, S; Hino, O; Watanabe, H; Sato, N; Shimoda, T; Fujii, H				Sakamoto, N; Terai, T; Ajioka, Y; Abe, S; Kobayasi, O; Hirai, S; Hino, O; Watanabe, H; Sato, N; Shimoda, T; Fujii, H			Frequent hypermethylation of RASSF1A in early flat-type colorectal tumors	ONCOGENE			English	Article						flat-type colorectal tumor; RASSF1A; 3p LOH; K-ras; tumor suppressor gene; methylation	K-RAS MUTATIONS; EPIGENETIC INACTIVATION; SUPPRESSOR GENE; PROMOTER HYPERMETHYLATION; CPG ISLAND; CANCER; METHYLATION; CARCINOMA; LUNG; 3P21.3	Flat colorectal tumors, characterized by high-grade dysplasia from early small. at mucosal lesions, exhibit a relatively aggressive clinical behavior and are known for their infrequent K-ras mutations. In this study, we investigated the methylation status of the RASSF1A promoter in association with 3p LOH and K-ras mutations in 48. at colorectal tumors (39 early carcinomas and nine intramucosal high-grade dysplasias). RASSF1A hypermethylation was detected in 39 of 48 (81.3%) tumors and RASSF1A methylation was also detected in 19 of 39 (49%) normal colonic mucosal tissues. 3p21.3 LOH was detected in 20 of 42 (47.6%) cases, but RASSF1 methylation was detected in cases with LOH (14 cases) and retention of 3p21.3 ( 20 cases). K-ras mutations were detected in seven of 48 (14.6%) tumors and the concordant occurrence of K-ras mutation and RASSF1A methylation was detected in three of 48 cases (6.3%). Overall, there was a statistically significant mutually exclusive relationship between K-ras mutations and RASSF1A methylation. In conclusion, promoter hypermethylation of RASSF1A is a frequent event and may start early in the background normal mucosa in this tumor type. An alternative cascade of abnormalities in RAS transduction pathways may be responsible for the. at morphology and aggressive nature of. at colorectal neoplasms.	Juntendo Univ, Sch Med, Dept Pathol 2, Tokyo 1138421, Japan; Juntendo Univ, Sch Med, Dept Gastroenterol, Tokyo 1138421, Japan; Niigata Univ, Grad Sch Med & Dent Sci, Course Mol & Cellular Med, Dept Mol Genet,Div Mol & Cellular Med, Niigata 9518514, Japan; Tokyo Rinkai Hosp, Div Pathol, Tokyo, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Expt Pathol, Tokyo 170, Japan; Natl Canc Ctr, Res Inst & Hosp, Div Pathol, Tokyo 104, Japan; Natl Canc Ctr, Res Inst & Hosp, Div Clin Lab, Tokyo 104, Japan	Juntendo University; Juntendo University; Niigata University; Japanese Foundation for Cancer Research; National Cancer Center - Japan; National Cancer Center - Japan	Fujii, H (corresponding author), Juntendo Univ, Sch Med, Dept Pathol 2, 2-1-1 Hongo, Tokyo 1138421, Japan.	hfujii@med.juntendo.ac.jp						Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chiang JM, 1998, CANCER RES, V58, P3289; Dammann R, 2003, ONCOGENE, V22, P3806, DOI 10.1038/sj.onc.1206582; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; FENOGLIO CM, 1974, CANCER, V34, P819, DOI 10.1002/1097-0142(197409)34:3+<819::AID-CNCR2820340706>3.0.CO;2-S; Fujii H, 2002, J PATHOL, V197, P298, DOI 10.1002/path.1122; FUJIMORI T, 1994, INT J CANCER, V57, P51, DOI 10.1002/ijc.2910570110; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Issa JPJ, 2001, CANCER RES, V61, P3573; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kuroki T, 2003, CANCER RES, V63, P3724; Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8; Lerman MI, 2000, CANCER RES, V60, P6116; Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814; Lo KW, 2001, CANCER RES, V61, P3877; Lusher ME, 2002, CANCER RES, V62, P5906; Maruyama R, 2001, CANCER RES, V61, P8659; MINAMOTO T, 1994, CANCER RES, V54, P2841; Morrissey C, 2001, CANCER RES, V61, P7277; MORSON B, 1974, P ROY SOC MED, V67, P451, DOI 10.1177/00359157740676P115; Mueller JD, 1998, AM J PATHOL, V153, P1977, DOI 10.1016/S0002-9440(10)65711-2; Olschwang S, 1998, INT J CANCER, V77, P366, DOI 10.1002/(SICI)1097-0215(19980729)77:3<366::AID-IJC10>3.0.CO;2-6; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Rubio CA, 1996, DIS COLON RECTUM, V39, P143, DOI 10.1007/BF02068067; Schagdarsurengin U, 2002, CANCER RES, V62, P3698; Schagdarsurengin U, 2003, ONCOGENE, V22, P1866, DOI 10.1038/sj.onc.1206338; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; SHIMODA T, 1989, CANCER, V64, P1138, DOI 10.1002/1097-0142(19890901)64:5<1138::AID-CNCR2820640529>3.0.CO;2-A; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Sparks AB, 1998, CANCER RES, V58, P1130; Spugnardi M, 2003, CANCER RES, V63, P1639; TADA S, 1994, CANCER, V74, P2430, DOI 10.1002/1097-0142(19941101)74:9<2430::AID-CNCR2820740907>3.0.CO;2-C; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wagner KJ, 2002, ONCOGENE, V21, P7277, DOI 10.1038/sj.onc.1205922; Yashiro M, 2001, CANCER RES, V61, P2676; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466; YUKAWA M, 1994, GUT, V35, P1258, DOI 10.1136/gut.35.9.1258	44	34	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8900	8907		10.1038/sj.onc.1207993	http://dx.doi.org/10.1038/sj.onc.1207993			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480433				2022-12-17	WOS:000225354600005
J	Tomita, M; Choe, J; Tsukazaki, T; Mori, N				Tomita, M; Choe, J; Tsukazaki, T; Mori, N			The Kaposi's sarcoma-associated herpesvirus K-bZIP protein represses transforming growth factor beta signaling through interaction with CREB-binding protein	ONCOGENE			English	Article						KSHV; K-bZIP; TGF-beta; Smad; CBP	FACTOR-KAPPA-B; MULTICENTRIC CASTLEMANS-DISEASE; EPSTEIN-BARR-VIRUS; TGF-BETA; DNA-SEQUENCES; TRANSCRIPTIONAL ACTIVATION; COACTIVATORS CBP/P300; NUCLEAR INTEGRATION; GENE-EXPRESSION; SMAD PROTEINS	Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) is involved in the pathogenesis of KS, primary effusion lymphoma, and multicentric Castleman's disease. K-bZIP, the protein encoded by the open reading frame K8 of KSHV, is a member of the basic region-leucine zipper family of transcription factors. We studied the mechanisms that underlie KSHV-induced oncogenesis by investigating whether K-bZIP perturbs signaling through transforming growth factor beta (TGF-beta), which inhibits proliferation of a wide range of cell types. K-bZIP repressed TGF-beta-induced, Smad-mediated transcriptional activity and antagonized the growth-inhibitory effects of TGF-beta. Since both K-bZIP and Smad are known to interact with CREB-binding protein (CBP), the effect of CBP on inhibition of Smad-mediated transcriptional activation by K-bZIP was examined. K-bZIP mutants, which lacked the CBP-binding site, could not repress TGF-beta-induced or Smad3-mediated transcriptional activity. Overexpression of CBP restored K-bZIP-induced inhibition of Smad3-mediated transcriptional activity. Competitive interaction studies showed that K-bZIP inhibited the interaction of Smad3 with CBP. These results suggest that K-bZIP, through its binding to CBP, disrupts TGF-beta signaling by interfering with the recruitment of CBP into transcription initiation complexes on TGF-beta-responsive elements. We propose a possibility that K-bZIP may contribute to oncogenesis through its ability to promote cell survival by repressing TGF-beta signaling.	Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Nishihara, Okinawa 9030215, Japan; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Nagasaki Univ, Grad Sch Biomed Sci, Div Orthopaed Pathomech, Nagasaki 8528588, Japan	University of the Ryukyus; Korea Advanced Institute of Science & Technology (KAIST); Nagasaki University	Mori, N (corresponding author), Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Nishihara, Okinawa 9030215, Japan.	n-mori@med.u-ryukyu.ac.jp	Choe, Joonho/F-3066-2011					Alkan S, 1997, BRIT J HAEMATOL, V96, P412, DOI 10.1046/j.1365-2141.1997.d01-2040.x; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Boshoff C, 1998, NATURE, V391, P24, DOI 10.1038/34054; Boshoff C, 1997, SCIENCE, V278, P290, DOI 10.1126/science.278.5336.290; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chan HM, 2001, J CELL SCI, V114, P2363; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Datto MB, 1997, MOL CELL BIOL, V17, P2030, DOI 10.1128/MCB.17.4.2030; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; Hwang S, 2001, J VIROL, V75, P9509, DOI 10.1128/JVI.75.19.9509-9516.2001; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Katano H, 2000, VIROLOGY, V269, P335, DOI 10.1006/viro.2000.0196; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Lin SF, 1999, J VIROL, V73, P1909, DOI 10.1128/JVI.73.3.1909-1917.1999; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Memar OM, 1995, J MOL MED-JMM, V73, P603; Miyazono Kohei, 1994, Seminars in Cell Biology, V5, P389, DOI 10.1006/scel.1994.1046; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Mori N, 2003, INT J CANCER, V105, P661, DOI 10.1002/ijc.11146; Mori N, 2001, BLOOD, V97, P2137, DOI 10.1182/blood.V97.7.2137; Mori N, 2000, BLOOD, V95, P3915; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Park J, 2000, J VIROL, V74, P11977, DOI 10.1128/JVI.74.24.11977-11982.2000; Portes-Sentis S, 2001, J GEN VIROL, V82, P507, DOI 10.1099/0022-1317-82-3-507; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; SPORN MB, 1990, ANN NY ACAD SCI, V593, P1, DOI 10.1111/j.1749-6632.1990.tb16095.x; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	52	34	36	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8272	8281		10.1038/sj.onc.1208059	http://dx.doi.org/10.1038/sj.onc.1208059			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15467747				2022-12-17	WOS:000224749500009
J	Yordy, JS; Li, RZ; Sementchenko, VI; Pei, HP; Muise-Helmericks, RC; Watson, DK				Yordy, JS; Li, RZ; Sementchenko, VI; Pei, HP; Muise-Helmericks, RC; Watson, DK			SP100 expression modulates ETS1 transcriptional activity and inhibits cell invasion	ONCOGENE			English	Article						Ets; transcription; invasion; SP100; MMP; UPA	PRIMARY BILIARY-CIRRHOSIS; NUCLEAR-BODIES; GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR; MATRIX METALLOPROTEINASE-1; PROTEIN INTERACTIONS; GENE-TRANSCRIPTION; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; ANDROGEN RECEPTOR	The ETS1 transcription factor is a member of the Ets family of conserved sequence-specific DNA-binding proteins. ETS1 has been shown to play important roles in various cellular processes such as proliferation, differentiation, lymphoid development, motility, invasion and angiogenesis. These diverse roles of ETS1 are likely to be dependent on specific protein interactions. To identify proteins that interact with ETS1, a yeast two-hybrid screen was conducted. Here, we describe the functional interaction between SP100 and ETS1. SP100 protein interacts with ETS1 both in vitro and in vivo. SP100 is localized to nuclear bodies and ETS1 expression alters the nuclear body morphology in living cells. SP100 negatively modulates ETS1 transcriptional activation of the MMP1 and uPA promoters in a dose-dependent manner, decreases the expression of these endogenous genes, and reduces ETS1 DNA binding. Expression of SP100 inhibits the invasion of breast cancer cells and is induced by Interferon-alpha, which has been shown to inhibit the invasion of cancer cells. These data demonstrate that SP100 modulates ETS1-dependent biological processes.	Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Watson, DK (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Room 332,86 Jonathan Lucas St, Charleston, SC 29425 USA.	watsondk@musc.edu			NCI NIH HHS [P01CA78582] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BERGERON D, 1995, CELL MOL BIOL RES, V41, P155; BHAT NK, 1994, HYBRIDOMA, V13, P1, DOI 10.1089/hyb.1994.13.1; Bloch DB, 1999, MOL CELL BIOL, V19, P4423; Cairns RA, 2003, CURR MOL MED, V3, P659, DOI 10.2174/1566524033479447; Chen ZQ, 1997, CANCER RES, V57, P2013; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; FISHER RJ, 1991, ONCOGENE, V6, P2249; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; GHYSDAEL J, 1997, ETS FAMILY TRANSCRIP; Gongora R, 2001, IMMUNITY, V14, P727, DOI 10.1016/S1074-7613(01)00152-2; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GULDNER HH, 1992, J IMMUNOL, V149, P4067; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kita D, 2001, CANCER RES, V61, P7985; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; Negorev D, 2001, J CELL SCI, V114, P59; Obika S, 2003, J MOL BIOL, V331, P345, DOI 10.1016/S0022-2836(03)00726-5; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Pei HP, 2003, ONCOGENE, V22, P2699, DOI 10.1038/sj.onc.1206374; Quaranta V, 2003, TUMORI J, V89, P343, DOI 10.1177/030089160308900401; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; Rutter JL, 1998, CANCER RES, V58, P5321; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Sternsdorf T, 1997, IMMUNOBIOLOGY, V198, P307, DOI 10.1016/S0171-2985(97)80051-4; SZOSTECKI C, 1992, SCAND J IMMUNOL, V36, P555, DOI 10.1111/j.1365-3083.1992.tb03224.x; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; Verger A, 2002, BIOESSAYS, V24, P362, DOI 10.1002/bies.10068; von Marschall Z, 2003, J NATL CANCER I, V95, P437, DOI 10.1093/jnci/95.6.437; Wang L, 2003, J GASTROINTEST SURG, V7, P587, DOI 10.1016/S1091-255X(03)00072-6; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 2002, ENCY CANC, V2, P751; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Xu DK, 2002, EMBO J, V21, P4081, DOI 10.1093/emboj/cdf413; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zong RT, 2000, EMBO J, V19, P4123, DOI 10.1093/emboj/19.15.4123	67	34	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6654	6665		10.1038/sj.onc.1207891	http://dx.doi.org/10.1038/sj.onc.1207891			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15247905				2022-12-17	WOS:000223530800013
J	Zugaza, JL; Caloca, MJ; Bustelo, XR				Zugaza, JL; Caloca, MJ; Bustelo, XR			Inverted signaling hierarchy between RAS and RAC in T-lymphocytes	ONCOGENE			English	Article						Vav; Rac1; RasGRP1; Ras; phospholipase C; T-lymphocytes	PROTEIN-KINASE-C; NUCLEOTIDE EXCHANGE FACTORS; CELL-RECEPTOR SIGNALS; PHOSPHOLIPASE-C; RHO-GTPASES; SELECTIVE INHIBITOR; PLASMA-MEMBRANE; VAV FAMILY; ACTIVATION; PATHWAY	In order to generate coherent biological responses to extracellular stimuli, cells have established synergistic and antagonistic crosstalk between pathways with similar or opposing functions, respectively. Two routes cooperating in the generation of mitogenic and cytoskeletal functions are those induced by Ras and Rho/Rac GTPases. In these signaling interactions, Rho/Rac proteins have been always placed in a downstream position respect to Ras in all cell systems analysed so far. In this report, we describe that such signaling hierarchy does not apply to T-lymphocytes. Thus, we show that both Racl GDP/GTP exchange factors such as Vav and constitutively active versions of Racl can promote the effective stimulation of the Ras pathway in T-lymphocytes. The molecular link for this new type of pathway interconnectivity is RasGRP1, a diacylglycerol-dependent GDP/GTP exchange factor for Ras that translocates to the plasma membrane in a Vav- and Racl-dependent manner. The effect of the Vav/Rac1 pathway on the Ras pathway is highly dependent on the activity of phospholipase C-gamma, the key cellular supplier of intracellular diacylglycerol. Signaling experiments suggest that this crosstalk represents a signaling strategy used by the T-cell receptor to promote robust biological responses of both the Rac/Rho and Ras pathways upon antigen engagement.	Univ Salamanca, CSIC, Ctr Invest Canc, E-37007 Salamanca, Spain; Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Campus Unamuno, E-37007 Salamanca, Spain.	xbustelo@usal.es	Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010; Caloca, María-José/K-9357-2014	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; ZUGAZA GURRUCHAGA, JOSE LUIS/0000-0003-2287-6671; Caloca, Maria-Jose/0000-0002-1003-2685	NCI NIH HHS [CA7373501] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Bustelo XR, 2002, BIOESSAYS, V24, P602, DOI 10.1002/bies.10107; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Bustelo XR, 2002, HISTOL HISTOPATHOL, V17, P871, DOI 10.14670/HH-17.871; Caloca MJ, 2003, J BIOL CHEM, V278, P33465, DOI 10.1074/jbc.M302807200; Caloca MJ, 2003, EMBO J, V22, P3326, DOI 10.1093/emboj/cdg316; Cantrell DA, 2003, IMMUNOL REV, V192, P122, DOI 10.1034/j.1600-065X.2003.00028.x; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Crespo P, 1996, ONCOGENE, V13, P455; Diaz-Flores E, 2003, J BIOL CHEM, V278, P29208, DOI 10.1074/jbc.M303165200; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ebinu JO, 2000, BLOOD, V95, P3199; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Hogquist K, 2001, Trends Immunol, V22, P69, DOI 10.1016/S1471-4906(00)01845-7; Inabe K, 2002, J EXP MED, V195, P189, DOI 10.1084/jem.20011571; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Kranewitter WJ, 1999, FEBS LETT, V455, P123, DOI 10.1016/S0014-5793(99)00857-1; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Layer K, 2003, IMMUNITY, V19, P243, DOI 10.1016/S1074-7613(03)00209-7; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Lorenzo PS, 2000, MOL PHARMACOL, V57, P840; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Ohtsuka T, 1996, BBA-MOL CELL RES, V1310, P223, DOI 10.1016/0167-4889(95)00172-7; OVERBECK AF, 1995, MOL REPROD DEV, V42, P468, DOI 10.1002/mrd.1080420415; POWIS G, 1994, CANCER RES, V54, P2419; Priatel JJ, 2002, IMMUNITY, V17, P617, DOI 10.1016/S1074-7613(02)00451-X; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Teixeira C, 2003, BLOOD, V102, P1414, DOI 10.1182/blood-2002-11-3621; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; VASSILOPOULOS D, 1995, CLIN IMMUNOL IMMUNOP, V77, P59, DOI 10.1016/0090-1229(95)90137-X; Villalba M, 2000, EUR J IMMUNOL, V30, P1587, DOI 10.1002/1521-4141(200006)30:6<1587::AID-IMMU1587>3.0.CO;2-T; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Villalba M, 2002, J CELL BIOL, V157, P253, DOI 10.1083/jcb.200201097; Wang XJ, 2001, EXP CELL RES, V267, P28, DOI 10.1006/excr.2001.5241; WU J, 1995, MOL CELL BIOL, V15, P4337; Yu H, 2001, J EXP MED, V194, P915, DOI 10.1084/jem.194.7.915; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	48	34	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5823	5833		10.1038/sj.onc.1207768	http://dx.doi.org/10.1038/sj.onc.1207768			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15184873				2022-12-17	WOS:000222629800012
J	O'Hagan, HM; Ljungman, M				O'Hagan, HM; Ljungman, M			Nuclear accumulation of p53 following inhibition of transcription is not due to diminished levels of MDM2	ONCOGENE			English	Article						DRB; nuclear export; ubiquitylation; nucleolus	PROTEASOME-MEDIATED DEGRADATION; DAMAGE-INDUCED PHOSPHORYLATION; ATM-DEPENDENT PHOSPHORYLATION; AUTOREGULATORY FEEDBACK LOOP; RING-FINGER DOMAIN; RNA-POLYMERASE-II; DNA-DAMAGE; TUMOR-SUPPRESSOR; DOWN-REGULATION; UV-RADIATION	A common mechanism by which the tumor suppressor p53 accumulates in the nucleus following cellular stress is through the attenuation of its interaction with MDM2, a protein involved in the nuclear export and degradation of p53. This is accomplished by induced modifications of p53, MDM2 or both. We have previously found that the kinase and mRNA synthesis inhibitor DRB (5,6-dichloro-1-b-D-ribofuranosylbenzimidazole) induces the nuclear accumulation of p53 without concomitant phosphorylation of the ser15 site of p53, which is thought to be a modification important for the attenuation of p53-MDM2 interaction. It has been proposed that the mechanism by which p53 accumulates following blockage of transcription involves the downregulation of MDM2 expression. In this study, we tested this hypothesis and found that after DRB treatment, p53 accumulated despite the fact that MDM2 levels remained high in human cells. Furthermore, over expression of MDM2 did not prevent the accumulation of p53 following DRB treatment. In, addition, p53 accumulating in the nucleus after DRB treatment was able to interact with MDM2 and was ubiquitylated. These findings suggest that blockage of transcription induce the nuclear accumulation of p53 without breaking the p53-MDM2 regulation loop.	Univ Michigan, Sch Med,Div Radiat & Canc Biol, Dept Radiat Oncol, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Environm Hlth Sci, Sch Publ Hlth, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ljungman, M (corresponding author), Univ Michigan, Sch Med,Div Radiat & Canc Biol, Dept Radiat Oncol, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA.	ljungman@umich.edu		O'Hagan, Heather/0000-0001-9750-5088	NATIONAL CANCER INSTITUTE [R01CA082376] Funding Source: NIH RePORTER; NCI NIH HHS [CA 82376] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arriola EL, 1999, ONCOGENE, V18, P1081, DOI 10.1038/sj.onc.1202391; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen LH, 1999, MOL MED, V5, P21, DOI 10.1007/BF03402136; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; David-Pfeuty T, 2001, ONCOGENE, V20, P5951, DOI 10.1038/sj.onc.1204741; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Inoue T, 2001, FEBS LETT, V490, P196, DOI 10.1016/S0014-5793(01)02123-8; Joseph TW, 2003, FASEB J, V17, P1622, DOI 10.1096/fj.02-0931com; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; KASTAN MB, 1991, CANCER RES, V51, P6304; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Klibanov SA, 2001, J CELL SCI, V114, P1867; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Latonen L, 2003, CELL SIGNAL, V15, P95, DOI 10.1016/S0898-6568(02)00044-X; LEACH FS, 1993, CANCER RES, V53, P2231; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Ljungman M, 2001, ONCOGENE, V20, P5964, DOI 10.1038/sj.onc.1204734; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; O'Hagan HM, 2004, MUTAT RES-FUND MOL M, V546, P7, DOI 10.1016/j.mrfmmm.2003.10.003; OHAGAN HM, IN PRESS EXP CELL RE; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; SCHEER U, 1984, J CELL BIOL, V99, P672, DOI 10.1083/jcb.99.2.672; SCHEER U, 1990, BIOESSAYS, V12, P14, DOI 10.1002/bies.950120104; Schneiderhan N, 2003, ONCOGENE, V22, P2857, DOI 10.1038/sj.onc.1206431; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shinozaki T, 2003, ONCOGENE, V22, P8870, DOI 10.1038/sj.onc.1207176; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Yu ZK, 2000, ONCOGENE, V19, P5892, DOI 10.1038/sj.onc.1203980; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	64	34	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5505	5512		10.1038/sj.onc.1207709	http://dx.doi.org/10.1038/sj.onc.1207709			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15094782				2022-12-17	WOS:000222588400010
J	Liu, SL; Sugimoto, Y; Sorio, C; Tecchio, C; Lin, YC				Liu, SL; Sugimoto, Y; Sorio, C; Tecchio, C; Lin, YC			Function analysis of estrogenically regulated protein tyrosine phosphatase gamma (PTP gamma) in human breast cancer cell line MCF-7	ONCOGENE			English	Article						human breast; human breast cancer; protein tyrosine phosphatase gamma; overexpression; antisense; soft agar assay	EXPRESSION; GENE; CLONING; REGION; BRAIN; DOMAIN; CDNA; LUNG	Protein tyrosine phosphatase gamma (PTPgamma) is a member of the receptor-like family of tyrosine phosphatases and has been implicated as a tumor suppressor gene in kidney and lung cancers. Based on our previous findings, we hypothesize that PTPgamma is a potential estrogen-regulated tumor suppressor gene in human breast cancer. To examine the effects of PTPgamma on growth of MCF-7 human breast cancer cells and compare the estrogenic responses of human breast cells with different PTPgamma expression levels, we established several stably transfected MCF-7 cell lines expressing different levels of PTPgamma, which were confirmed by RT-PCR and immunostaining. In our work, we used the antisense construct to breakdown endogenous PTPgamma level in MCF-7 cells. The results from doubling time assay suggested that PTPgamma is capable of inhibiting MCF-7 breast cancer cell growth. We further demonstrated that PTPgamma is able to inhibit anchorage-independent growth of breast cancer cells in soft agar and reduce the estrogenic responses of MCF-7 cell proliferation to estradiol-17beta (E-2) and zeranol (Z, a nonsteroidal growth promoter with estrogenic activity). Our data suggest that PTPgamma may function as an important modulator in regulating the process of tumorigenesis in human breast.	Ohio State Univ, Coll Vet Med, Lab Reprod & Mol Endocrinol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Univ Verona, Dipartimento Patol, I-37134 Verona, Italy	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Verona	Lin, YC (corresponding author), Ohio State Univ, Coll Vet Med, Lab Reprod & Mol Endocrinol, 1900 Coffey Rd, Columbus, OH 43210 USA.	lin.15@osu.edu	Sorio, Claudio/F-2764-2018; Liu, Suling/N-2796-2013; tecchio, cristina/GRX-9586-2022; liu, suling/AAF-5249-2019; Sugimoto, Yasuro/AAR-1423-2021; Sugimoto, Yasuro/B-4004-2012	Sorio, Claudio/0000-0003-2739-4014; Liu, Suling/0000-0002-0475-0242; liu, suling/0000-0002-0475-0242; Sugimoto, Yasuro/0000-0002-5094-4347	NCI NIH HHS [CA 95915, CA 94718] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA095915, R21CA094718] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; GAITS F, 1995, BIOCHEM J, V311, P97, DOI 10.1042/bj3110097; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; Kulp SK, 2000, BIOL REPROD, V62, P181; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LAFORGIA S, 1993, CANCER RES, V53, P3118; LEVY JB, 1993, J BIOL CHEM, V268, P10573; LIN YC, 1994, P AM ASS CANC RES 85, V35, pA607; Liu SL, 2002, BREAST CANCER RES TR, V71, P21, DOI 10.1023/A:1013343718942; LUBINSKI J, 1994, CANCER RES, V54, P3710; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; Poliseno L, 2002, CANCER CHEMOTH PHARM, V50, P127, DOI 10.1007/s00280-002-0467-x; SHOCK LP, 1995, MOL BRAIN RES, V28, P110, DOI 10.1016/0169-328X(94)00190-P; Sorio C, 1997, BLOOD, V90, P49; SORIO C, 1995, CANCER RES, V55, P4855; TSUKAMOTO T, 1992, CANCER RES, V52, P3506; van Niekerk CC, 1999, CANCER LETT, V137, P61, DOI 10.1016/S0304-3835(98)00344-9; Zheng J, 2000, ANTICANCER RES, V20, P11	23	34	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1256	1262		10.1038/sj.onc.1207235	http://dx.doi.org/10.1038/sj.onc.1207235			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14676845				2022-12-17	WOS:000188892200010
J	Ward, KR; Zhang, KX; Somasiri, AM; Roskelley, CD; Schrader, JW				Ward, KR; Zhang, KX; Somasiri, AM; Roskelley, CD; Schrader, JW			Expression of activated M-Ras in a murine mammary epithelial cell line induces epithelial-mesenchymal transition and tumorigenesis	ONCOGENE			English	Article						activated M-Ras; activated p21 Ras; epithelial-mesenchymal transition; transformation; tumorigenesis	R-RAS; BREAST-CANCER; GENE FAMILY; P21 RAS; PROTEIN; GROWTH; TRANSFORMATION; M-RAS/R-RAS3; IDENTIFICATION; GTPASE	The expression of activated mutants of M-Ras (G22V or Q71L), but not wild-type M-Ras, in a murine mammary epithelial cell line, scp2, resulted in epithelial - mesenchymal transition (EMT) and oncogenic transformation. Cells expressing constitutively active M-Ras continued to grow in the absence of serum and exhibited a loss of the epithelial markers cytokeratin, E-cadherin and beta-catenin, together with a gain of the mesenchymal marker vimentin, a loss of contact inhibition in monolayer growth and a gain of the capacity for anchorage-independent growth. Moreover, unlike the parental cells, they failed to form differentiated mammospheres on Matrigel and instead formed branched networks of cells that grew and invaded the Matrigel. The expression of activated p21 Ras (G12V H-Ras or Q61K N-Ras) also resulted in EMT and tumorigenesis, although there was evidence that expression of higher levels was toxic. Tumors derived from scp2 cells expressing activated M-Ras exhibited activation of Akt and of ERK. The levels of expression of Q71L M-Ras and G12V H-Ras required for tumorigenesis were comparable, although higher levels of the weaker G22V M-Ras mutant were selected for in vivo. These data indicate that the expression of activated mutants of M-Ras was sufficient for oncogenic transformation of a murine mammary epithelial cell line.	Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Anat & Cell Biol, Vancouver, BC V5Z 1M9, Canada	University of British Columbia; University of British Columbia	Schrader, JW (corresponding author), Univ British Columbia, Biomed Res Ctr, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	john@brc.ubc.ca	Roskelley, Calvin D/F-4630-2011					Barker KT, 1998, BRIT J CANCER, V78, P296, DOI 10.1038/bjc.1998.490; Boon K, 2002, P NATL ACAD SCI USA, V99, P11287, DOI 10.1073/pnas.152324199; BOS JL, 1990, CANCER RES, V50, P1352; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Clark GJ, 1996, ONCOGENE, V12, P169; COX AD, 1994, ONCOGENE, V9, P3281; CRISSMAN HA, 1985, SCIENCE, V228, P1321, DOI 10.1126/science.2408339; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; Desprez Pierre-Yves, 1993, Molecular and Cellular Differentiation, V1, P99; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; Ehrhardt GRA, 2001, ONCOGENE, V20, P188, DOI 10.1038/sj.onc.1204053; Fanton CP, 2001, J BIOL CHEM, V276, P18871, DOI 10.1074/jbc.M011514200; Gao XL, 2001, J BIOL CHEM, V276, P42219, DOI 10.1074/jbc.M105760200; Grill B, 2002, BLOOD, V100, P3183, DOI 10.1182/blood-2002-01-0154; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; Kimmelman AC, 2000, ONCOGENE, V19, P2014, DOI 10.1038/sj.onc.1203530; Lochter A, 1997, J BIOL CHEM, V272, P5007, DOI 10.1074/jbc.272.8.5007; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MACMANUS MP, 1990, EXP HEMATOL, V18, P848; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; Miyakis S, 1998, BIOCHEM BIOPH RES CO, V251, P609, DOI 10.1006/bbrc.1998.9527; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pritchard C, 1997, NAT GENET, V16, P214, DOI 10.1038/ng0797-214; Pruitt K, 2002, J BIOL CHEM, V277, P31808, DOI 10.1074/jbc.M203964200; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Quilliam LA, 2001, METHOD ENZYMOL, V333, P187; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Roskelley CD, 2000, METH MOL B, V136, P27; Tombes RM, 1998, BIOCHEM J, V330, P1451; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598	42	34	36	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1187	1196		10.1038/sj.onc.1207226	http://dx.doi.org/10.1038/sj.onc.1207226			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14961075				2022-12-17	WOS:000188892200002
J	Sulman, EP; White, PS; Brodeur, GM				Sulman, EP; White, PS; Brodeur, GM			Genomic annotation of the meningioma tumor suppressor locus on chromosome 1p34	ONCOGENE			English	Article						meningioma; tumor suppressor gene; chromosome 1	BASAL-CELL CARCINOMA; ALLELIC LOSSES; FORKHEAD GENE; HUMAN HOMOLOG; HRAD54 GENE; NF2 GENE; DELETION; MUTATIONS; REGION; MAPS	Meningioma is a frequently occurring tumor of the meninges surrounding the central nervous system. Loss of the short arm of chromosome 1 (1p) is the second most frequent chromosomal abnormality observed in these tumors. Previously, we identified a 3.7 megabase (Mb) region of consistent deletion on 1p33-p34 in a panel of 157 tumors. Loss of this region was associated with advanced disease and predictive for tumor relapse. In this report, a high-resolution integrated map of the region was constructed (CompView) to identify all markers in the smallest region of overlapping deletion (SRO). A regional somatic cell hybrid panel was used to more precisely localize those markers identified in CompView as within or overlapping the region. Additional deletion mapping using microsatellites localized to the region narrowed the SRO to approximately 2.8 Mb. The 88 markers remaining in the SRO were used to screen genomic databases to identify large-insert clones. Clones were assembled into a physical map of the region by PCR-based, sequence-tagged site (STS) content mapping. A sequence from clones was used to validate STS content by electronic PCR and to identify transcripts. A minimal tiling path of 43 clones was constructed across the SRO. Sequence data from the most current sequence assembly were used for further validation. A total of 59 genes were ordered within the SRO. In all, 17 of these were selected as likely candidates based on annotation using Gene Ontology Consortium terms, including the MUTYH, PRDX1, FOXD2, FOXE3, PTCH2, and RAD54L genes. This annotation of a putative tumor suppressor locus provides a resource for further analysis of meningioma candidate genes.	Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Oncol, Philadelphia, PA 19104 USA; Temple Univ, Sch Med, Fels Inst Mol Biol & Canc Res, Philadelphia, PA 19140 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania	Brodeur, GM (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Oncol, Room 902,Abramson Res Ctr,3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	brodeur@email.chop.edu		Sulman, Erik/0000-0003-4933-9120	NCI NIH HHS [CA-39771] Funding Source: Medline; NIMH NIH HHS [MH-60240] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039771] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH060240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ashburner M, 2001, GENOME RES, V11, P1425; Auburger G, 1996, GENOMICS, V31, P90, DOI 10.1006/geno.1996.0013; Bello MJ, 2000, CANCER GENET CYTOGEN, V116, P142, DOI 10.1016/S0165-4608(99)00122-3; BELLO MJ, 1995, INT J CANCER, V64, P207; BELLO MJ, 1995, CANCER GENET CYTOGEN, V83, P160, DOI 10.1016/0165-4608(95)00064-V; BIECHE I, 1993, CANCER RES, V53, P1990; Blixt A, 2000, GENE DEV, V14, P245; Bondy M, 1996, J NEURO-ONCOL, V29, P197, DOI 10.1007/BF00165649; Brooksbank C, 2003, NUCLEIC ACIDS RES, V31, P43, DOI 10.1093/nar/gkg066; Corman B, 1999, AM J HUM GENET, V64, P126, DOI 10.1086/302206; DOWNING JR, 1995, AM J PATHOL, V146, P626; DUMANSKI JP, 1990, CANCER RES, V50, P5863; DUMANSKI JP, 1987, P NATL ACAD SCI USA, V84, P9275, DOI 10.1073/pnas.84.24.9275; Engle EC, 1997, AM J HUM GENET, V60, P1150; Ernstsson S, 1997, GENOMICS, V46, P78, DOI 10.1006/geno.1997.4986; EVANS DGR, 1992, Q J MED, V84, P603; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; JIMENEZLARA AM, 1992, CANCER GENET CYTOGEN, V63, P174; Jogi A, 2000, INT J ONCOL, V16, P943; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Lamszus K, 2000, J NEUROPATH EXP NEUR, V59, P504, DOI 10.1093/jnen/59.6.504; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Leone PE, 1999, ONCOGENE, V18, P2231, DOI 10.1038/sj.onc.1202531; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; Mathiesen T, 1996, NEUROSURGERY, V39, P2, DOI 10.1097/00006123-199607000-00002; McPherson JD, 2001, NATURE, V409, P934, DOI 10.1038/35057157; Mendiola M, 1999, MOL CARCINOGEN, V24, P300, DOI 10.1002/(SICI)1098-2744(199904)24:4<300::AID-MC8>3.0.CO;2-G; Miller PR, 1999, CYTOGENET CELL GENET, V85, P157; Muller P, 1999, CLIN CANCER RES, V5, P3569; NAKASU S, 1987, SURG NEUROL, V27, P319, DOI 10.1016/0090-3019(87)90005-X; Niedermayer I, 1997, J NEUROPATH EXP NEUR, V56, P879, DOI 10.1097/00005072-199708000-00006; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; Prosperi MT, 1998, FEBS LETT, V423, P39, DOI 10.1016/S0014-5793(98)00057-X; Pruess M, 2003, NUCLEIC ACIDS RES, V31, P414, DOI 10.1093/nar/gkg105; Pruitt KD, 1997, GENOME RES, V7, P1118, DOI 10.1101/gr.7.12.1118; PYKETT MJ, 1994, CANCER RES, V54, P6340; Rasio D, 1997, CANCER RES, V57, P2378; REMPEL SA, 1993, CANCER RES, V53, P2386; ROBERTS L, 1991, SCIENCE, V254, P805, DOI 10.1126/science.1948063; Roberts T, 1996, ANN HUM GENET, V60, P213, DOI 10.1111/j.1469-1809.1996.tb00424.x; RUTTLEDGE MH, 1994, GENE CHROMOSOME CANC, V10, P122, DOI 10.1002/gcc.2870100207; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; Santarius T, 2000, NEUROPATH APPL NEURO, V26, P67, DOI 10.1046/j.1365-2990.2000.00219.x; Schuler GD, 1997, GENOME RES, V7, P541, DOI 10.1101/gr.7.5.541; Schutte BC, 2001, CYTOGENET CELL GENET, V92, P24; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Simon M, 1996, GENE CHROMOSOME CANC, V16, P265, DOI 10.1002/(SICI)1098-2264(199608)16:4<265::AID-GCC7>3.0.CO;2-W; SIMON M, 1995, CANCER RES, V55, P4696; Smyth I, 1999, HUM MOL GENET, V8, P291, DOI 10.1093/hmg/8.2.291; Sulman EP, 1998, CANCER RES, V58, P3226; Vance JM, 1997, CYTOGENET CELL GENET, V78, P154; VENTER JC, 2001, J BIOL CHEM, V276, P43604; WELLENREUTHER R, 1995, AM J PATHOL, V146, P827; White PS, 1999, GENOME RES, V9, P978, DOI 10.1101/gr.9.10.978; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3; Zaphiropoulos PG, 1999, CANCER RES, V59, P787; Zulch KJ, 1979, HISTOLOGICAL TYPING; 1998, CURR BIOL, V8, pR510	61	34	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					1014	1020		10.1038/sj.onc.1206623	http://dx.doi.org/10.1038/sj.onc.1206623			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14749765				2022-12-17	WOS:000188486600019
J	Cleaves, R; Wang, QF; Friedman, AD				Cleaves, R; Wang, QF; Friedman, AD			C/EBP alpha p30, a myeloid leukemia oncoprotein, limits G-CSF receptor expression but not terminal granulopoiesis via site-selective inhibition of C/EBP DNA binding	ONCOGENE			English	Article						C/EBP alpha; AML; leukemia; differentiation; cell cycle	PROTEIN-ALPHA; TRANSCRIPTION FACTOR; GRANULOCYTIC DIFFERENTIATION; MURINE MYELOPEROXIDASE; GENE-EXPRESSION; GROWTH ARREST; C-MYB; INDUCTION; PROLIFERATION; PU.1	Heterozygous mutations of the CEBPA gene are present in 5% of acute myeloid leukemia (AML) cases and often lead to the expression of an N-terminally truncated, 30 kDa isoform, C/EBPalphap30, from an internal translation start site. We have assessed the effect of C/EBPalphap30 on granulopoiesis utilizing C/EBPalphap30-ER, containing the estradiol receptor ligand-binding domain. In contrast to C/EBPalpha-ER, C/EBPalphap30-ER did not induce 32Dcl3 myeloid cell differentiation in IL-3. However, both isoforms, when expressed at high levels, were capable of inhibiting E2F activity in 32Dcl3 cells and of slowing their G1 to S progression. C/EBPalphap30 repressed expression of the endogenous G-CSF receptor several-fold. To facilitate investigation of the effect of C/EBPalphap30-ER on granulopoiesis downstream of G-CSF signalling, we coexpressed exogenous G-CSF receptor. C/EBPalphap30-ER/GR cells expressed several granulocytic markers in G-CSF and demonstrated nuclear maturation. Rat C/EBPalpha-ER and C/EBPalphap30-ER, expressed in 293T cells, bound the C/EBP site from the NE gene with similar affinity, as did human C/EBPalpha and C/EBPalphap30. In contrast, C/EBPalphap30 bound the C/EBP sites in the PU.1 or GR gene with 3-6-fold reduced affinity. Thus, the selective inhibition of GR expression by C/EBPalphap30-ER is due in part to its variable affinity for C/EBP sites. Variation in affinity for selected cis elements among isoforms may affect the biology of basic region-leucine zipper (bZIP) proteins.	Johns Hopkins Univ, Div Pediat Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Friedman, AD (corresponding author), Johns Hopkins Univ, Div Pediat Oncol, Sidney Kimmel Comprehens Canc Ctr, Canc Res Bldg,Rm 253,1650 Orleans St, Baltimore, MD 21231 USA.	afriedm2@jhem.jhmi.edu			NHLBI NIH HHS [R01 HL51388] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051388] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		An MR, 1996, MOL CELL BIOL, V16, P2295; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Britos-Bray M, 1998, BLOOD, V92, P4344, DOI 10.1182/blood.V92.11.4344.423a01_4344_4352; Calkhoven CF, 2000, GENE DEV, V14, P1920; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DIEHL AM, 1994, GASTROENTEROLOGY, V106, P1625, DOI 10.1016/0016-5085(94)90420-0; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Friedman AD, 1996, CANCER RES, V56, P3250; Friedman AD, 2002, J CELL BIOCHEM, V86, P624, DOI 10.1002/jcb.10271; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Iwasaki-Arai J, 2002, BLOOD, V100, p61A; JOHANSEN LM, 2003, IN PRESS BLOOD; Keeshan K, 2003, BLOOD, V102, P1267, DOI 10.1182/blood-2003-02-0477; Kummalue T, 2003, J LEUKOCYTE BIOL, V74, P464, DOI 10.1189/jlb.1202622; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Liu HT, 2003, BLOOD, V101, P3885, DOI 10.1182/blood-2002-07-2212; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Rangatia J, 2002, MOL CELL BIOL, V22, P8681, DOI 10.1128/MCB.22.24.8681-8694.2002; RAUGHT B, 1995, MOL ENDOCRINOL, V9, P1223, DOI 10.1210/me.9.9.1223; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; SCOTT LM, 1992, BLOOD, V80, P1725; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; Theilgaard-Moench K, 2002, BLOOD, V100, p298A; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wang QF, 2003, ONCOGENE, V22, P2548, DOI 10.1038/sj.onc.1206360; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Wang W, 2001, LEUKEMIA, V15, P779, DOI 10.1038/sj.leu.2402094; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 1998, J EXP MED, V188, P1173, DOI 10.1084/jem.188.6.1173	43	34	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					716	725		10.1038/sj.onc.1207172	http://dx.doi.org/10.1038/sj.onc.1207172			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737106				2022-12-17	WOS:000188304900010
J	Ree, AH; Bratland, A; Nome, RV; Stokke, T; Fodstad, O				Ree, AH; Bratland, A; Nome, RV; Stokke, T; Fodstad, O			Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1	ONCOGENE			English	Article						BRCA1; polo-like kinase 1; cell cycle control; DNA damage; breast cancer	POLO-LIKE-KINASE; DOWN-REGULATION; CHECKPOINT; EXPRESSION; ATM; PROTEIN; PHOSPHORYLATION; PHOSPHATASE; REGULATORS; LINKAGE	DNA damage activates the G(2) cell cycle checkpoint to allow time for DNA repair before mitotic entry. The mechanism involves inhibition of the enzymatic activity for polo-like kinase 1 (Plk1), rendering Cdc25C with a basal phosphatase activity that is insufficient for converting Cdc2 to the fully active G(2)/M transition kinase. We found that cell cycle arrest at the G(2)/M boundary after ionizing radiation (IR) of breast carcinoma cells may involve repression of the gene for Plk1, PLK, mediated by the tumor-suppressor protein BRCA1. The p53-defective MT-1 cell line had an apparent accumulation of G(2)/M phase cells 12 h after irradiation. This response was preceded by a transient downregulation of PLK mRNA expression with a barely detectable level 6 h after exposure to IR but recovered after 12 h. A significantly lower fraction of irradiated BRCA1(-/-) HCC1937 cells arrested in the G(2)/M phase after 12 h, and the transient response of PLK mRNA was also considerably impaired. After reconstitution of wild-type BRCA1 in the HCC1937 cells however, downregulation of PLK mRNA as well as Plk1 protein expression after IR was restored. Moreover, the suppression of PLK mRNA expression 6 h after irradiation was completely abolished by the specific CHEK1 kinase inhibitor UCN-01, further indicating that the effector mechanism of DNA damage on PLK signals through BRCA1 and its downstream CHEK1. Our observations provide new information about the diversity of regulatory mechanisms governed by BRCA1 in DNA damage checkpoint control.	Norwegian Radium Hosp, Dept Tumor Biol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Oncol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Biophys, N-0310 Oslo, Norway	University of Oslo; University of Oslo; University of Oslo	Ree, AH (corresponding author), Norwegian Radium Hosp, Dept Tumor Biol, N-0310 Oslo, Norway.			Ree, Anne H./0000-0002-8264-3223				Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; DATTA R, 1992, CELL GROWTH DIFFER, V3, P637; Deng CX, 2000, BIOESSAYS, V22, P728; Elez R, 2003, ONCOGENE, V22, P69, DOI 10.1038/sj.onc.1206038; Engebraaten O, 1999, INT J CANCER, V82, P219, DOI 10.1002/(SICI)1097-0215(19990719)82:2<219::AID-IJC12>3.0.CO;2-#; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Knecht R, 1999, CANCER RES, V59, P2794; Kneisel L, 2002, J CUTAN PATHOL, V29, P354, DOI 10.1034/j.1600-0560.2002.290605.x; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Tomlinson GE, 1998, CANCER RES, V58, P3237; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837	28	34	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8952	8955		10.1038/sj.onc.1207000	http://dx.doi.org/10.1038/sj.onc.1207000			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654792				2022-12-17	WOS:000186982200017
J	Kartasheva, NN; Lenz-Bauer, C; Hartmann, O; Schafer, H; Eilers, M; Dobbelstein, M				Kartasheva, NN; Lenz-Bauer, C; Hartmann, O; Schafer, H; Eilers, M; Dobbelstein, M			Delta Np73 can modulate the expression of various genes in a p53-independent fashion	ONCOGENE			English	Article						p53; p73; EGR1; NF-kappa B; c-MYC	WILD-TYPE P53; NF-KAPPA-B; P73 GENE; C-MYC; TRANSCRIPTION; MICROARRAY; INHIBITOR; CANCER; OVEREXPRESSION; NEUROBLASTOMA	DeltaNp73alpha is an isoform of the p53 homologue p73 that lacks an amino-terminal transactivation domain and antagonizes the induction of gene expression by p53. Here, we examined whether DeltaNp73alpha might also modulate cellular transcription in the absence of p53. The expression of DeltaNp73alpha in the p53-/- cell line H1299 reduced the mRNA levels of p21/CDKN1A, but did not affect other p53-responsive genes. Correspondingly, the p21/CDKN1A promoter was downregulated by DeltaNp73alpha in reporter assays, whereas other p53-responsive promoters were not inhibited. To identify additional genes that respond to DeltaNp73alpha in the absence of p53, microarrays carrying 4600 cDNA clones were hybridized. The expression of 30 genes was found to be altered more than threefold by overexpressed DeltaNp73alpha. For instance, DeltaNp73alpha increased the expression of EGR1 and CDC6, whereas it decreased the mRNA levels of c-MYC, cyclin A2/CCNA2, NF-kappaB1, ODC1, and RET finger protein/RFP. Semiquantitative reverse transcription-PCR confirmed these results and further revealed that the influence of DeltaNp73alpha on the regulation of these genes differs from other p73 isoforms and p53. We conclude that the impact of DeltaNp73alpha on gene expression is not limited to p53-responsive genes. Rather, DeltaNp73alpha can regulate the expression of a variety of genes independently of p53.	Univ Marburg, Inst Virol, D-35037 Marburg, Germany; Univ Marburg, Inst Mol Biol & Tumor Res IMT, D-35033 Marburg, Germany; Univ Marburg, Inst Med Biometrie & Epidemiol, D-35037 Marburg, Germany; Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia	Philipps University Marburg; Philipps University Marburg; Philipps University Marburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Russian Academy of Sciences	Dobbelstein, M (corresponding author), Univ Marburg, Inst Virol, Robert Koch Str 17, D-35037 Marburg, Germany.	dobbelst@mailer.uni-marburg.de		Dobbelstein, Matthias/0000-0001-5052-3967; Eilers, Martin/0000-0002-0376-6533				Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Douc-Rasy S, 2002, AM J PATHOL, V160, P631, DOI 10.1016/S0002-9440(10)64883-3; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Koch P, 2001, CANCER RES, V61, P5941; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; Lagger G, 2003, MOL CELL BIOL, V23, P2669, DOI 10.1128/MCB.23.8.2669-2679.2003; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Ng SW, 2000, ONCOGENE, V19, P1885, DOI 10.1038/sj.onc.1203512; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Roth J, 2000, ONCOGENE, V19, P1834, DOI 10.1038/sj.onc.1203500; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; STIEWE T, 2002, J BIOL CHEM, V13, P13; Takahashi H, 1998, CANCER RES, V58, P2076; Tokuchi Y, 1999, BRIT J CANCER, V80, P1623, DOI 10.1038/sj.bjc.6690572; Weigel S, 2000, J VIROL, V74, P764, DOI 10.1128/JVI.74.2.764-772.2000; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zaika AI, 1999, CANCER RES, V59, P3257; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179	44	34	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8246	8254		10.1038/sj.onc.1207138	http://dx.doi.org/10.1038/sj.onc.1207138			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614448				2022-12-17	WOS:000186541500003
J	Delia, D; Fontanella, E; Ferrario, C; Chessa, L; Mizutani, S				Delia, D; Fontanella, E; Ferrario, C; Chessa, L; Mizutani, S			DNA damage-induced cell-cycle phase regulation of p53 and p21(waf1) in normal and ATM-defective cells	ONCOGENE			English	Article							DEPENDENT PROTEIN-KINASE; ATAXIA-TELANGIECTASIA; INDUCED PHOSPHORYLATION; RADIOSENSITIZING AGENT; CHECKPOINT; APOPTOSIS; INHIBITION; G(1); DISSOCIATION; ARREST	The ATM-dependent accumulation of p53 and induction of p21(waf1) are key events for G1 cell-cycle checkpoint arrest following DNA damage. In ATM-null AT cells, even though the p53 and p21(waf1) responses are kinetically delayed and quantitatively reduced, the G1 checkpoint is virtually disrupted, suggesting that these proteins arrive too late in G1 to enforce the arrest. As the precise mechanism remains unclear, we examined the response to DNA double-strand breaks generated by gamma-radiation (IR), to determine if ATM deficiency affects the cell-cycle phase regulation of these molecules. We find that, after irradiation, whereas normal LCL-N cells markedly increase their levels of p53 in all phases of the cell cycle, AT cells fail to show any p53 increase in the G1 phase. In addition, whereas in LCL-N p21(waf1) is induced in G1 and G2-M, in AT cells this induction is partly seen in G2-M, but not in G1, indicating a different cell-cycle phase regulation of p53 and p21(waf1) as a result of ATM deficiency. The levels and catalytic activity of the p53-targeting kinases ATR and DNA-PK in LCL-N and AT cells are very similar throughout the cell cycle, both before and after IR, thus excluding a phase-specific activity for these kinases. Collectively, our findings demonstrate that, in ATM-deficient cells, the p53-dependent p21(waf1) response to DNA damage is not only quantitatively reduced, but also specifically suppressed in the G1 phase, thus providing a mechanistic explanation for the severe disruption of the G1 checkpoint in AT cells.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; IFOM, I-20139 Milan, Italy; Osped S Andrea, I-00189 Rome, Italy; Tokyo Med & Dent Univ, Postgrad Med Sch, Dept Pediat & Dev Biol, Bunkyo Ku, Tokyo 1138519, Japan	Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; Tokyo Medical & Dental University (TMDU)	Delia, D (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.				Telethon [GP0205Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; CANMAN CE, 1994, CANCER RES, V54, P5054; Chehab NH, 2000, GENE DEV, V14, P278; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; Delia D, 2000, BRIT J CANCER, V82, P1938; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Goi K, 1997, CANCER RES, V57, P1895; Jhappan C, 2000, MOL CELL BIOL, V20, P4075, DOI 10.1128/MCB.20.11.4075-4083.2000; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; KHANNA KK, 1995, ONCOGENE, V11, P609; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Takagi M, 1998, CANCER RES, V58, P4923; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Yoshida M, 2002, INT J RADIAT BIOL, V78, P503, DOI [10.1080/095530002317577321, 10.1080/09553000210123685]	28	34	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7866	7869		10.1038/sj.onc.1207086	http://dx.doi.org/10.1038/sj.onc.1207086			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586414				2022-12-17	WOS:000186240200018
J	Liao, GX; Sun, SC				Liao, GX; Sun, SC			Regulation of NF-kappa B2/p100 processing by its nuclear shuttling	ONCOGENE			English	Article						NF-kappa B; p100; protein processing; nuclear localization signal; leptomycin B	NF-KAPPA-B; TRCP UBIQUITIN LIGASE; MICE LACKING; P105; PROTEINS; SIGNAL; PHOSPHORYLATION; PRECURSOR; KINASE; DOMAIN	Processing of the NF-kappaB2 precursor protein p100 to generate p52 is an important step of NF-kappaB regulation. This proteolytic event is tightly regulated by sequences located at the C-terminal portion of p100. Constitutive processing of p100 occurs in certain lymphoma cells due to the loss of its C-terminal regulatory domain, although the underlying mechanisms remain unknown. We show here that the constitutive processing of C-terminal truncation mutants of p100 is associated with their active nuclear translocation. Deletion of the C-terminal death domain of p100 triggers a low, but significant, level of nuclear translocation and processing. Disruption of the ankyrin-repeat domain of p100 further enhances its nuclear shuttling activity, which is again associated with elevated level of processing. More importantly, mutation of the nuclear localization signal (NLS) of p100 abolishes its processing, and this defect can be rescued by fusion of a heterologous NLS to the amino- or carboxyl-terminus of the p100 mutant. These results suggest that nuclear shuttling is a mechanism regulating the processing of NF-kappaB2/p100.	Penn State Univ Hosp, Dept Microbiol & Immunol, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ Hosp, Dept Microbiol & Immunol, Coll Med, 500 Univ Dr, Hershey, PA 17033 USA.	sxs70@psu.edu			NCI NIH HHS [1R01 CA94922] Funding Source: Medline; NIAID NIH HHS [1R01 AI45045] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045045] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Blondel M, 2000, EMBO J, V19, P6085, DOI 10.1093/emboj/19.22.6085; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Harhaj EW, 1996, ONCOGENE, V12, P2385; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Neri A, 1996, LEUKEMIA LYMPHOMA, V23, P43, DOI 10.3109/10428199609054800; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Sadot E, 2000, ONCOGENE, V19, P1992, DOI 10.1038/sj.onc.1203519; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yu ZK, 2000, ONCOGENE, V19, P5892, DOI 10.1038/sj.onc.1203980	37	34	38	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4868	4874		10.1038/sj.onc.1206761	http://dx.doi.org/10.1038/sj.onc.1206761			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894228				2022-12-17	WOS:000184344600010
J	Hyland, S; Beerli, RR; Barbas, CF; Hynes, NE; Wels, W				Hyland, S; Beerli, RR; Barbas, CF; Hynes, NE; Wels, W			Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor	ONCOGENE			English	Article						epidermal growth factor receptor; receptor tyrosine kinase; single-chain Fv antibody; intrabody; yeast two-hybrid	GROWTH-FACTOR RECEPTOR; SINGLE-CHAIN ANTIBODY; ERBB SIGNALING NETWORK; MONOCLONAL-ANTIBODY; TARGETED THERAPY; HIV-1 INFECTION; FV FRAGMENTS; V-H; INHIBITION; PROTEIN	Intracellular expression of single-chain antibodies (scFvs) represents a promising approach for selective interference with cellular proto-oncogenes such as the epidermal growth factor receptor (EGFR). Previously, we have shown that intrabodies targeted to the lumen of the endoplasmic reticulum prevent the transit of EGFR or the related ErbB2 molecule to the cell surface, thereby inactivating their transforming potential. While intramolecular disulfide bridges important for antibody stability are correctly formed during expression in the secretory pathway, scFvs expressed in the reducing environment of the cytosol are often inactive. To overcome this problem and to generate antibody fragments that interact with the intracellular domain of human EGFR in the cytoplasm, here we have chosen a two-step approach combining classical selection of scFvs by phage display with subsequent expression in yeast. After enrichment of EGFR-specific antibody fragments from a combinatorial library by biopanning, a yeast two-hybrid screen was performed using the intracellular domain of EGFR as bait. Screening of 1.5 x 10(5) preselected scFv plasmids under highly stringent conditions yielded 223 colonies that represented at least five independent scFv clones functional in the intracellular milieu of eukaryotic cells. Interaction of selected antibody fragments with the intracellular domain of EGFR was confirmed in GST pull-down and coimmunoprecipitation experiments. Upon cytoplasmic expression in human tumor cells, scFvs colocalized with EGFR at the plasma membrane demonstrating their functionality in vivo.	Georg Speyer Haus, Chemotherapeut Forschungsinst, D-60596 Frankfurt, Germany; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Octapharma; Scripps Research Institute; Scripps Research Institute; Friedrich Miescher Institute for Biomedical Research	Wels, W (corresponding author), Georg Speyer Haus, Chemotherapeut Forschungsinst, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.	wels@em.uni-frankfurt.de		Wels, Winfried/0000-0001-9858-3643				Altenschmidt U, 1997, INT J CANCER, V73, P117, DOI 10.1002/(SICI)1097-0215(19970926)73:1<117::AID-IJC18>3.0.CO;2-D; Andris-Widhopf J, 2001, PHAGE DISPLAY LAB MA, V1st; Bach H, 2001, J MOL BIOL, V312, P79, DOI 10.1006/jmbi.2001.4914; Barbas C. F., 2001, PHAGE DISPLAY LAB MA; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; Beerli RR, 1996, BREAST CANCER RES TR, V38, P11, DOI 10.1007/BF01803779; BEERLI RR, 1994, BIOCHEM BIOPH RES CO, V204, P666, DOI 10.1006/bbrc.1994.2511; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BIOCCA S, 1995, BIO-TECHNOL, V13, P1110, DOI 10.1038/nbt1095-1110; BIOCCA S, 1994, BIO-TECHNOL, V12, P396, DOI 10.1038/nbt0494-396; Cardinale A, 2001, EUR J BIOCHEM, V268, P268, DOI 10.1046/j.1432-1327.2001.01876.x; Cattaneo A, 1999, TRENDS BIOTECHNOL, V17, P115, DOI 10.1016/S0167-7799(98)01268-2; De Jaeger G, 2000, FEBS LETT, V467, P316, DOI 10.1016/S0014-5793(00)01182-0; DESHANE J, 1994, GENE THER, V1, P332; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DUAN LX, 1994, P NATL ACAD SCI USA, V91, P5075, DOI 10.1073/pnas.91.11.5075; Gargano N, 1997, J GEN VIROL, V78, P2591, DOI 10.1099/0022-1317-78-10-2591; Goncalves J, 2002, J BIOL CHEM, V277, P32036, DOI 10.1074/jbc.M201906200; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; HILLS D, 1995, INT J CANCER, V63, P537, DOI 10.1002/ijc.2910630414; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Jannot CB, 1996, ONCOGENE, V13, P275; Jermutus L, 2001, P NATL ACAD SCI USA, V98, P75, DOI 10.1073/pnas.011311398; Kabat EA, 1991, SEQUENCES PROTEINS I; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; Klapper LN, 2000, ADV CANCER RES, V77, P25; Lener M, 2000, EUR J BIOCHEM, V267, P1196, DOI 10.1046/j.1432-1327.2000.01125.x; Marasco WA, 1997, GENE THER, V4, P11, DOI 10.1038/sj.gt.3300346; MARASCO WA, 1995, IMMUNOTECHNOLOGY, V1, P1, DOI 10.1016/1380-2933(95)00001-1; Martineau P, 1998, J MOL BIOL, V280, P117, DOI 10.1006/jmbi.1998.1840; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Mendelsohn J, 1997, CLIN CANCER RES, V3, P2703; MHASHILKAR AM, 1995, EMBO J, V14, P1542, DOI 10.1002/j.1460-2075.1995.tb07140.x; Ohage EC, 1999, J MOL BIOL, V291, P1129, DOI 10.1006/jmbi.1999.3020; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Parisien JP, 2001, VIROLOGY, V283, P230, DOI 10.1006/viro.2001.0856; Persic L, 1997, GENE, V187, P1, DOI 10.1016/S0378-1119(96)00627-0; Proba K, 1997, J MOL BIOL, V265, P161, DOI 10.1006/jmbi.1996.0726; Rader C, 1997, CURR OPIN BIOTECH, V8, P503, DOI 10.1016/S0958-1669(97)80075-4; RUSSO MW, 1985, J BIOL CHEM, V260, P5205; Shin DM, 2001, CLIN CANCER RES, V7, P1204; Steinberger P, 2000, P NATL ACAD SCI USA, V97, P805, DOI 10.1073/pnas.97.2.805; Tse E, 2002, J MOL BIOL, V317, P85, DOI 10.1006/jmbi.2002.5403; Visintin M, 1999, P NATL ACAD SCI USA, V96, P11723, DOI 10.1073/pnas.96.21.11723; Worn A, 2000, J BIOL CHEM, V275, P2795, DOI 10.1074/jbc.275.4.2795; Worn A, 1998, FEBS LETT, V427, P357, DOI 10.1016/S0014-5793(98)00463-3; Worn A, 2001, J MOL BIOL, V305, P989, DOI 10.1006/jmbi.2000.4265; Xu JL, 2000, IMMUNITY, V13, P37, DOI 10.1016/S1074-7613(00)00006-6; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yi KS, 2001, ONCOGENE, V20, P7954, DOI 10.1038/sj.onc.1204959; Zhu QA, 1999, J IMMUNOL METHODS, V231, P207, DOI 10.1016/S0022-1759(99)00158-1	58	34	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1557	1567		10.1038/sj.onc.1206299	http://dx.doi.org/10.1038/sj.onc.1206299			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629519				2022-12-17	WOS:000181411900013
J	Hodgson, L; Henderson, AJ; Dong, C				Hodgson, L; Henderson, AJ; Dong, C			Melanoma cell migration to type IV collagen requires activation of NF-kappa B	ONCOGENE			English	Article						chemotaxis; integrin; GTPase; transactivation; A2058	FOCAL ADHESION KINASE; ANTIINFLAMMATORY SESQUITERPENE LACTONE; ACTIN STRESS FIBERS; SIGNAL-TRANSDUCTION; TRANSCRIPTIONAL ACTIVITY; EXTRACELLULAR-MATRIX; RHO; CDC42; GTPASES; RAC	Chemotaxis is the consequence of environmental factors engaging their receptors to initiate signaling cascades. However, the biochemical mechanisms controlling this phenomenon are not clear. We employed an in vitro modified Boyden 48-well chemotaxis migration system to characterize the role of signal transducers in type IV collagen (CIV) induced A2058 human melanoma cell migration. Using specific pharmacological inhibitors and a series of dominant-negative and constitutively active signaling proteins, we show that Ras and Rac GTPases, PI-3K, and PKC participate in cell migration mediated by beta1 integrins. Collagen also induces a time-dependent degradation of IkappaB-alpha and an increase in nuclear translocation of NF-kappaB which is dependent on PKC pathway. More importantly, collagen-stimulated melanoma cell migration directly correlated with an increase in NF-kappaB transactivation. Furthermore, CIV induced an increase in beta1 integrin mRNA levels. Specific NF-kappaB inhibitors Helenalin and SN-50 inhibited melanoma cell migration to collagen, indicating a novel requirement for NF-kappaB transactivation in cell chemotaxis mediated by beta1 integrin signals. These results describe signal transduction events that are initiated by type IV collagen through beta1 integrins and demonstrate an important role for NF-kappaB in regulating melanoma chemotaxis.	Penn State Univ, Dept Bioengn, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Dong, C (corresponding author), Penn State Univ, Dept Bioengn, 229 Hallowell, University Pk, PA 16802 USA.	exd23@psu.edu		Henderson, Andrew/0000-0002-9299-5302; Hodgson, Louis/0000-0001-9188-7580	NATIONAL CANCER INSTITUTE [R29CA076434, R01CA097306] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR010732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046261] Funding Source: NIH RePORTER; NCI NIH HHS [CA76434, R01 CA097306, R01 CA097306-01A1, R01 CA097306-02] Funding Source: Medline; NCRR NIH HHS [M01 RR010732-110202, M01 RR010732-090202, M01 RR010732, M01 RR010732-080202, M01 RR010732-070202, M01 RR010732-100202, M01 RR010732-060202] Funding Source: Medline; NIAID NIH HHS [AI46261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300; AZNAVOORIAN S, 1990, J CELL BIOL, V110, P1427, DOI 10.1083/jcb.110.4.1427; Benoliel AM, 1997, J CELL SCI, V110, P2089; Boukerche H, 2000, CANCER RES, V60, P5848; Burow ME, 2000, BIOCHEM BIOPH RES CO, V271, P342, DOI 10.1006/bbrc.2000.2626; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; HARVATH L, 1980, J IMMUNOL METHODS, V37, P39, DOI 10.1016/0022-1759(80)90179-9; Hodgson L, 2001, AM J PHYSIOL-CELL PH, V281, pC106, DOI 10.1152/ajpcell.2001.281.1.C106; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; LU C, 1993, J CELL BIOL, V120, P1281, DOI 10.1083/jcb.120.5.1281; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Lyss G, 1997, BIOL CHEM, V378, P951, DOI 10.1515/bchm.1997.378.9.951; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Meredith JE, 1996, ENDOCR REV, V17, P207, DOI 10.1210/er.17.3.207; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Palmantier R, 2001, CANCER RES, V61, P2445; Paolucci L, 2000, AM J PHYSIOL-CELL PH, V278, pC33, DOI 10.1152/ajpcell.2000.278.1.C33; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Pasco S, 2000, CANCER RES, V60, P467; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; POWIS G, 1994, CANCER CHEMOTH PHARM, V34, P344, DOI 10.1007/BF00686043; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rong R, 2002, ONCOGENE, V21, P1062, DOI 10.1038/sj.onc.1205154; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; SAVARESE DMF, 1992, J BIOL CHEM, V267, P21928; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHNAPER HW, 1993, PEDIATR NEPHROL, V7, P96, DOI 10.1007/BF00861587; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Stracke M L, 1994, In Vivo, V8, P49; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; VAN AL, 1997, GENE DEV, V11, P2295; YEBRA M, 1995, MOL BIOL CELL, V6, P841, DOI 10.1091/mbc.6.7.841; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	55	34	37	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2003	22	1					98	108		10.1038/sj.onc.1206059	http://dx.doi.org/10.1038/sj.onc.1206059			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527912	Green Accepted			2022-12-17	WOS:000180166900011
J	Billottet, C; Janji, B; Thiery, JP; Jouanneau, J				Billottet, C; Janji, B; Thiery, JP; Jouanneau, J			Rapid tumor development and potent vascularization are independent events in carcinoma producing FGF-1 or FGF-2	ONCOGENE			English	Article						FGF signaling; tumor growth; angiogenesis; MMPs; uPA/uPAR	FIBROBLAST-GROWTH-FACTOR; RAT BLADDER-CARCINOMA; MEMBRANE-TYPE-1 MATRIX METALLOPROTEINASE; PLASMINOGEN-ACTIVATOR; ENDOTHELIAL-CELLS; FACTOR EXPRESSION; CANCER INVASION; HUMAN GLIOMAS; IN-VITRO; ANGIOGENESIS	FGF-1 and FGF-2 are pleiotropic growth factors for many cell types, operating through the activation of specific transmembrane FGF receptors (FGFRs). The role of these factors in tumor progression was investigated, with specific discrimination between their autocrine and non autocrine cellular activity. The rat bladder carcinoma NBT-II cells were engineered to produce FGF-1 or 18 kDa FGF-2 in the presence or absence of their specific receptor. Non-autocrine cells that produced FGF-1 or FGF-2 but lacked FGFRs were epithelial and reminiscent of the parental NBT-II cells. Whilst autocrine cells, which both constitutively produced and secreted the growth factor and expressed FGFRs, had a highly invasive mesenchymal phenotype. Correspondingly, the autocrine cells were highly tumorigenic in vivo compared to the parental and non-autocrine cells, which correlated with the increased production of uPAR and active uPA and increased in vitro invasive potential. Although all cells produced VEGF, only tumors derived from cells that produced FGF-1 or FGF-2 were highly vascularized, suggesting that these two growth factors could be involved in the angiogenic process by activating host endothelial cells. As a result of activation of the FGFR in autocrine cells, changes in cell morphology and an increase in the invasive and tumorigenic properties were observed, however no in vitro or in vivo differential functions between FGF-1 and FGF-2 could be identified in this system. In conclusion, our data demonstrates that rapid tumor development is not dependent upon increased tumor vascularization, suggesting that 'basal' angiogenesis, probably mediated by VEGF, is sufficient to support tumor growth.	Inst Curie, UMR 144 CNRS, Lab Cell Morphogenesis & Tumor Progress, Sect Rech, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Jouanneau, J (corresponding author), Inst Curie, UMR 144 CNRS, Lab Cell Morphogenesis & Tumor Progress, Sect Rech, 26 Rue Ulm, F-75248 Paris 05, France.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020; JANJI, Bassam/0000-0002-9763-0943; Billottet, Clotilde/0000-0003-1819-984X				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bergers G, 2000, CURR OPIN GENET DEV, V10, P120, DOI 10.1016/S0959-437X(99)00043-X; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Borgfeldt C, 2001, INT J CANCER, V92, P497, DOI 10.1002/ijc.1215; Claffey KP, 2001, LAB INVEST, V81, P61, DOI 10.1038/labinvest.3780212; Compagni A, 2000, CANCER RES, V60, P7163; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; GATELY S, 1995, NEUROSURGERY, V36, P780, DOI 10.1227/00006123-199504000-00020; Giavazzi R, 2001, CANCER RES, V61, P309; Giri D, 1999, CLIN CANCER RES, V5, P1063; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; Jouanneau J, 1997, ONCOGENE, V14, P671, DOI 10.1038/sj.onc.1200883; Jouanneau J, 1999, ONCOGENE, V18, P327, DOI 10.1038/sj.onc.1202285; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Maatta M, 2000, CLIN CANCER RES, V6, P2726; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; Miyake H, 1997, J UROLOGY, V157, P2351, DOI 10.1016/S0022-5347(01)64779-7; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; Oh LYS, 1999, J NEUROSCI, V19, P8464; Okada-Ban M, 1999, ONCOGENE, V18, P6719, DOI 10.1038/sj.onc.1203092; Pili R, 1997, INT J CANCER, V73, P258; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; Schmidt NO, 1999, INT J CANCER, V84, P10, DOI 10.1002/(SICI)1097-0215(19990219)84:1<10::AID-IJC3>3.3.CO;2-C; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Soslow RA, 1999, HISTOPATHOLOGY, V35, P31; TAKAHASHI JA, 1992, J NEUROSURG, V76, P792, DOI 10.3171/jns.1992.76.5.0792; TOYOSHIMA K, 1971, JNCI-J NATL CANCER I, V47, P979; TSUBOI R, 1990, J CELL BIOL, V110, P511, DOI 10.1083/jcb.110.2.511; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; Weidner N, 1999, J PATHOL, V189, P297; Zheng Q, 2000, J CANCER RES CLIN, V126, P641, DOI 10.1007/s004320000146	43	34	43	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2002	21	53					8128	8139		10.1038/sj.onc.1205935	http://dx.doi.org/10.1038/sj.onc.1205935			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444548				2022-12-17	WOS:000179231400006
J	Alcock, RA; Dey, S; Chendil, D; Inayat, MS; Mohiuddin, M; Hartman, G; Chatfield, LK; Gallicchio, VS; Ahmed, MM				Alcock, RA; Dey, S; Chendil, D; Inayat, MS; Mohiuddin, M; Hartman, G; Chatfield, LK; Gallicchio, VS; Ahmed, MM			Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2	ONCOGENE			English	Article						pancreatic cancer; TGF-beta signaling; radiosensitization; farnesyltransferase inhibitor (FTI); DNA methyltransferase; TGF-beta type II receptor (TGF-beta RII)	GROWTH-FACTOR-BETA; TRANSCRIPTION FACTOR EGR-1; DNA METHYLTRANSFERASE; ONCOGENIC RAS; ADENOCARCINOMA CELLS; SIGNALING PATHWAY; EPITHELIAL-CELLS; RESISTANCE; ACTIVATION; APOPTOSIS	Activated ras is known to dysregulate TGF-beta signaling by altering the expression of TGF-beta type 11 receptor (RII). It is well documented that tumor cells harboring mutant ras are, more resistant to radiation than cells with wild-type ras. In this study, we hypothesized that the use of farneyltransferase inhibitor (FTI, L-744,832) may directly restore TGF-beta signaling through RII expression via ras dependent or independent pathway leading to induction of radiation sensitivity. Two pancreatic cancer cell, lines, BxPC-3 and MIA PaCa-2 were used in this study. FTI inhibited farnesylation of Ras protein more significantly in MIA PaCa-2 than BxPC-3 cells. In contrast, MIA PaCa-2 cells were resistant to radiation when compared to BxPC-3 cells. BxPC-3 cells were more resistant to FTI than MIA PaCa-2 cells. In combination treatment, no significant radiosensitizing effect of FTI was 6 bserved in BxPC-3 cells at 5 or 10 pm. However, in MIA PaCa-2 cells, a significant radiosensitizing effect was observed at both 5 and 10 muM concentrations (P > 0.004). The TGF-beta effector gene p21(waf1/cip1) was elevated in combination treatment in MIA PaCa-2 but not in BxPC-3 cells. In MIA PaCa-2 cells, FTI induced TGF-beta responsive promoter activity as assessed by 3TP-luciferase activity. A further induction of luciferase activity was observed in MIA PaCa-2 cells treated with radiation and FTI. Induction of TGF-beta signaling by FTI was mediated through restoration of the RII expression, as demonstrated by RT - PCR analysis. In addition, re-expression of RII by FTI Was associated with a decrease in 131 A methyltransferase 1 (DNMT1) levels. Thus, these findings suggest that the L-744,832 treatment restores the RII expression through inhibition of DNMT1 levels causing induction of TGF-beta signaling by radiation and this forms a novel molecular mechanism of radiosensitization by FTI.	Univ Kentucky, Dept Radiat Med, UKMC, Lexington, KY 40536 USA; Univ Kentucky, Dept Clin Sci, Lexington, KY 40536 USA; Univ Cent Lancashire, Ctr Forens Sci, Preston PR1 2HE, Lancs, England; Merck Pharmaceut, Westpoint, PA USA	University of Kentucky; University of Kentucky; University of Central Lancashire; Merck & Company	Ahmed, MM (corresponding author), Univ Kentucky, Dept Radiat Med, UKMC, C-15,800 Rose St, Lexington, KY 40536 USA.		Ahmed, Mansoor/AAK-5988-2020		NATIONAL CANCER INSTITUTE [R01CA086937] Funding Source: NIH RePORTER; NCI NIH HHS [CA86937] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 2000, ONCOGENE, V19, P5525, DOI 10.1038/sj.onc.1203920; Ahmed MM, 2002, J BIOL CHEM, V277, P2234, DOI 10.1074/jbc.M110168200; Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; BASOLO F, 1994, INT J CANCER, V56, P736, DOI 10.1002/ijc.2910560521; Bernhard EJ, 2000, CANCER RES, V60, P6597; Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6; BRUYNEEL EA, 1993, EUR J CANCER, V29A, P1958, DOI 10.1016/0959-8049(93)90452-L; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3407; FILMUS J, 1992, ONCOGENE, V7, P521; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fralix KD, 2000, CANCER, V88, P2010, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2010::AID-CNCR5>3.0.CO;2-5; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; GALANG CK, 1994, ONCOGENE, V9, P2913; Grady WM, 1999, CANCER RES, V59, P320; Gupta AK, 2001, CANCER RES, V61, P4278; Gupta AK, 2000, RADIAT RES, V154, P64, DOI 10.1667/0033-7587(2000)154[0064:RMRRIN]2.0.CO;2; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HERMENS AF, 1992, CANCER RES, V52, P3073; Hu YX, 1998, CLIN CANCER RES, V4, P1147; JOSHIBARVE SS, 1993, J BIOL CHEM, V268, P18018; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; Leach SD, 1998, PANCREAS, V16, P491, DOI 10.1097/00006676-199805000-00006; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MASSAGUE J, 1990, ANN REV CELL BIOL, V6, P1; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; Nalca A, 1999, J BIOL CHEM, V274, P29976, DOI 10.1074/jbc.274.42.29976; Reiss M, 1997, BREAST CANCER RES TR, V45, P81, DOI 10.1023/A:1005865812918; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; SELLS SF, 1995, MOL CELL BIOL, V15, P682; Shichinohe T, 1996, J SURG RES, V66, P125, DOI 10.1006/jsre.1996.0383; Simeone DM, 2000, ANN SURG, V232, P73, DOI 10.1097/00000658-200007000-00011; Song SY, 2000, NEOPLASIA, V2, P261, DOI 10.1038/sj.neo.7900088; SPORN MB, 1990, ANN NY ACAD SCI, V593, P1, DOI 10.1111/j.1749-6632.1990.tb16095.x; Venkatasubbarao K, 2001, CANCER RES, V61, P6239; Venkatasubbarao K, 2000, ANTICANCER RES, V20, P43; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; ZHAO J, 1995, CANCER RES, V55, P6181	48	34	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 7	2002	21	51					7883	7890		10.1038/sj.onc.1205948	http://dx.doi.org/10.1038/sj.onc.1205948			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420225				2022-12-17	WOS:000178946000013
J	Mohanam, S; Chandrasekar, N; Yanamandra, N; Khawar, S; Mirza, F; Dinh, DH; Olivero, WC; Rao, JS				Mohanam, S; Chandrasekar, N; Yanamandra, N; Khawar, S; Mirza, F; Dinh, DH; Olivero, WC; Rao, JS			Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator	ONCOGENE			English	Article						ATF; uPA; glioblastoma; invasiveness	TUMOR-GROWTH; RECEPTOR CD87; IN-VIVO; METASTASIS; INHIBITION; SYSTEM; CANCER; ANGIOGENESIS; TRANSFECTION; LOCALIZATION	The binding of urokinase-type plasminogen activator (uPA) to its receptor (uPAR) on the surface of tumor cells is involved in the activation of proteolytic cascades responsible for the invasiveness of those cells. The diffuse, extensive infiltration of glioblastomas into the surrounding normal brain tissue is believed to rely on modifications of the proteolysis of extracellular matrix components; blocking the interaction between uPA and uPAR might be a suitable approach for inhibiting glioma tumorigenesis. We assessed how expression of an amino-terminal fragment (ATF) of uPA that contains binding site to uPAR affects the invasiveness of SNB19 human glioblastoma cells. SNB19 cells were transfected with an expression plasmid (pcDNA3-ATF) containing a cDNA sequence of ATF-uPA. The resulting ATF-uPA-expressing clones showed markedly less cell adhesion, spreading, and clonogenicity than did control cells. Endogenous ATF expression also significantly decreased the invasive capacity of transfected glioblastoma cells in Matrigel and spheroid-rat brain cell aggregate models. ATF-uPA transfectants were also markedly less invasive than parental SNB19 cells after injection into the brains of nude mice, suggesting that competitive inhibition of the uPA-uPAR interaction on SNB19 cells by means of transfection with ATF cDNA could be a useful therapeutic strategy for inhibiting tumor progression.	Univ Illinois, Coll Med, Div Canc Biol, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Div Canc Biol, Dept Biomed & Therapeut Sci, 1 Illini Dr, Peoria, IL 61656 USA.				NCI NIH HHS [CA75557, CA76350, CA85216] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076350, R01CA085216, R01CA075557] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Burgle M, 1997, BIOL CHEM, V378, P231, DOI 10.1515/bchm.1997.378.3-4.231; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; Dear AE, 1998, EUR J BIOCHEM, V252, P185, DOI 10.1046/j.1432-1327.1998.2520185.x; Duffy MJ, 1996, CLIN CANCER RES, V2, P613; Festuccia C, 1998, CLIN EXP METASTAS, V16, P513, DOI 10.1023/A:1006590217724; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; KOBAYASHI H, 1994, INT J CANCER, V57, P727, DOI 10.1002/ijc.2910570520; Kruger A, 2000, CANCER GENE THER, V7, P292, DOI 10.1038/sj.cgt.7700144; Li H, 1998, GENE THER, V5, P1105, DOI 10.1038/sj.gt.3300742; Luparello C, 1996, EUR J CANCER, V32A, P702, DOI 10.1016/0959-8049(95)00657-5; Min HY, 1996, CANCER RES, V56, P2428; Mohanam S, 2001, CLIN CANCER RES, V7, P2519; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; MOHANAM S, 1993, CANCER RES, V53, P4143; Quax PHA, 1998, ARTERIOSCL THROM VAS, V18, P693, DOI 10.1161/01.ATV.18.5.693; Quax PHA, 2001, CIRCULATION, V103, P562, DOI 10.1161/01.CIR.103.4.562; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; Reuning U, 1998, INT J ONCOL, V13, P893; Schmitt M, 2000, FIBRINOLYSIS PROTEOL, V14, P114, DOI 10.1054/fipr.2000.0079; Stahl A, 1997, INT J CANCER, V71, P116, DOI 10.1002/(SICI)1097-0215(19970328)71:1<116::AID-IJC19>3.3.CO;2-Z; Waltz DA, 2000, AM J RESP CELL MOL, V22, P316, DOI 10.1165/ajrcmb.22.3.3713; YAMAMOTO M, 1994, CANCER RES, V54, P5016; YAMAMOTO M, 1994, CANCER RES, V54, P3656; Zhu FX, 2001, DNA CELL BIOL, V20, P297, DOI 10.1089/104454901750232490	25	34	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 7	2002	21	51					7824	7830		10.1038/sj.onc.1205893	http://dx.doi.org/10.1038/sj.onc.1205893			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420219				2022-12-17	WOS:000178946000007
J	Ko, SC; Chapple, KS; Hawcroft, G; Coletta, PL; Markham, AF; Hull, MA				Ko, SC; Chapple, KS; Hawcroft, G; Coletta, PL; Markham, AF; Hull, MA			Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells	ONCOGENE			English	Article						adenomatous polyps; colorectal cancer; cyclooxygenase; macrophage	FAMILIAL ADENOMATOUS POLYPOSIS; NITRIC-OXIDE SYNTHASE; CELLULAR-LOCALIZATION; INCREASED EXPRESSION; TGF-BETA; IN-VITRO; CANCER; GROWTH; RECEPTOR; INHIBITOR	In human colorectal adenomas or polyps, cyclooxygenase-2 is expressed predominantly by stromal (or interstitial) macrophages. Therefore, we tested the hypothesis that macrophage cyclooxygenase-2 has paracrine pro-tumorigenic activity using in vitro models of macrophage-epithelial cell interactions. We report that macrophages can promote tumorigenic progression of intestinal epithelial cells (evidenced by decreased cell-cell contact inhibition, increased proliferation and apoptosis, gain of anchorage-independent growth capability, decreased membranous E-cadherin expression, up-regulation of cyclooxygenase-2 expression, down-regulation of transforming growth factor-beta type 11 receptor expression and resistance to the antiproliferative activity of transforming growth factor-beta(1)) in a paracrine, cyclooxygenase-2-dependent manner. Pharmacologically relevant concentrations (1-2 muM) of a selective cyclooxygenase-2 inhibitor had no detectable, direct effect on intestinal epithelial cells but inhibited the macrophage-epithelial cell signal mediating tumorigenic progression. Cyclooxygenase-2-mediated stromal-epithelial cell signalling during the early stages of intestinal tumorigenesis provides a novel target for chemoprevention of colorectal cancer (and other gastro-intestinal epithelial malignancies, which arise on a background of chronic inflammation, such as gastric cancer) and may explain the discrepancy between the concentrations of cyclooxygenase inhibitors required to produce antineoplastic effects in vitro and in vivo.	Univ Leeds, St James Univ Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Hull, MA (corresponding author), Univ Leeds, St James Univ Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England.	M.A.Hull@leeds.ac.uk	Chapple, Keith/AAL-6484-2020	Chapple, Keith/0000-0001-6523-2230				Bamba H, 1999, INT J CANCER, V83, P470, DOI 10.1002/(SICI)1097-0215(19991112)83:4<470::AID-IJC6>3.3.CO;2-6; Birchmeier C, 1996, ACTA ANAT, V156, P217; Chapple KS, 2000, AM J PATHOL, V156, P545, DOI 10.1016/S0002-9440(10)64759-1; Chulada PC, 2000, CANCER RES, V60, P4705; Cordon-Cardo C, 1999, J EXP MED, V190, P1367, DOI 10.1084/jem.190.10.1367; Coussens LM, 2001, J EXP MED, V193, pF23, DOI 10.1084/jem.193.6.F23; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Farrow DC, 1998, CANCER EPIDEM BIOMAR, V7, P97; Fu SD, 1999, GASTROENTEROLOGY, V116, P1319, DOI 10.1016/S0016-5085(99)70496-8; Fujita M, 2000, J GASTROEN HEPATOL, V15, P1277, DOI 10.1046/j.1440-1746.2000.02399.x; GAGLIARDI G, 1995, VIRCHOWS ARCH, V426, P149; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Giardiello FM, 2002, NEW ENGL J MED, V346, P1054, DOI 10.1056/NEJMoa012015; GOLDMAN R, 1979, J NATL CANCER I, V63, P1009; Hardwick JCH, 2001, ONCOGENE, V20, P819, DOI 10.1038/sj.onc.1204162; HAUPTMANN S, 1993, AM J PATHOL, V143, P1406; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Hull M, 2000, GASTROENTEROLOGY, V119, P600, DOI 10.1053/gast.2000.16156; Hull MA, 2000, CLIN EXP METASTAS, V18, P21, DOI 10.1023/A:1026553605636; Hull MA, 1999, BRIT J CANCER, V79, P1399, DOI 10.1038/sj.bjc.6690224; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; Jacoby RF, 2000, CANCER RES, V60, P5040; Khan KNM, 2001, SCAND J GASTROENTERO, V36, P865, DOI 10.1080/003655201750313405; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; MANNING AM, 1991, ONCOGENE, V6, P1471; Marx J, 2001, SCIENCE, V291, P581, DOI 10.1126/science.291.5504.581; Morris CD, 2001, AM J GASTROENTEROL, V96, P990; Muller-Decker K, 1999, INT J COLORECTAL DIS, V14, P212, DOI 10.1007/s003840050213; Mutoh M, 2002, CANCER RES, V62, P28; Nau GJ, 2002, P NATL ACAD SCI USA, V99, P1503, DOI 10.1073/pnas.022649799; O'Byrne KJ, 2001, BRIT J CANCER, V85, P473, DOI 10.1054/bjoc.2001.1943; Oshima M, 2001, CANCER RES, V61, P1733; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PARASKEVA C, 1990, ANTICANCER RES, V10, P1189; Pitot HC, 2000, ALIMENT PHARM THERAP, V14, P153, DOI 10.1046/j.1365-2036.2000.014s1153.x; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; Rosenberger CM, 2000, J IMMUNOL, V164, P5894, DOI 10.4049/jimmunol.164.11.5894; SANO H, 1995, CANCER RES, V55, P3785; Seno H, 2002, CANCER RES, V62, P506; Sharma RA, 2001, CARCINOGENESIS, V22, P1557, DOI 10.1093/carcin/22.9.1557; Shattuck-Brandt RL, 1999, MOL CARCINOGEN, V24, P177, DOI 10.1002/(SICI)1098-2744(199903)24:3<177::AID-MC4>3.0.CO;2-6; Shattuck-Brandt RL, 2000, GASTROENTEROLOGY, V118, P337, DOI 10.1016/S0016-5085(00)70216-2; Sheehan KM, 1999, JAMA-J AM MED ASSOC, V282, P1254, DOI 10.1001/jama.282.13.1254; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 1999, ONCOGENE, V18, P855, DOI 10.1038/sj.onc.1202397; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Sinicrope FA, 1996, CLIN CANCER RES, V2, P1999; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Sung JJY, 2000, AM J PATHOL, V157, P729, DOI 10.1016/S0002-9440(10)64586-5; Taketo MM, 1998, CLINICAL SIGNIFICANCE AND POTENTIAL OF SELECTIVE COX-2 INHIBITORS, P129; Takeuchi M, 2002, INT J COLORECTAL DIS, V17, P144, DOI 10.1007/s00384-001-0372-5; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Williams CS, 2000, CANCER RES, V60, P6045; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; WILLSON JKV, 1987, CANCER RES, V47, P2704; Wilson KT, 1998, CANCER RES, V58, P2929; Yang VW, 1998, CANCER RES, V58, P1750; Zhang T, 1997, CANCER RES, V57, P1638	64	34	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7175	7186		10.1038/sj.onc.1205869	http://dx.doi.org/10.1038/sj.onc.1205869			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370807				2022-12-17	WOS:000178504600005
J	Nayak, BK; Das, GM				Nayak, BK; Das, GM			Stabilization of p53 and transactivation of its target genes in response to replication blockade	ONCOGENE			English	Article						p53; transactivation; p21; replication blockade; hydroxyurea; aphidicolin	TUMOR-SUPPRESSOR PROTEIN; CELL-CYCLE; DNA-DAMAGE; ARREST; P21; TRANSCRIPTION; COACTIVATORS; CHECKPOINT; MODULATION; APOPTOSIS	Although it is clear that p53 plays a pivotal role in G1/G2 checkpoints to conserve genomic integrity, its role in S phase checkpoint is less well understood. Recently, it has been reported that p53 is transcriptionally impaired even though it is stabilized during replication blockade. However, the mechanisms underlying this phenomenon are not known. In the present study, it has been shown that p53 accumulates and transactivates its target genes such as p21, gadd45 and bax in response to replication blockade in normal and cancer cells. Lack of transcriptional activation under similar conditions in cells lacking p53 shows that p53-target gene activation during replication blockade is indeed p53-dependent. Further, transactivation of p21 in response to replication blockade by hydroxyurea and aphidicolin is similar to that in response to ionizing radiation except that the latter is more immediate compared to the response to replication blockade. These findings suggest that impairment of transcriptionally active p53 in response to replication blockade is not a general phenomenon.	Univ Texas, Hlth Sci Ctr, Dept Surg, Mol Oncol Res Program, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Das, GM (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.		Das, Gokul M/A-5772-2013	Das, Gokul M/0000-0003-2937-8093	NCI NIH HHS [R01 CA079911] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079911] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 2000, GENE DEV, V14, P1584; Chaudhry MA, 2002, ONCOGENE, V21, P1934, DOI 10.1038/sj.onc.1205264; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Ji C, 1997, ONCOGENE, V15, P2749, DOI 10.1038/sj.onc.1201441; Karuppayil SM, 1998, J BIOL CHEM, V273, P17303, DOI 10.1074/jbc.273.28.17303; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Scolnick DM, 1997, CANCER RES, V57, P3693; Takimoto R, 2001, P NATL ACAD SCI USA, V98, P781, DOI 10.1073/pnas.98.3.781; Taylor WR, 1999, ONCOGENE, V18, P283, DOI 10.1038/sj.onc.1202516; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	29	34	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7226	7229		10.1038/sj.onc.1205889	http://dx.doi.org/10.1038/sj.onc.1205889			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370812				2022-12-17	WOS:000178504600010
J	Vorburger, SA; Pataer, A; Yoshida, K; Barber, GN; Xia, WY; Chiao, P; Ellis, LM; Hung, MC; Swisher, SG; Hunt, KK				Vorburger, SA; Pataer, A; Yoshida, K; Barber, GN; Xia, WY; Chiao, P; Ellis, LM; Hung, MC; Swisher, SG; Hunt, KK			Role for the double-stranded RNA activated protein kinase PKR in E2F-1-induced apoptosis	ONCOGENE			English	Article						E2F-1; PKR; apoptosis; gene therapy; adenovirus	NF-KAPPA-B; TRANSCRIPTION FACTOR E2F-1; TUMOR-SUPPRESSOR P53; DNA-BINDING; CELLULAR ACTIVATOR; C-MYC; GENE; EXPRESSION; INDUCTION; INITIATION	The transcription factor E2F-1 induces cell cycle progression at the G1/S checkpoint, and deregulation of E2F-1 provokes apoptosis in a wide variety of malignant cells. To date only p14(ARF) and p73, a p53 homologue, have been identified as E2F-1-inducible genes capable of mediating an apoptotic response. Here we show that adenovirus-mediated E2F-1 overexpression in cancer cells induces expression and autophosphorylation of the double-stranded RNA-dependent protein kinase PKR leading to phosphorylation of its downstream target, the alpha-subunit of the eukaryotic translation initiation factor 2 (eIF-2alpha) and to apoptotic cell death. This PKR-dependent apoptosis occurs in cell lines with mutated p53 and in cell lines with mutated p53 and p73, and is significantly reduced by the chemical inhibition of PKR activation. Further, PKR-/- mouse embryo fibroblasts, but not PKR+/+ mouse embryo fibroblasits, demonstrate significant resistance to E2F-1-induced apoptosis. We conclude that an important pathway of E2F-1-mediated apoptosis is dependent on PKR activation and does not require p53 or p73.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Jikei Univ, Dept Surg, Sch Med, Tokyo 105, Japan; Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Jikei University; University of Miami	Hunt, KK (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd,Box 444, Houston, TX 77030 USA.	khunt@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Aktas H, 1998, P NATL ACAD SCI USA, V95, P8280, DOI 10.1073/pnas.95.14.8280; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blair LA, 2001, DIABETES, V50, P283, DOI 10.2337/diabetes.50.2.283; Carpick BW, 1997, J BIOL CHEM, V272, P9510, DOI 10.1074/jbc.272.14.9510; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; Gil J, 2001, ONCOGENE, V20, P385, DOI 10.1038/sj.onc.1204109; GUSELLA GL, 1995, J IMMUNOL, V154, P345; HAINES GK, 1993, ARCH OTOLARYNGOL, V119, P1142; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hunt KK, 1997, CANCER RES, V57, P4722; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishii T, 2001, ONCOGENE, V20, P1900, DOI 10.1038/sj.onc.1204267; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; KATZE MG, 1992, J INTERFERON RES, V12, P241, DOI 10.1089/jir.1992.12.241; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Lieber A, 1996, J VIROL, V70, P8944, DOI 10.1128/JVI.70.12.8944-8960.1996; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; MUNDSCHAU LJ, 1995, J BIOL CHEM, V270, P3100, DOI 10.1074/jbc.270.7.3100; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; Patel RC, 1998, MOL CELL BIOL, V18, P7009, DOI 10.1128/MCB.18.12.7009; Patel RC, 1999, J BIOL CHEM, V274, P20432, DOI 10.1074/jbc.274.29.20432; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; RICE AP, 1985, J VIROL, V54, P894, DOI 10.1128/JVI.54.3.894-898.1985; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SAMUEL CE, 1992, PHARMACOL THERAPEUT, V54, P307, DOI 10.1016/0163-7258(92)90005-K; Savinova O, 1999, INT J BIOCHEM CELL B, V31, P175, DOI 10.1016/S1357-2725(98)00140-X; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; Tanaka H, 2000, GENE, V246, P373, DOI 10.1016/S0378-1119(00)00080-9; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; Wong AHT, 2001, J BIOL CHEM, V276, P13727, DOI 10.1074/jbc.M011240200; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198; Yoshikawa H, 1999, ONCOGENE, V18, P3415, DOI 10.1038/sj.onc.1202677; Zamanian-Daryoush M, 1999, ONCOGENE, V18, P315, DOI 10.1038/sj.onc.1202293; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	58	34	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2002	21	41					6278	6288		10.1038/sj.onc.1205761	http://dx.doi.org/10.1038/sj.onc.1205761			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214268				2022-12-17	WOS:000177829000004
J	Sekine, S; Shibata, T; Sakamoto, M; Hirohashi, S				Sekine, S; Shibata, T; Sakamoto, M; Hirohashi, S			Target disruption of the mutant beta-catenin gene in colon cancer cell line HCT116: preservation of its malignant phenotype	ONCOGENE			English	Article						colorectal carcinoma; beta-catenin; mutation; gene targeting; TCF/LEF-dependent transcription	COLORECTAL-CANCER; METALLOPROTEINASE MATRILYSIN; INTESTINAL POLYPOSIS; GROWTH; TRANSACTIVATION; SUPPRESSION; PATHWAY; TUMORIGENESIS; EXPRESSION; MUTATIONS	Most colorectal carcinomas harbor genetic alterations that result in stabilization of beta-catenin. A colorectal carcinoma cell line, HCT116, which has both mutated and wild-type beta-catenin genes, was engineered by homologous recombination to investigate the significance of beta-catenin gene mutation. As expected, the mutant allele-targeted clones showed decreased beta-catenin expression and down-regulation of T-cell factor (TCF)/lymphoid enhancer factor (LEF)-dependent transcription. Morphologically, targeted clones were only minimally altered under usual culture conditions, but under low serum conditions, mutant allele-targeted clones still grew in plane, in contrast to parental cell line and wild allele-targeted clones, which formed spheroids. The mutant allele-targeted clones showed no significant changes in growth rate and anchorage-independent growth in vitro, and displayed rather increased growth in vivo. Although beta-catenin stabilization affects some biological characteristics including adhesive properties, it may not have growth-promoting effects at least in some colorectal carcinomas.	Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo, Japan	National Cancer Center - Japan	Hirohashi, S (corresponding author), Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, 5-1-1 Tsukiji, Tokyo, Japan.		Sakamoto, Michiie/N-2917-2015					Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Mariadason JM, 2001, CANCER RES, V61, P3465; Nagasawa Y, 1999, CANCER RES, V59, P3539; Naishiro Y, 2001, CANCER RES, V61, P2751; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Polakis P, 2000, GENE DEV, V14, P1837; Roh H, 2001, CANCER RES, V61, P6563; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sedivy JM, 1999, TRENDS GENET, V15, P88, DOI 10.1016/S0168-9525(98)01689-8; Sekine S, 2002, VIRCHOWS ARCH, V440, P381, DOI 10.1007/s004280100527; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shih IM, 2001, CANCER RES, V61, P818; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Sparks AB, 1998, CANCER RES, V58, P1130; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wagenaar RA, 2001, CANCER RES, V61, P2097; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Yamada T, 2000, CANCER RES, V60, P4761	22	34	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5906	5911		10.1038/sj.onc.1205756	http://dx.doi.org/10.1038/sj.onc.1205756			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185590	Green Submitted			2022-12-17	WOS:000177520900010
J	Xie, YT; Skytting, B; Nilsson, G; Grimer, RJ; Mangham, CD; Fisher, C; Shipley, J; Bjerkehagen, B; Myklebost, O; Larsson, O				Xie, YT; Skytting, B; Nilsson, G; Grimer, RJ; Mangham, CD; Fisher, C; Shipley, J; Bjerkehagen, B; Myklebost, O; Larsson, O			The SYT-SSX1 fusion type of synovial sarcoma is associated with increased expression of cyclin A and D1. A link between t(X;18)(p11. 2; q11.2) and the cell cycle machinery	ONCOGENE			English	Article						cyclin A; cyclin D1; SYT-SSX; synovial sarcoma	SYT; SSX; CANCER; OVEREXPRESSION; PROLIFERATION; TRANSLOCATION; PROGNOSIS; PROTEINS; GENES	A recent large multi-centre study convincingly confirmed previous observations that the SYT-SSX1 fusion type, compared to SYT-SSX2, of synovial sarcoma is associated with a worse clinical outcome. Apart from the clinical impact, this fact also suggests (1) that the SYT-SSX fusion gene may influence molecular mechanisms involved in tumour growth and progression; and (2) that the SYT-SSX1 fusion type has a stronger influence on these mechanisms than SYT-SSX2. The nature of the underlying mechanisms is, however, still unknown. In this study we made use of the SYT-SSX1 vs SYT-SSX2 concept to investigate whether major, tumour relevant, and growth regulatory proteins (e.g. cyclins and cyclin-dependent kinases) may be involved. Using Western blotting analysis on 74 fresh, fusion variant-typed, tumour samples from localized synovial sarcoma, we found a significant correlation between SYT-SSX1 and high expression of cyclin A (P=0.003) and D1 (P=0.025). Our data suggest that SYT-SSX may influence the cell cycle machinery, and that the more aggressive phenotype of the SYT-SSX1 variant is due to an accelerated tumour cell proliferation.	Karolinska Hosp, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Wuhan Univ, Zhongnan Hosp, Dept Oncol, Wuhan 430072, Peoples R China; Karolinska Hosp, Dept Orthoped, Stockholm, Sweden; Stockholm Soder Hosp, Dept Orthoped, Stockholm, Sweden; Royal Orthopaed Hosp, Birmingham B31 2AP, W Midlands, England; Royal Marsden NHS Trust, Dept Pathol, London, England; Canc Res Inst, Mol Cytogenet Team, Sutton, Surrey, England; Norwegian Radium Hosp, Dept Pathol, Canc Res Inst, Oslo, Norway; Norwegian Radium Hosp, Dept Tumor Biol, Canc Res Inst, Oslo, Norway	Karolinska Institutet; Karolinska University Hospital; Wuhan University; Karolinska Institutet; Karolinska University Hospital; Royal Orthopaedic Hospital; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Oslo; University of Oslo	Larsson, O (corresponding author), Karolinska Hosp, Dept Pathol & Oncol, CCK R8-04, SE-17176 Stockholm, Sweden.	olle.larsson@onkpat.ki.se	Myklebost, Ola/E-9335-2010	Myklebost, Ola/0000-0002-2866-3223; Shipley, Janet/0000-0001-6748-8678				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bukholm IRK, 2001, INT J CANCER, V93, P283, DOI 10.1002/ijc.1311; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Handa K, 1999, INT J CANCER, V84, P225, DOI 10.1002/(SICI)1097-0215(19990621)84:3<225::AID-IJC5>3.0.CO;2-A; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Huuhtanen RL, 1999, CANCER RES, V59, P2885; Inagaki H, 2000, MODERN PATHOL, V13, P482, DOI 10.1038/modpathol.3880083; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Kim SH, 1998, CLIN CANCER RES, V4, P2377; Ladanyi M, 2002, CANCER RES, V62, P135; Ladanyi M, 2001, ONCOGENE, V20, P5755, DOI 10.1038/sj.onc.1204601; Mancuso T, 2000, LAB INVEST, V80, P805, DOI 10.1038/labinvest.3780085; Mishina T, 2000, CLIN CANCER RES, V6, P11; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nilsson G, 1999, CANCER RES, V59, P3180; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Shamma A, 1998, INT J ONCOL, V13, P455; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; XIE Y, 2002, IN PRESS CANC RES, V62	27	34	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5791	5796		10.1038/sj.onc.1205700	http://dx.doi.org/10.1038/sj.onc.1205700			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173050				2022-12-17	WOS:000177463400015
J	Schneider, E; Kartarius, S; Schuster, N; Montenarh, M				Schneider, E; Kartarius, S; Schuster, N; Montenarh, M			The cyclin H/cdk7/Mat1 kinase activity is regulated by CK2 phosphorylation of cyclin H	ONCOGENE			English	Article						protein kinase CK-2; cyclin dependent kinases; phosphorylation regulation	CDK-ACTIVATING KINASE; RING FINGER PROTEIN; TRANSCRIPTION FACTOR; IN-VITRO; P53; TFIIH; CAK; COMPLEX; SUBUNIT; MAT1	Cyclin dependent kinases are regulated by phosphorylation and dephosphorylation of the catalytic cdk subunits, by assembly with specific cyclins and by specific inhibitor molecules. Recently, it turned out that cyclins are also phosphoproteins, which means that they are also potential targets for a regulation by phosphorylation and dephosphorylation. Here, we show that cyclin H was phosphorylated by protein kinase CK2. Like most other CK2 substrates cyclin H was much better phosphorylated by the CK2 holoenzyme than by the alpha-subunit alone. By using point mutants derived from the cyclin H sequence we mapped the CK2 phosphorylation site at threonine 315 at the C-terminal end of cyclin H. Phosphorylation at this position had no influence on the assembly of the cyclin H/cdk7/Mat1 complex. However, phosphorylation at amino acid 315 of cyclin H turned out to be critical for a full cyclin H/cdk7/Mat1 kinase activity when the CTD peptide of RNA polymerase II or cdk2 was used as a substrate.	Univ Saarland, D-66424 Homburg, Germany	Saarland University	Montenarh, M (corresponding author), Univ Saarland, Bldg 44, D-66424 Homburg, Germany.		Montenarh, Mathias/AAB-6689-2020					Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; ANGIOLILLO A, 1993, MOL CELL BIOCHEM, V125, P65, DOI 10.1007/BF00926836; APPEL K, 1995, ONCOGENE, V11, P1971; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Gotz C, 1996, ONCOGENE, V13, P391; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; LABBE JC, 1994, EMBO J, V13, P5155, DOI 10.1002/j.1460-2075.1994.tb06845.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MARIN O, 1994, BIOCHEM BIOPH RES CO, V198, P898, DOI 10.1006/bbrc.1994.1128; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; Schneider E, 1998, ONCOGENE, V17, P2733, DOI 10.1038/sj.onc.1202504; Schuster N, 2001, J CELL BIOCHEM, V81, P172, DOI 10.1002/1097-4644(20010401)81:1<172::AID-JCB1033>3.0.CO;2-O; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x	30	34	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5031	5037		10.1038/sj.onc.1205690	http://dx.doi.org/10.1038/sj.onc.1205690			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140753				2022-12-17	WOS:000176975900001
J	Yang, K; Lui, WO; Xie, YT; Zhang, AJ; Skytting, B; Mandahl, N; Larsson, C; Larsson, O				Yang, K; Lui, WO; Xie, YT; Zhang, AJ; Skytting, B; Mandahl, N; Larsson, C; Larsson, O			Co-existence of SYT-SSX1 and SYT-SSX2 fusions in synovial sarcomas	ONCOGENE			English	Article						synovial sarcoma; SYT-SSX; double fusion; double translocation	SYT; GENES; SSX; TRANSLOCATION; IDENTIFICATION; TRANSCRIPT; PROTEINS; VARIANT; TUMORS	The chromosomal translocation t(X;18)(p11.2;q11.2) is tightly linked to the tumorigenesis of synovial sarcoma. Through this translation the SYT gene on chromosome 18 is fused with a testis/cancer antigen gene on the X chromosome, generating either a SYT-SSX1, SYT-SSX2, or less often a SYT-SSX4 fusion gene. It has been anticipated that the individual synovial sarcoma carries only one of these variants, however, in this study we demonstrated that SYT-SSX1 and SYT-SSX2 coexist in a significant proportion of the cases. From 121 SYT-SSX positive primary tumors, co-expression of SYT-SSX1 and SYT-SSX2 was seen in 12 cases (10%), which were characterized in further detail both at the RNA, DNA and chromosomal level. In all 12 cases the SYT-SSX1 and SYT-SSX2 fusions resulted in identical SYT-SSX fusion transcripts. However, at the genomic level the translocations were different, and most likely occurred between variable intronic sites in the target genes. By interphase FISH analyses of 10 cases SYT-SSX2 translocations were found to be the most abundant in all but one of the cases, in which SYT-SSX1 was predominating. The findings reveal a new heterogenous feature of synovial sarcoma, accounting for approximately 10% of all cases, which may shed light on the molecular genetic mechanisms behind translocations in general, and on the etiology of synovial sarcoma in particular.	Karolinska Hosp, CCK R804, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Karolinska Hosp, CCK L801, Dept Mol Med, SE-17176 Stockholm, Sweden; Karolinska Inst, Stockholm Soder Hosp, SE-11883 Stockholm, Sweden; Univ Lund Hosp, Dept Clin Genet, SE-22185 Lund, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Lund University; Skane University Hospital	Larsson, C (corresponding author), Karolinska Hosp, CCK R804, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden.	Catharina.Larsson@cmm.ki.se	Lui, Weng-Onn/X-5957-2019; Lui, Weng-Onn/G-6703-2013	Lui, Weng-Onn/0000-0003-4717-4473; Lui, Weng-Onn/0000-0003-4717-4473				Aman P, 1999, SEMIN CANCER BIOL, V9, P303, DOI 10.1006/scbi.1999.0130; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Brodin B, 2001, GENE, V268, P173, DOI 10.1016/S0378-1119(01)00412-7; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; FLIGMAN I, 1995, AM J PATHOL, V147, P1592; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Kovalchuk AL, 1997, ONCOGENE, V15, P2369, DOI 10.1038/sj.onc.1201409; Ladanyi M, 2000, HUM PATHOL, V31, P532, DOI 10.1053/hp.2000.6706; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nilsson G, 1999, CANCER RES, V59, P3180; O'Dwyer ME, 2000, CURR OPIN ONCOL, V12, P594, DOI 10.1097/00001622-200011000-00013; Panagopoulos I, 2001, GENE CHROMOSOME CANC, V31, P362, DOI 10.1002/gcc.1155; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Sreekantaiah C, 1998, CYTOGENET CELL GENET, V82, P13, DOI 10.1159/000015056; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981	21	34	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2002	21	26					4181	4190		10.1038/sj.onc.1205569	http://dx.doi.org/10.1038/sj.onc.1205569			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037676				2022-12-17	WOS:000176186000014
J	Fleischer, A; Ayllon, V; Dumoutier, L; Renauld, JC; Rebollo, A				Fleischer, A; Ayllon, V; Dumoutier, L; Renauld, JC; Rebollo, A			Proapoptotic activity of ITM2B(s), a BH3-only protein induced upon IL-2-deprivation which interacts with Bcl-2	ONCOGENE			English	Article						apoptosis; BH3; ITM2B(s)	CELL-DEATH; CYTOCHROME-C; BH3 DOMAIN; APOPTOSIS; FAMILY; EXPRESSION; SURVIVAL; MITOCHONDRIA; BAD; PHOSPHORYLATION	Growth factor deprivation is a physiological mechanism to induce apoptosis. We used an IL-2-dependent murine T cell line to identify proteins that trigger apoptosis. Here we report the identification, the cloning and characterization of ITM2B(s), a protein induced upon IL-2-deprivation. ITM2B(s), which shares the BH3 domain of Bcl-2 family members, is a cytoplasmic and mitochondrial protein. Expression of ITM2B, induces apoptosis in IL-2-stimulated cells, but not in IL-4-stimulated cells, while overexpression of the long form of the protein is not able to induce apoptosis. In IL-2-stimulated cells, ITM2B(s) interacts with the antiapoptotic protein Bcl-2, and does not interact with the proapoptotic Bad. Mutation of the critical L and D residues within the BH3 domain abolished the ability of ITMBs, to promote apoptosis.	Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; Ludwig Inst Canc Res, Brussels Branch, Brussels, Belgium; Univ Catholique Louvain, Expt Med Unit, Christian de Duve Inst Cellular Pathol, B-1200 Brussels, Belgium	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Ludwig Institute for Cancer Research; Universite Catholique Louvain	Rebollo, A (corresponding author), Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.		Rebollo, Angelita/P-2118-2017; Ayllon, Veronica/L-7069-2014; Fleischer, Aarne/ABE-6966-2020; Renauld, Jean-Christophe/B-7268-2012	Ayllon, Veronica/0000-0002-7322-9282; Fleischer, Aarne/0000-0003-4146-3303; Renauld, Jean-Christophe/0000-0003-1736-2131; Dumoutier, Laure/0000-0002-6645-684X; Rebollo, Angelita/0000-0002-1293-9686				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Cerezo A, 1998, MOL BIOL CELL, V9, P3107, DOI 10.1091/mbc.9.11.3107; Cerezo A, 1999, CELL DEATH DIFFER, V6, P87, DOI 10.1038/sj.cdd.4400458; CHINTTENDEN T, 1995, NATURE, V374, P733; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Deleersnijder W, 1996, J BIOL CHEM, V271, P19475, DOI 10.1074/jbc.271.32.19475; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Ghosh A, 2001, J BIOL CHEM, V276, P25447, DOI 10.1074/jbc.M100496200; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han J, 1996, MOL CELL BIOL, V16, P5857; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; Lutz RJ, 2000, BIOCHEM SOC T, V28, P51, DOI 10.1042/bst0280051; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; PITTON C, 1993, CYTOKINE, V5, P362, DOI 10.1016/1043-4666(93)90069-H; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wei MC, 2000, GENE DEV, V14, P2060; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	29	34	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3181	3189		10.1038/sj.onc.1205464	http://dx.doi.org/10.1038/sj.onc.1205464			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082633				2022-12-17	WOS:000175373600009
J	Fest, T; Mougey, V; Dalstein, V; Hagerty, M; Milette, D; Silva, S; Mai, S				Fest, T; Mougey, V; Dalstein, V; Hagerty, M; Milette, D; Silva, S; Mai, S			c-MYC overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosis	ONCOGENE			English	Article						c-Myc; dihydrofolate reductase; genomic instability; polyploidy; apoptosis	GENE AMPLIFICATION; P53 MUTATIONS; CYCLE ARREST; TRANSFORMATION; TUMORIGENESIS; CHECKPOINT; LYMPHOMA; EXPRESSION; REDUCTASE; COOPERATE	Overexpression of c-Myc in tumors is usually associated with cell proliferation and increased susceptibility to apoptosis. Concomitantly, c-Myc contributes to tumorigenesis by its ability to destabilize the cellular genome. Here, we examined whether c-Myc induces genomic instability and apoptosis in c-Myc-activated cells. Wildtype Myc (wt-Myc) and two mutated Myc myc box II proteins (mt-Myc) were overexpressed in IL3-dependent murine Ba/F3 cells. As expected, wt-Myc triggered apoptosis in absence of IL3. Standard karyotyping, spectral karyotyping, and fluorescent in situ hybridization (FISH) were performed before and after c-Myc activation. Structural and numerical genomic instability was detected 48 h after wt-Myc activation and included gene amplification, the formation of extrachromosomal elements (EEs), chromosome breakage, deletions, increased aneuploidy, and polyploidization. Interestingly, some cells simultaneously displayed genomic instability and apoptosis. Both wt- and mt-Myc proteins were equally potent promoters of genomic instability. However, only wt-Myc simultaneously induced genomic instability and apoptosis. Mt-Myc proteins failed to induce apoptosis, thereby generating a strong imbalance towards the survival of genomically unstable cells.	CancerCare Manitoba Univ Manitoba, Manitoba Inst Cell Biol, Genom Ctr Canc Res & Diag, Winnipeg, MB R3E 0V9, Canada; Inst Etud & Transfert Genes, F-25030 Besancon, France; Karolinska Inst, Microbiol & Tumorbiol Ctr, Stockholm, Sweden	CancerCare Manitoba Foundation; Karolinska Institutet	Mai, S (corresponding author), CancerCare Manitoba Univ Manitoba, Manitoba Inst Cell Biol, Genom Ctr Canc Res & Diag, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.		Mai, Sabine/E-5667-2017; DALSTEIN, Véronique/P-5250-2016	Mai, Sabine/0000-0002-5797-2201; fest, thierry/0000-0002-6437-4189				ASKEW DS, 1991, ONCOGENE, V6, P1915; BHATIA KG, 1992, CANCER RES, V52, P4273; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; CHENG KC, 1993, ADV CANCER RES, V60, P121; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; *COMM STAND GEN NO, 1969, MOUSE NEWS LETT, V17, P481; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1993, CELL, V65, P113; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Kuschak TI, 1999, GENE, V238, P351, DOI 10.1016/S0378-1119(99)00341-8; Kuttler F, 2001, ONCOGENE, V20, P6084, DOI 10.1038/sj.onc.1204827; Li Q, 1999, MOL CELL BIOL, V19, P5339; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MAI S, 1994, GENE, V148, P253, DOI 10.1016/0378-1119(94)90696-3; Mai S, 1996, ONCOGENE, V12, P277; Mai S, 1996, CHROMOSOME RES, V4, P365, DOI 10.1007/BF02257272; Mai Sabine, 1999, Neoplasia (New York), V1, P241, DOI 10.1038/sj.neo.7900030; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; ORMEROD MG, 1990, PRACTICAL APPROACH, P69; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; WANG HC, 1971, NATURE, V235, P52; WIENER F, 2000, TECHNICAL TIPS ONLIN, V1, P8; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410	31	34	35	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 2	2002	21	19					2981	2990		10.1038/sj/onc/1205274	http://dx.doi.org/10.1038/sj/onc/1205274			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082528				2022-12-17	WOS:000175262700005
J	Wong, JC; Lee, SB; Bell, MD; Reynolds, PA; Fiore, E; Stamenkovic, I; Truong, V; Oliner, JD; Gerald, WL; Haber, DA				Wong, JC; Lee, SB; Bell, MD; Reynolds, PA; Fiore, E; Stamenkovic, I; Truong, V; Oliner, JD; Gerald, WL; Haber, DA			Induction of the interleukin-2/15 receptor beta-chain by the EWS-WT1 translocation product	ONCOGENE			English	Article						EWS-WT1; desmoplastic small round cell tumor; Wilms tumor; interleukin-2/15 receptor; microarrays; tumor-stromal interaction	TUMOR-SUPPRESSOR GENE; ROUND-CELL TUMOR; WILMS-TUMOR; IL-2 RECEPTOR; ALPHA-CHAIN; TRANSCRIPTIONAL ACTIVATOR; DNA-BINDING; EXPRESSION; FUSION; PROMOTER	EWS - WT1 is a chimeric transcription factor resulting from fusion of the N-terminal domain of the Ewing sarcoma gene EWS to the three C-terminal zinc fingers of the Wilms tumor suppressor WT1. This translocation underlies desmoplastic small round cell tumor (DSRCT), which is noted for the abundance of reactive stroma surrounding islets of tumor cells, suggestive of paracrine signals contributing to tumor cell proliferation. Hybridization to high-density oligonucleotide microarrays can be used to identify targets of EWS - WT1. Expression of EWS - WT1 from a tetracycline-regulated promoter leads to the induction of growth-associated genes, of which the most remarkable is the beta-chain of the interleukin-2/15 receptor (IL-2/15Rbeta). Potent transcriptional activation by the chimeric protein maps to two bindings sites within the IL-2/15Rbeta promoter. Analysis of primary DSRCT tumor specimens demonstrates high levels of IL-2/15Rbeta within the tumor cells, along with expression of IL-2 and IL-15 by the abundant hyperplastic endothelial cells within the reactive stroma. Activation of this cytokine signaling pathway is consistent with the nuclear localization of its downstream effectors, phosphorylated STAT3 and STAT5. These observations suggest that the transcriptional induction of a cytokine receptor by a tumor-associated translocation product enables a proliferative response of epithelial cancer cells to ligands secreted by the surrounding stroma.	Massachusetts Gen Hosp, Canc Ctr CNY 7, Mol Genet Lab, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA; Affymetrix, Santa Clara, CA 95051 USA	Harvard University; Massachusetts General Hospital; Harvard University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Harvard University; Massachusetts General Hospital; Affymetrix	Haber, DA (corresponding author), Massachusetts Gen Hosp, Canc Ctr CNY 7, Mol Genet Lab, Bldg 149,13th St, Charlestown, MA 02129 USA.	Haber@helix.mgh.harvard.edu		Reynolds, Paul/0000-0001-8738-1245; Lee, Sean/0000-0001-6211-3498; Wong, Jenise C./0000-0003-0573-6650	NATIONAL CANCER INSTITUTE [R01CA058596, R37CA058596, R01CA068273] Funding Source: NIH RePORTER; NCI NIH HHS [CA68273, CA58596] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; Azzarone B, 1996, EUR CYTOKINE NETW, V7, P27; Barzegar C, 1998, ONCOGENE, V16, P2503, DOI 10.1038/sj.onc.1201775; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; De Giovanni C, 1998, BRIT J CANCER, V78, P1541, DOI 10.1038/bjc.1998.721; Dobbeling U, 1998, BLOOD, V92, P252, DOI 10.1182/blood.V92.1.252.413k08_252_258; Doucet C, 1997, MELANOMA RES, V7, pS7; Dubois S, 1999, J BIOL CHEM, V274, P26978, DOI 10.1074/jbc.274.38.26978; Fehniger TA, 2001, BLOOD, V97, P14, DOI 10.1182/blood.V97.1.14; Frank DA, 1999, MOL MED, V5, P432; GERALD WL, 1991, AM J SURG PATHOL, V15, P499, DOI 10.1097/00000478-199106000-00001; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hjorth-Hansen H, 1999, BRIT J HAEMATOL, V106, P28, DOI 10.1046/j.1365-2141.1999.01510.x; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Karnieli E, 1996, J BIOL CHEM, V271, P19304, DOI 10.1074/jbc.271.32.19304; Kim J, 1998, ONCOGENE, V16, P1021, DOI 10.1038/sj.onc.1201616; Kim J, 1998, ONCOGENE, V16, P1973, DOI 10.1038/sj.onc.1201716; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LADANYI M, 1994, CANCER RES, V54, P2837; Lee SB, 1997, NAT GENET, V17, P309, DOI 10.1038/ng1197-309; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; Lin JX, 1997, MOL CELL BIOL, V17, P3714, DOI 10.1128/MCB.17.7.3714; LIN WC, 1995, J IMMUNOL, V155, P4805; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Miller MJ, 1996, J BIOL CHEM, V271, P23345; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.iy.11.040193.001333; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; Pileri SA, 1997, J PATHOL, V183, P116; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Suminami Y, 1998, ONCOGENE, V16, P1309, DOI 10.1038/sj.onc.1201640; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Tinhofer I, 2000, BLOOD, V95, P610, DOI 10.1182/blood.V95.2.610; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; Wernert N, 1997, VIRCHOWS ARCH, V430, P433, DOI 10.1007/s004280050053; Yamada Y, 1998, BLOOD, V91, P4265, DOI 10.1182/blood.V91.11.4265.411k06_4265_4272; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225	51	34	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2009	2019		10.1038/sj.onc.1205262	http://dx.doi.org/10.1038/sj.onc.1205262			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960373				2022-12-17	WOS:000174827000007
J	Ekman, S; Kallin, A; Engstrom, U; Heldin, CH; Ronnstrand, L				Ekman, S; Kallin, A; Engstrom, U; Heldin, CH; Ronnstrand, L			SHP-2 is involved in heterodimer specific loss of phosphorylation of Tyr771 in the PDGF beta-receptor	ONCOGENE			English	Article						platelet-derived growth factor; receptor tyrosine kinase; SHP-2; heterodimer; dephosphorylation	FACTOR-ALPHA-RECEPTOR; PHOSPHOLIPASE-C-GAMMA; PHOSPHOTYROSINE PHOSPHATASE; AUTOPHOSPHORYLATION SITES; SIGNAL-TRANSDUCTION; TYROSINE KINASE; DNA-SYNTHESIS; CDNA CLONING; GROWTH; IDENTIFICATION	We have previously shown that the binding site for GTPase activating protein of Ras (RasGAP) in the PDGF beta-receptor, Tyr771, is phosphorylated to a much lower extent in the heterodimeric configuration of PDGF alpha- and beta-receptors, compared to the PDGF beta-receptor homodimer. The decreased recruitment of the RasGAP to the receptor leads to prolonged activation of the Ras/MAP kinase pathway, which could explain the increase in mitogenicity seen upon induction of heterodimers. The molecular mechanism underlying these differences was investigated. We could show that the loss of phosphorylation of Tyr771 was dependent on presence of intact binding sites for the protein tyrosine phosphatase SHP-2 on the PDGF beta-receptor. Thus, in PDGF receptor mutants in which binding of SHP-2 was lost, a higher degree of phosphorylation of Tyr771 was seen, while other phosphorylation sites in the receptor remained virtually unaffected. Thus, SHP-2 appears to play an important role in modulating phosphorylation of Y771, thereby controlling RasGAP recruitment and Ras/MAP kinase signaling in the heterodimeric configuration of the PDGF receptors.	Ludwig Inst Canc Res, Ctr Biomed, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Ronnstrand, L (corresponding author), Ludwig Inst Canc Res, Ctr Biomed, Box 595, S-75124 Uppsala, Sweden.		Ronnstrand, Lars/A-2429-2011; Ekman, Simon/AAB-9387-2021	Ronnstrand, Lars/0000-0003-1275-5809; 				ANDREWS DM, 1991, INT J PEPT PROT RES, V38, P469; BAZENET CE, 1994, ONCOGENE, V9, P517; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Ekman S, 1999, ONCOGENE, V18, P2481, DOI 10.1038/sj.onc.1202606; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Pawson T, 2000, GENE DEV, V14, P1027; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Ronnstrand L, 1999, ONCOGENE, V18, P3696, DOI 10.1038/sj.onc.1202705; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; RUPP E, 1994, EUR J BIOCHEM, V225, P29, DOI 10.1111/j.1432-1033.1994.00029.x; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; XIAO S, 1994, J BIOL CHEM, V269, P21244; Yokote K, 1996, J BIOL CHEM, V271, P5101; Yokote K, 1998, ONCOGENE, V16, P1229, DOI 10.1038/sj.onc.1201641	29	34	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1870	1875		10.1038/sj.onc.1205210	http://dx.doi.org/10.1038/sj.onc.1205210			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896619				2022-12-17	WOS:000174284500009
J	Shamay, M; Agami, R; Shaul, Y				Shamay, M; Agami, R; Shaul, Y			HBV integrants of hepatocellular carcinoma cell lines contain an active enhancer	ONCOGENE			English	Article						HBV enhancer; in vivo footprinting; onco-DNA; fetoprotein transcription factor (FTF)	HEPATITIS-B-VIRUS; COMPARATIVE GENOMIC HYBRIDIZATION; TRANSCRIPTION FACTORS; NUCLEAR RECEPTOR; GENE PROMOTER; ACTIVATION; SEQUENCES; DNA; ELEMENT; ABERRATIONS	Hepatitis B virus (HBV) infection is a major risk factor worldwide for the development of hepatocellular carcinoma (HCC). Integrated HBV DNA fragments, often highly rearranged, are frequently detected in HCC. In woodchuck, the viral enhancer plays a central role in hepatocarcinogenesis, but in humans the mechanism of HBV oncogenesis has not been established. In this study we investigated the status of the viral enhancer in two human HCC cell lines, Hep3B and PLC/PRF/5 each containing one or more integrated HBV DNA fragments. Active enhancer was defined by virtue of its protein occupancy as determined by genomic in vivo DMS footprinting. In PLC/ PRF/5 cells, the HBV DNA was integrated in a cellular gene at chromosome 11q13, at a locus reported to be amplified in many tumors. We show here that in both cell lines, the integrated HBV DNA fragments contain an active enhancer-I. In particular, the occupation of the two previously defined basic enhancer elements, E and EP, was prominent. While in both cell lines the same protein binds to the EP elements, the E element, however, is occupied in a cell-line specific manner. In PLC/PRF/5 but not Hep3B, the prominent binding of an undefined protein was detected. Our data suggest that this protein is likely to be the fetoprotein transcription factor (FTF). The finding that enhancer sequences are conserved and functional in different cell lines suggests a selection pressure for their long-term maintenance. We therefore propose that the HBV enhancer-I might play a role in hepatocellular carcinogenesis.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shaul, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.		agami, reuven/GOG-8289-2022	Agami, Reuven/0000-0002-2848-2473				BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; BERGER I, 1987, J VIROL, V61, P1180, DOI 10.1128/JVI.61.4.1180-1186.1987; Blake M, 1996, J VIROL, V70, P6060, DOI 10.1128/JVI.70.9.6060-6066.1996; Bossard P, 1997, METHODS, V11, P180, DOI 10.1006/meth.1996.0404; BULLA GA, 1988, J VIROL, V62, P1437, DOI 10.1128/JVI.62.4.1437-1441.1988; Butel JS, 1996, TRENDS MICROBIOL, V4, P119, DOI 10.1016/0966-842X(96)81529-0; Chami M, 2000, ONCOGENE, V19, P2877, DOI 10.1038/sj.onc.1203605; CHANG HK, 1987, NUCLEIC ACIDS RES, V15, P2261, DOI 10.1093/nar/15.5.2261; CHEN JY, 1994, INTERVIROLOGY, V37, P41, DOI 10.1159/000150355; Datta S, 2000, J VIROL, V74, P8277, DOI 10.1128/JVI.74.18.8277-8285.2000; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P4427, DOI 10.1128/MCB.10.8.4427; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P3682; Doitsh G, 1999, ONCOGENE, V18, P7506, DOI 10.1038/sj.onc.1203209; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; FAKTOR O, 1988, VIROLOGY, V162, P362, DOI 10.1016/0042-6822(88)90476-X; Flajolet M, 1998, J VIROL, V72, P6175, DOI 10.1128/JVI.72.7.6175-6180.1998; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; Gilbert S, 2000, J VIROL, V74, P5032, DOI 10.1128/JVI.74.11.5032-5039.2000; GRAEF E, 1994, ONCOGENE, V9, P81; Greenblatt MS, 1997, CANCER RES, V57, P426; HAVIV I, 1995, MOL CELL BIOL, V15, P1079; Hershkovitz M, 1997, METHODS, V11, P253, DOI 10.1006/meth.1996.0412; Hildt E, 1998, RECENT RES CANCER, V154, P315; Ishida H, 2000, J VIROL, V74, P1241, DOI 10.1128/JVI.74.3.1241-1251.2000; Kairat A, 1999, INTERVIROLOGY, V42, P228, DOI 10.1159/000024982; Katan Y, 1997, NUCLEIC ACIDS RES, V25, P3621, DOI 10.1093/nar/25.18.3621; Kioussis D, 1997, CURR OPIN GENET DEV, V7, P614, DOI 10.1016/S0959-437X(97)80008-1; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; Kosovsky MJ, 1999, VIROLOGY, V259, P60, DOI 10.1006/viro.1999.9776; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Li M, 1998, J BIOL CHEM, V273, P29022, DOI 10.1074/jbc.273.44.29022; Miyaki M, 2000, INT J CANCER, V85, P518, DOI 10.1002/(SICI)1097-0215(20000215)85:4<518::AID-IJC12>3.0.CO;2-7; ORI A, 1995, VIROLOGY, V207, P98, DOI 10.1006/viro.1995.1055; OSTAPCHUK P, 1989, MOL CELL BIOL, V9, P2787, DOI 10.1128/MCB.9.7.2787; OU JH, 1987, NUCLEIC ACIDS RES, V15, P8919, DOI 10.1093/nar/15.21.8919; Paran N, 2000, MOL CELL BIOL, V20, P834, DOI 10.1128/MCB.20.3.834-841.2000; Rivkina M, 1996, CARCINOGENESIS, V17, P2689, DOI 10.1093/carcin/17.12.2689; Sakakura C, 1999, BRIT J CANCER, V80, P2034, DOI 10.1038/sj.bjc.6690638; SHAUL Y, 1986, J VIROL, V59, P731, DOI 10.1128/JVI.59.3.731-734.1986; SHAUL Y, 1984, J VIROL, V51, P776, DOI 10.1128/JVI.51.3.776-787.1984; SHAUL Y, 1987, EMBO J, V6, P1913, DOI 10.1002/j.1460-2075.1987.tb02451.x; Shuster MI, 2000, GENE CHROMOSOME CANC, V28, P153, DOI 10.1002/(SICI)1098-2264(200006)28:2<153::AID-GCC4>3.0.CO;2-9; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; Wang PC, 2001, J VIROL METHODS, V92, P83, DOI 10.1016/S0166-0934(00)00278-0; Wong N, 2000, CLIN CANCER RES, V6, P4000; ZHOU DX, 1990, J BIOL CHEM, V265, P20731; ZIEMER M, 1985, J VIROL, V53, P885, DOI 10.1128/JVI.53.3.885-892.1985	49	34	37	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6811	6819		10.1038/sj.onc.1204879	http://dx.doi.org/10.1038/sj.onc.1204879			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687960				2022-12-17	WOS:000171641000002
J	Bartholin, L; Maguer-Satta, W; Hayette, S; Martel, S; Gadoux, M; Bertrand, S; Corbo, L; Lamadon, C; Morera, AM; Magaud, JP; Rimokh, R				Bartholin, L; Maguer-Satta, W; Hayette, S; Martel, S; Gadoux, M; Bertrand, S; Corbo, L; Lamadon, C; Morera, AM; Magaud, JP; Rimokh, R			FLRG, an activin-binding protein, is a new target of TGF beta transcription activation through Smad proteins	ONCOGENE			English	Article						FLRG; TGF beta; Smad; activin; follistatin	GROWTH-FACTOR-BETA; ERYTHROID-DIFFERENTIATION FACTOR; MAD PROTEINS; PROMOTER; GENE; SP1; FOLLISTATIN; EXPRESSION; RECEPTORS; FAMILY	The FLRG gene encodes a secreted glycoprotein that binds to activin and is highly homologous to follistatin, an activin ligand. We cloned the promoter region of the human FLRG gene, and defined the minimal region necessary for transcription activation in a reporter-system assay. We showed that the fragment between positions -130 and +6, which consists of multiple consensus Sp1-binding sites, is required for the constitutive expression of the FLRG gene. We demonstrate here that FLRG mRNA expression is rapidly induced by TGF beta or by transfection with Smad protein expression vectors in human HepG2 cells. We investigated the transcription-regulation mechanism of FLRG expression in HepG2 cells following treatment with TGF beta. By deletion and point-mutation analysis of the FLRG promoter, we identified a Smad-binding element involved in the TGF beta -inducible expression of the FLRG gene. Moreover, transactivation of the FLRG promoter by TGF beta was compromised by dominant-negative mutants of Smad3 and Smad4 proteins. In addition, get electrophoresis mobility-shift assays demonstrated the specific interaction of Smad3 and Smad4 proteins with the Smad-binding element consensus motif found in the FLRG promoter. Taken together, our data imply that Smad proteins participate in the regulation of expression of FLRG, a new target of TGF beta transcription activation.	Ctr Leon Berard, INSERM, U453, F-69373 Lyon, France; Hop Edouard Herriot, Lab Cytogenet Mol, F-69437 Lyon, France; Hop Debrousse, INSERM, U329, F-69322 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; CHU Lyon; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)	Rimokh, R (corresponding author), Ctr Leon Berard, INSERM, U453, F-69373 Lyon, France.	rimokh@lyon.fnclcc.fr	Bartholin, Laurent/Q-6655-2017; Maguer-Satta, Veronique/U-8857-2019; Rimokh, Ruth/G-7506-2014; HAYETTE, sandrine/Z-2283-2019	Bartholin, Laurent/0000-0002-5637-3223; Maguer-Satta, Veronique/0000-0002-1556-068X; 				Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; Cook T, 1999, ANN NY ACAD SCI, V880, P94, DOI 10.1111/j.1749-6632.1999.tb09513.x; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DePaolo LV, 1997, P SOC EXP BIOL MED, V214, P328; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DYBEDAL I, 1995, BLOOD, V86, P949; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Hayette S, 1998, ONCOGENE, V16, P2949, DOI 10.1038/sj.onc.1201807; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kitamura K, 2000, BLOOD, V95, P3371, DOI 10.1182/blood.V95.11.3371.011k37_3371_3379; KRYSTAL G, 1994, J EXP MED, V180, P851, DOI 10.1084/jem.180.3.851; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Maguer-Satta V, 2001, EXP HEMATOL, V29, P301, DOI 10.1016/S0301-472X(00)00675-5; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Phillips DJ, 1998, FRONT NEUROENDOCRIN, V19, P287, DOI 10.1006/frne.1998.0169; Pierelli L, 2000, BLOOD, V95, P3001; SHAO LE, 1992, BLOOD, V79, P773; SHIOZAKI M, 1992, P NATL ACAD SCI USA, V89, P1553, DOI 10.1073/pnas.89.5.1553; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tsuchida K, 2000, J BIOL CHEM, V275, P40788, DOI 10.1074/jbc.M006114200; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; YAMASHITA T, 1992, BLOOD, V79, P304; Ying SY, 1997, P SOC EXP BIOL MED, V214, P114; Yu J, 1997, CYTOKINES CELL MOL T, V3, P169; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhang YQ, 1997, BBA-GENE STRUCT EXPR, V1354, P204, DOI 10.1016/S0167-4781(97)00085-7	44	34	42	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2001	20	39					5409	5419		10.1038/sj.onc.1204720	http://dx.doi.org/10.1038/sj.onc.1204720			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571638				2022-12-17	WOS:000170781100001
J	Brandt, R; Wong, AML; Hynes, NE				Brandt, R; Wong, AML; Hynes, NE			Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents	ONCOGENE			English	Article						HC11 mammary cells; cleared fat pad; ErbB2; NeuT; PKI166; Taxol (R)	TYROSINE KINASE INHIBITOR; METASTATIC BREAST-CANCER; GROWTH-FACTOR RECEPTOR; BETA-CASEIN GENE; IN-VIVO MODEL; TRANSGENIC MICE; NEU ONCOGENE; EPITHELIAL-CELLS; EXPRESSION; INDUCTION	The ErbB2 receptor tyrosine kinase (RTK) has been intensely pursued as a cancer therapy target due to its association with breast cancer. In this study we used the HC11 mammary epithelial cell line to develop an orthotopic, ErbB2-driven tumor model for testing efficacy of anti-cancer compounds. HC11 cells were infected with a retrovirus encoding oncogenic NeuT, the rat homolog of ErbB2. Drug-selected populations were introduced into mammary fat pads of Balb/c syngeneic mice cleared of host tissue. The majority of glands injected with HC11-NeuT cells developed mammary tumors which appeared after a 3-4 week latency period and grew rapidly. HC11 cells infected with the control retrovirus showed no tumor growth after injection. Tumor-bearing mice were used to compare the in vivo efficacy of two anti-cancer agents: PKI166, a kinase inhibitor selective for EGF receptor and ErbB2, and Taxol(R), a microtubule assembly blocker. PKI166 inhibited NeuT-induced mammary tumor growth in a dose-dependent manner and at a dose below the maximum tolerated dose (MTD) was significantly more inhibitory than Taxol(R) at its MTD (57% vs 25% tumor regression). Importantly, there was a dose-dependent decrease in the phosphotyrosine content of NeuT isolated from PKI166-treated, tumor-bearing mice, providing a mechanistic link between kinase inhibition and its antitumor activity. Thus, implantation of genetically manipulated HC11 cells into mammary glands appears to be an excellent model for studying effects of anti-cancer agents in an orthotopic site.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Novartis Pharma AG, Oncol Dept In Vivo Pharmacol, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; Novartis	Hynes, NE (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66,R-1066-206, CH-4058 Basel, Switzerland.							BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; BERGER MS, 1988, CANCER RES, V48, P1238; BRADBURY JM, 1993, ONCOGENE, V8, P1551; Bruns CJ, 2000, CANCER RES, V60, P2926; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; CHAMMAS R, 1994, J CELL SCI, V107, P1031; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Cuny M, 2000, CANCER RES, V60, P1077; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DEOME KB, 1959, CANCER RES, V19, P515; DiGiovanna MP, 1998, ONCOGENE, V17, P1877, DOI 10.1038/sj.onc.1202091; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; EDWARDS PAW, 1992, ONCOGENE, V7, P2041; Fabbro D, 2000, ANTI-CANCER DRUG DES, V15, P17; GIANNI L, 1997, SEM ONCOLOGY, V24; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Humphreys RC, 1997, CELL GROWTH DIFFER, V8, P839; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; MERLO GR, 1994, ONCOGENE, V9, P443; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Murphy KL, 2000, ONCOGENE, V19, P1045, DOI 10.1038/sj.onc.1203274; Norgaard P, 1999, CLIN CANCER RES, V5, P35; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rees CN, 1996, EUR J CANCER, V32A, P2354, DOI 10.1016/S0959-8049(96)00348-6; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; SEIDMAN AD, 1995, J CLIN ONCOL, V13, P2575, DOI 10.1200/JCO.1995.13.10.2575; Siegel PM, 2000, BIOESSAYS, V22, P554, DOI 10.1002/(SICI)1521-1878(200006)22:6<554::AID-BIES8>3.0.CO;2-A; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smith GH, 1996, BREAST CANCER RES TR, V39, P21, DOI 10.1007/BF01806075	37	34	34	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5459	5465		10.1038/sj.onc.1204709	http://dx.doi.org/10.1038/sj.onc.1204709			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571643				2022-12-17	WOS:000170781100006
J	Lutzker, SG; Mathew, R; Taller, DR				Lutzker, SG; Mathew, R; Taller, DR			A p53 dose-response relationship for sensitivity to DNA damage in isogenic teratocarcinoma cells	ONCOGENE			English	Article						p53; apoptosis; DNA damage; teratocarcinoma cells	APOPTOSIS; GENE; EXPRESSION; CISPLATIN; PROTEIN; TUMORS	Teratocarcinomas are tumors that arise from primordial germ cells and are readily curable with DNA-damaging chemotherapeutic drugs. Teratocarcinoma cells ex vivo in tissue culture are also relatively chemosensitive and undergo apoptotic death in response to DNA damage, We have previously hypothesized that the observed sensitivity of this tumor type to DNA damage is related to high basal expression of wild-type p53 protein, We have now addressed this issue by characterizing the DNA damage response of isogenic teratocarcinoma cells that differ only in their level of expression of wild-type p53 protein, We find a clear p53 dose-response relationship in these cells for rapid apoptosis following DNA damage that correlates with diminished colony formation in clonogenic survival assays. These results suggest that strategies to increase basal wild-type p53 protein expression prior to treatment with DNA-damaging drugs may improve curability in other tumor types. Oncogene (2001) 20, 2982-2986.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Genet & Microbiol, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Inst Canc, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Lutzker, SG (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ 08901 USA.							ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; Brown JM, 1999, CANCER RES, V59, P1391; Burger H, 1999, INT J CANCER, V81, P620, DOI 10.1002/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.3.CO;2-J; Chresta CM, 1996, CANCER RES, V56, P1834; Corbet SW, 1999, ONCOGENE, V18, P1537, DOI 10.1038/sj.onc.1202436; Eid H, 1997, ANTICANCER RES, V17, P2663; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; HALE TK, 1995, NUCLEIC ACIDS RES, V23, P663, DOI 10.1093/nar/23.4.663; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; Lutzker SG, 1998, MOL MED TODAY, V4, P404, DOI 10.1016/S1357-4310(98)01329-X; Lutzker SG, 1998, APMIS, V106, P85, DOI 10.1111/j.1699-0463.1998.tb01323.x; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Roy B, 1996, ONCOGENE, V13, P2359; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; SCHMID P, 1991, DEVELOPMENT, V113, P857; Schmidt-Kastner PK, 1998, ONCOGENE, V16, P3003, DOI 10.1038/sj.onc.1201835; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163	25	34	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2001	20	23					2982	2986		10.1038/sj.onc.1204394	http://dx.doi.org/10.1038/sj.onc.1204394			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420711				2022-12-17	WOS:000168901800014
J	Peters, DG; Klucher, KM; Perlingeiro, RCR; Dessain, SK; Koh, EY; Daley, GQ				Peters, DG; Klucher, KM; Perlingeiro, RCR; Dessain, SK; Koh, EY; Daley, GQ			Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice	ONCOGENE			English	Article						BCR/ABL; embryonic stem cell; chronic myeloid leukemia; interleukin-3	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; COLONY-STIMULATING FACTOR; EMBRYONIC STEM-CELLS; BCR-ABL; IN-VITRO; DIFFERENTIATION; GROWTH; EXPRESSION; ONCOGENE	During differentiation in vitro, Embryonic Stem (ES) cells generate both primitive erythroid and definitive myeloid lineages in a process that mimics hematopoiesis in the mammalian yolk sac, To investigate leukemic transformation of these embryonic hematopoietic progenitors, we infected differentiating cultures of ES cells with the Chronic Myeloid Leukemia-specific BCR/ABL oncoprotein. Following a period of liquid culture, we isolated two transformed subclones, EB57 and EB67, that retained characteristics of embryonic hematopoietic progenitors and induced a fatal leukemia in mice characterized by massive splenomegaly and granulocytosis, Histopathology of the spleen revealed an abundance of undifferentiated blast-like cells. Investigation of the clonal origins of the granulocytes in the peripheral blood demonstrated that the injected donor cells contributed modestly to the granulocyte population while the majority were host-derived, EB57 secretes IL-3 and unidentified cytokines that can stimulate autocrine and paracrine cell proliferation, presumably accounting for the reactive granulocytosis in diseased mice. These BCR/ABL transformed hematopoietic derivatives of ES cells recapitulate the relationship of BCR/ABL expression to IL-3 production that has been described for primitive hematopoietic progenitors from human CML patients, and illustrates the potential for autocrine and paracrine effects of BCR/ABL-infected cells in murine models.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02115 USA; Whitehead Inst, Cambridge, MA 02142 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Whitehead Institute	Daley, GQ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA086991, R29CA076418] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004463] Funding Source: NIH RePORTER; NCI NIH HHS [CA76418-01, CA86991-01] Funding Source: Medline; NHLBI NIH HHS [K08 HL 04463] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson SM, 1996, BLOOD, V87, P238; Choi K, 1998, DEVELOPMENT, V125, P725; CROSS NCP, 1994, LEUKEMIA, V8, P186; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dexter T M, 1984, Prog Clin Biol Res, V148, P13; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EAVES AC, 1979, EXP HEMATOL, V7, P65; ELEFANTY AG, 1992, BLOOD, V79, P1271; FORSTEN KE, 1992, BIOPHYS J, V63, P857, DOI 10.1016/S0006-3495(92)81661-2; Ghaffari S, 1999, P NATL ACAD SCI USA, V96, P13186, DOI 10.1073/pnas.96.23.13186; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GUTIERREZRAMOS JC, 1992, P NATL ACAD SCI USA, V89, P9171, DOI 10.1073/pnas.89.19.9171; Hariharan I K, 1988, Oncogene Res, V3, P387; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; ISSAAD C, 1994, BLOOD, V84, P3447; Jiang X, 2000, LEUKEMIA, V14, P1112, DOI 10.1038/sj.leu.2401752; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; Keller G, 1998, BLOOD, V92, P877, DOI 10.1182/blood.V92.3.877.415k11_877_887; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; KOH EY, 2001, IN PRESS CHRONIC MYE; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LEMOINE FM, 1988, EXP HEMATOL, V16, P718; Li S, 1999, BLOOD, V94, p600A; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; MANDANAS RA, 1992, LEUKEMIA, V6, P796; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; SIRARD C, 1994, BLOOD, V83, P1575; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; VANDERIJN M, 1989, P NATL ACAD SCI USA, V86, P4634; WILES MV, 1991, DEVELOPMENT, V111, P259; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	35	34	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2001	20	21					2636	2646		10.1038/sj.onc.1204374	http://dx.doi.org/10.1038/sj.onc.1204374			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420675				2022-12-17	WOS:000168652600004
J	Imamura, O; Fujita, K; Shimamoto, A; Tanabe, H; Takeda, S; Furuichi, Y; Matsumoto, T				Imamura, O; Fujita, K; Shimamoto, A; Tanabe, H; Takeda, S; Furuichi, Y; Matsumoto, T			Bloom helicase is involved in DNA surveillance in early S phase in vertebrate cells	ONCOGENE			English	Article						Bloom helicase; Bloom syndrome; DT40; chromosomal instability	SISTER-CHROMATID EXCHANGE; SYNDROME GENE-PRODUCT; WERNERS-SYNDROME GENES; HOMOLOGOUS RECOMBINATION; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SYNDROME FIBROBLASTS; ULTRAVIOLET-LIGHT; MOLECULAR-CLONING; MAMMALIAN-CELLS	Bloom syndrome (BS) is a recessive human genetic disorder characterized by short stature, immunodeficiency and an elevated risk of malignancy. The gene mutated in BS, BLM, encodes a RecQ-type DNA helicase. BS cells have mutator phenotypes such as hyper-recombination, chromosome instability and an increased frequency of sister chromatid exchange (SCE). To define the primary role of BLM, we generated BLM-/- mutants of the chicken B-cell line DT40. In addition to characteristics of BLM-/- cells reported previously by the other group, they are hypersensitive to genotoxic agents such as etoposide, bleomycin and 4-nitroquinoline-1-oxide and irradiation with the short wave length of UV (UVC) light, whereas they exhibit normal sensitivity to X-ray irradiation and hydroxyurea. UVC irradiation to BLM-/- cells during G(1) to early S phase caused chromosomal instability such as chromatid breaks and chromosomal quadriradials, leading to eventual cell death. These results suggest that BLM is involved in surveillance of base abnormalities in genomic DNA that may be encountered by replication forks in early S phase. Such surveillance would maintain genomic stability in vertebrate cells, resulting in the prevention of cellular tumorigenesis.	AGENE REs Inst, Kanagawa 2470063, Japan; Natl Inst Hlth Sci, Div Genet & Mutagenesis, Setagaya Ku, Tokyo 1588501, Japan; Kyoto Univ, Grad Sch Med, Dept Radiat Genet, Sakyo Ku, Kyoto 6068501, Japan	National Institute of Health Sciences - Japan; Kyoto University	Matsumoto, T (corresponding author), AGENE REs Inst, 200 Kajiwara, Kanagawa 2470063, Japan.			Takeda, Shunichi/0000-0002-7924-7991				Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; BEZZUBOVA OY, 1994, EXPERIENTIA, V50, P270, DOI 10.1007/BF01924010; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; Courcelle J, 1999, MOL GEN GENET, V262, P543, DOI 10.1007/s004380051116; Davey S, 1998, MOL CELL BIOL, V18, P2721, DOI 10.1128/MCB.18.5.2721; Dedon PC, 1998, P NATL ACAD SCI USA, V95, P11113, DOI 10.1073/pnas.95.19.11113; Ellis NA, 1999, AM J HUM GENET, V65, P1368, DOI 10.1086/302616; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GALIEGUEZOUITINA S, 1984, ANAL BIOCHEM, V138, P454, DOI 10.1016/0003-2697(84)90839-X; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; HEARTLEIN MW, 1987, EXP CELL RES, V169, P245; HENSON P, 1981, CANCER RES, V41, P760; Heo SJ, 1999, GENES CELLS, V4, P619, DOI 10.1046/j.1365-2443.1999.00288.x; KADYK LC, 1993, GENETICS, V133, P469; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; KREPINSKY AB, 1979, HUM GENET, V50, P151, DOI 10.1007/BF00390236; KREPINSKY AB, 1980, MUTAT RES, V69, P357, DOI 10.1016/0027-5107(80)90100-1; KURIHARA T, 1987, MUTAT RES, V183, P197, DOI 10.1016/0167-8817(87)90062-9; Kusano K, 1999, GENETICS, V151, P1027; LANGLOIS RG, 1989, P NATL ACAD SCI USA, V86, P670, DOI 10.1073/pnas.86.2.670; LINDAHL T, 1990, MUTAT RES, V238, P305, DOI 10.1016/0165-1110(90)90022-4; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; Matsumoto L, 1999, MUTAT RES-FUND MOL M, V426, P79, DOI 10.1016/S0027-5107(99)00042-1; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murray JM, 1997, MOL CELL BIOL, V17, P6868, DOI 10.1128/MCB.17.12.6868; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; Onoda F, 2000, MUTAT RES-DNA REPAIR, V459, P203, DOI 10.1016/S0921-8777(99)00071-3; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; RAY JH, 1984, CHROMOSOMA, V90, P383, DOI 10.1007/BF00294165; ROSIN MP, 1985, HUM GENET, V71, P187, DOI 10.1007/BF00284570; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Shimamoto A, 2000, NUCLEIC ACIDS RES, V28, P1647, DOI 10.1093/nar/28.7.1647; SHIRAISHI Y, 1985, EMBO J, V4, P2553, DOI 10.1002/j.1460-2075.1985.tb03970.x; SMITH GJ, 1983, MUTAT RES, V111, P405, DOI 10.1016/0027-5107(83)90036-2; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Takao N, 1999, ONCOGENE, V18, P7002, DOI 10.1038/sj.onc.1203172; Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang Y, 2000, GENE DEV, V14, P927; Watt PM, 1996, GENETICS, V144, P935; WERNERFAVRE C, 1984, AM J MED GENET, V18, P215, DOI 10.1002/ajmg.1320180205; Wood RD, 1999, BIOCHIMIE, V81, P39, DOI 10.1016/S0300-9084(99)80036-4; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	52	34	35	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1143	1151		10.1038/sj.onc.1204195	http://dx.doi.org/10.1038/sj.onc.1204195			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313858				2022-12-17	WOS:000167570100001
J	Tomomura, M; Fernandez-Gonzales, A; Yano, R; Yuzaki, M				Tomomura, M; Fernandez-Gonzales, A; Yano, R; Yuzaki, M			Characterization of the apoptosis-associated tyrosine kinase (AATYK) expressed in the CNS	ONCOGENE			English	Article						apoptosis; tyrosine kinase; phosphorylation; brain; cerebellum; Purkinje cells	CEREBELLAR GRANULE NEURONS; CELL-DEATH; C-JUN; PURKINJE-CELLS; MESSENGER-RNA; GROWTH-FACTOR; SURVIVAL; PROTEIN; DEPOLARIZATION; ACTIVATION	We isolated three related cDNA clones from a mouse cerebellar library; the type I cDNA was identical to the gene encoding the apoptosis-associated tyrosine kinase (AATYK), whose expression in myeloid precursor cells is increased during growth arrest or apoptosis, Low levels of AATYK mRNA expression mere seen in adult mouse brains but not in embryos. In situ hybridization confirmed the widespread expression of AATYK mRNA in neurons throughout the adult brain. AATYK possessed tyrosine kinase activity and was autophosphorylated when expressed in 293 cells. AATYK mRNA expression was rapidly induced in cultured cerebellar granule cells during apoptosis induced by a low concentration of KCl (5 mid). Levels of endogenous AATYK protein were increased only slightly, but they were accompanied by an increase in molecular weight during apoptosis, Results of the tyrosine phosphatase treatments indicated that the increase in molecular weight was partly caused by tyrosine phosphorylation, The number of apoptotic granule cells overexpressing mild-type AATYK protein was significantly greater than the number of apoptotic granule cells overexpressing a mutant AATYK that lacked tyrosine kinase activity in low concentrations of RCl. These findings suggest that through its tyrosine kinase activity, AATYK is involved in the apoptosis of mature neurons.	St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; RIKEN, Brain Sci Inst, Lab Cellular Informat Proc, Wako, Saitama 35101, Japan	St Jude Children's Research Hospital; RIKEN	Yuzaki, M (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA.		Yuzaki, Michisuke/K-5328-2013	Yuzaki, Michisuke/0000-0002-5750-3544	NCI NIH HHS [CA21765] Funding Source: Medline; NINDS NIH HHS [NS36925] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036925] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BESSHO Y, 1994, NEURON, V12, P87, DOI 10.1016/0896-6273(94)90154-6; BORASIO GD, 1989, NEURON, V2, P1087; BRENNEMAN DE, 1986, P NATL ACAD SCI USA, V83, P1159, DOI 10.1073/pnas.83.4.1159; CADDY KWT, 1979, PHILOS T ROY SOC B, V287, P167, DOI 10.1098/rstb.1979.0055; CharriautMarlangue C, 1996, J CEREBR BLOOD F MET, V16, P186, DOI 10.1097/00004647-199603000-00002; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Damgaard I, 1996, NEUROCHEM RES, V21, P267, DOI 10.1007/BF02529144; DRISCOLL BF, 1991, J NEUROCHEM, V56, P1201, DOI 10.1111/j.1471-4159.1991.tb11411.x; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eilers A, 1998, J NEUROSCI, V18, P1713; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GALLO V, 1987, J NEUROSCI, V7, P2203; Gaozza E, 1997, ONCOGENE, V15, P3127, DOI 10.1038/sj.onc.1201575; Gilmore EC, 2000, TRENDS NEUROSCI, V23, P100, DOI 10.1016/S0166-2236(99)01503-9; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Kurschner C, 1999, J NEUROSCI, V19, P7770; LI Y, 1995, STROKE, V26, P1252, DOI 10.1161/01.STR.26.7.1252; LIPTON SA, 1986, P NATL ACAD SCI USA, V83, P9774, DOI 10.1073/pnas.83.24.9774; Miller TM, 1996, J NEUROSCI, V16, P7487; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P543; SIDMAN RL, 1962, SCIENCE, V137, P610, DOI 10.1126/science.137.3530.610; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; Tanabe H, 1997, EUR J NEUROSCI, V9, P848, DOI 10.1111/j.1460-9568.1997.tb01434.x; Tanabe H, 1998, EUR J NEUROSCI, V10, P1403, DOI 10.1046/j.1460-9568.1998.00148.x; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Watson A, 1998, J NEUROSCI, V18, P751; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; YAN GM, 1994, BRAIN RES, V656, P43, DOI 10.1016/0006-8993(94)91364-1; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; YUZAKI M, 1992, J NEUROSCI, V12, P4253; Yuzaki M, 1996, J NEUROSCI, V16, P4651; YUZAKI M, 1994, LEARN MEMORY, V1, P230	44	34	36	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1022	1032		10.1038/sj.onc.1204210	http://dx.doi.org/10.1038/sj.onc.1204210			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314040				2022-12-17	WOS:000167232100002
J	Langlais, P; Dong, LQ; Hu, DR; Liu, F				Langlais, P; Dong, LQ; Hu, DR; Liu, F			Identification of Grb10 as a direct substrate for members of the Src tyrosine kinase family	ONCOGENE			English	Article						Grb10; Src; IR; SH2	ADAPTER PROTEIN GRB10; RECEPTOR-BINDING-PROTEIN; FACTOR-I RECEPTORS; INSULIN-RECEPTOR; AUTOPHOSPHORYLATION SITES; SIGNAL-TRANSDUCTION; HOMOLOGY-2 DOMAIN; SHC PROTEINS; V-SRC; GROWTH	Treatment of cells with insulin and protein tyrosine phosphatase inhibitors such as vanadate and pervanadate resulted in the tyrosine phosphorylation of Grb10, a Src homology 2 (SH2) and pleckstrin homology domain-containing adaptor protein,which binds to a number of receptor tyrosine kinases including the insulin receptor (IR), Although Grb10 binds directly to the kinase domain of the IR, our data show that Grb10 is not a direct substrate for the IR tyrosine kinase. Consistent with this finding, Grb10 tyrosine phosphorylation in cells was inhibited by herbimycin A, a relatively specific inhibitor for members of the Src tyrosine kinase family, and by the expression of dominant negative Src or Fyn. In addition, Grb10 tyrosine phosphorylation was stimulated by expression of constitutively active Src or Fyn in cells and by incubation with purified Src or Fyn in vitro. The insulin stimulated or Src/Fyn-mediated tyrosine phosphorylation iir vivo was significantly reduced when Grb10 tyrosine 67 was changed to glycine. This mutant form of Grb10 bound with higher affinity to the IR in cells than that of the wild-type protein, suggesting that tyrosine phosphorylation of Grb10 may normally negatively regulate its binding to the IR, Our data show that Grb10 is a new substrate for members of the Src tyrosine kinase family and that the tyrosine phosphorylation of the protein may play a potential role in cell signaling processes mediated by these kinases.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol & Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Liu, F (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol & Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052933] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai RY, 1998, ONCOGENE, V17, P941, DOI 10.1038/sj.onc.1202024; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; DELALUNA S, 1988, GENE, V62, P121; Dong LQ, 1998, J BIOL CHEM, V273, P17720, DOI 10.1074/jbc.273.28.17720; Dong LQ, 1997, MOL ENDOCRINOL, V11, P1757, DOI 10.1210/me.11.12.1757; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; HAEFNER B, 1995, J BIOL CHEM, V270, P7937, DOI 10.1074/jbc.270.14.7937; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; Liu F, 1998, MOL CELL BIOCHEM, V182, P73, DOI 10.1023/A:1006899832614; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Mano H, 1998, GENES CELLS, V3, P431, DOI 10.1046/j.1365-2443.1998.00201.x; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Morrione A, 1996, CANCER RES, V56, P3165; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1610; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Ruzzene M, 1997, EUR J BIOCHEM, V246, P433, DOI 10.1111/j.1432-1033.1997.t01-1-00433.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; Wang J, 1999, MOL CELL BIOL, V19, P6217; WENG Z, 1994, MOL CELL BIOL, V14, P509; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; ZHANG B, 1991, J BIOL CHEM, V266, P990	45	34	34	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2000	19	25					2895	2903		10.1038/sj.onc.1203616	http://dx.doi.org/10.1038/sj.onc.1203616			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871840				2022-12-17	WOS:000087544500003
J	Nicot, C; Mahieux, R; Opavsky, R; Cereseto, A; Wolff, L; Brady, JN; Franchini, G				Nicot, C; Mahieux, R; Opavsky, R; Cereseto, A; Wolff, L; Brady, JN; Franchini, G			HTLV-I Tax transrepresses the human c-Myb promoter independently of its interaction with CBP or p300	ONCOGENE			English	Article						tax; c-Myb; transrepression; CBP/p300	T-CELL LEUKEMIA; VIRUS TYPE-1 TAX; CREB BINDING-PROTEIN; INDUCED TRANSCRIPTION ACTIVATION; NEGATIVE REGULATORY DOMAIN; NF-KAPPA-B; MESSENGER-RNA; V-MYB; PHOSPHORYLATION SITE; ABERRANT EXPRESSION	The c-Myb proto-oncogene is preferentially expressed in hematopoietic lineages, and highly expressed in several leukemia types. The Human T-cell Leukemia Virus Type I (HTLV-I) is the etiological agent of Adult T-cell Leukemia/Lymphoma (ATLL), A previous report suggested that Tax, the viral transactivator, is able to suppress the transactivation potential of c-Myb protein by competing for recruitment of CBP, We tested whether such a competition could affect transcription from the c-Myb promoter in Tax expressing T-cells, Using several c-Myb promoter reporter constructs carrying mutations in various regions, we demonstrate that Tax suppression of c-Myb transactivation results in transrepression of the c-Myb promoter through the Myb responsive elements in Jurkat T-cells, The ability of Tax mutants M22, M47 and V89A to interact with the full-length CBP and p300 proteins in vitro, and their ability to repress the c-Myb promoter, was then evaluated. Although both M47 and M22 bind to CBP and p300 to a similar extent, only M47 was able to repress the c-Myb promoter, suggesting that competition for CBP/p300 binding was not the mechanism underlying Tax's effect. This concept was further supported by the fact that the Tax mutant V89A transrepresses the c-Myb promoter efficiently in spite of an impaired binding to CBP and p300, Therefore, Tax-mediated repression of the c-Myb promoter appears to be independent from a direct competition between c-Myb and Tax for recruitment of CBP/p300, Interestingly, a decreased transcription from the endogenous c-Myb promoter was observed in several HTLV-I transformed T-cell lines. Finally, the ability of Tax to directly repress the endogenous c-Myb promoter was demonstrated in a Jurkat cell line stably transfected with a tax gene driven by a cadmium-inducible promoter.	NCI, Div Basic Sci, Basic Res Lab, Bethesda, MD 20814 USA; NCI, Lab Receptor Biol & Gene Express, Bethesda, MD 20814 USA; NIH, Cellular Oncol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA	Nicot, C (corresponding author), NCI, Div Basic Sci, Basic Res Lab, 9000 Rockville Pike,Bldg 41,Room C303, Bethesda, MD 20814 USA.			Cereseto, Anna/0000-0003-4453-2597; mahieux, renaud/0000-0002-5129-6804	NATIONAL CANCER INSTITUTE [ZIABC005254, ZIABC005645, Z01BC005254, Z01BC005645] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BADING H, 1989, ONCOGENE, V4, P33; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; CASTRON KM, 1992, J IMMUNOL, V148, P934; Cereseto A, 1999, ONCOGENE, V18, P2441, DOI 10.1038/sj.onc.1202567; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Colgin MA, 1998, J VIROL, V72, P9396, DOI 10.1128/JVI.72.11.9396-9399.1998; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Davies J, 1999, ONCOGENE, V18, P3643, DOI 10.1038/sj.onc.1202956; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; Ganter B, 1997, ONCOGENE, V15, P193, DOI 10.1038/sj.onc.1201173; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GRIFFIN CA, 1985, CANCER RES, V45, P272; GUERIN M, 1990, ONCOGENE, V5, P131; GUERRA J, 1995, BLOOD, V86, P1873, DOI 10.1182/blood.V86.5.1873.bloodjournal8651873; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Jeang KT, 1997, J VIROL, V71, P6277, DOI 10.1128/JVI.71.9.6277-6278.1997; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kaspar P, 1999, J BIOL CHEM, V274, P14422, DOI 10.1074/jbc.274.20.14422; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MATSUMOTO K, 1994, VIROLOGY, V200, P813, DOI 10.1006/viro.1994.1248; MCCANN S, 1995, J BIOL CHEM, V270, P23785, DOI 10.1074/jbc.270.40.23785; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Ness SA, 1999, ONCOGENE, V18, P3039, DOI 10.1038/sj.onc.1202726; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; Nicot C, 1997, VIROLOGY, V236, P47, DOI 10.1006/viro.1997.8720; NICOT C, 1993, VIRUS RES, V30, P317, DOI 10.1016/0168-1702(93)90099-9; NICOT C, IN PRESS BLOOD; NOMURA T, 1993, J BIOL CHEM, V268, P21914; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Phan SC, 1996, MOL CELL BIOL, V16, P2387; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sullivan J, 1997, J BIOL CHEM, V272, P1943, DOI 10.1074/jbc.272.3.1943; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TATEWAKI M, 1995, BLOOD, V86, P3109; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; WATSON RJ, 1988, ONCOGENE, V2, P267; Weston K, 1999, ONCOGENE, V18, P3034, DOI 10.1038/sj.onc.1202728	71	34	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2000	19	17					2155	2164		10.1038/sj.onc.1203536	http://dx.doi.org/10.1038/sj.onc.1203536			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815807				2022-12-17	WOS:000086728000009
J	Blyth, K; Stewart, M; Bell, M; James, C; Evan, G; Neil, JC; Cameron, ER				Blyth, K; Stewart, M; Bell, M; James, C; Evan, G; Neil, JC; Cameron, ER			Sensitivity to myc-induced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycER (TM) mice	ONCOGENE			English	Article						c-myc; apoptosis; transgene; T-cell lymphoma	PROGRAMMED CELL-DEATH; WILD-TYPE P53; C-MYC; TRANSGENIC MICE; MEDIATED APOPTOSIS; THYMIC LYMPHOMAS; CYCLE ARREST; FACTOR-ALPHA; EXPRESSION; GROWTH	To study the effects of the Myc oncoprotein in a regulatable in vivo system, we generated lines of transgenic mice in which a tamoxifen inducible Myc fusion protein (c-mycER(TM)) is expressed under the control of the CD2 locus control region, Activation of the Myc oncoprotein resulted in both proliferation and apoptosis in vivo, Lines with a high transgene copy number developed spontaneous lymphomas at low frequency, but the tumour incidence was significantly increased with tamoxifen treatment. Surprisingly, we found that cellular sensitivity to Myc-induced apoptosis was retained in tumours from these mice and in most lymphoma cell lines, even when null for p53, Resistance to Myc-induced apoptosis could be conferred on these cells by co-expression of Bcl-2, However, acquired resistance is clearly not an obligatory progression event as sensitivity to apoptosis was retained in transplanted tumours in athymic mice, In conclusion, lymphomas arising in CD2-mycER(TM) mice retain the capacity to undergo apoptosis in response to Myc activation and show no phenotypic evidence of the presence of an active dominant inhibitor.	Univ Glasgow, Sch Vet, Mol Oncol Lab, Glasgow G61 1QH, Lanark, Scotland; Imperial Canc Res Fund, Biochem Cell Nucleas Lab, London WC2A 3PX, England	University of Glasgow; Cancer Research UK	Cameron, ER (corresponding author), Univ Glasgow, Sch Vet, Mol Oncol Lab, Glasgow G61 1QH, Lanark, Scotland.			Blyth, Karen/0000-0002-9304-439X				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; ASKEW DS, 1991, ONCOGENE, V6, P1915; BLYTH K, 1995, ONCOGENE, V10, P1717; BOISE LH, 1995, P NATL ACAD SCI USA, V92, P5491, DOI 10.1073/pnas.92.12.5491; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Genestier L, 1999, J EXP MED, V189, P231, DOI 10.1084/jem.189.2.231; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hogan B., 1994, MANIPULATING MOUSE E; HSU B, 1995, ONCOGENE, V11, P175; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Hundley JE, 1997, CANCER RES, V57, P600; JACOBSEN KA, 1994, BLOOD, V84, P2784; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Li WX, 1996, RADIAT RES, V145, P324, DOI 10.2307/3578988; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Prasad VS, 1997, MOL CARCINOGEN, V18, P66, DOI 10.1002/(SICI)1098-2744(199702)18:2<66::AID-MC2>3.0.CO;2-O; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; RENAULD JC, 1995, BLOOD, V85, P1300, DOI 10.1182/blood.V85.5.1300.bloodjournal8551300; Rupnow BA, 1998, CANCER RES, V58, P1779; Sakamuro D, 1995, ONCOGENE, V11, P2411; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; STEWART M, 1993, INT J CANCER, V53, P1023; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang RX, 1998, ONCOGENE, V17, P1503, DOI 10.1038/sj.onc.1202059; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	53	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					773	782		10.1038/sj.onc.1203321	http://dx.doi.org/10.1038/sj.onc.1203321			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698495				2022-12-17	WOS:000085192100007
J	Cong, F; Zou, XM; Hinrichs, K; Calame, K; Goff, SP				Cong, F; Zou, XM; Hinrichs, K; Calame, K; Goff, SP			Inhibition of v-Abl transformation by p53 and p19ARF	ONCOGENE			English	Article						v-Abl; p53; p19ARF; transformation	MURINE LEUKEMIA-VIRUS; HUMAN PAPILLOMAVIRUS TYPE-16; ARF TUMOR-SUPPRESSOR; TYROSINE KINASE; P53-DEPENDENT APOPTOSIS; GENE-PRODUCT; CELLS; P19(ARF); DNA; SENESCENCE	Tumorigenesis is a multistep process that involves the activation of oncogenes and the inactivation of tumor suppressor genes. The transforming activity of the v-Abl oncogene of Abelson murine leukemia virus (A-MuLV) in immortal cell lines has been well studied, while the effects of v-Abl in primary fibroblasts are less clear. Here we show that v-Abl causes cell cycle arrest in primary mouse embryonic fibroblasts (MEFs) and elevated levels of both p53 and the cyclin-dependent kinase inhibitor p21(Cip). p53(-/-) or p19ARF(-/-) MEFs were resistant to v-Abl-induced cell cycle arrest. Although wild-type MEFs were resistant to v-Abl transforming activity, p53(-/-) or p19ARF(-/-) MEFs were susceptible. The results indicate that loss of p19ARF and p53 function plays an important role during the transformation of primary cells by v-Abl. We suggest that although v-Abl is a potent oncogene, its full potential transforming activity cannot be realized until the ARF-, and p53-dependent growth inhibitory pathway is disabled. We also show that p53 is not the mediator of v-Abl toxicity in immortal fibroblasts and does not determine the susceptibility of immortal fibroblasts to v-Abl transformation.	Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Columbia Univ, Dept Biol Sci, New York, NY 10025 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute	Goff, SP (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, Room 1127 HHSC,701 W 168th St, New York, NY 10032 USA.		Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547	NATIONAL CANCER INSTITUTE [P01CA075399] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA75399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELSON HT, 1970, CANCER RES, V30, P2213; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Chen Y, 1996, J BIOL CHEM, V271, P19637, DOI 10.1074/jbc.271.33.19637; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GOGA A, 1995, ONCOGENE, V11, P791; GREEN PL, 1989, J VIROL, V63, P1989, DOI 10.1128/JVI.63.5.1989-1994.1989; GREEN PL, 1987, J VIROL, V61, P2192, DOI 10.1128/JVI.61.7.2192-2197.1987; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Huang TS, 1996, ONCOGENE, V13, P625; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; PRATT DM, 1977, CELL, V12, P683, DOI 10.1016/0092-8674(77)90268-9; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; PROKOCIMER M, 1994, BLOOD, V84, P2391; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Raffel GD, 1996, J BIOL CHEM, V271, P4640; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROSENBERG NE, 1980, J VIROL, V36, P766, DOI 10.1128/JVI.36.3.766-774.1980; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; Thome KC, 1997, J VIROL, V71, P8149, DOI 10.1128/JVI.71.11.8149-8156.1997; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Unnikrishnan I, 1999, MOL CELL BIOL, V19, P4825, DOI 10.1128/mcb.19.7.4825; WATANABE SM, 1983, J VIROL, V45, P1028, DOI 10.1128/JVI.45.3.1028-1036.1983; WHITLOCK CA, 1983, MOL CELL BIOL, V3, P596, DOI 10.1128/MCB.3.4.596; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654	51	34	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7731	7739		10.1038/sj.onc.1203290	http://dx.doi.org/10.1038/sj.onc.1203290			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618713	Bronze			2022-12-17	WOS:000084256900002
J	Okada-Ban, M; Moens, G; Thiery, JP; Jouanneau, J				Okada-Ban, M; Moens, G; Thiery, JP; Jouanneau, J			Nuclear 24 kD fibroblast growth factor (FGF)-2 confers metastatic properties on rat bladder carcinoma cells	ONCOGENE			English	Article						FGF-2; nuclear localization; tumor progression; lung metastasis	MOLECULAR-WEIGHT FORMS; IN-VIVO; TRANSCRIPTION; PROLIFERATION; TRANSLATION; TRANSITION; EXPRESSION; PHENOTYPE; BINDING; FAMILY	The tumorigenic and metastatic properties of rat bladder carcinoma NET-II cells transfected with a cDNA encoding the 24 kD nuclear isoform of human fibroblast growth factor-2 (FGF-2) were analysed and compared with those cells producing the 18 kD cytoplasmic isoform FGF-2. In transfected clones, 24 kD FGF-2 was found in the nucleus, and no FGF-2 was secreted. RT-PCR analysis shelved no upregulation of FGF-2-specific receptor FGFR2c expression in these proliferating transfected cells. A shorter latency period for in vivo tumor formation and abundant spontaneous lung metastases were only seen if nuclear FGF-2-producing cells were injected subcutaneously into nude mice. Intravenous injection of 24 kD FGF-2-producing cells led to extensive experimental lung metastases whereas injection of control NET-II cells or 18 kD FGF-a-producing cells did not. As FGF-2-producing cells have no specific FGF-2 receptors, our results suggest that the 24 kD FGF-2 has nuclear targets, and activates metastatic property of carcinoma cells via a mechanism other than the conventional FGF receptor-mediated signaling pathway.	Inst Curie, CNRS, UMR144, Sect Rech, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite	Okada-Ban, M (corresponding author), Inst Curie, CNRS, UMR144, Sect Rech, 26 Rue Ulm, F-75248 Paris 05, France.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020				Arnaud E, 1999, MOL CELL BIOL, V19, P505; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COLTRINI D, 1995, CANCER RES, V55, P4729; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; ESTIVAL A, 1993, CANCER RES, V53, P1182; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUALANDRIS A, 1993, GROWTH FACTORS, V8, P49, DOI 10.3109/08977199309029134; Hill DJ, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046926; Jouanneau J, 1997, ONCOGENE, V14, P671, DOI 10.1038/sj.onc.1200883; JOUANNEAU J, 1994, P NATL ACAD SCI USA, V91, P286, DOI 10.1073/pnas.91.1.286; JOUANNEAU J, 1995, GROWTH FACTORS, V12, P37, DOI 10.3109/08977199509003212; Joy A, 1997, ONCOGENE, V14, P171, DOI 10.1038/sj.onc.1200823; Levine JE, 1995, NEUROIMMUNOMODULAT, V2, P290, DOI 10.1159/000097208; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; NAKANISHI Y, 1992, P NATL ACAD SCI USA, V89, P5216, DOI 10.1073/pnas.89.12.5216; PASUMARTHI K, 1995, CIRC RES, V78, P126; Pintucci G, 1996, MOL BIOL CELL, V7, P1249, DOI 10.1091/mbc.7.8.1249; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; RENCO M, 1990, J CELL PHYSL, V144, P108; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; Sidransky D, 1997, SCIENCE, V278, P1054, DOI 10.1126/science.278.5340.1054; TESSLER S, 1990, J CELL PHYSIOL, V145, P310, DOI 10.1002/jcp.1041450216; TOSHIMA K, 1971, J NATL CANCER I, V47, P979	33	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6719	6724		10.1038/sj.onc.1203092	http://dx.doi.org/10.1038/sj.onc.1203092			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597279				2022-12-17	WOS:000083792000013
J	Gire, V; Marshall, CJ; Wynford-Thomas, D				Gire, V; Marshall, CJ; Wynford-Thomas, D			Activation of mitogen-activated protein kinase is necessary but not sufficient for proliferation of human thyroid epithelial cells induced by mutant Ras	ONCOGENE			English	Article						Ras; MAP kinase; epithelial; thyroid; signalling	SIGNAL-REGULATED KINASE; PHORBOL ESTER; DNA-SYNTHESIS; 3T3 CELLS; IN-VITRO; TRANSFORMATION; GROWTH; CASCADE; PHOSPHORYLATION; PATHWAY	Given the high frequency of ras oncogene activation in several common human cancers, its signal pathways are an important target for novel therapy, For practical reasons, however, these have been studied mainly in the context of transformation of established fibroblast cell lines, whereas ras acts at an earlier stage in human tumorigenesis and predominantly on epithelial cells, Here we have developed a more directly relevant model-human primary thyroid epithelial cells-which are a major target of naturally-occurring Pas mutation, and in which expression of mutant Pas in culture induces clonal expansion without morphological transformation, closely reproducing the phenotype of the corresponding tumour in vivo, Transient or stable expression of mutant H-ras (by scrapeloading or retroviral infection) at levels which stimulated proliferation induced sustained activation and translocation of MAP kinase (MAPK) in these cells, inhibition of the MAPK pathway at the level of MAPKK, by expression of a dominant-negative mutant or by the pharmacological inhibitor PD98059, efficiently blocked the proliferative response, Conversely, selective activation of MAPK by a constitutively-active MAPKK1 mutant failed to mimic the action of Pas and, although this was achievable with activated Raf, micro-injection of anti-ras antibodies showed that this still required endogenous wild-type Ras function, In contrast to recent results obtained with a rodent thyroid cell line (WRT), therefore, activation of the MAPK pathway is necessary, but not sufficient, for the proliferogenic action of mutant Pas on primary human thyroid cells, These data emphasize the unreliability of extrapolation from cell lines and establish the feasibility of using a more representative human epithelial model for Pas signalling studies.	Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Cardiff CF4 4XN, S Glam, Wales; Inst Canc Res, Chester Beatty Labs, Canc Res Campaign Ctr Cell & Mol Biol, London SW3 6JB, England	Cardiff University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Wynford-Thomas, D (corresponding author), Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Heath Pk, Cardiff CF4 4XN, S Glam, Wales.		Gire, Véronique/AAC-2218-2020; Gire, Veronique/N-7553-2017	Gire, Veronique/0000-0002-9009-2185				ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOND J, 1992, MOL CARCINOGEN, V5, P129, DOI 10.1002/mc.2940050208; BOND JA, 1994, ONCOGENE, V9, P281; BOND JA, 1996, INT J CANCER, V67, P56; BOS JL, 1989, CANCER RES, V49, P4682; Cobellis G, 1998, ONCOGENE, V17, P2047, DOI 10.1038/sj.onc.1202130; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; DAWSON TP, 1995, CANCER RES, V55, P915; DENT P, 1993, MOL BIOL CELL, V4, P483, DOI 10.1091/mbc.4.5.483; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Gallagher AP, 1998, CANCER RES, V58, P2029; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LAMY F, 1993, J BIOL CHEM, V268, P8398; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1989, BRIT J CANCER, V60, P897, DOI 10.1038/bjc.1989.387; LEMOINE NR, 1990, ONCOGENE, V5, P1833; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCNEIL PL, 1984, J CELL BIOL, V98, P1556, DOI 10.1083/jcb.98.4.1556; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; MORRIS JDH, 1989, ONCOGENE, V4, P27; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SUAREZ HG, 1990, ONCOGENE, V5, P565; Tombes RM, 1998, BIOCHEM J, V330, P1451; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; WYNFORDTHOMAS D, 1991, J PATHOL, V165, P187, DOI 10.1002/path.1711650302; WYNFORDTHOMAS D, 1993, CANCER SURV, V16, P115; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586	64	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4819	4832		10.1038/sj.onc.1202857	http://dx.doi.org/10.1038/sj.onc.1202857			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490815				2022-12-17	WOS:000082184800006
J	Alkhalaf, M; Ganguli, G; Messaddeq, N; Le Meur, M; Wasylyk, B				Alkhalaf, M; Ganguli, G; Messaddeq, N; Le Meur, M; Wasylyk, B			MDM2 overexpression generates a skin phenotype in both wild type and p53 null mice	ONCOGENE			English	Article						cytokeratins; desquamation; differentiation; epidermis; proliferation ichthyosis vulgaris	HUMAN PAPILLOMAVIRUS TYPE-16; TRANSGENIC MICE; TARGETED EXPRESSION; TRANSCRIPTIONAL ACTIVITY; MALIGNANT PROGRESSION; CELL-DIFFERENTIATION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ENHANCER PROMOTER; TUMOR-DEVELOPMENT	The MDM2 proto-oncogene is overexpressed in human tumours and regulates the activities of the tumour suppressors p53 and pRB We created mice that overexpress MDM2 under the control of the CMV promoter. These mice did not display an increased tumour incidence, but rather a specific skin phenotype, characterized by desquamation and hyperkeratosis. Transgenic MDM2 was found to be overexpressed in the epidermis, a tissue that normally expresses high levels of MDM2. The phenotype appeared during the first week after birth and then lessened with age, closely following the level of expression of the transgene. MDM2 overexpression was associated with an increase in proliferation in the basal layer, thickening of the epidermis, altered expression of the differentiation markers cytokeratin CK14, CK10 and CK1, and a decrease in the size and the number of granules that contain products of differentiation. Transgenic mice on a p53 null background displayed similar although not identical changes, showing that the effects of MDM2 are to a certain degree p53 independent. The skin is a major site of MDM2 expression in mice, raising the possibility that MDM2 overexpression perturbs the normal pattern of MDM2 expression and inhibits differentiation of the epidermis.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch Graffenstaden, France.		Indra, Gitali/G-2963-2016; Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; Arbeit JM, 1996, CANCER SURV, V26, P7; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; AUEWARAKUL P, 1994, MOL CELL BIOL, V14, P8250, DOI 10.1128/MCB.14.12.8250; BALE SJ, 1994, J INVEST DERMATOL, V102, pS49, DOI 10.1111/1523-1747.ep12388591; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bol D, 1998, MOL CARCINOGEN, V21, P2, DOI 10.1002/(SICI)1098-2744(199801)21:1<2::AID-MC2>3.0.CO;2-R; Bol DK, 1997, ONCOGENE, V14, P1725, DOI 10.1038/sj.onc.1201011; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Brown K, 1998, CURR BIOL, V8, P516, DOI 10.1016/S0960-9822(98)70203-9; BROWN K, 1995, CANCER METAST REV, V14, P113, DOI 10.1007/BF00665795; BuesoRamos CE, 1996, BREAST CANCER RES TR, V37, P179, DOI 10.1007/BF01806499; BUESORAMOS CE, 1995, LEUKEMIA LYMPHOMA, V17, P13, DOI 10.3109/10428199509051698; Byrne C, 1997, BIOESSAYS, V19, P691, DOI 10.1002/bies.950190809; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; Carroll JM, 1997, J INVEST DERMATOL, V108, P412, DOI 10.1111/1523-1747.ep12289702; CARROLL JM, 1995, CELL, V83, P957, DOI 10.1016/0092-8674(95)90211-2; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CORDONCARDO C, 1994, CANCER RES, V54, P794; Coussens LM, 1996, AM J PATHOL, V149, P1899; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Dazard JE, 1997, ONCOGENE, V14, P1123, DOI 10.1038/sj.onc.1200922; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Epstein EH, 1996, CURR OPIN GENET DEV, V6, P295, DOI 10.1016/S0959-437X(96)80005-0; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Francis Julie S., 1994, Current Opinion in Pediatrics, V6, P447, DOI 10.1097/00008480-199408000-00016; FUCHS E, 1992, P NATL ACAD SCI USA, V89, P6906, DOI 10.1073/pnas.89.15.6906; FURTH PA, 1991, NUCLEIC ACIDS RES, V19, P6205, DOI 10.1093/nar/19.22.6205; GREENHALGH DA, 1994, CELL GROWTH DIFFER, V5, P667; Haines DS, 1997, LEUKEMIA LYMPHOMA, V26, P227, DOI 10.3109/10428199709051772; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Hall PA, 1997, CURR BIOL, V7, pR144, DOI 10.1016/S0960-9822(97)70074-5; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; HOLBROOK KA, 1989, J INVEST DERMATOL, V92, pS84, DOI 10.1111/1523-1747.ep13075079; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jones SJ, 1997, J INVEST DERMATOL, V109, P187, DOI 10.1111/1523-1747.ep12319308; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KOEDOOD M, 1995, J VIROL, V69, P2194, DOI 10.1128/JVI.69.4.2194-2207.1995; Kondo S, 1996, ONCOGENE, V13, P1773; KONDO S, 1995, ONCOGENE, V10, P2001; KOTHARY R, 1991, MECH DEVELOP, V35, P25, DOI 10.1016/0925-4773(91)90038-8; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUNA RMD, 1995, NATURE, V378, P203; Luna RMDO, 1996, GENOMICS, V33, P352, DOI 10.1006/geno.1996.0210; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Marks DI, 1996, BRIT J HAEMATOL, V92, P890, DOI 10.1046/j.1365-2141.1996.439978.x; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MAXWELL SA, 1994, ANTICANCER RES, V14, P2541; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Momand J, 1997, J CELL BIOCHEM, V64, P343; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Neil JC, 1997, TRENDS MICROBIOL, V5, P115, DOI 10.1016/S0966-842X(96)10083-4; OLSON DC, 1993, ONCOGENE, V8, P2353; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Raskin CA, 1997, J AM ACAD DERMATOL, V36, P885, DOI 10.1016/S0190-9622(97)80266-6; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Santos M, 1997, MOL CARCINOGEN, V20, P3, DOI 10.1002/(SICI)1098-2744(199709)20:1<3::AID-MC2>3.0.CO;2-R; Schlott T, 1997, J PATHOL, V182, P54; SCHMIDT EV, 1990, MOL CELL BIOL, V10, P4406, DOI 10.1128/MCB.10.8.4406; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Wang XJ, 1998, ONCOGENE, V17, P35, DOI 10.1038/sj.onc.1201890; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WILLIAMS ML, 1992, PEDIATR DERMATOL, V9, P365, DOI 10.1111/j.1525-1470.1992.tb00632.x; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Xie W, 1998, CELL GROWTH DIFFER, V9, P313; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	88	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1419	1434		10.1038/sj.onc.1202448	http://dx.doi.org/10.1038/sj.onc.1202448			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050879	Bronze			2022-12-17	WOS:000078651600004
J	Munnes, M; Patrone, G; Schmitz, B; Romeo, G; Doerfler, W				Munnes, M; Patrone, G; Schmitz, B; Romeo, G; Doerfler, W			A 5 '-CG-3 '-rich region in the promoter of the transcriptionally frequently silenced RET protooncogene lacks methylated cytidine residues	ONCOGENE			English	Article						HSCR patients; RET protooncogene promoter; 5 '-CG-3 '-rich region in the RET promoter	NEUROBLASTOMA CELL-LINES; DNA METHYLATION; HIRSCHSPRUNGS-DISEASE; CHLORAMPHENICOL ACETYLTRANSFERASE; NEURONAL DIFFERENTIATION; ADENOVIRUS TYPE-2; MAMMALIAN-CELLS; GENE-EXPRESSION; MESSENGER-RNA; MUTATIONS	In a large proportion of familial and sporadic cases of Hirschsprung disease (HSCR) mutations in the RET (rearranged during transfection) protooncogene have been described. We have investigated the structure of the RET gene promoter and have analysed a region of approximately 1000 nucleotides in its promoter and 5'-upstream segments for the occurrence of 5-methyldeoxycytidine (5-mC) residues by using the bisulfite protocol of the genomic sequencing method. With an estimated sensitivity of about 93% of this technique, not a single 5-mC residue could be detected in the control region of a gene that seems to be silenced or exhibit low activity in many adult tissues. In these experiments, the DNAs of peripheral white blood cells (PWBC) from four healthy individuals, from seven patients with familial HSCR, as well as DNAs from different human tissues and from a human embryonic kidney (HEK) cell line have been included. Tn a DNA segment starting 790 nucleotides upstream of the transcriptional start site of the RET gene, a few 5-mC residues have been identified. This region possibly constitutes the transition site from an unmethylated promoter to a more extensively methylated region in the human genome. The data presented are remarkable in that a highly 5'-CG-3'-enriched segment of the human genome with 49 5'-CG-3' dinucleotide pairs in 400 bp within the putative promoter region is completely devoid of 5-mC residues, although this control region is not actively transcribed in most adult human tissues. By hybridization of a PCR-amplified RET protooncogene cDNA probe harboring exons 9-15 to a membrane (Clontech) containing poly-A selected RNAs from 50 different human tissues, weak RET protooncogene expression in many of the neural cell derived tissues has been detected. RNAs extracted from many other human tissues do not share sequence homologies to this P-32-labeled probe. Mechanisms other than DNA methylation obviously play the crucial role in the inactivation of the RET gene promoter in these tissues. We have also demonstrated by the in vitro premethylation of a RET promoter-chloramphenicol acetyltransferase (CAT) gene construct and transient transfection experiments into neuroblastoma cells that the transcriptional activity of the RET promoter is decreased by HpaII (5'-CCGG-3') methylation and abolished by SssI (5'-CG-3') methylation, Hence, the RET promoter region is sensitive to this regulatory signal. However in vivo, DNA methylation of the promoter region seems not to be the predominant regulatory mechanism for the RET protooncogene, Possibly, in adults the RET gene can be occasionally activated.	Univ Cologne, Inst Genet, D-5000 Cologne 41, Germany; Univ Genoa, Fac Med, I-16148 Genoa, Italy; Ist Giannina Gaslini, Genet Mol Lab, I-16148 Genoa, Italy	University of Cologne; University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini	Doerfler, W (corresponding author), Univ Cologne, Inst Genet, D-5000 Cologne 41, Germany.							ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BADNER JA, 1990, AM J HUM GENET, V46, P568; BEHNKRAPPA A, 1993, HUM MOL GENET, V2, P993, DOI 10.1093/hmg/2.7.993; BODIAN M, 1963, ANN HUM GENET, V26, P261, DOI 10.1111/j.1469-1809.1963.tb01983.x; BONGARZONE I, 1994, CANCER RES, V54, P2979; BUNONE G, 1995, EXP CELL RES, V217, P92, DOI 10.1006/excr.1995.1067; CECCHERINI I, 1994, ONCOGENE, V9, P3025; CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; CEDAR H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P1, DOI 10.1016/0167-4781(90)90076-E; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CONSTANTINIDES PG, 1977, NATURE, V267, P364, DOI 10.1038/267364a0; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DURBEC P, 1996, NATURE, V381, P785; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GOLDBERG EL, 1984, INT J EPIDEMIOL, V13, P479, DOI 10.1093/ije/13.4.479; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hofstra RMW, 1996, NAT GENET, V12, P445, DOI 10.1038/ng0496-445; IKEDA I, 1990, ONCOGENE, V5, P1291; ITOH F, 1992, ONCOGENE, V7, P1210; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; Kambouris M, 1996, HUM MUTAT, V8, P64, DOI 10.1002/(SICI)1098-1004(1996)8:1<64::AID-HUMU9>3.0.CO;2-P; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; KOCHANEK S, 1993, EMBO J, V12, P1141, DOI 10.1002/j.1460-2075.1993.tb05755.x; KOCHANEK S, 1990, P NATL ACAD SCI USA, V87, P8830, DOI 10.1073/pnas.87.22.8830; KRUCZEK I, 1983, P NATL ACAD SCI-BIOL, V80, P7586, DOI 10.1073/pnas.80.24.7586; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LANGNER KD, 1984, P NATL ACAD SCI-BIOL, V81, P2950, DOI 10.1073/pnas.81.10.2950; LARIMORE TC, 1993, P NATL ACAD SCI USA, V90, P492; LYONNET S, 1994, CR ACAD SCI III-VIE, V317, P358; MARTUCCIELLO G, 1992, PEDIATR SURG INT, V7, P308; MUNNES M, 1995, J VIROL, V69, P2240, DOI 10.1128/JVI.69.4.2240-2247.1995; NAGAO M, 1990, JPN J CANCER RES, V81, P309, DOI 10.1111/j.1349-7006.1990.tb02566.x; Okamoto E, 1967, J PEDIATR SURG, V2, P437; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PASINI B, 1995, ONCOGENE, V11, P1737; PASSARGE E, 1997, PRINCIPLES PRACTICE, P1527; Patrone G, 1997, FEBS LETT, V419, P76, DOI 10.1016/S0014-5793(97)01435-X; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; PULITI A, 1993, CYTOGENET CELL GENET, V63, P102, DOI 10.1159/000133510; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHUCHARDT A, 1995, ONCOGENE, V10, P641; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SZENTIRMAY Z, 1990, ONCOGENE, V5, P701; TAHIRA T, 1991, ONCOGENE, V6, P2333; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; Takaya K, 1996, J MOL MED-JMM, V74, P617, DOI 10.1007/s001090050065; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; WEISSHAAR B, 1988, J MOL BIOL, V202, P255, DOI 10.1016/0022-2836(88)90456-1; Zeschnigk M, 1997, HUM MOL GENET, V6, P387, DOI 10.1093/hmg/6.3.387	55	34	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2573	2583		10.1038/sj.onc.1202165	http://dx.doi.org/10.1038/sj.onc.1202165			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840920				2022-12-17	WOS:000077058900004
J	Lee, JM				Lee, JM			Inhibition of p53-dependent apoptosis by the KIT tyrosine kinase: regulation of mitochondrial permeability transition and reactive oxygen species generation	ONCOGENE			English	Article						p53; KIT; Steel; mitochondria; apoptosis; oxygen	PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR GENE; CYTOCHROME-C; STEEL FACTOR; P53-MEDIATED APOPTOSIS; LYMPHOCYTE APOPTOSIS; MAST-CELLS; W/C-KIT; BCL-2; P53	The KIT protein is a receptor tyrosine kinase of the platelet derived growth factor (PDGF) receptor family which regulates haematopoiesis, melanogenesis and gut and germ cell development. KIT regulates these diverse processes, at least in part, by inhibiting apoptosis. We have previously found that KIT can suppress p53-mediated apoptosis. The mechanism by which KIT suppresses apoptosis is, however, uncharacterized. Neither is it clear how p53 induces apoptosis. In this report me find that p53-dependent apoptosis proceeds through a pathway involving depolarization of the mitochondrial electropotential gradient (Delta Psi(m)) and the generation of reactive oxygen species (ROS). KIT activation suppresses p53-induced apoptosis in the mouse DP16 Friend erythroleukemia cell line by preventing Delta Psi(m) depolarization and ROS generation, Thus, the KIT kinase prevents apoptosis by regulating mitochondrial function and cellular redox state.	Hamilton Reg Canc Ctr, Hamilton, ON L8V 5C2, Canada; McMaster Univ, Dept Pathol, Hamilton, ON L8S 4K1, Canada	McMaster University; McMaster University	Lee, JM (corresponding author), Hamilton Reg Canc Ctr, 699 Concess St, Hamilton, ON L8V 5C2, Canada.							ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNSTEIN A, 1990, CIBA F SYMP, V148, P158; BERNSTEIN A, 1991, SEMIN HEMATOL, V28, P138; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CACERESCORTES J, 1994, J BIOL CHEM, V269, P12084; CARSON WE, 1994, P NATL ACAD SCI USA, V91, P7553, DOI 10.1073/pnas.91.16.7553; Castedo M, 1996, J IMMUNOL, V157, P512; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; delPeso L, 1997, SCIENCE, V278, P687; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Henkart PA, 1996, J EXP MED, V183, P1293, DOI 10.1084/jem.183.4.1293; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; HUNTER TV, 1994, ANN REV CELL BIOL, V10, P251; IEMURA A, 1994, AM J PATHOL, V144, P321; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LEE JM, 1995, CANCER METAST REV, V14, P149, DOI 10.1007/BF00665797; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEV S, 1992, J BIOL CHEM, V267, P15970; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LOWE SW, 1993, NATURE, V362, P849; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MEKORI YA, 1993, J IMMUNOL, V151, P3775; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; NETA R, 1993, BLOOD, V81, P324; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Shimizu S, 1996, ONCOGENE, V13, P21; SHUI CX, 1995, CANCER RES, V55, P3431; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Um HD, 1996, J IMMUNOL, V156, P3469; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YEE NS, 1994, J EXP MED, V179, P1777, DOI 10.1084/jem.179.6.1777; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	73	34	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1653	1662		10.1038/sj.onc.1202102	http://dx.doi.org/10.1038/sj.onc.1202102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796694				2022-12-17	WOS:000076200100003
J	Coxon, AB; Ward, JM; Geradts, J; Otterson, GA; Zajac-Kaye, M; Kaye, FJ				Coxon, AB; Ward, JM; Geradts, J; Otterson, GA; Zajac-Kaye, M; Kaye, FJ			RET cooperates with RB/p53 inactivation in a somatic multi-step model for murine thyroid cancer	ONCOGENE			English	Article						mouse model; p53; RB; Ret; thyroid cancer	GERMLINE MUTATIONS; MICE; RB; TUMORS; SYSTEM; P53	Mice bred to carry germline Rb and p53 null alleles are associated with a tumor spectrum that overlaps with the inherited multiple endocrine neoplasia-1 (MEN1) and MEN2 syndromes in humans, including medullary thyroid cancer (MTC). To study the genetic basis for these tumors, we microdissected MTC specimens or obtained fresh MTC tissue from nine independent Rb+/- p53(+/-) mice, amplified the region of the Ret gene known to be mutated in human MTC, and detected acquired missense Ret mutations in four different mice, These mutations were Localized to a group of tandem cysteines which are analogous to activating germline mutations observed in human MEN2A and familial MTC (FMTC), To determine whether the remaining wild type Rb allele was inactivated in these murine MTC samples, we subjected tumor tissue to immunohistochemical staining with an Rb antibody, and demonstrated the absence of RE staining in murine MTC, while normal tissue retained RE nuclear staining. These findings demonstrate the ability of the gene knockout model to recapitulate somatic multi-step tumorigenesis and suggest that the development of a murine neuroendocrine tumor requires mutational dysregulation within both receptor tyrosine kinase and nuclear tumor suppressor gene pathways.	NCI, Dept Genet, Bethesda, MD 20889 USA; Natl Naval Med Ctr, Bethesda, MD 20889 USA; Div Basic Sci, Anim Sci Branch, Vet & Tumor Pathol Sect, Frederick, MD 21702 USA; Univ N Carolina, Dept Lab Med & Pathol, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center; University of North Carolina; University of North Carolina Chapel Hill	Kaye, FJ (corresponding author), Naval Hosp, NCI, Bldg 8-Rm 5101, Bethesda, MD 20889 USA.		kaye, frederic/E-2437-2011					Edery P, 1997, BIOESSAYS, V19, P389, DOI 10.1002/bies.950190506; ERLANDSON RA, 1994, ULTRASTRUCT PATHOL, V18, P149, DOI 10.3109/01913129409016286; HARVEY M, 1995, CANCER RES, V55, P1146; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kloppel G, 1994, Ann N Y Acad Sci, V733, P19; LARSSON C, 1994, ANN NY ACAD SCI, V733, P453, DOI 10.1111/j.1749-6632.1994.tb17295.x; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SMITH DP, 1994, J CELL SCI, P43; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480	12	34	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1625	1628		10.1038/sj.onc.1202381	http://dx.doi.org/10.1038/sj.onc.1202381			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794240				2022-12-17	WOS:000076089900015
J	Jaakkola, P; Maatta, A; Jalkanen, M				Jaakkola, P; Maatta, A; Jalkanen, M			The activation and composition of FiRE (an FGF-inducible response element) differ in a cell type- and growth factor-specific manner	ONCOGENE			English	Article						AP-1; EGF; FGF; FIN-1; KGF; syndecan-1; transcription	HEPARAN-SULFATE PROTEOGLYCANS; LATE TRANSCRIPTION FACTOR; TERMINAL DIFFERENTIATION; HUMAN KERATINOCYTES; GENE-EXPRESSION; SYNDECAN-1 GENE; WOUND REPAIR; IN-VIVO; C-FOS; PROMOTER	The expression of the heparan sulfate proteoglycan, syndecan-1, is induced both in keratinocytes and in fibroblasts during development and tissue regeneration. Here we report that in keratinocytes the syndecan-1 gene was stimulated by EGF but not by FGF-2, In fibroblasts it was stimulated by FGF-2 but not by EGF, Likewise, the recently discovered FGF-inducible response element (FiRE) on the gene of syndecan-1 was stimulated by FGF-2 in fibroblasts and by EGF in keratinocytes, but not vice vel sn. The FIRE has two binding sites for an activator protein-1 (AP-1), one for an FGF-inducible nuclear factor (FIN-1) and one for an upstream stimulatory factor-1 (USF-1), The growth factor-stimulated binding of these transcription factors, as well as their requirement for FiRE activation, varied between the two cell types. First, although AP-ls were required for activation of FIRE in both cell types, the binding of AP-1 to FiRE was increased by growth factor-stimulation only in fibroblasts and not in keratinocytes, Secondly, FiRE did not bind FIN-1 nor needed the FIN-1 binding site for EGF-stimulated activation in keratinocytes, in contrast to the FGF-stimulated activation of FiRE in fibroblasts, Thirdly, EGF, which did not activate FIRE in fibroblasts, failed to activate FIN-1 in these cells. Finally, an USF-1 binding site that was necessary for activation of FIRE in keratinocytes was not needed in fibroblasts, These data suggest mechanisms by which members of the EGF- and FGF-families can differentially stimulate transcription through AP-1 regulated elements in a cell type-specific manner.	Univ Turku, Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland	University of Turku; Abo Akademi University	Jalkanen, M (corresponding author), Univ Turku, Ctr Biotechnol, Tykistokatu 6B, FIN-20520 Turku, Finland.		Jaakkola, Panu M/B-4355-2012	Maatta, Arto/0000-0003-3759-1310; Jaakkola, Panu/0000-0002-2365-4985				ANDREE C, 1994, P NATL ACAD SCI USA, V91, P12188, DOI 10.1073/pnas.91.25.12188; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BENNETT NT, 1993, AM J SURG, V165, P728, DOI 10.1016/S0002-9610(05)80797-4; BENZEEV A, 1990, CELL REGUL, V1, P621, DOI 10.1091/mbc.1.9.621; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BROWN GL, 1989, NEW ENGL J MED, V321, P76, DOI 10.1056/NEJM198907133210203; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAVIDSON JM, 1991, ANN NY ACAD SCI, V638, P306, DOI 10.1111/j.1749-6632.1991.tb49041.x; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; FELTS SJ, 1995, BIOCHEMISTRY-US, V34, P12355, DOI 10.1021/bi00038a032; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Jaakkola P, 1997, MOL CELL BIOL, V17, P3210, DOI 10.1128/MCB.17.6.3210; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; KLUCHER KM, 1990, J VIROL, V64, P4189, DOI 10.1128/JVI.64.9.4189-4198.1990; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LORET C, 1989, J BIOL CHEM, V264, P8319; PESTELL RG, 1995, J BIOL CHEM, V270, P18301, DOI 10.1074/jbc.270.31.18301; TAN Y, 1994, MOL CELL BIOL, V14, P7546, DOI 10.1128/MCB.14.11.7546; TSUBOI R, 1993, J INVEST DERMATOL, V101, P49, DOI 10.1111/1523-1747.ep12358892; USHIKAI M, 1994, J VIROL, V68, P6655, DOI 10.1128/JVI.68.10.6655-6666.1994; VAINIO S, 1992, DEV DYNAM, V194, P105, DOI 10.1002/aja.1001940204; VAINIO S, 1989, DEV BIOL, V134, P382, DOI 10.1016/0012-1606(89)90110-3; VIHINEN T, 1993, J BIOL CHEM, V268, P17261	32	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1279	1286		10.1038/sj.onc.1202002	http://dx.doi.org/10.1038/sj.onc.1202002			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771971				2022-12-17	WOS:000075803300010
J	Maouche-Chretien, L; Deleu, N; Badoual, C; Fraissignes, P; Berger, R; Gaulard, P; Romeo, PH; Leroy-Viard, K				Maouche-Chretien, L; Deleu, N; Badoual, C; Fraissignes, P; Berger, R; Gaulard, P; Romeo, PH; Leroy-Viard, K			Identification of a novel cDNA, encoding a cytoskeletal associated protein, differentially expressed in diffuse large B cell lymphomas	ONCOGENE			English	Article						lymphoma; cytoskeleton; cloning; DDRT	NON-HODGKINS-LYMPHOMA; GERMINAL CENTER FORMATION; MESSENGER-RNA; CHROMOSOMAL-ABNORMALITIES; CLINICAL CORRELATIONS; CYTOGENETIC ANALYSIS; KIEL CLASSIFICATION; ACTIN CYTOSKELETON; BTB/POZ DOMAIN; CROSS-LINKING	Diffuse large B-cell lymphomas (DLBL) constitute an heterogeneous clinico-pathological entity. To characterize molecular events related to histological subtypes, clinical presentation or outcome, we compared the mRNAs expressed in a limited series of DLBL by Differential display-reverse transcription (DDRT) and cloned a differential cDNA, that we called LB1, LB1 open reading frame encodes a 683 amino-acid polypeptide that does not show significant homology upon comparison to protein databases, nor any structural domain relating LB1 to an already known protein family, Immunofluorescence analysis of transfected COS cells showed a cytoplasmic filamentous staining, indicating that LB1 protein is tightly associated with cytoskeletal fibers, Two LB1 transcripts, a major 3,6 - 3.9 Kb and a minor 2.2 Kb transcripts, were detected among human haematopoietic and non-haematopoietic lines and tissues, LB1 transcripts were abundant in testis, thymus and in tumour derived cell lines, while barely detectable in liver, prostate and kidney, Concerning DLBL, LB1 expression was high in two cases of DLBL, and low or undetectable in four others, confirming the differential expression previously observed in the DDRT experiment. Furthermore, LB1 gene mapped to chromosome 13q14, a region that has been involved as a chromosomal breakpoint in DLBL, The cellular function of LB1 and its relationship with B cell maturation and/or oncogenesis remain to be established.	Hop Henri Mondor, INSERM, U474, F-94010 Creteil, France; Hop St Louis, Ctr G Hayem, INSERM, U301, F-75475 Paris, France; Hop Henri Mondor, Dept Pathol, F-94010 Creteil, France; Hop Henri Mondor, EA 2348, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Leroy-Viard, K (corresponding author), Hop Henri Mondor, INSERM, U474, 51 Av Mal De Lattre De Tassigny, F-94010 Creteil, France.		Leroy, Karen/E-9235-2011; maouche, leila/E-3887-2017; Romeo, Paul-Henri/L-5989-2017	Leroy, Karen/0000-0002-4379-0140; Romeo, Paul-Henri/0000-0002-8294-0367; Badoual, Cecile/0000-0002-1143-3085; CHRETIEN, LEILA/0000-0001-5747-9719				ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; BASTARD C, 1994, BLOOD, V83, P2423; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHERIF D, 1990, P NATL ACAD SCI USA, V87, P6639, DOI 10.1073/pnas.87.17.6639; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Engelhard M, 1997, BLOOD, V89, P2291; Foisner R, 1996, MOL BIOL CELL, V7, P273, DOI 10.1091/mbc.7.2.273; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Gomez J, 1997, J IMMUNOL, V158, P1516; HAILAT N, 1990, ONCOGENE, V5, P1615; HARRIS NL, 1994, BLOOD, V84, P1361; Hermine O, 1996, BLOOD, V87, P265, DOI 10.1182/blood.V87.1.265.bloodjournal871265; JACOBSON JO, 1993, CANCER, V72, P231, DOI 10.1002/1097-0142(19930701)72:1<231::AID-CNCR2820720141>3.0.CO;2-5; Jugloff LS, 1997, J IMMUNOL, V159, P1096; JUNEJA S, 1990, BRIT J HAEMATOL, V76, P231, DOI 10.1111/j.1365-2141.1990.tb07877.x; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KOCIALKOWSKI S, 1995, BRIT J HAEMATOL, V89, P55, DOI 10.1111/j.1365-2141.1995.tb08911.x; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LADANYI M, 1991, BLOOD, V77, P1057; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LO CF, 1994, BLOOD, V83, P1757; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; OFFIT K, 1991, BLOOD, V77, P1508; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; SCHOUTEN HC, 1990, BLOOD, V75, P1841; STANSFELD AG, 1988, LANCET, V1, P292; STAUDER R, 1995, BLOOD, V85, P2885, DOI 10.1182/blood.V85.10.2885.bloodjournal85102885; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VILLUENDAS R, 1993, BLOOD, V82, P3151; WHANGPENG J, 1995, BLOOD, V85, P203, DOI 10.1182/blood.V85.1.203.bloodjournal851203; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	42	34	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1245	1251		10.1038/sj.onc.1202048	http://dx.doi.org/10.1038/sj.onc.1202048			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771967				2022-12-17	WOS:000075803300006
J	Poirel, H; Lacronique, V; Mauchauffe, M; Le Coniat, M; Raffoux, E; Daniel, MT; Erickson, P; Drabkin, H; MacLeod, RAF; Drexler, HG; Ghysdael, J; Berger, R; Bernard, OA				Poirel, H; Lacronique, V; Mauchauffe, M; Le Coniat, M; Raffoux, E; Daniel, MT; Erickson, P; Drabkin, H; MacLeod, RAF; Drexler, HG; Ghysdael, J; Berger, R; Bernard, OA			Analysis of TEL proteins in human leukemias	ONCOGENE			English	Article						TEL/ETV6 proteins; AML1 proteins; t(12;21) translocation; acute leukemias; gene inactivation	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CELL-LINE; TRANSCRIPTIONAL ACTIVATION; MYELOMONOCYTIC LEUKEMIA; AML1 GENE; FUSION; TRANSLOCATION; T(12-21); DELETION	Chromosomal translocations involving the human 12p13 band frequently affect the TEL gene, usually resulting in gene fusion between TEL and genes encoding proteins of various types. The most frequent 12p13 translocation is the t(12;21)(p13;q22), which recombines TEL with the AMI;I gene on chromosome 21 and is frequently associated with deletion of the untranslocated TEL allele. Using antisera against different parts of TEL and against the AML1 proteins, we undertook Western blot and immunofluorescence analyses of leukemic samples with and without 12p13 abnormalities. In t(12;21) samples, TEL-AML1 was detected as several protein species in the nuclei, whereas the AML1-TEL protein, was inconsistently expressed. AML1 was found to be expressed but no normal TEL proteins were detected. A survey of the TEL proteins in a panel of human leukemic samples without t(12;21) revealed a variation in the ratio of TEL protein isoforms. We also analysed a leukemic cell line bearing a t(12;22)(p13;q11) that was found to affect the 5' untranslated CUT) region of TEL and to be associated with inactivation of the untranslocated TEL allele. No MN1-TEL fusion could be detected upon RT-PCR analysis, in contrast to the previously investigated t(12;22). Strikingly, extremely low levels of apparently normal TEL proteins, expressed from the translocated allele, were detected by Western blot analysis. These results suggest that the level of TEL expression can be important for leukemogenesis.	INSERM, U301, F-75010 Paris, France; Inst Genet Mol, CNRS, SD 301, F-75010 Paris, France; Hop St Louis, Cent Hematol Lab, Paris, France; Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA; Deutsch Sammlung Mikroorganism Zellkultur GmbH, German Collect Microorganisms & Cell Cultures, Braunschweig, Germany; Ctr Univ, Inst Curie, Sect Rech, CNRS,UMR 146, F-91405 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Leibniz Institut fur Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Bernard, OA (corresponding author), INSERM, U301, 27 Rue Juliette Dodu, F-75010 Paris, France.		Bernard, Olivier A./E-5721-2016; GHYSDAEL, Jacques/F-3377-2013; Penard-Lacronique, Virginie/R-1938-2019; Penard-Lacronique, Virginie/E-5729-2016	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; Bernard, Olivier/0000-0002-0463-9747				Andreasson P, 1997, GENE CHROMOSOME CANC, V19, P77, DOI 10.1002/(SICI)1098-2264(199706)19:2<77::AID-GCC2>3.0.CO;2-X; Baens M, 1996, GENOME RES, V6, P404, DOI 10.1101/gr.6.5.404; Bernard OA, 1996, LEUKEMIA LYMPHOMA, V23, P459, DOI 10.3109/10428199609054854; BUIJS A, 1995, ONCOGENE, V10, P1511; CAVE H, 1995, BLOOD, V86, P3869, DOI 10.1182/blood.V86.10.3869.bloodjournal86103869; Erickson PF, 1996, BLOOD, V88, P1813; GOLUB T, 1996, BIOCHIM BIOPHYS ACTA, V1288, P7; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kim DH, 1996, BLOOD, V88, P785, DOI 10.1182/blood.V88.3.785.bloodjournal883785; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LANOTTE M, 1991, BLOOD, V77, P1080; MacLeod RAF, 1996, GENE CHROMOSOME CANC, V16, P144; McLean TW, 1996, BLOOD, V88, P4252; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, CANCER RES, V57, P564; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; Raynaud SD, 1996, BLOOD, V88, P682, DOI 10.1182/blood.V88.2.682.bloodjournal882682; Romana SP, 1996, LEUKEMIA, V10, P167; ROMANA SP, 1994, GENE CHROMOSOME CANC, V9, P186, DOI 10.1002/gcc.2870090307; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; ROSENFELD C, 1977, NATURE, V267, P841, DOI 10.1038/267841a0; Stegmaier K, 1996, CANCER RES, V56, P1413; Suto Y, 1997, GENE CHROMOSOME CANC, V18, P254, DOI 10.1002/(SICI)1098-2264(199704)18:4<254::AID-GCC3>3.0.CO;2-#; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Tanaka T, 1996, MOL CELL BIOL, V16, P3967	34	34	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	1998	16	22					2895	2903		10.1038/sj.onc.1201817	http://dx.doi.org/10.1038/sj.onc.1201817			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671410				2022-12-17	WOS:000073988200008
J	Pan, S; Ming, KY; Dunn, TA; Li, KKC; Lee, KAW				Pan, S; Ming, KY; Dunn, TA; Li, KKC; Lee, KAW			The EWS/ATF1 fusion protein contains a dispersed activation domain that functions directly	ONCOGENE			English	Article						EWS/ATF1; oncogene; MMSP; transcriptional activation; yeast	TRANSCRIPTION FACTOR; DNA-BINDING; CHROMOSOME-TRANSLOCATION; MALIGNANT-MELANOMA; RESPONSIVE ELEMENT; EWING SARCOMA; GENE FUSION; SOFT PARTS; IN-VITRO; EWS	Naturally occurring chromosomal fusion of the Ewings Sarcoma Oncogene (EWS) to distinct cellular transcription factors, produces aberrant transcriptional activators that function as dominant oncogenes, In Malignant Melanoma of Soft Parts the N-terminal region of EWS is fused to C-terminal region of the cAMP-inducible transcription factor ATF1. The EWS/ATF1 fusion protein binds to ATF sites present in cAMP-responsive promoters via the ATF1 bZIP domain and activates transcription constitutively in a manner that is dependent on an activation domain (EAD) present in EWS. To further define the requirements for transactivation we have performed mutational analysis of EWS/ATF1 in mammalian cells and report several new findings. First, trans-activation by EWS/ATF1 does not require dimerisation with other ATF family members present in mammalian cells. Second, in contrast to the earlier suggestion of an allosteric role, the EAD can act directly. Third, determinants of trans-activation are dispersed throughout the EAD and cooperate synergistically to produce potent trans-activation. We also report that the region of EWS containing the EAD can activate transcription in Yeast, This latter finding might enable a genetic approach to understanding the mechanism of transcriptional activation by EWS and development of high-throughput screens for EWS inhibitors.	Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Lee, KAW (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Peoples R China.							BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BROWN AD, 1995, ONCOGENE, V10, P1749; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAREY M, 1992, J VIROL, V66, P4803, DOI 10.1128/JVI.66.8.4803-4813.1992; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Fujimura Y, 1996, ONCOGENE, V12, P159; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; JONES RH, 1989, P NATL ACAD SCI USA, V86, P2176, DOI 10.1073/pnas.86.7.2176; KIM J, 1997, IN PRESS ONCOGENE; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; LADANYI M, 1994, CANCER RES, V54, P2837; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIN YS, 1989, P NATL ACAD SCI USA, V86, P109, DOI 10.1073/pnas.86.1.109; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MASSON N, 1993, NUCLEIC ACIDS RES, V21, P4166, DOI 10.1093/nar/21.18.4166; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OHNO T, 1993, CANCER RES, V53, P5859; OUCHIDA M, 1995, ONCOGENE, V11, P1049; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RIBEIRO A, 1994, J BIOL CHEM, V269, P31124; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	36	34	36	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1625	1631		10.1038/sj.onc.1201671	http://dx.doi.org/10.1038/sj.onc.1201671			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569031				2022-12-17	WOS:000072743200014
J	Kim, J; Lee, K; Pelletier, J				Kim, J; Lee, K; Pelletier, J			The DNA binding domains of the WT1 tumor suppressor gene product and chimeric EWS/WT1 oncoprotein are functionally distinct	ONCOGENE			English	Article						EWS/WT1; DSRCT; oncogene; cancer genetics; transcription factor	ROUND-CELL TUMOR; EWINGS-SARCOMA TRANSLOCATION; EWS GENE; TRANSCRIPTIONAL ACTIVATOR; MALIGNANT-MELANOMA; FUSION PROTEIN; SOFT PARTS; RNA; APOPTOSIS; SEQUENCE	The t(11; 22)(p13; q12) translocation associated with desmosplastic small round cell tumor results in a chimeric molecule fusing the amino terminal domain (NTD) of the EWS1 gene to three of the four carboxyterminal zinc fingers of the WT1 tumor suppressor gene. Since the DNA binding domains of WT1 and EWS/WT1 are structurally different, we have assessed the functional consequences of the EWS/WT1 fusion. We find that the EWS/WT1 protein has a higher binding affinity for a given recognition target than the WT1 product. This is unlike other fusion products involving translocation of the NTD of EWS to DNA binding domains in which DNA binding specificity and affinity is not changed. We demonstrate that EWS/WT1 is a nuclear protein and that the NTD of EWS contains (a) nuclear localization signal(s). We also find that the integrity of a domain within the WT1 zinc fingers, responsible for mediating interaction between WT1 and the transcriptional repressor par-4, is disrupted in the EWS/WT1 fusion product. Deletion analysis of the NTD of EWS indicated that integrity of the entire domain was necessary to achieve full transactivation potential.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong	McGill University; McGill University; Hong Kong University of Science & Technology	Pelletier, J (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.							BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; BREUNING W, 1992, NAT GENET, V1, P144; BROWN AD, 1995, ONCOGENE, V10, P1749; Bruening W, 1996, FEBS LETT, V393, P41, DOI 10.1016/0014-5793(96)00853-8; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CLARKSON T, 1992, PCR A PRCTICAL APPRO, P187; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; GERALD WL, 1991, AM J SURG PATHOL, V15, P499, DOI 10.1097/00000478-199106000-00001; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; JEON IS, 1995, ONCOGENE, V10, P1229; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Karnieli E, 1996, J BIOL CHEM, V271, P19304, DOI 10.1074/jbc.271.32.19304; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; LADANYI M, 1994, CANCER RES, V54, P2837; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; OUCHIDA M, 1995, ONCOGENE, V11, P1049; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAUSCHER FJ, 1994, COLD SPRING HARB SYM, V59, P137, DOI 10.1101/SQB.1994.059.01.017; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Sambrook J, 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	41	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					1021	1030		10.1038/sj.onc.1201616	http://dx.doi.org/10.1038/sj.onc.1201616			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519876				2022-12-17	WOS:000072335900008
J	Matsuda, T; Sasaki, M; Kato, H; Yamada, H; Cohen, M; Barrett, JC; Oshimura, M; Wake, N				Matsuda, T; Sasaki, M; Kato, H; Yamada, H; Cohen, M; Barrett, JC; Oshimura, M; Wake, N			Human chromosome 7 carries a putative tumor suppressor gene(s) involved in choriocarcinoma	ONCOGENE			English	Article						tumor suppressor gene; choriocarcinoma; chromosome 7; homozygous deletion	HUMAN ENDOGENOUS RETROVIRUS; PRIMARY BREAST-CANCER; CARCINOMA CELL-LINE; HYDATIDIFORM MOLE; SQUAMOUS-CELL; MESSENGER-RNAS; TUMORIGENIC EXPRESSION; PANCREATIC-CARCINOMA; HOMOZYGOUS DELETIONS; FREQUENT LOSS	Choriocarcinoma developed from a complete hydatidiform mole has an unique genetic feature that involves monoallelic contribution from the paternal genome, To the chromosome carrying putative tumor gene(s), microcell-hybrids were isolated following fusion of choriocarcinoma cells with microcells from mouse A9 cells containing a single human chromosome (1, 2, 6, 7, 9 or 11), Microcell-hybrids with the introduction of chromosome 7 were suppressed or modulated for tumorigenicity and exhibited altered in vitro growth properties, Introduction of chromosomes 1, 2, 6, 9 or 11 had no effect, Tumorigenic revertants isolated from microcell-hybrids with the introduced chromosome 7 contains reduced numbers of chromosome 7, These findings suggest that chromosome 7 contains a putative tumor suppressor gene(s) for choriocarcinoma, Alterations in tumorigenic phenotypes seen in microcell-hybrids were not associated with the presence of either ERV3 or H-plk locus located on the introduced chromosome 7, indicating the putative tumor suppressor gene(s) is outside of ERV3 and H-plk gene loci, Furthermore, we obtained evidence to define a critical region on chromosome 7 (7p12-7q11.23) that was frequently lost in surgically removed choriocarcinoma tissues and cell lines, Using a panel of microsatellite markers, biallelic deletions were observed, which strongly suggests the presence of a tumor suppressor gene(s) within this critical region.	KYUSHU UNIV,MED INST BIOREGULAT,DEPT REPROD PHYSIOL & ENDOCRINOL,BEPPU,OITA 874,JAPAN; TOTTORI UNIV,FAC MED,SCH LIFE SCI,DEPT MOL & CELL GENET,YONAGO,TOTTORI 683,JAPAN; ABBOTT LABS,DEPT CORP MOL BIOL,ABBOTT PK,IL 60064; NIEHS,MOL CARCINOGENESIS LAB,NIH,RES TRIANGLE PK,NC 27709	Kyushu University; Tottori University; Abbott Laboratories; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)								Achille A, 1996, CANCER RES, V56, P3808; [Anonymous], 1982, MOL CLONING LAB MANU; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; ATKIN NB, 1993, CANCER GENET CYTOGEN, V67, P123, DOI 10.1016/0165-4608(93)90164-H; BELLEFROID EJ, 1989, DNA-J MOLEC CELL BIO, V8, P377, DOI 10.1089/dna.1.1989.8.377; BELLEFROID EJ, 1992, GENOMICS, V14, P780, DOI 10.1016/S0888-7543(05)80185-5; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; BOYD MT, 1993, VIROLOGY, V196, P905, DOI 10.1006/viro.1993.1556; CAVANEE WK, 1983, NATURE, V305, P779; CHERIF D, 1989, HUM GENET, V81, P358, DOI 10.1007/BF00283691; COHEN M, 1988, J CELL BIOCHEM, V36, P121, DOI 10.1002/jcb.240360203; CONWAY K, 1992, CANCER RES, V52, P6487; Decker HJH, 1996, HUM GENET, V97, P770; JACOBS PA, 1980, NATURE, V286, P714, DOI 10.1038/286714a0; KAJII T, 1977, NATURE, V268, P633, DOI 10.1038/268633a0; Kastury K, 1996, CANCER RES, V56, P978; KATO N, 1990, MOL CELL BIOL, V10, P4401, DOI 10.1128/MCB.10.8.4401; KATO N, 1987, J VIROL, V61, P2182, DOI 10.1128/JVI.61.7.2182-2191.1987; KATO N, 1988, INT J CANCER, V41, P380, DOI 10.1002/ijc.2910410310; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; MARTIN MA, 1981, P NATL ACAD SCI USA, V78, P4896; NOZAWA S, 1987, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V39, P889; OCONNELL C, 1984, VIROLOGY, V138, P225, DOI 10.1016/0042-6822(84)90347-7; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; OHAMA K, 1981, NATURE, V292, P551, DOI 10.1038/292551a0; Ohnishi H, 1996, LEUKEMIA, V10, P1104; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; PARK WW, 1971, CHORIOCARCINOMA STUD, P55; PATTILLO RA, 1971, IN VITRO CELL DEV B, V6, P398; PATTILLO RA, 1968, CANCER RES, V28, P1231; PATTILLO RA, 1981, AM J OBSTET GYNECOL, V141, P104; PORTEOUS DJ, 1989, GENOMICS, V5, P680, DOI 10.1016/0888-7543(89)90108-0; Roche J, 1996, ONCOGENE, V12, P1289; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCABLE H, 1989, P NATL ACAD SCI USA, V86, P7480; SCHUTTE M, 1995, P NATL ACAD SCI USA, V92, P5950, DOI 10.1073/pnas.92.13.5950; SPEICHER MR, 1995, CANCER RES, V55, P1010; SREEKANTAIAH C, 1993, AM J PATHOL, V142, P293; STANBRIDGE EJ, 1988, CANC SURVEYS, V29, P317; SUGIURA M, 1988, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V40, P1447; SURTI U, 1979, HUM GENET, V51, P153, DOI 10.1007/BF00287169; Suzumori K, 1983, Asia Oceania J Obstet Gynaecol, V9, P309; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TSUI LC, 1995, CYTOGENET CELL GENET, V71, P1, DOI 10.1159/000134055; VENABLES PJW, 1995, VIROLOGY, V211, P589, DOI 10.1006/viro.1995.1442; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WAKE N, 1978, J NATL CANCER I, V60, P51, DOI 10.1093/jnci/60.1.51; WAKE N, 1978, P JPN ACAD B-PHYS, V54, P533, DOI 10.2183/pjab.54.533; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; YAMADA H, 1990, ONCOGENE, V5, P1141; YAMASHITA K, 1979, AM J OBSTET GYNECOL, V135, P597, DOI 10.1016/S0002-9378(16)32983-0; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	59	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2773	2781		10.1038/sj.onc.1201461	http://dx.doi.org/10.1038/sj.onc.1201461			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419968				2022-12-17	WOS:A1997YJ80300003
J	Kwon, HJ; Yoshida, M; Nagaoka, R; Obinata, T; Beppu, T; Horinouchi, S				Kwon, HJ; Yoshida, M; Nagaoka, R; Obinata, T; Beppu, T; Horinouchi, S			Suppression of morphological transformation by radicicol is accompanied by enhanced gelsolin expression	ONCOGENE			English	Article						radicicol; transformation; oncogene; actin stress fiber; gelsolin	TYROSINE KINASE INHIBITORS; RAT-KIDNEY CELLS; TRICHOSTATIN-A; CARCINOMA-CELLS; NIH3T3 CELLS; HISTONE DEACETYLASE; ACTIN EXPRESSION; FLAT REVERTANTS; PROTEIN; FIBROBLASTS	Radicicol, an inhibitor of Src-family protein-tyrosine kinases, causes morphological reversion of v-src-and v-Ha-ras-transformed fibroblasts and arrest of the cell cycle at both the G1 and the G2 phases, Radicicol was found to inhibit the growth of several other oncogene-transformed cell lines and human carcinoma cell lines and to revert their cell morphology to be flat, In the radicicol-treated flat cells, actin stress fiber bundles were reorganized, Since this effect of radicicol on these cell lines was inhibited by cycloheximide, de novo protein synthesis is required for the morphological reversion, Screening of cellular proteins enhanced in response to radicicol by two-dimensional gel electrophoresis suggested that the amount of gelsolin, an actin regulatory. protein, was distinctly increased upon radicicol treatment, Western blot and Northern blot analyses showed that radicicol enhanced transcription of the gelsolin gene in human carcinoma cell lines, as a result of,which the amount of gelsolin was increased several folds, Injection with an anti-gelsolin antibody into cells and successive treatment with radicicol resulted in approximately 80% reduction of the number of flat cells with stress fibers in comparison with controls treated with an irrelevant antibody, These results show that elevated expression of gelsolin is suppression of transformation actin stress fibers in human carcinoma cells by radicicol.	UNIV TOKYO,GRAD SCH AGR & LIFE SCI,DEPT BIOTECHNOL,BUNKYO KU,TOKYO 113,JAPAN; CHIBA UNIV,FAC SCI,DEPT BIOL,CHIBA 263,JAPAN	University of Tokyo; Chiba University			Yoshida, Minoru/C-8049-2014; 권, 호정/AAS-3642-2021	Yoshida, Minoru/0000-0002-4376-5674; 				Arora PD, 1996, J BIOL CHEM, V271, P20516, DOI 10.1074/jbc.271.34.20516; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BANNO Y, 1992, J BIOL CHEM, V267, P6488; CHANMUGAM P, 1995, J BIOL CHEM, V270, P5418, DOI 10.1074/jbc.270.10.5418; CHAPONNIER C, 1989, AM J PATHOL, V134, P597; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DELCASTILLO AR, 1992, THROMB HAEMOSTASIS, V67, P248; DIEFFENBACH CW, 1989, J BIOL CHEM, V264, P13281; FUJITA H, 1990, EXP CELL RES, V186, P115, DOI 10.1016/0014-4827(90)90217-X; FUJITA H, 1995, EUR J BIOCHEM, V229, P615, DOI 10.1111/j.1432-1033.1995.tb20505.x; FUTAMURA M, 1995, ONCOGENE, V10, P1119; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; HALL MD, 1988, EXP CELL RES, V179, P115, DOI 10.1016/0014-4827(88)90353-9; HIGGINS PJ, 1991, BIOCHEM J, V279, P883, DOI 10.1042/bj2790883; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KUZUMAKI N, 1989, MOL CELL BIOL, V9, P2258, DOI 10.1128/MCB.9.5.2258; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P13857; KWON HJ, 1995, J BIOCHEM-TOKYO, V118, P221, DOI 10.1093/oxfordjournals.jbchem.a124882; KWON HJ, 1992, CANCER RES, V52, P6926; KWON HJ, 1992, BIOSCI BIOTECH BIOCH, V56, P538; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MORIYA S, 1994, INT J ONCOL, V5, P1347; MULLAUER L, 1990, BIOCHEM BIOPH RES CO, V171, P852, DOI 10.1016/0006-291X(90)91224-G; MULLAUER L, 1993, ONCOGENE, V8, P2531; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PATTON WF, 1990, BIOTECHNIQUES, V8, P518; PORTER RM, 1993, J PATHOL, V170, P435, DOI 10.1002/path.1711700406; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Sonoda H, 1996, ONCOGENE, V13, P143; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; SUGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P379, DOI 10.1016/S0006-291X(05)80156-1; SUGITA K, 1992, CANCER RES, V52, P168; TANAKA M, 1995, CANCER RES, V55, P3228; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VANDEKERCKHOVE J, 1990, J CELL BIOL, V111, P95, DOI 10.1083/jcb.111.1.95; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; ZHAO JF, 1995, ONCOGENE, V11, P161	43	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2625	2631		10.1038/sj.onc.1201443	http://dx.doi.org/10.1038/sj.onc.1201443			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399650				2022-12-17	WOS:A1997YG73200012
J	Gulliford, TJ; Huang, GC; Ouyang, XM; Epstein, RJ				Gulliford, TJ; Huang, GC; Ouyang, XM; Epstein, RJ			Reduced ability of transforming growth factor-alpha to induce EGF receptor heterodimerization and downregulation suggests a mechanism of oncogenic synergy with ErbB2	ONCOGENE			English	Article						ErbB2; transforming growth factor-alpha; EGF; oligomerization; downregulation	AUTOPHOSPHORYLATION SITES; BIOLOGICAL-ACTIVITIES; KINASE-ACTIVITY; A431 CELLS; NEU; ACTIVATION; EXPRESSION; C-ERBB-2; IDENTIFICATION; ANTIBODIES	The epidermal growth factor receptor (EGFR) is activated by a variety of ligands including EGF and transforming growth factor-alpha (TGF alpha), whereas no ligand for the homologous ErbB2 oncoprotein has yet been identified. Here we use both an ErbB2 phosphoantibody (aPY(1222)) and an activation-specific EGFR antibody to show that low concentrations of EGF induce more efficient tyrosine phosphorylation of ErbB2 in A431 cells than does equimolar TGF alpha, while EGFR is more potently activated by TGF alpha. Co-precipitation studies confirm that heterodimerization of activated EGFR and transphosphorylated ErbB2 is readily induced by EGF but not TGF alpha. ECFR downregulation is also more efficiently induced by EGF, suggesting that ligand-dependent modification of ErbB2 may be required to terminate EGFR signalling in cells expressing both receptor types. These findings indicate that EGF and TGF alpha differ in their abilities to induce tyrosine phosphorylation and heterodimerization of ErbB2, and raise the possibility that ErbB2 exerts its oncogenic effect in part by impairing TGF alpha-dependent EGFR downregulation.	UNIV LONDON IMPERIAL COLL SCI & TECHNOL, SCH MED, DIV MED, LONDON W6 8RF, ENGLAND; CHARING CROSS HOSP, CANC RES CAMPAIGN LABS, LONDON W6 8RF, ENGLAND	Imperial College London; Imperial College London					PHS HHS [R0169513] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Campos-Gonzalez R, 1991, GROWTH FACTORS, V4, P305, DOI 10.3109/08977199109043916; CARPENTIER JL, 1987, J CELL BIOL, V105, P2751, DOI 10.1083/jcb.105.6.2751; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; EPSTEIN RJ, 1990, J BIOL CHEM, V265, P10746; EPSTEIN RJ, 1995, ONCOGENE, V11, P315; GABELMAN BM, 1992, EXP CELL RES, V201, P113, DOI 10.1016/0014-4827(92)90354-B; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; GAN BS, 1987, J PHARMACOL EXP THER, V242, P331; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; LEE DC, 1995, PHARMACOL REV, V47, P51; Mellon JK, 1996, BRIT J CANCER, V73, P654, DOI 10.1038/bjc.1996.114; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; Ouyang XM, 1996, J BIOL CHEM, V271, P21786, DOI 10.1074/jbc.271.36.21786; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STROMBERG K, 1992, CANCER RES, V52, P341; Taylor ICA, 1995, ONCOGENE, V11, P2619; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Worthylake R, 1997, J BIOL CHEM, V272, P8594, DOI 10.1074/jbc.272.13.8594; XIE YM, 1995, ONCOGENE, V10, P2409; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	34	34	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	1997	15	18					2219	2223		10.1038/sj.onc.1201595	http://dx.doi.org/10.1038/sj.onc.1201595			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393980				2022-12-17	WOS:A1997YD01900010
J	Arap, W; Knudsen, E; Sewell, DA; Sidransky, D; Wang, JYJ; Huang, HJS; Cavenee, WK				Arap, W; Knudsen, E; Sewell, DA; Sidransky, D; Wang, JYJ; Huang, HJS; Cavenee, WK			Functional analysis of wild-type and malignant glioma derived CDKN2A beta alleles: Evidence for an RB-independent growth suppressive pathway	ONCOGENE			English	Article						CDKN2A; p16(INK4a); p16 beta; RB; tumor suppressor gene; malignant glioma	GENE; MUTATIONS; P16; DELETIONS; TRANSCRIPT; CANCER; LOCUS	The tumor suppressor gene CDKN2A (p16/MTS1/ 1NK4A), which encodes the cyclin-dependent kinase inhibitor p16(INK4a), is a target of 9p21 deletions during the malignant progression of human gliomas, This gene also encodes a second protein product (human p16 beta, murine p19(ARF)), which originates from an unrelated exon of CDKN2A (exon 1 beta) spliced onto exon 2 in an alternate reading frame, Cell cycle arrest by p16 beta is caused by an as yet unidentified pathway, In order to test the candidacy of p16 beta as a glioma suppressor, we replaced p16(INK4a), p15(INK4b) and p16 beta wild-type as well as a series of seven glioma-derived p16 beta alleles (R87H, A112V, R120H, A121V, G125R, A128A and A128V), into glioma cell lines that had either CDKN2A(-)/RB+ (U-87MG and U-251MG) or CDKN2A(+)/RB- (LN-319) endogenous backgrounds and demonstrated that p16 beta can act as a functional glioma cell growth suppressor, Moreover, p16 beta, but not p16(INK4a) or p15(INK4b) inhibited the growth of RE-negative LN-319 cells, indicating that p16 beta likely exerts its effects through an RB-independent pathway, In vitro and in vivo assays of pRB phosphorylation were consistent with this interpretation, Since none of the glioma-derived p16 beta mutations inactivated their growth suppressive activities, it appears that mutations in CDKN2A exon 2 (which is shared in the coding sequences of p16(INK4a) and p16 beta) likely exclusively target p16(INK4a).	UNIV CALIF SAN DIEGO,LUDWIG INST CANC RES,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093; STANFORD UNIV,CANC BIOL PROGRAM,STANFORD,CA 94305; JOHNS HOPKINS UNIV,DEPT OTOLARYNGOL HEAD & NECK SURG,HEAD & NECK CANC RES DIV,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT ONCOL,BALTIMORE,MD 21205	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Stanford University; Johns Hopkins University; Johns Hopkins University					NCI NIH HHS [R01 CA058320] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arap W, 1997, ONCOGENE, V14, P603, DOI 10.1038/sj.onc.1200870; ARAP W, 1995, CANCER RES, V55, P1351; DURO D, 1995, ONCOGENE, V11, P21; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; JAMES CD, 1993, CANCER RES, V53, P3674; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kyritsis AP, 1996, ONCOGENE, V12, P63; Liggett WH, 1996, CANCER RES, V56, P4119; Louis David N., 1997, P2013; LUCAS J, 1997, GENE DEV, V11, P1479; MAO L, 1995, CANCER RES, V55, P2995; MOULTON T, 1995, AM J PATHOL, V146, P613; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1992, CANCER RES, V52, P2523; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sewell D. A., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P80; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shores C., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P277; STONE S, 1995, CANCER RES, V55, P2988; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9	28	34	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2013	2020		10.1038/sj.onc.1201389	http://dx.doi.org/10.1038/sj.onc.1201389			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366518				2022-12-17	WOS:A1997YC28400002
J	Tang, JP; Feng, GS; Li, W				Tang, JP; Feng, GS; Li, W			Induced direct binding of the adapter protein Nck to the GTPase-activating protein-associated protein p62 by epidermal growth factor	ONCOGENE			English	Article						src-homology domains; adapters; receptor tyrosine kinases; signal transduction	RECEPTOR TYROSINE KINASES; ALDRICH SYNDROME PROTEIN; SRC HOMOLOGY-3 DOMAINS; SH3 DOMAINS; ACTIN POLYMERIZATION; MOLECULAR-CLONING; PHOSPHORYLATION; RAS; GAP; CELLS	The SH3-SH3-SH3-SH2 adapter protein Nck links receptor tyrosine kinases, such as EGF and PDGF receptors, to downstream signaling pathways, among which p21(cdc42/rac)-activated kinase cascade, Sos-activated Ras signaling and the human Wiskott-Aldrich Syndrome protein (WASp)-mediated actin cytoskeleton changes, have been implicated. In EGF stimulated cells, Nck coimmunoprecipitates with a number of phosphotyrosine proteins including the EGF receptor (Li et al., 1992 Mol. Cell. Biol. 12: 5824-2833). To identify the phosphotyrosine protein(s) that directly interacts with Nck and to distinguish it from indirectly associated proteins, preexisting phosphoytrosine protein complexes in the cell lysate were dissociated by heat and SDS prior to the test for binding to Nck. We found that Nck does not directly bind to EGF receptor, instead it binds via its SH2 domain to a 62 kDa phosphotyrosine protein. We present evidence demonstrating that the Nck-bound p62 is related to the previously identified GTPase-activating protein (GAP)-associated phosphotyrosine protein p62. (1) The Nck-bound and the GAP-bound p62 proteins comigrate with each other in SDS-PAGE. (2) SH2 domains from Nck and GAP compete for binding to p62 in vitro. (3) Purified GST-Nck-SH2 binds directly to the GAP-associated p62, Under these conditions, SH2 domains from PLC gamma, PI-3 kinase, SHC, and Grb2 did not bind p62. (4) Tryptic phosphopeptide maps of the Nck- and the GAP-associated p62 proteins are identical. However, Nck and GAP do not co-immunoprecipitate with each other and apparently bind to different pools of p62. This study suggests that the GAS-associated p62 acts as an SH2 domain docking protein and mediates the interaction between Nck and EGF receptor in response to EGF stimulation.	UNIV CHICAGO,BEN MAY INST CANC RES,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637; INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	University of Chicago; University of Chicago; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute					NATIONAL CANCER INSTITUTE [R01CA065567] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA65567-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS C, 1995, METHOD ENZYMOL, V255, P179; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HU QJ, 1995, MOL CELL BIOL, V15, P1169; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI W, 1991, J BIOL CHEM, V266, P6808; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; NEET K, 1995, MOL CELL BIOL, V15, P4908; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Rockow S, 1996, ONCOGENE, V12, P2351; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3	47	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1823	1832		10.1038/sj.onc.1201351	http://dx.doi.org/10.1038/sj.onc.1201351			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362449				2022-12-17	WOS:A1997XZ72500009
J	Larsson, LG; Bahram, F; Burkhardt, H; Luscher, B				Larsson, LG; Bahram, F; Burkhardt, H; Luscher, B			Analysis of the DNA-binding activities of Myc/Max/Mad network complexes during induced differentiation of U-937 monoblasts and F9 teratocarcinoma cells	ONCOGENE			English	Article						cell growth control; c-Myc; Mad1; oncoprotein	CASEIN KINASE-II; C-MYC PROTEIN; TRANSCRIPTIONAL ACTIVATION; RAS COTRANSFORMATION; OPPOSITE REGULATION; ONCOGENIC ACTIVITY; REPRESSOR SIN3; MAX; MXI1; TRANSFORMATION	The bHLHZip protein Max interacts with both the Myc and Mad family proteins forming heterodimers which specifically bind certain E-box DIVA recognition sequences, thereby regulating transcription, Whereas Myc proteins actively promote cell proliferation, Mad complexes have the opposite function, Although the main regulation of this network seems to be the control of myc- and mad family gene expression, regulation at the level of DNA-binding and transactivation may also be in operation, Few studies on the DNA-binding activity of native Myc:Max or Max:Mad complexes have been reported mainly due to technical difficulties, To overcome these problems we have developed a specific and sensitive solid phase DNA-binding assay based on partial purification of native Myc, Max and Mad1 complexes by immunological methods, Using this technique we report that the DNA-binding activity of c-Myc-containing complexes is reduced during induced differentiation of U-937 monoblasts and F9 embryonic teratocarcinoma cells. In contrast, the DNA-binding of Mad1-containing complexes increases during monocytic differentiation, In general, the DNA-binding activity of c-Myc and Mad1 correlate with their expression, However, our studies of early kinetics of TPA-induced differentiation of U-937 cells as well as of late events during F9 differentiation suggest that post-translational regulation of Myc and Max DNA-binding may also occur. The solid phase DNA-binding assay may thus provide a tool to study the regulation of DNA-binding in more detail.	HANNOVER MED SCH,INST MOL BIOL,D-30623 HANNOVER,GERMANY	Hannover Medical School	Larsson, LG (corresponding author), UNIV UPPSALA,DEPT PATHOL,LAB TUMOR BIOL,S-75185 UPPSALA,SWEDEN.		Larsson, Lars-Gunnar/D-9747-2012; Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUSSET K, 1993, ONCOGENE, V8, P3211; CERNI C, 1995, ONCOGENE, V11, P587; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DELGADO MD, 1995, ONCOGENE, V10, P1659; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DUNN BK, 1994, CELL GROWTH DIFFER, V5, P847; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HAN T, 1980, J CLIN LAB IMMUNOL, V4, P169; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HIHARA H, 1974, NATL I ANIM HEALTH Q, V14, P163; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LARSSON LG, 1994, ONCOGENE, V9, P1247; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Nilsson K., 1980, INT S NEW TRENDS HUM, P271; NISHIKORI M, 1984, CANCER GENET CYTOGEN, V12, P39, DOI 10.1016/0165-4608(84)90006-2; OBERG F, 1991, P NATL ACAD SCI USA, V88, P5567, DOI 10.1073/pnas.88.13.5567; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	52	34	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					737	748		10.1038/sj.onc.1201390	http://dx.doi.org/10.1038/sj.onc.1201390			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264414				2022-12-17	WOS:A1997XP68300013
J	Tanaka, Y; Watanabe, T; Chiba, N; Niki, M; Kuroiwa, Y; Nishihira, T; Satomi, S; Ito, Y; Satake, M				Tanaka, Y; Watanabe, T; Chiba, N; Niki, M; Kuroiwa, Y; Nishihira, T; Satomi, S; Ito, Y; Satake, M			The protooncogene product, PEBP2 beta/CBF beta, is mainly located in the cytoplasm and has an affinity with cytoskeletal structures	ONCOGENE			English	Article						PEBP2 beta/CBF beta; proto-oncogene; acute myeloid leukemia; transcription factor; cytoskeleton; immunocytochemistry	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; NF-KAPPA-B; TRANSCRIPTION FACTOR; DNA-BINDING; E-CADHERIN; AML1 GENE; FUSION TRANSCRIPT; PROTEIN; RUNT	The Pebp62/Cbfb gene encodes the non-DNA binding beta subunit of the heterodimeric transcription factor, PEBP2/CBF, and has been implicated in a subtype of human acute myeloid leukemia, as well as being indispensable for the development of definitive hematopoiesis in the murine fetal liver, By examining a subcellular localization of the PEBP2 beta/CBF beta protein in tissue culture cells, we could reveal an additional aspect of the protein other than to be a subunit of a transcription factor, Immunoblot and immunocytochemical staining showed that PEBP2 beta/CBF beta was mostly present in the cytoplasm, This PEBP2 beta/CBF beta was free from its DNA-binding partner, the cc subunit of PEBP2/CBF, as judged by the electrophoretic mobility shift assays, Furthermore, a significant amount of PEBP2 beta 1/CBF beta was retained in the cytoskeleton preparation after detergent extraction of the cells and was found by double immunofluorescence to colocalize with the F-actin on stress fibers and the vinculin in membrane processes, Thus, the present study extends PEBP2 beta/CBF beta to be a cytoskeleton-affinitive as well as nuclear protein, The implications of these results are discussed.	TOHOKU UNIV,SCH MED,INST DEV AGING & CANC,DEPT MOL IMMUNOL,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; TOHOKU UNIV,SCH MED,DEPT SURG 2,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; HITACHI LTD,CHEM,PHARMACEUT RES LABS,HITACHI,IBARAKI 317,JAPAN; KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SAKYO KU,KYOTO 60601,JAPAN	Tohoku University; Tohoku University; Hitachi Limited; Kyoto University								ABERLE H, 1994, J CELL SCI, V107, P3655; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chiba N, 1997, ONCOGENE, V14, P2543, DOI 10.1038/sj.onc.1201109; ERICKSON P, 1992, BLOOD, V80, P1825; Geiger B, 1989, CURR OPIN CELL BIOL, V1, P103, DOI 10.1016/S0955-0674(89)80045-6; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU J, 1995, MOL CELL BIOL, V15, P1651; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NIKI M, 1997, IN PRESS P NATL ACAD; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PRATT WB, 1993, J BIOL CHEM, V268, P21455; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SALGIA R, 1995, ONCOGENE, V11, P1149; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89	39	34	34	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					677	683		10.1038/sj.onc.1201235	http://dx.doi.org/10.1038/sj.onc.1201235			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264408				2022-12-17	WOS:A1997XP68300007
J	Nicholson, LJ; Hopwood, P; Johannessen, I; Salisbury, JR; Codd, J; ThorleyLawson, D; Crawford, DH				Nicholson, LJ; Hopwood, P; Johannessen, I; Salisbury, JR; Codd, J; ThorleyLawson, D; Crawford, DH			Epstein-Barr virus latent membrane protein does not inhibit differentiation and induces tumorigenicity of human epithelial cells	ONCOGENE			English	Article						EBV; LMP; epithelial cells; differentiation; tumorigenesis	NASOPHARYNGEAL CARCINOMA-CELLS; TERMINAL DIFFERENTIATION; HUMAN KERATINOCYTES; GROWTH TRANSFORMATION; DECREASED EXPRESSION; P53 MUTATIONS; KAPPA-B; LMP1; GENE; TRANSCRIPTS	Latent membrane protein (LMP) is a latent Epstein-Barr virus (EBV) protein expressed in the EBV associated malignancy, nasopharyngeal carcinoma (NPC). Properties ascribed to this protein include inhibition of epithelial cell differentiation and deregulation of epithelial cellular gene expression, and are believed to contribute to the development of NPC, Studies to evaluate the oncogenic potential of LMP in epithelial cells have not been conclusive, We carried out studies to determine the tumorigenic activity of LMP in two human epithelial cell lines, SCC12F and HaCaT; while SCC12F LMP transfectants were non-tumorigenic in severe combined immunodeficient mice, HaCaT LMP transfectants were strongly oncogenic, The tumours produced were well differentiated, keratinising squamous cell carcinomas suggesting that LMP does not inhibit epithelial cell differentiation which conflicts with a previous report by Dawson et al. (1990), To resolve this discrepancy we examined the ability of HaCaT and SCC12F LMP transfectants to differentiate in a suspension culture assay, Both lines were able to differentiate to a similar extent as parental lines and control transfectants. Our results indicate that LMP is strongly oncogenic in human epithelial cells but that inhibition of differentiation is not necessarily a mechanism by which LMP contributes to the pathogenesis of NPC.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1E 7HT,ENGLAND; TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111	University of London; London School of Hygiene & Tropical Medicine; Tufts University	Nicholson, LJ (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT HISTOPATHOL,LONDON SE5 9PJ,ENGLAND.			Salisbury, Jonathan/0000-0002-5889-4276	NCI NIH HHS [CA31893] Funding Source: Medline; NIAID NIH HHS [AI18757] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA031893, R01CA031893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018757] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; CHEN ML, 1992, ONCOGENE, V7, P2131; Chen WP, 1996, J VIROL, V70, P4849, DOI 10.1128/JVI.70.7.4849-4853.1996; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DOVER R, 1987, J INVEST DERMATOL, V89, P349, DOI 10.1111/1523-1747.ep12471751; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FAHRAEUS R, 1992, INT J CANCER, V52, P834, DOI 10.1002/ijc.2910520527; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GOLDEN HD, 1973, J INFECT DIS, V127, P471, DOI 10.1093/infdis/127.4.471; GREEN H, 1977, CELL, V11, P405, DOI 10.1016/0092-8674(77)90058-7; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HU LF, 1993, ONCOGENE, V8, P1575; KARIMI L, 1995, J GEN VIROL, V76, P759, DOI 10.1099/0022-1317-76-4-759; KARRAN L, 1992, P NATL ACAD SCI USA, V89, P8058, DOI 10.1073/pnas.89.17.8058; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KEG G, 1993, J CLIN PATHOL, V46, P1080; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LANE EB, 1985, ANN NY ACAD SCI, V455, P241, DOI 10.1111/j.1749-6632.1985.tb50415.x; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Li SN, 1996, ONCOGENE, V12, P2129; LONGNECKER R, 1991, J VIROL, V65, P3681, DOI 10.1128/JVI.65.7.3681-3692.1991; LOUVIDOU C, 1995, J CLIN PATHOL MOL PA, V48, P717; Lu JJY, 1996, J GEN VIROL, V77, P1883, DOI 10.1099/0022-1317-77-8-1883; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; MILLER G, 1972, P NATL ACAD SCI USA, V69, P383, DOI 10.1073/pnas.69.2.383; MILLER WE, 1995, J VIROL, V69, P4390, DOI 10.1128/JVI.69.7.4390-4398.1995; NICHOLSON LJ, 1991, J CELL SCI, V98, P225; NIEDERMAN JC, 1970, NEW ENGL J MED, V282, P361, DOI 10.1056/NEJM197002122820704; NIEDOBITEK G, 1993, J PATHOL, V170, P457, DOI 10.1002/path.1711700409; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; PATHMANATHAN R, 1995, AM J PATHOL, V146, P1355; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; Rheinwald J G, 1980, Methods Cell Biol, V21A, P229, DOI 10.1016/S0091-679X(08)60769-4; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; RICKINSON AB, 1996, FIELDS VIROLOGY, V2; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; SCULLEY TB, 1997, IN PRESS J VIROL; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SRINIVAS SK, 1995, J VIROL, V69, P8155, DOI 10.1128/JVI.69.12.8155-8158.1995; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; WOLF H, 1973, NATURE-NEW BIOL, V244, P245, DOI 10.1038/newbio244245a0; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	55	34	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					275	283		10.1038/sj.onc.1201187	http://dx.doi.org/10.1038/sj.onc.1201187			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233762				2022-12-17	WOS:A1997XK99900004
J	Miller, CW; Yeon, C; Aslo, A; Mendoza, S; Aytac, U; Koeffler, HP				Miller, CW; Yeon, C; Aslo, A; Mendoza, S; Aytac, U; Koeffler, HP			The p19(INK4D) Cyclin dependent kinase inhibitor gene is altered in osteosarcoma	ONCOGENE			English	Article						p19; osteosarcoma; rearrangement; mutation	CELL LUNG-CANCER; CDK6 INHIBITOR; P18 GENES; P53 GENE; RETINOBLASTOMA; PROTEIN; AMPLIFICATION; SUPPRESSION; EXPRESSION; P16(INK4)	Inhibition of cyclin dependent kinases (CDK) by cyclin dependent kinase inhibitors (CDKI) blocks cell cycle progression and inhibits cellular proliferation. The archetypical member of the INK4 CDKI family, p16(INK4A) (also called CDKN2), is a tumor suppressor frequently deleted or mutated in certain neoplasms and many cell lines. Because p19(INK4D) has strong structural and functional similarity to p16(INK4A), We have assessed its role as a tumor suppressor. This was accomplished by screening the p19(INK4D) coding region for mutations, deletions and rearrangements in sarcomas and non-small cell lung cancers. Alterations of the p19(INK4D) gene were found in samples from five of 67 (7%) patients with osteosarcomas and none were found in other types of sarcomas or in lung cancers. Five osteosarcoma samples had Southern blot patterns consistent with gene rearrangement. These samples included a primary and recurrent osteosarcoma from the same patient; both with the same rearrangement. Four samples had SSCP patterns consistent with sequence alterations, sequencing determined that three were due to silent base changes and apparently polymorphisms. Sequencing the fourth shifted band revealed a one base insertion causing a frameshift beginning with codon 27. In summary, these studies found alterations affecting the p19(INK4D) gene in a small but significant number of osteosarcomas. Presumably, abnormalities of this gene contribute to the development of cancer of bone cells.			Miller, CW (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,CEDARS SINAI RES INST,DEPT MED,DIV HEMATOL ONCOL,DAVIS 5019,LOS ANGELES,CA 90048, USA.							CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHIBA I, 1990, ONCOGENE, V5, P1603; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEVOS S, 1995, GENE CHROMOSOME CANC, V14, P164; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HIRAMA T, 1995, BLOOD, V86, P841; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAWAMATA N, 1995, CANCER RES, V55, P2266; Kawamata N, 1995, MOL CARCINOGEN, V14, P263, DOI 10.1002/mc.2940140406; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MILLER CW, 1990, CANCER RES, V50, P7950; Miller CW, 1996, CANCER GENET CYTOGEN, V86, P136, DOI 10.1016/0165-4608(95)00216-2; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARK DH, IN PRESS; REISSMANN PT, 1993, ONCOGENE, V8, P1913; RODENHUIS S, 1988, CANCER RES, V48, P5738; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEAFF RJ, 1995, CURR BIOL, V5, P28, DOI 10.1016/S0960-9822(95)00009-1; Shiohara M, 1996, LEUKEMIA, V10, P1897; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; STONE S, 1995, CANCER RES, V55, P2988; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; TAM SW, 1994, CANCER RES, V54, P5816; XU HJ, 1991, CANCER RES, V51, P2735; YAMAGUCHI T, 1992, CANCER RES, V52, P2419; YANG R, 1995, CANCER RES, V55, P2503; Zariwala M, 1996, ONCOGENE, V13, P2033	37	34	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					231	235		10.1038/sj.onc.1201185	http://dx.doi.org/10.1038/sj.onc.1201185			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244358				2022-12-17	WOS:A1997XK37200011
J	Mils, V; Piette, J; Barette, C; Veyrune, JL; Tesniere, A; Escot, C; Guilhou, JJ; BassetSeguin, N				Mils, V; Piette, J; Barette, C; Veyrune, JL; Tesniere, A; Escot, C; Guilhou, JJ; BassetSeguin, N			The proto-oncogene c-fos increases the sensitivity of keratinocytes to apoptosis	ONCOGENE			English	Article						c-fos; c-jun; keratinocytes; apoptosis; differentiation	CELL-DEATH; PROTOONCOGENE EXPRESSION; CARCINOMA-CELLS; AP-1 ELEMENT; JUN; DIFFERENTIATION; GENE; PHOSPHORYLATION; PROLIFERATION; TRANSLATION	In human skin, most studies have suggested a role of c-fos or c-fos related genes in keratinocyte differentiation. The aim of our work was to more directly address this question by transfecting more or less differentiated keratinocyte cell lines (A431 and HaCaT) with constitutive expression vectors for c-Fos or c-Fos+c-Jun. Our results showed that c-Fos expression decreased keratinocyte growth, yet addition of c-Jun seemed to revert this c-Fos induced growth inhibition. Whereas no obvious differentiation program was turned on by c-Fos or c-Fos+c-Jun expression in our tissular model, apoptotic figures were observed and confirmed by in situ DNA fragmentation studies. These results do not rule out a role of c-Fos in keratinocyte differentiation but may indicate that the cell lines we used have reached an irreversible state of transformation so that they no longer respond to differentiation signals and rather die from apoptosis. These data add further evidence in favor of a role of c-Fos in epidermal homeostasis.	IURC,LAB DERMATOL MOL,F-34093 MONTPELLIER 5,FRANCE; INST MOL GENET,UMR5535,F-34033 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier				BARETTE, Caroline/0000-0003-0999-7751				ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUWERX J, 1992, ONCOGENE, V7, P2271; BASSETSEGUIN N, 1994, ONCOGENE, V9, P765; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BASSETSEGUIN N, 1991, J INVEST DERMATOL, V97, P672, DOI 10.1111/1523-1747.ep12483807; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRIATA P, 1993, EXP CELL RES, V204, P136, DOI 10.1006/excr.1993.1018; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHEN SL, 1994, CANCER LETT, V85, P119, DOI 10.1016/0304-3835(94)90247-X; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; CONSCIENCE JF, 1986, EMBO J, V5, P317, DOI 10.1002/j.1460-2075.1986.tb04215.x; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; ESCOT C, 1991, ANAL CELL PATHOL, V3, P215; FISHER C, 1991, DEVELOPMENT, V111, P253; Gajate C, 1996, BIOCHEM BIOPH RES CO, V218, P267, DOI 10.1006/bbrc.1996.0047; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORCZYCA W, 1993, CANCER RES, V53, P1945; GREENHALGH DA, 1993, ONCOGENE, V8, P2145; HAAKE AR, 1993, J INVEST DERMATOL, V101, P107, DOI 10.1111/1523-1747.ep12363594; KERR JFK, 1991, CURRENT COMMUNICATIO; MARTI A, 1994, ONCOGENE, V9, P1213; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1984, EMBO J, V3, P1887, DOI 10.1002/j.1460-2075.1984.tb02063.x; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; Polakowska R R, 1994, Cell Death Differ, V1, P19; Preston GA, 1996, MOL CELL BIOL, V16, P211; PRUNIERAS M, 1983, J INVEST DERMATOL, V81, pS28, DOI 10.1111/1523-1747.ep12540324; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; VEYRUNE JL, 1995, ONCOGENE, V11, P2127; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	40	34	35	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1555	1561		10.1038/sj.onc.1200991	http://dx.doi.org/10.1038/sj.onc.1200991			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129146				2022-12-17	WOS:A1997WQ54800006
J	vanPuijenbroek, AAFL; vanWeering, DHJ; vandenBrink, CE; Bos, JL; vanderSaag, PT; deLaat, SW; denHertog, J				vanPuijenbroek, AAFL; vanWeering, DHJ; vandenBrink, CE; Bos, JL; vanderSaag, PT; deLaat, SW; denHertog, J			Cell scattering of SK-N-MC neuroepithelioma cells in response to Ret and FGF receptor tyrosine kinase activation is correlated with sustained ERK2 activation	ONCOGENE			English	Article						Ret; ERK2; signal transduction; transcription; cell scattering; growth inhibition	NEURO-BLASTOMA CELLS; TRANSFORMING GENE; NEUROBLASTOMA-CELLS; RET/PTC ONCOGENE; PROTOONCOGENE; PROTEIN; EXPRESSION; MUTATIONS; GROWTH; SPECIFICITY	The c-ret proto-oncogene encodes a receptor tyrosine kinase which plays an important role in kidney and enteric nervous system development. Germline mutations in c-ret are responsible for the dominantly inherited cancer syndromes, multiple endocrine neoplasia types 2A and 2B and familial medullary thyroid carcinoma as well as the developmental disorder Hirschsprung's disease. Using SK-N-MC neuroepithelioma cells stably transfected with an EGFR/Ret chimeric receptor, we have studied cellular consequences and signalling events following activation of exogenous EGFR/Ret and endogenous FGF and PDGF receptor tyrosine kinases in cells of neuroectodermal origin. Here we report that Ret activation led to cell scattering, growth inhibition and loss of anchorage-independent growth. Basic FGF, but not PDGF, evoked similar responses in those cells. Nevertheless, activation of all three receptor tyrosine kinases led to ERK2 activation. Analysis of the kinetics of ERK2 activation and downstream events revealed that Ret and FGF receptor activation led to sustained ERK2 activation and SRE transactivation, while PDGF treatment led to transient ERK2 activation and failed to induce SRE transactivation. Our results suggest that sustained, but not transient ERK2 activation may be involved in cell scattering.	UNIV UTRECHT,PHYSIOL CHEM LAB,NL-3508 TA UTRECHT,NETHERLANDS	Utrecht University	vanPuijenbroek, AAFL (corresponding author), NETHERLANDS INST DEV BIOL,HUBRECHT LAB,UPPSALALAAN 8,NL-3584 CT UTRECHT,NETHERLANDS.							ASAI N, 1995, MOL CELL BIOL, V15, P1613; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CALIFANO D, 1995, ONCOGENE, V11, P107; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CICCARONE V, 1989, CANCER RES, V49, P219; DALESSIO A, 1995, CELL GROWTH DIFFER, V6, P1387; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; DEHNER LP, 1986, ARCH PATHOL LAB MED, V110, P997; Duband JL, 1995, ACTA ANAT, V154, P63; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, MOL CELL BIOL, V2, P607; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; LO LC, 1995, NEURON, V15, P527, DOI 10.1016/0896-6273(95)90142-6; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MYERS SM, 1995, ONCOGENE, V11, P2039; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PRONK GJ, 1993, ONCOGENE, V8, P2773; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROMANO A, 1994, ONCOGENE, V9, P2923; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROSS RA, 1983, J NATL CANCER I, V71, P741; SACHS A, 1996, J CELL BIOL, V133, P1095; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHUCHARDT A, 1995, ONCOGENE, V10, P641; SHEN S, 1993, MECH DEVELOP, V40, P177, DOI 10.1016/0925-4773(93)90075-9; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1995, CRIT REV ONCOGENESIS, V6, P35, DOI 10.1615/CritRevOncog.v6.i1.30; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; vanWeering DHJ, 1995, ONCOGENE, V11, P2207	59	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1147	1157		10.1038/sj.onc.1200911	http://dx.doi.org/10.1038/sj.onc.1200911			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121763				2022-12-17	WOS:A1997WM78200003
J	Williams, KJ; Boyle, JM; Birch, JM; Norton, JD; Scott, D				Williams, KJ; Boyle, JM; Birch, JM; Norton, JD; Scott, D			Cell cycle arrest defect in Li-Fraumeni Syndrome: A mechanism of cancer predisposition?	ONCOGENE			English	Article						Li-Fraumeni; p53; transgenic; G(1) arrest	WILD-TYPE P53; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; PRONE FAMILY; G(1) ARREST; RADIOSENSITIVITY; CHECKPOINT; MUTATIONS; FIBROBLASTS; REPAIR	Cancer predisposition in approximately 60% of Li-Fraumeni Syndrome (LPS) families is associated with germline mutation of the TP53 gene. The p53 protein has been shown to mediate G(1) arrest following DNA damage, We have investigated gamma-irradiation-induced transient and permanent G(1) arrest in normal and LFS fibroblasts. The duration of transient G(1) arrest varied between strains, but there was no difference in the range between normal (2-12 h) and LFS (1-13 h) cells. However, the extent of permanent G(1) arrest was greatly reduced in LFS fibroblasts (mean 33 +/- 8% of the cell population) compared with normals (mean 67 +/- 9%) and correlated with their increased radiation survival (r = 0.97, P<0.001). This phenotype was observed in LFS fibroblasts both with (seven cases) and without (two cases) TP53 mutation. Parallel studies with fibroblasts derived from cancer-prone, p53-deficient mice revealed no radiation-induced G(1) cell cycle arrest in p53 null (-/-) cells, The p53 +/- cells were comparable to the wt p53 cells in transient G(1) arrest capacity, but showed a diminished permanent G(1) arrest. These data clearly implicate p53 function in permanent G(1) arrest, The reduced capacity for DNA damage-induced, permanent G(1) arrest in LFS may contribute significantly to cancer predisposition in this familial syndrome.	CHRISTIE HOSP NHS TRUST,CRC,PAEDIAT & FAMILIAL CANC RES GRP,PATERSON INST CANC RES,MANCHESTER M20 9BX,LANCS,ENGLAND; CHRISTIE HOSP NHS TRUST,CRC,DEPT GENE REGULAT,PATERSON INST CANC RES,MANCHESTER M20 9BX,LANCS,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Williams, KJ (corresponding author), CHRISTIE HOSP NHS TRUST,CRC,DEPT CANC GENET,PATERSON INST CANC RES,MANCHESTER M20 9BX,LANCS,ENGLAND.							BECHHANSEN NT, 1981, LANCET, V1, P1335; BIRCH JM, 1994, CANCER RES, V54, P1298; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BURNET NG, 1994, RADIOTHER ONCOL, V33, P228, DOI 10.1016/0167-8140(94)90358-1; CAMPLEJOHN RS, 1995, BRIT J CANCER, V72, P654, DOI 10.1038/bjc.1995.390; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LALLE P, 1995, ONCOGENE, V10, P2447; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI CY, 1995, ONCOGENE, V11, P1885; LI FP, 1969, J NATL CANCER I, V43, P1365; LITTLE JB, 1994, RADIAT RES, V140, P299, DOI 10.2307/3579106; LITTLE JB, 1985, RADIAT RES, V101, P81, DOI 10.2307/3576305; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; NAGASAWA H, 1995, CANCER RES, V55, P1842; OCONNOR PM, 1993, CANCER RES, V53, P4776; PARSHAD R, 1993, RADIAT RES, V136, P236, DOI 10.2307/3578616; PAULES RS, 1995, CANCER RES, V55, P1763; POOT M, 1990, FLOW CYTOMETRY PRACT, P105; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; Sproston ARM, 1996, INT J RADIAT BIOL, V70, P145, DOI 10.1080/095530096145139; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEWART N, 1995, ONCOGENE, V10, P109; WEEKS DE, 1991, RADIAT RES, V128, P90, DOI 10.2307/3578071; Williams KJ, 1996, BRIT J CANCER, V74, P698, DOI 10.1038/bjc.1996.424; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	35	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					277	282		10.1038/sj.onc.1200838	http://dx.doi.org/10.1038/sj.onc.1200838			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018113				2022-12-17	WOS:A1997WD51600003
J	Guillot, C; Falette, N; Paperin, MP; Courtois, S; GentilPerret, A; Treilleux, I; Ozturk, M; Puisieux, A				Guillot, C; Falette, N; Paperin, MP; Courtois, S; GentilPerret, A; Treilleux, I; Ozturk, M; Puisieux, A			P21(WAF1/CIP1) response to genotoxic agents in wild-type TP53 expressing breast primary tumours	ONCOGENE			English	Article						breast cancer; p53; functional inactivation; p21(WAF1/CIP1)	P53-MEDIATED G(1) ARREST; P53 MUTATIONS; P53-INDEPENDENT PATHWAY; MONOCLONAL-ANTIBODIES; SUPPRESSOR GENE; HUMAN CANCER; CELL-LINES; PROTEIN; TUMORS; P21	Functional inactivation of the wild-type p53 protein has been described in different human cancers. Since a significant proportion of breast tumours express wildtype TP53, the p53 antiproliferative activity could be inactivated in transformed mammary epithelial cells by a mechanism independent on structural alteration of the gene, To test this hypothesis, we analysed the p53 activity in primary breast tumour cells. As a preliminary study, we demonstrated in breast adenocarcinoma cell lines that the nuclear accumulation of the inhibitor of cyclin dependent kinase p21(WAF1/CIP1), in response to adriamycin treatment, specifically reflected the activity of a functional wild-type p53 protein. Then, we used this strategy to study the p53 activity in 23 primary breast tumours. p21(WAF1/CIP1) accumulation was detected in all tumours expressing wild-type TP53. In contrast, no p21(WAF1/CIP1) response was detected in cells harboring a mutant TP53 gene. This report is the first functional study of p53 in primary breast tumours. The results demonstrate that TP53 mutation represents the only common mechanism leading to an irreversible inactivation of p53 functions in this cancer type.	INSERM U453,F-69008 LYON,FRANCE; CTR LEON BERARD,DEPT ANAT & CYTOL PATHOL,F-69008 LYON,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard			ozturk, mehmet/G-3330-2014; OZTURK, MEHMET/AAS-7241-2021	OZTURK, MEHMET/0000-0002-6092-9706; PUISIEUX, Alain/0000-0002-9938-3798				BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DIELLA F, 1993, LIFE SCI ADV BIOCH, V12, P47; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DOMAGALA W, 1993, AM J PATHOL, V142, P669; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FISHER CJ, 1994, BRIT J CANCER, V69, P26, DOI 10.1038/bjc.1994.4; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; GUILLOT C, IN PRESS CLIN CANC R; Hecker D, 1996, ONCOGENE, V12, P953; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACQUEMIER J, 1994, BRIT J CANCER, V69, P846, DOI 10.1038/bjc.1994.164; JAIYESIMI IA, 1992, J CLIN ONCOL, V10, P1014, DOI 10.1200/JCO.1992.10.6.1014; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; Kovach JS, 1996, P NATL ACAD SCI USA, V93, P1093, DOI 10.1073/pnas.93.3.1093; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEACH FS, 1993, CANCER RES, V53, P2231; LEGROS Y, 1993, B CANCER, V80, P102; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MAZARS R, 1992, CANCER RES, V52, P3918; MICHIELI P, 1994, CANCER RES, V54, P3391; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Ozcelik H, 1995, CLIN CANCER RES, V1, P907; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; SOULE HD, 1990, CANCER RES, V50, P6075; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; THORLACIUS S, 1993, CANCER RES, V53, P1637; WALDMAN T, 1995, CANCER RES, V55, P5187; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	47	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					45	52		10.1038/sj.onc.1200803	http://dx.doi.org/10.1038/sj.onc.1200803			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010231				2022-12-17	WOS:A1997WB76000004
J	McConkey, DJ; Goodrich, D; Bucana, C; Klostergaard, J				McConkey, DJ; Goodrich, D; Bucana, C; Klostergaard, J			The human retinoblastoma gene product suppresses ceramide-induced apoptosis in human bladder tumor cells	ONCOGENE			English	Article						Rb; N-hexanoyl-D-sphingosine; DNA fragmentation; bladder carcinoma	ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; SIGNALING PATHWAY; CARCINOMA-CELLS; HL-60 CELLS; BCL-2; DIFFERENTIATION; INACTIVATION; EXPRESSION; MECHANISM	The retinoblastoma gene product, Rb, has previously been implicated as an obligatory component in the antiproliferative effects mediated by the lipid second messenger, ceramide. We have evaluated both the apoptotic effects and the effects on cell cycle distribution of the exogenous cell-permeable ceramide, N-hexanoyl-D-sphingosine, in an Rb-null human bladder tumor cell line, 5637, as well as in retrovirally infected, Rb(+) clones derived therefrom. These cell lines demonstrated comparable sensitivity to N-hexanoyl-D-sphingosine in a neutral red dye uptake assay. Exposure of the Rb-null parental cell line to 20 mu M N-hexanoyl-D-sphingosine for 24 h resulted in a classical pattern of DNA fragmentation that was accompanied by apoptotic nuclear morphological alterations, In contrast, the Rb(+) clones demonstrated suppression of DNA fragmentation in response to N-hexanoyl-D-sphingosine. Similarly, the frequency and degree of alteration of nuclear morphology in Rb(+) cells was also suppressed, Flow cytometric analysis of the parental and infected clones indicated that expression of Rb was without effect on their cell cycle distribution, with or without exposure to N-hexanoyl-D-sphingosine for 25 h; tunel assay confirmed that in this time frame apoptotic cells were far less frequent in the Rb(+) clones than in the parental 5637 cells, Human tumor cell lines derived from three other histological origins, breast and prostatic carcinomas and osteogenic sarcoma, also demonstrated very similar cytotoxic sensitivities to N-hexanoyl-D-sphingosine, irrespective of the expression of Rb, We conclude that Rb is not required for ceramide-induced apoptosis and that Rb can actually inhibit the DNA fragmentation and nuclear morphological changes associated with classical apoptosis.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	McConkey, DJ (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Chang Y, 1995, P NATL ACAD SCI USA, V92, P12275, DOI 10.1073/pnas.92.26.12275; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; FERNANDEZ A, 1995, ONCOGENE, V10, P769; GILL BM, 1994, IMMUNOL REV, V142, P114; GOODRICH DW, 1992, CANCER RES, V52, P1968; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAUSER JML, 1994, J BIOL CHEM, V269, P6803; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jarvis WD, 1996, CLIN CANCER RES, V2, P1; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JAYADEV S, 1994, CMB, V1, P289; JOHNSTON DA, 1978, COMPUT BIOMED RES, V11, P393, DOI 10.1016/0010-4809(78)90020-4; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KALEN A, 1992, BIOCHIM BIOPHYS ACTA, V1125, P90, DOI 10.1016/0005-2760(92)90160-W; KIM MY, 1991, J BIOL CHEM, V266, P484; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LIU J, 1994, J BIOL CHEM, V269, P3047; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MULLER HK, 1994, CELL IMMUNOL, V157, P263, DOI 10.1006/cimm.1994.1221; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OBRHAMMER F, 1993, EMBO J, V120, P3679; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OVERTON WR, 1988, CYTOMETRY, V9, P619, DOI 10.1002/cyto.990090617; SCHNIER JB, 1996, IN PRESS P NATL ACAD, V93; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; STECK KD, 1995, CYTOMETRY, V20, P154, DOI 10.1002/cyto.990200208; STRUM JC, 1994, J BIOL CHEM, V269, P15493; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YANG ZH, 1993, J BIOL CHEM, V268, P20520	41	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1693	1700						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895515				2022-12-17	WOS:A1996VM88700014
J	Wang, BL; Mysliwiec, T; Feller, SM; Knudsen, B; Hanafusa, H; Kruh, GD				Wang, BL; Mysliwiec, T; Feller, SM; Knudsen, B; Hanafusa, H; Kruh, GD			Proline-rich sequences mediate the interaction of the Arg protein tyrosine kinase with Crk	ONCOGENE			English	Article						Abl; myristoylation	SRC HOMOLOGY-3 DOMAIN; C-ABL; SH3 DOMAIN; CELL-CYCLE; BINDING; PHOSPHORYLATION; IDENTIFICATION; PRODUCT; GENE; LEUKEMIA	Arg is a ubiquitously expressed member of the Abelson family of nonreceptor protein-tyrosine kinases, Defining the Arg sequences that mediate its interaction with other proteins is essential to elucidating its role in cellular signaling, In this report we demonstrate that Arg associates with c-Crk, an adaptor protein composed of an SH2 domain and two SH3 domains, and examine the molecular mechanism of the interaction, In vitro experiments revealed that three proline-rich sequences with distinct specificities for SH3 domains are located in the Arg C-terminal domain, just C-terminal to the kinase domain, and that two of these sequences bind to the Crk N-terminal SH3 domain, These two sequences conform to the PsLPxK/R motif that has been observed in other proteins that bind the Crk N-terminal SH3 domain, The interaction of Arg with c-Crk in living cells was confirmed by the detection of coimmunoprecipitation in coinfected Sf9 cells, In addition, increased phosphorylation of c-Crk was observed in cotransfected COS cells, indicating that Crk is an Arg substrate, The site of c-Crk phosphorylation by Arg was identified as tyrosine 221, a residue whose modification has been shown to result in an intramolecular SH2 interaction and a folded conformation, These experiments extend the known Arg protein interacting motifs to include SH3 binding sites and suggest that Arg may function as an effector as well as a regulator of Crk activity.	FOX CHASE CANC CTR, DEPT MED ONCOL, PHILADELPHIA, PA 19111 USA; UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA; BAVARIAN JULIUS MAXIMILIANS UNIV, INST RADIOBIOL & CELL BIOL, WURZBURG, GERMANY; ROCKEFELLER UNIV, MOL ONCOL LAB, NEW YORK, NY 10021 USA	Fox Chase Cancer Center; University of Pennsylvania; University of Wurzburg; Rockefeller University					NCI NIH HHS [CA44356, CA60453-03S1, CA57273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA060453, R01CA057273, R55CA057273, R35CA044356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LAEMMLI UK, 1968, MOL GEN GENET, V101, P333, DOI 10.1007/BF00436231; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATTIONI T, 1995, ONCOGENE, V10, P1325; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MORRIS JF, 1991, ONCOGENE, V6, P2339; Mysliwiec T, 1996, ONCOGENE, V12, P631; NICHOLS GL, 1994, BLOOD, V84, P2912; OGAWA S, 1994, ONCOGENE, V9, P1669; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PEREGO R, 1991, ONCOGENE, V6, P1899; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG B, IN PRESS ONCOGENE; Wang BL, 1996, ONCOGENE, V12, P1921; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	44	34	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1379	1385						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875975				2022-12-17	WOS:A1996VL38400002
J	Kawamura, M; Yamashita, T; Segawa, K; Kaneuchi, M; Shindoh, M; Fujinaga, K				Kawamura, M; Yamashita, T; Segawa, K; Kaneuchi, M; Shindoh, M; Fujinaga, K			The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity	ONCOGENE			English	Article						p53 tumor suppressor gene; codon 273; missense mutant; transactivation; ras-collaborative transformation	WILD-TYPE P53; CELL-CYCLE CONTROL; TRANSCRIPTIONAL ACTIVITY; BINDING-SITE; DNA-BINDING; SUPPRESSOR; MUTATIONS; PROTEIN; GENE; ANTIGEN	Cancer-related mutations of the p53 tumor suppressor gene are clustered in the four so-called 'hot spots', codons 175, 248, 273 and 281/282, By using recombination PCR in vitro mutagenesis, we introduced point mutations into the codon 273 of wild-type (wt) p53 (pC53-SN3) from Arg to His (pC53-273H [273H]), Asp (273D),Pro (273P), Lys (273K), Leu (273L) or Thr (273T), and compared their biological and biochemical activities with wt p53 and cancer-derived 175H, 248W and 273H/309S, Among them, 273H/309S, 273H and 273D as well as wt p53 transactivated the chloramphenicol acetyltransferase (CAT) gene placed downstream of the p53 binding consensus, while none of the other mutants including 273L did, Transcriptions from human c-fos and rat PCNA promoters were suppressed by wt p53 and 273D, while they were enhanced variously by all other mutants in Saos-2 and/or NIH3T3 cells. On the other hand, growth of human squamous carcinoma cell lines measured by the plating efficiency of G418-resistant colonies was enhanced by transfection of 175H, 248W, 273H/309S and 273P, while suppressed by not only wt p53, 273D and 273H but also 273L, Thus, 273H/309S enhanced cell growth in spite of its p53-specific transactivation activity, while 273L suppressed cell growth in spite of its complete loss of the p53-specific transactivation, We concluded that the sequence-specific transactivation of p53 is not always correlated with its growth inhibitory activity.	SAPPORO MED UNIV,SCH MED,CANC RES INST,DEPT MOLEC BIOL,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN; KEIO UNIV,SCH MED,DEPT MICROBIOL,SHINJUKU KU,TOKYO 160,JAPAN	Sapporo Medical University; Keio University			Shindoh, Masanobu/A-4799-2012	Shindoh, Masanobu/0000-0002-7782-5823				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHEN JY, 1993, ONCOGENE, V8, P2159; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; JONES DH, 1991, BIOTECHNIQUES, V10, P62; KANDA T, 1994, MOL CELL BIOL, V14, P2651, DOI 10.1128/MCB.14.4.2651; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; OHASHI Y, 1992, BIOCHIM BIOPHYS ACTA, V1130, P175, DOI 10.1016/0167-4781(92)90525-5; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SAKAI E, 1992, ONCOGENE, V7, P927; SEGAWA K, 1993, ONCOGENE, V8, P543; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; van der Eb A J, 1980, Methods Enzymol, V65, P826; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMASHITA T, 1993, ONCOGENE, V8, P2433; YAMASHITA T, 1986, Tumor Research, V21, P67; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZHANG W, 1993, ONCOGENE, V8, P2555	58	34	35	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2361	2367						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649776				2022-12-17	WOS:A1996UQ22000013
J	Rockow, S; Tang, JP; Xiong, W; Li, W				Rockow, S; Tang, JP; Xiong, W; Li, W			Nck inhibits NGF and basic FGF induced PC12 cell differentiation via mitogen-activated protein kinase-independent pathway	ONCOGENE			English	Article						receptor tyrosine kinases; src-homology domains; adapter molecules; signal transduction	NERVE GROWTH-FACTOR; PHEOCHROMOCYTOMA CELLS; SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; SH3 DOMAINS; MAP KINASE; SRC; PHOSPHOTYROSINE; PHOSPHORYLATION; TYROSINE	Proto-oncogene Nck, an adapter molecule containing three SH3 and one SH2 domains, binds to cell surface receptors and mediate mitogenic effects in the cells. Overexpression of Nck caused cell transformation in vitro and tumor formation in the nude mice. The mechanism of this action by Nck, however, remained unclear. Rat adrenal pheochromocytoma cell line PC12 provides a useful system for studying growth factor-regulated cell proliferation and differentiation. Serum and epidermal growth factor (EGF) stimulate proliferation, whereas nerve growth factor (NGF) and basic fibroblast growth factor (bFGF) cause growth arrest and sympathetic neurite outgrowth in these cells. To study the function of Nck, we generated stable clones of PC12 cells overexpressing the human Nck. We report here that the overexpressed Nck caused continued proliferation of PC12 cells even in the presence of NGF and blocked both the NGF- and bFGF-induced neurite outgrowth. Anti-sense but not sense oligonucleotides to the human Nck resumed the NGF-induced differentiation, indicating the specific inhibitory effect of Nck. Interestingly, Nck did not interfere with the kinetics of NGF- and EGF-stimulated protein tyrosine phosphorylation and the mitogen-activated protein kinase (MAPK) activation, suggesting that Nck inhibited the induced PC12 cell differentiation via a MAPK-independent mechanism. This study has provided a useful system for further understanding the function of Nck.	UNIV CHICAGO, BEN MAY INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago					NCI NIH HHS [CA65567] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065567] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COHEN P, 1992, BIOCHEM SOC T, V20, P671, DOI 10.1042/bst0200671; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; HU QJ, 1995, MOL CELL BIOL, V15, P1169; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KWAN SP, 1995, P NATL ACAD SCI USA, V92, P4706, DOI 10.1073/pnas.92.10.4706; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA M, 1992, J VIROL, V66, P115, DOI 10.1128/JVI.66.1.115-121.1992; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1993, CURR BIOL, V3, P343; PAWSON T, 1995, NATURE, V373, P575; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; THOMAS SM, 1992, CELL, V68, P1030; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	42	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2351	2359						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649775				2022-12-17	WOS:A1996UQ22000012
J	Marhin, WW; Hei, YJ; Chen, SJ; Jiang, Z; Gallie, BL; Phillips, RA; Penn, LZ				Marhin, WW; Hei, YJ; Chen, SJ; Jiang, Z; Gallie, BL; Phillips, RA; Penn, LZ			Loss of Rb and Myc activation co-operate to suppress cyclin D1 and contribute to transformation	ONCOGENE			English	Article						Myc; Rb; cyclin D1; MEF; transformation	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; CELL-CYCLE; SUSCEPTIBILITY GENE; NEGATIVE AUTOREGULATION; BINDING PROTEIN; G1 PHASE; LARGE-T; EXPRESSION; PHOSPHORYLATION	Cyclin D1 can bind and phosphorylate the product (pRb) of the retinoblastoma gene (RB-1) and recent evidence suggests pRb, in turn, may regulate cyclin D1 protein expression. In transformed cell lines, loss of pRb activity strongly correlates with a decrease in cyclin D1 protein expression, and conversely, introduction of pRb can induce cyclin D1 promoter activity. We show here that pRb does not regulate cyclin D1 directly as basal and serum-stimulated levels of cyclin D1 protein and kinase activity are similar in wildtype and pRb-deficient primary mouse embryonic fibroblasts (MEFs). These observations suggest that the suppression of cyclin D1 in pRb-minus tumour cell lines requires both loss of pRb and at least one additional genetic event. We have determined that constitutive, ectopic Myc expression in pRb-deficient, but not wildtype, MEFs suppresses cyclin D1 protein expression and kinase activity. Regulation is evident at either the level of RNA or protein expression. Phenotypically, pRb-deficient MEFs consistently exhibited a delayed growth response in comparison to wildtype MEFs. This growth delay is abrogated in pRb-deficient MEFs which are expressing ectopic Myc protein, coincident with the loss of cyclin D1 protein expression. Moreover, these cells exhibit an increased proliferative capacity, and they no longer show contact inhibition. Our results support a cross-regulatory mechanism between Myc, pRb and cyclin D1 and suggest a novel role for cyclin D1 in tumorigenesis.	HOSP SICK CHILDREN, RES INST, DEPT MICROBIOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, RES INST, DEPT IMMUNOL & CANC, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, RES INST, DEPT MED & MOLEC GENET, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, TORONTO, ON M5G 1X8, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto				Penn, Linda/0000-0001-8133-5459; Gallie, Brenda/0000-0002-9697-9211				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1994, ONCOGENE, V9, P71; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUCHOU T, 1993, ONCOGENE, V8, P1765; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cleveland J L, 1988, Oncogene Res, V3, P357; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FACCHINI LM, 1994, CELL GROWTH DIFFER, V5, P637; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; FUNG YKT, 1993, ONCOGENE, V8, P2659; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAMEL PA, 1990, MOL CELL BIOL, V10, P6586, DOI 10.1128/MCB.10.12.6586; HAUPT Y, 1995, ONCOGENE, V10, P1563; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HORTON LE, 1995, CELL GROWTH DIFFER, V6, P395; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NEVINS JR, 1992, SCIENCE, V258, P424; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Penn L J, 1990, Semin Cancer Biol, V1, P69; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SQUIRE J, 1986, NATURE, V322, P555, DOI 10.1038/322555a0; TAM SW, 1994, ONCOGENE, V9, P2663; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	82	34	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	1996	12	1					43	52						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552398				2022-12-17	WOS:A1996TQ01400006
J	DEJONG, R; HAATAJA, L; VONCKEN, JW; HEISTERKAMP, N; GROFFEN, J				DEJONG, R; HAATAJA, L; VONCKEN, JW; HEISTERKAMP, N; GROFFEN, J			TYROSINE PHOSPHORYLATION OF MURINE CRKL	ONCOGENE			English	Article						SH2-SH3 ADAPTER PROTEIN; BCR/ABL; LEUKEMIA	BCR/ABL TRANSGENIC MICE; P210 BCR-ABL; SH3 DOMAINS; P160 BCR; PROTEINS; GENE; TRANSFORMATION; LEUKEMIA; BINDING; CELLS	The SH2/SH3 adaptor protein Crkl is abnormally phosphorylated on tyrosine by the Bcr/Abl protein in leukemic cells from patients with Philadelphia-chromosome (Ph)positive leukemia. However, the state of tyrosine-phosphorylation of crkl in normal tissues is unknown. In the current study, we identified mouse crkl by cDNA cloning and examined expression levels and tyrosine-phosphorylation of the mouse crkl protein during embryogenesis and in adult tissues. Tyrosine-phosphorylation of crkl was prominent during early development, but decreased at later embryonic stages and in newborn mice. Expression of both crkl and the related crk was ubiquitous in the adult. However, crkl differed considerably from crk in relative tissue distribution, and was more abundant in hematopoietic tissues. With exception of the lung, crkl was mostly present in a non-tyrosine phosphorylated form. Consistent with our previous findings in human patients, murine crkl was phosphorylated on tyrosine in leukemic tissues of BCR/ABL transgenic animals, but was non-tyrosine phosphorylated in normal mouse bone marrow. We conclude that this crkl tyrosine-phosphorylation by Bcr/Abl in hematopoietic cells is clearly aberrant and is consistently linked to the development of leukemia. Identification of proteins interacting with tyrosine-phosphorylated crkl in the leukemic cells of BCR/ABL transgenic mice should reveal members of signal transduction pathways activated in Ph-positive leukemia.	CHILDRENS HOSP LOS ANGELES,DEPT PATHOL,MOLEC DIAGNOST SECT,LOS ANGELES,CA 90027	Children's Hospital Los Angeles			Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NCI NIH HHS [CA 50248, CA 47456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047456, R01CA050248, R55CA047456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; CAMPBELL ML, 1990, ONCOGENE, V5, P773; DRUKER B, 1992, BLOOD, V79, P2215; ERNST TJ, 1994, J BIOL CHEM, V269, P5764; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1993, CAUSES CONSEQUENCES, P359; Heisterkamp Nora, 1991, Transgenic Research, V1, P45, DOI 10.1007/BF02512996; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LU D, 1993, BLOOD, V82, P1257; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUGUCHI T, 1994, J BIOL CHEM, V7, P5016; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MURRAY JF, 1986, NORMAL LUNG; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TENHOEVE J, 1993, GENOMICS, V18, P588, DOI 10.1016/S0888-7543(05)80360-X; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VANETTEN RA, 1993, LEUKEMIA ADV RES TRE; VONCKEN, IN PRESS; VONCKEN JW, 1992, BLOOD, V79, P1029; VONCKEN JW, 1992, CANCER RES, V52, P4534; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F	37	34	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1469	1474						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478571				2022-12-17	WOS:A1995TC53500005
J	TAHARA, H; KAMADA, K; SATO, E; TSUYAMA, N; KIM, JK; HARA, E; ODA, K; IDE, T				TAHARA, H; KAMADA, K; SATO, E; TSUYAMA, N; KIM, JK; HARA, E; ODA, K; IDE, T			INCREASE IN EXPRESSION LEVELS OF INTERFERON-INDUCIBLE GENES IN SENESCENT HUMAN-DIPLOID FIBROBLASTS AND IN SV40-TRANSFORMED HUMAN FIBROBLASTS WITH EXTENDED LIFE-SPAN	ONCOGENE			English	Article						SENESCENT CELLS; SV40-TRANSFORMED CELLS; INTERFERON; INTERFERON-INDUCIBLE GENES	GROWTH-FACTOR; DNA-SYNTHESIS; HUMAN-CELLS; SIMIAN VIRUS-40; MESSENGER-RNA; T-ANTIGEN; BETA; INHIBITION; INVITRO; SPAN	The normal human fibroblast line, TIG-3 which senesces at around 80 population doubling levels (PDLs), expressed interferon (IFN)-inducible genes such as 6-16, 2', 5'-oligoadenylate synthetase (2,5-A) and HLA B7 near the end of the proliferative lifespan. Other normal fibroblast line such as MRC-5 also expressed IFN-inducible genes when senesced. Clones transformed with SV40 T-antigen, which extended their proliferative lifespan by about 20-30 PDLs, also expressed IFN-inducible genes during their extended life. Anti-IFN-beta antibodies added in culture medium repressed the expression of IFN-inducible gene in both senescent and life-extended SV40-transformed IFN-beta repressed DNA synthesis in normal TIG-3 and induced IFN-inducible genes in both normal and SV40-transformed TIG-3. Conditioned medium recovered from life-extended SV40-transformed cells contained IFN-beta, but not IFN-alpha, IFN-gamma or TNF-alpha and possessed an activity that inhibited DNA synthesis of young TIG-3. Addition of anti-IFN-beta antibodies into the medium enhanced the serum-induced DNA synthesis of near senescent (91% lifespan completed) TIG-3, while it neither induced DNA synthesis in fully senescent TIG-3 nor extended the proliferative lifespan of TIG-3. These results suggest that normal and SV40-transformed human fibroblasts increase expression of IFN-beta with increasing proliferative age especially near the end of their lifespan resulting in induction of IFN-inducible genes and possibly in growth repression.	HIROSHIMA UNIV,SCH MED,DEPT CELLULAR & MOLEC BIOL,HIROSHIMA 734,JAPAN; SCI UNIV TOKYO,DEPT APPL BIOL SCI,NODA,CHIBA 278,JAPAN	Hiroshima University; Tokyo University of Science								BURMER GC, 1983, EXP CELL RES, V145, P79, DOI 10.1016/S0014-4827(83)80010-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRISTOFINIS GJ, 1981, J GEN VIROL, V52, P169, DOI 10.1099/0022-1317-52-1-169; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DRESCHERLINCOLN CK, 1984, EXP CELL RES, V153, P208, DOI 10.1016/0014-4827(84)90462-2; DRESCHERLINCOLN CK, 1983, EXP CELL RES, V144, P455, DOI 10.1016/0014-4827(83)90424-X; EINAT M, 1985, P NATL ACAD SCI USA, V82, P7608, DOI 10.1073/pnas.82.22.7608; ELEFTHERIOU CS, 1993, BIOCHIM BIOPHYS ACTA, V1180, P304, DOI 10.1016/0925-4439(93)90055-6; FELLOUS M, 1982, P NATL ACAD SCI-BIOL, V79, P3082, DOI 10.1073/pnas.79.10.3082; FORSBERG K, 1988, J CELL PHYSIOL, V136, P266, DOI 10.1002/jcp.1041360208; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; FRIEDMAN RL, 1979, INTERFERON INTERACTI, V1; GERFAUX J, 1989, CANCER RES, V49, P1241; GIRARDI AJ, 1966, ANN MED EXP BIOL FEN, V44, P242; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GOLDSTEIN S, 1969, LANCET, V1, P424; GOLDSTEIN S, 1978, SCIENCE, V199, P781, DOI 10.1126/science.622567; GOLDSTEIN S, 1989, EXP GERONTOL, V24, P461, DOI 10.1016/0531-5565(89)90052-1; HARA E, 1993, ANAL BIOCHEM, V214, P58, DOI 10.1006/abio.1993.1456; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HERZOG H, 1990, NUCLEIC ACIDS RES, V18, P4600, DOI 10.1093/nar/18.15.4600; HISCOTT J, 1988, MOL CELL BIOL, V8, P3397, DOI 10.1128/MCB.8.8.3397; IDE T, 1984, EXP CELL RES, V150, P321, DOI 10.1016/0014-4827(84)90575-5; IWATA A, 1988, J BIOCHEM-TOKYO, V104, P247, DOI 10.1093/oxfordjournals.jbchem.a122451; JACOBS JP, 1970, NATURE, V227, P168, DOI 10.1038/227168a0; KOHASE M, 1987, MOL CELL BIOL, V7, P273, DOI 10.1128/MCB.7.1.273; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; KUMAR S, 1992, P NATL ACAD SCI USA, V89, P4683, DOI 10.1073/pnas.89.10.4683; LALLEMAND C, 1992, ONCOGENE, V7, P1109; LUMPKIN CK, 1986, SCIENCE, V232, P393, DOI 10.1126/science.2421407; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MARTIN GM, 1970, LAB INVEST, V23, P86; MATSUO M, 1982, J GERONTOL, V37, P33, DOI 10.1093/geronj/37.1.33; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NORWOOD TH, 1974, P NATL ACAD SCI USA, V71, P2231, DOI 10.1073/pnas.71.6.2231; OHASHI M, 1980, EXP GERONTOL, V15, P121, DOI 10.1016/0531-5565(80)90083-2; OLESZAK E, 1980, J INTERFERON RES, V1, P37, DOI 10.1089/jir.1980.1.37; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; SCHNEIDER EL, 1976, P NATL ACAD SCI USA, V73, P3584, DOI 10.1073/pnas.73.10.3584; TAHARA H, 1994, BIOCHEM BIOPH RES CO, V199, P1108, DOI 10.1006/bbrc.1994.1345; TOVEY MG, 1987, P NATL ACAD SCI USA, V84, P5038, DOI 10.1073/pnas.84.14.5038; TSUYAMA N, 1991, CELL STRUCT FUNCT, V16, P55, DOI 10.1247/csf.16.55; WISTROM C, 1992, EXP CELL RES, V199, P355, DOI 10.1016/0014-4827(92)90445-E; YANISHEVSKY RM, 1980, EXP CELL RES, V126, P469, DOI 10.1016/0014-4827(80)90290-6; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	49	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1125	1132						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566972				2022-12-17	WOS:A1995RX18000015
J	QIAN, XL; DOUGALL, WC; FEI, ZZ; GREENE, MI				QIAN, XL; DOUGALL, WC; FEI, ZZ; GREENE, MI			INTERMOLECULAR ASSOCIATION AND TRANS-PHOSPHORYLATION OF DIFFERENT NEU-KINASE FORMS PERMIT SH2-DEPENDENT SIGNALING AND ONCOGENIC TRANSFORMATION	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; FACTOR RECEPTOR FAMILY; NIH 3T3 CELLS; POINT MUTATION; MONOCLONAL-ANTIBODIES; TRANSMEMBRANE DOMAIN; PDGF RECEPTOR; LIVING CELLS; HUMAN-BREAST	The nea oncogene encodes a 185 kDa receptor tyrosine kinase, A single point mutation (Val664-->Glu) within the p185(neu) transmembrane region results in higher efficiency of receptor dimerization, constitutive activity of tyrosine kinase and cellular transformation, The oncogenic potential of this mutated form of p185(neu) (termed Tneu) can be inactivated by site-directed alteration of a lysine residue in the conserved catalytic domain. In this report, we have utilized the physical and functional interaction of a full-length kinase-deficient neu protein (T757) and truncated kinase-active Tneu forms to determine critical protein domains for Tneu oligomerization and the resultant biological consequences. Analysis of various truncated Tneu mutants confirmed that the transmembrane region was crucial for p185 dimerization. Receptor association facilitates intermolecular phosphorylation of kinase-deficient mutant T757 by truncated kinase-active p185 proteins, and the trans-phosphorylated kinase-deficient T757 was able to associate in vitro with proteins containing SH2 domains. Receptor-receptor interactions resulted in enhanced signal transduction potential and transformation of cell-lines co-expressing different neu-kinase forms. These studies emphasize a novel feature of protein-protein interaction and the functional significance of p185 dimerization, intermolecular phosphorylation and signaling which may result in cellular transformation.	UNIV PENN,SCH MED,DEPT PHYSIOL,PHILADELPHIA,PA 19104	University of Pennsylvania	QIAN, XL (corresponding author), UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,CTR RECEPTOR BIOL,PHILADELPHIA,PA 19104, USA.			Dougall, William/0000-0001-9487-251X				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; CAO HN, 1991, ONCOGENE, V6, P705; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; HACK N, 1993, J BIOL CHEM, V268, P26441; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEVEA CM, 1993, RECEPTOR, V3, P293; LI W, 1991, MOL CELL BIOL, V11, P3756, DOI 10.1128/MCB.11.7.3756; LOFTS FJ, 1993, ONCOGENE, V8, P2813; MARGOLIS B, 1992, CELL GROWTH DIFFER, V7, P73; MIKAMI Y, 1992, P NATL ACAD SCI USA, V89, P7335, DOI 10.1073/pnas.89.16.7335; MYERS JN, 1992, RECEPTOR, V2, P1; OTSU M, 1991, CELL, V65, P359; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELES E, 1992, J BIOL CHEM, V267, P12266; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; QIAN XL, 1994, ONCOGENE, V9, P1507; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; SAMANTA A, 1993, UNPUB SCIENCE; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SELVA E, 1993, J BIOL CHEM, V268, P2250; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAMAMOTO T, 1992, J BIOL CHEM, P11337; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	58	34	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					211	219						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824275				2022-12-17	WOS:A1995QA98000025
J	OETKEN, C; COUTURE, C; BERGMAN, M; BONNEFOYBERARD, N; WILLIAMS, S; ALITALO, K; BURN, P; MUSTELIN, T				OETKEN, C; COUTURE, C; BERGMAN, M; BONNEFOYBERARD, N; WILLIAMS, S; ALITALO, K; BURN, P; MUSTELIN, T			TCR/CD3-TRIGGERING CAUSES INCREASED ACTIVITY OF THE P50(CSK) TYROSINE KINASE AND ENGAGEMENT OF ITS SH2 DOMAIN	ONCOGENE			English	Article							CELL ANTIGEN RECEPTOR; CD45 PHOSPHOTYROSINE PHOSPHATASE; TERMINAL SRC KINASE; PROTEIN-KINASE; PHOSPHOLIPASE C-GAMMA-1; SIGNAL TRANSDUCTION; C-SRC; T-CELLS; AUTOPHOSPHORYLATION SITE; CROSS-LINKING	The majority of known protein tyrosine kinases are integral membrane proteins or bound to cellular membranes via a covalently attached myristic acid. An exception is the newly described p50(csk) tyrosine kinase, which is believed to control the activity of the sue-family of protein tyrosine kinases. This small kinase does not contain a myristylation signal or other known membrane attachment motifs, and indeed appears to be cytosolic. Recently, we found that p50(csk) specifically phosphorylates the negative regulatory Tyr-505 of the T cell-specific sue-family kinase p56(lck), and thereby suppresses its catalytic activity. Here we show that p50(csk) is activated in Jurkat T cells within one minute after stimulation of the cells with anti-CD3 MAbs. In parallel with this activation, p50(csk) formed a stable complex with one major 72 kDa tyrosine phosphorylated protein and minor polypeptides at 90 and 110 kDa. The isolated SH2 domain of p50(csk) specifically bound the 72 kDa protein in lysates from activated, but not resting, T or B cells, By several criteria, the 72 kDa protein was not a tyrosine kinase itself and it did not react with antibodies to a panel of known proteins of this molecular size. Our results suggest that p50(csk) is rapidly engaged via its SH2 domain and participates in the earliest events of T cell activation.	LA JOLLA INST ALLERGY & IMMUNOL, DIV CELL BIOL, LA JOLLA, CA 92037 USA; UNIV HELSINKI, DEPT PATHOL, CANC BIOL LAB, SF-00014 HELSINKI, FINLAND; F HOFFMANN LA ROCHE & CO LTD, PHARMACEUT RES NEW TECHNOL, DEPT BIOL, BASEL, SWITZERLAND	La Jolla Institute for Immunology; University of Helsinki; Roche Holding			Alitalo, Kari K/J-5013-2014; Bonnefoy, Nathalie/J-2536-2012	Alitalo, Kari K/0000-0002-7331-0902; Bonnefoy, Nathalie/0000-0003-4814-6722; Mustelin, Tomas/0000-0001-5912-8840	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048960] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-48960] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BENNETT BD, 1994, IN PRESS J BIOL CHEM; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOUGERET C, 1993, ONCOGENE, V8, P1241; CHALUPNY NJ, 1991, EMBO J, V10, P1201, DOI 10.1002/j.1460-2075.1991.tb08061.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COUTURE C, 1994, IN PRESS P NAT ACAD; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DASILVA AJ, 1992, MOL IMMUNOL, V29, P1417, DOI 10.1016/0161-5890(92)90215-J; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HSI ED, 1989, J BIOL CHEM, V264, P10836; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KLAGES S, 1994, IN PRESS P NATL ACAD; LIU XQ, 1993, ONCOGENE, V8, P1119; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; MUSTELIN T, 1989, IMMUNOL TODAY, V10, P189, DOI 10.1016/0167-5699(89)90322-8; MUSTELIN T, 1990, ONCOGENE, V5, P809; MUSTELIN T, 1991, SCAND J IMMUNOL, V34, P259, DOI 10.1111/j.1365-3083.1991.tb01545.x; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OETKEN C, 1992, EUR J HAEMATOL, V49, P208; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PARTANEN J, 1991, ONCOGENE, V6, P2013; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, NATURE, V324, P674, DOI 10.1038/324674a0; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VONWILLEBRAND M, 1994, EUR J IMMUNOL, V24, P234, DOI 10.1002/eji.1830240137; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484	58	34	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1625	1631						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183556				2022-12-17	WOS:A1994NL81500013
J	YOUNG, J; BUTTENSHAW, R; BUTTERWORTH, L; WARD, M; SEARLE, J; LEGGETT, B; CHENEVIXTRENCH, G				YOUNG, J; BUTTENSHAW, R; BUTTERWORTH, L; WARD, M; SEARLE, J; LEGGETT, B; CHENEVIXTRENCH, G			ASSOCIATION OF THE SS GENOTYPE OF THE L-MYC GENE AND LOSS OF 18Q SEQUENCES WITH A WORSE CLINICAL PROGNOSIS IN COLORECTAL CANCERS	ONCOGENE			English	Article							FRAGMENT-LENGTH-POLYMORPHISM; HUMAN-BREAST-CANCER; LUNG-CANCER; METASTASIS; HETEROZYGOSITY; CARCINOMAS; FREQUENCY; TUMORS; COLON; LOCUS	L-myc is a nuclear oncogene which is sometimes activated late in tumourigenesis. Digestion of DNA with EcoRI reveals a simple restriction fragment length polymorphism (RFLP) located in the second intron of L-myc, with allele sizes 10 kb (L-allele) and 6.6 kb (S-allele). Some studies have suggested that the presence of the S-allele in the constitutional DNA of a patient with cancer is associated with a higher risk of metastasis in lung, breast and renal cell carcinomas. The aims of this study were to determine if the S-allele was significantly associated with metastasis and also with inactivation of tumour suppressor genes in colorectal cancer. One hundred and twenty-four Caucasian colorectal cancer patients were studied for L-myc genotype, and a subgroup of these (108) had their tumours examined for allele loss at multiple loci on nine chromosomal arms (1p, 1q, 5q, 8p, 14q, 17p, 17q, 18q, 22q) and for mutations in the 12th codon of K-ras. The percentage of individuals with the SS genotype was 19% (4/21) Dukes Stage A, 19% (10/54) Dukes B, 25% (8/32) Dukes C and 40% (8/20) Dukes D. The trend observed here is significant (P<0.05, Wilcoxon Rank Sum Test). Also, the SS genotype was significantly more common in individuals whose tumours showed allelic loss on 18q (P<0.01, Fishers Exact Test). This work suggests that the S-allele of L-myc, or a gene in linkage disequilibrium with it, may modify the development of colorectal cancer.	UNIV QUEENSLAND,SCH MED,DEPT PATHOL,BRISBANE,QLD 4029,AUSTRALIA; ROYAL BRISBANE HOSP,DEPT PATHOL,BRISBANE,QLD 4029,AUSTRALIA; QUEENSLAND INST MED RES,BRISBANE,QLD 4029,AUSTRALIA	University of Queensland; Royal Brisbane & Women's Hospital; QIMR Berghofer Medical Research Institute	YOUNG, J (corresponding author), GLAXO GASTROENTEROL LAB,CLIN RES CTR,BANCROFT CTR,300 HERSTON RD,BRISBANE,QLD 4029,AUSTRALIA.		Young, Joanne P/H-7774-2014; Leggett, Barbara A/D-3579-2011; Young, Joanne P/B-9981-2011	Chenevix-Trench, Georgia/0000-0002-1878-2587; Leggett, Barbara/0000-0003-2062-7380				BELL SM, 1991, BRIT J CANCER, V64, P174, DOI 10.1038/bjc.1991.264; BIECHE I, 1990, HUM GENET, V85, P101; CHAMPEME MH, 1992, INT J CANCER, V50, P6, DOI 10.1002/ijc.2910500103; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; CHENEVIXTRENCH G, 1989, BRIT J CANCER, V60, P872, DOI 10.1038/bjc.1989.382; DEPHINO RA, 1987, GENE DEV, V1, P1311; IKEDA I, 1988, JPN J CANCER RES, V79, P674, DOI 10.1111/j.1349-7006.1988.tb02220.x; ISHIZAKI K, 1990, J NATL CANCER I, V82, P238, DOI 10.1093/jnci/82.3.238; KAKEHI Y, 1989, INT J CANCER, V43, P391, DOI 10.1002/ijc.2910430307; KATO M, 1990, INT J CANCER, V45, P47, DOI 10.1002/ijc.2910450110; KAWASHIMA K, 1988, P NATL ACAD SCI USA, V85, P2353, DOI 10.1073/pnas.85.7.2353; KAWASHIMA K, 1992, INT J CANCER, V50, P557, DOI 10.1002/ijc.2910500411; KAWASHIMA K, 1987, P JPN ACAD B-PHYS, V63, P300, DOI 10.2183/pjab.63.300; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; LAURENTPUIG P, 1992, GASTROENTEROLOGY, V102, P1136; LEISTER I, 1990, CANCER RES, V50, P7232; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NEWLAND RC, 1987, CANCER, V60, P852, DOI 10.1002/1097-0142(19870815)60:4<852::AID-CNCR2820600422>3.0.CO;2-5; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; SARANATH D, 1990, BRIT J CANCER, V61, P530, DOI 10.1038/bjc.1990.119; TAMAI S, 1990, INT J CANCER, V46, P411, DOI 10.1002/ijc.2910460314; TAYLOR JA, 1993, INT J CANCER, V54, P927, DOI 10.1002/ijc.2910540610; TEFRE T, 1990, BRIT J CANCER, V61, P809, DOI 10.1038/bjc.1990.182; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEINBERG RA, 1989, CANCER RES, V49, P3713; YOUNG J, 1992, CANCER RES, V52, P285	29	34	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1053	1056						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	7907781				2022-12-17	WOS:A1994NC04800007
J	JACKSON, PK; PASKIND, M; BALTIMORE, D				JACKSON, PK; PASKIND, M; BALTIMORE, D			MUTATION OF A PHENYLALANINE CONSERVED IN SH3-CONTAINING TYROSINE KINASES ACTIVATES THE TRANSFORMING ABILITY OF C-ABL	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; NORMAL CELLULAR HOMOLOG; FUJINAMI SARCOMA-VIRUS; STRUCTURAL SIMILARITY; SIGNAL TRANSDUCTION; NUCLEOTIDE-SEQUENCE; CATALYTIC DOMAINS; PHOSPHOLIPASE-C; LYMPHOID-CELLS; GENE-PRODUCTS	c-abl is the normal cellular homolog of the v-abl transforming gene of Abelson murine leukemia virus. By constructing recombinants between c- and v-abl retroviruses, we show that a point mutation in c-Abl is sufficient to change the myristoylated form of c-Abl into a protein able to transform fibroblasts, but not capable of transforming bone marrow or inducing Abelson disease. This activating mutation, which changes the phenylalanine at amino acid 420 to valine (F420V) found in the homologous position of v-Abl, is positioned outside of the SH3 domain, a region typically modified in transforming alleles of abl. Phenylalanine 420 is perfectly conserved among tyrosine kinases with N-terminal SH3 domains (the Src and Abl families). The equivalent position in other protein tyrosine kinases is a conserved hydrophobic residue that predicts the specific family to which that kinase belongs. Mutation of phenylalanine 420 to other hydrophobic residues activates c-Abl. Unlike other transforming variants of Abl, the F420V mutant protein is not highly phosphorylated on tyrosine. Mutation of the nearby proposed autophosphorylation site, tyrosine 412, shows that this tyrosine is not strictly required for fibroblast transformation in either F420V or SH3-deleted variants of c-Abl (IV).	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; ROCKEFELLER UNIV,NEW YORK,NY 10021	Massachusetts Institute of Technology (MIT); Whitehead Institute; Rockefeller University				Jackson, Peter/0000-0002-1742-2539	NATIONAL CANCER INSTITUTE [R01CA051462] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA51462-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELSON HT, 1970, CANCER RES, V30, P2213; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERNARDS A, 1988, ONCOGENE, V2, P297; BERNARDS A, 1987, MOL CELL BIOL, V7, P3231, DOI 10.1128/MCB.7.9.3231; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LATT SA, 1983, J VIROL, V45, P1195, DOI 10.1128/JVI.45.3.1195-1199.1983; LEE R, 1985, RNA TUMOR VIRUSES, P861; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MELO JV, 1992, LEUKEMIA, V6, P786; MURTAGH K, 1986, J VIROL, V60, P599, DOI 10.1128/JVI.60.2.599-606.1986; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; PAWSON T, 1988, ONCOGENE, V3, P491; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PIWINICAWORMS H, 1987, CELL, V49, P75; PONTICELLI AS, 1982, CELL, V29, P953, DOI 10.1016/0092-8674(82)90458-5; PROBER JM, 1987, SCIENCE, V238, P336, DOI 10.1126/science.2443975; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; REYNOLDS FH, 1980, J VIROL, V36, P374, DOI 10.1128/JVI.36.2.374-386.1980; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; ROSENBERG NE, 1980, J VIROL, V36, P563; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TAKEMORI T, 1987, EMBO J, V6, P951, DOI 10.1002/j.1460-2075.1987.tb04844.x; WANG JYJ, 1988, ONCOGENE RES, V3, P293; WANG JYJ, 1984, CELL, V36, P349; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WEINMASTER GA, 1988, J VIROL, V62, P2016, DOI 10.1128/JVI.62.6.2016-2025.1988; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; WITTE ON, 1979, NATURE, V5730, P396; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	57	34	37	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1943	1956						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510937				2022-12-17	WOS:A1993LG68200027
J	WADEWITZ, AG; WINER, MA; WOLGEMUTH, DJ				WADEWITZ, AG; WINER, MA; WOLGEMUTH, DJ			DEVELOPMENTAL AND CELL LINEAGE SPECIFICITY OF RAF FAMILY GENE-EXPRESSION IN MOUSE TESTIS	ONCOGENE			English	Article							COMPLETE CODING SEQUENCE; MALE GERM-CELLS; COMPLETE NUCLEOTIDE-SEQUENCE; RIBOSOMAL-RNA GENE; KINASE-ACTIVITY; PROTEIN-KINASE; INSITU HYBRIDIZATION; BIOLOGICAL-ACTIVITY; MESSENGER-RNAS; A-RAF	The proto-oncogene c-raf-1 and the related genes A-raf and B-raf encode serine/threonine protein kinases thought to be involved in regulating gene expression by transducing extracellular signals into the cell. All three raf family genes have been shown previously to be expressed in mouse testis. Northern and in situ hybridization analyses with probes specific for each gene demonstrated that c-raf-1 mRNA is ubiquitously expressed in both somatic and germ cells as a 3.1-kb transcript. Additionally, the levels of c-raf-1 expression are developmentally regulated in the germ cells, exhibiting highest expression in early pachytene spermatocytes and decreasing progressively through later stages. A-raf is expressed predominantly in the somatic compartment as two transcripts of 2.6 and 4.3 kb. A-raf expression in Leydig cells appears to be elevated in testes undergoing spermatogenesis. In contrast, B-raf is expressed as two major transcripts of 4.0 and 2.6 kb, with the 4.0-kb transcript first expressed at low levels in pachytene spermatocytes and the more abundant 2.6-kb transcript restricted to post-meiotic spermatids. These studies indicate that each raf gene exhibits a characteristic, limited pattern of expression and suggests that the different forms may play a unique regulatory role in androgen production and/or spermatogenesis.	COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,630 W 168TH ST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR REPROD SCI,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT OBSTET & GYNECOL,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University					NCRR NIH HHS [2-S07-RR05395] Funding Source: Medline; NICHD NIH HHS [P50 HD05077, F32 HD07414-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD005077, F32HD007414] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005395] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adashi EY, 1992, SPERMATOGENESIS FERT, P143; ALCIVAR AA, 1990, J BIOL CHEM, V265, P20160; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BECK TW, 1990, MOL CELL BIOL, V10, P3325, DOI 10.1128/MCB.10.7.3325; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHAPMAN DL, 1992, IN PRESS MOL REPROD; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; ERICKSON RP, 1990, TRENDS GENET, V6, P264, DOI 10.1016/0168-9525(90)90209-O; GIZANGGINSBERG E, 1987, P NATL ACAD SCI USA, V84, P1600, DOI 10.1073/pnas.84.6.1600; GIZANGGINSBERG E, 1985, DEV BIOL, V111, P293, DOI 10.1016/0012-1606(85)90484-1; HANDEL MA, 1979, BIOL REPROD, V20, P1031, DOI 10.1095/biolreprod20.5.1031; HASSOUNA N, 1984, NUCLEIC ACIDS RES, V12, P3563, DOI 10.1093/nar/12.8.3563; HECHT NB, 1990, J REPROD FERTIL, V88, P679, DOI 10.1530/jrf.0.0880679; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; HUMMEL KP, 1966, MOUSE NEWS LETT, V34, P31; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; JAFFE L, 1990, J IMMUNOL, V145, P3474; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KRUMLAUF R, 1987, DEVELOPMENT, V99, P603; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; MATHER JP, 1992, SPERMATOGENESIS FERT, P169; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NEBEL BR, 1961, SCIENCE, V134, P832, DOI 10.1126/science.134.3482.832; PARVINEN M, 1991, GROWTH FACTORS FERTI, P157; PONZETTO C, 1989, ONCOGENE, V4, P685; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAYNAL F, 1984, FEBS LETT, V167, P263, DOI 10.1016/0014-5793(84)80139-8; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; STEPHENS RM, 1992, UNPUB MOL CELL BIOL; STORM SM, 1990, ONCOGENE, V5, P345; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; WOLGEMUTH DJ, 1991, MAMM GENOME, V1, P283, DOI 10.1007/BF00352340; WOLGEMUTH DJ, 1985, GAMETE RES, V12, P1, DOI 10.1002/mrd.1120120102	48	34	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1055	1062						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455932				2022-12-17	WOS:A1993KT22000030
J	GILLET, G; MICHEL, D; CRISANTI, P; GUERIN, M; HERAULT, Y; PESSAC, B; CALOTHY, G; BRUN, G; VOLOVITCH, M				GILLET, G; MICHEL, D; CRISANTI, P; GUERIN, M; HERAULT, Y; PESSAC, B; CALOTHY, G; BRUN, G; VOLOVITCH, M			SERUM FACTORS AND V-SRC CONTROL 2 COMPLEMENTARY MITOGENIC PATHWAYS IN QUAIL NEURORETINAL CELLS IN CULTURE	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; EPIDERMAL GROWTH-FACTOR; AMINO-ACID-SEQUENCES; PROTEIN GENES RPS12; TYROSINE KINASES; C-JUN; PLATELET PROTEIN; RAT FIBROBLASTS; INDUCIBLE GENE; TRANSFORMATION	Quail neuroretinal cells (QNR cells) from 7-day-old embryos do not proliferate even in the presence of 8% fetal calf serum. After infection by the Rous sarcoma virus (RSV) they proliferate actively and exhibit a transformed phenotype; this effect is mediated by the oncoprotein pp60v-src. Secondary cultures infected by the thermosensitive strain tsNY68 of RSV are blocked in G0 either by thermal inactivation of pp60v-src at 41.5-degrees-C or by serum deprivation at the permissive temperature (36.5-degrees-C). Cell division is reinduced either by pp60v-src thermal renaturation or by subsequent serum addition. Our results indicate that v-src and serum control two synergic pathways leading to G0/G1 transition in QNR cells. In order to characterize genes related to the mitogenic and transforming effects of v-src in nerve cells, we have constructed a cDNA library from QNR cells transformed by tsNY68. We report the properties of five molecular clones isolated by differential screening of this library. Unlike immediate-early genes like c-fos, they are induced in mid and late G1. Four of them correspond to unknown mRNAs and the last one codes for nucleolin. This set of v-src-regulated genes is likely to code for functions deficient in terminally differentiated QNR cells and necessary for the progression in G1.	CNRS,CTR BIOL CELLULAIRE,F-94205 IVRY,FRANCE; INST CURIE,F-91405 ORSAY,FRANCE; INST CURIE,BIOCHIM LAB,F-75231 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	GILLET, G (corresponding author), ENS LYON,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 49,46 ALLEE ITALIE,F-69364 LYON,FRANCE.		gillet, germain/A-9095-2013; Herault, Yann/B-5500-2012	Herault, Yann/0000-0001-7049-6900; Volovitch, Michel/0000-0002-7488-764X; GILLET, Germain/0000-0002-1514-327X				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BELL SM, 1990, J BIOL CHEM, V265, P1333; BRUN G, 1989, NUCLEIC ACIDS RES, V17, P6393, DOI 10.1093/nar/17.15.6393; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GLAICHENHAUS N, 1986, EMBO J, V5, P1261, DOI 10.1002/j.1460-2075.1986.tb04355.x; GOLDEN A, 1988, ONCOGENE HDB, P149; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAMAGUCHI M, 1990, MOL CELL BIOL, V10, P830, DOI 10.1128/MCB.10.2.830; HERAULT Y, 1992, NUCLEIC ACIDS RES, V20, P6377, DOI 10.1093/nar/20.23.6377; HERAULT Y, 1991, NUCLEIC ACIDS RES, V19, P4001, DOI 10.1093/nar/19.14.4001; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JAHNER D, 1991, ONCOGENE, V6, P1259; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MICHEL D, 1989, ONCOGENE RES, V4, P127; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; PESSAC B, 1983, NATURE, V302, P616, DOI 10.1038/302616a0; PESSAC B, 1983, BRAIN RES, V275, P53, DOI 10.1016/0006-8993(83)90416-X; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; PINES J, 1990, New Biologist, V2, P389; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; REED JC, 1991, CELL GROWTH DIFFER, V2, P231; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; RYAZANOV A G, 1990, New Biologist, V2, P843; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Sambrook J., 1989, MOL CLONING LAB MANU; SEFTON BM, 1980, J VIROL, V33, P220, DOI 10.1128/JVI.33.1.220-229.1980; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SRIVASTAVA M, 1990, J BIOL CHEM, V265, P14922; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; VIK TA, 1990, P NATL ACAD SCI USA, V87, P2685, DOI 10.1073/pnas.87.7.2685; WEHLAM MJ, 1990, ONCOGENE, V5, P161; WHITE MK, 1990, MOL CELL BIOL, V10, P1301, DOI 10.1128/MCB.10.4.1301; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	48	34	34	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					565	574						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437841				2022-12-17	WOS:A1993KN00800006
J	TULCHINSKY, E; KRAMEROV, D; FORD, HL; RESHETNYAK, E; LUKANIDIN, E; ZAIN, S				TULCHINSKY, E; KRAMEROV, D; FORD, HL; RESHETNYAK, E; LUKANIDIN, E; ZAIN, S			CHARACTERIZATION OF A POSITIVE REGULATORY ELEMENT IN THE MTS1 GENE	ONCOGENE			English	Article							CALCIUM-BINDING PROTEIN; LIGATION-MEDIATED PCR; CULTURED MOUSE CELLS; 1ST INTRON; DNA METHYLATION; MESSENGER-RNAS; CD3-DELTA GENE; COLLAGEN GENE; PROMOTER; TRANSCRIPTION	The first intron of the mts1 gene, a gene that is selectively expressed in metastatic cells and in normal cells that are motile, was found to be highly homologous to the CD3delta enhancer element. Because of the homology between the CD3delta enhancer and the first intron of mts1, we analysed the first intron of the mts1 gene to determine whether it functions as a transcriptional regulatory element. Highly metastatic CSML-100 cells transfected with chloramphenicol acetyl transferase-containing plasmids demonstrated the ability of the mts1 first intron to function as a positive regulatory element. In vitro foot-printing analysis using extracts from CSML-0 cells (which express mts1 at low levels) or CSML-100 cells (which express mts1 at high levels) identified a protected 16-nucleotide element in the first intron of mts1, regardless of the extract used. However, in vivo footprinting analysis of the same region identified the protected 16-nucleotide fragment only in the mts1 intron from CSML-100 cells, not from CSML-0 cells. Differences in the methylation pattern of the mts1 gene in CSML-100 cells and CSML-0 cells are known to exist, and may in part be responsible for the mts1 footprinting differences observed in vivo from the different cell tines.	UNIV ROCHESTER,601 ELMWOOD AVE,ROCHESTER,NY 14642; MOSCOW GENE BIOL INST,MOSCOW,RUSSIA	University of Rochester; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences			Tulchinsky, Eugene/ABD-7070-2021		NCI NIH HHS [R01 CA46635, R01-CA36432, 2-P30-CA11198] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198, R01CA036432] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V2; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BORNSTEIN P, 1987, P NATL ACAD SCI USA, V84, P8869, DOI 10.1073/pnas.84.24.8869; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CEDAR H, 1984, DNA METHYLATION BIOC, P147; CELANDER D, 1987, J VIROL, V61, P269, DOI 10.1128/JVI.61.2.269-275.1987; DELEON M, 1991, J NEUROSCI RES, V29, P155; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FREDERICKSON RM, 1989, NUCLEIC ACIDS RES, V17, P253, DOI 10.1093/nar/17.1.253; GEORGOPOULOS K, 1990, EMBO J, V9, P109, DOI 10.1002/j.1460-2075.1990.tb08086.x; GEORGOPOULOS K, 1988, EMBO J, V7, P2401, DOI 10.1002/j.1460-2075.1988.tb03085.x; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GLENNEY JR, 1989, J CELL BIOL, V108, P569, DOI 10.1083/jcb.108.2.569; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; KILLEN PD, 1988, J BIOL CHEM, V263, P12310; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; LAHERTY CD, 1989, J BIOL CHEM, V264, P11222; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; Maniatis T, 1989, DECONTAMINATION DILU; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURAKAMI T, 1990, MOL CELL BIOL, V10, P1180, DOI 10.1128/MCB.10.3.1180; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; RASSART E, 1986, J VIROL, V58, P96, DOI 10.1128/JVI.58.1.96-106.1986; REID LH, 1990, P NATL ACAD SCI USA, V87, P4299, DOI 10.1073/pnas.87.11.4299; SELIG S, 1988, EMBO J, V7, P419, DOI 10.1002/j.1460-2075.1988.tb02829.x; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; TULCHINSKY EM, 1990, GENE, V87, P219, DOI 10.1016/0378-1119(90)90305-B; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397	46	34	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					79	86						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423998				2022-12-17	WOS:A1993KN00500009
J	LINDER, S; POPOWICZ, P; SVENSSON, C; MARSHALL, H; BONDESSON, M; AKUSJARVI, G				LINDER, S; POPOWICZ, P; SVENSSON, C; MARSHALL, H; BONDESSON, M; AKUSJARVI, G			ENHANCED INVASIVE PROPERTIES OF RAT EMBRYO FIBROBLASTS TRANSFORMED BY ADENOVIRUS E1A MUTANTS WITH DELETIONS IN THE CARBOXY-TERMINAL EXON	ONCOGENE			English	Article							TOXIC LYMPHOCYTES-T; REGULATORY FUNCTIONS; CELL-TRANSFORMATION; TUMOR-CELLS; EXPRESSION; ONCOGENE; GENE; REGION; METASTASIS; PROTEIN	E1A genes deficient in the carboxy-terminal exon can cooperate with activated ras oncogenes to induce transformation of rat embryo fibroblasts. However, the resulting transformed foci show a distinct appearance characterized by a decreased adhesion of the cells to the substrate. Here, we demonstrate that cell lines derived from foci showing the variant morphology are defective in down-regulation of stromelysin 1 metalloprotease expression and show an increased invasive propensity compared with cells transformed by wild-type E1A. The altered focus morphology, the high invasive propensity and the elevated stromelysin 1 expression were abrogated by glucocorticoid treatment. Our results show that E1A functions necessary for transformation and inhibition of invasive properties may be separated, and indicate that a 23 amino acid serine/threonine-rich region within the E1A carboxy-terminal exon is required for efficient repression of metalloprotease expression in transformed cells.	KAROLINSKA INST & HOSP, RADIUMHEMMET, DEPT ONCOL, DIV EXPTL ONCOL, S-10401 STOCKHOLM, SWEDEN; KAROLINSKA INST, DEPT MICROBIAL GENET, S-10401 STOCKHOLM 60, SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet			Bondesson, Maria/H-3027-2012	Bondesson, Maria/0000-0001-6358-5788				ALBINI A, 1987, CANCER RES, V47, P3239; COOK JL, 1986, P NATL ACAD SCI USA, V83, P6965, DOI 10.1073/pnas.83.18.6965; DEAR TN, 1990, MOL ASPECTS MED, V11, P243, DOI 10.1016/0098-2997(90)90005-M; EDMONDS M, 1969, J BIOL CHEM, V244, P1314; FRISCH SM, 1990, ONCOGENE, V5, P75; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GOPAS J, 1989, ADV CANCER RES, V53, P89; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; MARTENS I, 1990, EXP CELL RES, V187, P143, DOI 10.1016/0014-4827(90)90128-W; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SAWADA Y, 1985, VIROLOGY, V147, P413, DOI 10.1016/0042-6822(85)90143-6; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; SVENSSON C, 1991, VIROLOGY, V182, P553, DOI 10.1016/0042-6822(91)90596-4; SVENSSON C, 1983, J MOL BIOL, V165, P475, DOI 10.1016/S0022-2836(83)80214-9; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIMMERS HTM, 1988, ONCOGENE RES, V3, P67; TREMBLAY ML, 1988, J BIOL CHEM, V263, P6375; ULFENDAHL PJ, 1987, EMBO J, V6, P2037, DOI 10.1002/j.1460-2075.1987.tb02468.x; URBANELLI D, 1989, VIROLOGY, V173, P607, DOI 10.1016/0042-6822(89)90572-2; VANDAM H, 1989, ONCOGENE, V4, P1207; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	37	34	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					439	443						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1532246				2022-12-17	WOS:A1992HK00500006
J	WEI, C; LUTZ, R; SINENSKY, M; MACARA, IG				WEI, C; LUTZ, R; SINENSKY, M; MACARA, IG			P23RAB2, A RAS-LIKE GTPASE WITH A -GGGCC C-TERMINUS, IS ISOPRENYLATED BUT NOT DETECTABLY CARBOXYMETHYLATED IN NIH3T3 CELLS	ONCOGENE			English	Article							BINDING YPT1 PROTEIN; ESCHERICHIA-COLI; CARBOXYL-METHYLATION; PLASMA-MEMBRANE; PALMITIC ACID; P21RAS; YEAST; SECRETION; CYSTEINE; EXPRESSION	With the development of a specific anti-rab2 antiserum, p23rab2, a ras-like GTPase with a -GGGCC C-terminus, has been localized mainly to the particulate (P100) fraction in NIH3T3 cells, although a small amount of this protein also appears in the soluble fraction. The endogenous p23rab2 is isoprenylated in intact cells, and recombinant murine p23rab2 is also isoprenylated in an in vitro system using reticulocyte lysate. Both the cytosolic and membrane-bound forms of p23rab2 are isoprenylated in intact cells. Recombinant p23rab2 is specifically geranyl-geranylated at one or both of the C-terminal cysteine residues in the in vitro system. Blocking isoprenoid synthesis with lovastatin results in an accumulation of a totally cytosolic unisoprenylated form, indicating that isoprenylation is a prerequisite for membrane association of p23rab2. Surprisingly, unlike p21ras and p25rab3A, no carboxymethylation of p23rab2 is detectable in either the soluble or particulate fractions.	UNIV VERMONT, DEPT PATHOL, BURLINGTON, VT 05405 USA; ELEANOR ROOSEVELT INST CANC RES, DENVER, CO 80206 USA	University of Vermont	WEI, C (corresponding author), UNIV ROCHESTER, DEPT BIOCHEM, ROCHESTER, NY 14642 USA.				NATIONAL CANCER INSTITUTE [R01CA056300, R01CA043551] Funding Source: NIH RePORTER; NCI NIH HHS [CA43551, CA56300] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; Gooderham K, 1984, Methods Mol Biol, V1, P193, DOI 10.1385/0-89603-062-8:193; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WINGROVE TG, 1988, J BIOL CHEM, V263, P8918; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	29	34	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					467	473						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549360				2022-12-17	WOS:A1992HK00500010
J	HEIDARAN, MA; MOLLOY, CJ; PANGELINAN, M; CHOUDHURY, GG; WANG, LM; FLEMING, TP; SAKAGUCHI, AY; PIERCE, JH				HEIDARAN, MA; MOLLOY, CJ; PANGELINAN, M; CHOUDHURY, GG; WANG, LM; FLEMING, TP; SAKAGUCHI, AY; PIERCE, JH			ACTIVATION OF THE COLONY-STIMULATING FACTOR-I RECEPTOR LEADS TO THE RAPID TYROSINE PHOSPHORYLATION OF GTPASE-ACTIVATING PROTEIN AND ACTIVATION OF CELLULAR P21RAS	ONCOGENE			English	Article							FACTOR-I RECEPTOR; GAP-ASSOCIATED PROTEINS; GROWTH-FACTOR RECEPTORS; PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; KINASE-ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; CSF-1; TRANSFORMATION; PRODUCT	We have previously reported that platelet-derived growth factor (PDGF) induced tyrosine phosphorylation of GTPase-activating protein (GAP) in intact quiescent fibroblasts under conditions in which insulin and basic fibroblast growth factor (bFGF) were ineffective (Molloy et al., 1988). In the present study, we have provided evidence that colony-stimulating factor 1 (CSF-1) is capable of inducing tyrosine phosphorylation of GAP and its associated cellular proteins, p62 and p190, in NIH3T3 cells overexpressing the human CSF-1 receptor (CSF-1R). However, the extent of GAP tyrosine phosphorylation induced by CSF-1 was approximately 10% of that induced by PDGF-BB in the NIH3T3 fibroblasts. Despite this significant difference, both PDGF-BB and CSF-1 increased the activation of p21ras, the extent of which correlated well with the mitogenic response induced by each growth factor in these cells. Taken together, our findings provide evidence for a possible role of tyrosine phosphorylation of GAP and GAP-associated phosphoproteins in regulating transduction of CSF-1-induced mitogenic signals through p21ras activation.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Health San Antonio			Molloy, Christopher/A-6821-2013	Molloy, Christopher/0000-0003-2964-6166				BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P8068; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; DEVENDITTIS E, 1986, EMBO J, V5, P3657, DOI 10.1002/j.1460-2075.1986.tb04696.x; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARSHALL MS, 1987, MOL CELL BIOL, V7, P2309, DOI 10.1128/MCB.7.7.2309; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STACEY DW, 1987, EXP CELL RES, V171, P232, DOI 10.1016/0014-4827(87)90266-7; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VOGEL US, 1989, PROTEIN STRUCT FUNCT, V6, P306; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WANG LM, 1989, BIOTECHNIQUES, V7, P1000; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	40	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					147	152						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1311060				2022-12-17	WOS:A1992HC22700020
J	MORRISON, LE; BOEHMELT, G; BEUG, H; ENRIETTO, PJ				MORRISON, LE; BOEHMELT, G; BEUG, H; ENRIETTO, PJ			EXPRESSION OF V-REL IN A REPLICATION COMPETENT VIRUS - TRANSFORMATION AND BIOCHEMICAL-CHARACTERIZATION	ONCOGENE			English	Article							AVIAN RETICULOENDOTHELIOSIS VIRUS; NF-KAPPA-B; DNA-BINDING SUBUNIT; LYMPHOID-CELLS; C-REL; MONOCLONAL-ANTIBODIES; CHICKEN FIBROBLASTS; EMBRYO FIBROBLASTS; ONCOGENE ENCODES; LEUKEMIA VIRUSES	The avian reticuloendotheliosis virus strain T (REV-T) transforms bone marrow cells and may cause phenotypic changes in fibroblasts. Both events are thought to result from expression of the v-rel oncoprotein, a member of the NF-kappa-B family of transcription factors. Most REV stocks contain a cytopathic and immunosuppressive helper virus (REV-A) unrelated to standard avian retroviruses, and thus the degree to which v-rel expression alone contributes to the transformed phenotype in bone marrow cells and fibroblasts is complicated by helper virus expression. To gain a more accurate picture of how v-rel contributes to transformation, we have cloned the v-rel gene into a replication-competent avian retrovirus vector (RCAS) and have expressed it in both chick embryo fibroblasts (CEF) and bone marrow cells. Transfection of RCAS-rel into CEF readily produced a partially transformed phenotype, demonstrating that expression of the v-rel protein is sufficient for fibroblast transformation. The RCAS-rel virus also transformed bone marrow cells in vitro, but required culture conditions different from those normally required for transformation by REV-T. The v-rel protein expressed in transformed CEF was biochemically indistinguishable from that expressed in transformed bone marrow cells, being localized to the cytoplasm and the nucleus, and forming a complex with cellular proteins. We also demonstrate that the RCAS-rel-transformed hematopoietic cells exhibited a distinct differentiation phenotype.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)					NATIONAL CANCER INSTITUTE [R01CA051792] Funding Source: NIH RePORTER; NCI NIH HHS [CA 51792] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; BAUERLE PA, 1988, CELL, V53, P211; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CLH, 1982, J IMMUNOL, V129, P2580; CHEN CLH, 1986, J EXP MED, V164, P375, DOI 10.1084/jem.164.1.375; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; FRANKLIN RB, 1977, VIROLOGY, V83, P313, DOI 10.1016/0042-6822(77)90176-3; FUHRMANN U, 1989, GENE DEV, V3, P2027; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KABRUN N, 1990, P NATL ACAD SCI USA, V88, P1095; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MORRISON LE, 1989, ONCOGENE, V4, P677; PALMERI S, 1982, VIROLOGY, V123, P209; ROYERPOKORA B, 1978, CELL, V13, P751, DOI 10.1016/0092-8674(78)90225-8; RUSJHLOW AC, 1990, CELL, V59, P1165; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK S, 1988, ONCOGENE RES, V2, P102; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; THEILEN GH, 1966, J NATL CANCER I, V37, P731; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUNG HYL, 1988, P NATL ACAD SCI USA, V85, P2479, DOI 10.1073/pnas.85.8.2479; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198	44	34	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1657	1666						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1656369				2022-12-17	WOS:A1991GX27400022
J	BRAITHWAITE, AW; BLAIR, GE; NELSON, CC; MCGOVERN, J; BELLETT, AJD				BRAITHWAITE, AW; BLAIR, GE; NELSON, CC; MCGOVERN, J; BELLETT, AJD			ADENOVIRUS E1B-58 KD ANTIGEN BINDS TO P53 DURING INFECTION OF RODENT CELLS - EVIDENCE FOR AN N-TERMINAL BINDING-SITE ON P53	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; T-ANTIGEN; MONOCLONAL-ANTIBODIES; TRANSFORMED-CELLS; SV40-TRANSFORMED CELLS; GENE-PRODUCTS; PROTEINS BIND; ONCOGENE; DNA; MOUSE	We show using mild extraction procedures that the p53 proto-oncogene forms a complex with adenovirus 5 E1b-58 kD during infection. These complexes are detected as coimmunoprecipitates from radiolabeled extracts of adenovirus infected cells on SDS-PAGE. Furthermore, adenovirus mutants with defects in E1b-58 kD fail to form complexes, whereas mutants in other early region genes still show evidence of complex. Using a panel of monoclonal antibodies to mouse p53, we show that antibodies reacting with N-terminal epitopes on p53, displace E1b-58 KD. This result suggests that E1b-58 kD binds to an N-terminal region of mouse p53. In addition, in a transient transfection assay in monkey COS cells, we show that an N-terminal deletion mutant of mouse p53 does not bind to E1b-58 kD but wild-type mouse p53 does bind. This result again suggests that E1b-58 kD binds an N-terminal determinant on p53.	UNIV LEEDS,DEPT BIOCHEM,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA V8W 2Y2,BC,CANADA	University of Leeds; University of Victoria	BRAITHWAITE, AW (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CANBERRA,ACT 2601,AUSTRALIA.		Blair, George Eric/A-5906-2008	Blair, George Eric/0000-0003-0440-1795				BABISS LE, 1984, J VIROL, V50, P2552; BELLETT AJD, 1985, MOL CELL BIOL, V5, P1933, DOI 10.1128/MCB.5.8.1933; BRAITHWAITE A, 1990, VIROLOGY, V177, P595, DOI 10.1016/0042-6822(90)90525-V; BRAITHWAITE AW, 1989, J VIROL, V63, P1792, DOI 10.1128/JVI.63.4.1792-1799.1989; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BRIDGE E, 1989, J VIROL, V63, P631, DOI 10.1128/JVI.63.2.631-638.1989; BURGER C, 1983, VIROLOGY, V126, P19, DOI 10.1016/0042-6822(83)90459-2; CHALLBERG SS, 1981, VIROLOGY, V114, P193; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; DUTHU A, 1985, VIROLOGY, V147, P275, DOI 10.1016/0042-6822(85)90130-8; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GREAVES R, 1988, THESIS U LONDON; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, ONCOGENE HDB, P403; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; REICH NC, 1984, NATURE, V308, P188; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; Russell W C, 1967, J Gen Virol, V1, P495, DOI 10.1099/0022-1317-1-4-495; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; THOMAS R, 1983, VIROLOGY, V131, P502, DOI 10.1016/0042-6822(83)90516-0; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; ZHANG XL, 1990, VIROLOGY, V180, P199	45	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					781	787						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1828873				2022-12-17	WOS:A1991GT82500014
J	BUSCH, SJ; SASSONECORSI, P				BUSCH, SJ; SASSONECORSI, P			FOS, JUN AND CREB BASIC-DOMAIN PEPTIDES HAVE INTRINSIC DNA-BINDING ACTIVITY ENHANCED BY A NOVEL STABILIZING FACTOR	ONCOGENE			English	Article									FAC MED STRASBOURG,INST CHIM BIOL,INSERM,UNITE BIOL MOLEC & GENIE GENET 184,CNRS,F-67085 STRASBOURG,FRANCE; MERRELL DOW RES INST,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Sassone-Corsi, Paolo/H-6182-2011					AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; BUSCH SJ, 1989, LIFE SCI, V45, P615, DOI 10.1016/0024-3205(89)90047-7; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DETOGNI P, 1988, MOL CELL BIOL, V8, P2251, DOI 10.1128/MCB.8.5.2251; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1425; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAO L, 1988, P NATL ACAD SCI USA, V85, P4491, DOI 10.1073/pnas.85.12.4491; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MARTIN GA, 1988, J BIOL CHEM, V263, P10907; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701	29	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1990	5	10					1549	1556						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	2147467				2022-12-17	WOS:A1990EK50200015
J	HAGAG, N; DIAMOND, L; PALERMO, R; LYUBSKY, S				HAGAG, N; DIAMOND, L; PALERMO, R; LYUBSKY, S			HIGH EXPRESSION OF RAS P21 CORRELATES WITH INCREASED RATE OF ABNORMAL MITOSIS IN NIH3T3 CELLS	ONCOGENE			English	Article									SUNY STONY BROOK, HLTH SCI CTR, DEPT PATHOL, STONY BROOK, NY 11794 USA; VET ADM MED CTR, LAB SERV, NORTHPORT, NY 11768 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; US Department of Veterans Affairs; Veterans Health Administration (VHA)	HAGAG, N (corresponding author), SUNY STONY BROOK, HLTH SCI CTR, DIV ONCOL, STONY BROOK, NY 11794 USA.							AGRANOFF BW, 1983, J BIOL CHEM, V258, P2076; Ausubel F.M., 1987, CURRENT PROTOCOLS MO; BERGER R, 1985, CYTOGENET CELL GENET, V40, P490, DOI 10.1159/000132181; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOURGUIGNON LYW, 1977, P NATL ACAD SCI USA, V74, P5031, DOI 10.1073/pnas.74.11.5031; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; BRINKLEY BR, 1975, P NATL ACAD SCI USA, V72, P4981, DOI 10.1073/pnas.72.12.4981; CHAFOULEAS JG, 1981, P NATL ACAD SCI-BIOL, V78, P996, DOI 10.1073/pnas.78.2.996; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; DELATTRE O, 1989, LANCET, V2, P353; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DURKIN JP, 1986, MOL CELL BIOL, V6, P1386, DOI 10.1128/MCB.6.5.1386; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FERAMISCO JR, 1985, NATURE, V314, P639, DOI 10.1038/314639a0; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FUKUSHIMA S, 1981, AM J PATHOL, V102, P373; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GARBISA S, 1987, CANCER RES, V47, P1523; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HERSTERBERG TW, 1985, CARCINOGENESIS, V6, P473; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; JACOBS JB, 1976, CANCER RES, V36, P2512; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; LACAL JC, 1986, CELL, V44, P609, DOI 10.1016/0092-8674(86)90270-9; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEVINSON AD, 1986, TRENDS GENET, V2, P81, DOI 10.1016/0168-9525(86)90184-8; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; PAWELETZ N, 1988, EUR J CELL BIOL, V47, P334; PIMENTEL E, 1985, CANCER GENET CYTOGEN, V14, P347, DOI 10.1016/0165-4608(85)90201-8; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RICHARDS GK, 1981, MITOSIS CYTOKINESIS, P103; RODBELL M, 1980, NATURE, V284, P17, DOI 10.1038/284017a0; ROSS EM, 1980, ANNU REV BIOCHEM, V49, P553, DOI 10.1146/annurev.bi.49.070180.002533; ROVENSKY YA, 1984, INT REV CYTOL, V90, P273, DOI 10.1016/S0074-7696(08)61492-8; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SANDBERG AA, 1980, CHROMOSOMES HUMAN CA, P776; SCOLNICK EM, 1979, P NATL ACAD SCI USA, V76, P5355, DOI 10.1073/pnas.76.10.5355; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SHIH TY, 1982, J VIROL, V42, P253, DOI 10.1128/JVI.42.1.253-261.1982; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; SISKEN JE, 1982, J CELL PHYSIOL, V113, P219, DOI 10.1002/jcp.1041130206; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; TONEGUZZO F, 1986, P NATL ACAD SCI USA, V83, P3496, DOI 10.1073/pnas.83.10.3496; TSUTSUI T, 1983, CANCER RES, V43, P3814; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WINTER E, 1985, P NATL ACAD SCI USA, V82, P7575, DOI 10.1073/pnas.82.22.7575	63	34	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1990	5	10					1481	1489						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	2174524				2022-12-17	WOS:A1990EK50200006
J	BLASBAND, AJ; GILLIGAN, DM; WINCHELL, LF; WONG, ST; LUETTEKE, NC; ROGERS, KT; LEE, DC				BLASBAND, AJ; GILLIGAN, DM; WINCHELL, LF; WONG, ST; LUETTEKE, NC; ROGERS, KT; LEE, DC			EXPRESSION OF THE TGF-ALPHA INTEGRAL MEMBRANE PRECURSOR INDUCES TRANSFORMATION OF NRK CELLS	ONCOGENE			English	Article									UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NCI NIH HHS [CA43793, CA08542, CA08519] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA008519, F32CA008542, R01CA043793] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BESTWICK RK, 1988, P NATL ACAD SCI USA, V85, P5404, DOI 10.1073/pnas.85.15.5404; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; CHE WS, 1989, CELL, V59, P33; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1987, CANCER RES, V47, P707; GENTRY LE, 1987, MOL CELL BIOL, V7, P1585, DOI 10.1128/MCB.7.5.1585; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KOBRIN MS, 1986, J BIOL CHEM, V261, P4414; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LEE DC, 1985, MOL CELL BIOL, V5, P3644, DOI 10.1128/MCB.5.12.3644; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MAXFIELD FR, 1979, P NATL ACAD SCI USA, V76, P5731, DOI 10.1073/pnas.76.11.5731; MCCUNE BK, 1989, J BIOL CHEM, V264, P15501; MERCOLA M, 1988, SCIENCE, V241, P1223, DOI 10.1126/science.3413486; PIKE LJ, 1982, J BIOL CHEM, V257, P4628; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; STROOBANT P, 1985, CELL, V42, P383, DOI 10.1016/S0092-8674(85)80133-1; TEIXIDO J, 1987, NATURE, V326, P883, DOI 10.1038/326883a0; TEIXIDO J, 1988, J BIOL CHEM, V263, P3924; TEIXIDO J, 1990, IN PRESS J BIOL CHEM; TODARO GJ, 1976, NATURE, V264, P26, DOI 10.1038/264026a0; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; VALVERIUS EM, 1989, MOL ENDOCRINOL, V3, P203, DOI 10.1210/mend-3-1-203; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; WILCOX JN, 1988, J NEUROSCI, V8, P1901; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	49	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1213	1221						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	2392325				2022-12-17	WOS:A1990DX36100015
J	STEELE, RE; DENG, JC; GHOSN, CR; FERO, JB				STEELE, RE; DENG, JC; GHOSN, CR; FERO, JB			STRUCTURE AND EXPRESSION OF FYN GENES IN XENOPUS-LAEVIS	ONCOGENE			English	Article									UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717	University of California System; University of California Irvine	STEELE, RE (corresponding author), UNIV CALIF IRVINE,DEPT BIOL CHEM,IRVINE,CA 92717, USA.							AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BISBEE CA, 1977, SCIENCE, V195, P785, DOI 10.1126/science.65013; BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLLETT MS, 1980, NATURE, V285, P167, DOI 10.1038/285167a0; COOPER JA, 1989, MOL CELL BIOL, V9, P3143, DOI 10.1128/MCB.9.7.3143; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1989, IN PRESS PEPTIDES PR; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; HOSBACH HA, 1983, CELL, V32, P45, DOI 10.1016/0092-8674(83)90495-6; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINSON AD, 1980, J BIOL CHEM, V255, P1973; LOHKA MJ, 1987, MOL CELL BIOL, V7, P760, DOI 10.1128/MCB.7.2.760; MANIATIS T, 1975, P NATL ACAD SCI USA, V72, P1184, DOI 10.1073/pnas.72.3.1184; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; MARTENS GJM, 1984, NATURE, V310, P251, DOI 10.1038/310251a0; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MAY FEB, 1983, J MOL BIOL, V168, P229, DOI 10.1016/S0022-2836(83)80016-3; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; POLISKY B, 1975, P NATL ACAD SCI USA, V72, P3310, DOI 10.1073/pnas.72.9.3310; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; REINSCHMIDT DC, 1979, J EXP ZOOL, V210, P137, DOI 10.1002/jez.1402100115; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; SALIM M, 1981, NATURE, V291, P205, DOI 10.1038/291205a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEELE RE, 1985, NUCLEIC ACIDS RES, V13, P1747, DOI 10.1093/nar/13.5.1747; STEELE RE, 1989, J BIOL CHEM, V264, P10649; STEELE RE, 1989, ONCOGENE RES, V4, P223; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WAHLI W, 1982, P NATL ACAD SCI-BIOL, V79, P6832, DOI 10.1073/pnas.79.22.6832; WARE VC, 1983, NUCLEIC ACIDS RES, V11, P7795, DOI 10.1093/nar/11.22.7795; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724	62	34	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					369	376						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	2179818				2022-12-17	WOS:A1990CW41500015
J	ADACHI, M; TSUJIMOTO, Y				ADACHI, M; TSUJIMOTO, Y			JUXTAPOSITION OF HUMAN BCL-2 AND IMMUNOGLOBULIN-LAMBDA LIGHT CHAIN GENE IN CHRONIC LYMPHOCYTIC-LEUKEMIA IS THE RESULT OF A RECIPROCAL CHROMOSOME-TRANSLOCATION BETWEEN CHROMOSOME-18 AND CHROMOSOME-22	ONCOGENE			English	Article									WISTAR INST,36TH ST & SPRUCE,PHILADELPHIA,PA 19104	The Wistar Institute								ADACHI M, 1989, P NATL ACAD SCI USA, V86, P2771, DOI 10.1073/pnas.86.8.2771; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; CROCE CM, 1986, COLD SPRING HARB SYM, V51, P891, DOI 10.1101/SQB.1986.051.01.102; DREAZEN O, 1987, LANCET, V1, P1402; HIETER PA, 1981, NATURE, V294, P536, DOI 10.1038/294536a0; HOLLIS GF, 1984, NATURE, V307, P752, DOI 10.1038/307752a0; MORRIS CM, 1986, NATURE, V320, P281, DOI 10.1038/320281a0; NOWELL PC, 1988, CANCER GENET CYTOGEN, V33, P155, DOI 10.1016/0165-4608(88)90025-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0	16	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1073	1075						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2506501				2022-12-17	WOS:A1989AM53100003
J	DARLING, D; TAVASSOLI, M; LINSKENS, MHK; FARZANEH, F				DARLING, D; TAVASSOLI, M; LINSKENS, MHK; FARZANEH, F			DMSO INDUCED MODULATION OF C-MYC STEADY-STATE RNA LEVELS IN A VARIETY OF DIFFERENT CELL-LINES	ONCOGENE			English	Article									UNIV LONDON KINGS COLL HOSP, SCH MED & DENT,DEPT OBSTET & GYNAECOL, MOLEC GENET UNIT,DENMARK HILL, LONDON SE5 8RX, ENGLAND; UNIV SUSSEX, SUSSEX CTR MED RES, BRIGHTON BN1 9QH, E SUSSEX, ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of Sussex			Farzaneh, Farzin/B-4902-2009	Farzaneh, Farzin/0000-0002-9275-2415				ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ANDERSSON LC, 1979, NATURE, V278, P364, DOI 10.1038/278364a0; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLOMHOFF HK, 1987, J CELL PHYSIOL, V131, P426, DOI 10.1002/jcp.1041310315; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CELANO P, 1988, J BIOL CHEM, V263, P5491; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DALLAFAVERA R, 1982, NATURE, V299, P61; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; ELY CM, 1987, CANCER RES, V47, P4595; ERIKSON J, 1982, P NATL ACAD SCI-BIOL, V79, P5611, DOI 10.1073/pnas.79.18.5611; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; GALLAGHER R, 1979, BLOOD, V54, P713; GEY GO, 1952, CANCER RES, V12, P264; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROSSO L, 1981, BIOCHEM BIOPH RES CO, V119, P473; HAMLYN PH, 1983, NATURE, V304, P135, DOI 10.1038/304135a0; JONAK GJ, 1984, P NATL ACAD SCI-BIOL, V81, P1747, DOI 10.1073/pnas.81.6.1747; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KANEKO Y, 1987, BIOCHEM BIOPH RES CO, V145, P549, DOI 10.1016/0006-291X(87)91355-6; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLEIN E, 1968, CANCER RES, V28, P1300; KNIGHT E, 1985, P NATL ACAD SCI USA, V82, P1151, DOI 10.1073/pnas.82.4.1151; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LOMO J, 1987, EXP CELL RES, V172, P84, DOI 10.1016/0014-4827(87)90095-4; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MAGUIRE RT, 1983, P NATL ACAD SCI-BIOL, V80, P1947, DOI 10.1073/pnas.80.7.1947; MCCARTHY DM, 1983, LEUKEMIA RES, V7, P51, DOI 10.1016/0145-2126(83)90057-7; MIYAURA C, 1981, BIOCHEM BIOPH RES CO, V102, P937, DOI 10.1016/0006-291X(81)91628-4; MOORE GE, 1966, JNCI-J NATL CANCER I, V36, P405; POLACK A, 1987, EMBO J, V6, P2959, DOI 10.1002/j.1460-2075.1987.tb02601.x; POLACK A, 1988, 4TH ANN M ONC ABSTR, P57; PULVERTAFT RJV, 1964, LANCET, V1, P238; QUINN LA, 1979, CANCER RES, V39, P4914; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; RYFFEL B, 1982, P NATL ACAD SCI-BIOL, V79, P7336, DOI 10.1073/pnas.79.23.7336; SCARRA GLB, 1986, CANCER RES, V46, P6327; SCHOFIELD PN, 1987, J CELL SCI, V88, P57; SHENONG GLC, 1987, P NATL ACAD SCI USA, V84, P199, DOI 10.1073/pnas.84.1.199; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SZABO G, 1988, EXP CELL RES, V175, P334, DOI 10.1016/0014-4827(88)90197-8; TAVASSOLI M, 1988, ONCOGENE, V2, P337; TONINI GP, 1987, CANCER RES, V47, P4544; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WERKMEISTER JA, 1982, J IMMUNOL, V129, P413; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; YARDEN A, 1986, SCIENCE, V234, P1419, DOI 10.1126/science.3097823	59	34	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1989	4	2					175	179						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2648255				2022-12-17	WOS:A1989U567500008
J	STARNAUD, R; NEPVEU, A; MARCU, KB; MCBURNEY, MW				STARNAUD, R; NEPVEU, A; MARCU, KB; MCBURNEY, MW			2 TRANSIENT INCREASES IN C-MYC GENE-EXPRESSION DURING NEUROECTODERMAL DIFFERENTIATION OF MOUSE EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article									UNIV OTTAWA,DEPT MED,451 SMYTH RD,OTTAWA K1H 8M5,ONTARIO,CANADA; ROYAL VICTORIA HOSP,LUDWIG INST CANC RES,MONTREAL BRANCH,MONTREAL H3A 1A1,QUEBEC,CANADA; SUNY STONY BROOK,DEPT BIOCHEM,STONY BROOK,NY 11794	University of Ottawa; Ludwig Institute for Cancer Research; McGill University; Royal Victoria Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			/AAB-8315-2020					AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BOER PH, 1987, MOL CELL BIOL, V7, P3107, DOI 10.1128/MCB.7.9.3107; CAMPIONEPICCARDO J, 1985, EXP CELL RES, V156, P544, DOI 10.1016/0014-4827(85)90561-0; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DAMBLYCHAUDIERE C, 1987, GENE DEV, V1, P297, DOI 10.1101/gad.1.3.297; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DENIS N, 1987, EXP CELL RES, V172, P212, DOI 10.1016/0014-4827(87)90107-8; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; EDWARDS MKS, 1983, DEV BIOL, V98, P187, DOI 10.1016/0012-1606(83)90348-2; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; EDWARDS SA, 1986, EXP CELL RES, V165, P473, DOI 10.1016/0014-4827(86)90600-2; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; JIMENEZ F, 1979, NATURE, V282, P310, DOI 10.1038/282310a0; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCCACHREN SS, 1986, BLOOD, V68, P412; MUMMERY CL, 1987, DEV BIOL, V121, P10, DOI 10.1016/0012-1606(87)90133-3; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1985, NATURE, V317, P440, DOI 10.1038/317440a0; NEPVEU A, 1987, ONCOGENE, V1, P243; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; RAY D, 1987, MOL CELL BIOL, V7, P940, DOI 10.1128/MCB.7.2.940; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; RUPPERT C, 1986, EMBO J, V5, P1897, DOI 10.1002/j.1460-2075.1986.tb04442.x; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEJERSEN T, 1987, EXP CELL RES, V172, P304, DOI 10.1016/0014-4827(87)90389-2; SEJERSEN T, 1986, J CELL PHYSIOL, V127, P274, DOI 10.1002/jcp.1041270213; SMITH SC, 1987, J CELL PHYSIOL, V131, P74, DOI 10.1002/jcp.1041310112; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; SWARTWOUT SG, 1987, MOL CELL BIOL, V7, P2052, DOI 10.1128/MCB.7.6.2052; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	67	34	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					553	559						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	3078960				2022-12-17	WOS:A1988R516300011
J	HUBER, BE; CORDINGLEY, MG				HUBER, BE; CORDINGLEY, MG			EXPRESSION AND PHENOTYPIC ALTERATIONS CAUSED BY AN INDUCIBLE TRANSFORMING RAS ONCOGENE INTRODUCED INTO RAT-LIVER EPITHELIAL-CELLS	ONCOGENE			English	Article									NCI,HORMONE ACT & ONCOGENESIS SECT,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HUBER, BE (corresponding author), WELLCOME RES LABS,3030 CORNWALLIS RD,RES TRIANGLE PK,NC 27709, USA.							ALTMAN S, 1970, J MOL BIOL, V50, P235, DOI 10.1016/0022-2836(70)90190-7; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; DAMANTE G, 1987, P NATL ACAD SCI USA, V84, P774, DOI 10.1073/pnas.84.3.774; DARNELL J, 1986, MOL CELL BIOL, P1046; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; EMERMAN M, 1984, J VIROL, V50, P42, DOI 10.1128/JVI.50.1.42-49.1984; EMERMAN M, 1984, CELL, V39, P459, DOI 10.1016/0092-8674(84)90453-7; FASEL N, 1982, EMBO J, V1, P3, DOI 10.1002/j.1460-2075.1982.tb01115.x; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; FURMAN PA, 1979, J VIROL, V32, P72, DOI 10.1128/JVI.32.1.72-77.1979; GEORGE DL, 1986, P NATL ACAD SCI USA, V83, P1651, DOI 10.1073/pnas.83.6.1651; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; GRUSS P, 1981, NATURE, V293, P486, DOI 10.1038/293486a0; HAGER GL, 1983, PROG NUCLEIC ACID RE, V29, P193, DOI 10.1016/S0079-6603(08)60447-X; HAGER GL, 1985, MAMMALIAN VIRAL VECT; HSIEH LL, 1987, CANCER RES, V47, P3421; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; HUBER BE, 1987, CANCER RES, V47, P3414; HUBER BE, 1985, CANCER RES, V45, P4322; HUBER BE, 1986, J BIOL CHEM, V261, P2400; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARDER B, 1987, EMBO J, V6, P3133, DOI 10.1002/j.1460-2075.1987.tb02623.x; LEVINSON AD, 1986, TRENDS GENET, V2, P81, DOI 10.1016/0168-9525(86)90184-8; Lizardi PM, 1984, GENE ANAL TECH, V1, P33; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MCLAREN C, 1983, ANTIVIR RES, V3, P223, DOI 10.1016/0166-3542(83)90001-3; MCMAHON G, 1986, P NATL ACAD SCI USA, V83, P9418, DOI 10.1073/pnas.83.24.9418; MCMAHON JB, 1986, CANCER RES, V46, P4665; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILLER AD, 1984, SCIENCE, V225, P993, DOI 10.1126/science.6089340; NOTARIO V, 1984, CANCER CELLS, V2; OSTROWSKI MC, 1981, P NATL ACAD SCI-BIOL, V78, P4485, DOI 10.1073/pnas.78.7.4485; OSTROWSKI MC, 1984, EMBO J, V3, P1891, DOI 10.1002/j.1460-2075.1984.tb02064.x; OWEN RD, 1987, MOL CELL BIOL, V7, P2512, DOI 10.1128/MCB.7.7.2512; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; REYNOLDS SH, 1986, P NATL ACAD SCI USA, V83, P33, DOI 10.1073/pnas.83.1.33; RUTA M, 1986, MOL CELL BIOL, V6, P1706, DOI 10.1128/MCB.6.5.1706; SCHWEIZER J, 1980, EUR J BIOCHEM, V112, P243, DOI 10.1111/j.1432-1033.1980.tb07200.x; SCOLNICK EM, 1976, J VIROL, V18, P559, DOI 10.1128/JVI.18.2.559-566.1976; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; SVEC J, 1977, NEOPLASMA, V24, P601; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TEMELES GL, 1985, NATURE, V313, P700, DOI 10.1038/313700a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARMUS HE, 1982, SCIENCE, V216, P812, DOI 10.1126/science.6177038; WEBER MJ, 1984, FED PROC, V43, P2246; WISEMAN RW, 1986, P NATL ACAD SCI USA, V83, P5825, DOI 10.1073/pnas.83.16.5825; WONG G, 1986, CANCER RES, V46, P6029; YASWEN P, 1985, MOL CELL BIOL, V5, P780, DOI 10.1128/MCB.5.4.780	58	34	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					245	256						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	3060790				2022-12-17	WOS:A1988Q436700002
J	JAFFE, BD; SABATH, DE; JOHNSON, GD; MOSCINSKI, LC; JOHNSON, KR; ROVERA, G; NAUSEEF, WM; PRYSTOWSKY, MB				JAFFE, BD; SABATH, DE; JOHNSON, GD; MOSCINSKI, LC; JOHNSON, KR; ROVERA, G; NAUSEEF, WM; PRYSTOWSKY, MB			MYELOPEROXIDASE AND ONCOGENE EXPRESSION IN GM-CSF INDUCED BONE-MARROW DIFFERENTIATION	ONCOGENE			English	Article									UNIV PENN, SCH MED, DEPT PATHOL, 36TH & HAMILTON WALK, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, MED LAB, PHILADELPHIA, PA 19104 USA; WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA; VET ADM MED CTR, DEPT MED, IOWA CITY, IA 52240 USA; UNIV IOWA, IOWA CITY, IA 52242 USA	University of Pennsylvania; University of Pennsylvania; The Wistar Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa				Nauseef, William/0000-0003-4032-757X	NCI NIH HHS [CA-09140] Funding Source: Medline; NIAID NIH HHS [AI-21681] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM-07170] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007170] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); BLRD VA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)		ANDERSEN MR, 1982, ARCH BIOCHEM BIOPHYS, V214, P273, DOI 10.1016/0003-9861(82)90031-5; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BRADLEY TR, 1966, AUST J EXP BIOL MED, V44, P287, DOI 10.1038/icb.1966.28; CEROTTINI JC, 1984, J EXP MED, V40, P703; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLOTTA F, 1987, J EXP MED, V165, P1224, DOI 10.1084/jem.165.4.1224; CRAMER E, 1985, BLOOD, V65, P423; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DEIMANN W, 1985, BLOOD, V66, P514; EMILIA G, 1986, BRIT J HAEMATOL, V62, P287, DOI 10.1111/j.1365-2141.1986.tb02931.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FILMUS J, 1985, CANCER RES, V45, P822; GODEAU F, 1986, EMBO J, V5, P3571, DOI 10.1002/j.1460-2075.1986.tb04684.x; GOLDWASSER E, 1983, NORMAL NEOPLASTIC HE, P301; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GOWDA SD, 1986, J CLIN INVEST, V77, P271, DOI 10.1172/JCI112287; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HASILIK A, 1984, EMBO J, V3, P2671, DOI 10.1002/j.1460-2075.1984.tb02192.x; HEIDORN K, 1987, BLOOD, V70, P456; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOEFFLER HP, 1985, BLOOD, V65, P484; KUN SC, 1986, BLOOD, V68, P1411; LAVU S, 1985, CANCER CELL, V3, P301; MANIATIS T, 1982, MOL CLONING LABORATO, P466; METCALF D, 1982, J CELL PHYSIOL, V111, P275, DOI 10.1002/jcp.1041110308; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; NAUSEEF WM, 1986, BLOOD, V67, P1504; NAUSEEF WM, 1986, BLOOD, V67, P865; NAUSEEF WM, 1986, BLOOD, V68, P442; OLSSON I, 1984, BIOCHEM J, V223, P911, DOI 10.1042/bj2230911; PARNES JR, 1981, P NATL ACAD SCI-BIOL, V78, P2253, DOI 10.1073/pnas.78.4.2253; PRYSTOWSKY MB, 1983, EXP HEMATOL, V11, P931; PRYSTOWSKY MB, 1984, AM J PATHOL, V114, P149; REED JC, 1985, MOL CELL BIOL, V5, P3361, DOI 10.1128/MCB.5.12.3361; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SPEAR BT, 1985, J EXP MED, V162, P1802, DOI 10.1084/jem.162.6.1802; STANLEY IJ, 1983, J CELL BIOCHEM, V23, P241, DOI 10.1002/jcb.240230121; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; YEN A, 1986, CANCER RES, V46, P4156	44	34	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1988	2	2					167	174						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	2835725				2022-12-17	WOS:A1988M086000010
J	VONMELCHNER, H; HOUSMAN, DE				VONMELCHNER, H; HOUSMAN, DE			THE EXPRESSION OF NEOMYCIN PHOSPHOTRANSFERASE IN HUMAN PROMYELOCYTIC LEUKEMIA-CELLS (HL60) DELAYS THEIR DIFFERENTIATION	ONCOGENE			English	Article									MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [R37CA017575, R01CA017575] Funding Source: NIH RePORTER; NCI NIH HHS [CA 17575] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CONE RD, 1984, P NATL ACAD SCI-BIOL, V81, P6349, DOI 10.1073/pnas.81.20.6349; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; VONMELCHNER H, 1985, J CELL PHYSIOL, V125, P573, DOI 10.1002/jcp.1041250329	11	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					137	140						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	2835723				2022-12-17	WOS:A1988M086000006
J	Jessen, C; Kress, JKC; Baluapuri, A; Hufnagel, A; Schmitz, W; Kneitz, S; Roth, S; Marquardt, A; Appenzeller, S; Ade, CP; Glutsch, V; Wobser, M; Friedmann-Angeli, JP; Mosteo, L; Goding, CR; Schilling, B; Geissinger, E; Wolf, E; Meierjohann, S				Jessen, Christina; Kress, Julia K. C.; Baluapuri, Apoorva; Hufnagel, Anita; Schmitz, Werner; Kneitz, Susanne; Roth, Sabine; Marquardt, Andre; Appenzeller, Silke; Ade, Carsten P.; Glutsch, Valerie; Wobser, Marion; Friedmann-Angeli, Jose Pedro; Mosteo, Laura; Goding, Colin R.; Schilling, Bastian; Geissinger, Eva; Wolf, Elmar; Meierjohann, Svenja			The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression	ONCOGENE			English	Article							OXIDATIVE STRESS; INFLAMMATION; CANCER; MELANOCYTES; RESISTANCE; PATHWAY; GENE; SENESCENCE; MUTATIONS; PHENOTYPE	The transcription factor NRF2 is the major mediator of oxidative stress responses and is closely connected to therapy resistance in tumors harboring activating mutations in the NRF2 pathway. In melanoma, such mutations are rare, and it is unclear to what extent melanomas rely on NRF2. Here we show that NRF2 suppresses the activity of the melanocyte lineage marker MITF in melanoma, thereby reducing the expression of pigmentation markers. Intriguingly, we furthermore identified NRF2 as key regulator of immune-modulating genes, linking oxidative stress with the induction of cyclooxygenase 2 (COX2) in an ATF4-dependent manner. COX2 is critical for the secretion of prostaglandin E2 and was strongly induced by H(2)O(2)or TNF alpha only in presence of NRF2. Induction of MITF and depletion of COX2 and PGE2 were also observed in NRF2-deleted melanoma cells in vivo. Furthermore, genes corresponding to the innate immune response such asRSAD2andIFIH1were strongly elevated in absence of NRF2 and coincided with immune evasion parameters in human melanoma datasets. Even in vitro, NRF2 activation or prostaglandin E2 supplementation blunted the induction of the innate immune response in melanoma cells. Transcriptome analyses from lung adenocarcinomas indicate that the observed link between NRF2 and the innate immune response is not restricted to melanoma.	[Jessen, Christina; Kress, Julia K. C.; Hufnagel, Anita; Kneitz, Susanne; Meierjohann, Svenja] Univ Wurzburg, Dept Physiol Chem, Wurzburg, Germany; [Jessen, Christina; Kress, Julia K. C.; Hufnagel, Anita; Roth, Sabine; Marquardt, Andre; Geissinger, Eva; Meierjohann, Svenja] Univ Wurzburg, Inst Pathol, Wurzburg, Germany; [Baluapuri, Apoorva; Schmitz, Werner; Ade, Carsten P.; Wolf, Elmar] Univ Wurzburg, Dept Biochem & Mol Biol, Wurzburg, Germany; [Marquardt, Andre; Appenzeller, Silke; Schilling, Bastian; Geissinger, Eva; Meierjohann, Svenja] Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany; [Glutsch, Valerie; Wobser, Marion; Schilling, Bastian] Univ Hosp Wurzburg, Dept Dermatol Venereol & Allergol, Wurzburg, Germany; [Glutsch, Valerie; Wobser, Marion; Schilling, Bastian] Univ Hosp Wurzburg, Skin Canc Ctr, Wurzburg, Germany; [Friedmann-Angeli, Jose Pedro] Univ Wurzburg, Rudolf Virchow Ctr Integrat & Translat Bioimaging, Wurzburg, Germany; [Mosteo, Laura; Goding, Colin R.] Univ Oxford, Nuffield Dept Med, Ludwig Inst Canc Res, Oxford, England	University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg; Ludwig Institute for Cancer Research; University of Oxford	Meierjohann, S (corresponding author), Univ Wurzburg, Dept Physiol Chem, Wurzburg, Germany.; Meierjohann, S (corresponding author), Univ Wurzburg, Inst Pathol, Wurzburg, Germany.; Meierjohann, S (corresponding author), Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany.	svenja.meierjohann@uni-wuerzburg.de	Marquardt, André/AAY-8844-2021; Schilling, Bastian/AAY-8646-2020; Baluapuri, Apoorva/AAF-4624-2020; Wolf, Elmar/AAY-8493-2021	Schilling, Bastian/0000-0001-8859-4103; Baluapuri, Apoorva/0000-0002-3723-7891; Wolf, Elmar/0000-0002-5299-6335; Marquardt, Andre/0000-0002-2425-7033; Schmitz, Werner/0000-0003-0485-7303; Ade, Carsten/0000-0001-7226-1179; Mosteo, Laura/0000-0002-4410-2370; Appenzeller, Silke/0000-0002-5472-8692	German Research Foundation [ME1899/4-1, ME1899/6-1, FR3746/3-1]; Interdisciplinary Center for Clinical Research, IZKF, University Hospital Wurzburg [Z-14]	German Research Foundation(German Research Foundation (DFG)); Interdisciplinary Center for Clinical Research, IZKF, University Hospital Wurzburg	This work was supported by the research grants ME1899/4-1 and ME1899/6-1 (German Research Foundation), as well as project Z-14 (Central Unit for Personalized Oncology) (Interdisciplinary Center for Clinical Research, IZKF, University Hospital Wurzburg). JPFA receives funding from FR3746/3-1 (German Research Foundation). We are furthermore grateful to Harald Wajant (Dept. of Molecular Internal Medicine, University Hospital Wurzburg) for providing TNF alpha. Where indicated, some results are based upon data generated by the TCGA Research Network.	Aguilera TA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13898; Appenzeller S, 2019, CANCER-AM CANCER SOC, V125, P586, DOI 10.1002/cncr.31843; Bottcher JP, 2018, CELL, V172, P1022, DOI 10.1016/j.cell.2018.01.004; Chang YL, 2015, J INVEST DERMATOL, V135, P807, DOI 10.1038/jid.2014.385; Corazzari M, 2015, CELL DEATH DIFFER, V22, P946, DOI 10.1038/cdd.2014.183; Corrales L, 2016, J CLIN INVEST, V126, P2404, DOI 10.1172/JCI86892; Cotter MA, 2007, CLIN CANCER RES, V13, P5952, DOI 10.1158/1078-0432.CCR-07-1187; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; DeNicola GM, 2015, NAT GENET, V47, P1475, DOI 10.1038/ng.3421; Dong ZY, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1356145; Falahat R, 2019, CANCER IMMUNOL RES, V7, P1837, DOI 10.1158/2326-6066.CIR-19-0229; Falletta P, 2017, GENE DEV, V31, P18, DOI 10.1101/gad.290940.116; Fassler M, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0523-2; Ferguson J, 2017, ONCOTARGET, V8, P32946, DOI 10.18632/oncotarget.16514; Frank R, 2018, CLIN CANCER RES, V24, P3087, DOI 10.1158/1078-0432.CCR-17-3416; Gunderstofte C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02101; Hintsala HR, 2016, ANTICANCER RES, V36, P1497; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Konno H, 2018, CELL REP, V23, P1112, DOI 10.1016/j.celrep.2018.03.115; Landsberg J, 2012, NATURE, V490, P412, DOI 10.1038/nature11538; Leikam C, 2014, ONCOGENE, V33, P771, DOI 10.1038/onc.2012.641; Leikam C, 2008, ONCOGENE, V27, P7070, DOI 10.1038/onc.2008.323; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; Lokaj K, 2009, J PROTEOME RES, V8, P1818, DOI 10.1021/pr800578a; Markosyan N, 2019, J CLIN INVEST, V129, P3594, DOI 10.1172/JCI127755; Marloye M, 2019, PHARM PAT ANAL, V8, P87, DOI 10.4155/ppa-2019-0013; Meierjohann S, 2014, EUR J CELL BIOL, V93, P36, DOI 10.1016/j.ejcb.2013.11.005; Mitra D, 2012, NATURE, V491, P449, DOI 10.1038/nature11624; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Olagnier D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05861-7; Park SH, 2018, FASEB J; Qu XL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00563; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Riesenberg S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9755; Sander CS, 2004, INT J DERMATOL, V43, P326, DOI 10.1111/j.1365-4632.2004.02222.x; Schepsky A, 2006, MOL CELL BIOL, V26, P8914, DOI 10.1128/MCB.02299-05; Schmitt A, 2015, BIOCHEM J, V471, P267, DOI 10.1042/BJ20141204; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Subbarayan V, 2001, CANCER RES, V61, P2720; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Tsoi J, 2018, CANCER CELL, V33, P890, DOI 10.1016/j.ccell.2018.03.017; Vivas-Garcia Y, 2020, MOL CELL, V77, P120, DOI 10.1016/j.molcel.2019.10.014; Widmer DS, 2013, J INVEST DERMATOL, V133, P2436, DOI 10.1038/jid.2013.115; Wiemer AJ, 2011, J IMMUNOL, V187, P3663, DOI 10.4049/jimmunol.1100103; Xia TL, 2016, CANCER RES, V76, P6747, DOI 10.1158/0008-5472.CAN-16-1404; Zelenay S, 2015, CELL, V162, P1257, DOI 10.1016/j.cell.2015.08.015; Zhu B, 2018, ONCOGENE, V37, P4941, DOI 10.1038/s41388-018-0314-0	52	33	33	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2020	39	44					6841	6855		10.1038/s41388-020-01477-8	http://dx.doi.org/10.1038/s41388-020-01477-8		SEP 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OH9QS	32978520	hybrid, Green Published, Green Submitted			2022-12-17	WOS:000572714000003
J	Xu, GL; Feng, DJ; Yao, Y; Li, PP; Sun, H; Yang, H; Li, CX; Jiang, RQ; Sun, BC; Chen, Y				Xu, Guolong; Feng, Dongju; Yao, Yao; Li, Peipei; Sun, Hua; Yang, Hong; Li, Changxian; Jiang, Runqiu; Sun, Beicheng; Chen, Yun			Listeria-based hepatocellular carcinoma vaccine facilitates anti-PD-1 therapy by regulating macrophage polarization	ONCOGENE			English	Article							PD-1/PD-L1 BLOCKADE; TUMOR MICROENVIRONMENT; COLORECTAL-CANCER; T-CELLS; AUTOPHAGY; ACTIVATION; IMMUNOTHERAPY; MECHANISMS; BGJ398; GROWTH	Recently, patients with advanced cancers have been benefited greatly from immune checkpoint blockade immunotherapy. However, immune checkpoint blockade is still suboptimal in HCC treatment and more immune modifications are needed to achieve an efficient therapeutic goal. Here, we investigated the combined administration of a Listeria-based HCC vaccine, Lmdd-MPFG, and the anti-PD-1 immune checkpoint blockade antibody. We found that Lmdd-MPFG promoted the expression of PD-L1 in HCC cells but resensitized the tumor local T cell to respond to the anti-PD-1 immunotherapy. Mechanistically, the Lmdd-MPFG vaccine activates the NF-kappa B pathway in the tumor-associated macrophages (TAMs) through the TLR2 and MyD88 pathway, and recruits p62 to activate the autophagy pathway. The overall effect is skewing the TAMs from M2-polarized TAMs into the M1-polarized TAMs. Most importantly, it skewed the cytokine profiles into antitumor one in the tumor microenvironment (TME). This change restores the T-cell reactivity to the anti-PD-1 blockade. Our results suggested that Lmdd-MPFG combined with PD-1 blockade exerted synergistic antitumor effects through modifying TAMs in the TME and removing T-cell inhibitory signals, thereby providing a new potential strategy for HCC treatment.	[Xu, Guolong; Feng, Dongju; Li, Peipei; Yang, Hong; Chen, Yun] Nanjing Med Univ, Dept Immunol, Key Lab Immune Microenvironm & Dis, Nanjing 211166, Jiangsu, Peoples R China; [Xu, Guolong; Li, Peipei; Chen, Yun] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China; [Yao, Yao; Chen, Yun] Jiangsu Canc Hosp, Res Ctr Clin Oncol, Dept Head & Neck Surg, Nanjing 210018, Jiangsu, Peoples R China; [Yao, Yao; Chen, Yun] Jiangsu Inst Canc Res, Nanjing 210018, Jiangsu, Peoples R China; [Yao, Yao; Chen, Yun] Nanjing Med Univ, Canc Hosp, Nanjing 210018, Jiangsu, Peoples R China; [Sun, Hua] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med, Dept Immunol, Houston, TX 77030 USA; [Li, Changxian] Nanjing Med Univ, Liver Transplantat Ctr, Affiliated Hosp 1, Guangzhou Rd 300, Nanjing 210029, Jiangsu, Peoples R China; [Jiang, Runqiu; Sun, Beicheng] Nanjing Univ, Affiliated Drum Tower Hosp, Dept Hepatobiliary Surg, Med Sch, Nanjing 210093, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; University of Texas System; University of Texas Health Science Center Houston; Nanjing Medical University; Nanjing University	Chen, Y (corresponding author), Nanjing Med Univ, Dept Immunol, Key Lab Immune Microenvironm & Dis, Nanjing 211166, Jiangsu, Peoples R China.; Chen, Y (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China.; Chen, Y (corresponding author), Jiangsu Canc Hosp, Res Ctr Clin Oncol, Dept Head & Neck Surg, Nanjing 210018, Jiangsu, Peoples R China.; Chen, Y (corresponding author), Jiangsu Inst Canc Res, Nanjing 210018, Jiangsu, Peoples R China.; Chen, Y (corresponding author), Nanjing Med Univ, Canc Hosp, Nanjing 210018, Jiangsu, Peoples R China.	chenyun@njmu.edu.cn		Xu, Guolong/0000-0002-0425-2040; Sun, Beicheng/0000-0002-8657-7024	National Natural Science Foundation [81772602, 9174210027, 81902780]; Qing Lan Project; Six Talent Peaks Project [JY-018]; Jiangsu Provincial key research development program of China [BE2018750]; "333" project	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Qing Lan Project(Jiangsu Polytech Institute); Six Talent Peaks Project; Jiangsu Provincial key research development program of China; "333" project(Natural Science Foundation of Jiangsu Province)	This work was supported by grants from the National Natural Science Foundation (Grant Number: 81772602, 9174210027 to YC, 81902780 to YY). The Qing Lan Project, the Six Talent Peaks Project (JY-018), the "333" project, Jiangsu Provincial key research development program of China (BE2018750 to YC).	Atkins MB, 2017, ANN ONCOL, V28, P1484, DOI 10.1093/annonc/mdx151; Ayers M, 2019, CLIN CANCER RES, V25, P1564, DOI 10.1158/1078-0432.CCR-18-1316; Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392; Bel S, 2017, SCIENCE, V357, P1047, DOI 10.1126/science.aal4677; Chen PW, 2014, AUTOPHAGY, V10, P192, DOI 10.4161/auto.26927; Chen Y, 2012, ONCOGENE, V31, P2140, DOI 10.1038/onc.2011.395; Christopher MJ, 2018, NEW ENGL J MED, V379, P2330, DOI 10.1056/NEJMoa1808777; Concha-Benavente F, 2016, CANCER RES, V76, P1031, DOI 10.1158/0008-5472.CAN-15-2001; Conway KL, 2013, GASTROENTEROLOGY, V145, P1347, DOI 10.1053/j.gastro.2013.08.035; Doria A, 2013, NEW ENGL J MED, V368, P1845, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]; Drolia R, 2018, CELL HOST MICROBE, V23, P470, DOI 10.1016/j.chom.2018.03.004; Dunai C, 2018, J CLIN INVEST, V128, P4251, DOI 10.1172/JCI123121; El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2; Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2; Galdiero MR, 2013, IMMUNOBIOLOGY, V218, P1402, DOI 10.1016/j.imbio.2013.06.003; Garris CS, 2018, IMMUNITY, V49, P1148, DOI 10.1016/j.immuni.2018.09.024; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Javle M, 2018, J CLIN ONCOL, V36, P276, DOI 10.1200/JCO.2017.75.5009; Jung C, 2012, J CLIN INVEST, V122, P2239, DOI 10.1172/JCI58147; Kroemer G, 2015, J CLIN INVEST, V125, P1, DOI 10.1172/JCI78652; Ktistakis NT, 2016, TRENDS CELL BIOL, V26, P624, DOI 10.1016/j.tcb.2016.03.006; Landais I, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004881; Lane RS, 2018, J EXP MED, V215, P3057, DOI 10.1084/jem.20180654; Lin PL, 2017, CANCER MED-US, V6, P2052, DOI 10.1002/cam4.1143; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Lo Russo G, 2019, CLIN CANCER RES, V25, P989, DOI 10.1158/1078-0432.CCR-18-1390; Lu X, 2017, NATURE, V543, P728, DOI 10.1038/nature21676; Makarova-Rusher OV, 2015, J HEPATOL, V62, P1420, DOI 10.1016/j.jhep.2015.02.038; Martini DJ, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0273-y; Motzer RJ, 2015, J CLIN ONCOL, V33, P1430, DOI 10.1200/JCO.2014.59.0703; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Nogova L, 2017, J CLIN ONCOL, V35, P157, DOI 10.1200/JCO.2016.67.2048; Ouyang ZX, 2019, BIOMATERIALS, V205, P50, DOI 10.1016/j.biomaterials.2019.03.018; Ruffell B, 2015, CANCER CELL, V27, P462, DOI 10.1016/j.ccell.2015.02.015; Sheng CJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06756-3; Shi XJ, 2017, CANCER LETT, V406, P27, DOI 10.1016/j.canlet.2017.07.029; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Siu EHL, 2018, TRANSL GASTROENT HEP, V3, DOI 10.21037/tgh.2018.10.16; Sorbara MT, 2018, CELL HOST MICROBE, V23, P644, DOI 10.1016/j.chom.2018.04.008; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Vareki SM, 2017, CRIT REV ONCOL HEMAT, V116, P116, DOI 10.1016/j.critrevonc.2017.06.001; Wallecha A, 2013, J IMMUNOTHER, V36, P468, DOI 10.1097/CJI.0000000000000000; Webster JA, 2010, J PATHOL, V222, P158, DOI 10.1002/path.2738; Wu SP, 2018, J THORAC ONCOL, V13, P521, DOI 10.1016/j.jtho.2017.11.132; Yanik EL, 2017, JAMA ONCOL, V3, P974, DOI 10.1001/jamaoncol.2017.0115; Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008; Zhao S, 2019, CANCER IMMUNOL RES, V7, P630, DOI 10.1158/2326-6066.CIR-17-0640; Zhong J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.102; Zhong ZY, 2016, CELL, V164, P896, DOI 10.1016/j.cell.2015.12.057	50	33	35	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1429	1444		10.1038/s41388-019-1072-3	http://dx.doi.org/10.1038/s41388-019-1072-3			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31659256				2022-12-17	WOS:000513289600004
J	Li, T; Forbes, ME; Fuller, GN; Li, JB; Yang, XJ; Zhang, W				Li, Tao; Forbes, M. Elizabeth; Fuller, Gregory N.; Li, Jiabo; Yang, Xuejun; Zhang, Wei			IGFBP2: integrative hub of developmental and oncogenic signaling network	ONCOGENE			English	Review							GROWTH-FACTOR-BINDING; NF-KAPPA-B; NEUROBLASTOMA-CELL PROLIFERATION; DISTINCT EXPRESSION PATTERNS; ACUTE LYMPHOBLASTIC-LEUKEMIA; EX-VIVO EXPANSION; PROSTATE-CANCER; GENE-EXPRESSION; FACTOR-II; PROTEIN-2 IGFBP-2	Insulin-like growth factor (IGF) binding protein 2 (IGFBP2) was discovered and identified as an IGF system regulator, controlling the distribution, function, and activity of IGFs in the pericellular space. IGFBP2 is a developmentally regulated gene that is highly expressed in embryonic and fetal tissues and markedly decreases after birth. Studies over the last decades have shown that in solid tumors, IGFBP2 is upregulated and promotes several key oncogenic processes, such as epithelial-to-mesenchymal transition, cellular migration, invasion, angiogenesis, stemness, transcriptional activation, and epigenetic programming via signaling that is often independent of IGFs. Growing evidence indicates that aberrant expression of IGFBP2 in cancer acts as a hub of an oncogenic network, integrating multiple cancer signaling pathways and serving as a potential therapeutic target for cancer treatment.	[Li, Tao; Forbes, M. Elizabeth; Zhang, Wei] Wake Forest Sch Med, Dept Canc Biol, Winston Salem, NC 27101 USA; [Li, Tao; Li, Jiabo; Yang, Xuejun] Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China; [Li, Tao; Li, Jiabo; Yang, Xuejun] Tianjin Neurol Inst, Lab Neurooncol, Tianjin, Peoples R China; [Fuller, Gregory N.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	Wake Forest University; Tianjin Medical University; University of Texas System; UTMD Anderson Cancer Center	Zhang, W (corresponding author), Wake Forest Sch Med, Dept Canc Biol, Winston Salem, NC 27101 USA.; Yang, XJ (corresponding author), Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China.; Yang, XJ (corresponding author), Tianjin Neurol Inst, Lab Neurooncol, Tianjin, Peoples R China.	ydenny@126.com; wezhang@wakehealth.edu		Li, Jiabo/0000-0002-9288-9673; Forbes, Elizabeth/0000-0003-3300-5476	NCI Cancer Center Support Grant [P30CA012197]; Hanes and Willis Professorship in Cancer; National Foundation for Cancer Research; National Natural Science Foundation of China [81872063]	NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Hanes and Willis Professorship in Cancer; National Foundation for Cancer Research; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We would like to thank all of the investigators who have contributed to the study of IGFBP2 in cancer that inspired this review article. This work was supported in part by the NCI Cancer Center Support Grant to the Comprehensive Cancer Center of Wake Forest University Health Sciences (P30CA012197). WZ is supported by the Hanes and Willis Professorship in Cancer and a Fellowship from the National Foundation for Cancer Research. XY and TL are supported by the National Natural Science Foundation of China (No. 81872063).	ADASHI EY, 1993, ANN NY ACAD SCI, V687, P10; AKMAL SN, 1995, HUM PATHOL, V26, P846, DOI 10.1016/0046-8177(95)90005-5; Allander SV, 2002, AM J PATHOL, V161, P1587, DOI 10.1016/S0002-9440(10)64437-9; Arai T, 1996, ENDOCRINOLOGY, V137, P4571, DOI 10.1210/en.137.11.4571; Arguelles B, 2000, J CLIN ENDOCR METAB, V85, P4087, DOI 10.1210/jc.85.11.4087; Azar WJ, 2014, ONCOGENE, V33, P578, DOI 10.1038/onc.2012.630; Azar WJ, 2011, ENDOCRINOLOGY, V152, P3332, DOI 10.1210/en.2011-1121; Bach LA, 2005, TRENDS ENDOCRIN MET, V16, P228, DOI 10.1016/j.tem.2005.05.005; Baron-Hay S, 2004, CLIN CANCER RES, V10, P1796, DOI 10.1158/1078-0432.CCR-0672-2; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Ben-Shmuel A, 2013, ONCOGENE, V32, P3220, DOI 10.1038/onc.2012.340; Biernacka KM, 2013, ENDOCR-RELAT CANCER, V20, P741, DOI 10.1530/ERC-13-0077; BINKERT C, 1989, EMBO J, V8, P2497, DOI 10.1002/j.1460-2075.1989.tb08386.x; Blank U, 2008, BLOOD, V111, P492, DOI 10.1182/blood-2007-07-075168; Boulle N, 1998, J CLIN ENDOCR METAB, V83, P1713, DOI 10.1210/jc.83.5.1713; Boulle N, 2001, EUR J ENDOCRINOL, V144, P29, DOI 10.1530/eje.0.1440029; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Bunn RC, 2003, TRENDS ENDOCRIN MET, V14, P176, DOI 10.1016/S1043-2760(03)00049-3; Busund LT, 2005, J CLIN PATHOL, V58, P361, DOI 10.1136/jcp.2004.020834; Cai JQ, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1426516; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Carrick FE, 2005, J MOL ENDOCRINOL, V34, P685, DOI 10.1677/jme.1.01756; Carrick FE, 2001, J BIOL CHEM, V276, P27120, DOI 10.1074/jbc.M101317200; Cecil DL, 2014, CANCER RES, V74, P2710, DOI 10.1158/0008-5472.CAN-13-3286; Chen R, 2007, MOL CELL PROTEOMICS, V6, P1331, DOI 10.1074/mcp.M700072-MCP200; Chen R, 2006, PROTEOMICS, V6, P3871, DOI 10.1002/pmic.200500702; Chesik D, 2004, NEUROSCI LETT, V362, P14, DOI 10.1016/j.neulet.2004.01.039; Chua CY, 2016, ONCOGENE, V35, P738, DOI 10.1038/onc.2015.131; COHEN P, 1993, J CLIN ENDOCR METAB, V76, P1031, DOI 10.1210/jc.76.4.1031; Colman H, 2010, NEURO-ONCOLOGY, V12, P49, DOI 10.1093/neuonc/nop007; Coverley JA, 1997, MOL CELL ENDOCRINOL, V128, P1, DOI 10.1016/S0303-7207(97)04032-X; Crofton PM, 2000, PEDIATR RES, V48, P490, DOI 10.1203/00006450-200010000-00012; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Das SK, 2013, CANCER RES, V73, P844, DOI 10.1158/0008-5472.CAN-12-1681; Dawczynski K, 2003, BONE MARROW TRANSPL, V32, P411, DOI 10.1038/sj.bmt.1704149; Dawczynski K, 2008, PEDIATR BLOOD CANCER, V50, P24, DOI 10.1002/pbc.21294; Dean SJR, 2014, AM J CLIN PATHOL, V141, P323, DOI 10.1309/AJCPR11DEAYPTUSL; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Dunlap SM, 2007, P NATL ACAD SCI USA, V104, P11736, DOI 10.1073/pnas.0703145104; ELATIQ F, 1994, INT J CANCER, V57, P491, DOI 10.1002/ijc.2910570409; Elmlinger MW, 2001, ENDOCRINOLOGY, V142, P1652, DOI 10.1210/en.142.4.1652; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Flyvbjerg A, 1997, J CLIN ENDOCR METAB, V82, P2308, DOI 10.1210/jc.82.7.2308; Forbes BE, 1998, J BIOL CHEM, V273, P4647, DOI 10.1074/jbc.273.8.4647; Fottner C, 2008, EUR J ENDOCRINOL, V159, P317, DOI 10.1530/EJE-08-0033; Foulstone EJ, 2013, ENDOCRINOLOGY, V154, P1780, DOI 10.1210/en.2012-1970; Frommer KW, 2006, J MOL ENDOCRINOL, V37, P13, DOI 10.1677/jme.1.01955; Fuller GN, 1999, CANCER RES, V59, P4228; Galea CA, 2012, BIOCHIMIE, V94, P608, DOI 10.1016/j.biochi.2011.09.012; Perez-Larraya JG, 2014, CANCER-AM CANCER SOC, V120, P3972, DOI 10.1002/cncr.28949; Gao S, 2016, CANCER RES, V76, P6543, DOI 10.1158/0008-5472.CAN-16-0438; Godard S, 2003, CANCER RES, V63, P6613; GREEN BN, 1994, ENDOCRINOLOGY, V134, P954, DOI 10.1210/en.134.2.954; Guo CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074973; Han S, 2014, BRIT J CANCER, V111, P1400, DOI 10.1038/bjc.2014.435; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Higgins RJ, 2010, J NEURO-ONCOL, V98, P49, DOI 10.1007/s11060-009-0072-5; Ho PJ, 1997, ENDOCRINOLOGY, V138, P3811, DOI 10.1210/en.138.9.3811; Hobba GD, 1998, J BIOL CHEM, V273, P19691, DOI 10.1074/jbc.273.31.19691; Hoeflich A, 2000, CANCER RES, V60, P834; Hoeflich A, 2004, BIOCHEM BIOPH RES CO, V324, P705, DOI 10.1016/j.bbrc.2004.09.111; Holland EC, 2000, AM J PATHOL, V157, P1031, DOI 10.1016/S0002-9440(10)64615-9; Holmes KM, 2012, P NATL ACAD SCI USA, V109, P3475, DOI 10.1073/pnas.1120375109; Hsieh D, 2010, BIOCHEM BIOPH RES CO, V397, P367, DOI 10.1016/j.bbrc.2010.05.145; Huynh HD, 2008, STEM CELLS, V26, P1628, DOI 10.1634/stemcells.2008-0064; Huynh H, 2011, BLOOD, V118, P3236, DOI 10.1182/blood-2011-01-331876; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; JAQUES G, 1992, EUR J CANCER, V28A, P1899, DOI 10.1016/0959-8049(92)90032-W; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; Kanety H, 1996, BRIT J CANCER, V73, P1069, DOI 10.1038/bjc.1996.206; KANETY H, 1993, J CLIN ENDOCR METAB, V77, P229, DOI 10.1210/jc.77.1.229; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kendrick ZW, 2014, HPB, V16, P670, DOI 10.1111/hpb.12199; Kim YW, 2013, INT J ONCOL, V43, P539, DOI 10.3892/ijo.2013.1961; Kuang ZH, 2006, J MOL BIOL, V364, P690, DOI 10.1016/j.jmb.2006.09.006; Kuhnl A, 2011, LEUKEMIA RES, V35, P1585, DOI 10.1016/j.leukres.2011.08.006; Ladd JJ, 2012, CANCER PREV RES, V5, P655, DOI 10.1158/1940-6207.CAPR-11-0412; Laffaire J, 2011, NEURO-ONCOLOGY, V13, P84, DOI 10.1093/neuonc/noq110; Lamalice L, 2007, CIRC RES, V100, P782, DOI 10.1161/01.RES.0000259593.07661.1e; Lancaster JM, 2004, J SOC GYNECOL INVEST, V11, P51, DOI 10.1016/j.jsgi.2003.07.004; Lee CF, 2008, WORLD J GASTROENTERO, V14, P6072, DOI 10.3748/wjg.14.6072; Lee DY, 1999, J KOREAN MED SCI, V14, P401, DOI 10.3346/jkms.1999.14.4.401; Lee EJ, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-7; LEE WH, 1993, NEUROSCIENCE, V53, P251, DOI 10.1016/0306-4522(93)90303-W; Levitt RJ, 2005, BIOCHEM BIOPH RES CO, V336, P1056, DOI 10.1016/j.bbrc.2005.08.229; Li X, 2015, ONCOGENE, V34, P1619, DOI 10.1038/onc.2014.98; Lin Y, 2009, NEURO-ONCOLOGY, V11, P468, DOI 10.1215/15228517-2008-114; Liou JM, 2010, J CLIN ENDOCR METAB, V95, P1717, DOI 10.1210/jc.2009-2668; Liu Y, 2019, ONCOGENE, V38, P1815, DOI 10.1038/s41388-018-0525-4; Lu HB, 2013, MOL CANCER THER, V12, P2864, DOI 10.1158/1535-7163.MCT-13-0233; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marucci G, 2008, VIRCHOWS ARCH, V453, P599, DOI 10.1007/s00428-008-0685-7; Matuschek C, 2011, EUR J MED RES, V16, P451; McDonald KL, 2007, J NEUROPATH EXP NEUR, V66, P405, DOI 10.1097/nen.0b013e31804567d7; Mehrian-Shai R, 2007, P NATL ACAD SCI USA, V104, P5563, DOI 10.1073/pnas.0609139104; Menouny M, 1997, ENDOCRINOLOGY, V138, P683, DOI 10.1210/en.138.2.683; Migita T, 2010, AM J PATHOL, V176, P1756, DOI 10.2353/ajpath.2010.090500; Miyake H, 2005, ONCOL REP, V13, P341; Miyake H, 2000, CANCER RES, V60, P3058; Moore MG, 2003, INT J CANCER, V105, P14, DOI 10.1002/ijc.11015; Moorehead RA, 2003, J BIOL CHEM, V278, P50422, DOI 10.1074/jbc.M306894200; MULLER HL, 1994, J CLIN ENDOCR METAB, V79, P428, DOI 10.1210/jc.79.2.428; Myers AL, 2015, ONCOTARGET, V6, P25897, DOI 10.18632/oncotarget.4532; Nakano H, 2010, INT J CANCER, V127, P1072, DOI 10.1002/ijc.25143; Neuhouser ML, 2013, CANCER PREV RES, V6, P91, DOI 10.1158/1940-6207.CAPR-12-0250; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; OLNEY RC, 1995, MOL CELL ENDOCRINOL, V110, P213, DOI 10.1016/0303-7207(95)03536-G; Park KH, 2008, CANCER RES, V68, P8400, DOI 10.1158/0008-5472.CAN-07-5891; Patil SS, 2016, NEURO-ONCOLOGY, V18, P1487, DOI 10.1093/neuonc/now053; Patil SS, 2015, J NEURO-ONCOL, V123, P225, DOI 10.1007/s11060-015-1800-7; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pereira JJ, 2004, CANCER RES, V64, P977, DOI 10.1158/0008-5472.CAN-03-3056; Perks CM, 2007, ONCOGENE, V26, P5966, DOI 10.1038/sj.onc.1210397; Phillips LM, 2016, J PATHOL, V239, P355, DOI 10.1002/path.4734; PINTAR JE, 1991, ADV EXP MED BIOL, V293, P325; Planque C, 2009, MOL CELL PROTEOMICS, V8, P2746, DOI 10.1074/mcp.M900134-MCP200; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Probst-Hensch NM, 2010, CLIN CANCER RES, V16, P1025, DOI 10.1158/1078-0432.CCR-09-0957; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Ranke MB, 2003, HORM RES, V60, P174, DOI 10.1159/000073229; Renehan AG, 2000, J CLIN ENDOCR METAB, V85, P3402, DOI 10.1210/jc.85.9.3402; Renehan AG, 2000, BRIT J CANCER, V83, P1344, DOI 10.1054/bjoc.2000.1462; Rickman DS, 2001, CANCER RES, V61, P6885; Rorive S, 2008, GLIA, V56, P1679, DOI 10.1002/glia.20719; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Russo VC, 2015, CYTOKINE GROWTH F R, V26, P329, DOI 10.1016/j.cytogfr.2014.12.001; Russo VC, 1999, ENDOCRINOLOGY, V140, P3082, DOI 10.1210/en.140.7.3082; Russo VC, 1997, ENDOCRINOLOGY, V138, P4858, DOI 10.1210/en.138.11.4858; Russo VC, 2005, ENDOCRINOLOGY, V146, P4445, DOI 10.1210/en.2005-0467; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Schutt BS, 2004, J MOL ENDOCRINOL, V32, P859, DOI 10.1677/jme.0.0320859; Scrideli CA, 2007, J NEURO-ONCOL, V83, P233, DOI 10.1007/s11060-007-9328-0; Sehgal P, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-63; Shariat SF, 2002, J CLIN ONCOL, V20, P833, DOI 10.1200/JCO.20.3.833; Shen XC, 2012, MOL CELL BIOL, V32, P4116, DOI 10.1128/MCB.01011-12; Shi LH, 2006, WORLD J GASTROENTERO, V12, P6285, DOI 10.3748/wjg.v12.i39.6285; So AI, 2008, CLIN CANCER RES, V14, P6944, DOI 10.1158/1078-0432.CCR-08-0408; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Song SW, 2003, P NATL ACAD SCI USA, V100, P13970, DOI 10.1073/pnas.2332186100; STRECK RD, 1992, ENDOCRINOLOGY, V131, P2030, DOI 10.1210/en.131.4.2030; Tombolan L, 2011, AM J PATHOL, V179, P2611, DOI 10.1016/j.ajpath.2011.07.018; Uzoh CC, 2011, BRIT J CANCER, V104, P1587, DOI 10.1038/bjc.2011.127; van Kleffens M, 1998, MOL CELL ENDOCRINOL, V140, P129, DOI 10.1016/S0303-7207(98)00041-0; Villani RM, 2010, CANCER PREV RES, V3, P1222, DOI 10.1158/1940-6207.CAPR-10-0082; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Vorwerk P, 2005, J CLIN ENDOCR METAB, V90, P3022, DOI 10.1210/jc.2004-0461; Wang HM, 2003, J CUTAN PATHOL, V30, P599, DOI 10.1034/j.1600-0560.2003.00120.x; Wang HM, 2002, BRAIN PATHOL, V12, P95; Wang HM, 2008, BREAST J, V14, P261, DOI 10.1111/j.1524-4741.2008.00572.x; Wang HM, 2006, MODERN PATHOL, V19, P1149, DOI 10.1038/modpathol.3800637; WANG JF, 1988, BIOCHEM BIOPH RES CO, V157, P718, DOI 10.1016/S0006-291X(88)80309-7; WOOD TL, 1992, DEVELOPMENT, V114, P59; Yao XF, 2018, CANCER LETT, V432, P38, DOI 10.1016/j.canlet.2018.06.008; Yi HK, 2001, EUR J CANCER, V37, P2257, DOI 10.1016/S0959-8049(01)00269-6; Yoneyama T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161009; Yu CJ, 2011, J PROTEOME RES, V10, P4671, DOI 10.1021/pr2004743; Zhai HY, 2011, GLIA, V59, P472, DOI 10.1002/glia.21117; Zhang CC, 2008, BLOOD, V111, P3415, DOI 10.1182/blood-2007-11-122119; Zhang LH, 2007, DIGEST DIS SCI, V52, P248, DOI 10.1007/s10620-006-9358-z; Zhang Y, 2013, INT J ONCOL, V42, P93, DOI 10.3892/ijo.2012.1699; Zhao Y, 2017, CANCER LETT, V408, P102, DOI 10.1016/j.canlet.2017.08.027; Zheng SC, 2011, NEURO-ONCOLOGY, V13, P280, DOI 10.1093/neuonc/noq190; Zhou Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046851; ZUMKELLER W, 1993, EUR J CANCER, V29A, P1973, DOI 10.1016/0959-8049(93)90455-O	170	33	34	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2243	2257		10.1038/s41388-020-1154-2	http://dx.doi.org/10.1038/s41388-020-1154-2		JAN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31925333	Green Accepted			2022-12-17	WOS:000508151400002
J	Pique, L; de Paz, AM; Pineyro, D; Martinez-Cardus, A; de Moura, MC; Llinas-Arias, P; Setien, F; Gomez-Miragaya, J; Gonzalez-Suarez, E; Sigurdsson, S; Jonasson, JG; Villanueva, A; Vidal, A; Davalos, V; Esteller, M				Pique, Laia; Martinez de Paz, Alexia; Pineyro, David; Martinez-Cardus, Anna; Castro de Moura, Manuel; Llinas-Arias, Pere; Setien, Fernando; Gomez-Miragaya, Jorge; Gonzalez-Suarez, Eva; Sigurdsson, Stefan; Jonasson, Jon G.; Villanueva, Alberto; Vidal, August; Davalos, Veronica; Esteller, Manel			Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer	ONCOGENE			English	Article							TUMOR; IDENTIFICATION; ACTIVATION	Human tumors show altered patterns of protein isoforms that can be related to the dysregulation of messenger RNA alternative splicing also observed in transformed cells. Although somatic mutations in core spliceosome components and their associated factors have been described in some cases, almost nothing is known about the contribution of distorted epigenetic patterns to aberrant splicing. Herein, we show that the splicing RNA-binding protein CELF2 is targeted by promoter hypermethylation-associated transcriptional silencing in human cancer. Focusing on the context of breast cancer, we also demonstrate that CELF2 restoration has growth-inhibitory effects and that its epigenetic loss induces an aberrant downstream pattern of alternative splicing, affecting key genes in breast cancer biology such as the autophagy factor ULK1 and the apoptotic protein CARD10. Furthermore, the presence of CELF2 hypermethylation in the clinical setting is associated with shorter overall survival of the breast cancer patients carrying this epigenetic lesion.	[Pique, Laia; Martinez de Paz, Alexia; Pineyro, David; Martinez-Cardus, Anna; Castro de Moura, Manuel; Llinas-Arias, Pere; Setien, Fernando; Gomez-Miragaya, Jorge; Gonzalez-Suarez, Eva; Davalos, Veronica; Esteller, Manel] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Lhospitalet Barcelona, Catalonia, Spain; [Sigurdsson, Stefan] Biomed Ctr, Dept Biochem & Mol Biol, Vatnsmyrarvegur 16, IS-101 Reykjavik, Iceland; [Jonasson, Jon G.] Univ Iceland, Fac Med, Sturlugata 8, IS-101 Reykjavik, Iceland; [Jonasson, Jon G.] Landspitali Univ Hosp, Dept Pathol, Reykjavik, Iceland; [Villanueva, Alberto] IDIBELL Inst Catala Oncol, Translat Res Lab, Barcelona, Catalonia, Spain; [Vidal, August] Bellvitge Univ Hosp, Dept Pathol, Barcelona, Catalonia, Spain; [Esteller, Manel] Ctr Invest Biomed Red Canc CIBERONC, Madrid 28029, Spain; [Esteller, Manel] ICREA, Barcelona, Catalonia, Spain; [Esteller, Manel] UB, Sch Med & Hlth Sci, Physiol Sci Dept, Barcelona, Catalonia, Spain; [Esteller, Manel] Josep Carreras Leukaemia Res Inst IJC, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Iceland; Landspitali National University Hospital; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; ICREA; University of Barcelona; Institut de Recerca Contra la Leucemia Josep Carreras (IJC)	Esteller, M (corresponding author), Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Lhospitalet Barcelona, Catalonia, Spain.; Esteller, M (corresponding author), Ctr Invest Biomed Red Canc CIBERONC, Madrid 28029, Spain.; Esteller, M (corresponding author), ICREA, Barcelona, Catalonia, Spain.; Esteller, M (corresponding author), UB, Sch Med & Hlth Sci, Physiol Sci Dept, Barcelona, Catalonia, Spain.; Esteller, M (corresponding author), Josep Carreras Leukaemia Res Inst IJC, Barcelona, Catalonia, Spain.	mesteller@carrerasresearch.org	Esteller, Manel/L-5956-2014; Davalos, Veronica/AAR-8547-2020; Llinàs-Arias, Pere/M-4501-2014; Llinàs-Arias, Pere/AAB-8254-2022; Martinez, Anna/AAA-4939-2020; Gonzalez-Suarez, Eva/L-6298-2014; Sigurdsson, Stefan/L-9820-2015; Davalos, Veronica/S-1668-2016; Castro de Moura, Manuel/L-4259-2017	Esteller, Manel/0000-0003-4490-6093; Llinàs-Arias, Pere/0000-0002-3666-0532; Gonzalez-Suarez, Eva/0000-0003-0858-8171; Martinez de Paz, Alexia/0000-0003-0808-1389; Pineyro, David/0000-0001-5633-3339; Sigurdsson, Stefan/0000-0002-5284-0058; Jonasson, Jon G./0000-0002-2635-5032; Davalos, Veronica/0000-0003-4077-5137; Castro de Moura, Manuel/0000-0002-8488-5306; Martinez Cardus, Anna/0000-0002-3937-8794	Health Department PERIS-project of the Catalan Government (Generalitat de Catalunya) [SLT/002/16/00374]; AGAUR of the Catalan Government (Generalitat de Catalunya) [2017SGR1080, 2014SGR633, 2009SGR1315]; Spanish Institute of Health Carlos III (ISCIII) [DTS16/00153]; Ministerio de Economia y Competitividad (MINECO) [SAF2014-55000-R]; European Development Regional Fund, "A way to achieve Europe" ERDF; Cellex Foundation; "la Caixa" Banking Foundation [LCF/PR/PR15/11100003]	Health Department PERIS-project of the Catalan Government (Generalitat de Catalunya); AGAUR of the Catalan Government (Generalitat de Catalunya); Spanish Institute of Health Carlos III (ISCIII)(Instituto de Salud Carlos III); Ministerio de Economia y Competitividad (MINECO); European Development Regional Fund, "A way to achieve Europe" ERDF; Cellex Foundation(Foundation CELLEX); "la Caixa" Banking Foundation(La Caixa Foundation)	We thank CERCA Program/Generalitat de Catalunya for institutional support. This work was supported by the Health Department PERIS-project no. SLT/002/16/00374 and AGAUR-projects nos. 2017SGR1080, 2014SGR633, and 2009SGR1315 of the Catalan Government (Generalitat de Catalunya); the Spanish Institute of Health Carlos III (ISCIII) project no. DTS16/00153 and Ministerio de Economia y Competitividad (MINECO) project no. SAF2014-55000-R, co-financed by the European Development Regional Fund, "A way to achieve Europe" ERDF; the Cellex Foundation; and "la Caixa" Banking Foundation (LCF/PR/PR15/11100003).	Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Carey KT, 2018, TRENDS GENET, V34, P279, DOI 10.1016/j.tig.2017.12.012; Dasgupta T, 2012, WIRES RNA, V3, P104, DOI 10.1002/wrna.107; Dvinge H, 2016, NAT REV CANCER, V16, P413, DOI 10.1038/nrc.2016.51; Dvinge H, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0168-9; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Feinberg AP, 2018, NEW ENGL J MED, V378, P1323, DOI [10.1056/nejmra1402513, 10.1056/NEJMra1402513]; Gomez-Miragaya J, 2017, STEM CELL REP, V8, P1392, DOI 10.1016/j.stemcr.2017.03.026; Han J, 2005, NUCLEIC ACIDS RES, V33, P2769, DOI 10.1093/nar/gki561; Hosur V, 2014, P NATL ACAD SCI USA, V111, pE2200, DOI 10.1073/pnas.1323908111; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Johnson KC, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0094-0; Jung- H, 2015, NAT GENET, V47, P1242, DOI 10.1038/ng.3414; Kalsotra A, 2011, NAT REV GENET, V12, P715, DOI 10.1038/nrg3052; Kuchay S, 2017, NATURE, V546, P554, DOI 10.1038/nature22965; Nilsen TW, 2010, NATURE, V463, P457, DOI 10.1038/nature08909; Pan D, 2016, MOL CANCER RES, V14, P93, DOI 10.1158/1541-7786.MCR-15-0229-T; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Papasaikas P, 2016, TRENDS BIOCHEM SCI, V41, P33, DOI 10.1016/j.tibs.2015.11.003; Rodriguez-Pinto D, 2009, CANCER IMMUNOL IMMUN, V58, P221, DOI 10.1007/s00262-008-0543-0; Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196; Sveen A, 2016, ONCOGENE, V35, P2413, DOI 10.1038/onc.2015.318; Vlasova IA, 2008, RNA BIOL, V5, P201, DOI 10.4161/rna.7056; Zhang L, 2018, J MED CHEM, V61, P6491, DOI 10.1021/acs.jmedchem.7b01684	24	33	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2019	38	45					7106	7112		10.1038/s41388-019-0936-x	http://dx.doi.org/10.1038/s41388-019-0936-x			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JL9XI	31409895	Green Published, hybrid			2022-12-17	WOS:000495878400006
J	Shankaraiah, RC; Callegari, E; Guerriero, P; Rimessi, A; Pinton, P; Gramantieri, L; Silini, EM; Sabbioni, S; Negrini, M				Shankaraiah, Ram C.; Callegari, Elisa; Guerriero, Paola; Rimessi, Alessandro; Pinton, Paolo; Gramantieri, Laura; Silini, Enrico M.; Sabbioni, Silvia; Negrini, Massimo			Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma	ONCOGENE			English	Article							RISK; CANCER; PHOSPHORYLATION; EPIDEMIOLOGY; CIRRHOSIS; DISEASE; OBESITY	Metformin is a hypoglycaemic agent used to treat type 2 diabetes mellitus (DM2) patients, with a broad safety profile. Since previous epidemiological studies had shown that the incidence of hepatocellular carcinoma (HCC) decreased significantly in metformin treated DM2 patients, we hypothesised that intervention with metformin could reduce the risk of neoplastic transformation of hepatocytes. HCC is the most common primary liver malignancy and it generally originates in a background of liver fibrosis and cirrhosis. In the present study, we took advantage of a transgenic mouse (TG221) characterized by microRNA-221 overexpression, with cirrhotic liver background induced by chronic administration of carbon tetrachloride (CC14). This mouse model develops fibrosis, cirrhosis and liver tumours that become visible in 100% of mice at 5-6 months of age. Our results demonstrated that metformin intervention improves liver function, inhibits hepatic stellate cell (HSC) activation, reduces liver fibrosis, depletes lipid accumulation in hepatocytes, halts progression to decompensated cirrhosis and abrogates development HCC in CC14 challenged transgenic mouse model. The study establishes the rationale for investigating metformin in cirrhotic patients regardless of concomitant DM2 status.	[Shankaraiah, Ram C.; Callegari, Elisa; Guerriero, Paola; Rimessi, Alessandro; Pinton, Paolo; Negrini, Massimo] Univ Ferrara, Dept Morphol Surg & Expt Med, Ferrara, Italy; [Gramantieri, Laura] St Orsola Malpighi Univ Hosp, Ctr Appl Biomed Res, I-40138 Bologna, Italy; [Silini, Enrico M.] Univ Hosp Parma, Sect Anat & Pathol, Parma, Italy; [Sabbioni, Silvia] Univ Ferrara, Dept Life Sci & Biotechnol, Ferrara, Italy	University of Ferrara; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Parma; University Hospital of Parma; University of Ferrara	Negrini, M (corresponding author), Univ Ferrara, Dept Morphol Surg & Expt Med, Ferrara, Italy.	ngm@unife.it	SILINI, ENRICO MARIA/AAB-8747-2019; Pinton, Paolo/J-8025-2012; rimessi, alessandro/O-3335-2019; Gramantieri, Laura/K-8603-2016; NEGRINI, Massimo/J-2377-2016; Callegari, Elisa/J-5763-2016	SILINI, ENRICO MARIA/0000-0003-2578-3059; Pinton, Paolo/0000-0001-7108-6508; rimessi, alessandro/0000-0001-7091-5765; Gramantieri, Laura/0000-0002-5187-9559; NEGRINI, Massimo/0000-0002-0007-1920; GUERRIERO, Paola/0000-0003-3724-7472; Callegari, Elisa/0000-0002-4969-5400	Italian Association for Cancer Research [AIRG IG-15615, AIRC IG-20055]	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the Italian Association for Cancer Research (AIRG IG-15615, AIRC IG-20055) to Massimo Negrini, PhD.	Akinyemiju T, 2017, JAMA ONCOL, V3, P1683, DOI 10.1001/jamaoncol.2017.3055; Blachier M, 2013, J HEPATOL, V58, P593, DOI 10.1016/j.jhep.2012.12.005; Bo S, 2012, DIABETES OBES METAB, V14, P23, DOI 10.1111/j.1463-1326.2011.01480.x; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Callegari E, 2012, HEPATOLOGY, V56, P1025, DOI 10.1002/hep.25747; Chaube B, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.404; Chen HP, 2013, GUT, V62, P606, DOI 10.1136/gutjnl-2011-301708; Dasgupta B, 2016, TRENDS PHARMACOL SCI, V37, P192, DOI 10.1016/j.tips.2015.11.007; DePeralta DK, 2016, CANCER-AM CANCER SOC, V122, P1216, DOI 10.1002/cncr.29912; Deutsch MJ, 2014, ANAL BIOCHEM, V445, P87, DOI 10.1016/j.ab.2013.10.001; Donadon V, 2009, WORLD J GASTROENTERO, V15, P2506, DOI 10.3748/wjg.15.2506; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI 10.1016/j.ejca.2011.12.021; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Fukumura D, 2016, MICROCIRCULATION, V23, P191, DOI 10.1111/micc.12270; Fullerton MD, 2013, NAT MED, V19, P1649, DOI 10.1038/nm.3372; Gardini AC, 2017, EUR J CANCER, V86, P106, DOI 10.1016/j.ejca.2017.09.003; Gardini AC, 2015, EXPERT OPIN PHARMACO, V16, P2719, DOI 10.1517/14656566.2015.1102887; Gluchowski NL, 2017, NAT REV GASTRO HEPAT, V14, P343, DOI 10.1038/nrgastro.2017.32; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; Hassan MM, 2010, CANCER-AM CANCER SOC, V116, P1938, DOI 10.1002/cncr.24982; Hollander MC, 2011, ONCOGENE, V30, P1812, DOI 10.1038/onc.2010.556; Incio J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141392; Ioannou GN, 2018, J HEPATOL, V68, P25, DOI 10.1016/j.jhep.2017.08.030; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kao JH, 2002, LANCET INFECT DIS, V2, P395, DOI 10.1016/S1473-3099(02)00315-8; Kasmari AJ, 2017, AM J MED, V130, DOI 10.1016/j.amjmed.2016.12.029; Kim JH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18762-4; Kim JH, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2015.115; Kluwe J, 2011, GUT, V60, P1260, DOI 10.1136/gut.2010.209551; Kodack DP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal4682; Lee JH, 2012, INT J CANCER, V131, P752, DOI 10.1002/ijc.26421; Lee MS, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-20; Linnerth-Petrik NM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094595; Liu WJ, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1629-z; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Memmott RM, 2010, CANCER PREV RES, V3, P1066, DOI 10.1158/1940-6207.CAPR-10-0055; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Muir AJ, 2015, CLIN THER, V37, P1822, DOI 10.1016/j.clinthera.2015.05.507; Murff HJ, 2018, CANCER CAUSE CONTROL, V29, P823, DOI 10.1007/s10552-018-1058-4; Nkontchou G, 2011, J CLIN ENDOCR METAB, V96, P2601, DOI 10.1210/jc.2010-2415; Nordenstedt H, 2010, DIGEST LIVER DIS, V42, pS206, DOI 10.1016/S1590-8658(10)60507-5; Qian WK, 2018, LIFE SCI, V208, P253, DOI 10.1016/j.lfs.2018.07.046; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Scaglione S, 2015, J CLIN GASTROENTEROL, V49, P690, DOI 10.1097/MCG.0000000000000208; Schulte L, 2019, LIVER INT, V39, P714, DOI 10.1111/liv.14048; Singh S, 2013, AM J GASTROENTEROL, V108, P881, DOI 10.1038/ajg.2013.5; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tandra S, 2011, J HEPATOL, V55, P654, DOI 10.1016/j.jhep.2010.11.021; Tennant DA, 2009, CARCINOGENESIS, V30, P1269, DOI 10.1093/carcin/bgp070; Tsuchida T, 2017, NAT REV GASTRO HEPAT, V14, P397, DOI 10.1038/nrgastro.2017.38; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wong FWY, 1998, TOXICOL APPL PHARM, V153, P109, DOI 10.1006/taap.1998.8547; Yang XL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0308-4; Yoon KH, 2006, LANCET, V368, P1681, DOI 10.1016/S0140-6736(06)69703-1	56	33	34	1	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2019	38	45					7035	7045		10.1038/s41388-019-0942-z	http://dx.doi.org/10.1038/s41388-019-0942-z			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JL9XI	31409896	Green Submitted			2022-12-17	WOS:000495878400001
J	Zhang, YJ; Yan, LB; Zeng, J; Zhou, H; Liu, HR; Yu, G; Yao, WM; Chen, K; Ye, ZQ; Xu, H				Zhang, Yangjun; Yan, Libin; Zeng, Jin; Zhou, Hui; Liu, Haoran; Yu, Gan; Yao, Weimin; Chen, Ke; Ye, Zhangqun; Xu, Hua			Pan-cancer analysis of clinical relevance of alternative splicing events in 31 human cancers	ONCOGENE			English	Article							MESSENGER-RNA DECAY; FUNCTIONAL CONSEQUENCES; PROSTATE-CANCER; GENE; PROTEIN; TRANSCRIPTOME; REGULATOR; IMPACT; EXONS; PBRM1	Alternative splicing represents a critical posttranscriptional regulation of gene expression, which contributes to the protein complexity and mRNA processing. Defects of alternative splicing including genetic alteration and/or altered expression of both pre-mRNA and trans-acting factors give rise to many cancers. By integrally analyzing clinical data and splicing data from TCGA and SpliceSeq databases, a number of splicing events were found clinically relevant in tumor samples. Alternative splicing of KLK2 (KLK2_51239) was found as a potential inducement of nonsense-mediated mRNA decay and associated with poor survival in prostate cancer. Consensus K-means clustering analysis indicated that alternative splicing events could be potentially used for molecular subtype classification of cancers. By random forest survival algorithm, prognostic prediction signatures with well performances were constructed for 31 cancers by using survival-associated alternative splicing events. Furthermore, an online tool for visualization of Kaplan-Meier plots of splicing events in 31 cancers was explored. Briefly, alternative splicing was found of significant clinical relevance with cancers.	[Zhang, Yangjun; Yan, Libin; Zeng, Jin; Zhou, Hui; Liu, Haoran; Yu, Gan; Yao, Weimin; Chen, Ke; Ye, Zhangqun; Xu, Hua] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Urol, Wuhan 430030, Hubei, Peoples R China; [Zhang, Yangjun; Yan, Libin; Zeng, Jin; Zhou, Hui; Liu, Haoran; Yu, Gan; Yao, Weimin; Chen, Ke; Ye, Zhangqun; Xu, Hua] Inst Urol Hubei Prov, Wuhan 430030, Hubei, Peoples R China	Huazhong University of Science & Technology	Xu, H (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Urol, Wuhan 430030, Hubei, Peoples R China.; Xu, H (corresponding author), Inst Urol Hubei Prov, Wuhan 430030, Hubei, Peoples R China.	xuhuawhu@163.com	Zhou, Hui/AAV-2680-2020		National Natural Science Foundation of China [81702522, 81602236]; National Major Scientific and Technological Special Project for Significant New Drugs Development [2017ZX09304022]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Major Scientific and Technological Special Project for Significant New Drugs Development	The authors would like to thank Xudong Zhang of Genek Company for helpful advices of data processing. This work was funded by the National Natural Science Foundation of China (81702522, 81602236) and National Major Scientific and Technological Special Project for Significant New Drugs Development (2017ZX09304022).	Arzalluz-Luque A, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1496-z; Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2; Baralle FE, 2017, NAT REV MOL CELL BIO, V18, P437, DOI 10.1038/nrm.2017.27; Bates DO, 2017, PHARMACOL REV, V69, P63, DOI 10.1124/pr.115.011239; Bauman JA, 2010, NUCLEIC ACIDS RES, V38, P8348, DOI 10.1093/nar/gkq731; Blencowe BJ, 2017, TRENDS BIOCHEM SCI, V42, P407, DOI 10.1016/j.tibs.2017.04.001; Chang YF, 2007, ANNU REV BIOCHEM, V76, P51, DOI 10.1146/annurev.biochem.76.050106.093909; Chen FJ, 2018, CLIN CANCER RES, V24, P2182, DOI 10.1158/1078-0432.CCR-17-3378; Climente-Gonzalez H, 2017, CELL REP, V20, P2215, DOI 10.1016/j.celrep.2017.08.012; da Costa PJ, 2017, INT J BIOCHEM CELL B, V91, P168, DOI 10.1016/j.biocel.2017.07.013; Davuluri RV, 2008, TRENDS GENET, V24, P167, DOI 10.1016/j.tig.2008.01.008; Eilertsen IA, 2019, INT J CANCER, V144, P841, DOI 10.1002/ijc.31809; Fu XD, 2014, NAT REV GENET, V15, P689, DOI 10.1038/nrg3778; Gao WH, 2017, P NATL ACAD SCI USA, V114, P1027, DOI 10.1073/pnas.1619726114; Ge Y, 2014, BIOESSAYS, V36, P236, DOI 10.1002/bies.201300156; Gerstberger S, 2014, NAT REV GENET, V15, P829, DOI 10.1038/nrg3813; Green RE, 2003, BIOINFORMATICS, V19, pi118, DOI 10.1093/bioinformatics/btg1015; Guo ZQ, 2016, CANCER CELL, V30, P474, DOI 10.1016/j.ccell.2016.08.003; Han L, 2015, CANCER CELL, V28, DOI 10.1016/j.ccell.2015.08.013; Han T, 2017, SCIENCE, V356, DOI 10.1126/science.aal3755; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Hogner A, 2018, UROL ONCOL, V36, pe1, DOI DOI 10.1016/J.UR0L0NC.2017.10.027; Hong SK, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/526341; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jayasinghe RG, 2018, CELL REP, V23, P270, DOI 10.1016/j.celrep.2018.03.052; Kahles A, 2018, CANCER CELL, V34, P211, DOI 10.1016/j.ccell.2018.07.001; Kahles A, 2016, BIOINFORMATICS, V32, P1840, DOI 10.1093/bioinformatics/btw076; Karpinski P, 2017, EPIGENOMICS-UK, V9, P1341, DOI 10.2217/epi-2017-0070; Kelemen O, 2013, GENE, V514, P1, DOI 10.1016/j.gene.2012.07.083; Kim JY, 2015, J UROLOGY, V194, DOI 10.1016/j.juro.2015.04.114; Ladomery MR, 2007, CANCER LETT, V249, P133, DOI 10.1016/j.canlet.2006.08.015; Li H, 2018, MODERN PATHOL, V31, P198, DOI 10.1038/modpathol.2017.74; Li Y, 2017, CANCER LETT, V393, P40, DOI 10.1016/j.canlet.2017.02.016; Lindeboom RGH, 2016, NAT GENET, V48, P1112, DOI 10.1038/ng.3664; Lu JW, 2016, J CLIN INVEST, V126, P3058, DOI 10.1172/JCI86508; Miller MB, 2017, J NEUROCHEM, V140, P889, DOI 10.1111/jnc.13749; Nam RK, 2006, CLIN CANCER RES, V12, P6452, DOI 10.1158/1078-0432.CCR-06-1485; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Popp MWL, 2013, ANNU REV GENET, V47, P139, DOI 10.1146/annurev-genet-111212-133424; Prinos P, 2011, NAT STRUCT MOL BIOL, V18, P673, DOI 10.1038/nsmb.2040; Ryan MC, 2012, BIOINFORMATICS, V28, P2385, DOI 10.1093/bioinformatics/bts452; Schafer Sebastian, 2015, Curr Protoc Hum Genet, V87, DOI 10.1002/0471142905.hg1116s87; Sebestyen E, 2016, GENOME RES, V26, P732, DOI 10.1101/gr.199935.115; Shum EY, 2016, CELL, V165, P382, DOI 10.1016/j.cell.2016.02.046; Stros M, 2007, CELL MOL LIFE SCI, V64, P2590, DOI 10.1007/s00018-007-7162-3; Tabrez SS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00370-5; Taliaferro JM, 2016, MOL CELL, V61, P821, DOI 10.1016/j.molcel.2016.01.020; Tian JB, 2019, NUCLEIC ACIDS RES, V47, pD909, DOI 10.1093/nar/gky954; Tien JF, 2017, NUCLEIC ACIDS RES, V45, P6698, DOI 10.1093/nar/gkx187; Tilgner H, 2018, GENOME RES, V28, P231, DOI 10.1101/gr.230516.117; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Traunmuller L, 2016, SCIENCE, V352, P982, DOI 10.1126/science.aaf2397; Ushijima T, 2017, CELL, V171, P1316, DOI 10.1016/j.cell.2017.10.018; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Vuong CK, 2016, NAT REV NEUROSCI, V17, P265, DOI 10.1038/nrn.2016.27; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wollerton MC, 2004, MOL CELL, V13, P91, DOI 10.1016/S1097-2765(03)00502-1; Yan QH, 2015, P NATL ACAD SCI USA, V112, P3445, DOI 10.1073/pnas.1502849112; Ylitalo EB, 2017, EUR UROL, V72, pE147, DOI 10.1016/j.eururo.2017.07.043; Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.1523/JNEUROSCI.1860-14.2014, 10.11772/j.issn.1001-9081.2014.07.1929]	60	33	34	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2019	38	40					6678	6695		10.1038/s41388-019-0910-7	http://dx.doi.org/10.1038/s41388-019-0910-7			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC0EY	31391553				2022-12-17	WOS:000488953500003
J	Totsch, SK; Schlappi, C; Kang, KD; Ishizuka, AS; Lynn, GM; Fox, B; Beierle, EA; Whitley, RJ; Markert, JM; Gillespie, GY; Bernstock, JD; Friedman, GK				Totsch, Stacie K.; Schlappi, Charles; Kang, Kyung-Don; Ishizuka, Andrew S.; Lynn, Geoffrey M.; Fox, Brandon; Beierle, Elizabeth A.; Whitley, Richard J.; Markert, James M.; Gillespie, G. Yancey; Bernstock, Joshua D.; Friedman, Gregory K.			Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance	ONCOGENE			English	Review							INTRATUMORAL INJECTION; VIRAL REPLICATION; MALIGNANT GLIOMA; EXPRESSING IL-12; CANCER VACCINES; CLINICAL-TRIAL; ENTER CELLS; GLIOBLASTOMA; HSV-1; G207	Malignant tumors of the central nervous system (CNS) continue to be a leading cause of cancer-related mortality in both children and adults. Traditional therapies for malignant brain tumors consist of surgical resection and adjuvant chemoradiation; such approaches are often associated with extreme morbidity. Accordingly, novel, targeted therapeutics for neoplasms of the CNS, such as immunotherapy with oncolytic engineered herpes simplex virus (HSV) therapy, are urgently warranted. Herein, we discuss treatment challenges related to HSV virotherapy delivery, entry, replication, and spread, and in so doing focus on host anti-viral immune responses and the immune microenvironment. Strategies to overcome such challenges including viral re-engineering, modulation of the immunoregulatory microenvironment and combinatorial therapies with virotherapy, such as checkpoint inhibitors, radiation, and vaccination, are also examined in detail.	[Totsch, Stacie K.; Schlappi, Charles; Kang, Kyung-Don; Friedman, Gregory K.] Univ Alabama Birmingham, Dept Pediat, Div Pediat Hematol & Oncol, Birmingham, AL 35294 USA; [Ishizuka, Andrew S.; Lynn, Geoffrey M.; Bernstock, Joshua D.] Avidea Technol Inc, Baltimore, MD 21205 USA; [Fox, Brandon; Bernstock, Joshua D.] Univ Alabama Birmingham, Med Scientist Training Program, Birmingham, AL 35294 USA; [Beierle, Elizabeth A.; Friedman, Gregory K.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; [Whitley, Richard J.] Univ Alabama Birmingham, Div Pediat Infect Dis, Dept Pediat, Birmingham, AL USA; [Markert, James M.; Gillespie, G. Yancey; Friedman, Gregory K.] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA; [Bernstock, Joshua D.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Friedman, GK (corresponding author), Univ Alabama Birmingham, Dept Pediat, Div Pediat Hematol & Oncol, Birmingham, AL 35294 USA.; Bernstock, JD (corresponding author), Avidea Technol Inc, Baltimore, MD 21205 USA.; Bernstock, JD (corresponding author), Univ Alabama Birmingham, Med Scientist Training Program, Birmingham, AL 35294 USA.; Friedman, GK (corresponding author), Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA.; Friedman, GK (corresponding author), Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA.; Bernstock, JD (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.	jdb82@uab.edu; gfriedman@peds.uab.edu		Ishizuka, Andrew/0000-0002-3024-7536; Friedman, Gregory/0000-0002-6653-7420; Gillespie, George/0000-0001-6436-9542; Bernstock, Joshua/0000-0002-7814-3867; Fox, Brandon/0000-0003-2242-2477	Food and Drug Administration Office of Orphan Products Development [R01FD005379]; Department of Defense [W81XWH-15-1-0108]; Rally Foundation for Childhood Cancer Research; Hyundai Hope on Wheels; Kaul Pediatric Research Institute; UAB Medical Scientist Training Program (MSTP); American Brain Tumor Association; National Cancer Institute of the National Institutes of Health [T32CA183926];  [R01CA217179]; FOOD AND DRUG ADMINISTRATION [R01FD005379] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA183926, R01CA217179] Funding Source: NIH RePORTER	Food and Drug Administration Office of Orphan Products Development; Department of Defense(United States Department of Defense); Rally Foundation for Childhood Cancer Research; Hyundai Hope on Wheels; Kaul Pediatric Research Institute; UAB Medical Scientist Training Program (MSTP); American Brain Tumor Association; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; FOOD AND DRUG ADMINISTRATION(United States Department of Health & Human Services); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported in part by grants from the Food and Drug Administration Office of Orphan Products Development (R01FD005379), the Department of Defense (W81XWH-15-1-0108) Rally Foundation for Childhood Cancer Research, Hyundai Hope on Wheels, and the Kaul Pediatric Research Institute to GKF and R01CA217179 to JMM and GYG. JDB was supported by the UAB Medical Scientist Training Program (MSTP) and an American Brain Tumor Association summer fellowship. SKT was supported by the National Cancer Institute of the National Institutes of Health under Award Number T32CA183926. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the U.S. FDA or the Department of Defense. The authors apologize to colleagues we couldn't cite given limitations on the number of references.	Aghi MK, 2009, MOL THER, V17, P51, DOI 10.1038/mt.2008.232; Aldape K, 2019, NAT REV CLIN ONCOL, V16, P509, DOI 10.1038/s41571-019-0177-5; Alvarez-Breckenridge CA, 2012, NAT MED, V18, P1827, DOI 10.1038/nm.3013; Alvarez-Breckenridge CA, 2012, J VIROL, V86, P4566, DOI 10.1128/JVI.05545-11; Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; Banchereau J, 2018, NAT REV CLIN ONCOL, V15, P9, DOI 10.1038/nrclinonc.2017.149; Bernstock JD, 2019, WORLD NEUROSURG, V122, pE1592, DOI 10.1016/j.wneu.2018.11.122; Bookstaver ML, 2018, TRENDS IMMUNOL, V39, P135, DOI 10.1016/j.it.2017.10.002; Bradley JD, 1999, CLIN CANCER RES, V5, P1517; Brencicova E, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00037; Cassady KA, 2005, J VIROL, V79, P8707, DOI 10.1128/JVI.79.14.8707-8715.2005; Cheema TA, 2013, P NATL ACAD SCI USA, V110, P12006, DOI 10.1073/pnas.1307935110; Chesney J, 2018, J CLIN ONCOL, V36, P1658, DOI 10.1200/JCO.2017.73.7379; Currier MA, 2013, MOL THER, V21, P1014, DOI 10.1038/mt.2013.39; Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405; Dmitrieva N, 2011, CLIN CANCER RES, V17, P1362, DOI 10.1158/1078-0432.CCR-10-2213; Draper SJ, 2010, NAT REV MICROBIOL, V8, P62, DOI 10.1038/nrmicro2240; Evans SM, 2004, CLIN CANCER RES, V10, P8177, DOI 10.1158/1078-0432.CCR-04-1081; Facciabene A, 2012, CANCER RES, V72, P2162, DOI 10.1158/0008-5472.CAN-11-3687; Filley AC, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00106; Flingai S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00354; Foreman PM, 2017, NEUROTHERAPEUTICS, V14, P333, DOI 10.1007/s13311-017-0516-0; Friedman GK, 2015, GENE THER, V22, P348, DOI 10.1038/gt.2014.107; Friedman GK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32353-x; Friedman GK, 2012, TRANSL ONCOL, V5, P200, DOI 10.1593/tlo.12115; Friedman GK, 2009, MOL THER, V17, P1125, DOI 10.1038/mt.2009.73; Fukuhara H, 2016, CANCER SCI, V107, P1373, DOI 10.1111/cas.13027; Fulci G, 2007, CANCER RES, V67, P9398, DOI 10.1158/0008-5472.CAN-07-1063; Fulci G, 2006, P NATL ACAD SCI USA, V103, P12873, DOI 10.1073/pnas.0605496103; Ghonime MG, 2018, TRANSL ONCOL, V11, P86, DOI 10.1016/j.tranon.2017.10.005; Guo CQ, 2013, ADV CANCER RES, V119, P421, DOI 10.1016/B978-0-12-407190-2.00007-1; Han JF, 2015, CANCER RES, V75, P5273, DOI 10.1158/0008-5472.CAN-15-0894; Hardcastle J, 2010, MOL THER, V18, P285, DOI 10.1038/mt.2009.232; Harrow S, 2004, GENE THER, V11, P1648, DOI 10.1038/sj.gt.3302289; Herrera FG, 2017, CA-CANCER J CLIN, V67, P65, DOI 10.3322/caac.21358; Jackson JD, 2014, GENE THER, V21, P984, DOI 10.1038/gt.2014.72; Kambara H, 2005, CANCER RES, V65, P2832, DOI 10.1158/0008-5472.CAN-04-3227; Kamiyama H, 2006, GENE THER, V13, P621, DOI 10.1038/sj.gt.3302685; Kanai R, 2006, GENE THER, V13, P106, DOI 10.1038/sj.gt.3302636; Kaur B, 2009, CURR GENE THER, V9, P341, DOI 10.2174/156652309789753329; Kesari S, 1998, J GEN VIROL, V79, P525, DOI 10.1099/0022-1317-79-3-525; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; Krull KR, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2017.76.4696; Laquerre S, 1998, J VIROL, V72, P9683, DOI 10.1128/JVI.72.12.9683-9697.1998; Leddon JL, 2015, MOL THER-ONCOLYTICS, V2, DOI 10.1038/mto.2014.10; Leoni V, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007209; Liu R, 2005, GENE THER, V12, P647, DOI 10.1038/sj.gt.3302445; Liu ZQ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14754; Longo SL, 2011, CANCER GENE THER, V18, P123, DOI 10.1038/cgt.2010.62; Lynn GM, 2015, NAT BIOTECHNOL, V33, P1201, DOI 10.1038/nbt.3371; Markert JM, 2014, MOL THER, V22, P1048, DOI 10.1038/mt.2014.22; Markert JM, 2012, J VIROL, V86, P5304, DOI 10.1128/JVI.06998-11; Markert JM, 2009, MOL THER, V17, P199, DOI 10.1038/mt.2008.228; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; Maroun J, 2017, FUTURE VIROL, V12, P193, DOI 10.2217/fvl-2016-0129; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; Menotti L, 2008, J VIROL, V82, P10153, DOI 10.1128/JVI.01133-08; Miest TS, 2014, NAT REV MICROBIOL, V12, P23, DOI 10.1038/nrmicro3140; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Mitchell BM, 1996, J IMMUNOL, V156, P246; MITTNACHT S, 1988, VIROLOGY, V164, P201, DOI 10.1016/0042-6822(88)90637-X; Nakashima H, 2018, CLIN CANCER RES, V24, P2574, DOI 10.1158/1078-0432.CCR-17-2954; Nakashima H, 2015, J CLIN INVEST, V125, P4269, DOI 10.1172/JCI80713; Okemoto K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071932; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223; Papanastassiou V, 2002, GENE THER, V9, P398, DOI 10.1038/sj.gt.3301664; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Parker JN, 2000, P NATL ACAD SCI USA, V97, P2208, DOI 10.1073/pnas.040557897; Passaro C, 2019, CLIN CANCER RES, V25, P290, DOI 10.1158/1078-0432.CCR-18-2311; Patel DM, 2016, HUM GENE THER CL DEV, V27, P69, DOI 10.1089/humc.2016.031; POND SM, 1984, CLIN PHARMACOKINET, V9, P1, DOI 10.2165/00003088-198409010-00001; Pulluri B, 2017, PHARMACOL RES, V123, P95, DOI 10.1016/j.phrs.2017.07.006; Rampling R, 2000, GENE THER, V7, P859, DOI 10.1038/sj.gt.3301184; Rasmussen SB, 2007, J VIROL, V81, P13315, DOI 10.1128/JVI.01167-07; Ricklefs FL, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar2766; Ring EK, 2017, MOL THER-ONCOLYTICS, V7, P27, DOI 10.1016/j.omto.2017.09.003; Ring EK, 2017, CLIN CANCER RES, V23, P342, DOI 10.1158/1078-0432.CCR-16-1829; Roizman B, 1996, P NATL ACAD SCI USA, V93, P11307, DOI 10.1073/pnas.93.21.11307; Saha D, 2018, CLIN CANCER RES, V24, P3409, DOI 10.1158/1078-0432.CCR-17-1717; Saha D, 2017, CANCER CELL, V32, P253, DOI 10.1016/j.ccell.2017.07.006; Sarkaria JN, 2018, NEURO-ONCOLOGY, V20, P184, DOI 10.1093/neuonc/nox175; Shah AC, 2003, J NEURO-ONCOL, V65, P203, DOI 10.1023/B:NEON.0000003651.97832.6c; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Spear PG, 2004, CELL MICROBIOL, V6, P401, DOI 10.1111/j.1462-5822.2004.00389.x; Streby KA, 2017, CLIN CANCER RES, V23, P3566, DOI 10.1158/1078-0432.CCR-16-2900; Stronen E, 2016, SCIENCE, V352, P1337, DOI 10.1126/science.aaf2288; Sundaresan P, 2000, J VIROL, V74, P3832, DOI 10.1128/JVI.74.8.3832-3841.2000; Suschak JJ, 2017, HUM VACC IMMUNOTHER, V13, P2837, DOI 10.1080/21645515.2017.1330236; Tanaka T, 1997, NAT MED, V3, P437, DOI 10.1038/nm0497-437; Thorne AH, 2014, MOL THER, V22, P1678, DOI 10.1038/mt.2014.101; Trybala E, 2000, J VIROL, V74, P9106, DOI 10.1128/JVI.74.19.9106-9114.2000; Uchida H, 2013, MOL THER, V21, P561, DOI 10.1038/mt.2012.211; Wakimoto H, 2009, CANCER RES, V69, P3472, DOI 10.1158/0008-5472.CAN-08-3886; Wang PY, 2016, GENE THER, V23, P135, DOI 10.1038/gt.2015.105; Waters AM, 2017, HUM GENE THER CL DEV, V28, P7, DOI 10.1089/humc.2017.002; Yarchoan M, 2017, NAT REV CANCER, V17, DOI 10.1038/nrc.2017.74; Zhai LJ, 2018, CELL MOL IMMUNOL, V15, P447, DOI 10.1038/cmi.2017.143; Zhou GY, 2006, P NATL ACAD SCI USA, V103, P5508, DOI 10.1073/pnas.0601258103; Zhou GY, 2003, J VIROL, V77, P3759, DOI 10.1128/JVI.77.6.3759-3767.2003; Zhu H, 2007, CANCER BIOL THER, V6, P724, DOI 10.4161/cbt.6.5.3953	100	33	35	0	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2019	38	34					6159	6171		10.1038/s41388-019-0870-y	http://dx.doi.org/10.1038/s41388-019-0870-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IS5RM	31289361	Green Accepted			2022-12-17	WOS:000482210100001
J	Cao, TF; Jiang, Y; Wang, ZS; Zhang, N; Al-Hendy, A; Mamillapalli, R; Kallen, AN; Kodaman, P; Taylor, HS; Li, D; Huang, YQ				Cao, Tiefeng; Jiang, Ying; Wang, Zhangsheng; Zhang, Na; Al-Hendy, Ayman; Mamillapalli, Ramanaiah; Kallen, Amanda N.; Kodaman, Pinar; Taylor, Hugh S.; Li, Da; Huang, Yingqun			H19 lncRNA identified as a master regulator of genes that drive uterine leiomyomas	ONCOGENE			English	Article							EXTRACELLULAR-MATRIX; PULMONARY-FIBROSIS; GENOME-WIDE; TGF-BETA; GROWTH; LET-7; MED12; PROLIFERATION; EXPRESSION; PATHWAYS	Uterine leiomyomas or fibroids (UFs) are benign tumors characterized by hyperplastic smooth muscle cells and excessive deposition of extracellular matrix (ECM). Afflicting similar to 80% of women, and symptomatic in 25%, UFs bring tremendous suffering and are an economic burden worldwide; they cause severe pain and bleeding, and are the leading cause of hysterectomy. Yet, UFs are severely understudied with few effective treatment options available; those that are available frequently have significant side effects such as menopausal symptoms. Recently, integrated genome-scale studies have revealed mutations and fibroid subtype-specific expression changes in key driver genes, with MED12 and HMGA2 together contributing to nearly 90% of all UFs, but their regulation of expression is poorly characterized. Here we report that the expression of H19 long noncoding RNA (lncRNA) is aberrantly increased in UFs. Using cell culture and genome-wide transcriptome and methylation profiling analyses, we demonstrate that H19 promotes expression of MED12, HMGA2, and key ECM-remodeling genes via multiple mechanisms including a new class of epigenetic modification by TET3. Our results mark the first example of an evolutionarily conserved lncRNA in pathogenesis of UFs and regulation of TET expression. Given the link between a H19 single-nucleotide polymorphism (SNP) and increased risk and tumor size of UFs, and the existence of multiple fibroid subtypes driven by key pathway genes regulated by H19, we propose a unifying mechanism for pathogenesis of uterine fibroids mediated by H19 and identify a pathway for future exploration of novel target therapies for uterine leiomyomas.	[Cao, Tiefeng; Jiang, Ying; Wang, Zhangsheng; Mamillapalli, Ramanaiah; Kallen, Amanda N.; Kodaman, Pinar; Taylor, Hugh S.; Huang, Yingqun] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, 333 Cedar St, New Haven, CT 06510 USA; [Cao, Tiefeng] Sun Yat Sen Univ, Dept Gynecol & Obstet, Affiliated Hosp 1, Guangzhou 510070, Guangdong, Peoples R China; [Jiang, Ying] Zhejiang Univ, Dept Obstet, Womens Hosp, Sch Med, Hangzhou 310006, Zhejiang, Peoples R China; [Wang, Zhangsheng] Fudan Univ, Peoples Hosp Shanghai 5, Dept Cardiol, Shanghai 200240, Peoples R China; [Zhang, Na] Univ Connecticut, Dept Genet & Genome Sci, Hlth Ctr, Farmington, CT 06030 USA; [Al-Hendy, Ayman] Univ Illinois, Coll Med, Dept Obstet & Gynecol, Chicago, IL 60612 USA; [Li, Da] China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, Ctr Reprod Med, Shenyang 110004, Liaoning, Peoples R China	Yale University; Sun Yat Sen University; Zhejiang University; Fudan University; University of Connecticut; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; China Medical University	Huang, YQ (corresponding author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, 333 Cedar St, New Haven, CT 06510 USA.; Li, D (corresponding author), China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, Ctr Reprod Med, Shenyang 110004, Liaoning, Peoples R China.	leeda@ymail.com; Yingqun.huang@yale.edu			Albert Mckern Scholar Award; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD000849] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER	Albert Mckern Scholar Award; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This work was supported by an Albert Mckern Scholar Award to YH.	Aissani B, 2015, INT J MOL EPIDEMIOL, V6, P9; Aissani B, 2015, FERTIL STERIL, V103, P528, DOI 10.1016/j.fertnstert.2014.10.025; Al-Hendy A, 2017, ENDOCRINOLOGY, V158, P592, DOI 10.1210/en.2016-1097; An J, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.5; Bogusiewicz M, 2012, HISTOL HISTOPATHOL, V27, P1495, DOI 10.14670/HH-27.1495; Borahay MA, 2015, MOL MED, V21, P242, DOI 10.2119/molmed.2014.00053; Carney SA, 2002, LAB INVEST, V82, P719, DOI 10.1097/01.LAB.0000017499.51216.3E; Chegini N, 2010, SEMIN REPROD MED, V28, P179, DOI 10.1055/s-0030-1251476; Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296; Gabory A, 2010, BIOESSAYS, V32, P473, DOI 10.1002/bies.200900170; Ghazal S, 2015, EMBO MOL MED, V7, P996, DOI 10.15252/emmm.201505245; Ishikawa H, 2010, ENDOCRINOLOGY, V151, P2433, DOI 10.1210/en.2009-1225; Islam MS, 2018, HUM REPROD UPDATE, V24, P59, DOI 10.1093/humupd/dmx032; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Koh KP, 2011, CELL STEM CELL, V8, P200, DOI 10.1016/j.stem.2011.01.008; Laughlin SK, 2010, SEMIN REPROD MED, V28, P203, DOI 10.1055/s-0030-1251477; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Liu RJ, 2013, CIRCULATION, V128, P2047, DOI 10.1161/CIRCULATIONAHA.113.002887; Lu QC, 2018, INFLAMMATION, V41, P896, DOI 10.1007/s10753-018-0744-4; Makinen N, 2011, SCIENCE, V334, P252, DOI 10.1126/science.1208930; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Mehine M, 2016, P NATL ACAD SCI USA, V113, P1315, DOI 10.1073/pnas.1518752113; Mehine M, 2014, FERTIL STERIL, V102, P621, DOI 10.1016/j.fertnstert.2014.06.050; Meng XM, 2016, NAT REV NEPHROL, V12, P325, DOI 10.1038/nrneph.2016.48; Mittal P, 2015, J CLIN INVEST, V125, P3280, DOI 10.1172/JCI81534; Murphy-Ullrich JE, 2018, MATRIX BIOL, V68-69, P28, DOI 10.1016/j.matbio.2017.12.009; Navarro A, 2014, J CLIN ENDOCR METAB, V99, pE2437, DOI 10.1210/jc.2014-2264; Philibert RA, 1999, HUM GENET, V105, P174, DOI 10.1007/s004390051084; Song YF, 2017, HEPATOLOGY, V66, P1183, DOI 10.1002/hep.29209; Stenina-Adognravi O, 2014, MATRIX BIOL, V37, P69, DOI 10.1016/j.matbio.2014.02.001; Stewart EA, 2015, NEW ENGL J MED, V372, P1646, DOI [10.1056/NEJMcp1411029, 10.1038/nrdp.2016.43]; Styer AK, 2016, BEST PRACT RES CL OB, V34, P3, DOI 10.1016/j.bpobgyn.2015.11.018; Wong SLI, 2017, BRIT J PHARMACOL, V174, P3, DOI 10.1111/bph.13653; Xie H, 2016, ONCOTARGET, V7, P51473, DOI 10.18632/oncotarget.10444; Yamashita S, 2008, CANCER RES, V68, P2112, DOI 10.1158/0008-5472.CAN-07-5282; Yan L, 2015, ONCOGENE, V34, P3076, DOI 10.1038/onc.2014.236; Zhong T, 2017, ONCOGENE, V36, P2345, DOI 10.1038/onc.2016.391; Zhou JC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10221; Zuckerwise L, 2016, ONCOTARGET, V7, P38398, DOI 10.18632/oncotarget.9534	39	33	37	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5356	5366		10.1038/s41388-019-0808-4	http://dx.doi.org/10.1038/s41388-019-0808-4			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	31089260	hybrid, Green Published			2022-12-17	WOS:000473842500002
J	Wei, T; Weiler, SME; Toth, M; Sticht, C; Lutz, T; Thomann, S; De La Torre, C; Straub, B; Merker, S; Ruppert, T; Marquardt, J; Singer, S; Gretz, N; Schirmacher, P; Breuhahn, K				Wei, Teng; Weiler, Sofia Maria Elisabeth; Toth, Marcell; Sticht, Carsten; Lutz, Teresa; Thomann, Stefan; De La Torre, Carolina; Straub, Beate; Merker, Sabine; Ruppert, Thomas; Marquardt, Jens; Singer, Stephan; Gretz, Norbert; Schirmacher, Peter; Breuhahn, Kai			YAP-dependent induction of UHMK1 supports nuclear enrichment of the oncogene MYBL2 and proliferation in liver cancer cells	ONCOGENE			English	Article							YES-ASSOCIATED PROTEIN; ORGAN SIZE CONTROL; HIPPO PATHWAY; EXPRESSION; KINASE; GENE; KIS; HOMEOSTASIS; INSTABILITY; ACTIVATION	The oncogene yes-associated protein (YAP) is a key modifier of liver homeostasis and regulates mitosis in hepatocytes as well as in malignantly transformed cells. However, the question of how YAP supports cell proliferation in hepatocellular carcinoma (HCC) is not well understood. Here we identified U2AF momology motif kinase 1 (UHMK1) as a direct transcriptional target of YAP and the transcription factor forkhead box M1 (FOXM1), which supports HCC cell proliferation but not migration. Indeed, UHMK1 stimulates the expression of genes that are specific for cell cycle regulation and which are known downstream effectors of YAP. By using BioID labeling and mass spectrometry, the dimerization partner, RB-like, E2F and multi-vulval class B (DREAM) complex constituent MYB proto-oncogene like 2 (MYBL2, B-MYB) was identified as a direct UHMK1 interaction partner. Like YAP, UHMK1 stimulates nuclear enrichment of MYBL2, which is associated HCC cell proliferation and the expression of the cell cycle regulators CCNB1, CCNB2, KIF20A, and MAD2L1. The association between YAP, UHMK1, MYBL2, and proliferation was confirmed in YAP(s127A)-transgenic mice and human HCC tissues. In summary, we provide a model by which YAP supports cell proliferation through the induction of important cell cycle regulators in a UHMK1- and MYBL2-dependent manner.	[Wei, Teng; Weiler, Sofia Maria Elisabeth; Toth, Marcell; Lutz, Teresa; Thomann, Stefan; Schirmacher, Peter; Breuhahn, Kai] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany; [Sticht, Carsten; De La Torre, Carolina; Gretz, Norbert] Heidelberg Univ, Med Fac Mannheim, Med Res Ctr, Mannheim, Germany; [Straub, Beate] Johannes Gutenberg Univ Mainz, Inst Pathol, Mainz, Germany; [Merker, Sabine; Ruppert, Thomas] Univ Heidelberg ZMBH, DKFZ ZMBH Alliance, Zentrum Mol Biol, Heidelberg, Germany; [Marquardt, Jens] Johannes Gutenberg Univ Mainz, Dept Med 1, Mainz, Germany; [Singer, Stephan] Univ Med Greifswald, Inst Pathol, Greifswald, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Johannes Gutenberg University of Mainz; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Johannes Gutenberg University of Mainz; Greifswald Medical School	Breuhahn, K (corresponding author), Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany.	kai.breuhahn@med.uni-heidelberg.de	Ruppert, Thomas/AAC-2467-2021	Ruppert, Thomas/0000-0001-9152-2266; wei, teng/0000-0001-7560-2848; Thomann, Stefan/0000-0002-3500-0014	German Cancer Aid (Deutsche Krebshilfe) [DKH 111524]; China Scholarship Council/CSC; German Research Foundation [MA 4443/2-2]; Volkswagen Foundation (Lichtenberg program);  [SFB/TR 209];  [SPP1782/2]	German Cancer Aid (Deutsche Krebshilfe)(Deutsche Krebshilfe); China Scholarship Council/CSC(China Scholarship Council); German Research Foundation(German Research Foundation (DFG)); Volkswagen Foundation (Lichtenberg program); ; 	We thank M. Bissinger and J. Schmitt for excellent technical assistance, Dr. A. Ori for providing us with the BirA vector, as well as T. R. Brummelkamp and F. D. Camargo for providing Col1A1-YAPS127A transgenic mice. Tissue samples were provided by the tissue bank of the National Center of Tumor Diseases (Heidelberg, Germany) in accordance with the regulations of the tissue bank and the approval of the Ethics Committee of Heidelberg University. We also thank the Center of Model System and Comparative Pathology (CMCP; Dr. F. Lasitschka, Dr. T. Poth) and H. Conrad for their support. This study was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe/Dr. Mildred Scheel Stiftung, to K.B., DKH 111524), the SFB/TR 209 "Liver Cancer" (to K.B., S.S., and P.S.), the priority program SPP1782/2 (to K. B.), and the China Scholarship Council/CSC (to T.W.). J.U.M. is supported by grants from the German Research Foundation (MA 4443/2-2) and the Volkswagen Foundation (Lichtenberg program).	Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Benhamouche S, 2010, GENE DEV, V24, P1718, DOI 10.1101/gad.1938710; Bieche I, 2003, MOL BRAIN RES, V114, P55, DOI 10.1016/S0169-328X(03)00132-3; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Calvisi DF, 2011, HEPATOLOGY, V53, P1226, DOI 10.1002/hep.24174; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Eisinger-Mathason TSK, 2015, P NATL ACAD SCI USA, V112, pE3402, DOI 10.1073/pnas.1420005112; Guan Z, 2018, CURR RES TRANSL MED, V66, P27, DOI 10.1016/j.retram.2017.11.002; Guiley KZ, 2015, GENE DEV, V29, P961, DOI 10.1101/gad.257568.114; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Langenickel TH, 2008, J CLIN INVEST, V118, P3848, DOI 10.1172/JCI33206; Manceau V, 2006, FEBS J, V273, P577, DOI 10.1111/j.1742-4658.2005.05091.x; Manceau V, 2008, J MOL BIOL, V381, P748, DOI 10.1016/j.jmb.2008.06.026; Manceau V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043946; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; Panciera T, 2017, NAT REV MOL CELL BIO, V18, P758, DOI 10.1038/nrm.2017.87; Petrovic V, 2008, J BIOL CHEM, V283, P453, DOI 10.1074/jbc.M705792200; Qiao YT, 2017, CELL REP, V19, P1495, DOI 10.1016/j.celrep.2017.04.075; Roux KJ, 2012, J CELL BIOL, V196, P801, DOI 10.1083/jcb.201112098; Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556; Schopp IM, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15690; Song H, 2010, P NATL ACAD SCI USA, V107, P1431, DOI 10.1073/pnas.0911409107; Tschaharganeh DF, 2013, GASTROENTEROLOGY, V144, P1530, DOI 10.1053/j.gastro.2013.02.009; Weiler SME, 2017, GASTROENTEROLOGY, V152, P2037, DOI 10.1053/j.gastro.2017.02.018; Xu MZ, 2011, ONCOGENE, V30, P1229, DOI 10.1038/onc.2010.504; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408	29	33	35	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5541	5550		10.1038/s41388-019-0801-y	http://dx.doi.org/10.1038/s41388-019-0801-y			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30936457				2022-12-17	WOS:000473842500015
J	Pidugu, VK; Wu, MM; Yen, AH; Pidugu, HB; Chang, KW; Liu, CJ; Lee, TC				Pidugu, Vijaya Kumar; Wu, Meei-Maan; Yen, Ai-Hsin; Pidugu, Hima Bindu; Chang, Kuo-Wei; Liu, Chung-Ji; Lee, Te-Chang			IFIT1 and IFIT3 promote oral squamous cell carcinoma metastasis and contribute to the anti-tumor effect of gefitinib via enhancing p-EGFR recycling	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; LYMPH-NODE METASTASIS; INTERFERON-INDUCED PROTEIN; IFN-INDUCED PROTEIN; REPEATS 3 IFIT3; NECK-CANCER; PROGNOSTIC MARKER; ANNEXIN A2; HEAD; INVASION	IFIT1 and IFIT3 are abundant products of interferon-stimulating genes. While the importance of IFIT1 and IFIT3 in the prognosis of cancer has been reported, the molecular basis of IFIT1 and IFIT3 in cancer progression remains unexplored. In the present study, we investigated the modes of action and the clinical significance of IFIT1 and IFIT3 in oral squamous cell carcinoma (OSCC). Ectopic expression of IFIT1 or IFIT3 induced OSCC cell invasion by promoting the epithelial-mesenchymal transition, whereas IFIT1 or IFIT3 knockdown exhibited opposite effects. Overexpression of IFIT1 or IFIT3 promoted tumor growth, regional and distant metastasis in xenograft and orthotopic nude mice models. Most importantly, IFIT1 or IFIT3 overexpression increased the levels of p-EGFR(Y1068) and p-AKT(S473) in OSCC cells and also enhanced tumor inhibitory effect of gefitinib. By immunoprecipitation and LC-MS/MS analysis, we found that IFIT1 and IFIT3 interacted with ANXA2 that enhanced p-EGFR(Y1068) endosomal recycling. Depletion of ANXA2 using siRNA therefore abolished p-EGFR(Y1068) and p-AKT(S473) expression in IFIT1- or IFIT3-overexpressed cells. Furthermore, a significant positive association of increased IFIT1 and IFIT3 expression with advanced T-stage, lymph node metastasis, perineural invasion, lymphovascular invasion, extranodal extension, and poor overall survival rate was confirmed in OSCC patients. We also found a statistically positive correlation of p-EGFR(Y1068) expression with IFIT1 and IFIT3 in OSCC tumors and poor clinical outcome in patients. Collectively, we demonstrated a novel role of IFIT1 and IFIT3 in driving OSCC progression and metastasis by interacting with ANXA2 and hence enhancing p-EGFR recycling and its downstream signaling.	[Pidugu, Vijaya Kumar; Lee, Te-Chang] Natl Yang Ming Univ, Taiwan Int Grad Program Mol Med, Taipei, Taiwan; [Pidugu, Vijaya Kumar; Lee, Te-Chang] Acad Sinica, Taipei, Taiwan; [Pidugu, Vijaya Kumar; Yen, Ai-Hsin; Pidugu, Hima Bindu; Lee, Te-Chang] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; [Wu, Meei-Maan] Taipei Med Univ, Sch Med, Dept Publ Hlth, Coll Med, Taipei 11031, Taiwan; [Chang, Kuo-Wei] Natl Yang Ming Univ, Sch Dent, Dept Dent, Taipei 11221, Taiwan; [Liu, Chung-Ji] Mackay Mem Hosp, Dept Oral & Maxillofacial Surg, Taipei 10449, Taiwan; [Lee, Te-Chang] Natl Yang Ming Univ, Sch Med, Inst Pharmacol, Taipei 11221, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Academia Sinica - Taiwan; Taipei Medical University; National Yang Ming Chiao Tung University; Mackay Memorial Hospital; National Yang Ming Chiao Tung University	Lee, TC (corresponding author), Natl Yang Ming Univ, Taiwan Int Grad Program Mol Med, Taipei, Taiwan.; Lee, TC (corresponding author), Acad Sinica, Taipei, Taiwan.; Lee, TC (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan.; Liu, CJ (corresponding author), Mackay Mem Hosp, Dept Oral & Maxillofacial Surg, Taipei 10449, Taiwan.; Lee, TC (corresponding author), Natl Yang Ming Univ, Sch Med, Inst Pharmacol, Taipei 11221, Taiwan.	cjliu@ms2.mmh.org.tw; bmtcl@ibms.sinica.edu.tw	Pidugu, Vijaya Kumar/B-2798-2012; Yen, Ai-Hsin/AAS-8409-2021; Lee, TC/B-3245-2011	Pidugu, Vijaya Kumar/0000-0001-5435-0100; Lee, TC/0000-0003-4448-1507; Yen, Ai-Hsin/0000-0001-9469-360X	Ministry of Science and Technology [NSC 101-2321-B-001-044, NSC 102-2321-B-001-032, MOST 103-2321-B-001-019, MOST 104-2320-B-001-008]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea)	This work was supported by grants from the Ministry of Science and Technology (NSC 101-2321-B-001-044, NSC 102-2321-B-001-032, MOST 103-2321-B-001-019, and MOST 104-2320-B-001-008), Taiwan (T.C. Lee).	Bagan J, 2010, ORAL ONCOL, V46, P414, DOI 10.1016/j.oraloncology.2010.03.009; Bharadwaj A, 2013, INT J MOL SCI, V14, P6259, DOI 10.3390/ijms14036259; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.3.CO;2-E; Borden EC, 2007, NAT REV DRUG DISCOV, V6, P975, DOI 10.1038/nrd2422; Bossi P, 2016, ONCOTARGET, V7, P74362, DOI 10.18632/oncotarget.11413; Bruzzese F, 2006, CLIN CANCER RES, V12, P617, DOI 10.1158/1078-0432.CCR-05-1671; Chen IH, 2003, BRIT J CANCER, V89, P681, DOI 10.1038/sj.bjc.6601171; Cheon H, 2014, SEMIN ONCOL, V41, P156, DOI 10.1053/j.seminoncol.2014.02.002; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007; Danish HH, 2013, BREAST J, V19, P231, DOI 10.1111/tbj.12097; de Graauw M, 2014, ONCOGENE, V33, P2610, DOI 10.1038/onc.2013.219; Diamond MS, 2014, CYTOKINE GROWTH F R, V25, P543, DOI 10.1016/j.cytogfr.2014.05.002; Fang YT, 2012, J CELL PHYSIOL, V227, P2775, DOI 10.1002/jcp.23026; Fensterl V, 2015, J VIROL, V89, P2462, DOI 10.1128/JVI.02744-14; Fensterl V, 2011, J INTERF CYTOK RES, V31, P71, DOI 10.1089/jir.2010.0101; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Futter CE, 2007, TRAFFIC, V8, P951, DOI 10.1111/j.1600-0854.2007.00590.x; Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661; Grandal MV, 2008, J CELL MOL MED, V12, P1527, DOI 10.1111/j.1582-4934.2008.00298.x; Grewal T, 2009, CELL SIGNAL, V21, P847, DOI 10.1016/j.cellsig.2009.01.031; Hayes MJ, 2006, EMBO J, V25, P1816, DOI 10.1038/sj.emboj.7601078; Hong KO, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-28; Huang SF, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3586-9; Jimenez L, 2015, ARCH PATHOL LAB MED, V139, P1334, DOI 10.5858/arpa.2014-0498-RA; Kapoor C, 2015, INDIAN J CANCER, V52, P417, DOI 10.4103/0019-509X.176750; Kirby AM, 2006, BRIT J CANCER, V94, P631, DOI 10.1038/sj.bjc.6602999; Krisanaprakornkit Suttichai, 2012, ISRN Oncol, V2012, P681469, DOI 10.5402/2012/681469; Lai KC, 2013, ONCOGENE, V32, P3686, DOI 10.1038/onc.2012.384; Lai KC, 2008, MOL CANCER RES, V6, P1431, DOI 10.1158/1541-7786.MCR-08-0141; Lang JY, 2014, FUTURE ONCOL, V10, P1635, DOI [10.2217/FON.14.44, 10.2217/fon.14.44]; Lorusso A, 2006, EMBO J, V25, P5443, DOI 10.1038/sj.emboj.7601419; Matsushita Y, 2015, INT J ORAL MAX SURG, V44, P543, DOI 10.1016/j.ijom.2015.01.018; Mehra R, 2011, DRUG RESIST UPDATE, V14, P260, DOI 10.1016/j.drup.2011.08.002; Moon C, 2010, EXP BIOL MED, V235, P907, DOI 10.1258/ebm.2009.009181; Moreira J, 2017, DRUGS, V77, P843, DOI 10.1007/s40265-017-0734-0; Morel E, 2009, J BIOL CHEM, V284, P1604, DOI 10.1074/jbc.M806499200; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Murphy JE, 2009, P NATL ACAD SCI USA, V106, P17615, DOI 10.1073/pnas.0906541106; Niess H, 2015, ONCOTARGET, V6, P3306, DOI 10.18632/oncotarget.2494; Ono M, 2006, CLIN CANCER RES, V12, P7242, DOI 10.1158/1078-0432.CCR-06-0646; Parker BS, 2016, NAT REV CANCER, V16, P131, DOI 10.1038/nrc.2016.14; Perea S, 2004, J CLIN ONCOL, V22, p196S; Ribeiro FAP, 2014, ANTICANCER RES, V34, P1547; Rao SVK, 2013, ASIAN PAC J CANCER P, V14, P5567, DOI 10.7314/APJCP.2013.14.10.5567; Rivera C, 2014, ONCOL LETT, V8, P7, DOI 10.3892/ol.2014.2103; Schmid SL, 2017, J CELL BIOL, V216, P2623, DOI 10.1083/jcb.201705017; Shetty PK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044299; Shield KD, 2017, CA-CANCER J CLIN, V67, P51, DOI 10.3322/caac.21384; Shingaki S, 2003, AM J SURG, V185, P278, DOI 10.1016/S0002-9610(02)01378-8; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Staquicini DI, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03470-w; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Vermorken JB, 2007, J CLIN ONCOL, V25, P2171, DOI 10.1200/JCO.2006.06.7447; Yang JL, 2007, BJU INT, V99, P1539, DOI 10.1111/j.1464-410X.2007.06778.x; Yang JL, 2005, CANCER LETT, V225, P61, DOI 10.1016/j.canlet.2004.11.041; Yang YY, 2017, HEPATOLOGY, V66, P152, DOI 10.1002/hep.29156; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yoon H, 2015, J HISTOCHEM CYTOCHEM, V63, P114, DOI 10.1369/0022155414561498; Zhang JF, 2016, HUM PATHOL, V52, P136, DOI 10.1016/j.humpath.2016.01.013; Zhao Y, 2017, J CANCER RES CLIN, V143, P1061, DOI 10.1007/s00432-017-2351-4; Zhou XF, 2006, NEOPLASIA, V8, P925, DOI 10.1593/neo.06430; Zuo JH, 2011, J CELL BIOCHEM, V112, P2508, DOI 10.1002/jcb.23175; [No title captured], DOI DOI 10.1016/J.JFMA.2015.10.011	64	33	34	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3232	3247		10.1038/s41388-018-0662-9	http://dx.doi.org/10.1038/s41388-018-0662-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30626937				2022-12-17	WOS:000465557200009
J	Cortes, E; Lachowski, D; Rice, A; Thorpe, SD; Robinson, B; Yeldag, G; Lee, DA; Ghemtio, L; Rombouts, K; Hernandez, AED				Cortes, Ernesto; Lachowski, Dariusz; Rice, Alistair; Thorpe, Stephen D.; Robinson, Benjamin; Yeldag, Gulcen; Lee, David A.; Ghemtio, Leo; Rombouts, Krista; Hernandez, Armando E. del Rio			Tamoxifen mechanically deactivates hepatic stellate cells via the G protein-coupled estrogen receptor	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTORS; HEPATOCELLULAR-CARCINOMA; EXTRACELLULAR-MATRIX; ACTIVATION; STIFFNESS; MECHANOTRANSDUCTION; EXPRESSION; PRESTRESS; RISK; GPER	Tamoxifen has been used for many years to target estrogen receptor signalling in breast cancer cells. Tamoxifen is also an agonist of the G protein-coupled estrogen receptor (GPER), a GPCR ubiquitously expressed in tissues that mediates the acute response to estrogens. Here we report that tamoxifen promotes mechanical quiescence in hepatic stellate cells (HSCs), stromal fibroblast-like cells whose activation triggers and perpetuates liver fibrosis in hepatocellular carcinomas. This mechanical deactivation is mediated by the GPER/RhoA/myosin axis and induces YAP deactivation. We report that tamoxifen decreases the levels of hypoxia-inducible factor-1 alpha (HIF-1 alpha) and the synthesis of extracellular matrix proteins through a mechanical mechanism that involves actomyosin-dependent contractility and mechanosensing of tissue stiffness. Our results implicate GPER-mediated estrogen signalling in the mechanosensory-driven activation of HSCs and put forward estrogenic signalling as an option for mechanical reprogramming of myofibroblast-like cells in the tumour microenvironment. Tamoxifen, with half a century of safe clinical use, might lead this strategy of drug repositioning.	[Cortes, Ernesto; Lachowski, Dariusz; Rice, Alistair; Robinson, Benjamin; Yeldag, Gulcen; Hernandez, Armando E. del Rio] Imperial Coll London, Dept Bioengn, Cellular & Mol Biomech Lab, London SW7 2AZ, England; [Thorpe, Stephen D.; Lee, David A.] Queen Mary Univ London, Sch Engn & Mat Sci, Inst Bioengn, London E1 4NS, England; [Ghemtio, Leo] Univ Helsinki, Fac Pharm, Div Pharmaceut Biosci, Drug Res Program, FI-00014 Helsinki, Finland; [Rombouts, Krista] UCL, Royal Free Hosp, Inst Liver & Digest Hlth, Regenerat Med & Fibrosis Grp, London, England	Imperial College London; University of London; Queen Mary University London; University of Helsinki; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Hernandez, AED (corresponding author), Imperial Coll London, Dept Bioengn, Cellular & Mol Biomech Lab, London SW7 2AZ, England.	a.del-rio-hernandez@imperial.ac.uk	Rombouts, Krista/ABB-2602-2020; del Río Hernández, Armando E/D-3555-2012; Thorpe, Stephen/C-1656-2018; Cortes Lopez, Ernesto/ABE-5343-2021; del rio hernandez, armando e/N-4262-2013; Rombouts, Krista/AAE-8179-2020	del Río Hernández, Armando E/0000-0001-5062-8910; Thorpe, Stephen/0000-0002-4707-7756; Cortes Lopez, Ernesto/0000-0001-6106-1323; del rio hernandez, armando e/0000-0001-5062-8910; Rombouts, Krista/0000-0001-9440-0571; ghemtio, leo/0000-0003-3591-5676; Lachowski, Dariusz/0000-0003-1194-8019; Lee, David/0000-0001-7646-4643	European Research Council (ERC) [282051]; Drug Discovery and Chemical Biology - Biocenter Finland; BBSRC [BB/N018532/1] Funding Source: UKRI	European Research Council (ERC)(European Research Council (ERC)); Drug Discovery and Chemical Biology - Biocenter Finland; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by the European Research Council (ERC grant 282051). LG gratefully acknowledges the support of The Drug Discovery and Chemical Biology - Biocenter Finland.	Balogh J, 2016, J HEPATOCELL CARCINO, V3, P41, DOI 10.2147/JHC.S61146; Bologa CG, 2006, NAT CHEM BIOL, V2, P207, DOI 10.1038/nchembio775; Calvo F, 2013, NAT CELL BIOL, V15, P637, DOI 10.1038/ncb2756; Cano A, 2012, FUTURE ONCOL, V8, P1095, DOI [10.2217/FON.12.105, 10.2217/fon.12.105]; Carloni V, 2014, LIVER INT, V34, P834, DOI 10.1111/liv.12465; Chakrabarti S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052357; Chen C, 2017, ONCOTARGET, V8, P46691, DOI 10.18632/oncotarget.17358; Chen SY, 2016, J CELL BIOCHEM, V117, P267, DOI 10.1002/jcb.25283; Chronopoulos A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12630; Copple BL, 2011, LIVER INT, V31, P230, DOI 10.1111/j.1478-3231.2010.02347.x; Cortes E, 2019, HEPATOLOGY, V69, P785, DOI 10.1002/hep.30193; Coulouarn C, 2012, CANCER RES, V72, P2533, DOI 10.1158/0008-5472.CAN-11-3317; Cui XD, 2014, MOL MED REP, V9, P1641, DOI 10.3892/mmr.2014.2036; Cuzick J, 2004, JNCI-J NATL CANCER I, V96, P621, DOI 10.1093/jnci/djh106; Cuzick J, 2015, LANCET ONCOL, V16, P67, DOI 10.1016/S1470-2045(14)71171-4; Dennis MK, 2009, NAT CHEM BIOL, V5, P421, DOI 10.1038/nchembio.168; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gastro.2004.09.014; Feng S, 2017, ARTERIOSCL THROM VAS, V37, P2087, DOI 10.1161/ATVBAHA.117.309249; Guilluy C, 2011, NAT CELL BIOL, V13, P722, DOI 10.1038/ncb2254; Haining AWM, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005599; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Howell A, 2000, CANCER-AM CANCER SOC, V89, P817, DOI 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6; Humphrey JD, 2014, NAT REV MOL CELL BIO, V15, P802, DOI 10.1038/nrm3896; Ju C, 2016, J MOL MED, V94, P613, DOI 10.1007/s00109-016-1408-1; Kelloff G J, 1994, J Cell Biochem Suppl, V20, P252; Kim CH, 2002, CIRC RES, V90, pE25, DOI 10.1161/hh0202.104923; Krishnamachary B, 2003, CANCER RES, V63, P1138; Kuznetsova TG, 2007, MICRON, V38, P824, DOI 10.1016/j.micron.2007.06.011; Lachowski D, 2018, FASEB J, V32, P1099, DOI 10.1096/fj.201700721R; Lachowski D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02689-x; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Mandlekar S, 2000, CANCER RES, V60, P6601; Moreira RK, 2007, ARCH PATHOL LAB MED, V131, P1728; Mueller S, 2010, HEPATIC MED-EVID RES, V2, P49; Nathan L, 2001, P NATL ACAD SCI USA, V98, P3589, DOI 10.1073/pnas.051003698; Prossnitz ER, 2011, NAT REV ENDOCRINOL, V7, P715, DOI 10.1038/nrendo.2011.122; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Rice AJ, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.54; Robinson BK, 2016, BIOL OPEN, V5, P875, DOI 10.1242/bio.017632; Rodriguez-Hernandez Irene, 2016, F1000Res, V5, DOI 10.12688/f1000research.7909.1; Sakurai T, 2013, LIVER CANCER, V2, P365, DOI 10.1159/000343851; Sarper M, 2016, SCI REP-UK, V6, DOI 10.1038/srep27639; Shi L, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-93; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Soon RK, 2008, CLIN LIVER DIS, V12, P791, DOI 10.1016/j.cld.2008.07.004; Stamenovic D, 2005, ACTA BIOMATER, V1, P255, DOI 10.1016/j.actbio.2005.01.004; Wang N, 2002, AM J PHYSIOL-CELL PH, V282, pC606, DOI 10.1152/ajpcell.00269.2001; Wells RG, 2005, J CLIN GASTROENTEROL, V39, pS158, DOI 10.1097/01.mcg.0000155516.02468.0f; Wilson GK, 2014, J HEPATOL, V61, P1397, DOI 10.1016/j.jhep.2014.08.025; Yin CY, 2013, J CLIN INVEST, V123, P1902, DOI 10.1172/JCI66369; Zimmerman MA, 2016, CLIN SCI, V130, P1005, DOI 10.1042/CS20160114	54	33	34	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					2910	2922		10.1038/s41388-018-0631-3	http://dx.doi.org/10.1038/s41388-018-0631-3			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30575816	Green Published, Green Submitted, hybrid			2022-12-17	WOS:000465167600003
J	Zepecki, JP; Snyder, KM; Moreno, MM; Fajardo, E; Fiser, A; Ness, J; Sarkar, A; Toms, SA; Tapinos, N				Zepecki, J. P.; Snyder, K. M.; Moreno, M. M.; Fajardo, E.; Fiser, A.; Ness, J.; Sarkar, A.; Toms, S. A.; Tapinos, N.			Regulation of human glioma cell migration, tumor growth, and stemness gene expression using a Lck targeted inhibitor	ONCOGENE			English	Article							SCHWANN-CELLS; KINASE LCK; INVASION; NEURONS; HETEROGENEITY; MYELINATION; ACTIVATION; PHENOTYPE	Migration of human glioma cells (hGCs) within the brain parenchyma makes glioblastoma one of the most aggressive and lethal tumors. Studies of the cellular and molecular mechanisms underlying hGC migration are hindered by the limitations of existing glioma models. Here we developed a dorsal root ganglion axon-oligodendrocyte-hGC co-culture to study in real time the migration and interaction of hGCs with their microenvironment. hGCs interact with myelinated and non-myelinated axons through the formation of pseudopodia. Isolation of pseudopodia-localized polysome-bound RNA reveals transcripts of Lck, Paxillin, Crk-II, and Rac I that undergo local translation. Inhibition of Lck phosphorylation using a small-molecule inhibitor (Lck-I), blocks the phosphorylation of Paxillin and Crk-II, the formation of pseudopodia and the migration of hGCs. In vivo intraventricular administration of the Lck-I using an orthotopic xenograft glioma model, results in statistically significant inhibition of tumor size and significant down-regulation of Nanog-targeted genes, which are associated with glioblastoma patient survival. Moreover, treatment of human glioma stem cells (hGSCs) with Lck-I, results in significant inhibition of self-renewal and tumor-sphere formation. The involvement of Lck in different levels of glioma malignant progression, such as migration, tumor growth, and regulation of cancer stemness, makes Lck a potentially important therapeutic target for human glioblastomas.	[Zepecki, J. P.; Moreno, M. M.; Toms, S. A.; Tapinos, N.] Brown Univ, Mol Neurosci & Neurooncol Lab, Providence, RI 02912 USA; [Snyder, K. M.] Univ Minnesota, Coll Vet Med, St Paul, MN 55108 USA; [Fajardo, E.; Fiser, A.] Albert Einstein Coll Med, Dept Syst & Computat Biol, Bronx, NY 10467 USA; [Ness, J.] Messiah Coll, Dept Biol Sci, Mechanicsburg, PA USA; [Sarkar, A.] Geisinger Med Clin, Dept Neurosurg, Danville, PA USA; [Toms, S. A.; Tapinos, N.] Brown Univ, Rhode Isl Hosp, Dept Neurosurg, Providence, RI 02903 USA	Brown University; University of Minnesota System; University of Minnesota Twin Cities; Yeshiva University; Albert Einstein College of Medicine; Geisinger Medical Center; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Tapinos, N (corresponding author), Brown Univ, Mol Neurosci & Neurooncol Lab, Providence, RI 02912 USA.; Tapinos, N (corresponding author), Brown Univ, Rhode Isl Hosp, Dept Neurosurg, Providence, RI 02903 USA.	nikos_tapinos@brown.edu		Zepecki, John P/0000-0003-4127-4668; Toms, Steven/0000-0001-8732-0522; Snyder, Kristin M./0000-0002-6598-1837	Molecular Pathology Core of the COBRE Center for Cancer Research Development - National Institute of General Medical Sciences of the National Institutes of Health [P30GM110759]; Geisinger Clinic; Department of Neurosurgery of Brown University; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI141816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM110759] Funding Source: NIH RePORTER	Molecular Pathology Core of the COBRE Center for Cancer Research Development - National Institute of General Medical Sciences of the National Institutes of Health; Geisinger Clinic; Department of Neurosurgery of Brown University; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank members of the Tapinos lab for critically reviewing the manuscript. We would like to thank Kara Lombardo and Ashlee Sturtevant at the Pathology Core of Rhode Island Hospital for the assistance with glioblastoma tissue sections and stainings. We also thank Oliver Tang for analysis of the TCGA dataset. All animal work was performed according to institutional guidelines and approved by the IACUC committee of Rhode Island Hospital and Geisinger Clinic. Work included in this publication was supported by the Molecular Pathology Core of the COBRE Center for Cancer Research Development, funded by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number P30GM110759. This research project was also supported by institutional funds of the Geisinger Clinic to N.T., S.A.T., and A.S. and by institutional funds of the Department of Neurosurgery of Brown University to N.T. and S.A.T.	Adilakshmi T, 2011, J NEUROSCI, V31, P5106, DOI 10.1523/JNEUROSCI.5635-10.2011; Aubert M, 2008, J R SOC INTERFACE, V5, P75, DOI 10.1098/rsif.2007.1070; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Bedard PL, 2013, NATURE, V501, P355, DOI 10.1038/nature12627; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; CAMPENOT RB, 1982, DEV BIOL, V93, P1, DOI 10.1016/0012-1606(82)90232-9; Chambers I, 2007, NATURE, V450, P1230, DOI 10.1038/nature06403; Chan JR, 2004, NEURON, V43, P183, DOI 10.1016/j.neuron.2004.06.024; de la Iglesia N, 2009, CURR MOL MED, V9, P580; de la Roche M, 2013, SCIENCE, V342, P1247, DOI 10.1126/science.1244689; Deakin NO, 2008, J CELL SCI, V121, P2435, DOI 10.1242/jcs.018044; Demuth T, 2004, J NEURO-ONCOL, V70, P217, DOI 10.1007/s11060-004-2751-6; Diemert S, 2012, J NEUROSCI METH, V203, P69, DOI 10.1016/j.jneumeth.2011.09.012; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gandin V, 2014, JOVE-J VIS EXP, DOI 10.3791/51455; Giese A, 1996, NEUROSURGERY, V38, P755, DOI 10.1227/00006123-199604000-00026; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Joy AM, 2003, J CELL SCI, V116, P4409, DOI 10.1242/jcs.00712; Jung H, 2014, CELL, V157, P26, DOI 10.1016/j.cell.2014.03.005; Kaur H, 2012, MOL CANCER RES, V10, P293, DOI 10.1158/1541-7786.MCR-11-0457; Kim RK, 2010, BIOCHEM BIOPH RES CO, V402, P631, DOI 10.1016/j.bbrc.2010.10.072; Koul D, 2005, MOL CANCER THER, V4, P1681, DOI 10.1158/1535-7163.MCT-05-0258; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Merzak A, 1997, CANCER METAST REV, V16, P155, DOI 10.1023/A:1005760726850; Mili S, 2008, NATURE, V453, P115, DOI 10.1038/nature06888; Ness JK, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2928; Park JB, 2014, ONCOTARGET, V5, P9382, DOI 10.18632/oncotarget.2412; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Pinto JP, 2015, NUCLEIC ACIDS RES, V43, pW72, DOI 10.1093/nar/gkv529; Rao SS, 2013, BIOMATERIALS, V34, P5181, DOI 10.1016/j.biomaterials.2013.03.069; Reyes SB, 2013, MOL BIOL CELL, V24, P474, DOI 10.1091/mbc.E12-07-0521; REYNOLDS PJ, 1992, ONCOGENE, V7, P1949; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Ruffini F, 2004, AM J PATHOL, V165, P2167, DOI 10.1016/S0002-9440(10)63266-X; Singh SK, 2003, CANCER RES, V63, P5821; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Soni Priyanka, 2017, Asian Pac J Cancer Prev, V18, P2215; Stachlewitz RF, 2005, J PHARMACOL EXP THER, V315, P36, DOI 10.1124/jpet.105.089169; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2015, JAMA-J AM MED ASSOC, V314, P2535, DOI 10.1001/jama.2015.16669; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang Y., 2007, SCI STKE, V2007, P14; Wick W, 2001, J NEUROSCI, V21, P3360, DOI 10.1523/JNEUROSCI.21-10-03360.2001; WINDEBANK AJ, 1985, J NEUROSCI, V5, P1563; WOOD PM, 1976, BRAIN RES, V115, P361, DOI 10.1016/0006-8993(76)90355-3; Wu KY, 2005, NATURE, V436, P1020, DOI 10.1038/nature03885; Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137	56	33	34	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1734	1750		10.1038/s41388-018-0546-z	http://dx.doi.org/10.1038/s41388-018-0546-z			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30353164	Green Published, hybrid			2022-12-17	WOS:000460423800012
J	Zhang, JL; Zhou, YH; Huang, TT; Wu, F; Pan, Y; Dong, YJ; Wang, Y; Chan, AKY; Liu, LP; Kwan, JSH; Cheung, AHK; Wong, CC; Lo, AKF; Cheng, ASL; Yu, J; Lo, KW; Kang, W; To, KF				Zhang, Jinglin; Zhou, Yuhang; Huang, Tingting; Wu, Feng; Pan, Yi; Dong, Yujuan; Wang, Yan; Chan, Aden K. Y.; Liu, Liping; Kwan, Johnny S. H.; Cheung, Alvin H. K.; Wong, Chi Chun; Lo, Angela K. F.; Cheng, Alfred S. L.; Yu, Jun; Lo, Kwok Wai; Kang, Wei; To, Ka Fai			FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p	ONCOGENE			English	Article							MICRORNA TARGET PREDICTION; GENE AMPLIFICATION; CANCER; GROWTH; EXPRESSION; INVASION; INHIBITOR; MIGRATION; MIRDB; CELLS	Fibroblast growth factors (FGFs) and their receptors are significant components during fundamental cellular processes. FGF18 plays a distinctive role in modulating the activity of both tumor cells and tumor microenvironment. This study aims to comprehensively investigate the expression and functional role of FGF18 in gastric cancer (GC) and elucidate its regulatory mechanisms. The upregulation of FGF18 was detected in seven out of eleven (63.6%) GC cell lines. In primary GC samples, FGF18 was overexpressed in genomically stable and chromosomal instability subtypes of GC and its overexpression was associated with poor survival. Knocking down FGF18 inhibited tumor formation abilities, induced G1 phase cell cycle arrest and enhanced anti-cancer drug sensitivity. Expression microarray profiling revealed that silencing of FGF18 activated ATM pathway but quenched TGF-beta pathway. The key factors that altered in the related signaling were validated by western blot and immunofluorescence. Meanwhile, treating GC cells with human recombinant FGF18 or FGF18-conditioned medium accelerated tumor growth through activation of ERK-MAPK signaling. FGF18 was further confirmed to be a direct target of tumor suppressor, miR-590-5p. Their expressions showed a negative correlation in primary GC samples and more importantly, re-overexpression of FGF18 partly abolished the tumor-suppressive effect of miR-590-5p. Our study not only identified that FGF18 serves as a novel prognostic marker and a therapeutic target in GC but also enriched the knowledge of FGF-FGFR signaling during gastric tumorigenesis.	[Zhang, Jinglin; Zhou, Yuhang; Huang, Tingting; Wu, Feng; Pan, Yi; Chan, Aden K. Y.; Kwan, Johnny S. H.; Cheung, Alvin H. K.; Lo, Angela K. F.; Lo, Kwok Wai; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Oncol South China, Hong Kong, Peoples R China; [Zhang, Jinglin; Zhou, Yuhang; Huang, Tingting; Wu, Feng; Pan, Yi; Dong, Yujuan; Wong, Chi Chun; Yu, Jun; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Inst Digest Dis, Partner State Key Lab Digest Dis, Hong Kong, Peoples R China; [Zhang, Jinglin; Zhou, Yuhang; Huang, Tingting; Wu, Feng; Pan, Yi; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Sir YK Pao Canc Ctr, Hong Kong, Peoples R China; [Huang, Tingting; Cheng, Alfred S. L.; Yu, Jun; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China; [Wang, Yan] Shanxi Med Univ, Key Lab Cardiovasc Med & Clin Pharmacol Shanxi Pr, Taiyuan, Shanxi, Peoples R China; [Liu, Liping] Jinan Univ, Shenzhen Peoples Hosp, Dept Hepatobiliary & Pancreat Surg, Second Clin Med Coll, Shenzhen, Guangdong, Peoples R China; [Cheng, Alfred S. L.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China; [Yu, Jun] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; State Key Lab Oncology South China; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong, Shenzhen; Shanxi Medical University; Jinan University; Chinese University of Hong Kong; Chinese University of Hong Kong	Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Oncol South China, Hong Kong, Peoples R China.; Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Partner State Key Lab Digest Dis, Hong Kong, Peoples R China.; Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Sir YK Pao Canc Ctr, Hong Kong, Peoples R China.; Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China.	weikang@cuhk.edu.hk; kfto@cuhk.edu.hk	Dong, Yujuan/AAS-3467-2021; Cheng, Alfred SL/C-3327-2014; KANG, Wei/C-5451-2016; Yu, Jun/D-8569-2015; Wong, Chi Chun/C-4636-2016	Cheng, Alfred SL/0000-0003-2345-6951; KANG, Wei/0000-0002-4651-677X; Yu, Jun/0000-0001-5008-2153; PAN, YI/0000-0001-9734-6398; Lo, Kwok Wai/0000-0002-3488-6124	General Research Fund (RGC) from The Research Grants Council of Hong Kong [CUHK14110016]; CUHK Direct Grant for Research [2017.001]	General Research Fund (RGC) from The Research Grants Council of Hong Kong; CUHK Direct Grant for Research	We acknowledge the TCGA Research Network (http://cancergenome.nih.gov/) for providing the gastric cancer dataset and analysis. This study is supported by General Research Fund (RGC Reference No. CUHK14110016) from The Research Grants Council of Hong Kong and CUHK Direct Grant for Research (2017.001). We also acknowledge the technical support from Core Utilities of Cancer Genomics and Pathobiology of Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong.	Ahn S, 2016, MODERN PATHOL, V29, P1095, DOI 10.1038/modpathol.2016.96; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792; Belov AA, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a015958; Chen G, 2014, INT J CLIN EXP MED, V7, P5947; Chu YX, 2014, J CELL BIOCHEM, V115, P847, DOI 10.1002/jcb.24726; Davidson D, 2005, J BIOL CHEM, V280, P20509, DOI 10.1074/jbc.M410148200; Gauglhofer C, 2011, HEPATOLOGY, V53, P854, DOI 10.1002/hep.24099; Gotoh N, 2008, CANCER SCI, V99, P1319, DOI 10.1111/j.1349-7006.2008.00840.x; Huang TT, 2018, ONCOGENE, V37, P1159, DOI 10.1038/s41388-017-0029-7; Huang TT, 2017, INT J ONCOL, V50, P1501, DOI 10.3892/ijo.2017.3927; Huang TT, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0493-7; Ishiguro H, 2014, WORLD J GASTROENTERO, V20, P5694, DOI 10.3748/wjg.v20.i19.5694; Itoh N, 2011, J BIOCHEM, V149, P121, DOI 10.1093/jb/mvq121; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kang W, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0134-0; Kang W, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0323-3; Katoh Y, 2006, INT J MOL MED, V17, P529; Katz LH, 2013, EXPERT OPIN THER TAR, V17, P743, DOI 10.1517/14728222.2013.782287; Liu YH, 2017, BIOMED PHARMACOTHER, V86, P466, DOI 10.1016/j.biopha.2016.12.003; Maehara O, 2017, CARCINOGENESIS, V38, P1073, DOI 10.1093/carcin/bgx095; Marechal Alexandre, 2013, Cold Spring Harb Perspect Biol, V5, DOI 10.1101/cshperspect.a012716; Marek L, 2009, MOL PHARMACOL, V75, P196, DOI 10.1124/mol.108.049544; Matsumoto K, 2012, BRIT J CANCER, V106, P727, DOI 10.1038/bjc.2011.603; McLean MIH, 2014, NAT REV GASTRO HEPAT, V11, P664, DOI 10.1038/nrgastro.2014.143; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702; Ou CL, 2017, CANCER LETT, V399, P53, DOI 10.1016/j.canlet.2017.04.011; Shimokawa T, 2003, CANCER RES, V63, P6116; Shoji H, 2015, ANTICANCER RES, V35, P5055; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun C, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1353-3; TAKAHASHI JA, 1992, J NEUROSURG, V76, P792, DOI 10.3171/jns.1992.76.5.0792; Touat M, 2015, CLIN CANCER RES, V21, P2684, DOI 10.1158/1078-0432.CCR-14-2329; Wang FF, 2016, MOL CELL BIOCHEM, V423, P29, DOI 10.1007/s11010-016-2822-y; Wang QX, 2015, CELL PHYSIOL BIOCHEM, V35, P933, DOI 10.1159/000369750; Wang XW, 2008, RNA, V14, P1012, DOI 10.1261/rna.965408; Wei W, 2013, J CLIN INVEST, V123, P4435, DOI 10.1172/JCI70625; Wiedemann M, 2000, GENOMICS, V69, P275, DOI 10.1006/geno.2000.6332; Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104; Xie L, 2013, CLIN CANCER RES, V19, P2572, DOI 10.1158/1078-0432.CCR-12-3898; Zhang JL, 2018, MOL CARCINOGEN, V57, P1144, DOI 10.1002/mc.22831; Zhou L, 2017, EUR REV MED PHARMACO, V21, P87; Zhou QX, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.306; Zhou Y, 2017, ONCOGENE, V36, P6518, DOI 10.1038/onc.2017.257; Zhou YH, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0647-2	46	33	35	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					33	46		10.1038/s41388-018-0430-x	http://dx.doi.org/10.1038/s41388-018-0430-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30082912	hybrid, Green Published			2022-12-17	WOS:000454775900003
J	Xu, ZY; Wang, YL; Xiao, ZG; Zou, C; Zhang, X; Wang, Z; Wu, DL; Yu, S; Chan, FL				Xu, Zhenyu; Wang, Yuliang; Xiao, Zhan Gang; Zou, Chang; Zhang, Xian; Wang, Zhu; Wu, Dinglan; Yu, Shan; Chan, Franky Leung			Nuclear receptor ERRa and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ANDROGEN RECEPTOR; MOLECULAR CHARACTERIZATION; INCREASED EXPRESSION; PSA RECURRENCE; CELL-LINE; ALPHA; REARRANGEMENT; ASSOCIATION; HIF-1-ALPHA	The TMPRSS2:ERG (T:E) fusion gene is generally believed to be mainly regulated by the activated androgen receptor (AR) signaling in androgen-dependent prostate cancer. However, its persistent expression in castration-resistant and neuroendocrine prostate cancers implies that other transcription factors might also regulate its expression. Here, we showed that up-regulation of nuclear receptor estrogen-related receptor alpha (ERR alpha) was closely associated with the oncogenic transcription factor ERG expression in prostate cancer, and their increased coexpression patterns were closely associated with high Gleason scores and metastasis in patients. Both ERRa and ERG exhibited a positive expression correlation in a castration-resistant prostate cancer (CRPC) xenograft model VCaP-CRPC. We showed that ERR alpha could directly transactivate T:E fusion gene in both AR-positive and -negative prostate cancer cells via both ERR-binding element- and AR-binding element-dependent manners. Ectopic T:E expression under ERRa regulation could promote both in vitro invasion and in vivo metastasis capacities of AR-negative prostatic cells. Intriguingly, ERG expressed by the T:E fusion could also transactivate the ERR alpha (ESRRA) gene. Hereby, ERR alpha and ERG can synergistically regulate each other and form a reciprocal regulatory loop to promote the advanced growth of prostate cancer. Inhibition of ERR alpha activity by ERR alpha inverse agonist could suppress T:E expression in prostate cancer cells, implicating that targeting ERR alpha could be a potential therapeutic strategy for treating the aggressive T:E-positive prostate cancer.	[Xu, Zhenyu; Zhang, Xian] Wannan Med Coll, Yijishan Affiliated Hosp, Dept Pharm, Wuhu, Anhui, Peoples R China; [Xu, Zhenyu; Wang, Yuliang; Xiao, Zhan Gang; Zou, Chang; Wang, Zhu; Wu, Dinglan; Yu, Shan; Chan, Franky Leung] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Xiao, Zhan Gang] Southwest Med Univ, Dept Pharmacol, Luzhou, Peoples R China; [Zou, Chang] Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Clin Med Res Ctr, Shenzhen, Peoples R China	Wannan Medical College; Chinese University of Hong Kong; Southwest Medical University; Jinan University	Yu, S; Chan, FL (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.	yushan771@hotmail.com; franky-chan@cuhk.edu.hk	Zou, Chang/AAS-3356-2021; Chan, Franky L./M-1043-2018	Zou, Chang/0000-0002-2003-7834; Chan, Franky L./0000-0003-0567-2052; Wu, Dinglan/0000-0002-5057-9626; Wang, Zhu/0000-0002-5457-3731	General Research Funds [14100914, 14107116]; Research Grants Council of Hong Kong; University Natural Science Research Project of Anhui Province [KJ2016A732]; National Natural Science Foundation of China [81602240, 81402370]	General Research Funds; Research Grants Council of Hong Kong(Hong Kong Research Grants Council); University Natural Science Research Project of Anhui Province(Natural Science Foundation of Anhui Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the General Research Funds (Project numbers 14100914 and 14107116), Research Grants Council of Hong Kong (to F.L.C.), University Natural Science Research Project of Anhui Province (KJ2016A732) (to Z.X.) and National Natural Science Foundation of China (81602240 to Z.X.; 81402370 to C.Z.).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Adamo P, 2016, ONCOGENE, V35, P403, DOI 10.1038/onc.2015.109; Attard G, 2008, ONCOGENE, V27, P253, DOI 10.1038/sj.onc.1210640; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Bismar TA, 2012, EUR J CANCER, V48, P538, DOI 10.1016/j.ejca.2012.01.001; Bonaccorsi L, 2009, J ENDOCRINOL INVEST, V32, P590, DOI 10.1007/BF03346514; Boormans JL, 2010, EUR UROL, V57, P830, DOI 10.1016/j.eururo.2009.08.013; Cai CM, 2009, CANCER RES, V69, P6027, DOI 10.1158/0008-5472.CAN-09-0395; Cai G, 2017, ONCOGENE, V36, P546, DOI 10.1038/onc.2016.227; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheung CP, 2005, J CLIN ENDOCR METAB, V90, P1830, DOI 10.1210/jc.2004-1421; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Chu JH, 2009, PROSTATE, V69, P428, DOI 10.1002/pros.20897; Clark J, 2007, ONCOGENE, V26, P2667, DOI 10.1038/sj.onc.1210070; Clark JP, 2009, NAT REV UROL, V6, P429, DOI 10.1038/nrurol.2009.127; Danila DC, 2011, EUR UROL, V60, P897, DOI 10.1016/j.eururo.2011.07.011; Demichelis F, 2007, ONCOGENE, V26, P4596, DOI 10.1038/sj.onc.1210237; Esgueva R, 2010, MODERN PATHOL, V23, P539, DOI 10.1038/modpathol.2009.193; Falzarano SM, 2010, MODERN PATHOL, V23, P1499, DOI 10.1038/modpathol.2010.150; Feng FY, 2014, CLIN CANCER RES, V20, P4442, DOI 10.1158/1078-0432.CCR-13-0275; Font-Tello A, 2015, PROSTATE, V75, P1216, DOI 10.1002/pros.23004; Fradet A, 2016, ONCOTARGET, V7, P77071, DOI 10.18632/oncotarget.12787; Fujimura T, 2007, INT J CANCER, V120, P2325, DOI 10.1002/ijc.22363; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giguere V, 2008, ENDOCR REV, V29, P677, DOI 10.1210/er.2008-0017; Hagglof C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086824; Hermans KG, 2006, CANCER RES, V66, P10658, DOI 10.1158/0008-5472.CAN-06-1871; Hoogland AM, 2012, MODERN PATHOL, V25, P471, DOI 10.1038/modpathol.2011.176; Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105; Lanvin O, 2007, J BIOL CHEM, V282, P28328, DOI 10.1074/jbc.M704295200; Leinonen KA, 2010, CLIN CANCER RES, V16, P2845, DOI 10.1158/1078-0432.CCR-09-2505; Mehra R, 2008, CANCER RES, V68, P3584, DOI 10.1158/0008-5472.CAN-07-6154; Mehra R, 2007, MODERN PATHOL, V20, P538, DOI 10.1038/modpathol.3800769; Mertz KD, 2007, NEOPLASIA, V9, P200, DOI 10.1593/neo.07103; Minner S, 2011, CLIN CANCER RES, V17, P5878, DOI 10.1158/1078-0432.CCR-11-1251; Mosquera JM, 2009, CLIN CANCER RES, V15, P4706, DOI 10.1158/1078-0432.CCR-08-2927; Nam RK, 2007, BRIT J CANCER, V97, P1690, DOI 10.1038/sj.bjc.6604054; Perner S, 2007, AM J SURG PATHOL, V31, P882, DOI 10.1097/01.pas.0000213424.38503.aa; Perner S, 2006, CANCER RES, V66, P8337, DOI 10.1158/0008-5472.CAN-06-1482; Polson ES, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2627; Rubin MA, 2012, ASIAN J ANDROL, V14, P393, DOI 10.1038/aja.2011.145; Scheble VJ, 2012, VIRCHOWS ARCH, V461, P157, DOI 10.1007/s00428-012-1270-7; Schelling LA, 2013, HUM PATHOL, V44, P2227, DOI 10.1016/j.humpath.2013.05.005; Setlur SR, 2008, JNCI-J NATL CANCER I, V100, P815, DOI 10.1093/jnci/djn150; Spencer ES, 2013, PROSTATE, V73, P905, DOI 10.1002/pros.22636; Teyssier C, 2008, NUCLEIC ACIDS RES, V36, P5350, DOI 10.1093/nar/gkn520; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Toubaji A, 2011, MODERN PATHOL, V24, P1511, DOI 10.1038/modpathol.2011.111; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang Z, 2018, ENDOCR-RELAT CANCER, V25, P35, DOI 10.1530/ERC-17-0280; Washington MN, 2010, ENDOCRINOLOGY, V151, P1409, DOI 10.1210/en.2009-0991; Wu DL, 2016, BBA-REV CANCER, V1866, P23, DOI 10.1016/j.bbcan.2016.06.001; Yu S, 2008, ONCOGENE, V27, P3313, DOI 10.1038/sj.onc.1210986; Yu S, 2014, J PATHOL, V234, P514, DOI 10.1002/path.4413; Yu S, 2013, CANCER LETT, V328, P83, DOI 10.1016/j.canlet.2012.09.006; Yu S, 2009, BIOCHEM BIOPH RES CO, V382, P756, DOI 10.1016/j.bbrc.2009.03.110; Zou C, 2014, J PATHOL, V233, P61, DOI 10.1002/path.4329	58	33	34	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2018	37	48					6259	6274		10.1038/s41388-018-0409-7	http://dx.doi.org/10.1038/s41388-018-0409-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC2HE	30042415	Green Published, hybrid			2022-12-17	WOS:000451622100005
J	Serrao, A; Jenkins, LM; Chumanevich, AA; Horst, B; Liang, JX; Gatza, ML; Lee, NY; Roninson, IB; Broude, EV; Mythreye, K				Serrao, Anne; Jenkins, Laura M.; Chumanevich, Alexander A.; Horst, Ben; Liang, Jiaxin; Gatza, Michael L.; Lee, Nam Y.; Roninson, Igor B.; Broude, Eugenia V.; Mythreye, Karthikeyan			Mediator kinase CDK8/CDK19 drives YAP1-dependent BMP4-induced EMT in cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL-TRANSITION; TGF-BETA RECEPTOR; BREAST-CANCER; COLORECTAL-CANCER; PANCREATIC-CANCER; CDK8; ACTIVATION; BMP; CELLS; EXPRESSION	CDK8 is a transcription-regulating kinase that controls TGF-beta/BMP-responsive SMAD transcriptional activation and turnover through YAP1 recruitment. However, how the CDK8/YAP1 pathway influences SMAD1 response in cancer remains unclear. Here we report that SMAD1-driven epithelial-to-mesenchymal transition (EMT) is critically dependent on matrix rigidity and YAP1 in a wide spectrum of cancer models. We find that both genetic and pharmacological inhibition of CDK8 and its homologous twin kinase CDK19 leads to abrogation of BMP-induced EMT. Notably, selectively blocking CDK8/19 specifically abrogates tumor cell invasion, changes in EMT-associated transcription factors, E-cadherin expression and YAP nuclear localization both in vitro and in vivo in a murine syngeneic EMT model. Furthermore, RNA-seq meta-analysis reveals a direct correlation between CDK8 and EMT-associated transcription factors in patients. Our findings demonstrate that CDK8, an emerging therapeutic target, coordinates growth factor and mechanical cues during EMT and invasion.	[Serrao, Anne; Jenkins, Laura M.; Horst, Ben; Mythreye, Karthikeyan] Univ South Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; [Chumanevich, Alexander A.; Liang, Jiaxin; Roninson, Igor B.; Broude, Eugenia V.; Mythreye, Karthikeyan] Univ South Carolina, Dept Drug Discovery & Biomed Sci, Columbia, SC 29208 USA; [Gatza, Michael L.] Rutgers Canc Inst New Jersey, Dept Radiat Oncol, New Brunswick, NJ USA; [Gatza, Michael L.] Univ Med & Dent New Jersey, New Brunswick, NJ USA; [Lee, Nam Y.] Ohio State Univ, Coll Pharm, Div Pharmacol, Columbus, OH 43210 USA	University of South Carolina System; University of South Carolina Columbia; University of South Carolina System; University of South Carolina Columbia; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Ohio; Ohio State University	Mythreye, K (corresponding author), Univ South Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA.; Mythreye, K (corresponding author), Univ South Carolina, Dept Drug Discovery & Biomed Sci, Columbia, SC 29208 USA.	mythreye@sc.edu	liang, jiaxin/AAC-3469-2021; Karthikeyan, Mythreye/ABC-7345-2020	liang, jiaxin/0000-0003-2129-3626; Karthikeyan, Mythreye/0000-0001-5478-0098; Gatza, Michael/0000-0001-6796-7791	NIH [P20GM109091, GM122379-01]; Marsha Rivkin Foundation; Ovarian Cancer Research Fund; University of South Carolina startup funds; University of South Carolina SPARC Graduate Student Research; NATIONAL CANCER INSTITUTE [R01CA230628, R01CA219495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM122379, P20GM109091] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Marsha Rivkin Foundation; Ovarian Cancer Research Fund; University of South Carolina startup funds; University of South Carolina SPARC Graduate Student Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the COBRE Functional Genomics Core (USC Center for Targeted Therapeutics) for lentiviral preparations, COBRE Microscopy and Flow cytometry Core (USC Center for Targeted Therapeutics) for assistance with imaging, Qi Zhang, Zach Mack, Nick Lenze, Priyanka Singh, and Pratik Patel for technical assistance. Grant Support: NIH P20GM109091 (E.V.B., K.M., I.B.R.), Marsha Rivkin Foundation (K.M.), Ovarian Cancer Research Fund (K.M.), University of South Carolina startup funds (K.M.), University of South Carolina SPARC Graduate Student Research, and Predoctoral NIH GM122379-01 (L.M.J.).	Acloque H, 2008, EMBO REP, V9, P322, DOI 10.1038/embor.2008.30; Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; Ampuja M, 2016, CANCER LETT, V375, P238, DOI 10.1016/j.canlet.2016.03.008; Calvo MB, 2009, CLIN TRANSL ONCOL, V11, P126, DOI 10.1007/S12094-009-0328-8; Broude EV, 2015, CURR CANCER DRUG TAR, V15, P739, DOI 10.2174/156800961508151001105814; Chen HB, 2005, J BIOL CHEM, V280, P21329, DOI 10.1074/jbc.M500362200; Chen MQ, 2017, P NATL ACAD SCI USA, V114, P10208, DOI 10.1073/pnas.1710467114; Chumanevich AA, 2017, ONCOTARGET, V8, P228, DOI 10.18632/oncotarget.13894; Crown J, 2017, ONCOTARGET, V8, P14269, DOI 10.18632/oncotarget.15354; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Donner AJ, 2010, NAT STRUCT MOL BIOL, V17, P194, DOI 10.1038/nsmb.1752; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Galbraith MD, 2013, CELL, V153, P1327, DOI 10.1016/j.cell.2013.04.048; Galbraith MD, 2010, TRANSCR-AUSTIN, V1, P4, DOI 10.4161/trns.1.1.12373; Gordon KJ, 2009, CARCINOGENESIS, V30, P238, DOI 10.1093/carcin/bgn274; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Holtzhausen A, 2014, FASEB J, V28, P1248, DOI 10.1096/fj.13-239178; Hover LD, 2016, NEURO-ONCOLOGY, V18, P928, DOI 10.1093/neuonc/nov310; Huang ZH, 2016, DEVELOPMENT, V143, P2398, DOI 10.1242/dev.130658; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Le Page C, 2009, J OVARIAN RES, V2, DOI 10.1186/1757-2215-2-4; Leight JL, 2012, MOL BIOL CELL, V23, P781, DOI 10.1091/mbc.E11-06-0537; Liu YL, 2017, BIOMEDICINE-TAIWAN, V7, P1, DOI 10.1051/bmdcn/2017070101; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; McDermott MSJ, 2017, ONCOTARGET, V8, P12558, DOI 10.18632/oncotarget.14894; Nallet-Staub F, 2015, DEV CELL, V32, P640, DOI 10.1016/j.devcel.2015.01.011; Osborne LD, 2014, MOL BIOL CELL, V25, P3528, DOI 10.1091/mbc.E14-05-1015; Owens P, 2015, ONCOGENE, V34, P2437, DOI 10.1038/onc.2014.189; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; Pannu J, 2007, J BIOL CHEM, V282, P10405, DOI 10.1074/jbc.M611742200; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Petridou S, 2000, INVEST OPHTH VIS SCI, V41, P89; Pickup MW, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022285; Richter A, 2014, STEM CELLS, V32, P636, DOI 10.1002/stem.1592; Rzymski T, 2015, BBA-PROTEINS PROTEOM, V1854, P1617, DOI 10.1016/j.bbapap.2015.05.011; Schmierer B, 2005, MOL CELL BIOL, V25, P9845, DOI 10.1128/MCB.25.22.9845-9858.2005; Swaminathan V, 2011, CANCER RES, V71, P5075, DOI 10.1158/0008-5472.CAN-11-0247; Theriault BL, 2007, CARCINOGENESIS, V28, P1153, DOI 10.1093/carcin/bgm015; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Varadaraj A, 2015, NEOPLASIA, V17, P826, DOI 10.1016/j.neo.2015.11.003; Varelas X, 2008, NAT CELL BIOL, V10, P837, DOI 10.1038/ncb1748; Waldmeier L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048651; Wentland, 2016, U.S. Patent, Patent No. 09321737; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrighton Katharine H, 2011, Nat Rev Mol Cell Biol, V12, P404, DOI 10.1038/nrm3136; Xu W, 2015, CANCER LETT, V356, P613, DOI 10.1016/j.canlet.2014.10.008; Yamashita H, 1996, BONE, V19, P569, DOI 10.1016/S8756-3282(96)00259-1; Yokoyama Y, 2017, CANCER RES, V77, P4026, DOI 10.1158/0008-5472.CAN-17-0112; Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54	54	33	34	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2018	37	35					4792	4808		10.1038/s41388-018-0316-y	http://dx.doi.org/10.1038/s41388-018-0316-y			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS0BA	29780169	Green Accepted			2022-12-17	WOS:000443146000003
J	Cheng, Y; Gao, XH; Li, XJ; Cao, QH; Zhao, DD; Zhou, JR; Wu, HX; Wang, Y; You, LJ; Yang, HB; He, YL; Li, YR; Bian, JS; Zhu, QY; Birnbaumer, L; Yang, Y				Cheng, Yan; Gao, Xing-Hua; Li, Xian-Jing; Cao, Qiu-Hua; Zhao, Dan-Dan; Zhou, Jin-Rong; Wu, Hong-Xi; Wang, Yun; You, Lin-Jun; Yang, Hong-Bao; He, Yun-Long; Li, Yong-Ren; Bian, Jin-Song; Zhu, Qing-Yi; Birnbaumer, Lutz; Yang, Yong			Depression promotes prostate cancer invasion and metastasis via a sympathetic-cAMP-FAK signaling pathway	ONCOGENE			English	Article							TUMOR-GROWTH; CHRONIC STRESS; MILD STRESS; RECEPTOR; MODEL; PROGRESSION; ACTIVATION; ONCOLOGY; MICE; PHOSPHORYLATION	Depression drives cancer progression and induces poor clinical outcome. However, the mechanisms underlying depression and cancer outcomes are unclear. In this work, we investigated 98 prostate cancer patients and found that patients with high score of psychological depression were correlated with tumor invasion and metastasis. We found focal adhesion kinase (FAK) was increased in cancer patients with metastatic features and high score of depression. FAK knockdown completely blocked depression-promoted tumor invasion in orthotopic transplantation tumors. In Hi-myc mice and a murine model of depression, sympathetic activation was detected in the prostate tissue. Further we showed that FAK activation was dependent on a cAMP-PKA signaling pathway. Our results demonstrated that the activation of a sympathetic-FAK signaling pathway in prostate cancer patients with high degrees of depression facilitates tumor invasion. We suggest that blocking beta 2AR with propranolol or inhibiting FAK activation with PF562 271 may be novel strategies for depressed patients with invasive prostate cancer.	[Cheng, Yan; Gao, Xing-Hua; Li, Xian-Jing; Cao, Qiu-Hua; Zhao, Dan-Dan; Wu, Hong-Xi; Wang, Yun; You, Lin-Jun; Yang, Hong-Bao; He, Yun-Long; Li, Yong-Ren; Yang, Yong] China Pharmaceut Univ, Ctr New Drug Safety Evaluat & Res, State Key Lab Nat Med, Jiangsu Key Lab Drug Discovery Metab Dis, Nanjing 211198, Jiangsu, Peoples R China; [Zhou, Jin-Rong] Harvard Med Sch, Dept Surg, Beth Israel Deaconess Med Ctr, Nutr Metab Lab, Boston, MA 02138 USA; [Bian, Jin-Song] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117597, Singapore; [Zhu, Qing-Yi] Jiangsu Prov Hosp Tradit Chinese Med, Dept Urol, Nanjing 210029, Jiangsu, Peoples R China; [Birnbaumer, Lutz] NIEHS, Neurobiol Lab, Durham, NC 27709 USA; [Birnbaumer, Lutz] BOMED Catholic Univ Argentina, Biomed Res Inst, C1107AAZ, Buenos Aires, DF, Argentina	China Pharmaceutical University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; National University of Singapore; Nanjing University of Chinese Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Yang, Y (corresponding author), China Pharmaceut Univ, Ctr New Drug Safety Evaluat & Res, State Key Lab Nat Med, Jiangsu Key Lab Drug Discovery Metab Dis, Nanjing 211198, Jiangsu, Peoples R China.; Birnbaumer, L (corresponding author), NIEHS, Neurobiol Lab, Durham, NC 27709 USA.; Birnbaumer, L (corresponding author), BOMED Catholic Univ Argentina, Biomed Res Inst, C1107AAZ, Buenos Aires, DF, Argentina.	birnbau1@gmail.com; yy@cpu.edu.cn		Bian, Jinsong/0000-0002-7741-598X	Intramural Research Program of the NIH [Z01-ES101684]; 111 Project [111-2-07]; National Science Foundation of China [91529304, 81673468, 81603132, 81403020]; Natural Science Foundation of Jiangsu Province [BK20160753]; China Postdoctoral Science Foundation [2016M591965]	Intramural Research Program of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); 111 Project(Ministry of Education, China - 111 Project); National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	We thank Mrs. Ning Su for IHC studies, Mrs. Jian-hua Ding for HPLC studies, and Dr. Wen-tao Liu for gelatin zymography experiments and helpful suggestions. This study was supported by grants from Intramural Research Program of the NIH (Z01-ES101684 to LB), The 111 Project (No. 111-2-07), National Science Foundation of China (91529304, 81673468 to YY, 81603132 to XG and 81403020 to LY), Natural Science Foundation of Jiangsu Province (No. BK20160753 to XG), and China Postdoctoral Science Foundation (No. 2016M591965 to XG).	Agudelo LZ, 2014, CELL, V159, P33, DOI 10.1016/j.cell.2014.07.051; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Ayala GE, 2008, CLIN CANCER RES, V14, P7593, DOI 10.1158/1078-0432.CCR-08-1164; Barbieri A, 2015, INT J ONCOL, V47, P527, DOI 10.3892/ijo.2015.3038; BATKIN S, 1970, P NATL ACAD SCI USA, V67, P1521, DOI 10.1073/pnas.67.3.1521; Batty GD, 2017, BMJ-BRIT MED J, V356, P108; Cole SW, 2012, CLIN CANCER RES, V18, P1201, DOI 10.1158/1078-0432.CCR-11-0641; de la Taille A, 2000, EUR UROL, V38, P79, DOI 10.1159/000020256; Dimitrov S, 2010, J IMMUNOL, V184, P503, DOI 10.4049/jimmunol.0902189; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; Feng Y, 2016, PSYCHIAT RES, V243, P92, DOI 10.1016/j.psychres.2016.06.021; Furukawa TA, 2010, J PSYCHOSOM RES, V68, P581, DOI 10.1016/j.jpsychores.2009.05.003; Gaston SM, 2005, NAT MED, V11, P95, DOI 10.1038/nm1169; Glaser R, 2005, NAT REV IMMUNOL, V5, P243, DOI 10.1038/nri1571; Gundem G, 2015, NATURE, V520, P353, DOI 10.1038/nature14347; Harryman WL, 2016, BBA-REV CANCER, V1866, P221, DOI 10.1016/j.bbcan.2016.09.005; Hassan S, 2013, J CLIN INVEST, V123, P874, DOI 10.1172/JCI63324; Hill MN, 2012, NEUROSCI BIOBEHAV R, V36, P2085, DOI 10.1016/j.neubiorev.2012.07.001; Incio J, 2016, CANCER DISCOV, V6, P852, DOI 10.1158/2159-8290.CD-15-1177; Jayson GC, 2016, LANCET, V388, P518, DOI 10.1016/S0140-6736(15)01088-0; Jin JK, 2015, ONCOGENE, V34, P1811, DOI 10.1038/onc.2014.116; KATZ RJ, 1982, PHARMACOL BIOCHEM BE, V16, P965, DOI 10.1016/0091-3057(82)90053-3; Ko CJ, 2015, CANCER RES, V75, P2949, DOI 10.1158/0008-5472.CAN-14-3297; Kupfer DJ, 2012, LANCET, V379, P1045, DOI 10.1016/S0140-6736(11)60602-8; Law NC, 2017, ENDOCRINOLOGY, V158, P2043, DOI 10.1210/en.2017-00163; Le CP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10634; Li XJ, 2015, P NATL ACAD SCI USA, V112, P4731, DOI 10.1073/pnas.1503779112; Lopez-Calderero I, 2017, ACTAS UROL ESP, V41, P368, DOI 10.1016/j.acuro.2016.12.006; Lu DH, 2016, CLIN CANCER RES, V22, P765, DOI 10.1158/1078-0432.CCR-15-0101; Ma XJ, 2012, J BIOL CHEM, V287, P18925, DOI 10.1074/jbc.M112.352260; Madden KS, 2017, DEV COMP IMMUNOL, V66, P92, DOI 10.1016/j.dci.2016.04.015; Magnon C, 2013, SCIENCE, V341, P143, DOI 10.1126/science.1236361; Malik R, 2015, TRENDS BIOTECHNOL, V33, P230, DOI 10.1016/j.tibtech.2015.01.004; Mao J, 2016, CANCER LETT, V380, P134, DOI 10.1016/j.canlet.2016.06.020; Lopez-Colome AM, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0418-y; Marchesi F, 2010, CYTOKINE GROWTH F R, V21, P77, DOI 10.1016/j.cytogfr.2009.11.001; Mehta RD, 2015, CA-CANCER J CLIN, V65, P299, DOI 10.3322/caac.21285; Mo F, 2017, EUR UROL; Nader GPF, 2016, NAT CELL BIOL, V18, P491, DOI 10.1038/ncb3333; Pavlov VA, 2017, NAT NEUROSCI, V20, P156, DOI 10.1038/nn.4477; Pedersen L, 2016, CELL METAB, V23, P554, DOI 10.1016/j.cmet.2016.01.011; Piiper A, 2003, BIOCHEM BIOPH RES CO, V301, P848, DOI 10.1016/S0006-291X(03)00055-X; Prasad SM, 2014, J CLIN ONCOL, V32, P2471, DOI 10.1200/JCO.2013.51.1048; Qin JF, 2015, BMB REP, V48, P295, DOI 10.5483/BMBRep.2015.48.5.008; Slack-Davis JK, 2009, MOL CANCER THER, V8, P2470, DOI 10.1158/1535-7163.MCT-09-0262; Sood AK, 2010, J CLIN INVEST, V120, P1515, DOI 10.1172/JCI40802; Sullivan DR, 2016, J CLIN ONCOL, V34, P3984, DOI 10.1200/JCO.2016.66.8459; Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; Uehara A, 2016, SCI REP-UK, V6, DOI 10.1038/srep34012; Venkatesh H, 2017, TRENDS CANCER, V3, P89, DOI 10.1016/j.trecan.2016.12.008; Venkitaraman R, 2015, EUR UROL, V67, P673, DOI 10.1016/j.eururo.2014.10.004; WILLNER P, 1987, PSYCHOPHARMACOLOGY, V93, P358; Zhao CM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009569	55	33	36	4	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	22					2953	2966		10.1038/s41388-018-0177-4	http://dx.doi.org/10.1038/s41388-018-0177-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GH8RM	29515233	Green Accepted			2022-12-17	WOS:000433936300004
J	Itoh, H; Kadomatsu, T; Tanoue, H; Yugami, M; Miyata, K; Endo, M; Morinaga, J; Kobayashi, E; Miyamoto, T; Kurahashi, R; Terada, K; Mizuta, H; Oike, Y				Itoh, Hitoshi; Kadomatsu, Tsuyoshi; Tanoue, Hironori; Yugami, Masaki; Miyata, Keishi; Endo, Motoyoshi; Morinaga, Jun; Kobayashi, Eisuke; Miyamoto, Takeshi; Kurahashi, Ryoma; Terada, Kazutoyo; Mizuta, Hiroshi; Oike, Yuichi			TET2-dependent IL-6 induction mediated by the tumor microenvironment promotes tumor metastasis in osteosarcoma	ONCOGENE			English	Article							MESENCHYMAL STEM-CELLS; INTEGRATIVE ANALYSIS; DNA METHYLATION; STROMAL CELLS; C-MYC; CANCER; EXPRESSION; METABOLISM; GROWTH; STAT3	The tumor microenvironment promotes epigenetic changes in tumor cells associated with tumor aggressiveness. Here we report that in primary tumor cells, increased interleukin-6 (IL-6) expression brought on by DNA demethylation of its promoter by ten-eleven translocation 2 (TET2) promotes lung metastasis in osteosarcoma (OS). Xenograft experiments show increased IL-6 expression and decreased methylation of its promoter in OS cells after implantation relative to before implantation. In addition, changes in IL-6 methylation and expression seen in OS cells at the primary site were maintained at the metastatic site. TET2 knockdown in OS cells suppressed upregulation of IL-6 and demethylation of its promoter in xenograft tumors and decreased tumor metastasis. We also present evidence showing that tumor cell-derived IL-6 facilitates glycolytic metabolism in tumor cells by activating the MEK/ERK1/2/hypoxia-inducible transcription factor-1 alpha (HIF-1 alpha) pathway and increases lung colonization by OS cells by upregulating expression of intercellular adhesion molecule-1 (ICAM-1), enhancing tumor metastasis. Blocking IL-6 signaling with a humanized monoclonal antibody against the IL-6 receptor reduced lung metastasis and prolonged survival of xenografted mice. These findings suggest that TET2-dependent IL-6 induction enables acquisition of aggressive phenotypes in OS cells via the tumor microenvironment and that blocking IL-6 signaling could be serve as a potential therapy to antagonize metastasis.	[Itoh, Hitoshi; Kadomatsu, Tsuyoshi; Tanoue, Hironori; Yugami, Masaki; Miyata, Keishi; Endo, Motoyoshi; Morinaga, Jun; Kurahashi, Ryoma; Terada, Kazutoyo; Oike, Yuichi] Kumamoto Univ, Grad Sch Med Sci, Dept Mol Genet, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan; [Itoh, Hitoshi; Tanoue, Hironori; Yugami, Masaki; Mizuta, Hiroshi] Kumamoto Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan; [Morinaga, Jun] Kumamoto Univ, Grad Sch Med Sci, Clin Res Ctr, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan; [Morinaga, Jun] Kumamoto Univ, Grad Sch Med Sci, Dept Nephrol, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan; [Kobayashi, Eisuke; Miyamoto, Takeshi] Keio Univ, Sch Med, Dept Orthoped Surg, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608525, Japan; [Kobayashi, Eisuke] Natl Canc Ctr, Div Muscloskeletal Oncol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan; [Kurahashi, Ryoma] Kumamoto Univ, Grad Sch Med Sci, Dept Urol, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan; [Oike, Yuichi] Japan Agcy Med Res & Dev, AMED, CREST, Tokyo, Japan	Kumamoto University; Kumamoto University; Kumamoto University; Kumamoto University; Keio University; National Cancer Center - Japan; Kumamoto University; Japan Science & Technology Agency (JST)	Kadomatsu, T; Oike, Y (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Mol Genet, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan.; Oike, Y (corresponding author), Japan Agcy Med Res & Dev, AMED, CREST, Tokyo, Japan.	tkado@gpo.kumamoto-u.ac.jp; oike@gpo.kumamoto-u.ac.jp	Endo, Motoyoshi/T-5840-2019; Miyata, Keishi/HGF-1876-2022	Miyata, Keishi/0000-0003-0336-1859	Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [26116722, 15K06836, 17K08663]; Core Research for Evolutional Science and Technology (CREST) program of the Japan Science and Technology Agency (JST) [13417915]; CREST program of the Japan Agency for Medical Research and Development (AMED) [17gm0610007h0005]	Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; Core Research for Evolutional Science and Technology (CREST) program of the Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST)Core Research for Evolutional Science and Technology (CREST)); CREST program of the Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED))	We thank our colleagues for valuable suggestions and discussion. We also thank K. Tabu, N. Shirai, S. Iwaki, Y. Shogenji, and M. Kamada for technical assistance. This work was supported by the Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (grant 26116722 to YO, grant 15K06836 to TK, grant 17K08663 to ME), and by the Core Research for Evolutional Science and Technology (CREST) program of the Japan Science and Technology Agency (JST) (grant 13417915 to YO) and by the CREST program of the Japan Agency for Medical Research and Development (AMED) (grant 17gm0610007h0005 to YO).	Agger K, 2016, GENE DEV, V30, P1278, DOI 10.1101/gad.280495.116; Alfranca A, 2015, CELL MOL LIFE SCI, V72, P3097, DOI 10.1007/s00018-015-1918-y; Avnet S, 2017, INT J CANCER, V140, P1331, DOI 10.1002/ijc.30540; Baglio SR, 2017, CLIN CANCER RES, V23, P3721, DOI 10.1158/1078-0432.CCR-16-2726; Bharti R, 2016, CANCER LETT, V375, P51, DOI 10.1016/j.canlet.2016.02.048; Bian ZY, 2010, CANCER SCI, V101, P2554, DOI 10.1111/j.1349-7006.2010.01731.x; Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006; Booth MJ, 2012, SCIENCE, V336, P934, DOI 10.1126/science.1220671; Borsig L, 2014, ONCOGENE, V33, P3217, DOI 10.1038/onc.2013.272; Branco MR, 2012, NAT REV GENET, V13, P7, DOI 10.1038/nrg3080; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chang Q, 2013, NEOPLASIA, V15, P848, DOI 10.1593/neo.13706; Chen QC, 2015, MOL MED REP, V12, P219, DOI 10.3892/mmr.2015.3375; Cortini M, 2017, CANCER LETT, V405, P90, DOI 10.1016/j.canlet.2017.07.024; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Demaria M, 2012, CELL DEATH DIFFER, V19, P1390, DOI 10.1038/cdd.2012.20; Deng M, 2017, CANCER RES, V77, P6069, DOI 10.1158/0008-5472.CAN-16-2964; Eason K, 2016, CANCER RES, V76, P5195, DOI 10.1158/0008-5472.CAN-16-0141; Fan L, 2016, ONCOGENE, V35, P2441, DOI 10.1038/onc.2015.309; Flint TR, 2017, TRENDS MOL MED, V23, P451, DOI 10.1016/j.molmed.2017.03.001; Gianferante DM, 2017, NAT REV ENDOCRINOL, V13, P480, DOI 10.1038/nrendo.2017.16; Gordan JD, 2007, CANCER CELL, V12, P108, DOI 10.1016/j.ccr.2007.07.006; Goumas FA, 2015, INT J CANCER, V137, P1035, DOI 10.1002/ijc.29445; Guo X, 2011, NEOPLASMA, V58, P153, DOI 10.4149/neo_2011_02_153; Han J, 2016, ONCOL LETT, V12, P4665, DOI 10.3892/ol.2016.5227; Han XG, 2015, CANCER LETT, V369, P405, DOI 10.1016/j.canlet.2015.09.002; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He XD, 2016, CANCER BIOL THER, V17, P188, DOI 10.1080/15384047.2016.1139228; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Isobe A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118080; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kadomatsu T, 2014, TRENDS ENDOCRIN MET, V25, P245, DOI 10.1016/j.tem.2014.03.012; Kadomatsu T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057921; Kuijjer ML, 2012, GENE CHROMOSOME CANC, V51, P696, DOI 10.1002/gcc.21956; Lamora A, 2016, J CLIN MED, V5, DOI 10.3390/jcm5110096; Lin YM, 2013, CANCER LETT, V328, P135, DOI 10.1016/j.canlet.2012.08.029; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mariani CJ, 2014, CELL REP, V7, P1343, DOI 10.1016/j.celrep.2014.04.040; Mauer J, 2015, TRENDS IMMUNOL, V36, P92, DOI 10.1016/j.it.2014.12.008; Meyer FRL, 2015, VET J, V206, P67, DOI 10.1016/j.tvjl.2015.06.003; Mylonis I, 2017, J CELL SCI, V130, P466, DOI 10.1242/jcs.195339; Nile CJ, 2008, ARTHRITIS RHEUM, V58, P2686, DOI 10.1002/art.23758; Odagiri H, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004612; Ohba T, 2014, MOL CANCER RES, V12, P1100, DOI 10.1158/1541-7786.MCR-14-0037; Ohba T, 2014, J BONE MINER RES, V29, P1431, DOI 10.1002/jbmr.2182; Okada S, 2008, INT J HEMATOL, V88, P476, DOI 10.1007/s12185-008-0215-z; Qiu GZ, 2017, TRENDS PHARMACOL SCI, V38, P669, DOI 10.1016/j.tips.2017.05.002; Rasmussen KD, 2016, GENE DEV, V30, P733, DOI 10.1101/gad.276568.115; Reimann E, 2014, HUM GENOMICS, V8, DOI 10.1186/s40246-014-0020-0; Rokavec M, 2016, CELL MOL LIFE SCI, V73, P23, DOI 10.1007/s00018-015-2045-5; Sechler M, 2017, ONCOGENE, V36, P4150, DOI 10.1038/onc.2017.44; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008; Shimizu T, 2010, ONCOGENE, V29, P5687, DOI 10.1038/onc.2010.312; Smida J, 2017, INT J CANCER, V141, P816, DOI 10.1002/ijc.30778; Soga T, 2013, CANCER SCI, V104, P275, DOI 10.1111/cas.12085; Tu B, 2012, CANCER LETT, V325, P80, DOI 10.1016/j.canlet.2012.06.006; Turley SJ, 2015, NAT REV IMMUNOL, V15, P669, DOI 10.1038/nri3902; Ueda J, 2014, MOL CELL BIOL, V34, P3702, DOI 10.1128/MCB.00099-14; Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105-2896.2005.00332.x; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Williams K, 2012, EMBO REP, V13, P28, DOI 10.1038/embor.2011.233; Wilson C, 2017, ONCOGENE, V36, P2565, DOI 10.1038/onc.2016.412; Wu H, 2014, CELL, V156, P45, DOI 10.1016/j.cell.2013.12.019; Wu MZ, 2015, CANCER RES, V75, P3912, DOI 10.1158/0008-5472.CAN-14-3208; Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67; You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Zhao L, 2013, CLIN CANCER RES, V19, P6419, DOI 10.1158/1078-0432.CCR-13-0254	70	33	33	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	22					2903	2920		10.1038/s41388-018-0160-0	http://dx.doi.org/10.1038/s41388-018-0160-0			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GH8RM	29515232				2022-12-17	WOS:000433936300001
J	Liu, Q; Gheorghiu, L; Drumm, M; Clayman, R; Eidelman, A; Wszolek, MF; Olumi, A; Feldman, A; Wang, M; Marcar, L; Citrin, DE; Wu, CL; Benes, CH; Efstathiou, JA; Willers, H				Liu, Qi; Gheorghiu, Liliana; Drumm, Michael; Clayman, Rebecca; Eidelman, Alec; Wszolek, Matthew F.; Olumi, Aria; Feldman, Adam; Wang, Meng; Marcar, Lynnette; Citrin, Deborah E.; Wu, Chin-Lee; Benes, Cyril H.; Efstathiou, Jason A.; Willers, Henning			PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53	ONCOGENE			English	Article							HOMOLOGOUS RECOMBINATION REPAIR; DOUBLE-STRAND BREAKS; POLY(ADP-RIBOSE) POLYMERASE; OXIDATIVE STRESS; SYNTHETIC LETHALITY; BLADDER-CANCER; TUMOR-CELLS; NSCLC CELLS; IN-VIVO; PLATFORM	Biomarkers and mechanisms of poly (ADP-ribose) polymerase (PARP) inhibitor-mediated cytotoxicity in tumor cells lacking a BRCA-mutant or BRCA-like phenotype are poorly defined. We sought to explore the utility of PARP-1 inhibitor (PARPi) treatment with/without ionizing radiation in muscle-invasive bladder cancer (MIBC), which has poor therapeutic outcomes. We assessed the DNA damaging and cytotoxic effects of the PARPi olaparib in nine bladder cancer cell lines. Olaparib radiosensitized all cell lines with dose enhancement factors from 1.22 to 2.27. Radiosensitization was correlated with the induction of potentially lethal DNA double-strand breaks (DSB) but not with RAD51 foci formation. The ability of olaparib to radiosensitize MIBC cells was linked to the extent of cell kill achieved with the drug alone. Unexpectedly, increased levels of reactive oxygen species (ROS) resulting from PARPi treatment were the cause of DSB throughout the cell cycle in vitro and in vivo. ROS originated from mitochondria and were required for the radiosensitizing effects of olaparib. Consistent with the role of TP53 in ROS regulation, loss of p53 function enhanced radiosensitization by olaparib in non-isogenic and isogenic cell line models and was associated with increased PARP-1 expression in bladder cancer cell lines and tumors. Impairment of ATM in addition to p53 loss resulted in an even more pronounced radiosensitization. In conclusion, ROS suppression by PARP-1 in MIBC is a potential therapeutic target either for PARPi combined with radiation or drug alone treatment. The TP53 and ATM genes, commonly mutated in MIBC and other cancers, are candidate biomarkers of PARPi-mediated radiosensitization.	[Liu, Qi; Gheorghiu, Liliana; Drumm, Michael; Clayman, Rebecca; Eidelman, Alec; Wang, Meng; Marcar, Lynnette; Efstathiou, Jason A.; Willers, Henning] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02115 USA; [Liu, Qi] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA; [Wszolek, Matthew F.; Olumi, Aria; Feldman, Adam] Harvard Med Sch, Massachusetts Gen Hosp, Dept Urol, Boston, MA USA; [Citrin, Deborah E.] NIH, Radiat Oncol Branch, Ctr Canc Res, Bldg 10, Bethesda, MD 20892 USA; [Wu, Chin-Lee] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA; [Benes, Cyril H.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; University of California System; University of California San Francisco; Harvard University; Harvard Medical School; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Willers, H (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02115 USA.	hwillers@partners.org	Liu, Qi/AAE-7874-2020	Liu, Qi/0000-0002-3285-7864; Citrin, Deborah/0000-0002-4391-2734	Massachusetts General Hospital [C06 CA059267]; Proton Therapy Research and Treatment Center; UK Wellcome Trust [102696]; NATIONAL CANCER INSTITUTE [C06CA059267, ZIABC010850, ZIABC011552] Funding Source: NIH RePORTER	Massachusetts General Hospital(General Electric); Proton Therapy Research and Treatment Center; UK Wellcome Trust(Wellcome Trust); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Federal Share of program income earned by Massachusetts General Hospital on C06 CA059267, Proton Therapy Research and Treatment Center (J. A. Efstathiou, H. Willers), UK Wellcome Trust 102696 (C.H. Benes).	Ameziane-El-Hassani R, 2013, BIO-PROTOCOL, V3, pe313, DOI [10.21769/bioprotoc.313, DOI 10.21769/BIOPROTOC.313]; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Bai P, 2011, CELL METAB, V13, P461, DOI 10.1016/j.cmet.2011.03.004; Birkelbach M, 2013, J THORAC ONCOL, V8, P279, DOI 10.1097/JTO.0b013e31827ecf83; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Bridges KA, 2014, ONCOTARGET, V5, P5076, DOI 10.18632/oncotarget.2083; Bryant HE, 2006, NUCLEIC ACIDS RES, V34, P1685, DOI 10.1093/nar/gkl108; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Bryant HE, 2009, EMBO J, V28, P2601, DOI 10.1038/emboj.2009.206; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chalmers AJ, 2010, SEMIN RADIAT ONCOL, V20, P274, DOI 10.1016/j.semradonc.2010.06.001; Chan N, 2010, CANCER RES, V70, P8045, DOI 10.1158/0008-5472.CAN-10-2352; Coleman CN, 2016, CLIN CANCER RES, V22, P3138, DOI 10.1158/1078-0432.CCR-16-0069; Deschenes F, 2005, HUM MOL GENET, V14, P3293, DOI 10.1093/hmg/ddi362; Dulaney C, 2017, SEMIN CELL DEV BIOL, V63, P144, DOI 10.1016/j.semcdb.2017.01.007; Engert F, 2015, MOL CANCER THER, V14, P2818, DOI 10.1158/1535-7163.MCT-15-0587; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Feng FY, 2015, MOL CELL, V58, P925, DOI 10.1016/j.molcel.2015.04.016; Gani C, 2015, RADIOTHER ONCOL, V116, P486, DOI 10.1016/j.radonc.2015.08.003; Gibson BA, 2012, NAT REV MOL CELL BIO, V13, P411, DOI 10.1038/nrm3376; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Hempel N, 2009, FREE RADICAL BIO MED, V46, P42, DOI 10.1016/j.freeradbiomed.2008.09.020; Ireno IC, 2014, CARCINOGENESIS, V35, P2273, DOI 10.1093/carcin/bgu160; Kamat AM, 2016, LANCET, V388, P2796, DOI 10.1016/S0140-6736(16)30512-8; Kamsler A, 2001, CANCER RES, V61, P1849; Kotter A, 2014, MOL ONCOL, V8, P1616, DOI 10.1016/j.molonc.2014.06.008; Lamy A, 2006, J UROLOGY, V176, P2686, DOI 10.1016/j.juro.2006.07.132; Lee HJ, 2013, MOL CANCER THER, V12, P2591, DOI 10.1158/1535-7163.MCT-13-0338; Lee JS, 2010, J CLIN ONCOL, V28, P2660, DOI 10.1200/JCO.2009.25.0977; Liu Q, 2015, MOL CANCER RES, V13, P713, DOI 10.1158/1541-7786.MCR-14-0570; Liu Q, 2015, INT J RADIAT ONCOL, V91, P1081, DOI 10.1016/j.ijrobp.2014.12.046; Maillet A, 2012, ANTIOXID REDOX SIGN, V16, P1285, DOI 10.1089/ars.2011.4434; Martin-Cordero C, 2012, CURR DRUG TARGETS, V13, P1006, DOI 10.2174/138945012802009044; Michels J, 2014, ONCOGENE, V33, P3894, DOI 10.1038/onc.2013.352; Mukhopadhyay P, 2007, BIOCHEM BIOPH RES CO, V358, P203, DOI 10.1016/j.bbrc.2007.04.106; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Nisimoto Y, 2014, BIOCHEMISTRY-US, V53, P5111, DOI 10.1021/bi500331y; Paxinou E, 2001, P NATL ACAD SCI USA, V98, P11575, DOI 10.1073/pnas.201293198; Pommier Y, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9246; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041; Rossi MN, 2009, J BIOL CHEM, V284, P31616, DOI 10.1074/jbc.M109.025882; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Senra JM, 2011, MOL CANCER THER, V10, P1949, DOI 10.1158/1535-7163.MCT-11-0278; Strom CE, 2011, NUCLEIC ACIDS RES, V39, P3166, DOI 10.1093/nar/gkq1241; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Van Allen EM, 2014, CANCER DISCOV, V4, P1140, DOI 10.1158/2159-8290.CD-14-0623; Verhagen CVM, 2015, RADIOTHER ONCOL, V116, P358, DOI 10.1016/j.radonc.2015.03.028; Wang M, 2014, CANCER RES, V74, P2825, DOI 10.1158/0008-5472.CAN-13-3157; Wang M, 2011, CANCER RES, V71, P6261, DOI 10.1158/0008-5472.CAN-11-0213; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Wurster S, 2016, ONCOTARGET, V7, P9732, DOI 10.18632/oncotarget.6947	53	33	33	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	21					2793	2805		10.1038/s41388-018-0130-6	http://dx.doi.org/10.1038/s41388-018-0130-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG8EE	29511347	Green Accepted			2022-12-17	WOS:000432929800003
J	Tang, JT; Chen, HR; Wong, CC; Liu, DB; Li, T; Wang, XH; Ji, JF; Sung, JJY; Fang, JY; Yu, J				Tang, Jieting; Chen, Huarong; Wong, Chi-Chun; Liu, Dabin; Li, Tong; Wang, Xiaohong; Ji, Jiafu; Sung, Joseph J. Y.; Fang, Jing-Yuan; Yu, Jun			DEAD-box helicase 27 promotes colorectal cancer growth and metastasis and predicts poor survival in CRC patients	ONCOGENE			English	Article							NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITION; COPY NUMBER ALTERATIONS; CARCINOMA PROGRESSION; COLON-CANCER; ACTIVATION; GENE; TRANSCRIPTION; ADENOMA; DDX1	Copy number alterations (CNAs) are crucial for colorectal cancer (CRC) development. In this study, DEAD box polypeptide 27 (DDX27) was identified to be highly amplified in both TCGA CRC (474/615) and primary CRC (47/103), which was positively correlated with its mRNA overexpression. High DDX27 mRNA (N = 199) and protein expression (N = 260) predicted poor survival in CRC patients. Ectopic expression of DDX27 increased CRC cells proliferation, migration and invasion, but suppressed apoptosis. Conversely, silencing of DDX27 exerted opposite effects in vitro and significantly inhibited murine xenograft tumor growth and lung metastasis in vivo. Up-regulation of DDX27 enhanced and prolonged TNF-alpha-mediated NF-kappa B signaling. Nucleophosmin (NPM1) was identified as a binding partner of DDX27. DDX27 increased nuclear NPM1 and NF-kappa B-p65 interaction to enhance DNA binding activity of NF-kappa B. Silencing NPM1 abrogated DDX27-activating NF-kappa B signaling and its tumor-promoting function. Together, DDX27 is overexpressed and plays a pivotal oncogenic role in CRC.	[Tang, Jieting; Chen, Huarong; Wong, Chi-Chun; Liu, Dabin; Li, Tong; Sung, Joseph J. Y.; Yu, Jun] Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Tang, Jieting; Chen, Huarong; Wong, Chi-Chun; Liu, Dabin; Li, Tong; Sung, Joseph J. Y.; Yu, Jun] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut,CUHK Shenzhen Res Inst, State Key Lab Digest Dis,Li Ka Shing Inst Hlth Sc, Hong Kong, Hong Kong, Peoples R China; [Tang, Jieting; Fang, Jing-Yuan; Yu, Jun] Shanghai Jiao Tong Univ, Shanghai Canc Inst,Minist Hlth,Div Gastroenterol, Shanghai Inst Digest Dis,Ren Ji Hosp,Sch Med, State Key Lab Oncogenes & Related Genes,Key Lab G, Shanghai 200001, Peoples R China; [Wang, Xiaohong; Ji, Jiafu] Peking Univ, Canc Hosp & Inst, Dept Surg, Beijing 100142, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Shanghai Jiao Tong University; Peking University	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut,CUHK Shenzhen Res Inst, State Key Lab Digest Dis,Li Ka Shing Inst Hlth Sc, Hong Kong, Hong Kong, Peoples R China.; Fang, JY; Yu, J (corresponding author), Shanghai Jiao Tong Univ, Shanghai Canc Inst,Minist Hlth,Div Gastroenterol, Shanghai Inst Digest Dis,Ren Ji Hosp,Sch Med, State Key Lab Oncogenes & Related Genes,Key Lab G, Shanghai 200001, Peoples R China.	jingyuanfang@sjtu.edu.cn; junyu@cuhk.edu.hk	chen, huarong/ABH-8561-2020; Liu, Dabin/GNH-2648-2022; Chen, Huarong/ABZ-5810-2022; Yu, Jun/D-8569-2015; Wong, Chi Chun/C-4636-2016; Sung, Joseph J. Y./R-3203-2018	chen, huarong/0000-0003-2192-1864; Yu, Jun/0000-0001-5008-2153; Sung, Joseph J. Y./0000-0003-3125-5199; Liu, Dabin/0000-0002-3811-8317	CUHK-SJTU Joint Research Collaboration Fund; RGC-GRF Hong Kong [766613, 14106145]; 973 Program China [2013CB531401]; Natural Science Foundation of China (NSFC) [81201963, 81372600]; Shenzhen Municipal Science and Technology R D fund [JCYJ20120619152326450]; Shenzhen Virtual University Park Support Scheme; CUHK	CUHK-SJTU Joint Research Collaboration Fund; RGC-GRF Hong Kong(Hong Kong Research Grants Council); 973 Program China(National Basic Research Program of China); Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Shenzhen Municipal Science and Technology R D fund; Shenzhen Virtual University Park Support Scheme; CUHK(Chinese University of Hong Kong)	This project was supported by CUHK-SJTU Joint Research Collaboration Fund (Jun Yu and Jing-Yuan Fang), RGC-GRF Hong Kong (766613, 14106145), 973 Program China (2013CB531401), Natural Science Foundation of China (NSFC) (81201963, 81372600), Shenzhen Municipal Science and Technology R & D fund (JCYJ20120619152326450) and Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute. CUHK direct grant to FKL Chan.	Botlagunta M, 2008, ONCOGENE, V27, P3912, DOI 10.1038/onc.2008.33; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Camps J, 2009, GENE CHROMOSOME CANC, V48, P1002, DOI 10.1002/gcc.20699; Carvalho B, 2009, GUT, V58, P79, DOI 10.1136/gut.2007.143065; Chen H, 2017, ONCOGENE, V36, P4415, DOI 10.1038/onc.2017.73; Cheng XS, 2014, CANCER LETT, V348, P77, DOI 10.1016/j.canlet.2014.03.008; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Fiume G, 2012, NUCLEIC ACIDS RES, V40, P3548, DOI 10.1093/nar/gkr1224; Flora M, 2012, CANCER GENET-NY, V205, P630, DOI 10.1016/j.cancergen.2012.10.005; Fuller-Pace FV, 2013, RNA BIOL, V10, P121, DOI 10.4161/rna.23312; George RE, 1996, ONCOGENE, V12, P1583; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; Gui SL, 2016, INT UROL NEPHROL, V48, P701, DOI 10.1007/s11255-016-1222-2; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Ishaq M, 2009, J CELL BIOCHEM, V106, P296, DOI 10.1002/jcb.22004; Issa JP, 2008, CLIN CANCER RES, V14, P5939, DOI 10.1158/1078-0432.CCR-08-1596; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kumar A, 2011, DIABETES OBES METAB, V13, P750, DOI 10.1111/j.1463-1326.2011.01402.x; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lim MJ, 2006, CANCER DETECT PREV, V30, P481, DOI 10.1016/j.cdp.2006.10.008; Lin JH, 2017, NUCLEIC ACIDS RES, V45, P3707, DOI 10.1093/nar/gkw1285; Lind DS, 2001, SURGERY, V130, P363, DOI 10.1067/msy.2001.116672; Luanpitpong S, 2016, ONCOGENE, V35, P2824, DOI 10.1038/onc.2015.351; Mahoney DJ, 2008, P NATL ACAD SCI USA, V105, P11778, DOI 10.1073/pnas.0711122105; Mallam AL, 2012, NATURE, V490, P121, DOI 10.1038/nature11402; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034; Poulogiannis G, 2010, P NATL ACAD SCI USA, V107, P15145, DOI 10.1073/pnas.1009941107; Qian Y, 2017, CANCER RES, V77, P1968, DOI 10.1158/0008-5472.CAN-16-1595; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Roux KJ, 2012, J CELL BIOL, V196, P801, DOI 10.1083/jcb.201112098; Sakamoto K, 2009, CLIN CANCER RES, V15, P2248, DOI 10.1158/1078-0432.CCR-08-1383; Shin S, 2007, CANCER RES, V67, P7572, DOI 10.1158/0008-5472.CAN-06-4652; Sillars-Hardebol AH, 2012, J PATHOL, V226, P442, DOI 10.1002/path.2983; Tanaka K, 2009, ONCOGENE, V28, P2142, DOI 10.1038/onc.2009.89; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang H, 2016, ONCOGENE, V35, P2011, DOI 10.1038/onc.2015.304; Wang R, 2012, NEURO-ONCOLOGY, V14, P1116, DOI 10.1093/neuonc/nos131	41	33	37	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	22					3006	3021		10.1038/s41388-018-0196-1	http://dx.doi.org/10.1038/s41388-018-0196-1			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GH8RM	29535419	Green Published, hybrid			2022-12-17	WOS:000433936300008
J	von Muhlinen, N; Horikawa, I; Alam, F; Isogaya, K; Lissa, D; Vojtesek, B; Lane, DP; Harris, CC				von Muhlinen, Natalia; Horikawa, Izumi; Alam, Fatima; Isogaya, Kazunobu; Lissa, Delphine; Vojtesek, Borek; Lane, David P.; Harris, Curtis C.			p53 isoforms regulate premature aging in human cells	ONCOGENE			English	Article							DNA-DAMAGE RESPONSES; DEFECTIVE MATURATION; GENOMIC INSTABILITY; PROGERIA SYNDROMES; DOWN-REGULATION; SENESCENCE; RAD51; PROMOTES; PRELAMIN; ACCUMULATION	Cellular senescence is a hallmark of normal aging and aging-related syndromes, including the premature aging disorder Hutchinson-Gilford Progeria Syndrome (HGPS), a rare genetic disorder caused by a single mutation in the LMNA gene that results in the constitutive expression of a truncated splicing mutant of lamin A known as progerin. Progerin accumulation leads to increased cellular stresses including unrepaired DNA damage, activation of the p53 signaling pathway and accelerated senescence. We previously established that the p53 isoforms Delta 133p53 and p53 beta regulate senescence in normal human cells. However, their role in premature aging is unknown. Here we report that p53 isoforms are expressed in primary fibroblasts derived from HGPS patients, are associated with their accelerated senescence and that their manipulation can restore the replication capacity of HGPS fibroblasts. We found that in near-senescent HGPS fibroblasts, which exhibit low levels of Delta 133p53 and high levels of p53 beta, restoration of Delta 133p53 expression was sufficient to extend replicative lifespan and delay senescence, despite progerin levels and abnormal nuclear morphology remaining unchanged. Conversely, Delta 133p53 depletion or p53 beta overexpression accelerated the onset of senescence in otherwise proliferative HGPS fibroblasts. Our data indicate that Delta 133p53 exerts its role by modulating full-length p53 (FLp53) signaling to extend the replicative lifespan and promotes the repair of spontaneous progerin-induced DNA double-strand breaks (DSBs). We showed that Delta 133p53 dominant-negative inhibition of FLp53 occurs directly at the p21/CDKN1A and miR-34a promoters, two p53 senescence-associated genes. In addition, Delta 133p53 expression increased the expression of DNA repair RAD51, likely through upregulation of E2F1, a transcription factor that activates RAD51, to promote repair of DSBs. In summary, our data indicate that Delta 133p53 modulates p53 signaling to repress progerin-induced early onset of senescence in HGPS cells. Therefore, restoration of Delta 133p53 expression may be a novel therapeutic strategy to treat aging-associated phenotypes of HGPS in vivo.	[von Muhlinen, Natalia; Horikawa, Izumi; Alam, Fatima; Isogaya, Kazunobu; Lissa, Delphine; Harris, Curtis C.] NCI, Lab Human Carcinogenesis, NIH, Bldg 37, Bethesda, MD 20892 USA; [Vojtesek, Borek] Masaryk Mem Canc Inst, Reg Ctr Appl & Mol Oncol, Brno, Czech Republic; [Lane, David P.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, Stockholm, Sweden	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Masaryk Memorial Cancer Institute; Karolinska Institutet	Harris, CC (corresponding author), NCI, Lab Human Carcinogenesis, NIH, Bldg 37, Bethesda, MD 20892 USA.	harrisc@mail.nih.gov	Ponce, Richard/A-3109-2017	Ponce, Richard/0000-0001-5077-8417; Lane, David/0000-0003-0551-3545	National Cancer Institute, National Institutes of Health; Czech Science Foundation [P206/12/G151];  [MEYS - NPS I - LO1413]; NATIONAL CANCER INSTITUTE [ZIABC011496] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Czech Science Foundation(Grant Agency of the Czech Republic); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by the National Cancer Institute, National Institutes of Health. B.V. was supported with project from Czech Science Foundation P206/12/G151 and project MEYS - NPS I - LO1413.	ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Aoubala M, 2011, CELL DEATH DIFFER, V18, P248, DOI 10.1038/cdd.2010.91; Arias-Lopez C, 2006, EMBO REP, V7, P219, DOI 10.1038/sj.embor.7400587; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Brosh R, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.65; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Burtner CR, 2010, NAT REV MOL CELL BIO, V11, P567, DOI 10.1038/nrm2944; Campisi J, 2014, INTERD T GERONT GERI, V39, P45, DOI 10.1159/000358899; De Sandre-Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Goldman RD, 2004, P NATL ACAD SCI USA, V101, P8963, DOI 10.1073/pnas.0402943101; Gong L, 2015, CELL RES, V25, P351, DOI 10.1038/cr.2015.22; Gonzalo S, 2015, CURR OPIN CELL BIOL, V34, P75, DOI 10.1016/j.ceb.2015.05.007; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hennekam RCM, 2006, AM J MED GENET A, V140A, P2603, DOI 10.1002/ajmg.a.31346; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; Horikawa I, 2017, CELL DEATH DIFFER, V24, P1017, DOI 10.1038/cdd.2017.48; Horikawa I, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5706; Kachhap SK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011208; Khoury MP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000927; Kubben N, 2016, CELL, V165, P1361, DOI 10.1016/j.cell.2016.05.017; Kudlow BA, 2007, NAT REV MOL CELL BIO, V8, P394, DOI 10.1038/nrm2161; Linke SP, 2003, CANCER RES, V63, P2596; Liu BH, 2005, NAT MED, V11, P780, DOI 10.1038/nm1266; Liu Y, 2008, FASEB J, V22, P603, DOI 10.1096/fj.07-8598com; Liu YY, 2006, J CELL SCI, V119, P4644, DOI 10.1242/jcs.03263; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; Maki CG, 1996, CANCER RES, V56, P2649; Malhas AN, 2009, J CELL BIOL, V184, P45, DOI 10.1083/jcb.200804155; McCord RP, 2013, GENOME RES, V23, P260, DOI 10.1101/gr.138032.112; Merideth MA, 2008, NEW ENGL J MED, V358, P592, DOI 10.1056/NEJMoa0706898; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mondal AM, 2013, J CLIN INVEST, V123, P5247, DOI 10.1172/JCI70355; Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823; Musich PR, 2011, BIOCHEM SOC T, V39, P1764, DOI 10.1042/BST20110687; Musich PR, 2009, AGING-US, V1, P28, DOI 10.18632/aging.100012; Olive M, 2010, ARTERIOSCL THROM VAS, V30, P2301, DOI 10.1161/ATVBAHA.110.209460; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Osorio FG, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002847; Pereira S, 2008, MECH AGEING DEV, V129, P449, DOI 10.1016/j.mad.2008.04.003; Ragnauth CD, 2010, CIRCULATION, V121, P2200, DOI 10.1161/CIRCULATIONAHA.109.902056; Scaffidi P, 2008, NAT CELL BIOL, V10, P452, DOI 10.1038/ncb1708; Sedelnikova OA, 2004, NAT CELL BIOL, V6, P168, DOI 10.1038/ncb1095; Sedelnikova OA, 2008, AGING CELL, V7, P89, DOI 10.1111/j.1474-9726.2007.00354.x; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shumaker DK, 2006, P NATL ACAD SCI USA, V103, P8703, DOI 10.1073/pnas.0602569103; Soria-Valles C, 2015, NAT CELL BIOL, V17, P1004, DOI 10.1038/ncb3207; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Tang Y, 2013, ONCOGENE, V32, P2792, DOI 10.1038/onc.2012.288; Turnquist C, 2016, CELL DEATH DIFFER, V23, P1515, DOI 10.1038/cdd.2016.37; Varela I, 2005, NATURE, V437, P564, DOI 10.1038/nature04019; Varga R, 2006, P NATL ACAD SCI USA, V103, P3250, DOI 10.1073/pnas.0600012103; Vidak S, 2015, GENE DEV, V29, P2022, DOI 10.1101/gad.263939.115; Wei JX, 2012, P NATL ACAD SCI USA, V109, pE2543, DOI 10.1073/pnas.1205664109; Wu MH, 2014, MOL PHARMACOL, V85, P866, DOI 10.1124/mol.113.090688; Yanez RJ, 1999, GENE THER, V6, P1282, DOI 10.1038/sj.gt.3300945; Zhang HY, 2014, P NATL ACAD SCI USA, V111, pE2261, DOI 10.1073/pnas.1320843111	60	33	33	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	18					2379	2393		10.1038/s41388-017-0101-3	http://dx.doi.org/10.1038/s41388-017-0101-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE7BW	29429991	Green Accepted			2022-12-17	WOS:000431386000003
J	Li, GB; Zhang, HW; Fu, RQ; Hu, XY; Liu, L; Li, YN; Liu, YX; Liu, X; Hu, JJ; Deng, Q; Luo, QS; Zhang, R; Gao, N				Li, Guo-Bing; Zhang, Hong-Wei; Fu, Ruo-Qiu; Hu, Xiao-Ye; Liu, Lei; Li, Yu-Nong; Liu, Yan-Xia; Liu, Xin; Hu, Jin-Jiao; Deng, Qin; Luo, Qing-Song; Zhang, Rong; Gao, Ning			Mitochondrial fission and mitophagy depend on cofilin-mediated actin depolymerization activity at the mitochondrial fission site	ONCOGENE			English	Article							PINK1; APOPTOSIS; DYNAMICS; TRANSLOCATION; CYTOSKELETON; PARKIN; CONTRIBUTES; MECHANISMS; REGULATORS; RELEASE	Mitochondria fission and mitophagy are fundamentally crucial to cellular physiology and play important roles in cancer progression. Developing a comprehensive understanding of the molecular mechanism underlying mitochondrial fission and mitophagy will provide novel strategies for cancer prevention and treatment. Actin has been shown to participate in mitochondrial fission and mitophagy regulation. Cofilin is best known as an actin-depolymerizing factor. However, the molecular mechanism by which cofilin regulates mitochondrial fission and mitophagy remains largely unknown. Here we report that knockdown of cofilin attenuates and overexpression of cofilin potentiates mitochondrial fission as well as PINK1/PARK2-dependent mitophagy induced by staurosporine (STS), etoposide (ETO), and carbonyl cyanide 3-chlorophenylhydrazone (CCCP). Cofilin-mediated-PINK1 (PTEN-induced putative kinase 1) accumulation mainly depends on its regulation of mitochondrial proteases, including peptidase mitochondrial processing beta (MPP beta), presenilin-associated rhomboid-like protease (PARL), and ATPase family gene 3-like 2 (AFG3L2), via mitochondrial membrane potential activity. We also found that the interaction and colocalization of G-actin/F-actin with cofilin at mitochondrial fission sites undergo constriction after CCCP treatment. Pretreatment with the actin polymerization inhibitor latrunculin B (LatB) increased and actin-depolymerization inhibitor jasplakinolide (Jas) decreased mitochondrial translocation of actin induced by STS, ETO, and CCCP. Both LatB and Jas abrogated CCCP-mediated mitochondrial fission and mitophagy. Our data suggest that G-actin is the actin form that is translocated to mitochondria, and the actin-depolymerization activity regulated by cofilin at the mitochondrial fission site is crucial for inducing mitochondrial fission and mitophagy.	[Li, Guo-Bing; Zhang, Hong-Wei; Fu, Ruo-Qiu; Hu, Xiao-Ye; Liu, Lei; Li, Yu-Nong; Liu, Yan-Xia; Liu, Xin; Hu, Jin-Jiao; Deng, Qin; Luo, Qing-Song; Gao, Ning] Third Mil Med Univ, Coll Pharm, Chongqing, Peoples R China; [Li, Guo-Bing; Zhang, Rong] Third Mil Med Univ, Affiliated Hosp 2, Dept Pharm, Chongqing, Peoples R China	Army Medical University; Army Medical University	Gao, N (corresponding author), Third Mil Med Univ, Coll Pharm, Chongqing, Peoples R China.; Zhang, R (corresponding author), Third Mil Med Univ, Affiliated Hosp 2, Dept Pharm, Chongqing, Peoples R China.	xqpharmacylab@126.com; gaoning59@163.com	Hu, Xiaoye/AAY-2495-2020		National Natural Science Foundation of China [31571425, 81402970, 81402013]; Clinical Research Projects of Xinqiao Hospital, Third Military Medical University [2016YLC12]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Clinical Research Projects of Xinqiao Hospital, Third Military Medical University	We thank James Bamburg (University of Wisconsin) for providing Cofilin-WT; Tamotsu Yoshimori (Osaka University) for RFP-LC3, and Nico Dantuma (Karolinska Institutet) for GFP-UB. This study was supported by the grants from National Natural Science Foundation of China (31571425; 81402970; 81402013) and Clinical Research Projects of Xinqiao Hospital, Third Military Medical University (2016YLC12).	Ashrafi G, 2013, CELL DEATH DIFFER, V20, P31, DOI 10.1038/cdd.2012.81; Ban-Ishihara R, 2013, P NATL ACAD SCI USA, V110, P11863, DOI 10.1073/pnas.1301951110; Beck H, 2012, P NATL ACAD SCI USA, V109, pE2523, DOI 10.1073/pnas.1208141109; Bernstein BW, 2010, TRENDS CELL BIOL, V20, P187, DOI 10.1016/j.tcb.2010.01.001; Bordi M, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00081; Campello S, 2014, BBA-BIOENERGETICS, V1837, P451, DOI 10.1016/j.bbabio.2013.11.010; Chen HC, 2009, HUM MOL GENET, V18, pR169, DOI 10.1093/hmg/ddp326; Chourasia AH, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0130-8; Chua BT, 2003, NAT CELL BIOL, V5, P1083, DOI 10.1038/ncb1070; De Vos KJ, 2005, CURR BIOL, V15, P678, DOI 10.1016/j.cub.2005.02.064; de Vries RLA, 2013, MOL CELL NEUROSCI, V55, P37, DOI 10.1016/j.mcn.2012.07.008; Ding WX, 2012, BIOL CHEM, V393, P547, DOI 10.1515/hsz-2012-0119; Estaquier J, 2007, CELL DEATH DIFFER, V14, P1086, DOI 10.1038/sj.cdd.4402107; Fedorowicz MA, 2014, EMBO REP, V15, P86, DOI 10.1002/embr.201337294; Frank M, 2012, BBA-MOL CELL RES, V1823, P2297, DOI 10.1016/j.bbamcr.2012.08.007; Greene AW, 2012, EMBO REP, V13, P378, DOI 10.1038/embor.2012.14; Hatch AL, 2014, J CELL SCI, V127, P4549, DOI 10.1242/jcs.153791; Huttemann M, 2008, J BIOENERG BIOMEMBR, V40, P445, DOI 10.1007/s10863-008-9169-3; Jeong SY, 2008, BMB REP, V41, P11, DOI 10.1146/annurev-genet-102108-134850; Ji WK, 2015, ELIFE, V4, DOI [10.7554/eLife.11553, 10.7554/eLife.11553.001]; Jin SM, 2010, J CELL BIOL, V191, P933, DOI 10.1083/jcb.201008084; Karbowski M, 2010, ADV EXP MED BIOL, V687, P131; Kasahara A, 2014, TRENDS CELL BIOL, V24, P761, DOI 10.1016/j.tcb.2014.08.005; Kast DJ, 2015, AUTOPHAGY, V11, P1702, DOI 10.1080/15548627.2015.1073434; Kim JE, 2014, CELL DEATH DIFFER, V21, P1036, DOI 10.1038/cdd.2014.17; Korobova F, 2014, CURR BIOL, V24, P409, DOI 10.1016/j.cub.2013.12.032; Korobova F, 2013, SCIENCE, V339, P464, DOI 10.1126/science.1228360; Kulikov AV, 2017, BIOCHEM BIOPH RES CO, V482, P432, DOI 10.1016/j.bbrc.2016.10.088; Li GB, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-50; Li GB, 2015, ONCOTARGET, V6, P1834, DOI 10.18632/oncotarget.2795; Li SA, 2015, J CELL BIOL, V208, P109, DOI 10.1083/jcb.201404050; Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762; Matsuda S, 2015, FRONT BIOSCI-LANDMRK, V20, P491, DOI 10.2741/4321; Nagai Shoichi, 2011, Genes Cancer, V2, P859, DOI 10.1177/1947601911431839; Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298; O'Flanagan CH, 2014, BBA-REV CANCER, V1846, P590, DOI 10.1016/j.bbcan.2014.10.006; Aguilera MO, 2012, AUTOPHAGY, V8, P1590, DOI 10.4161/auto.21459; Pereira C, 2008, BBA-MOL CELL RES, V1783, P1286, DOI 10.1016/j.bbamcr.2008.03.010; Pi HF, 2013, AUTOPHAGY, V9, P1780, DOI 10.4161/auto.25665; Pon LA, 2013, CURR BIOL, V23, pR279, DOI 10.1016/j.cub.2013.02.042; Preau S, 2016, ANTIOXID REDOX SIGN, V24, P529, DOI 10.1089/ars.2015.6421; Sekino Y, 2007, NEUROCHEM INT, V51, P92, DOI 10.1016/j.neuint.2007.04.029; Senft D, 2016, CURR OPIN CELL BIOL, V39, P43, DOI 10.1016/j.ceb.2016.02.001; Seo AY, 2010, J CELL SCI, V123, P2533, DOI 10.1242/jcs.070490; Springer W, 2011, AUTOPHAGY, V7, P266, DOI 10.4161/auto.7.3.14348; van Raam BJ, 2006, INT J HEMATOL, V84, P199, DOI 10.1532/IJH97.06131; Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028; Zhu JS, 2012, PHARMACOLOGY, V89, P348, DOI 10.1159/000338757	50	33	34	1	27	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	11					1485	1502		10.1038/s41388-017-0064-4	http://dx.doi.org/10.1038/s41388-017-0064-4			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ3AZ	29321664				2022-12-17	WOS:000427459500007
J	Zhou, H; Qin, Y; Ji, S; Ling, J; Fu, J; Zhuang, Z; Fan, X; Song, L; Yu, X; Chiao, PJ				Zhou, H.; Qin, Y.; Ji, S.; Ling, J.; Fu, J.; Zhuang, Z.; Fan, X.; Song, L.; Yu, X.; Chiao, P. J.			SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer	ONCOGENE			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; CELL-PROLIFERATION; UP-REGULATION; DNA-DAMAGE; INHIBITION; ACTIVATION; CARCINOMA	SRY (sex determining region Y)-box 9 (SOX9) is required for oncogenic Kras-mediated acinar-to-ductal metaplasia (ADM), pancreatic intraepithelial neoplasias (PanINs) and ultimately pancreatic ductal adenocarcinoma (PDAC). However, how oncogenic Kras affects SOX9 activity is not yet understood, and SOX9-associated genes in PDAC are also unknown at all. Here, we investigated the mechanistic link between SOX9 and oncogenic Kras, studied biological function of SOX9, and identified SOX9-related genes and their clinical significance in patients with PDAC. Our studies reveal that oncogenic Kras induces SOX9 mRNA and protein expression as well as phosphorylated SOX9 expression in human pancreatic ductal progenitor cells (HPNE) and pancreatic ductal cells (HPDE). Moreover, oncogenic Kras promoted nuclear translocation and transcriptional activity of SOX9 in these cells. TAK1/I kappa Ba/NF-kappa B pathway contributed to induction of SOX9 by oncogenic Kras, and SOX9 in turn enhanced NF-kappa B activation. SOX9 promoted the proliferation of HPNE and PDAC cells, and correlated with minichromosome maintenance complex components (MCMs) and mediator of DNA damage checkpoint 1 (MDC1) expression. The overexpressive MDC1 was associated with less perineural and lymph node invasion of tumors and early TNM-stage of patients. Our results indicate that oncogenic Kras induces constitutive activation of SOX9 in HPNE and HPDE cells, and Kras/TAK1/I kappa Ba/NF-kappa B pathway and a positive feedback between SOX9 and NF-kappa B are involved in this inducing process. SOX9 accelerates proliferation of cells and affects MCMs and MDC1 expression. MDC1 is associated negatively with invasion and metastasis of PDAC.	[Zhou, H.; Ling, J.; Fu, J.; Zhuang, Z.; Chiao, P. J.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 107,1515 Holcombe Blvd, Houston, TX 77030 USA; [Zhou, H.; Ling, J.; Fu, J.; Zhuang, Z.; Fan, X.; Chiao, P. J.] Fudan Univ, Liver Canc Inst, Shanghai, Peoples R China; [Zhou, H.; Ling, J.; Fu, J.; Zhuang, Z.; Fan, X.; Chiao, P. J.] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China; [Qin, Y.; Ji, S.; Yu, X.] Fudan Univ, Shanghai Canc Ctr, Dept Pancreat & Hepatobiliary Surg, Shanghai 200032, Peoples R China; [Qin, Y.; Ji, S.; Yu, X.] Fudan Univ, Pancreat Canc Inst, Shanghai 200032, Peoples R China; [Zhuang, Z.] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Dept Gen Surg, Beijing, Peoples R China; [Song, L.] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Henan, Peoples R China; [Chiao, P. J.] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; Fudan University; Fudan University; Fudan University; Fudan University; Tsinghua University; Zhengzhou University; University of Texas System; University of Texas Health Science Center Houston	Chiao, PJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 107,1515 Holcombe Blvd, Houston, TX 77030 USA.; Yu, X (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Pancreat & Hepatobiliary Surg, Shanghai 200032, Peoples R China.	yuxianjun@fudan.edu.cn; pjchiao@mdanderson.org			Skip Viragh foundation; National Cancer Institute [CA109405, CA142674]; Cancer Center Core Supporting grant [CA16672]; China National Natural Science Foundation [81272733]; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA207031] Funding Source: NIH RePORTER	Skip Viragh foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Center Core Supporting grant; China National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Jun Yao in the Department of Biostatistics, MD Anderson Cancer Center, for statistical analysis of data from RNA-seq. This work was supported in part by grants from Skip Viragh foundation (to PJC), the National Cancer Institute (CA109405 and CA142674 to PJC), a Cancer Center Core Supporting grant (CA16672) and China National Natural Science Foundation (81272733).	Belo J, 2013, STEM CELLS DEV, V22, P2935, DOI 10.1089/scd.2013.0106; Chang Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101452; Chang Z, 2013, CLIN CANCER RES, V19, P549, DOI 10.1158/1078-0432.CCR-12-0032; Chen LM, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1234570; Coster G, 2010, NUCLEUS-PHILA, V1, P166, DOI 10.4161/nucl.1.2.11176; di Magliano MP, 2013, GASTROENTEROLOGY, V144, P1220, DOI 10.1053/j.gastro.2013.01.071; Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9; Espersen MLM, 2016, HUM PATHOL, V52, P38, DOI 10.1016/j.humpath.2015.12.026; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Fujioka S, 2003, ONCOGENE, V22, P1365, DOI 10.1038/sj.onc.1206323; Grimont A, 2015, GUT, V64, P1790, DOI 10.1136/gutjnl-2014-307075; Guo D, 2012, MOL CELL BIOCHEM, V363, P179, DOI 10.1007/s11010-011-1170-1; Hong YC, 2015, ONCOTARGET, V6, P31241, DOI 10.18632/oncotarget.5160; Kawaguchi Y, 2013, J CLIN INVEST, V123, P1881, DOI 10.1172/JCI66022; Kim JE, 2006, MOL CARCINOGEN, V45, P403, DOI 10.1002/mc.20221; Kist R., MUS MUSCULUS SRY BOX; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Lee KM, 2005, LAB INVEST, V85, P1003, DOI 10.1038/labinvest.3700298; Lei M, 2001, J CELL SCI, V114, P1447; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Luanpitpong S, 2016, ONCOGENE, V35, P2824, DOI 10.1038/onc.2015.351; Melisi D, 2007, EXPERT OPIN THER TAR, V11, P133, DOI 10.1517/14728222.11.2.133; Melisi D, 2011, JNCI-J NATL CANCER I, V103, P1190, DOI 10.1093/jnci/djr243; Melisi D, 2009, MOL CANCER RES, V7, P624, DOI 10.1158/1541-7786.MCR-08-0201; Morris JP, 2010, J CLIN INVEST, V120, P508, DOI 10.1172/JCI40045; Piper K, 2002, MECH DEVELOP, V116, P223, DOI 10.1016/S0925-4773(02)00145-4; Saegusa M, 2012, AM J PATHOL, V181, P684, DOI 10.1016/j.ajpath.2012.05.008; Simon NE, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/549719; Staudt LM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000109; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Sun L, 2013, STEM CELLS, V31, P1454, DOI 10.1002/stem.1394; Wang CY, 2015, NUCLEIC ACIDS RES, V43, P4893, DOI 10.1093/nar/gkv394; Wang HY, 2015, ONCOTARGET, V6, P20711, DOI 10.18632/oncotarget.4133; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wu LM, 2008, P NATL ACAD SCI USA, V105, P11200, DOI 10.1073/pnas.0802885105; Xia SH, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0358-0; Ying HQ, 2016, GENE DEV, V30, P355, DOI 10.1101/gad.275776.115; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Zhou HJ, 2010, GUT, V59, P1699, DOI 10.1136/gut.2010.218404; Zou RL, 2015, INT J BIOL SCI, V11, P992, DOI 10.7150/ijbs.10918	40	33	35	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					912	923		10.1038/onc.2017.393	http://dx.doi.org/10.1038/onc.2017.393			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059173	Green Accepted			2022-12-17	WOS:000425281800008
J	Jing, Y; Nguyen, MM; Wang, D; Pascal, LE; Guo, W; Xu, Y; Ai, J; Deng, FM; Masoodi, KZ; Yu, X; Zhang, J; Nelson, JB; Xia, S; Wang, Z				Jing, Y.; Nguyen, M. M.; Wang, D.; Pascal, L. E.; Guo, W.; Xu, Y.; Ai, J.; Deng, F-M; Masoodi, K. Z.; Yu, X.; Zhang, J.; Nelson, J. B.; Xia, S.; Wang, Z.			DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor	ONCOGENE			English	Article							NUCLEAR EXPORT SIGNAL; BOX RNA HELICASE; TRANSCRIPTIONAL ACTIVITY; LIGASE SIAH2; TERMINAL SEQUENCES; SPLICING FACTORS; SPLICEOSOME; BINDING; STABILITY; RESPONSES	Androgen receptor (AR) activation is critical for prostate cancer (PCa) development and progression, including castration resistance. The nuclear export signal of AR (NESAR) has an important role in AR intracellular trafficking and proteasome-dependent degradation. Here, we identified the RNA helicase DHX15 as a novel AR co-activator using a yeast mutagenesis screen and revealed that DHX15 regulates AR activity by modulating E3 ligase Siah2-mediated AR ubiquitination independent of its ATPase activity. DHX15 and Siah2 form a complex with AR, through NESAR. DHX15 stabilized Siah2 and enhanced its E3 ubiquitin-ligase activity, resulting in AR activation. Importantly, DHX15 was upregulated in PCa specimens and its expression was correlated with Gleason scores and prostate-specific antigen recurrence. Furthermore, DHX15 immunostaining correlated with Siah2. Finally, DHX15 knockdown inhibited the growth of C4-2 prostate tumor xenografts in mice. Collectively, our data argue that DHX15 enhances AR transcriptional activity and contributes to PCa progression through Siah2.	[Jing, Y.; Xia, S.] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Urol, Sch Med, Shanghai, Peoples R China; [Jing, Y.; Nguyen, M. M.; Wang, D.; Pascal, L. E.; Guo, W.; Xu, Y.; Ai, J.; Masoodi, K. Z.; Nelson, J. B.; Wang, Z.] Univ Pittsburgh, Sch Med, Dept Urol, Inst Canc, Pittsburgh, PA 15232 USA; [Guo, W.] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Pathol, Sch Med, Shanghai, Peoples R China; [Xu, Y.] Cent S Univ, Xiangya Hosp 2, Dept Urol, Changsha, Hunan, Peoples R China; [Xu, Y.] Cent S Univ, Xiangya Hosp 3, Changsha, Hunan, Peoples R China; [Deng, F-M] NYU, Sch Med, Dept Pathol, New York, NY USA; [Masoodi, K. Z.] SKUAST K, Div Plant Biotechnol, Transcript Lab, Srinagar, Jammu & Kashmir, India; [Yu, X.] Guangzhou Gen Hosp Guangzhou Mil Command, Dept Geriatr, Guangzhou, Guangdong, Peoples R China; [Yu, X.] Guangdong Prov Key Lab Geriatr Infect & Organ Fun, Guangzhou, Guangdong, Peoples R China; [Yu, X.] Guangzhou Key Lab Geriatr Infect & Organ Funct Su, Guangzhou, Guangdong, Peoples R China; [Yu, X.] Southern Med Univ, Tradit Chinese Med Integrated Hosp, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Zhang, J.] Guangxi Med Univ, Ctr Translat Med, Nanning, Guangxi, Peoples R China; [Zhang, J.] Univ Pittsburgh, Sch Med, Inst Canc, Pittsburgh, PA 15232 USA; [Nelson, J. B.; Wang, Z.] Univ Pittsburgh, Sch Med, Inst Canc, Dept Mol Pharmacol & Chem Biol, Pittsburgh, PA 15232 USA; [Wang, Z.] Univ Pittsburgh, Sch Med, Inst Canc, Dept Pathol, Pittsburgh, PA 15232 USA	Shanghai Jiao Tong University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Shanghai Jiao Tong University; Central South University; Central South University; New York University; Sher-e-Kashmir University of Agricultural Sciences & Technology of Kashmir (SKUAST Kashmir); Southern Theater Command General Hospital; Southern Medical University - China; Guangxi Medical University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Xia, S; Wang, Z (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Pathol, Pittsburgh, PA 15232 USA.; Xia, S; Wang, Z (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Urol,Dept Mol Pharmacol & Chem Biol, Pittsburgh, PA 15232 USA.	xsjurologist@163.com; wangz2@upmc.edu	Pascal, Laura E./AAH-5743-2019; Masoodi, Khalid Z/F-1787-2015; Masoodi, KhalidZ./ABG-5492-2021	Pascal, Laura E./0000-0003-3840-1662; Masoodi, Khalid Z/0000-0002-4889-5558; Masoodi, KhalidZ./0000-0002-4889-5558	NIH [R01 CA186780, R01 CA108675, R50 CA211242-01]; ACS [PF-05-229-01-CSM]; Department of Defense Prostate Cancer Research Program Award [W81XWH-14-2-0182, W81XWH-14-2-0183, W81XWH-14-2-0185, W81XWH-14-2-0186, W81XWH-15-2-0062 PCBN]; National Nature Science Foundation of China [81402091]; National Natural Science Foundation of China [81130046, 2013GXNSFEA053004]; Urology Care Foundation of the American Urological Association; Mellam Family Fellowship; Tippens Scholarship; UPCI; Tissue and Research Pathology Services (TARPS) [NCI CCSG P30CA047904]; NATIONAL CANCER INSTITUTE [R01CA108675, R01CA186780, R50CA211242, P30CA047904] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ACS(American Cancer Society); Department of Defense Prostate Cancer Research Program Award(United States Department of Defense); National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Urology Care Foundation of the American Urological Association; Mellam Family Fellowship; Tippens Scholarship; UPCI; Tissue and Research Pathology Services (TARPS); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Aiyuan Zhang for technical support, Richard Gaber (Northwestern University) for advice on yeast screen, the PCBN for TMA with PCa specimens, Megan Lambert, Krystal Roskov and Robin Frederick for animal husbandry, and members of the Wang Lab for discussion. This work was supported in part by NIH R01 CA186780 (ZW), NIH R01 CA108675 (ZW), ACS #PF-05-229-01-CSM (MMN), the Department of Defense Prostate Cancer Research Program Award No W81XWH-14-2-0182, W81XWH-14-2-0183, W81XWH-14-2-0185, W81XWH-14-2-0186, and W81XWH-15-2-0062 PCBN, National Nature Science Foundation of China # 81402091 (YJ), and National Natural Science Foundation of China Key Project 81130046 (JZ) and 2013GXNSFEA053004 (JZ). This work was also supported by a post-doctoral fellowship from the Urology Care Foundation of the American Urological Association (DW), the Mellam Family Fellowship (DW and KZM), the Tippens Scholarship (LEP) and NIH R50 CA211242-01 (LEP). In addition, this research was supported by the UPCI Animal Facility, Vector Core and Tissue and Research Pathology Services (TARPS) funded through NCI CCSG P30CA047904.	Arenas JE, 1997, P NATL ACAD SCI USA, V94, P11798, DOI 10.1073/pnas.94.22.11798; BROWN JD, 1992, EMBO J, V11, P3721, DOI 10.1002/j.1460-2075.1992.tb05457.x; Chan Siu Chiu, 2014, Adv Pharmacol, V70, P327, DOI 10.1016/B978-0-12-417197-8.00011-0; Chymkowitch P, 2011, EMBO J, V30, P468, DOI 10.1038/emboj.2010.337; Clark EL, 2008, CANCER RES, V68, P7938, DOI 10.1158/0008-5472.CAN-08-0932; Coffey K, 2012, J ENDOCRINOL, V215, P221, DOI 10.1530/JOE-12-0238; Combs DJ, 2006, MOL CELL BIOL, V26, P523, DOI 10.1128/MCB.26.2.523-534.2006; Dong XS, 2007, MOL CELL BIOL, V27, P4863, DOI 10.1128/MCB.02144-06; Ferraldeschi R, 2015, ONCOGENE, V34, P1745, DOI 10.1038/onc.2014.115; Fouraux MA, 2002, RNA, V8, P1428, DOI 10.1017/S1355838202021076; Fourmann JB, 2013, GENE DEV, V27, P413, DOI 10.1101/gad.207779.112; Freeman MR, 2013, ASIAN J ANDROL, V15, P447, DOI 10.1038/aja.2013.62; Fukuba H, 2008, NEUROSCI LETT, V433, P209, DOI 10.1016/j.neulet.2007.12.069; Gaughan L, 2005, NUCLEIC ACIDS RES, V33, P13, DOI 10.1093/nar/gki141; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Gong YQ, 2012, ENDOCRINOLOGY, V153, P5716, DOI 10.1210/en.2012-1841; Grosso AR, 2008, EMBO REP, V9, P1087, DOI 10.1038/embor.2008.189; Haider AS, 2010, INTERN MED J, V40, P281, DOI 10.1111/j.1445-5994.2009.02041.x; Hellerstedt BA, 2002, CA-CANCER J CLIN, V52, P154, DOI 10.3322/canjclin.52.3.154; Hu G, 1999, MOL CELL BIOL, V19, P724; Kobayashi T, 2013, INT J MOL SCI, V14, P15615, DOI 10.3390/ijms140815615; Koodathingal P, 2010, MOL CELL, V39, P385, DOI 10.1016/j.molcel.2010.07.014; Li B., 2014, RECEPTORS CLIN INVES, V1, DOI 10.14800%14802Frci.14122; Lonergan Peter E, 2011, J Carcinog, V10, P20, DOI 10.4103/1477-3163.83937; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Mosallanejad K, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004841; Nadeau RJ, 2007, J CELL BIOCHEM, V100, P151, DOI 10.1002/jcb.21040; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Nakayama K, 2009, MOL CANCER RES, V7, P443, DOI 10.1158/1541-7786.MCR-08-0458; Nguyen MM, 2014, INT J CLIN EXP PATHO, V7, P2768; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Poukka H, 2000, J CELL SCI, V113, P2991; Qi JF, 2013, CANCER CELL, V23, P332, DOI 10.1016/j.ccr.2013.02.016; Rajan P, 2008, J PATHOL, V215, P67, DOI 10.1002/path.2324; Reed JC, 2002, NAT STRUCT BIOL, V9, P8, DOI 10.1038/nsb0102-8; Saporita AJ, 2003, J BIOL CHEM, V278, P41998, DOI 10.1074/jbc.M302460200; Scortegagna M, 2011, J BIOL CHEM, V286, P27333, DOI 10.1074/jbc.M111.218214; Shafi AA, 2013, PHARMACOL THERAPEUT, V140, P223, DOI 10.1016/j.pharmthera.2013.07.003; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tanaka N, 2007, GENE DEV, V21, P2312, DOI 10.1101/gad.1580507; Walbott H, 2010, EMBO J, V29, P2194, DOI 10.1038/emboj.2010.102; Xu KX, 2009, CANCER CELL, V15, P270, DOI 10.1016/j.ccr.2009.02.021; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775; Zhao HL, 2010, BIOCHEM BIOPH RES CO, V399, P623, DOI 10.1016/j.bbrc.2010.07.127; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	46	33	34	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					638	650		10.1038/onc.2017.371	http://dx.doi.org/10.1038/onc.2017.371			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	28991234	Green Accepted			2022-12-17	WOS:000423812200009
J	Mizrahi, A; Barzilai, A; Gur-Wahnon, D; Ben-Dov, IZ; Glassberg, S; Meningher, T; Elharar, E; Masalha, M; Jacob-Hirsch, J; Tabibian-Keissar, H; Barshack, I; Roszik, J; Leibowitz-Amit, R; Sidi, Y; Avni, D				Mizrahi, A.; Barzilai, A.; Gur-Wahnon, D.; Ben-Dov, I. Z.; Glassberg, S.; Meningher, T.; Elharar, E.; Masalha, M.; Jacob-Hirsch, J.; Tabibian-Keissar, H.; Barshack, I.; Roszik, J.; Leibowitz-Amit, R.; Sidi, Y.; Avni, D.			Alterations of microRNAs throughout the malignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 in epithelial to mesenchymal transition of keratinocytes	ONCOGENE			English	Article							DOWN-REGULATION; POOR-PROGNOSIS; CYCLIN D1; CANCER; EXPRESSION; METASTASIS; CLUSTER; DIFFERENTIATION; METHYLATION; SYSTEM	Skin carcinogenesis is known to be a multi-step process with several stages along its malignant evolution. We hypothesized that transformation of normal epidermis to cutaneous squamous cell carcinoma (cSCC) is causally linked to alterations in microRNAs (miRNA) expression. For this end we decided to evaluate their alterations in the pathologic states ending in cSCC. Total RNA was extracted from formalin fixed paraffin embedded biopsies of five stages along the malignant evolution of keratinocytes towards cSCC: Normal epidermis, solar elastosis, actinic keratosis KIN1-2, advanced actinic keratosis KIN3 and well-differentiated cSCC. Next-generation small RNA sequencing was performed. We found that 18 miRNAs are overexpressed and 28 miRNAs are underexpressed in cSCC compared to normal epidermis. miR-424, miR-320, miR-222 and miR-15a showed the highest fold change among the overexpressed miRNAs. And miR-100, miR-101 and miR-497 showed the highest fold change among the underexpressed miRNAs. Heat map of hierarchical clustering analysis of significantly changed miRNAs and principle component analysis disclosed that the most prominent change in miRNAs expression occurred in the switch from 'early' stages; normal epidermis, solar elastosis and early actinic keratosis to the 'late' stages of epidermal carcinogenesis; late actinic keratosis and cSCC. We found several miRNAs with 'stage specific' alterations while others display a clear 'gradual', either progressive increase or decrease in expression along the malignant evolution of keratinocytes. The observed alterations focused in miRNAs involved in the regulation of AKT/mTOR or in those involved in epithelial to mesenchymal transition. We chose to concentrate on the evaluation of the molecular role of miR-497. We found that it induces reversion of epithelial to mesenchymal transition. We proved that SERPINE-1 is its biochemical target. The present study allows us to further study the pathways that are regulated by miRNAs along the malignant evolution of keratinocytes towards cSCC.	[Mizrahi, A.; Glassberg, S.; Meningher, T.; Elharar, E.; Masalha, M.; Sidi, Y.; Avni, D.] Sheba Med Ctr, Ctr Canc Res, Lab Mol Cell Biol, Tel Hashomer, Israel; [Mizrahi, A.; Glassberg, S.; Meningher, T.; Elharar, E.; Masalha, M.; Sidi, Y.; Avni, D.] Sheba Med Ctr, Dept Med C, Tel Hashomer, Israel; [Barzilai, A.] Sheba Med Ctr, Dept Dermatol, Tel Hashomer, Israel; [Barzilai, A.] Sheba Med Ctr, Inst Pathol, Tel Hashomer, Israel; [Gur-Wahnon, D.; Ben-Dov, I. Z.] Hadassah Hebrew Univ, Med Ctr, Lab Med Transcript Nephrol & Hypertens Serv, Jerusalem, Israel; [Masalha, M.; Barshack, I.; Leibowitz-Amit, R.; Sidi, Y.] Tel Aviv Univ, Sackler Sch Med, Fac Med, Tel Aviv, Israel; [Jacob-Hirsch, J.] Sheba Med Ctr, Ctr Canc Res, Tel Hashomer, Israel; [Tabibian-Keissar, H.] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, Ramat Gan, Israel; [Tabibian-Keissar, H.; Barshack, I.] Sheba Med Ctr, Dept Pathol, Tel Hashomer, Israel; [Roszik, J.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA; [Roszik, J.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Leibowitz-Amit, R.] Sheba Med Ctr, Inst Oncol, Tel Hashomer, Israel	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Bar Ilan University; Chaim Sheba Medical Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Chaim Sheba Medical Center	Sidi, Y; Avni, D (corresponding author), Sheba Med Ctr, Ctr Canc Res, Lab Mol Cell Biol, IL-52621 Ramat Gan, Israel.; Sidi, Y; Avni, D (corresponding author), Sheba Med Ctr, Dept Med C, IL-52621 Ramat Gan, Israel.	yehezkel.sidi@sheba.health.gov.il; droravni@msn.com	Avni, Dror/GRE-8325-2022; Ben-Dov, Iddo/F-3282-2010	Ben-Dov, Iddo/0000-0002-9180-3604; Roszik, Jason/0000-0002-4561-6170; sidi, yechezkel/0000-0001-7781-6153; Avni, Dror/0000-0002-8738-1840	Israel Cancer Association (ICA) [20110076, 20160038]; Ministry of Health, State of Israel (Ministry of Health) [3-10132]	Israel Cancer Association (ICA); Ministry of Health, State of Israel (Ministry of Health)	This work was funded by: Israel Cancer Association (ICA)-grant number 20110076 to Avni D, and Ministry of Health, State of Israel (Ministry of Health)-grant number 3-10132 to Avni D, and Israel Cancer Association (ICA)-grant number 20160038 to Avni D.	Alam M, 2001, NEW ENGL J MED, V344, P975, DOI 10.1056/NEJM200103293441306; Barrette K, 2014, BRIT J DERMATOL, V171, P1014, DOI 10.1111/bjd.12967; Barzilai A, 2007, J AM ACAD DERMATOL, V57, P669, DOI 10.1016/j.jaad.2007.04.025; Boominathan L, 2010, CANCER METAST REV, V29, P613, DOI 10.1007/s10555-010-9257-9; Boukamp P, 2005, CARCINOGENESIS, V26, P1657, DOI 10.1093/carcin/bgi123; Boukamp Petra, 2005, J Dtsch Dermatol Ges, V3, P493, DOI 10.1111/j.1610-0387.2005.05037.x; Boyerinas B, 2010, ENDOCR-RELAT CANCER, V17, pF19, DOI 10.1677/ERC-09-0184; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Burnworth B, 2007, EUR J CELL BIOL, V86, P763, DOI 10.1016/j.ejcb.2006.11.002; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen ZJ, 2012, ORAL ONCOL, V48, P686, DOI 10.1016/j.oraloncology.2012.02.020; Cleaver JE, 2002, FRONT BIOSCI-LANDMRK, V7, pD1024, DOI 10.2741/cleaver; Cockerell CJ, 2000, J AM ACAD DERMATOL, V42, pS11, DOI 10.1067/mjd.2000.103344; Cockerell Clay J, 2005, J Drugs Dermatol, V4, P462; Corbalan-Velez R, 2010, ACTAS DERMO-SIFILOGR, V101, P517, DOI 10.1016/j.ad.2010.01.008; Dziunycz P, 2010, J INVEST DERMATOL, V130, P2686, DOI 10.1038/jid.2010.169; Eshkoor SA, 2009, BIOSCI TRENDS, V3, P105; Farazi TA, 2012, METHODS, V58, P171, DOI 10.1016/j.ymeth.2012.07.020; Feng FQ, 2016, HUM PATHOL, V58, P47, DOI 10.1016/j.humpath.2016.04.022; Freytag J, 2010, J INVEST DERMATOL, V130, P2179, DOI 10.1038/jid.2010.106; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Gaujoux R, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-367; Geiger TR, 2009, BBA-REV CANCER, V1796, P293, DOI 10.1016/j.bbcan.2009.07.006; Gillespie J, 2016, J EUR ACAD DERMATOL, V30, P1043, DOI 10.1111/jdv.13098; Green J, 2006, BRIT J CANCER, V94, P1446, DOI 10.1038/sj.bjc.6603135; Guarino M, 2007, INT J BIOCHEM CELL B, V39, P2153, DOI 10.1016/j.biocel.2007.07.011; Guo R, 2017, J CELL BIOCHEM, V118, P3401, DOI 10.1002/jcb.25997; Guo ST, 2013, ONCOGENE, V32, P1910, DOI 10.1038/onc.2012.214; Hafner M, 2012, METHODS, V58, P164, DOI 10.1016/j.ymeth.2012.07.030; He XX, 2015, MOL BIOSYST, V11, P532, DOI 10.1039/c4mb00563e; Hu Yang, 2014, Microrna, V3, P108; Hu YS, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0093310, 10.1371/journal.pone.0093425, 10.1371/journal.pone.0092099]; Huang Hou-Gang, 2015, Asian Pac J Cancer Prev, V16, P4937; Huntley MA, 2013, BIOINFORMATICS, V29, P3220, DOI 10.1093/bioinformatics/btt551; Jin Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064434; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Ksiazkiewicz M, 2012, PATHOBIOLOGY, V79, P195, DOI 10.1159/000337106; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lerman G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020916; Li D, 2011, CLIN CANCER RES, V17, P1722, DOI 10.1158/1078-0432.CCR-10-1800; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Luo M, 2013, SURGERY, V153, P836, DOI 10.1016/j.surg.2012.12.004; Ma L, 2008, CELL CYCLE, V7, P570, DOI 10.4161/cc.7.5.5547; Mathias RA, 2013, J PROTEOMICS, V78, P545, DOI 10.1016/j.jprot.2012.10.016; Menigatti M, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.21; Moustakas A, 2016, J CLIN MED, V5, DOI 10.3390/jcm5070063; Moustakas A, 2012, SEMIN CANCER BIOL, V22, P446, DOI 10.1016/j.semcancer.2012.04.002; Mu P, 2009, GENE DEV, V23, P2806, DOI 10.1101/gad.1872909; Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409; Omori K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148969; Pang L., 2014, SCI WORLD J, V2014, P1; Papageorgis P, 2015, J ONCOL, V2015, DOI 10.1155/2015/587193; Ra SH, 2011, MODERN PATHOL, V24, P963, DOI 10.1038/modpathol.2011.39; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Sand M, 2012, J DERMATOL SCI, V68, P119, DOI 10.1016/j.jdermsci.2012.09.004; Schickel R, 2008, ONCOGENE, V27, P5959, DOI 10.1038/onc.2008.274; Solly K, 2004, ASSAY DRUG DEV TECHN, V2, P363, DOI 10.1089/adt.2004.2.363; Sun D, 2014, ONCOGENE, V33, P1448, DOI 10.1038/onc.2013.77; Sun YM, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-6; TILGEN W, 1983, CANCER RES, V43, P5995; Toll A, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0537-z; Toll A, 2013, J DERMATOL SCI, V72, P93, DOI 10.1016/j.jdermsci.2013.07.001; van Haaften G, 2010, GENE DEV, V24, P1, DOI 10.1101/gad.1887110; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Wang A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103206; Wang N, 2014, ASIAN PAC J CANCER P, V15, P10355, DOI 10.7314/APJCP.2014.15.23.10355; Wang SH, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-172; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wu ZH, 2016, TUMOR BIOL, V37, P7939, DOI 10.1007/s13277-015-4665-7; Xu N, 2012, J BIOL CHEM, V287, P29899, DOI 10.1074/jbc.M112.391243; Yan H, 2014, MOL CARCINOGEN, V53, P960, DOI 10.1002/mc.22064; Yu X, 2016, J CELL MOL MED, V20, P3, DOI 10.1111/jcmm.12649; Zaravinos A., 2015, J ONCOL, V2015, DOI DOI 10.1155/2015/865816; Zehavi L, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0338-9; Zehavi L, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-44; Zhang JC, 2012, BIOCHEM BIOPH RES CO, V417, P1100, DOI 10.1016/j.bbrc.2011.12.121; Zhang JS, 2012, CANCER METAST REV, V31, P653, DOI 10.1007/s10555-012-9368-6; Zhang L, 2016, WORLD J PSYCHIATR, V6, P1, DOI 10.5498/wjp.v6.i1.1; Zhang N, 2016, ONCOTARGETS THER, V9, P6597, DOI 10.2147/OTT.S114609; Zhao XL, 2015, INT J CLIN EXP PATHO, V8, P758	81	33	35	0	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					218	230		10.1038/onc.2017.315	http://dx.doi.org/10.1038/onc.2017.315			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28925390				2022-12-17	WOS:000422631700008
J	Giono, LE; Resnick-Silverman, L; Carvajal, LA; St Clair, S; Manfredi, JJ				Giono, L. E.; Resnick-Silverman, L.; Carvajal, L. A.; St Clair, S.; Manfredi, J. J.			Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase	ONCOGENE			English	Article							INDEPENDENT PROTEASOMAL DEGRADATION; DUAL-SPECIFICITY PHOSPHATASE; UBIQUITIN-DEPENDENT DEGRADATION; INDUCED DOWN-REGULATION; TUMOR-SUPPRESSOR P53; DNA-DAMAGE; ONCOPROTEIN MDM2; S-PHASE; TRANSCRIPTIONAL REPRESSION; EMBRYONIC LETHALITY	Upon different types of stress, the gene encoding the mitosis-promoting phosphatase Cdc25C is transcriptionally repressed by p53, contributing to p53's enforcement of a G2 cell cycle arrest. In addition, Cdc25C protein stability is also decreased following DNA damage. Mdm2, another p53 target gene, encodes a ubiquitin ligase that negatively regulates p53 levels by ubiquitination. Ablation of Mdm2 by siRNA led to an increase in p53 protein and repression of Cdc25C gene expression. However, Cdc25C protein levels were actually increased following Mdm2 depletion. Mdm2 is shown to negatively regulate Cdc25C protein levels by reducing its half-life independently of the presence of p53. Further, Mdm2 physically interacts with Cdc25C and promotes its degradation through the proteasome in a ubiquitin-independent manner. Either Mdm2 overexpression or Cdc25C downregulation delays cell cycle progression through the G2/M phase. Thus, the repression of the Cdc25C promoter by p53, together with p53-dependent induction of Mdm2 and subsequent degradation of Cdc25C, could provide a dual mechanism by which p53 can enforce and maintain a G2/M cell cycle arrest.	Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10021 USA; Icahn Sch Med Mt Sinai, Grad Sch Biol Sci, New York, NY 10021 USA; [Giono, L. E.] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Fisiol Biol Mol & Celular, Buenos Aires, DF, Argentina; [Giono, L. E.] Univ Buenos Aires, CONICET, Inst Fisiol Biol Mol & Neurociencias IFIBYNE, Buenos Aires, DF, Argentina; [Carvajal, L. A.] Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Yeshiva University; Albert Einstein College of Medicine	Manfredi, JJ (corresponding author), Icahn Sch Med Mt Sinai, Oncol Sci, One Gustave L Levy Pl,Box 1130, New York, NY 10021 USA.	james.manfredi@mssm.edu			National Cancer Institute [F31CA150539, R03CA216466];  [P30CA196521]; NATIONAL CANCER INSTITUTE [R03CA216466, P30CA196521, F31CA150539] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Matthew O'Connell and Zhen-Qiang Pan for their technical advice, helpful discussions and sharing reagents. Present and past members of the Manfredi laboratory: Dana Lukin, Anthony Mastropietro, Wendy Liu, Sejal Patel, Shohreh Varmeh-Ziaie, Pierre-Jacques Hamard and Kester Haye are thanked for their help and support. Quantitative PCR was performed at the Mount Sinai shared research facility. These studies were supported by grants from the National Cancer Institute F31CA150539 to LAC, R03CA216466 to JJM, and developmental support from P30CA196521. Grant support: National Cancer Institute F31CA150539 to LAC, R03CA216466 to JJM, and developmental support from P30CA196521.	Asher G, 2002, P NATL ACAD SCI USA, V99, P13125, DOI 10.1073/pnas.202480499; Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Boyd MT, 2000, J BIOL CHEM, V275, P31883, DOI 10.1074/jbc.M004252200; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Calabro V, 2002, J BIOL CHEM, V277, P2674, DOI 10.1074/jbc.M107173200; Chen F, 2002, P NATL ACAD SCI USA, V99, P1990, DOI 10.1073/pnas.032428899; Chen XY, 2004, MOL CELL, V16, P839, DOI 10.1016/j.molcel.2004.11.011; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Ciznadija D, 2011, CELL CYCLE, V10, P2714, DOI 10.4161/cc.10.16.16725; Clair SS, 2006, CELL CYCLE, V5, P709, DOI 10.4161/cc.5.7.2628; Coutts AS, 2007, EMBO REP, V8, P84, DOI 10.1038/sj.embor.7400855; Dang JJ, 2002, CANCER RES, V62, P1222; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; Eymin B, 2006, CELL CYCLE, V5, P759, DOI 10.4161/cc.5.7.2625; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Folberg-Blum A, 2002, ONCOGENE, V21, P2413, DOI 10.1038/sj.onc.1205305; Garcia P, 1996, ONCOGENE, V13, P695; Giono LE, 2007, MOL CELL BIOL, V27, P4166, DOI 10.1128/MCB.01967-06; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Le Gac G, 2006, J BIOL CHEM, V281, P24161, DOI 10.1074/jbc.M603724200; Little NA, 2001, ONCOGENE, V20, P4576, DOI 10.1038/sj.onc.1204615; Liu TT, 2012, J BIOL INORG CHEM, V17, P311, DOI 10.1007/s00775-011-0852-1; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Manfredi JJ, 2010, GENE DEV, V24, P1580, DOI 10.1101/gad.1941710; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Obeyesekere MN, 2004, CELL CYCLE, V3, P655; Ohkubo S, 2006, J BIOL CHEM, V281, P16943, DOI 10.1074/jbc.M601388200; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Perry ME, 2000, J BIOL CHEM, V275, P5733, DOI 10.1074/jbc.275.8.5733; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Piwnica-Worms H, 1999, NATURE, V401, P535, DOI 10.1038/44029; Raj K, 2001, NATURE, V412, P914, DOI 10.1038/35091082; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Shabbeer S, 2013, ONCOGENE, V32, P5005, DOI 10.1038/onc.2012.522; Shmueli A, 2007, MOL CELL, V25, P794, DOI 10.1016/j.molcel.2007.03.006; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Singh SV, 2004, J BIOL CHEM, V279, P25813, DOI 10.1074/jbc.M313538200; St Clair S, 2004, MOL CELL, V16, P725; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Thanasoula M, 2012, EMBO J, V31, P3398, DOI 10.1038/emboj.2012.191; Turowski P, 2003, MOL BIOL CELL, V14, P2984, DOI 10.1091/mbc.E02-08-0515; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486; Varmeh-Ziaie S, 2007, J BIOL CHEM, V282, P24633, DOI 10.1074/jbc.M703105200; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vecchione A, 2007, CANCER CELL, V11, P275, DOI 10.1016/j.ccr.2007.01.014; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang B, 2010, MOL CELL BIOL, V30, P1508, DOI 10.1128/MCB.01335-09; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Xiao D, 2004, MOL CANCER THER, V3, P567; Xu HX, 2010, J BIOL CHEM, V285, P18407, DOI 10.1074/jbc.M109.059568; Yan Y, 2005, ONCOGENE, V24, P3285, DOI 10.1038/sj.onc.1208492; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhou RZ, 2005, CANCER RES, V65, P1839, DOI 10.1158/0008-5472.CAN-03-3755	82	33	34	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2017	36	49					6762	6773		10.1038/onc.2017.254	http://dx.doi.org/10.1038/onc.2017.254			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FP0IK	28806397	Green Accepted, Green Published			2022-12-17	WOS:000417282500002
J	Nakatsuka, T; Tateishi, K; Kudo, Y; Yamamoto, K; Nakagawa, H; Fujiwara, H; Takahashi, R; Miyabayashi, K; Asaoka, Y; Tanaka, Y; Ijichi, H; Hirata, Y; Otsuka, M; Kato, M; Sakai, J; Tachibana, M; Aburatani, H; Shinkai, Y; Koike, K				Nakatsuka, T.; Tateishi, K.; Kudo, Y.; Yamamoto, K.; Nakagawa, H.; Fujiwara, H.; Takahashi, R.; Miyabayashi, K.; Asaoka, Y.; Tanaka, Y.; Ijichi, H.; Hirata, Y.; Otsuka, M.; Kato, M.; Sakai, J.; Tachibana, M.; Aburatani, H.; Shinkai, Y.; Koike, K.			Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation	ONCOGENE			English	Article							ADVANCED HEPATOCELLULAR-CARCINOMA; MUTATIONAL LANDSCAPE; GENE-EXPRESSION; STEM-CELLS; IN-VIVO; CANCER; LIVER; IDENTIFICATION; JMJD1A; JHDM2A	Epigenetic gene regulation linked to oncogenic pathways is an important focus of cancer research. KDM3A, a histone H3 lysine 9 (H3K9) demethylase, is known to have a pro-tumorigenic function. Here, we showed that KDM3A contributes to liver tumor formation through the phosphatidylinositol 3-kinase (PI3K) pathway, which is often activated in hepatocellular carcinoma. Loss of Kdm3a attenuated tumor formation in Pik3ca transgenic (Tg) mouse livers. Transcriptome analysis of pre-cancerous liver tissues revealed that the expression of activator protein 1 (AP-1) target genes was induced by PI3K activation, but blunted upon Kdm3a ablation. Particularly, the expression of Cd44, a liver cancer stem marker, was regulated by AP-1 in a Kdm3a-dependent manner. We identified Cd44-positive hepatocytes with epithelial-mesenchymal transition-related expression profiles in the Pik3ca Tg liver and confirmed their in vivo tumorigenic capacity. Notably, the number and tumor-initiating capacity of Cd44-positive hepatocytes were governed by Kdm3a. As a mechanism in Kdm3a-dependent AP-1 transcription, Kdm3a recruited c-Jun to the AP-1 binding sites of Cd44, Mmp7 and Pdgfrb without affecting c-Jun expression. Moreover, Brg1, a component of the SWI/SNF chromatin remodeling complex, interacted with c-Jun in a Kdm3a-dependent manner and was bound to the AP-1 binding site of these genes. Finally, KDM3A and c-JUN were co-expressed in 33% of human premalignant lesions with PI3K activation. Our data suggest a critical role for KDM3A in the PI3K/AP-1 oncogenic axis and propose a novel strategy for inhibition of KDM3A against liver tumor development under PI3K pathway activation.	[Nakatsuka, T.; Tateishi, K.; Kudo, Y.; Yamamoto, K.; Nakagawa, H.; Fujiwara, H.; Takahashi, R.; Miyabayashi, K.; Asaoka, Y.; Tanaka, Y.; Ijichi, H.; Hirata, Y.; Otsuka, M.; Koike, K.] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan; [Kato, M.] RIKEN, Adv Sci Inst, Cellular Memory Lab, Wako, Saitama, Japan; [Sakai, J.] Univ Tokyo, RCAST, Div Metab Med, Meguro Ku, Tokyo, Japan; [Tachibana, M.] Tokushima Univ, Inst Enzyme Res, Dept Enzyme Chem, Tokushima, Tokushima, Japan; [Aburatani, H.] Univ Tokyo, RCAST, Genome Sci Div, Meguro Ku, Tokyo, Japan	University of Tokyo; RIKEN; University of Tokyo; Tokushima University; University of Tokyo	Tateishi, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	ktate-tky@umin.ac.jp	Nakagawa, Hayato/I-2837-2012; Yamamoto, Keisuke/AAT-2794-2021; Ijichi, Hideaki/V-2720-2019; Ijichi, Hideaki/AAE-6692-2022; Nakatsuka, Takuma/T-6886-2017; IJICHI, Hideaki/AGZ-2874-2022; Otsuka, Motoyuki/H-9067-2019; Asaoka, Yoshinari/ABC-5412-2021; Masaki, Kato/AAW-2603-2020	Nakagawa, Hayato/0000-0002-6973-5094; Yamamoto, Keisuke/0000-0002-6323-9540; Ijichi, Hideaki/0000-0002-2379-7986; Nakatsuka, Takuma/0000-0002-5727-5385; IJICHI, Hideaki/0000-0002-2379-7986; Otsuka, Motoyuki/0000-0003-2869-2881; Asaoka, Yoshinari/0000-0002-2805-8226; Tanaka, Yasuo/0000-0002-2917-3365; Sakai, Juro/0000-0003-4043-1035	Japan Society for the Promotion of Science [23590962]; New Energy and Industrial Technology Development Organization (NEDO); Research Program on Hepatitis from Japan Agency for Medical Research and Development (AMED); Grants-in-Aid for Scientific Research [17H06424, 16H01409, 16H01218] Funding Source: KAKEN	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); New Energy and Industrial Technology Development Organization (NEDO)(New Energy and Industrial Technology Development Organization (NEDO)); Research Program on Hepatitis from Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This project is supported by Grants-in-Aid for Scientific Research (23590962) from Japan Society for the Promotion of Science, the grant from New Energy and Industrial Technology Development Organization (NEDO), and the Research Program on Hepatitis from Japan Agency for Medical Research and Development (AMED). We thank Dr E.P. Sandgren for MUP-uPA mice, Mitsuko Tsubouchi for providing assistance with various cell cultures, and all the lab members for their helpful comments.	Abe Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8052; Beyaz S, 2016, NATURE, V531, P53, DOI 10.1038/nature17173; Bitzer M, 2016, J HEPATOL, V65, P280, DOI 10.1016/j.jhep.2016.02.043; Chu TH, 2014, ONCOTARGET, V5, P1475, DOI 10.18632/oncotarget.1745; Ding XM, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003884; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fan L, 2015, 11 INT C WIR COMM NE, V2015, P1; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Friedman JR, 2004, P NATL ACAD SCI USA, V101, P12986, DOI 10.1073/pnas.0402875101; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Fujimoto A, 2016, NAT GENET, V48, P500, DOI 10.1038/ng.3547; Hasenfuss SC, 2014, CELL METAB, V19, P84, DOI 10.1016/j.cmet.2013.11.018; He GB, 2013, CELL, V155, P384, DOI 10.1016/j.cell.2013.09.031; Hoshida Y, 2008, NEW ENGL J MED, V359, P1995, DOI 10.1056/NEJMoa0804525; Huch M, 2013, NATURE, V494, P247, DOI 10.1038/nature11826; Inagaki T, 2009, GENES CELLS, V14, P991, DOI 10.1111/j.1365-2443.2009.01326.x; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Krieg AJ, 2010, MOL CELL BIOL, V30, P344, DOI 10.1128/MCB.00444-09; Kudo Y, 2011, J HEPATOL, V55, P1400, DOI 10.1016/j.jhep.2011.03.025; Kuroki S, 2013, SCIENCE, V341, P1106, DOI 10.1126/science.1239864; Llovet JM, 2015, NAT REV CLIN ONCOL, V12, P408, DOI [10.1038/nrclinonc.2015.103, 10.1038/nrclinonc.2015.121]; Maass T, 2011, INT J CANCER, V128, P1259, DOI 10.1002/ijc.25469; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mann DA, 2014, HEPATOLOGY, V60, P1418, DOI 10.1002/hep.27131; Min LH, 2012, NAT CELL BIOL, V14, P1203, DOI 10.1038/ncb2590; Minguez B, 2009, CURR OPIN GASTROEN, V25, P186, DOI 10.1097/MOG.0b013e32832962a1; Nakagawa H, 2014, CANCER CELL, V26, P331, DOI 10.1016/j.ccr.2014.07.001; Nakagawa H, 2014, P NATL ACAD SCI USA, V111, P1090, DOI 10.1073/pnas.1322731111; Okabe H, 2014, Br J Cancer, V110, P958, DOI 10.1038/bjc.2013.759; Okada Y, 2007, NATURE, V450, P119, DOI 10.1038/nature06236; Osawa T, 2013, CANCER RES, V73, P3019, DOI 10.1158/0008-5472.CAN-12-3231; Park SJ, 2013, BIOCHEM BIOPH RES CO, V434, P722, DOI 10.1016/j.bbrc.2013.03.091; Ramadoss S, 2017, ONCOGENE, V36, P47, DOI 10.1038/onc.2016.174; Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653; Shakya A, 2011, J BIOL CHEM, V286, P450, DOI 10.1074/jbc.M110.174045; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005; Tateishi K, 2009, NATURE, V458, P757, DOI 10.1038/nature07777; Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126; Uemura M, 2010, CLIN CANCER RES, V16, P4636, DOI 10.1158/1078-0432.CCR-10-0407; Weglarz TC, 2000, AM J PATHOL, V157, P1963, DOI 10.1016/S0002-9440(10)64835-3; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Xin HW, 2013, GUT, V62, P1777, DOI 10.1136/gutjnl-2012-303261; Yamada D, 2012, ANN SURG ONCOL, V19, pS355, DOI 10.1245/s10434-011-1797-x; Yamamoto K, 2014, CARCINOGENESIS, V35, P2404, DOI 10.1093/carcin/bgu136; Yamamoto S, 2013, CARCINOGENESIS, V34, P2380, DOI 10.1093/carcin/bgt174; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013; Zeybel M, 2013, J HEPATOL, V59, P1349, DOI 10.1016/j.jhep.2013.05.039; Zhu AX, 2014, JAMA-J AM MED ASSOC, V312, P57, DOI 10.1001/jama.2014.7189; Zhu Z, 2010, INT J CANCER, V126, P2067, DOI 10.1002/ijc.24868; Zucman-Rossi J, 2015, GASTROENTEROLOGY, V149, P1226, DOI 10.1053/j.gastro.2015.05.061	53	33	35	5	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6262	6271		10.1038/onc.2017.222	http://dx.doi.org/10.1038/onc.2017.222			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28692045				2022-12-17	WOS:000414774800005
J	Frisch, SM; Farris, JC; Pifer, PM				Frisch, S. M.; Farris, J. C.; Pifer, P. M.			Roles of Grainyhead-like transcription factors in cancer	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; 2 GRHL2; TUMOR-SUPPRESSOR; RECIPROCAL FEEDBACK; TIGHT JUNCTIONS; CELL POLARITY; BREAST-CANCER; MOUSE MODELS; BETA-CATENIN; WOUND REPAIR	The mammalian homologs of the D. melanogaster Grainyhead gene, Grainyhead-like 1-3 (GRHL1, GRHL2 and GRHL3), are transcription factors implicated in wound healing, tubulogenesis and cancer. Their induced target genes encode diverse epithelial cell adhesion molecules, while mesenchymal genes involved in cell migration and invasion are repressed. Moreover, GRHL2 suppresses the oncogenic epithelial-mesencyhmal transition, thereby acting as a tumor suppressor. Mechanisms, some involving established cancer-related signaling/transcription factor pathways (for example, Wnt, TGF-beta, mir200, ZEB1, OVOL2, p63 and p300) and translational implications of the Grainyhead proteins in cancer are discussed in this review article.	[Frisch, S. M.; Farris, J. C.; Pifer, P. M.] West Virginia Univ, Inst Canc, 1 Med Ctr Dr,Room 2833, Morgantown, WV 26506 USA	West Virginia University	Frisch, SM (corresponding author), West Virginia Univ, Inst Canc, 1 Med Ctr Dr,Room 2833, Morgantown, WV 26506 USA.	sfrisch@hsc.wvu.edu						Adrain C, 2011, EMBO REP, V12, P421, DOI 10.1038/embor.2011.50; Almeida MS, 2005, MECH DEVELOP, V122, P1282, DOI 10.1016/j.mod.2005.08.004; Castilla MA, 2014, ENDOCR-RELAT CANCER, V21, P587, DOI 10.1530/ERC-13-0485; Auden A, 2006, GENE EXPR PATTERNS, V6, P964, DOI 10.1016/j.modgep.2006.03.011; Aue A, 2015, J AM SOC NEPHROL, V26, P2704, DOI 10.1681/ASN.2014080759; Beerling E, 2016, CELL REP, V14, P2281, DOI 10.1016/j.celrep.2016.02.034; Beltran AS, 2014, ONCOGENE, V33, P4767, DOI 10.1038/onc.2013.422; Bhandari A, 2013, ONCOGENE, V32, P1497, DOI 10.1038/onc.2012.168; Boglev Y, 2011, DEV BIOL, V349, P512, DOI 10.1016/j.ydbio.2010.11.011; Boon M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5418; Boxer LD, 2014, GENE DEV, V28, P2013, DOI 10.1101/gad.246579.114; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; BRAY SJ, 1989, GENE DEV, V3, P1130, DOI 10.1101/gad.3.8.1130; BRAY SJ, 1991, GENE DEV, V5, P1672, DOI 10.1101/gad.5.9.1672; Brouns MR, 2011, HUM MOL GENET, V20, P1536, DOI 10.1093/hmg/ddr031; Broussard JA, 2015, CELL TISSUE RES, V360, P501, DOI 10.1007/s00441-015-2136-5; Caddy J, 2010, DEV CELL, V19, P138, DOI 10.1016/j.devcel.2010.06.008; Chen W, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.190; Chen W, 2013, J BIOL CHEM, V285, P40852; Chen W, 2016, CARCINOGENESIS, V37, P500, DOI 10.1093/carcin/bgw027; Cho MH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8821; Chung MI, 2014, ELIFE, V3, DOI 10.7554/eLife.01439; Chung VY, 2016, SCI REP-UK, V6, DOI 10.1038/srep19943; Cieply B, 2016, CELL REP, V15, P247, DOI 10.1016/j.celrep.2016.03.025; Cieply B, 2013, CANCER RES, V73, P6299, DOI 10.1158/0008-5472.CAN-12-4082; Cieply B, 2012, CANCER RES, V72, P2440, DOI 10.1158/0008-5472.CAN-11-4038; Clausen KA, 2011, BREAST CANCER RES TR, V129, P737, DOI 10.1007/s10549-010-1261-9; Creedon H, 2016, ONCOTARGET, V7, P11539, DOI 10.18632/oncotarget.7317; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Darido C, 2016, ONCOGENE, V35, P5705, DOI 10.1038/onc.2016.84; Darido C, 2011, CANCER CELL, V20, P635, DOI 10.1016/j.ccr.2011.10.014; Delvecchio M, 2013, NAT STRUCT MOL BIOL, V20, P1040, DOI 10.1038/nsmb.2642; Dompe N, 2011, P NATL ACAD SCI USA, V108, pE943, DOI 10.1073/pnas.1100132108; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; Fabian J, 2014, CANCER RES, V74, P2604, DOI 10.1158/0008-5472.CAN-13-1904; Farris JC, 2016, MOL CANCER RES, V14, P528, DOI 10.1158/1541-7786.MCR-16-0050; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Frisch SM, 1997, BIOESSAYS, V19, P705, DOI 10.1002/bies.950190811; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Gao X, 2015, J CELL BIOL, V211, P669, DOI 10.1083/jcb.201506014; Gao X, 2013, P NATL ACAD SCI USA, V110, P9356, DOI 10.1073/pnas.1307589110; Gopal S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14105; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hazawa M, 2017, ONCOGENE, V36, P2243, DOI 10.1038/onc.2016.377; Hemphala J, 2003, DEVELOPMENT, V130, P249, DOI 10.1242/dev.00218; Hopkin AS, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002829; Huang JD, 1995, GENE DEV, V9, P3177, DOI 10.1101/gad.9.24.3177; Hugo HJ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3580; Humphreys RC, 2000, ONCOGENE, V19, P1085, DOI 10.1038/sj.onc.1203278; Humphries B, 2015, ONCOTARGET, V6, P6472, DOI 10.18632/oncotarget.3052; Jazbutyte V, 2010, CURR DRUG TARGETS, V11, P926, DOI 10.2174/138945010791591403; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Jozwik KM, 2016, CELL REP, V17, P2715, DOI 10.1016/j.celrep.2016.11.028; Kang X, 2009, ONCOGENE, V28, P565, DOI 10.1038/onc.2008.404; Kessenbrock K, 2015, MATRIX BIOL, V44-46, P184, DOI 10.1016/j.matbio.2015.01.022; Kokoszynska K, 2008, CELL CYCLE, V7, P2907, DOI 10.4161/cc.7.18.6680; Leshem O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021650; List K, 2009, FUTURE ONCOL, V5, P97, DOI 10.2217/14796694.5.1.97; Mace KA, 2005, SCIENCE, V308, P381, DOI 10.1126/science.1107573; Marazuela M, 2004, HISTOL HISTOPATHOL, V19, P925, DOI 10.14670/HH-19.925; Marcucci F, 2016, NAT REV DRUG DISCOV, V15, P311, DOI 10.1038/nrd.2015.13; Margadant C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065341; Martin TA, 2014, SEMIN CELL DEV BIOL, V36, P224, DOI 10.1016/j.semcdb.2014.09.008; Martin-Belmonte F, 2008, CURR OPIN CELL BIOL, V20, P227, DOI 10.1016/j.ceb.2008.01.001; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; Matthews CP, 2007, CURR CANCER DRUG TAR, V7, P317, DOI 10.2174/156800907780809723; Mehrazarin S, 2015, J BIOL CHEM, V290, P19999, DOI 10.1074/jbc.M115.659144; Melino G, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa1033; Mitra A, 2015, ONCOTARGET, V6, P10697, DOI 10.18632/oncotarget.4037; Mlacki M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089247; Morrison CD, 2013, CANCER LETT, V341, P30, DOI 10.1016/j.canlet.2013.02.048; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; Oliveras-Ferraros C, 2012, CELL CYCLE, V11, P4020, DOI 10.4161/cc.22225; Ortega-Molina A, 2013, TRENDS ENDOCRIN MET, V24, P184, DOI 10.1016/j.tem.2012.11.002; Pifer PM, 2016, MOL BIOL CELL, V27, P2479, DOI 10.1091/mbc.E16-04-0249; Previs RA, 2015, CLIN CANCER RES, V21, P955, DOI 10.1158/1078-0432.CCR-14-0809; Pyrgaki C, 2011, DEV BIOL, V353, P38, DOI 10.1016/j.ydbio.2011.02.027; Qin L, 2009, CANCER RES, V69, P3819, DOI 10.1158/0008-5472.CAN-08-4389; Ramena G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147489; Ray HJ, 2016, DEVELOPMENT, V143, P1192, DOI 10.1242/dev.129825; Riethdorf S, 2016, INT J CANCER, V138, P949, DOI 10.1002/ijc.29841; Rifat Y, 2010, DEV BIOL, V345, P237, DOI 10.1016/j.ydbio.2010.07.017; Ringel AE, 2013, STRUCTURE, V21, P1479, DOI 10.1016/j.str.2013.08.011; Santer FR, 2011, MOL CANCER THER, V10, P1644, DOI 10.1158/1535-7163.MCT-11-0182; Schafer M, 2008, NAT REV MOL CELL BIO, V9, P628, DOI 10.1038/nrm2455; Senga K, 2012, MOL BIOL CELL, V23, P2845, DOI 10.1091/mbc.E12-02-0097; Shien K, 2013, CANCER RES, V73, P3051, DOI 10.1158/0008-5472.CAN-12-4136; Singh BN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106937; Somarelli JA, 2016, MOL CELL BIOL, V36, P2503, DOI 10.1128/MCB.00373-16; Szabo R, 2007, ONCOGENE, V26, P1546, DOI 10.1038/sj.onc.1209966; Tanimizu N, 2013, J CELL SCI, V126, P5239, DOI 10.1242/jcs.133082; Tarbe NG, 2005, INT J CANCER, V117, P913, DOI 10.1002/ijc.21275; Ting SB, 2003, NAT MED, V9, P1513, DOI 10.1038/nm961; Ting SB, 2003, BIOCHEM J, V370, P953, DOI 10.1042/BJ20021476; Traylor-Knowles N, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-101; Truong AB, 2006, GENE DEV, V20, P3185, DOI 10.1101/gad.1463206; Trzpis M, 2007, AM J PATHOL, V171, P386, DOI 10.2353/ajpath.2007.070152; Varma S, 2014, AM J PHYSIOL-LUNG C, V306, pL405, DOI 10.1152/ajplung.00143.2013; Varma S, 2012, J BIOL CHEM, V287, P37282, DOI 10.1074/jbc.M112.408401; Walentin K, 2015, DEVELOPMENT, V142, P1125, DOI 10.1242/dev.113829; Wang SQ, 2012, CURR TOP DEV BIOL, V98, P35, DOI 10.1016/B978-0-12-386499-4.00002-1; Watanabe K, 2014, DEV CELL, V29, P59, DOI 10.1016/j.devcel.2014.03.006; Werner S, 2013, J BIOL CHEM, V288, P22993, DOI 10.1074/jbc.M113.456293; Werth M, 2010, DEVELOPMENT, V137, P3835, DOI 10.1242/dev.055483; Wilanowski T, 2002, MECH DEVELOP, V114, P37, DOI 10.1016/S0925-4773(02)00046-1; Wilanowski T, 2008, EMBO J, V27, P886, DOI 10.1038/emboj.2008.24; Xiang J, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2016.83; Xiang JF, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0714-5; Xiang XY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050781; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xu Y, 2014, INT J BIOL SCI, V10, P396, DOI 10.7150/ijbs.8193; Yamaguchi Y, 2006, DEVELOPMENT, V133, P4737, DOI 10.1242/dev.02658; Yang CS, 2014, CELL REP, V8, P326, DOI 10.1016/j.celrep.2014.07.002; Yang H, 2013, MOL CANCER THER, V12, P610, DOI 10.1158/1535-7163.MCT-12-0930; Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012; Yeung TL, 2017, ONCOTARGET, V8, P16951, DOI 10.18632/oncotarget.15208; Yu ZQ, 2008, DEV BIOL, V319, P56, DOI 10.1016/j.ydbio.2008.04.001; Yu ZQ, 2006, DEV BIOL, V299, P122, DOI 10.1016/j.ydbio.2006.07.015; Yu ZQ, 2009, EMBO J, V28, P1890, DOI 10.1038/emboj.2009.142; Zhang PJ, 2015, CELL CYCLE, V14, P481, DOI 10.1080/15384101.2015.1006048; Zheng H, 2014, ONCOGENE, V33, P1755, DOI 10.1038/onc.2013.128; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zhou BY, 2012, J BIOL CHEM, V287, P7026, DOI 10.1074/jbc.M111.276311	126	33	34	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6067	6073		10.1038/onc.2017.178	http://dx.doi.org/10.1038/onc.2017.178			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28714958				2022-12-17	WOS:000414249800001
J	To, SKY; Mak, ASC; Fung, YME; Che, CM; Li, SS; Deng, W; Ru, B; Zhang, J; Wong, AST				To, S. K. Y.; Mak, A. S. C.; Fung, Y. M. Eva; Che, C-M; Li, S-S; Deng, W.; Ru, B.; Zhang, J.; Wong, A. S. T.			beta-catenin downregulates Dicer to promote ovarian cancer metastasis	ONCOGENE			English	Article							CLINICOPATHOLOGICAL FEATURES; POOR-PROGNOSIS; STEM-CELLS; EXPRESSION; ROLES; CARCINOMAS; CONTRIBUTE; PATTERN; GRADE	Ovarian cancer is a nearly uniform lethal disease and its highly aggressive metastatic phenotype portends a poor prognosis. Lack of a well-controlled, relevant experimental model has been a major obstacle to identifying key molecules causing metastasis. Here we describe the creation of a new isogenic model of spontaneous human ovarian cancer metastasis exhibiting opposite phenotypes-highly metastatic (HM) and non-metastatic (NM)-both in vitro and in vivo. HM was unique in its ability to metastasize consistently to the peritoneum, mimicking the major dissemination route of human ovarian cancer. In contrast, NM failed to form detectable metastases, although it was equally tumorigenic. Using comparative label-free quantitative liquid chromatography tandem mass spectrometry (LC-MS/MS), we identified beta-catenin, which we demonstrated for the first time as having a direct role in the pathogenesis of ovarian cancer metastasis. Our studies also revealed a previously unrecognized role of beta-catenin in the downregulation of multiple microRNAs (miRNAs) through attenuating miRNA biogenesis by targeting Dicer, a key component of the miRNA-processing machinery. One such downregulated miRNAs was miR-29s involved in epithelial-to-mesenchymal transition and subsequent stem cell traits. Silencing beta-catenin or overexpressing Dicer or miR-29 mimics in HM significantly reduced the ability of these cells to migrate. beta-catenin-knockdown cells also failed to metastasize in an orthotopic model of ovarian cancer. Meta-analysis revealed an increase in CTNNB1 and a decrease in DICER1 expression levels in the high-risk group. These results uncover beta-catenin as a critical factor in promoting ovarian cancer aggressiveness and a new mechanism linking between beta-catenin and miRNA downregulation underlying this process.	[To, S. K. Y.; Mak, A. S. C.; Li, S-S; Ru, B.; Zhang, J.; Wong, A. S. T.] Univ Hong Kong, Sch Biol Sci, 4S-14 Kadoorie Biol Sci Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China; [Fung, Y. M. Eva; Che, C-M] Univ Hong Kong, Dept Chem, Chem Biol Ctr, State Key Lab Synthet Chem, Hong Kong, Hong Kong, Peoples R China; [Deng, W.] Univ Hong Kong, Sch Nursing, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Wong, AST (corresponding author), Univ Hong Kong, Sch Biol Sci, 4S-14 Kadoorie Biol Sci Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	awong1@hku.hk	Deng, Wen/M-5208-2019; Zhang, Jiangwen/A-7654-2013; Wong, Alice/AFJ-4595-2022; Ru, Beibei/F-3830-2011	Zhang, Jiangwen/0000-0002-2911-8446; Wong, Alice/0000-0002-0676-6475; To, Sally Kit Yan/0000-0002-8683-2101	Research Grant Council [17141216]; University Grants Committee of the Hong Kong Special Administrative Region, China [SEG_HKU02]; Croucher Senior Research Fellowship	Research Grant Council(Hong Kong Research Grants Council); University Grants Committee of the Hong Kong Special Administrative Region, China; Croucher Senior Research Fellowship	We thank the assistance of the Faculty Core Facility of the Li Ka Shing Faculty of Medicine at the University of Hong Kong. The work described in this paper was supported by the Research Grant Council grant (17141216) and partially the Special Equipment Grant from the University Grants Committee of the Hong Kong Special Administrative Region, China (Project Code: SEG_HKU02). ASTW is a recipient of the Croucher Senior Research Fellowship.	Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Alvero AB, 2009, CELL CYCLE, V8, P158, DOI 10.4161/cc.8.1.7533; Ayantunde AA, 2007, ANN ONCOL, V18, P945, DOI 10.1093/annonc/mdl499; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Brodsky AS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094476; BUICK RN, 1985, CANCER RES, V45, P3668; Burgos-Ojeda D, 2012, CANCER LETT, V322, P1, DOI 10.1016/j.canlet.2012.02.002; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chau WK, 2013, ONCOGENE, V32, P2767, DOI 10.1038/onc.2012.290; Condello S, 2015, ONCOGENE, V34, P2297, DOI 10.1038/onc.2014.178; Dai FR, 2014, HUM PATHOL, V45, P1285, DOI 10.1016/j.humpath.2014.02.008; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; Faggad A, 2010, J PATHOL, V220, P382, DOI 10.1002/path.2658; Faith JJ, 2007, PLOS BIOL, V5, P54, DOI 10.1371/journal.pbio.0050008; Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002-9440(10)65148-6; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hasan N, 2015, TRANSL CANCER RES, V4, P14, DOI 10.3978/j.issn.2218-676X.2015.01.02; Hayes J, 2014, TRENDS MOL MED, V20, P460, DOI 10.1016/j.molmed.2014.06.005; Jiang HS, 2014, ONCOL REP, V31, P1509, DOI 10.3892/or.2014.3036; Kang KS, 2013, BIOCHEM BIOPH RES CO, V432, P333, DOI 10.1016/j.bbrc.2013.01.102; Kenny HA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7220; Kildal W, 2005, EUR J CANCER, V41, P1127, DOI 10.1016/j.ejca.2005.01.022; Kim J, 2012, P NATL ACAD SCI USA, V109, P3921, DOI 10.1073/pnas.1117135109; Kok KH, 2007, J BIOL CHEM, V282, P17649, DOI 10.1074/jbc.M611768200; Latifi A, 2011, J CELL BIOCHEM, V112, P2850, DOI 10.1002/jcb.23199; Lee CM, 2003, GYNECOL ONCOL, V88, P363, DOI 10.1016/S0090-8258(02)00015-X; Lengyel E, 2014, ONCOGENE, V33, P3619, DOI 10.1038/onc.2013.321; Lenz HJ, 2014, CANCER SCI, V105, P1087, DOI 10.1111/cas.12471; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; McCloskey CW, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00053; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Nagaraj AB, 2015, ONCOTARGET, V6, P23720, DOI 10.18632/oncotarget.4690; Naito AT, 2006, P NATL ACAD SCI USA, V103, P19812, DOI 10.1073/pnas.0605768103; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Pampalakis G, 2010, CLIN BIOCHEM, V43, P324, DOI 10.1016/j.clinbiochem.2009.09.014; Ricci F, 2013, CANCER TREAT REV, V39, P561, DOI 10.1016/j.ctrv.2013.01.005; Rosano L, 2009, P NATL ACAD SCI USA, V106, P2806, DOI 10.1073/pnas.0807158106; Roussos ET, 2011, NAT REV CANCER, V11, P573, DOI 10.1038/nrc3078; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stahl S, 2009, MOL CELL PROTEOMICS, V8, P1117, DOI 10.1074/mcp.M800274-MCP200; Steg AD, 2012, CLIN CANCER RES, V18, P869, DOI 10.1158/1078-0432.CCR-11-2188; Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196; Teng Y, 2015, ONCOTARGET, V6, P40799, DOI 10.18632/oncotarget.5695; Toth K, 2004, CANCER RES, V64, P3638, DOI 10.1158/0008-5472.CAN-03-3882; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; van den Beucken T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6203; Vizcaino JA, 2016, NUCLEIC ACIDS RES, V44, pD447, DOI 10.1093/nar/gkv1145; Wang H, 2014, INT J CLIN EXP PATHO, V7, P264; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364	51	33	34	0	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					5927	5938		10.1038/onc.2017.185	http://dx.doi.org/10.1038/onc.2017.185			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28650464				2022-12-17	WOS:000413841400002
J	Volpin, F; Casaos, J; Sesen, J; Mangraviti, A; Choi, J; Gorelick, N; Frikeche, J; Lott, T; Felder, R; Scotland, SJ; Eisinger-Mathason, TSK; Brem, H; Tyler, B; Skuli, N				Volpin, F.; Casaos, J.; Sesen, J.; Mangraviti, A.; Choi, J.; Gorelick, N.; Frikeche, J.; Lott, T.; Felder, R.; Scotland, S. J.; Eisinger-Mathason, T. S. K.; Brem, H.; Tyler, B.; Skuli, N.			Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic	ONCOGENE			English	Article							INITIATION-FACTOR 4E; ACUTE MYELOID-LEUKEMIA; ADJUVANT TEMOZOLOMIDE; STEM-CELLS; INHIBITION; EIF4E; TRANSLATION; TARGET; TUMORS; RADIOTHERAPY	The median survival for glioblastoma patients is similar to 15 months despite aggressive surgery and radio-chemotherapy approaches. Thus, developing new therapeutics is necessary to improve the treatment of these invasive brain tumors, which are known to show high levels of the eukaryotic initiation factor, eIF4E, a potent oncogene. Ribavirin, the only clinically approved drug known to target eIF4E, is an anti-viral molecule currently used in hepatitis C treatment. Here, we report the effect of ribavirin on proliferation, cell cycle, cell death and migration of several human and murine glioma cell lines, as well as human glioblastoma stem-like cells, in vitro. In addition, we tested ribavirin efficacy in vivo, alone and in combination with temozolomide and radiation. Our work showed that ribavirin inhibits glioma cell growth and migration, and increases cell cycle arrest and cell death, potentially through modulation of the eIF4E, EZH2 and ERK pathways. We also demonstrate that ribavirin treatment in combination with temozolomide or irradiation increases cell death in glioma cells. Finally and most importantly, ribavirin treatment in vivo significantly enhances chemoradiotherapy efficacy and improves survival of rats and mice orthotopically implanted with gliosarcoma tumors or glioma stem-like cells, respectively. On the basis of these results, we propose that ribavirin represents a new therapeutic option for glioblastoma patients as an enhancer of the cytotoxic effects of temozolomide and radiotherapy.	[Volpin, F.; Casaos, J.; Sesen, J.; Mangraviti, A.; Choi, J.; Gorelick, N.; Frikeche, J.; Lott, T.; Felder, R.; Scotland, S. J.; Brem, H.; Tyler, B.; Skuli, N.] Johns Hopkins Univ, Dept Neurosurg, Hunterian Neurosurg Res Lab, Johns Hopkins Sch Med, Baltimore, MD USA; [Sesen, J.; Skuli, N.] CRCT, INSERM U1037, Toulouse, France; [Eisinger-Mathason, T. S. K.] Univ Penn, Dept Pathol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	Johns Hopkins University; Johns Hopkins Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Pennsylvania; Pennsylvania Medicine	Skuli, N (corresponding author), Johns Hopkins Univ, Dept Neurosurg, Hunterian Brain Tumor Lab, 1550 Orleans St,Koch Canc Res Bldg, Baltimore, MD 21231 USA.	nicolas.skuli@inserm.fr		Skuli, Sarah/0000-0001-7711-0732; FRIKECHE, Jihane/0000-0003-1291-6908; Gorelick, Noah/0000-0003-1313-1061; Mangraviti, Antonella/0000-0003-2843-0718	INSERM [U1037SPDOTSKULI]	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	We thank the Hunterian Neurosurgical Research Laboratory, Dr Thomas Simon for helpful comments, and Mr and Mrs Peter Jennison and Mr and Mrs Josh Fidler for their kind and generous support. This work was supported by INSERM (Grant number: U1037SPDOTSKULI).	Alimova I, 2013, NEURO-ONCOLOGY, V15, P149, DOI 10.1093/neuonc/nos285; Assouline S, 2015, HAEMATOLOGICA, V100, pE7, DOI 10.3324/haematol.2014.111245; Assouline S, 2009, BLOOD, V114, P257, DOI 10.1182/blood-2009-02-205153; Bertolini F, 2015, NAT REV CLIN ONCOL, V12, P732, DOI 10.1038/nrclinonc.2015.169; Borden KLB, 2010, LEUKEMIA LYMPHOMA, V51, P1805, DOI 10.3109/10428194.2010.496506; Chen DF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087281; Colombo G, 2011, ANTIVIR RES, V92, P408, DOI 10.1016/j.antiviral.2011.09.012; Dadgostari S, 2004, DRUG CHEM TOXICOL, V27, P191, DOI 10.1081/DCT-200031953; De La Cruz-Hernandez E, 2015, ONCOL REP, V33, P2384, DOI 10.3892/or.2015.3816; Dubois L, 2009, INT J RADIAT ONCOL, V73, P1219, DOI 10.1016/j.ijrobp.2008.12.003; EGGLESTON M, 1987, INFECT CONT HOSP EP, V8, P215, DOI 10.1017/S0195941700065978; Fan TY, 2014, INT J CLIN EXP PATHO, V7, P6662; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Gallia GL, 2009, MOL CANCER THER, V8, P386, DOI 10.1158/1535-7163.MCT-08-0680; Ge YQ, 2010, BIOCHEM BIOPH RES CO, V397, P711, DOI 10.1016/j.bbrc.2010.06.015; Grzmil M, 2014, J CLIN INVEST, V124, P742, DOI 10.1172/JCI70198; Gu X, 2005, APPL IMMUNOHISTO M M, V13, P178, DOI 10.1097/01.pai.0000135615.07325.a2; Harvie P, 1996, J ACQ IMMUN DEF SYND, V12, P451, DOI 10.1097/00042560-199608150-00003; Hayman TJ, 2012, CANCER RES, V72, P2362, DOI 10.1158/0008-5472.CAN-12-0329; Hsieh AC, 2010, CLIN CANCER RES, V16, P4914, DOI 10.1158/1078-0432.CCR-10-0433; Jeulin H, 2009, ANTIVIR RES, V81, P261, DOI 10.1016/j.antiviral.2008.12.006; Kentsis A, 2005, RNA, V11, P1762, DOI 10.1261/rna.2238705; Kentsis A, 2004, P NATL ACAD SCI USA, V101, P18105, DOI 10.1073/pnas.0406927102; Kim SH, 2015, STEM CELL REP, V4, P226, DOI 10.1016/j.stemcr.2014.12.006; Kokeny S, 2009, ANTICANCER RES, V29, P1971; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Loustaud-Ratti V, 2016, WORLD J HEPATOL, V8, P123, DOI 10.4254/wjh.v8.i2.123; Mangraviti A, 2016, BIOMATERIALS, V100, P53, DOI 10.1016/j.biomaterials.2016.05.025; McGirt MJ, 2009, J NEUROSURG, V110, P583, DOI 10.3171/2008.5.17557; Mijatovic S, 2005, CELL MOL LIFE SCI, V62, P589, DOI 10.1007/s00018-005-4425-8; Myung JK, 2014, INT J CLIN EXP PATHO, V7, P1977; Narayana K, 2002, MUTAT RES-GEN TOX EN, V521, P179, DOI 10.1016/S1383-5718(02)00239-5; Ogino A, 2014, ONCOL LETT, V8, P2469, DOI 10.3892/ol.2014.2569; Olah E, 2006, ADV ENZYME REGUL, V46, P176, DOI 10.1016/j.advenzreg.2006.01.002; Paeshuyse J, 2011, CURR OPIN VIROL, V1, P590, DOI 10.1016/j.coviro.2011.10.030; Papanagnou P, 2016, PHARMACEUTICALS-BASE, V9, DOI 10.3390/ph9020024; Pettersson F, 2015, CANCER RES, V75, P1102, DOI 10.1158/0008-5472.CAN-14-1996; Pettersson F, 2014, EXPERT OPIN THER TAR, V18, P1035, DOI 10.1517/14728222.2014.937426; Pettersson F, 2011, CLIN CANCER RES, V17, P2874, DOI 10.1158/1078-0432.CCR-10-2334; Piccirillo SGM, 2009, ONCOGENE, V28, P1807, DOI 10.1038/onc.2009.27; Richard SM, 2015, J CANCER RES THER, V11, P336, DOI 10.4103/0973-1482.157317; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Russmann S, 2006, CURR MED CHEM, V13, P3351, DOI 10.2174/092986706778773059; Savary K, 2013, ONCOGENE, V32, P5409, DOI 10.1038/onc.2013.67; SCHEIDEL LM, 1987, VIROLOGY, V158, P1, DOI 10.1016/0042-6822(87)90230-3; Scotland S, 2013, LEUKEMIA, V27, P2129, DOI 10.1038/leu.2013.107; Sesen J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123721; Sesen J, 2014, INT J MOL SCI, V15, P2172, DOI 10.3390/ijms15022172; Shi FF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136746; Skuli N, 2012, J CLIN INVEST, V122, P1427, DOI 10.1172/JCI57322; Skuli N, 2009, BLOOD, V114, P469, DOI 10.1182/blood-2008-12-193581; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Sunayama J, 2010, STEM CELLS, V28, P1930, DOI 10.1002/stem.521; Suva ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622; Tamburini J, 2009, CELL CYCLE, V8, P3893, DOI 10.4161/cc.8.23.10091; Vallee S, 2000, EUR J PHARMACOL, V404, P49, DOI 10.1016/S0014-2999(00)00596-3; Vignon C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068425; Wicks RT, 2015, NEURO-ONCOLOGY, V17, P70, DOI 10.1093/neuonc/nou143; Zambon AC, 2010, CYTOM PART A, V77A, P564, DOI 10.1002/cyto.a.20890; Zekri ARN, 2014, J ADV RES, V5, P27, DOI 10.1016/j.jare.2012.11.002; Zhang W, 2014, GENET MOL BIOL, V37, P716, DOI 10.1590/S1415-47572014000500015; Zopf S, 2016, WORLD J HEPATOL, V8, P139, DOI 10.4254/wjh.v8.i3.139	63	33	33	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					3037	3047		10.1038/onc.2016.457	http://dx.doi.org/10.1038/onc.2016.457			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	27941882				2022-12-17	WOS:000402000400011
J	Yang, Q; Li, X; Chen, H; Cao, Y; Xiao, Q; He, Y; Wei, J; Zhou, J				Yang, Q.; Li, X.; Chen, H.; Cao, Y.; Xiao, Q.; He, Y.; Wei, J.; Zhou, J.			IRF7 regulates the development of granulocytic myeloid-derived suppressor cells through S100A9 transrepression in cancer	ONCOGENE			English	Article							TUMOR-METASTASIS; ACCUMULATION; ACTIVATION; DIFFERENTIATION; EXPANSION; CORRELATE	Accumulation of myeloid-derived suppressor cells (MDSCs) is one of the major obstacles against achieving appropriate anti-tumor immune responses and successful tumor immunotherapy. Granulocytic MDSCs (G-MDSCs) are common in tumor-bearing hosts. However, the mechanisms regulating the development of MDSCs, especially G-MDSCs, remain poorly understood. In this report, we showed that interferon regulatory factor 7 (IRF7) plays an important role in the development of G-MDSCs, but not monocytic MDSCs. IRF7 deficiency caused significant elevation of G-MDSCs, and therefore enhanced tumor growth and metastasis in mice. IRF7 deletion did not affect the suppressive activity of G-MDSCs. Mechanistic studies showed that S100A9, a negative regulator of myeloid cell differentiation, was transrepressed by the IRF7 protein. S100A9 knockdown almost completely abrogated the effects of IRF7 deletion on G-MDSC development and tumor metastasis. Importantly, IRF7 expression levels negatively correlated with the G-MDSC frequency and tumor metastasis, as well as S100A9 expression, in cancer patients. In summary, our study demonstrated that IRF7 represents a novel regulator of G-MDSC development in cancer, which may have predictive value for tumor progression.	[Yang, Q.; Zhou, J.] Zhongshan Sch Med, Affiliated Guangzhou Women & Childrens Med Ctr, Program Immunol, Guangzhou, Guangdong, Peoples R China; [Yang, Q.; Li, X.; Chen, H.; Cao, Y.; Xiao, Q.; He, Y.; Wei, J.; Zhou, J.] Sun Yat Sen Univ, Inst Human Virol, Zhongshan Sch Med, 74 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China; [Yang, Q.; Zhou, J.] Guangzhou Med Univ, Sch Basic Sci, Guangzhou, Guangdong, Peoples R China; [Li, X.] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China; [Zhou, J.] Sun Yat Sen Univ, Chinese Minist Educ, Key Lab Trop Dis Control, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Guangzhou Medical University; Sun Yat Sen University; Sun Yat Sen University	Zhou, J (corresponding author), Sun Yat Sen Univ, Inst Human Virol, Zhongshan Sch Med, 74 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.	zhouj72@mail.sysu.edu.cn			National Natural Science Foundation of China [81571520, 91542112, 31270921]; Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS); National Key Basic Research Program of China [2012CB524900]; Guangdong Innovative Research Team Program [2009010058]; Fundamental Research Funds for the Central Universities; Provincial Talents Cultivated by 'Thousand-Hundred-Ten' program of Guangdong Province, 111 Project [B12003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS); National Key Basic Research Program of China(National Basic Research Program of China); Guangdong Innovative Research Team Program; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Provincial Talents Cultivated by 'Thousand-Hundred-Ten' program of Guangdong Province, 111 Project	This work was supported by the following grants to JZ: National Natural Science Foundation of China (No. 81571520; 91542112; and 31270921), Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS, 2014), National Key Basic Research Program of China (No. 2012CB524900), Guangdong Innovative Research Team Program (No. 2009010058), The Fundamental Research Funds for the Central Universities, the Provincial Talents Cultivated by 'Thousand-Hundred-Ten' program of Guangdong Province, 111 Project (No. B12003).	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Bidwell BN, 2012, NAT MED, V18, P1224, DOI 10.1038/nm.2830; Capietto AH, 2013, J EXP MED, V210, P2257, DOI 10.1084/jem.20130281; Cheng PY, 2008, J EXP MED, V205, P2235, DOI 10.1084/jem.20080132; Chernov AV, 2015, J BIOL CHEM, V290, P11771, DOI 10.1074/jbc.M114.622316; Clark HL, 2016, J IMMUNOL, V196, P336, DOI 10.4049/jimmunol.1502037; Condamine T, 2015, ANNU REV MED, V66, P97, DOI 10.1146/annurev-med-051013-052304; Condamine T, 2014, J CLIN INVEST, V124, P2626, DOI 10.1172/JCI74056; Damuzzo V, 2015, CYTOM PART B-CLIN CY, V88, P77, DOI [10.1002/cyto.b.21206, 10.1002/cytob.21206]; Foell D, 2007, J LEUKOCYTE BIOL, V81, P28, DOI 10.1189/jlb.0306170; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Hibino T, 2013, CANCER RES, V73, P172, DOI 10.1158/0008-5472.CAN-11-3843; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Huang A, 2013, CANCER IMMUNOL IMMUN, V62, P1439, DOI 10.1007/s00262-013-1450-6; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; Kalathil S, 2013, CANCER RES, V73, P2435, DOI 10.1158/0008-5472.CAN-12-3381; Kim JK, 2015, TUMOR BIOL, V36, P5561, DOI 10.1007/s13277-015-3226-4; Lu RQ, 2001, J BIOL CHEM, V276, P45491, DOI 10.1074/jbc.C100421200; Marigo I, 2008, IMMUNOL REV, V222, P162, DOI 10.1111/j.1600-065X.2008.00602.x; Marigo I, 2010, IMMUNITY, V32, P790, DOI 10.1016/j.immuni.2010.05.010; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; Mauti LA, 2011, J CLIN INVEST, V121, P2794, DOI 10.1172/JCI41936; McNeill E, 2014, INT J CANCER, V135, P798, DOI 10.1002/ijc.28725; Ning S, 2011, GENES IMMUN, V12, P399, DOI 10.1038/gene.2011.21; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Peranzoni E, 2010, CURR OPIN IMMUNOL, V22, P238, DOI 10.1016/j.coi.2010.01.021; Qin AP, 2013, J VIROL, V87, P1477, DOI 10.1128/JVI.01759-12; Romieu-Mourez R, 2006, CANCER RES, V66, P10576, DOI 10.1158/0008-5472.CAN-06-1279; Shojaei F, 2007, NATURE, V450, P825, DOI 10.1038/nature06348; Sinha P, 2008, J IMMUNOL, V181, P4666, DOI 10.4049/jimmunol.181.7.4666; Solito S, 2014, ANN NY ACAD SCI, V1319, P47, DOI 10.1111/nyas.12469; Talmadge JE, 2013, NAT REV CANCER, V13, P739, DOI 10.1038/nrc3581; Thevenot PT, 2014, IMMUNITY, V41, P389, DOI 10.1016/j.immuni.2014.08.015; Vasquez-Dunddel D, 2013, J CLIN INVEST, V123, P1580, DOI 10.1172/JCI60083; Waight JD, 2013, J CLIN INVEST, V123, P4464, DOI 10.1172/JCI68189; Wang L, 2013, J IMMUNOL, V190, P794, DOI 10.4049/jimmunol.1202088; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Yang Q, 2014, BLOOD, V124, P1610, DOI 10.1182/blood-2014-03-559658; Yang Q, 2015, MOL CELL BIOL, V35, P63, DOI 10.1128/MCB.00805-14; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Yu LX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6256; Zhang LW, 2004, J VIROL, V78, P12987, DOI 10.1128/JVI.78.23.12987-12995.2004	44	33	35	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					2969	2980		10.1038/onc.2016.448	http://dx.doi.org/10.1038/onc.2016.448			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	28092673				2022-12-17	WOS:000402000400005
J	Kumazoe, M; Takai, M; Bae, J; Hiroi, S; Huang, Y; Takamatsu, K; Won, Y; Yamashita, M; Hidaka, S; Yamashita, S; Yamada, S; Murata, M; Tsukamoto, S; Tachibana, H				Kumazoe, M.; Takai, M.; Bae, J.; Hiroi, S.; Huang, Y.; Takamatsu, K.; Won, Y.; Yamashita, M.; Hidaka, S.; Yamashita, S.; Yamada, S.; Murata, M.; Tsukamoto, S.; Tachibana, H.			FOXO3 is essential for CD44 expression in pancreatic cancer cells	ONCOGENE			English	Article							STEM-CELLS; GEMCITABINE; IDENTIFICATION; BAY-41-2272; METASTASIS; RESISTANCE; APOPTOSIS; BREAST; CGMP	Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal types of cancer and the 5-year survival rate is only 5%. Several studies have suggested that cancer stem cells (CSCs) are thought to be involved in recurrence and metastasis and so it is essential to establish an approach targeting CSCs. Here we have demonstrated that cyclic guanosine monophosphate (cGMP) suppressed CD44 expression and the properties of CSCs in PDAC. Microarray analysis suggested that cGMP inhibited Forkhead box O3 (FOXO3), which is known as a tumor suppressor. Surprisingly, our data demonstrated that FOXO3 is essential for CD44 expression and the properties of CSCs. Our data also indicated that patients with high FOXO3 activation signatures had poor prognoses. This evidence suggested that cGMP induction and FOXO3 inhibition could be ideal candidates for pancreatic CSC.	[Kumazoe, M.; Takai, M.; Bae, J.; Hiroi, S.; Huang, Y.; Takamatsu, K.; Won, Y.; Yamashita, M.; Hidaka, S.; Yamashita, S.; Yamada, S.; Murata, M.; Tsukamoto, S.; Tachibana, H.] Kyushu Univ, Div Appl Biol Chem, Dept Biosci & Biotechnol, Fac Agr, Fukuoka, Japan	Kyushu University	Kumazoe, M (corresponding author), Kyushu Univ, Div Appl Biol Chem, Dept Biosci & Biotechnol, Fac Agr,Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	tatibana@agr.kyushu-u.ac.jp		Kumazoe, Motofumi/0000-0002-3002-2994	JSPS KAKENHI [22228002, 15H02448, 15K18821]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part by JSPS KAKENHI grant 22228002 and 15H02448 to H Tachibana. This work was also supported in part by a Grant-in-Aid for JSPS Fellows to MK (PD) and JSPS KAKENHI grant 15K18821. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We appreciate the technical support from the Research Support Center, Graduate School of Medical Sciences, Kyushu University, and the Center for Accelerator and Beam Applied Science, Kyushu University. We thank Takeshi Iwasaki (Kyushu University, Faculty of Medicine) for helpful advice on bioinformatics analysis. The authors would like to thank Enago (www.enago.jp) for the English language review.	Adikrisna R, 2012, GASTROENTEROLOGY, V143, P234, DOI 10.1053/j.gastro.2012.03.054; Bera A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106343; Bischoff E, 2004, CIRCULATION, V110, pE320, DOI 10.1161/01.CIR.0000142209.28862.12; Boreddy SR, 2011, CLIN CANCER RES, V17, P1784, DOI 10.1158/1078-0432.CCR-10-1891; Bourguignon LYW, 2008, J BIOL CHEM, V283, P17635, DOI 10.1074/jbc.M800109200; Burnett Arthur L, 2006, J Clin Hypertens (Greenwich), V8, P53; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Eyster CA, 2011, MOL BIOL CELL, V22, P3218, DOI 10.1091/mbc.E10-11-0874; Furuyama T, 2004, J BIOL CHEM, V279, P34741, DOI 10.1074/jbc.M314214200; Gao Y, 2015, ONCOTARGET, V6, P7828, DOI 10.18632/oncotarget.3488; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hong SP, 2009, INT J CANCER, V125, P2323, DOI 10.1002/ijc.24573; Huang SD, 2012, CELL, V151, P937, DOI 10.1016/j.cell.2012.10.035; Ilmer Matthias, 2015, Genes Cancer, V6, P365; Klotz LO, 2015, REDOX BIOL, V6, P51, DOI 10.1016/j.redox.2015.06.019; Kumazoe M, 2013, J CLIN INVEST, V123, P787, DOI 10.1172/JCI64768; Lee HY, 2008, ARTERIOSCL THROM VAS, V28, P112, DOI 10.1161/ATVBAHA.107.153304; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li L, 2014, GASTROENTEROLOGY, V146, P1108, DOI 10.1053/j.gastro.2013.12.035; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Miranda-Lorenzo I, 2014, NAT METHODS, V11, P1161, DOI [10.1038/NMETH.3112, 10.1038/nmeth.3112]; Molejon MI, 2015, ONCOTARGET, V6, P7408, DOI 10.18632/oncotarget.3510; Nojiri T, 2012, J THORAC CARDIOV SUR, V143, P488, DOI 10.1016/j.jtcvs.2011.09.003; Ohara Y, 2013, CANCER SCI, V104, P1127, DOI 10.1111/cas.12198; Penchev VR, 2012, CLIN CANCER RES, V18, P4277, DOI 10.1158/1078-0432.CCR-11-3112; Quint K, 2012, INT J ONCOL, V41, P2093, DOI 10.3892/ijo.2012.1648; Roesch A, 2013, CANCER CELL, V23, P811, DOI 10.1016/j.ccr.2013.05.003; Sergeant G, 2009, NAT REV CLIN ONCOL, V6, P580, DOI 10.1038/nrclinonc.2009.127; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Smith SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050867; Stratford JK, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000307; Su YJ, 2011, EMBO J, V30, P3186, DOI 10.1038/emboj.2011.211; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Teixeira CE, 2006, HYPERTENSION, V47, P596, DOI 10.1161/01.HYP.0000199914.36936.1b; Vaz AP, 2014, J CANC STEM CELL RES, V2, P1, DOI [10.14343/JCSCR.2014.2e1004, DOI 10.14343/JCSCR.2014.2E1004, 10.14343/jcscr.2014.2e1004]; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Wang ZW, 2011, NAT REV GASTRO HEPAT, V8, P27, DOI 10.1038/nrgastro.2010.188; Zhang G, 2013, CLIN CANCER RES, V19, P4983, DOI 10.1158/1078-0432.CCR-13-0209	40	33	36	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2643	2654		10.1038/onc.2016.426	http://dx.doi.org/10.1038/onc.2016.426			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27893718				2022-12-17	WOS:000401120900003
J	Kim, YJ; Jung, K; Baek, DS; Hong, SS; Kim, YS				Kim, Y-J; Jung, K.; Baek, D-S; Hong, S-S; Kim, Y-S			Co-targeting of EGF receptor and neuropilin-1 overcomes cetuximab resistance in pancreatic ductal adenocarcinoma with integrin beta 1-drivenSrc-Akt bypass signaling	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; BREAST-CANCER CELLS; TUMOR-GROWTH; BISPECIFIC ANTIBODY; MONOCLONAL-ANTIBODY; ACTIVATION; ANGIOGENESIS; PENETRATION; FIBRONECTIN; METASTASIS	Pancreatic ductal adenocarcinoma (PDAC) cells usually overexpress the epidermal growth factor receptor (EGFR); however, most are resistant to the anti-EGFR monoclonal antibody, cetuximab. In this study, we report that the molecular mechanism of resistance to cetuximab in PDAC cells is mediated by the overexpression of active integrin beta 1 with downstream Src-Akt activation; this triggers an EGFR ligand-independent proliferation signaling, bypassing EGFR-blocking effect. Knockdown of integrin beta 1 or inhibition of Src or Akt sensitized cetuximab-resistant (Ctx(R)) PDAC cells to cetuximab. We found that neuropilin-1 (NRP1) physically interacts with active integrin beta 1, but not inactive one, on the cell surface. To inhibit active integrin beta 1-driven signaling by targeting NRP1, while suppressing EGFR signaling, we generated an EGFR and NRP1 dual targeting antibody, Ctx-TPP11, by genetic fusion of the NRP1-targeting peptide, TPP11, to the C terminus of the cetuximab heavy chain (Ctx-TPP11). We demonstrate that Ctx-TPP11 efficiently inhibited the growth of CtxR PDAC cells, in vitro and in vivo. The sensitization mechanism involved downregulating active integrin beta 1 levels through NRP1-coupled internalization mediated by the TPP11 moiety, leading to the inhibition of active integrin beta 1-driven bypass signaling. Our findings identify aberrant active integrin beta 1-driven Src-Akt hyperactivation as a primary resistance mechanism to cetuximab in PDAC cells and offer an effective therapeutic strategy to overcome this resistance using an EGFR and NRP1 dual targeting antibody.	[Kim, Y-J; Jung, K.; Baek, D-S; Kim, Y-S] Ajou Univ, Dept Mol Sci & Technol, 206 Worldcup Ro, Suwon 16499, South Korea; [Hong, S-S] Inha Univ, Dept Biomed Sci, Coll Med, Incheon, South Korea	Ajou University; Inha University	Kim, YS (corresponding author), Ajou Univ, Dept Mol Sci & Technol, 206 Worldcup Ro, Suwon 16499, South Korea.	kimys@ajou.ac.kr		Baek, Du-San/0000-0002-5356-6716; Kim, Yong-Sung/0000-0003-2673-1509; Jung, Keunok/0000-0003-2967-8432	Mid-career Researcher Program from the National Research Foundation - Korean government [2016R1A2A2A05005108]; Pioneer Research Center Program from the National Research Foundation - the Korean government [2014M3C1A3051470]	Mid-career Researcher Program from the National Research Foundation - Korean government; Pioneer Research Center Program from the National Research Foundation - the Korean government	This work was supported by grants from the Mid-career Researcher Program (2016R1A2A2A05005108) and the Pioneer Research Center Program (2014M3C1A3051470) from the National Research Foundation funded by the Korean government.	Arjonen A, 2012, TRAFFIC, V13, P610, DOI 10.1111/j.1600-0854.2012.01327.x; Arnoletti JP, 2004, J GASTROINTEST SURG, V8, P960, DOI 10.1016/j.gassur.2004.09.021; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Choi DK, 2014, MABS-AUSTIN, V6, P1402, DOI 10.4161/mabs.36389; Choi HJ, 2013, MOL CANCER THER, V12, P2748, DOI 10.1158/1535-7163.MCT-13-0628; Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; De Franceschi N, 2015, J CELL SCI, V128, P839, DOI 10.1242/jcs.161653; Fotopoulou C, 2010, ANTICANCER RES, V30, P4619; Fukahi K, 2004, CLIN CANCER RES, V10, P581, DOI 10.1158/1078-0432.CCR-0930-03; Fukasawa M, 2007, CANCER BIOL THER, V6, P1173; Garrido-Laguna I, 2015, NAT REV CLIN ONCOL, V12, P319, DOI 10.1038/nrclinonc.2015.53; Guo HF, 2015, J BIOL CHEM, V290, P29120, DOI 10.1074/jbc.R115.687327; Hou S, 2016, SCI REP-UK, V6, DOI 10.1038/srep18430; Iida M, 2013, ONCOGENE, V32, P759, DOI 10.1038/onc.2012.90; Jia H, 2010, BRIT J CANCER, V102, P541, DOI 10.1038/sj.bjc.6605539; Kanda R, 2013, CANCER RES, V73, P6243, DOI 10.1158/0008-5472.CAN-12-4502; Kim YJ, 2015, J CONTROL RELEASE, V216, P56, DOI 10.1016/j.jconrel.2015.08.016; Larbouret C, 2012, NEOPLASIA, V14, P121, DOI 10.1593/neo.111602; Li BH, 2013, CANCER RES, V73, P6471, DOI 10.1158/0008-5472.CAN-13-0657; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Matsushita A, 2007, CANCER RES, V67, P10309, DOI 10.1158/0008-5472.CAN-07-3256; Nguyen DH, 2002, J IMMUNOL, V168, P4121, DOI 10.4049/jimmunol.168.8.4121; Okon IS, 2014, J CLIN INVEST, V124, P4590, DOI 10.1172/JCI75371; Oliveira-Cunha Melissa, 2011, Cancers (Basel), V3, P1513, DOI 10.3390/cancers3021513; Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018; Philip PA, 2010, J CLIN ONCOL, V28, P3605, DOI 10.1200/JCO.2009.25.7550; Prud'homme GJ, 2012, ONCOTARGET, V3, P921, DOI 10.18632/oncotarget.626; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Shin TH, 2014, MOL CANCER THER, V13, P651, DOI 10.1158/1535-7163.MCT-13-0748; Sugahara KN, 2015, MOL CANCER THER, V14, P120, DOI 10.1158/1535-7163.MCT-14-0366; Sung ES, 2009, MOL CANCER THER, V8, P2276, DOI 10.1158/1535-7163.MCT-09-0235; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Valdembri D, 2009, PLOS BIOL, V7, P115, DOI 10.1371/journal.pbio.1000025; Wey JS, 2005, BRIT J CANCER, V93, P233, DOI 10.1038/sj.bjc.6602663; Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97; Wong MH, 2014, CLIN CANCER RES, V20, P4047, DOI 10.1158/1078-0432.CCR-13-3377; Yaqoob U, 2012, CANCER RES, V72, P4047, DOI 10.1158/0008-5472.CAN-11-3907; Ye F, 2012, BLOOD, V119, P26, DOI 10.1182/blood-2011-04-292128; Zeng FW, 2014, ANTI-CANCER DRUG, V25, P663, DOI 10.1097/CAD.0000000000000091	40	33	34	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2543	2552		10.1038/onc.2016.407	http://dx.doi.org/10.1038/onc.2016.407			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27797376				2022-12-17	WOS:000400597300005
J	Nickerson, ML; Das, S; Im, KM; Turan, S; Berndt, SI; Li, H; Lou, H; Brodie, SA; Billaud, JN; Zhang, T; Bouk, AJ; Butcher, D; Wang, Z; Sun, L; Misner, K; Tan, W; Esnakula, A; Esposito, D; Huang, WY; Hoover, RN; Tucker, MA; Keller, JR; Boland, J; Brown, K; Anderson, SK; Moore, LE; Isaacs, WB; Chanock, SJ; Yeager, M; Dean, M; Andresson, T				Nickerson, M. L.; Das, S.; Im, K. M.; Turan, S.; Berndt, S. I.; Li, H.; Lou, H.; Brodie, S. A.; Billaud, J. N.; Zhang, T.; Bouk, A. J.; Butcher, D.; Wang, Z.; Sun, L.; Misner, K.; Tan, W.; Esnakula, A.; Esposito, D.; Huang, W. Y.; Hoover, R. N.; Tucker, M. A.; Keller, J. R.; Boland, J.; Brown, K.; Anderson, S. K.; Moore, L. E.; Isaacs, W. B.; Chanock, S. J.; Yeager, M.; Dean, M.; Andresson, T.			TET2 binds the androgen receptor and loss is associated with prostate cancer	ONCOGENE			English	Article							GENE; MUTATIONS; LANDSCAPE; HYDROXYMETHYLATION; IDENTIFICATION; HOMEODOMAIN; PREDICTION; INSIGHT; GENOME	Genetic alterations associated with prostate cancer (PCa) may be identified by sequencing metastatic tumour genomes to identify molecular markers at this lethal stage of disease. Previously, we characterized somatic alterations in metastatic tumours in the methylcytosine dioxygenase ten-eleven translocation 2 (TET2), which is altered in 5-15% of myeloid, kidney, colon and PCas. Genome-wide association studies previously identified non-coding risk variants associated with PCa and melanoma. We perform fine-mapping of PCa risk across TET2 using genotypes from the PEGASUS case-control cohort and identify six new risk variants in introns 1 and 2. Oligonucleotides containing two risk variants are bound by the transcription factor octamer-binding protein 1 (Oct1/POU2F1) and TET2 and Oct1 expression are positively correlated in prostate tumours. TET2 is expressed in normal prostate tissue and reduced in a subset of tumours from the Cancer Genome Atlas (TCGA). Small interfering RNA-mediated TET2 knockdown (KD) increases LNCaP cell proliferation, migration and wound healing, verifying loss drives a cancer phenotype. Endogenous TET2 bound the androgen receptor (AR) and AR-coactivator proteins in LNCaP cell extracts, and TET2 KD increases prostate-specific antigen (KLK3/PSA) expression. Published data reveal TET2 binding sites and hydroxymethylcytosine proximal to KLK3. A gene co-expression network identified using TCGA prostate tumour RNA-sequencing identifies co-regulated cancer genes associated with 2-oxoglutarate (2-OG) and succinate metabolism, including TET2, lysine demethylase (KDM) KDM6A, BRCA1-associated BAP1, and citric acid cycle enzymes IDH1/2, SDHA/B, and FH. The co-expression signature is conserved across 31 TCGA cancers suggesting a putative role for TET2 as an energy sensor (of 2-OG) that modifies aspects of androgen-AR signalling. Decreased TET2 mRNA expression in TCGA PCa tumours is strongly associated with reduced patient survival, indicating reduced expression in tumours may be an informative biomarker of disease progression and perhaps metastatic disease.	[Nickerson, M. L.; Turan, S.; Li, H.; Lou, H.; Misner, K.; Tan, W.; Anderson, S. K.; Dean, M.] NCI, Canc & Inflammat Program, NIH, Frederick, MD 21701 USA; [Das, S.; Andresson, T.] Leidos Biomed Res Inc, Prot Characterizat Lab, Canc Res Technol Program, Frederick Natl Lab Canc Res, Frederick, MD USA; [Im, K. M.] Data Sci Genom, Ellicott City, MD USA; [Berndt, S. I.; Brodie, S. A.; Bouk, A. J.; Wang, Z.; Huang, W. Y.; Hoover, R. N.; Tucker, M. A.; Boland, J.; Moore, L. E.; Chanock, S. J.; Yeager, M.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA; [Li, H.; Lou, H.] Leidos Biomed Res Inc, Basic Res Program, Frederick Natl Lab Canc Res, Frederick, MD USA; [Brodie, S. A.; Boland, J.; Yeager, M.] Leidos Biomed Res Inc, Canc Genom Res, Frederick Natl Lab Canc Res, Frederick, MD USA; [Billaud, J. N.] Ingenu Syst Inc, Redwood City, CA USA; [Nickerson, M. L.; Zhang, T.; Brown, K.; Dean, M.] NCI, Lab Translat Genom, 8717 Grovemont Circle,Rm 225C, Bethesda, MD 20892 USA; [Butcher, D.] Leidos Biomed Res Inc, Pathol & Histotechnol Lab, Frederick Natl Lab Canc Res, Frederick, MD USA; [Sun, L.; Keller, J. R.] NCI, Mouse Canc Genet Program, NIH, Frederick, MD 21701 USA; [Esnakula, A.] Howard Univ, Coll Med, Dept Pathol, Howard Univ Hosp, Washington, DC USA; [Esposito, D.] Leidos Biomed Res Inc, Prot Express Lab, Frederick Natl Lab Canc Res, Frederick, MD USA; [Isaacs, W. B.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University	Nickerson, ML (corresponding author), NCI, Lab Translat Genom, 8717 Grovemont Circle,Rm 225C, Bethesda, MD 20892 USA.	nickersonml@mail.nih.gov	Brodie, Seth/U-9035-2019; Dean, Michael C/G-8172-2012; Anderson, Stephen K/B-1727-2012; Dean, Michael/R-7501-2019; Keller, Jonathan R./O-6677-2018; Yeager, Meredith/AAA-5322-2020	Dean, Michael C/0000-0003-2234-0631; Anderson, Stephen K/0000-0002-7856-4266; Esposito, Dominic/0000-0002-9987-1687	Intramural Research Program of the National Institutes of Health; National Cancer Institute; Leidos Biomedical Research, Inc. [HHSN261200800001E]; NATIONAL CANCER INSTITUTE [ZIABC010001] Funding Source: NIH RePORTER	Intramural Research Program of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Leidos Biomedical Research, Inc.; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported in part by the Intramural Research Program of the National Institutes of Health, the National Cancer Institute and by Leidos Biomedical Research, Inc., under contract # HHSN261200800001E.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Chen Q, 2013, NATURE, V493, P561, DOI 10.1038/nature11742; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Dong XS, 2007, MOL CELL BIOL, V27, P4863, DOI 10.1128/MCB.02144-06; Eeles RA, 2009, NAT GENET, V41, P1116, DOI 10.1038/ng.450; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Fu LJ, 2014, J AM CHEM SOC, V136, P11582, DOI 10.1021/ja505305z; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Hsieh CL, 2014, P NATL ACAD SCI USA, V111, P7319, DOI 10.1073/pnas.1324151111; Hu LL, 2015, NATURE, V527, P118, DOI 10.1038/nature15713; Hu LL, 2013, CELL, V155, P1545, DOI 10.1016/j.cell.2013.11.020; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586; Lilja H, 2008, NAT REV CANCER, V8, P268, DOI 10.1038/nrc2351; Linehan WM, 2010, NAT REV UROL, V7, P277, DOI 10.1038/nrurol.2010.47; Liu WN, 2009, NAT MED, V15, P559, DOI 10.1038/nm.1944; Loy CJ, 2003, P NATL ACAD SCI USA, V100, P4562, DOI 10.1073/pnas.0736237100; Lynch TP, 2012, J BIOL CHEM, V287, P11070, DOI 10.1074/jbc.M111.302547; Metzeler KH, 2011, J CLIN ONCOL, V29, P1373, DOI 10.1200/JCO.2010.32.7742; Nickerson ML, 2014, CLIN CANCER RES, V20, P4935, DOI 10.1158/1078-0432.CCR-14-0330; Nickerson ML, 2013, HUM MUTAT, V34, P1231, DOI 10.1002/humu.22346; Norris JD, 2009, MOL CELL, V36, P405, DOI 10.1016/j.molcel.2009.10.020; Obinata D, 2012, INT J CANCER, V130, P1021, DOI 10.1002/ijc.26043; Passon DM, 2012, P NATL ACAD SCI USA, V109, P4846, DOI 10.1073/pnas.1120792109; Pena-Llopis S, 2013, CANCER RES, V73, P4173, DOI 10.1158/0008-5472.CAN-13-0360; Pena-LlopiS S, 2012, NAT GENET, V44, P751, DOI 10.1038/ng.2323; Pomerantz MM, 2011, CANCER PREV RES, V4, P719, DOI 10.1158/1940-6207.CAPR-10-0292; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Saint-Martin C, 2009, BLOOD, V114, P1628, DOI 10.1182/blood-2009-01-197525; Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699; Scopim-Ribeiro R, 2015, EUR J HAEMATOL, V94, P413, DOI 10.1111/ejh.12445; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; Serandour AA, 2012, NUCLEIC ACIDS RES, V40, P8255, DOI 10.1093/nar/gks595; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Setiawan VW, 2014, CARCINOGENESIS, V35, P2068, DOI 10.1093/carcin/bgu107; Sharan R, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100129; Song FJ, 2014, CARCINOGENESIS, V35, P2097, DOI 10.1093/carcin/bgu140; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Takayama K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9219; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tonin P, 1996, NAT MED, V2, P1179, DOI 10.1038/nm1196-1179; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67; Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128	53	33	34	0	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2172	2183		10.1038/onc.2016.376	http://dx.doi.org/10.1038/onc.2016.376			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27819678	Green Accepted			2022-12-17	WOS:000399782500012
J	Chan, DW; Hui, WWY; Wang, JJ; Yung, MMH; Hui, LMN; Qin, Y; Liang, RR; Leung, THY; Xu, D; Chan, KKL; Yao, KM; Tsang, BK; Ngan, HYS				Chan, D. W.; Hui, W. W. Y.; Wang, J. J.; Yung, M. M. H.; Hui, L. M. N.; Qin, Y.; Liang, R. R.; Leung, T. H. Y.; Xu, D.; Chan, K. K. L.; Yao, K-M; Tsang, B. K.; Ngan, H. Y. S.			DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-beta/SMAD4 signaling	ONCOGENE			English	Article							FORKHEAD BOX M1; ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTION FACTOR; TGF-BETA; MESENCHYMAL TRANSITION; CELL-PROLIFERATION; GENE-EXPRESSION; POOR-PROGNOSIS; INVASION; MIGRATION	Recent evidence from a comprehensive genome analysis and functional studies have revealed that FOXM1 is a crucial metastatic regulator that drives cancer progression. However, the regulatory mechanism by which FOXM1 exerts its metastatic functions in cancer cells remains obscure. Here, we report that DLX1 acts as a FOXM1 downstream target, exerting pro-metastatic function in ovarian cancers. Both FOXM1 isoforms (FOXM1B or FOXM1C) could transcriptionally upregulate DLX1 through two conserved binding sites, located at + 61 to + 69bp downstream (TFBS1) and -675 to -667bp upstream (TFBS2) of the DLX1 promoter, respectively. This regulation was further accentuated by the significant correlation between the nuclear expression of FOXM1 and DLX1 in high-grade serous ovarian cancers. Functionally, the ectopic expression of DLX1 promoted ovarian cancer cell growth, cell migration/ invasion and intraperitoneal dissemination of ovarian cancer in mice, whereas small interfering RNA-mediated DLX1 knockdown in FOXM1-overexpressing ovarian cancer cells abrogated these oncogenic capacities. In contrast, depletion of FOXM1 by shRNAi only partially attenuated tumor growth and exerted almost no effect on cell migration/invasion and the intraperitoneal dissemination of DLX1-overexpressing ovarian cancer cells. Furthermore, the mechanistic studies showed that DLX1 positively modulates transforming growth factor-beta (TGF-beta) signaling by upregulating PAI-1 and JUNB through direct interaction with SMAD4 in the nucleus upon TGF-beta 1 induction. Taken together, these data strongly suggest that DLX1 has a pivotal role in FOXM1 signaling to promote cancer aggressiveness through intensifying TGF-beta/SMAD4 signaling in high-grade serous ovarian cancer cells.	[Chan, D. W.; Hui, W. W. Y.; Yung, M. M. H.; Hui, L. M. N.; Liang, R. R.; Leung, T. H. Y.; Chan, K. K. L.; Ngan, H. Y. S.] Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China; [Wang, J. J.; Yao, K-M] Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Wang, J. J.; Qin, Y.] Univ Hong Kong, Ctr Genom Sci, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China; [Xu, D.] Shanghai Jiao Tong Univ, Dept Med Lab Sci, Sch Med, Shanghai, Peoples R China; [Xu, D.] Hudson Inst Med Res, Clayton, Vic, Australia; [Tsang, B. K.] Macau Univ Sci & Technol, Macau Inst Appl Res Med & Hlth, State Key Lab Qual Res Chinese Med, Macau, Peoples R China; [Tsang, B. K.] Univ Ottawa, Dept Obstet & Gynaecol, Interdisciplinary Sch Hlth Sci, Ottawa, ON, Canada; [Tsang, B. K.] Univ Ottawa, Dept Cellular & Mol Med, Interdisciplinary Sch Hlth Sci, Ottawa, ON, Canada; [Tsang, B. K.] Ottawa Hosp Res Inst, Chron Dis Program, Ottawa, ON, Canada	University of Hong Kong; University of Hong Kong; University of Hong Kong; Shanghai Jiao Tong University; Hudson Institute of Medical Research; Macau University of Science & Technology; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Chan, DW (corresponding author), Univ Hong Kong, Dept Obstet & Gynaecol, LKS Fac Med, L747 Lab Block,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	dwchan@hku.hk	Chan, David/O-9896-2018; YUNG, Mingo Ming Ho/AHB-5775-2022; Leung, Rongrui/GQY-7360-2022; Wang, Junwen/D-3700-2011; /C-4457-2009	Chan, David/0000-0002-6951-3467; YUNG, Mingo Ming Ho/0000-0003-0903-1164; Wang, Junwen/0000-0002-4432-4707; /0000-0002-5923-0869; Ngan, Hextan Y S/0000-0003-3945-159X	Wong Check She Charitable Foundation; NATIONAL CANCER INSTITUTE [P30CA015083] Funding Source: NIH RePORTER	Wong Check She Charitable Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Shigeru Chiba (Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Japan) for providing pTracer-CMV-DLX1-Flag plasmid, Professor Makoto Mark Taketo (Graduate School of Medicine, Kyoto University, Sakyo, Kyoto, Japan) for providing Myc-tagged SMAD4 expressing plasmid, and Prof. George Tsao (Department of Anatomy, The University of Hong Kong) for providing HOSE 6-3, HOSE 17-1 and HOSE 11-12. This study was supported by Wong Check She Charitable Foundation.	Bao B, 2011, J CELL BIOCHEM, V112, P2296, DOI 10.1002/jcb.23150; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Cantile M, 2005, J CELL PHYSIOL, V205, P202, DOI 10.1002/jcp.20384; Chan DW, 2008, J PATHOL, V215, P245, DOI 10.1002/path.2355; Chan DW, 2009, BRIT J CANCER, V101, P1433, DOI 10.1038/sj.bjc.6605316; Chan DW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052578; Chan DW, 2011, J PATHOL, V225, P525, DOI 10.1002/path.2901; Chiba S, 2003, P NATL ACAD SCI USA, V100, P15577, DOI 10.1073/pnas.2536757100; Cobos I, 2005, NAT NEUROSCI, V8, P1059, DOI 10.1038/nn1499; Cobos I, 2007, NEURON, V54, P873, DOI 10.1016/j.neuron.2007.05.024; Costa RH, 2003, HEPATOLOGY, V38, P1331, DOI 10.1016/j.hep.2003.09.034; Dai B, 2007, ONCOGENE, V26, P6212, DOI 10.1038/sj.onc.1210443; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Eeckhoute J, 2009, J CELL SCI, V122, P4027, DOI 10.1242/jcs.054916; Gusarova GA, 2007, J CLIN INVEST, V117, P99, DOI 10.1172/JCI27527; Hara F, 2007, AM J PATHOL, V170, P1594, DOI 10.2353/ajpath.2007.061025; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; Huang C, 2012, CANCER RES, V72, P655, DOI 10.1158/0008-5472.CAN-11-3102; Jakowlew SB, 2006, CANCER METAST REV, V25, P435, DOI 10.1007/s10555-006-9006-2; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kim IM, 2005, J BIOL CHEM, V280, P22278, DOI 10.1074/jbc.M500936200; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Lam AKY, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00011; Lam AY, 2013, FRONT MOL CELL ONCOL, V3, P1; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; Le TN, 2007, J BIOL CHEM, V282, P19071, DOI 10.1074/jbc.M607486200; Levy S, 2002, MAMM GENOME, V13, P510, DOI 10.1007/s00335-002-2175-6; Lezot F, 2008, J CELL PHYSIOL, V216, P688, DOI 10.1002/jcp.21448; Li JP, 2012, FEBS LETT, V586, P3761, DOI 10.1016/j.febslet.2012.09.016; Li MJ, 2010, BIOINFORMATICS, V26, P2897, DOI 10.1093/bioinformatics/btq540; Lin SW, 2007, EXP CELL RES, V313, P602, DOI 10.1016/j.yexcr.2006.11.003; Lin SW, 2001, CLIN EXP METASTAS, V18, P493; Lok GTM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023790; Maira M, 2010, J NEURODEV DISORD, V2, P48, DOI [10.1007/s11689-009-9035-6, 10.1007/s11689-009-9040-9]; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Merlo GR, 2000, INT J DEV BIOL, V44, P619; Morini M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-649; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; Myatt S.S., 2008, CANCER, V8, P242, DOI DOI 10.1038/NRC2223-C2; Papageorgis P, 2015, J ONCOL, V2015, DOI 10.1155/2015/587193; Park HJ, 2011, EMBO MOL MED, V3, P21, DOI 10.1002/emmm.201000107; Pleasure SJ, 2000, NEURON, V28, P727, DOI 10.1016/S0896-6273(00)00149-5; Potter GB, 2009, MOL CELL NEUROSCI, V40, P167, DOI 10.1016/j.mcn.2008.10.003; Qin J, 2011, NUCLEIC ACIDS RES, V39, pW430, DOI 10.1093/nar/gkr332; Rao ZY, 2010, CARCINOGENESIS, V31, P1576, DOI 10.1093/carcin/bgq150; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; Sanders DA, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-1-r6; Shiou SR, 2006, J BIOL CHEM, V281, P33971, DOI 10.1074/jbc.M607010200; Starkova J, UP REGULATION HOMEOD; Sundqvist A, 2013, ONCOGENE, V32, P3606, DOI 10.1038/onc.2012.370; Tan YF, 2010, CANCER RES, V70, P9197, DOI 10.1158/0008-5472.CAN-10-1568; Teng Y, 2014, CELL PHYSIOL BIOCHEM, V33, P717, DOI 10.1159/000358647; Trinh BQ, 2011, ONCOGENE, V30, P2718, DOI 10.1038/onc.2011.4; Wang JW, 2006, BIOCHEM BIOPH RES CO, V348, P1261, DOI 10.1016/j.bbrc.2006.07.198; Wang ZW, 2007, CANCER RES, V67, P8293, DOI 10.1158/0008-5472.CAN-07-1265; Wen N, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-134; Wierstra I, 2013, ADV CANCER RES, V119, P191, DOI 10.1016/B978-0-12-407190-2.00016-2; Wierstra I, 2013, ADV CANCER RES, V118, P97, DOI 10.1016/B978-0-12-407173-5.00004-2; Xia JT, 2012, PANCREAS, V41, P629, DOI 10.1097/MPA.0b013e31823bcef2; Xue JF, 2014, J CLIN INVEST, V124, P564, DOI 10.1172/JCI71104; Yang N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.333; Zeng JP, 2009, J PATHOL, V218, P419, DOI 10.1002/path.2530; Zhang LM, 2012, INT J BIOL SCI, V8, P1178, DOI 10.7150/ijbs.4458; Zhang YJ, 2008, CANCER RES, V68, P8733, DOI 10.1158/0008-5472.CAN-08-1968	65	33	36	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1404	1416		10.1038/onc.2016.307	http://dx.doi.org/10.1038/onc.2016.307			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27593933	Green Published, hybrid			2022-12-17	WOS:000395862500009
J	Chang, SS; Yamaguchi, H; Xia, W; Lim, SO; Khotskaya, Y; Wu, Y; Chang, WC; Liu, Q; Hung, MC				Chang, S-S; Yamaguchi, H.; Xia, W.; Lim, S-O; Khotskaya, Y.; Wu, Y.; Chang, W-C; Liu, Q.; Hung, M-C			Aurora A kinase activates YAP signaling in triple-negative breast cancer	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; HIPPO PATHWAY; CELL-MIGRATION; PROTEIN; PHOSPHORYLATION; KIBRA; COMPLEX; CHEMORESISTANCE; REGULATOR; TAZ	The Yes-associated protein (YAP) is an effector that transduces the output of the Hippo pathway to transcriptional modulation. Considering the role of YAP in cancers, this protein has emerged as a key node in malignancy development. In this study, we determined that Aurora A kinase acts as a positive regulator for YAP-mediated transcriptional machinery. Specifically, YAP associates with Aurora A predominantly in the nucleus. Activation of Aurora A can impinge on YAP activity through direct phosphorylation. Moreover, aberrant expression of YAP and Aurora A signaling is highly correlated with triple-negative breast cancer (TNBC). We herein provide evidence to establish the functional relevance of this newly discovered regulatory axis in TNBC.	[Chang, S-S; Yamaguchi, H.; Xia, W.; Lim, S-O; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 108, Houston, TX 77030 USA; [Chang, S-S; Hung, M-C] Univ Texas Houston, Grad Sch Biomed Sci Houston, Canc Biol Program, Houston, TX USA; [Khotskaya, Y.] Univ Texas Houston, MD Anderson Canc Ctr, Sheikh Khalifa Bin Zayed Nahyan Inst Personalized, Houston, TX USA; [Wu, Y.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX USA; [Chang, W-C; Hung, M-C] China Med Univ, Ctr Mol Med, Taichung, Taiwan; China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan; [Liu, Q.] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China; [Liu, Q.] Dalian Med Univ, First Affiliated Hosp, Collaborat Innovat Ctr Onco, Inst Canc Stem Cell, Dalian, Peoples R China; [Hung, M-C] Asia Univ, Dept Biotechnol, Taichung, Taiwan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Taiwan; State Key Lab Oncology South China; Sun Yat Sen University; Dalian Medical University; Asia University Taiwan	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 108, Houston, TX 77030 USA.	mhung@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021; Lim, Seung-Oe/D-3703-2011	Hung, Mien-Chie/0000-0003-4317-4740; 	National Institutes of Health [CA109311, CA099031]; Cancer Center Support [CA016672]; National Breast Cancer Foundation; Patel Memorial Breast Cancer Endowment Fund; University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund; Ministry of Science and Technology; International Research-intensive Centers of Excellence in Taiwan (I-RiCE) [MOST 105-2911-I-002-302]; Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence [MOHW105-TDU-B-212-134003]; Center for Biological Pathways at MD Anderson and Ting Tsung and Wei Fong Chao Research Fund; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center Support; National Breast Cancer Foundation; Patel Memorial Breast Cancer Endowment Fund; University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund; Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); International Research-intensive Centers of Excellence in Taiwan (I-RiCE); Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence; Center for Biological Pathways at MD Anderson and Ting Tsung and Wei Fong Chao Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was funded in part by the following: National Institutes of Health grants (CA109311, CA099031 and Cancer Center Support Grant CA016672); National Breast Cancer Foundation; Patel Memorial Breast Cancer Endowment Fund; The University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund (to M-CH); Ministry of Science and Technology, International Research-intensive Centers of Excellence in Taiwan (I-RiCE; MOST 105-2911-I-002-302); Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence (MOHW105-TDU-B-212-134003); Center for Biological Pathways at MD Anderson and Ting Tsung and Wei Fong Chao Research Fund. We also thank Tamara K Locke of the Department of Scientific Publications at The University of Texas MD Anderson Cancer Center for her editorial assistance.	Baumgartner R, 2010, DEV CELL, V18, P309, DOI 10.1016/j.devcel.2009.12.013; Bayliss R, 2003, MOL CELL, V12, P851, DOI 10.1016/S1097-2765(03)00392-7; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Cammareri P, 2010, CANCER RES, V70, P4655, DOI 10.1158/0008-5472.CAN-09-3953; Chen J, 2012, CURR BIOL, V22, P1582, DOI 10.1016/j.cub.2012.06.074; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; D'Assoro AB, 2014, ONCOGENE, V33, P599, DOI 10.1038/onc.2012.628; Do TV, 2014, ONCOGENE, V33, P539, DOI 10.1038/onc.2012.632; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; Genevet A, 2010, DEV CELL, V18, P300, DOI 10.1016/j.devcel.2009.12.011; Guan Z, 2007, CANCER RES, V67, P10436, DOI 10.1158/0008-5472.CAN-07-1379; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Karthigeyan D, 2011, MED RES REV, V31, P757, DOI 10.1002/med.20203; Kim M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6370; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Lau AN, 2014, EMBO J, V33, P468, DOI 10.1002/embj.201386082; Lee DF, 2012, CELL STEM CELL, V11, P179, DOI 10.1016/j.stem.2012.05.020; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; Li CW, 2016, CANCER RES, V76, P1451, DOI 10.1158/0008-5472.CAN-15-1941; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Nikonova AS, 2013, CELL MOL LIFE SCI, V70, P661, DOI 10.1007/s00018-012-1073-7; Nishio H, 2004, P NATL ACAD SCI USA, V101, P11257, DOI 10.1073/pnas.0401343101; Paleologou KE, 2008, J BIOL CHEM, V283, P16895, DOI 10.1074/jbc.M800747200; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Poon CLC, 2012, CURR BIOL, V22, P1587, DOI 10.1016/j.cub.2012.06.075; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Skibinski A, 2014, CELL REP, V6, P1059, DOI 10.1016/j.celrep.2014.02.038; Song SM, 2015, CLIN CANCER RES, V21, P2580, DOI 10.1158/1078-0432.CCR-14-2191; Sun SG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9402; Sun Y, 2015, AM J TRANSL RES, V7, P319; Toji S, 2004, GENES CELLS, V9, P383, DOI 10.1111/j.1356-9597.2004.00732.x; Wang G, 2004, J VIROL, V78, P7097, DOI 10.1128/JVI.78.13.7097-7111.2004; Wang LH, 2010, CANCER RES, V70, P9118, DOI 10.1158/0008-5472.CAN-10-1246; Wang WQ, 2015, NAT CELL BIOL, V17, P490, DOI 10.1038/ncb3113; Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527; Xiao L, 2011, J BIOL CHEM, V286, P36304, DOI 10.1074/jbc.M111.246850; Yabuta N, 2011, CELL CYCLE, V10, P2724, DOI 10.4161/cc.10.16.16873; Yang H, 2006, INT J CANCER, V119, P2304, DOI 10.1002/ijc.22154; Yang J, 2013, INT J CANCER, V133, P2706, DOI 10.1002/ijc.28277; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Yu JZ, 2010, DEV CELL, V18, P288, DOI 10.1016/j.devcel.2009.12.012; Zhang K, 2014, ONCOTARGET, V5, P12916, DOI 10.18632/oncotarget.2682; Zhang L, 2012, J BIOL CHEM, V287, P34069, DOI 10.1074/jbc.M112.385518; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhao YL, 2014, CANCER RES, V74, P4493, DOI 10.1158/0008-5472.CAN-13-2712; Zorba A, 2014, ELIFE, V3, DOI 10.7554/eLife.02667	57	33	36	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1265	1275		10.1038/onc.2016.292	http://dx.doi.org/10.1038/onc.2016.292			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27593935				2022-12-17	WOS:000395861300010
J	Huang, MY; Xuan, F; Liu, W; Cui, HJ				Huang, M-Y; Xuan, F.; Liu, W.; Cui, H-J			MINA controls proliferation and tumorigenesis of glioblastoma by epigenetically regulating cyclins and CDKs via H3K9me3 demethylation	ONCOGENE			English	Article							MYC TARGET GENE; CHROMATIN MODIFICATIONS; COLON-CANCER; LUNG-CANCER; EXPRESSION; GROWTH; MDIG; NEUROBLASTOMA; CELLS	It is generally known that histone demethylases regulate gene transcription by altering the methylate status on histones, but their roles in cancers and the underlying molecular mechanisms still remain unclear. MYC-induced nuclear antigen (MINA) is reported to be a histone demethylase and highly expressed in many cancers. Here, for the first time, we show that MINA is involved in glioblastoma carcinogenesis and reveal the probable mechanisms of it in cell-cycle control. Kaplan-Meier analysis of progressionfree survival showed that high MINA expression was strongly correlated with poor outcome and advancing tumor stage. MINA knockdown significantly repressed the cell proliferation and tumorigenesis abilities of glioblastoma cells in vitro and in vivo that were rescued by overexpressing the full-length MINA afterwards. Microarray analysis after knockdown of MINA revealed that MINA probably regulated glioblastoma carcinogenesis through the predominant cell-cycle pathways. Further investigation showed that MINA deficiency led to a cell-cycle arrest in G1 and G2 phases. And among the downstream genes, we found that cyclins and cyclin-dependent kinases were directly activated by MINA via the demethylation of H3K9me3.	[Huang, M-Y; Xuan, F.; Liu, W.; Cui, H-J] Southwest Univ, State Key Lab Silkworm Genome Biol, Chongqing, Peoples R China	Southwest University - China	Cui, HJ (corresponding author), Southwest Univ, Dept Cell Biol, State Key Lab Silkworm Genome Biol, 2 Tianshenglu, Chongqing 400716, Peoples R China.	hongjuan.cui@gmail.com	Xuan, Fan/G-6580-2016	Xuan, Fan/0000-0002-8070-3309	National Basic Research Program of China [2012CB114603]; National Natural Science Foundation of China [31501100, 81502574]; Research Fund for the Doctoral Program of Higher Education of China [20130182110003]; Basal Research Fund of Central Higher Education Institutions [XDJK2016D003]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Fund for the Doctoral Program of Higher Education of China(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); Basal Research Fund of Central Higher Education Institutions	This work was supported by the National Basic Research Program of China (No. 2012CB114603), the National Natural Science Foundation of China (No. 31501100, 81502574), the Research Fund for the Doctoral Program of Higher Education of China (20130182110003) and the Basal Research Fund of Central Higher Education Institutions (XDJK2016D003).	Benjamin R, 2003, CANCER J, V9, P82, DOI 10.1097/00130404-200303000-00003; Chen BL, 2013, ONCOTARGET, V4, P1427, DOI 10.18632/oncotarget.1155; Chowdhury R, 2014, NATURE, V510, P422, DOI 10.1038/nature13263; Cohen Idan, 2011, Genes Cancer, V2, P631, DOI 10.1177/1947601911417176; Eilbracht J, 2005, EUR J CELL BIOL, V84, P279, DOI 10.1016/j.ejcb.2004.12.022; Fukahori S, 2007, J PEDIATR SURG, V42, P1831, DOI 10.1016/j.jpedsurg.2007.07.008; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kim TD, 2012, J CELL BIOCHEM, V113, P1368, DOI 10.1002/jcb.24009; Komiya K, 2010, LUNG CANCER, V69, P232, DOI 10.1016/j.lungcan.2009.10.010; Komiya K, 2010, J CANCER RES CLIN, V136, P465, DOI 10.1007/s00432-009-0679-0; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744; Lin HQ, 2010, CELL RES, V20, P899, DOI 10.1038/cr.2010.84; Lu YJ, 2009, CELL CYCLE, V8, P2101, DOI 10.4161/cc.8.13.8927; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tan XP, 2014, CELL BIOCHEM BIOPHYS, V69, P619, DOI 10.1007/s12013-014-9841-7; Tan XP, 2012, ONCOL LETT, V3, P1037, DOI 10.3892/ol.2012.620; Teye K, 2004, AM J PATHOL, V164, P205, DOI 10.1016/S0002-9440(10)63111-2; Teye K, 2007, ONCOL REP, V18, P841; Toyokawa G, 2011, CANCER PREV RES, V4, P2051, DOI 10.1158/1940-6207.CAPR-11-0290; Tsuneoka M, 2004, CLIN CANCER RES, V10, P7347, DOI 10.1158/1078-0432.CCR-03-0543; Tsuneoka M, 2002, J BIOL CHEM, V277, P35450, DOI 10.1074/jbc.M204458200; Wang M, 2015, ONCOTARGET, V6, P9517, DOI 10.18632/oncotarget.3367; Weller M, 2013, NEURO-ONCOLOGY, V15, P4, DOI 10.1093/neuonc/nos273; Xie Q, 2014, NEURO-ONCOLOGY, V16, P1575, DOI 10.1093/neuonc/nou147; Xing J, 2014, ONCOL REP, V31, P634, DOI 10.3892/or.2013.2918; Xuan F, 2016, NEURO-ONCOLOGY, V18, P819, DOI 10.1093/neuonc/nov281; Yang R, 2015, ONCOTARGET, V6, P7644, DOI 10.18632/oncotarget.3223; Yu M, 2014, PLOS ONE, V9; Zhang YD, 2005, ONCOGENE, V24, P4873, DOI 10.1038/sj.onc.1208668; Zhao EH, 2016, CELL REP, V14, P506, DOI 10.1016/j.celrep.2015.12.053	33	33	33	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					387	396		10.1038/onc.2016.208	http://dx.doi.org/10.1038/onc.2016.208			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27292258				2022-12-17	WOS:000394166000008
J	Li, XD; Zhang, JX; Jiang, LJ; Wang, FW; Liu, LL; Liao, YJ; Jin, XH; Chen, WH; Chen, X; Guo, SJ; Zhou, FJ; Zeng, YX; Guan, XY; Liu, ZW; Xie, D				Li, X-D; Zhang, J-X; Jiang, L-J; Wang, F-W; Liu, L-L; Liao, Y-J; Jin, X-H; Chen, W-H; Chen, X.; Guo, S-J; Zhou, F-J; Zeng, Y-X; Guan, X-Y; Liu, Z-W; Xie, D.			Overexpression of maelstrom promotes bladder urothelial carcinoma cell aggressiveness by epigenetically downregulating MTSS1 through DNMT3B	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; TUMOR-SUPPRESSOR; COLORECTAL-CARCINOMA; GASTRIC-CANCER; CO-REPRESSOR; METASTASIS; EXPRESSION; DNA; COMPLEX; HETEROZYGOSITY	We have recently identified and characterized a novel oncogene, maelstrom (MAEL) from 1q24, in the pathogenesis of hepatocellular carcinoma. In this study, MAEL was investigated for its oncogenic role in urothelial carcinoma of the bladder (UCB) tumorigenesis/aggressiveness and underlying molecular mechanisms. Here, we report that overexpression of MAEL in UCB is important in the acquisition of an aggressive and/or poor prognostic phenotype. In UCB cell lines, knockdown of MAEL by short hairpin RNA is sufficient to inhibit cell growth, invasiveness/metastasis and suppressed epithelial-mesenchymal transition (EMT), whereas ectopic overexpression of MAEL promoted cell growth, invasive and/or metastatic capacity and enhanced EMT both in vitro and in vivo. We further demonstrate that MAEL could induce UCB cell EMT by downregulating a critical downstream target, the metastasis suppressor 1 (MTSS1) gene, ultimately leading to an increased invasiveness of cancer cells. Notably, overexpression of MAEL in UCB cells substantially enhanced the enrichment of DNA methyltrans-ferase (DNMT) 3B and histone deacetylase (HDAC) 1/2 on the promoter of the MTSS1, and thereby epigenetically suppressing the MTSS1 transcription. Downregulation of MTSS1 by MAEL in UCB cells is partially dependent on DNMT3B. Furthermore, we identify that beside the gene amplification of MAEL, miR-186 is a key negative regulator of MAEL and downregulation of miR-186 is another important mechanism for MAEL overexpression in UCBs. These data suggest that overexpression of MAEL, caused by gene amplification and/or decreased miR-186, has a critical oncogenic role in UCB pathogenesis by downregulation of MTSS1, and MAEL could be used as a novel prognostic marker and/or effective therapeutic target for human UCB.	[Li, X-D; Zhang, J-X; Jiang, L-J; Wang, F-W; Liu, L-L; Liao, Y-J; Jin, X-H; Chen, W-H; Chen, X.; Guo, S-J; Zhou, F-J; Zeng, Y-X; Guan, X-Y; Liu, Z-W; Xie, D.] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Li, X-D; Jiang, L-J; Chen, X.; Guo, S-J; Zhou, F-J; Liu, Z-W] Sun Yat Sen Univ, Ctr Canc, Dept Urol, Guangzhou, Guangdong, Peoples R China; [Zhang, J-X] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Guangdong, Peoples R China; [Guan, X-Y] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; University of Hong Kong	Liu, ZW; Xie, D (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.	liuzhw@sysucc.org.cn; xiedan@sysucc.org.cn	LIAO, YIJI/Z-4902-2019; /A-3639-2009	LIAO, YIJI/0000-0002-0849-4573; /0000-0003-1874-9805	Nature Science Foundation of China [81225018, 81472385]; Fundamental Research Funds for the Central Universities (Sun Yat-Sen University Young Teachers Plan) [14ykpy39]; Natural Science Foundation of Guangdong Province, China [2015A030313009]; Science and Technology Foundation of the Guangdong Province, China [2013B021800173]	Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities (Sun Yat-Sen University Young Teachers Plan); Natural Science Foundation of Guangdong Province, China(National Natural Science Foundation of Guangdong Province); Science and Technology Foundation of the Guangdong Province, China	This work was supported by grants from the Nature Science Foundation of China (no. 81225018 and no. 81472385), the Fundamental Research Funds for the Central Universities (Sun Yat-Sen University Young Teachers Plan) (no. 14ykpy39), Natural Science Foundation of Guangdong Province (no. 2015A030313009), China and Science and Technology Foundation of the Guangdong Province, China (grant no. 2013B021800173).	Aravin AA, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000764; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Burger M, 2013, EUR UROL, V63, P234, DOI 10.1016/j.eururo.2012.07.033; Cai Y, 2014, ONCOGENE, V33, P2157, DOI 10.1038/onc.2013.178; Cheng J, 2012, CANCER LETT, V315, P12, DOI 10.1016/j.canlet.2011.10.004; Clegg NJ, 1997, DEVELOPMENT, V124, P4661; Du P, 2011, ANTICANCER RES, V31, P3205; Fan H, 2012, ONCOGENE, V31, P2298, DOI 10.1038/onc.2011.411; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Giacobbe A, 2016, ONCOGENE, V35, P1602, DOI 10.1038/onc.2015.230; He LR, 2010, INT J CANCER, V127, P138, DOI 10.1002/ijc.25031; Kayser G, 2015, BRIT J CANCER, V112, P866, DOI 10.1038/bjc.2015.2; Kottakis F, 2011, MOL CELL, V43, P285, DOI 10.1016/j.molcel.2011.06.020; Lim SL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099687; Liu K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-428; Liu LL, 2014, HEPATOLOGY, V59, P531, DOI 10.1002/hep.26677; Loberg RD, 2005, INT J ONCOL, V26, P1699; Lopez V, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-182; Ma J, 2006, J PATHOL, V210, P205, DOI 10.1002/path.2050; Ma NF, 2008, HEPATOLOGY, V47, P503, DOI 10.1002/hep.22072; Malkowicz SB, 2007, UROLOGY, V69, P3, DOI 10.1016/j.urology.2006.10.040; Maru DM, 2009, CANCER, V115, P1576, DOI 10.1002/cncr.24122; Matsumoto N, 2015, CELL REP, V11, P366, DOI 10.1016/j.celrep.2015.03.030; Mertz KD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4465; Mesquita B, 2013, BREAST CANCER RES TR, V138, P37, DOI 10.1007/s10549-013-2408-2; Nixdorf S, 2004, CANCER LETT, V215, P209, DOI 10.1016/j.canlet.2004.05.002; PODDIGHE PJ, 1992, CANCER RES, V52, P4929; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; Sternberg CN, 2013, EUR UROL, V63, P58, DOI 10.1016/j.eururo.2012.08.010; Tong ZT, 2012, ONCOGENE, V31, P583, DOI 10.1038/onc.2011.254; Xiao L, 2010, MOL BIOL REP, V37, P2355, DOI 10.1007/s11033-009-9741-x; Xie D, 2005, HUM PATHOL, V36, P777, DOI 10.1016/j.humpath.2005.05.007; Yao K, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0372-3; Yoshino H, 2011, BRIT J CANCER, V104, P808, DOI 10.1038/bjc.2011.23; Zheng F, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004873; Zhou CZ, 2008, WORLD J GASTROENTERO, V14, P1582, DOI 10.3748/wjg.14.1582	38	33	36	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2016	35	49					6281	6292		10.1038/onc.2016.165	http://dx.doi.org/10.1038/onc.2016.165			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TJ	27181205				2022-12-17	WOS:000390247000002
J	Nezu, Y; Hagiwara, K; Yamamoto, Y; Fujiwara, T; Matsuo, K; Yoshida, A; Kawai, A; Saito, T; Ochiya, T				Nezu, Y.; Hagiwara, K.; Yamamoto, Y.; Fujiwara, T.; Matsuo, K.; Yoshida, A.; Kawai, A.; Saito, T.; Ochiya, T.			miR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma	ONCOGENE			English	Article							ROUND-CELL LIPOSARCOMA; MICRORNA SIGNATURES; EXPRESSION ANALYSIS; COLORECTAL-CANCER; FUS/TLS-CHOP; METASTASIS; INVASION; IDENTIFICATION; GENE; THROMBOSPONDIN-2	Myxoid/round cell (RC) liposarcomas (MLS) were originally classified into two distinct populations based on histological differences; a myxoid component and a RC component. It is notable that, depending on an increase of the RC component, the prognosis significantly differs. Hence, the RC component is associated with metastasis and poor prognosis. However, the molecular mechanisms that contribute to the malignancy of the RC component still remain largely unknown. Here, we report microRNA-135b (miR-135b), a key regulator of the malignancy, highly expressed in the RC component and promoting MLS cell invasion in vitro and metastasis in vivo through the direct suppression of thrombospondin 2 (THBS2). Decreased THBS2 expression by miR-135b increases the total amount of matrix metalloproteinase 2 (MMP2) and influences cellular density and an extracellular matrix structure, thereby resulting in morphological change in tumor. The expression levels of miR-135b and THBS2 significantly correlated with a poor prognosis in MLS patients. Overall, our study reveals that the miR-135b/THBS2/MMP2 axis is tightly related to MLS pathophysiology and has an important clinical implication. This work provides noteworthy evidence for overcoming metastasis and improving patient outcomes, and sheds light on miR-135b and THBS2 as novel molecular targets for diagnosis and therapy in MLS.	[Nezu, Y.; Hagiwara, K.; Yamamoto, Y.; Ochiya, T.] Natl Canc Ctr, Div Mol & Cellular Med, Res Inst, Tokyo, Japan; [Nezu, Y.; Matsuo, K.; Saito, T.] Yokohama City Univ, Grad Sch Med, Dept Orthopaed Surg, Yokohama, Kanagawa, Japan; [Fujiwara, T.] Okayama Univ, Dept Orthopaed Surg, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan; [Yoshida, A.] Natl Canc Ctr, Div Pathol, Tokyo, Japan; [Yoshida, A.] Natl Canc Ctr, Clin Labs, Tokyo, Japan; [Kawai, A.] Natl Canc Ctr, Div Musculoskeletal Oncol, Tokyo, Japan	National Cancer Center - Japan; Yokohama City University; Okayama University; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan	Ochiya, T (corresponding author), Natl Canc Ctr, Div Mol & Cellular Med, Res Inst, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan.	tochiya@ncc.go.jp	Ochiya, Takahiro/AAH-7585-2019		Ministry of Education, Culture, Sports, Science, and Technology; Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NiBio); Japan Society for the Promotion of Science through the Funding Program for world-leading innovative R&D on science and technology (FIRST Program); Council for Science and Technology Policy; Japanese Ministry of Education, Culture, Sports, Science, and Technology	Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NiBio)(National Institute of Biomedical Innovation); Japan Society for the Promotion of Science through the Funding Program for world-leading innovative R&D on science and technology (FIRST Program)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Council for Science and Technology Policy(Council for Science and Technology Policy (CSTP)); Japanese Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Masahiko Kuroda for kindly providing MLS cell lines. We also acknowledge Luc Gailhouste for his careful review of the manuscript. This work was supported in part by a grant-in-aid for the third term of a comprehensive 10-year strategy for cancer control, a grant-in-aid for scientific research on priority area cancers from the Ministry of Education, Culture, Sports, Science, and Technology, and the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NiBio), the Japan Society for the Promotion of Science through the Funding Program for world-leading innovative R&D on science and technology (FIRST Program) initiated by the Council for Science and Technology Policy, and a grant-in-aid for Scientific Research on Innovative Areas (functional machinery for non-coding RNAs) from the Japanese Ministry of Education, Culture, Sports, Science, and Technology.	AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Borjigin N, 2012, BIOCHEM BIOPH RES CO, V427, P355, DOI 10.1016/j.bbrc.2012.09.063; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen K, 2006, NAT GENET, V38, P1452, DOI 10.1038/ng1910; Chijiwa Tsuyoshi, 2009, Int J Oncol, V34, P5; Chou J, 2013, CELL CYCLE, V12, P3262, DOI 10.4161/cc.26087; De Cecco L, 2014, ONCOTARGET, V5, P5965, DOI 10.18632/oncotarget.2023; Dei Tos AP, 2014, HISTOPATHOLOGY, V64, P38, DOI 10.1111/his.12311; Demicco EG, 2012, MODERN PATHOL, V25, P212, DOI 10.1038/modpathol.2011.148; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fiore M, 2007, CANCER-AM CANCER SOC, V109, P2522, DOI 10.1002/cncr.22720; Fritchie KJ, 2012, AM J CLIN PATHOL, V137, P229, DOI 10.1309/AJCP90YNOKBAGCDM; Fujiwara T, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/592868; Gits CMM, 2014, INT J CANCER, V135, P348, DOI 10.1002/ijc.28694; Grosso F, 2007, LANCET ONCOL, V8, P595, DOI 10.1016/S1470-2045(07)70175-4; Guan ZH, 2015, ONCOTARGETS THER, V8, P125, DOI 10.2147/OTT.S72722; Haniball J, 2011, SARCOMA, V2011, P1; He YQ, 2015, AM J CANCER RES, V5, P1382; Kim HS, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-205; KNIGHT JC, 1995, CANCER RES, V55, P24; Kosaka N, 2010, CANCER SCI, V101, P2087, DOI 10.1111/j.1349-7006.2010.01650.x; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Lee DH, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.10; Li Y, 2015, ONCOTARGET, V6, P2421, DOI 10.18632/oncotarget.2965; Lin CW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2876; Matos AR, 2013, EXP MOL PATHOL, V94, P438, DOI 10.1016/j.yexmp.2013.02.002; Matushansky I, 2008, AM J PATHOL, V172, P1069, DOI 10.2353/ajpath.2008.070284; Moreau LC, 2012, ANN SURG ONCOL, V19, P1081, DOI 10.1245/s10434-011-2127-z; Munding JB, 2012, INT J CANCER, V131, pE86, DOI 10.1002/ijc.26466; Nabeshima A, 2015, BRIT J CANCER, V112, P547, DOI 10.1038/bjc.2014.637; Nagel R, 2008, CANCER RES, V68, P5795, DOI 10.1158/0008-5472.CAN-08-0951; Nakamura M, 2008, MOL MED REP, V1, P423; Oda Y, 2005, J PATHOL, V207, P410, DOI 10.1002/path.1848; Pei H, 2015, MOL CELL BIOCHEM, V400, P245, DOI 10.1007/s11010-014-2281-2; Perez-Losada J, 2000, ONCOGENE, V19, P6015, DOI 10.1038/sj.onc.1204018; Perez-Losada J, 2000, ONCOGENE, V19, P2413, DOI 10.1038/sj.onc.1203572; Renner M, 2012, GENE CHROMOSOME CANC, V51, P982, DOI 10.1002/gcc.21980; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Sato H, 2010, CANCER SCI, V101, P843, DOI 10.1111/j.1349-7006.2010.01498.x; Saunders MA, 2007, P NATL ACAD SCI USA, V104, P3300, DOI 10.1073/pnas.0611347104; Schneider-Stock R, 2003, J PATHOL, V199, P517, DOI 10.1002/path.1315; Schwarzenbach H, 2014, NAT REV CLIN ONCOL, V11, P145, DOI 10.1038/nrclinonc.2014.5; Sethupathy P, 2008, TRENDS GENET, V24, P489, DOI 10.1016/j.tig.2008.07.004; Smith SM, 2015, J SURG ONCOL, V111, P520, DOI 10.1002/jso.23882; Smith TA, 1996, AM J SURG PATHOL, V20, P171, DOI 10.1097/00000478-199602000-00005; Sun RC, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-225; Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033; Thelin-Jarnum S, 1999, INT J CANCER, V83, P30, DOI 10.1002/(SICI)1097-0215(19990924)83:1<30::AID-IJC6>3.0.CO;2-4; Tokunaga T, 1999, BRIT J CANCER, V79, P354, DOI 10.1038/sj.bjc.6690056; Tsukamoto O, 2014, GYNECOL ONCOL, V132, P715, DOI 10.1016/j.ygyno.2014.01.029; Valeri N, 2014, CANCER CELL, V25, P469, DOI 10.1016/j.ccr.2014.03.006; Wu CW, 2014, CLIN CANCER RES, V20, P2994, DOI 10.1158/1078-0432.CCR-13-1750; Wu WY, 2014, MOL CELL BIOCHEM, V388, P249, DOI 10.1007/s11010-013-1916-z; Yang ZT, 2001, J BIOL CHEM, V276, P8403, DOI 10.1074/jbc.M008925200; Yang ZT, 2000, MOL BIOL CELL, V11, P3353, DOI 10.1091/mbc.11.10.3353; Zen K, 2012, MED RES REV, V32, P326, DOI 10.1002/med.20215	58	33	35	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6177	6188		10.1038/onc.2016.157	http://dx.doi.org/10.1038/onc.2016.157			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27157622	Green Published, hybrid			2022-12-17	WOS:000388857700003
J	Joshi, S; Kumar, S; Ponnusamy, MP; Batra, SK				Joshi, S.; Kumar, S.; Ponnusamy, M. P.; Batra, S. K.			Hypoxia-induced oxidative stress promotes MUC4 degradation via autophagy to enhance pancreatic cancer cells survival	ONCOGENE			English	Article							EXPRESSION; GROWTH; METASTASIS; ALPHA; DEATH; ADENOCARCINOMA; ANGIOGENESIS; INHIBITION; STABILIZES; REQUIRES	Pancreatic cancer (PC) and associated pre-neoplastic lesions have been reported to be hypoxic, primarily due to hypovascular nature of PC. Though the presence of hypoxia under cancerous condition has been associated with the overexpression of oncogenic proteins (MUC1), multiple emerging reports have also indicated the growth inhibitory effects of hypoxia. In spite of being recognized as the top-most differentially expressed and established oncogenic protein in PC, MUC4 regulation in terms of micro-environmental stress has not been determined. Herein, for the first time, we are reporting that MUC4 protein stability is drastically affected in PC, under hypoxic condition in a hypoxia inducible factor 1 alpha (HIF-1 alpha)-independent manner. Mechanistically, we have demonstrated that hypoxia-mediated induction of reactive oxygen species (ROS) promotes autophagy by inhibiting pAkt/mTORC1 pathway, one of the central regulators of autophagy. Immunohistofluorescence analyses revealed significant negative correlation (P-value = 0.017) between 8-hydroxy guanosine (8-OHG) and MUC4 in primary pancreatic tumors (n=25). Moreover, we found pronounced colocalization between MUC4 and LAMP1/LC3 (microtubule-associated protein 1A/1B-light chain 3) in PC tissues and also observed their negative relationship in their expression pattern, suggesting that areas with high autophagy rate had less MUC4 expression. We also found that hypoxia and ROS have negative impact on overall cell growth and viability, which was partially, though significantly (P<0.05), rescued in the presence of MUC4. Altogether, hypoxia-mediated oxidative stress induces autophagy in PC, leading to the MUC4 degradation to enhance survival, possibly by offering required metabolites to stressed cells.	[Joshi, S.; Kumar, S.; Ponnusamy, M. P.; Batra, S. K.] Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Batra, S. K.] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Buffett Canc Ctr, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Kumar, S; Batra, SK (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	skumar@unmc.edu; sbatra@unmc.edu		Palanimuthu Ponnusamy, Moorthy/0000-0001-5744-193X	NIH [UO1 CA111294, P50 CA127297, U54 CA163120, RO1 CA183459]; NATIONAL CANCER INSTITUTE [U01CA111294, P50CA127297, U54CA163120, R01CA183459] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Jerred Garrison, Dr Pankaj K Singh and Dr Michael Hollingsworth for providing us hypoxia chamber, HIF-1 alpha Sh RNA constructs and human MUC1 antibody, respectively. We would also like to thank Kavita Mallya, James Talaska, Janice Taylor, Dr Nilesh Wagh and Dr Phillip Hexley for technical support. Finally, we would like to thank RAPID autopsy program and related personnel and UNMC graduate studies fellowship. The work was supported, in parts, by grants from the NIH (UO1 CA111294, P50 CA127297, U54 CA163120 and RO1 CA183459).	Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Aubert S, 2009, CANCER RES, V69, P5707, DOI 10.1158/0008-5472.CAN-08-4905; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Blanco FF, 2016, ONCOGENE, V35, P2529, DOI 10.1038/onc.2015.325; Chaika NV, 2012, P NATL ACAD SCI USA, V109, P13787, DOI 10.1073/pnas.1203339109; Chandel NS, 2014, NEW ENGL J MED, V371, P177, DOI 10.1056/NEJMcibr1405701; Chaturvedi P, 2008, CANCER RES, V68, P2065, DOI 10.1158/0008-5472.CAN-07-6041; Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138; Dhillon H, 2014, TOXICOL REP, V1, P309, DOI 10.1016/j.toxrep.2014.05.011; Ding WX, 2007, AM J PATHOL, V171, P513, DOI 10.2353/ajpath.2007.070188; Endo H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098858; Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150; Ge PF, 2009, ACTA PHARMACOL SIN, V30, P1046, DOI 10.1038/aps.2009.71; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Greco E, 2010, PANCREAS, V39, P662, DOI 10.1097/MPA.0b013e3181c8b48c; Gupta D, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-69; Hashimoto D, 2014, EUR J CANCER, V50, P1382, DOI 10.1016/j.ejca.2014.01.011; Hinoda Y, 2003, J GASTROENTEROL, V38, P1162, DOI 10.1007/s00535-003-1224-6; Joshi S, 2015, CANCER METAST REV, V34, P593, DOI 10.1007/s10555-015-9549-1; Joshi S, 2014, ONCOTARGET, V5, P7272, DOI 10.18632/oncotarget.2370; Kamphorst JJ, 2015, CANCER RES, V75, P544, DOI 10.1158/0008-5472.CAN-14-2211; Kasai H, 2002, FREE RADICAL BIO MED, V33, P450, DOI 10.1016/S0891-5849(02)00818-3; Kaur S, 2013, NAT REV GASTRO HEPAT, V10, P607, DOI 10.1038/nrgastro.2013.120; Kim YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098136; Kitamoto S, 2013, ONCOGENE, V32, P4614, DOI 10.1038/onc.2012.478; Kitamoto S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044108; Kumar S, 2015, ONCOGENE, V34, P4879, DOI 10.1038/onc.2014.409; Liu C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-622; Liu ZH, 2007, DEV CELL, V12, P484, DOI 10.1016/j.devcel.2007.03.016; Mimeault M, 2010, CANCER LETT, V295, P69, DOI 10.1016/j.canlet.2010.02.015; Moniaux N, 2007, BRIT J CANCER, V97, P345, DOI 10.1038/sj.bjc.6603868; Munafo DB, 2001, J CELL SCI, V114, P3619; Papandreou I, 2005, CANCER RES, V65, P3171, DOI 10.1158/0008-5472.CAN-04-3395; Rachagani S, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-68; Rachagani S, 2012, CARCINOGENESIS, V33, P1953, DOI 10.1093/carcin/bgs225; Sayin VI, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007653; Senapati S, 2011, CLIN CANCER RES, V17, P267, DOI 10.1158/1078-0432.CCR-10-1937; Sendoel A, 2014, PHYSIOLOGY, V29, P168, DOI 10.1152/physiol.00016.2013; Seshacharyulu P, 2015, ONCOTARGET, V6, P5164, DOI 10.18632/oncotarget.3286; Shao MXG, 2005, J IMMUNOL, V175, P4009, DOI 10.4049/jimmunol.175.6.4009; Siddiqui A, 2007, AM J SURG, V194, P362, DOI 10.1016/j.amjsurg.2007.02.007; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Sullivan R, 2008, MOL CANCER THER, V7, P1961, DOI 10.1158/1535-7163.MCT-08-0198; Vasseur Sophie, 2010, Cancers (Basel), V2, P2138, DOI 10.3390/cancers2042138; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Wang R., 2012, MATH PROBL ENG, V2012, P1, DOI DOI 10.1109/IEVC2012.6183284.URL; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076; Zhang XW, 2004, CHEMOSPHERE, V55, P1303, DOI 10.1016/j.chemosphere.2003.12.004; Zhi XF, 2014, CANCER LETT, V346, P104, DOI 10.1016/j.canlet.2013.12.021; Zhou J, 2013, EURASIP J WIREL COMM, DOI 10.1186/1687-1499-2013-218	52	33	34	0	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5882	5892		10.1038/onc.2016.119	http://dx.doi.org/10.1038/onc.2016.119			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27109098	Green Accepted			2022-12-17	WOS:000387560800007
J	Lee, T; Paquet, M; Larsson, O; Pelletier, J				Lee, T.; Paquet, M.; Larsson, O.; Pelletier, J.			Tumor cell survival dependence on the DHX9 DExH-box helicase	ONCOGENE			English	Article							BREAST-CANCER CELLS; RNA-POLYMERASE-II; TRANSLATION INITIATION; MESSENGER-RNAS; A INTERACTS; MUTANT P53; DNA; PROTEIN; PROLIFERATION; INHIBITOR	The NTP-dependent DExH/D-box helicase DHX9 is a key participant in a number of gene regulatory steps, including transcriptional, translational, and microRNA-mediated control, DNA replication and maintenance of genomic stability. DHX9 has also been implicated in tumor cell maintenance and drug response. Here we report that inhibition of DHX9 expression is lethal to human cancer cell lines and murine E mu-Myc lymphomas. Using a novel conditional shDHX9 mouse model, we demonstrate that sustained and prolonged (6 months) suppression of DHX9 does not result in any deleterious effects at the organismal level. Body weight, blood biochemistry and histology of various tissues were comparable to control mice. Global gene expression profiling revealed that, although reduction of DHX9 expression resulted in multiple transcriptome changes, these were relatively benign and did not lead to any discernible phenotype. Our results demonstrate a robust tolerance for systemic DHX9 suppression in vivo and support the targeting of DHX9 as an effective and specific chemotherapeutic approach.	[Lee, T.; Pelletier, J.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; [Paquet, M.] Univ Montreal, Fac Med Vet, Dept Pathol & Microbiol, St Hyacinthe, PQ, Canada; [Larsson, O.] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Pelletier, J.] McGill Univ, Dept Oncol, Montreal, PQ, Canada; [Pelletier, J.] McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ, Canada	McGill University; Universite de Montreal; Karolinska Institutet; McGill University; McGill University	Pelletier, J (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada.	jerry.pelletier@mcgill.ca	Paquet, Marilene/L-3414-2019	Paquet, Marilene/0000-0002-3562-4636; Larsson, Ola/0000-0003-1412-1308	CIHR; Canadian Cancer Society Research Institute [701362]; National Institutes of Health [CA163291]; Swedish Research Council; Swedish Cancer Society; NATIONAL CANCER INSTITUTE [R01CA163291] Funding Source: NIH RePORTER	CIHR(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Francis Robert for performing tail-vein injections of lymphoma cells into mice. TL was supported by a Maysie MacSporran graduate studentship and fellowships from the CIHR-sponsored Chemical Biology and Systems Biology Training Programs. This work is supported by grants from the Canadian Cancer Society Research Institute (no. 701362) and National Institutes of Health (CA163291) to JP and grants from the Swedish Research Council and the Swedish Cancer Society to OL.	Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Barde I., 2010, CURR PROTOC NEUROSCI; Calcabrini A, 2006, CARCINOGENESIS, V27, P1699, DOI 10.1093/carcin/bgl044; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chakraborty P, 2011, DNA REPAIR, V10, P654, DOI 10.1016/j.dnarep.2011.04.013; Dardenne E, 2012, NAT STRUCT MOL BIOL, V19, P1139, DOI 10.1038/nsmb.2390; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Fukuda T, 2007, NAT CELL BIOL, V9, P604, DOI 10.1038/ncb1577; Gartel AL, 2002, MOL CANCER THER, V1, P639; HARPER JW, 1993, CELL, V75, P805; Hartman TR, 2006, NAT STRUCT MOL BIOL, V13, P509, DOI 10.1038/nsmb1092; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; Hui L, 2006, ONCOGENE, V25, P7305, DOI 10.1038/sj.onc.1209735; Huo LF, 2010, P NATL ACAD SCI USA, V107, P16125, DOI 10.1073/pnas.1000743107; Jain A, 2013, NUCLEIC ACIDS RES, V41, P10345, DOI 10.1093/nar/gkt804; Jain A, 2010, BIOCHEMISTRY-US, V49, P6992, DOI 10.1021/bi100795m; LEE CG, 1993, J BIOL CHEM, V268, P16822; Lee CG, 1998, P NATL ACAD SCI USA, V95, P13709, DOI 10.1073/pnas.95.23.13709; LEE CG, 1992, J BIOL CHEM, V267, P4398; Lee T, 2014, J BIOL CHEM, V289, P22798, DOI 10.1074/jbc.M114.568535; Lin CJ, 2012, CELL REPORTS, V1, P325, DOI 10.1016/j.celrep.2012.02.010; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Manojlovic Z, 2012, RNA, V18, P321, DOI 10.1261/rna.030288.111; Mazurek A, 2014, CELL REP, V7, P1887, DOI 10.1016/j.celrep.2014.05.019; McJunkin K, 2011, P NATL ACAD SCI USA, V108, P7113, DOI 10.1073/pnas.1104097108; Mills JR, 2013, BLOOD, V121, P3402, DOI 10.1182/blood-2012-06-434365; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Parsyan A, 2009, P NATL ACAD SCI USA, V106, P22217, DOI 10.1073/pnas.0909773106; Premsrirut PK, 2011, CELL, V145, P145, DOI 10.1016/j.cell.2011.03.012; Robb GB, 2007, MOL CELL, V26, P523, DOI 10.1016/j.molcel.2007.04.016; Robert F, 2014, P NATL ACAD SCI USA, V111, P13421, DOI 10.1073/pnas.1402650111; Saporita AJ, 2011, CANCER RES, V71, P6708, DOI 10.1158/0008-5472.CAN-11-1472; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Tang H, 1999, MOL CELL BIOL, V19, P3540; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Tetsuka T, 2004, EUR J BIOCHEM, V271, P3741, DOI 10.1111/j.1432-1033.2004.04314.x; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Trudel S, 2007, CLIN CANCER RES, V13, P621, DOI 10.1158/1078-0432.CCR-06-1526; Walstrom KM, 2005, MECH DEVELOP, V122, P707, DOI 10.1016/j.mod.2004.12.002; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZHANG SS, 1994, BIOCHEMISTRY-US, V33, P3906, DOI 10.1021/bi00179a016; Zhang SS, 1997, J BIOL CHEM, V272, P11487; Zhang SS, 2004, NUCLEIC ACIDS RES, V32, P1, DOI 10.1093/nar/gkg933; ZHANG SS, 1991, J BIOL CHEM, V266, P20483; Zuber J, 2011, NAT BIOTECHNOL, V29, P79, DOI 10.1038/nbt.1720	47	33	33	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5093	5105		10.1038/onc.2016.52	http://dx.doi.org/10.1038/onc.2016.52			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	26973242	Green Accepted, Bronze			2022-12-17	WOS:000384433000002
J	Zhang, QB; Zhang, BH; Zhang, KZ; Meng, XT; Jia, QA; Zhang, QB; Bu, Y; Zhu, XD; Ma, DN; Ye, BG; Zhang, N; Ren, ZG; Sun, HC; Tang, ZY				Zhang, Q-B; Zhang, B-H; Zhang, K-Z; Meng, X-T; Jia, Q-A; Zhang, Q-B; Bu, Y.; Zhu, X-D; Ma, D-N; Ye, B-G; Zhang, N.; Ren, Z-G; Sun, H-C; Tang, Z-Y			Moderate swimming suppressed the growth and metastasis of the transplanted liver cancer in mice model: with reference to nervous system	ONCOGENE			English	Article							PHYSICAL-ACTIVITY; HEPATOCELLULAR-CARCINOMA; CELL-PROLIFERATION; TUMOR-GROWTH; TGF-BETA; EXERCISE INTERVENTION; PREFRONTAL CORTEX; DOWN-REGULATION; GASTRIC-CANCER; T-CELLS	Physical activity has been shown to suppress tumor initiation and progression. The neurotransmitter dopamine (DA) is closely related to movement and exhibits antitumor properties. However, whether the suppressive effects of physical activity on tumors was mediated by the nervous system via increased DA level remains unknowns. Here we show that regular moderate swimming (8 min/day, 9 weeks) raised DA levels in the prefrontal cortex, serum and tumor tissue, suppressed growth, reduced lung metastasis of transplanted liver cancer, and prolonged survival in a C57BL/6 mouse model, while overload swimming (16 and 32 min/day, 9 weeks) had the opposite effect. In nude mice that were orthotopically implanted with human liver cancer cell lines, DA treatment significantly suppressed growth and lung metastasis by acting on the D2 receptor (DR2). Furthermore, DR2 blockade attenuated the suppressive effect of moderate swimming on liver cancer. Both moderate swimming and DA treatment suppressed the transforming growth factor-beta (TGF-beta 1)-induced epithelial-mesenchymal transition of transplanted liver cancer cells. At the molecular level, DR2 signaling inhibited extracellular signal-regulated kinase phosphorylation and expression of TGF-beta 1 in vitro. Together, these findings demonstrated a novel mechanism by which the moderate exercise suppressed liver cancer through boosting DR2 activity, while overload exercise had the opposite effect, highlighting the possible importance of the dopaminergic system in tumor growth and metastasis of liver cancer.	[Zhang, Q-B; Zhang, B-H; Zhang, K-Z; Jia, Q-A; Zhang, Q-B; Bu, Y.; Zhu, X-D; Ma, D-N; Ye, B-G; Zhang, N.; Ren, Z-G; Sun, H-C; Tang, Z-Y] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Shanghai, Peoples R China; [Zhang, Q-B; Jia, Q-A] Minist Educ, Key Lab Carcinogenesis & Canc Invas, Shanghai, Peoples R China; [Zhang, K-Z] Fudan Univ, Huashan Hosp, Canc Metastasis Inst, Shanghai, Peoples R China; [Meng, X-T] Peoples Hosp Taizhou City, Dept Gen Surg, Taizhou, Peoples R China; [Zhang, Q-B] Xuzhou Med Coll, Sch Anesthesiol, Xuzhou, Peoples R China; [Zhang, Q-B] Shandong Univ, Qilu Hosp, Dept Gen Surg, Jinan, Peoples R China	Fudan University; Fudan University; Xuzhou Medical University; Shandong University	Tang, ZY (corresponding author), Fudan Univ, Liver Canc Inst, 180 Fenglin Rd, Shanghai 200032, Peoples R China.; Tang, ZY (corresponding author), Fudan Univ, Zhongshan Hosp, 180 Fenglin Rd, Shanghai 200032, Peoples R China.	tang.zhaoyou@zs-hospital.sh.cn	Zhu, Xiao-Dong/A-8197-2010	Zhu, Xiao-Dong/0000-0001-9864-6763; Sun, Hui-Chuan/0000-0003-3761-7058	National Natural Science Foundation of China [81372314]; National Key Project for Infectious Diseases of China [2012ZX10002012-004]; Shanghai Natural Science Fund for Youth Scholars [12ZR1442300]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Project for Infectious Diseases of China; Shanghai Natural Science Fund for Youth Scholars	This project was supported by the National Natural Science Foundation of China (grant number: 81372314), the National Key Project for Infectious Diseases of China (2012ZX10002012-004) and the Shanghai Natural Science Fund for Youth Scholars (12ZR1442300). The authors appreciate the instruction in writing of the manuscript provided by Professor Hong Tu and Assistant Professor Yu Gan (State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, China).	Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Almeida PWM, 2009, J APPL PHYSIOL, V107, P261, DOI 10.1152/japplphysiol.00249.2009; Ballard-Barbash R, 2012, JNCI-J NATL CANCER I, V104, P815, DOI 10.1093/jnci/djs207; Chakroborty D, 2004, CLIN CANCER RES, V10, P4349, DOI 10.1158/1078-0432.CCR-04-0059; Chakroborty D, 2008, J CLIN INVEST, V118, P1380, DOI 10.1172/JCI33125; Demarzo MMP, 2004, CANCER LETT, V216, P31, DOI 10.1016/j.canlet.2004.06.002; Friedenreich CM, 2010, J CLIN ONCOL, V28, P1458, DOI 10.1200/JCO.2009.24.9557; Ganguly S, 2010, AM J PATHOL, V177, P2701, DOI 10.2353/ajpath.2010.100617; Gao Q, 2007, J CLIN ONCOL, V25, P2586, DOI 10.1200/JCO.2006.09.4565; Giovannucci EL, 2012, JNCI-J NATL CANCER I, V104, P797, DOI 10.1093/jnci/djs229; Goldacre MJ, 2005, BRIT J PSYCHIAT, V187, P334, DOI 10.1192/bjp.187.4.334; Gray JR, 2002, P NATL ACAD SCI USA, V99, P4115, DOI 10.1073/pnas.062381899; He SB, 2012, INT J SPORTS MED, V33, P525, DOI 10.1055/s-0032-1306325; Heinen MM, 2011, AM J CLIN NUTR, V94, P1314, DOI 10.3945/ajcn.110.007542; Herz DM, 2014, NEUROIMAGE, V90, P15, DOI 10.1016/j.neuroimage.2013.11.023; Hoglinger GU, 2004, NAT NEUROSCI, V7, P726, DOI 10.1038/nn1265; ISHIBASHI M, 1994, CANCER RES, V54, P3442; Jia QA, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-89; Klaissle P, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-132; Lee J, 2012, J NUTR BIOCHEM, V23, P1341, DOI 10.1016/j.jnutbio.2011.08.003; Li Y, 2003, J CANCER RES CLIN, V129, P43, DOI 10.1007/s00432-002-0396-4; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Moderate exercise may reduce ovarian cancer risk, 2006, MAYO CLIN WOMENS HLT, V10, P3; Moreno-Smith M, 2011, CLIN CANCER RES, V17, P3649, DOI 10.1158/1078-0432.CCR-10-2441; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Muller HK, 2011, BRAIN RES, V1385, P26, DOI 10.1016/j.brainres.2011.02.048; Murphy EA, 2004, J APPL PHYSIOL, V97, P955, DOI 10.1152/japplphysiol.00252.2004; Pacheco R, 2009, J NEUROIMMUNOL, V216, P8, DOI 10.1016/j.jneuroim.2009.07.018; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Peng H, 2013, HEPATOLOGY, V57, P2299, DOI 10.1002/hep.26258; Pickett M, 2002, CANCER PRACT, V10, P284, DOI 10.1046/j.1523-5394.2002.106006.x; Saez MD, 2007, MOL CELL BIOCHEM, V294, P19, DOI 10.1007/s11010-005-9067-5; Sasvari M, 2011, J SPORT SCI MED, V10, P93; Tang ZY, 2012, CHIN J INTEGR MED, V18, P323, DOI 10.1007/s11655-012-1103-1; Tang ZY, 2004, J CANCER RES CLIN, V130, P187, DOI 10.1007/s00432-003-0511-1; THOMPSON HJ, 1994, CANCER RES, V54, pS1960; Tian F, 2003, CANCER RES, V63, P8284; Wan DF, 2004, P NATL ACAD SCI USA, V101, P15724, DOI 10.1073/pnas.0404089101; Wang J, 2012, SCAND J MED SCI SPOR, V22, P643, DOI 10.1111/j.1600-0838.2010.01288.x; Wise RA, 2008, NEUROTOX RES, V14, P169, DOI 10.1007/BF03033808; World Health Organization, 2010, GLOB REC PHYS ACT HL, P10; Zhang Q, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054250, 10.1371/journal.pone.0059667]; Zhang W, 2012, GASTROENTEROLOGY, V143, P1641, DOI 10.1053/j.gastro.2012.08.032; Zhang W, 2010, CLIN CANCER RES, V16, P3420, DOI 10.1158/1078-0432.CCR-09-2904	45	33	39	3	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4122	4131		10.1038/onc.2015.484	http://dx.doi.org/10.1038/onc.2015.484			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26686088				2022-12-17	WOS:000381020900010
J	Mizutani, A; Koinuma, D; Seimiya, H; Miyazono, K				Mizutani, A.; Koinuma, D.; Seimiya, H.; Miyazono, K.			The Arkadia-ESRP2 axis suppresses tumor progression: analyses in clear-cell renal cell carcinoma	ONCOGENE			English	Article							TARGETED UBIQUITIN LIGASE; TGF-BETA; MESENCHYMAL TRANSITION; MESSENGER-RNA; EXPRESSION; COMPLEX; DEGRADATION; METASTASIS; PROTEINS; ESRP1	Tumor-specific alternative splicing is implicated in the progression of cancer, including clear-cell renal cell carcinoma (ccRCC). Using ccRCC RNA sequencing data from The Cancer Genome Atlas, we found that epithelial splicing regulatory protein 2 (ESRP2), one of the key regulators of alternative splicing in epithelial cells, is expressed in ccRCC. ESRP2 mRNA expression did not correlate with the overall survival rate of ccRCC patients, but the expression of some ESRP-target exons correlated with the good prognosis and with the expression of Arkadia ( also known as RNF111) in ccRCC. Arkadia physically interacted with ESRP2, induced polyubiquitination and modulated its splicing function. Arkadia and ESRP2 suppressed ccRCC tumor growth in a coordinated manner. Lower expression of Arkadia correlated with advanced tumor stages and poor outcomes in ccRCC patients. This study thus reveals a novel tumor-suppressive role of the Arkadia-ESRP2 axis in ccRCC.	[Mizutani, A.; Koinuma, D.; Miyazono, K.] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan; [Mizutani, A.; Seimiya, H.] Japanese Fdn Canc Res, Div Mol Biotherapy, Ctr Canc Chemotherapy, Koto Ku, Tokyo, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Miyazono, K (corresponding author), Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono@m.u-tokyo.ac.jp	Koinuma, Daizo/Y-8716-2018	Koinuma, Daizo/0000-0001-5611-2122; Seimiya, Hiroyuki/0000-0003-3314-9736	KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) [22112002, 24700968, 26830066, 24501311]; Grants-in-Aid for Scientific Research [22112002, 26830066] Funding Source: KAKEN	KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are grateful to Dr Hiroshi I Suzuki (The University of Tokyo) for discussion and advice. We also thank Keiko Yuki for technical assistance, as well as the members of the Miyazono laboratory for discussion and advice. This research was supported by KAKENHI grants-in-aid for scientific research on Innovative Area (Integrative Research on Cancer Microenvironment Network; 22112002, to KM), Young Scientists (B) (24700968 and 26830066, to AM) and Scientific Research (C) (24501311, to DK), from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT). This study was performed, in part, as a research program for the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), MEXT.	Barzik M, 2005, J BIOL CHEM, V280, P28653, DOI 10.1074/jbc.M503957200; Biamonti G, 2014, SEMIN CELL DEV BIOL, V32, P30, DOI 10.1016/j.semcdb.2014.03.016; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Briones-Orta MA, 2013, CANCER RES, V73, P1800, DOI 10.1158/0008-5472.CAN-12-1916; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen J, 2015, ONCOGENE, V34, P1, DOI 10.1038/onc.2013.570; Cybulsky AV, 2009, AM J PHYSIOL-RENAL, V297, pF971, DOI 10.1152/ajprenal.00294.2009; Di Modugno F, 2007, CANCER RES, V67, P2657, DOI 10.1158/0008-5472.CAN-06-1997; Erker Y, 2013, MOL CELL BIOL, V33, P2163, DOI 10.1128/MCB.01019-12; Gamazon ER, 2014, HUM GENET, V133, P679, DOI 10.1007/s00439-013-1411-3; Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; Horiguchi K, 2012, ONCOGENE, V31, P3190, DOI 10.1038/onc.2011.493; Horvath A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02256; Hsu RJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047649; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Ishii H, 2014, J BIOL CHEM, V289, P27386, DOI 10.1074/jbc.M114.589432; Isogaya K, 2014, CELL RES, V24, P994, DOI 10.1038/cr.2014.97; Kalsotra A, 2011, NAT REV GENET, V12, P715, DOI 10.1038/nrg3052; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Koinuma D, 2003, EMBO J, V22, P6458, DOI 10.1093/emboj/cdg632; Kulathu Y, 2012, NAT REV MOL CELL BIO, V13, P508, DOI 10.1038/nrm3394; Le Scolan E, 2008, CANCER RES, V68, P3277, DOI 10.1158/0008-5472.CAN-07-6793; Levy L, 2007, MOL CELL BIOL, V27, P6068, DOI 10.1128/MCB.00664-07; Miyazono K, 2011, J BIOCHEM, V149, P1, DOI 10.1093/jb/mvq133; Mizutani A, 2011, J BIOL CHEM, V286, P29848, DOI 10.1074/jbc.M110.217745; Mizutani A, 2010, J BIOCHEM, V148, P733, DOI 10.1093/jb/mvq127; Nagano Y, 2007, J BIOL CHEM, V282, P20492, DOI 10.1074/jbc.M701294200; Park JH, 2011, J BIOL CHEM, V286, P10911, DOI 10.1074/jbc.C110.210211; Peng DJ, 2011, J IMMUNOL, V186, P5638, DOI 10.4049/jimmunol.1003801; Poulsen SL, 2013, J CELL BIOL, V201, P797, DOI 10.1083/jcb.201212075; Ray KC, 2014, ONCOGENE, V33, P823, DOI 10.1038/onc.2013.3; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Sharma V, 2011, CANCER RES, V71, P6438, DOI 10.1158/0008-5472.CAN-11-1645; Shirakihara T, 2011, EMBO J, V30, P783, DOI 10.1038/emboj.2010.351; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Ueda J, 2014, ONCOGENE, V33, P4485, DOI 10.1038/onc.2013.392; Warzecha CC, 2012, SEMIN CANCER BIOL, V22, P417, DOI 10.1016/j.semcancer.2012.04.003; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Wild JRL, 2012, INT J EXP PATHOL, V93, P81, DOI 10.1111/j.1365-2613.2012.00810.x; Yae T, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1892; Yuzawa H, 2009, BONE, V44, P53, DOI 10.1016/j.bone.2008.09.013; Zhao Q, 2013, CLIN CANCER RES, V19, P2460, DOI 10.1158/1078-0432.CCR-12-3708; Zhou ZN, 2014, ONCOGENE, V33, P3784, DOI 10.1038/onc.2013.363	46	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3514	3523		10.1038/onc.2015.412	http://dx.doi.org/10.1038/onc.2015.412			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26522722	Green Published, hybrid			2022-12-17	WOS:000379621500004
J	Auvergne, R; Wu, C; Connell, A; Au, S; Cornwell, A; Osipovitch, M; Benraiss, A; Dangelmajer, S; Guerrero-Cazares, H; Quinones-Hinojosa, A; Goldman, SA				Auvergne, R.; Wu, C.; Connell, A.; Au, S.; Cornwell, A.; Osipovitch, M.; Benraiss, A.; Dangelmajer, S.; Guerrero-Cazares, H.; Quinones-Hinojosa, A.; Goldman, S. A.			PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo	ONCOGENE			English	Article							PROTEASE-ACTIVATED RECEPTOR-1; SMALL-MOLECULE ANTAGONISTS; CANCER STEM-CELLS; HUMAN GLIOBLASTOMA; GENE-EXPRESSION; HUMAN BRAIN; THROMBIN; IDENTIFICATION; EGFR; ANGIOGENESIS	Glioblastoma (GBM) remains the most common and lethal intracranial tumor. In a comparison of gene expression by A2B5-defined tumor-initiating progenitor cells (TPCs) to glial progenitor cells derived from normal adult human brain, we found that the F2R gene encoding PAR1 was differentially overexpressed by A2B5-sorted TPCs isolated from gliomas at all stages of malignant development. In this study, we asked if PAR1 is causally associated with glioma progression. Lentiviral knockdown of PAR1 inhibited the expansion and self-renewal of human GBM-derived A2B5(+) TPCs in vitro, while pharmacological inhibition of PAR 1 similarly slowed both the growth and migration of A2B5(+) TPCs in culture. In addition, PAR1 silencing potently suppressed tumor expansion in vivo, and significantly prolonged the survival of mice following intracranial transplantation of human TPCs. These data strongly suggest the importance of PAR1 to the self-renewal and tumorigenicity of A2B5-defined glioma TPCs; as such, the abrogation of PAR1-dependent signaling pathways may prove a promising strategy for gliomas.	[Auvergne, R.; Wu, C.; Connell, A.; Au, S.; Cornwell, A.; Osipovitch, M.; Benraiss, A.; Goldman, S. A.] Neurol Univ Rochester, Med Ctr, Ctr Translat Neuromed, Dept Neurol, Rochester, NY USA; [Auvergne, R.; Wu, C.; Connell, A.; Au, S.; Cornwell, A.; Osipovitch, M.; Benraiss, A.; Goldman, S. A.] Neurol Univ Rochester, Med Ctr, Ctr Translat Neuromed, Rochester, NY 14642 USA; [Dangelmajer, S.; Guerrero-Cazares, H.; Quinones-Hinojosa, A.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA; [Goldman, S. A.] Univ Copenhagen, Ctr Basic & Translat Neurosci, Copenhagen, Denmark	University of Rochester; University of Rochester; Johns Hopkins University; University of Copenhagen	Auvergne, R; Goldman, SA (corresponding author), Neurol Univ Rochester, Med Ctr, Ctr Translat Neuromed, Rochester, NY 14642 USA.; Auvergne, R; Goldman, SA (corresponding author), Neurol Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA.	romane_auvergne@urmc.rochester.edu; steven_goldman@urmc.rochester.edu	Benraiss, Abdellatif/AAI-8584-2021; Auvergne, Romane M/N-2624-2016	Benraiss, Abdellatif/0000-0002-0325-6234; Auvergne, Romane M/0000-0002-9497-0184; Au, Sandra/0000-0002-7924-3982; Cornwell, Adam/0000-0002-0572-3107; Goldman, Steven/0000-0002-5498-4303; Guerrero-Cazares, Hugo/0000-0003-1307-719X	Dr Miriam and Sheldon G Adelson Medical Research Foundation; New York State Stem Cell Research Program; NIH [R01NS070024]; Novo Nordisk Fonden [NNF13OC0004260] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH099578, R01MH104701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS075345] Funding Source: NIH RePORTER	Dr Miriam and Sheldon G Adelson Medical Research Foundation; New York State Stem Cell Research Program; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Novo Nordisk Fonden(Novo Nordisk Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr Mahlon Johnson for the histopathological validation of tumor stage, Dr Kevin Walter for arranging tissue donation and Shengtao Qu and Eric Franklin for technical assistance. This work was supported by the Dr Miriam and Sheldon G Adelson Medical Research Foundation, and by the New York State Stem Cell Research Program. Tissue collection, processing and studies on human tissue derived from Johns Hopkins University were supported by NIH R01NS070024.	Adams MN, 2011, PHARMACOL THERAPEUT, V130, P248, DOI 10.1016/j.pharmthera.2011.01.003; Arora P, 2008, ONCOGENE, V27, P4434, DOI 10.1038/onc.2008.84; Auvergne RM, 2013, CELL REP, V3, P2127, DOI 10.1016/j.celrep.2013.04.035; Baumer N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094993; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bar-Shavit R, 2011, IUBMB LIFE, V63, P397, DOI 10.1002/iub.452; Bergmann S, 2006, ONCOL REP, V15, P889; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Brat DJ, 2004, LAB INVEST, V84, P397, DOI 10.1038/labinvest.3700070; Carneiro-Lobo TC, 2014, ONCOL REP, V31, P679, DOI 10.3892/or.2013.2880; Coughlin SR, 2005, J THROMB HAEMOST, V3, P1800, DOI 10.1111/j.1538-7836.2005.01377.x; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Defeo K, 2010, CANCER BIOL THER, V10, P1001, DOI 10.4161/cbt.10.10.13236; Du XL, 2011, JPN J CLIN ONCOL, V41, P1086, DOI 10.1093/jjco/hyr108; Elste AP, 2010, J MOL HISTOL, V41, P89, DOI 10.1007/s10735-010-9274-6; Eroglu A, 2012, ANN SURG ONCOL, V19, P1365, DOI 10.1245/s10434-011-1969-8; Feve M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091519; Fujimoto D, 2008, ANTICANCER RES, V28, P847; Garcia-Lopez MT, 2010, CURR MED CHEM, V17, P109, DOI 10.2174/092986710790112639; Garnier D, 2010, THROMB RES, V125, pS44, DOI 10.1016/S0049-3848(10)70012-8; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Ghio P, 2006, CLIN LUNG CANCER, V7, P395, DOI 10.3816/CLC.2006.n.023; Gibson E, 2012, CURR OPIN ONCOL, V24, P672, DOI 10.1097/CCO.0b013e3283571a8e; Gieseler F, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-86; Guo H, 2013, J NEUROSCI, V33, P6181, DOI 10.1523/JNEUROSCI.4491-12.2013; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Junge CE, 2004, EXP NEUROL, V188, P94, DOI 10.1016/j.expneurol.2004.02.018; Kaufmann R, 1998, NEUROREPORT, V9, P709, DOI 10.1097/00001756-199803090-00027; Kaufmann R, 2012, ADV EXP MED BIOL, V740, P979, DOI 10.1007/978-94-007-2888-2_45; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kuhn SA, 2014, NEUROL RES, V36, P709, DOI 10.1179/1743132813Y.0000000303; Lee CJ, 2011, BRIT J CLIN PHARMACO, V72, P581, DOI 10.1111/j.1365-2125.2011.03916.x; Lin N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094871; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Magnus N, 2013, J THROMB HAEMOST, V11, P1197, DOI 10.1111/jth.12242; Massi D, 2005, HUM PATHOL, V36, P676, DOI 10.1016/j.humpath.2005.04.008; Milsom C, 2009, ARTERIOSCL THROM VAS, V29, P2005, DOI 10.1161/ATVBAHA.108.177444; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; Ogden AT, 2008, NEUROSURGERY, V62, P505, DOI 10.1227/01.neu.0000316019.28421.95; Perry JR, 2012, NEURO-ONCOLOGY, V14, P73, DOI 10.1093/neuonc/nos197; Persson AI, 2010, CANCER CELL, V18, P669, DOI 10.1016/j.ccr.2010.10.033; Queiroz KCS, 2014, INT J CANCER, V135, P2294, DOI 10.1002/ijc.28726; Ramachandran R, 2012, NAT REV DRUG DISCOV, V11, P69, DOI 10.1038/nrd3615; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Soh UJK, 2010, BRIT J PHARMACOL, V160, P191, DOI 10.1111/j.1476-5381.2010.00705.x; Stangier J, 2008, CLIN PHARMACOKINET, V47, P285, DOI 10.2165/00003088-200847050-00001; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Talloen W, 2007, BIOINFORMATICS, V23, P2897, DOI 10.1093/bioinformatics/btm478; Tchoghandjian A, 2010, BRAIN PATHOL, V20, P211, DOI 10.1111/j.1750-3639.2009.00269.x; Tsopanoglou NE, 2007, SEMIN THROMB HEMOST, V33, P680, DOI 10.1055/s-2007-991535; Venere M, 2011, GLIA, V59, P1148, DOI 10.1002/glia.21185; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Villares GJ, 2011, ONCOTARGET, V2, P8; Zania P, 2006, J PHARMACOL EXP THER, V318, P246, DOI 10.1124/jpet.105.099069; Zhang Y, 2011, PATHOL RES PRACT, V207, P24, DOI 10.1016/j.prp.2010.10.003; Zhao PS, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00067; Zigler M, 2011, CANCER RES, V71, P6561, DOI 10.1158/0008-5472.CAN-11-1432	60	33	34	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3817	3828		10.1038/onc.2015.452	http://dx.doi.org/10.1038/onc.2015.452			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26616854	Green Accepted			2022-12-17	WOS:000380753200007
J	Yang, YC; Cheng, TY; Huang, SM; Su, CY; Yang, PW; Lee, JM; Chen, CK; Hsiao, M; Hua, KT; Kuo, ML				Yang, Y-C; Cheng, T-Y; Huang, S-M; Su, C-Y; Yang, P-W; Lee, J-M; Chen, C-K; Hsiao, M.; Hua, K-T; Kuo, M-L			Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90-EGFR association	ONCOGENE			English	Article							PYRUVATE-KINASE M2; CELL LUNG-CANCER; ACQUIRED-RESISTANCE; GENE-TRANSCRIPTION; MUTATIONS; GEFITINIB; PROMOTES; ISOFORM; ACTIVATION; ADENOCARCINOMAS	Secondary mutation of epidermal growth factor receptor (EGFR) resulting in drug resistance is one of the most critical issues in lung cancer therapy. Several drugs are being developed to overcome EGFR tyrosine kinase inhibitor (TKI) resistance. Here, we report that pyruvate kinase M2 (PKM2) stabilized mutant EGFR protein by direct interaction and sustained cell survival signaling in lung cancer cells. PKM2 silencing resulted in markedly reduced mutant EGFR expression in TKI-sensitive or-resistant human lung cancer cells, and in inhibition of tumor growth in their xenografts, concomitant with downregulation of EGFR-related signaling. Mechanistically, PKM2 directly interacted with mutant EGFR and heat-shock protein 90 (HSP90), and thus stabilized EGFR by maintaining its binding with HSP90 and co-chaperones. Stabilization of EGFR relied on dimeric PKM2, and the protein half-life of mutant EGFR decreased when PKM2 was forced into its tetramer form. Clinical levels of PKM2 positively correlated with mutant EGFR expression and with patient outcome. These results reveal a previously undescribed non-glycolysis function of PKM2 in the cytoplasm, which contribute to EGFR-dependent tumorigenesis and provide a novel strategy to overcome drug resistance to EGFR TKIs.	[Yang, Y-C] Natl Taiwan Univ, Coll Med, Grad Inst Oncol, Taipei, Taiwan; [Cheng, T-Y] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan; [Huang, S-M; Chen, C-K; Hua, K-T; Kuo, M-L] Natl Taiwan Univ, Coll Med, Grad Inst Toxicol, 1,Sect 1,Jen Ai Rd, Taipei 10055, Taiwan; [Su, C-Y; Chen, C-K; Hsiao, M.] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Yang, P-W; Lee, J-M] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Kuo, M-L] Natl Taiwan Univ, Coll Life Sci Sci, Inst Biochem Sci, 1,Roosevelt Rd,Sect 4, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Hua, KT (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Toxicol, 1,Sect 1,Jen Ai Rd, Taipei 10055, Taiwan.; Kuo, ML (corresponding author), Natl Taiwan Univ, Coll Life Sci Sci, Inst Biochem Sci, 1,Roosevelt Rd,Sect 4, Taipei, Taiwan.	kthua@ntu.edu.tw; kuominliang@ntu.edu.tw	Yang, Yi-Chieh/D-6248-2019; Cheng, TY/X-1695-2019; Su, Chia-Yi/L-5378-2016; Hsiao, Michael/U-6238-2019	Su, Chia-Yi/0000-0002-9483-4510; Hsiao, Michael/0000-0001-8529-9213; LEE, JANG-MING/0000-0001-9727-227X; CHENG, TSU-YAO/0000-0002-7370-5605; Hua, Kuo-Tai/0000-0002-8468-4977	National Science Council, Taiwan [NSC 104-2321-B-002-006, NSC-104-2911-I-002-302, NSC 104-2923-B-002-003]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	We thank Dr Zhimin Lu for the Flag-tagged K367M, K433E and wild-type PKM2, Dr Zhi-Ren Liu for HA-tagged R399E and wild-type PKM2, Dr Mien-Chie Hung for myc-tagged EGFR-ECM and -ICM, Dr Ann-Lii Cheng and Dr James Chih-Hsin Yang for helpful discussion, Integrated Core Facility for Functional Genomics of the National Core Facility Program for Biotechnology, the Microarray Core Facility of the National Taiwan University Center of Genomic Medicine and Dr Sung-Liang Yu for technical support. This study was supported by grants from National Science Council, Taiwan (NSC 104-2321-B-002-006, NSC-104-2911-I-002-302 and NSC 104-2923-B-002-003).	Anastasiou D, 2012, NAT CHEM BIOL, V8, P839, DOI 10.1038/NCHEMBIO.1060; Arcila ME, 2011, CLIN CANCER RES, V17, P1169, DOI 10.1158/1078-0432.CCR-10-2277; Chaneton B, 2012, NATURE, V491, P458, DOI 10.1038/nature11540; Chiosis G, 2013, NAT STRUCT MOL BIOL, V20, P1, DOI 10.1038/nsmb.2481; Chou YT, 2010, CANCER RES, V70, P8822, DOI 10.1158/0008-5472.CAN-10-0638; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Chung BM, 2009, ONCOGENE, V28, P1821, DOI 10.1038/onc.2009.31; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Cortes-Cros M, 2013, P NATL ACAD SCI USA, V110, P489, DOI 10.1073/pnas.1212780110; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Haspinger ER, 2014, J CLIN ONCOL, V32, P859, DOI 10.1200/JCO.2013.52.8794; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Israelsen WJ, 2013, CELL, V155, P397, DOI 10.1016/j.cell.2013.09.025; Jiang YH, 2014, MOL CELL, V53, P75, DOI 10.1016/j.molcel.2013.11.001; Keller KE, 2014, MOL CELL, V53, P700, DOI 10.1016/j.molcel.2014.02.015; Kobayashi N, 2012, LUNG CANCER, V75, P161, DOI 10.1016/j.lungcan.2011.04.022; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kobayashi S, 2006, CANCER RES, V66, P11389, DOI 10.1158/0008-5472.CAN-06-2318; Le Mellay V, 2002, ADV ENZYME REGUL, V42, P317, DOI 10.1016/S0065-2571(01)00036-X; Li J, 2014, CLIN TRANSL ONCOL, V16, P200, DOI 10.1007/s12094-013-1063-8; Lim JY, 2012, WORLD J GASTROENTERO, V18, P4037, DOI 10.3748/wjg.v18.i30.4037; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Lv L, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/507103; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Nyati MK, 2006, NAT REV CANCER, V6, P876, DOI 10.1038/nrc1953; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; Parnell KM, 2013, MOL CANCER THER, V12, P1453, DOI 10.1158/1535-7163.MCT-13-0026; Pirazzoli V, 2014, CELL REP, V7, P999, DOI 10.1016/j.celrep.2014.04.014; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Shimamura T, 2005, CANCER RES, V65, P6401, DOI 10.1158/0008-5472.CAN-05-0933; Solit DB, 2007, CLIN CANCER RES, V13, P1775, DOI 10.1158/1078-0432.CCR-06-1863; Taipale M, 2010, NAT REV MOL CELL BIO, V11, P515, DOI 10.1038/nrm2918; VOLLMER SH, 1994, J BIOL CHEM, V269, P8082; Walter AO, 2013, CANCER DISCOV, V3, P1404, DOI 10.1158/2159-8290.CD-13-0314; Wang P, 2015, PROTEIN CELL, V6, P275, DOI 10.1007/s13238-015-0132-x; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Yang JCH, 2013, J CLIN ONCOL, V31, P3342, DOI 10.1200/JCO.2012.46.1764; Yang SC, 2006, CANCER RES, V66, P6990, DOI 10.1158/0008-5472.CAN-06-1042; Yang WW, 2012, MOL CELL, V48, P771, DOI 10.1016/j.molcel.2012.09.028; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yuan SS, 2011, J CLIN ONCOL, V29, P3435, DOI 10.1200/JCO.2011.35.3979	50	33	34	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3387	3398		10.1038/onc.2015.397	http://dx.doi.org/10.1038/onc.2015.397			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26500058				2022-12-17	WOS:000379270100004
J	D'Abramo, M; Besker, N; Desideri, A; Levine, AJ; Melino, G; Chillemi, G				D'Abramo, M.; Besker, N.; Desideri, A.; Levine, A. J.; Melino, G.; Chillemi, G.			The p53 tetramer shows an induced-fit interaction of the C-terminal domain with the DNA-binding domain	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; MUTANT P53; CELL-DEATH; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; LUNG-CANCER; TRANSCRIPTIONAL ACTIVATION; ENZYME SPECIFICITY; LYSINE METHYLATION; STRUCTURAL BASIS	The Trp53 gene is the most frequently mutated gene in all human cancers. Its protein product p53 is a very powerful transcription factor that can activate different biochemical pathways and affect the regulation of metabolism, senescence, DNA damage response, cell cycle and cell death. The understanding of its function at the molecular level could be of pivotal relevance for therapy. Investigation of long-range intra- and interdomain communications in the p53 tetramer-DNA complex was performed by means of an atomistic model that included the tetramerization helices in the C-terminal domain, the DNA-binding domains and a consensus DNA-binding site of 18 base pairs. Nonsymmetric dynamics are illustrated in the four DNA-binding domains, with loop L1 switching from inward to outward conformations with respect to the DNA major groove. Direct intra- and intermonomeric longrange communications between the tetramerization and DNA-binding domains are noted. These long-distance conformational changes link the C terminus with the DNA-binding domain and provide a biophysical rationale for the reported functional regulation of the p53 C-terminal region. A fine characterization of the DNA deformation caused by p53 binding is obtained, with `static' deformations always present and measured by the slide parameter in the central thymine-adenine base pairs; we also detect `dynamic' deformations switched on and off by particular p53 tetrameric conformations and measured by the roll and twist parameters in the same base pairs. These different conformations can indeed modulate the electrostatic potential isosurfaces of the whole p53-DNA complex. These results provide a molecular/biophysical understanding of the evident role of the C terminus in post-translational modification that regulates the transcriptional function of p53. Furthermore, the unstructured C terminus is able to facilitate contacts between the core DNA-binding domains of the tetramer.	[D'Abramo, M.] Univ Roma La Sapienza, Dipartimento Chim, Via Tizii 6, I-00185 Rome, Italy; [Besker, N.; Chillemi, G.] CINECA, SCAI SuperComp Applicat & Innovat Dept, Via Tizii 6, I-00185 Rome, Italy; [Desideri, A.] Univ Roma Tor Vergata, Dept Biol, I-00173 Rome, Italy; [Levine, A. J.] Inst Adv Study, Olden Lane, Princeton, NJ 08540 USA; [Levine, A. J.] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA; [Melino, G.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Rome, Italy; [Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England	Sapienza University Rome; CINECA, Italy; University of Rome Tor Vergata; Institute for Advanced Study - USA; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; University of Rome Tor Vergata; University of Leicester	Chillemi, G (corresponding author), CINECA, SCAI SuperComp Applicat & Innovat Dept, Via Tizii 6, I-00185 Rome, Italy.	giochillemi@gmail.com	Chillemi, Giovanni/E-5201-2010; Chillemi, Giovanni/O-2825-2019; D'Abramo, Marco/B-7035-2008; Deri, Desi/K-1086-2018	Chillemi, Giovanni/0000-0003-3901-6926; Chillemi, Giovanni/0000-0003-3901-6926; D'Abramo, Marco/0000-0001-6020-8581; desideri, alessandro/0000-0003-1541-4217; Besker, Neva/0000-0002-7024-7178	MIUR-FIRB grant [RBFR12BGHO]; 'Rita Levi Montalcini' research program; Medical Research Council [MC_U132670600] Funding Source: researchfish; MRC [MC_U132670600] Funding Source: UKRI	MIUR-FIRB grant(Ministry of Education, Universities and Research (MIUR)); 'Rita Levi Montalcini' research program; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by a MIUR-FIRB grant (no. RBFR12BGHO) and 'Rita Levi Montalcini' research program. We acknowledge the Cineca Supercomputing centre for computational resources.	AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408; Amelio I, 2014, ONCOGENE, V33, P5039, DOI 10.1038/onc.2013.456; Antonov AV, 2014, ONCOGENE, V33, P1621, DOI 10.1038/onc.2013.119; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Balatti V, 2015, P NATL ACAD SCI USA, V112, P2169, DOI 10.1073/pnas.1500010112; Bochkareva E, 2005, P NATL ACAD SCI USA, V102, P15412, DOI 10.1073/pnas.0504614102; Brune M, 2013, ONCOGENE, V32, P1460, DOI 10.1038/onc.2012.150; Buckley NE, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.31; Burns DM, 2011, NATURE, V473, P105, DOI 10.1038/nature09908; Canadillas JMP, 2006, P NATL ACAD SCI USA, V103, P2109, DOI 10.1073/pnas.0510941103; Carr SM, 2012, ESSAYS BIOCHEM, V52, P79, DOI [10.1042/bse0520079, 10.1042/BSE0520079]; Chari NS, 2009, APOPTOSIS, V14, P336, DOI 10.1007/s10495-009-0327-9; Chen YH, 2010, STRUCTURE, V18, P246, DOI 10.1016/j.str.2009.11.011; Chillemi G, 2013, CELL CYCLE, V12, P3098, DOI 10.4161/cc.26162; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Ci Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.506; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Dashzeveg N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.176; Demir O, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002238; Drosten M, 2014, P NATL ACAD SCI USA, V111, P15155, DOI 10.1073/pnas.1417549111; Dudgeon C, 2014, GENE DEV, V28, P2613, DOI 10.1101/gad.252148.114; Emamzadah S, 2014, J MOL BIOL, V426, P936, DOI 10.1016/j.jmb.2013.12.020; Emerling BM, 2013, CELL, V155, P844, DOI 10.1016/j.cell.2013.09.057; Evstafieva AG, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.469; Fan YH, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.400; Fatt MP, 2014, CELL DEATH DIFFER, V21, P1546, DOI 10.1038/cdd.2014.61; Feng HQ, 2009, STRUCTURE, V17, P202, DOI 10.1016/j.str.2008.12.009; Fiori ME, 2014, CELL DEATH DIFFER, V21, P774, DOI 10.1038/cdd.2014.6; Foijer F, 2014, P NATL ACAD SCI USA, V111, P13427, DOI 10.1073/pnas.1400892111; Fortunato O, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.507; Garufi A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.217; Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689; Gomes LR, 2015, ONCOGENE, V34, P5329, DOI 10.1038/onc.2014.461; Gorrini C, 2014, P NATL ACAD SCI USA, V111, P11576, DOI 10.1073/pnas.1405580111; Han F, 2015, ONCOGENE, V34, P4391, DOI 10.1038/onc.2014.370; He Z, 2013, CELL DEATH DIFFER, V20, P1415, DOI 10.1038/cdd.2013.104; Henzler-Wildman K, 2007, NATURE, V450, P964, DOI 10.1038/nature06522; Hoffman Y, 2014, CELL DEATH DIFFER, V21, P302, DOI 10.1038/cdd.2013.146; Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Jiang P, 2013, NATURE, V493, P689, DOI 10.1038/nature11776; Johnson KA, 2008, J BIOL CHEM, V283, P26297, DOI 10.1074/jbc.R800034200; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kelly GL, 2014, GENE DEV, V28, P58, DOI 10.1101/gad.232009.113; Kern D, 2003, CURR OPIN STRUC BIOL, V13, P748, DOI 10.1016/j.sbi.2003.10.008; Kim J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.87; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; Kuszewski J, 1999, J AM CHEM SOC, V121, P2337, DOI 10.1021/ja9843730; Lange OF, 2008, PROTEINS, V70, P1294, DOI 10.1002/prot.21618; Laptenko O, 2015, MOL CELL, V57, P1034, DOI 10.1016/j.molcel.2015.02.015; Lavery R, 2009, NUCLEIC ACIDS RES, V37, P5917, DOI 10.1093/nar/gkp608; Leroy B, 2013, NUCLEIC ACIDS RES, V41, pD962, DOI 10.1093/nar/gks1033; Levine AJ, 2011, NAT REV MOL CELL BIO, V12, P259, DOI 10.1038/nrm3086; Lezina L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.483; Li D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.158; Li H, 2014, CELL DEATH DIFFER, V21, P1493, DOI 10.1038/cdd.2014.69; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Link N, 2013, GENE DEV, V27, P2433, DOI 10.1101/gad.225565.113; Lu Q, 2007, J PHYS CHEM B, V111, P11538, DOI 10.1021/jp0742261; Lu XJ, 2003, NUCLEIC ACIDS RES, V31, P5108, DOI 10.1093/nar/gkg680; Lubin DJ, 2010, J MOL BIOL, V395, P705, DOI 10.1016/j.jmb.2009.11.013; Lujambio A, 2013, CELL, V153, P449, DOI 10.1016/j.cell.2013.03.020; Maddocks ODK, 2013, NATURE, V493, P542, DOI 10.1038/nature11743; Malatesta M, 2013, ONCOGENE, V32, P4721, DOI 10.1038/onc.2012.463; Manzl C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.470; Marcel V, 2014, CELL DEATH DIFFER, V21, P1377, DOI 10.1038/cdd.2014.73; McCammon JA, 1988, DYNAMICS PROTEINS NU, P289; Melero R, 2011, P NATL ACAD SCI USA, V108, P557, DOI [10.1073/pnas.1015520107, 10.1073/pnas.101S520107]; Mello SS, 2013, CELL DEATH DIFFER, V20, P855, DOI 10.1038/cdd.2013.53; Meniel V, 2015, ONCOGENE, V34, P4118, DOI 10.1038/onc.2014.342; Merlo P, 2014, P NATL ACAD SCI USA, V111, P18055, DOI 10.1073/pnas.1419083111; Muller M, 2006, DRUG RESIST UPDATE, V9, P288, DOI 10.1016/j.drup.2007.01.001; Nair BC, 2014, CELL DEATH DIFFER, V21, P1409, DOI 10.1038/cdd.2014.55; Okada N, 2014, GENE DEV, V28, P438, DOI 10.1101/gad.233585.113; Oldfield CJ, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-S1-S1; Pan YP, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000878; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Petty TJ, 2011, EMBO J, V30, P2167, DOI 10.1038/emboj.2011.127; Peuget S, 2014, CELL DEATH DIFFER, V21, P1107, DOI 10.1038/cdd.2014.28; Phesse TJ, 2014, CELL DEATH DIFFER, V21, P956, DOI 10.1038/cdd.2014.15; Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055; Ren ZJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.327; Rossi M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.113; Rowell JP, 2012, STRUCTURE, V20, P2014, DOI 10.1016/j.str.2012.09.004; Rufini A, 2013, ONCOGENE, V32, P5129, DOI 10.1038/onc.2012.640; Rufini A, 2012, GENE DEV, V26, P2009, DOI 10.1101/gad.197640.112; Saldana-Meyer R, 2014, GENE DEV, V28, P723, DOI 10.1101/gad.236869.113; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Senturk S, 2014, P NATL ACAD SCI USA, V111, pE3287, DOI 10.1073/pnas.1321640111; Shetzer Y, 2014, CELL DEATH DIFFER, V21, P1419, DOI 10.1038/cdd.2014.57; Shi Y, 2014, CELL DEATH DIFFER, V21, P612, DOI 10.1038/cdd.2013.186; Simon HU, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.308; Solomon H, 2014, CELL DEATH DIFFER, V21, P1347, DOI 10.1038/cdd.2014.99; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Tan EH, 2014, ONCOGENE, V33, P3325, DOI 10.1038/onc.2013.287; Tang ZY, 2013, CELL, V154, P297, DOI 10.1016/j.cell.2013.06.027; Terrinoni A, 2011, ONCOGENE, V30, P3096, DOI 10.1038/onc.2011.31; Tidow H, 2007, P NATL ACAD SCI USA, V104, P12324, DOI 10.1073/pnas.0705069104; Tomasini R, 2008, TRENDS CELL BIOL, V18, P244, DOI 10.1016/j.tcb.2008.03.003; Tschaharganeh DF, 2014, CELL, V158, P579, DOI 10.1016/j.cell.2014.05.051; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; Van Nostrand JL, 2014, NATURE, V514, P228, DOI 10.1038/nature13585; VanAalten DMF, 1997, J COMPUT CHEM, V18, P169, DOI 10.1002/(SICI)1096-987X(19970130)18:2<169::AID-JCC3>3.0.CO;2-T; Vaseva AV, 2012, CELL, V149, P1536, DOI 10.1016/j.cell.2012.05.014; Venkatanarayan A, 2015, NATURE, V517, P626, DOI 10.1038/nature13910; Wang GZ, 2015, P NATL ACAD SCI USA, V112, P2437, DOI 10.1073/pnas.1500243112; Wang GZ, 2015, P NATL ACAD SCI USA, V112, P2443, DOI 10.1073/pnas.1500262112; Wassman CD, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2361; Weilbacher A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.284; Weissmueller S, 2014, CELL, V157, P382, DOI 10.1016/j.cell.2014.01.066; Xu J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.75; Yang-Hartwich Y, 2015, ONCOGENE, V34, P3605, DOI 10.1038/onc.2014.296; Yoshida K, 2010, CANCER SCI, V101, P831, DOI 10.1111/j.1349-7006.2010.01488.x; Zaccara S, 2014, CELL DEATH DIFFER, V21, P1522, DOI 10.1038/cdd.2014.79; Zhang EB, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.201; Zhang HH, 2014, CELL DEATH DIFFER, V21, P1656, DOI 10.1038/cdd.2014.78; Zhu L, 2015, ONCOGENE, V34, P4547, DOI 10.1038/onc.2014.399	120	33	33	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3272	3281		10.1038/onc.2015.388	http://dx.doi.org/10.1038/onc.2015.388			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26477317	Green Published, hybrid			2022-12-17	WOS:000378306400006
J	Jen, J; Lin, LL; Chen, HT; Liao, SY; Lo, FY; Tang, YA; Su, WC; Salgia, R; Hsu, CL; Huang, HC; Juan, HF; Wang, YC				Jen, J.; Lin, L-L; Chen, H-T; Liao, S-Y; Lo, F-Y; Tang, Y-A; Su, W-C; Salgia, R.; Hsu, C-L; Huang, H-C; Juan, H-F; Wang, Y-C			Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer	ONCOGENE			English	Article							ZINC-FINGER PROTEIN; MARCKS-RELATED DOMAIN; KINASE-C; GASTRIC-CANCER; CELL-GROWTH; SPECTRIN; COMPLEX; PHOSPHORYLATION; IDENTIFICATION; PROGRESSION	ZNF322A encoding a classical Cys2His2 zinc finger transcription factor was previously revealed as a potential oncogene in lung cancer patients. However, the oncogenic role of ZNF322A and its underlying mechanism in lung tumorigenesis remain elusive. Here we show ZNF322A protein overexpression in 123 Asian and 74 Caucasian lung cancer patients. Multivariate Cox regression analysis indicated that ZNF322A was an independent risk factor for a poor outcome in lung cancer, corroborating the Kaplan-Meier results that patients with ZNF322A protein overexpression had significantly poorer overall survival than other patients. Overexpression of ZNF322A promoted cell proliferation and soft agar growth by prolonging cell cycle in S phase in multiple lung cell lines, including the immortalized lung cell BEAS-2B. In addition, ZNF322A overexpression enhanced cell migration and invasion, whereas knockdown of ZNF322A reduced cell growth, invasion and metastasis abilities in vitro and in vivo. Quantitative proteomic analysis revealed potential ZNF322A-regulated downstream targets, including alpha-adducin (ADD1), cyclin D1 (CCND1), and p53. Using luciferase promoter activity assay combined with site-directed mutagenesis and sequential chromatin immunoprecipitation-PCR assay, we found that ZNF322A could form a complex with c-Jun and cooperatively activate ADD1 and CCND1 but repress p53 gene transcription by recruiting differential chromatin modifiers, such as histone deacetylase 3, in an AP-1 element dependent manner. Reconstitution experiments indicated that CCND1 and p53 were important to ZNF322A-mediated promotion of cell proliferation, whereas ADD1 was necessary for ZNF322A-mediated cell migration and invasion. Our results provide compelling evidence that ZNF322A overexpression transcriptionally dysregulates genes involved in cell growth and motility therefore contributes to lung tumorigenesis and poor prognosis.	[Jen, J.; Liao, S-Y; Wang, Y-C] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, 1 Univ Rd, Tainan 701, Taiwan; [Lin, L-L; Hsu, C-L; Juan, H-F] Natl Taiwan Univ, Dept Life Sci, Inst Mol & Cellular Biol, Grad Inst Biomed Elect & Bioinformat, 1,Sec 4,Roosevelt Rd, Taipei 116, Taiwan; [Chen, H-T; Lo, F-Y; Tang, Y-A; Wang, Y-C] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan; [Su, W-C] Natl Cheng Kung Univ, Dept Internal Med, Coll Med, Tainan 701, Taiwan; [Salgia, R.] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA; [Huang, H-C] Natl Yang Ming Univ, Inst Biomed Informat, Taipei 112, Taiwan; [Huang, H-C] Natl Yang Ming Univ, Ctr Syst & Synthet Biol, Taipei 112, Taiwan	National Cheng Kung University; National Taiwan University; National Cheng Kung University; National Cheng Kung University; University of Chicago; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Wang, YC (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, 1 Univ Rd, Tainan 701, Taiwan.; Juan, HF (corresponding author), Natl Taiwan Univ, Dept Life Sci, Inst Mol & Cellular Biol, Grad Inst Biomed Elect & Bioinformat, 1,Sec 4,Roosevelt Rd, Taipei 116, Taiwan.	yukijuan@ntu.edu.tw; ycw5798@mail.ncku.edu.tw	Huang, Hsuan-Cheng/C-7266-2011; Hsu, Chia-Lang/O-1458-2013; Wang, Yi-Ching/J-8702-2019	Huang, Hsuan-Cheng/0000-0002-3386-0934; Hsu, Chia-Lang/0000-0002-7447-8045; Wang, Yi-Ching/0000-0002-7694-2067; JUAN, HSUEH-FEN/0000-0003-4876-3309; Su, Wu-Chou/0000-0003-2953-4105	Taiwan Ministry of Science and Technology Grant [103-2627-B-006-007, 103-2627-B-002-002]; Taiwan Ministry of Health and Welfare Grant [MOHW103-TD-B-111-06]; Aim for the Top University Project Grant; Human Biobank, Research Center of Clinical Medicine, National Cheng Kung University Hospital	Taiwan Ministry of Science and Technology Grant; Taiwan Ministry of Health and Welfare Grant; Aim for the Top University Project Grant; Human Biobank, Research Center of Clinical Medicine, National Cheng Kung University Hospital	This work was supported by the Taiwan Ministry of Science and Technology Grant (103-2627-B-006-007; 103-2627-B-002-002), Taiwan Ministry of Health and Welfare Grant (MOHW103-TD-B-111-06) and the Aim for the Top University Project Grant. We are grateful for the support from the Human Biobank, Research Center of Clinical Medicine, National Cheng Kung University Hospital. Accession numbers: Data from proteomics was deposited in the ProteomeXchange Consortium with accession number PXD001123.	Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; BENNETT V, 1988, J BIOL CHEM, V263, P5860; Chauhan S, 2013, MOL CELL, V50, P16, DOI 10.1016/j.molcel.2013.01.024; Chen CL, 2007, J CELL SCI, V120, P1157, DOI 10.1242/jcs.03408; Cheng YD, 2012, MOL CANCER RES, V10, P925, DOI 10.1158/1541-7786.MCR-11-0594; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Cowger JJM, 2007, ONCOGENE, V26, P3378, DOI 10.1038/sj.onc.1210126; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Evans PM, 2008, ACTA BIOCH BIOPH SIN, V40, P554, DOI 10.1111/j.1745-7270.2008.00439.x; Frietze S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015082; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; Gocke CB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003255; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Jeon BN, 2014, NUCLEIC ACIDS RES, V42, P11447, DOI 10.1093/nar/gku857; Jheon AH, 2001, J BIOL CHEM, V276, P18282, DOI 10.1074/jbc.M010885200; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kim MK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004864; Lai KP, 2014, INT J CANCER, V135, P1790, DOI 10.1002/ijc.28819; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li D, 2011, MOL CANCER RES, V9, P577, DOI 10.1158/1541-7786.MCR-10-0534; Li XL, 1998, J BIOL CHEM, V273, P19329, DOI 10.1074/jbc.273.30.19329; Li YQ, 2004, BIOCHEM BIOPH RES CO, V325, P1383, DOI 10.1016/j.bbrc.2004.10.183; Lo FY, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-235; Matsuoka Y, 1998, J CELL BIOL, V142, P485, DOI 10.1083/jcb.142.2.485; Meruvu S, 2011, J BIOL CHEM, V286, P26516, DOI 10.1074/jbc.M110.212506; Ogawa S, 2004, P NATL ACAD SCI USA, V101, P14461, DOI 10.1073/pnas.0405786101; Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Selamat SA, 2012, GENOME RES, V22, P1197, DOI 10.1101/gr.132662.111; Shen Q, 2008, ONCOGENE, V27, P366, DOI 10.1038/sj.onc.1210643; Tian C, 2009, NAT CELL BIOL, V11, P580, DOI 10.1038/ncb1864; Tupler R, 2001, NATURE, V409, P832, DOI 10.1038/35057011; Wagner S, 2000, J BIOL CHEM, V275, P15685, DOI 10.1074/jbc.M910152199; Wei Z, 2009, STEM CELLS, V27, P2969, DOI 10.1002/stem.231; Yang GL, 2014, ONCOL REP, V31, P1877, DOI 10.3892/or.2014.2997; Yu J, 2013, ONCOGENE, V32, P307, DOI 10.1038/onc.2012.54; Zhang L, 2014, ONCOGENE, V33, P5491, DOI 10.1038/onc.2013.495	38	33	33	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2357	2369		10.1038/onc.2015.296	http://dx.doi.org/10.1038/onc.2015.296			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26279304	hybrid, Green Published			2022-12-17	WOS:000376165000008
J	Meng, X; Vander Ark, A; Lee, P; Hostetter, G; Bhowmick, NA; Matrisian, LM; Williams, BO; Miranti, CK; Li, X				Meng, X.; Vander Ark, A.; Lee, P.; Hostetter, G.; Bhowmick, N. A.; Matrisian, L. M.; Williams, B. O.; Miranti, C. K.; Li, X.			Myeloid-specific TGF-beta signaling in bone promotes basic-FGF and breast cancer bone metastasis	ONCOGENE			English	Article							TUMOR-METASTASIS; II RECEPTOR; GROWTH; CELLS; PROGRESSION; EXPRESSION	Breast cancer (BCa) bone metastases cause osteolytic bone lesions, which result from the interactions of metastatic BCa cells with osteoclasts and osteoblasts. Osteoclasts differentiate from myeloid lineage cells. To understand the cell-specific role of transforming growth factor beta (TGF-beta) in the myeloid lineage, in BCa bone metastases, MDA-MB-231 BCa cells were intra-tibially or intra-cardially injected into LysM(Cre)/Tgfbr2(floxE2/floxE2) knockout (LysM(Cre)/Tgfbr2 KO) or Tgfbr2(floxE2/floxE2) mice. Metastatic bone lesion development was compared by analysis of both lesion number and area. We found that LysM(Cre)/Tgfbr2 knockout significantly decreased MDA-MB-231 bone lesion development in both the cardiac and tibial injection models. LysM(Cre)/Tgfbr2 knockout inhibited the tumor cell proliferation, angiogenesis and osteoclastogenesis of the metastatic bones. Cytokine array analysis showed that basic fibroblast growth factor (bFGF) was downregulated in MDA-MB-231-injected tibiae from the LysM(Cre)/Tgfbr2 KO group, and intravenous injection of the recombinant bFGF to LysM(Cre)/Tgfbr2 KO mice rescued the inhibited metastatic bone lesion development. The mechanism by which bFGF rescued the bone lesion development was by promotion of tumor cell proliferation through the downstream mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK)-cFos pathway after binding to the FGF receptor 1 (FGFR1). Consistent with animal studies, we found that in human BCa bone metastatic tissues, TGF-beta type II receptor (T beta RII) and p-Smad2 were expressed in osteoclasts and tumor cells, and were correlated with the expression of FGFR1. Our studies suggest that myeloid-specific TGF-beta signaling-mediated bFGF in the bone promotes BCa bone metastasis.	[Meng, X.; Vander Ark, A.; Lee, P.; Williams, B. O.; Miranti, C. K.; Li, X.] Van Andel Res Inst, Ctr Canc & Cell Biol, Program Skeletal Dis & Tumor Microenvironm, Grand Rapids, MI 49503 USA; [Hostetter, G.] Van Andel Res Inst, Pathol & Biorepository Core, Grand Rapids, MI 49503 USA; [Bhowmick, N. A.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA; [Bhowmick, N. A.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA; [Matrisian, L. M.] Pancreat Canc Act Network, Washington, DC USA	Van Andel Institute; Van Andel Institute; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Li, X (corresponding author), Van Andel Res Inst, Ctr Canc & Cell Biol, Program Skeletal Dis & Tumor Microenvironm, Grand Rapids, MI 49503 USA.	xiaohong.li@vai.org	Miranti, Cindy/AAJ-3783-2020; Bhowmick, Neil/AAA-7302-2019; Williams, Bart/A-3539-2013	Bhowmick, Neil/0000-0001-8747-5989; Williams, Bart/0000-0002-5261-5301; , Xiaohong/0000-0001-5074-193X; Meng, Xiangqi/0000-0002-6407-6122	Van Andel Research Institute [53010A]	Van Andel Research Institute	We thank Dr Julie A Sterling from Vanderbilt University and Dr Yibin Kang from Princeton University for providing cell lines. The Van Andel Research Institute supported this research (VARI start-up to X Li, 53010A). We thank Lisa Turner of the Pathology and Biorepository Core for her pathology expertise, the Vivarium and Transgenics Core for animal technical assistance and Diana Lewis for administrative support. We thank Dr Travis Burgers for the construction of 3D micro-CT pictures. Special thanks to Dr Mary E Winn from the Bioinformatics and Biostatistics Core for her great help in answering statistical questions. Finally, we thank David Nadziejka for his technical editing of this manuscript. The content is solely the responsibility of the authors.	Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; BRUNNER G, 1993, BLOOD, V81, P631; Busch S, 2015, ONCOGENE, V34, P27, DOI 10.1038/onc.2013.527; Cheng N, 2005, ONCOGENE, V24, P5053, DOI 10.1038/sj.onc.1208685; Cheng N, 2007, CANCER RES, V67, P4869, DOI 10.1158/0008-5472.CAN-06-3381; Chytil A, 2002, GENESIS, V32, P73, DOI 10.1002/gene.10046; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; Courjal F, 1997, CANCER RES, V57, P4360; Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Johnson RW, 2014, CLIN EXP METASTAS, V31, P945, DOI 10.1007/s10585-014-9682-1; Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846; Li X, 2008, ONCOGENE, V27, P7118, DOI 10.1038/onc.2008.293; Li XH, 2012, MOL CANCER RES, V10, P494, DOI 10.1158/1541-7786.MCR-11-0506; Novitskiy SV, 2012, J LEUKOCYTE BIOL, V92, P641, DOI 10.1189/jlb.1211639; Pang YL, 2013, CANCER DISCOV, V3, P936, DOI 10.1158/2159-8290.CD-12-0527; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Reddi AH, 2003, J BONE MINER RES, V18, P190, DOI 10.1359/jbmr.2003.18.2.190; Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wan XH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009332; Zhong ZD, 2012, P NATL ACAD SCI USA, V109, pE2197, DOI 10.1073/pnas.1120407109	23	33	34	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2370	2378		10.1038/onc.2015.297	http://dx.doi.org/10.1038/onc.2015.297			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26279296				2022-12-17	WOS:000376165000009
J	Lee, S; Kim, W; Ko, C; Ryu, WS				Lee, S.; Kim, W.; Ko, C.; Ryu, W-S			Hepatitis B virus X protein enhances Myc stability by inhibiting SCFSkp2 ubiquitin E3 ligase-mediated Myc ubiquitination and contributes to oncogenesis	ONCOGENE			English	Article							BOX RNA HELICASE; C-MYC; HEPATOCELLULAR-CARCINOMA; TRANSGENIC MICE; F-BOX; CANCER-CELLS; HBX GENE; DEGRADATION; SKP2; HEPATOCARCINOGENESIS	The stability of Myc oncoprotein is regulated by Skp/cullin/F-box (SCF) ubiquitin E3 ligase, in particular, via either SCFSkp2 or SCFFbw7 ubiquitin E3 ligases. An earlier study has shown that hepatitis B virus X protein (HBx) augments Myc stability via a mechanism involving the inhibition of Myc ubiquitination. However, the underlying mechanism by which HBx inhibits Myc ubiquitination remained to be elucidated. Moreover, to what extent HBx-mediated Myc stabilization contributes to viral oncogenesis is unknown. First, we corroborated the physiological significance of HBx-mediated Myc stabilization in HBV-replicating cells by demonstrating that (1) the elevation of Myc level in a HBV-replicating HepG2.2.15 cell compared to parental cells; (2) HBx-mediated Myc stabilization in a HBV replicon transfected cells; and (3) the inhibition of Myc ubiquitination by HBx in a HBV replicon transfected cells. Then, the molecular interaction between HBx and Myc protein was revealed via coimmunoprecipitation and immunofluorescence experiments. Subsequent analysis indicated that HBx stabilizes Myc oncoprotein by blocking Skp2, as opposed to Fbw7, -mediated Myc ubiquitination. Next, we defined the Myc-binding region to four residues (VFVL) near the C-terminus of HBx polypeptide. An HBx variant with mutated VFVL consistently failed to not only interact with Myc but also suppress Myc ubiquitination. Importantly, the VFVL mutant lost the ability to transform NIH3T3 cells in concert with Ras, implying that the HBx-Myc interaction is critical for viral oncogenesis. Consistently, immunohistochemistry of liver biopsies revealed that Myc protein is elevated in HBV-infected tissues. We concluded that HBx stabilizes Myc oncoprotein by inhibiting SCFSkp2 ubiquitin E3 ligase-mediated Myc ubiquitination, and the HBx-mediated Myc stabilization greatly contributes to viral oncogenesis.	[Lee, S.; Kim, W.; Ko, C.; Ryu, W-S] Yonsei Univ, Dept Biochem, 50 Yonsei Ro, Seoul 120749, South Korea	Yonsei University	Ryu, WS (corresponding author), Yonsei Univ, Dept Biochem, 50 Yonsei Ro, Seoul 120749, South Korea.	wsryu@yonsei.ac.kr		Ryu, Wang-Shick/0000-0002-0383-5666	National Research Foundation of Korea (NRF) grant - Korean government (MSIP) [NRF-2012R1A2A2A01007811]; BK21 PLUS program	National Research Foundation of Korea (NRF) grant - Korean government (MSIP); BK21 PLUS program	This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP; NRF-2012R1A2A2A01007811). SL and WK are fellowship awardee by BK21 PLUS program.	Bajaj BG, 2008, J VIROL, V82, P4082, DOI 10.1128/JVI.02500-07; Baresova P, 2012, J BIOL CHEM, V287, P16199, DOI 10.1074/jbc.M111.335216; Barry Michele, 2006, Sci STKE, V2006, ppe21; Benhenda S, 2009, ADV CANCER RES, V103, P75, DOI 10.1016/S0065-230X(09)03004-8; Bouchard MJ, 2004, J VIROL, V78, P12725, DOI 10.1128/JVI.78.23.12725-12734.2004; Cha MY, 2009, J GEN VIROL, V90, P978, DOI 10.1099/vir.0.009928-0; Cho HS, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2074; Choi SH, 2010, GENE DEV, V24, P1236, DOI 10.1101/gad.1920310; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Geng X, 2012, P NATL ACAD SCI USA, V109, P18471, DOI 10.1073/pnas.1204668109; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Hu ZY, 1999, J VIROL, V73, P7231, DOI 10.1128/JVI.73.9.7231-7240.1999; Kalra N, 2006, FEBS LETT, V580, P431, DOI 10.1016/j.febslet.2005.12.034; Kaposi-Novak P, 2009, CANCER RES, V69, P2775, DOI 10.1158/0008-5472.CAN-08-3357; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim S, 2010, J VIROL, V84, P52, DOI 10.1128/JVI.01232-09; Kim S, 2007, J VIROL, V81, P1714, DOI 10.1128/JVI.01863-06; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kim YC, 2001, ONCOGENE, V20, P16, DOI 10.1038/sj.onc.1203840; Ko C, 2014, J VIROL, V88, P13689, DOI 10.1128/JVI.02035-14; Kusunoki H, 2014, BIOCHEM BIOPH RES CO, V450, P741, DOI 10.1016/j.bbrc.2014.06.042; Lakhtakia R, 2003, J GASTROEN HEPATOL, V18, P80, DOI 10.1046/j.1440-1746.2003.02902.x; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; Li T, 2010, NAT STRUCT MOL BIOL, V17, P105, DOI 10.1038/nsmb.1719; Ma NF, 2008, CLIN CANCER RES, V14, P5061, DOI 10.1158/1078-0432.CCR-07-5082; Madden CR, 2001, J VIROL, V75, P3851, DOI 10.1128/JVI.75.8.3851-3858.2001; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; Neuveut C, 2010, J HEPATOL, V52, P594, DOI 10.1016/j.jhep.2009.10.033; Ng SA, 2011, J GASTROENTEROL, V46, P974, DOI 10.1007/s00535-011-0415-9; Oishi N, 2007, CANCER SCI, V98, P1540, DOI 10.1111/j.1349-7006.2007.00579.x; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Reifenberg K, 1997, J HEPATOL, V26, P119, DOI 10.1016/S0168-8278(97)80018-9; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Slagle BL, 2015, HEPATOLOGY, V61, P1416, DOI 10.1002/hep.27360; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Sze KMF, 2013, HEPATOLOGY, V57, P131, DOI 10.1002/hep.25979; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Thomas LR, 2011, ADV CANCER RES, V110, P77, DOI 10.1016/B978-0-12-386469-7.00004-9; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Tu H, 2001, CANCER RES, V61, P7803; Utku Y, 2006, MOL BIOSYST, V2, P312, DOI 10.1039/b603229j; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang H, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000986; Wang HF, 2009, J VIROL, V83, P5815, DOI 10.1128/JVI.00011-09; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101	49	33	36	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1857	1867		10.1038/onc.2015.251	http://dx.doi.org/10.1038/onc.2015.251			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26165841				2022-12-17	WOS:000373610400011
J	Peng, C; Zeng, W; Su, J; Kuang, Y; He, Y; Zhao, S; Zhang, J; Ma, W; Bode, AM; Dong, Z; Chen, X				Peng, C.; Zeng, W.; Su, J.; Kuang, Y.; He, Y.; Zhao, S.; Zhang, J.; Ma, W.; Bode, A. M.; Dong, Z.; Chen, X.			Cyclin-dependent kinase 2 (CDK2) is a key mediator for EGF-induced cell transformation mediated through the ELK4/c-Fos signaling pathway	ONCOGENE			English	Article							TERNARY COMPLEX FACTOR; C-FOS PROMOTER; ACTIVATED PROTEIN-KINASE; TUMOR-SUPPRESSOR; TRANSCRIPTION FACTOR; PROSTATE-CANCER; FACTOR SAP-1A; INHIBITION; RB; DNA	Cyclin-dependent kinase 2 (CDK2) is a known regulator in the cell cycle control of the G1/S and S/G2 transitions. However, the role of CDK2 in tumorigenesis is controversial. Evidence from knockout mice as well as colon cancer cell lines indicated that CDK2 is dispensable for cell proliferation. In this study, we found that ectopic CDK2 enhances Ras (G12V)-induced foci formation and knocking down CDK2 expression markedly decreases epidermal growth factor (EGF)-induced cell transformation mediated through the downregulation of c-fos expression. Interestingly, CDK2 directly phosphorylates ELK4 at Thr194 and Ser387 and regulates the ELK4 transcriptional activity, which serves as a mechanism to regulate c-fos expression. In addition, ELK4 is overexpressed in melanoma and knocking down the ELK4 or CDK2 expression significantly attenuated the malignant phenotype of melanoma cells. Taken together, our study reveals a novel function of CDK2 in EGF-induced cell transformation and the associated signal transduction pathways. This indicates that CDK2 is a useful molecular target for the chemoprevention and therapy against skin cancer.	[Peng, C.; Ma, W.; Bode, A. M.; Dong, Z.] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Peng, C.; Zeng, W.; Su, J.; Kuang, Y.; He, Y.; Zhao, S.; Zhang, J.; Chen, X.] Cent S Univ, Xiangya Hosp, Dept Dermatol, Xiangya Rd 87, Changsha 410008, Hunan, Peoples R China	University of Minnesota System; Central South University	Dong, Z (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.; Chen, X (corresponding author), Cent S Univ, Xiangya Hosp, Dept Dermatol, Xiangya Rd 87, Changsha 410008, Hunan, Peoples R China.	zgdong@hi.umn.edu; chenxiangck@gmail.com		Jianglin, Zhang/0000-0003-0434-1729	Hormel Foundation; National Institutes of Health in China [CA172457, CA1669011, CA827502, R37, CA081064, 81225013, 81430075, 2015JJ2161]; NATIONAL CANCER INSTITUTE [R01CA166011, R37CA081064, R21CA172457, P01CA027502] Funding Source: NIH RePORTER	Hormel Foundation; National Institutes of Health in China; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by The Hormel Foundation and National Institutes of Health grants ZD: CA172457, CA1669011, CA827502, R37, CA081064 and by grant no. 81225013, 81430075, 2015JJ2161 in China.	Akiyama T, 1997, CANCER RES, V57, P1495; Ayadi A, 2001, MECH DEVELOP, V102, P205, DOI 10.1016/S0925-4773(01)00289-1; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Berthet C, 2006, DEV CELL, V10, P563, DOI 10.1016/j.devcel.2006.03.004; Calbo J, 2004, CELL DEATH DIFFER, V11, P1055, DOI 10.1038/sj.cdd.4401481; Cen L, 2012, NEURO-ONCOLOGY, V14, P870, DOI 10.1093/neuonc/nos114; Chai YL, 2001, ONCOGENE, V20, P1357, DOI 10.1038/sj.onc.1204256; Elkeles A, 1999, MOL CELL BIOL, V19, P2594; Ferguson KL, 2000, J BIOL CHEM, V275, P33593, DOI 10.1074/jbc.M004879200; Findeisen M, 1999, EUR J BIOCHEM, V264, P415, DOI 10.1046/j.1432-1327.1999.00613.x; Gebhardt C, 2005, AM J PATHOL, V167, P243, DOI 10.1016/S0002-9440(10)62969-0; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; Guinea-Viniegra J, 2012, J CLIN INVEST, V122, P2898, DOI 10.1172/JCI63103; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; Hjortoe GM, 2005, DNA CELL BIOL, V24, P35, DOI 10.1089/dna.2005.24.35; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; Ishimi Y, 2000, J BIOL CHEM, V275, P16235, DOI 10.1074/jbc.M909040199; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; Kumar-Sinha C, 2012, CANCER DISCOV, V2, P582, DOI 10.1158/2159-8290.CD-12-0212; Li J, 2003, J BIOL CHEM, V278, P13183, DOI 10.1074/jbc.M300269200; Li JN, 2002, BIOCHEMISTRY-US, V41, P3977, DOI 10.1021/bi011550s; Maher CA, 2009, NATURE, V458, P97, DOI 10.1038/nature07638; Martin A, 2005, CANCER CELL, V7, P591, DOI 10.1016/j.ccr.2005.05.006; Masutani H, 1997, ONCOGENE, V15, P1661, DOI 10.1038/sj.onc.1201328; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; Mo Y, 2000, NAT STRUCT BIOL, V7, P292; Rickman DS, 2009, CANCER RES, V69, P2734, DOI 10.1158/0008-5472.CAN-08-4926; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SKOUV J, 1986, CARCINOGENESIS, V7, P331, DOI 10.1093/carcin/7.2.331; Takahashi S., 1994, Journal of Dermatological Science, V7, P54, DOI 10.1016/0923-1811(94)90022-1; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Vanden Bush T.J., 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019468; Volm M, 1997, INT J CANCER, V74, P508, DOI 10.1002/(SICI)1097-0215(19971021)74:5<508::AID-IJC5>3.0.CO;2-7; Wallace M, 2004, MOL CELL BIOL, V24, P5606, DOI 10.1128/MCB.24.12.5606-5619.2004; WU WS, 1992, ONCOGENE, V7, P2287; Zheng D, 2008, CANCER RES, V68, P7650, DOI 10.1158/0008-5472.CAN-08-1137; Zhou Y, 1999, J BIOL REG HOMEOS AG, V13, P207	45	33	35	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1170	1179		10.1038/onc.2015.175	http://dx.doi.org/10.1038/onc.2015.175			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	26028036	Green Accepted			2022-12-17	WOS:000371351700011
J	Chen, X; Bosques, L; Sung, P; Kupfer, GM				Chen, X.; Bosques, L.; Sung, P.; Kupfer, G. M.			A novel role for non-ubiquitinated FANCD2 in response to hydroxyurea-induced DNA damage	ONCOGENE			English	Article							FANCONI-ANEMIA PATHWAY; CROSS-LINK REPAIR; HOMOLOGOUS RECOMBINATION; REPLICATION FORK; TRANSLESION SYNTHESIS; PHYSICAL INTERACTION; POLYMERASE SWITCH; PCNA; ACTIVATION; MUTAGENESIS	Fanconi anemia (FA) is a genetic disease of bone marrow failure, cancer susceptibility, and sensitivity to DNA crosslinking agents. FANCD2, the central protein of the FA pathway, is monoubiquitinated upon DNA damage, such as crosslinkers and replication blockers such as hydroxyurea (HU). Even though FA cells demonstrate unequivocal sensitivity to crosslinkers, such as mitomycin C (MMC), we find that they are largely resistant to HU, except for cells absent for expression of FANCD2. FANCD2, RAD51 and RAD18 form a complex, which is enhanced upon HU exposure. Surprisingly, although FANCD2 is required for this enhanced interaction, its monoubiquitination is not. Similarly, non-ubiquitinated FANCD2 can still support proliferation cell nuclear antigen (PCNA) monoubiquitination. RAD51, but not BRCA2, is also required for PCNA monoubiquitination in response to HU, suggesting that this function is independent of homologous recombination (HR). We further show that translesion (TLS) polymerase PolH chromatin localization is decreased in FANCD2 deficient cells, FANCD2 siRNA knockdown cells and RAD51 siRNA knockdown cells, and PolH knockdown results in HU sensitivity only. Our data suggest that FANCD2 and RAD51 have an important role in PCNA monoubiquitination and TLS in a FANCD2 monoubiquitination and HR-independent manner in response to HU. This effect is not observed with MMC treatment, suggesting a non-canonical function for the FA pathway in response to different types of DNA damage.	[Chen, X.; Bosques, L.; Kupfer, G. M.] Yale Univ, Sch Med, Yale Canc Ctr, Dept Pediat,Sect Hematol Oncol, New Haven, CT 06520 USA; [Chen, X.; Bosques, L.; Kupfer, G. M.] Yale Univ, Sch Med, Yale Canc Ctr, Dept Pathol,Sect Hematol Oncol, New Haven, CT 06520 USA; [Sung, P.] Yale Univ, Sch Med, Yale Canc Ctr, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Kupfer, GM (corresponding author), Yale Univ, Sch Med, Yale Canc Ctr, Dept Pediat,Sect Hematol Oncol, LMP2073,333 Cedar St, New Haven, CT 06520 USA.	gary.kupfer@yale.edu			NCI NIH HHS [R01 CA168635] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA168635] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alpi AF, 2009, DNA REPAIR, V8, P430, DOI 10.1016/j.dnarep.2009.01.019; Bagby GC, 2006, SEMIN HEMATOL, V43, P147, DOI 10.1053/j.seminhematol.2006.04.005; Bindra RS, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt255; Brown S, 2009, CELL CYCLE, V8, P689, DOI 10.4161/cc.8.5.7707; Chang DJ, 2009, NAT CHEM BIOL, V5, P82, DOI 10.1038/nchembio.139; Chaudhury I, 2013, NUCLEIC ACIDS RES, V41, P6444, DOI 10.1093/nar/gkt348; Chen JJ, 2011, CELL BIOCHEM BIOPHYS, V60, P47, DOI 10.1007/s12013-011-9187-3; Dunn J, 2006, CANCER RES, V66, P11140, DOI 10.1158/0008-5472.CAN-06-0563; Fu DC, 2013, CELL CYCLE, V12, P803, DOI 10.4161/cc.23755; Garaycoechea JI, 2014, BLOOD, V123, P26, DOI 10.1182/blood-2013-09-427740; Green AM, 2009, HEMATOL ONCOL CLIN N, V23, P193, DOI 10.1016/j.hoc.2009.01.008; Hirano S, 2005, EMBO J, V24, P418, DOI 10.1038/sj.emboj.7600534; Ho V, 2010, ENVIRON MOL MUTAGEN, V51, P552, DOI 10.1002/em.20573; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Holloman WK, 2011, NAT STRUCT MOL BIOL, V18, P748, DOI 10.1038/nsmb.2096; Howlett NG, 2005, HUM MOL GENET, V14, P693, DOI 10.1093/hmg/ddi065; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Howlett NG, 2009, J BIOL CHEM, V284, P28935, DOI 10.1074/jbc.M109.016352; Huang TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378; Hussain S, 2004, HUM MOL GENET, V13, P1241, DOI 10.1093/hmg/ddh135; Johnstone P, 1997, SOMAT CELL MOLEC GEN, V23, P371, DOI 10.1007/BF02673747; Kannouche PL, 2004, CELL CYCLE, V3, P1011; Kim H, 2012, GENE DEV, V26, P1393, DOI 10.1101/gad.195248.112; Knipscheer P, 2009, SCIENCE, V326, P1698, DOI 10.1126/science.1182372; Koc A, 2004, J BIOL CHEM, V279, P223, DOI 10.1074/jbc.M303952200; Lehmann AR, 2007, DNA REPAIR, V6, P891, DOI 10.1016/j.dnarep.2007.02.003; Lin JR, 2011, MOL CELL, V42, P237, DOI 10.1016/j.molcel.2011.02.026; Lossaint G, 2013, MOL CELL, V51, P678, DOI 10.1016/j.molcel.2013.07.023; MAURERSCHULTZE B, 1988, EXP CELL RES, V174, P230, DOI 10.1016/0014-4827(88)90157-7; McCabe KM, 2008, MOL GENET METAB, V95, P66, DOI 10.1016/j.ymgme.2008.06.009; Mirchandani KD, 2008, DNA REPAIR, V7, P902, DOI 10.1016/j.dnarep.2008.03.001; Miyase S, 2005, J BIOL CHEM, V280, P515, DOI 10.1074/jbc.M409219200; Moldovan GL, 2012, MOL CELL, V45, P75, DOI 10.1016/j.molcel.2011.11.010; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008; Palle K, 2011, CELL CYCLE, V10, P1625, DOI 10.4161/cc.10.10.15617; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Pickering A, 2013, CANCER BIOL THER, V14, P1089, DOI 10.4161/cbt.26380; Qiao FY, 2001, J BIOL CHEM, V276, P23391, DOI 10.1074/jbc.M101855200; Reliene R, 2010, CANCER RES, V70, P9703, DOI 10.1158/0008-5472.CAN-09-1022; Schlacher K, 2012, CANCER CELL, V22, P106, DOI 10.1016/j.ccr.2012.05.015; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Suhasini AN, 2011, EMBO J, V30, P692, DOI 10.1038/emboj.2010.362; Tanaka T, 2007, CYTOM PART A, V71A, P648, DOI 10.1002/cyto.a.20426; Terai K, 2010, MOL CELL, V37, P143, DOI 10.1016/j.molcel.2009.12.018; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383; Williams SA, 2011, HUM MOL GENET, V20, P4395, DOI 10.1093/hmg/ddr366; Williams SA, 2011, BLOOD, V117, P5078, DOI 10.1182/blood-2010-10-311761; Zeman MK, 2014, J CELL BIOL, V206, P183, DOI 10.1083/jcb.201311063	50	33	33	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					22	34		10.1038/onc.2015.68	http://dx.doi.org/10.1038/onc.2015.68			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25893307	Green Accepted			2022-12-17	WOS:000367812400003
J	Choi, JA; Jung, YS; Kim, JY; Kim, HM; Lim, IK				Choi, J-A; Jung, Y. S.; Kim, J. Y.; Kim, H. M.; Lim, I. K.			Inhibition of breast cancer invasion by TIS21(/BTG2/Pc3)-Akt1-Sp1-Nox4 pathway targeting actin nucleators, mDia genes	ONCOGENE			English	Article							DIAPHANOUS-RELATED FORMINS; CELL-MIGRATION; INVADOPODIA FORMATION; TRANSCRIPTION FACTOR; TUMOR PROGRESSION; BTG2 EXPRESSION; DOWN-REGULATION; AKT ISOFORMS; PROTEIN; ACTIVATION	The mammalian homolog of Drosophila diaphanous (mDia), actin nucleator, has been known to participate in the process of invasion and metastasis of cancer cells via regulating a number of actin-related biological processes. We have previously reported that tumor suppressor TIS21(/BTG2/Pc3) (TIS21) inhibits invadopodia formation by downregulating reactive oxygen species (ROS) in MDA-MB-231 cells. We herein report that TIS21(/BTG2/Pc3) downregulates diaphanous-related formin (DRF) expression via reducing NADPH oxidase 4 (Nox4)-derived ROS generation by Akt1 activation and subsequently impairs invasion activity of the highly invasive breast cancer cells. Knockdown of Akt1 by RNA interference recovered the TIS21(/BTG2/Pc3)-inhibited F-actin remodeling and ROS generation by recovering Nox4 expression. Furthermore, Sp1-mediated Nox4 transcription was downregulated by TIS21(/BTG2/Pc3)-Akt1 signals, leading to the inhibition of cancer cell invasion via F-actin remodeling by mDia genes. To our best knowledge, this is the first study to show that TIS21(/BTG2/Pc3)-Akt1 inhibited Sp1-Nox4-ROS cascade, subsequently reducing invasion activity via inhibition of mDia family genes.	[Choi, J-A; Lim, I. K.] Ajou Univ, Sch Med, Dept Biochem & Mol Biol, Suwon 443380, South Korea; [Choi, J-A; Lim, I. K.] Ajou Univ, Grad Sch Med, Dept Biomed Sci, Suwon 443380, South Korea; [Jung, Y. S.; Kim, J. Y.] Ajou Univ, Sch Med, Dept Surg, Suwon 443380, South Korea; [Kim, H. M.] Ajou Univ, Dept Energy Syst Res, Suwon 443380, South Korea	Ajou University; Ajou University; Ajou University; Ajou University	Lim, IK (corresponding author), Ajou Univ, Sch Med, Dept Biochem & Mol Biol, San 5, Suwon 443380, South Korea.	iklim@ajou.ac.kr	Jung, Yongsik/ABH-9311-2020	Jung, Yongsik/0000-0002-2011-1459	Korea Health technology R&D Project, Ministry of Health & Welfare, Republic of Korea [A121725]; National R&D Program for Cancer Control, Ministry for Health and Welfare, Republic of Korea [131280]	Korea Health technology R&D Project, Ministry of Health & Welfare, Republic of Korea; National R&D Program for Cancer Control, Ministry for Health and Welfare, Republic of Korea	Authors greatly appreciate Professor Young-Joon Chwae for his kind help in lucigenin-enhanced chemiluminescence assay, excellent advice for statistical analysis by Professor Seung-Soo Sheen, technical help for two-photon fluorescence microscopy by Cheol Ho Heo and careful reading of this manuscript by Professor Woon Ki Paik at Ajou University School of Medicine. This work was supported by a grant of the Korea Health technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A121725) and a grant from the National R&D Program for Cancer Control, Ministry for Health and Welfare, Republic of Korea (131280).	Arboleda MJ, 2003, CANCER RES, V63, P196; Boiko AD, 2006, GENE DEV, V20, P236, DOI 10.1101/gad.1372606; Bondi CD, 2010, J AM SOC NEPHROL, V21, P93, DOI 10.1681/ASN.2009020146; Boudreau HE, 2012, FREE RADICAL BIO MED, V53, P1489, DOI 10.1016/j.freeradbiomed.2012.06.016; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Buganim Y, 2010, CANCER RES, V70, P2274, DOI 10.1158/0008-5472.CAN-09-2661; Carramusa L, 2007, J CELL SCI, V120, P3870, DOI 10.1242/jcs.014365; Chin YR, 2009, CELL SIGNAL, V21, P470, DOI 10.1016/j.cellsig.2008.11.015; Choi JA, 2013, J CANCER RES CLIN, V139, P1657, DOI 10.1007/s00432-013-1484-3; Choi JA, 2010, CARCINOGENESIS, V31, P543, DOI 10.1093/carcin/bgp203; Colvin RA, 2010, NAT IMMUNOL, V11, P495, DOI 10.1038/ni.1878; Coppola V, 2013, ONCOGENE, V32, P1843, DOI 10.1038/onc.2012.194; Devanand P, 2014, FEBS J, V281, P5581, DOI 10.1111/febs.13099; Diebold I, 2010, MOL BIOL CELL, V21, P2087, DOI 10.1091/mbc.E09-12-1003; Dillon RL, 2010, CANCER RES, V70, P4260, DOI 10.1158/0008-5472.CAN-10-0266; Esteve PO, 2011, NAT STRUCT MOL BIOL, V18, P42, DOI 10.1038/nsmb.1939; Farioli-Vecchioli S, 2007, FASEB J, V21, P2215, DOI 10.1096/fj.06-7548com; Ficazzola MA, 2001, CARCINOGENESIS, V22, P1271, DOI 10.1093/carcin/22.8.1271; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Grabinski N, 2011, CELL SIGNAL, V23, P1952, DOI 10.1016/j.cellsig.2011.07.003; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Hong JW, 2005, J BIOL CHEM, V280, P21256, DOI 10.1074/jbc.M500318200; Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Imran M, 2013, CELL SIGNAL, V25, P2400, DOI 10.1016/j.cellsig.2013.07.015; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Katsuyama M, 2011, FEBS J, V278, P964, DOI 10.1111/j.1742-4658.2011.08018.x; Kawakubo H, 2004, ONCOGENE, V23, P8310, DOI 10.1038/sj.onc.1208008; Kawakubo H, 2006, CANCER RES, V66, P7075, DOI 10.1158/0008-5472.CAN-06-0379; Kim BC, 2008, STEM CELLS, V26, P2339, DOI 10.1634/stemcells.2008-0327; Kim EY, 2010, FREE RADICAL BIO MED, V49, P1072, DOI 10.1016/j.freeradbiomed.2010.06.023; Kitzing TM, 2007, GENE DEV, V21, P1478, DOI 10.1101/gad.424807; Lassegue B, 2012, CIRC RES, V110, P1364, DOI 10.1161/CIRCRESAHA.111.243972; LIM IK, 1995, J CANCER RES CLIN, V121, P279, DOI 10.1007/BF01209594; Lim IK, 1998, MOL CARCINOGEN, V23, P25, DOI 10.1002/(SICI)1098-2744(199809)23:1<25::AID-MC4>3.0.CO;2-G; Lim SK, 2012, CLIN EXP METASTAS, V29, P901, DOI 10.1007/s10585-012-9479-z; Liu H, 2006, P NATL ACAD SCI USA, V103, P4134, DOI 10.1073/pnas.0511342103; Liu M, 2009, CELL RES, V19, P828, DOI 10.1038/cr.2009.72; Lizarraga F, 2009, CANCER RES, V69, P2792, DOI 10.1158/0008-5472.CAN-08-3709; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; Matheny RW, 2010, CELL DEATH DIFFER, V17, P677, DOI 10.1038/cdd.2009.150; Melamed J, 2002, TISSUE CELL, V34, P28, DOI 10.1054/tice.2001.0220; Mouneimne G, 2012, CANCER CELL, V22, P615, DOI 10.1016/j.ccr.2012.09.027; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Park S, 2004, MOL CELL BIOL, V24, P10256, DOI 10.1128/MCB.24.23.10256-10262.2004; Park TJ, 2008, HEPATOLOGY, V47, P1533, DOI 10.1002/hep.22212; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Saji M, 2011, ONCOGENE, V30, P4307, DOI 10.1038/onc.2011.136; Sarmiento C, 2008, J CELL BIOL, V180, P1245, DOI 10.1083/jcb.200708123; Schirenbeck A, 2005, NAT CELL BIOL, V7, P619, DOI 10.1038/ncb1266; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; Shimada A, 2004, MOL CELL, V13, P511, DOI 10.1016/S1097-2765(04)00059-0; Solomon H, 2012, J CELL SCI, V125, P3144, DOI 10.1242/jcs.099663; Struckmann K, 2004, CANCER RES, V64, P1632, DOI 10.1158/0008-5472.CAN-03-1687; Sundaramoorthy S, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-69; Takahashi F, 2011, ONCOGENE, V30, P3084, DOI 10.1038/onc.2011.24; Turner DP, 2007, CANCER RES, V67, P1618, DOI 10.1158/0008-5472.CAN-06-2913; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Xing H, 2007, ONCOL REP, V17, P117; Yamaguchi H, 2011, J CELL BIOL, V193, P1275, DOI 10.1083/jcb.201009126; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Zhang L, 2008, FREE RADICAL BIO MED, V45, P679, DOI 10.1016/j.freeradbiomed.2008.05.019	70	33	34	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					83	93		10.1038/onc.2015.64	http://dx.doi.org/10.1038/onc.2015.64			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25798836				2022-12-17	WOS:000367812400008
J	Gui, Y; Yeganeh, M; Donates, YC; Tobelaim, WS; Chababi, W; Mayhue, M; Yoshimura, A; Ramanathan, S; Saucier, C; Ilangumaran, S				Gui, Y.; Yeganeh, M.; Donates, Y-C; Tobelaim, W-S; Chababi, W.; Mayhue, M.; Yoshimura, A.; Ramanathan, S.; Saucier, C.; Ilangumaran, S.			Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma	ONCOGENE			English	Article							LIVER-REGENERATION; GROWTH-FACTOR; DOWN-REGULATION; TARGETING MET; TPR-MET; C-CBL; CANCER; INHIBITORS; PATHWAY; UBIQUITINATION	Suppressor of cytokine signaling 1 (SOCS1) is considered as a tumor suppressor protein in hepatocellular carcinoma (HCC), but the underlying mechanisms remain unclear. Previously, we have shown that SOCS1-deficient hepatocytes displayed increased responsiveness to hepatocyte growth factor (HGF) due to enhanced signaling via the MET receptor tyrosine kinase. As aberrant MET activation occurs in many tumors including HCC, here we elucidated the mechanisms of SOCS1-mediated regulation. SOCS1 attenuated HGF-induced proliferation of human and mouse HCC cell lines and their growth as tumors in NOD. scid. gamma mice. Tumors formed by SOCS1 expressing HCC cells showed significantly reduced MET expression, indicating that SOCS1 not only attenuates MET signaling but also regulates MET expression. Mechanistically, SOCS1 interacted with MET via the Src homology 2 domain and this interaction was promoted by MET tyrosine kinase activity. The SOCS1-mediated reduction in MET expression does not require the juxtamembrane Y1003 residue implicated in Cbl-mediated downmodulation. Moreover, the proteasome inhibitor MG-132, but not the inhibitors of lysosomal degradation bafilomycin and chloroquine, reversed the SOCS1-mediated reduction in MET expression, indicating that this process is distinct from Cbl-mediated downmodulation. Accordingly, SOCS1 promoted polyubiquitination of MET via K48-dependent but not K63-mediated ubiquitin chain elongation. Furthermore, siRNA-mediated downmodulation of Cbl did not abolish SOCS1-mediated reduction in MET expression in HCC cells. SOCS1-dependent ubiquitination of endogenous MET receptor occurred rapidly following HGF stimulation in HCC cells, leading to proteasomal degradation of phosphorylated MET receptor. These findings indicate that SOCS1 mediates its tumor suppressor functions, at least partly, by binding to MET and interfering with downstream signaling pathways as well as by promoting the turnover of the activated MET receptor. We propose that loss of this control mechanism due to epigenetic repression of SOCS1 could contribute to oncogenic MET signaling in HCC and other cancers, and that MET inhibitors might be useful in treating these patients.	[Gui, Y.; Yeganeh, M.; Donates, Y-C; Mayhue, M.; Ramanathan, S.; Ilangumaran, S.] Univ Sherbrooke, Ctr Rech Clin Etienne Le Bel, Fac Med & Hlth Sci, Immunol Div,Dept Pediat,Ctr Hosp, Sherbrooke, PQ J1H 5N4, Canada; [Tobelaim, W-S; Chababi, W.; Saucier, C.] Univ Sherbrooke, Ctr Rech Clin Etienne Le Bel, Fac Med & Hlth Sci, Dept Anat & Cell Biol,Ctr Hosp, Sherbrooke, PQ J1H 5N4, Canada; [Yoshimura, A.] Keio Univ, Sch Med, Dept Microbiol & Immunol, Tokyo, Japan	University of Sherbrooke; University of Sherbrooke; Keio University	Ilangumaran, S (corresponding author), Univ Sherbrooke, Ctr Rech Clin Etienne Le Bel, Fac Med & Hlth Sci, Immunol Div,Dept Pediat,Ctr Hosp, 3001 North 12th Ave, Sherbrooke, PQ J1H 5N4, Canada.	Subburaj.Ilangumaran@Usherbrooke.ca	Yoshimura, Akihiko/K-5515-2013; Saucier, Caroline/Q-9250-2019	Saucier, Caroline/0000-0001-7678-9886; Ilangumaran, Subburaj/0000-0002-7563-576X	Cancer Research Society, Montreal, Canada; Centre de Recherche Clinique du CHUS	Cancer Research Society, Montreal, Canada; Centre de Recherche Clinique du CHUS	We thank Dr Morag Park for generously providing CSF-MET and Tpr-MET expression plasmids. Centre de Recherche Clinique du CHUS is an FRSQ-funded research center. This work was supported by the Cancer Research Society, Montreal, Canada (SI and CS).	Abella JV, 2010, J BIOL CHEM, V285, P24956, DOI 10.1074/jbc.M110.127985; Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Babar IA, 2012, P NATL ACAD SCI USA, V109, pE1695, DOI 10.1073/pnas.1201516109; Casaletto JB, 2012, NAT REV CANCER, V12, P386, DOI 10.1038/nrc3277; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; De Sepulveda P, 1999, EMBO J, V18, P904; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Fausto N, 2006, HEPATOLOGY, V43, pS45, DOI 10.1002/hep.20969; Fukushima N, 2003, BRIT J CANCER, V89, P338, DOI 10.1038/sj.bjc.6601039; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Goyal L, 2013, CLIN CANCER RES, V19, P2310, DOI 10.1158/1078-0432.CCR-12-2791; Grassian AR, 2011, J BIOL CHEM, V286, P79, DOI 10.1074/jbc.M110.169821; Gui YR, 2011, J HEPATOL, V55, P1300, DOI 10.1016/j.jhep.2011.03.027; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Ilangumaran S, 2004, SEMIN IMMUNOL, V16, P351, DOI 10.1016/j.smim.2004.08.015; Ilangumaran S, 2002, J IMMUNOL, V169, P5010, DOI 10.4049/jimmunol.169.9.5010; Inagaki-Ohara Kyoko, 2013, JAKSTAT, V2, pe24053, DOI 10.4161/jkst.24053; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250; Johnston JA, 2004, J LEUKOCYTE BIOL, V75, P743, DOI 10.1189/jlb.1003507; Karamouzis MV, 2009, LANCET ONCOL, V10, P709, DOI 10.1016/S1470-2045(09)70137-8; Kazi JU, 2014, CELL MOL LIFE SCI, V71, P3297, DOI 10.1007/s00018-014-1619-y; Kermorgant S, 2008, J CELL BIOL, V182, P855, DOI 10.1083/jcb.200806076; Kobayashi N, 2012, ONCOTARGET, V3, P1455; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Mak HHL, 2007, ONCOGENE, V26, P7213, DOI 10.1038/sj.onc.1210522; Okumura F, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00010; Peschard P, 2007, ONCOGENE, V26, P1276, DOI 10.1038/sj.onc.1210201; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Seki E, 2008, J HEPATOL, V48, P237, DOI 10.1016/j.jhep.2007.08.020; Shakya R, 2013, CANCER RES, V73, P885, DOI 10.1158/0008-5472.CAN-12-1880; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Thien CBF, 2005, BIOCHEM J, V391, P153, DOI 10.1042/BJ20050892; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Woelk T, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-11; Xu AM, 2010, CANCER RES, V70, P3857, DOI 10.1158/0008-5472.CAN-10-0163; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zardo G, 2002, NAT GENET, V32, P453, DOI 10.1038/ng1007; Zhou L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023936; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359	46	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2015	34	46					5718	5728		10.1038/onc.2015.20	http://dx.doi.org/10.1038/onc.2015.20			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GC	25728680				2022-12-17	WOS:000364594600004
J	Greenall, SA; Donoghue, JF; Van Sinderen, M; Dubljevic, V; Budiman, S; Devlin, M; Street, I; Adams, TE; Johns, TG				Greenall, S. A.; Donoghue, J. F.; Van Sinderen, M.; Dubljevic, V.; Budiman, S.; Devlin, M.; Street, I.; Adams, T. E.; Johns, T. G.			EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; FOCAL ADHESION KINASE; DOMAIN BINDING-SITE; CELLS; GLIOBLASTOMAS; AMPLIFICATION; ACTIVATION; RESISTANCE; INHIBITORS; MUTATIONS	A truncation mutant of the epidermal growth factor receptor, EGFRvIII, is commonly expressed in glioma, an incurable brain cancer. EGFRvIII is tumorigenic, in part, through its transactivation of other receptor tyrosine kinases (RTKs). Preventing the effects of this transactivation could form part of an effective therapy for glioma; however, the mechanism by which the transactivation occurs is unknown. Focusing on the RTK MET, we show that MET transactivation in U87MG human glioma cells in vitro is proportional to EGFRvIII activity and involves MET heterodimerization associated with a focal adhesion kinase (FAK) scaffold. The transactivation of certain other RTKs was, however, independent of FAK. Simultaneously targeting EGFRvIII (with panitumumab) and the transactivated RTKs themselves (with motesanib) in an intracranial mouse model of glioma resulted in significantly greater survival than with either agent alone, indicating that cotargeting these RTKs has potent antitumor efficacy and providing a strategy for treating EGFRvIII-expressing gliomas, which are usually refractory to treatment.	[Greenall, S. A.; Donoghue, J. F.; Van Sinderen, M.; Dubljevic, V.; Budiman, S.; Johns, T. G.] MIMR PHI Inst Med Res, Ctr Canc Res, Oncogen Signalling Lab, Clayton, Vic 3168, Australia; [Greenall, S. A.; Donoghue, J. F.; Van Sinderen, M.; Dubljevic, V.; Budiman, S.; Johns, T. G.] MIMR PHI Inst Med Res, Ctr Canc Res, Brain Canc Discovery Collaborat, Clayton, Vic 3168, Australia; [Greenall, S. A.; Donoghue, J. F.; Van Sinderen, M.; Dubljevic, V.; Budiman, S.; Johns, T. G.] Monash Univ, Clayton, Vic, Australia; [Greenall, S. A.; Adams, T. E.] CSIRO, Div Mat Sci & Engn, Parkville, Vic, Australia; [Devlin, M.] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia; [Street, I.] CRC Canc Therapeut, Bundoora, Vic, Australia; [Street, I.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; [Street, I.] Univ Melbourne, Dept Med Biol, Parkville, Vic 3052, Australia	Prince Henry's Institute of Medical Research; Prince Henry's Institute of Medical Research; Monash University; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Peter Maccallum Cancer Center; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Melbourne	Johns, TG (corresponding author), MIMR PHI Inst Med Res, Ctr Canc Res, Oncogen Signalling Lab, 27-31 Wright St, Clayton, Vic 3168, Australia.	terry.johns@monash.edu	Adams, Timothy E/I-6231-2012; Johns, Terrance/C-2441-2008; Street, Ian/GXG-9517-2022	Adams, Timothy E/0000-0003-3436-0066; Johns, Terrance/0000-0002-8874-4543; Dubljevic, Valentina/0000-0002-7944-8937; Greenall, Sameer/0000-0002-1461-7111; Street, Ian/0000-0003-2684-4239; Donoghue, Jacqueline/0000-0003-1370-2469	Commonwealth Scientific and Industrial Research Organisation (CSIRO) OCE Postdoctoral Fellowship; Cure Cancer Australia Foundation postdoctoral fellowship; Victorian Cancer Agency Early Career Seed Grant [ECSG1108]; National Health and Medical Research Council [1028552, 1012020]; Victorian Government's Operational and Infrastructure Support Program; Cure Brain Cancer Foundation; CRC for Cancer Therapeutics, an initiative of the Australian Government	Commonwealth Scientific and Industrial Research Organisation (CSIRO) OCE Postdoctoral Fellowship; Cure Cancer Australia Foundation postdoctoral fellowship; Victorian Cancer Agency Early Career Seed Grant; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government's Operational and Infrastructure Support Program; Cure Brain Cancer Foundation; CRC for Cancer Therapeutics, an initiative of the Australian Government	We acknowledge the facilities and scientific and technical assistance of the Histology Facility, Microimaging facility and Monash Animal Services, at MIMR-PHI Institute of Medical Research. We thank Dr D Dadley-Moore for editing the manuscript. SAG is funded by a Commonwealth Scientific and Industrial Research Organisation (CSIRO) OCE Postdoctoral Fellowship. JFD is funded by a Cure Cancer Australia Foundation postdoctoral fellowship and a Victorian Cancer Agency Early Career Seed Grant (ECSG1108). TGJ is funded by National Health and Medical Research Council Project Grants 1028552 and 1012020, the Victorian Government's Operational and Infrastructure Support Program and the Cure Brain Cancer Foundation. This work was supported by the CRC for Cancer Therapeutics, an initiative of the Australian Government. Rilotumumab and motesanib must be obtained through an MTA. Rilotumumab, panitumumab and motesanib were provided by Amgen (rilotumumab and motesanib through an MTA); and dacomitinib was provided by Pfizer.	Akhavan D, 2013, CANCER DISCOV, V3, P534, DOI 10.1158/2159-8290.CD-12-0502; Chen TH, 2011, ONCOGENE, V30, P153, DOI 10.1038/onc.2010.398; Del Vecchio CA, 2013, ONCOGENE, V32, P2670, DOI 10.1038/onc.2012.280; Ding LS, 2010, TRANSL RES, V156, P45, DOI 10.1016/j.trsl.2010.05.001; Donoghue JF, 2011, JOVE-J VIS EXP, DOI 10.3791/3157; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Gan HK, 2013, FEBS J, V280, P5350, DOI 10.1111/febs.12393; Gan HK, 2009, J CLIN NEUROSCI, V16, P748, DOI 10.1016/j.jocn.2008.12.005; Grandal MV, 2007, CARCINOGENESIS, V28, P1408, DOI 10.1093/carcin/bgm058; Greenall SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034658; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Johns TG, 2007, CLIN CANCER RES, V13, P1911, DOI 10.1158/1078-0432.CCR-06-1453; Johns TG, 2002, INT J CANCER, V98, P398, DOI 10.1002/ijc.10189; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Kong XB, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0033381, 10.1371/journal.pone.0041523]; Liu MZ, 2010, ARCH BIOCHEM BIOPHYS, V502, P89, DOI 10.1016/j.abb.2010.07.014; Liu TJ, 2007, MOL CANCER THER, V6, P1357, DOI 10.1158/1535-7163.MCT-06-0476; Martinvalet D, 2005, IMMUNITY, V22, P355, DOI 10.1016/j.immuni.2005.02.004; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Meyer AS, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004155; Mukherjee B, 2009, CANCER RES, V69, P4252, DOI 10.1158/0008-5472.CAN-08-4853; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Peschard P, 2004, J BIOL CHEM, V279, P29565, DOI 10.1074/jbc.M403954200; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Pillay V, 2009, NEOPLASIA, V11, P448, DOI 10.1593/neo.09230; Polverino A, 2006, CANCER RES, V66, P8715, DOI 10.1158/0008-5472.CAN-05-4665; Riemenschneider MJ, 2005, AM J PATHOL, V167, P1379, DOI 10.1016/S0002-9440(10)61225-4; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Street I, 2012, P 103 ANN M AM ASS C, P72; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vivanco I, 2012, CANCER DISCOV, V2, P458, DOI 10.1158/2159-8290.CD-11-0284; Wen PY, 2014, NEURO-ONCOLOGY, V16, P567, DOI 10.1093/neuonc/not247; Ymer Susie I, 2011, Cancers (Basel), V3, P2032, DOI 10.3390/cancers3022032	36	33	34	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2015	34	41					5277	5287		10.1038/onc.2014.448	http://dx.doi.org/10.1038/onc.2014.448			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CT1QL	25659577				2022-12-17	WOS:000362575400007
J	Menon, DR; Das, S; Krepler, C; Vultur, A; Rinner, B; Schauer, S; Kashofer, K; Wagner, K; Zhang, G; Rad, EB; Haass, NK; Soyer, HP; Gabrielli, B; Somasundaram, R; Hoefler, G; Herlyn, M; Schaider, H				Menon, D. Ravindran; Das, S.; Krepler, C.; Vultur, A.; Rinner, B.; Schauer, S.; Kashofer, K.; Wagner, K.; Zhang, G.; Rad, E. Bonyadi; Haass, N. K.; Soyer, H. P.; Gabrielli, B.; Somasundaram, R.; Hoefler, G.; Herlyn, M.; Schaider, H.			A stress-induced early innate response causes multidrug tolerance in melanoma (vol 34, pg 4448, 2015)	ONCOGENE			English	Correction													Ravindran Menon, Dinoop/F-9247-2014; Haass, Nikolas K/M-8507-2015; Gabrielli, Brian G/B-3655-2011; Soyer, H. Peter/E-6000-2010; Menon, Dinoop Ravindran/AAC-3620-2021; Soyer, H. Peter/W-3791-2017; Zhang, Gao/D-3471-2017; das, suman kumar/E-1270-2015	Ravindran Menon, Dinoop/0000-0002-6335-9227; Haass, Nikolas K/0000-0002-3928-5360; Gabrielli, Brian G/0000-0003-3933-1651; Soyer, H. Peter/0000-0002-4770-561X; Soyer, H. Peter/0000-0002-4770-561X; das, suman kumar/0000-0002-0539-5174; Somasundaram, Rajasekharan/0000-0002-8444-8472	NATIONAL CANCER INSTITUTE [P30CA010815, P01CA025874] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA010815, P01 CA025874] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Menon DR, 2015, ONCOGENE, V34, P4448, DOI 10.1038/onc.2014.372	1	33	34	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4545	4545		10.1038/onc.2014.432	http://dx.doi.org/10.1038/onc.2014.432			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25619837	Bronze			2022-12-17	WOS:000360189200013
J	Quist, T; Jin, H; Zhu, JF; Smith-Fry, K; Capecchi, MR; Jones, KB				Quist, T.; Jin, H.; Zhu, J-F; Smith-Fry, K.; Capecchi, M. R.; Jones, K. B.			The impact of osteoblastic differentiation on osteosarcomagenesis in the mouse	ONCOGENE			English	Article							CANCER STEM-CELLS; TUMOR HETEROGENEITY; EXPRESSION; PROMOTER; MICE; P53; RB; SARCOMA; TUMORIGENESIS; DISRUPTION	Osteosarcomas remain an enigmatic group of malignancies that share in common the presence of transformed cells producing osteoid matrix, even if these cells comprise a minority of the tumor volume. The differentiation state of osteosarcomas has therefore become a topic of interest and challenge to those who study this disease. In order to test how the cell of origin contributes to the final state of differentiation in the transformed cells, we compared the relative tumorigenicity of Cre-LoxP conditional disruption of the cell cycle checkpoint tumor-suppressor genes Trp53 and Rb1 using Prx1-Cre, Collagen-1a1-Cre and Osteocalcin-Cre to transform undifferentiated mesenchyme, preosteoblasts and mature osteoblasts, respectively. The Prx1 and Col1a1 lineages developed tumors with nearly complete penetrance, as anticipated. Osteosarcomas also developed in 44% of Oc-Cre; Rb1(fl/fl); Trp53(fl/fl) mice. We confirmed using 5-ethynyl-2'-deoxyuridine click chemistry that the Oc-Cre lineage includes very few actively cycling cells. By assessing radiographic mineralization and histological osteoid production, the differentiation state of tumors did not correlate with the differentiation state of the lineage of origin. Some of the osteocalcin-lineage-derived osteosarcomas were among the least osteoblastic. Osteocalcin immunohistochemistry in tumors correlated well with the expression of DNA methyl transferases, suggesting that silencing of these epigenetic regulators may influence the final differentiation state of an osteosarcoma. Transformation of differentiated, minimally proliferative osteoblasts is possible but may require such an epigenetic reprogramming that the tumors no longer resemble their differentiated origins.	[Quist, T.; Jin, H.; Zhu, J-F; Smith-Fry, K.; Jones, K. B.] Univ Utah, Dept Orthopaed, Salt Lake City, UT 84112 USA; [Quist, T.; Jin, H.; Zhu, J-F; Smith-Fry, K.; Jones, K. B.] Univ Utah, Ctr Childrens Canc Res, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Capecchi, M. R.] Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; [Capecchi, M. R.] Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Jones, KB (corresponding author), Univ Utah, Dept Orthopaed, Sarcoma Serv, 2000 Circle Hope Dr,Room 4263, Salt Lake City, UT 84112 USA.	kevin.jones@hci.utah.edu			National Cancer Institute (National Institutes of Health, NIH) [K08CA138764]; Damon Runyon Cancer Research Foundation; National Cancer Institute [P30CA042014]; NATIONAL CANCER INSTITUTE [R01CA210165, P30CA042014, K08CA138764] Funding Source: NIH RePORTER	National Cancer Institute (National Institutes of Health, NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Damon Runyon Cancer Research Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Thomas Clemens for the Oc-Cre mouse line, Malcolm Logan for Prx1-Cre and Benoit de Crombrugghe for Col1a1-Cre. This work was directly supported by National Cancer Institute (National Institutes of Health, NIH) K08CA138764. KBJ receives additional career development support from the Damon Runyon Cancer Research Foundation. This work was also partly supported by P30CA042014 from the National Cancer Institute.	Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913; Angus-Hill ML, 2011, P NATL ACAD SCI USA, V108, P4914, DOI 10.1073/pnas.1102300108; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100; Damron TA, 2007, CLIN ORTHOP RELAT R, P40, DOI 10.1097/BLO.0b013e318059b8c9; Desandes E, 2007, CANCER TREAT REV, V33, P609, DOI 10.1016/j.ctrv.2006.12.007; Dick JE, 2003, P NATL ACAD SCI USA, V100, P3547, DOI 10.1073/pnas.0830967100; Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394; Gutierrez GM, 2008, P NATL ACAD SCI USA, V105, P18402, DOI 10.1073/pnas.0805925105; Haydon RC, 2002, CLIN CANCER RES, V8, P1288; He BC, 2010, CLIN CANCER RES, V16, P2235, DOI 10.1158/1078-0432.CCR-09-2499; Hopyan S, 1999, J ORTHOPAED RES, V17, P633, DOI 10.1002/jor.1100170503; Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130; Levings PP, 2009, CANCER RES, V69, P5648, DOI 10.1158/0008-5472.CAN-08-3580; Lin PP, 2008, CANCER RES, V68, P8968, DOI 10.1158/0008-5472.CAN-08-0573; Lin PP, 2009, CARCINOGENESIS, V30, P1789, DOI 10.1093/carcin/bgp180; LIU F, 1994, DEV BIOL, V166, P220, DOI 10.1006/dbio.1994.1309; Liu F, 2004, INT J DEV BIOL, V48, P645, DOI 10.1387/ijdb.041816fl; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Molyneux SD, 2010, J CLIN INVEST, V120, P3310, DOI 10.1172/JCI42391; Mutsaers AJ, 2014, BONE, V62, P56, DOI 10.1016/j.bone.2014.02.003; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P5129, DOI 10.1073/pnas.87.13.5129; Ragland BD, 2002, LAB INVEST, V82, P365, DOI 10.1038/labinvest.3780431; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; San Martin IA, 2009, J CELL PHYSIOL, V221, P560, DOI 10.1002/jcp.21894; SHARKEY FE, 1983, ARCH PATHOL LAB MED, V107, P411; Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; UNNI KK, 1989, SEMIN ROENTGENOL, V24, P143, DOI 10.1016/0037-198X(89)90010-2; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Walkley CR, 2007, CELL, V129, P1081, DOI 10.1016/j.cell.2007.03.055; Wang XY, 2006, J CELL BIOL, V172, P115, DOI 10.1083/jcb.200507106; Weiss A, 2007, CANCER, V109, P1627, DOI 10.1002/cncr.22574; Wu CL, 2007, CANCER RES, V67, P8216, DOI 10.1158/0008-5472.CAN-07-0999; Yeo HJ, 2007, J BIOL CHEM, V282, P35318, DOI 10.1074/jbc.M702435200	36	33	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4278	4284		10.1038/onc.2014.354	http://dx.doi.org/10.1038/onc.2014.354			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25347737	Green Accepted			2022-12-17	WOS:000359199800014
J	Rajapaksa, G; Nikolos, F; Bado, I; Clarke, R; Gustafsson, JA; Thomas, C				Rajapaksa, G.; Nikolos, F.; Bado, I.; Clarke, R.; Gustafsson, J-A; Thomas, C.			ER beta decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway	ONCOGENE			English	Article							UNFOLDED PROTEIN RESPONSE; ESTROGEN-RECEPTOR-BETA; ENDOPLASMIC-RETICULUM STRESS; BOX BINDING PROTEIN-1; GENE-EXPRESSION; KAPPA-B; PROMOTES; XBP-1; BORTEZOMIB; AUTOPHAGY	Unfolded protein response (UPR) is an adaptive reaction that allows cancer cells to survive endoplasmic reticulum (EnR) stress that is often induced in the tumor microenvironment because of inadequate vascularization. Previous studies report an association between activation of the UPR and reduced sensitivity to antiestrogens and chemotherapeutics in estrogen receptor alpha (ER alpha)-positive and triple-negative breast cancers, respectively. ER alpha has been shown to regulate the expression of a key mediator of the EnR stress response, the X-box-binding protein-1 (XBP-1). Although network prediction models have associated ER beta with the EnR stress response, its role as regulator of the UPR has not been experimentally tested. Here, upregulation of wild-type ER beta (ER beta 1) or treatment with ER beta agonists enhanced apoptosis in breast cancer cells in the presence of pharmacological inducers of EnR stress. Targeting the BCL-2 to the EnR of the ER beta 1-expressing cells prevented the apoptosis induced by EnR stress but not by non-EnR stress apoptotic stimuli indicating that ER beta 1 promotes EnR stress-regulated apoptosis. Downregulation of inositol-requiring kinase 1 alpha (IRE1 alpha) and decreased splicing of XBP-1 were associated with the decreased survival of the EnR-stressed ER beta 1-expressing cells. ER beta 1 was found to repress the IRE1 pathway of the UPR by inducing degradation of IRE1 alpha. These results suggest that the ability of ER beta 1 to target the UPR may offer alternative treatment strategies for breast cancer.	[Rajapaksa, G.; Nikolos, F.; Bado, I.; Gustafsson, J-A; Thomas, C.] Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, Houston, TX 77204 USA; [Clarke, R.] Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC USA	University of Houston System; University of Houston; Georgetown University	Thomas, C (corresponding author), Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, 3605 Cullen Blvd, Houston, TX 77204 USA.	chthomas@uh.edu	Clarke, Robert/A-6485-2008; Bado, Igor/AAY-1214-2021; Nikolos, Fotis/AGF-3489-2022	Clarke, Robert/0000-0002-9278-0854; Bado, Igor/0000-0001-8855-4750; Nikolos, Fotis/0000-0002-8622-0017	Swedish Cancer Society; Robert A Welch Foundation [E-0004]; Emerging Technology Fund of Texas [300-9-1958];  [U54-CA149147]; NATIONAL CANCER INSTITUTE [U54CA149147] Funding Source: NIH RePORTER	Swedish Cancer Society(Swedish Cancer Society); Robert A Welch Foundation(The Welch Foundation); Emerging Technology Fund of Texas; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank C Koumenis for the Bcl-2 expression vector and Anders Strom for the ER beta 2 expression lentivirus. We also thank Efrocini Cuko for technical assistance with confocal microscopy. This study was supported by grants from the Swedish Cancer Society, the Robert A Welch Foundation (E-0004), the Emerging Technology Fund of Texas under Agreement 300-9-1958 and the U54-CA149147.	BUTLER WB, 1992, CANCER RES, V52, P6164; BUTLER WB, 1986, CANCER RES, V46, P6339; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119; Cheng L, 2012, J CLIN INVEST, V122, P2857, DOI 10.1172/JCI62676; Clarke R, 2012, CANCER RES, V72, P1321, DOI 10.1158/0008-5472.CAN-11-3213; Clarke Robert, 2011, Horm Mol Biol Clin Investig, V5, P35, DOI 10.1515/HMBCI.2010.073; Cook KL, 2012, CANCER RES, V72, P3337, DOI 10.1158/0008-5472.CAN-12-0269; Crawford AC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008604; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Davies MPA, 2008, INT J CANCER, V123, P85, DOI 10.1002/ijc.23479; Davis AM, 2008, J MOL ENDOCRINOL, V41, P205, DOI 10.1677/JME-08-0029; Ding LH, 2003, NUCLEIC ACIDS RES, V31, P5266, DOI 10.1093/nar/gkg731; Fu Y, 2007, CANCER RES, V67, P3734, DOI 10.1158/0008-5472.CAN-06-4594; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; Gao BX, 2008, EMBO REP, V9, P480, DOI 10.1038/embor.2008.37; Gomez BP, 2007, FASEB J, V21, P4013, DOI 10.1096/fj.06-7990com; Gu ZP, 2002, CANCER RES, V62, P3428; Hartman J, 2009, CANCER RES, V69, P6100, DOI 10.1158/0008-5472.CAN-09-0506; Hodges-Gallagher L, 2008, BREAST CANCER RES TR, V109, P241, DOI 10.1007/s10549-007-9640-6; Honma N, 2008, J CLIN ONCOL, V26, P3727, DOI 10.1200/JCO.2007.14.2968; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jones MD, 2010, CLIN CANCER RES, V16, P4978, DOI 10.1158/1078-0432.CCR-09-3293; Kane RC, 2007, CLIN CANCER RES, V13, P5291, DOI 10.1158/1078-0432.CCR-07-0871; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koong AC, 2006, CANCER BIOL THER, V5, P756, DOI 10.4161/cbt.5.7.2973; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee E, 2011, INT J CANCER, V128, P726, DOI 10.1002/ijc.25370; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Leung YK, 2006, NEOPLASIA, V8, P242, DOI 10.1593/neo.05853; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030; Marcu MG, 2002, MOL CELL BIOL, V22, P8506, DOI 10.1128/MCB.22.24.8506-8513.2002; Nakajima Y, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001551; Nikolos F, 2014, MOL CANCER RES, V12, P843, DOI 10.1158/1541-7786.MCR-13-0663; Rodriguez DA, 2012, EMBO J, V31, P2322, DOI 10.1038/emboj.2012.84; Sengupta S, 2010, HORM MOL BIOL CLIN I, V2, P235, DOI 10.1515/HMBCI.2010.025; Shaaban AM, 2008, CLIN CANCER RES, V14, P5228, DOI 10.1158/1078-0432.CCR-07-4528; Shajahan AN, 2012, J BIOL CHEM, V287, P17682, DOI 10.1074/jbc.M111.304022; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Thomas C, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3358; Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093; Thomas CG, 2011, BREAST CANCER RES TR, V127, P417, DOI 10.1007/s10549-010-1011-z; Thomas CG, 2009, J BIOL CHEM, V284, P6282, DOI 10.1074/jbc.M806189200; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Yang CH, 2006, ANN ONCOL, V17, P813, DOI 10.1093/annonc/mdj131; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Zhang B, 2009, BIOINFORMATICS, V25, P526, DOI 10.1093/bioinformatics/btn660; Zhang KZ, 2006, NEUROLOGY, V66, pS102, DOI 10.1212/01.wnl.0000192306.98198.ec	50	33	34	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4130	4141		10.1038/onc.2014.343	http://dx.doi.org/10.1038/onc.2014.343			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25347741				2022-12-17	WOS:000358780500011
J	Yang, CS; Matsuura, K; Huang, NJ; Robeson, AC; Huang, B; Zhang, L; Kornbluth, S				Yang, C-S; Matsuura, K.; Huang, N-J; Robeson, A. C.; Huang, B.; Zhang, L.; Kornbluth, S.			Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death	ONCOGENE			English	Article							METABOLIC-REGULATION; LIPID-METABOLISM; THERAPEUTIC TARGET; APOPTOSIS; ACTIVATION; MTOR; SUPPRESSOR; HYPOXIA; STRESS; RTP801	Blockade of fatty acid synthase (FASN), a key enzyme involved in de novo lipogenesis, results in robust death of ovarian cancer cells. However, known FASN inhibitors have proven to be poor therapeutic agents due to their ability to induce cachexia. Therefore, we sought to identify additional targets in the pathway linking FASN inhibition and cell death whose modulation might kill ovarian cancer cells without the attendant side effects. Here, we show that the initiator caspase-2 is required for robust death of ovarian cancer cells induced by FASN inhibitors. REDD1 (also known as Rtp801 or DDIT4), a known mTOR inhibitor previously implicated in the response to FASN inhibition, is a novel caspase-2 regulator in this pathway. REDD1 induction is compromised in ovarian cancer cells that do not respond to FASN inhibition. Inhibition of FASN induced an ATF4-dependent transcriptional induction of REDD1; downregulation of REDD1 prevented orlistat-induced activation of caspase-2, as monitored by its cleavage, proteolytic activity and dimerization. Abrogation of REDD1-mediated suppression of mTOR by TSC2 RNAi protected FASN inhibitor-sensitive ovarian cancer cells (OVCA420 cells) from orlistat-induced death. Conversely, suppression of mTOR with the chemical inhibitors PP242 or rapamycin-sensitized DOV13, an ovarian cancer cell line incapable of inducing REDD1, to orlistat-induced cell death through caspase-2. These findings indicate that REDD1 positively controls caspase-2-dependent cell death of ovarian cancer cells by inhibiting mTOR, placing mTOR as a novel upstream regulator of caspase-2 and supporting the possibility of manipulating mTOR to enhance caspase-2 activation in ovarian cancer.	[Yang, C-S; Matsuura, K.; Huang, N-J; Robeson, A. C.; Huang, B.; Zhang, L.; Kornbluth, S.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Kornbluth, S (corresponding author), Duke Univ, Box 90005, Durham, NC 27710 USA.	sally.kornbluth@duke.edu		Matsuura, Kenkyo/0000-0003-4612-6031	 [R01 GM080333]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080333, T32GM007184] Funding Source: NIH RePORTER	; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs Susan Murphy and Andrew Berchuck for de-identified human ovarian cancer biopsy samples, and the members of the Kornbluth laboratory for sharing reagents and discussion. This work was supported by R01 GM080333 to SK.	Alo PL, 2000, ONCOL REP, V7, P1383; Andersen JL, 2011, MOL CELL, V43, P834, DOI 10.1016/j.molcel.2011.07.028; Baliga BC, 2004, CELL DEATH DIFFER, V11, P1234, DOI 10.1038/sj.cdd.4401492; Bandyopadhyay S, 2006, CANCER RES, V66, P5934, DOI 10.1158/0008-5472.CAN-05-3197; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bonzon C, 2006, MOL BIOL CELL, V17, P2150, DOI 10.1091/mbc.E05-12-1107; Bouchier-Hayes L, 2010, J CELL MOL MED, V14, P1212, DOI 10.1111/j.1582-4934.2010.01037.x; Bouchier-Hayes L, 2009, MOL CELL, V35, P830, DOI 10.1016/j.molcel.2009.07.023; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; DeYoung MP, 2008, GENE DEV, V22, P239, DOI 10.1101/gad.1617608; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ho LH, 2008, ONCOGENE, V27, P3393, DOI 10.1038/sj.onc.1211005; Ho LH, 2009, P NATL ACAD SCI USA, V106, P5336, DOI 10.1073/pnas.0811928106; Ho TS, 2007, BIOMED PHARMACOTHER, V61, P578, DOI 10.1016/j.biopha.2007.08.020; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Huang NJ, 2012, J CELL BIOL, V197, P361, DOI [10.1083/jcb.201111141, 10.1083/jcb.201108062]; Jin HO, 2011, ONCOGENE, V30, P3792, DOI 10.1038/onc.2011.102; Knowles LM, 2008, J BIOL CHEM, V283, P31378, DOI 10.1074/jbc.M803384200; Lin CF, 2004, J BIOL CHEM, V279, P40755, DOI 10.1074/jbc.M404726200; Little JL, 2007, CANCER RES, V67, P1262, DOI 10.1158/0008-5472.CAN-06-1794; Malagelada C, 2006, J NEUROSCI, V26, P9996, DOI 10.1523/JNEUROSCI.3292-06.2006; Manzl C, 2009, J CELL BIOL, V185, P291, DOI 10.1083/jcb.200811105; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Nutt LK, 2009, DEV CELL, V16, P856, DOI 10.1016/j.devcel.2009.04.005; Nutt LK, 2005, CELL, V123, P89, DOI 10.1016/j.cell.2005.07.032; Parsons MJ, 2013, CELL DEATH DIFFER, V20, P1174, DOI 10.1038/cdd.2013.38; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Puccini J, 2013, P NATL ACAD SCI USA, V110, P19920, DOI 10.1073/pnas.1311947110; Pyragius CE, 2013, INT J MOL SCI, V14, P7742, DOI 10.3390/ijms14047742; Rahman MT, 2012, BRIT J CANCER, V107, P300, DOI 10.1038/bjc.2012.246; Ribe EM, 2012, BIOCHEM J, V444, P591, DOI 10.1042/BJ20111588; Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; Shin S, 2005, EMBO J, V24, P3532, DOI 10.1038/sj.emboj.7600827; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005; Tania M, 2010, CURR ONCOL, V17, P6; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tomek K, 2011, MOL CANCER RES, V9, P1767, DOI 10.1158/1541-7786.MCR-10-0467; Upreti M, 2008, MOL CANCER THER, V7, P2224, DOI 10.1158/1535-7163.MCT-07-2299; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P555, DOI 10.1038/sj.cdd.4402286; Yang CS, 2010, EMBO J, V29, P3196, DOI 10.1038/emboj.2010.191; Yoshida T, 2010, NAT MED, V16, P767, DOI 10.1038/nm.2157; Zhang YP, 2007, MECH AGEING DEV, V128, P213, DOI 10.1016/j.mad.2006.11.030; Zhou WB, 2007, CANCER RES, V67, P2964, DOI 10.1158/0008-5472.CAN-06-3439	50	33	36	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3264	3272		10.1038/onc.2014.271	http://dx.doi.org/10.1038/onc.2014.271			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25151963	Green Accepted			2022-12-17	WOS:000356592300005
J	Martinez, E; Yoshihara, K; Kim, H; Mills, GM; Trevino, V; Verhaak, RGW				Martinez, E.; Yoshihara, K.; Kim, H.; Mills, G. M.; Trevino, V.; Verhaak, R. G. W.			Comparison of gene expression patterns across 12 tumor types identifies a cancer supercluster characterized by TP53 mutations and cell cycle defects	ONCOGENE			English	Article							PREDICTOR; KNOWLEDGE; RESPONSES; ANTI-PD-1; SUBTYPES; REVEALS; SAFETY; EGFR	Transcriptional profile-based subtypes of cancer are often viewed as identifying different diseases from the same tissue origin. Understanding the mechanisms driving the subtypes may be key in development of novel therapeutics but is challenged by lineage-specific expression signals. Using a t-test statistics approach, we compared gene expression subtypes across 12 tumor types, which identified eight transcriptional superclusters characterized by commonly activated disease pathways and similarities in gene expression. One of the largest superclusters was determined by the upregulation of a proliferation signature, significant enrichment in TP53 mutations, genomic loss of CDKN2A (p16(ARF)), evidence of increased numbers of DNA double strand breaks and high expression of cyclin B1 protein. These correlations suggested that abrogation of the P53-mediated apoptosis response to DNA damage results in activation of cell cycle pathways and represents a common theme in cancer. A second consistent pattern, observed in 9 of 11 solid tumor types, was a subtype related to an activated tumor-associated stroma. The similarity in transcriptional footprints across cancers suggested that tumor subtypes are commonly unified by a limited number of molecular themes.	[Martinez, E.; Yoshihara, K.; Kim, H.; Verhaak, R. G. W.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Martinez, E.; Trevino, V.] Tecnol Monterrey, Catedra Bioinformat, Monterrey, Nuevo Leon, Mexico; [Yoshihara, K.] Niigata Univ, Grad Sch Med & Dent Sci, Dept Obstet & Gynecol, Niigata, Niigata, Japan; [Mills, G. M.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Verhaak, R. G. W.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Tecnologico de Monterrey; Niigata University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Verhaak, RGW (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, 1400 Pressler St, Houston, TX 77030 USA.	rverhaak@mdanderson.org	Kim, Hoon/AAL-9283-2020; Yoshihara, Kosuke/AAU-9874-2020; Verhaak, Roel/ABE-7058-2020; Trevino, Victor/C-9219-2009	Kim, Hoon/0000-0003-4244-6126; Yoshihara, Kosuke/0000-0002-2254-3378; Trevino, Victor/0000-0002-7472-9844; Martinez Ledesma, Juan Emmanuel/0000-0003-1191-7917	U.S. National Cancer Institute (NCI; MD Anderson TCGA Genome Data Analysis Center) [CA143883, CA083639]; Odyssey Program; Theodore N, Law Endowment for Scientific Achievement at The University of Texas MD Anderson Cancer Center; MD Anderson Cancer Center [P30 CA016672]; NATIONAL CANCER INSTITUTE [P50CA083639, U24CA143883, P30CA016672] Funding Source: NIH RePORTER	U.S. National Cancer Institute (NCI; MD Anderson TCGA Genome Data Analysis Center); Odyssey Program; Theodore N, Law Endowment for Scientific Achievement at The University of Texas MD Anderson Cancer Center; MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The results published here are in whole or part based upon data generated by The Cancer Genome Atlas pilot project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions who constitute the TCGA research network can be found at 'http://cancergenome.nih.gov'. This work was supported in part by U.S. National Cancer Institute (NCI; MD Anderson TCGA Genome Data Analysis Center) grant numbers CA143883 and CA083639, and MD Anderson Cancer Center Support Grant P30 CA016672. HK is supported in part by the Odyssey Program and the Theodore N, Law Endowment for Scientific Achievement at The University of Texas MD Anderson Cancer Center.	Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Brunet JP, 2004, P NATL ACAD SCI USA, V101, P4164, DOI 10.1073/pnas.0308531101; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; Everitt BS, 2011, CLUSTER ANAL, DOI DOI 10.1002/9780470977811; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Heiser LM, 2012, P NATL ACAD SCI USA, V109, P2724, DOI 10.1073/pnas.1018854108; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Kanehisa M, 2014, NUCLEIC ACIDS RES, V42, pD199, DOI 10.1093/nar/gkt1076; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Li JN, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.61; Martinsson-Ahlzen HS, 2008, MOL CELL BIOL, V28, P5698, DOI 10.1128/MCB.01833-07; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Noble WS, 2006, NAT BIOTECHNOL, V24, P1565, DOI 10.1038/nbt1206-1565; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; ROSNER B, 1983, TECHNOMETRICS, V25, P165, DOI 10.2307/1268549; Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Team RC, 2013, RA LANG ENV STAT COM, V13, P497; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vaske CJ, 2010, BIOINFORMATICS, V26, pi237, DOI 10.1093/bioinformatics/btq182; Verhaak RGW, 2013, J CLIN INVEST, V123, P517, DOI 10.1172/JCI65833; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Verhaak RGW, 2009, HAEMATOL-HEMATOL J, V94, P131, DOI 10.3324/haematol.13299; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zheng SY, 2013, GENE DEV, V27, P1462, DOI 10.1101/gad.213686.113; Zheng Y, 2013, NATURE, V499, P166, DOI 10.1038/nature12308	43	33	35	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2732	2740		10.1038/onc.2014.216	http://dx.doi.org/10.1038/onc.2014.216			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25088195	Green Accepted			2022-12-17	WOS:000354979500006
J	Zhang, Y; Gong, Y; Hu, D; Zhu, P; Wang, N; Zhang, Q; Wang, M; Aldeewan, A; Xia, H; Qu, X; Ring, BZ; Minato, N; Su, L				Zhang, Y.; Gong, Y.; Hu, D.; Zhu, P.; Wang, N.; Zhang, Q.; Wang, M.; Aldeewan, A.; Xia, H.; Qu, X.; Ring, B. Z.; Minato, N.; Su, L.			Nuclear SIPA1 activates integrin beta 1 promoter and promotes invasion of breast cancer cells	ONCOGENE			English	Article							DOWN-REGULATION; FOCAL ADHESION; MATRIX-METALLOPROTEINASE-9 SECRETION; SUBCELLULAR-LOCALIZATION; TUMOR PROGRESSION; MELANOMA-CELLS; RAP1 GTPASE; EXPRESSION; METASTASIS; MIGRATION	SIPA1 (signal-induced proliferation-associated protein 1) is a GTPase activation protein that can catalyze the hydrolysis of Rap1 bound GTP to GDP. Recently attention has been paid to a potential role for SIPA1 in cancer metastasis; however, the underlying mechanism of how changes in SIPA1 levels may lead to increased metastasis remains poorly understood. In this study, we showed that SIPA1 was mainly localized to the nuclei in highly invasive breast cancer tumor tissue and MDA-MB-231 cells. Knockdown of SIPA1 in MDA-MB-231 altered cell morphology and cell proliferation ability. Furthermore, this study is the first to establish that nuclear SIPA1 can interact with the integrin beta 1 promoter and activate its transcription; this interaction appears to be important for SIPA1-dependent MDA-MB-231 cell adhesion and invasion. We also demonstrated that the phosphorylation of FAK, Akt and the expression of MMP9, downstream signaling molecules of integrin beta 1, were decreased upon SIPA1 knockdown, and MDA-MB-231 cell invasion was impaired. Taken together, these results suggest nuclear SIPA1 contributes to breast cancer cell invasion through the regulation of integrin beta 1 signaling.	[Zhang, Y.; Hu, D.; Zhu, P.; Wang, N.; Zhang, Q.; Aldeewan, A.; Su, L.] Huazhong Univ Sci & Technol, Sch Life Sci & Technol, Minist Educ, Key Lab Mol Biophys, Wuhan 430074, Peoples R China; [Gong, Y.] Hubei Canc Hosp, Dept Breast Surg, Wuhan, Peoples R China; [Wang, M.; Xia, H.] Hubei Canc Hosp, Dept Pathol, Wuhan, Peoples R China; [Qu, X.] Huazhong Univ Sci & Technol, Union Hosp Tongji Med Coll, Dept Thyroid & Breast Surg, Wuhan 430074, Peoples R China; [Ring, B. Z.] Huazhong Univ Sci & Technol, Sch Life Sci & Technol, Inst Genom & Personalized Med, Wuhan 430074, Peoples R China; [Minato, N.] Kyoto Univ, Grad Sch Med, Dept Immunol & Cell Biol, Kyoto, Japan	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Kyoto University	Su, L (corresponding author), Huazhong Univ Sci & Technol, Sch Life Sci & Technol, Minist Educ, Key Lab Mol Biophys, 1037 Luoyu Rd, Wuhan 430074, Peoples R China.	lisu@mail.hust.edu.cn	Zhang, Yilei/I-8997-2014	Zhang, Yilei/0000-0003-1407-0301	National Basic Research Program of China [2011CB910401]; NSFC [31271504]; Ministry of Science and Technology, China [2009DFA31940]	National Basic Research Program of China(National Basic Research Program of China); NSFC(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology, China(Ministry of Science and Technology, China)	This work was supported partly by grants of National Basic Research Program of China (2011CB910401), NSFC (31271504) and 2009DFA31940 from The Ministry of Science and Technology, China.	Alsarraj J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080746; Alsarraj J, 2011, CANCER RES, V71, P3121, DOI 10.1158/0008-5472.CAN-10-4417; Bailey CL, 2009, CANCER RES, V69, P4962, DOI 10.1158/0008-5472.CAN-08-4269; Bivona TG, 2004, J CELL BIOL, V164, P461, DOI 10.1083/jcb.200311093; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Camp RL, 1999, CANCER, V86, P2259, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2; Carmona G, 2009, BLOOD, V113, P488, DOI 10.1182/blood-2008-02-138438; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Cayrol C, 2006, ONCOGENE, V25, P4421, DOI 10.1038/sj.onc.1209484; Chen C, 2009, BIOMATERIALS, V30, P2912, DOI 10.1016/j.biomaterials.2009.02.010; Chou KC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009931; Colzani E, 2011, J CLIN ONCOL, V29, P4014, DOI 10.1200/JCO.2010.32.6462; Crawford NPS, 2008, P NATL ACAD SCI USA, V105, P6380, DOI 10.1073/pnas.0710331105; Crawford NPS, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1389; Drukker CA, 2013, INT J CANCER, V133, P929, DOI 10.1002/ijc.28082; Farina A, 2004, MOL CELL BIOL, V24, P9059, DOI 10.1128/MCB.24.20.9059-9069.2004; FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.1093/biomet/38.1-2.141; Gao L, 2006, CANCER RES, V66, P7880, DOI 10.1158/0008-5472.CAN-06-0254; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hernandez-Varas P, 2011, J BIOL CHEM, V286, P18492, DOI 10.1074/jbc.M110.189811; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Hsu TI, 2012, ONCOGENE, V31, P3973, DOI 10.1038/onc.2011.568; Hung MC, 2011, J CELL SCI, V124, P3381, DOI 10.1242/jcs.089110; Ji K, 2012, CANCER GENOM PROTEOM, V9, P321; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Keely S, 2009, FASEB J, V23, P1338, DOI 10.1096/fj.08-125344; Kunapuli P, 2003, ONCOGENE, V22, P3985, DOI 10.1038/sj.onc.1206584; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lindberg K, 2010, J CELL PHYSIOL, V222, P156, DOI 10.1002/jcp.21932; Liu JF, 2002, BIOCHEM BIOPH RES CO, V293, P1174, DOI 10.1016/S0006-291X(02)00350-9; Lyle KS, 2008, CELL SIGNAL, V20, P1104, DOI 10.1016/j.cellsig.2008.01.018; Maity G, 2011, TUMOR BIOL, V32, P129, DOI 10.1007/s13277-010-0106-9; Maity G, 2010, MOL CELL BIOCHEM, V336, P65, DOI 10.1007/s11010-009-0256-5; Malchinkhuu E, 2009, MOL BIOL CELL, V20, P5156, DOI 10.1091/mbc.E09-08-0692; Marques IJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-128; Mathieu V, 2012, ONCOTARGET, V3, P399; McSherry EA, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2853; Mitra RS, 2008, CANCER RES, V68, P3959, DOI 10.1158/0008-5472.CAN-07-2755; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Mizugaki H, 2012, BRIT J CANCER, V106, P1953, DOI 10.1038/bjc.2012.178; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; Park YG, 2005, NAT GENET, V37, P1055, DOI 10.1038/ng1635; Redig AJ, 2013, J INTERN MED, V274, P113, DOI 10.1111/joim.12084; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; Scott MS, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-317; Sen T, 2010, BIOCHIMIE, V92, P1422, DOI 10.1016/j.biochi.2010.07.005; Shimizu Y, 2011, CANCER SCI, V102, P828, DOI 10.1111/j.1349-7006.2011.01876.x; Su L, 2003, J BIOL CHEM, V278, P15232, DOI 10.1074/jbc.M211888200; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Tsygankova OA, 2007, MOL CELL BIOL, V27, P6647, DOI 10.1128/MCB.00155-07; Tu HJ, 2010, J NEUROSCI, V30, P749, DOI 10.1523/JNEUROSCI.2343-09.2010; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Valles AM, 2004, J BIOL CHEM, V279, P44490, DOI 10.1074/jbc.M405144200; Zheng H, 2009, CANCER RES, V69, P449, DOI 10.1158/0008-5472.CAN-08-2399; Zuo H, 2010, CANCER RES, V70, P1389, DOI 10.1158/0008-5472.CAN-09-2812	59	33	33	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1451	1462		10.1038/onc.2014.36	http://dx.doi.org/10.1038/onc.2014.36			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24704834				2022-12-17	WOS:000350806500011
J	Kreis, NN; Sanhaji, M; Rieger, MA; Louwen, F; Yuan, J				Kreis, N-N; Sanhaji, M.; Rieger, M. A.; Louwen, F.; Yuan, J.			p21Waf1/Cip1 deficiency causes multiple mitotic defects in tumor cells	ONCOGENE			English	Article						p21; Cdk1; Aurora B; chromosome segregation; cytokinesis	SMALL-MOLECULE INHIBITOR; DNA-REPLICATION; CYCLIN B1; P21; PHOSPHORYLATION; CANCER; P21(WAF1/CIP1); MITOSIS; ARREST; PRC1	As a multifaceted molecule, p21 plays multiple critical roles in cell cycle regulation, differentiation, apoptosis, DNA repair, senescence, aging and stem cell reprogramming. The important roles of p21 in the interphase of the cell cycle have been intensively investigated. The function of p21 in mitosis has been proposed but not systematically studied. We show here that p21 is abundant in mitosis and binds to and inhibits the activity of Cdk1/cyclin B1. Deficiency of p21 prolongs the duration of mitosis by extending metaphase, anaphase and cytokinesis. The activity of Aurora B is reduced and the localization of Aurora B on the central spindle is disturbed in anaphase cells without p21. Moreover, HCT116 p21(-/-), HeLa and Saos-2 cells depleted of p21 encounter problems in chromosome segregation and cytokinesis. Gently inhibiting the mitotic Cdk1 or add-back of p21 rescues segregation defect in HCT116 p21(-/-) cells. Our data demonstrate that p21 is important for a fine-tuned control of the Cdk1 activity in mitosis, and its proper function facilitates a smooth mitotic progression. Given that p21 is downregulated in the majority of tumors, either by the loss of tumor suppressors like p53 or by hyperactive oncogenes such as c-myc, this finding also sheds new light on the molecular mechanisms by which p21 functions as a tumor suppressor.	[Kreis, N-N; Sanhaji, M.; Louwen, F.; Yuan, J.] Dept Gynecol & Obstet, Frankfurt, Germany; [Rieger, M. A.] Goethe Univ Frankfurt, Dept Hematol Oncol, D-60590 Frankfurt, Germany; [Rieger, M. A.] Georg Speyer Haus, Frankfurt, Germany; [Rieger, M. A.] German Canc Consortium DKTK, Heidelberg, Germany; [Rieger, M. A.] German Canc Res Ctr, Heidelberg, Germany	Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Yuan, J (corresponding author), Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	yuan@em.uni-frankfurt.de	Rieger, Michael A/L-8324-2017; Strebhardt, Klaus/E-8765-2011; Kreis, Nina-Naomi/AAF-5407-2019	Rieger, Michael A/0000-0002-4158-5872; Kreis, Nina-Naomi/0000-0003-4304-0160; Yuan, Juping/0000-0003-0694-0565	Deutsche Krebshilfe [108553, 109672]; Deutsche Forschungsgemeinschaft [Yu 156/2-1]; LOEWE Center for Cell and Gene Therapy Frankfurt [III L 4-518/17.004 (2010)]	Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); LOEWE Center for Cell and Gene Therapy Frankfurt	The work was supported by Deutsche Krebshilfe (#108553 and #109672 to JY), Deutsche Forschungsgemeinschaft (#Yu 156/2-1 to JY) and by the LOEWE Center for Cell and Gene Therapy Frankfurt (III L 4-518/17.004 (2010) to MAR). We thank Dr TU Mayer, University of Konstanz, for kindly providing the MKLP2 antibody. We are grateful to Drs KW Kinzler and B Vogelstein, Ludwig Center at Johns Hopkins, Howard Hughes Medical Institute, Baltimore, for the cell lines HCT116 p21 +/+ and HCT116 p21 -/-.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Amador V, 2007, MOL CELL, V27, P462, DOI 10.1016/j.molcel.2007.06.013; Barrett RMA, 2009, CELL CYCLE, V8, P278, DOI 10.4161/cc.8.2.7587; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Baus F, 2003, EMBO J, V22, P3992, DOI 10.1093/emboj/cdg387; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Bloom J, 2004, CELL CYCLE, V3, P138; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009; Charrier-Savournin FB, 2004, MOL BIOL CELL, V15, P3965, DOI 10.1091/mbc.E03-12-0871; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Dash BC, 2005, MOL CELL BIOL, V25, P3364, DOI 10.1128/MCB.25.8.3364-3387.2005; Date D, 2012, J BIOCHEM, V151, P361, DOI 10.1093/jb/mvs015; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 2009, BIOFACTORS, V35, P161, DOI 10.1002/biof.26; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; Hall CC, 1995, BIOCHEM BIOPH RES CO, V217, P728, DOI 10.1006/bbrc.1995.2833; HARPER JW, 1993, CELL, V75, P805; Hu CK, 2012, MOL BIOL CELL, V23, P2702, DOI 10.1091/mbc.E12-01-0058; Hummer S, 2009, CURR BIOL, V19, P607, DOI 10.1016/j.cub.2009.02.046; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; Kreis NN, 2010, ONCOGENE, V29, P5591, DOI 10.1038/onc.2010.290; Kreis NN, 2009, CELL CYCLE, V8, P460, DOI 10.4161/cc.8.3.7651; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lindqvist A, 2007, PLOS BIOL, V5, P1127, DOI 10.1371/journal.pbio.0050123; Lindqvist A, 2009, J CELL BIOL, V185, P193, DOI 10.1083/jcb.200812045; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; Mishima M, 2002, DEV CELL, V2, P41, DOI 10.1016/S1534-5807(01)00110-1; Mollinari C, 2002, J CELL BIOL, V157, P1175, DOI 10.1083/jcb.200111052; Nakajima Y, 2011, J CELL BIOL, V194, P137, DOI 10.1083/jcb.201009137; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Pomerening JR, 2008, MOL BIOL CELL, V19, P3426, DOI 10.1091/mbc.E08-02-0172; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Sanhaji M, 2013, CELL CYCLE, V12, P1340, DOI 10.4161/cc.24573; Sanhaji M, 2010, MOL CELL BIOL, V30, P2594, DOI 10.1128/MCB.00098-10; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Trakala M, 2013, CELL CYCLE, V12, P1030, DOI 10.4161/cc.24004; Tsukahara T, 2010, NATURE, V467, P719, DOI 10.1038/nature09390; van der Waal MS, 2012, EXP CELL RES, V318, P1407, DOI 10.1016/j.yexcr.2012.03.015; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; WALDMAN T, 1995, CANCER RES, V55, P5187; Wolf F, 2007, CELL CYCLE, V6, P1408; Wolf F, 2006, EMBO J, V25, P2802, DOI 10.1038/sj.emboj.7601163; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu ZJ, 2009, J CELL BIOL, V187, P637, DOI 10.1083/jcb.200906053; Yang WC, 2001, CANCER RES, V61, P6297; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Yuan JP, 2011, AM J PATHOL, V179, P2091, DOI 10.1016/j.ajpath.2011.06.031; Zimniak T, 2012, CURR BIOL, V22, P787, DOI 10.1016/j.cub.2012.03.007	60	33	36	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2014	33	50					5716	5728		10.1038/onc.2013.518	http://dx.doi.org/10.1038/onc.2013.518			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW2AB	24317508				2022-12-17	WOS:000346089300007
J	Katara, GK; Jaiswal, MK; Kulshrestha, A; Kolli, B; Gilman-Sachs, A; Beaman, KD				Katara, G. K.; Jaiswal, M. K.; Kulshrestha, A.; Kolli, B.; Gilman-Sachs, A.; Beaman, K. D.			Tumor-associated vacuolar ATPase subunit promotes tumorigenic characteristics in macrophages	ONCOGENE			English	Article						a2V-ATPase; a2NTD; tumor-associated macrophages; M2 macrophages; invasion assay; angiogenesis	N-TERMINUS DOMAIN; H+-ATPASE; V-ATPASE; A2 ISOFORM; IN-VITRO; CANCER; POLARIZATION; ACTIVATION; CELLS; ATP6L	Macrophage polarization contributes to distinct human pathologies. In tumors, a polarized M2 phenotype called tumor-associated macrophages (TAMs) are associated with promotion of invasion and angiogenesis. In cancer cells, vacuolar ATPase (V-ATPase), a multi-subunit enzyme, is expressed on the plasma/vesicular membranes and critically influences the metastatic behavior. In addition, the soluble, cleaved N-terminal domain of a2 isoform of V-ATPase (a2NTD) is associated with in vitro induction of pro-tumorigenic properties in monocytes. This activity of a2 isoform of V-ATPase (a2V) caused us to investigate its role in cancer progression through the evaluation of the immunomodulatory properties of a2NTD. Here, we present direct evidence that surface expression of V-ATPase is associated with macrophage polarization in tumor tissue. Macrophages from BALB/c mice (peritoneal/bone marrow derived) were stimulated with recombinant a2NTD in both ex vivo and in vivo systems and evaluated for TAM characteristics. a2V was highly expressed in tumor tissues (breast and skin) as well as on the surface of tumor cell lines. The a2NTD-stimulated macrophages (a2M Phi) acquired TAM phenotype, which was characterized by elevated expression of mannose receptor-1, Arginase-1, interleukin-10 and transforming growth factor-beta. a2M Phi also exhibited increased production of other tumorigenic factors including matrix metalloproteinase-9 and vascular endothelial growth factor. Further, a2M Phi were cocultured with mouse B-16F0 melanoma cells for their functional characterization. The coculture of these a2M Phi subsequently increased the invasion and angiogenesis of less invasive B-16F0 cells. When cocultured with naive T cells, a2M Phi significantly inhibited T-cell activation. The present data establish the role of V-ATPase in modulating a macrophage phenotype towards TAMs through the action of a2NTD, suggesting it to be a potential therapeutic target in cancer.	[Katara, G. K.; Jaiswal, M. K.; Kulshrestha, A.; Kolli, B.; Gilman-Sachs, A.; Beaman, K. D.] Rosalind Franklin Univ Med & Sci, Dept Microbiol & Immunol, 3333 Green Bay Rd, N Chicago, IL 60064 USA	Rosalind Franklin University Medical & Science	Beaman, KD (corresponding author), Rosalind Franklin Univ Med & Sci, Dept Microbiol & Immunol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	kenneth.beaman@rosalindfranklin.edu			Clinical Immunology Laboratory, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA	Clinical Immunology Laboratory, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA	We thank Robert Dickinson for technical assistance and the Rosalind Franklin University of Medicine and Science Flow Cytometry Core Facility. This work was supported by grants from the Clinical Immunology Laboratory, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA.	De Milito A, 2012, CURR PHARM DESIGN, V18, P1395, DOI 10.2174/138161212799504911; Derks R, 2004, HUM IMMUNOL, V65, P676, DOI 10.1016/j.humimm.2004.04.006; Farber MJ, 2011, MOL BIOL CELL, V22, P795, DOI 10.1091/mbc.E10-06-0505; Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Hao NB, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/948098; Hinton A, 2009, J BIOL CHEM, V284, P16400, DOI 10.1074/jbc.M901201200; Jaiswal MK, 2012, REPRODUCTION, V143, P713, DOI 10.1530/REP-12-0036; Kwong C, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22978; Kwong C, 2011, J IMMUNOL, V186, P1781, DOI 10.4049/jimmunol.1002998; Lu YD, 2005, CANCER RES, V65, P6843, DOI 10.1158/0008-5472.CAN-04-3822; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; Matlack R, 2006, IMMUNOLOGY, V117, P386, DOI 10.1111/j.1365-2567.2005.02312.x; Nishisho T, 2011, MOL CANCER RES, V9, P845, DOI 10.1158/1541-7786.MCR-10-0449; Ntrivalas E, 2007, HUM IMMUNOL, V68, P469, DOI 10.1016/j.humimm.2007.02.010; Ntrivalas E, 2007, AM J REPROD IMMUNOL, V57, P201, DOI 10.1111/j.1600-0897.2006.00463.x; Sennoune SR, 2004, AM J PHYSIOL-CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003; Sennoune SR, 2004, CELL BIOCHEM BIOPHYS, V40, P185, DOI 10.1385/CBB:40:2:185; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Torigoe T, 2002, J BIOL CHEM, V277, P36534, DOI 10.1074/jbc.M202605200; Watkins SK, 2007, J IMMUNOL, V178, P1357, DOI 10.4049/jimmunol.178.3.1357; You HY, 2009, CANCER LETT, V280, P110, DOI 10.1016/j.canlet.2009.02.023	25	33	35	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2014	33	49					5649	5654		10.1038/onc.2013.532	http://dx.doi.org/10.1038/onc.2013.532			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZW	24362525				2022-12-17	WOS:000346088700009
J	Cagnoni, G; Tamagnone, L				Cagnoni, G.; Tamagnone, L.			Semaphorin receptors meet receptor tyrosine kinases on the way of tumor progression	ONCOGENE			English	Review						plexin; neuropilin; met; ErbB2; EGFR; VEGF	ENDOTHELIAL-GROWTH-FACTOR; CONTROLS INVASIVE GROWTH; SUPPRESSES C-MET; PLEXIN B1; HUMAN-BREAST; INDUCED ANGIOGENESIS; ACTIVATING PROTEIN; DOSE-ESCALATION; CARCINOMA-CELLS; CANCER-CELLS	Semaphorins are extracellular signals known to guide migrating cells during developmental morphogenesis and in adult tissues. Semaphorin receptors, that is plexins and neuropilins, have been found in association with diverse receptor tyrosine kinases (RTKs), such as Met, ErbB2 and VEGFR2. These receptor complexes are formed in a cell-specific manner and can mediate distinctive signalling cascades, sometimes leading to divergent functional outcomes. This is particularly intriguing in cancer, since the same semaphorin has been found to mediate either tumor-promoting or tumor-suppressing functions, depending on the cancer type and cellular context. We will therefore review the current understanding about the role of RTKs in neuropilin and plexin signalling, putatively accounting for the multifaceted role of semaphorins in cancer.	[Cagnoni, G.; Tamagnone, L.] IRCC Inst Canc Res Candiolo, Candiolo, Italy; [Cagnoni, G.; Tamagnone, L.] Univ Turin, Sch Med, Candiolo, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Tamagnone, L (corresponding author), Univ Turin, IRCC, Str Prov 142,Km 3-95, I-10060 Turin, Italy.	luca.tamagnone@ircc.it	Tamagnone, Luca/J-8948-2018	Tamagnone, Luca/0000-0002-2884-7946; Cagnoni, Gabriella/0000-0002-9718-0321	Italian Association for Cancer Research (AIRC) [IG-11598]; Italian Ministry for Research; University of Torino-Compagnia di San Paolo [ORTO11RKTW]	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry for Research(Ministry of Education, Universities and Research (MIUR)); University of Torino-Compagnia di San Paolo(Compagnia di San Paolo)	The authors wish to thank all Tamagnone lab members, in particular Sabrina Rizzolio for advice and suggestions. Thanks to Francesca Natale for revising the English. Research activity in the author's lab is supported by the Italian Association for Cancer Research (AIRC, IG-11598), the Italian Ministry for Research (PRIN Grant) and the University of Torino-Compagnia di San Paolo (Grant ORTO11RKTW).	Akagi M, 2003, BRIT J CANCER, V88, P796, DOI 10.1038/sj.bjc.6600811; Argast GM, 2009, ONCOGENE, V28, P2697, DOI 10.1038/onc.2009.133; Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Bachelder RE, 2001, CANCER RES, V61, P5736; Bachelder RE, 2003, CANCER RES, V63, P5230; Bais C, 2010, CELL, V141, P166, DOI 10.1016/j.cell.2010.01.033; Barberis D, 2005, J CELL SCI, V118, P4689, DOI 10.1242/jcs.02590; Barberis D, 2004, FASEB J, V18, P592, DOI 10.1096/fj.03-0957fje; Basile JR, 2006, P NATL ACAD SCI USA, V103, P9017, DOI 10.1073/pnas.0508825103; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Bellon A, 2010, NEURON, V66, P205, DOI 10.1016/j.neuron.2010.04.006; Bielenberg DR, 2006, EXP CELL RES, V312, P584, DOI 10.1016/j.yexcr.2005.11.024; Cai HB, 1999, J NEUROSCI, V19, P6519; Capparuccia L, 2009, J CELL SCI, V122, P1723, DOI 10.1242/jcs.030197; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Casazza A, 2012, EMBO MOL MED, V4, P234, DOI 10.1002/emmm.201100205; Casazza A, 2010, J CLIN INVEST, V120, P2684, DOI 10.1172/JCI42118; Catalano A, 2009, CANCER RES, V69, P1485, DOI 10.1158/0008-5472.CAN-08-3659; Christensen C, 2005, CANCER RES, V65, P6167, DOI 10.1158/0008-5472.CAN-04-4309; Conrotto P, 2005, BLOOD, V105, P4321, DOI 10.1182/blood-2004-07-2885; Conrotto P, 2004, ONCOGENE, V23, P5131, DOI 10.1038/sj.onc.1207650; Dhanabal M, 2005, CANCER BIOL THER, V4, P659, DOI 10.4161/cbt.4.6.1733; Ellis LM, 2006, MOL CANCER THER, V5, P1099, DOI 10.1158/1535-7163.MCT-05-0538; Franco M, 2008, EMBO REP, V9, P865, DOI 10.1038/embor.2008.139; Fuh G, 2000, J BIOL CHEM, V275, P26690; Fukushima Y, 2011, J CLIN INVEST, V121, P1974, DOI 10.1172/JCI44900; Gherardi E, 2004, CURR OPIN STRUC BIOL, V14, P669, DOI 10.1016/j.sbi.2004.10.010; Giacobini P, 2008, J CELL BIOL, V183, P555, DOI 10.1083/jcb.200806160; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; Gu CH, 2005, SCIENCE, V307, P265, DOI 10.1126/science.1105416; Gu CH, 2013, EXP CELL RES, V319, P1306, DOI 10.1016/j.yexcr.2013.02.003; Guttmann-Raviv N, 2006, CANCER LETT, V231, P1, DOI 10.1016/j.canlet.2004.12.047; Guttmann-Raviv N, 2007, J BIOL CHEM, V282, P26294, DOI 10.1074/jbc.M609711200; Hofman EG, 2010, J BIOL CHEM, V285, P39481, DOI 10.1074/jbc.M110.164731; Horowitz A, 2012, CELL SIGNAL, V24, P1810, DOI 10.1016/j.cellsig.2012.05.007; Hota PK, 2012, CELL MOL LIFE SCI, V69, P3765, DOI 10.1007/s00018-012-1019-0; Karpanen T, 2006, FASEB J, V20, P1462, DOI 10.1096/fj.05-5646com; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Kigel B, 2011, BLOOD, V118, P4285, DOI 10.1182/blood-2011-03-341388; Kluger HM, 2004, MELANOMA RES, V14, P207, DOI 10.1097/01.cmr.0000130874.33504.2f; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kruger RR, 2005, NAT REV MOL CELL BIO, V6, P789, DOI 10.1038/nrm1740; Lassen U, 2012, BRIT J CANCER, V106, P678, DOI 10.1038/bjc.2011.609; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Martinsson-Niskanen T, 2011, CLIN THER, V33, P1142, DOI 10.1016/j.clinthera.2011.08.007; McClelland L, 2011, PIGM CELL MELANOMA R, V24, P165, DOI 10.1111/j.1755-148X.2010.00797.x; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; Muratori C, 2012, ADV CANCER RES, V114, P59, DOI 10.1016/B978-0-12-386503-8.00003-X; Narumiya S, 2009, CANCER METAST REV, V28, P65, DOI 10.1007/s10555-008-9170-7; Oinuma I, 2004, SCIENCE, V305, P862, DOI 10.1126/science.1097545; Otsuka T, 1998, CANCER RES, V58, P5157; Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018; Parikh AA, 2003, CANCER, V98, P720, DOI 10.1002/cncr.11560; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Pellet-Many C, 2008, BIOCHEM J, V411, P211, DOI 10.1042/BJ20071639; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; Prahst C, 2008, J BIOL CHEM, V283, P25110, DOI 10.1074/jbc.C800137200; Rehman M, 2013, SEMIN CELL DEV BIOL, V24, P179, DOI 10.1016/j.semcdb.2012.10.005; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Rizzolio S, 2011, CURR MED CHEM, V18, P3563, DOI 10.2174/092986711796642544; Rizzolio S, 2012, CANCER RES, V72, P5801, DOI 10.1158/0008-5472.CAN-12-0995; Rody A, 2007, CLIN CANCER RES, V13, P1115, DOI 10.1158/1078-0432.CCR-06-2433; Rody A, 2009, EUR J CANCER, V45, P405, DOI 10.1016/j.ejca.2008.10.016; Rohm B, 2000, FEBS LETT, V486, P68, DOI 10.1016/S0014-5793(00)02240-7; Roodink I, 2005, CANCER RES, V65, P8317, DOI 10.1158/0008-5472.CAN-04-4366; Rossiter H, 2004, CANCER RES, V64, P3508, DOI 10.1158/0008-5472.CAN-03-2581; Routhier A, 2010, ONCOL REP, V23, P861, DOI 10.3892/or_00000708; Sakurai A, 2011, J BIOL CHEM, V286, P34335, DOI 10.1074/jbc.M111.259499; Sakurai A, 2010, MOL CELL BIOL, V30, P3086, DOI 10.1128/MCB.01652-09; Salikhova A, 2008, CIRC RES, V103, pE71, DOI 10.1161/CIRCRESAHA.108.183327; Segarra M, 2012, BLOOD, V120, P4104, DOI 10.1182/blood-2012-02-410076; Serini G, 2003, NATURE, V424, P391, DOI 10.1038/nature01784; Sierra JR, 2008, J EXP MED, V205, P1673, DOI 10.1084/jem.20072602; Sigismund S, 2008, DEV CELL, V15, P209, DOI 10.1016/j.devcel.2008.06.012; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Slongo ML, 2007, NEURO-ONCOLOGY, V9, P384, DOI 10.1215/15228517-2007-032; Snuderl M, 2013, CELL, V152, P1065, DOI 10.1016/j.cell.2013.01.036; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Soone J, 2012, J INVEST DERMATOL, V132, P1230, DOI 10.1038/jid.2011.414; Soong J, 2013, J CELL SCI, V126, P688, DOI 10.1242/jcs.119487; Sorkin A, 2001, BIOCHEM SOC T, V29, P480, DOI 10.1042/BST0290480; Stevens L, 2010, J INVEST DERMATOL, V130, P1636, DOI 10.1038/jid.2010.13; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; Sun TL, 2012, J CELL SCI, V125, P3557, DOI 10.1242/jcs.101063; Suto F, 2005, J NEUROSCI, V25, P3628, DOI 10.1523/JNEUROSCI.4480-04.2005; Swiercz JM, 2008, J BIOL CHEM, V283, P1893, DOI 10.1074/jbc.M706822200; Swiercz JM, 2004, J CELL BIOL, V165, P869, DOI 10.1083/jcb.200312094; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962-8924(00)01816-X; Tamagnone L, 2012, CANCER CELL, V22, P145, DOI 10.1016/j.ccr.2012.06.031; Toyofuku T, 2004, GENE DEV, V18, P435, DOI 10.1101/gad.1167304; Uesugi K, 2009, J BIOL CHEM, V284, P6743, DOI 10.1074/jbc.M805213200; Valente G, 2009, CELL ONCOL, V31, P423, DOI 10.3233/CLO-2009-0504; van der ZB, 2002, DEV DYNAM, V225, P336; Wang H, 2011, J BIOL CHEM, V286, P26093, DOI 10.1074/jbc.M110.197053; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Wong OGW, 2007, P NATL ACAD SCI USA, V104, P19040, DOI 10.1073/pnas.0702544104; Worzfeld T, 2012, J CLIN INVEST, V122, P1296, DOI 10.1172/JCI60568; Yang TH, 2012, NEURON, V74, P108, DOI 10.1016/j.neuron.2011.12.034; Yao J, 2011, P NATL ACAD SCI USA, V108, P11590, DOI 10.1073/pnas.1109029108; Zhou C, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-11; Zhou YP, 2008, TRENDS BIOCHEM SCI, V33, P161, DOI 10.1016/j.tibs.2008.01.006	108	33	33	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2014	33	40					4795	4802		10.1038/onc.2013.474	http://dx.doi.org/10.1038/onc.2013.474			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0EH	24213581	Green Submitted			2022-12-17	WOS:000343240100001
J	Lin, KT; Shann, YJ; Chau, GY; Hsu, CN; Huang, CYF				Lin, K-T; Shann, Y-J; Chau, G-Y; Hsu, C-N; Huang, C-Y F.			Identification of latent biomarkers in hepatocellular carcinoma by ultra-deep whole-transcriptome sequencing	ONCOGENE			English	Article						hepatocellular carcinoma; DUNQU1; FGFR2; alternative splicing; RNA-Seq	ALTERNATIVE EXON USE; ADAM15 GENE; EXPRESSION; CANCER; QUANTIFICATION; PATHWAYS	There is an urgent need to identify biomarkers for hepatocellular carcinoma due to limited treatment options and the poor prognosis of this common lethal disease. Whole-transcriptome shotgun sequencing (RNA-Seq) provides new possibilities for biomarker identification. We sequenced similar to 250 million pair-end reads from a pair of adjacent normal and tumor liver samples. With the aid of bioinformatics tools, we determined the transcriptome landscape and sought novel biomarkers by further empirical validations in 55 pairs of adjacent normal and tumor liver samples with various viral statuses such as HBV(+), HCV(+) and HBV(-) HCV(-). We identified a novel gene with coding regions, termed DUNQU1, which has a tissue-specific expression pattern in tumor liver samples of HCV(+) and HBV(-) HCV(-) hepatocellular carcinomas. Overexpression of DUNQU1 in Huh7 cell lines enhances the ability to form colonies in soft agar. Also, we identified three novel differentially-expressed protein-coding genes (ALG1L, SERPINA11 and TMEM82) that lack documented expression profiles in liver cancer and showed that the level of SREPINA11 is correlated with pathology stages. Moreover, we showed that the alternative splicing event of FGFR2 is associated with virus infection, tumor size, cirrhosis and tumor recurrence. The findings indicate that these new markers of hepatocellular carcinoma may be of value in improving prognosis and could have potential as new targets for developing new treatment options.	[Lin, K-T; Huang, C-Y F.] Natl Yang Ming Univ, Inst Biomed Informat, Taipei 112, Taiwan; [Shann, Y-J; Huang, C-Y F.] Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan; [Chau, G-Y] Taipei Vet Gen Hosp, Div Gen Surg, Dept Surg, Taipei, Taiwan; [Hsu, C-N] Acad Sinica, Inst Informat Sci, Taipei, Taiwan; [Hsu, C-N] USC Informat Sci Inst, Marina Del Rey, CA USA; [Hsu, C-N] Univ Calif San Diego, Dept Med, Div Biomed Informat, La Jolla, CA 92093 USA; [Huang, C-Y F.] Natl Yang Ming Univ, Canc Res Ctr, Taipei 112, Taiwan; [Huang, C-Y F.] Natl Yang Ming Univ, Genome Res Ctr, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; Academia Sinica - Taiwan; University of Southern California; University of California System; University of California San Diego; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Huang, CYF (corresponding author), Natl Yang Ming Univ, Inst Clin Med, 155,Li Non St,Sec 2, Taipei 112, Taiwan.	cyhuang5@ym.edu.tw	Huang, Chi-Ying/AFL-7729-2022; Huang, Chi-Ying/AAG-7672-2022	Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937	National Science Council [NSC94-3112-B-182-002, NSC97-3112-B-182-004, NSC101-2627-B-010-001-, NSC102-2627-B-010-001-, NSC 100-2917-I-010-001]; National Health Research Institutes, Taiwan; Taipei Veterans General Hospital [V102E2-006]; National Health Research Institutes [NHRI-EX102-10029BI]; Ministry of Economic Affairs [101-EC-17-A-17-S1-152]; Ministry of Education, Aim for the Top University Plan (National Yang-Ming University)	National Science Council(Ministry of Science and Technology, Taiwan); National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan); Taipei Veterans General Hospital(Taipei Veterans General Hospital); National Health Research Institutes(National Health Research Institutes, Japan); Ministry of Economic Affairs; Ministry of Education, Aim for the Top University Plan (National Yang-Ming University)	We thank the Taiwan Liver Cancer Network for providing the liver tumor tissue samples and related clinical data (all are anonymous) for this work. This network currently includes five major medical centers in Taiwan (National Taiwan University Hospital, Chang-Gung Memorial Hospital-Linko, Veteran General Hospital-Taichung, Chang-Gung Memorial Hospital-Kaohsiung and Veteran General Hospital-Kaohsiung). Taiwan Liver Cancer Network is supported by grants from the National Science Council (NSC94-3112-B-182-002, NSC97-3112-B-182-004) and National Health Research Institutes, Taiwan. We also want to thank National Core Facility Program for Biotechnology (Bioinformatics Consortium of Taiwan, NSC102-2319-B-010-002), National Research Program for Biopharmaceuticals (NRPB, NSC10102325-B-492-001) and National Center for High-performance Computing of National Applied Research Laboratories (NCHC, NARLabs) for providing computing and storage resources. Finally, we want to thank Professor Adrian R Krainer for his valuable comments on the manuscript and hosting at Cold Spring Harbor Laboratory.; This research was supported by grants from the National Science Council (NSC101-2627-B-010-001- and NSC102-2627-B-010-001-), Taipei Veterans General Hospital (V102E2-006), the National Health Research Institutes (NHRI-EX102-10029BI), Ministry of Economic Affairs (101-EC-17-A-17-S1-152) and the Ministry of Education, Aim for the Top University Plan (National Yang-Ming University) to C-YF. Huang. This research was also supported by the research aboard grant from the National Science Council (NSC 100-2917-I-010-001) to K-T. Lin.	Amann T, 2010, AM J PATHOL, V176, P1433, DOI 10.2353/ajpath.2010.090356; Barrett T, 2011, NUCLEIC ACIDS RES, V39, pD1005, DOI 10.1093/nar/gkq1184; Bochukova EG, 2010, NATURE, V463, P666, DOI 10.1038/nature08689; Cheng Y, 2007, BRIT J CANCER, V97, P1441, DOI 10.1038/sj.bjc.6604013; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; Ecker JR, 2012, NATURE, V489, P52, DOI 10.1038/489052a; Eichler EE, 2008, NEW ENGL J MED, V358, P737, DOI 10.1056/NEJMe0708756; Flicek P, 2011, NUCLEIC ACIDS RES, V39, pD800, DOI 10.1093/nar/gkq1064; Garber M, 2011, NAT METHODS, V8, P469, DOI [10.1038/NMETH.1613, 10.1038/nmeth.1613]; Grosso AR, 2008, EMBO REP, V9, P1087, DOI 10.1038/embor.2008.189; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Hertervig E, 1997, CANCER, V79, P448, DOI 10.1002/(SICI)1097-0142(19970201)79:3<448::AID-CNCR4>3.3.CO;2-Z; Hua YM, 2011, NATURE, V478, P123, DOI 10.1038/nature10485; Huang QC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026168; Huijts PEA, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2917; Kamburov A, 2011, NUCLEIC ACIDS RES, V39, pD712, DOI 10.1093/nar/gkq1156; Kapushesky M, 2012, NUCLEIC ACIDS RES, V40, pD1077, DOI 10.1093/nar/gkr913; Kleino I, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-90; Lander ES, 2011, NATURE, V470, P187, DOI 10.1038/nature09792; Lin R, 2007, ONCOGENE, V26, P851, DOI 10.1038/sj.onc.1209846; Mochizuki S, 2007, CANCER SCI, V98, P621, DOI 10.1111/j.1349-7006.2007.00434.x; Morin RD, 2008, BIOTECHNIQUES, V45, P81, DOI 10.2144/000112900; Myers RM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001046; Ortiz RM, 2004, GENE CHROMOSOME CANC, V41, P366, DOI 10.1002/gcc.20102; Ozsolak F, 2011, NAT REV GENET, V12, P87, DOI 10.1038/nrg2934; Panzitt K, 2007, GASTROENTEROLOGY, V132, P330, DOI 10.1053/j.gastro.2006.08.026; Parkinson H, 2011, NUCLEIC ACIDS RES, V39, pD1002, DOI 10.1093/nar/gkq1040; Parris TZ, 2010, CLIN CANCER RES, V16, P3860, DOI 10.1158/1078-0432.CCR-10-0889; Petretti T, 2000, GUT, V46, P359, DOI 10.1136/gut.46.3.359; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Somarelli JA, 2013, RNA, V19, P116, DOI 10.1261/rna.035097.112; Sultan M, 2008, SCIENCE, V321, P956, DOI 10.1126/science.1160342; Takai H, 2007, CELL, V131, P1248, DOI 10.1016/j.cell.2007.10.052; Toung JM, 2011, GENOME RES, V21, P991, DOI 10.1101/gr.116335.110; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq622; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Wu J, 2011, BIOINFORMATICS, V27, P3010, DOI 10.1093/bioinformatics/btr508; Zdobnov EM, 2001, BIOINFORMATICS, V17, P847, DOI 10.1093/bioinformatics/17.9.847	42	33	37	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2014	33	39					4786	4794		10.1038/onc.2013.424	http://dx.doi.org/10.1038/onc.2013.424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0ED	24141781				2022-12-17	WOS:000343239500009
J	Li, L; Chakraborty, S; Yang, CR; Hatanpaa, KJ; Cipher, DJ; Puliyappadamba, VT; Rehman, A; Jiwani, AJ; Mickey, B; Madden, C; Raisanen, J; Burma, S; Saha, D; Wang, Z; Pingle, SC; Kesari, S; Boothman, DA; Habib, AA				Li, L.; Chakraborty, S.; Yang, C-R; Hatanpaa, K. J.; Cipher, D. J.; Puliyappadamba, V. T.; Rehman, A.; Jiwani, A. J.; Mickey, B.; Madden, C.; Raisanen, J.; Burma, S.; Saha, D.; Wang, Z.; Pingle, S. C.; Kesari, S.; Boothman, D. A.; Habib, A. A.			An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII	ONCOGENE			English	Article						EGFRvIII; glioblastoma; EGFR wild type; activation; dimerization; HB-EGF	GROWTH-FACTOR RECEPTOR; CONFERS ENHANCED TUMORIGENICITY; TYROSINE KINASES; SIGNAL-TRANSDUCTION; TARGETED THERAPIES; GLIOBLASTOMA CELLS; GLIOMA-CELLS; EXPRESSION; GENE; PATHWAYS	EGFRvIII is a key oncogene in glioblastoma (GBM). EGFRvIII results from an in-frame deletion in the extracellular domain of EGFR, does not bind ligand and is thought to be constitutively active. Although EGFRvIII dimerization is known to activate EGFRvIII, the factors that drive EGFRvIII dimerization and activation are not well understood. Here we present a new model of EGFRvIII activation and propose that oncogenic activation of EGFRvIII in glioma cells is driven by co-expressed activated EGFR wild type (EGFRwt). Increasing EGFRwt leads to a striking increase in EGFRvIII tyrosine phosphorylation and activation while silencing EGFRwt inhibits EGFRvIII activation. Both the dimerization arm and the kinase activity of EGFRwt are required for EGFRvIII activation. EGFRwt activates EGFRvIII by facilitating EGFRvIII dimerization. We have previously identified HB-EGF, a ligand for EGFRwt, as a gene induced specifically by EGFRvIII. In this study, we show that HB-EGF is induced by EGFRvIII only when EGFRwt is present. Remarkably, altering HB-EGF recapitulates the effect of EGFRwt on EGFRvIII activation. Thus, increasing HB-EGF leads to a striking increase in EGFRvIII tyrosine phosphorylation while silencing HB-EGF attenuates EGFRvIII phosphorylation, suggesting that an EGFRvIII-HB-EGF-EGFRwt feed-forward loop regulates EGFRvIII activation. Silencing EGFRwt or HB-EGF leads to a striking inhibition of EGFRvIII-induced tumorigenicity, while increasing EGFRwt or HB-EGF levels resulted in accelerated EGFRvIII-mediated oncogenicity in an orthotopic mouse model. Furthermore, we demonstrate the existence of this loop in human GBM. Thus, our data demonstrate that oncogenic activation of EGFRvIII in GBM is likely maintained by a continuous EGFRwt-EGFRvIII-HB-EGF loop, potentially an attractive target for therapeutic intervention.	[Li, L.; Chakraborty, S.; Puliyappadamba, V. T.; Rehman, A.; Jiwani, A. J.; Habib, A. A.] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75216 USA; [Yang, C-R; Boothman, D. A.; Habib, A. A.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Simmons Comprehens Canc Ctr, Dallas, TX 75216 USA; [Hatanpaa, K. J.; Raisanen, J.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75216 USA; [Cipher, D. J.] Univ Texas Arlington, Coll Nursing, Arlington, TX 76019 USA; [Mickey, B.; Madden, C.] Univ Texas SW Med Ctr Dallas, Dept Neurosurg, Dallas, TX 75216 USA; [Burma, S.; Saha, D.] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75216 USA; [Wang, Z.] Univ Alberta, Dept Cell Biol, Edmonton, AB, Canada; [Pingle, S. C.; Kesari, S.] Moores Canc Ctr, Translat Neurooncol Labs, Dept Neurosci, UC San Diego, CA USA; [Habib, A. A.] VA North Texas Hlth Care Syst, Dallas, TX USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Arlington; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Alberta; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA North Texas Health Care System	Habib, AA (corresponding author), Univ Texas SW Med Ctr Dallas, North Texas VA Healthcare Syst, Dept Neurol & Neurotherapeut, Mail Code 151,4500 S Lancaster Rd, Dallas, TX 75216 USA.	Amyn.Habib@UTSouthwestern.edu	Kesari, Santosh/E-8461-2013; Boothman, David/Q-7776-2019		NIH [RO1NS062080, RO1 CA139217]; National Institutes of Health [RO1 CA149461]; National Aeronautics and Space Administration [NNX13AI13G]; Cancer Prevention and Research Institute of Texas [RP100644]; NATIONAL CANCER INSTITUTE [R01CA139217, P30CA142543, R01CA149461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062080] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Aeronautics and Space Administration(National Aeronautics & Space Administration (NASA)); Cancer Prevention and Research Institute of Texas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr Mien-Chie Hung (MD Anderson Cancer Center) for the EGFRwt-Myc plasmid and Dr James Van Brocklyn (Ohio State University) for GBM9 cells. This work was supported in part by NIH grant RO1NS062080 to AH and by RO1 CA139217 to DAB. SB is supported by grants from the National Institutes of Health (RO1 CA149461), National Aeronautics and Space Administration (NNX13AI13G) and the Cancer Prevention and Research Institute of Texas (RP100644).	Acquaviva J, 2011, CANCER RES, V71, P7198, DOI 10.1158/0008-5472.CAN-11-1514; Barkovich KJ, 2012, CANCER DISCOV, V2, P450, DOI 10.1158/2159-8290.CD-11-0287; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; Biernat W, 2004, BRAIN PATHOL, V14, P131, DOI 10.1111/j.1750-3639.2004.tb00045.x; Chung I, 2010, NATURE, V464, P783, DOI 10.1038/nature08827; Del Vecchio CA, 2013, ONCOGENE, V32, P2670, DOI 10.1038/onc.2012.280; Dowlati A, 2004, MOL CANCER THER, V3, P459; Estrada-Bernal A, 2011, J NEURO-ONCOL, V102, P353, DOI 10.1007/s11060-010-0345-z; Feng HZ, 2011, J CLIN INVEST, V121, P4670, DOI 10.1172/JCI58559; Ferguson KM, 2008, ANNU REV BIOPHYS, V37, P353, DOI 10.1146/annurev.biophys.37.032807.125829; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Hatanpaa KJ, 2010, NEOPLASIA, V12, P675, DOI 10.1593/neo.10688; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Huang PH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.287re6; Hwang Y, 2011, MOL CANCER RES, V9, P1199, DOI 10.1158/1541-7786.MCR-11-0229; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Johns TG, 2007, CLIN CANCER RES, V13, P1911, DOI 10.1158/1078-0432.CCR-06-1453; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Luwor RB, 2004, ONCOGENE, V23, P6095, DOI 10.1038/sj.onc.1207870; Magnus N, 2010, BLOOD, V116, P815, DOI 10.1182/blood-2009-10-250639; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Mishima K, 1998, ACTA NEUROPATHOL, V96, P322, DOI 10.1007/s004010050901; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Nishikawa Ryo, 2004, Brain Tumor Pathol, V21, P53, DOI 10.1007/BF02484510; Pillay V, 2009, NEOPLASIA, V11, P448, DOI 10.1593/neo.09230; Puliyappadamba VT, 2013, CELL REP, V4, P764, DOI 10.1016/j.celrep.2013.07.025; Ramnarain DB, 2008, CELL DEATH DIFFER, V15, P344, DOI 10.1038/sj.cdd.4402268; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; Reardon DA, 2006, ONCOLOGIST, V11, P152, DOI 10.1634/theoncologist.11-2-152; SAMUELS V, 1989, AM J PATHOL, V134, P895; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Smith K, 2005, CANCER RES, V65, P5221, DOI 10.1158/0008-5472.CAN-05-0169; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Tang CK, 2000, CANCER RES, V60, P3081; Thomas CY, 2003, INT J CANCER, V104, P19, DOI 10.1002/ijc.10880; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vivanco I, 2012, CANCER DISCOV, V2, P458, DOI 10.1158/2159-8290.CD-11-0284; Wang Q, 2005, EMBO REP, V6, P942, DOI 10.1038/sj.embor.7400491; Zhu H, 2009, P NATL ACAD SCI USA, V106, P2712, DOI 10.1073/pnas.0813314106	43	33	36	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2014	33	33					4253	4264		10.1038/onc.2013.400	http://dx.doi.org/10.1038/onc.2013.400			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MB	24077285	Green Accepted			2022-12-17	WOS:000341155800007
J	Nie, J; Liu, L; Xing, G; Zhang, M; Wei, R; Guo, M; Li, X; Xie, P; Li, L; He, F; Han, W; Zhang, L				Nie, J.; Liu, L.; Xing, G.; Zhang, M.; Wei, R.; Guo, M.; Li, X.; Xie, P.; Li, L.; He, F.; Han, W.; Zhang, L.			CKIP-1 acts as a colonic tumor suppressor by repressing oncogenic Smurf1 synthesis and promoting Smurf1 autodegradation	ONCOGENE			English	Article						colon cancer; CKIP-1; Smurf1; PI3K/Akt/mTOR signaling; tumor suppression	DOMAIN-CONTAINING PROTEIN; UBIQUITIN LIGASE SMURF1; BETA-CATENIN; CANCER; IDENTIFICATION; DEGRADATION; ACTIVATION; MUTATIONS; POLARITY	Dysregulation of cellular signaling pathways can lead to colon cancer. However, research on the key signaling effectors or regulators in colon carcinogenesis is limited. Casein kinase-2 interacting protein-1 (CKIP-1; also known as PLEKHO1) is crucial during adult bone formation and is a promising drug target for osteoporosis therapy. In this study, we observed that CKIP-1 was downregulated in human colon cancer tissues and colon cancer cell lines, and this result was correlated with colon cancer progression. CKIP-1 silencing in colon cancers involved promoter methylation. In colon cancer HCT116 and SW480 cells, CKIP-1 overexpression inhibited cell growth and migration. CKIP-1 also suppressed in-vivo tumor formation. Notably, the growth-suppressive role of CKIP-1 was dependent on the downregulation of the cell cycle-regulated oncogene Smad ubiquitylation regulatory factor-1 (Smurf1). During cell cycle progression, phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling increased Smurf1 production by an mTOR-dependent translational control mechanism. Rapamycin, the mTOR inhibitor, significantly reduced Smurf1 protein levels, and Smurf1 was degraded in mitosis. In colon cancer, CKIP-1 controlled Smurf1 expression by suppressing PI3K/Akt/mTOR signaling and enhancing Smurf1 autodegradation, and CKIP-1 downregulation was correlated with Smurf1 upregulation in colon carcinogenesis. These findings provide novel insight into the mechanisms of the candidate tumor suppressor CKIP-1.	[Nie, J.; Li, X.; Han, W.] Peoples Liberat Army Gen Hosp, Inst Basic Med, Dept Mol Biol, Beijing, Peoples R China; [Nie, J.; Xing, G.; Zhang, M.; Wei, R.; Xie, P.; Li, L.; He, F.; Zhang, L.] Beijing Inst Radiat Med, Beijing Proteome Res Ctr, State Key Lab Prote, Beijing, Peoples R China; [Liu, L.] Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing, Peoples R China; [Wei, R.; He, F.] Tsinghua Univ, Sch Life Sci, Beijing 100084, Peoples R China; [Guo, M.] Peoples Liberat Army Gen Hosp, Dept Gastroenterol & Hepatol, Beijing, Peoples R China; [Zhang, L.] Dalian Med Univ, Inst Canc Stem Cell, Dalian, Peoples R China	Chinese People's Liberation Army General Hospital; Academy of Military Medical Sciences - China; Chinese People's Liberation Army General Hospital; Tsinghua University; Chinese People's Liberation Army General Hospital; Dalian Medical University	Han, W (corresponding author), Gen Hosp PLA, Dept Mol Biol, Beijing 100853, Peoples R China.	hanwdrsw69@yahoo.com; zhanglq@nic.bmi.ac.cn	Zhang, Minghua/AAC-4782-2020	Li, Li/0000-0003-2342-3658; Zhang, Lingqiang/0000-0002-9795-2141	National Basic Research Programs [2012CB910702, 2011CB910602, 2012CB518103]; National Natural Science Foundation Projects [31125010, 31100554, 31270820, 31230061, 81221004]; Beijing Nova Program [Z121107002512121]	National Basic Research Programs(National Basic Research Program of China); National Natural Science Foundation Projects(National Natural Science Foundation of China (NSFC)); Beijing Nova Program(Beijing Municipal Science & Technology Commission)	The excellent technical assistance of Qian Mei and Zhiqiang Wu is gratefully acknowledged. The study was supported by the National Basic Research Programs (2012CB910702, 2011CB910602 and 2012CB518103) and National Natural Science Foundation Projects (31125010, 31100554, 31270820, 31230061 and 81221004) and Beijing Nova Program (Z121107002512121).	Bosc DG, 2000, J BIOL CHEM, V275, P14295, DOI 10.1074/jbc.275.19.14295; Canton DA, 2006, J BIOL CHEM, V281, P36347, DOI 10.1074/jbc.M607595200; Chen XF, 2012, MOL BIOL REP, V39, P3549, DOI 10.1007/s11033-011-1128-0; Cui Y, 2011, EMBO J, V30, P2675, DOI 10.1038/emboj.2011.155; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kannan M, 2012, DEVELOPMENT, V139, P3600, DOI 10.1242/dev.081786; Lammi L, 2004, AM J HUM GENET, V74, P1043, DOI 10.1086/386293; Li H, 2002, CANCER BIOL THER, V1, P621, DOI 10.4161/cbt.309; Lu KF, 2008, NAT CELL BIOL, V10, P994, DOI 10.1038/ncb1760; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Narimatsu M, 2009, CELL, V137, P295, DOI 10.1016/j.cell.2009.02.025; Nie J, 2011, CHINESE SCI BULL, V56, P3155, DOI 10.1007/s11434-011-4703-9; Nie J, 2010, J BIOL CHEM, V285, P22816, DOI 10.1074/jbc.M110.126920; Nie J, 2010, FEBS LETT, V584, P3005, DOI 10.1016/j.febslet.2010.05.033; Osmundson EC, 2008, J CELL BIOL, V183, P267, DOI 10.1083/jcb.200801049; Osmundson EC, 2009, CELL DIV, V4, DOI 10.1186/1747-1028-4-14; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Safi A, 2004, MOL CELL BIOL, V24, P1245, DOI 10.1128/MCB.24.3.1245-1255.2004; Suzuki A, 2008, CANCER SCI, V99, P986, DOI 10.1111/j.1349-7006.2008.00779.x; Tokuda E, 2007, CANCER RES, V67, P9666, DOI 10.1158/0008-5472.CAN-07-1050; Wang YF, 2012, EMBO REP, V13, P1004, DOI 10.1038/embor.2012.144; Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035; Zhang BX, 2010, GASTROENTEROLOGY, V138, P969, DOI 10.1053/j.gastro.2009.11.004; Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617; Zhang LQ, 2007, CELL SIGNAL, V19, P932, DOI 10.1016/j.cellsig.2006.11.002; Zhang LQ, 2005, EMBO J, V24, P766, DOI 10.1038/sj.emboj.7600532	27	33	36	3	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3677	3687		10.1038/onc.2013.340	http://dx.doi.org/10.1038/onc.2013.340			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23995790				2022-12-17	WOS:000338942900007
J	Petrilli, A; Copik, A; Posadas, M; Chang, LS; Welling, DB; Giovannini, M; Fernandez-Valle, C				Petrilli, A.; Copik, A.; Posadas, M.; Chang, L-S; Welling, D. B.; Giovannini, M.; Fernandez-Valle, C.			LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2	ONCOGENE			English	Article						LIMK; cell proliferation; Neurofibromatosis; schwannomas; cytoskeleton dynamics; cell cycle	NF2 TUMOR-SUPPRESSOR; COFILIN PHOSPHORYLATION; ACTIN DYNAMICS; PROTEIN-KINASE; SCHWANN-CELLS; AURORA-A; MERLIN; GENE; RAC; PROLIFERATION	Neurofibromatosis type 2 (NF2) is caused by mutations in the NF2 gene that encodes a tumor-suppressor protein called merlin. NF2 is characterized by formation of multiple schwannomas, meningiomas and ependymomas. Merlin loss-of-function is associated with increased activity of Rac and p21-activated kinases (PAKs) and deregulation of cytoskeletal organization. LIM domain kinases (LIMK1 and 2) are substrate for Cdc42/Rac-PAK and modulate actin dynamics by phosphorylating cofilin at serine-3. This modification inactivates the actin severing and depolymerizing activity of cofilin. LIMKs also translocate into the nucleus and regulate cell cycle progression. Significantly, LIMKs are overexpressed in several tumor types, including skin, breast, lung, liver and prostate. Here we report that mouse Schwann cells (MSCs) in which merlin function is lost as a result of Nf2 exon2 deletion (Nf2(Delta Ex2)) exhibited increased levels of LIMK1, LIMK2 and active phospho-Thr508/505-LIMK1/2, as well as phospho-Ser3-cofilin, compared with wild-type normal MSCs. Similarly, levels of LIMK1 and 2 total protein and active phosphorylated forms were elevated in human vestibular schwannomas compared with normal human Schwann cells (SCs). Reintroduction of wild-type NF2 into Nf2(Delta Ex2) MSC reduced LIMK1 and LIMK2 levels. We show that pharmacological inhibition of LIMK with BMS-5 decreased the viability of Nf2(Delta Ex2) MSCs in a dose-dependent manner, but did not affect viability of control MSCs. Similarly, LIMK knockdown decreased viability of Nf2(Delta Ex2) MSCs. The decreased viability of Nf2(Delta Ex2) MSCs was not due to caspase-dependent or -independent apoptosis, but rather due to inhibition of cell cycle progression as evidenced by accumulation of cells in G(2)/M phase. Inhibition of LIMKs arrests cells in early mitosis by decreasing aurora A activation. Our results suggest that LIMKs are potential drug targets for NF2 and tumors associated with merlin deficiency.	[Petrilli, A.; Copik, A.; Posadas, M.; Fernandez-Valle, C.] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32827 USA; [Chang, L-S] Nationwide Childrens Hosp, Res Inst, Ctr Childhood Canc, Columbus, OH USA; [Chang, L-S] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Welling, D. B.] Ohio State Univ, Coll Med, Dept Otolaryngol, Columbus, OH 43210 USA; [Giovannini, M.] House Res Inst, Div Clin & Translat Res, Los Angeles, CA USA	State University System of Florida; University of Central Florida; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Fernandez-Valle, C (corresponding author), Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, 6900 Lake Nona Blvd, Orlando, FL 32827 USA.	cfv@ucf.edu	Welling, D Bradley/H-1503-2014	Welling, D. Bradley/0000-0002-9963-469X; Chang, Long-Sheng/0000-0002-5178-2992	DHHS/NIH [5R01DC10189]; Children's Tumor Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC010189] Funding Source: NIH RePORTER	DHHS/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Tumor Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We thank Dr Patrick Wood, The Miami Project to Cure Paralysis, Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USA, for vials of cultured human Schwann cells, Dr Maria Elisa Manetti for the Halo-tag NF2 plasmid, Nicklaus Sparrow and Marga Bott for their creation of the Nf2<SUP>Delta Ex2</SUP> MSCs and Rashell Hallford for animal husbandry. This work was supported in part by a DHHS/NIH award to CF-V (5R01DC10189), and AP is the recipient of a Young Investigator Award from the Children's Tumor Foundation.	Amano T, 2002, J BIOL CHEM, V277, P22093, DOI 10.1074/jbc.M201444200; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Asthagiri AR, 2009, LANCET, V373, P1974, DOI 10.1016/S0140-6736(09)60259-2; Bagheri-Yarmand R, 2006, INT J CANCER, V118, P2703, DOI 10.1002/ijc.21650; Barr AR, 2007, J CELL SCI, V120, P2987, DOI 10.1242/jcs.013136; Baser ME, 2002, NEUROLOGY, V59, P290, DOI 10.1212/WNL.59.2.290; Bashour AM, 2002, MOL CELL BIOL, V22, P1150, DOI 10.1128/MCB.22.4.1150-1157.2002; Cote MC, 2010, J BIOL CHEM, V285, P8013, DOI 10.1074/jbc.M109.098665; Giovannini M, 2000, GENE DEV, V14, P1617; Goyal P, 2005, J BIOL CHEM, V280, P27569, DOI 10.1074/jbc.M504448200; Horita Y, 2008, J BIOL CHEM, V283, P6013, DOI 10.1074/jbc.M706538200; Hung G, 2002, INT J ONCOL, V20, P475; Iacovelli J, 2007, GLIA, V55, P1638, DOI 10.1002/glia.20578; Johnson EO, 2012, J CELL SCI, V125, P1204, DOI 10.1242/jcs.092304; Kaji N, 2008, J BIOL CHEM, V283, P4983, DOI 10.1074/jbc.M708644200; Kalamarides Michel, 2012, Acta Neuropathol, V123, P369, DOI 10.1007/s00401-011-0905-0; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Li W, 2012, EMBO REP, V13, P204, DOI 10.1038/embor.2012.11; Manetti F, 2012, CURR CANCER DRUG TAR, V12, P543, DOI 10.2174/156800912800673266; Manetti F, 2012, MED RES REV, V32, P968, DOI 10.1002/med.20230; McConnell BV, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-75; Nakai Y, 2006, J NEUROSCI, V26, P3390, DOI 10.1523/JNEUROSCI.4865-05.2006; Nikonova AS, 2013, CELL MOL LIFE SCI, V70, P661, DOI 10.1007/s00018-012-1073-7; Okamoto I, 2005, NEOPLASIA, V7, P303, DOI 10.1593/neo.04514; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; Plotkin SR, 2009, NEW ENGL J MED, V361, P358, DOI 10.1056/NEJMoa0902579; Po'uha ST, 2010, ONCOGENE, V29, P597, DOI 10.1038/onc.2009.367; Ritchey L, 2012, CELL CYCLE, V11, P296, DOI 10.4161/cc.11.2.18734; Ross-Macdonald P, 2008, MOL CANCER THER, V7, P3490, DOI 10.1158/1535-7163.MCT-08-0826; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Scott RW, 2007, J MOL MED, V85, P555, DOI 10.1007/s00109-007-0165-6; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sparrow N, 2012, J NEUROSCI, V32, P5284, DOI 10.1523/JNEUROSCI.6207-11.2012; Stamenkovic I, 2010, CURR PROTEIN PEPT SC, V11, P471, DOI 10.2174/138920310791824011; Sumi T, 2006, EXP CELL RES, V312, P1021, DOI 10.1016/j.yexcr.2005.12.030; Thaxton C, 2008, ONCOGENE, V27, P2705, DOI 10.1038/sj.onc.1210923; Thaxton C, 2011, MOL CELL NEUROSCI, V47, P1, DOI 10.1016/j.mcn.2010.12.006; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yi CL, 2008, CANCER RES, V68, P7932, DOI 10.1158/0008-5472.CAN-08-0866; Yokoo T, 2003, J BIOL CHEM, V278, P52919, DOI 10.1074/jbc.M309334200	42	33	34	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3571	3582		10.1038/onc.2013.320	http://dx.doi.org/10.1038/onc.2013.320			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23934191	Green Accepted			2022-12-17	WOS:000338941100009
J	Butinar, M; Prebanda, MT; Rajkovic, J; Jeric, B; Stoka, V; Peters, C; Reinheckel, T; Kruger, A; Turk, V; Turk, B; Vasiljeva, O				Butinar, M.; Prebanda, M. T.; Rajkovic, J.; Jeric, B.; Stoka, V.; Peters, C.; Reinheckel, T.; Krueger, A.; Turk, V.; Turk, B.; Vasiljeva, O.			Stefin B deficiency reduces tumor growth via sensitization of tumor cells to oxidative stress in a breast cancer model	ONCOGENE			English	Article						cathepsin inhibitor; stefin; breast cancer; mouse model; oxidative stress	PROGRESSIVE MYOCLONUS EPILEPSY; PEROXIDE-INDUCED APOPTOSIS; CYSTEINE CATHEPSINS; HYDROGEN-PEROXIDE; CYSTATIN-B; MULTISTAGE TUMORIGENESIS; PROTEASE ACTIVITY; CUTTING EDGE; MOUSE MODEL; MICE	Lysosomal cysteine cathepsins contribute to proteolytic events promoting tumor growth and metastasis. Their enzymatic activity, however, is tightly regulated by endogenous inhibitors. To investigate the role of cathepsin inhibitor stefin B (Stfb) in mammary cancer, Stfb null mice were crossed with transgenic polyoma virus middle T oncogene (PyMT) breast cancer mice. We show that ablation of Stfb resulted in reduced size of mammary tumors but did not affect their rate of metastasis. Importantly, decrease in tumor growth was correlated with an increased incidence of dead cell islands detected in tumors of Stfb-deficient mice. Ex vivo analysis of primary PyMT tumor cells revealed no significant effects of ablation of Stfb expression on proliferation, angiogenesis, migration and spontaneous cell death as compared with control cells. However, upon treatment with the lysosomotropic agent Leu-Leu-OMe, cancer cells lacking Stfb exhibited a significantly higher sensitivity to apoptosis. Moreover, Stfb-ablated tumor cells were significantly more prone to cell death under increased oxidative stress. These results indicate an in vivo role for Stfb in protecting cancer cells by promoting their resistance to oxidative stress and to apoptosis induced through the lysosomal pathway.	[Butinar, M.; Prebanda, M. T.; Rajkovic, J.; Jeric, B.; Stoka, V.; Turk, V.; Turk, B.; Vasiljeva, O.] Jozef Stefan Inst, Dept Biochem & Mol & Struct Biol, Ljubljana 1000, Slovenia; [Butinar, M.; Rajkovic, J.; Jeric, B.; Stoka, V.; Turk, V.; Vasiljeva, O.] Jozef Stefan Int Postgrad Sch, Ljubljana, Slovenia; [Peters, C.; Reinheckel, T.] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Inst Mol Med & Cell Res, D-79106 Freiburg, Germany; [Krueger, A.] Tech Univ Munich, Klinikums Rechts Isar, Inst Expt Onkol & Therapieforsch, D-80290 Munich, Germany; [Turk, V.; Turk, B.] Ctr Excellence Integrated Approaches Chem & Biol, Ljubljana, Slovenia; [Turk, B.] Univ Ljubljana, Fac Chem & Chem Technol, Ljubljana, Slovenia	Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute; Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute; University of Freiburg; Technical University of Munich; University of Ljubljana	Vasiljeva, O (corresponding author), Jozef Stefan Inst, Dept Biochem & Mol & Struct Biol, Jamova 39, Ljubljana 1000, Slovenia.	olga.vasiljeva@ijs.si	Reinheckel, Thomas/AAL-9761-2021; Stoka, Veronika/AAM-2283-2021	Reinheckel, Thomas/0000-0001-9866-9105; Turk, Boris/0000-0002-9007-5764	European Commission [201279]; Slovenian Research Agency [J3-4267, P1-0140]; Deutsche Forschungsgemeinschaft [SFB 850]	European Commission(European CommissionEuropean Commission Joint Research Centre); Slovenian Research Agency(Slovenian Research Agency - Slovenia); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Richard Myers and Len Pennacchio, formerly of Stanford University, for providing with Stfb knockout mouse strain, Georgy Mikhaylov and Matej Vizovisek for their technical and methodological assistance, Eva Zerovnik for valuable discussions and Roger H. Pain for critical reading of the manuscript. This work was supported by the European Commission FP7 grant 201279 (Microenvimet: CP, TR, AK, BT and OV), the Slovenian Research Agency (research grants no. J3-4267 to OV and P1-0140 to BT) and Deutsche Forschungsgemeinschaft SFB 850 project B7 (CP and TR).	Alakurtti K, 2005, EUR J HUM GENET, V13, P208, DOI 10.1038/sj.ejhg.5201300; Antunes F, 2001, BIOCHEM J, V356, P549, DOI 10.1042/0264-6021:3560549; Bell-McGuinn KM, 2007, CANCER RES, V67, P7378, DOI 10.1158/0008-5472.CAN-07-0602; Bojic L, 2007, FEBS LETT, V581, P5185, DOI 10.1016/j.febslet.2007.10.005; Brown NS, 2001, BREAST CANCER RES, V3, P323, DOI 10.1186/bcr315; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Datta K, 2002, INT J BIOCHEM CELL B, V34, P148, DOI 10.1016/S1357-2725(01)00106-6; Droga-Mazovec G, 2008, J BIOL CHEM, V283, P19140, DOI 10.1074/jbc.M802513200; Feldman AS, 2009, CLIN CANCER RES, V15, P1024, DOI 10.1158/1078-0432.CCR-08-1143; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669; GOLDMAN R, 1973, BIOCHIM BIOPHYS ACTA, V318, P205, DOI 10.1016/0005-2736(73)90114-4; Gopinathan A, 2012, GUT, V61, P877, DOI 10.1136/gutjnl-2011-300850; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hileman EO, 2004, CANCER CHEMOTH PHARM, V53, P209, DOI 10.1007/s00280-003-0726-5; Ishisaka R, 2002, BIOSCI BIOTECH BIOCH, V66, P1865, DOI 10.1271/bbb.66.1865; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Kariya S, 2009, INT J RADIAT ONCOL, V75, P449, DOI 10.1016/j.ijrobp.2009.04.092; Kopitar-Jerala NA, 2005, FEBS LETT, V579, P2149, DOI 10.1016/j.febslet.2005.03.002; Kos J, 2000, CLIN CANCER RES, V6, P505; Kuopio T, 1998, CANCER RES, V58, P432; Lehtinen MK, 2009, J NEUROSCI, V29, P5910, DOI 10.1523/JNEUROSCI.0682-09.2009; Mao YB, 2006, CELL BIOL INT, V30, P332, DOI 10.1016/j.cellbi.2005.12.008; Mikhaylov G, 2011, NAT NANOTECHNOL, V6, P594, DOI [10.1038/NNANO.2011.112, 10.1038/nnano.2011.112]; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Pennacchio LA, 1998, NAT GENET, V20, P251, DOI 10.1038/3059; Pennacchio LA, 1996, SCIENCE, V271, P1731, DOI 10.1126/science.271.5256.1731; Repnik U, 2010, MITOCHONDRION, V10, P662, DOI 10.1016/j.mito.2010.07.008; Rygiel TP, 2008, J CELL SCI, V121, P1183, DOI 10.1242/jcs.017194; Sevenich L, 2010, P NATL ACAD SCI USA, V107, P2497, DOI 10.1073/pnas.0907240107; Shree T, 2011, GENE DEV, V25, P2465, DOI 10.1101/gad.180331.111; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Stoka V, 2007, BIOL CHEM, V388, P555, DOI 10.1515/BC.2007.064; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Takahashi T, 2004, INT J MOL MED, V14, P197; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; Turk B, 2002, CURR PHARM DESIGN, V8, P1623, DOI 10.2174/1381612023394124; Turk B, 1997, BIOL CHEM, V378, P141; Turk B, 2012, EMBO J, V31, P1630, DOI 10.1038/emboj.2012.42; Turk B, 2009, J BIOL CHEM, V284, P21783, DOI 10.1074/jbc.R109.023820; Turk V, 2004, CANCER CELL, V5, P409, DOI 10.1016/S1535-6108(04)00117-5; Turk V, 2008, FRONT BIOSCI-LANDMRK, V13, P5406, DOI 10.2741/3089; Turk V, 2012, BBA-PROTEINS PROTEOM, V1824, P68, DOI 10.1016/j.bbapap.2011.10.002; Uchimoto T, 1999, APOPTOSIS, V4, P357, DOI 10.1023/A:1009695221038; Vasiljeva O, 2008, ONCOGENE, V27, P4191, DOI 10.1038/onc.2008.59; Vasiljeva O, 2008, BIOCHIMIE, V90, P380, DOI 10.1016/j.biochi.2007.10.004; Vasiljeva O, 2007, CURR PHARM DESIGN, V13, P387, DOI 10.2174/138161207780162962; Vasiljeva O, 2006, CANCER RES, V66, P5242, DOI 10.1158/0008-5472.CAN-05-4463; Yang F, 2010, CELL DEATH DIFFER, V17, P1354, DOI 10.1038/cdd.2010.29; Yin L, 2005, J CELL BIOCHEM, V94, P433, DOI 10.1002/jcb.20277; Yu WF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013973; Zullani T, 2005, FREE RADICAL BIO MED, V38, P307, DOI 10.1016/j.freeradbiomed.2004.09.021	53	33	34	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3392	3400		10.1038/onc.2013.314	http://dx.doi.org/10.1038/onc.2013.314			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23955077				2022-12-17	WOS:000338779300006
J	Lu, X; An, H; Jin, R; Zou, M; Guo, Y; Su, PF; Liu, D; Shyr, Y; Yarbrough, WG				Lu, X.; An, H.; Jin, R.; Zou, M.; Guo, Y.; Su, P-F; Liu, D.; Shyr, Y.; Yarbrough, W. G.			PPM1A is a RelA phosphatase with tumor suppressor-like activity	ONCOGENE			English	Article						NF-kappa B; PPM1A; phosphatase; prostate cancer; tumor suppressor	NF-KAPPA-B; MONOCYTE CHEMOATTRACTANT PROTEIN-1; THERAPEUTIC TARGET; WIP1 PHOSPHATASE; PROSTATE; PHOSPHORYLATION; GENE; GROWTH; P65; BONE	Nuclear factor-kappa B (NF-kappa B) signaling contributes to human disease processes, notably inflammatory diseases and cancer. NF-kappa B has a role in tumorigenesis and tumor growth, as well as promotion of metastases. Mechanisms responsible for abnormal NF-kappa B activation are not fully elucidated; however, RelA phosphorylation, particularly at serine residues S536 and S276, is critical for RelA function. Kinases that phosphorylate RelA promote oncogenic behaviors, suggesting that phosphatases targeting RelA could have tumor-inhibiting activities; however, few RelA phosphatases have been identified. Here, we identified tumor inhibitory and RelA phosphatase activities of the protein phosphatase 2C (PP2C) phosphatase family member, PPM1A. We show that PPM1A directly dephosphorylated RelA at residues S536 and S276 and selectively inhibited NF-kappa B transcriptional activity, resulting in decreased expression of monocyte chemotactic protein-1/chemokine (C-C motif) ligand 2 and interleukin-6, cytokines implicated in cancer metastasis. PPM1A depletion enhanced NF-kappa B-dependent cell invasion, whereas PPM1A expression inhibited invasion. Analyses of human expression data revealed that metastatic prostate cancer deposits had lower PPM1A expression compared with primary tumors without distant metastases. A hematogenous metastasis mouse model revealed that PPM1A expression inhibited bony metastases of prostate cancer cells after vascular injection. In summary, our findings suggest that PPM1A is a RelA phosphatase that regulates NF-kappa B activity and that PPM1A has tumor suppressor-like activity. Our analyses also suggest that PPM1A inhibits prostate cancer metastases and as neither gene deletions nor inactivating mutations of PPM1A have been described, increasing PPM1A activity in tumors represents a potential therapeutic strategy to inhibit NF-kappa B signaling or bony metastases in human cancer.	[Lu, X.; An, H.; Guo, Y.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37235 USA; [An, H.] Vanderbilt Univ, Div Surg Sci, Nashville, TN 37235 USA; [Jin, R.] Vanderbilt Univ, Vanderbilt Prostate Canc Ctr, Nashville, TN 37235 USA; [Jin, R.] Vanderbilt Univ, Dept Urol, Nashville, TN 37235 USA; [Zou, M.; Liu, D.; Yarbrough, W. G.] Yale Univ, Div Otolaryngol, Dept Surg, New Haven, CT 06519 USA; [Su, P-F; Shyr, Y.] Vanderbilt Univ, Dept Biostat, Nashville, TN 37235 USA; [Yarbrough, W. G.] Yale Univ, Dept Pathol, New Haven, CT 06519 USA; [Yarbrough, W. G.] Yale Canc Ctr, New Haven, CT USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Yale University; Vanderbilt University; Yale University; Yale University	Yarbrough, WG (corresponding author), Yale Univ, Sch Med, Dept Surg, Div Otolaryngol, 800 Howard Ave,4th Floor, New Haven, CT 06519 USA.	Wendell.yarbrough@yale.edu			Vanderbilt Ingram Cancer Center; Department of Otolaryngology at Vanderbilt University; Vanderbilt Bill Wilkerson Center;  [NIH R01 DE013173]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE013173] Funding Source: NIH RePORTER	Vanderbilt Ingram Cancer Center; Department of Otolaryngology at Vanderbilt University; Vanderbilt Bill Wilkerson Center; ; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank W Sun, LA Donehower, N Perkins, Reuven Agami and IM Verma for providing constructs and cell lines. We are extremely grateful to A Richmond, R Matusik, J McLean, A Weaver, D Webb and to Baker Lab members for insightful advice. This work was supported by Grant NIH R01 DE013173 (to WGY) and by funds provided through an endowment from Barry and Amy Baker to the Barry Baker Laboratory for Head & Neck Oncology, from the Vanderbilt Ingram Cancer Center, from the Department of Otolaryngology at Vanderbilt University and from the Vanderbilt Bill Wilkerson Center.	Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; An HB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016427; Arun P, 2009, CLIN CANCER RES, V15, P5974, DOI 10.1158/1078-0432.CCR-09-1352; Azevedo A, 2011, WORLD J CLIN ONCOL, V2, P384, DOI 10.5306/wjco.v2.i12.384; Browning DD, 1997, J BIOL CHEM, V272, P7995, DOI 10.1074/jbc.272.12.7995; Buss H, 2004, J BIOL CHEM, V279, P49571, DOI 10.1074/jbc.C400442200; Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Chaturvedi MM, 2011, ONCOGENE, V30, P1615, DOI 10.1038/onc.2010.566; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chew J, 2009, NAT CELL BIOL, V11, P659, DOI 10.1038/ncb1873; Coward J, 2011, CLIN CANCER RES, V17, P6083, DOI 10.1158/1078-0432.CCR-11-0945; Craig MJ, 2006, CANCER METAST REV, V25, P611, DOI 10.1007/s10555-006-9027-x; Drake JM, 2005, CLIN EXP METASTAS, V22, P674, DOI 10.1007/s10585-006-9011-4; Gardam S, 2011, EXPERT OPIN THER TAR, V15, P207, DOI 10.1517/14728222.2011.548861; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038/nri2423; Grivennikov SI, 2010, CURR OPIN GENET DEV, V20, P65, DOI 10.1016/j.gde.2009.11.004; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kim JS, 2006, BIOCHEM BIOPH RES CO, V351, P253, DOI 10.1016/j.bbrc.2006.10.028; Lammers T, 2007, CRIT REV BIOCHEM MOL, V42, P437, DOI 10.1080/10409230701693342; Lammers T, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-65; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Lu Y, 2006, PROSTATE, V66, P1311, DOI 10.1002/pros.20464; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Mueller L, 2010, BIOCHEM BIOPH RES CO, V397, P586, DOI 10.1016/j.bbrc.2010.05.163; Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Neumann M, 2007, FASEB J, V21, P2642, DOI 10.1096/fj.06-7615rev; Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Schwabe RF, 2005, FASEB J, V19, P1758, DOI 10.1096/fj.05-3736fje; Shohat M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032438; Smale ST, 2011, NAT IMMUNOL, V12, P689, DOI 10.1038/ni.2070; Sosnoski DM, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/160265; Sun WJ, 2009, CELL SIGNAL, V21, P95, DOI 10.1016/j.cellsig.2008.09.012; UEDA A, 1994, J IMMUNOL, V153, P2052; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang JL, 2007, CANCER CELL, V12, P239, DOI 10.1016/j.ccr.2007.07.002; Wolf MJ, 2012, CANCER CELL, V22, P91, DOI 10.1016/j.ccr.2012.05.023; Wu JT, 2005, J SURG RES, V123, P158, DOI 10.1016/j.jss.2004.06.006; Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z; Yamaguchi H, 2005, BIOCHEMISTRY-US, V44, P5285, DOI 10.1021/bi0476634; Yamaguchi H, 2007, BIOCHEMISTRY-US, V46, P12594, DOI 10.1021/bi701096s; Yang JM, 2001, J BIOL CHEM, V276, P47828, DOI 10.1074/jbc.M106103200; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zhang BH, 2009, HISTOCHEM CELL BIOL, V132, P169, DOI 10.1007/s00418-009-0601-5; Zhang J, 2010, PROG MOL BIOL TRANSL, V95, P31, DOI 10.1016/B978-0-12-385071-3.00003-4; Zhang J, 2010, CYTOKINE GROWTH F R, V21, P41, DOI 10.1016/j.cytogfr.2009.11.009; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; Zollo M, 2012, CLIN EXP METASTAS, V29, P585, DOI 10.1007/s10585-012-9473-5	56	33	38	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2918	2927		10.1038/onc.2013.246	http://dx.doi.org/10.1038/onc.2013.246			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23812431	Green Accepted			2022-12-17	WOS:000337231800011
J	Vargas, TR; Boudoukha, S; Simon, A; Souidi, M; Cuvellier, S; Pinna, G; Polesskaya, A				Vargas, T. Rivera; Boudoukha, S.; Simon, A.; Souidi, M.; Cuvellier, S.; Pinna, G.; Polesskaya, A.			Post-transcriptional regulation of cyclins D1, D3 and G1 and proliferation of human cancer cells depend on IMP-3 nuclear localization	ONCOGENE			English	Article						IMP-3; IGF2BP3; cyclins D1,D3 and G1; HNRNPM; post-transcriptional regulation	RNA-BINDING-PROTEIN; ACTIN MESSENGER-RNA; UNFAVORABLE PROGNOSIS; 3 IGF2BP3; TRANSLATION; EXPRESSION; ZBP1; TRANSCRIPTION; RADIATION; SURVIVAL	RNA-binding proteins of the IMP family (insulin-like growth factor 2 (IGF2) mRNA-binding proteins 1-3) are important post-transcriptional regulators of gene expression. Multiple studies have linked high expression of IMP proteins, and especially of IMP-3, to an unfavorable prognosis in numerous types of cancer. The specific importance of IMP-3 for cancer transformation remains poorly understood. We here show that all three IMPs can directly bind the mRNAs of cyclins D1, D3 and G1 (CCND1, D3 and G1) in vivo and in vitro, and yet only IMP-3 regulates the expression of these cyclins in a significant manner in six human cancer cell lines of different origins. In the absence of IMP-3, the levels of CCND1, D3 and G1 proteins fall dramatically, and the cells accumulate in the G1 phase of the cell cycle, leading to almost complete proliferation arrest. Our results show that, compared with IMP-1 and IMP2, IMP-3 is enriched in the nucleus, where it binds the transcripts of CCND1, D3 and G1. The nuclear localization of IMP-3 depends on its protein partner HNRNPM and is indispensable for the post-transcriptional regulation of expression of the cyclins. Cytoplasmic retention of IMP-3 and HNRNPM in human cancer cells leads to significant drop in proliferation. In conclusion, a nuclear IMP-3-HNRNPM complex is important for the efficient synthesis of CCND1, D3 and G1 and for the proliferation of human cancer cells.	[Vargas, T. Rivera; Boudoukha, S.; Simon, A.; Cuvellier, S.; Pinna, G.; Polesskaya, A.] CNR, FRE 3377, Gif Sur Yvette, France; [Vargas, T. Rivera; Boudoukha, S.; Simon, A.; Souidi, M.; Pinna, G.; Polesskaya, A.] Univ Paris 11, FRE 3377, Gif Sur Yvette, France; [Vargas, T. Rivera; Boudoukha, S.; Simon, A.; Souidi, M.; Pinna, G.; Polesskaya, A.] CEA, FRE 3377, Gif Sur Yvette, France; [Boudoukha, S.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; [Cuvellier, S.] Inserm, Inst Cochin, Dept Genet & Dev, U1016, Paris, France	UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; University of California System; University of California San Francisco; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Polesskaya, A (corresponding author), CEA Saclay, CNRS, IBiTeC S, SBIGeM,FRE 3377, Bat 144,P 65, F-91191 Gif Sur Yvette, France.	anna.polesskaya@cea.fr	SOUIDI, Mouloud/ABI-1444-2020	PINNA, Guillaume/0000-0001-7841-7250	Association Francais contre les Myopathies; Fondation ARC pour la Recherche sur le Cancer	Association Francais contre les Myopathies(Association Francaise contre les Myopathies); Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer)	We thank Drs Annick Harel-Bellan and Linda L Pritchard for critical reading of the manuscript, Drs Jan Christianssen and Finn C Nielsen for the kind gifts of antibodies and for helpful discussions, Dr Yuh Min Chook for the kind gift of the M9M plasmid, and Dr Antoinette Lemoine for the HCC cell lines. This work was supported by a grant from the Association Francais contre les Myopathies to AP and from Fondation ARC pour la Recherche sur le Cancer to TRV.	Bell JL, 2012, CELL MOL LIFE SCI; Boudoukha S, 2010, MOL CELL BIOL, V30, P5710, DOI 10.1128/MCB.00665-10; Cansizoglu AE, 2007, NAT STRUCT MOL BIOL, V14, P452, DOI 10.1038/nsmb1229; Chao JA, 2010, GENE DEV, V24, P148, DOI 10.1101/gad.1862910; Dai N, 2011, GENE DEV, V25, P1159, DOI 10.1101/gad.2042311; Fornari F, 2009, CANCER RES, V69, P5761, DOI 10.1158/0008-5472.CAN-08-4797; Gu W, 2012, J CELL SCI, V125, P81, DOI 10.1242/jcs.086132; Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009; Hammer NA, 2005, REPRODUCTION, V130, P203, DOI 10.1530/rep.1.00664; Jonson L, 2007, MOL CELL PROTEOMICS, V6, P798, DOI 10.1074/mcp.M600346-MCP200; Kobel M, 2009, MODERN PATHOL, V22, P469, DOI 10.1038/modpathol.2008.206; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Liao BS, 2011, J BIOL CHEM, V286, P31145, DOI 10.1074/jbc.M111.263913; Liao BS, 2005, J BIOL CHEM, V280, P18517, DOI 10.1074/jbc.M500270200; Lochhead P, 2012, EUR J CANCER, V48, P3405, DOI 10.1016/j.ejca.2012.06.021; Mongroo PS, 2011, CANCER RES, V71, P2172, DOI 10.1158/0008-5472.CAN-10-3295; Munro TP, 2006, J CELL BIOL, V172, P577, DOI 10.1083/jcb.200510044; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Nielsen J, 2003, BIOCHEM J, V376, P383, DOI 10.1042/BJ20030943; Oleynikov Y, 2003, CURR BIOL, V13, P199, DOI 10.1016/S0960-9822(03)00044-7; Pan F, 2007, MOL CELL BIOL, V27, P8340, DOI 10.1128/MCB.00972-07; Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200; Schaeffer DF, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-59; Seo HR, 2006, CELL DEATH DIFFER, V13, P1475, DOI 10.1038/sj.cdd.4401822; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Stohr N, 2012, GENE DEV, V26, P176, DOI 10.1101/gad.177642.111; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Yisraeli JK, 2005, BIOL CELL, V97, P87	28	33	33	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2866	2875		10.1038/onc.2013.252	http://dx.doi.org/10.1038/onc.2013.252			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23812426				2022-12-17	WOS:000337231800006
J	Hill, KS; Erdogan, E; Khoor, A; Walsh, MP; Leitges, M; Murray, NR; Fields, AP				Hill, K. S.; Erdogan, E.; Khoor, A.; Walsh, M. P.; Leitges, M.; Murray, N. R.; Fields, A. P.			Protein kinase C alpha suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGF beta signaling axis	ONCOGENE			English	Article						tumor suppressor; lung adenocarcinoma; bronchio-alveolar stem cells; p38 MAPK; Wilm's Tumor 1 gene; inhibitors of DNA Binding (Id)	ANTISENSE OLIGONUCLEOTIDE INHIBITOR; SMOOTH-MUSCLE-CELLS; TRANSFORMED GROWTH; K-RAS; MOUSE MODELS; PKC-IOTA; CANCER; SENESCENCE; MICE; EXPRESSION	Protein kinase C alpha (PKC alpha) can activate both pro- and anti-tumorigenic signaling depending upon cellular context. Here, we investigated the role of PKC alpha in lung tumorigenesis in vivo. Gene expression data sets revealed that primary human non-small lung cancers (NSCLC) express significantly decreased PKC alpha levels, indicating that loss of PKC alpha expression is a recurrent event in NSCLC. We evaluated the functional relevance of PKC alpha loss during lung tumorigenesis in three murine lung adenocarcinoma models (LSL-Kras, LA2-Kras and urethane exposure). Genetic deletion of PKC alpha resulted in a significant increase in lung tumor number, size, burden and grade, bypass of oncogene-induced senescence, progression from adenoma to carcinoma and a significant decrease in survival in vivo. The tumor promoting effect of PKC alpha loss was reflected in enhanced Kras-mediated expansion of bronchio-alveolar stem cells (BASCs), putative tumor-initiating cells, both in vitro and in vivo. LSL-Kras/Prkca(-/-) mice exhibited a decrease in phospho-p38 MAPK in BASCs in vitro and in tumors in vivo, and treatment of LSL-Kras BASCs with a p38 inhibitor resulted in increased colony size indistinguishable from that observed in LSL-Kras/Prkca(-/-) BASCs. In addition, LSL-Kras/Prkca(-/-) BASCs exhibited a modest but reproducible increase in TGF beta 1 mRNA, and addition of exogenous TGF beta 1 to LSL-Kras BASCs results in enhanced growth similar to untreated BASCs from LSL-Kras/Prkca(-/-) mice. Conversely, a TGF beta R1 inhibitor reversed the effects of PKC alpha loss in LSL-Kras/Prkca(-/-) BASCs. Finally, we identified the inhibitors of DNA binding (Id) Id1-3 and the Wilm's Tumor 1 as potential downstream targets of PKC alpha-dependent tumor suppressor activity in vitro and in vivo. We conclude that PKC alpha suppresses tumor initiation and progression, at least in part, through a PKC alpha-p38MAPK-TGF beta signaling axis that regulates tumor cell proliferation and Kras-induced senescence. Our results provide the first direct evidence that PKC alpha exhibits tumor suppressor activity in the lung in vivo.	[Hill, K. S.; Erdogan, E.; Walsh, M. P.; Murray, N. R.; Fields, A. P.] Mayo Clin, Dept Canc Biol, Jacksonville, FL 32224 USA; [Khoor, A.] Mayo Clin, Dept Pathol, Jacksonville, FL 32224 USA; [Leitges, M.] Oslo Biotechnol Ctr, Oslo, Norway	Mayo Clinic; Mayo Clinic	Fields, AP (corresponding author), Mayo Clin, Dept Canc Biol, Griffin Canc Res Bldg,Rm 212,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	fields.alan@mayo.edu	Leitges, Michael/AAN-1953-2021	Leitges, Michael/0000-0003-4203-6995; Hill, Kristen/0000-0003-3757-2822	National Cancer Institute [R01 CA081436-16, R01 CA140290-03]; NATIONAL CANCER INSTITUTE [R01CA140290, R01CA081436, P30CA015083] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Brandy Edenfield for immunohistochemical staining procedures, Capella Weems for technical assistance, Justin Weems and Dr Lee Jamieson for animal husbandry and members of the Fields laboratory for support, encouragement and critical review of the manuscript. This work was supported in part by grants from the National Cancer Institute (R01 CA081436-16 to APF and R01 CA140290-03 to NRM). APF is the Monica Flynn Jacoby Endowed Professor of Cancer Research.	Advani R, 2004, CANCER-AM CANCER SOC, V100, P321, DOI 10.1002/cncr.11909; Bivona TG, 2006, MOL CELL, V21, P481, DOI 10.1016/j.molcel.2006.01.012; Cacace AM, 1996, ONCOGENE, V13, P2517; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Dalgaard P, 2008, STAT COMPUT SER, P1, DOI 10.1007/978-0-387-79054-1_1; Dean N, 1996, CANCER RES, V56, P3499; Dehan E, 2007, LUNG CANCER, V56, P175, DOI 10.1016/j.lungcan.2006.12.010; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Erdogan E, 2006, J BIOL CHEM, V281, P28450, DOI 10.1074/jbc.M606054200; Fasbender A, 1998, J CLIN INVEST, V102, P184, DOI 10.1172/JCI2732; Fields AP, 2007, BIOCHEM SOC T, V35, P996, DOI 10.1042/BST0350996; Fields Alan P, 2003, Methods Mol Biol, V233, P519; Fields AP, 2008, ADV ENZYME REGUL, V48, P166, DOI 10.1016/j.advenzreg.2007.11.014; Galvez AS, 2009, MOL CELL BIOL, V29, P104, DOI 10.1128/MCB.01294-08; Geiger T, 1998, ANTI-CANCER DRUG DES, V13, P35; Grossman SA, 2005, NEURO-ONCOLOGY, V7, P32, DOI 10.1215/S1152851703000353; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Hao F, 2011, J BIOL CHEM, V286, P18104, DOI 10.1074/jbc.M110.208488; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Hsieh YH, 2007, CANCER RES, V67, P4320, DOI 10.1158/0008-5472.CAN-06-2486; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Justilien V, 2010, PROTEIN KINASE C IN CANCER SIGNALING AND THERAPY, P455, DOI 10.1007/978-1-60761-543-9_23; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; Kikuchi K, 2013, ONCOGENE, V32, P286, DOI 10.1038/onc.2012.46; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Leitges M, 2002, MOL ENDOCRINOL, V16, P1203; Lindschau C, 2003, HYPERTENSION, V42, P335, DOI 10.1161/01.HYP.0000087839.72582.DD; Luo XP, 2005, ENDOCRINOLOGY, V146, P1097, DOI 10.1210/en.2004-1377; MALKINSON AM, 1985, J NATL CANCER I, V75, P971, DOI 10.1093/jnci/75.5.971; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; Nakagawa M, 2005, J BIOL CHEM, V280, P33926, DOI 10.1074/jbc.M505748200; Nazarenko I, 2010, MOL CANCER RES, V8, P919, DOI 10.1158/1541-7786.MCR-09-0358; Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376; Oliva JL, 2008, J BIOL CHEM, V283, P5466, DOI 10.1074/jbc.M707576200; Oster H, 2006, CANCER RES, V66, P6955, DOI 10.1158/0008-5472.CAN-06-0268; Paz-Ares L, 2006, J CLIN ONCOL, V24, P1428, DOI 10.1200/JCO.2005.04.3299; Pysz MA, 2009, EXP CELL RES, V315, P1415, DOI 10.1016/j.yexcr.2009.02.002; Reddig PJ, 1999, CANCER RES, V59, P5710; Reddig PJ, 2000, CANCER RES, V60, P595; Regala RP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026439; Regala RP, 2009, CANCER RES, V69, P7603, DOI 10.1158/0008-5472.CAN-09-2066; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Sanchez-Palencia A, 2011, INT J CANCER, V129, P355, DOI 10.1002/ijc.25704; Scotti ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030509; Scotti ML, 2010, CANCER RES, V70, P2064, DOI 10.1158/0008-5472.CAN-09-2684; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Stallings-Mann M, 2006, CANCER RES, V66, P1767, DOI 10.1158/0008-5472.CAN-05-3405; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Tossidou I, 2009, CELL PHYSIOL BIOCHEM, V24, P627, DOI 10.1159/000257518; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037; Vicent S, 2010, J CLIN INVEST, V120, P3940, DOI 10.1172/JCI44165; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Yang Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002220; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527	64	33	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2134	2144		10.1038/onc.2013.147	http://dx.doi.org/10.1038/onc.2013.147			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23604119	Green Accepted			2022-12-17	WOS:000334599100012
J	Miura, K; Wakayama, Y; Tanino, M; Orba, Y; Sawa, H; Hatakeyama, M; Tanaka, S; Sabe, H; Mochizuki, N				Miura, K.; Wakayama, Y.; Tanino, M.; Orba, Y.; Sawa, H.; Hatakeyama, M.; Tanaka, S.; Sabe, H.; Mochizuki, N.			Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase	ONCOGENE			English	Article						Shp2; EphA2; Erk; cancer; LEOPARD syndrome	EPIDERMAL-GROWTH-FACTOR; PHOSPHATASE SHP2; LEOPARD-SYNDROME; EPHA2 RECEPTOR; PATHWAY; CANCER; PROTEIN; TARGET; MECHANISM; CELLS	Shp2 is a positive regulator for Erk activation downstream of receptor tyrosine kinases for growth factors. It has been controversial how Shp2 induces Erk activation. We here demonstrate that EphA2 is responsible for Shp2-mediated Erk activation by phosphorylating Tyr542 and Tyr580 of Shp2 in the cells stimulated with growth factors. In NMuMG mammary epithelial cells stimulated with hepatocyte growth factor (HGF), HGF-dependent Erk phosphorylation was prolonged only in the presence of EphA2. This Erk activation paralleled the phosphorylation of Tyr542/580 of Shp2 and the association of Grb2 with Shp2, suggesting the positive signal involving Grb2 signal to activate Ras-Erk pathway. Immunohistochemical studies of mammary cancer specimens revealed that the cancer progression was associated with both Tyr580 phosphorylation of Shp2 and increased expression of EphA2, which were also correlated with increased Erk phosphorylation. Overexpression of either Shp2Thr468Met (a phosphatase-defective mutant found in Lentigines, Electrocardiographic abnormalities, Ocular hypertelorism, Pulmonary stenosis, Abnormal genitalia, Retardation of growth and sensorineural Deafness (LEOPARD) syndrome) or Shp2Asn308Asp (a phosphatase-active mutant found in Noonan syndrome) with EphA2 exhibited comparable activation of Erk and stronger activation than wild-type Shp2, suggesting the phosphatase-independent Erk activation. Expression of Shp2Thr468Met with Tyr542/580Phe mutations resulted in the suppression of Erk activation. Phosphatase-active and -inactive, and wild-type Shp2s bound equally to Grb2, suggesting that phosphorylation of Tyr542/580 of Shp2 was essential but not sufficient for Shp2-mediated Erk activation. We found that Gab1 (Grb2-associated binder 1) was involved in the mutant Shp2-mediated Erk activation. Zebrafish injected with Shp2Thr468Met mRNA showed cardiac edema, whereas those depleted of EphA2b showed less phenotype, suggesting that EphA2 might partly account for the phenotype of LEOPARD syndrome. Collectively, tyrosine phosphorylation of Shp2 by EphA2 contributes to the phosphatase-independent Shp2-mediated activation of Erk and might be involved in Shp2-associated diseases.	[Miura, K.; Wakayama, Y.; Mochizuki, N.] Natl Cerebral & Cardiovasc Ctr, Dept Cell Biol, Res Inst, Suita, Osaka 5658565, Japan; [Tanino, M.; Tanaka, S.] Hokkaido Univ, Grad Sch Med, Lab Canc Res, Dept Pathol,Kita Ku, Sapporo, Hokkaido, Japan; [Orba, Y.; Sawa, H.] Hokkaido Univ, Dept Mol Pathobiol, Res Ctr Zoonosis Control, Sapporo, Hokkaido, Japan; [Hatakeyama, M.] Univ Tokyo, Grad Sch Med, Div Microbiol, Bunkyo Ku, Tokyo, Japan; [Sabe, H.] Hokkaido Univ, Grad Sch Med, Dept Mol Biol, Kita Ku, Sapporo, Hokkaido, Japan	National Cerebral & Cardiovascular Center - Japan; Hokkaido University; Hokkaido University; University of Tokyo; Hokkaido University	Miura, K (corresponding author), Natl Cerebral & Cardiovasc Ctr, Dept Cell Biol, Res Inst, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan.	miurako@ri.ncvc.go.jp; nmochizu@ri.ncvc.go.jp	Sawa, Hirofumi/AAW-8816-2021; Sabe, Hisataka/GPF-4385-2022; Tanaka, Shinya/D-3586-2011; Sawa, Hirofumi/F-6954-2012	Sawa, Hirofumi/0000-0003-2569-2755	Ministry of Education, Science, Sports and Culture of Japan; Ministry of Health, Labor and Welfare of Japan; Takeda Science Foundation; AstraZeneca; Grants-in-Aid for Scientific Research [24590406, 22114001, 22240085, 22114002] Funding Source: KAKEN	Ministry of Education, Science, Sports and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Takeda Science Foundation(Takeda Science Foundation (TSF)); AstraZeneca(AstraZeneca); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank M Matsuda (Kyoto University), T Akagi (KAN Research Institute), T Hirano (Osaka University) and S Kunimoto (Nippon University) for reagents; M Masuda, S Fukuhara and H Fukui for valuable advice; and M Sone, K Hiratomi, M Minamimoto, H Yonekawa, W Koeda and Y Matsuura for technical assistance. This work was supported, in part, by grants from the Ministry of Education, Science, Sports and Culture of Japan; the Ministry of Health, Labor and Welfare of Japan; Takeda Science Foundation; and AstraZeneca Research Grant.	Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; Araujo J, 2010, CANCER TREAT REV, V36, P492, DOI 10.1016/j.ctrv.2010.02.015; Bin Fang W, 2008, J BIOL CHEM, V283, P16017, DOI 10.1074/jbc.M709934200; Brantley-Sieders DM, 2008, J CLIN INVEST, V118, P64, DOI 10.1172/JCI33154; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; Carvajal-Vergara X, 2010, NATURE, V465, P808, DOI 10.1038/nature09005; Cha Y, 2010, FEBS LETT, V584, P4241, DOI 10.1016/j.febslet.2010.09.016; Chan G, 2008, CANCER METAST REV, V27, P179, DOI 10.1007/s10555-008-9126-y; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Dance M, 2008, CELL SIGNAL, V20, P453, DOI 10.1016/j.cellsig.2007.10.002; Edouard T, 2007, CELL MOL LIFE SCI, V64, P1585, DOI 10.1007/s00018-007-6509-0; Grossmann KS, 2010, ADV CANCER RES, V106, P53, DOI 10.1016/S0065-230X(10)06002-1; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Ireton RC, 2005, CURR CANCER DRUG TAR, V5, P149, DOI 10.2174/1568009053765780; Jopling C, 2007, PLOS GENET, V3, P2468, DOI 10.1371/journal.pgen.0030225; Lemeer S, 2007, MOL CELL PROTEOMICS, V6, P2088, DOI 10.1074/mcp.M600482-MCP200; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Stewart RA, 2010, DEV CELL, V18, P750, DOI [10.1016/j.devcel.2010.03.009, 10.1016/j.devce1.2010.03.009]; Tartaglia M, 2010, ANN NY ACAD SCI, V1214, P99, DOI 10.1111/j.1749-6632.2010.05790.x; Tidyman WE, 2009, CURR OPIN GENET DEV, V19, P230, DOI 10.1016/j.gde.2009.04.001; Wang YJ, 2002, BIOCHEM BIOPH RES CO, V296, P214, DOI 10.1016/S0006-291X(02)00806-9	30	33	39	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2013	32	45					5292	5301		10.1038/onc.2012.571	http://dx.doi.org/10.1038/onc.2012.571			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IS	23318428	hybrid			2022-12-17	WOS:000326922100005
J	Lainey, E; Wolfromm, A; Marie, N; Enot, D; Scoazec, M; Bouteloup, C; Leroy, C; Micol, JB; De Botton, S; Galluzzi, L; Fenaux, P; Kroemer, G				Lainey, E.; Wolfromm, A.; Marie, N.; Enot, D.; Scoazec, M.; Bouteloup, C.; Leroy, C.; Micol, J-B; De Botton, S.; Galluzzi, L.; Fenaux, P.; Kroemer, G.			Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia	ONCOGENE			English	Article						ATPase-binding cassette (ABC) transporters; ABT-263; MG-132; MOLM-13; obatoclax; SKM1	ACUTE MYELOGENOUS LEUKEMIA; CELL LUNG-CANCER; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; KINASE INHIBITOR; DOWN-REGULATION; MYELODYSPLASTIC SYNDROMES; APOPTOSIS RESISTANCE; SIGNALING PATHWAYS; DRUG-RESISTANCE; MCL-1	The term myelodysplastic syndrome (MDS) identifies a heterogeneous group of clonal disorders originating from bone marrow stem cells that often progress to acute myeloid leukemia (AML). The reference treatments for MDS include the DNA methyltransferase inhibitors azacytidine and decitabine. Recently, the epidermal growth factor receptor (EGFR) inhibitor erlotinib has been shown to exert antileukemic activity in vitro and in vivo, independent of the EGFR. Thanks to this feature, erlotinib is currently being tested as an antileukemic drug in clinical trials. Here, we report that azacytidine and erlotinib mediate synergistic antineoplastic effects in several primary or secondary (post-MDS) AML cell lines. The combination of azacytidine and erlotinib blocked cell-cycle progression and induced caspase-dependent apoptosis more consistently than either of the two agents alone. These effects were not a consequence of cellular differentiation and could be discriminated from each other, as the former depended on caspases whereas the latter did not. The synergy between azacitidine and erlotinib, which involved the proteasomal degradation of the anti-apoptotic Bcl-2 family members MCL-1 and BCL2L10 and the upregulation of their pro-apoptotic counterpart PUMA, was abolished when azacytidine was replaced by decitabine but persisted when erlotinib was substituted with gefitinib, another EGFR inhibitor. Of note, the intracellular accumulation of azacytidine was exacerbated by both erlotinib and gefitinib, pointing to a pharmacokinetic mechanism of synergy. In approximately half of the cases studied, marrow and circulating blasts from MDS and AML patients, respectively, exhibited hyperadditive cytotoxic responses to the combination of azacytidine and erlotinib. These results strongly suggest that the combination of azacytidine and erlotinib may exert clinically relevant antileukemic effects.	[Lainey, E.; Wolfromm, A.; Enot, D.; Scoazec, M.; Bouteloup, C.; Leroy, C.; Fenaux, P.; Kroemer, G.] INSERM, U848, Villejuif, France; [Lainey, E.; Wolfromm, A.; Enot, D.; Scoazec, M.; Bouteloup, C.; Leroy, C.; Galluzzi, L.; Kroemer, G.] Inst Gustave Roussy, F-94805 Villejuif, France; [Lainey, E.] Hop Robert Debre, AP HP, F-75019 Paris, France; [Wolfromm, A.] Univ Paris 07, Paris, France; [Marie, N.] CNRS, UMR8206, Paris, France; [Marie, N.] INSERM, U705, Paris, France; [Marie, N.] Inst Medicament Toxicol Chim Environm, Lab Neuropsychopharmacol Addict, Paris, France; [Micol, J-B; De Botton, S.] Inst Gustave Roussy, Serv Hematol Clin, F-94805 Villejuif, France; [Galluzzi, L.; Kroemer, G.] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Fenaux, P.] Hop Avicenne, AP HP, Serv Hematol Clin, F-93009 Bobigny, France; [Kroemer, G.] Ctr Rech Cordeliers, Paris, France; [Kroemer, G.] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, PR1, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@orange.fr	Kroemer, Guido/AAY-9859-2020; Galluzzi, Lorenzo/AAG-6294-2019; Marie, Nicolas/I-9129-2014; KROEMER, Guido/B-4263-2013; Galluzzi, Lorenzo/AAG-6432-2019; Galluzzi, Lorenzo/AAH-3286-2021	Marie, Nicolas/0000-0002-6491-9898; KROEMER, Guido/0000-0002-9334-4405; 	Ligue Nationale contre le Cancer (Equipe labellisee); Agence Nationale pour la Recherche (ANR AUTOPH, ANR Emergence); European Commission (ChemoRes, ArtForce); Fondation de France; Institut National du Cancer (INCa); Canceropole Ile-de-France; Fondation Bettencourt-Schueller; LabEx Immuno-Oncology; Institut National de la Sante et de la recherche Medicale; Association de recherche sur le cancer (ARC); Fondation de la Recherche Medicale (FRM)	Ligue Nationale contre le Cancer (Equipe labellisee)(Ligue nationale contre le cancer); Agence Nationale pour la Recherche (ANR AUTOPH, ANR Emergence)(French National Research Agency (ANR)); European Commission (ChemoRes, ArtForce); Fondation de France(Fondation de France); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Canceropole Ile-de-France(Region Ile-de-France); Fondation Bettencourt-Schueller; LabEx Immuno-Oncology; Institut National de la Sante et de la recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Association de recherche sur le cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Fondation de la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale)	GK is supported by the Ligue Nationale contre le Cancer (Equipe labellisee), Agence Nationale pour la Recherche (ANR AUTOPH, ANR Emergence), European Commission (ChemoRes, ArtForce), Fondation de France, Institut National du Cancer (INCa), Canceropole Ile-de-France, Fondation Bettencourt-Schueller and the LabEx Immuno-Oncology. EL receives a PhD fellowship from Institut National de la Sante et de la recherche Medicale, AW is supported by a fellowship from Association de recherche sur le cancer (ARC) and MS by Fondation de la Recherche Medicale (FRM).	Aimiuwu J, 2012, BLOOD, V119, P5229, DOI 10.1182/blood-2011-11-382226; Boehrer S, 2008, BLOOD, V111, P2170, DOI 10.1182/blood-2007-07-100362; Boehrer S, 2011, CELL CYCLE, V10, P3168, DOI 10.4161/cc.10.18.16599; Boehrer S, 2008, BIOCHEM PHARMACOL, V76, P1417, DOI 10.1016/j.bcp.2008.05.024; Chan G, 2007, BLOOD, V110, P1079, DOI 10.1182/blood-2007-01-069856; Chapuis N, 2010, CLIN CANCER RES, V16, P5424, DOI 10.1158/1078-0432.CCR-10-1102; Chen LS, 2011, BLOOD, V118, P693, DOI 10.1182/blood-2010-12-323022; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cluzeau T, 2012, ONCOTARGET, V3, P490; Criollo A, 2007, APOPTOSIS, V12, P3, DOI 10.1007/s10495-006-0328-x; Eghtedar A, 2012, BLOOD, V119, P4614, DOI 10.1182/blood-2011-12-400051; Fabiani E, 2010, LEUKEMIA LYMPHOMA, V51, P2275, DOI 10.3109/10428194.2010.528093; Fabre C, 2008, CELL CYCLE, V7, P2139, DOI 10.4161/cc.7.14.6268; Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Galluzzi L, 2007, APOPTOSIS, V12, P803, DOI 10.1007/s10495-007-0720-1; Galluzzi L, 2012, NAT REV DRUG DISCOV, V11, P215, DOI 10.1038/nrd3626; Galluzzi L, 2010, CANCER RES, V70, P1793, DOI 10.1158/0008-5472.CAN-09-3112; Glaser SP, 2012, GENE DEV, V26, P120, DOI 10.1101/gad.182980.111; Hoffmann J, 2008, CANCER RES, V68, P5301, DOI 10.1158/0008-5472.CAN-08-0237; Huber S, 2011, LEUKEMIA, V25, P838, DOI 10.1038/leu.2011.2; Jemaa M, 2012, EMBO MOL MED, V4, P500, DOI 10.1002/emmm.201200228; Kepp O, 2011, NAT REV DRUG DISCOV, V10, P221, DOI 10.1038/nrd3373; Kimura S, 2012, ANTICANCER RES, V32, P795; Klimek VM, 2012, LEUKEMIA RES, V36, P1093, DOI 10.1016/j.leukres.2012.04.025; Komrokji RS, 2010, BLOOD, V116; Kornblau SM, 2006, BLOOD, V108, P2358, DOI 10.1182/blood-2006-02-003475; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Lainey E, 2011, BIOCHEM PHARMACOL, V82, P1457, DOI 10.1016/j.bcp.2011.05.011; Lee JJ, 2009, STAT BIOPHARM RES, V1, P4, DOI 10.1198/sbr.2009.0001; Meng XW, 2007, J BIOL CHEM, V282, P29831, DOI 10.1074/jbc.M706110200; Noguchi K, 2009, CANCER SCI, V100, P1701, DOI 10.1111/j.1349-7006.2009.01213.x; Pitini V, 2008, J CLIN ONCOL, V26, P3645, DOI 10.1200/JCO.2008.17.0357; Rahmani M, 2005, J BIOL CHEM, V280, P35217, DOI 10.1074/jbc.M506551200; Rahmani M, 2012, BLOOD, V119, P6089, DOI 10.1182/blood-2011-09-378141; Rosen DB, 2012, LEUKEMIA RES, V36, P900, DOI 10.1016/j.leukres.2012.02.022; Rouge TD, 2007, CANCER RES, V67, P6253, DOI 10.1158/0008-5472.CAN-07-0538; Sansonetti A, 2012, LEUKEMIA RES, V36, P358, DOI 10.1016/j.leukres.2011.09.022; Scholl C, 2008, SEMIN ONCOL, V35, P336, DOI 10.1053/j.seminoncol.2008.04.004; Shi Z, 2007, CANCER RES, V67, P11012, DOI 10.1158/0008-5472.CAN-07-2686; Stegmaier K, 2005, BLOOD, V106, P2841, DOI 10.1182/blood-2005-02-0488; Tefferi A, 2009, NAT REV CLIN ONCOL, V6, P627, DOI 10.1038/nrclinonc.2009.149; van Stijn A, 2003, HAEMATOLOGICA, V88, P497; Weber C, 2012, J PROTEOMICS, V75, P1343, DOI 10.1016/j.jprot.2011.11.004; Weisberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025351; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yu CR, 2005, ONCOGENE, V24, P6861, DOI 10.1038/sj.onc.1208841; Zantl N, 2007, ONCOGENE, V26, P7038, DOI 10.1038/sj.onc.1210510	48	33	35	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2013	32	37					4331	4342		10.1038/onc.2012.469	http://dx.doi.org/10.1038/onc.2012.469			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23085751				2022-12-17	WOS:000324404200002
J	Skalka, N; Caspi, M; Caspi, E; Loh, YP; Rosin-Arbesfeld, R				Skalka, N.; Caspi, M.; Caspi, E.; Loh, Y. P.; Rosin-Arbesfeld, R.			Carboxypeptidase E: a negative regulator of the canonical Wnt signaling pathway	ONCOGENE			English	Article						Wnt signaling; carboxypeptidase E (CPE); beta-catenin; functional screen	NEUROPEPTIDE-PROCESSING ENZYME; BETA-CATENIN; SECRETORY GRANULES; CANCER CELLS; AXIN; POLYMERIZATION; TRANSDUCTION; ENDOCRINE; MUTATIONS; PROTEINS	Aberrant activation of the canonical Wnt signal transduction pathway is involved in many diseases including cancer and is especially implicated in the development and progression of colorectal cancer. The key effector protein of the canonical Wnt pathway is beta-catenin, which functions with T-cell factor/lymphoid enhancer factor to activate expression of Wnt target genes. In this study, we used a new functional screen based on cell survival in the presence of cDNAs encoding proteins that activate the Wnt pathway thus identifying novel Wnt signaling components. Here we identify carboxypeptidase E (vertical bar CPE) and its splice variant, Delta N-CPE, as novel regulators of the Wnt pathway. We show that whereas Delta N-CPE activates the Wnt signal, the full-length CPE (F-CPE) protein is an inhibitor of Wnt/beta-catenin signaling. F-CPE forms a complex with the Wnt3a ligand and the Frizzled receptor. Moreover, F-CPE disrupts disheveled-induced signalosomes that are important for transducing the Wnt signal and reduces beta-catenin protein levels and activity. Taken together, our data indicate that F-CPE and Delta N-CPE regulate the canonical Wnt signaling pathway negatively and positively, respectively, and demonstrate that this screening approach can be a rapid means for isolation of novel Wnt signaling components.	[Skalka, N.; Caspi, M.; Caspi, E.; Rosin-Arbesfeld, R.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Loh, Y. P.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Cellular Neurobiol, Program Dev Neurosci, NIH, Bethesda, MD USA	Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Rosin-Arbesfeld, R (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.	arina@post.tau.ac.il			Israel Science Foundation; Public Committee for Allocation of Estate Funds, Ministry of Justice, Israel [20120016]; Recanati Foundation; Israel Cancer Association through the Estate of the late Alexander Smidoda; US-Israel Binational Science Foundation; Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008804, ZIAHD000056] Funding Source: NIH RePORTER	Israel Science Foundation(Israel Science Foundation); Public Committee for Allocation of Estate Funds, Ministry of Justice, Israel; Recanati Foundation; Israel Cancer Association through the Estate of the late Alexander Smidoda; US-Israel Binational Science Foundation(US-Israel Binational Science Foundation); Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by the Israel Science Foundation, by grant no. 20120016 from the Public Committee for Allocation of Estate Funds, Ministry of Justice, Israel, the Recanati Foundation, Israel Cancer Association through the Estate of the late Alexander Smidoda, US-Israel Binational Science Foundation and in part by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development to YPL.	Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Cawley NX, 2012, ENDOCR REV, V33, P216, DOI 10.1210/er.2011-1039; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cliffe A, 2003, CURR BIOL, V13, P960, DOI 10.1016/S0960-9822(03)00370-1; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Dobrowolski R, 2012, NAT REV MOL CELL BIO, V13, P53, DOI 10.1038/nrm3244; Du JL, 2001, CANCER LETT, V165, P211, DOI 10.1016/S0304-3835(01)00409-8; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; FRICKER LD, 1983, J BIOL CHEM, V258, P950; FRICKER LD, 1993, J NEUROCHEM, V61, P1404, DOI 10.1111/j.1471-4159.1993.tb13634.x; Golan T, 2004, J BIOL CHEM, V279, P14879, DOI 10.1074/jbc.M306421200; Hausmann G, 2007, NAT REV MOL CELL BIO, V8, P331, DOI 10.1038/nrm2141; He P, 2004, HUM PATHOL, V35, P1196, DOI 10.1016/j.humpath.2004.06.014; Horing E, 2012, ACTA NEUROPATHOL, V124, P83, DOI 10.1007/s00401-011-0940-x; Lee TK, 2011, J CLIN INVEST, V121, P880, DOI 10.1172/JCI40433; Liu YT, 2011, J BIOL CHEM, V286, P8597, DOI 10.1074/jbc.M110.186742; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Metcalfe C, 2011, J CELL SCI, V124, P3537, DOI 10.1242/jcs.091991; Metcalfe C, 2010, J CELL SCI, V123, P1588, DOI 10.1242/jcs.067546; Moeller C, 2003, DEVELOPMENT, V130, P5103, DOI 10.1242/dev.00686; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Murthy SRK, 2010, CELL MOL NEUROBIOL, V30, P1377, DOI 10.1007/s10571-010-9592-y; Murthy SR, 2012, AACR ANN M 2012 CHIC; Park J, 2009, J MOL NEUROSCI, V37, P151, DOI 10.1007/s12031-008-9098-y; Polakis P, 2000, GENE DEV, V14, P1837; Reznik SE, 2001, CELL MOL LIFE SCI, V58, P1790, DOI 10.1007/PL00000819; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Schwarz-Romond T, 2007, J CELL SCI, V120, P2402, DOI 10.1242/jcs.002956; Schwarz-Romond T, 2007, NAT STRUCT MOL BIOL, V14, P484, DOI 10.1038/nsmb1247; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; STROUS GJAM, 1983, J CELL BIOL, V97, P1815, DOI 10.1083/jcb.97.6.1815; Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tang SS, 2009, MOL CELL ENDOCRINOL, V303, P43, DOI 10.1016/j.mce.2009.01.020; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wang L, 2009, J BONE MINER RES, V24, P265, DOI [10.1359/jbmr.081014, 10.1359/JBMR.081014]; Zeng X, 2008, DEVELOPMENT, V135, P367, DOI 10.1242/dev.013540	39	33	35	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 6	2013	32	23					2836	2847		10.1038/onc.2012.308	http://dx.doi.org/10.1038/onc.2012.308			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WR	22824791	Green Accepted			2022-12-17	WOS:000320369100004
J	Rodriguez-Blanco, J; Schilling, NS; Tokhunts, R; Giambelli, C; Long, J; Fei, DL; Singh, S; Black, KE; Wang, Z; Galimberti, F; Bejarano, PA; Elliot, S; Glassberg, MK; Nguyen, DM; Lockwood, WW; Lam, WL; Dmitrovsky, E; Capobianco, AJ; Robbins, DJ				Rodriguez-Blanco, J.; Schilling, N. S.; Tokhunts, R.; Giambelli, C.; Long, J.; Fei, D. Liang; Singh, S.; Black, K. E.; Wang, Z.; Galimberti, F.; Bejarano, P. A.; Elliot, S.; Glassberg, M. K.; Nguyen, D. M.; Lockwood, W. W.; Lam, W. L.; Dmitrovsky, E.; Capobianco, A. J.; Robbins, D. J.			The Hedgehog processing pathway is required for NSCLC growth and survival	ONCOGENE			English	Article						dispatched; lung cancer; hedgehog; hedgehog acyltransferase; skinny hedgehog	BASAL-CELL CARCINOMA; SMALL-MOLECULE MODULATION; HUMAN SONIC HEDGEHOG; LUNG-CANCER; SIGNALING PATHWAY; LONG-RANGE; CHROMOSOMAL IMBALANCES; ANIMAL DEVELOPMENT; GENE-EXPRESSION; HUMAN HOMOLOG	Considerable interest has been generated from the results of recent clinical trials using smoothened (SMO) antagonists to inhibit the growth of hedgehog (HH) signaling-dependent tumors. This interest is tempered by the discovery of SMO mutations mediating resistance, underscoring the rationale for developing therapeutic strategies that interrupt HH signaling at levels distinct from those inhibiting SMO function. Here, we demonstrate that HH-dependent non-small cell lung carcinoma (NSCLC) growth is sensitive to blockade of the HH pathway upstream of SMO, at the level of HH ligand processing. Individually, the use of different lentivirally delivered shRNA constructs targeting two functionally distinct HH-processing proteins, skinny hedgehog (SKN) or dispatched-1 (DISP-1), in NSCLC cell lines produced similar decreases in cell proliferation and increased cell death. Further, providing either an exogenous source of processed HH or a SMO agonist reverses these effects. The attenuation of HH processing, by knocking down either of these gene products, also abrogated tumor growth in mouse xenografts. Finally, we extended these findings to primary clinical specimens, showing that SKN is frequently overexpressed in NSCLC and that higher DISP-1 expression is associated with an unfavorable clinical outcome. Our results show a critical role for HH processing in HH-dependent tumors, identifies two potential druggable targets in the HH pathway, and suggest that similar therapeutic strategies could be explored to treat patients harboring HH ligand-dependent cancers.	[Rodriguez-Blanco, J.; Schilling, N. S.; Tokhunts, R.; Giambelli, C.; Long, J.; Fei, D. Liang; Singh, S.; Black, K. E.; Wang, Z.; Nguyen, D. M.; Capobianco, A. J.; Robbins, D. J.] Univ Miami, Dept Surg, Mol Oncol Program, Miami, FL 33136 USA; [Schilling, N. S.; Tokhunts, R.; Fei, D. Liang; Galimberti, F.; Dmitrovsky, E.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03756 USA; [Bejarano, P. A.] Univ Miami, Dept Pathol, Miami, FL 33136 USA; [Elliot, S.] Univ Miami, Dept Surg, Lab Sex & Gender Differences Hlth & Dis, Miami, FL 33136 USA; [Glassberg, M. K.] Univ Miami, Jackson Mem Hosp, Dept Med, Miami, FL 33136 USA; [Glassberg, M. K.] Univ Miami, Jackson Mem Hosp, Dept Surg, Miami, FL 33136 USA; [Nguyen, D. M.; Capobianco, A. J.; Robbins, D. J.] Univ Miami, Miller Sch Med, Sylvester Canc Ctr, Miami, FL 33136 USA; [Lockwood, W. W.] NHGRI, Canc Genet Branch, Bethesda, MD 20892 USA; [Lam, W. L.] British Columbia Canc Res Ctr, Dept Integrat Biol, Vancouver, BC V5Z 1L3, Canada; [Dmitrovsky, E.] Dartmouth Med Sch, Norris Cotton Canc Ctr, Lebanon, NH USA; [Dmitrovsky, E.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA; [Robbins, D. J.] Univ Miami, Dept Biochem & Mol Biol, Miami, FL 33136 USA	University of Miami; Dartmouth College; University of Miami; University of Miami; University of Miami; University of Miami; University of Miami; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); British Columbia Cancer Agency; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; University of Miami	Robbins, DJ (corresponding author), Univ Miami, Miller Sch Med, Sylvester Canc Ctr, 1042 RMSB,1600 NW 10th Ave, Miami, FL 33136 USA.	drobbins@med.miami.edu	Lockwood, William W/A-2879-2009; LONG, JUN/N-7270-2015; Singh, Samer/H-8468-2013; Wang, Zhiqiang/O-6810-2014; Rodriguez, Jezabel/B-7613-2019; Long, Jun/S-2382-2019	Singh, Samer/0000-0002-0921-1686; Rodriguez, Jezabel/0000-0003-1839-6181; Long, Jun/0000-0002-8229-9653; Capobianco, Anthony/0000-0002-3706-6797; Fei, Dennis Liang/0000-0002-1953-0584	NIH [GM64011, R03-CA132166, R01-CA087546, R01-CA111422]; Samuel Waxman Cancer Research Foundation; American Lung Association/LUNGevity Foundation;  [FICYT-POST10-27]; NATIONAL CANCER INSTITUTE [R01CA111422, R01CA087546, P30CA023108, R03CA132166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM064011, R01GM064011] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Samuel Waxman Cancer Research Foundation; American Lung Association/LUNGevity Foundation; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the NIH grants GM64011 (DJ Robbins), R03-CA132166 (E Dmitrovsky), R01-CA087546 (E Dmitrovsky) and R01-CA111422 (E Dmitrovsky); grants from the Samuel Waxman Cancer Research Foundation (E Dmitrovsky, A Capobianco); FICYT-POST10-27 (J Rodriguez-Blanco) and from the American Lung Association/LUNGevity Foundation (DJ Robbins). E Dmitrovsky is an American Cancer Society Professor supported by a generous gift from the FM Kirby Foundation.	Adolphe C, 2006, CANCER RES, V66, P2081, DOI 10.1158/0008-5472.CAN-05-2146; Amanai K, 2001, DEVELOPMENT, V128, P5119; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Buglino JA, 2008, J BIOL CHEM, V283, P22076, DOI 10.1074/jbc.M803901200; Burke R, 1999, CELL, V99, P803, DOI 10.1016/S0092-8674(00)81677-3; Caspary T, 2002, CURR BIOL, V12, P1628, DOI 10.1016/S0960-9822(02)01147-8; Chamoun Z, 2001, SCIENCE, V293, P2080, DOI 10.1126/science.1064437; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Chen MH, 2004, GENE DEV, V18, P641, DOI 10.1101/gad.1185804; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Dijkgraaf GJP, 2011, CANCER RES, V71, P435, DOI 10.1158/0008-5472.CAN-10-2876; Farzan SF, 2008, AM J PHYSIOL-GASTR L, V294, pG844, DOI 10.1152/ajpgi.00564.2007; Fei DL, 2010, CANCER RES, V70, P1981, DOI 10.1158/0008-5472.CAN-09-2898; Fernandez C, 2010, DEV NEUROSCI-BASEL, V32, P59, DOI 10.1159/000274458; Gialmanidis IP, 2009, LUNG CANCER, V66, P64, DOI 10.1016/j.lungcan.2009.01.007; Goetz JA, 2006, J BIOL CHEM, V281, P4087, DOI 10.1074/jbc.M511427200; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Katoh Y, 2009, CURR MOL MED, V9, P873, DOI 10.2174/156652409789105570; Kawakami T, 2002, DEVELOPMENT, V129, P5753, DOI 10.1242/dev.00178; Kohtz JD, 2001, DEVELOPMENT, V128, P2351; Kubo M, 2004, CANCER RES, V64, P6071, DOI 10.1158/0008-5472.CAN-04-0416; Kuner R, 2009, LUNG CANCER, V63, P32, DOI 10.1016/j.lungcan.2008.03.033; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Lauth M, 2010, NAT STRUCT MOL BIOL, V17, P718, DOI 10.1038/nsmb.1833; Lee ES, 2008, CLIN CANCER RES, V14, P7397, DOI 10.1158/1078-0432.CCR-07-4937; Lee JD, 2001, CURR BIOL, V11, P1147, DOI 10.1016/S0960-9822(01)00323-2; LEGRAND C, 1992, J BIOTECHNOL, V25, P231, DOI 10.1016/0168-1656(92)90158-6; Liu X, 2009, CLIN CANCER RES, V15, P1177, DOI 10.1158/1078-0432.CCR-08-1355; Lockwood WW, 2010, PLOS MED, V7; Low JA, 2010, J CLIN ONCOL, V28, P5321, DOI 10.1200/JCO.2010.27.9943; Ma Y, 2002, CELL, V111, P63, DOI 10.1016/S0092-8674(02)00977-7; Ma Y, 2007, P NATL ACAD SCI USA, V104, P4089, DOI 10.1073/pnas.0606537104; Mann RK, 2004, ANNU REV BIOCHEM, V73, P891, DOI 10.1146/annurev.biochem.73.011303.073933; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Mas C, 2010, BIOCHEM PHARMACOL, V80, P712, DOI 10.1016/j.bcp.2010.04.016; Micchelli CA, 2002, DEVELOPMENT, V129, P843; Miura GI, 2006, DEV CELL, V10, P167, DOI 10.1016/j.devcel.2005.11.017; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Neal JW, 2010, CURR TREAT OPTION ON, V11, P36, DOI 10.1007/s11864-010-0120-6; Ng JMY, 2011, NAT REV CANCER, V11, P493, DOI 10.1038/nrc3079; Park KS, 2011, NAT MED, V17, P1504, DOI 10.1038/nm.2473; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Petersen I, 1997, CANCER RES, V57, P2331; Petty WJ, 2005, J NATL CANCER I, V97, P1645, DOI 10.1093/jnci/dji371; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Quirk J, 1997, COLD SPRING HARB SYM, V62, P217; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Shen TL, 1999, HUM PATHOL, V30, P284, DOI 10.1016/S0046-8177(99)90006-0; Singh S, 2011, CANCER RES, V71, P4454, DOI 10.1158/0008-5472.CAN-10-2313; Singh S, 2009, HUM GENET, V125, P95, DOI 10.1007/s00439-008-0599-0; Sinha S, 2006, NAT CHEM BIOL, V2, P29, DOI 10.1038/nchembio753; Stanton BZ, 2010, MOL BIOSYST, V6, P44, DOI 10.1039/b910196a; Stecca B, 2010, J MOL CELL BIOL, V2, P84, DOI 10.1093/jmcb/mjp052; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Tai ALS, 2004, CANCER, V100, P1918, DOI 10.1002/cncr.20190; Taylor FR, 2001, BIOCHEMISTRY-US, V40, P4359, DOI 10.1021/bi002487u; Teglund S, 2010, BBA-REV CANCER, V1805, P181, DOI 10.1016/j.bbcan.2010.01.003; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tostar U, 2006, J PATHOL, V208, P17, DOI 10.1002/path.1882; Von Hoff DD, 2009, NEW ENGL J MED, V361, P1164, DOI 10.1056/NEJMoa0905360; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Xie JW, 1997, CANCER RES, V57, P2369; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yang L, 2010, ONCOGENE, V29, P469, DOI 10.1038/onc.2009.392; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386; Yuan Z, 2007, ONCOGENE, V26, P1046, DOI 10.1038/sj.onc.1209860; Zeng X, 2001, NATURE, V411, P716, DOI 10.1038/35079648; Zhang XM, 2001, CELL, V105, P781, DOI 10.1016/S0092-8674(01)00385-3	79	33	33	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2013	32	18					2335	2345		10.1038/onc.2012.243	http://dx.doi.org/10.1038/onc.2012.243			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22733134	Green Accepted			2022-12-17	WOS:000318683600010
J	Colas, E; Muinelo-Romay, L; Alonso-Alconada, L; Llaurado, M; Monge, M; Barbazan, J; Gonzalez, M; Schoumacher, M; Pedrola, N; Ertekin, T; Devis, L; Ruiz, A; Castellvi, J; Doll, A; Gil-Moreno, A; Vazquez-Levin, M; Lapyckyj, L; Lopez-Lopez, R; Robine, S; Friederich, E; Castro, M; Reventos, J; Vignjevic, D; Abal, M				Colas, E.; Muinelo-Romay, L.; Alonso-Alconada, L.; Llaurado, M.; Monge, M.; Barbazan, J.; Gonzalez, M.; Schoumacher, M.; Pedrola, N.; Ertekin, T.; Devis, L.; Ruiz, A.; Castellvi, J.; Doll, A.; Gil-Moreno, A.; Vazquez-Levin, M.; Lapyckyj, L.; Lopez-Lopez, R.; Robine, S.; Friederich, E.; Castro, M.; Reventos, J.; Vignjevic, D.; Abal, M.			ETV5 cooperates with LPP as a sensor of extracellular signals and promotes EMT in endometrial carcinomas	ONCOGENE			English	Article						ETV5; EMT; LPP; carcinoma invasion; endometrial cancer	EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTOR; MYOMETRIAL INFILTRATION; CELL-ADHESION; UP-REGULATION; CANCER; FIBROBLASTS; PROGRESSION; EXPRESSION; INITIATION	Endometrial carcinoma (EC) is the most frequent among infiltrating tumors of the female genital tract, with myometrial invasion representing an increase in the rate of recurrences and a decrease in survival. We have previously described ETV5 transcription factor associated with myometrial infiltration in human ECs. In this work, we further investigated ETV5 orchestrating downstream effects to confer the tumor the invasive capabilities needed to disseminate in the early stages of EC dissemination. Molecular profiling evidenced ETV5 having a direct role on epithelial-to-mesenchymal transition (EMT). In particular, ETV5 modulated Zeb1 expression and E-Cadherin repression leading to a complete reorganization of cell-cell and cell-substrate contacts. ETV5-promoted EMT resulted in the acquisition of migratory and invasive capabilities in endometrial cell lines. Furthermore, we identified the lipoma-preferred partner protein as a regulatory partner of ETV5, acting as a sensor for extracellular signals promoting tumor invasion. All together, we propose ETV5-transcriptional regulation of the EMT process through a crosstalk with the tumor surrounding microenvironment, as a principal event initiating EC invasion.	[Muinelo-Romay, L.; Alonso-Alconada, L.; Barbazan, J.; Lopez-Lopez, R.; Abal, M.] Complexo Hosp Univ Santiago SERGAS, Dept Med Oncol, Translat Lab, Santiago De Compostela 15706, Spain; [Colas, E.; Llaurado, M.; Monge, M.; Gonzalez, M.; Pedrola, N.; Ertekin, T.; Devis, L.; Ruiz, A.; Doll, A.; Reventos, J.; Abal, M.] Vall dHebron Univ Hosp, Res Inst, Biomed Res Unit, Barcelona, Spain; [Schoumacher, M.; Robine, S.; Vignjevic, D.] Inst Curie, CNRS, UMR 144, F-75231 Paris, France; [Castellvi, J.] Vall dHebron Univ Hosp, Dept Gynecol Oncol, Barcelona, Spain; [Gil-Moreno, A.] Vall dHebron Univ Hosp, Dept Pathol, Barcelona, Spain; [Vazquez-Levin, M.; Lapyckyj, L.] Consejo Nacl Invest Cient & Tecn, Natl Res Council Argentina, Inst Biol & Med Expt, RA-1033 Buenos Aires, DF, Argentina; [Friederich, E.] Univ Luxembourg, Life Sci Res Unit, Luxembourg, Luxembourg; [Castro, M.] Univ Santiago de Compostela, Dept Pharmacol, BioFarma Res Grp, Santiago De Compostela, Spain; [Colas, E.; Gil-Moreno, A.; Reventos, J.] Univ Autonoma Barcelona, E-08193 Barcelona, Spain	Complexo Hospitalario Universitario de Santiago de Compostela; Hospital Universitari Vall d'Hebron; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; University of Luxembourg; Universidade de Santiago de Compostela; Autonomous University of Barcelona	Abal, M (corresponding author), Complexo Hosp Univ Santiago SERGAS, Dept Med Oncol, Translat Lab, Trav Choupana S-N, Santiago De Compostela 15706, Spain.	miguel.abal.posada@sergas.es	Vignjevic, Danijela/L-9721-2017; Castro, Marián/K-5747-2014; Doll, Andreas/I-1449-2012; Jauregui, Laura Devis/ABH-5740-2020; Castellvi, Josep/C-5092-2014; Barbazán, Jorge/AAM-3263-2020; Monge, Marta/I-3667-2015; vignjevic, Danijela Matic/R-5160-2019; Gil-Moreno, Antonio/C-1122-2016	Castro, Marián/0000-0002-4732-1966; Castellvi, Josep/0000-0001-5745-9996; Barbazán, Jorge/0000-0002-7165-8497; Monge, Marta/0000-0002-9839-4903; vignjevic, Danijela Matic/0000-0003-4250-703X; Gil-Moreno, Antonio/0000-0003-1106-5590; Lopez Lopez, Rafael/0000-0003-1315-655X; Devis-Jauregui, Laura/0000-0003-3736-3983; Doll, Andreas/0000-0001-8965-8682; Abal Posada, Miguel/0000-0003-3533-7781	Spanish Ministry of Science and Innovation [SAF 2005-06771, SAF 2008-03996]; Spanish Ministry of Health [RTICC RD06/0020/0058, CP08/00142, PI08/0797]; European Commission Program Fondo Europeo de Desarrollo Regional (FEDER); Catalan Institute of Health [DURSI 2005SGR00553]; Fundacio La Marato de TV3 [050431]; ACCIO [RDITSCON07-1-0001]; AECC; National Programme of Biotecnology [FIT-010000-2007-26]; Basque Government (Spain); Spanish Ministry of Education and Science	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); European Commission Program Fondo Europeo de Desarrollo Regional (FEDER); Catalan Institute of Health; Fundacio La Marato de TV3; ACCIO; AECC; National Programme of Biotecnology; Basque Government (Spain)(Basque Government); Spanish Ministry of Education and Science(Spanish Government)	This work was supported by the Spanish Ministry of Science and Innovation (SAF 2005-06771; SAF 2008-03996), Spanish Ministry of Health (RTICC RD06/0020/0058; CP08/00142, PI08/0797), European Commission Program Fondo Europeo de Desarrollo Regional (FEDER), Catalan Institute of Health (DURSI 2005SGR00553), Fundacio La Marato de TV3 (grant 050431), ACCIO (RDITSCON07-1-0001), AECC (Grupos Estables de Investigacion 2011) and National Programme of Biotecnology (FIT-010000-2007-26). LAA and JB are recipients of fellowships from the Basque Government (Spain) and the Spanish Ministry of Education and Science, respectively.	Abal M, 2007, CLIN TRANSL ONCOL, V9, P272, DOI 10.1007/s12094-007-0054-z; Castilla MA, 2011, J PATHOL, V223, P72, DOI 10.1002/path.2802; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Chacon MR, 2011, CELL ADHES MIGR, V5, P52, DOI 10.4161/cam.5.1.13681; de Launoit Y, 2006, BBA-REV CANCER, V1766, P79, DOI 10.1016/j.bbcan.2006.02.002; Eo J, 2008, J ENDOCRINOL, V198, P281, DOI 10.1677/JOE-08-0142; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Guo BQ, 2006, MOL CELL BIOL, V26, P4529, DOI 10.1128/MCB.01667-05; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hurt EM, 2008, MOL CELL BIOCHEM, V318, P89, DOI 10.1007/s11010-008-9860-z; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Llaurado M, 2012, INT J CANCER, V130, P1532, DOI 10.1002/ijc.26148; Monge M, 2007, CANCER RES, V67, P6753, DOI 10.1158/0008-5472.CAN-06-4487; Monge M, 2009, J PROTEOME RES, V8, P4676, DOI 10.1021/pr900390t; Monge M, 2009, CARCINOGENESIS, V30, P1288, DOI 10.1093/carcin/bgp119; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Muinelo-Romay L, 2011, MOL CANCER THER, V10, P1357, DOI 10.1158/1535-7163.MCT-10-1019; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Petit MMR, 2003, J BIOL CHEM, V278, P2157, DOI 10.1074/jbc.M206106200; Petit MMR, 2000, MOL BIOL CELL, V11, P117, DOI 10.1091/mbc.11.1.117; Planaguma J, 2004, CANCER RES, V64, P8846, DOI 10.1158/0008-5472.CAN-04-2066; Planaguma J, 2005, J PATHOL, V207, P422, DOI 10.1002/path.1853; Prat J, 2004, HUM PATHOL, V35, P649, DOI 10.1016/j.humpath.2004.02.007; Radisky DC, 2007, J CELL BIOCHEM, V101, P830, DOI 10.1002/jcb.21186; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Sivridis E, 2001, ANTICANCER RES, V21, P4383; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Stoletov K, 2010, J CELL SCI, V123, P2332, DOI 10.1242/jcs.069443; Swart GWM, 2005, CANCER METAST REV, V24, P223, DOI 10.1007/s10555-005-1573-0; Tavora B, 2010, EMBO MOL MED, V2, P516, DOI 10.1002/emmm.201000106; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2004, NAT MED, V10, P777, DOI 10.1038/nm0804-777; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Tsukamoto H, 2007, CLIN EXP METASTAS, V24, P423, DOI 10.1007/s10585-007-9079-5; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009	43	33	34	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	45					4778	4788		10.1038/onc.2011.632	http://dx.doi.org/10.1038/onc.2011.632			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036NF	22266854	Green Published			2022-12-17	WOS:000311033000006
J	Gaude, H; Aznar, N; Delay, A; Bres, A; Buchet-Poyau, K; Caillat, C; Vigouroux, A; Rogon, C; Woods, A; Vanacker, JM; Hohfeld, J; Perret, C; Meyer, P; Billaud, M; Forcet, C				Gaude, H.; Aznar, N.; Delay, A.; Bres, A.; Buchet-Poyau, K.; Caillat, C.; Vigouroux, A.; Rogon, C.; Woods, A.; Vanacker, J-M; Hoehfeld, J.; Perret, C.; Meyer, P.; Billaud, M.; Forcet, C.			Molecular chaperone complexes with antagonizing activities regulate stability and activity of the tumor suppressor LKB1	ONCOGENE			English	Article						LKB1; Hsp90; CHIP; tumor suppressor; chaperones	ACTIVATED PROTEIN-KINASE; PEUTZ-JEGHERS-SYNDROME; E3 UBIQUITIN LIGASE; HEAT-SHOCK PROTEINS; QUALITY-CONTROL; SPLICE VARIANT; CELL STRUCTURE; HSP90; CHIP; INHIBITION	LKB1 is a tumor suppressor that is constitutionally mutated in a cancer-prone condition, called Peutz-Jeghers syndrome, as well as somatically inactivated in a sizeable fraction of lung and cervical neoplasms. The LKB1 gene encodes a serine/threonine kinase that associates with the pseudokinase STRAD (STE-20-related pseudokinase) and the scaffolding protein MO25, the formation of this heterotrimeric complex promotes allosteric activation of LKB1. We have previously reported that the molecular chaperone heat shock protein 90 (Hsp90) binds to and stabilizes LKB1. Combining pharmacological studies and RNA interference approaches, we now provide evidence that the co-chaperone Cdc37 participates to the regulation of LKB1 stability. It is known that the Hsp90-Cdc37 complex recognizes a surface within the N-terminal catalytic lobe of client protein kinases. In agreement with this finding, we found that the chaperones Hsp90 and Cdc37 interact with an LKB1 isoform that differs in the C-terminal region, but not with a novel LKB1 variant that lacks a portion of the kinase N-terminal lobe domain. Reconstitution of the two complexes LKB1-STRAD and LKB1-Hsp90-Cdc37 with recombinant proteins revealed that the former is catalytically active whereas the latter is inactive. Furthermore, consistent with a documented repressor function of Hsp90, LKB1 kinase activity was transiently stimulated upon dissociation of Hsp90. Finally, disruption of the LKB1-Hsp90 complex favors the recruitment of both Hsp/Hsc70 and the U-box dependent E3 ubiquitin ligase CHIP (carboxyl terminus of Hsc70-interacting protein) that triggers LKB1 degradation. Taken together, our results establish that the Hsp90-Cdc37 complex controls both the stability and activity of the LKB1 kinase. This study further shows that two chaperone complexes with antagonizing activities, Hsp90-Cdc37 and Hsp/Hsc70-CHIP, finely control the cellular level of LKB1 protein. Oncogene (2012) 31, 1582-1591; doi:10.1038/onc.2011.342; published online 22 August 2011	[Billaud, M.] UFJ, Inst Albert Bonniot, CRI, INSERM,U823, F-38706 La Tronche, France; [Gaude, H.; Aznar, N.; Delay, A.; Bres, A.; Buchet-Poyau, K.] CRCL, CNRS, INSERM, U1052,UMR 5286, Lyon, France; [Caillat, C.; Vigouroux, A.; Meyer, P.] Ctr Rech, CNRS Gif Sur Yvette, Lab Enzymol & Biochim Struct, UPR 3082, Gif Sur Yvette, France; [Rogon, C.; Hoehfeld, J.] Univ Bonn, Inst Cell Biol & Bonner Forum Biomed, Bonn, Germany; [Woods, A.] Univ London Imperial Coll Sci Technol & Med, MRC Clin Sci Ctr, Cellular Stress Grp, London, England; [Vanacker, J-M; Forcet, C.] Ecole Normale Super Lyon, Inst Genom Fonctionnelle Lyon, CNRS UCBL ENS UMR 5242, F-69364 Lyon, France; [Perret, C.] Univ Paris 05, Inst Cochin, CNRS, UMR 8104, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centre de Recherche en cancerologie (CRCL); University of Bonn; Imperial College London; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Ecole Normale Superieure de Lyon (ENS de LYON); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Billaud, M (corresponding author), UFJ, Inst Albert Bonniot, CRI, INSERM,U823, F-38706 La Tronche, France.	Marc.Billaud@ujf-grenoble.fr; christelle.forcet@ens-lyon.fr	Billaud, Marc N/M-6954-2013; Meyer, Philippe/AAC-6038-2019; Perret-Mayeux, Christine/L-3297-2017	Meyer, Philippe/0000-0002-6220-0679; perret, christine/0000-0003-4710-7051; Aznar, Nicolas/0000-0003-3338-9932; christophe, caillat/0000-0003-2959-1871	Ligue Nationale Contre le Cancer; Association de Recherche sur le Cancer; Comite de l'Isere; Fondation pour la Recherche Medicale; CNRS	Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Association de Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Comite de l'Isere; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); CNRS(Centre National de la Recherche Scientifique (CNRS))	We thank Len Neckers and Dirk Bohmann for the kind gifts of the CHIP and HA-ubiquitin vectors, respectively. This work was supported by the Ligue Nationale Contre le Cancer, and Association de Recherche sur le Cancer. During this work HG, NA and CC have been the recipients of fellowship from the Ligue Nationale Contre le Cancer, Ligue Nationale Contre le Cancer, Comite de l'Isere, Association de Recherche sur le Cancer and Fondation pour la Recherche Medicale and CNRS, respectively.	Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Beers M, 2006, DEVELOPMENT, V133, P3745, DOI 10.1242/dev.02544; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Boudeau J, 2003, BIOCHEM J, V370, P849, DOI 10.1042/BJ20021813; Brajenovic M, 2004, J BIOL CHEM, V279, P12804, DOI 10.1074/jbc.M312171200; Caplan AJ, 2007, TRENDS CELL BIOL, V17, P87, DOI 10.1016/j.tcb.2006.12.002; Citri A, 2006, J BIOL CHEM, V281, P14361, DOI 10.1074/jbc.M512613200; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; Denison FC, 2009, J BIOL CHEM, V284, P67, DOI 10.1074/jbc.M806153200; Donze O, 2001, EMBO J, V20, P3771, DOI 10.1093/emboj/20.14.3771; Ehrlich ES, 2009, P NATL ACAD SCI USA, V106, P20330, DOI 10.1073/pnas.0810571106; Fan MY, 2005, MOL ENDOCRINOL, V19, P2901, DOI 10.1210/me.2005-0111; Hardie DG, 2008, FEBS LETT, V582, P81, DOI 10.1016/j.febslet.2007.11.018; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Jansen M, 2009, PHYSIOL REV, V89, P777, DOI 10.1152/physrev.00026.2008; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Koga F, 2006, P NATL ACAD SCI USA, V103, P11318, DOI 10.1073/pnas.0604705103; Lee JH, 2007, NATURE, V447, P1017, DOI 10.1038/nature05828; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Murata S, 2003, INT J BIOCHEM CELL B, V35, P572, DOI 10.1016/S1357-2725(02)00394-1; Nony P, 2003, ONCOGENE, V22, P9165, DOI 10.1038/sj.onc.1207179; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Sreeramulu S, 2009, ANGEW CHEM INT EDIT, V48, P5853, DOI 10.1002/anie.200900929; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Towler MC, 2008, BIOCHEM J, V416, P1, DOI 10.1042/BJ20081447; Vaughan CK, 2008, MOL CELL, V31, P886, DOI 10.1016/j.molcel.2008.07.021; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Xu WP, 2007, MOL CELL BIOL, V27, P220, DOI 10.1128/MCB.00899-06; Xu WP, 2005, NAT STRUCT MOL BIOL, V12, P120, DOI 10.1038/nsmb885; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Yano A, 2008, P NATL ACAD SCI USA, V105, P15541, DOI 10.1073/pnas.0805354105; Zeqiraj E, 2009, SCIENCE, V326, P1707, DOI 10.1126/science.1178377; Zhang T, 2009, J BIOL CHEM, V284, P35381, DOI 10.1074/jbc.M109.051532	46	33	35	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	12					1582	1591		10.1038/onc.2011.342	http://dx.doi.org/10.1038/onc.2011.342			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21860411				2022-12-17	WOS:000302132000010
J	Mathiasen, DP; Egebjerg, C; Andersen, SH; Rafn, B; Puustinen, P; Khanna, A; Daugaard, M; Valo, E; Tuomela, S; Bottzauw, T; Nielsen, CF; Willumsen, BM; Hautaniemi, S; Lahesmaa, R; Westermarck, J; Jaattela, M; Kallunki, T				Mathiasen, D. P.; Egebjerg, C.; Andersen, S. H.; Rafn, B.; Puustinen, P.; Khanna, A.; Daugaard, M.; Valo, E.; Tuomela, S.; Bottzauw, T.; Nielsen, C. F.; Willumsen, B. M.; Hautaniemi, S.; Lahesmaa, R.; Westermarck, J.; Jaattela, M.; Kallunki, T.			Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation	ONCOGENE			English	Article						JNK knockout; CIP2A; ATF3; c-Myc; Ras transformation	PROTEIN-KINASE ACTIVATION; TRANSCRIPTION FACTOR; HA-RAS; NH2-TERMINAL KINASE; GENE-EXPRESSION; RESPONSE GENE; GROWTH; PHOSPHORYLATION; ATF3; JNK	Ras is one of the most frequently activated oncogenes in cancer. Two mitogen-activated protein kinases (MAPKs) are important for ras transformation: extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase 2 (JNK2). Here we present a downstream signal amplification cascade that is critical for ras transformation in murine embryonic fibroblasts. This cascade is coordinated by ERK and JNK2 MAPKs, whose Ras-mediated activation leads to the enhanced levels of three oncogenic transcription factors, namely, c-Myc, activating transcription factor 2 (ATF2) and ATF3, all of which are essential for ras transformation. Previous studies show that ERK-mediated serine 62 phosphorylation protects c-Myc from proteasomal degradation. ERK is, however, not alone sufficient to stabilize c-Myc but requires the cooperation of cancerous inhibitor of protein phosphatase 2A (CIP2A), an oncogene that counteracts protein phosphatase 2A-mediated dephosphorylation of c-Myc. Here we show that JNK2 regulates Cip2a transcription via ATF2. ATF2 and c-Myc cooperate to activate the transcription of ATF3. Remarkably, not only ectopic JNK2, but also ectopic ATF2, CIP2A, c-Myc and ATF3 are sufficient to rescue the defective ras transformation of JNK2-deficient cells. Thus, these data identify the key signal converging point of JNK2 and ERK pathways and underline the central role of CIP2A in ras transformation. Oncogene (2012) 31, 390-401; doi:10.1038/onc.2011.230; published online 27 June 2011	[Mathiasen, D. P.; Egebjerg, C.; Andersen, S. H.; Rafn, B.; Puustinen, P.; Daugaard, M.; Bottzauw, T.; Nielsen, C. F.; Jaattela, M.; Kallunki, T.] Danish Canc Soc, Inst Canc Biol, Apoptosis Dept, DK-2100 Copenhagen, Denmark; [Mathiasen, D. P.; Egebjerg, C.; Andersen, S. H.; Rafn, B.; Puustinen, P.; Daugaard, M.; Bottzauw, T.; Nielsen, C. F.; Jaattela, M.; Kallunki, T.] Danish Canc Soc, Inst Canc Biol, Ctr Genotox Stress Res, DK-2100 Copenhagen, Denmark; [Khanna, A.] Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; [Valo, E.; Hautaniemi, S.] Univ Helsinki, Inst Biomed, Computat Syst Biol Lab, Helsinki, Finland; [Valo, E.; Hautaniemi, S.] Univ Helsinki, Genome Scale Biol Res Program, Helsinki, Finland; [Tuomela, S.; Lahesmaa, R.; Westermarck, J.] Univ Turku, Turku Ctr Biotechnol, Turku, Finland; [Tuomela, S.; Lahesmaa, R.; Westermarck, J.] Abo Akad Univ, Turku, Finland; [Willumsen, B. M.] Univ Copenhagen, Dept Biol, Copenhagen, Denmark; [Westermarck, J.] Univ Turku, Dept Pathol, Turku, Finland	Danish Cancer Society; Danish Cancer Society; Tampere University; University of Helsinki; University of Helsinki; University of Turku; Abo Akademi University; University of Copenhagen; University of Turku	Kallunki, T (corresponding author), Danish Canc Soc, Inst Canc Biol, Apoptosis Dept, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.	tk@cancer.dk	Willumsen, Berthe M/H-1903-2012; Jäättelä, Marja/AAT-7932-2021; Westermarck, Jukka/AAL-6464-2020; Hautaniemi, Sampsa/A-3122-2009; Nielsen, Christian Friberg/HHN-0347-2022; Hautaniemi, Sampsa/CAG-0362-2022; Daugaard, Mads/Y-6483-2018	Willumsen, Berthe M/0000-0002-2277-6999; Jäättelä, Marja/0000-0001-5950-7111; Westermarck, Jukka/0000-0001-7478-3018; Hautaniemi, Sampsa/0000-0002-7749-2694; Hautaniemi, Sampsa/0000-0002-7749-2694; Daugaard, Mads/0000-0001-8383-055X; Nielsen, Christian Friberg/0000-0002-2886-317X; Valo, Erkka/0000-0003-0672-554X; Kallunki, Tuula/0000-0002-8571-383X	Danish Cancer Society; Danish Medical Research Council; Ellen and Aage Fausboll Helsefond; Danish National Research Foundation; Danish Cancer Research Foundation; Novo Nordisk Foundation; Academy of Finland; Pirkanmaa Hospital District; Finnish Cancer Society; Finnish Cancer Organizations; Finnish Microarray and Sequencing Centre at Turku Centre for Biotechnology; Cancer Foundation Finland sr [110134, 120139] Funding Source: researchfish	Danish Cancer Society(Danish Cancer Society); Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Ellen and Aage Fausboll Helsefond; Danish National Research Foundation(Danmarks Grundforskningsfond); Danish Cancer Research Foundation; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Academy of Finland(Academy of Finland); Pirkanmaa Hospital District; Finnish Cancer Society; Finnish Cancer Organizations; Finnish Microarray and Sequencing Centre at Turku Centre for Biotechnology; Cancer Foundation Finland sr	This work was supported by the Danish Cancer Society (TK, MJ), the Danish Medical Research Council (TK), Ellen and Aage Fausboll Helsefond (TK), the Danish National Research Foundation (MJ), Danish Cancer Research Foundation (CE), the Novo Nordisk Foundation (CE), the Academy of Finland (JW, RL, SH), Competetive Research Funding of the Pirkanmaa Hospital District (JW, AK), the Finnish Cancer Society (JW, SH) and the Finnish Cancer Organizations (RL) and the Finnish Microarray and Sequencing Centre at Turku Centre for Biotechnology. We additionally thank Dr G Nolan for the pB-puro and pB-hygro constructs, Dr H Land for the c-Myc pB-puro construct, Dr S Kitajima for the ATF3 reporter constructs and Dr T Hai for the ATF3 construct. We are thankful for KG Henriksen and P Rammer for excellent assistance and LB Larsen and L Jorgensen for the in vivo tumorigenicity assay.	Alarcon-Vargas D, 2004, J BIOL CHEM, V279, P5008, DOI 10.1074/jbc.M312054200; Amati B, 2001, BBA-REV CANCER, V1471, pM135, DOI 10.1016/S0304-419X(01)00020-8; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Berger AJ, 2003, CANCER RES, V63, P8103; Bhoumik A, 2004, CANCER RES, V64, P8222, DOI 10.1158/0008-5472.CAN-04-0714; Bhoumik A, 2008, CELL CYCLE, V7, P2341, DOI 10.4161/cc.6388; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Bost F, 1999, MOL CELL BIOL, V19, P1938; BRUNET A, 1994, ONCOGENE, V9, P3379; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; Chen NY, 2001, CANCER RES, V61, P3908; CIARDIELLO F, 1990, J CELL BIOCHEM, V42, P45, DOI 10.1002/jcb.240420105; Come C, 2009, CLIN CANCER RES, V15, P5092, DOI 10.1158/1078-0432.CCR-08-3283; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dietrich N, 2004, CELL DEATH DIFFER, V11, P301, DOI 10.1038/sj.cdd.4401353; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hubbard TJP, 2009, NUCLEIC ACIDS RES, V37, pD690, DOI 10.1093/nar/gkn828; Jacobsen K, 2002, ONCOGENE, V21, P3058, DOI 10.1038/sj.onc.1205423; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KAWAGISHI J, 1995, GENOMICS, V30, P224, DOI 10.1006/geno.1995.9883; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Ke HN, 2010, CANCER RES, V70, P3080, DOI 10.1158/0008-5472.CAN-09-2923; Kemp CJ, 2005, SEMIN CANCER BIOL, V15, P460, DOI 10.1016/j.semcancer.2005.06.003; Khanna A, 2009, JNCI-J NATL CANCER I, V101, P793, DOI 10.1093/jnci/djp103; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Krautwald S, 1996, MOL CELL BIOL, V16, P5955; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Lopez-Bergami P, 2010, J BIOL CHEM, V285, P903, DOI 10.1074/jbc.M109.075630; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Martinato F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003650; Mei Y, 2008, NEUROSCIENCE, V151, P771, DOI 10.1016/j.neuroscience.2007.10.057; Nielsen C, 2007, CANCER RES, V67, P178, DOI 10.1158/0008-5472.CAN-06-2801; Nielsen KH, 2001, ONCOGENE, V20, P2091, DOI 10.1038/sj.onc.1204306; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; Ovaska K, 2010, GENOME MED, V2, DOI 10.1186/gm186; Pearn L, 2007, BLOOD, V109, P4461, DOI 10.1182/blood-2006-09-047217; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Schimanski CC, 2010, INT J COLORECTAL DIS, V25, P181, DOI 10.1007/s00384-009-0843-7; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Sharma A, 2010, J BIOL CHEM, V285, P15724, DOI 10.1074/jbc.M109.100016; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Tamura K, 2005, EMBO J, V24, P2590, DOI 10.1038/sj.emboj.7600742; Teruel T, 1998, J CELL PHYSIOL, V176, P99, DOI 10.1002/(SICI)1097-4652(199807)176:1<99::AID-JCP12>3.3.CO;2-6; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Wang A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-268; Yao DC, 2010, DIABETES, V59, P249, DOI 10.2337/db09-0801; Yin X, 2008, ONCOGENE, V27, P2118, DOI 10.1038/sj.onc.1210861; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	65	33	36	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	3					390	401		10.1038/onc.2011.230	http://dx.doi.org/10.1038/onc.2011.230			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21706057				2022-12-17	WOS:000299542100011
J	Rudner, LA; Brown, KH; Dobrinski, KP; Bradley, DF; Garcia, MI; Smith, ACH; Downie, JM; Meeker, ND; Look, AT; Downing, JR; Gutierrez, A; Mullighan, CG; Schiffman, JD; Lee, C; Trede, NS; Frazer, JK				Rudner, L. A.; Brown, K. H.; Dobrinski, K. P.; Bradley, D. F.; Garcia, M. I.; Smith, A. C. H.; Downie, J. M.; Meeker, N. D.; Look, A. T.; Downing, J. R.; Gutierrez, A.; Mullighan, C. G.; Schiffman, J. D.; Lee, C.; Trede, N. S.; Frazer, J. K.			Shared acquired genomic changes in zebrafish and human T-ALL	ONCOGENE			English	Article						T-cell acute lymphoblastic leukemia (T-ALL); array comparative genome hybridization (aCGH); zebrafish; copy number aberration (CNA); leukemogenesis	ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSGENIC ZEBRAFISH; CELL TRANSPLANTATION; MODEL; ARRAY; HYBRIDIZATION; MUTATIONS; DELETION; MYC; SELECTION	T-cell acute lymphoblastic leukemia (T-ALL) is a challenging clinical entity with high rates of induction failure and relapse. To discover the genetic changes occurring in T-ALL, and those contributing to relapse, we studied zebrafish (Danio rerio) T-ALL samples using array comparative genomic hybridization (aCGH). We performed aCGH on 17 T-ALLs from four zebrafish T-ALL models, and evaluated similarities between fish and humans by comparing all D. rerio genes with copy number aberrations (CNAs) with a cohort of 75 published human T-ALLs analyzed by aCGH. Within all D. rerio CNAs, we identified 893 genes with human homologues and found significant overlap (67%) with the human CNA dataset. In addition, when we restricted our analysis to primary T-ALLs (14 zebrafish and 61 human samples), 10 genes were recurrently altered in 43 zebrafish cancers and >= 4 human cases, suggesting a conserved role for these loci in T-ALL transformation across species. We also conducted iterative allo-transplantation with three zebrafish malignancies. This technique selects for aggressive disease, resulting in shorter survival times in successive transplant rounds and modeling refractory and relapsed human T-ALL. Fifty-five percent of original CNAs were preserved after serial transplantation, demonstrating clonality between each primary and passaged leukemia. Cancers acquired an average of 34 new CNAs during passaging. Genes in these loci may underlie the enhanced malignant behavior of these neoplasias. We also compared genes from CNAs of passaged zebrafish malignancies with aCGH results from 50 human T-ALL patients who failed induction, relapsed or would eventually relapse. Again, many genes (88/164) were shared by both datasets. Further, nine recurrently altered genes in passaged D. rerio T-ALL were also found in multiple human T-ALL cases. These results suggest that zebrafish and human T-ALLs are similar at the genomic level, and are governed by factors that have persisted throughout evolution. Oncogene (2011) 30, 4289-4296; doi: 10.1038/onc.2011.138; published online 9 May 2011	[Schiffman, J. D.; Trede, N. S.; Frazer, J. K.] Univ Utah, Dept Pediat, Dept Oncol Sci, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Brown, K. H.; Dobrinski, K. P.; Lee, C.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Garcia, M. I.] Univ Texas Brownsville, Brownsville, TX 78520 USA; [Look, A. T.; Gutierrez, A.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Look, A. T.; Gutierrez, A.] Childrens Hosp, Boston, MA 02115 USA; [Downing, J. R.; Mullighan, C. G.] St Jude Childrens Hosp, Memphis, TN 38105 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Harvard University; Brigham & Women's Hospital; University of Texas System; University of Texas Rio Grande Valley; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; St Jude Children's Research Hospital	Frazer, JK (corresponding author), Univ Utah, Dept Pediat, Dept Oncol Sci, Huntsman Canc Inst, 2000 Circle Hope,HCI 4264, Salt Lake City, UT 84112 USA.	kimble.frazer@hsc.utah.edu	Downie, Jonathan/GPK-5981-2022; Mullighan, Charles/H-3253-2011; Downing, James R./N-8102-2018	Downie, Jonathan/0000-0002-5424-4401; Mullighan, Charles/0000-0002-1871-1850; Frazer, John Kimble/0000-0003-2936-2817; Brown, Kim/0000-0002-2358-8578; Gutierrez, Alejandro/0000-0002-0249-9007; Dobrinski, Kimberly/0000-0002-2626-1204	NIAID [R21-AI079784]; Huntsman Cancer Foundation; Eunice Kennedy Shriver NICHD [K08-HD053350]; CHRC at the University of Utah; PCMC Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD053350] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA042014, K08CA133103] Funding Source: NIH RePORTER	NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Huntsman Cancer Foundation; Eunice Kennedy Shriver NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); CHRC at the University of Utah; PCMC Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Brett Milash for bioinformatics analyses, Ken Boucher for statistical expertise, and Bradley Demarest for assistance with figure preparation. NST was supported by NIAID award R21-AI079784 and the Huntsman Cancer Foundation. JKF was supported by Eunice Kennedy Shriver NICHD award K08-HD053350, the CHRC at the University of Utah, and the PCMC Foundation. Huntsman Cancer Institute core facilities supported by NCI P30-CA042014 also contributed to this work.	Armstrong SA, 2005, J CLIN ONCOL, V23, P6306, DOI 10.1200/JCO.2005.05.047; Chen J, 2007, LEUKEMIA, V21, P462, DOI 10.1038/sj.leu.2404546; Choi S, 2007, BLOOD, V110, P632, DOI 10.1182/blood-2007-01-067785; Frazer JK, 2009, LEUKEMIA, V23, P1825, DOI 10.1038/leu.2009.116; Freeman JL, 2009, GENE CHROMOSOME CANC, V48, P155, DOI 10.1002/gcc.20623; Gutierrez A, 2010, J CLIN ONCOL, V28, P3816, DOI 10.1200/JCO.2010.28.3390; Gutierrez A, 2010, BLOOD, V115, P2845, DOI 10.1182/blood-2009-07-234377; Haire RN, 2000, IMMUNOGENETICS, V51, P915, DOI 10.1007/s002510000229; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; Langenau DM, 2005, P NATL ACAD SCI USA, V102, P6068, DOI 10.1073/pnas.0408708102; Langenau DM, 2003, SCIENCE, V299, P887, DOI 10.1126/science.1080280; Maydan JS, 2007, GENOME RES, V17, P337, DOI 10.1101/gr.5690307; Meeker ND, 2010, IMMUNOGENETICS, V62, P23, DOI 10.1007/s00251-009-0407-6; Mione MC, 2010, DIS MODEL MECH, V3, P517, DOI 10.1242/dmm.004747; Mullighan CG, 2008, SCIENCE, V322, P1377, DOI 10.1126/science.1164266; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Panzer-Grumayer ER, 2005, CLIN CANCER RES, V11, P7720, DOI 10.1158/1078-0432.CCR-05-1239; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Peterson SM, 2009, ZEBRAFISH, V6, P355, DOI 10.1089/zeb.2009.0600; Pinkel D, 2005, ANNU REV GENOM HUM G, V6, P331, DOI 10.1146/annurev.genom.6.080604.162140; Remke M, 2009, BLOOD, V114, P1053, DOI 10.1182/blood-2008-10-186536; Ren MQ, 2009, BLOOD, V114, P1576, DOI 10.1182/blood-2009-03-212704; RUDNER LA, 2010, CURR TRENDS IMMUNOL, V10, P119; Sabaawy HE, 2006, P NATL ACAD SCI USA, V103, P15166, DOI 10.1073/pnas.0603349103; Schorpp M, 2006, J IMMUNOL, V177, P2463, DOI 10.4049/jimmunol.177.4.2463; Smith ACH, 2010, BLOOD, V115, P3296, DOI 10.1182/blood-2009-10-246488; Sulong S, 2009, BLOOD, V113, P100, DOI 10.1182/blood-2008-07-166801; Thomas R, 2007, J HERED, V98, P474, DOI 10.1093/jhered/esm053; Vago L, 2009, NEW ENGL J MED, V361, P478, DOI 10.1056/NEJMoa0811036; Van Vlierberghe P, 2010, NAT GENET, V42, P338, DOI 10.1038/ng.542; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160	33	33	34	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	41					4289	4296		10.1038/onc.2011.138	http://dx.doi.org/10.1038/onc.2011.138			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HO	21552289	Green Accepted			2022-12-17	WOS:000296356300006
J	Gramling, S; Rogers, C; Liu, G; Reisman, D				Gramling, S.; Rogers, C.; Liu, G.; Reisman, D.			Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy	ONCOGENE			English	Article						SWI/SNF; epigenetic; tumor suppressor; target therapy; chromatin remodeling; cancer therapy	CANCER CELL-LINES; SWI-SNF COMPLEX; SWI/SNF COMPLEX; TRANSCRIPTIONAL ACTIVATORS; EXPRESSION; CHROMATIN; BRG1; GENE; ARREST; ATPASE	Tumor suppressor genes and oncogenes are both commonly altered during carcinogenesis. For oncogenes and other genes that drive growth, targeting mutated or activated forms (such as the EGFR-Her2/Nneu pathway) has been shown to be an effective anti-cancer approach. Pharmacologically targeting tumor suppressor genes has not been as fruitful, as many tumor suppressor genes are irreversibly silenced through somatic mutation or entirely deleted during carcinogenesis, thereby making it difficult to restore gene function. BRM, a key SWI/SNF complex subunit and a putative tumor suppressor gene, is inactivated in 15-20% of many solid tumor types. Unlike other tumor suppressor genes, the loss of BRM has been shown to be a reversible epigenetic change, rather than an irreversible genetic alteration. Using a high throughput drug screen, we identified a number of compounds that could effectively restore BRM expression and function. Two of these compounds, RH (RH02032) and GK (GK0037), were found to be such reactivating agents. Both compounds led to robust re-expression of BRM, induced downstream expression of BRM-dependent genes and inhibited BRM-dependent growth across a wide range of BRM-deficient cancer cell lines of different origins. We therefore show, for the first time, that pharmacologic reversal of epigenetic changes of the SWI/SNF chromatic remodeling complex subunit, BRM, is a potentially viable and novel therapeutic approach. Oncogene (2011) 30, 3289-3294; doi:10.1038/onc.2011.80; published online 11 April 2011	[Gramling, S.; Rogers, C.; Reisman, D.] Univ Florida, Dept Med, Div Hematol Oncol, Gainesville, FL 32610 USA; [Liu, G.] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Ontario Canc Inst,Dept Med, Toronto, ON, Canada; [Liu, G.] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Ontario Canc Inst,Dept Med Biophys, Toronto, ON, Canada	State University System of Florida; University of Florida; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Reisman, D (corresponding author), Univ Florida, Dept Med, Div Hematol Oncol, 2033 Mowry Rd,Off 294, Gainesville, FL 32610 USA.	dnreisman@ufl.edu	Liu, Geoffrey/N-4421-2016	Liu, Geoffrey/0000-0002-2603-7296	Alan B Brown Chair in Molecular Genomics; CCO Chair in Experimental Therapeutics and Population Studies; Posluns Family Foundation; NCI [R03CA128038-02, 1R01CA136683-01A1]; NATIONAL CANCER INSTITUTE [R01CA136683, T32CA009126, R03CA128038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R03DA028854] Funding Source: NIH RePORTER	Alan B Brown Chair in Molecular Genomics; CCO Chair in Experimental Therapeutics and Population Studies; Posluns Family Foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	GL is funded by the Alan B Brown Chair in Molecular Genomics, CCO Chair in Experimental Therapeutics and Population Studies, and the Posluns Family Foundation; Reisman lab funding for this paper is from NCI: R03CA128038-02 and 1R01CA136683-01A1.	Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Bourachot B, 2003, EMBO J, V22, P6505, DOI 10.1093/emboj/cdg621; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514; Gramling S, 2011, LETT DRUG DES DISCOV, V8, P93, DOI 10.2174/157018011793663840; Hendricks KB, 2004, MOL CELL BIOL, V24, P362, DOI 10.1128/MCB.24.1.362-376.2004; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Mizutani T, 2002, J BIOL CHEM, V277, P15859, DOI 10.1074/jbc.M112421200; Morrison AJ, 2006, RES PRO CEL, V41, P109, DOI 10.1007/008; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Reisman DN, 2005, APPL IMMUNOHISTO M M, V13, P66, DOI 10.1097/00129039-200503000-00011; Reisman DN, 2003, CANCER RES, V63, P560; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Sansam CG, 2006, CELL CYCLE, V5, P621, DOI 10.4161/cc.5.6.2579; Shen H, 2008, CANCER RES, V68, P10154, DOI 10.1158/0008-5472.CAN-08-1794; Simone C, 2006, J CELL PHYSIOL, V207, P309, DOI 10.1002/jcp.20514; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Wong AKC, 2000, CANCER RES, V60, P6171; Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716; Yarnamichi N, 2007, CANCER RES, V67, P10727, DOI 10.1158/0008-5472.CAN-07-2601	30	33	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	29					3289	3294		10.1038/onc.2011.80	http://dx.doi.org/10.1038/onc.2011.80			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	795VW	21478905	Green Accepted			2022-12-17	WOS:000293006800007
J	Harada, T; Lopez-Chavez, A; Xi, L; Raffeld, M; Wang, Y; Giaccone, G				Harada, T.; Lopez-Chavez, A.; Xi, L.; Raffeld, M.; Wang, Y.; Giaccone, G.			Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry	ONCOGENE			English	Article						EGFR; mutation; African American; EGFR-TKI	TYROSINE KINASE; GEFITINIB TREATMENT; GENE-MUTATIONS; EGFR MUTANTS; RESISTANCE; ACTIVATION; INHIBITOR; SENSITIVITY; ERLOTINIB; MECHANISM	Epidermal growth factor receptor (EGFR) mutations are predictive markers for response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC). The most common mutations, exon 19 short deletions and exon 20 point mutation (L858R), activate the tyrosine kinase and confer sensitivity to EGFR-TKIs. However, the function and sensitivity of rare mutations to EGFR-TKIs are unknown. In this study, we found five EGFR mutations out of 16 patients with NSCLC of African-American descent. The frequency of such mutations in this patient population appears to be significantly higher than previously reported. Two of them (N771GY and A767-V769dup) are rare insertion mutations located in exon 20. Using YFP-tagged EGFR mutants, we demonstrated that the mutations confer increased kinase activity, but no sensitivity to erlotinib at clinically available concentrations. In addition, we examined efficacy of PF00299804, an irreversible EGFR-TKI. Although the drug failed to show efficacy to T790M and S768N mutations, the exon 20 insertion mutations were sensitive to PF00299804. These data suggest that rare mutations in exon 20 are resistant to erlotinib but may be sensitive to irreversible inhibitors. Oncogene (2011) 30, 1744-1752; doi:10.1038/onc.2010.545; published online 6 December 2010	[Harada, T.; Lopez-Chavez, A.; Wang, Y.; Giaccone, G.] NCI, Med Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Xi, L.; Raffeld, M.] NCI, Pathol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Giaccone, G (corresponding author), NCI, Med Oncol Branch, Ctr Canc Res, NIH, 10 Ctr Dr,Bldg 10,Room 12N226, Bethesda, MD 20892 USA.	giacconeg@mail.nih.gov	Giaccone, Giuseppe/E-8297-2017	Giaccone, Giuseppe/0000-0002-5023-7562	NATIONAL CANCER INSTITUTE [ZIABC011269, ZICBC011079] Funding Source: NIH RePORTER; Intramural NIH HHS [ZIA BC010854, Z01 BC010453-07] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Calvo E, 2006, J CLIN ONCOL, V24, P2158, DOI 10.1200/JCO.2006.06.5961; Chen YR, 2006, ONCOGENE, V25, P1205, DOI 10.1038/sj.onc.1209159; de Gunst MM, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-56; Engelman JA, 2007, CANCER RES, V67, P11924, DOI 10.1158/0008-5472.CAN-07-1885; Eskens F, 2008, BRIT J CANCER, V98, P80, DOI 10.1038/sj.bjc.6604108; Han SW, 2005, J CLIN ONCOL, V23, P2493, DOI 10.1200/JCO.2005.01.388; Hughes AN, 2009, J CLIN ONCOL, V27, P1220, DOI 10.1200/JCO.2008.19.3995; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kosaka T, 2006, CLIN CANCER RES, V12, P5764, DOI 10.1158/1078-0432.CCR-06-0714; Krishnaswamy S, 2009, CLIN CANCER RES, V15, P5714, DOI 10.1158/1078-0432.CCR-09-0070; Leidner RS, 2009, J CLIN ONCOL, V27, P5620, DOI 10.1200/JCO.2009.23.1431; Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Niculescu-Duvaz D, 2007, CANCER CELL, V11, P209, DOI 10.1016/j.ccr.2007.02.021; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Sos ML, 2010, CANCER RES, V70, P868, DOI 10.1158/0008-5472.CAN-09-3106; Wong KK, 2007, CLIN CANCER RES, V13, p4593S, DOI 10.1158/1078-0432.CCR-07-0369; Wu JY, 2008, CLIN CANCER RES, V14, P4877, DOI 10.1158/1078-0432.CCR-07-5123; Yang SH, 2005, CLIN CANCER RES, V11, P2106, DOI 10.1158/1078-0432.CCR-04-1853; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	25	33	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	15					1744	1752		10.1038/onc.2010.545	http://dx.doi.org/10.1038/onc.2010.545			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21132006	Green Accepted			2022-12-17	WOS:000289512200002
J	Olanich, ME; Moss, BL; Piwnica-Worms, D; Townsend, RR; Weber, JD				Olanich, M. E.; Moss, B. L.; Piwnica-Worms, D.; Townsend, R. R.; Weber, J. D.			Identification of FUSE-binding protein 1 as a regulatory mRNA-binding protein that represses nucleophosmin translation	ONCOGENE			English	Article						FBP1; Nucleophosmin; ribosome biogenesis; translation	RIBOSOME BIOGENESIS; STRESS GRANULES; PROCESSING BODIES; MAMMALIAN TARGET; P53 TRANSLATION; NUCLEAR EXPORT; C-MYC; PHOSPHORYLATION; EXPRESSION; RAPAMYCIN	Nucleophosmin (NPM/B23) is a multifunctional oncoprotein whose protein expression levels dictate cellular growth and proliferation rates. NPM is translationally responsive to hyperactive mammalian target of rapamycin (mTOR) signals, but the mechanism of this regulation is not understood. Using chimeric translational reporters, we found that the 30 untranslated region (UTR) of the NPM messenger (m) RNA is sufficient to mediate its translational modulation by mTOR signalling. We show that far upstream element (FUSE)-binding protein 1 (FBP1) interacts specifically with the 30 UTR of NPM to repress translation. Overexpression of FBP1 resulted in translational repression of NPM mRNAs, whereas depletion of FBP1 caused a dramatic increase in NPM translation and resulted in enhanced overall cell proliferation. Thus, we propose that FBP1 is a key regulator of cell growth and proliferation through its ability to selectively bind the NPM 30 UTR and repress NPM translation. Oncogene (2011) 30, 77-86; doi: 10.1038/onc.2010.404; published online 30 August 2010	[Olanich, M. E.; Weber, J. D.] Washington Univ, Sch Med, Div Mol Oncol, Dept Internal Med, St Louis, MO 63110 USA; [Olanich, M. E.; Moss, B. L.; Piwnica-Worms, D.; Weber, J. D.] Washington Univ, Sch Med, BRIGHT Inst, St Louis, MO 63110 USA; [Moss, B. L.; Piwnica-Worms, D.] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Mol Imaging Ctr, St Louis, MO 63110 USA; [Townsend, R. R.] Washington Univ, Sch Med, Siteman Canc Ctr, Div Metab & Prote Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL)	Weber, JD (corresponding author), Washington Univ, Sch Med, Div Mol Oncol, Dept Internal Med, 660 S Euclid Ave,Campus Box 8069, St Louis, MO 63110 USA.	jweber@dom.wustl.edu		Moss, Britney/0000-0002-1037-5717; Weber, Jason/0000-0002-1069-6983	Washington University Imaging Center; NIH [5T32 GM007067, P30 CA91842, P50 CA94056, CA128007]; National Center for Research Resources [P41RR000954, UL1 RR024992]; Era of Hope Scholar Award in Breast Cancer Research [BC007304]; NATIONAL CANCER INSTITUTE [R01CA127008, P30CA091842, P50CA094056] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024992, P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007067] Funding Source: NIH RePORTER	Washington University Imaging Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Era of Hope Scholar Award in Breast Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the members of the Weber, Townsend and Piwnica-Worms laboratories for their advice and technical assistance. The luciferase reporter work was initiated through a Pilot Grant from the Washington University Imaging Center. MEO was supported by NIH 5T32 GM007067. This research was supported with Grants from the National Institutes of Health, P30 CA91842 to the Siteman Comprehensive Cancer Center and P41RR000954 and UL1 RR024992 from the National Center for Research Resources to the Proteomics Center. DPW and BLM were supported by NIH P50 CA94056. This work was supported by NIH Grant CA128007 and an Era of Hope Scholar Award in Breast Cancer Research (BC007304) to JDW.	Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Brady SN, 2009, ONCOGENE, V28, P3209, DOI 10.1038/onc.2009.178; Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Briata P, 2005, MOL CELL, V20, P891, DOI 10.1016/j.molcel.2005.10.021; Briata P, 2003, MOL CELL, V12, P1201, DOI 10.1016/S1097-2765(03)00407-6; Chung HJ, 2006, MOL CELL BIOL, V26, P6584, DOI 10.1128/MCB.00754-06; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; de Moor CH, 2005, SEMIN CELL DEV BIOL, V16, P49, DOI 10.1016/j.semcdb.2004.11.007; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; Galban S, 2008, MOL CELL BIOL, V28, P93, DOI 10.1128/MCB.00973-07; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Gross S, 2005, NAT METHODS, V2, P607, DOI 10.1038/NMETH779; Hamilton BJ, 2008, J BIOL CHEM, V283, P25606, DOI 10.1074/jbc.M802492200; He LS, 2000, EMBO J, V19, P1034, DOI 10.1093/emboj/19.5.1034; He YW, 2009, CELL MOL LIFE SCI, V66, P1239, DOI 10.1007/s00018-008-8532-1; Irwin N, 1997, NUCLEIC ACIDS RES, V25, P1281, DOI 10.1093/nar/25.6.1281; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Jiang Y, 2006, MOL CELL BIOL, V26, P2419, DOI 10.1128/MCB.26.6.2419-2429.2006; Kedersha N, 2005, J CELL BIOL, V169, P871, DOI 10.1083/jcb.200502088; King JB, 2006, ANAL CHEM, V78, P2171, DOI 10.1021/ac051520l; Kroll TT, 2002, DEVELOPMENT, V129, P5609, DOI 10.1242/dev.00160; Li H, 2009, J LIPID RES, V50, P820, DOI 10.1194/jlr.M800375-JLR200; Maggi LB, 2008, MOL CELL BIOL, V28, P7050, DOI 10.1128/MCB.01548-07; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okuwaki M, 2002, MOL BIOL CELL, V13, P2016, DOI 10.1091/mbc.02-03-0036; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; Patursky-Polischuk I, 2009, MOL CELL BIOL, V29, P640, DOI 10.1128/MCB.00980-08; Pelletier CL, 2007, CANCER RES, V67, P1609, DOI 10.1158/0008-5472.CAN-06-2875; Pontrelli L, 2004, BIOCHEMISTRY-US, V43, P6734, DOI 10.1021/bi049887s; Proud CG, 2007, BIOCHEM J, V403, P217, DOI 10.1042/BJ20070024; Proud CG, 2009, BIOCHEM SOC T, V37, P227, DOI 10.1042/BST0370227; Qi W, 2008, ONCOGENE, V27, P4210, DOI 10.1038/onc.2008.54; Sandsmark DK, 2007, HISTOL HISTOPATHOL, V22, P895, DOI 10.14670/HH-22.895; Sidiropoulos KG, 2007, ARCH BIOCHEM BIOPHYS, V459, P10, DOI 10.1016/j.abb.2006.11.003; Snee M, 2002, J CELL SCI, V115, P4661, DOI 10.1242/jcs.00137; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Wickens M, 2002, TRENDS GENET, V18, P150, DOI 10.1016/S0168-9525(01)02616-6; Wilczynska A, 2005, J CELL SCI, V118, P981, DOI 10.1242/jcs.01692; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang WH, 2006, RNA, V12, P547, DOI 10.1261/rna.2302706; Yu JH, 2005, RNA, V11, P1795, DOI 10.1261/rna.2142405; Yu Y, 2006, MOL CELL BIOL, V26, P3798, DOI 10.1128/MCB.26.10.3798-3809.2006; Zhang J, 2008, CANCER RES, V68, P1046, DOI 10.1158/0008-5472.CAN-07-1927; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952	57	33	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					77	86		10.1038/onc.2010.404	http://dx.doi.org/10.1038/onc.2010.404			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20802533	Green Accepted			2022-12-17	WOS:000285959300007
J	Titz, B; Low, T; Komisopoulou, E; Chen, SS; Rubbi, L; Graeber, TG				Titz, B.; Low, T.; Komisopoulou, E.; Chen, S. S.; Rubbi, L.; Graeber, T. G.			The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization	ONCOGENE			English	Article						adaptor protein; BCR-ABL1; phospho-complex; quantitative mass spectrometry; signaling network; systems biology	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; BCR-ABL KINASE; ADAPTER PROTEIN; PARKINSONS-DISEASE; NEGATIVE REGULATOR; MASS-SPECTROMETRY; TYROSINE KINASE; BINDING-SITE	BCR-ABL1 is a fusion tyrosine kinase, which causes multiple types of leukemia. We used an integrated proteomic approach that includes label-free quantitative protein complex and phosphorylation profiling by mass spectrometry to systematically characterize the proximal signaling network of this oncogenic kinase. The proximal BCR-ABL1 signaling network shows a modular and layered organization with an inner core of three leukemia transformation-relevant adaptor protein complexes (Grb2/Gab2/Shc1 complex, CrkI complex and Dok1/Dok2 complex). We introduced an 'interaction directionality' analysis, which annotates static protein networks with information on the directionality of phosphorylation-dependent interactions. In this analysis, the observed network structure was consistent with a step-wise phosphorylation-dependent assembly of the Grb2/Gab2/Shc1 and the Dok1/Dok2 complexes on the BCR-ABL1 core. The CrkI complex demonstrated a different directionality, which supports a candidate assembly on the Nedd9 (Hef1, CasL) scaffold. As adaptor protein family members can compensate for each other in leukemic transformation, we compared members of the Dok and Crk protein families and found both overlapping and differential binding patterns. We identified an additional level of regulation for the CrkII protein via binding to 14-3-3 proteins, which was independent from its inhibitory phosphorylation. We also identified novel components of the inner core complexes, including the kinases Pragmin (Sgk223) and Lrrk1 (Lrrk2 paralog). Pragmin was found as a component of the CrkI complex and is a potential link between BCR-ABL1/CrkI and RhoA signaling. Lrrk1 is an unusual kinase with a GTPase domain. We detected Lrrk1 as a component of the Grb2/Gab2/Shc1 complex and found that it functionally interacts with the regulator of small GTPases Arap1 (Centd2) and possibly participates in the mitogen-activated protein kinase response to cellular stresses. This modular and phosphorylation-driven interaction network provides a framework for the integration of pleiotropic signaling effects of BCR-ABL1 toward leukemic transformation. Oncogene (2010) 29, 5895-5910; doi:10.1038/onc.2010.331; published online 9 August 2010	[Titz, B.; Low, T.; Komisopoulou, E.; Chen, S. S.; Rubbi, L.; Graeber, T. G.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Crump Inst Mol Imaging, Calif Nanosyst Inst,Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Graeber, TG (corresponding author), Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Crump Inst Mol Imaging, Calif Nanosyst Inst,Jonsson Comprehens Canc Ctr, 570 Westwood Plaza,Bldg 114, Los Angeles, CA 90095 USA.	tgraeber@mednet.ucla.edu	Titz, Bjoern/G-6317-2017; Titz, Björn/B-9516-2008	Titz, Bjoern/0000-0003-4414-4105; Graeber, Thomas/0000-0001-8574-9181	NIH NHGRI [HG002807]; University of California, Cancer Research Coordinating Committee; German Academic Exchange Service; UCLA, USHHS [T32 CA009056]; NATIONAL CANCER INSTITUTE [T32CA009056] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K22HG002807] Funding Source: NIH RePORTER	NIH NHGRI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); University of California, Cancer Research Coordinating Committee(University of California System); German Academic Exchange Service(Deutscher Akademischer Austausch Dienst (DAAD)); UCLA, USHHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This work was funded by grants to TGG from the NIH NHGRI (HG002807) and the University of California, Cancer Research Coordinating Committee, and by postdoctoral fellowships of the German Academic Exchange Service to BT and the UCLA Tumor Biology Program USHHS Ruth L Kirschstein Institutional National Research Service Award # T32 CA009056 to SSC. TGG is an Alfred P Sloan Research Fellow. We thank M Negishi, D Korr and T Burckstummer for kindly providing plasmids. Flow cytometry was performed in the UCLA Jonsson Comprehensive Cancer Center and Center for AIDS Research Flow Cytometry Core.	Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; BAIER T, 2009, R D COM SERVER; Berger AH, 2010, NAT GENET, V42, P216, DOI 10.1038/ng.527; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Brehme M, 2009, P NATL ACAD SCI USA, V106, P7414, DOI 10.1073/pnas.0900653106; Burckstummer T, 2006, NAT METHODS, V3, P1013, DOI 10.1038/nmeth968; Burgess MR, 2005, P NATL ACAD SCI USA, V102, P3395, DOI 10.1073/pnas.0409770102; Caplan AJ, 2007, TRENDS CELL BIOL, V17, P87, DOI 10.1016/j.tcb.2006.12.002; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Daniele T, 2008, TRAFFIC, V9, P2221, DOI 10.1111/j.1600-0854.2008.00823.x; de Jong R, 1997, J BIOL CHEM, V272, P32649, DOI 10.1074/jbc.272.51.32649; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; Diella F, 2008, FRONT BIOSCI-LANDMRK, V13, P6580, DOI 10.2741/3175; Dosztanyi Z, 2005, BIOINFORMATICS, V21, P3433, DOI 10.1093/bioinformatics/bti541; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Faisal A, 2004, J BIOL CHEM, V279, P3202, DOI 10.1074/jbc.M310010200; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Gautreau A, 2004, P NATL ACAD SCI USA, V101, P4379, DOI 10.1073/pnas.0400628101; Gilks WP, 2005, LANCET, V365, P415, DOI 10.1016/S0140-6736(05)17830-1; Gloeckner CJ, 2009, J NEUROCHEM, V109, P959, DOI 10.1111/j.1471-4159.2009.06024.x; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Goss VL, 2006, BLOOD, V107, P4888, DOI 10.1182/blood-2005-08-3399; Goudreault M, 2009, MOL CELL PROTEOMICS, V8, P157, DOI 10.1074/mcp.M800266-MCP200; Graeber TG, 2010, P NATL ACAD SCI USA, V107, P6112, DOI 10.1073/pnas.1001149107; Harada JN, 2005, GENOME RES, V15, P1136, DOI 10.1101/gr.3889305; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; He YP, 2002, BLOOD, V99, P2957, DOI 10.1182/blood.V99.8.2957; Hemmeryckx B, 2002, ONCOGENE, V21, P3225, DOI 10.1038/sj.onc.1205452; Heo HY, 2010, EXP CELL RES, V316, P649, DOI 10.1016/j.yexcr.2009.09.014; Hornbeck PV, 2004, PROTEOMICS, V4, P1551, DOI 10.1002/pmic.200300772; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Hu YG, 2006, P NATL ACAD SCI USA, V103, P16870, DOI 10.1073/pnas.0606509103; Hughan SC, 2007, J THROMB HAEMOST, V5, P387, DOI 10.1111/j.1538-7836.2007.02307.x; Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760; Johnson KJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007439; Kanazawa C, 2003, BIOCHEM BIOPH RES CO, V309, P848, DOI 10.1016/j.bbrc.2003.08.078; Kantarjian HM, 2007, CLIN CANCER RES, V13, P1089, DOI 10.1158/1078-0432.CCR-06-2147; Kerrien S, 2007, NUCLEIC ACIDS RES, V35, pD561, DOI 10.1093/nar/gkl958; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; Kobashigawa Y, 2007, NAT STRUCT MOL BIOL, V14, P503, DOI 10.1038/nsmb1241; Korr D, 2006, CELL SIGNAL, V18, P910, DOI 10.1016/j.cellsig.2005.08.015; Leng Y, 2005, P NATL ACAD SCI USA, V102, P1098, DOI 10.1073/pnas.0409120102; Liou AKF, 2008, NEUROBIOL DIS, V32, P116, DOI 10.1016/j.nbd.2008.06.016; Marchler-Bauer A, 2009, NUCLEIC ACIDS RES, V37, pD205, DOI 10.1093/nar/gkn845; McGavin MKH, 2001, J EXP MED, V194, P1777, DOI 10.1084/jem.194.12.1777; Million RP, 2000, BLOOD, V96, P664; Miura K, 2002, MOL CELL, V9, P109, DOI 10.1016/S1097-2765(02)00428-8; Morrison DK, 2009, TRENDS CELL BIOL, V19, P16, DOI 10.1016/j.tcb.2008.10.003; Mullighan CG, 2009, P NATL ACAD SCI USA, V106, P9414, DOI 10.1073/pnas.0811761106; Neduva V, 2006, CURR OPIN BIOTECH, V17, P465, DOI 10.1016/j.copbio.2006.08.002; NICHOLS GL, 1994, BLOOD, V84, P2912; Niki M, 2004, J EXP MED, V200, P1689, DOI 10.1084/jem.20041306; O'Neill GM, 2007, CANCER RES, V67, P8975, DOI 10.1158/0008-5472.CAN-07-1328; ODA T, 1994, J BIOL CHEM, V269, P22925; Paisan-Ruiz C, 2004, NEURON, V44, P595, DOI 10.1016/j.neuron.2004.10.023; Pawson T, 2007, CURR OPIN CELL BIOL, V19, P112, DOI 10.1016/j.ceb.2007.02.013; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; Pflieger D, 2008, MOL CELL PROTEOMICS, V7, P326, DOI 10.1074/mcp.M700282-MCP200; Prakash A, 2006, MOL CELL PROTEOMICS, V5, P423, DOI 10.1074/mcp.M500133-MCP200; Prosser DC, 2008, J CELL SCI, V121, P3052, DOI 10.1242/jcs.028696; Pui CH, 2007, NAT REV DRUG DISCOV, V6, P149, DOI 10.1038/nrd2240; R Development Core Team, 2009, R LANG ENV STAT COMP; Raetz EA, 2008, J CLIN ONCOL, V26, P3971, DOI 10.1200/JCO.2008.16.1414; Ramshaw HS, 2007, BLOOD, V110, P3582, DOI 10.1182/blood-2007-01-070391; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Sarmann J, 2009, J BIOL CHEM, V284, P16482, DOI 10.1074/jbc.M808255200; Saha S, 2009, J NEUROSCI, V29, P9210, DOI 10.1523/JNEUROSCI.2281-09.2009; Sasaoka T, 2001, ENDOCRINOLOGY, V142, P5226, DOI 10.1210/en.142.12.5226; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Shah NP, 2008, CANCER CELL, V14, P485, DOI 10.1016/j.ccr.2008.11.001; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Skaggs BJ, 2006, P NATL ACAD SCI USA, V103, P19466, DOI 10.1073/pnas.0609239103; SKEHEL PA, 1995, SCIENCE, V269, P1580, DOI 10.1126/science.7667638; Skehel PA, 2000, P NATL ACAD SCI USA, V97, P1101, DOI 10.1073/pnas.97.3.1101; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Sonoyama J, 2002, J BIOL CHEM, V277, P8076, DOI 10.1074/jbc.M111501200; Spirin V, 2003, P NATL ACAD SCI USA, V100, P12123, DOI 10.1073/pnas.2032324100; Stuart JR, 2006, J BIOL CHEM, V281, P31290, DOI 10.1074/jbc.M602389200; Tanaka H, 2006, J BIOL CHEM, V281, P10355, DOI 10.1074/jbc.M511314200; Taylor IW, 2009, NAT BIOTECHNOL, V27, P199, DOI 10.1038/nbt.1522; Titz B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002292; Trinkle-Mulcahy L, 2008, J CELL BIOL, V183, P223, DOI 10.1083/jcb.200805092; Wang LZ, 2008, J NEUROSCI, V28, P3384, DOI 10.1523/JNEUROSCI.0185-08.2008; Wong S, 2004, ANNU REV IMMUNOL, V22, P247, DOI 10.1146/annurev.immunol.22.012703.104753; Yasuda T, 2004, J EXP MED, V200, P1681, DOI 10.1084/jem.20041247; Yasuda T, 2007, INT IMMUNOL, V19, P487, DOI 10.1093/intimm/dxm015; Yoon HY, 2008, TRAFFIC, V9, P2236, DOI 10.1111/j.1600-0854.2008.00839.x; Yu WD, 2008, CARCINOGENESIS, V29, P1717, DOI 10.1093/carcin/bgn098; Zimman A, 2010, J PROTEOME RES, V9, P2812, DOI 10.1021/pr901194x; Zipfel PA, 2006, CURR BIOL, V16, P35, DOI 10.1016/j.cub.2005.12.024	92	33	33	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	44					5895	5910		10.1038/onc.2010.331	http://dx.doi.org/10.1038/onc.2010.331			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	675PS	20697350	Green Accepted			2022-12-17	WOS:000283843400004
J	Cheng, L; Zhou, Z; Flesken-Nikitin, A; Toshkov, IA; Wang, W; Camps, J; Ried, T; Nikitin, AY				Cheng, L.; Zhou, Z.; Flesken-Nikitin, A.; Toshkov, I. A.; Wang, W.; Camps, J.; Ried, T.; Nikitin, A. Y.			Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency	ONCOGENE			English	Article						breast cancer; genomic maintenance; mouse; models of cancer; oncogenomics; tumor suppressor	CONDITIONAL MOUSE MODEL; TUMOR-SUPPRESSOR; BREAST-CANCER; SOMATIC INACTIVATION; HIGH-FREQUENCY; DNA-DAMAGE; CYCLIN D1; IN-VIVO; MICE; EXPRESSION	Genetically defined mouse models offer an important tool to identify critical secondary genetic alterations with relevance to human cancer pathogenesis. We used newly generated MMTV-Cre105Ayn mice to inactivate p53 and/or Rb strictly in the mammary epithelium, and to determine recurrent genomic changes associated with deficiencies of these genes. p53 inactivation led to formation of estrogen receptor-positive raloxifene-responsive mammary carcinomas with features of luminal subtype B. Rb deficiency was insufficient to initiate carcinogenesis but promoted genomic instability and growth rate of neoplasms associated with p53 inactivation. Genome-wide analysis of mammary carcinomas identified a recurrent amplification at chromosome band 9A1, a locus orthologous to human 11q22, which contains protooncogenes cIAP1 (Birc2), cIAP2 (Birc3) and Yap1. It is interesting that this amplicon was preferentially detected in carcinomas carrying wild-type Rb. However, all three genes were overexpressed in carcinomas with p53 and Rb inactivation, likely due to E2F-mediated transactivation, and cooperated in carcinogenesis according to gene knockdown experiments. These findings establish a model of luminal subtype B mammary carcinoma, identify critical role of cIAP1, cIAP2 and Yap1 co-expression in mammary carcinogenesis and provide an explanation for the lack of recurrent amplifications of cIAP1, cIAP2 and Yap1 in some tumors with frequent Rb deficiency, such as mammary carcinoma. Oncogene (2010) 29, 5700-5711; doi:10.1038/onc.2010.300; published online 2 August 2010	[Cheng, L.; Zhou, Z.; Flesken-Nikitin, A.; Toshkov, I. A.; Nikitin, A. Y.] Cornell Univ, Dept Biomed Sci, Ithaca, NY 14853 USA; [Wang, W.] Cornell Univ, Microarray Core Facil, Ithaca, NY 14853 USA; [Camps, J.; Ried, T.] NCI, Genet Branch, NIH, Bethesda, MD 20892 USA	Cornell University; Cornell University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Nikitin, AY (corresponding author), Cornell Univ, Dept Biomed Sci, T2 014A VRT Campus Rd, Ithaca, NY 14853 USA.	an58@cornell.edu	Camps, Jordi/AAG-3080-2020	Camps, Jordi/0000-0002-3165-3640	NIH/NCI [R01 CA96823]; NYSTEM [C023050]; NATIONAL CANCER INSTITUTE [ZIABC010836, R01CA096823] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NYSTEM; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank David C Corney for critical reading of this paper and Dr Anton Berns (Netherlands Cancer Institute, Amsterdam, The Netherlands) for the generous gift of the p53<SUP>floxP/floxP</SUP> and Rb<SUP>floxP/floxP</SUP> mice. This work was supported by grants R01 CA96823 (NIH/NCI) and C023050 (NYSTEM) to AYN.	Borresen-Dale AL, 2003, HUM MUTAT, V21, P292, DOI 10.1002/humu.10174; Bosco EE, 2007, CELL CYCLE, V6, P667, DOI 10.4161/cc.6.6.3988; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Chai Y, 2000, DEVELOPMENT, V127, P1671; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Flesken-Nikitin A, 2003, CANCER RES, V63, P3459; Frasor J, 2009, CANCER RES, V69, P8918, DOI 10.1158/0008-5472.CAN-09-2608; Geradts J, 1996, AM J PATHOL, V149, P15; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jiang XB, 2000, DEVELOPMENT, V127, P1607; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Knudsen ES, 2006, CURR MOL MED, V6, P749; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; LaCasse EC, 2008, ONCOGENE, V27, P6252, DOI 10.1038/onc.2008.302; Li ML, 2000, ONCOGENE, V19, P1010, DOI 10.1038/sj.onc.1203271; Lin SCJ, 2004, CANCER RES, V64, P3525, DOI 10.1158/0008-5472.CAN-03-3524; Liu X, 2007, P NATL ACAD SCI USA, V104, P12111, DOI 10.1073/pnas.0702969104; Ma O, 2009, CANCER RES, V69, P2559, DOI 10.1158/0008-5472.CAN-08-2929; MALKIN D, 1994, ANNU REV GENET, V28, P443; Marino S, 2000, GENE DEV, V14, P994; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; Mayhew CN, 2007, GASTROENTEROLOGY, V133, P976, DOI 10.1053/j.gastro.2007.06.025; Mayhew CN, 2005, CANCER RES, V65, P4568, DOI 10.1158/0008-5472.CAN-04-4221; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Minakuchi Y, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh093; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Reed CA, 2009, ONCOGENE, V28, P4434, DOI 10.1038/onc.2009.303; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Robinson GW, 2001, ONCOGENE, V20, P7115, DOI 10.1038/sj.onc.1204888; Roy PG, 2006, BREAST, V15, P718, DOI 10.1016/j.breast.2006.02.005; Scambia G, 2006, ONCOGENE, V25, P5302, DOI 10.1038/sj.onc.1209620; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Simin K, 2004, PLOS BIOL, V2, P194, DOI 10.1371/journal.pbio.0020022; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sporn MB, 2004, CLIN THER, V26, P830, DOI 10.1016/S0149-2918(04)90127-0; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wijnhoven SWP, 2005, CANCER RES, V65, P8166, DOI 10.1158/0008-5472.CAN-05-1650; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhou ZX, 2007, CANCER RES, V67, P5683, DOI 10.1158/0008-5472.CAN-07-0768; Zhou ZX, 2006, CANCER RES, V66, P7889, DOI 10.1158/0008-5472.CAN-06-0486	50	33	33	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	42					5700	5711		10.1038/onc.2010.300	http://dx.doi.org/10.1038/onc.2010.300			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20676140	Green Accepted			2022-12-17	WOS:000283262500006
J	Lee, SH; Shen, GN; Jung, YS; Lee, SJ; Chung, JY; Kim, HS; Xu, Y; Choi, Y; Lee, JW; Ha, NC; Song, GY; Park, BJ				Lee, S-H; Shen, G-N; Jung, Y. S.; Lee, S-J; Chung, J-Y; Kim, H-S; Xu, Y.; Choi, Y.; Lee, J-W; Ha, N-C; Song, G. Y.; Park, B-J			Antitumor effect of novel small chemical inhibitors of Snail-p53 binding in K-Ras-mutated cancer cells	ONCOGENE			English	Article						anticancer drug; p53; K-Ras; Snail; pancreatic cancer	PANCREATIC-CANCER; IN-VIVO; P53; EXPRESSION; BREAST; RESTORATION; SENESCENCE; MUTATIONS; PATHWAY; CATENIN	p53 is frequently mutated by genetic alternation or suppressed by various kinds of cellular signaling pathways in human cancers. Recently, we have revealed that p53 is suppressed and eliminated from cells by direct binding with oncogenic K-Ras-induced Snail. On the basis of the fact, we generated specific inhibitors against p53-Snail binding (GN25 and GN29). These chemicals can induce p53 expression and functions in K-Ras-mutated cells. However, it does not show cytotoxic effect on normal cells or K-Raswild- type cells. Moreover, GN25 can selectively activate wild-type p53 in p53(WT/MT) cancer cells. But single allelic mt p53 containing cell line, Panc-1, does not respond to our chemical. In vivo xenograft test also supports the antitumor effect of GN25 in K-Ras-mutated cell lines. These results suggest that our compounds are strong candidate for anticancer drug against K-Ras-initiated human cancers including pancreatic and lung cancers. Oncogene (2010) 29, 4576-4587; doi: 10.1038/onc.2010.208; published online 7 June 2010	[Lee, S-H; Jung, Y. S.; Lee, S-J; Chung, J-Y; Park, B-J] Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea; [Lee, S-H; Shen, G-N; Choi, Y.] Korea Univ, Sch Life Sci & Biotechnol, Seoul, South Korea; [Shen, G-N; Song, G. Y.] Chungnam Natl Univ, Coll Pharm, Taejon 305764, South Korea; [Kim, H-S; Xu, Y.; Lee, J-W; Ha, N-C] Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea	Pusan National University; Korea University; Chungnam National University; Pusan National University	Park, BJ (corresponding author), Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea.	gysong@cnu.ac.kr; bjpark1219@pusan.ac.kr	Kim, Heui-Soo/ABF-3773-2021; Choi, Yongseok/F-8375-2012; Lee, Jaewon/N-9064-2013; Lee, Sang Joon/AAG-2448-2019	Kim, Heui-Soo/0000-0002-5226-6594; Choi, Yongseok/0000-0002-3622-3439; Lee, Jaewon/0000-0003-3203-2130; Song, Gyu Yong/0000-0001-6058-5790	national cancer center of Korea [0920250]; Pusan National University [PNU-2008-101-20080596000]; Ministry of Education, Science and Technology [2009-0093815]	national cancer center of Korea; Pusan National University(Pusan National University); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by national cancer center of Korea (0920250; BJP), by the Bio-Scientific Research Grant funded by the Pusan National University (PNU-2008-101-20080596000; BJP) and by the Priority Research Center Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2009-0093815; GYS).	Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Butz J, 2003, BMC BIOTECHNOL, V3, DOI 10.1186/1472-6750-3-11; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Deramaudt T, 2005, BBA-REV CANCER, V1756, P97, DOI 10.1016/j.bbcan.2005.08.003; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Kumaravel TS, 2005, BREAST CANCER RES TR, V91, P89, DOI 10.1007/s10549-004-5780-0; Lee SH, 2009, ONCOGENE, V28, P2005, DOI 10.1038/onc.2009.67; Lee SJ, 2009, INT J ONCOL, V34, P1637, DOI 10.3892/ijo_00000294; Lee SH, 2009, NEOPLASIA, V11, P22, DOI 10.1593/neo.81006; Leslie A, 2003, CANCER RES, V63, P4656; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Park BJ, 2005, CELL, V120, P209, DOI 10.1016/j.cell.2004.11.054; Piao S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004046; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; WEINBERG RA, 2001, BIOL CANC, P311; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yan WS, 2009, J BIOL CHEM, V284, P12178, DOI 10.1074/jbc.M900994200; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508	25	33	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2010	29	32					4576	4587		10.1038/onc.2010.208	http://dx.doi.org/10.1038/onc.2010.208			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20531295				2022-12-17	WOS:000280862300008
J	Wu, Q; Sahasrabudhe, RM; Luo, LZ; Lewis, DW; Gollin, SM; Saunders, WS				Wu, Q.; Sahasrabudhe, R. M.; Luo, L. Z.; Lewis, D. W.; Gollin, S. M.; Saunders, W. S.			Deficiency in myosin light-chain phosphorylation causes cytokinesis failure and multipolarity in cancer cells	ONCOGENE			English	Article						cytokinesis; myosin light-chain kinase; multinucleation; multipolar spindles; myosin phosphatase; myosin regulatory light chain	RHO-ASSOCIATED KINASE; SMOOTH-MUSCLE MYOSIN; CHROMOSOMAL INSTABILITY; CLEAVAGE FURROW; CITRON-KINASE; CENTROSOME; LINES; CONSEQUENCES; PHOSPHATASE; INVASION	Cancer cells often have unstable genomes and increased centrosome and chromosome numbers, which are an important part of malignant transformation in the most recent model of tumorigenesis. However, very little is known about divisional failures in cancer cells that may lead to chromosomal and centrosomal amplifications. In this study, we show that cancer cells often failed at cytokinesis because of decreased phosphorylation of the myosin regulatory light chain (MLC), a key regulatory component of cortical contraction during division. Reduced MLC phosphorylation was associated with high expression of myosin phosphatase and/or reduced myosin light-chain kinase levels. Furthermore, expression of phosphomimetic MLC largely prevented cytokinesis failure in the tested cancer cells. When myosin light-chain phosphorylation was restored to normal levels by phosphatase knockdown, multinucleation and multipolar mitosis were markedly reduced, resulting in enhanced genome stabilization. Furthermore, both overexpression of myosin phosphatase or inhibition of the myosin light-chain kinase in nonmalignant cells could recapitulate some of the mitotic defects of cancer cells, including multinucleation and multipolar spindles, indicating that these changes are sufficient to reproduce the cytokinesis failures we see in cancer cells. These results for the first time define the molecular defects leading to divisional failure in cancer cells. Oncogene ( 2010) 29, 4183-4193; doi: 10.1038/onc.2010.165; published online 24 May 2010	[Wu, Q.; Sahasrabudhe, R. M.; Saunders, W. S.] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; [Luo, L. Z.] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA; [Lewis, D. W.; Gollin, S. M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15260 USA; [Lewis, D. W.; Gollin, S. M.; Saunders, W. S.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; City of Hope; Beckman Research Institute of City of Hope; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Saunders, WS (corresponding author), Univ Pittsburgh, Dept Biol Sci, 258 Crawford Hall, Pittsburgh, PA 15260 USA.	wsaund@pitt.edu		Luo, Li/0000-0002-8680-4119; Gollin, Susanne/0000-0001-5438-6808	NIH [R01DE016086, R01DE14729, P30CA47904]; NATIONAL CANCER INSTITUTE [P30CA047904] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE016086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014729] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr David J Hartshorne (University of Arizona) for kindly providing the UPCI:SCC103 cell line and HEK293 with the MYPT1 expression cell line, respectively. We are also grateful to Dr Jeffrey D Hildebrand (University of Pittsburgh), Dr Anne R Bresnick (Albert Einstein College of Medicine), Dr Kathleen Kelly (National Cancer Institute), Dr David J Hartshorne (University of Arizona) and Dr James T Stull (University of Texas Southwestern Medical Center) for plasmids and antibodies. We also thank Dr Xiaojing Wang (University of Pittsburgh) for helpful discussions regarding statistical analysis and Dr Jian Huang (University of Texas Southwestern Medical Center) for helpful suggestions about urea glycerol electrophoresis. This study was supported in part by NIH grants R01DE016086 to WSS and SMG and R01DE14729 to SMG and WSS. Cytogenetic analyses were carried out in the UPCI Cytogenetics Facility, supported in part by NIH grant P30CA47904 to Ronald B Herberman/SMG.	Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Eda M, 2001, J CELL SCI, V114, P3273; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Geigl JB, 2008, TRENDS GENET, V24, P64, DOI 10.1016/j.tig.2007.11.006; Gu LZ, 2006, EUR J CANCER, V42, P948, DOI 10.1016/j.ejca.2005.12.017; IKEBE M, 1988, J BIOL CHEM, V263, P6432; IKEBE M, 1985, J BIOL CHEM, V260, P27; Ito M, 2004, MOL CELL BIOCHEM, V259, P197, DOI 10.1023/B:MCBI.0000021373.14288.00; Kaneko K, 2002, PANCREAS, V24, P34, DOI 10.1097/00006676-200201000-00005; King RW, 2008, BBA-REV CANCER, V1786, P4, DOI 10.1016/j.bbcan.2008.07.007; Komatsu S, 2000, J BIOL CHEM, V275, P34512, DOI 10.1074/jbc.M003019200; Kosako H, 1999, ONCOGENE, V18, P2783, DOI 10.1038/sj.onc.1202633; Lemez P, 1998, LEUKEMIA RES, V22, P581, DOI 10.1016/S0145-2126(97)00177-X; Lothschutz D, 2002, INFLAMM RES, V51, P416, DOI 10.1007/PL00000323; Lucero A, 2006, MOL BIOL CELL, V17, P4093, DOI 10.1091/mbc.E06-02-0119; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; MOUSSAVI RS, 1993, MOL CELL BIOCHEM, V128, P219, DOI 10.1007/BF01076773; Nigg EA, 2006, INT J CANCER, V119, P2717, DOI 10.1002/ijc.22245; Olaharski AJ, 2006, CARCINOGENESIS, V27, P337, DOI 10.1093/carcin/bgi218; PARK SH, 1995, CANCER GENET CYTOGEN, V83, P127, DOI 10.1016/0165-4608(95)00040-V; Poperechnaya A, 2000, J CELL BIOL, V151, P697, DOI 10.1083/jcb.151.3.697; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Schenker T, 1998, EXP CELL RES, V239, P161, DOI 10.1006/excr.1997.3896; SCHOLEY JM, 1980, NATURE, V287, P233, DOI 10.1038/287233a0; SHACKNEY SE, 1989, CANCER RES, V49, P3344; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Silverman-Gavrila RV, 2001, CELL MOTIL CYTOSKEL, V50, P180, DOI 10.1002/cm.10006; Sluder G, 2004, CURR OPIN CELL BIOL, V16, P49, DOI 10.1016/j.ceb.2003.11.006; Takanishi DM, 1996, ARCH SURG-CHICAGO, V131, P587; Thompson SL, 2008, J CELL BIOL, V180, P665, DOI 10.1083/jcb.200712029; Tohtong R, 2003, PROSTATE CANCER P D, V6, P212, DOI 10.1038/sj.pcan.4500663; VANELDIK LJ, 1984, MOL CELL BIOL, V4, P2224, DOI 10.1128/MCB.4.10.2224; Wang Q, 2004, DNA CELL BIOL, V23, P475, DOI 10.1089/1044549041562276; White JS, 2007, ORAL ONCOL, V43, P701, DOI 10.1016/j.oraloncology.2006.09.001; WORD RA, 1991, AM J PHYSIOL, V260, pC861, DOI 10.1152/ajpcell.1991.260.4.C861; Xia DL, 2005, EXP CELL RES, V304, P506, DOI 10.1016/j.yexcr.2004.11.025	36	33	34	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2010	29	29					4183	4193		10.1038/onc.2010.165	http://dx.doi.org/10.1038/onc.2010.165			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20498637	Green Accepted			2022-12-17	WOS:000280151500006
J	Hsu, FF; Lin, TY; Chen, JY; Shieh, SY				Hsu, F-F; Lin, T-Y; Chen, J-Y; Shieh, S-Y			p53-Mediated transactivation of LIMK2b links actin dynamics to cell cycle checkpoint control	ONCOGENE			English	Article						cell cycle checkpoint; LIMK2; p53	TISSUE-SPECIFIC EXPRESSION; PROTEIN-KINASE; COFILIN PHOSPHORYLATION; ALTERNATIVE TRANSCRIPTS; DEPOLYMERIZING FACTOR; TARGET-GENE; P53; ROCK; RHO; ACTIVATION	The p53 tumor suppressor protein is widely known for its role as a sequence-specific transcription factor that regulates the expression of stress response genes. Here, we report the identification of LIMK2, which encodes a kinase that regulates actin dynamics through phosphorylation of cofilin, as a p53 target upregulated by DNA damage. Interestingly, the splice variant LIMK2b, but not LIMK2a, was induced in a p53-dependent manner through an intronic consensus p53-binding site. Depletion of LIMK2b leads to early exit of G2/M arrest after DNA damage, whereas its overexpression prolongs the arrest. These responses are recapitulated by ectopic expression of the active cofilin S3A mutant and the inactive cofilin S3D mutant, respectively, suggesting that LIMK2b may modulate G2/M arrest through cofilin phosphorylation. Furthermore, in support of its potential role as a tumor suppressor, LIMK2b was downregulated in esophageal and thyroid cancers, as well as in a number of established cancer cell lines, and its expression suppresses cancer cell migration. Taken together, our results unveil a novel pathway whereby LIMK2b, acting downstream of p53, ensures proper execution of checkpoint arrest by modulating the dynamics of actin polymerization. Oncogene (2010) 29, 2864-2876; doi: 10.1038/onc.2010.40; published online 1 March 2010	[Hsu, F-F; Lin, T-Y; Chen, J-Y; Shieh, S-Y] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; [Hsu, F-F] Natl Yang Ming Univ, Program Mol Med, Inst Biochem & Mol Biol, Taipei 112, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University	Shieh, SY (corresponding author), Acad Sinica, Inst Biomed Sci, 128,Sec 2,Acad Rd, Taipei 115, Taiwan.	sy88@ibms.sinica.edu.tw	Chen, Joanne Jeou-Yuan/S-7022-2018; Shieh, Sheau-Yann/N-9512-2018	Shieh, Sheau-Yann/0000-0002-5351-4430	Academia Sinica	Academia Sinica(Academia Sinica - Taiwan)	We thank Hsiu-Ting Lin for her expert technical assistance with the RT-PCR. This work was supported by funding from Academia Sinica to S-Y Shieh.	Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; Amano T, 2002, J BIOL CHEM, V277, P22093, DOI 10.1074/jbc.M201444200; Amano T, 2001, BIOCHEM J, V354, P149, DOI 10.1042/0264-6021:3540149; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Croft DR, 2006, MOL CELL BIOL, V26, P4612, DOI 10.1128/MCB.02061-05; Gadea G, 2002, EMBO J, V21, P2373, DOI 10.1093/emboj/21.10.2373; Gadea G, 2007, J CELL BIOL, V178, P23, DOI 10.1083/jcb.200701120; Goyal P, 2005, J BIOL CHEM, V280, P27569, DOI 10.1074/jbc.M504448200; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; Guo FK, 2003, J BIOL CHEM, V278, P14414, DOI 10.1074/jbc.M300341200; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; Hotulainen P, 2005, MOL BIOL CELL, V16, P649, DOI 10.1091/mbc.E04-07-0555; Ikebe C, 1997, GENOMICS, V46, P504, DOI 10.1006/geno.1997.5060; Jetten Anton M, 2009, Nucl Recept Signal, V7, pe003, DOI 10.1621/nrs.07003; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Li ZP, 2006, MOL CELL BIOL, V26, P4240, DOI 10.1128/MCB.02124-05; Lu Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001149; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Murray-Zmijewski F, 2008, NAT REV MOL CELL BIO, V9, P702, DOI 10.1038/nrm2451; Nomoto S, 1999, GENE, V236, P259, DOI 10.1016/S0378-1119(99)00280-2; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Olsson A, 2007, CELL DEATH DIFFER, V14, P1561, DOI 10.1038/sj.cdd.4402196; Ongusaha PP, 2006, CURR BIOL, V16, P2466, DOI 10.1016/j.cub.2006.10.056; Osada H, 1996, BIOCHEM BIOPH RES CO, V229, P582, DOI 10.1006/bbrc.1996.1847; Ou YH, 2007, EMBO J, V26, P3968, DOI 10.1038/sj.emboj.7601825; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Scott RW, 2007, J MOL MED, V85, P555, DOI 10.1007/s00109-007-0165-6; Smolich B, 1997, J BIOCHEM-TOKYO, V121, P382; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Sumi T, 2001, J BIOL CHEM, V276, P670, DOI 10.1074/jbc.M007074200; Takahashi T, 2001, DEV BIOL, V229, P554, DOI 10.1006/dbio.2000.9999; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Vardouli L, 2005, J BIOL CHEM, V280, P11448, DOI 10.1074/jbc.M402651200; Zhu Y, 2006, ONCOGENE, V25, P2901, DOI 10.1038/sj.onc.1209314	39	33	35	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	19					2864	2876		10.1038/onc.2010.40	http://dx.doi.org/10.1038/onc.2010.40			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20190821				2022-12-17	WOS:000277591900011
J	Thalappilly, S; Soubeyran, P; Iovanna, JL; Dusetti, NJ				Thalappilly, S.; Soubeyran, P.; Iovanna, J. L.; Dusetti, N. J.			VAV2 regulates epidermal growth factor receptor endocytosis and degradation	ONCOGENE			English	Article						VAV2; EGFR; endosome; receptor internalization	NUCLEOTIDE EXCHANGE FACTOR; EGF RECEPTOR; C-CBL; PANCREATIC-CANCER; TRAFFICKING; ACTIVATION; PROTEIN; RAC1; FAMILY; CDC42	Vav proteins are guanine nucleotide exchange factors for Rho GTPases that regulate cell adhesion, motility, spreading and proliferation in response to growth factor signalling. In this work, we show that Vav2 expression delayed epidermal growth factor receptor (EGFR) internalization and degradation, and enhanced EGFR, ERK and Akt phosphorylations. This effect of Vav2 on EGFR degradation is dependent on its guanine nucleotide exchange function. Knockdown of Vav2 in HeLa cells enhanced EGFR degradation and reduced cell proliferation. epidermal growth factor stimulation led to colocalization of Vav2 with EGFR and Rab5 in endosomes. We further show that the effect of Vav2 on EGFR stability is modulated by its interaction with two endosome-associated proteins and require RhoA function. Thus, in this work, we report for the first time that Vav2 can regulate growth factors receptor signalling by slowing receptor internalization and degradation through its interaction with endosome-associated proteins. Oncogene (2010) 29, 2528-2539; doi:10.1038/onc.2010.1; published online 8 February 2010	[Thalappilly, S.; Soubeyran, P.; Iovanna, J. L.; Dusetti, N. J.] INSERM, U624, F-13288 Marseille, France; [Thalappilly, S.; Soubeyran, P.; Iovanna, J. L.; Dusetti, N. J.] Aix Marseille Univ, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Dusetti, NJ (corresponding author), INSERM, U624, Parc Sci Luminy,Case 915, F-13288 Marseille, France.	nelson.dusetti@inserm.fr	Iovanna, Juan/M-9805-2017; Soubeyran, Philippe/P-1758-2018; Dusetti, Nelson/O-7919-2017	Iovanna, Juan/0000-0003-1822-2237; Dusetti, Nelson/0000-0002-6161-8483; Thalappilly, Subhash/0000-0003-1766-3057; Soubeyran, Philippe/0000-0002-5876-3217	INSERM; Ligue Contre le Cancer; ARC (Association pour la Recherche sur le Cancer)	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ligue Contre le Cancer(Ligue nationale contre le cancer); ARC (Association pour la Recherche sur le Cancer)(Fondation ARC pour la Recherche sur le Cancer)	We gratefully acknowledge M Seux for help throughout the work and P Spotto for technical help. Dr Alan Saltiel (University of Michigan, Ann Arbor, MI, USA) kindly provided Gapvd1 constructs and Dr Laszlo Buday (Semmelweis University, Budapest, Hungary) Vav2-GFP plasmids. This work was supported in part by INSERM and grants from the Ligue Contre le Cancer. ST was supported by a postdoctoral fellowship from ARC (Association pour la Recherche sur le Cancer).	Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Aoki K, 2005, MOL BIOL CELL, V16, P2207, DOI 10.1091/mbc.e04-10-0904; Bache KG, 2006, MOL BIOL CELL, V17, P2513, DOI 10.1091/mbc.E05-10-0915; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; BUSTELO XR, 1994, ONCOGENE, V9, P2405; Bustelo XR, 2002, FRONT BIOSCI, V7, pD24, DOI 10.2741/bustelo; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Ceresa BP, 2006, HISTOL HISTOPATHOL, V21, P987, DOI 10.14670/HH-21.987; Clague MJ, 2006, TRENDS CELL BIOL, V16, P551, DOI 10.1016/j.tcb.2006.09.002; Cowan CW, 2005, NEURON, V46, P205, DOI 10.1016/j.neuron.2005.03.019; de Melker AA, 2001, J CELL SCI, V114, P2167; Donepudi M, 2008, CELL SIGNAL, V20, P1359, DOI 10.1016/j.cellsig.2008.03.007; Doody GM, 2000, EMBO J, V19, P6173, DOI 10.1093/emboj/19.22.6173; Ellis S, 2000, TRENDS CELL BIOL, V10, P85, DOI 10.1016/S0962-8924(99)01710-9; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; Franco M, 2006, MOL CELL BIOL, V26, P1932, DOI 10.1128/MCB.26.5.1932-1947.2006; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Goel S, 2007, J EXP THER ONCOL, V6, P305; Gomez TS, 2005, NAT IMMUNOL, V6, P261, DOI 10.1038/ni1168; Hornstein I, 2004, CELL SIGNAL, V16, P1, DOI 10.1016/S0898-6568(03)00110-4; Houlard M, 2002, J EXP MED, V195, P1115, DOI 10.1084/jem.20011701; Hunker CM, 2006, BIOCHEM BIOPH RES CO, V340, P967, DOI 10.1016/j.bbrc.2005.12.099; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Lodhi IJ, 2007, CELL METAB, V5, P59, DOI 10.1016/j.cmet.2006.12.006; Marcoux N, 2003, ONCOGENE, V22, P6100, DOI 10.1038/sj.onc.1206712; Morita E, 2007, EMBO J, V26, P4215, DOI 10.1038/sj.emboj.7601850; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Narumiya S, 2006, CURR OPIN CELL BIOL, V18, P199, DOI 10.1016/j.ceb.2006.02.002; Orth JD, 2006, CANCER RES, V66, P3603, DOI 10.1158/0008-5472.CAN-05-2916; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; Patel V, 2007, CARCINOGENESIS, V28, P1145, DOI 10.1093/carcin/bgm008; Peng FF, 2010, CELL SIGNAL, V22, P34, DOI 10.1016/j.cellsig.2009.09.003; Puertollano R, 2005, J BIOL CHEM, V280, P9258, DOI 10.1074/jbc.M412481200; Romero F, 1996, CELL SIGNAL, V8, P545, DOI 10.1016/S0898-6568(96)00118-0; Schuebel KE, 1996, ONCOGENE, V13, P363; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Seye CI, 2004, J BIOL CHEM, V279, P35679, DOI 10.1074/jbc.M401799200; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Stuffers S, 2009, EXP CELL RES, V315, P1619, DOI 10.1016/j.yexcr.2008.10.013; Su X, 2007, J BIOL CHEM, V282, P21278, DOI 10.1074/jbc.M703725200; Swat W, 2005, IMMUNOL RES, V32, P259, DOI 10.1385/IR:32:1-3:259; Tamas P, 2003, J BIOL CHEM, V278, P5163, DOI 10.1074/jbc.M207555200; Tamas P, 2001, CELL SIGNAL, V13, P475, DOI 10.1016/S0898-6568(01)00172-3; Thalappilly S, 2008, PROTEOMICS, V8, P3071, DOI 10.1002/pmic.200701157; Tu S, 2003, J BIOL CHEM, V278, P49293, DOI 10.1074/jbc.M307021200; Umebayashi K, 2008, MOL BIOL CELL, V19, P3454, DOI 10.1091/mbc.E07-10-0988; Ung CY, 2008, FEBS LETT, V582, P2283, DOI 10.1016/j.febslet.2008.05.026; Wadsworth P, 2005, CURR BIOL, V15, pR871, DOI 10.1016/j.cub.2005.10.021; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; Williams RL, 2007, NAT REV MOL CELL BIO, V8, P355, DOI 10.1038/nrm2162; Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092-8674(03)00688-3; Yamazaki T, 2002, J CELL SCI, V115, P1791; Yanagida-Ishizaki Y, 2008, CELL STRUCT FUNCT, V33, P91, DOI 10.1247/csf.07037; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000	57	33	34	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	17					2528	2539		10.1038/onc.2010.1	http://dx.doi.org/10.1038/onc.2010.1			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20140013				2022-12-17	WOS:000277169400008
J	Rattan, R; Narita, K; Chien, J; Maguire, JL; Shridhar, R; Giri, S; Shridhar, V				Rattan, R.; Narita, K.; Chien, J.; Maguire, J. L.; Shridhar, R.; Giri, S.; Shridhar, V.			TCEAL7, a putative tumor suppressor gene, negatively regulates NF-kappa B pathway	ONCOGENE			English	Article						TCEAL7; NF-kappa B; ovarian cancer; tumor suppressor gene	HUMAN OVARIAN-CARCINOMA; RNA-POLYMERASE-II; INDUCED APOPTOSIS; CANCER MODELS; EARLY-STAGE; IN-VITRO; EXPRESSION; CELLS; CHEMORESISTANCE; IDENTIFICATION	We have previously shown that a frequently downregulated gene, transcription elongation factor A-like 7 (TCEAL7), promoted anchorage-independent growth and modulated Myc activity in ovarian surface epithelial cells immortalized with temperature-sensitive large T antigen and human telomerase reverse transcriptase (OSEtsT/hTERT). Analysis of protein/DNA array showed that TCEAL7 downregulation resulted in an approximately twofold increase in nuclear factor (NF)-kappa B binding to its target DNA sequence. In this study we showed that short hairpin RNA (shRNA)-mediated downregulation of TCEAL7 in two different immortalized OSE cells showed higher NF-kappa B activity, as determined using reporter and gel-shift assays. Transient transfection of TCEAL7 inhibited the activation of NF-kappa B in TCEAL7-downregulated clones, IOSE-523 and in other ovarian cancer cell lines (OVCAR8, SKOV3ip and DOV13), suggesting that TCEAL7 negatively regulates NF-kappa B pathway. Consistent with this observation, TCEAL7-downregulated clones showed higher levels of NF-kappa B targets, such as pro-proliferative (cyclin-D1 and cMyc), pro-angiogenic (interleukin (IL)-6, IL-8 and vascular endothelial growth factor (VEGF)), inflammatory (intercellular adhesion molecule 1 (ICAM-1) and cyclooxygenase-2 (Cox-2)) and antiapoptotic (B-cell lymphoma-extra large (Bcl-xl)) genes when compared with vector controls. Inhibition of NF-kappa B by I kappa B kinase (IKK) inhibitor (BMS 345541) attenuated cell survival and proliferation of TCEAL-knockdown clones. Although TCEAL7 inhibited p65 transcriptional activity, it did not modulate the cytoplasmic signaling of the NF-kappa B pathway, by itself or by tumor necrosis factor alpha (TNF-alpha). Chromatin immunoprecipitation (ChIP) assays revealed increased recruitment of p65 and p300 to the promoters of IL-8 and IL-6 in TCEAL7-downregulated clones. Collectively, these results indicate a novel role for TCEAL7 in the negative regulation of NF-kappa B signaling at the basal level by modulating transcriptional activity of NF-kappa B on its target gene promoters, potentially providing a novel mechanism by which NF-kappa B activity may be deregulated in ovarian cancer cells. Oncogene (2010) 29, 1362-1373; doi:10.1038/onc.2009.431; published online 7 December 2009	[Rattan, R.; Chien, J.; Maguire, J. L.; Giri, S.; Shridhar, V.] Mayo Clin, Coll Med, Dept Expt Pathol, Rochester, MN 55905 USA; [Narita, K.] Univ Yamanashi, Fac Med, Dept Anat & Cell Biol, Chuo Ku, Yamanashi, Japan; [Shridhar, R.] Barbara Ann Karmanos Canc Inst, Gershenson Radiat Oncol Ctr, Detroit, MI USA	Mayo Clinic; University of Yamanashi; Barbara Ann Karmanos Cancer Institute	Shridhar, V (corresponding author), Mayo Clin, Coll Med, Dept Lab Med & Expt Pathol, Rochester, MN 55905 USA.	shridhar.vijayalakshmi@mayo.edu	Narita, Keishi/E-3539-2010; Chien, Jeremy/AID-8939-2022; Seal, Sudipta/A-7698-2012	Narita, Keishi/0000-0002-7602-8523; Chien, Jeremy/0000-0003-4744-8374	Ovarian Cancer Research Fund; Mayo Foundation; Bernard and Edith Waterman Foundation	Ovarian Cancer Research Fund; Mayo Foundation; Bernard and Edith Waterman Foundation	This work was supported by Ovarian Cancer Research Fund to RR as a Program of Excellence grant and with funds from Mayo Foundation and Bernard and Edith Waterman Foundation to VS.	Abdollahi T, 2003, CANCER RES, V63, P4521; Aggarwal BB, 2004, EXPERT OPIN INV DRUG, V13, P1327, DOI 10.1517/13543784.13.10.1327; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Ahn KS, 2007, CURR MOL MED, V7, P619, DOI 10.2174/156652407782564363; Arlt A, 2002, INT J CLIN PHARM TH, V40, P336; Camp ER, 2004, J AM COLL SURGEONS, V199, P249, DOI 10.1016/j.jamcollsurg.2004.04.015; Chen R, 2007, AM J REPROD IMMUNOL, V57, P93, DOI 10.1111/j.1600-0897.2006.00441.x; Chien J, 2005, ONCOGENE, V24, P5089, DOI 10.1038/sj.onc.1208700; Chien J, 2008, ONCOGENE, V27, P7223, DOI 10.1038/onc.2008.360; Collinson FJ, 2008, EXPERT REV ANTICANC, V8, P21, DOI 10.1586/14737140.8.1.21; Ferrandina G, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-182; Friedlander ML, 1998, SEMIN ONCOL, V25, P305; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GIAVAZZI R, 1994, EUR J CANCER, V30A, P1865, DOI 10.1016/0959-8049(94)00345-6; Giri S, 2002, FASEB J, V16, DOI 10.1096/fj.01-0798com; Jeon C, 1996, P NATL ACAD SCI USA, V93, P13677, DOI 10.1073/pnas.93.24.13677; Kalli KR, 2002, ENDOCRINOLOGY, V143, P3259, DOI 10.1210/en.2001-211408; Kar R, 2007, CANCER BIOL THER, V6, P1101, DOI 10.4161/cbt.6.7.4329; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kenny HA, 2008, J CLIN INVEST, V118, P1367, DOI 10.1172/JCI33775; Mabuchi S, 2004, CLIN CANCER RES, V10, P7645, DOI 10.1158/1078-0432.CCR-04-0958; Mabuchi S, 2004, J BIOL CHEM, V279, P23477, DOI 10.1074/jbc.M313709200; Mukai J, 2002, J BIOL CHEM, V277, P13973, DOI 10.1074/jbc.M106342200; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; Nath N, 2009, J IMMUNOL, V182, P8005, DOI 10.4049/jimmunol.0803563; Nilsson MB, 2007, J BIOL CHEM, V282, P29919, DOI 10.1074/jbc.M611539200; Opala T, 2003, EUR J GYNAECOL ONCOL, V24, P255; RAPP G, 1990, DNA CELL BIOL, V9, P479, DOI 10.1089/dna.1990.9.479; Roland CL, 2007, SURGERY, V141, P705, DOI 10.1016/j.surg.2007.01.016; Shridhar V, 2002, CANCER RES, V62, P262; Shridhar V, 2001, CANCER RES, V61, P5895; Thomas MJ, 1998, CELL, V93, P627, DOI 10.1016/S0092-8674(00)81191-5; Toutirais O, 2003, EUR CYTOKINE NETW, V14, P246; Williams J, 2005, GYNECOL ONCOL, V96, P287, DOI 10.1016/j.ygyno.2004.10.026; YEH CH, 1994, P NATL ACAD SCI USA, V91, P11002, DOI 10.1073/pnas.91.23.11002	35	33	36	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1362	1373		10.1038/onc.2009.431	http://dx.doi.org/10.1038/onc.2009.431			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19966855				2022-12-17	WOS:000275170600011
J	Joannes, A; Bonnomet, A; Bindels, S; Polette, M; Gilles, C; Burlet, H; Cutrona, J; Zahm, JM; Birembaut, P; Nawrocki-Raby, B				Joannes, A.; Bonnomet, A.; Bindels, S.; Polette, M.; Gilles, C.; Burlet, H.; Cutrona, J.; Zahm, J-M; Birembaut, P.; Nawrocki-Raby, B.			Fhit regulates invasion of lung tumor cells	ONCOGENE			English	Article						Fhit; tumor invasion; epithelial-mesenchymal transition; cell-cell adhesion molecules; matrix metalloproteinases; vimentin	FRAGILE HISTIDINE TRIAD; EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER CELLS; MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; BETA-CATENIN; SUPPRESSES TUMORIGENICITY; ZONULA OCCLUDENS-1; PROTEIN EXPRESSION; GENE; CARCINOMA	In many types of cancers, the fragile histidine triad (Fhit) gene is frequently targeted by genomic alterations leading to a decrease or loss of gene and protein expression. Fhit has been described as a tumor suppressor gene because of its ability to induce apoptosis and to inhibit proliferation of tumor cells. Moreover, several studies have shown a correlation between the lack of Fhit expression and tumor aggressiveness, thus suggesting that Fhit could be involved in tumor progression. In this study, we explored the potential role of Fhit during tumor cell invasion. We first showed that a low Fhit expression is associated with in vivo and in vitro invasiveness of tumor cells. Then, we showed that Fhit overexpression in Fhit-negative highly invasive NCI-H1299 cells by transfection of Fhit cDNA and Fhit inhibition in Fhit-positive poorly invasive HBE4-E6/E7 cells by transfection of Fhit small interfering RNA induce, respectively, a decrease and an increase in migratory/invasive capacities. These changes in cell behavior were associated with a reorganization of tight and adherens junction molecules and a regulation of matrix metalloproteinase and vimentin expression. These results show that Fhit controls the invasive phenotype of lung tumor cells by regulating the expression of genes associated with epithelial-mesenchymal transition. Oncogene (2010) 29, 1203-1213; doi: 10.1038/onc.2009.418; published online 23 November 2009	[Nawrocki-Raby, B.] CHU Maison Blanche, INSERM, U903, UMRS 903, F-51100 Reims, France; [Joannes, A.; Polette, M.; Burlet, H.; Zahm, J-M; Birembaut, P.; Nawrocki-Raby, B.] Univ Reims, IFR53, UMR S903, Reims, France; [Bonnomet, A.; Bindels, S.; Gilles, C.] Univ Liege, CHU Sart Tilman, Lab Biol Tumeurs & Dev, Liege, Belgium; [Polette, M.; Birembaut, P.] Hop Maison Blanche, CHU Reims, Lab Pol Bouin, Reims, France; [Cutrona, J.] Univ Reims, CRESTIC, Reims, France	CHU de Reims; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Reims Champagne-Ardenne; Universite de Reims Champagne-Ardenne; University of Liege; CHU de Reims; Universite de Reims Champagne-Ardenne; Universite de Reims Champagne-Ardenne	Nawrocki-Raby, B (corresponding author), CHU Maison Blanche, INSERM, U903, UMRS 903, 45 Rue Cognacq Jay, F-51100 Reims, France.	beatrice.raby@univ-reims.fr	Raby, Beatrice/P-5666-2016; BIREMBAUT, Philippe/P-5210-2016; Cutrona, Jérôme/P-6658-2016; POLETTE, Myriam/P-5147-2016	Raby, Beatrice/0000-0002-3163-8619; BONNOMET, Arnaud/0000-0002-4933-3338; POLETTE, Myriam/0000-0001-8173-3246	Region Champagne-Ardenne; Ligue Contre le Cancer (Comite de la Marne); Lions Club of Soissons; Un Euro contre le Cancer; Fond National pour la Sante [ACI 2004-2010 INCa]	Region Champagne-Ardenne(Region Grand-Est); Ligue Contre le Cancer (Comite de la Marne); Lions Club of Soissons; Un Euro contre le Cancer; Fond National pour la Sante	This study was supported by the Region Champagne-Ardenne, the Ligue Contre le Cancer (Comite de la Marne), the Lions Club of Soissons, Un Euro contre le Cancer and the Fond National pour la Sante ACI 2004-2010 INCa (Canceropole Grand-Est project).	Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Campiglio M, 2006, J CELL PHYSIOL, V208, P274, DOI 10.1002/jcp.20633; Cavazzoni A, 2004, ONCOGENE, V23, P8439, DOI 10.1038/sj.onc.1207847; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Gavert N, 2008, TRENDS MOL MED, V14, P199, DOI 10.1016/j.molmed.2008.03.004; Gavert N, 2007, J CELL BIOCHEM, V102, P820, DOI 10.1002/jcb.21505; Gilles C, 1999, J CELL SCI, V112, P4615; Gilles C, 1996, J PATHOL, V180, P175, DOI 10.1002/(SICI)1096-9896(199610)180:2<175::AID-PATH630>3.0.CO;2-G; Gilles C, 2003, CANCER RES, V63, P2658; GILLES C, 1996, BREAST J, V2, P83; Hazgui S, 2005, AM J PHYSIOL-CELL PH, V289, pC1547, DOI 10.1152/ajpcell.00319.2005; Hendrix MJC, 1997, AM J PATHOL, V150, P483; Huebner K, 2003, BRIT J CANCER, V88, P1501, DOI 10.1038/sj.bjc.6600937; Ishii H, 2001, JAMA-J AM MED ASSOC, V286, P2441, DOI 10.1001/jama.286.19.2441; Jayachandran G, 2007, CANCER RES, V67, P10379, DOI 10.1158/0008-5472.CAN-07-0677; Ji L, 1999, CANCER RES, V59, P3333; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Luo J, 1999, CANCER RES, V59, P3552; Marchenko GN, 2002, BIOCHEM J, V363, P253, DOI 10.1042/0264-6021:3630253; Maruyama R, 2004, CANCER-AM CANCER SOC, V100, P1472, DOI 10.1002/cncr.20144; Nakagawa Y, 2006, EXP CELL RES, V312, P2433, DOI 10.1016/j.yexcr.2006.04.004; Nakata S, 2006, CANCER-AM CANCER SOC, V106, P2190, DOI 10.1002/cncr.21870; Nawrocki-Raby B, 2003, AM J PATHOL, V163, P653, DOI 10.1016/S0002-9440(10)63692-9; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Pace HC, 1998, P NATL ACAD SCI USA, V95, P5484, DOI 10.1073/pnas.95.10.5484; Pekarsky Y, 2004, P NATL ACAD SCI USA, V101, P3775, DOI 10.1073/pnas.0400481101; Pekarsky Y, 2002, LANCET ONCOL, V3, P748, DOI 10.1016/S1470-2045(02)00931-2; Polette M, 2005, CANCER RES, V65, P7691, DOI 10.1158/0008-5472.CAN-04-4230; Polette M, 2004, CRIT REV ONCOL HEMAT, V49, P179, DOI 10.1016/j.critrevonc.2003.10.008; Polette M, 2007, CELLS TISSUES ORGANS, V185, P61, DOI 10.1159/000101304; Pylkkanen L, 2002, INT J ONCOL, V20, P285; Reichert M, 2000, J BIOL CHEM, V275, P9492, DOI 10.1074/jbc.275.13.9492; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Semba S, 2006, ONCOGENE, V25, P2860, DOI 10.1038/sj.onc.1209323; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sozzi G, 1998, CANCER RES, V58, P5032; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Takahashi M, 2002, ONCOGENE, V21, P5861, DOI 10.1038/sj.onc.1205755; Tobioka H, 2004, HUM PATHOL, V35, P159, DOI 10.1016/j.humpath.2003.09.013; Trapasso F, 2003, P NATL ACAD SCI USA, V100, P1592, DOI 10.1073/pnas.0437915100; Van Aken E, 2001, VIRCHOWS ARCH, V439, P725, DOI 10.1007/S004280100516; Weiske J, 2007, P NATL ACAD SCI USA, V104, P20344, DOI 10.1073/pnas.0703664105; Zahm JM, 1997, CELL MOTIL CYTOSKEL, V37, P33, DOI 10.1002/(SICI)1097-0169(1997)37:1<33::AID-CM4>3.0.CO;2-I	48	33	35	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1203	1213		10.1038/onc.2009.418	http://dx.doi.org/10.1038/onc.2009.418			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19935706				2022-12-17	WOS:000274912100011
J	Montanez-Wiscovich, ME; Seachrist, DD; Landis, MD; Visvader, J; Andersen, B; Keri, RA				Montanez-Wiscovich, M. E.; Seachrist, D. D.; Landis, M. D.; Visvader, J.; Andersen, B.; Keri, R. A.			LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression	ONCOGENE			English	Article						breast cancer; cullin-3; ErbB2; HER2; LMO4	MAMMARY EPITHELIAL-CELLS; DOMAIN PROTEIN LMO4; MESSENGER-RNA STABILITY; ADJUVANT CHEMOTHERAPY; TRANSGENIC MICE; ERBB RECEPTORS; IN-VITRO; GENE; EXPRESSION; KINASE	ErbB2/HER2/Neu-overexpressing breast cancers are characterized by poor survival due to high proliferation and metastasis rates and identifying downstream targets of ErbB2 should facilitate developing novel therapies for this disease. Gene expression pro. ling revealed the transcriptional regulator LIM-only protein 4 (LMO4) is upregulated during ErbB2-induced mouse mammary gland tumorigenesis. Although LMO4 is frequently overexpressed in breast cancer and LMO4-overexpressing mice develop mammary epithelial tumors, the mechanisms involved are unknown. In this study, we report that LMO4 is a downstream target of ErbB2 and PI3K in ErbB2-dependent breast cancer cells. Furthermore, LMO4 silencing reduces proliferation of these cells, inducing a G2/M arrest that was associated with decreased cullin-3, an E3-ubiquitin ligase component important for mitosis. Loss of LMO4 subsequently results in reduced Cyclin D1 and Cyclin E. Further supporting a role for LMO4 in modulating proliferation by regulating cullin-3 expression, we found that LMO4 expression oscillates throughout the cell cycle with maximum expression occurring during G2/M and these changes precede oscillations in cullin-3 levels. LMO4 levels are also highest in high-grade/less differentiated breast cancers, which are characteristically highly proliferative. We conclude that LMO4 is a novel cell cycle regulator with a key role in mediating ErbB2-induced proliferation, a hallmark of ErbB2-positive disease. Oncogene (2009) 28, 3608-3618; doi:10.1038/onc.2009.221; published online 3 August 2009	[Keri, R. A.] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; [Visvader, J.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Victorian Breast Canc Res Consortium Lab, Parkville, Vic 3050, Australia; [Andersen, B.] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; [Andersen, B.] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92717 USA; [Keri, R. A.] Case Western Reserve Univ, Div Gen Med Sci Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of California System; University of California Irvine; University of California System; University of California Irvine; Case Western Reserve University	Keri, RA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	keri@case.edu	Keri, Ruth/ABF-2209-2021	Keri, Ruth/0000-0002-1640-3088	CURE [RO1-CA090398]; NIH [AR44882, T32-GM007250, F31-CA123642]; NATIONAL CANCER INSTITUTE [R01CA090398, F31CA123642, P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER	CURE; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Jonathan Mosley for help with statistical analyses, Meredith Sorenson for technical support and members of the Keri laboratory, especially Gina Bernardo and Emhonta Johnson, for useful discussions. We are grateful for assistance from the Case Comprehensive Cancer Center core facilities (P30 CA43703). This work was supported by: RO1-CA090398 (RAK), CURE supplementary grant to RO1-CA090398 (RAK), NIH AR44882 (BA), T32-GM007250 (MEMW) and F31-CA123642 (MEMW).	Andrechek ER, 2005, ONCOGENE, V24, P932, DOI 10.1038/sj.onc.1208230; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; CAPOROSSI D, 1995, HUM GENET, V96, P269; Chen HH, 2007, BIOCHEM BIOPH RES CO, V357, P56, DOI 10.1016/j.bbrc.2007.03.113; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Desai KV, 2002, P NATL ACAD SCI USA, V99, P6967, DOI 10.1073/pnas.102172399; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Ismail IA, 2007, EUR J PHARMACOL, V575, P12, DOI 10.1016/j.ejphar.2007.07.039; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Junaid A, 2007, AM J PHYSIOL-CELL PH, V292, pC919, DOI 10.1152/ajpcell.00477.2006; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Kuraguchi M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000367; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Landis MD, 2005, ONCOGENE, V24, P5173, DOI 10.1038/sj.onc.1208712; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lenferink AEG, 2001, CANCER RES, V61, P6583; Lewis GD, 1996, CANCER RES, V56, P1457; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Mosley JD, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-11; Mousses S, 2002, CANCER RES, V62, P1256; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, J BIOL CHEM, V267, P12266; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ribar B, 2007, MOL CELL BIOL, V27, P3211, DOI 10.1128/MCB.00091-07; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; Seidman A, 2002, J CLIN ONCOL, V20, P1215, DOI 10.1200/JCO.20.5.1215; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Stern DF, 2003, EXP CELL RES, V284, P89, DOI 10.1016/S0014-4827(02)00103-9; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; Sum EYM, 2005, P NATL ACAD SCI USA, V102, P7659, DOI 10.1073/pnas.0502990102; Sum EYM, 2005, J HISTOCHEM CYTOCHEM, V53, P475, DOI 10.1369/jhc.4A6553.2005; Sum EYM, 2005, ONCOGENE, V24, P4820, DOI 10.1038/sj.onc.1208638; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Sumara I, 2007, DEV CELL, V12, P887, DOI 10.1016/j.devcel.2007.03.019; Sutherland KD, 2003, INT J CANCER, V107, P155, DOI 10.1002/ijc.11343; Taniwaki M, 2006, INT J ONCOL, V29, P567; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; Wang N, 2007, ONCOGENE, V26, P6431, DOI 10.1038/sj.onc.1210465; Wang N, 2004, ONCOGENE, V23, P1507, DOI 10.1038/sj.onc.1207288; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wittlin S, 2003, GENOMICS, V82, P280, DOI 10.1016/S0888-7543(03)00147-2; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yakes FM, 2002, CANCER RES, V62, P4132; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	53	33	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2009	28	41					3608	3618		10.1038/onc.2009.221	http://dx.doi.org/10.1038/onc.2009.221			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KJ	19648968	Green Accepted, Green Submitted			2022-12-17	WOS:000270851800002
J	de la Chapelle, A				de la Chapelle, A.			Genetic predisposition to human disease: allele-specific expression and low-penetrance regulatory loci	ONCOGENE			English	Review						allele-specific expression; TGFBR1; APC; DAPK1	TGFBR1	The two alleles of a gene can be expressed at different levels, the extreme example being imprinting, a condition in which one allele is totally suppressed. Recently, subtle differences in the expression of the two alleles have been detected in numerous human genes and in a few cases, have been associated with a genetic predisposition to disease. The underlying mechanisms are largely unexplored. Oncogene (2009) 28, 3345-3348; doi: 10.1038/onc.2009.194; published online 13 July 2009	Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	de la Chapelle, A (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, 804 Biomed Res Tower,460 W 12th Ave, Columbus, OH 43210 USA.	albert.delachapelle@osumc.edu			NIH [CA67941, CA16058, P01 124570]; NATIONAL CANCER INSTITUTE [R01CA098933, U01CA067941, P01CA124570, T32CA106196, R01CA067941, P30CA016058] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Work in the author's laboratory was supported by NIH grants CA67941, CA16058 and P01 124570.	Carninci P, 2009, NATURE, V457, P974, DOI 10.1038/457974b; Cowles CR, 2002, NAT GENET, V32, P432, DOI 10.1038/ng992; Gimelbrant A, 2007, SCIENCE, V318, P1136, DOI 10.1126/science.1148910; Goring HHH, 2007, NAT GENET, V39, P1208, DOI 10.1038/ng2119; Guda K, 2009, CANCER RES, V69, P4959, DOI 10.1158/0008-5472.CAN-09-0225; He YP, 2008, SCIENCE, V322, P1855, DOI 10.1126/science.1163853; Houlston RS, 2008, NAT GENET, V40, P1426, DOI 10.1038/ng.262; Knight JC, 2004, TRENDS GENET, V20, P113, DOI 10.1016/j.tig.2004.01.001; Lo HS, 2003, GENOME RES, V13, P1855, DOI 10.1101/gr.1006603; Lynch HT, 2002, AM J MED GENET, V115, P113, DOI 10.1002/ajmg.10686; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; Raval A, 2007, CELL, V129, P879, DOI 10.1016/j.cell.2007.03.043; Stranger BE, 2007, NAT GENET, V39, P1217, DOI 10.1038/ng2142; Valle L, 2008, SCIENCE, V321, P1361, DOI 10.1126/science.1159397; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799; Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545; Zeng QH, 2009, CANCER RES, V69, P678, DOI 10.1158/0008-5472.CAN-08-3980	17	33	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2009	28	38					3345	3348		10.1038/onc.2009.194	http://dx.doi.org/10.1038/onc.2009.194			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	497ZD	19597467	Green Accepted			2022-12-17	WOS:000270103300001
J	Kopanja, D; Stoyanova, T; Okur, MN; Huang, E; Bagchi, S; Raychaudhuri, P				Kopanja, D.; Stoyanova, T.; Okur, M. N.; Huang, E.; Bagchi, S.; Raychaudhuri, P.			Proliferation defects and genome instability in cells lacking Cul4A	ONCOGENE			English	Article						Cul4A; proliferation; genome instability; p53	PROTEOLYSIS; PROTEIN; DDB1; AMPLIFICATION; DEGRADATION; TARGETS; MOUSE; GENE; P53; STABILITY	The Cul4A gene, which encodes a core component of a cullin-based E3 ubiquitin ligase complex, is overexpressed in breast and hepatocellular cancers. In breast cancers, overexpression of Cul4A strongly correlates with poor prognosis. In addition, Cul4A is required for early embryonic development. The early lethality of mouse embryos prevented a detailed analysis of the functions of Cul4A. Here, we used a strain of mice carrying floxed alleles of Cul4A to study its role in cell division, in vitro and in vivo. Embryonic fibroblasts (MEFs) show a severe deficiency in cell proliferation after deletion of Cul4A. We observed that the Cul4A protein is abundantly expressed in the brain, liver and the mammary tissue of pregnant mice. Deletion of Cul4A in the liver impairs hepatocyte proliferation during regeneration after carbon tetrachloride (CCl4)-induced injury. The Cul4A-deleted cells are slow in entering the S phase, and are deficient in progressing through the early M phase. Several cell-cycle regulators, including p53 and p27Kip1, are deregulated in the Cul4A-deleted cells. Expression of a dominant negative mutant of p53 causes significant reversal of the proliferation defects in Cul4A-deleted cells. The Cul4A-deleted cells show an aberrant number of centrosome, multipolar spindles and micronuclei formation. Furthermore, those cells are sensitive to UV irradiation and show reduced levels of unscheduled DNA synthesis (UDS). Together, our observations indicate that Cul4A is required for efficient cell proliferation, control of centrosome amplification and genome stability. Oncogene (2009) 28, 2456-2465; doi:10.1038/onc.2009.86; published online 11 May 2009	[Kopanja, D.; Stoyanova, T.; Okur, M. N.; Huang, E.; Raychaudhuri, P.] Univ Illinois, Dept Biochem & Mol Genet, Coll Med, Chicago, IL 60607 USA; [Bagchi, S.] Univ Illinois, Ctr Mol Biol Oral Dis, Coll Dent, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raychaudhuri, P (corresponding author), Univ Illinois, Dept Biochem & Mol Genet MC 699, Coll Med, 900 S Ashland Ave,2302 MBRB, Chicago, IL 60607 USA.	sbagchi@uic.edu; pradip@uic.edu			National Institute of Health [CA 77637, AG 02413]; NATIONAL CANCER INSTITUTE [R01CA077637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG024138] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The Cul4A fl/fl mouse strain was generated in collaboration with Xenogen Biosciences, NJ, USA. The work was supported by grants from the National Institute of Health (CA 77637 to PR and AG 02413 to PR and SB).	Abba MC, 2007, CANCER RES, V67, P4104, DOI 10.1158/0008-5472.CAN-06-4672; Banks D, 2006, CELL CYCLE, V5, P1719, DOI 10.4161/cc.5.15.3150; Belzile JP, 2007, PLOS PATHOG, V3, P882, DOI 10.1371/journal.ppat.0030085; Bergametti F, 2002, J VIROL, V76, P6495, DOI 10.1128/JVI.76.13.6495-6501.2002; Bondar T, 2006, MOL CELL BIOL, V26, P2531, DOI 10.1128/MCB.26.7.2531-2539.2006; Bondar T, 2004, J BIOL CHEM, V279, P9937, DOI 10.1074/jbc.M312570200; Cang Y, 2006, CELL, V127, P929, DOI 10.1016/j.cell.2006.09.045; Chen LC, 1998, CANCER RES, V58, P3677; El-Mahdy MA, 2006, J BIOL CHEM, V281, P13404, DOI 10.1074/jbc.M511834200; FAUSTO N, 1996, HEPATOLOGY TXB LIVER, P32; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Higa LA, 2006, CELL CYCLE, V5, P71, DOI 10.4161/cc.5.1.2266; Higa LAA, 2003, NAT CELL BIOL, V5, P1008, DOI 10.1038/ncb1061; Holmberg C, 2005, GENE DEV, V19, P853, DOI 10.1101/gad.329905; Kim Y, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-18; Li BH, 2002, MOL CELL BIOL, V22, P4997, DOI 10.1128/MCB.22.14.4997-5005.2002; Li BH, 2006, BLOOD, V107, P4291, DOI 10.1182/blood-2005-08-3349; Nag A, 2004, CANCER RES, V64, P8152, DOI 10.1158/0008-5472.CAN-04-2598; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Schindl M, 2007, ANTICANCER RES, V27, P949; Serfas MS, 1997, CELL GROWTH DIFFER, V8, P951; Shinmura K, 2007, ONCOGENE, V26, P2939, DOI 10.1038/sj.onc.1210085; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Ulane CM, 2002, VIROLOGY, V304, P160, DOI 10.1006/viro.2002.1773; Waning DL, 2008, BLOOD, V112, P320, DOI 10.1182/blood-2007-11-126300; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Yasui K, 2002, HEPATOLOGY, V35, P1476, DOI 10.1053/jhep.2002.33683; Zhang Y, 2003, EMBO J, V22, P6057, DOI 10.1093/emboj/cdg577	29	33	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	26					2456	2465		10.1038/onc.2009.86	http://dx.doi.org/10.1038/onc.2009.86			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465QH	19430492	Green Accepted			2022-12-17	WOS:000267601400004
J	Al-Ahmadi, W; Al-Haj, L; Al-Mohanna, FA; Silverman, RH; Khabar, KSA				Al-Ahmadi, W.; al-Haj, L.; Al-Mohanna, F. A.; Silverman, R. H.; Khabar, K. S. A.			RNase L downmodulation of the RNA-binding protein, HuR, and cellular growth	ONCOGENE			English	Article						3 ' untranslated regions; RNase L; HuR; RNA-binding proteins; cell growth	DOUBLE-STRANDED-RNA; MESSENGER-RNA; PROGNOSTIC-FACTOR; PROSTATE-CANCER; RIBONUCLEASE-L; 3'-UNTRANSLATED REGION; INTERFERON RESPONSE; CELLS; EXPRESSION; KINASE	Ribonuclease L (RNase L) is an intracellular enzyme that is vital in innate immunity, but also is a tumor suppressor candidate. Here, we show that overexpression of RNase L decreases cellular growth and downmodulates the RNA-binding protein, HuR, a regulator of cell-cycle progression and tumorigenesis. The effect is temporal, occurring in specific cell-cycle phases and correlated with the cytoplasmic localization of RNase L. Both cellular growth and HuR were increased in RNASEL-null mouse fibroblast lines when compared to wild-type cells. Moreover, the stability of HuR mRNA was enhanced in RNASEL-null cells. The HuR 30 untranslated region (UTR), which harbors U-rich and adenylate-uridylate-rich elements, was potently responsive to RNase L when compared to control 30 UTR. Our results may offer a new explanation to the tumor suppressor function of RNase L.	[Al-Ahmadi, W.; al-Haj, L.; Al-Mohanna, F. A.; Khabar, K. S. A.] King Faisal Specialist Hosp & Res Ctr, Program BioMol Res, Riyadh 11211, Saudi Arabia; [Silverman, R. H.; Khabar, K. S. A.] Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA	King Faisal Specialist Hospital & Research Center; Cleveland Clinic Foundation	Khabar, KSA (corresponding author), King Faisal Specialist Hosp & Res Ctr, Program BioMol Res, P3354,MBC 03,Takhasusi Rd, Riyadh 11211, Saudi Arabia.	khabar@kfshrc.edu.sa	Khabar, Khalid/A-4772-2011; Khabar, Khalid/AAG-3487-2019	Khabar, Khalid/0000-0003-1003-9788; Khabar, Khalid/0000-0003-1003-9788	NATIONAL CANCER INSTITUTE [R01CA044059] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA044059-26, R01 CA044059] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Zoghaibi F, 2007, GENE, V391, P130, DOI 10.1016/j.gene.2006.12.013; Andersen JB, 2007, ONCOGENE, V26, P3081, DOI 10.1038/sj.onc.1210111; Atasoy U, 1998, J CELL SCI, V111, P3145; BAYARD BA, 1993, BIOCHEM J, V296, P155, DOI 10.1042/bj2960155; Bisbal C, 2000, MOL CELL BIOL, V20, P4959, DOI 10.1128/MCB.20.14.4959-4969.2000; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; Castelli JC, 1998, CELL DEATH DIFFER, V5, P313, DOI 10.1038/sj.cdd.4400352; Cirino NM, 1997, P NATL ACAD SCI USA, V94, P1937, DOI 10.1073/pnas.94.5.1937; de Silanes IL, 2003, ONCOGENE, V22, P7146, DOI 10.1038/sj.onc.1206862; Denkert C, 2004, CANCER RES, V64, P189, DOI 10.1158/0008-5472.CAN-03-1987; DiazGuerra M, 1997, VIROLOGY, V236, P354, DOI 10.1006/viro.1997.8719; Dormoy-Raclet V, 2007, MOL CELL BIOL, V27, P5365, DOI 10.1128/MCB.00113-07; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Heinonen M, 2005, CANCER RES, V65, P2157, DOI 10.1158/0008-5472.CAN-04-3765; JACOBSEN H, 1983, P NATL ACAD SCI-BIOL, V80, P4954, DOI 10.1073/pnas.80.16.4954; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; KHABAR K, 1999, J INTERFERON CYTOKIN, V19, P68; Khabar KSA, 2000, J INTERF CYTOK RES, V20, P653, DOI 10.1089/107999000414835; Khabar KSA, 2004, J MOL BIOL, V342, P833, DOI 10.1016/j.jmb.2004.07.065; Khabar KSA, 2003, J BIOL CHEM, V278, P20124, DOI 10.1074/jbc.M208766200; KUMAR R, 1994, J BIOL CHEM, V269, P25437; KUMAR R, 1988, J VIROL, V62, P3175, DOI 10.1128/JVI.62.9.3175-3181.1988; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Li XL, 2007, J BIOL CHEM, V282, P7950, DOI 10.1074/jbc.M607939200; Li XL, 2000, J BIOL CHEM, V275, P8880, DOI 10.1074/jbc.275.12.8880; Li XL, 1998, J VIROL, V72, P2752, DOI 10.1128/JVI.72.4.2752-2759.1998; Liu W, 2007, EUR J CANCER, V43, P202, DOI 10.1016/j.ejca.2006.08.024; Malathi K, 2007, NATURE, V448, P816, DOI 10.1038/nature06042; Mazan-Mamczarz K, 2008, ONCOGENE, V27, P6151, DOI 10.1038/onc.2008.215; Molinaro RJ, 2006, NUCLEIC ACIDS RES, V34, P6684, DOI 10.1093/nar/gkl968; Mrena J, 2005, CLIN CANCER RES, V11, P7362, DOI 10.1158/1078-0432.CCR-05-0764; Silverman RH, 2003, BIOCHEMISTRY-US, V42, P1805, DOI 10.1021/bi027147i; Solly K, 2004, ASSAY DRUG DEV TECHN, V2, P363, DOI 10.1089/adt.2004.2.363; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; SUBBARAMAIAH K, 2003, J BIOL CHEM, V25, P25; Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003; Urisman A, 2006, PLOS PATHOG, V2, P211, DOI 10.1371/journal.ppat.0020025; van der Giessen K, 2003, J BIOL CHEM, V278, P47119, DOI 10.1074/jbc.M308889200; Wang QQ, 2004, MICROBIOL MOL BIOL R, V68, P432, DOI 10.1128/MMBR.68.3.432-452.2004; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang WG, 2001, MOL CELL BIOL, V21, P5889, DOI 10.1128/MCB.21.17.5889-5898.2001; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; WRESCHNER DH, 1981, NUCLEIC ACIDS RES, V9, P1571, DOI 10.1093/nar/9.7.1571; Xiang Y, 2003, CANCER RES, V63, P6795; Zhou AM, 1998, J INTERF CYTOK RES, V18, P953, DOI 10.1089/jir.1998.18.953; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355; Zhu J, 2006, J IMMUNOL METHODS, V309, P25, DOI 10.1016/j.jim.2005.10.018	48	33	34	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2009	28	15					1782	1791		10.1038/onc.2009.16	http://dx.doi.org/10.1038/onc.2009.16			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PV	19252527	Green Accepted			2022-12-17	WOS:000265640400005
J	Gresko, E; Ritterhoff, S; Sevilla-Perez, J; Roscic, A; Frobius, K; Kotevic, I; Vichalkovski, A; Hess, D; Hemmings, BA; Schmitz, ML				Gresko, E.; Ritterhoff, S.; Sevilla-Perez, J.; Roscic, A.; Froebius, K.; Kotevic, I.; Vichalkovski, A.; Hess, D.; Hemmings, B. A.; Schmitz, M. L.			PML tumor suppressor is regulated by HIPK2-mediated phosphorylation in response to DNA damage	ONCOGENE			English	Article						HIPK2; PML; phosphorylation; cell death	ACUTE PROMYELOCYTIC LEUKEMIA; HOMEODOMAIN-INTERACTING PROTEIN-KINASE-2; NUCLEAR-BODIES; RAR-ALPHA; PROTEIN KINASE-2; P53 ACTIVITY; CELL-DEATH; HIPK2; TRANSCRIPTION; APOPTOSIS	The promyelocytic leukemia (PML) tumor suppressor protein, a central regulator of cell proliferation and apoptosis, is frequently fused to the retinoic acid receptor-alpha (RAR alpha) in acute PML. Here we show the interaction of PML with another tumor suppressor protein, the serine/threonine kinase homeodomain-interacting protein kinase (HIPK2). In response to DNA damage, HIPK2 phosphorylates PML at serines 8 and 38. Although HIPK2-mediated phosphorylation of PML occurs early during the DNA damage response, the oncogenic PML-RAR alpha fusion protein is phosphorylated with significantly delayed kinetics. DNA damage or HIPK2 expression leads to the stabilization of PML and PML-RARa proteins. The N-terminal phosphorylation sites contribute to the DNA damage-induced PML SUMOylation and are required for the ability of PML to cooperate with HIPK2 for the induction of cell death.	[Ritterhoff, S.; Sevilla-Perez, J.; Roscic, A.; Froebius, K.; Schmitz, M. L.] Univ Giessen, Inst Biochem, D-35392 Giessen, Germany; [Gresko, E.] Univ Bern, Dept Chem & Biochem, Bern, Switzerland; [Gresko, E.; Vichalkovski, A.; Hess, D.; Hemmings, B. A.] Friedrich Miescher Inst Biomed Res, Basel, Switzerland; [Roscic, A.] Novartis Pharma AG, Basel, Switzerland; [Kotevic, I.] Univ Zurich, Inst Biomed Engn, Zurich, Switzerland; [Kotevic, I.] ETH, Zurich, Switzerland	Justus Liebig University Giessen; University of Bern; Friedrich Miescher Institute for Biomedical Research; Novartis; University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Schmitz, ML (corresponding author), Univ Giessen, Inst Biochem, Friedrichstr 24, D-35392 Giessen, Germany.	lienhard.schmitz@biochemie.med.uni-giessen.de	Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192	Deutsche Forschungsgemeinschaft [SCHM 1417/4-1, SCHM 1417/5-1, SFB 547]; ECCPS-Excellence Cluster Cardio-Pulmonary System; Swiss Cancer League [OCS 01667-02-2005]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); ECCPS-Excellence Cluster Cardio-Pulmonary System(German Research Foundation (DFG)); Swiss Cancer League	We are grateful to Drs Giannino Del Sal (Trieste, Italy) and Myung K Kim (NIH, USA) for generously providing expression vectors. The study from our laboratory was supported by grants from the Deutsche Forschungsgemeinschaft projects SCHM 1417/4-1, SCHM 1417/5-1, SFB 547 and the ECCPS-Excellence Cluster Cardio-Pulmonary System. FMI is a part of Novartis Research Foundation and EG was supported by the Swiss Cancer League Grant OCS 01667-02-2005.	Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Borden KLB, 2008, BBA-MOL CELL RES, V1783, P2145, DOI 10.1016/j.bbamcr.2008.06.005; Calzado MA, 2007, CELL CYCLE, V6, P139, DOI 10.4161/cc.6.2.3788; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dauth I, 2007, CANCER RES, V67, P2274, DOI 10.1158/0008-5472.CAN-06-2884; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Dellaire G, 2006, J CELL BIOL, V175, P55, DOI 10.1083/jcb.200604009; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Di Stefano V, 2004, ONCOGENE, V23, P5185, DOI 10.1038/sj.onc.1207656; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Gresko E, 2006, EMBO J, V25, P1883, DOI 10.1038/sj.emboj.7601077; Hayakawa F, 2004, CANCER CELL, V5, P389, DOI 10.1016/S1535-6108(04)00082-0; Hess D, 2008, J BIOL CHEM, V283, P7354, DOI 10.1074/jbc.M710251200; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kramer OH, 2008, FASEB J, V22, P1369, DOI 10.1096/fj.06-8050com; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Li XL, 2007, ONCOGENE, V26, P7231, DOI 10.1038/sj.onc.1210523; Link N, 2007, J CELL BIOL, V178, P567, DOI 10.1083/jcb.200702125; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; Moller A, 2003, CANCER RES, V63, P4310; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Reineke EL, 2008, MOL CELL BIOL, V28, P997, DOI 10.1128/MCB.01848-07; Rinaldo C, 2007, BIOCHEM CELL BIOL, V85, P411, DOI 10.1139/O07-071; Roscic A, 2006, MOL CELL, V24, P77, DOI 10.1016/j.molcel.2006.08.004; Scaglioni PP, 2006, CELL, V126, P269, DOI 10.1016/j.cell.2006.05.041; Shen TH, 2006, MOL CELL, V24, P331, DOI 10.1016/j.molcel.2006.09.013; Tagata Y, 2008, LEUKEMIA, V22, P273, DOI 10.1038/sj.leu.2405024; Takahashi Y, 2004, ONCOGENE, V23, P2819, DOI 10.1038/sj.onc.1207533; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; Villa R, 2007, CANCER CELL, V11, P513, DOI 10.1016/j.ccr.2007.04.009; Wang ZY, 2008, BLOOD, V111, P2505, DOI 10.1182/blood-2007-07-102798; Wei GW, 2007, P NATL ACAD SCI USA, V104, P13040, DOI 10.1073/pnas.0703213104; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869	39	33	37	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					698	708		10.1038/onc.2008.420	http://dx.doi.org/10.1038/onc.2008.420			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19015637	Bronze			2022-12-17	WOS:000263076400007
J	Cao, Y; Liu, X; Zhang, W; Deng, X; Zhang, H; Liu, Y; Chen, L; Thompson, EA; Townsend, CM; Ko, TC				Cao, Y.; Liu, X.; Zhang, W.; Deng, X.; Zhang, H.; Liu, Y.; Chen, L.; Thompson, E. A.; Townsend, C. M., Jr.; Ko, T. C.			TGF-beta repression of Id2 induces apoptosis in gut epithelial cells	ONCOGENE			English	Article						apoptosis; affymetrix oligonucleotide microarrays; inhibitor of differentiation; TranSignal Protein/DNA arrays; hypoxia-inducing factor	GROWTH-FACTOR-BETA; LOOP-HELIX PROTEINS; INDUCIBLE TRANSCRIPTION; FACTOR GENE; HYPOXIA; DIFFERENTIATION; EXPRESSION; PROLIFERATION; ID-1; COOPERATION	Transforming growth factor-beta (TGF-beta) regulates epithelial tissue homeostasis by activating processes that control cell cycle arrest, differentiation and apoptosis. Disruption of the TGF-beta signaling pathway often occurs in colorectal cancers. Earlier, we have shown that TGF-beta induces apoptosis through the transcription factor Smad3. Affymetrix oligonucleotide microarrays were used to identify TGF-beta/Smad3 target genes that regulate apoptosis in rat intestinal epithelial cells (RIE-1). We found that TGF-beta repressed the expression of the inhibitor of differentiation (Id) gene family. Knockdown of Id1 and Id2 gene expression induced apoptosis in RIE-1 cells, whereas overexpression of Id2 attenuated TGF-beta-induced apoptosis. TranSignal Protein/ DNA arrays were used to identify the hypoxia-inducing factor-1 (HIF-1) as a downstream target of TGF-beta. HIF-1 is a basic helix-loop-helix protein, and overexpression of Id2 blocked HIF-1 activation by TGF-beta. Furthermore, knockdown of HIF-1 blocked TGF-beta-induced apoptosis. Thus, we have identified HIF-1 as a novel mediator downstream of Id2 in the pathway of TGF-beta-induced apoptosis.	[Cao, Y.; Liu, X.; Zhang, W.; Deng, X.; Zhang, H.; Ko, T. C.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX 77030 USA; [Liu, Y.; Chen, L.; Thompson, E. A.] Mayo Clin, Ctr Comprehens Canc, Jacksonville, FL 32224 USA; [Townsend, C. M., Jr.] Univ Texas Galveston, Med Branch, Dept Surg, Galveston, TX 77550 USA	University of Texas System; University of Texas Health Science Center Houston; Mayo Clinic; University of Texas System; University of Texas Medical Branch Galveston	Cao, Y (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Surg, MSB4-608,6431 Fannin St, Houston, TX 77030 USA.	Yanna.Cao@uth.tmc.edu; Tien.C.Ko@uth.tmc.edu			Gastrointestinal Research Interdisciplinary Program at the University of Texas Medical Branch (YC); Public Health Service [R01 DK060105, P01 DK035608, P50GM038529]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035608, R01DK060105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM038529] Funding Source: NIH RePORTER	Gastrointestinal Research Interdisciplinary Program at the University of Texas Medical Branch (YC); Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank D Deng, Dr D Song and Z Chen for technical support; Dr H Guo for real-time quantitative PCR assay at the Real-Time PCR Core Facility, Sealy Center for Cancer Cell Biology, UTMB; Dr C Cox Jr and F Jimenez in the Department of Pediatric Surgery, UTHSC-Houston, and M Grif. n in the Flow Cytometry and Cell Sorting Core Facility, UTMB, for flow cytometric analysis. E Figueroa and S Schuenke in the Department of Surgery, UTMB, for manuscript preparation. This study was supported by a grant from the Gastrointestinal Research Interdisciplinary Program at the University of Texas Medical Branch (YC), and Public Health Service Grants R01 DK060105 (TCK), P01 DK035608 (CMT and TCK) and P50GM038529 (TCK).	Alliston T, 2005, J BIOL CHEM, V280, P24227, DOI 10.1074/jbc.M414305200; AndresBarquin PJ, 1997, CANCER RES, V57, P215; Babyatsky M. W., 1991, TXB GASTROENTEROLOGY, P475; Cao YN, 2007, AM J PHYSIOL-GASTR L, V292, pG28, DOI 10.1152/ajpgi.00437.2005; Cao YN, 2006, SURGERY, V140, P322, DOI 10.1016/j.surg.2006.05.006; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Hasskarl J, 2002, CANCER BIOL THER, V1, P91, DOI 10.4161/cbt.50; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kim D, 1999, MOL CELL BIOL, V19, P8240; Kim HJ, 2007, MOL CANCER RES, V5, P321, DOI 10.1158/1541-7786.MCR-06-0218; Ko T C, 1997, Prog Cell Cycle Res, V3, P43; Kondo M, 2004, CELL DEATH DIFFER, V11, P1092, DOI 10.1038/sj.cdd.4401467; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Ling MT, 2002, BBA-GEN SUBJECTS, V1570, P145, DOI 10.1016/S0304-4165(02)00189-7; Lofstedt T, 2004, J BIOL CHEM, V279, P39223, DOI 10.1074/jbc.M402904200; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Nakajima T, 1998, P NATL ACAD SCI USA, V95, P10590, DOI 10.1073/pnas.95.18.10590; Nemetski SM, 2007, J BIOL CHEM, V282, P240, DOI 10.1074/jbc.M607275200; Nguyen KA, 2006, ANN SURG, V243, P619, DOI 10.1097/01.sla.0000216783.85214.c1; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Parrinello S, 2001, J BIOL CHEM, V276, P39213, DOI 10.1074/jbc.M104473200; Sanchez-Elsner T, 2004, J MOL BIOL, V336, P9, DOI 10.1016/j.jmb.2003.12.023; Sanchez-Elsner T, 2002, J BIOL CHEM, V277, P43799, DOI 10.1074/jbc.M207160200; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Shih SC, 2001, GROWTH FACTORS, V19, P19, DOI 10.3109/08977190109001073; Siegel PM, 2003, J BIOL CHEM, V278, P35444, DOI 10.1074/jbc.M301413200; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Tanaka K, 1998, J BIOL CHEM, V273, P25922, DOI 10.1074/jbc.273.40.25922; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Yokota Y, 2002, J CELL PHYSIOL, V190, P21, DOI 10.1002/jcp.10042; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092	44	33	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	8					1089	1098		10.1038/onc.2008.456	http://dx.doi.org/10.1038/onc.2008.456			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19137015	Green Accepted			2022-12-17	WOS:000263722900004
J	Russell, MR; Jamieson, WL; Dolloff, NG; Fatatis, A				Russell, M. R.; Jamieson, W. L.; Dolloff, N. G.; Fatatis, A.			The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells	ONCOGENE			English	Article						skeletal metastasis; prostate adenocarcinoma; PDGFR alpha	PHASE-II TRIAL; IMATINIB MESYLATE; BONE-MARROW; BIOCHEMICAL RELAPSE; MOUSE MODEL; SURVIVAL; PROGRESSION; MECHANISMS; EXPRESSION; PATHWAY	Bone resorption by osteoclasts is thought to promote the proliferation of prostate cancer cells disseminated to the skeleton (Mundy, 2002). Using a mouse model of experimental metastasis, we found that although late-stage metastatic tumors were indeed surrounded by osteoclasts, these cells were spatially unrelated to the small foci of cancer cells in early-stage metastases. This is the first evidence that survival and growth of disseminated prostate cancer cells immediately after their extravasation may not depend on osteoclast involvement. Interestingly, prostate cancer cells expressing the alpha-receptor for platelet-derived growth factor (PDGFR alpha) progress during early-stages of skeletal dissemination, whereas cells expressing lower levels or lacking this receptor fail to survive after extravasation in the bone marrow. However, non-metastatic cells acquire bone-metastatic potential upon ectopic overexpression of PDGFR alpha. Finally, functional blockade of human PDGFR alpha on prostate cancer cells utilizing a novel humanized monoclonal antibody-soon to undergo phase-II clinical trials-significantly impairs the establishment of early skeletal metastases. In conclusion, our results strongly implicate PDGFR alpha in prostate cancer bone tropism through its promotion of survival and progression of early-metastatic foci, providing ground for therapeutic strategies aimed at preventing or containing the initial progression of skeletal metastases in patients affected by prostate adenocarcinoma.	[Russell, M. R.; Jamieson, W. L.; Dolloff, N. G.; Fatatis, A.] Drexel Univ, Coll Med, Dept Physiol & Pharmacol, Philadelphia, PA 19102 USA; [Fatatis, A.] Drexel Univ, Coll Med, Dept Pathol & Lab Med, Philadelphia, PA 19102 USA	Drexel University; Drexel University	Fatatis, A (corresponding author), Drexel Univ, Coll Med, Dept Physiol & Pharmacol, 245 N 15th St,New Coll Bldg MS488, Philadelphia, PA 19102 USA.	afatatis@drexelmed.edu			NIH [GM067892]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067892] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The cDNA for human PDGFR alpha was a kind gift of Dr Carl-Henrik Heldin (Ludwig Institute for Cancer Research, Uppsala, Sweden). We thank Dr Olimpia Meucci (Department of Pharmacology and Physiology) for critically reading the manuscript and helpful discussion, Dr Mark Stearns (Department of Pathology and Laboratory Medicine) for helpful discussion, Dr Gregg Johannes (Department of Pathology and Laboratory Medicine) for help with the PDGFR alpha-expressing vector, Mr Michael Amatangelo for his contribution to the immuno-detection of PDGFR alpha in human tissues and Dr Nick Loizos (ImClone Systems Inc., New York, NY, USA) for kindly providing the IMC-3G3 antibody. This study was supported in part by the NIH Grant GM067892 to AF.	Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Bajaj GK, 2007, UROLOGY, V69, P526, DOI 10.1016/j.urology.2006.12.006; Betsholtz C, 2004, CYTOKINE GROWTH F R, V15, P215, DOI 10.1016/j.cytogfr.2004.03.005; Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585-007-9127-1; Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Dolloff NG, 2007, CANCER RES, V67, P555, DOI 10.1158/0008-5472.CAN-06-2593; Dolloff NG, 2005, ONCOGENE, V24, P6848, DOI 10.1038/sj.onc.1208815; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Fritz V, 2007, BONE, V40, P1032, DOI 10.1016/j.bone.2006.11.026; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Jamieson WL, 2008, CANCER RES, V68, P1715, DOI 10.1158/0008-5472.CAN-07-1315; Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535-7163.MCT-07-0234; Lee YP, 2002, CANCER RES, V62, P5564; Lin AM, 2006, BJU INT, V98, P763, DOI 10.1111/j.1464-410X.2006.06396.x; Loizos N, 2005, MOL CANCER THER, V4, P369; Mathew P, 2004, J CLIN ONCOL, V22, P3323, DOI 10.1200/JCO.2004.10.116; Mathew P, 2007, CLIN CANCER RES, V13, P5816, DOI 10.1158/1078-0432.CCR-07-1269; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Nemeth JA, 1999, CANCER RES, V59, P1987; Paget S., 1889, 1889 CANC METASTASIS, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; Rao K, 2005, PROSTATE, V62, P115, DOI 10.1002/pros.20130; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; ROSS RW, 2006, CANC MED, P1431; Schneider A, 2005, ENDOCRINOLOGY, V146, P1727, DOI 10.1210/en.2004-1211; Shulby SA, 2004, CANCER RES, V64, P4693, DOI 10.1158/0008-5472.CAN-03-3437; Thorarinsdottir HK, 2008, CLIN CANCER RES, V14, P3386, DOI 10.1158/1078-0432.CCR-07-1616; van der Pluijm G, 2005, CANCER RES, V65, P7682, DOI 10.1158/0008-5472.CAN-04-4188; Vantyghem SA, 2005, CLIN EXP METASTAS, V22, P351, DOI 10.1007/s10585-005-0745-1; WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432-0436.1991.tb00250.x; Wetterwald A, 2002, AM J PATHOL, V160, P1143, DOI 10.1016/S0002-9440(10)64934-6; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	33	33	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					412	421		10.1038/onc.2008.390	http://dx.doi.org/10.1038/onc.2008.390			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18850002				2022-12-17	WOS:000262550300009
J	Zhu, ZH; Yu, YP; Shi, YK; Nelson, JB; Luo, JH				Zhu, Z-H; Yu, Y. P.; Shi, Y-K; Nelson, J. B.; Luo, J-H			CSR1 induces cell death through inactivation of CPSF3	ONCOGENE			English	Article						CSR1; CPSF3; cell death; RNA polyadenylation	POLYADENYLATION FACTOR CPSF-73; PROSTATE-CANCER; METASTASIS; HETEROZYGOSITY; STATISTICS; 8P21-23; MARKERS	CSR1 (cellular stress response 1), a newly characterized tumor-suppressor gene, undergoes hypermethylation in over 30% of prostate cancers. Re-expression of CSR1 inhibits cell growth and induces cell death, but the mechanism by which CSR1 suppresses tumor growth is not clear. In this study, we screened a prostate cDNA library using a yeast two-hybrid system and found that the cleavage and polyadenylation-specific factor 3 (CPSF3), an essential component for converting heteronuclear RNA to mRNA, binds with high affinity to the CSR1 C terminus. Further analyses determined that the binding motifs for CPSF3 are located between amino acids 440 and 543. The interaction between CSR1 and CPSF3 induced CPSF3 translocation from the nucleus to the cytoplasm, resulting in inhibition of polyadenylation both in vitro and in vivo. Downregulation of CPSF3 using small interfering RNA induced cell death in a manner similar to CSR1 expression. A CSR1 mutant unable to bind to CPSF3 did not alter CPSF3 subcellular distribution, did not inhibit its polyadenylation activity and did not induce cell death. In summary, CSR1 appears to induce cell death through a novel mechanism by hijacking a critical RNA processing enzyme.	[Zhu, Z-H; Yu, Y. P.; Shi, Y-K; Luo, J-H] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15260 USA; [Nelson, J. B.] Univ Pittsburgh, Sch Med, Dept Urol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Luo, JH (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15260 USA.	luoj@msx.upmc.edu			National Cancer Institute [RO1 CA098249]; NATIONAL CANCER INSTITUTE [R01CA098249] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This study was supported by grants from the National Cancer Institute to JHL (RO1 CA098249), the development fund from the Department of Urology, University of Pittsburgh and the John Rangos Foundation for Enhancement of Research in Pathology.	Coon SW, 2004, INT J CANCER, V111, P206, DOI 10.1002/ijc.20254; Dominski Z, 2005, CELL, V123, P37, DOI 10.1016/j.cell.2005.08.002; Dominski Z, 2005, MOL CELL BIOL, V25, P1489, DOI 10.1128/MCB.25.4.1489-1500.2005; Gallucci M, 2006, CANCER LETT, V237, P76, DOI 10.1016/j.canlet.2005.05.033; Han HJ, 1998, HUM MOL GENET, V7, P1039, DOI 10.1093/hmg/7.6.1039; Isaacs JT, 1997, AM J PATHOL, V150, P1511; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kurimoto F, 2001, INT J MOL MED, V8, P89; Luo JH, 2002, MOL CARCINOGEN, V33, P25, DOI 10.1002/mc.10018; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; Ryan K, 2004, RNA, V10, P565, DOI 10.1261/rna.5214404; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; Wistuba II, 1999, CANCER RES, V59, P1973; Yu GY, 2006, AM J PATHOL, V168, P597, DOI 10.2353/ajpath.2006.050620; Yu YP, 2006, CANCER RES, V66, P7414, DOI 10.1158/0008-5472.CAN-06-0227; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158	18	33	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					41	51		10.1038/onc.2008.359	http://dx.doi.org/10.1038/onc.2008.359			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18806823	Green Accepted			2022-12-17	WOS:000262294100005
J	Nihira, K; Taira, N; Miki, Y; Yoshida, K				Nihira, K.; Taira, N.; Miki, Y.; Yoshida, K.			TTK/Mps1 controls nuclear targeting of c-Abl by 14-3-3-coupled phosphorylation in response to oxidative stress	ONCOGENE			English	Article						c-Abl; TTK; oxidative stress; phosphorylation	LYN TYROSINE KINASE; DNA-DAMAGE; BCR-ABL; APOPTOTIC RESPONSE; SUBCELLULAR-LOCALIZATION; CELL-DEATH; PROTEIN; DELTA; ACTIVATION; MECHANISMS	Upon exposure to genotoxic stress, the c-Abl tyrosine kinase is released from cytoplasmic 14-3-3 proteins and then is targeted to the nucleus. Phosphorylation of Thr735 in c-Abl is critical for binding to 14-3-3; however, kinases responsible for this phosphorylation are unknown. Here, we identify CLK1, CLK4, MST1, MST2 and TTK (also known as Mps1) as novel Thr735 kinases in vitro by expression cloning strategy using phosphospeci. c antibody. We also demonstrate that ectopic expression of these kinases is capable for phosphorylation of Thr735 in cells. Importantly, upon exposure to oxidative stress, phosphorylation of Thr735 is transiently upregulated, and the status of this phosphorylation remains unchanged in cells silenced for CLK1, CLK4, MST1 or MST2. By contrast, knockdown of TTK attenuates phosphorylation of Thr735, suggesting that TTK is a physiological kinase that phosphorylates Thr735. In concert with these results, we show that, in cells silenced for TTK, c-Abl is accumulated in the nucleus even in unstressed condition and no further targeting into the nucleus occurs after oxidative stress. Moreover, nuclear entrapment of c-Abl by knocking down TTK enhances oxidative stress-induced apoptosis. These findings provide evidence that TTK phosphorylates c-Abl at Thr735 and that this phosphorylation is of importance to the cytoplasmic sequestration of c-Abl.	[Nihira, K.; Taira, N.; Miki, Y.; Yoshida, K.] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Genet, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU)	Yoshida, K (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Genet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	yos.mgen@mri.tmd.ac.jp		Nihira, Keishi/0000-0002-3797-9289	Ministry of Education, Science and Culture of Japan; Mochida Memorial Foundation for Medical and Pharmaceutical Research; Sumitomo Foundation; Yasuda Memorial Foundation; Astellas Foundation for Research on Metabolic Disorders; Sagawa Foundation for Promotion of Cancer Research; Osaka Cancer Research Foundation; Kato Memorial Bioscience Foundation; Uehara Memorial Foundation	Ministry of Education, Science and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Mochida Memorial Foundation for Medical and Pharmaceutical Research; Sumitomo Foundation; Yasuda Memorial Foundation; Astellas Foundation for Research on Metabolic Disorders; Sagawa Foundation for Promotion of Cancer Research; Osaka Cancer Research Foundation; Kato Memorial Bioscience Foundation; Uehara Memorial Foundation(Uehara Memorial Foundation)	We thank Dr Xuebiao Yao for the GFP-TTK. This work was supported by grants from the Ministry of Education, Science and Culture of Japan (to KY and YM), the Mochida Memorial Foundation for Medical and Pharmaceutical Research (to KY), the Sumitomo Foundation (to KY), the Yasuda Memorial Foundation (to KY), Astellas Foundation for Research on Metabolic Disorders (to KY), the Sagawa Foundation for Promotion of Cancer Research (to KY), Osaka Cancer Research Foundation (to KY), Kato Memorial Bioscience Foundation (to KY) and Uehara Memorial Foundation (to KY).	Aitken A, 2002, BIOCHEM SOC T, V30, P351, DOI 10.1042/bst0300351; Cao C, 2003, J BIOL CHEM, V278, P29667, DOI 10.1074/jbc.M301292200; Castillo AR, 2002, J CELL BIOL, V156, P453, DOI 10.1083/jcb.200111025; de Souza PM, 2004, BIOCHEM SOC T, V32, P485, DOI 10.1042/BST0320485; Dierov J, 2004, CANCER CELL, V5, P275, DOI 10.1016/S1535-6108(04)00056-X; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Hagiwara M, 2005, BBA-PROTEINS PROTEOM, V1754, P324, DOI 10.1016/j.bbapap.2005.09.010; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Jones MH, 1999, MOL BIOL CELL, V10, P2377, DOI 10.1091/mbc.10.7.2377; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Matsuo R, 2001, J IMMUNOL METHODS, V247, P141, DOI 10.1016/S0022-1759(00)00313-6; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Straight PD, 2000, MOL BIOL CELL, V11, P3525, DOI 10.1091/mbc.11.10.3525; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Taira N, 2007, MOL CELL, V25, P725, DOI 10.1016/j.molcel.2007.02.007; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; Yoshida K, 2006, MOL CELL BIOL, V26, P3414, DOI 10.1128/MCB.26.9.3414-3431.2006; Yoshida K, 1999, J BIOL CHEM, V274, P34663, DOI 10.1074/jbc.274.49.34663; Yoshida K, 2000, MOL CELL BIOL, V20, P5370, DOI 10.1128/MCB.20.15.5370-5380.2000; Yoshida K, 2005, CELL CYCLE, V4, P777, DOI 10.4161/cc.4.6.1746; Yoshida K, 2005, NAT CELL BIOL, V7, P278, DOI 10.1038/ncb1228; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Yoshida K, 2002, J BIOL CHEM, V277, P48372, DOI 10.1074/jbc.M205485200; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Yoshida K, 2001, MOL PHARMACOL, V60, P1431, DOI 10.1124/mol.60.6.1431; Yoshida K, 2008, TRENDS MOL MED, V14, P305, DOI 10.1016/j.molmed.2008.05.003; Yoshida K, 2007, CELL SIGNAL, V19, P892, DOI 10.1016/j.cellsig.2007.01.027; Yoshikawa S, 2006, J JPN SOC FOOD SCI, V53, P281, DOI 10.3136/nskkk.53.281; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zhu JY, 2004, CURR TOP DEV BIOL, V59, P165, DOI 10.1016/S0070-2153(04)59007-5	40	33	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	58					7285	7295		10.1038/onc.2008.334	http://dx.doi.org/10.1038/onc.2008.334			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382FI	18794806				2022-12-17	WOS:000261590300006
J	Leung, N; Turbide, C; Balachandra, B; Marcus, V; Beauchemin, N				Leung, N.; Turbide, C.; Balachandra, B.; Marcus, V.; Beauchemin, N.			Intestinal tumor progression is promoted by decreased apoptosis and dysregulated Wnt signaling in Ceacam(1-/-) mice	ONCOGENE			English	Article						CEACAM1; Wnt signaling; intestinal cancer; tumor suppressor; mouse model	FAMILIAL ADENOMATOUS POLYPOSIS; CELL-ADHESION MOLECULE; ABERRANT CRYPT FOCI; COLORECTAL-CANCER; BETA-CATENIN; BILIARY GLYCOPROTEIN; C-CAM; K-RAS; CEACAM1; APC	The carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) is downregulated in colonic and intestinal hyperplastic lesions as well as in other cancers, where it functions as a tumor suppressor. To investigate the functions of CEACAM1 in the normal intestine and in intestinal tumors, we generated a compound knockout mouse model and examined both Ceacam1(-/-) and Apc(1638N/+): Ceacam1(-/-) mice. Ceacam1(-/-) intestinal cells exhibited a significant decrease in apoptosis, with no change in proliferation or migration, however. Compound Apc(1638N/+): Ceacam1(-/-) mice demonstrated an increase in intestinal tumor multiplicity and tumor progression. Increases in intussusceptions and desmoid lesions were also observed. We have shown that CEACAM1-L associates with beta-catenin by co-immunoprecipitation and colocalization in CEACAM1-L-transfected CT26 and CT51 mouse colon carcinoma cells. Ceacam1(-/-) enterocytes displayed decreased glycogen synthase kinase 3-beta activity with corresponding nuclear localization of beta-catenin. Increased T-cell factor/Lef transcriptional activity was observed in CEACAM1-null CT51 colonic cells and in Caco2 colon cancer cells in which CEACAM1 was downregulated. A significant increased expression in c-Myc and cyclin D1 targets of the Wnt signaling pathway was also revealed in the Ceacam1(-/-) intestine. CEACAM1 therefore actively participates in Wnt signaling in intestinal cells and its downregulation in intestinal tissue contributes to malignancy by augmenting tumor multiplicity and progression.	[Beauchemin, N.] McGill Univ, McGill Canc Ctr, Lab 711, Montreal, PQ H3G 1Y6, Canada; [Leung, N.; Beauchemin, N.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; [Balachandra, B.] Univ Alberta, Dept Pathol, Royal Alexandra Hosp, Edmonton, AB T6G 2E1, Canada; [Marcus, V.] McGill Univ, Ctr Hlth, Dept Pathol, Montreal, PQ H3G 1Y6, Canada; [Beauchemin, N.] McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; [Beauchemin, N.] McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; Royal Alexandra Hospital; University of Alberta; McGill University; McGill University; McGill University	Beauchemin, N (corresponding author), McGill Univ, McGill Canc Ctr, Lab 711, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	nicole.beauchemin@mcgill.ca						Abou-Rjaily GA, 2004, J CLIN INVEST, V114, P944, DOI 10.1172/JCI200421786; Aoki K, 2007, ONCOGENE, V26, P3511, DOI 10.1038/sj.onc.1210141; Azar T, 1997, ANN SURG, V226, P134, DOI 10.1097/00000658-199708000-00003; Beauchemin N, 1999, EXP CELL RES, V252, P243; Buckhaults P, 2001, CANCER RES, V61, P6996; de la Chapelle A, 2004, NAT REV CANCER, V4, P769, DOI 10.1038/nrc1453; Demant P, 2003, NAT REV GENET, V4, P721, DOI 10.1038/nrg1157; DVEKSLER GS, 1993, P NATL ACAD SCI USA, V90, P1716, DOI 10.1073/pnas.90.5.1716; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Fodde R, 2001, TRENDS MOL MED, V7, P369, DOI 10.1016/S1471-4914(01)02050-0; Gray-Owen SD, 2006, NAT REV IMMUNOL, V6, P433, DOI 10.1038/nri1864; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hokari M, 2007, LIFE SCI, V81, P336, DOI 10.1016/j.lfs.2007.06.002; Horst AK, 2004, HANDB EXP PHARM, V165, P283, DOI 10.1007/978-3-540-68170-0_10; Horst AK, 2006, J CLIN INVEST, V116, P1596, DOI 10.1172/JCI24340; HSIEH JT, 1995, CANCER RES, V55, P190; JIN L, 2008, EXP BIOL ME IN PRESS, V233; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kobrossy L, 2006, J BIOL CHEM, V281, P25926, DOI 10.1074/jbc.M602555200; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kunath T, 1995, ONCOGENE, V11, P2375; Leung N, 2006, ONCOGENE, V25, P5527, DOI 10.1038/sj.onc.1209541; Liu W, 2007, ONCOGENE, V26, P2747, DOI 10.1038/sj.onc.1210077; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagaishi T, 2006, IMMUNITY, V25, P769, DOI 10.1016/j.immuni.2006.08.026; Najjar SM, 2002, TRENDS ENDOCRIN MET, V13, P240, DOI 10.1016/S1043-2760(02)00608-2; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nittka S, 2004, ONCOGENE, V23, P9306, DOI 10.1038/sj.onc.1208259; Nollau P, 1997, CANCER RES, V57, P2354; Notterman DA, 2001, CANCER RES, V61, P3124; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; Patel S, 2004, BIOCHEM SOC T, V32, P803, DOI 10.1042/BST0320803; Poy MN, 2002, NAT GENET, V30, P270, DOI 10.1038/ng840; Poy MN, 2002, J BIOL CHEM, V277, P1076, DOI 10.1074/jbc.M108415200; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Takayama T, 2001, GASTROENTEROLOGY, V121, P599, DOI 10.1053/gast.2001.27203; Turbide C, 1997, CANCER RES, V57, P2781; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; VIVONA AA, 1993, CARCINOGENESIS, V14, P1777, DOI 10.1093/carcin/14.9.1777; Yang WC, 2005, CANCER RES, V65, P9363, DOI 10.1158/0008-5472.CAN-05-2113	45	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2008	27	36					4943	4953		10.1038/onc.2008.136	http://dx.doi.org/10.1038/onc.2008.136			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18454175				2022-12-17	WOS:000258596900008
J	Unger, K; Malisch, E; Thomas, G; Braselmann, H; Walch, A; Jackl, G; Lewis, P; Lengfelder, E; Bogdanova, T; Wienberg, J; Zitzelsberger, H				Unger, K.; Malisch, E.; Thomas, G.; Braselmann, H.; Walch, A.; Jackl, G.; Lewis, P.; Lengfelder, E.; Bogdanova, T.; Wienberg, J.; Zitzelsberger, H.			Array CGH demonstrates characteristic aberration signatures in human papillary thyroid carcinomas governed by RET/PTC	ONCOGENE			English	Article						papillary thyroid carcinoma; array CGH; RET/PTC; candidate genes; tumour development; aberration signature	COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; SQUAMOUS-CELL CARCINOMA; HIGH PREVALENCE; PROSTATE-CANCER; DOWN-REGULATION; BREAST-CANCER; EXPRESSION; RET; REARRANGEMENTS	The aim of this study is to investigate additional genetic alterations in papillary thyroid carcinomas (PTCs) with known RET/PTC rearrangements. We applied array-based comparative genomic hybridization (array CGH) to 33 PTC (20 PTC from adults, 13 post-Chernobyl PTC from children) with known RET/PTC status. Principal component analysis and hierarchical cluster analysis identified cases with similar aberration patterns. Significant deviations between tumour-groups were obtained by statistical testing (Fisher's exact test in combination with Benjamini-Hochberg FDR-controlling procedure). FISH analysis on FFPE sections was applied to validate the array CGH data. Deletions were found more frequently in RET/PTC-positive and RET/PTC-negative tumours than amplifications. Specific aberration signatures were identified that discriminated between RET/PTC-positive and RET/PTC-negative cases (aberrations on chromosomes 1p, 3q, 4p, 7p, 9p/q, 10q, 12q, 13q and 21q). In addition, childhood and adult RET/PTC-positive cases differ significantly for a deletion on the distal part of chromosome 1p. There are additional alterations in RET/PTC-positive tumours, which may act as modifiers of RET activation. In contrast, alterations in RET/PTC-negative tumours indicate alternative routes of tumour development. The data presented serve as a starting point for further studies on gene expression and function of genes identified in this study.	[Unger, K.; Malisch, E.; Braselmann, H.; Jackl, G.; Zitzelsberger, H.] Deutsch Forschungszentrum Gesundheit & Umwelt Gmb, Inst Mol Strahlenbiol, Helmholtz Zentrum Munchen, D-85764 Neuherberg, Germany; [Unger, K.; Thomas, G.] Hammersmith Hosp, Dept Histopathol, London W12 0HS, England; [Walch, A.] Deutsch Forschungszentrum Gesundheit & Umwelt Gmb, Helmholtz Zentrum Munchen, Inst Pathol, D-85764 Neuherberg, Germany; [Lewis, P.] Swansea Univ, Swansea Med Sch, Swansea, W Glam, Wales; [Lengfelder, E.] Univ Munich, Inst Strahlenbiol, Munich, Germany; [Bogdanova, T.] Ukraine Acad Med Sci, Inst Endocrinol & Metab, Kiev, Ukraine; [Wienberg, J.] Univ Munich, Dept Biol 2, Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Imperial College London; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Swansea University; University of Munich; National Academy of Medical Sciences of Ukraine; V. P. Komissarenko Institute of Endocrinology & Metabolism of the National Academy of Medical Science of Ukraine; University of Munich	Zitzelsberger, H (corresponding author), Helmholtz Zentrum Munchen, Inst Mol Radiobiol, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany.	zitzelsberger@helmholtz-muenchen.de	Walch, Axel/B-4554-2012; Unger, Kristian/F-3730-2018	Walch, Axel/0000-0001-5578-4023; Unger, Kristian/0000-0002-0374-2320; Bogdanova, Tetiana/0000-0001-5119-0236				Adolphe C, 2006, CANCER RES, V66, P2081, DOI 10.1158/0008-5472.CAN-05-2146; [Anonymous], 2016, J CLIN INVEST, DOI DOI 10.1172/JCI85271; Azuma K, 2005, ONCOGENE, V24, P4754, DOI 10.1038/sj.onc.1208654; Camacho-Vanegas O, 2007, INT J CANCER, V121, P1390, DOI 10.1002/ijc.22809; Chang M, 2005, EMBO J, V24, P2024, DOI 10.1038/sj.emboj.7600684; Cheung CC, 2000, J CLIN ENDOCR METAB, V85, P878, DOI 10.1210/jc.85.2.878; Chunduru S, 2002, J NEURO-ONCOL, V60, P201, DOI 10.1023/A:1021130620178; Ciampi R, 2007, ENDOCRINOLOGY, V148, P936, DOI 10.1210/en.2006-0921; COLLINS CM, 1996, P INT SOC MAGN RES M, V1, P253; Corson TW, 2007, GENE CHROMOSOME CANC, V46, P617, DOI 10.1002/gcc.20457; De Falco V, 2005, ONCOGENE, V24, P6303, DOI 10.1038/sj.onc.1208776; Demichelis F, 2007, ONCOGENE, V26, P4596, DOI 10.1038/sj.onc.1210237; Dickinson RE, 2004, BRIT J CANCER, V91, P2071, DOI 10.1038/sj.bjc.6602222; Djeu JY, 2002, CLIN CANCER RES, V8, P636; Dong M, 2007, J CLIN INVEST, V117, P206, DOI 10.1172/JCI29293; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Duquette ML, 2007, CANCER RES, V67, P2586, DOI 10.1158/0008-5472.CAN-06-2419; Elisei R, 2001, J CLIN ENDOCR METAB, V86, P3211, DOI 10.1210/jc.86.7.3211; Engers R, 2006, BRIT J CANCER, V95, P1081, DOI 10.1038/sj.bjc.6603385; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Finn SP, 2004, VIRCHOWS ARCH, V445, P396, DOI 10.1007/s00428-004-1070-9; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Hammarsund M, 2004, FEBS LETT, V556, P75, DOI 10.1016/S0014-5793(03)01371-1; Hou P, 2007, CLIN CANCER RES, V13, P1161, DOI 10.1158/1078-0432.CCR-06-1125; Hou W, 2005, CLIN CANCER RES, V11, P5595, DOI 10.1158/1078-0432.CCR-05-0384; Hu SY, 2006, INT J CANCER, V119, P2322, DOI 10.1002/ijc.22110; Huang H, 2007, J CANCER RES CLIN, V133, P761, DOI 10.1007/s00432-007-0221-1; Hupe P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418; ISHIZAKA Y, 1991, ONCOGENE, V6, P1667; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; Jimenez-Velasco A, 2005, LEUKEMIA, V19, P2347, DOI 10.1038/sj.leu.2403974; Kadota M, 2003, ONCOL REP, V10, P35; Kitamura Y, 1999, J CLIN ENDOCR METAB, V84, P4043, DOI 10.1210/jc.84.11.4043; Klugbauer S, 1995, ONCOGENE, V11, P2459; Konishi T, 2006, ONCOGENE, V25, P3160, DOI 10.1038/sj.onc.1209342; La Rosa P, 2006, BIOINFORMATICS, V22, P2066, DOI 10.1093/bioinformatics/btl359; Li L, 2007, J CELL BIOCHEM, V102, P1368, DOI 10.1002/jcb.21593; Louhelainen JP, 2006, ONCOGENE, V25, P2409, DOI 10.1038/sj.onc.1209228; NAGATA S, 1994, ADV IMMUNOL, V57, P129, DOI 10.1016/S0065-2776(08)60672-0; Neuvial P, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-264; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; O'Donnell KA, 2006, MOL CELL BIOL, V26, P2373, DOI 10.1128/MCB.26.6.2373-2386.2006; Okawa ER, 2008, ONCOGENE, V27, P803, DOI 10.1038/sj.onc.1210675; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; Powell N, 2005, J PATHOL, V205, P558, DOI 10.1002/path.1736; Puxeddu E, 2005, ENDOCR-RELAT CANCER, V12, P319, DOI 10.1677/erc.1.00947; Rabes HM, 2000, CLIN CANCER RES, V6, P1093; Repana K, 2006, ANTICANCER RES, V26, P4949; Rhoden KJ, 2006, J CLIN ENDOCR METAB, V91, P2414, DOI 10.1210/jc.2006-0240; Rhoden KJ, 2004, LAB INVEST, V84, P1557, DOI 10.1038/labinvest.3700198; Richter H, 2004, THYROID, V14, P1061, DOI 10.1089/thy.2004.14.1061; Riedl SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153; Rouveirol C, 2006, BIOINFORMATICS, V22, P849, DOI 10.1093/bioinformatics/btl004; Santoro M, 2004, CELL MOL LIFE SCI, V61, P2954, DOI 10.1007/s00018-004-4276-8; Shan ZH, 2004, ONCOGENE, V23, P6612, DOI 10.1038/sj.onc.1207857; Singh B, 2000, SURGERY, V128, P888, DOI 10.1067/msy.2000.110847; Smida J, 1999, INT J CANCER, V80, P32, DOI 10.1002/(SICI)1097-0215(19990105)80:1<32::AID-IJC7>3.0.CO;2-L; Takakura S, 2001, INT J ONCOL, V18, P817; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Thomas GA, 1999, J CLIN ENDOCR METAB, V84, P4232, DOI 10.1210/jc.84.11.4232; Torosyan Y, 2006, CANCER RES, V66, P9609, DOI 10.1158/0008-5472.CAN-06-1574; Unger K, 2006, BRIT J CANCER, V94, P1472, DOI 10.1038/sj.bjc.6603109; Unger K, 2004, J CLIN ENDOCR METAB, V89, P4272, DOI 10.1210/jc.2003-031870; van Beers EH, 2006, BRIT J CANCER, V94, P333, DOI 10.1038/sj.bjc.6602889; Wang YG, 2007, J CLIN ENDOCR METAB, V92, P2387, DOI 10.1210/jc.2006-2019; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Wreesmann VB, 2007, ORL-J OTO-RHIN-LARYN, V69, P218, DOI 10.1159/000101542; Yang LC, 2005, ONCOGENE, V24, P697, DOI 10.1038/sj.onc.1208179; Yoo NJ, 2007, APMIS, V115, P354, DOI 10.1111/j.1600-0463.2007.apm_632.x; Zhang Q, 2005, J HISTOCHEM CYTOCHEM, V53, P1371, DOI 10.1369/jhc.4A6508.2005	70	33	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2008	27	33					4592	4602		10.1038/onc.2008.99	http://dx.doi.org/10.1038/onc.2008.99			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18408749				2022-12-17	WOS:000258077300008
J	Ramsey, CS; Yeung, F; Stoddard, PB; Li, D; Creutz, CE; Mayo, MW				Ramsey, C. S.; Yeung, F.; Stoddard, P. B.; Li, D.; Creutz, C. E.; Mayo, M. W.			Copine-I represses NF-kappa B transcription by endoproteolysis of p65	ONCOGENE			English	Article						NF-kappa B; copine-I; endoproteolysis; p65; transcription; repressor	PHOSPHOLIPID-BINDING PROTEINS; DEPENDENT TRANSCRIPTION; KINASE ALPHA; SUBUNIT; FAMILY; DOMAIN; PHOSPHORYLATION; ACETYLATION; SURVIVAL; DNA	Nuclear factor-kappa B (NF-kappa B) is a dynamic transcription factor that regulates important biological processes involved in cancer initiation and progression. Identifying regulators that control the half-life of NF-kappa B is important to understanding molecular processes that control the duration of transcriptional responses. In this study we identify copine-I, a calcium phospholipid-binding protein, as a novel repressor that physically interacts with p65 to inhibit NF-kappa B transcription. Knockdown of copine-I by siRNA increases tumor necrosis factor alpha-stimulated NF-kappa B transcription, while copine-I expression blocks endogenous transcription. Copine-I abolishes NF-kappa B transcription by inducing endoprotease processing of the N-terminus of p65, a process antagonized by I kappa B alpha. Copine-I stimulates endoproteolysis of p65 within a conserved region that is required for base-specific contact with DNA. p65 proteins lacking the N-terminus fail to bind to DNA and act as dominant-negative molecules that inhibit NF-kappa B transcription. Our work provides evidence that copine-I regulates the half-life of NF-kappa B transcriptional responses through a novel mechanism that involves endoproteolysis of the p65 protein.	[Ramsey, C. S.; Yeung, F.; Stoddard, P. B.; Li, D.; Mayo, M. W.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; [Creutz, C. E.] Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Mayo, MW (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, Box 800733, Charlottesville, VA 22908 USA.	mwm3y@virginia.edu			NCI NIH HHS [R01CA104397, R01CA095644] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095644, R01CA104397] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; BALDWIN AS, 1996, ANNU REV IMMUNOL, V14, P681; Burstein E, 2005, J BIOL CHEM, V280, P22222, DOI 10.1074/jbc.M501928200; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Creutz CE, 1998, J BIOL CHEM, V273, P1393, DOI 10.1074/jbc.273.3.1393; David A, 2003, J LEUKOCYTE BIOL, V74, P551, DOI 10.1189/jlb.1202624; Dickeson SK, 1998, CELL MOL LIFE SCI, V54, P556, DOI 10.1007/s000180050184; Fujikawa K, 2001, BLOOD, V98, P1662, DOI 10.1182/blood.V98.6.1662; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Kang KH, 2001, J BIOL CHEM, V276, P24638, DOI 10.1074/jbc.M101291200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kim TM, 2005, CLIN CANCER RES, V11, P79; Kurosawa S, 2000, J IMMUNOL, V165, P4697, DOI 10.4049/jimmunol.165.8.4697; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Lin L, 1996, MOL CELL BIOL, V16, P2248; Maine GN, 2007, EMBO J, V26, P436, DOI 10.1038/sj.emboj.7601489; Maitra R, 2003, BIOCHEM BIOPH RES CO, V303, P842, DOI 10.1016/S0006-291X(03)00445-5; Mayo MW, 2002, J BIOL CHEM, V277, P11116, DOI 10.1074/jbc.M108670200; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Phelps CB, 2000, J BIOL CHEM, V275, P24392, DOI 10.1074/jbc.M003784200; Preston GA, 2002, J AM SOC NEPHROL, V13, P2840, DOI 10.1097/01.ASN.0000034911.03334.C3; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196; Tomsig JL, 2004, BIOCHEM J, V378, P1089, DOI 10.1042/BJ20031654; Tomsig JL, 2003, J BIOL CHEM, V278, P10048, DOI 10.1074/jbc.M212632200; Tomsig JL, 2002, CELL MOL LIFE SCI, V59, P1467, DOI 10.1007/s00018-002-8522-7; Tomsig JL, 2000, BIOCHEMISTRY-US, V39, P16163, DOI 10.1021/bi0019949; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Wilson KS, 2002, AM J PATHOL, V161, P1171, DOI 10.1016/S0002-9440(10)64394-5; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	42	33	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3516	3526		10.1038/sj.onc.1211030	http://dx.doi.org/10.1038/sj.onc.1211030			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18212740				2022-12-17	WOS:000256468500003
J	Bennett, HL; Brummer, T; Jeanes, A; Yap, AS; Daly, RJ				Bennett, H. L.; Brummer, T.; Jeanes, A.; Yap, A. S.; Daly, R. J.			Gab2 and Src co-operate in human mammary epithelial cells to promote growth factor independence and disruption of acinar morphogenesis	ONCOGENE			English	Article						tyrosine kinase; signal transduction; E-cadherin; cell-cell adhesion; cell invasion	DOCKING PROTEIN GAB2; E-CADHERIN; SIGNALING PATHWAY; ACTIVATION; PHOSPHORYLATION; PROLIFERATION; ADHESION; ROLES; AKT; DEPHOSPHORYLATION	The Gab2 docking protein is a target of several oncogenic protein tyrosine kinases and potentiates activation of the Ras/extracellular signal regulated kinase and phosphatidylinositol 3-kinase (PI3-kinase) pathways. Since Gab2 is phosphorylated by c-Src, and both proteins are over-expressed in breast cancers, we have determined the biological consequences of their co-expression in the immortalized human mammary epithelial cell line MCF-10A. While overexpression of c-Src did not affect acinar morphogenesis or growth factor dependence in three-dimensional culture, c-Src co-operated with Gab2 to promote epidermal growth factor (EGF)-independent acinar growth. In contrast, expression of v-Src or the activated mutant c-SrcY527F led to a spectrum of aberrant phenotypes ranging from spheroids with incomplete luminal clearance to highly disrupted, dispersed structures. Gab2 co-expression shifted the phenotypic distribution towards the dispersed phenotype, an effect not observed with a Gab2 mutant unable to bind the p85 subunit of PI3-kinase (Gab2 Delta p85). In v-Src-expressing cells, Gab2, but not Gab2 Delta p85, significantly decreased E-cadherin adhesive strength without altering its surface expression. Gab2 associated with E-cadherin in the presence and absence of v-Src, indicating that the ability of Gab2 to weaken the strength of cell-cell contacts may reflect enhanced activation of PI3-kinase at adherens junctions. Gab2 also increased migration and invasion of these cells in transwell assays, but these effects were p85-independent. Overall, these findings demonstrate a novel mechanism whereby Gab2 may promote metastatic spread and indicate that Gab2 may play several roles during breast cancer progression.	[Bennett, H. L.; Brummer, T.; Daly, R. J.] Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; [Jeanes, A.; Yap, A. S.] Univ Queensland, Inst Mol Biosci, Queensland, Australia	Garvan Institute of Medical Research; University of Queensland	Daly, RJ (corresponding author), Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	r.daly@garvan.org.au	Daly, Roger J/C-8179-2009; Jeanes, Angela/D-9770-2011; Brummer, Tilman/B-6218-2016; Brummer, Tilman/AAA-9428-2020; Yap, Alpha S./J-1554-2014	Jeanes, Angela/0000-0003-0717-6298; Brummer, Tilman/0000-0003-4387-7905; Brummer, Tilman/0000-0003-4387-7905; Yap, Alpha S./0000-0002-1038-8956; Daly, Roger/0000-0002-5739-8027				Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; BRIEHER WM, 1994, J CELL BIOL, V126, P519, DOI 10.1083/jcb.126.2.519; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Gonzalez L, 2006, J BIOL CHEM, V281, P20851, DOI 10.1074/jbc.M601570200; Grille SJ, 2003, CANCER RES, V63, P2172; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Guan KL, 2000, J BIOL CHEM, V275, P27354; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Ischenko I, 2003, ONCOGENE, V22, P6311, DOI 10.1038/sj.onc.1206742; JANES PW, 1994, ONCOGENE, V9, P3601; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Ke Y, 2007, ONCOGENE, V26, P4951, DOI 10.1038/sj.onc.1210315; Kong M, 2003, J BIOL CHEM, V278, P5837, DOI 10.1074/jbc.M208286200; Kotelevets L, 2004, FASEB J, V18, P115, DOI 10.1096/fj.04-1942fje; Kotelevets L, 2001, J CELL BIOL, V155, P1129, DOI 10.1083/jcb.200105109; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Lynch DK, 2002, EMBO J, V21, P72, DOI 10.1093/emboj/21.1.72; Mege RM, 2006, CURR OPIN CELL BIOL, V18, P541, DOI 10.1016/j.ceb.2006.08.004; Mohi MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Nyga R, 2005, BIOCHEM J, V390, P359, DOI 10.1042/BJ20041523; Pang JH, 2005, J BIOL CHEM, V280, P3043, DOI 10.1074/jbc.M412148200; Podar K, 2004, J BIOL CHEM, V279, P21658, DOI 10.1074/jbc.M305783200; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Shewan AM, 2005, MOL BIOL CELL, V16, P4531, DOI 10.1091/mbc.E05-04-0330; SHORE EM, 1991, J BIOL CHEM, V266, P19672; Verma S, 2004, J BIOL CHEM, V279, P34062, DOI 10.1074/jbc.M404814200; Vogelmann R, 2005, J CELL SCI, V118, P4901, DOI 10.1242/jcs.02594; Wada T, 2005, NAT MED, V11, P394, DOI 10.1038/nm1203; Wang FM, 2005, BREAST CANCER RES TR, V89, P5, DOI 10.1007/s10549-004-1002-z; Wrobel CN, 2004, J CELL BIOL, V165, P263, DOI 10.1083/jcb.200309102; Yamasaki S, 2001, J BIOL CHEM, V276, P45175, DOI 10.1074/jbc.M105384200; Yu M, 2006, J IMMUNOL, V176, P2421, DOI 10.4049/jimmunol.176.4.2421; Yu WM, 2002, BLOOD, V99, P2351, DOI 10.1182/blood.V99.7.2351	44	33	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2008	27	19					2693	2704		10.1038/sj.onc.1210928	http://dx.doi.org/10.1038/sj.onc.1210928			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	17998934				2022-12-17	WOS:000255259500004
J	Reinbold, M; Luo, JL; Nedelko, T; Jerchow, B; Murphy, ME; Whibley, C; Wei, Q; Hollstein, M				Reinbold, M.; Luo, J-L; Nedelko, T.; Jerchow, B.; Murphy, M. E.; Whibley, C.; Wei, Q.; Hollstein, M.			Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72	ONCOGENE			English	Article						lung cancer; mutation hotspot; embryonic broblasts; senescence; polymorphism	LUNG-CANCER; POLYMORPHIC VARIANTS; MURINE FIBROBLASTS; GENE-MUTATIONS; DNA-DAMAGE; HOT-SPOTS; TRANSVERSIONS; INHIBITION; HOTSPOTS; ADDUCTS	Codon 72 of human p53 gene is polymorphic, encoding arginine or proline. Here we report construction of a human p53 knock-in (Hupki) mouse encoding the codon 72(pro) variant. The new strain was crossed with the original Hupki mice (codon 72(arg/arg)) to obtain primary embryonic fibroblasts polymorphic at codon 72 or homozygous for codon 72(pro). The fibroblasts, cultured under standard conditions, immortalized within 12 weeks and acquired p53 mutations similarly to Hupki codon 72(arg/arg) cells investigated previously. Sequencing of human p53 exons 4-9 in immortalized cultures revealed missense mutations found repeatedly in human tumours. In cell lines ensuing from benzo(a) pyrene-treated cultures the combined p53 mutation pattern from experiments with the 3 codon 72 genotypes showed a predominance of strand-biased G to T transversions (18 of 36 mutations), and mutations recurring at smokers' lung tumour hotspot codons 157 and 273, supporting involvement of tobacco carcinogens in shaping the mutation signature in lung cancers of smokers. Mutations in cell lines from unexposed cultures did not cluster at these codons and G to T transversions were uncommon (2 of 52 mutations) (Fisher's exact test P < 0.0001). Most mutations (13/16) in cell lines derived from cells polymorphic at codon 72 were found on the proline allele, with loss of the arginine allele.	[Whibley, C.; Hollstein, M.] Univ Leeds, Fac Med & Hlth, LIGHT Labs, Leeds LS2 9JT, W Yorkshire, England; [Reinbold, M.; Nedelko, T.; Wei, Q.; Hollstein, M.] German Canc Res Ctr, Dept Genet Alternat Carcinogenesis, D-6900 Heidelberg, Germany; [Luo, J-L] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Jerchow, B.] Max Delbruck Ctr, Berlin, Germany; [Murphy, M. E.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	University of Leeds; Helmholtz Association; German Cancer Research Center (DKFZ); University of California System; University of California San Diego; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Fox Chase Cancer Center	Hollstein, M (corresponding author), Univ Leeds, Fac Med & Hlth, LIGHT Labs, Clarendon Way, Leeds LS2 9JT, W Yorkshire, England.	m.hollstein@leeds.ac.uk		Jerchow, Boris-Alexander/0000-0002-7031-8730; Murphy, Maureen/0000-0001-7644-7296	NATIONAL CANCER INSTITUTE [R01CA102184] Funding Source: NIH RePORTER; Cancer Research UK Funding Source: Medline; NCI NIH HHS [R01 CA102184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research UK(Cancer Research UK); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergamaschi D, 2006, NAT GENET, V38, P1133, DOI 10.1038/ng1879; Chen JX, 1998, CANCER RES, V58, P2070; Dearth LR, 2007, CARCINOGENESIS, V28, P289, DOI 10.1093/carcin/bgl132; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Denissenko MF, 1998, ONCOGENE, V16, P1241, DOI 10.1038/sj.onc.1201647; Denissenko MF, 1997, P NATL ACAD SCI USA, V94, P3893, DOI 10.1073/pnas.94.8.3893; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Feng ZH, 2006, P NATL ACAD SCI USA, V103, P15404, DOI 10.1073/pnas.0607031103; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hu YC, 2005, CLIN CANCER RES, V11, P2502, DOI 10.1158/1078-0432.CCR-04-1913; Liu Zhipei, 2007, Genet Eng (N Y), V28, P45, DOI 10.1007/978-0-387-34504-8_3; Liu ZP, 2005, CANCER RES, V65, P2583, DOI 10.1158/0008-5472.CAN-04-3675; Liu ZP, 2004, P NATL ACAD SCI USA, V101, P2963, DOI 10.1073/pnas.0308607101; Luo JL, 2001, ONCOGENE, V20, P320, DOI 10.1038/sj.onc.1204080; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Nelson HH, 2005, CARCINOGENESIS, V26, P1770, DOI 10.1093/carcin/bgi125; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Pfeifer GP, 2003, MUTAT RES-FUND MOL M, V526, P39, DOI 10.1016/S0027-5107(03)00013-7; Pietsch EC, 2006, ONCOGENE, V25, P1602, DOI 10.1038/sj.onc.1209367; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Szymanowska A, 2006, LUNG CANCER, V52, P9, DOI 10.1016/j.lungcan.2005.12.007; Thomas M, 1999, MOL CELL BIOL, V19, P1092; vom Brocke J, 2006, CARCINOGENESIS, V27, P2141, DOI 10.1093/carcin/bg1101; Zienolddiny S, 2001, BRIT J CANCER, V84, P226, DOI 10.1054/bjoc.2000.1528	29	33	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2008	27	19					2788	2794		10.1038/sj.onc.1210932	http://dx.doi.org/10.1038/sj.onc.1210932			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	17998932	Green Accepted			2022-12-17	WOS:000255259500014
J	Morozov, VM; Massoll, NA; Vladimirova, OV; Maul, GG; Ishov, AM				Morozov, V. M.; Massoll, N. A.; Vladimirova, O. V.; Maul, G. G.; Ishov, A. M.			Regulation of c-met expression by transcription repressor Daxx	ONCOGENE			English	Article						Daxx; c-met; transcription; DNA methylation; histone acetylation; metastatic breast cancer	HEPATOCYTE GROWTH-FACTOR; FACTOR RECEPTOR; HGF RECEPTOR; FUNCTIONAL INTERACTIONS; EPITHELIAL-CELLS; SYNDROME PROTEIN; PROTOONCOGENE; INHIBITION; ACTIVATION; CANCER	The protooncogene c-met encodes the tyrosine kinase receptor for the hepatocyte growth factor/scatter factor (HGF/SF). While overexpression of c-met is documented in many types of tumors, the mechanism of c-met regulation remains elusive. Here, we demonstrate Daxx as a repressor of c-met transcription. The expression of c-met is elevated in Daxx knockout mouse cells and is reversed by Daxx reconstitution. C-met promoter analysis of Daxx(-/-) cells reveled changes in chromatin acetylation, but not in DNA methylation. Daxx binds to the mouse c-met promoter and Daxx-binding region is sufficient for transcription repression, while HDAC2 is associated with c-met promoter mostly in Daxx(+/+) cells, pointing to Daxx-dependent HDAC2 recruitment as a potential mechanism of c-met repression. HGF-induced cell mobility and invasion confirmed augmented activity of c-Met/HGF pathway in Daxx(-/-) cells. Finally, inverse correlation between Daxx and c-Met in cancer cell lines and in metastatic breast cancer specimens suggests potential function of Daxx as a c-met repressor during cancer progression.	[Morozov, V. M.; Ishov, A. M.] Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; [Morozov, V. M.; Ishov, A. M.] Univ Florida, Shands Canc Ctr, Gainesville, FL 32610 USA; [Massoll, N. A.] Univ Florida, Dept Pathol, Gainesville, FL 32610 USA; [Massoll, N. A.] Univ Florida, Lab Med, Gainesville, FL 32610 USA; [Vladimirova, O. V.; Maul, G. G.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; The Wistar Institute	Ishov, AM (corresponding author), Univ Florida, Dept Anat & Cell Biol, 1376 Mowry Rd,Room 358, Gainesville, FL 32610 USA.	ishov@ufl.edu	Ishov, Alexander/E-4912-2010	Morozov, Viacheslav/0000-0002-4901-7722				Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boon EMJ, 2002, CANCER RES, V62, P5126; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; Gambarotta G, 1996, ONCOGENE, V13, P1911; Gibbons RJ, 2000, NAT GENET, V24, P368, DOI 10.1038/74191; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Hollenbach AD, 2002, J CELL SCI, V115, P3319; Ishov AM, 2004, J CELL SCI, V117, P3807, DOI 10.1242/jcs.01230; Kim EJ, 2003, NUCLEIC ACIDS RES, V31, P5356, DOI 10.1093/nar/gkg741; Leroy C, 2006, ANN NY ACAD SCI, V1090, P188, DOI 10.1196/annals.1378.021; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Michaelson JS, 2003, J CELL SCI, V116, P345, DOI 10.1242/jcs.00234; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Morotti A, 2002, ONCOGENE, V21, P4885, DOI 10.1038/sj.onc.1205622; Muromoto R, 2004, J IMMUNOL, V172, P2985, DOI 10.4049/jimmunol.172.5.2985; Ohiro Y, 2003, MOL CELL BIOL, V23, P322, DOI 10.1128/MCB.23.1.322-334.2003; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Radaeva S, 2002, GASTROENTEROLOGY, V122, P1020, DOI 10.1053/gast.2002.32388; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Salomoni P, 2006, TRENDS CELL BIOL, V16, P97, DOI 10.1016/j.tcb.2005.12.002; Seol DW, 1999, J BIOL CHEM, V274, P3565, DOI 10.1074/jbc.274.6.3565; Seol DW, 2000, ONCOGENE, V19, P1132, DOI 10.1038/sj.onc.1203404; Seol DW, 1998, BBA-GENE STRUCT EXPR, V1395, P252, DOI 10.1016/S0167-4781(97)00202-9; Shimoda K, 2002, J IMMUNOL, V169, P4707, DOI 10.4049/jimmunol.169.9.4707; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tang J, 2004, J BIOL CHEM, V279, P20369, DOI 10.1074/jbc.M401321200; Tzeng SL, 2006, J BIOL CHEM, V281, P15405, DOI 10.1074/jbc.M601807200; Xue YT, 2003, P NATL ACAD SCI USA, V100, P10635, DOI 10.1073/pnas.1937626100; Zhang XH, 2005, AM J PHYSIOL-RENAL, V288, pF16, DOI 10.1152/ajprenal.00318.2003; Zhang XH, 2003, AM J PHYSIOL-RENAL, V284, pF1216, DOI 10.1152/ajprenal.00426.2002; Zhao LY, 2003, J VIROL, V77, P11809, DOI 10.1128/JVI.77.21.11809-11821.2003	35	33	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2008	27	15					2177	2186		10.1038/sj.onc.1210865	http://dx.doi.org/10.1038/sj.onc.1210865			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17952115				2022-12-17	WOS:000254621300008
J	Vilgelm, A; Wei, JX; Piazuelo, MB; Washington, MK; Prassolov, V; El-Rifai, W; Zaika, A				Vilgelm, A.; Wei, J. X.; Piazuelo, M. B.; Washington, M. K.; Prassolov, V.; El-Rifai, W.; Zaika, A.			Delta Np73 alpha regulates MDR1 expression by inhibiting p53 function	ONCOGENE			English	Article						p73; p53; gastric tumor	P-GLYCOPROTEIN; P73 ISOFORMS; IN-VIVO; GASTRIC ADENOCARCINOMA; CLINICAL-RELEVANCE; GENE-EXPRESSION; POOR-PROGNOSIS; HUMAN TUMORS; CANCER; CELLS	The p73 protein is a transcription factor and member of the p53 protein family that expresses as a complex variety of isoforms. Delta Np73 alpha is an N-terminally truncated isoform of p73. We found that Delta Np73 protein is upregulated in human gastric carcinoma suggesting that DNp73 may play an oncogenic role in these tumors. Although it has been shown that DNp73a inhibits apoptosis and counteracts the effect of chemotherapeutic drugs, the underlying mechanism by which this p73 isoform contributes to chemotherapeutic drug response remains to be explored. We found that DNp73a upregulates MDR1 mRNA and p-glycoprotein (p-gp), which is involved in chemotherapeutic drug transport. This p-gp upregulation was accompanied by increased p-gp functional activity in gastric cancer cells. Our data suggest that upregulation of MDR1 by DNp73a is mediated by interaction with p53 at the MDR1 promoter.	[Vilgelm, A.; Wei, J. X.; El-Rifai, W.; Zaika, A.] Vanderbilt Univ, Med Ctr, Dept Surg & Canc Biol, Nashville, TN 37232 USA; [El-Rifai, W.; Zaika, A.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA; [Piazuelo, M. B.] Vanderbilt Univ, Med Ctr, Div Gastroenterol, Nashville, TN 37232 USA; [Washington, M. K.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; [Vilgelm, A.; Prassolov, V.] Russian Acad Sci, VA Engelhardt Mol Biol Inst, Dept Cell Biol, Moscow 117901, Russia	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Zaika, A (corresponding author), Vanderbilt Univ, Med Ctr, Dept Surg & Canc Biol, 1255 Light Hall,2215 Garland Ave, Nashville, TN 37232 USA.	alex.zaika@vanderbilt.edu		Vilgelm, Anna/0000-0002-4446-913X	NCI NIH HHS [R01 CA138833, P50 CA095103, R01 CA108956, R21 CA129655] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA129655, R01CA138833, P50CA095103, R01CA108956] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Choi JH, 2002, BRIT J CANCER, V86, P1578, DOI 10.1038/sj.bjc.6600305; Concin N, 2005, CLIN CANCER RES, V11, P8372, DOI 10.1158/1078-0432.CCR-05-0899; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dominguez G, 2006, J CLIN ONCOL, V24, P805, DOI 10.1200/JCO.2005.02.2350; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Guan M, 2005, J CLIN PATHOL, V58, P1175, DOI 10.1136/jcp.2005.026955; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; Hotta T, 1999, SURG TODAY, V29, P591, DOI 10.1007/BF02482982; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; Johnson RA, 2005, J BIOL CHEM, V280, P13213, DOI 10.1074/jbc.M414646200; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Lacueva FJ, 1998, HISTOPATHOLOGY, V32, P328; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Petrenko O, 2003, MOL CELL BIOL, V23, P5540, DOI 10.1128/MCB.23.16.5540-5555.2003; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037; Tomkova K, 2006, ONCOGENE, V25, P6032, DOI 10.1038/sj.onc.1209610; Tomkova K, 2004, CANCER RES, V64, P6390, DOI 10.1158/0008-5472.CAN-04-2176; Uramoto H, 2004, CLIN CANCER RES, V10, P6905, DOI 10.1158/1078-0432.CCR-04-0290; VOLLRATH V, 1991, VIRCHOWS ARCH B, V60, P133, DOI 10.1007/BF02899538; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Vousden KH, 2006, J CELL SCI, V119, P5015, DOI 10.1242/jcs.03293; WALLNER J, 1993, CANCER, V71, P667, DOI 10.1002/1097-0142(19930201)71:3<667::AID-CNCR2820710303>3.0.CO;2-6; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179	30	33	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2008	27	15					2170	2176		10.1038/sj.onc.1210862	http://dx.doi.org/10.1038/sj.onc.1210862			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17952118	Green Accepted			2022-12-17	WOS:000254621300007
J	Julian, LM; Palander, O; Seifried, LA; Foster, JEG; Dick, FA				Julian, L. M.; Palander, O.; Seifried, L. A.; Foster, J. E. G.; Dick, F. A.			Characterization of an E2F1-specific binding domain in pRB and its implications for apoptotic regulation	ONCOGENE			English	Article						cell cycle; retinoblastoma; E2F; apoptosis; transcription	CELL-CYCLE ARREST; E2F; PROTEINS; FAMILY; PROLIFERATION	The retinoblastoma protein (pRB) has the dual capability to negatively regulate both E2F-induced cell cycle entry and E2F1-induced apoptosis. In this report, we characterize a unique pRB-E2F1 interaction. Using mutagenesis to disrupt E2F1 binding, we find that the ability of pRB to regulate E2F1-induced apoptosis is diminished when this interaction is lost. Strikingly, this mutant form of pRB retains the ability to control E2F responsive cell cycle genes and blocks cell proliferation. These functional properties are the reciprocal of a previously described E2F binding mutant of pRB that interacts with E2F1, but lacks the ability to interact with other E2Fs. Our work shows that these distinct interactions allow pRB to separately regulate E2F-induced cell proliferation and apoptosis. This suggests a novel form of regulation whereby separate types of binding contacts between the same types of molecules can confer distinct functional outcomes.	[Julian, L. M.; Palander, O.; Seifried, L. A.; Foster, J. E. G.; Dick, F. A.] Univ Western Ontario, Dept Biochem, Childrens Hlth Res Inst, London, ON N6A 4L6, Canada	Western University (University of Western Ontario)	Dick, FA (corresponding author), Univ Western Ontario, Dept Biochem, Childrens Hlth Res Inst, 790 Commiss Rd E, London, ON N6A 4L6, Canada.	fdick@uwo.ca		Foster, Julia/0000-0002-6971-5683				Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; Dick FA, 2002, J VIROL, V76, P6224, DOI 10.1128/JVI.76.12.6224-6234.2002; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; Johnson DG, 2006, CURR MOL MED, V6, P731; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rubin SM, 2005, CELL, V123, P1093, DOI 10.1016/j.cell.2005.09.044; Stevens C, 2003, CELL CYCLE, V2, P435, DOI 10.4161/cc.2.5.462; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Takahashi Y, 2000, GENE DEV, V14, P804; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000	16	33	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1572	1579		10.1038/sj.onc.1210803	http://dx.doi.org/10.1038/sj.onc.1210803			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17891180				2022-12-17	WOS:000253815800009
J	Berenguer, C; Boudouresque, F; Dussert, C; Daniel, L; Muracciole, X; Grino, M; Rossi, D; Mabrouk, K; Figarella-Branger, D; Martin, PM; Ouafik, L				Berenguer, C.; Boudouresque, F.; Dussert, C.; Daniel, L.; Muracciole, X.; Grino, M.; Rossi, D.; Mabrouk, K.; Figarella-Branger, D.; Martin, P-M; Ouafik, L'Houcine			Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells	ONCOGENE			English	Article						prostate cancer; LNCaP cells; adrenomedullin; adrenomedullin receptors; neuroendocrine differentiation; LNCaP xenograft; androgen; regulation; cGMP-dependent protein kinase G	DEPENDENT PROTEIN-KINASE; CANCER CELLS; IN-VITRO; DIFFERENTIATION; GENE; ANGIOGENESIS; PROGRESSION; EXPRESSION; PEPTIDE; GROWTH	Neuroendocrine (NE) differentiation in prostate cancer (CaP) has been reported to be an early marker associated with the development of androgen independence. The mechanisms by which CaP acquires NE properties are poorly understood. In this study, a putative role of adrenomedullin (AM) in the NE differentiation was investigated. The expression of AM and AM receptors (calcitonin receptor-like receptor (CRLR)/receptor activity modifying protein-2 and -3 (RAMP2 and RAMP3) was evaluated after experimental manipulation of androgen status. Levels of AM mRNA and immunoreactive AM (ir-AM) increased four-to sevenfold in androgen-sensitive LNCaP cells after androgen withdrawal in vitro and in LNCaP xenograftsin animals after castration. Treatment of LNCaP cells with androgen analogue (dihydrotestosterone; 10(-9) M) prevented the increase in AM mRNA and ir-AM levels. Interestingly, the expression of CRLR, RAMP2 and RAMP3 is not regulated by androgen status. We demonstrate that in the presence of serum, AM is able to induce an NE phenotype in LNCaP cells via CRLR/ RAMP2 and RAMP3, which includes extension of neuritic processes and expression of the neuron-specific enolase (NSE), producing cGMP in a dose-dependent manner, which is mediated by a pertussis toxin-sensitive GTP-binding protein. 8-bromo-cGMP mimicked the effects of AM on cell differentiation. We demonstrate that AM induces a G-kinase I alpha translocation to the nucleus. The protein kinase G inhibitor KT-5823 inhibited the neurite outgrowth induced by both AM and 8-bromo-cGMP. In noncastrated animals, administration of AM enhanced expression of NSE and chromogranin A in LNCaP xenografts with a significant increase of NSE levels in serum and no changes in tumor growth. In castrated animals, intraperitoneal injection of AM resulted in a 240 +/- 18% ( P<0.001) increase in tumor volume 36 days after treatment, indicating that the nature of effect of AM in CaP depends on the presence or absence of endogenous androgen. Together, these results demonstrate that AM may function as a mediator of NE-like differentiation in culture as well as in vivo and indicate that its product ion may be important for tumor resurgence following androgen ablation.	[Berenguer, C.; Boudouresque, F.; Dussert, C.; Martin, P-M; Ouafik, L'Houcine] Univ Aix Marseille 2, Fac Med Secteur Nord, IFR Jean Roche, Expt Cancerol Lab, F-13916 Marseille 20, France; [Berenguer, C.; Boudouresque, F.; Dussert, C.; Martin, P-M; Ouafik, L'Houcine] INSERM E 359, Marseille, France; [Daniel, L.; Figarella-Branger, D.] Univ Aix Marseille 2, Fac Med, Lab Adhes & Signalisat EA3281, Marseille, France; [Muracciole, X.] Assistance Publ Hop Marseille, CHU Timone, Serv Radiotherapie, Marseille, France; [Grino, M.] INSERM, UMR 626, Marseille, France; [Rossi, D.] Assistance Publ Hop Marseille, CHU Nord, Serv Urol, Marseille, France; [Mabrouk, K.] CNRS, FRE 2738, Marseille, France; [Martin, P-M; Ouafik, L'Houcine] Assistance Publ Hop Marseille, CHU Nord, Lab Transfer Oncol Biol & Mol, Marseille, France	UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Ouafik, L (corresponding author), Univ Aix Marseille 2, Fac Med Secteur Nord, IFR Jean Roche, Expt Cancerol Lab, Bd Pierre Dramard, F-13916 Marseille 20, France.	lhoucine.ouafik@univmed.fr	Grino, Michel/M-7548-2017; Grino, Michel/O-5361-2017; Grino, Michel/GYD-8559-2022; Muracciole, Xavier/P-5640-2016; daniel, laurent/R-2826-2016	daniel, laurent/0000-0002-7539-0109; Ouafik, L'Houcine/0000-0002-4848-1232				Abasolo I, 2003, MOL CELL ENDOCRINOL, V199, P179, DOI 10.1016/S0303-7207(02)00229-0; Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; Chung TDK, 1999, PROSTATE, V38, P199; Costantini LC, 2000, EXP NEUROL, V164, P60, DOI 10.1006/exnr.2000.7417; Cox ME, 1999, CANCER RES, V59, P3821; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; Fernandez-Sauze S, 2004, INT J CANCER, V108, P797, DOI 10.1002/ijc.11663; GKONOS PJ, 1995, UROL RES, V23, P81, DOI 10.1007/BF00307937; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Kim J, 2002, CANCER RES, V62, P1549; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Nikitenko LL, 2006, BRIT J CANCER, V94, P1, DOI 10.1038/sj.bjc.6602832; Ouafik L, 2002, AM J PATHOL, V160, P1279, DOI 10.1016/S0002-9440(10)62555-2; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; Rocchi P, 2001, CANCER RES, V61, P1196; Spiotto MT, 2000, PROSTATE, V42, P186, DOI 10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E	19	33	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					506	518		10.1038/sj.onc.1210656	http://dx.doi.org/10.1038/sj.onc.1210656			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637748				2022-12-17	WOS:000252426100011
J	Raho, G; Miranda, C; Tamborini, E; Pierotti, MA; Greco, A				Raho, G.; Miranda, C.; Tamborini, E.; Pierotti, M. A.; Greco, A.			Detection of novel mRNA splice variants of human ING4 tumor suppressor gene	ONCOGENE			English	Article						ING4; alternative splicing; PHD domain	PHD-FINGER; CANCER; EXPRESSION; PROTEINS; APOPTOSIS; FAMILY; DOMAIN; P53; TRANSCRIPTION; ACETYLATION	Inhibitor of growth (ING) 4, member of a gene family encoding potential tumor suppressors, is implicated as a repressor of angiogenesis and tumor growth and suppresses loss of contact inhibition in vitro. Here, we report that ING4 undergoes alternative splicing. Expression analysis identified novel ING4 spliced variant mRNAs encoding proteins devoid of different portions. The ING4 variants were detected in both normal and tumor tissues. The existence of ING4 variants was confirmed by several approaches, including reverse transcriptase-polymerase chain reaction, real-time PCR and in silico experiments. To investigate the functional consequences of alternative splicing the ING4 variant cDNAs were expressed in mammalian cells. Our studies indicated that (i) the ING4 variants do not differ from wild-type in their nuclear localization, interaction with p53 and association to HBO1 complex; and (ii) the ING4-Delta Ex6A variant, devoid of the C-terminal portion, loses the capability to inhibit NF-kappa B. On the whole our data suggest that alternative splicing could modulate the activity of ING4 tumor suppressor protein.	Ist Nazl Tumori, Dept Expt Oncol, Operat Unit Mol Mech Canc Growth & Progress, I-20133 Milan, Italy; Ist Nazl Tumori, Dept Pathol Expt Mol Pathol, I-20133 Milan, Italy; Ist Nazl Tumori, Sci Direct, I-20133 Milan, Italy; IFOM Fdn, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology	Pierotti, MA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Operat Unit Mol Mech Canc Growth & Progress, Via Venezian 1, I-20133 Milan, Italy.	marco.pierotti@istitutotumori.mi.it; angela.greco@istitutotumori.mi.it	Tamborini, Elena/C-3307-2017; Pierotti, Marco Alessandro/AAC-4728-2022; Greco, Angela/C-1953-2017	Tamborini, Elena/0000-0002-3819-8687; Pierotti, Marco Alessandro/0000-0002-7431-8332; Greco, Angela/0000-0003-2994-0349				Bienz M, 2006, TRENDS BIOCHEM SCI, V31, P35, DOI 10.1016/j.tibs.2005.11.001; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Feng XL, 2002, TRENDS CELL BIOL, V12, P532, DOI 10.1016/S0962-8924(02)02391-7; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Gong W, 2005, INT J BIOCHEM CELL B, V37, P1054, DOI 10.1016/j.biocel.2004.09.008; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; GRECO A, 1995, MOL CELL BIOL, V15, P6118; Gunduz M, 2005, GENE, V356, P109, DOI 10.1016/j.gene.2005.02.014; Gunduz M, 2002, ONCOGENE, V21, P4462, DOI 10.1038/sj.onc.1205540; He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256; Huiping C, 2002, EUR J CANCER, V38, P728, DOI 10.1016/S0959-8049(01)00432-4; Kalnina Z, 2005, GENE CHROMOSOME CANC, V42, P342, DOI 10.1002/gcc.20156; Kataoka H, 2003, CANCER RES, V63, P5785; Kaufmann D, 2002, CANCER RES, V62, P1503; Kim S, 2004, P NATL ACAD SCI USA, V101, P16251, DOI 10.1073/pnas.0407158101; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; Lu F, 2006, BRIT J CANCER, V95, P80, DOI 10.1038/sj.bjc.6603205; Nagashima M, 2003, ONCOGENE, V22, P343, DOI 10.1038/sj.onc.1206115; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nouman GS, 2002, HYBRIDOMA HYBRIDOM, V21, P1, DOI 10.1089/15368590252917584; Okano T, 2006, ONCOL REP, V15, P545; Ozer A, 2005, P NATL ACAD SCI USA, V102, P7481, DOI 10.1073/pnas.0502716102; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Russell M, 2006, EXP CELL RES, V312, P951, DOI 10.1016/j.yexcr.2006.01.020; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Shiseki M, 2003, CANCER RES, V63, P2373; Tsai KW, 2006, GENOMICS, V88, P855, DOI 10.1016/j.ygeno.2006.07.004; Unoki M, 2006, J BIOL CHEM, V281, P34677, DOI 10.1074/jbc.M606296200; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Wagner MJ, 2005, GEN COMP ENDOCR, V144, P38, DOI 10.1016/j.ygcen.2005.04.008; Zhang X, 2005, BIOCHEM BIOPH RES CO, V331, P1032, DOI 10.1016/j.bbrc.2005.04.023; Zhou MI, 2005, P NATL ACAD SCI USA, V102, P11035, DOI 10.1073/pnas.0500757102	33	33	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2007	26	36					5247	5257		10.1038/sj.onc.1210335	http://dx.doi.org/10.1038/sj.onc.1210335			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17325660				2022-12-17	WOS:000248674200008
J	Ramer, R; Eichele, K; Hinz, B				Ramer, R.; Eichele, K.; Hinz, B.			Upregulation of tissue inhibitor of matrix metalloproteinases-1 confers the anti-invasive action of cisplatin on human cancer cells	ONCOGENE			English	Article						cisplatin; matrigel cell invasion; tissue inhibitor of matrix metalloproteinases-1; matrix metalloproteinase-2; human cervical cancer cells; human lung; carcinoma cells	PROMOTES INVASION; INDUCED APOPTOSIS; EPITHELIAL-CELLS; TUMOR INVASION; KAPPA-B; P38; ACTIVATION; EXPRESSION; STRESS; TIMP-1	Cancer cell invasion is one of the crucial events in local spreading, growth and metastasis of tumors. The present study investigates the mechanism underlying the antiinvasive action of the chemotherapeutic cisplatin. In human cervical carcinoma cells (HeLa), cisplatin caused a time- and concentration-dependent suppression of cell invasion through Matrigel. Inhibition of invasion was accompanied by upregulation of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), whereas levels of matrix metalloproteinase-2 (MMP-2), MMP-9 and TIMP-2 remained unchanged. Cisplatin's effects on TIMP-I expression and invasion were associated with phosphorylations of p38 and p42/44 mitogen-activated protein kinases and were abrogated by specific inhibitors of both pathways. The impact of TIMP-I in the anti-invasive action of cisplatin was proven by transfecting cells with small interfering RNA targeting TIMP-1, which completely reversed suppression of invasion by cisplatin. A functional relevance of TIMP-1 upregulation was substantiated by findings showing a concentration-dependent inhibition of Matrigel invasion by recombinant TIMP-1. The essential role of TIMP-1 in the anti-invasive action of cisplatin was confirmed using another human cervical carcinoma cell line (C33A) and human lung carcinoma cells (A549). Altogether, our data demonstrate a hitherto unknown mechanism by which cisplatin exerts its antimetastatic properties on highly invasive cancer cells.	Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol & Toxicol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Hinz, B (corresponding author), Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol & Toxicol, Fahrstr 17, D-91054 Erlangen, Germany.	hinz@pharmakologie.uni-eriangen.de						Biroccio A, 2004, NEOPLASIA, V6, P195, DOI 10.1593/neo.03370; Chan VYW, 2005, REGUL PEPTIDES, V127, P87, DOI 10.1016/j.regpep.2004.10.016; Chintala SK, 1997, CLIN EXP METASTAS, V15, P361, DOI 10.1023/A:1018442003163; Choi J, 2005, CANCER RES, V65, P5554, DOI 10.1158/0008-5472.CAN-04-4570; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; Han R, 2005, J IMMUNOL, V174, P3072, DOI 10.4049/jimmunol.174.5.3072; Hartmann JT, 2003, EXPERT OPIN PHARMACO, V4, P889, DOI 10.1517/eoph.4.6.889.22200; Hinz B, 2005, FASEB J, V19, P1929, DOI 10.1096/fj.04-3626fje; HONG JH, 2006, CHEM REV, V99, P2467; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; KHOKHA R, 1992, J NATL CANCER I, V84, P1017, DOI 10.1093/jnci/84.13.1017; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; LOCHRER PJ, 1984, ANN INTERN MED, V100, P704; Mabuchi S, 2004, J BIOL CHEM, V279, P23477, DOI 10.1074/jbc.M313709200; Mori K, 2004, CANCER RES, V64, P7464, DOI 10.1158/0008-5472.CAN-04-1725; Morikawa T, 1995, Nihon Ika Daigaku Zasshi, V62, P320; Park MJ, 2005, J CELL BIOCHEM, V95, P955, DOI 10.1002/jcb.20452; Razzaque MS, 1999, HISTOCHEM CELL BIOL, V111, P359, DOI 10.1007/s004180050368; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Tong L, 2004, CELL SIGNAL, V16, P1123, DOI 10.1016/j.cellsig.2004.03.003; Villedieu M, 2006, GYNECOL ONCOL, V101, P507, DOI 10.1016/j.ygyno.2005.11.017; Zhang QX, 2005, WORLD J GASTROENTERO, V11, P4451, DOI 10.3748/wjg.v11.i29.4451	22	33	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5822	5827		10.1038/sj.onc.1210358	http://dx.doi.org/10.1038/sj.onc.1210358			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17369856				2022-12-17	WOS:000248885100014
J	Dawson, DW; Hong, JS; Shen, RR; French, SW; Troke, JJ; Wu, YZ; Chen, SS; Gui, D; Regelson, M; Marahrens, Y; Morse, HC; Said, J; Plass, C; Teitell, MA				Dawson, D. W.; Hong, J. S.; Shen, R. R.; French, S. W.; Troke, J. J.; Wu, Y-Z; Chen, S-S; Gui, D.; Regelson, M.; Marahrens, Y.; Morse, H. C., III; Said, J.; Plass, C.; Teitell, M. A.			Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas	ONCOGENE			English	Article						DNA methylation; B-cell lymphoma; TCL1	RECEPTORS; EXPRESSION; EPHRINS; GENE; LEUKEMIA; ADHESION; CANCER; HYPERMETHYLATION; EPIGENETICS	Most human lymphomas originate from transformed germinal center (GC) B lymphocytes. While activating mutations and translocations of MYC, BCL2 and BCL6 promote specific GC lymphoma subtypes, other genetic and epigenetic modi. cations that contribute to malignant progression in the GC remain poorly defined. Recently, aberrant expression of the TCL1 proto-oncogene was identified in major GC lymphoma subtypes. TCL1 transgenic mice offer unique models of both aggressive GC and marginal zone B-cell lymphomas, further supporting a role for TCL1 in B-cell transformation. Here, restriction landmark genomic scanning was employed to discover tumor-associated epigenetic alterations in malignant GC and marginal zone B-cells in TCL1 transgenic mice. Multiple genes were identified that underwent DNA hypermethylation and decreased expression in TCL1 transgenic tumors. Further, we identified a secreted isoform of EPHA7, a member of the Eph family of receptor tyrosine kinases that are able to influence tumor invasiveness, metastasis and neovascularization. EPHA7 was hypermethylated and repressed in both mouse and human GC B-cell non-Hodgkin lymphomas, with the potential to influence tumor progression and spread. These data provide the first set of hypermethylated genes with the potential to complement TCL1-mediated GC B-cell transformation and spread.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Ohio State Univ, Div Human Canc Genet, Columbus, OH 43210 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA USA; NIAID, Natl Inst Hlth, Immunopathol Lab, Rockville, MD USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Inst Stem Cell Biol & Med, Los Angeles, CA USA; Univ Calif Los Angeles, Calif Nanosyst Inst, Los Angeles, CA USA; Univ Calif Los Angeles, Inst Cell Mimet Studies, Los Angeles, CA USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University System of Ohio; Ohio State University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Teitell, MA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, 10833 LeConte Ave,Mail Code 173216, Los Angeles, CA 90095 USA.	mteitell@ucla.edu	Dawson, David/I-5917-2014; Plass, Christoph/H-7192-2014	Morse, Herbert/0000-0002-9331-3705	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041451] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA090571, T32CA009056, R01CA107300, T32CA009120] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [PN2EY018228] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073981] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [T32CA09056, R01 CA090571, R01 CA107300, T32CA009120, T32 CA009056, T32 CA009120] Funding Source: Medline; NEI NIH HHS [PN2 EY018228, PN2 EY018228-02] Funding Source: Medline; NICHD NIH HHS [HD041451, R01 HD041451] Funding Source: Medline; NIGMS NIH HHS [R01GM073981, R01 GM073981] Funding Source: Medline; PHS HHS [T32A107126] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aasheim HC, 2000, BLOOD, V95, P221, DOI 10.1182/blood.V95.1.221.001k01_221_230; Aasheim HC, 1997, BLOOD, V90, P3613, DOI 10.1182/blood.V90.9.3613; Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Cheng N, 2003, NEOPLASIA, V5, P445, DOI 10.1016/S1476-5586(03)80047-7; CIOSSEK T, 1995, ONCOGENE, V10, P97; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Costello JF, 2002, METHODS, V27, P144, DOI 10.1016/S1046-2023(02)00067-1; de Saint-Vis B, 2003, BLOOD, V102, P4431, DOI 10.1182/blood-2003-02-0500; Dobrzanski P, 2004, CANCER RES, V64, P910, DOI 10.1158/0008-5472.CAN-3430-2; Esteller M, 2003, CLIN IMMUNOL, V109, P80, DOI 10.1016/S1521-6616(03)00208-0; Esteller M, 2003, ADV EXP MED BIOL, V532, P39; Esteller M, 2002, J NATL CANCER I, V94, P26; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Galm O, 2006, BLOOD REV, V20, P1, DOI 10.1016/j.blre.2005.01.006; Hafner C, 2004, CLIN CHEM, V50, P490, DOI 10.1373/clinchem.2003.026849; Herman JG, 1997, CANCER RES, V57, P837; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Holmberg J, 2000, NATURE, V408, P203, DOI 10.1038/35041577; Holmberg J, 2002, TRENDS NEUROSCI, V25, P239, DOI 10.1016/S0166-2236(02)02149-5; Hoyer KK, 2002, P NATL ACAD SCI USA, V99, P14392, DOI 10.1073/pnas.212410199; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Klein U, 2005, CURR TOP MICROBIOL, V294, P31, DOI 10.1007/3-540-29933-5_3; Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782; Narducci MG, 2000, CANCER RES, V60, P2095; Palmer A, 2003, GENE DEV, V17, P1429, DOI 10.1101/gad.1093703; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Rush LJ, 2004, CANCER RES, V64, P2424, DOI 10.1158/0008-5472.CAN-03-2870; Rush LJ, 2002, CANCER LETT, V185, P1, DOI 10.1016/S0304-3835(02)00288-4; Rush LJ, 2001, BLOOD, V97, P3226, DOI 10.1182/blood.V97.10.3226; Said JW, 2001, LAB INVEST, V81, P555, DOI 10.1038/labinvest.3780264; Sharfe N, 2002, EUR J IMMUNOL, V32, P3745, DOI 10.1002/1521-4141(200212)32:12<3745::AID-IMMU3745>3.0.CO;2-M; Shen RR, 2006, BLOOD, V108, P1991, DOI 10.1182/blood-2006-02-001354; Surawska H, 2004, CYTOKINE GROWTH F R, V15, P419, DOI 10.1016/j.cytogfr.2004.09.002; Teitell M, 1999, P NATL ACAD SCI USA, V96, P9809, DOI 10.1073/pnas.96.17.9809; Teitell MA, 2005, NAT REV CANCER, V5, P640, DOI 10.1038/nrc1672; Wang JD, 2005, ONCOGENE, V24, P5637, DOI 10.1038/sj.onc.1208720; Wimmer-Kleikamp SH, 2005, IUBMB LIFE, V57, P421, DOI 10.1080/15216540500138337; Wu Jiangping, 2005, Curr Opin Hematol, V12, P292, DOI 10.1097/01.moh.0000166497.26397.9f; Yan XJ, 2006, P NATL ACAD SCI USA, V103, P11713, DOI 10.1073/pnas.0604564103; Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521	41	33	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4243	4252		10.1038/sj.onc.1210211	http://dx.doi.org/10.1038/sj.onc.1210211			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17260020	Green Accepted			2022-12-17	WOS:000247619900007
J	Buschbeck, M; Uribesalgo, I; Ledl, A; Gutierrez, A; Minucci, S; Muller, S; Di Croce, L				Buschbeck, M.; Uribesalgo, I.; Ledl, A.; Gutierrez, A.; Minucci, S.; Muller, S.; Di Croce, L.			PML4 induces differentiation by Myc destabilization	ONCOGENE			English	Article						cancer; differentiation; gene repression; Myc; promyelocytic leukemia protein; protein degradation	RAR-ALPHA; ACUTE-LEUKEMIA; C-MYC; UBIQUITIN; EXPRESSION; DEGRADATION; PATHOGENESIS; ASSOCIATION; PROTEASOMES; BINDING	Opposing functions like oncogene and tumor suppressions have been established for c-Myc and promyelocytic leukemia (PML) protein, respectively. Myc is known to inhibit differentiation of hematopoietic precursor cells, and here we report that PML promotes cell differentiation. We further demonstrate that PML and Myc form a complex in vivo. The interaction of the two proteins leads to the destabilization of Myc in a manner dependent on the really interesting new gene (RING) domain of PML. Although several PML isoforms are able to interact with Myc, the ability to destabilize Myc is specific for PML4. Importantly, the PML-induced destabilization resulted in a reduction of promoter-bound Myc on Myc-repressed genes. Thereby, PML induced the re-activation of Myc-repressed target genes including the tumor, suppressive genes of the cell cycle inhibitors cdkn1a/p21 and cdkn2b/ p15. Together, these results establish PML-mediated destabilization of Myc and the derepression of cell cycle inhibitor genes as an important regulatory mechanism that allows cell differentiation and prevents aberrant proliferation driven by uncontrolled Myc activity.	PRBB, CRG, Barcelona, Spain; Univ Pompeu Fabra, Barcelona, Spain; Max Planck Inst Biochem, D-82152 Martinsried, Germany; IEO, Milan, Italy	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; Max Planck Society; IRCCS European Institute of Oncology (IEO)	Di Croce, L (corresponding author), ICREA, C Dr Aiguaer 88, Barcelona 08003, Spain.	luciano.dicroce@crg.es	Gutierrez, Arantxa/K-8213-2015; Di Croce, Luciano/E-7759-2015; Minucci, Saverio/J-9669-2012; Buschbeck, Marcus/J-8204-2017	Gutierrez, Arantxa/0000-0001-9033-3834; Di Croce, Luciano/0000-0003-3488-6228; Buschbeck, Marcus/0000-0002-3218-4567; Muller, Stefan/0000-0002-8792-7700	ICREA Funding Source: Custom	ICREA(ICREA)		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Amati B, 2004, P NATL ACAD SCI USA, V101, P8843, DOI 10.1073/pnas.0403046101; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Buschbeck M, 2005, EMBO REP, V6, P63, DOI 10.1038/sj.embor.7400316; Cairo S, 2005, ONCOGENE, V24, P2195, DOI 10.1038/sj.onc.1208338; Di Croce L, 2005, HUM MOL GENET, V14, pR77, DOI 10.1093/hmg/ddi109; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; Herbst A, 2004, ONCOGENE, V23, P3863, DOI 10.1038/sj.onc.1207492; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kalejta RF, 2003, P NATL ACAD SCI USA, V100, P3263, DOI 10.1073/pnas.0538058100; Kanatani Y, 1999, CELL GROWTH DIFFER, V10, P705; Lafarga M, 2002, MOL BIOL CELL, V13, P2771, DOI 10.1091/mbc.E02-03-0122; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Rockel TD, 2005, J CELL SCI, V118, P5231, DOI 10.1242/jcs.02642; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Smith KP, 2004, J CELL BIOCHEM, V93, P1282, DOI 10.1002/jcb.20273; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Strudwick S, 2002, LEUKEMIA, V16, P1906, DOI 10.1038/sj.leu.2402724; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Villa R, 2006, P NATL ACAD SCI USA, V103, P1400, DOI 10.1073/pnas.0509343103; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145	29	33	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2007	26	23					3415	3422		10.1038/sj.onc.1210128	http://dx.doi.org/10.1038/sj.onc.1210128			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17146439				2022-12-17	WOS:000246579600011
J	Lemee, F; Bavoux, C; Pillaire, MJ; Bieth, A; Machado, CR; Pena, SD; Guimbaud, R; Selves, J; Hoffmann, JS; Cazaux, C				Lemee, F.; Bavoux, C.; Pillaire, M. J.; Bieth, A.; Machado, C. R.; Pena, S. D.; Guimbaud, R.; Selves, J.; Hoffmann, J. S.; Cazaux, C.			Characterization of promoter regulatory elements involved in downexpression of the DNA polymerase kappa in colorectal cancer	ONCOGENE			English	Article						DNA polymerase kappa; promoter; colorectal cancer; SP1; CRE; genetic instability	TRANSCRIPTION FACTOR; PROXIMAL PROMOTER; EXPRESSION; GENE; REPAIR; DAMAGE; CELLS; BETA; TUMORIGENESIS; LOCALIZATION	The low-fidelity DNA polymerases thought to be specialized in DNA damage processing are frequently misregulated in cancers. We show here that DNA polymerase kappa (pol kappa), prone to replicate across oxidative and aromatic adducts and known to function in nucleotide excision repair (NER), is downregulated in colorectal tumour biopsies. Contrary to the replicative pol delta and pol alpha, for which only activating domains were described, we identified an upstream 465-bp-long repressor region in the promoter of POLK. We also found an activating 237-bp region that includes stimulating protein-1 (SP1) and cyclic AMP-responsive element (CRE)-binding sites. Mutations at one CRE-binding site led to a dramatic 80% decrease in promoter activity. Alterations of the SP1-binding site also affected, to a lesser extent, the transcription. Gel shift assays confirmed the role played by CRE/SP1 recognition sequences. Moreover, ectopic expression of SP1 or CRE-binding protein (CREB) protein favoured Pol kappa transcription. Finally, we found that Pol kappa down-expression in colorectal biopsies correlated with a decreased level of CREB and SP1 transcripts. This work shows that the promoter of POLK is cis-controlled and suggests that silencing of CREB and SP1 proteins could contribute to downregulation of this repair polymerase in colorectal tumours.	Univ Toulouse 3, UMR 5089, CNRS, Inst Pharmacol & Struct Biol,Lab Genet Instabil &, F-31077 Toulouse, France; Univ Fed Minas Gerais, Dept biochem & Immunol, Belo Horizonte, MG, Brazil; Univ Toulouse 3, INSERM, U563, Ctr Physiopathol Toulouse Purpan,Federat Digest C, F-31062 Toulouse, France; Univ Toulouse 3, Dept Anat Pathol, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universidade Federal de Minas Gerais; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Cazaux, C (corresponding author), Univ Toulouse 3, UMR 5089, CNRS, Inst Pharmacol & Struct Biol,Lab Genet Instabil &, 205 Route Narbonne, F-31077 Toulouse, France.	cazaux@ipbs.fr	MACHADO, CARLOS/AAW-1492-2020; Pillaire, Marie-Jeanne/P-1579-2014; Machado, Carlos Renato/H-1043-2015; Hoffmann, Jean-Sebastien/O-9183-2014; GUIMBAUD, Rosine/M-7503-2014	Pillaire, Marie-Jeanne/0000-0001-6866-7416; Machado, Carlos Renato/0000-0002-8724-3165; Hoffmann, Jean-Sebastien/0000-0003-2222-354X; 				Albertella MR, 2005, DNA REPAIR, V4, P583, DOI 10.1016/j.dnarep.2005.01.005; Anacleto C, 2005, NEOPLASIA, V7, P331, DOI 10.1593/neo.04502; Arita M, 2003, GENE, V306, P57, DOI 10.1016/S0378-1119(03)00385-8; Atlas E, 2001, ONCOGENE, V20, P7110, DOI 10.1038/sj.onc.1204890; Bannister AJ, 2000, CELL MOL LIFE SCI, V57, P1184, DOI 10.1007/PL00000758; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bavoux C, 2005, BIOCHIMIE, V87, P637, DOI 10.1016/j.biochi.2005.02.007; Bavoux C, 2005, CANCER RES, V65, P325; Bergoglio V, 2003, J MOL BIOL, V331, P1017, DOI 10.1016/S0022-2836(03)00837-4; Bergoglio V, 2002, J CELL SCI, V115, P4413, DOI 10.1242/jcs.00162; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Capp JP, 2006, NUCLEIC ACIDS RES, V34, P2998, DOI 10.1093/nar/gkl380; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Duriseti S, 2006, NEOPLASIA, V8, P250, DOI 10.1593/neo.05766; Feng YM, 2004, GENE, V330, P75, DOI 10.1016/j.gene.2004.01.006; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Iwanaga R, 2004, ONCOGENE, V23, P8581, DOI 10.1038/sj.onc.1207976; KEDAR PS, 1991, P NATL ACAD SCI USA, V88, P3729, DOI 10.1073/pnas.88.9.3729; LEHMANN A, 2003, CURR BIOL, V5, P13; McElhinny SAN, 2005, MOL CELL, V19, P357, DOI 10.1016/j.molcel.2005.06.012; McIlwraith MJ, 2005, MOL CELL, V20, P783, DOI 10.1016/j.molcel.2005.10.001; Ogi T, 2005, J CELL SCI, V118, P129, DOI 10.1242/jcs.01603; Ogi T, 2006, NAT CELL BIOL, V8, P640, DOI 10.1038/ncb1417; RAY R, 1989, J CLIN INVEST, V83, P2003, DOI 10.1172/JCI114110; Servant L, 2002, J MOL BIOL, V315, P1039, DOI 10.1006/jmbi.2001.5307; Shin T, 2005, ARCH BIOCHEM BIOPHYS, V435, P291, DOI 10.1016/j.abb.2005.01.002; SINGHAL R, 2006, J BIOL CHEM, V270, P949; Velasco-Miguel S, 2003, DNA REPAIR, V2, P91, DOI 10.1016/S1568-7864(02)00189-1	31	33	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2007	26	23					3387	3394		10.1038/sj.onc.1210116	http://dx.doi.org/10.1038/sj.onc.1210116			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17099721				2022-12-17	WOS:000246579600008
J	Bejsovec, A				Bejsovec, A.			Flying at the head of the pack: Wnt biology in Drosophila	ONCOGENE			English	Review						wingless; Wnt; Drosophila; patterning; signal transduction	SEGMENT POLARITY GENE; WINGLESS SIGNALING PATHWAY; MAMMARY ONCOGENE INT-1; CATENIN-TCF COMPLEX; BETA-CATENIN; EMBRYONIC-DEVELOPMENT; NEGATIVE REGULATION; PLASMA-MEMBRANE; PROTEIN; ARMADILLO	The fruitfly, Drosophila melanogaster, has been of central importance in analysing the mechanics of cellular processes. Classic forward genetic screens in the fly have identified many of the genes that de. ne critical cell signaling pathways, for example. Our understanding of the Wnt pathway, in particular, has benefited from the many advantages that the fly offers as a model system. Here, I review the history of these discoveries and highlight the utility of the fly in dissecting the molecular workings of Wnt signal transduction.	Duke Univ, Dept Biol, Durham, NC 27708 USA	Duke University	Bejsovec, A (corresponding author), Duke Univ, Dept Biol, Box 91000,B336 LSRC,Res Dr, Durham, NC 27708 USA.	bejsovec@duke.edu		Bejsovec, Amy/0000-0002-8019-5789				Adler PN, 2002, DEV CELL, V2, P525, DOI 10.1016/S1534-5807(02)00176-4; Adler PN, 2001, CURR OPIN CELL BIOL, V13, P635, DOI 10.1016/S0955-0674(00)00263-5; Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; BABU P, 1977, MOL GEN GENET, V151, P289, DOI 10.1007/BF00268792; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; Banziger C, 2006, CELL, V125, P509, DOI 10.1016/j.cell.2006.02.049; Bartscherer K, 2006, CELL, V125, P523, DOI 10.1016/j.cell.2006.04.009; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEJSOVEC A, 1995, GENETICS, V139, P309; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; Belenkaya TY, 2002, DEVELOPMENT, V129, P4089; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhanot P, 1999, DEVELOPMENT, V126, P4175; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Brunner E, 1999, DEV BIOL, V206, P178, DOI 10.1006/dbio.1998.9136; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Cliffe A, 2003, CURR BIOL, V13, P960, DOI 10.1016/S0960-9822(03)00370-1; Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; DasGupta R, 2005, SCIENCE, V308, P826, DOI 10.1126/science.1109374; Dierick HA, 1998, DEVELOPMENT, V125, P4729; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; Jones WM, 2005, GENETICS, V169, P2075, DOI 10.1534/genetics.104.039735; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Lawrence PA, 1995, DEVELOPMENT, V121, P4303; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; McCartney BM, 1999, J CELL BIOL, V146, P1303, DOI 10.1083/jcb.146.6.1303; McCartney BM, 2006, DEVELOPMENT, V133, P2407, DOI 10.1242/dev.02398; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moline MM, 2000, CURR BIOL, V10, P1127, DOI 10.1016/S0960-9822(00)00697-7; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; Morgan T. H., 1936, YB CARNEGIE I WASH, V35, P289; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller HAJ, 1999, DEVELOPMENT, V126, P577; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; Pai LM, 1997, DEVELOPMENT, V124, P2255; Parker DS, 2002, DEVELOPMENT, V129, P2565; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1994, DEV BIOL, V166, P543, DOI 10.1006/dbio.1994.1336; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PERRIMON N, 1989, GENETICS, V121, P333; PERRIMON N, 1983, DEV BIOL, V100, P365, DOI 10.1016/0012-1606(83)90231-2; Polakis P, 2000, GENE DEV, V14, P1837; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rulifson EJ, 2000, MOL CELL, V6, P117, DOI 10.1016/S1097-2765(00)00013-7; SHARMA RP, 1976, DEV BIOL, V48, P461, DOI 10.1016/0012-1606(76)90108-1; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; Smits R, 2000, GENE CHROMOSOME CANC, V29, P229, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1033>3.0.CO;2-R; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Thompson B, 2002, NAT CELL BIOL, V4, P367, DOI 10.1038/ncb786; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Willert K, 1999, DEVELOPMENT, V126, P4165; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Wu CH, 2002, J BIOL CHEM, V277, P41762, DOI 10.1074/jbc.M207850200; Yu X, 1999, NAT CELL BIOL, V1, P144, DOI 10.1038/11064	76	33	35	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2006	25	57					7442	7449		10.1038/sj.onc.1210051	http://dx.doi.org/10.1038/sj.onc.1210051			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143288				2022-12-17	WOS:000242514900002
J	Shimazu, T; Komatsu, Y; Nakayama, KI; Fukazawa, H; Horinouchi, S; Yoshida, M				Shimazu, T.; Komatsu, Y.; Nakayama, K. I.; Fukazawa, H.; Horinouchi, S.; Yoshida, M.			Regulation of SV40 large T-antigen stability by reversible acetylation	ONCOGENE			English	Article						SV40 T-Ag; acetylation; TSA; HDAC	ANCHORAGE-INDEPENDENT GROWTH; HISTONE DEACETYLASE; DNA-REPLICATION; TRICHOSTATIN-A; IN-VIVO; P53; PHOSPHORYLATION; SIMIAN-VIRUS-40; PROTEIN; P300	Reversible acetylation on protein lysine residues has been shown to regulate the function of both nuclear proteins such as histones and p53 and cytoplasmic proteins such as alpha-tubulin. To identify novel acetylated proteins, we purified several proteins by the affinity to an anti-acetylated-lysine antibody from cells treated with trichostatin A (TSA). Among the proteins identified, here we report acetylation of the SV40 large T antigen (T-Ag). The acetylation site was determined to be lysine-697, which is located adjacent to the C-terminal Cdc4 phosphodegron (CPD). Overexpression of the CBP acetyltransferase acetylated T-Ag, whereas HDAC1, HDAC3 and SIRT1 bound and deacetylated T-Ag. The acetylation and deacetylation occurred independently of p53, a binding partner of T-Ag, but the acetylation was enhanced in the presence of p53. T-Ag in the cells treated with TSA and NA or the acetylation mimic mutant (K697Q) became unstable in COS-7 cells, suggesting that acetylation regulates stability of T-Ag. Indeed, NIH3T3 cells stably expressing K697Q showed decreased anchorage-independent growth compared with those expressing wild type or the K697R mutant. These results demonstrate that acetylation destabilizes T-Ag and regulates the transforming activity of T-Ag in NIH3T3 cells.	RIKEN, Chem Genet Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo, Japan; Adv Life Sci Inst Inc, Wako, Saitama, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 812, Japan; Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, Tokyo, Japan	RIKEN; University of Tokyo; Kyushu University; National Institute of Infectious Diseases (NIID)	Yoshida, M (corresponding author), RIKEN, Chem Genet Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	yoshidam@riken.jp	SHIMAZU, Tadahiro/ABC-3950-2020; Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674; Komatsu, Yasuhiko/0000-0003-1739-8222				Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; Caron C, 2003, BIOESSAYS, V25, P58, DOI 10.1002/bies.10202; Caron C, 2005, BIOESSAYS, V27, P408, DOI 10.1002/bies.20210; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Fukazawa H, 2004, MOL CANCER THER, V3, P1281; FUKAZAWA H, 1995, ANAL BIOCHEM, V228, P83, DOI 10.1006/abio.1995.1318; Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598; Giandomenico V, 2003, MOL CELL BIOL, V23, P2587, DOI 10.1128/MCB.23.7.2587-2599.2003; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Komatsu Y, 2003, J IMMUNOL METHODS, V272, P161, DOI 10.1016/S0022-1759(02)00500-8; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; LEDUC C, 2006, IN PRESS ONCOGENE; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Muth V, 2001, EMBO J, V20, P1353, DOI 10.1093/emboj/20.6.1353; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Poulin DL, 2004, J VIROL, V78, P8245, DOI 10.1128/JVI.78.15.8245-8253.2004; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; SPENCE SL, 1994, J VIROL, V68, P4227, DOI 10.1128/JVI.68.7.4227-4240.1994; STACY T, 1989, J VIROL, V63, P5208, DOI 10.1128/JVI.63.12.5208-5215.1989; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Welcker M, 2005, J BIOL CHEM, V280, P7654, DOI 10.1074/jbc.M413377200; Xie AY, 2002, MOL CELL BIOL, V22, P7907, DOI 10.1128/MCB.22.22.7907-7918.2002; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	41	33	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	56					7391	7400		10.1038/sj.onc.1209731	http://dx.doi.org/10.1038/sj.onc.1209731			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16767160				2022-12-17	WOS:000242419100008
J	Hirohashi, Y; Wang, Q; Liu, Q; Li, B; Du, X; Zhang, H; Furuuchi, K; Masuda, K; Sato, N; Greene, MI				Hirohashi, Y.; Wang, Q.; Liu, Q.; Li, B.; Du, X.; Zhang, H.; Furuuchi, K.; Masuda, K.; Sato, N.; Greene, M. I.			Centrosomal proteins Nde1 and Su48 form a complex regulated by phosphorylation	ONCOGENE			English	Article						centrosome; mitosis; cancer; phosphorylation	CYTOPLASMIC DYNEIN; MALIGNANT-TUMORS; MITOTIC SPINDLE; LIVING CELLS; DEFECTS; LIS1; KINETOCHORES; INSTABILITY; PROGRESSION; CARCINOMA	The centrosome modulates spindle formation and plays a critical role in guiding proper segregation of chromosomes during cell division. Centrosome aberrations, frequently seen in human tumors, may cause abnormal chromosome segregation and contribute to malignant transformation. To explore the components of the centrosomes, we previously identified a novel centrosomal protein called Su48. To further characterize the Su48-containing protein ensemble in the centrosome, we performed yeast two-hybrid screens and isolated a number of Su48- interacting molecules, including the centrosomal protein Nde1. Here, we demonstrate that Su48 can associate with Nde1. Moreover, we found that Nde1 is subjected to phosphorylation in vivo. In particular, we identified six putative Cdc2 phosphorylation sites in Nde1 and found that alteration of these sites diminishes phosphorylation by Cdc2 in vitro and affects the stability of Su48- Nde1 interactions and the centrosomal localization of Nde1. Ablation of Nde1 by gene specific small interfering RNA causes mitotic delay and cell death, coupled with a modest decrease in the incidence of the cells that harbor excessive centrosomes. Collectively, our findings indicate that Nde1 can form a protein complex with Su48 in the centrosome and plays an important role for successful mitosis.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Sapporo Med Univ, Sch Med, Dept Pathol, Chuo Ku, Sapporo, Hokkaido, Japan	University of Pennsylvania; Sapporo Medical University	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 36th Hamilton Walk,252 John Morgan Bldg, Philadelphia, PA 19104 USA.	greene@reo.med.upenn.edu	Hirohashi, Yoshihiko/AFQ-4227-2022; Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; Zhang, Hongtao/0000-0001-9173-0049				Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; Efimov VP, 2000, J CELL BIOL, V150, P681, DOI 10.1083/jcb.150.3.681; Faulkner NE, 2000, NAT CELL BIOL, V2, P784, DOI 10.1038/35041020; Feng YY, 2004, NEURON, V44, P279, DOI 10.1016/j.neuron.2004.09.023; Feng YY, 2000, NEURON, V28, P665, DOI 10.1016/S0896-6273(00)00145-8; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Howell BJ, 2004, CURR BIOL, V14, P953, DOI 10.1016/j.cub.2004.05.053; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 2000, CURR TOP DEV BIOL, V49, P313; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Pihan GA, 2001, CANCER RES, V61, P2212; Pihan GA, 1998, CANCER RES, V58, P3974; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; Sato N, 1999, CLIN CANCER RES, V5, P963; Shono M, 2001, LAB INVEST, V81, P945, DOI 10.1038/labinvest.3780306; Wang Q, 2004, DNA CELL BIOL, V23, P475, DOI 10.1089/1044549041562276; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang Q, 2001, ONCOGENE, V20, P4640, DOI 10.1038/sj.onc.1204625; Yan XM, 2003, MOL CELL BIOL, V23, P1239, DOI 10.1128/MCB.23.4.1239-1250.2003; Young A, 2000, MOL BIOL CELL, V11, P2047, DOI 10.1091/mbc.11.6.2047	22	33	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2006	25	45					6048	6055		10.1038/sj.onc.1209637	http://dx.doi.org/10.1038/sj.onc.1209637			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16682949				2022-12-17	WOS:000241101200002
J	Noda, D; Itoh, S; Watanabe, Y; Inamitsu, M; Dennler, S; Itoh, F; Koike, S; Danielpour, D; ten Dijke, P; Kato, M				Noda, D.; Itoh, S.; Watanabe, Y.; Inamitsu, M.; Dennler, S.; Itoh, F.; Koike, S.; Danielpour, D.; Dijke, P. ten; Kato, M.			ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF-beta/Smad-induced growth arrest of prostate cells	ONCOGENE			English	Article						ELAC2; cell proliferation; p21; Smad TGF-beta	BETA TYPE-I; SMAD PROTEINS; SIGNALING PATHWAY; EPITHELIAL-CELLS; FAMILY-MEMBERS; RECEPTOR; EXPRESSION; PROMOTER; SP1; ACTIVATION	Transforming growth factor-beta (TGF-beta) elicits a potent growth inhibitory effect on many normal cells by binding to specific serine/threonine kinase receptors and activating specific Smad proteins, which regulate the expression of cell cycle genes, including the p21 cyclin-dependent kinase (CDK) inhibitor gene. Interestingly, cancer cells are often insensitive to the anti-mitogenic effects of TGF-beta for which the molecular mechanisms are not well understood. In this study, we found that the candidate prostate cancer susceptibility gene ELAC2 potentiates TGF-beta/Smad-induced transcriptional responses. ELAC2 associates with activated Smad2; the C-terminal MH2 domain of Smad2 interacts with the N-terminal region of ELAC2. Small interfering siRNA-mediated knock-down of ELAC2 in prostate cells suppressed TGF-beta-induced growth arrest. Moreover, ELAC2 was shown to specifically associate with the nuclear Smad2 partner, FAST-1 and to potentiate the interaction of activated Smad2 with transcription factor Sp1. Furthermore, activation of the p21 CDK inhibitor promoter by TGF-beta is potentiated by ELAC2. Taken together our data indicate an important transcriptional scaffold function for ELAC2 in TGF-beta/Smad signaling mediated growth arrest.	Univ Tsukuba, Dept Expt Pathol, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058575, Japan; Yamagata Univ, Sch Med, Dept Otolaryngol, Yamagata 990, Japan; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Case Western Reserve Univ, Sch Med, Div Gen Med Sci Oncol, Cleveland, OH 44106 USA; Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2300 RA Leiden, Netherlands	University of Tsukuba; Yamagata University; Netherlands Cancer Institute; Case Western Reserve University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Itoh, S (corresponding author), Univ Tsukuba, Dept Expt Pathol, Grad Sch Comprehens Human Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	sitoh@md.tsukuba.ac.jp	Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Itoh, Susumu/0000-0002-7967-0730; Itoh, Fumiko/0000-0002-6134-5331				Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Chen GC, 2005, J BIOL CHEM, V280, P36355, DOI 10.1074/jbc.M506147200; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen Y, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-12; Danielpour D, 2005, EUR J CANCER, V41, P846, DOI 10.1016/j.ejca.2004.12.027; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Guo YP, 1999, CANCER RES, V59, P1366; Guo YP, 1997, INT J CANCER, V71, P573, DOI 10.1002/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.3.CO;2-1; Guo YP, 1998, CELL GROWTH DIFFER, V9, P185; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Itoh S, 2003, J BIOL CHEM, V278, P3751, DOI 10.1074/jbc.M208258200; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim IY, 1996, CLIN CANCER RES, V2, P1255; Korver W, 2003, INT J CANCER, V104, P283, DOI 10.1002/ijc.10945; Kundu SD, 2000, PROSTATE, V43, P118; Larisch-Bloch S, 2000, CELL GROWTH DIFFER, V11, P1; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Minagawa A, 2005, CANCER LETT, V222, P211, DOI 10.1016/j.canlet.2004.09.013; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Moustakas A, 2001, J CELL SCI, V114, P4359; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nicolas FJ, 2004, J CELL SCI, V117, P4113, DOI 10.1242/jcs.01289; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shea PR, 2002, HUM GENET, V111, P398, DOI 10.1007/s00439-002-0816-1; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; SONG K, 2000, CANCER RES, V63, P4358; Takaku H, 2003, NUCLEIC ACIDS RES, V31, P2272, DOI 10.1093/nar/gkg337; Tang BW, 1999, CANCER RES, V59, P4834; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Wang L, 2001, CANCER RES, V61, P6494; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	45	33	36	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5591	5600		10.1038/sj.onc.1209571	http://dx.doi.org/10.1038/sj.onc.1209571			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636667				2022-12-17	WOS:000240599100001
J	Gudi, R; Barkinge, J; Hawkins, S; Chu, F; Manicassamy, S; Sun, Z; Duke-Cohan, JS; Prasad, KVS				Gudi, R.; Barkinge, J.; Hawkins, S.; Chu, F.; Manicassamy, S.; Sun, Z.; Duke-Cohan, J. S.; Prasad, K. V. S.			Siva-1 negatively regulates NF-kappa B activity: effect on T-cell receptor-mediated activation-induced cell death (AICD)	ONCOGENE			English	Article						TCR; apoptosis; NF-kappa B; Bcl-xL; c-FLIP; AICD	APOPTOSIS; INTERACTS; PATHWAY; BINDING; FAMILY; MEMBER; CD27	Ligation of TCRs on stimulated T cells leads to activation-induced cell death (AICD) resulting in the downregulation of immune responses, a process essential for T-cell homeostasis. In this study, using transformed T-cell lines such as Jurkat and Do11.10 as cellular models of TCR-mediated AICD, we have demonstrated that the proapoptotic protein Siva-1 is required for TCR-induced apoptosis. Knockdown of Siva-1 rendered T cells specifically resistant to anti-CD3 but not Fas-induced apoptosis. Further, we observed that in Siva-1 knockout Jurkat cells, TCR-mediated activation of the canonical and non-canonical limbs of the NF-kappa B pathway are significantly enhanced as reflected by elevated nuclear levels of p65 and RelB, respectively. In addition, loss of endogenous Siva-1 also resulted in the enhanced expression of NF-kappa B-responsive anti-apoptotic genes such as Bcl-xL and c-FLIP. Interestingly, the c-FLIPshort was detected only in TCR-ligated Siva-1 knockdown Jurkat cells. These results demonstrate a significant role for endogenous Siva-1, through its inhibitory effect on NF-kappa B activity, in TCR-mediated AICD with implications in peripheral tolerance, T-cell homeostasis and cancer.	Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Prasad, KVS (corresponding author), Univ Illinois, Dept Microbiol & Immunol, 835 S Wolcott Ave,Room 820, Chicago, IL 60612 USA.	kanteti@uic.edu	Duke-Cohan, Jonathan/A-5812-2010	Duke-Cohan, Jonathan/0000-0002-9478-9609				Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cao C, 2001, J BIOL CHEM, V276, P11465, DOI 10.1074/jbc.C100050200; Chu F, 2005, CANCER RES, V65, P5301, DOI 10.1158/0008-5472.CAN-04-3270; Chu F, 2004, APOPTOSIS, V9, P83, DOI 10.1023/B:APPT.0000012125.01799.4c; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; Hauer J, 2005, P NATL ACAD SCI USA, V102, P2874, DOI 10.1073/pnas.0500187102; Henke A, 2000, J VIROL, V74, P4284, DOI 10.1128/JVI.74.9.4284-4290.2000; Hildeman DA, 2002, CURR OPIN IMMUNOL, V14, P354, DOI 10.1016/S0952-7915(02)00335-7; Li YQ, 2005, J BIOL CHEM, V280, P1217, DOI 10.1074/jbc.M409492200; MULLER MM, 1989, NUCLEIC ACIDS RES, V17, P6420, DOI 10.1093/nar/17.15.6420; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; Prasad KVS, 1997, P NATL ACAD SCI USA, V94, P6346, DOI 10.1073/pnas.94.12.6346; Schmitz I, 2004, J IMMUNOL, V172, P2194, DOI 10.4049/jimmunol.172.4.2194; Spinicelli S, 2002, CELL DEATH DIFFER, V9, P1382, DOI 10.1038/sj.cdd.4401140; Wan YSY, 2003, IMMUNITY, V18, P331, DOI 10.1016/S1074-7613(03)00053-0; XIAO N, 2005, LYMPHOMA J INVEST DE, V124, P741; Xue L, 2002, P NATL ACAD SCI USA, V99, P6925, DOI 10.1073/pnas.102182299; Yoon Y, 1999, ONCOGENE, V18, P7174, DOI 10.1038/sj.onc.1203144	20	33	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3458	3462		10.1038/sj.onc.1209381	http://dx.doi.org/10.1038/sj.onc.1209381			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16491128				2022-12-17	WOS:000238448100010
J	Dumay, A; Laulier, C; Bertrand, P; Saintigny, Y; Lebrun, F; Vayssiere, JL; Lopez, BS				Dumay, A.; Laulier, C.; Bertrand, P.; Saintigny, Y.; Lebrun, F.; Vayssiere, J-L; Lopez, B. S.			Bax and Bid, two proapoptotic Bcl-2 family members, inhibit homologous recombination, independently of apoptosis regulation	ONCOGENE			English	Article						homologous recombination; double-strand break repair; genetic instability; Bcl-2 family; BAX; BID; apoptosis	NUCLEOTIDE EXCISION-REPAIR; DEPENDENT PROTEIN-KINASE; DNA-DAMAGE RESPONSE; MAMMALIAN-CELLS; DIRECTED REPAIR; C-TERMINUS; RAD51; MITOCHONDRIA; SUPPRESSION; MUTAGENESIS	In order to analyse the relationships between regulation of apoptosis and homologous recombination (HR), we over-expressed proapoptotic Bax or only-BH3 Bid proteins or antiapoptotic Bcl-2 or Bcl-XL, in hamster CHO cells or in SV40-transformed human fibroblasts. We measured HR induced by gamma-rays, UVC or a specific double-strand cleavage targeted in the recombination substrate by the meganuclease I-SceI. We show here that the induction of both recombinant cells and recombinant colonies was impaired when expressing Bcl-2 family members, in hamster as well as in human cells. Moreover, the pro- as well as antiapoptotic Bcl-2 family members inhibited HR, independently of degradation of the RAD51 recombination protein and of their impact on apoptosis. These data reveal a mechanism of HR downregulation by potentially proapoptotic proteins, distinct from and parallel to degradation of recombination proteins, a situation that should also optimize the efficiency of programmed cell death.	CEA, CNRS, UMR 217, DSV,DRR, F-92265 Fontenay Aux Roses, France; Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, FRE 2445, F-78000 Versailles, France	CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Lopez, BS (corresponding author), CEA, CNRS, UMR 217, DSV,DRR, 18 Route Panorama,BP06, F-92265 Fontenay Aux Roses, France.	bernard.lopez@cea.fr	Lopez, Bernard S/O-7308-2017; Saintigny, Yannick/C-2697-2008	Lopez, Bernard S/0000-0001-5088-0155; Saintigny, Yannick/0000-0002-3839-3562; BERTRAND, Pascale/0000-0002-9019-742X; dumay, anne/0000-0002-8188-4658				Ausubel F., 1999, CURRENT PROTOCOLS MO; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; CherbonnelLasserre C, 1996, ONCOGENE, V13, P1489; Cho SH, 2002, EXP CELL RES, V278, P158, DOI 10.1006/excr.2002.5572; Delsite RL, 2003, MUTAGENESIS, V18, P497, DOI 10.1093/mutage/geg027; Flygare J, 1998, FEBS LETT, V427, P247, DOI 10.1016/S0014-5793(98)00433-5; FRIEDBERG EC, 1995, DNA REPAIR; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; Heimlich G, 2004, BIOCHEM J, V378, P247, DOI 10.1042/BJ20031152; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Huang YY, 1999, MOL CELL BIOL, V19, P2986; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kitao H, 2002, J BIOL CHEM, V277, P48944, DOI 10.1074/jbc.M208151200; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuo ML, 1999, MOL PHARMACOL, V55, P894; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Lambert S, 2002, ONCOGENE, V21, P4065, DOI 10.1038/sj.onc.1205535; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Liu YF, 1997, CANCER RES, V57, P1650; MacLachlan TK, 2000, J BIOL CHEM, V275, P31869, DOI 10.1074/jbc.M003338200; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Priault M, 2003, CELL DEATH DIFFER, V10, P1068, DOI 10.1038/sj.cdd.4401270; Radman M, 1975, Basic Life Sci, V5A, P355; Saintigny Y, 2001, EMBO J, V20, P2596, DOI 10.1093/emboj/20.10.2596; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Sambrook J., 1989, MOL CLONING; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tremblais K, 1999, BIOCHEM BIOPH RES CO, V260, P582, DOI 10.1006/bbrc.1999.0904; Wiese C, 2002, CANCER RES, V62, P1279; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Youn CK, 2005, NAT CELL BIOL, V7, P137, DOI 10.1038/ncb1215; Yuan SSF, 2003, MUTAT RES-FUND MOL M, V525, P85, DOI 10.1016/S0027-5107(03)00009-5; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	45	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3196	3205		10.1038/sj.onc.1209344	http://dx.doi.org/10.1038/sj.onc.1209344			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16407825				2022-12-17	WOS:000237951000010
J	Mongiat-Artus, P; Miquel, C; Van der Aa, M; Buhard, O; Hamelin, R; Soliman, H; Bangma, C; Janin, A; Teillac, P; van der Kwast, T; Praz, F				Mongiat-Artus, P; Miquel, C; Van der Aa, M; Buhard, O; Hamelin, R; Soliman, H; Bangma, C; Janin, A; Teillac, P; van der Kwast, T; Praz, F			Microsatellite instability and mutation analysis of candidate genes in urothelial cell carcinomas of upper urinary tract	ONCOGENE			English	Article						upper urinary tract; urothelial cell carcinoma; renal pelvis; hereditary non-polyposis colorectal cancer; microsatellite instability; MSI phenotype	NONPOLYPOSIS COLORECTAL-CANCER; REPAIR-DEFICIENT CANCERS; MISMATCH-REPAIR; MONONUCLEOTIDE REPEATS; FRAMESHIFT MUTATIONS; MRE11 EXPRESSION; TARGET GENES; TUMORS; HMLH1; LINES	A subset of upper urinary tract urothelial cell carcinomas (UUC), arising sporadically or as a manifestation of hereditary non-polyposis colorectal cancer, displays microsatellite instability (MSI). MSI tumours are characterized by defective mismatch repair and accumulation of frameshift mutations in numerous genes harbouring repeats in their coding sequences. We have evaluated the incidence of MSI in UUC and the intratumoral distribution of mutations in 13 candidate target genes. A total of 58 unselected UUC were screened for MSI using the panel of five mononucleotide markers recently recommended by the National Cancer Institute for a precise MSI assessment. Four tumours displayed MSI (7%), among which at least three had alterations in the genes MSH3, BAX, MRE11, RAD50. Mutations in genes involved in key cellular pathways (ATR, DNA-PKcs, MBD4, TCF-4, MSH6, and BLM) were further detected. BAX and MRE11 mutations tend to present homogeneously within the three MSI UUC. Immunohistochemistry (MLH1, MSH2, MSH6) showed that loss of mismatch repair protein expression occurred in all MSI UUC de. ning the gene defect and that MRE11 and RAD50 mutations were associated with their concomitant loss expression. In conclusion, MSI UUC represent a small proportion of UUC in which BAX and MRE11 mutations are frequent and may play a role early in UUC tumorigenesis.	Univ Paris 07, Hop St Louis, Dept Urol, Paris, France; CNRS, UPR 2169, Villejuif, France; Erasmus Med Ctr, Dept Pathol, Rotterdam, Netherlands; INSERM, Ctr Etud Polymorphisme Humain, U434, Paris, France; Hop St Louis, CNRS, UPR 9051, Dept Biochem, Paris, France; Erasmus Med Ctr, Dept Urol, Rotterdam, Netherlands; Hop St Louis, INSERM, U728, Dept Pathol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Erasmus University Rotterdam; Erasmus MC; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Erasmus University Rotterdam; Erasmus MC; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Mongiat-Artus, P (corresponding author), Hop St Louis, Dept Urol, 1 Ave Claude Vellefaux, F-75010 Paris, France.	pierre.mongiat-artus@sls.aphp.fr	PRAZ, Françoise/AAF-7761-2020; PRAZ, Françoise/A-7291-2008; miquel, catherine/B-5536-2013	PRAZ, Françoise/0000-0002-5353-8889; PRAZ, Françoise/0000-0002-5353-8889; Van der Kwast, Theodorus/0000-0001-8640-5786				Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L; Abdel-Rahman WM, 1999, ONCOGENE, V18, P2139, DOI 10.1038/sj.onc.1202589; Aben KKH, 2002, INT J CANCER, V98, P274, DOI 10.1002/ijc.10191; Barnetson R, 2000, GENE CHROMOSOME CANC, V29, P130, DOI 10.1002/1098-2264(200010)29:2<130::AID-GCC1023>3.0.CO;2-Z; Blaszyk H, 2002, MODERN PATHOL, V15, P790, DOI 10.1097/01.MP.0000024263.25043.0C; Boland CR, 1998, CANCER RES, V58, P5248; Brennetot C, 2005, INT J CANCER, V113, P446, DOI 10.1002/ijc.20586; Buhard O, 2004, DIS MARKERS, V20, P251, DOI 10.1155/2004/159347; Catto JWF, 2003, ONCOGENE, V22, P8699, DOI 10.1038/sj.onc.1206964; Dietmaier W, 1997, CANCER RES, V57, P4749; Duval A, 2002, CANCER RES, V62, P1609; Duval A, 2002, CANCER RES, V62, P2447; Epstein JI, 1998, AM J SURG PATHOL, V22, P1435, DOI 10.1097/00000478-199812000-00001; Ericson KM, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-23; Giannini G, 2004, ONCOGENE, V23, P2640, DOI 10.1038/sj.onc.1207409; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Hartmann A, 2003, HUM PATHOL, V34, P222, DOI 10.1053/hupa.2003.22; Hartmann A, 2002, CANCER RES, V62, P6796; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Jacob S, 2005, NUCLEIC ACIDS RES, V33, P106, DOI 10.1093/nar/gki154; Kane MF, 1997, CANCER RES, V57, P808; Kim NG, 2001, CANCER RES, V61, P36; Ottini L, 2004, CARCINOGENESIS, V25, P2337, DOI 10.1093/carcin/bgh257; Parc Y, 2004, GUT, V53, P371, DOI 10.1136/gut.2003.019190; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Roupret M, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.017871; Sijmons RH, 1998, J UROLOGY, V160, P466, DOI 10.1016/S0022-5347(01)62926-4; Suraweera N, 2002, GASTROENTEROLOGY, V123, P1804, DOI 10.1053/gast.2002.37070; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Vasen HFA, 1996, GASTROENTEROLOGY, V110, P1020, DOI 10.1053/gast.1996.v110.pm8612988; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; Verma L, 1999, J MED GENET, V36, P678; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421	36	33	34	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	14					2113	2118		10.1038/sj.onc.1209229	http://dx.doi.org/10.1038/sj.onc.1209229			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16288216				2022-12-17	WOS:000236359700014
J	Royds, JA; Hibma, M; Dix, BR; Hananeia, L; Russell, IA; Wiles, A; Wynford-Thomas, D; Braithwaite, AW				Royds, JA; Hibma, M; Dix, BR; Hananeia, L; Russell, IA; Wiles, A; Wynford-Thomas, D; Braithwaite, AW			P53 promotes adenoviral replication and increases late viral gene expression	ONCOGENE			English	Article						p53; adenovirus; E1b55kDa; oncology	CARCINOMA CELL-LINES; MAJOR LATE PROMOTER; PHASE-II TRIAL; TUMOR-CELLS; 55-KILODALTON PROTEIN; NUCLEAR-LOCALIZATION; DELETED ADENOVIRUS; BINDING PROTEIN; NECK-CANCER; ONYX-015	The tumor suppressor protein, p53, plays a critical role in viro-oncology. However, the role of p53 in adenoviral replication is still poorly understood. In this paper, we have explored further the effect of p53 on adenoviral replicative lysis. Using well-characterized cells expressing a functional p53 (A549, K1neo, RKO) and isogenic derivatives that do not (K1scx, RKOp53.13), we show that virus replication, late virus protein expression and both wtAd5 and ONYX-015 virus-induced cell death are impaired in cells deficient in functional p53. Conversely, by transfecting p53 into these and other cells (IIICF/c, HeLa), we increase late virus protein expression and virus yield. We also show, using reporter assays in IIICF/c, HeLa and K1scx cells, that p53 can cooperate with E1a to enhance transcription from the major late promoter of the virus. Late viral protein production is enhanced by exogenous p53. Taken together, our data suggest that functional p53 can promote the adenovirus (Ad) lytic cycle. These results have implications for the use of Ad mutants that are defective in p53 degradation, such as ONYX-015, as agents for the treatment of cancers.	Univ Otago, Dept Pathol, Dunedin 9001, New Zealand; Univ Otago, Dept Microbiol, Dunedin 9001, New Zealand; Univ Cardiff Wales, Coll Med, Dept Pathol, Cardiff, Wales	University of Otago; University of Otago; Cardiff University	Royds, JA (corresponding author), Univ Otago, Dept Pathol, POB 913, Dunedin 9001, New Zealand.	janice.royds@stonebow.otago.ac.nz						BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BRAITHWAITE A, 1990, VIROLOGY, V177, P595, DOI 10.1016/0042-6822(90)90525-V; BRAITHWAITE AW, 1981, J VIROL, V39, P331, DOI 10.1128/JVI.39.2.331-340.1981; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; Dix BR, 2000, CANCER RES, V60, P2666; Dix BR, 2001, J VIROL, V75, P5443, DOI 10.1128/JVI.75.12.5443-5447.2001; Edwards SJ, 2002, J VIROL, V76, P12483, DOI 10.1128/JVI.76.24.12483-12490.2002; Geoerger B, 2002, CANCER RES, V62, P764; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057; Hann B, 2003, J VIROL, V77, P11588, DOI 10.1128/JVI.77.21.11588-11595.2003; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Hobom U, 2004, J VIROL, V78, P7685, DOI 10.1128/JVI.78.14.7685-7697.2004; Holm PS, 2002, J BIOL CHEM, V277, P10427, DOI 10.1074/jbc.M106955200; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; JONES N, 1978, CELL, V13, P181, DOI 10.1016/0092-8674(78)90148-4; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; Koch P, 2001, CANCER RES, V61, P5941; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; KRUIJER W, 1981, NUCLEIC ACIDS RES, V9, P4439, DOI 10.1093/nar/9.18.4439; Lee H, 2000, INT J CANCER, V88, P454, DOI 10.1002/1097-0215(20001101)88:3<454::AID-IJC19>3.0.CO;2-T; LEHMAN TA, 1991, CANCER RES, V51, P4090; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; Nemunaitis J, 2000, CANCER RES, V60, P6359; Nemunaitis J, 2001, J CLIN ONCOL, V19, P289, DOI 10.1200/JCO.2001.19.2.289; O'Carroll SJ, 2000, BIOTECHNIQUES, V28, P408, DOI 10.2144/00283bm03; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Parks CL, 1997, J VIROL, V71, P9600, DOI 10.1128/JVI.71.12.9600-9607.1997; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1999, J PATHOL, V187, P112; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; Rauen KA, 2002, CANCER RES, V62, P3812; Ries SJ, 2000, NAT MED, V6, P1128, DOI 10.1038/80466; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Rogulski KR, 2000, CANCER RES, V60, P1193; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; Sauthoff H, 2002, HUM GENE THER, V13, P1859, DOI 10.1089/104303402760372954; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHENK T, 1996, VIROLOGY, V2, P2111; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; WEYER U, 1985, EMBO J, V4, P3015, DOI 10.1002/j.1460-2075.1985.tb04037.x; WILLIAMS JF, 1974, COLD SPRING HARB SYM, V39, P427, DOI 10.1101/SQB.1974.039.01.055; Wyllie FS, 1999, BRIT J CANCER, V79, P1111, DOI 10.1038/sj.bjc.6690177; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Zhang YF, 2003, ONCOGENE, V22, P2782, DOI 10.1038/sj.onc.1206357	53	33	34	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	10					1509	1520		10.1038/sj.onc.1209185	http://dx.doi.org/10.1038/sj.onc.1209185			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16247442				2022-12-17	WOS:000235890400008
J	Melnikova, VO; Pacifico, A; Chimenti, S; Peris, K; Ananthaswamy, HN				Melnikova, VO; Pacifico, A; Chimenti, S; Peris, K; Ananthaswamy, HN			Fate of UVB-induced p53 mutations in SKH-hr1 mouse skin after discontinuation of irradiation: relationship to skin cancer development	ONCOGENE			English	Article						UVB carcinogenesis; p53; tumor progression; differentiation; skin tumor	ULTRAVIOLET-B IRRADIATION; GROWTH-FACTOR; MUTANT P53; SIGNAL-TRANSDUCTION; HUMAN KERATINOCYTES; HAIRLESS MICE; FAS-LIGAND; DNA-REPAIR; RECEPTOR; ACTIVATION	Chronic exposure to ultraviolet (UV) radiation causes skin cancer in humans and mice. We have previously shown that in hairless SKH-hr1 mice, UVB-induced p53 mutations arise very early, well before tumor development. In this study, we investigated whether discontinuation of UVB exposure before the onset of skin tumors results in the disappearance of p53 mutations in the skin of hairless SKH-hr1 mice. Irradiation of mice at a dose of 2.5 kJ/m(2) three times a week for 8 weeks induced p53 mutations in the epidermal keratinocytes of 100% of the mice. UVB irradiation was discontinued after 8 weeks, but p53 mutations at most hotspot codons were still present even 22 weeks later. During that period, the percent of mice carrying p53(V154A/R155C), p53(H175H/H176Y), and p53(R275C) mutant alleles remained at or near 100%, whereas the percentage of mice with p53(R270C) mutation decreased by 45%. As expected, discontinuation of UVB after 8 weeks resulted in a delay in tumor development. A 100% of tumors carried p53(V154A/R155C) mutant alleles, 76% carried p53(H175H/H176Y) mutants, and 24 and 19% carried p53(R270C) and p53(R275C) mutants, respectively. These results suggest that different UVB-induced p53 mutants may provide different survival advantages to keratinocytes in the absence of further UVB exposure and that skin cancer development can be delayed but not prevented by avoidance of further exposure to UVB radiation.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Univ Roma Tor Vergata, Dept Dermatol, Rome, Italy; Univ Aquila, Dept Dermatol, I-67100 Laquila, Italy	University of Texas System; UTMD Anderson Cancer Center; University of Rome Tor Vergata; University of L'Aquila	Ananthaswamy, HN (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, POB 301402, Houston, TX 77030 USA.	hanantha@mdanderson.org	Pacifico, Alessia/AAE-9908-2019; Pacifico, Alessia/J-3525-2018	Pacifico, Alessia/0000-0003-0348-0620; Pacifico, Alessia/0000-0003-0348-0620; Peris, Ketty/0000-0002-5237-0463	NCI NIH HHS [CA 16672, CA 46523, U01 CA105345] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, U01CA105345, R01CA046523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; Blum HF, 1969, BIOL EFFECTS ULTRAVI, P543; Brash DE, 1996, NAT MED, V2, P525, DOI 10.1038/nm0596-525; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; CHUNG KY, 1993, CANCER RES, V53, P1676; COFFER PJ, 1995, ONCOGENE, V11, P561; DEGRUIJL FR, 1991, CANCER RES, V51, P979; DEGRUIJL FR, 1995, BIOESSAYS, V17, P651, DOI 10.1002/bies.950170711; DeMeyts P, 1995, ANN NY ACAD SCI, V766, P388, DOI 10.1111/j.1749-6632.1995.tb26688.x; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; EPSTEIN JH, 1962, J INVEST DERMATOL, V39, P455, DOI 10.1038/jid.1962.142; GILCHREST BA, 1990, ANNU REV MED, V41, P199; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Jost M, 2000, EUR J DERMATOL, V10, P505; KANJILAL S, 1995, CANCER RES, V55, P3604; KANJILAL S, 1993, CANCER RES, V53, P2961; KIESER A, 1994, ONCOGENE, V9, P963; KRIPKE M L, 1991, Journal of Dermatology (Tokyo), V18, P429; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kuhn C, 1999, INT J CANCER, V80, P431, DOI 10.1002/(SICI)1097-0215(19990129)80:3<431::AID-IJC16>3.3.CO;2-X; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Leffell DJ, 1996, SCI AM, V275, P52, DOI 10.1038/scientificamerican0796-52; Li G, 1996, AM J PATHOL, V148, P1113; LIN JY, 1995, ONCOGENE, V10, P2387; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Marconi A, 1999, J INVEST DERMATOL, V113, P920, DOI 10.1046/j.1523-1747.1999.00773.x; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; Melnikova VO, 2003, ONCOGENE, V22, P5958, DOI 10.1038/sj.onc.1206595; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Mudgil AV, 2003, J INVEST DERMATOL, V121, P191, DOI 10.1046/j.1523-1747.2003.12320.x; Ouhtit A, 2000, AM J PATHOL, V157, P1975, DOI 10.1016/S0002-9440(10)64836-5; Ouhtit A, 2000, AM J PATHOL, V156, P201, DOI 10.1016/S0002-9440(10)64720-7; Peus D, 2000, PHOTOCHEM PHOTOBIOL, V72, P135, DOI 10.1562/0031-8655(2000)072<0135:UIEGFR>2.0.CO;2; Rebel H, 2001, CANCER RES, V61, P977; Remenyik E, 2003, ONCOGENE, V22, P6369, DOI 10.1038/sj.onc.1206657; Ren ZP, 1996, ONCOGENE, V12, P765; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sigal A, 2000, CANCER RES, V60, P6788; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; Ullrich SE, 2000, BIOCHEMICAL MODULATION OF SKIN REACTIONS, P281; URBACH F, 1991, DERMATOL CLIN, V9, P751; Urbach F, 1997, J PHOTOCH PHOTOBIO B, V40, P3, DOI 10.1016/S1011-1344(97)00029-8; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Walterscheid JP, 2002, J EXP MED, V195, P171, DOI 10.1084/jem.20011450; YOUNG AR, 1990, SEMIN DERMATOL, V9, P25; Zhang WG, 2001, P NATL ACAD SCI USA, V98, P13948, DOI 10.1073/pnas.241353198; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	53	33	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7055	7063		10.1038/sj.onc.1208863	http://dx.doi.org/10.1038/sj.onc.1208863			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007135				2022-12-17	WOS:000232833200007
J	Cepero, E; King, AM; Coffey, LM; Perez, RG; Boise, LH				Cepero, E; King, AM; Coffey, LM; Perez, RG; Boise, LH			Caspase-9 and effector caspases have sequential and distinct effects on mitochondria	ONCOGENE			English	Article						mitochondria; apoptosis; caspase; ROS	CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; BCL-2 FAMILY-MEMBERS; INDUCED APOPTOSIS; COMPLEX-I; MEMBRANE; NECROSIS; DEATH; BAX; INHIBITION	Proapoptotic Bcl-2 family members alter mitochondrial permeability resulting in the release of apoptogenic factors that initiate a caspase cascade. These changes are well described; however, the effects of caspases on mitochondrial function are less well characterized. Here we describe the consequence of caspase-9 and effector caspase inhibition on mitochondrial physiology during intrinsic cell death. Caspase inhibition prevents the complete loss of mitochondrial membrane potential without affecting cytochrome c release. When effector caspases are inhibited, mitochondria become uncoupled and produce reactive oxygen species. Interestingly, the effector caspase-mediated depolarization of the mitochondria occurs independent of the activity of complexes I-IV of the electron transport chain. In contrast, caspase-9 inhibition prevents mitochondrial uncoupling and ROS production and allows for continued electron transport despite the release of cytochrome c. Taken together, these data suggest that activated caspase-9 prevents the accessibility of cytochrome c to complex III, resulting in the production of reactive oxygen species, and that effector caspases may depolarize mitochondria to terminate ROS production and preserve an apoptotic phenotype.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33101 USA	University of Miami	Boise, LH (corresponding author), Univ Miami, Sch Med, Dept Microbiol & Immunol, POB 016960 R-138,RMSB Room 3045A,1600 NW 10th Ave, Miami, FL 33101 USA.	lboise@med.miami.edu	Boise, Lawrence/AAD-2314-2019; Perez, Ruth G./AAK-9844-2020	Boise, Lawrence/0000-0001-9436-8815	NIGMS NIH HHS [R01 GM65813, F31 GM20435] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM020435, R01GM065813] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrientos A, 1998, J BIOL CHEM, V273, P14210, DOI 10.1074/jbc.273.23.14210; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bratton SB, 2001, CELL DEATH DIFFER, V8, P425, DOI 10.1038/sj.cdd.4400834; Burlacu A, 2001, CELL TISSUE RES, V306, P409, DOI 10.1007/s004410100424; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Chandel NS, 1999, FEBS LETT, V454, P173, DOI 10.1016/S0014-5793(99)00783-8; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Deshmukh M, 2000, J CELL BIOL, V150, P131, DOI 10.1083/jcb.150.1.131; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Higuchi M, 1998, ONCOGENE, V17, P2753, DOI 10.1038/sj.onc.1202211; Higuchi Y, 2002, ARCH BIOCHEM BIOPHYS, V400, P133, DOI 10.1006/abbi.2002.2784; Johnson BW, 2000, J BIOL CHEM, V275, P31546, DOI 10.1074/jbc.M001363200; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; Mootha VK, 2001, EMBO J, V20, P661, DOI 10.1093/emboj/20.4.661; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Raha S, 2001, AM J MED GENET, V106, P62, DOI 10.1002/ajmg.1398; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; Rego AC, 2001, CELL DEATH DIFFER, V8, P995, DOI 10.1038/sj.cdd.4400916; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Ryan CA, 2002, BIOCHEM J, V366, P595, DOI 10.1042/BJ20020863; Samali A, 1999, BIOCHEM BIOPH RES CO, V255, P6, DOI 10.1006/bbrc.1998.0139; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	47	33	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6354	6366		10.1038/sj.onc.1208793	http://dx.doi.org/10.1038/sj.onc.1208793			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007191				2022-12-17	WOS:000232038200003
J	Taubert, H; Kappler, M; Bache, M; Bartel, F; Kohler, T; Lautenschlager, C; Blumke, K; Wurl, P; Schmidt, H; Meye, A; Hauptmann, S				Taubert, H; Kappler, M; Bache, M; Bartel, F; Kohler, T; Lautenschlager, C; Blumke, K; Wurl, P; Schmidt, H; Meye, A; Hauptmann, S			Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients	ONCOGENE			English	Article						soft-tissue sarcoma; survivin splice variants; prognosis	BREAST-CANCER; SURVIVIN-DELTA-EX3; APOPTOSIS; CARCINOMAS	The aim of this study was to investigate the level and the prognostic value of the expression of different survivin transcript variants - survivin, survivin-Delta Ex3 and survivin-2B - in tumours of 76 soft tissue sarcoma (STS) patients. The expression of survivin transcript variants in STS tissue samples and in 12 nonmalignant control tissues was analysed by quantitative RT-PCRs. Expression levels of all survivin transcript variants were strongly elevated in STS compared to normal tissues. A positive correlation between expression of splice variants and tumour stage was found (P = 0.02; chi(2) test). The multivariate Cox's proportional hazards regression model revealed a 7.3-fold increased risk of tumour-related death for patients with survivin-Delta Ex3 overexpressing tumours (P = 0.007). The effect of surivivin ( wildtype variant) and survivin-2B was less pronounced but still significant (2.2- and 1.9-fold, resp., P < 0.05 each). Our results show for the first time that mRNA expression of survivin-variants is significantly correlated to a poor prognosis for STS patients, and we suggest expression of survivin splice variants together with tumour stage as independent predictor of survival.	Univ Halle Wittenberg, Fac Med, Inst Pathol, D-06097 Halle Saale, Germany; Univ Halle Wittenberg, Dept Radiotherapy, Halle Saale, Germany; Roboscreen GmbH, Leipzig, Germany; Univ Halle Wittenberg, Inst Med Biometry & Informat, D-06097 Halle Saale, Germany; Univ Halle Wittenberg, Dept Urol, D-06097 Halle Saale, Germany; Univ Ulm, Ulm, Germany; Tech Univ Dresden, Dept Urol, D-8027 Dresden, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Ulm University; Technische Universitat Dresden	Taubert, H (corresponding author), Univ Halle Wittenberg, Fac Med, Inst Pathol, Magdeburger Str 14, D-06097 Halle Saale, Germany.	helge.taubert@medizin.uni-halle.de	Kappler, Matthias/ABG-9644-2020	Kappler, Matthias/0000-0003-2002-0271; Taubert, Helge/0000-0002-9077-1727				Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Badran A, 2004, BIOCHEM BIOPH RES CO, V314, P902, DOI 10.1016/j.bbrc.2003.12.178; Fangusaro JR, 2005, BRIT J CANCER, V92, P359, DOI 10.1038/sj.bjc.6602317; Hirohashi Y, 2002, CLIN CANCER RES, V8, P1731; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Kappler M, 2001, INT J CANCER, V95, P360, DOI 10.1002/1097-0215(20011120)95:6<360::AID-IJC1063>3.0.CO;2-1; Krieg A, 2002, BRIT J CANCER, V86, P737, DOI 10.1038/sj.bjc.6600153; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Mahotka C, 1999, CANCER RES, V59, P6097; Mahotka C, 2002, CELL DEATH DIFFER, V9, P1334, DOI 10.1038/sj.cdd.4401091; Mahotka C, 2002, INT J CANCER, V100, P30, DOI 10.1002/ijc.10450; Nakagawa Y, 2004, LEUKEMIA RES, V28, P487, DOI 10.1016/j.leukres.2003.10.013; O'Driscoll L, 2003, CANCER LETT, V201, P225, DOI 10.1016/S0304-3835(03)00518-4; Ryan B, 2005, BRIT J CANCER, V92, P120, DOI 10.1038/sj.bjc.6602314; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Wurl P, 2002, LANCET, V359, P943, DOI 10.1016/S0140-6736(02)07990-4; Yamada Y, 2003, J NEUROSURG, V99, P738, DOI 10.3171/jns.2003.99.4.0738	17	33	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2005	24	33					5258	5261		10.1038/sj.onc.1208702	http://dx.doi.org/10.1038/sj.onc.1208702			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15856009				2022-12-17	WOS:000230964600013
J	Hsu, HL; Shi, B; Gartenhaus, RB				Hsu, HL; Shi, B; Gartenhaus, RB			The MCT-1 oncogene product impairs cell cycle checkpoint control and transforms human mammary epithelial cells	ONCOGENE			English	Article						transformation; cell cycle	DOUBLE-STRAND BREAKS; HISTONE H2AX; GENOMIC INSTABILITY; CANDIDATE ONCOGENE; IONIZING-RADIATION; PROTEIN 53BP1; DNA-DAMAGE; ATM; PHOSPHORYLATION; ACTIVATION	Multiple copies in T-cell maligancy (MCT-1) is a putative oncogene initially identified in a human T-cell lymphoma. Forced expression of MCT-1 has recently been shown to induce cell transformation and proliferation, as well as to activate survival-related PI-3K/AKT pathways protecting cells from apoptosis. MCT-1 protein is stabilized in response to DNA damage. The impact of MCT-1 overexpression on DNA damage response remains unknown. Here, we show that MCT-1 deregulates cell cycle checkpoints. The phosphorylation of genomic stabilizers H2AX and NBS1 are enhanced in MCT-1-overexpressing cells. Forced expression of MCT-1 significantly increases the number of DNA damage-induced foci involving gamma-H2AX and 53BP1. In MCT-1-overexpressing cells, the proportion of S-phase cell population is preferentially increased after exposure to gamma-irradiation compared to controls. Knockdown of endogenous MCT-1 using an siRNA approach attenuates the H2AX phosphorylation and the G1/S checkpoint defect. Furthermore, MCT-1 is capable of transforming immortalized human mammary epithelial cells and promoting genomic instability. These data shed light on the role of MCT-1 in the cellular response to DNA damage and its involvement in malignant transformation.				rgartenhaus@som.umaryland.edu	Hsu, Hsin-Ling/E-3672-2010	Shi, Bo/0000-0002-0780-0372				Aten JA, 2004, SCIENCE, V303, P92, DOI 10.1126/science.1088845; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Dierov J, 1999, J CELL BIOCHEM, V74, P544, DOI 10.1002/(SICI)1097-4644(19990915)74:4<544::AID-JCB4>3.3.CO;2-W; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Herbert GB, 2001, ONCOGENE, V20, P6777, DOI 10.1038/sj.onc.1204881; Kang JS, 1996, MOL CELL BIOL, V16, P3370; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Morales JC, 2003, J BIOL CHEM, V278, P14971, DOI 10.1074/jbc.M212484200; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Prosniak M, 1998, CANCER RES, V58, P4233; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Shi B, 2003, BLOOD, V102, P297, DOI 10.1182/blood-2002-11-3486; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Wang HC, 2001, ONCOGENE, V20, P2212, DOI 10.1038/sj.onc.1204350; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200	26	33	34	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4956	4964		10.1038/sj.onc.1208680	http://dx.doi.org/10.1038/sj.onc.1208680			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897892				2022-12-17	WOS:000230646500008
J	Ceballos, E; Munoz-Alonso, MJ; Berwanger, B; Acosta, JC; Hernandez, R; Krause, M; Hartmann, O; Eilers, M; Leon, J				Ceballos, E; Munoz-Alonso, MJ; Berwanger, B; Acosta, JC; Hernandez, R; Krause, M; Hartmann, O; Eilers, M; Leon, J			Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells. Microarray analysis reveals defective induction of p53 target genes and upregulation of chaperone genes	ONCOGENE			English	Article						c-Myc; p53; apoptosis; microarrays; chaperones; ARF	CHRONIC MYELOGENOUS LEUKEMIA; TUMOR-SUPPRESSOR P53; HEAT-SHOCK PROTEINS; P53-DEPENDENT APOPTOSIS; GROWTH ARREST; DNA-DAMAGE; IN-VIVO; DIFFERENTIAL REGULATION; TRANSCRIPTION FACTOR; NEGATIVE REGULATION	We have previously demonstrated that c-Myc impairs p53-mediated apoptosis in K562 human leukemia cells, which lack ARF. To investigate the mechanisms by which c-Myc protects from p53-mediated apoptosis, we used K562 cells that conditionally express c-Myc and harbor a temperature-sensitive allele of p53. Gene expression profiles of cells expressing wild-type conformation p53 in the presence of either uninduced or induced c-Myc were analysed by cDNA microarrays. The results show that multiple p53 target genes are downregulated when c-Myc is present, including p21(WAF1), MDM2, PERP, NOXA, GADD45, DDB2, PIR121 and p53R2. Also, a number of genes that are upregulated by c-Myc in cells expressing wild-type conformation p53 encode chaperones related to cell death protection as HSP105, HSP90 and HSP27. Both downregulation of p53 target genes and upregulation of chaperones could explain the inhibition of apoptosis observed in K562 cells with ectopic c-Myc. Myc-mediated impairment of p53 transactivation was not restricted to K562 cells, but it was reproduced in a panel of human cancer cell lines derived from different tissues. Our data suggest that elevated levels of Myc counteract p53 activity in human tumor cells that lack ARF. This mechanism could contribute to explain the c- Myc deregulation frequently found in cancer.	Univ Cantabria, CSIC, Dept Mol Biol, Grp Biol Mol Canc,Fac Med, Santander 39011, Spain; Univ Cantabria, CSIC, Unidad Biomed, Grp Biol Mol Canc,Fac Med, Santander 39011, Spain; Univ Marburg, IMT, Inst Mol Biol & Tumor Res, Marburg, Germany; Hosp Univ Marques Valdecilla, Urol Serv, Santander, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC); Philipps University Marburg; Hospital Universitario Marques de Valdecilla (HUMV)	Leon, J (corresponding author), Univ Cantabria, CSIC, Dept Mol Biol, Grp Biol Mol Canc,Fac Med, Santander 39011, Spain.	leonj@unican.es	Acosta, Juan/AAE-6320-2021; Leon, Javier/K-4615-2014	Acosta, Juan/0000-0002-7989-7329; Leon, Javier/0000-0001-5803-0112; Eilers, Martin/0000-0002-0376-6533				Adachi J, 1998, CELL DEATH DIFFER, V5, P148, DOI 10.1038/sj.cdd.4400325; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Barsyte-Lovejoy D, 2004, ONCOGENE, V23, P3481, DOI 10.1038/sj.onc.1207487; Bearss DJ, 2002, CANCER RES, V62, P2077; Beck Z, 1998, LEUKEMIA LYMPHOMA, V30, P293, DOI 10.3109/10428199809057542; Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Ceballos E, 2000, ONCOGENE, V19, P2194, DOI 10.1038/sj.onc.1203541; Chang CC, 2000, AM J CLIN PATHOL, V113, P512, DOI 10.1309/YHFE-R65B-D3LK-3GGV; CHANG H, 1994, BLOOD, V83, P452; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; D'Agnano I, 2001, ONCOGENE, V20, P2814, DOI 10.1038/sj.onc.1204392; Dang CV, 1999, MOL CELL BIOL, V19, P1; Delgado MD, 2000, ONCOGENE, V19, P783, DOI 10.1038/sj.onc.1203384; DELGADO MD, 1995, ONCOGENE, V10, P1659; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Ebinuma H, 2001, J CELL PHYSIOL, V188, P56, DOI 10.1002/jcp.1195; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Handa H, 1997, LEUKEMIA RES, V21, P479, DOI 10.1016/S0145-2126(97)00006-4; Haupt Ygal, 2002, Oncogene, V21, P8223, DOI 10.1038/sj.onc.1206137; Haviernik P, 2003, ONCOGENE, V22, P1600, DOI 10.1038/sj.onc.1206268; Henriksson M, 2001, APOPTOSIS, V6, P133, DOI 10.1023/A:1009644716727; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ihrie RA, 2003, CURR BIOL, V13, P1985, DOI 10.1016/j.cub.2003.10.055; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; Insinga A, 2004, EMBO J, V23, P1144, DOI 10.1038/sj.emboj.7600109; Iwata A, 2001, J BIOL CHEM, V276, P45320, DOI 10.1074/jbc.M103736200; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Karlsson A, 2003, P NATL ACAD SCI USA, V100, P9974, DOI 10.1073/pnas.1732638100; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Kuschak TI, 2002, ONCOGENE, V21, P909, DOI 10.1038/sj.onc.1205145; Lewis JL, 2001, BLOOD, V97, P2604, DOI 10.1182/blood.V97.9.2604; Li Q, 1999, MOL CELL BIOL, V19, P5339; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Liu HL, 2000, J BIOL CHEM, V275, P40155, DOI 10.1074/jbc.M001565200; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Mauleon I, 2004, MOL CARCINOGEN, V39, P85, DOI 10.1002/mc.20000; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Motwani M, 2002, CANCER RES, V62, P3950; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Pierzchalski P, 1997, EXP CELL RES, V234, P57, DOI 10.1006/excr.1997.3604; PREUDHOMME C, 1995, J CLIN ONCOL, V13, P812, DOI 10.1200/JCO.1995.13.4.812; Rizzo MG, 1998, BRIT J CANCER, V77, P1429, DOI 10.1038/bjc.1998.236; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sheen JH, 2002, MOL CELL BIOL, V22, P1819, DOI 10.1128/MCB.22.6.1819-1833.2002; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Strutt H, 1999, METH MOL B, V119, P455; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wanzel M, 2005, NAT CELL BIOL, V7, P30, DOI 10.1038/ncb1202; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Wu M, 1998, J EXP MED, V187, P1671, DOI 10.1084/jem.187.10.1671; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Zhou WB, 2002, BRAIN RES, V926, P42, DOI 10.1016/S0006-8993(01)03292-9; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	84	33	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4559	4571		10.1038/sj.onc.1208652	http://dx.doi.org/10.1038/sj.onc.1208652			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856024	Bronze			2022-12-17	WOS:000230157100009
J	Vadlamudi, RK; Manavathi, B; Singh, RR; Nguyen, D; Li, F; Kumar, R				Vadlamudi, RK; Manavathi, B; Singh, RR; Nguyen, D; Li, F; Kumar, R			An essential role of Pak1 phosphorylation of SHARP in Notch signaling	ONCOGENE			English	Article						Pak1 signaling; SHARP; Notch; repression	P21-ACTIVATED KINASES; SMRT COREPRESSOR; ACTIVATION; PATHWAY; DIFFERENTIATION; EFFECTORS; COMPLEX; CANCER; CELLS; CDC42	The p21-activated kinases (Paks), an evolutionarily conserved family of serine/threonine kinases, play an important role in cytoskeletal reorganization in mammalian cells. The Notch signaling pathway plays an important role in the determination of cell fate/differentiation in a number of organs. Notch signaling is a complex process, and the mechanism by which Notch regulates multiple cellular processes is intriguing. The expression of both Notch and Pak1 has been shown to be deregulated in several human cancers. Using yeast two-hybrid screening, we identified SHARP, one of the Notch signaling components, as a Pak1-interacting protein. We found that SHARP is a physiologic interacting substrate of Pak1, and that this interaction enhances SHARP-mediated repression of Notch target genes. Pak1 phosphorylation sites in SHARP were mapped to Ser3486 and Thr3568 within the SHARP repression domain. Mutation of Pak1 phosphorylation sites in SHARP, inhibition of Pak1 functions by a Pak1-autoinhibitory fragment ( amino acids 83-149), or expression of Pak1-specific siRNA interfered with SHARP-mediated repression of Notch target reporter gene activation. These results demonstrate that Pak1-SHARP interaction plays an essential role in enhancing the corepressor functions of SHARP, thereby modulating Notch signaling in human cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org		Manavathi, Bramanandam/0000-0002-1797-398X	PHS HHS [80066, 90970] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Barnes CJ, 2003, NAT STRUCT BIOL, V10, P622, DOI 10.1038/nsb957; Beatus P, 1998, J NEUROSCI RES, V54, P125, DOI 10.1002/(SICI)1097-4547(19981015)54:2<125::AID-JNR1>3.3.CO;2-C; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; Giniger E, 1998, NEURON, V20, P667, DOI 10.1016/S0896-6273(00)81007-7; Hayashi K, 2002, MOL CELL NEUROSCI, V20, P579, DOI 10.1006/mcne.2002.1144; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Ishaq M, 2003, J BIOL CHEM, V278, P39296, DOI 10.1074/jbc.M302767200; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Oswald F, 2002, EMBO J, V21, P5417, DOI 10.1093/emboj/cdf549; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Vadlamudi RK, 2003, CANCER METAST REV, V22, P385, DOI 10.1023/A:1023729130497; Zhou SF, 2001, MOL CELL BIOL, V21, P6222, DOI 10.1128/MCB.21.18.6222-6232.2001; Zhou YY, 2001, MOL CELL BIOCHEM, V220, P1, DOI 10.1023/A:1011087910699	24	33	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4591	4596		10.1038/sj.onc.1208672	http://dx.doi.org/10.1038/sj.onc.1208672			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15824732				2022-12-17	WOS:000230157100013
J	Klampfer, L; Swaby, LA; Huang, H; Sasazuki, T; Shirasawa, S; Augenlicht, L				Klampfer, L; Swaby, LA; Huang, H; Sasazuki, T; Shirasawa, S; Augenlicht, L			Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis	ONCOGENE			English	Article						Ras; 5-FU; colon cancer; gelsolin	ADVANCED COLORECTAL-CANCER; C-MYC; KI-RAS; INTERFERON ALPHA-2A; GELSOLIN EXPRESSION; CARCINOMA CELLS; PHASE-III; P53; 5-FLUOROURACIL; OVEREXPRESSION	Despite the fact that objective response rates to 5-FU are as low as 20%, 5-FU remains the most commonly used drug for the treatment of colorectal cancer. The lack of understanding of resistance to 5-FU, therefore, remains a significant impediment in maximizing its efficacy. We used intestinal epithelial cells with an inducible K-RasV12 to demonstrate that expression of oncogenic Ras promotes cell death upon 5-FU treatment. Accordingly, transient expression of the mutant RasV12, but not the WT Ras, enhanced 5-FU-induced apoptosis in 293T cells. Consistent with these data, we showed that targeted deletion of the mutant Ras allele in the HCT116 colon cancer cell line protected cells from 5-FU-induced apoptosis. Using isogenic colon cancer cell lines that differ only by the presence of the mutant Ras allele, HCT116 and Hke-3 cells, we demonstrated that signaling by oncogenic Ras promotes both accumulation of p53 and its phosphorylation on serine15 in response to 5-FU, a situation that favors apoptosis over growth arrest. However, despite the differential induction of p53 in HCT116 and Hke-3 cells, the expression of Puma, a gene with an important role in p53-dependent apoptosis, was not affected by Ras signaling. In contrast, we showed that Ras interferes with 5-FU-induced expression of gelsolin, a protein with known antiapoptotic activity. We ascertained the role of gelsolin in 5-FU-induced apoptosis by demonstrating that silencing of gelsolin expression through RNAi sensitized cells to 5-FU-induced apoptosis and that re-expression of gelsolin in cells harboring mutant Ras protected cells from 5-FU-induced apoptosis. These data therefore demonstrate that Ras mutations increase sensitivity to 5-FU-induced apoptosis at least in part through the negative regulation of gelsolin expression. Our data indicate that Ras mutations promote apoptosis in response to 5-FU treatment and imply that tumors with Ras mutations and/or reduced expression of gelsolin may show enhanced apoptosis in response to 5-FU also in vivo.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA; Int Med Ctr Japan, Res Inst, Shinjuku Ku, Tokyo 1628655, Japan	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; National Center for Global Health & Medicine - Japan	Klampfer, L (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.	lklampf@aecom.yu.edu			NATIONAL CANCER INSTITUTE [U01CA088104, P30CA013330] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA 88104, P30 CA 13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal B, 1999, CLIN CANCER RES, V5, P2223; Ahnen DJ, 1998, CANCER RES, V58, P1149; Andreyev HJN, 1998, J NATL CANCER I, V90, P675, DOI 10.1093/jnci/90.9.675; Arango D, 2003, BRIT J CANCER, V89, P1757, DOI 10.1038/sj.bjc.6601338; Arango D, 2001, CANCER RES, V61, P4910; Augenlicht LH, 1997, CANCER RES, V57, P1769; Azuma T, 2000, J BIOL CHEM, V275, P3761, DOI 10.1074/jbc.275.6.3761; BENZ C, 1982, CANCER RES, V42, P2081; BERTINO JR, 1983, SEMIN ONCOL, V10, P2; Bertucci F, 2004, ONCOGENE, V23, P1377, DOI 10.1038/sj.onc.1207262; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Gnanasampanthan G, 2001, J PATHOL, V195, P543, DOI 10.1002/path.990; Gomez J, 1997, EUR J IMMUNOL, V27, P1610, DOI 10.1002/eji.1830270704; Greco FA, 1996, J CLIN ONCOL, V14, P2674, DOI 10.1200/JCO.1996.14.10.2674; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Huang YC, 2000, CANCER RES, V60, P3200; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; JONES DV, 1995, CANCER-AM CANCER SOC, V76, P1709, DOI 10.1002/1097-0142(19951115)76:10<1709::AID-CNCR2820761006>3.0.CO;2-5; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Klampfer L, 2004, J BIOL CHEM, V279, P36680, DOI 10.1074/jbc.M405197200; Klampfer L, 2003, MOL CANCER RES, V1, P855; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Kusano H, 2000, ONCOGENE, V19, P4807, DOI 10.1038/sj.onc.1203868; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Mariadason JM, 2003, CANCER RES, V63, P8791; MARKOWITZ S, 1995, CLIN CANCER RES, V1, P441; MARSONI S, 1995, LANCET, V345, P1582; Maxwell PJ, 2003, CANCER RES, V63, P4602; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NADAL JC, 1988, BIOMED PHARMACOTHER, V42, P387; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PRETLOW TP, 1995, GASTROENTEROLOGY, V108, P600, DOI 10.1016/0016-5085(95)90092-6; Seymour MT, 1996, J CLIN ONCOL, V14, P2280, DOI 10.1200/JCO.1996.14.8.2280; Sheng HM, 2001, CANCER RES, V61, P2670; Shieh DB, 1999, CANCER-AM CANCER SOC, V85, P47, DOI 10.1002/(SICI)1097-0142(19990101)85:1<47::AID-CNCR7>3.0.CO;2-L; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Tseng YS, 2003, EXP CELL RES, V288, P403, DOI 10.1016/S0014-4827(03)00225-8; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wolmark N, 1998, J NATL CANCER I, V90, P1810, DOI 10.1093/jnci/90.23.1810; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721	50	33	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3932	3941		10.1038/sj.onc.1208552	http://dx.doi.org/10.1038/sj.onc.1208552			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15856030				2022-12-17	WOS:000229435300009
J	Zhang, S; Wang, GZ; Liu, D; Bao, ZZ; Fernig, DG; Rudland, PS; Barraclough, R				Zhang, S; Wang, GZ; Liu, D; Bao, ZZ; Fernig, DG; Rudland, PS; Barraclough, R			The C-terminal region of S100A4 is important for its metastasis-inducing properties	ONCOGENE			English	Article						S100A4; breast cancer; metastasis; calcium; EF-hand	CALCIUM-BINDING PROTEIN; PROGNOSTIC-SIGNIFICANCE; IN-VITRO; NONMUSCLE MYOSIN; ESCHERICHIA-COLI; BREAST-CANCER; EXPRESSION; P9KA; MTS1; GENE	The EF-hand protein, S100A4, binds calcium ions and interacts specifically in vitro with protein targets. Elevated levels of S100A4 have been shown to produce a metastatic phenotype in independent models of breast cancer. The presence of S100A4 in the carcinoma cells of patients with different carcinomas is associated with reduced patient survival. In order to identify the region of the S100A4 molecule that is responsible for its metastasis-inducing properties, specific mutant S100A4 genes and proteins have been produced which contain targeted mutations to the two calcium-binding sites and a deletion of the last 15 amino-acid residues of the protein. The ability of the mutant proteins to bind to a potential specific target in vitro, nonmuscle myosin heavy chain, is correlated with their ability to cause motile, invasive and metastatic phenotypes. Mutation of the C-EF hand of S100A4 virtually abolished calcium binding, and motility/invasion in vitro, abolished interaction with a molecular target, and reduced metastasis induction by 2.5-3-fold. However, deletion of the last 15 amino acids of S100A4 reduced motility/invasion, target binding and metastasis-induction to similar extents as the C-EF-hand mutant, but reduced calcium binding by only 26%. The results suggest that the ability to interact with protein target(s) is important in S100A4-induced metastasis.	Univ Liverpool, Canc & Polio Res Fund Labs, Liverpool L69 7ZB, Merseyside, England	University of Liverpool	Barraclough, R (corresponding author), Univ Liverpool, Canc & Polio Res Fund Labs, Biosci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.	brb@liv.ac.uk	Barraclough, Roger/AAH-6516-2020; Fernig, David G/A-3590-2008; Barraclough, Dong/V-4230-2019; Barraclough, Dong/E-2205-2012	Fernig, David G/0000-0003-4875-4293; Barraclough, Dong/0000-0001-8440-0623; Barraclough, Roger/0000-0002-7203-1194				Ambartsumian N, 1999, INVAS METAST, V18, P96; Ambartsumian NS, 1996, ONCOGENE, V13, P1621; ANANDAPPA SY, 1994, BRIT J CANCER, V69, P772, DOI 10.1038/bjc.1994.146; BARRACLOUGH R, 1990, BIOCHEM BIOPH RES CO, V169, P660, DOI 10.1016/0006-291X(90)90381-V; Chen HL, 2003, BIOCHEM BIOPH RES CO, V308, P408, DOI 10.1016/S0006-291X(03)01310-X; Chen HL, 2001, BIOCHEM BIOPH RES CO, V286, P1212, DOI 10.1006/bbrc.2001.5517; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIES BR, 1993, ONCOGENE, V8, P999; Davies BR, 2002, J PATHOL, V196, P292, DOI 10.1002/path.1051; Davies MPA, 1996, ONCOGENE, V13, P1631; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; Ford HL, 1997, BIOCHEMISTRY-US, V36, P16321, DOI 10.1021/bi971182l; FORD HL, 1995, ONCOGENE, V10, P1597; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; Gongoll S, 2002, GASTROENTEROLOGY, V123, P1478, DOI 10.1053/gast.2002.36606; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jenkinson SR, 2004, BRIT J CANCER, V90, P253, DOI 10.1038/sj.bjc.6601483; Ke YQ, 1997, INT J CANCER, V71, P832, DOI 10.1002/(SICI)1097-0215(19970529)71:5<832::AID-IJC22>3.0.CO;2-8; Kim EJ, 2003, J BIOL CHEM, V278, P30063, DOI 10.1074/jbc.M304909200; Kimura K, 2000, INT J ONCOL, V16, P1125; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Kriajevska M, 2002, J BIOL CHEM, V277, P5229, DOI 10.1074/jbc.M110976200; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Lloyd BH, 1998, ONCOGENE, V17, P465, DOI 10.1038/sj.onc.1201948; Nakamura T, 2002, INT J ONCOL, V20, P937; Ninomiya I, 2001, INT J ONCOL, V18, P715; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; Rudland PS, 2000, CANCER RES, V60, P1595; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHAFER B, 1996, GUIDEBOOK CALCIUM BI, P132; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; Tarabykina S, 2000, FEBS LETT, V475, P187, DOI 10.1016/S0014-5793(00)01652-5; Tarabykina S, 2001, J BIOL CHEM, V276, P24212, DOI 10.1074/jbc.M009477200; Vallely KM, 2002, BIOCHEMISTRY-US, V41, P12670, DOI 10.1021/bi020365r; Wang GZ, 2000, J BIOL CHEM, V275, P11141, DOI 10.1074/jbc.275.15.11141; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; Zhang S, 2005, EUR BIOPHYS J BIOPHY, V34, P19, DOI 10.1007/s00249-004-0428-x	42	33	37	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4401	4411		10.1038/sj.onc.1208663	http://dx.doi.org/10.1038/sj.onc.1208663			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15856021				2022-12-17	WOS:000229976900009
J	Smith, DP; Bath, ML; Harris, AW; Cory, S				Smith, DP; Bath, ML; Harris, AW; Cory, S			T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC	ONCOGENE			English	Article						MYC; transgenic; lymphoma; haemopoiesis; progenitor	C-MYC; RAG-1-DEFICIENT MICE; MOUSE; DIFFERENTIATION; MUTATIONS; APOPTOSIS; LEUKEMIA; BCL-2; CHEMORESISTANCE; CLASSIFICATION	Deregulation of MYC expression occurs in many haematological malignancies. Previous studies modelling MYC-induced lymphomagenesis in the mouse used transgenic vectors that directed MYC overexpression in a lineage-specific manner. Here, we describe a transgenic mouse strain in which constitutive MYC expression is driven broadly in haemopoiesis by a vector containing regulatory elements of the Vav gene. Healthy young VavP-MYC17 mice had multiple haemopoietic abnormalities, most notably increased size and numbers of B-lymphoid cells, monocytes and megakaryocytes. The mice rapidly developed tumours and, surprisingly, these were exclusively T-cell lymphomas, mostly of mature CD4(+) CD8(-) T cells, a tumour type that is seldom seen in mouse models. To examine tumour development in the absence of the susceptible T cells, we bred VavP-MYC17 mice lacking the Rag1 recombinase. They survived longer and succumbed to tumours of several different haemopoietic cell types: pre-T cells, pro-B cells, macrophages and unusual progenitor cells. Thus, although T-lineage cells have the shortest latent period to transformation, the VavP-MYC17 transgene drives malignant transformation of multiple cell types and VavP-MYC17 mice provide a new model for tumours of multiple haemopoietic lineages.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Cory, S (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Melbourne, Vic 3050, Australia.	cory@wehi.edu.au	Cory, Suzanne/E-1642-2013	Cory, Suzanne/0000-0002-6818-3451				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; Bath ML, 2003, BIOL REPROD, V68, P19, DOI 10.1095/biolreprod.102.007344; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Ceredig R, 2002, NAT REV IMMUNOL, V2, P888, DOI 10.1038/nri937; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Elghetany MT, 1997, LEUKEMIA, V11, P762, DOI 10.1038/sj.leu.2400628; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hann B, 2001, CURR OPIN CELL BIOL, V13, P778, DOI 10.1016/S0955-0674(00)00283-0; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HARRIS NL, 1994, BLOOD, V84, P1361; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; MALJAIE SH, 1995, LEUKEMIA, V9, P1694; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029; Michie AM, 2002, SEMIN IMMUNOL, V14, P311, DOI 10.1016/S1044-5323(02)00064-7; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; Min BK, 2003, IMMUNITY, V18, P131, DOI 10.1016/S1074-7613(02)00508-3; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; Ogilvy S, 1999, BLOOD, V94, P1855; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; Pekarsky Y, 2001, JAMA-J AM MED ASSOC, V286, P2308, DOI 10.1001/jama.286.18.2308; Renno T, 1998, EUR J IMMUNOL, V28, P540, DOI 10.1002/(SICI)1521-4141(199802)28:02<540::AID-IMMU540>3.3.CO;2-P; Sanchez-Beato M, 2003, BLOOD, V101, P1220, DOI 10.1182/blood-2002-07-2009; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STEWART M, 1993, INT J CANCER, V53, P1023; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 1996, EMBO J, V15, P3823, DOI 10.1002/j.1460-2075.1996.tb00756.x; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519	42	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3544	3553		10.1038/sj.onc.1208399	http://dx.doi.org/10.1038/sj.onc.1208399			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15688022				2022-12-17	WOS:000229221800002
J	Daly, NL; Arvanitis, DA; Fairley, JA; Gomez-Roman, N; Morton, JP; Graham, SV; Spandidos, DA; White, RJ				Daly, NL; Arvanitis, DA; Fairley, JA; Gomez-Roman, N; Morton, JP; Graham, SV; Spandidos, DA; White, RJ			Deregulation of RNA polymerase III transcription in cervical epithelium in response to high-risk human papillomavirus	ONCOGENE			English	Article						cervical cancer; human papillomavirus (HPV); RNA polymerase III (pol III); TFIIIB; transcription	TATA-BINDING-PROTEIN; GENE; EXPRESSION; ACTIVATION; CANCER; INTEGRATION; SEQUENCES; TYPE-16; HPV; REPRESSION	RNA polymerase (pol) III transcription is a major determinant of biosynthetic capacity, providing essential products such as tRNA and 5S rRNA. It is controlled directly by the tumour suppressors RB and p53. High-risk types of human papillomavirus (HPV), such as HPV16, express the oncoproteins E6 and E7 that can inactivate p53 and RB, respectively. Accordingly, both E6 and E7 stimulate pol III transcription in cultured cells. HPV16-positive cervical biopsies express elevated levels of tRNA and 5S rRNA when compared to biopsies that test negative for HPV or are infected with the lower risk HPV11. Integration of viral DNA into the host cell genome stimulates expression of E6 and E7 and correlates with induction of tRNA and 5S rRNA. Expression of mRNA encoding the pol III-specific transcription factor Brf1 also correlates with the presence of integrated HPV16. Brf1 levels are limiting for tRNA and 5S rRNA synthesis in cervical cells. Furthermore, pol III-transcribed genes that do not use Brf1 are not induced in HPV16-positive biopsies. Three complementary mechanisms may therefore allow high-risk HPV to stimulate production of tRNA and 5S rRNA: E6-mediated removal of p53; E7-mediated neutralization of RB; and induction of Brf1. The resultant increase in biosynthetic capacity may contribute to deregulated cell growth.	Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Univ Crete, Sch Med, Virol Lab, Iraklion 71409, Greece	University of Glasgow; University of Crete	White, RJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.	rwhite@udcf.gla.ac.uk	Arvanitis, Demetrios A/J-6434-2017; Morton, Jennifer P/E-1633-2011; Morton, Jennifer/AAJ-5113-2021	Arvanitis, Demetrios A/0000-0003-1231-320X; Morton, Jennifer P/0000-0001-5766-9141; Morton, Jennifer/0000-0001-5766-9141; Spandidos, Demetrios/0000-0002-1146-931X; Graham, Sheila/0000-0002-7140-8279; Gomez-Roman, Natividad/0000-0002-2325-7517				Aasen T, 2003, ONCOGENE, V22, P7969, DOI 10.1038/sj.onc.1206709; Alazawi W, 2002, CANCER RES, V62, P6959; ARENDS MJ, 1991, J PATHOL, V165, P301, DOI 10.1002/path.1711650405; BALDWIN P, 2003, NAT REV CANCER, V3, P1; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chen W, 1997, J PATHOL, V183, P345, DOI 10.1002/(SICI)1096-9896(199711)183:3<345::AID-PATH930>3.0.CO;2-8; Chen W, 1997, EUR J CANCER, V33, P288, DOI 10.1016/S0959-8049(96)00453-4; Clayton DA, 2001, NATURE, V410, P29, DOI 10.1038/35065191; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Felton-Edkins ZA, 2002, J BIOL CHEM, V277, P48182, DOI 10.1074/jbc.M201333200; Felton-Edkins ZA, 2003, CELL CYCLE, V2, P181, DOI 10.4161/cc.2.3.375; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; GEY GO, 1952, CANCER RES, V12, P264; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; KOFFA M, 1994, INT J ONCOL, V5, P189; Larminie CGC, 1999, MOL CELL BIOL, V19, P4927; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SCOTT MRD, 1983, CELL, V34, P557, DOI 10.1016/0092-8674(83)90388-4; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675; SNIJDERS PJF, 1990, J GEN VIROL, V71, P173, DOI 10.1099/0022-1317-71-1-173; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; Stein T, 2002, ONCOGENE, V21, P2961, DOI 10.1038/sj.onc.1205372; Sutcliffe JE, 1999, MOL CELL BIOL, V19, P4255; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE RJ, 1995, MOL CELL BIOL, V15, P6653; White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547; White RJ, 2004, EUR J CANCER, V40, P21, DOI 10.1016/j.ejca.2003.09.027; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; WHITE RJ, 2002, RNA POLYM 3 TRANSCRI; Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; YEE C, 1985, AM J PATHOL, V119, P361; YUAN Y, 1991, BIOCHIM BIOPHYS ACTA, V1089, P33, DOI 10.1016/0167-4781(91)90081-V; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	49	33	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					880	888		10.1038/sj.onc.1208031	http://dx.doi.org/10.1038/sj.onc.1208031			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592529				2022-12-17	WOS:000226577100014
J	Bernard-Pierrot, I; Ricol, D; Cassidy, A; Graham, A; Elvin, P; Caillault, A; Lair, S; Broet, P; Thiery, JP; Radvanyi, F				Bernard-Pierrot, I; Ricol, D; Cassidy, A; Graham, A; Elvin, P; Caillault, A; Lair, S; Broet, P; Thiery, JP; Radvanyi, F			Inhibition of human bladder tumour cell growth by fibroblast growth factor receptor 2b is independent of its kinase activity. Involvement of the carboxy-terminal region of the receptor	ONCOGENE			English	Article						bladder; fibroblast growth factor receptor; urothelial cell carcinoma; IGF-II; tumour suppressor gene; DNA array		The b isoform of fibroblast growth factor receptor 2, FGFR2b/FGFR2-IIIb/Ksam-IIC1/KGFR, a tyrosine kinase receptor, is expressed in a wide variety of epithelia and is downregulated in several human carcinomas including prostate, salivary and urothelial cell carcinomas. FGFR2b has been shown to inhibit growth in tumour cell lines derived from these carcinomas. Here, we investigated the molecular mechanisms underlying the inhibition of human urothelial carcinoma cell growth following FGFR2b expression. Using a nylon DNA array, we analysed the gene expression pro. le of the T24 bladder tumour cell line, transfected or not with a construct encoding FGFR2b. The expression of FGFR2b in T24 cells decreased insulin-like growth factor (IGF)-II mRNA levels. This decrease was correlated with a decrease in IGF-II secretion and may have been responsible for the observed inhibition of cell growth because the addition of exogenous IGF-II restored growth rates to normal levels. Using SU5402, an inhibitor of FGFR tyrosine kinase activity, and a kinase dead mutant of the receptor, FGFR2b Y659F/Y660F, we also demonstrated that the growth inhibition and decrease in IGF-II secretion induced by FGFR2b did not require tyrosine kinase activity. Finally, we demonstrated the involvement of the distal carboxy-terminal domain of the receptor in decreasing IGF-II expression and inhibiting T24 cell growth, as Ksam-IIC3, a variant of FGFR2b carrying a short carboxy-terminus, neither downregulated IGF-II nor inhibited cell proliferation. Our data suggest that FGFR2b inhibits the growth of bladder carcinoma cells by reducing IGF-II levels via its carboxy-terminal domain, independent of its tyrosine kinase activity.	Inst Curie, Sect Rech, CNRS, UMR144, F-75248 Paris, France; AstraZeneca, Canc & Infect Res Area, Macclesfield SK10 4TG, Cheshire, England; Hop Paul Brousse, F-94807 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; AstraZeneca; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP	Radvanyi, F (corresponding author), Inst Curie, Sect Rech, CNRS, UMR144, 26 Rue Ulm, F-75248 Paris, France.	francois.radvanyi@curie.fr	Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Radvanyi, Francois/0000-0002-5696-6424; BROET, PHILIPPE/0000-0001-9122-2810; Thiery, Jean Paul/0000-0003-0478-5020				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Berger W, 1999, INT J CANCER, V83, P415, DOI 10.1002/(SICI)1097-0215(19991029)83:3<415::AID-IJC19>3.0.CO;2-Y; Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Broet P, 2002, J COMPUT BIOL, V9, P671, DOI 10.1089/106652702760277381; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; Ezzat S, 2002, J CLIN INVEST, V109, P69, DOI 10.1172/JCI200214036; FENG S, 1997, CANCER RES, V23, P5369; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Freeman KW, 2003, CANCER RES, V63, P6237; ISHII H, 1995, MOL CELL BIOL, V15, P3664; ITOH H, 1994, CANCER RES, V54, P3237; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Lorenzi MV, 1997, ONCOGENE, V15, P817, DOI 10.1038/sj.onc.1201242; Matsubara A, 1998, CANCER RES, V58, P1509; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MORRISON RS, 1994, J NEURO-ONCOL, V18, P207, DOI 10.1007/BF01328955; Myoken Y, 1996, INT J CANCER, V65, P650, DOI 10.1002/(SICI)1097-0215(19960301)65:5<650::AID-IJC15>3.0.CO;2-B; Naimi B, 2002, PROSTATE, V52, P245, DOI 10.1002/pros.10104; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Ricol D, 1999, ONCOGENE, V18, P7234, DOI 10.1038/sj.onc.1203186; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; Sakaguchi K, 1999, ONCOGENE, V18, P5497, DOI 10.1038/sj.onc.1202947; Volm M, 1997, EUR J CANCER, V33, P691, DOI 10.1016/S0959-8049(96)00411-X; WARE LB, 2002, AM J PHYSIOL-LUNG C, V5, P924; WILKIE AOM, 1995, CURR BIOL, V5, P500; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P11336, DOI 10.1073/pnas.191377098	46	33	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9201	9211		10.1038/sj.onc.1208150	http://dx.doi.org/10.1038/sj.onc.1208150			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516981				2022-12-17	WOS:000225638000005
J	Wakabayashi, K; Kambe, F; Cao, X; Murakami, R; Mitsuyama, H; Nagaya, T; Saito, K; Yoshida, J; Seo, H				Wakabayashi, K; Kambe, F; Cao, X; Murakami, R; Mitsuyama, H; Nagaya, T; Saito, K; Yoshida, J; Seo, H			Inhibitory effects of cyclosporin A on calcium mobilization-dependent interleukin-8 expression and invasive potential of human glioblastoma U251MG cells	ONCOGENE			English	Article						interleukin-8; cyclosporin A; glioblastoma; calcium mobilization; migration; proliferation	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-C; HUMAN GLIOMA-CELLS; AUTOCRINE GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; NUCLEAR FACTOR-KB; INTRACELLULAR CALCIUM; MELANOMA-CELLS; IN-VITRO	Interleukin (IL)-8 produced from glioblastoma is suggested to contribute to its own proliferation and progression. Since various external stimuli have been shown to increase intracellular Ca2+ in glioma cells, we investigated Ca2+ mobilization-dependent IL-8 expression and effect of cyclosporin A (CsA), an inhibitor of calcineurin (Cn), on the expression and invasive potential of human glioblastoma U251MG cells. Combined treatment with Ca2+-ionophore and phorbol-myristate-acetate (A23187/PMA) increased IL-8 mRNA and protein levels. This increase was suppressed by CsA and by another Cn inhibitor FK506. Luciferase reporter gene assay and electrophoretic mobility shift assay revealed that activation of p65-containing nuclear factor-kappaB was essential for A23187/PMA-dependent activation of IL-8 promoter. CsA suppressed the promoter activity by attenuating IkappaB-alpha degradation. U251MG cells expressed IL-8 receptors CXCR-1 and -2, and Matrigel invasion assay revealed that CsA attenuated A23187/PMA-dependent stimulation of invasive potential, probably by inhibiting IL-8 production. In addition, IL-8-dependent proliferation was also suppressed by CsA. Taken together, these results demonstrate the novel inhibitory effects of CsA on glioblastoma cell functions, suggesting CsA as a potential therapeutic adjuvant for glioma treatment.	Nagoya Univ, Environm Med Res Inst, Div Mol & Cellular Adaptat, Dept Endocrinol & Metab,Chikusa Ku, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Sch Med, Dept Neurosurg, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University	Kambe, F (corresponding author), Nagoya Univ, Environm Med Res Inst, Div Mol & Cellular Adaptat, Dept Endocrinol & Metab,Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	kambe@riem.nagoya-u.ac.jp						BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bando Kazuhiko, 1995, Neurologia Medico-Chirurgica, V35, P631, DOI 10.2176/nmc.35.631; Brew R, 2000, CYTOKINE, V12, P78, DOI 10.1006/cyto.1999.0518; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Choi C, 2002, MOL CELL BIOL, V22, P724, DOI 10.1128/MCB.22.3.724-736.2002; Choi C, 2001, CANCER RES, V61, P3084; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COULDWELL WT, 1990, J NEUROSURG, V73, P594, DOI 10.3171/jns.1990.73.4.0594; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; DeBernardi MA, 1996, J BIOL CHEM, V271, P6092, DOI 10.1074/jbc.271.11.6092; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Flynn G, 2003, J NEUROIMMUNOL, V136, P84, DOI 10.1016/S0165-5728(03)00009-2; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; Hayes IM, 1998, ARTERIOSCL THROM VAS, V18, P397, DOI 10.1161/01.ATV.18.3.397; Hemenway Charles S., 1999, Cell Biochemistry and Biophysics, V30, P115, DOI 10.1007/BF02737887; Iseki A, 2000, ENDOCRINOLOGY, V141, P4373, DOI 10.1210/en.141.12.4373; Iseki A, 2000, BIOCHEM BIOPH RES CO, V276, P88, DOI 10.1006/bbrc.2000.3452; KAMBE F, 1988, MOL ENDOCRINOL, V2, P181, DOI 10.1210/mend-2-2-181; Kasahara T, 1998, EUR CYTOKINE NETW, V9, P47; Kehlen A, 1999, J NEUROIMMUNOL, V101, P1, DOI 10.1016/S0165-5728(99)00111-3; Kelly JS, 2001, TRANSPLANT P, V33, P2217, DOI 10.1016/S0041-1345(01)01945-5; Kikumori T, 1998, ENDOCRINOLOGY, V139, P1715, DOI 10.1210/en.139.4.1715; Kikumori T, 2001, BIOCHEM J, V354, P573, DOI 10.1042/0264-6021:3540573; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KUGAYA A, 1995, BRAIN RES, V682, P151, DOI 10.1016/0006-8993(95)00345-Q; Kuhns D, 1998, J IMMUNOL, V161, P4332; Luca M, 1997, AM J PATHOL, V151, P1105; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Meyer S, 1997, FEBS LETT, V413, P354, DOI 10.1016/S0014-5793(97)00930-7; Miyamoto M, 1998, CANCER IMMUNOL IMMUN, V47, P47, DOI 10.1007/s002620050503; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Mukaida N, 1998, CYTOKINE GROWTH F R, V9, P9, DOI 10.1016/S1359-6101(97)00022-1; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582; Palma C, 1998, J NEUROIMMUNOL, V81, P127, DOI 10.1016/S0165-5728(97)00167-7; Pita I, 1999, INT J DEV NEUROSCI, V17, P813, DOI 10.1016/S0736-5748(99)00063-5; Pyrzynska B, 2002, J BIOL CHEM, V277, P14102, DOI 10.1074/jbc.M104443200; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reiland J, 1999, PROSTATE, V41, P78; Saijo K, 2002, J EXP MED, V195, P1647, DOI 10.1084/jem.20020408; Saqr HE, 1999, NEUROCHEM INT, V35, P411, DOI 10.1016/S0197-0186(99)00092-3; Sarkar D, 2000, ENDOCR J, V47, P63, DOI 10.1507/endocrj.47.63; Sato M, 1996, J RHEUMATOL, V23, P432; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; SHAPIRO WR, 1989, J NEUROSURG, V71, P1, DOI 10.3171/jns.1989.71.1.0001; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; SMYTH MJ, 1991, J IMMUNOL, V146, P3815; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; Vertegaal ACO, 2000, CELL SIGNAL, V12, P759, DOI 10.1016/S0898-6568(00)00133-9; WANG JM, 1990, BIOCHEM BIOPH RES CO, V169, P165, DOI 10.1016/0006-291X(90)91449-3; Wilson AJ, 1999, CLIN SCI, V97, P385, DOI 10.1042/CS19980351; YAMANAKA R, 1995, J NEURO-ONCOL, V25, P59, DOI 10.1007/BF01054723; Yamanaka Ryuya, 1993, Neurologia Medico-Chirurgica, V33, P744, DOI 10.2176/nmc.33.744; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200	58	33	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6924	6932		10.1038/sj.onc.1207778	http://dx.doi.org/10.1038/sj.onc.1207778			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15286717				2022-12-17	WOS:000223750700009
J	Schmelz, K; Wieder, T; Tamm, I; Muller, A; Essmann, F; Geilen, CC; Schulze-Osthoff, K; Dorken, B; Daniel, PT				Schmelz, K; Wieder, T; Tamm, I; Muller, A; Essmann, F; Geilen, CC; Schulze-Osthoff, K; Dorken, B; Daniel, PT			Tumor necrosis factor alpha sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-kappa B	ONCOGENE			English	Article						tumor necrosis factor alpha (TNF alpha); apoptosis; NF-kappa B; mitochondria; caspase-8; drug resistance	TRAIL-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; IRRADIATION-INDUCED APOPTOSIS; HUMAN CARCINOMA-CELLS; IONIZING-RADIATION; LYMPHOMA-CELLS; CD95 FAS/APO-1; DEATH DOMAIN; TNF-ALPHA; CONFORMATIONAL-CHANGE	The Hodgkin cell line HD-MyZ is resistant to apoptosis induced by tumor necrosis factor alpha (TNFalpha). In the present work, we show that pretreatment with TNFalpha sensitized the cells to apoptosis induced by antineoplastic agents and ceramide. TNFalpha pretreatment resulted in enhanced cleavage and activity of caspase-3 upon addition of etoposide, epirubicin or ceramide. No caspase-8 activation was detectable, although caspase-8 could be activated in cell-free extracts. Inhibition of caspase-8 by z-IETD-fmk did not block the sensitizing effect of TNFalpha. Furthermore, exogenous ceramide, a mediator of TNFalpha signaling, could not substitute for TNFalpha in sensitization to drug-induced apoptosis. In contrast, we observed mitochondrial changes following cotreatment of cells with TNFalpha and drugs. Mitochondrial permeability transition, cytochrome c release and subsequent processing of caspase-9 preceded the onset of apoptosis, and were enhanced by TNFalpha pretreatment. Interestingly, although transcription factor NF-kappaB protected HD-MyZ cells from drug-induced apoptosis, TNFalpha-mediated sensitization was independent of NF-kappaB, since overexpressing a dominant-negative IkappaB mutant did not alter the TNFalpha effect. Sensitization for drug-induced apoptosis by TNFalpha was abrogated by Bclx(L). Thus, the sensitizing effect of TNFalpha is mediated by the mitochondrial pathway and involves processing of caspase-2, - 3 and - 9, but appears to be independent of caspase-8 processing, Bid cleavage and NF-kappaB signaling. Therefore, sensitization by TNFalpha is mediated at least in part through different pathways, as reported for TRAIL. There, sensitization occurs through a FADD/caspase-8-dependent mechanism. Regarding TNFalpha, the sensitizing effect was also observed in myeloid leukemia cells. Therefore, TNFalpha or alternate molecules activating its pathways might be useful as sensitizers for chemotherapy in hematological malignancies.	Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Free Univ Berlin, Univ Med Ctr, Dept Dermatol, D-1000 Berlin, Germany; Univ Dusseldorf, Inst Mol Med, D-4000 Dusseldorf, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Heinrich Heine University Dusseldorf	Daniel, PT (corresponding author), Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de	Schulze-Osthoff, Klaus/N-9025-2013; Essmann, Frank/ABG-7409-2020	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Essmann, Frank/0000-0003-4369-8456				Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; BARGOU RC, 1993, J EXP MED, V177, P1257, DOI 10.1084/jem.177.5.1257; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 1999, INT J RADIAT BIOL, V75, P1257, DOI 10.1080/095530099139412; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; BEYAERT R, 1993, CANCER RES, V53, P2623; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Busuttil V, 2002, ONCOGENE, V21, P3213, DOI 10.1038/sj.onc.1205433; Carpentier I, 1998, FEBS LETT, V425, P195, DOI 10.1016/S0014-5793(98)00226-9; Carpentier I, 1999, FEBS LETT, V460, P246, DOI 10.1016/S0014-5793(99)01356-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; DANIEL PT, 1994, J IMMUNOL, V152, P5624; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Daniel PT, 1997, EUR J IMMUNOL, V27, P1029, DOI 10.1002/eji.1830270433; de Almodovar CR, 2001, ONCOGENE, V20, P7128, DOI 10.1038/sj.onc.1204887; De Valck D, 1999, ONCOGENE, V18, P4182, DOI 10.1038/sj.onc.1202787; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DHEIN J, 1994, BIOCHEM SOC T, V22, P598, DOI 10.1042/bst0220598; Droin N, 2001, BLOOD, V97, P1835, DOI 10.1182/blood.V97.6.1835; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Fiers W, 1996, J INFLAMM, V47, P67; Fortis C, 1999, EUR J IMMUNOL, V29, P3654, DOI 10.1002/(SICI)1521-4141(199911)29:11<3654::AID-IMMU3654>3.0.CO;2-B; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Geilen CC, 1996, FEBS LETT, V378, P88, DOI 10.1016/0014-5793(95)01421-7; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Gridley DS, 1997, ONCOL RES, V9, P217; Guiet C, 2002, CELL DEATH DIFFER, V9, P138, DOI 10.1038/sj/cdd/4400947; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hasenjager A, 2004, ONCOGENE, V23, P4523, DOI 10.1038/sj.onc.1207594; He Q, 2004, ONCOGENE, V23, P1321, DOI 10.1038/sj.onc.1207212; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Heyninck Karen, 2001, Molecular Cell Biology Research Communications, V4, P259, DOI 10.1006/mcbr.2001.0295; Janicke RU, 2001, ONCOGENE, V20, P5043, DOI 10.1038/sj.onc.1204659; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; Kim JY, 2002, ONCOGENE, V21, P3139, DOI 10.1038/sj.onc.1205406; Kimura K, 1999, CANCER RES, V59, P1606; KOLESNICK RN, 1994, BIOCHEM CELL BIOL, V72, P471, DOI 10.1139/o94-063; Kontny HU, 2001, CELL DEATH DIFFER, V8, P506, DOI 10.1038/sj.cdd.4400836; Kronke M, 1999, CHEM PHYS LIPIDS, V102, P157, DOI 10.1016/S0009-3084(99)00084-5; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; MacFarlane M, 2002, ONCOGENE, V21, P6809, DOI 10.1038/sj.onc.1205853; Milner AE, 2002, CELL DEATH DIFFER, V9, P287, DOI 10.1038/sj/cdd/4400945; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Peter ME, 2000, CELL DEATH DIFFER, V7, P759, DOI 10.1038/sj.cdd.4400735; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Shatrov VA, 2000, INT J CANCER, V85, P93, DOI 10.1002/(SICI)1097-0215(20000101)85:1<93::AID-IJC17>3.0.CO;2-I; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Smirnov AS, 2001, CELL DEATH DIFFER, V8, P621, DOI 10.1038/sj.cdd.4400853; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; SUFFYS P, 1989, ANTICANCER RES, V9, P167; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; VAN AD, 1996, SCIENCE, V274, P787; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wallach D, 2002, ARTHRITIS RES THER, V4, pS189, DOI 10.1186/ar585; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; Wieder T, 2001, LEUKEMIA, V15, P1735, DOI 10.1038/sj.leu.2402284; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Xiang H, 2002, ONCOGENE, V21, P3611, DOI 10.1038/sj.onc.1205449; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	94	33	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6743	6759		10.1038/sj.onc.1207848	http://dx.doi.org/10.1038/sj.onc.1207848			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273737				2022-12-17	WOS:000223653600006
J	Ramaswamy, M; Efimova, EV; Martinez, O; Mulherkar, NU; Singh, SP; Prabhakar, BS				Ramaswamy, M; Efimova, EV; Martinez, O; Mulherkar, NU; Singh, SP; Prabhakar, BS			IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC	ONCOGENE			English	Article						IG20; MADD; TRAIL; DISC; caspase-8; apoptosis; cancer	NUCLEOTIDE EXCHANGE PROTEIN; DEATH DOMAIN; TUMORICIDAL ACTIVITY; NEOPLASTIC-CELLS; RECEPTOR FAMILY; DECOY RECEPTORS; IN-VIVO; DENN-SV; EXPRESSION; LIGAND	Recently, we identified (I) under bar nsulinoma -(G) under bar lucagonoma clone 20 (IG20) that can render cells more susceptible to tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis. In addition, it can slow cell proliferation, and enhance drug- and radiation-induced cell death. TNF-related apoptosis-inducing ligand (TRAIL) can selectively induce apoptosis in some cancer cells and render others susceptible to cotreatment with drugs and irradiation, with little or no effect on most normal cells. In this study, we investigated the potential of IG20 to enhance TRAIL-induced apoptosis and found that it can render cells more susceptible to TRAIL treatment through enhanced activation of caspases. Further, we showed that this effect can be suppressed by caspase inhibitors, p35 and CrmA, and a (d) under bar ominant-(n) under bar egative (F) under bar as- (a) under bar ssociated (d) under bar eath (d) under bar omain-containing protein (DN-FADD). Results from colocalization and immunoprecipitation studies showed that IG20 can interact with TRAIL death receptors (DR), DR4 and DR5 and increase recruitment of FADD and caspase-8 into the TRAIL death-inducing signaling complex (DISC). These results indicate that IG20 is a novel protein that can enhance TRAIL-induced apoptosis by facilitating DISC formation.	Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Univ Illinois, Ctr Mol Biol & Oral Dis, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Prabhakar, BS (corresponding author), Univ Illinois, Dept Microbiol & Immunol, M-C 790,Room E-705,Bldg 935,835 S Wolcott Ave, Chicago, IL 60612 USA.	bprabhak@uic.edu		Ramaswamy, Madhu/0000-0001-8870-5328; Martinez, Osvaldo/0000-0001-7335-4342; Singh, Surya/0000-0001-5668-1712				Al-Zoubi AM, 2001, J BIOL CHEM, V276, P47202, DOI 10.1074/jbc.M104835200; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Brown TL, 1998, CURR BIOL, V8, pR191; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Chow VTK, 1998, GENOME, V41, P543, DOI 10.1139/gen-41-4-543; Chow VTK, 1996, DNA SEQUENCE, V6, P263, DOI 10.3109/10425179609020873; Coppola T, 2002, BIOCHEM J, V362, P273, DOI 10.1042/0264-6021:3620273; Cunningham SJ, 1996, THESIS U TEXAS MED B; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Efimova E, 2003, CANCER RES, V63, P8768; Efimova EV, 2004, ONCOGENE, V23, P1076, DOI 10.1038/sj.onc.1207210; GOTO Y, 1992, J BIOL CHEM, V267, P15252; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim KH, 2000, CLIN CANCER RES, V6, P335; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Leverkus M, 2000, CANCER RES, V60, P553; Lim KM, 2004, INT J CANCER, V109, P24, DOI 10.1002/ijc.11660; Lim KM, 2002, MOL CARCINOGEN, V35, P110, DOI 10.1002/mc.10082; Miyazaki T, 2001, NAT IMMUNOL, V2, P493, DOI 10.1038/88684; NEZNANOV N, 2002, MED SCI MONIT, V8, P391; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Sarker M, 2002, ONCOGENE, V21, P4323, DOI 10.1038/sj.onc.1205523; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; Tanaka M, 2001, MOL BIOL CELL, V12, P1421, DOI 10.1091/mbc.12.5.1421; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	48	33	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6083	6094		10.1038/sj.onc.1207804	http://dx.doi.org/10.1038/sj.onc.1207804			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208670				2022-12-17	WOS:000223261000008
J	Akula, SM; Ford, PW; Whitman, AG; Hamden, KE; Shelton, JG; McCubrey, JA				Akula, SM; Ford, PW; Whitman, AG; Hamden, KE; Shelton, JG; McCubrey, JA			Raf promotes human herpesvirus-8 (HHV-8/KSHV) infection	ONCOGENE			English	Article						HHV-8; KSHV; Raf; VEGF; HB-EGF	SARCOMA-ASSOCIATED HERPESVIRUS; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR SYNTHESIS; IMMUNODEFICIENCY-VIRUS TYPE-1; ABROGATE CYTOKINE DEPENDENCY; SIGNAL-REGULATED KINASE; SMOOTH-MUSCLE-CELLS; KAPOSIS-SARCOMA; ENDOTHELIAL-CELLS; TARGET-CELLS	Human herpesvirus-8 (HHV-8/KSHV) is etiologically associated with Kaposi's sarcoma (KS) and other tumors. Constitutive activation of the mitogen-activated protein kinase ( MAPK) signaling pathway has been associated with a variety of tumors, including AIDS-related KS. The oncoprotein Raf is situated at a pivotal position in regulating the MAPK pathway. Hence, we analysed the effect of oncoprotein Raf on HHV-8 infectious entry into target cells. Here we report Raf expression to significantly enhance HHV-8 infection of target cells. These findings implicate a role for Raf not only in the infectious entry of HHV-8 but also in modulating KS pathogenesis.	E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA	University of North Carolina; East Carolina University	Akula, SM (corresponding author), E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA.	akulas@mail.ecu.edu		McCubrey, James/0000-0001-6027-3156	NCI NIH HHS [R01CA098195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ablashi DV, 2002, CLIN MICROBIOL REV, V15, P439, DOI 10.1128/CMR.15.3.439-464.2002; ADAMS V, 1995, J MED VIROL, V46, P189, DOI 10.1002/jmv.1890460304; Akula SM, 2003, J VIROL, V77, P7978, DOI 10.1128/JVI.77.14.7978-7990.2003; Akula SM, 2002, CELL, V108, P407, DOI 10.1016/S0092-8674(02)00628-1; Akula SM, 2001, VIROLOGY, V282, P245, DOI 10.1006/viro.2000.0851; Akula SM, 2001, VIROLOGY, V284, P235, DOI 10.1006/viro.2001.0921; Aoki Y, 2001, LEUKEMIA LYMPHOMA, V41, P229, DOI 10.3109/10428190109057978; Aoki Y, 2000, J HEMATOTH STEM CELL, V9, P137, DOI 10.1089/152581600319351; BAILER RT, 1995, J INTERF CYTOK RES, V15, P473, DOI 10.1089/jir.1995.15.473; Bairey O, 2004, LEUKEMIA RES, V28, P243, DOI 10.1016/S0145-2126(03)00256-X; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; Birkmann A, 2001, J VIROL, V75, P11583, DOI 10.1128/JVI.75.23.11583-11593.2001; Blackbourn DJ, 2000, AIDS, V14, P1123, DOI 10.1097/00002030-200006160-00009; Blasig C, 1997, J VIROL, V71, P7963, DOI 10.1128/JVI.71.10.7963-7968.1997; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890, DOI 10.1073/pnas.91.8.2890; Cerimele F, 2001, J VIROL, V75, P2435, DOI 10.1128/JVI.75.5.2435-2443.2001; Chandran B, 1998, VIROLOGY, V243, P208, DOI 10.1006/viro.1998.9055; Chang FM, 2001, ONCOGENE, V20, P4354, DOI 10.1038/sj.onc.1204564; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Clercq E, 2001, REV MED VIROL, V11, P381, DOI 10.1002/rmv.336; De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771; ELLIS PD, 2001, BIOCHEM J, V15, P99; Ensoli B, 2000, SEMIN CANCER BIOL, V10, P367, DOI 10.1006/scbi.2000.0329; Ensoli B, 2001, EUR J CANCER, V37, P1251, DOI 10.1016/S0959-8049(01)00121-6; Faris M, 1996, AIDS, V10, P369, DOI 10.1097/00002030-199604000-00004; Gallo RC, 1998, SCIENCE, V282, P1837, DOI 10.1126/science.282.5395.1837; Ganem D, 1998, CURR CLIN TOPICS INF, V18, P237; Geraminejad P, 2002, J AM ACAD DERMATOL, V47, P641, DOI 10.1067/mjd.2002.128383; GIRALDO G, 1980, INT J CANCER, V26, P23, DOI 10.1002/ijc.2910260105; Gorden A, 2003, CANCER RES, V63, P3955; Hayward GS, 2003, CANCER CELL, V3, P1, DOI 10.1016/S1535-6108(03)00002-3; Hermouet S, 2003, NEW ENGL J MED, V348, P178, DOI 10.1056/NEJM200301093480219; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Hilger RA, 2002, ONKOLOGIE, V25, P511, DOI 10.1159/000068621; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; Iivanainen E, 2003, FASEB J, V17, P1609, DOI 10.1096/fj.02-0939com; Ingram JL, 2003, AM J PHYSIOL-LUNG C, V284, pL774, DOI 10.1152/ajplung.00189.2002; Janssen RAJ, 1998, J BIOL CHEM, V273, P32182, DOI 10.1074/jbc.273.48.32182; Karkkainen MJ, 2000, ONCOGENE, V19, P5598, DOI 10.1038/sj.onc.1203855; Kempf W, 1996, BIOCHEM MOL MED, V58, P1, DOI 10.1006/bmme.1996.0025; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Le Gall M, 2003, J CELL PHYSIOL, V196, P98, DOI 10.1002/jcp.10276; Lee John T Jr, 2002, Expert Opin Ther Targets, V6, P659; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; Masood R, 2002, AM J PATHOL, V160, P23, DOI 10.1016/S0002-9440(10)64344-1; Masson-Gadais B, 2003, CELL STRESS CHAPERON, V8, P37, DOI 10.1379/1466-1268(2003)8<37:IVRFVA>2.0.CO;2; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Monini P, 1996, INT J CANCER, V66, P717, DOI 10.1002/(SICI)1097-0215(19960611)66:6<717::AID-IJC1>3.3.CO;2-N; Morand P, 1999, LEUKEMIA LYMPHOMA, V35, P379, DOI 10.3109/10428199909145743; Myoung H, 2003, CANCER SCI, V94, P215, DOI 10.1111/j.1349-7006.2003.tb01422.x; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Naranatt PP, 2003, J VIROL, V77, P1524, DOI 10.1128/JVI.77.2.1524-1539.2003; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Planz O, 2001, J VIROL, V75, P4871, DOI 10.1128/JVI.75.10.4871-4877.2001; Popik W, 1996, MOL CELL BIOL, V16, P6532; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Shelton JG, 2003, LEUKEMIA, V17, P1765, DOI 10.1038/sj.leu.2403052; SHEN H, 1993, BLOOD, V81, P2767; Sirianni MC, 1997, LANCET, V349, P255, DOI 10.1016/S0140-6736(05)64866-0; Spear PG, 2003, J VIROL, V77, P10179, DOI 10.1128/JVI.77.19.10179-10185.2003; Takenaka M, 2003, BIOCHEM BIOPH RES CO, V301, P198, DOI 10.1016/S0006-291X(02)03014-0; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; Tokuda H, 2003, ARCH BIOCHEM BIOPHYS, V415, P117, DOI 10.1016/S0003-9861(03)00225-X; Vieira J, 2001, J VIROL, V75, P1378, DOI 10.1128/JVI.75.3.1378-1386.2001; Wang FZ, 2001, J VIROL, V75, P7517, DOI 10.1128/JVI.75.16.7517-7527.2001; Wang H, 1998, CIRC RES, V83, P832, DOI 10.1161/01.RES.83.8.832; Weinstein-Oppenheimer CR, 2002, CANCER BIOL THER, V1, P256, DOI 10.4161/cbt.77; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Yang SY, 2002, ARTERIOSCL THROM VAS, V22, P1797, DOI 10.1161/01.ATV.0000038995.31179.24; Yang XY, 1999, J VIROL, V73, P3460, DOI 10.1128/JVI.73.4.3460-3466.1999; Yoshiizumi K, 2003, BIOORGAN MED CHEM, V11, P433, DOI 10.1016/S0968-0896(02)00426-1; Zhang L, 2002, CANCER RES, V62, P5463; Zhu LJ, 1999, VIROLOGY, V262, P237, DOI 10.1006/viro.1999.9900	84	33	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5227	5241		10.1038/sj.onc.1207643	http://dx.doi.org/10.1038/sj.onc.1207643			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122343				2022-12-17	WOS:000222382500012
J	Gangisetty, O; Lauffart, B; Sondarva, GV; Chelsea, DM; Still, IH				Gangisetty, O; Lauffart, B; Sondarva, GV; Chelsea, DM; Still, IH			The transforming acidic coiled coil proteins interact with nuclear histone acetyltransferases	ONCOGENE			English	Article						breast cancer; histone acetyltransferase; TACC; nucleus; chromatin	ACUTE MYELOID-LEUKEMIA; BREAST-TUMOR SUPPRESSOR; MESSENGER-RNA; ACETYLASE COMPLEX; HUMAN CANCERS; GENE FAMILY; D-TACC; MICROTUBULES; CLONING; CELLS	Dysregulation of the human transforming acidic coiled coil (TACC) genes is thought to be important in the development of multiple myeloma, breast and gastric cancer. However, even though these proteins have been implicated in the control of cell growth and differentiation, the mechanism by which they function still remains to be clarified. Using the yeast two-hybrid assay, we have now identified the histone acetyltransferase (HAT) hGCN5L2 as a TACC2-binding protein. GST pull-down analysis subsequently confirmed that all human TACC family members can bind in vitro to hGCN5L2. The authenticity of these interactions was validated by coimmunoprecipitation assays within the human embryonic kidney cell line HEK293, which identified the TACC2s isoform as a component consistently bound to several different members of HAT family. This raises the possibility that aberrant expression of one or more TACC proteins may affect gene regulation through their interaction with components of chromatin remodeling complexes, thus contributing to tumorigenesis.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; Quark Biotech, Cleveland, OH 44106 USA	Roswell Park Cancer Institute	Still, IH (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.	Ivan.still@roswellpark.org		Gangisetty, Omkaram/0000-0001-6280-0642	NCI NIH HHS [CA 16056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aitola M, 2003, J HISTOCHEM CYTOCHEM, V51, P455, DOI 10.1177/002215540305100407; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Chaffanet M, 1999, GENE CHROMOSOME CANC, V26, P161, DOI 10.1002/(SICI)1098-2264(199910)26:2<161::AID-GCC8>3.3.CO;2-Y; Chen HM, 2000, MOL BIOL CELL, V11, P1357, DOI 10.1091/mbc.11.4.1357; Conte N, 2002, ONCOGENE, V21, P5619, DOI 10.1038/sj.onc.1205658; Conte N, 2003, ONCOGENE, V22, P8102, DOI 10.1038/sj.onc.1206972; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Gergely F, 2002, BIOESSAYS, V24, P915, DOI 10.1002/bies.10162; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Lauffart B, 2003, GENOMICS, V81, P192, DOI 10.1016/S0888-7543(02)00039-3; Lauffart B, 2002, BIOCHEM J, V363, P195, DOI 10.1042/0264-6021:3630195; Le Bot N, 2003, CURR BIOL, V13, P1499, DOI 10.1016/S0960-9822(03)00577-3; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Line A, 2002, CANCER GENET CYTOGEN, V139, P78, DOI 10.1016/S0165-4608(02)00607-6; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; Niederacher D, 1997, GENE CHROMOSOME CANC, V18, P181, DOI 10.1002/(SICI)1098-2264(199703)18:3<181::AID-GCC5>3.0.CO;2-Y; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Pu JJ, 2001, CYTOKINE, V13, P129, DOI 10.1006/cyto.2000.0812; Sadek CM, 2000, MECH DEVELOP, V97, P13, DOI 10.1016/S0925-4773(00)00415-9; Sadek CM, 2003, GENE EXPR PATTERNS, V3, P203, DOI 10.1016/S1567-133X(02)00066-2; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Srayko M, 2003, CURR BIOL, V13, P1506, DOI 10.1016/S0960-9822(03)00597-9; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Tangir J, 1996, ONCOGENE, V12, P735; TIEN AC, 2003, MOL CELL PROTEOMICS; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	34	33	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2559	2563		10.1038/sj.onc.1207424	http://dx.doi.org/10.1038/sj.onc.1207424			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14767476				2022-12-17	WOS:000220558000014
J	Wang, N; Kudryavtseva, E; Ch'en, IL; McCormick, J; Sugihara, TM; Ruiz, R; Andersen, B				Wang, N; Kudryavtseva, E; Ch'en, IL; McCormick, J; Sugihara, TM; Ruiz, R; Andersen, B			Expression of an engrailed-LMO4 fusion protein in mammary epithelial cells inhibits mammary gland development in mice	ONCOGENE			English	Article						LMO4; mammary gland development; heregulin; engrailed fusion protein	LIM DOMAIN GENE; TRANSGENIC MICE; LOBULOALVEOLAR DEVELOPMENT; TRANSCRIPTION FACTORS; HOMEODOMAIN PROTEINS; BREAST-CANCER; GROWTH-FACTOR; LMO PROTEINS; DIFFERENTIATION; BINDING	LIM domain factors and associated cofactors are important developmental regulators in pattern formation and organogenesis. In addition, overexpression of two LIM-only factors (LMOs) causes acute lymphocytic leukemia. The more recently discovered LMO factor LMO4 is highly expressed in proliferating epithelial cells, and frequently overexpressed in breast carcinoma. Here we show that while LMO4 is expressed throughout mammary gland development, it is dramatically upregulated in mammary epithelial cells during midpregnancy. The LMO coactivator Clim2/Ldb1/NLI showed a similar expression pattern, consistent with the idea that LMO4 and Clim2 act as a complex in mammary epithelial cells. In MCF-7 cells, LMO4 transcripts were upregulated by heregulin, an activator of ErbB receptors that are known to be important in mammary gland development and breast cancer. To test the hypothesis that LMO4 plays roles in mammary gland development, we created an engrailed-LMO4 fusion protein. This fusion protein maintains the ability to interact with Clim2, but acts as a dominant repressor of both basal and activated transcription when recruited to a DNA-regulatory region. When the engrailed-LMO4 fusion protein was expressed under control of the MMTV promoter in transgenic mice, both ductular development in virgin mice and alveolar development in pregnant mice were inhibited. These results suggest that LMO4 plays a role in promoting mammary gland development.	Univ Calif Irvine, Dept Med, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Div Endocrinol & Metab, Irvine, CA 92697 USA; Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California San Diego	Andersen, B (corresponding author), Univ Calif Irvine, Dept Med, Sprague Hall,Room 206, Irvine, CA 92697 USA.	bogi@uci.edu			NIAMS NIH HHS [AR02080] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR002080] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; Andersen B, 1997, GENE DEV, V11, P1873, DOI 10.1101/gad.11.14.1873; Bach I, 1999, NAT GENET, V22, P394, DOI 10.1038/11970; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; Bao JX, 2000, DEVELOPMENT, V127, P425; Brisken C, 1999, DEV BIOL, V210, P96, DOI 10.1006/dbio.1999.9271; Chen CB, 2002, DEVELOPMENT, V129, P2401; Dasen JS, 1999, CELL, V97, P587, DOI 10.1016/S0092-8674(00)80770-9; Eceles SA, 2001, J MAMMARY GLAND BIOL, V6, P393, DOI 10.1023/A:1014730829872; Grutz G, 1998, ONCOGENE, V17, P2799, DOI 10.1038/sj.onc.1202502; Gruvberger S, 2001, CANCER RES, V61, P5979; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; Hollemann T, 1998, DEVELOPMENT, V125, P2425; Jones FE, 1999, ONCOGENE, V18, P3481, DOI 10.1038/sj.onc.1202698; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Kenny DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/pnas.95.19.11257; Kitsberg DI, 1996, ONCOGENE, V13, P2507; Krane IM, 1996, ONCOGENE, V12, P1781; Kudoh T, 2001, P NATL ACAD SCI USA, V98, P7852, DOI 10.1073/pnas.141224098; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Li L, 2002, ONCOGENE, V21, P4900, DOI 10.1038/sj.onc.1205634; Liu C, 2002, AM J PHYSIOL-LUNG C, V283, pL468, DOI 10.1152/ajplung.00044.2002; Mead PE, 2001, DEVELOPMENT, V128, P2301; Montross WT, 2000, J CELL SCI, V113, P1759; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Ono Y, 1998, MOL CELL BIOL, V18, P6939, DOI 10.1128/MCB.18.12.6939; Osada H., 1997, Leukemia (Basingstoke), V11, P307; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; Rabbitts TH, 1999, CANCER RES, V59, p1794S; Racevskis J, 1999, BBA-GENE STRUCT EXPR, V1445, P148, DOI 10.1016/S0167-4781(99)00037-8; Rudland PS, 1998, BIOCHEM SOC SYMP, P1; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Stern DF, 2003, EXP CELL RES, V284, P89, DOI 10.1016/S0014-4827(02)00103-9; Sugihara TM, 2001, J BIOL CHEM, V276, P33036, DOI 10.1074/jbc.M103000200; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Sykes TG, 1998, DEVELOPMENT, V125, P4595; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Visvader JE, 1997, P NATL ACAD SCI USA, V94, P13707, DOI 10.1073/pnas.94.25.13707; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Zeng CY, 1998, P NATL ACAD SCI USA, V95, P10637, DOI 10.1073/pnas.95.18.10637	52	33	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1507	1513		10.1038/sj.onc.1207288	http://dx.doi.org/10.1038/sj.onc.1207288			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14676840				2022-12-17	WOS:000189219500003
J	Efimova, EV; Al-Zoubi, AM; Martinez, O; Kaithamana, S; Lu, SF; Arima, T; Prabhakar, BS				Efimova, EV; Al-Zoubi, AM; Martinez, O; Kaithamana, S; Lu, SF; Arima, T; Prabhakar, BS			IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs	ONCOGENE			English	Article						IG20; MADD; DENN-SV; apoptosis; mRNA splicing; tumor	NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; DEATH DOMAIN PROTEIN; KINASE RIP; SIGNALING COMPLEX; NEOPLASTIC-CELLS; TNF; ACTIVATION; ALPHA; MECHANISM	We identified seven putative splice variants of the human IG20 gene. Four variants namely, IG20, MADD, IG20-SV2 and DENN-SV are expressed in human tissues. While DENN-SV is constitutively expressed in all tissues, expression of IG20 appears to be regulated. Interestingly, overexpression of DENN-SV enhanced cell replication and resistance to treatments with TNFalpha, vinblastine, etoposide and gamma-radiation. In contrast, IG20 expression suppressed cell replication and increased susceptibility to the above treatments. Moreover, cells that were resistant and susceptible to TNFalpha-induced apoptosis exclusively expressed endogenous DENN-SV and IG20, respectively. When PA-1 ovarian cancer cells that are devoid of endogenous IG20 variant, but express higher levels of DENN-SV, were transfected with IG20, they showed reduced cell proliferation and increased susceptibility to apoptosis induced by TNFalpha, TRAIL and gamma-radiation. This indicated that overexpression of IG20 can override endogenous DENN-SV function. CrmA reversed the effects of IG20, but not DENN-SV. In contrast, dominant-negative-I-kappa B reversed the effects of DENN-SV, but not IG20, and showed that DENN-SV most likely exerted its effects through NFkappaB activation. Together, our data show that IG20 gene can play a novel and significant role in regulating cell proliferation, survival and death through alternative mRNA splicing.	Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Miltenyi Biotec Inc, Div Mol Biol, Auburn, CA 95602 USA; Human Genome Sci Inc, Dept Lead Dev & Characterizat, Gaithersburg, MD 20878 USA; MeridianLink Inc, Costa Mesa, CA 92626 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; GlaxoSmithKline; Human Genome Sciences Inc	Prabhakar, BS (corresponding author), Univ Illinois, Dept Microbiol & Immunol, M-C 790,Room E-709,Bldg 935,835 S Wolcott Ave, Chicago, IL 60612 USA.	bprabhak@uic.edu		Martinez, Osvaldo/0000-0001-7335-4342				Al-Zoubi AM, 2001, J BIOL CHEM, V276, P47202, DOI 10.1074/jbc.M104835200; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; Brinkman BMN, 1999, J BIOL CHEM, V274, P30882, DOI 10.1074/jbc.274.43.30882; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Brown TL, 1998, CURR BIOL, V8, pR191; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Chow VTK, 1998, GENOME, V41, P543, DOI 10.1139/gen-41-4-543; Chow VTK, 1996, DNA SEQUENCE, V6, P263, DOI 10.3109/10425179609020873; Cunningham SJ, 1996, THESIS U TEXAS MED B; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; GOTO Y, 1992, J BIOL CHEM, V267, P15252; Herbert A, 1999, NAT GENET, V21, P265, DOI 10.1038/6780; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Iwasaki K, 2000, EMBO J, V19, P4806, DOI 10.1093/emboj/19.17.4806; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Levivier E, 2001, BIOCHEM BIOPH RES CO, V287, P688, DOI 10.1006/bbrc.2001.5652; Lim KM, 2002, MOL CARCINOGEN, V35, P110, DOI 10.1002/mc.10082; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Murakami-Mori K, 1999, J IMMUNOL, V162, P3672; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Smrcka M, 2003, PHYSIOL RES, V52, P117; Telliez JB, 2000, BBA-PROTEIN STRUCT M, V1478, P280, DOI 10.1016/S0167-4838(00)00029-7; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zhang Y, 1998, P NATL ACAD SCI USA, V95, P2586, DOI 10.1073/pnas.95.5.2586	38	33	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1076	1087		10.1038/sj.onc.1207210	http://dx.doi.org/10.1038/sj.onc.1207210			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14716293				2022-12-17	WOS:000188749900006
J	Li, YW; Rao, PK; Wen, R; Song, Y; Muir, D; Wallace, P; van Horne, SJ; Tennekoon, GI; Kadesch, T				Li, YW; Rao, PK; Wen, R; Song, Y; Muir, D; Wallace, P; van Horne, SJ; Tennekoon, GI; Kadesch, T			Notch and Schwann cell transformation	ONCOGENE			English	Article						Notch; NICD; Schwann; neurofibromatosis; MPNST; p53	TRANSCRIPTION FACTOR SOX10; NERVE SHEATH TUMORS; NEUROFIBROMATOSIS TYPE-1; PERIPHERAL-NERVE; NEOPLASTIC TRANSFORMATION; INTRACELLULAR DOMAIN; SIGNALING PATHWAY; PROGENITOR CELLS; HUMAN HOMOLOG; BONE-MARROW	Benign plexiform neurofibromas in NF1 patients can transform spontaneously into malignant peripheral nerve sheath tumors (MPNSTs). Although mutations in the p53 gene have been found in a subset of MPNSTs and mouse models support a role for p53 mutations in malignant conversion, we found that each of three Schwann cell lines derived from human MPNSTs possessed active p53. One of the lines expressed the Notch intracellular domain (NICD), indicative of ongoing Notch signaling. Consistent with a role in malignancy, NICD was able to transform primary rat Schwann cells. Transformation was robust NICD-transduced cells generated tumors in nude rats and was associated with the loss of markers associated with Schwann cell differentiation. These data suggest that aberrant Notch signaling may contribute to the conversion of benign neurofibromas to MPNSTs.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurol & Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA; Univ Florida, Coll Med, Div Neurol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Kadesch, T (corresponding author), Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA.	kadesch@mail.med.upenn.edu			NEI NIH HHS [R01 EY12727] Funding Source: Medline; NIGMS NIH HHS [R01 GM58228] Funding Source: Medline; NINDS NIH HHS [R01 NS21700] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058228] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021700] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allman D, 2002, CELL, V109, pS1, DOI 10.1016/S0092-8674(02)00689-X; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Beatus P, 1999, DEVELOPMENT, V126, P3925; Birindelli S, 2001, LAB INVEST, V81, P833, DOI 10.1038/labinvest.3780293; Britsch S, 2001, GENE DEV, V15, P66, DOI 10.1101/gad.186601; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; delaPompa J, 1997, DEVELOPMENT, V124, P1139; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Gutmann DH, 2001, HUM MOL GENET, V10, P747, DOI 10.1093/hmg/10.7.747; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Jehn BM, 1999, J IMMUNOL, V162, P635; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; John GR, 2002, NAT MED, V8, P1115, DOI 10.1038/nm781; Kourea HP, 1999, AM J PATHOL, V155, P1855, DOI 10.1016/S0002-9440(10)65504-6; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Muir D, 2001, AM J PATHOL, V158, P501, DOI 10.1016/S0002-9440(10)63992-2; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; RAO P, 2003, IN PRESS MOL CELL BI; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Ross DA, 2001, MOL CELL BIOL, V21, P7537, DOI 10.1128/MCB.21.22.7537-7544.2001; Rutkowski JL, 2000, HUM MOL GENET, V9, P1059, DOI 10.1093/hmg/9.7.1059; Small D, 2003, J BIOL CHEM, V278, P16405, DOI 10.1074/jbc.M300464200; Soriano JV, 2000, INT J CANCER, V86, P652; Stolt CC, 2002, GENE DEV, V16, P165, DOI 10.1101/gad.215802; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Tanigaki K, 2001, NEURON, V29, P45, DOI 10.1016/S0896-6273(01)00179-9; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Wang SL, 2000, NEURON, V27, P197, DOI 10.1016/S0896-6273(00)00028-3; Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866	51	33	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1146	1152		10.1038/sj.onc.1207068	http://dx.doi.org/10.1038/sj.onc.1207068			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14762442				2022-12-17	WOS:000188749900013
J	Yoshida, K; Oyaizu, N; Dutta, A; Inoue, I				Yoshida, K; Oyaizu, N; Dutta, A; Inoue, I			The destruction box of human Geminin is critical for proliferation and tumor growth in human colon cancer cells	ONCOGENE			English	Article						Geminin; destruction box; DNA replication initiation; tumor growth	DNA-REPLICATION; CHECKPOINT; INHIBITION; COMPLEXES; ARREST; ORIP; CDT1; P53; PROTEINS; ANAPHASE	A domain-specific disruption was performed on the destruction box sequence of endogenous Geminin gene, an inhibitor of the DNA replication initiation complex, in a human cancer cell line HCT116 resulting in the formation of a protein that was stable in the G1 phase of the cell cycle. Although the total amount of Geminin in asynchronous cultures was not elevated, the G1-specific stabilization of Geminin, diminished chromatin loading of minichromosome maintenance complex, inhibited DNA replication, and resulted in the accumulation of cells in G1. The mutated Geminin suppressed in vivo tumorigenicity and in vitro cell growth. Cells carrying this mutation failed to support the replication of a plasmid bearing the oriP replicator of Epstein-Barr virus. The DNA damage checkpoint pathway was activated in the mutated cells with increased levels of p53 protein and its target, the p21 protein. All these deficits were rescued by overexpression of Cdt1, a replication initiator protein that binds to Geminin. Therefore, alteration of the cell cycle-dependent regulation of endogenous Geminin in human cells without increasing total protein level inhibits DNA replication and suppresses tumor growth.	Univ Tokyo, Inst Med Sci, Div Genet Diag, Minato Ku, Tokyo, Japan; Univ Tokyo, Inst Med Sci, Dept Lab Med, Div Mol Pathol,Minato Ku, Tokyo, Japan; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	University of Tokyo; University of Tokyo; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Yoshida, K (corresponding author), Univ Tokyo, Inst Med Sci, Div Genet Diag, Minato Ku, 4-6-1 Shirokanedai, Tokyo, Japan.	yoshidak@ims.u-tokyo.ac.jp	Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; Chaudhuri B, 2001, P NATL ACAD SCI USA, V98, P10085, DOI 10.1073/pnas.181347998; Chehab NH, 2000, GENE DEV, V14, P278; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley JFX, 2001, CURR BIOL, V11, pR367, DOI 10.1016/S0960-9822(01)00196-8; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; Kroll KL, 1998, DEVELOPMENT, V125, P3247; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Lei M, 2001, J CELL SCI, V114, P1447; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 2002, MOL BIOL CELL, V13, P3662, DOI 10.1091/mbc.E02-04-0199; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Shieh SY, 2000, GENE DEV, V14, P289; Shreeram S, 2002, ONCOGENE, V21, P6624, DOI 10.1038/sj.onc.1205910; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; WALDMAN T, 1995, CANCER RES, V55, P5187; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wohlschlegel JA, 2002, AM J PATHOL, V161, P267, DOI 10.1016/S0002-9440(10)64178-8; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; Yates JL, 2000, J VIROL, V74, P4512, DOI 10.1128/JVI.74.10.4512-4522.2000; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	36	33	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					58	70		10.1038/sj.onc.1206987	http://dx.doi.org/10.1038/sj.onc.1206987			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712211				2022-12-17	WOS:000187895300007
J	Moller, A; Sirma, H; Hofmann, TG; Staege, H; Gresko, E; Ludi, KS; Klimczak, E; Droge, W; Will, H; Schmitz, ML				Moller, A; Sirma, H; Hofmann, TG; Staege, H; Gresko, E; Ludi, KS; Klimczak, E; Droge, W; Will, H; Schmitz, ML			Sp100 is important for the stimulatory effect of homeodomain-interacting protein kinase-2 on p53-dependent gene expression	ONCOGENE			English	Article						HIPK2; Sp100; p53; PML nuclear body	PRIMARY BILIARY-CIRRHOSIS; NUCLEAR-BODIES; TRANSCRIPTIONAL ACTIVITY; P53; PML; LOCALIZATION; CELLS; DOMAINS; PHOSPHORYLATION; COMPONENTS	HIPK2 shows overlapping localization with p53 in promyelocytic leukemia (PML) nuclear bodies (PML-NBs) and functionally interacts with p53 to increase gene expression. Here we demonstrate that HIPK2 and the PML-NB resident protein Sp100 synergize for the activation of p53-dependent gene expression. Sp100 and HIPK2 interact and partially colocalize in PML-NBs. The cooperation of HIPK2 and Sp100 for the induction of p21(Waf1) is completely dependent on the presence of p53 and the kinase function of HIPK2. Downregulation of Sp100 levels by expression of siRNA does not interfere with p53-mediated transcription, but obviates the enhancing effect of HIPK2. In summary, these experiments reveal a novel function for Sp100 as a coactivator for HIPK2-mediated p53 activation.	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland; German Canc Res Ctr, Div Immunochem G0200, D-69120 Heidelberg, Germany; Heinrich Pette Inst Expt Virol & Immunol, Dept Gen Virol, D-20251 Hamburg, Germany	University of Bern; Helmholtz Association; German Cancer Research Center (DKFZ); Heinrich Pette Institute	Schmitz, ML (corresponding author), Univ Bern, Dept Chem & Biochem, Freiestr 3, CH-3012 Bern, Switzerland.		Möller, Andreas/O-1063-2015; Schmitz, M. Lienhard/D-9328-2017	Möller, Andreas/0000-0002-8618-6998; Schmitz, M. Lienhard/0000-0002-6984-7192				Bloch DB, 2000, MOL CELL BIOL, V20, P6138, DOI 10.1128/MCB.20.16.6138-6146.2000; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Ecsedy JA, 2003, MOL CELL BIOL, V23, P950, DOI 10.1128/MCB.23.3.950-960.2003; EL DW, 1993, CELL, V75, P817; Engelhardt OG, 2003, EXP CELL RES, V283, P36, DOI 10.1016/S0014-4827(02)00025-3; Eskiw CH, 2002, BIOCHEM CELL BIOL, V80, P301, DOI 10.1139/O02-079; Greenwood E, 2002, NAT REV CANCER, V2, P5, DOI 10.1038/nrc715; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Kondo S, 2003, P NATL ACAD SCI USA, V100, P5431, DOI 10.1073/pnas.0530308100; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Moller A, 2003, CANCER RES, V63, P4310; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Negorev D, 2001, J CELL SCI, V114, P59; Rogalla P, 2000, GENOMICS, V63, P117, DOI 10.1006/geno.1999.6008; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Sourvinos G, 2002, EMBO J, V21, P4989, DOI 10.1093/emboj/cdf458; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; Vogel A, 2002, J MOL MED, V80, P201, DOI 10.1007/s00109-001-0306-2; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Zong RT, 2000, EMBO J, V19, P4123, DOI 10.1093/emboj/19.15.4123	30	33	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8731	8737		10.1038/sj.onc.1207079	http://dx.doi.org/10.1038/sj.onc.1207079			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647468				2022-12-17	WOS:000186844900011
J	Spahn, L; Siligan, C; Bachmaier, R; Schmid, JA; Aryee, DNT; Kovar, H				Spahn, L; Siligan, C; Bachmaier, R; Schmid, JA; Aryee, DNT; Kovar, H			Homotypic and heterotypic interactions of EWS, FLI1 and their oncogenic fusion protein	ONCOGENE			English	Article						EWS; FLI1; Ewing's sarcoma; dimerization; protein interaction	RESONANCE ENERGY-TRANSFER; RNA-POLYMERASE-II; EWINGS-SARCOMA; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; TYROSINE KINASE; ETS-FAMILY; TERNARY COMPLEXES; IQ DOMAIN; GENE	In Ewing's sarcoma family tumors, the ets transcription factor gene FLI1 is rearranged with one EWS allele resulting in coexpression of germline EWS and chimeric EWS-FLI1 proteins. Here, we investigated the potential of germline EWS, FLI1 and EWS-FLI1 to oligomerize. In two functional in vivo tests, fluorescence resonance energy transfer (FRET) and the mammalian two-hybrid (MTH) assay, self-association of EWS and EWS-FLI1, but not of FLI1 was detected. In addition, interaction of EWS-FLI1 with EWS and FLI1 was observed. GST pull-down assays and immunoprecipitation experiments largely confirmed these results. The EWS N-terminal domain present in both EWS and EWS-FLI1 was found to contribute to homotypic and heterotypic interactions of these proteins. However, in the context of germline EWS, the presence of the whole or part of the C-terminal RNA-binding domain greatly supported the self-association potential of the protein. Involvement of an RNA component in EWS oligomerization was confirmed by sensitivity of the corresponding GST pull-down assay to RNaseA treatment. In contrast, EWS-FLI1 was able to self-associate and also bind to FLI1 via its C-terminal domain, which comprises the FLI1 DNA-binding motif. Accordingly, the EWS-FLI1 interaction was not disrupted by RNaseA treatment. Despite its potential to oligomerize, EWS-FLI1 bound to a tandem ets-binding site of the TGFbeta type II receptor promoter as a monomer. Therefore, the functional consequences of homo- and hetero-oligomerization of EWS and EWS-FLI1 proteins remain to be elucidated.	St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; Univ Vienna, Dept Vasc Biol & Thrombosis Res, A-1235 Vienna, Austria; Competence Ctr Biomol Therapeut, A-1235 Vienna, Austria	Saint Anna Children's Hospital; University of Vienna	Kovar, H (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.		Schmid, Johannes A./C-7659-2009	Schmid, Johannes A./0000-0002-6586-3507; Kovar, Heinrich/0000-0001-6873-9109				Arvand A, 2001, CANCER RES, V61, P5311; Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; Chansky HA, 2001, CANCER RES, V61, P3586; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deloulme JC, 1997, J BIOL CHEM, V272, P27369, DOI 10.1074/jbc.272.43.27369; Felsch JS, 1999, CURR BIOL, V9, P485, DOI 10.1016/S0960-9822(99)80214-0; Feng L, 2001, ONCOGENE, V20, P4161, DOI 10.1038/sj.onc.1204522; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; Ginsberg JP, 1999, J CLIN ONCOL, V17, P1809, DOI 10.1200/JCO.1999.17.6.1809; Guinamard R, 1997, SCAND J IMMUNOL, V45, P587, DOI 10.1046/j.1365-3083.1997.d01-447.x; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; Kim J, 1999, P NATL ACAD SCI USA, V96, P14300, DOI 10.1073/pnas.96.25.14300; Kim J, 2000, FEBS LETT, V474, P121, DOI 10.1016/S0014-5793(00)01590-8; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(01)00270-7; Knoop LL, 2000, J BIOL CHEM, V275, P24865, DOI 10.1074/jbc.M001661200; Knoop LL, 2001, J BIOL CHEM, V276, P22317, DOI 10.1074/jbc.M008950200; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kovar H, 2001, CANCER RES, V61, P5992; LADANYI M, 1994, CANCER RES, V54, P2837; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; LESSNICK SL, 1995, ONCOGENE, V10, P423; Li KKC, 2000, J BIOL CHEM, V275, P23053, DOI 10.1074/jbc.M002961200; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Lin PP, 1999, CANCER RES, V59, P1428; Matsumoto Y, 2001, BRIT J CANCER, V84, P768, DOI 10.1054/bjoc.2000.1652; Mavrothalassitis G, 2000, ONCOGENE, V19, P6524, DOI 10.1038/sj.onc.1204045; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; OHNO T, 1993, CANCER RES, V53, P5859; Olsen RJ, 2001, ONCOGENE, V20, P1756, DOI 10.1038/sj.onc.1204268; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; RAO VN, 1993, ONCOGENE, V8, P2167; Schmid JA, 2003, CURR OPIN ONCOL, V15, P55, DOI 10.1097/00001622-200301000-00008; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Spahn L, 2002, CANCER RES, V62, P4583; Thompson AD, 1996, ONCOGENE, V13, P2649; Toretsky JA, 1997, J NEURO-ONCOL, V31, P9, DOI 10.1023/A:1005716926800; Venkitaraman AR, 2001, J CELL SCI, V114, P3591; Welford SM, 2001, J BIOL CHEM, V276, P41977, DOI 10.1074/jbc.M106757200; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Zhang D, 1998, J BIOL CHEM, V273, P18086, DOI 10.1074/jbc.273.29.18086; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	52	33	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2003	22	44					6819	6829		10.1038/sj.onc.1206810	http://dx.doi.org/10.1038/sj.onc.1206810			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534527				2022-12-17	WOS:000185843400001
J	Starczynowski, DT; Reynolds, JG; Gilmore, TD				Starczynowski, DT; Reynolds, JG; Gilmore, TD			Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells	ONCOGENE			English	Article						c-Rel; Rel; NF-kappa B; malignant transformation; lymphoma	KAPPA-B-ALPHA; V-REL; LYMPHOMA; ACTIVATION; EXPRESSION; PROTEIN; ONCOPROTEIN; AMPLIFICATION; DOMAIN; GAINS	The REL gene is amplified in many human B-cell lymphomas and we have previously shown that expression of REL from a retroviral vector can malignantly transform chicken spleen cells in vitro. To identify REL protein functions necessary for malignant transformation, we have performed deletion analysis on REL sequences encoding residues of two C-terminal subdomains that are involved in transcriptional activation. We find that deletion of both C-terminal transactivation subdomains abolishes the ability of REL to transform chicken spleen cells in vitro. In contrast, deletion of either transactivation subdomain alone, which reduces the transactivation ability of REL, enhances the transforming activity of REL. Transforming REL mutants missing C-terminal sequences can also be selected at a low frequency in vitro. The REL transactivation domain can be functionally replaced in transformation assays by a portion of the VP16 transactivation domain that activates at a level similar to REL-transforming mutants. We also find that deletion of 29 C-terminal amino acids causes the subcellular localization of REL to change from cytoplasmic to nuclear in chicken embryo fibroblasts. In contrast, wild-type REL and all transforming REL mutants are located primarily in the cytoplasm of transformed spleen cells. Nevertheless, treatment of transformed spleen cells with leptomycin B causes wild-type REL and two REL mutants to relocalize to the nucleus, and nuclear extracts from these transformed cells contain REL DNA-binding activity. Taken together, these results suggest the following: ( 1) that REL must activate transcription to transform cells in vitro; ( 2) that a reduced level of transactivation enhances the oncogenicity of REL; ( 3) that REL shuttles from the cytoplasm to the nucleus in transformed chicken spleen cells; and ( 4) that mutations in REL, in addition to amplifications, could activate its oncogenicity in human lymphomas.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu			NCI NIH HHS [CA47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barkett M, 2001, BBA-GEN SUBJECTS, V1526, P25, DOI 10.1016/S0304-4165(01)00092-7; Barth TFE, 1998, BLOOD, V91, P4321, DOI 10.1182/blood.V91.11.4321.411k08_4321_4330; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Barth TFE, 2001, GENE CHROMOSOME CANC, V31, P316, DOI 10.1002/gcc.1150; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; Chen CL, 1999, MOL CELL BIOL, V19, P307; Donnelly GB, 2001, BLOOD, V98, p302A; ENGELKE U, 1995, VIROLOGY, V208, P467, DOI 10.1006/viro.1995.1177; Epinat JC, 2000, ONCOGENE, V19, P599, DOI 10.1038/sj.onc.1203376; Epinat JC, 2000, ONCOGENE, V19, P3131, DOI 10.1038/sj.onc.1203651; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; GILMORE TD, 1995, DNA PROVIRUS, P109; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Goff LK, 2000, BRIT J HAEMATOL, V111, P618, DOI 10.1046/j.1365-2141.2000.02352.x; Grigoriadis G, 1996, EMBO J, V15, P7099, DOI 10.1002/j.1460-2075.1996.tb01101.x; Houldsworth J, 1996, BLOOD, V87, P25; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; Kalaitzidis D, 2002, GENE CHROMOSOME CANC, V34, P129, DOI 10.1002/gcc.10051; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kralova J, 2002, J VIROL, V76, P11960, DOI 10.1128/JVI.76.23.11960-11970.2002; LU D, 1991, ONCOGENE, V6, P1235; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; Nagy M, 2000, LEUKEMIA, V14, P2142, DOI 10.1038/sj.leu.2401978; Neat MJ, 2001, GENE CHROMOSOME CANC, V32, P236, DOI 10.1002/gcc.1187; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; Palanisamy N, 2002, GENE CHROMOSOME CANC, V33, P114, DOI 10.1002/gcc.10016; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Sachdev S, 1997, ONCOGENE, V14, P2585, DOI 10.1038/sj.onc.1201108; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIF S, 1993, ONCOGENE, V8, P2501; SMARDOVA J, 1995, ONCOGENE, V10, P2017; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang Y, 2001, BBA-MOL CELL RES, V1538, P260, DOI 10.1016/S0167-4889(01)00077-5; White DW, 1996, MOL CELL BIOL, V16, P1169; White DW, 1996, ONCOGENE, V13, P891	51	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6928	6936		10.1038/sj.onc.1206801	http://dx.doi.org/10.1038/sj.onc.1206801			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534540				2022-12-17	WOS:000185843400014
J	De Falco, G; Bellan, C; Lazzi, S; Claudio, P; La Sala, D; Cinti, C; Tosi, P; Giordano, A; Leoncini, L				De Falco, G; Bellan, C; Lazzi, S; Claudio, P; La Sala, D; Cinti, C; Tosi, P; Giordano, A; Leoncini, L			Interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis of AIDS-related neoplasms	ONCOGENE			English	Article						pRb2/p130; Tat; HIV; lymphoma; cell cycle	HUMAN-IMMUNODEFICIENCY-VIRUS; KAPOSIS-SARCOMA PATHOGENESIS; LARGE T-ANTIGEN; TRANSGENIC MICE; CELL-CYCLE; GENE-EXPRESSION; GROWTH-FACTOR; IN-VIVO; PROTEIN; TYPE-1	Tat protein is an early nonstructural protein necessary for virus replication, which is secreted by infected cells and taken up by uninfected cells. Extensive evidence indicates that Tat may be a cofactor in the development of AIDS-related neoplasms. The molecular mechanism underlying Tat's oncogenic activity may include deregulation of cellular genes. Among these genes, it has recently been shown that pRb2/p130 oncosuppressor protein is one of the targets in the interaction between HIV gene product Tat and host proteins. However, whether the HIV-1 gene product Tat may inactivate the oncosuppressive function of pRb2/p130 has not yet been elucidated. Here, we show that mRNA levels of pRb2/p130 increase in the presence of Tat, whereas no change in the phosphorylation status of pRb2/p130 is observed. In addition, Tat can inhibit the growth control activity exerted by pRb2/p130 in the T98G cell line. Finally, Tat does not compete with E2F-4 in binding to pRb2/p130. The interaction between Tat and pRb2/p130 seems to result in the deregulation of the control exerted by pRb2/p130 on the cell cycle. Taken together, these results open a window on the role of pRb2/ p130 in AIDS-related oncogenesis.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; CNR, ITOI, Bologna Unit, I-40126 Bologna, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena; Consiglio Nazionale delle Ricerche (CNR)	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, BioLife Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.	giordano@temple.edu	BELLAN, CRISTIANA/ABG-4750-2021; LEONCINI, Lorenzo/U-4413-2019; Giordano, Antonio/F-1927-2010; Claudio, Pier Paolo/AAW-7282-2021; leoncini, lorenzo/P-8361-2018; Lazzi, Stefano/P-8265-2018; BELLAN, CRISTIANA/L-3903-2013	BELLAN, CRISTIANA/0000-0001-6119-9007; LEONCINI, Lorenzo/0000-0002-7457-300X; Giordano, Antonio/0000-0002-5959-016X; Claudio, Pier Paolo/0000-0001-7790-1622; leoncini, lorenzo/0000-0002-7457-300X; Lazzi, Stefano/0000-0002-2218-3771; BELLAN, CRISTIANA/0000-0001-6119-9007; Cinti, Caterina/0000-0001-8049-0369	NCI NIH HHS [R21-CA099955] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA099955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838; Altavilla G, 1999, AM J PATHOL, V154, P1231, DOI 10.1016/S0002-9440(10)65375-8; Ambrosino C, 2002, J BIOL CHEM, V277, P31448, DOI 10.1074/jbc.M112398200; BARILLARI G, 1992, J IMMUNOL, V149, P3727; Barillari G, 2002, CLIN MICROBIOL REV, V15, P310, DOI 10.1128/CMR.15.2.310-326.2002; Boshoff C, 2002, NAT REV CANCER, V2, P373, DOI 10.1038/nrc797; Chang Hsiao-Kuey, 1995, Journal of Biomedical Science, V2, P189, DOI 10.1007/BF02253380; Cinti C, 2000, CANCER RES, V60, P383; Cinti C, 2000, AM J PATHOL, V156, P751, DOI 10.1016/S0002-9440(10)64941-3; Clark E, 2000, J VIROL, V74, P5040, DOI 10.1128/JVI.74.11.5040-5052.2000; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 2000, CANCER RES, V60, P8; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Claudio PP, 2001, CANCER RES, V61, P462; CORALLINI A, 1993, CANCER RES, V53, P5569; Corallini A, 1996, AIDS, V10, P701, DOI 10.1097/00002030-199606001-00003; Dalgleish AG, 2002, ADV CANCER RES, V84, P231, DOI 10.1016/S0065-230X(02)84008-8; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; de la Fuente C, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-14; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; Fiorelli V, 1999, J IMMUNOL, V162, P1165; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Gaidano G, 1998, AM J PATHOL, V152, P623; Gatignol A, 2000, Adv Pharmacol, V48, P209; Kashanchi F, 2000, J VIROL, V74, P652, DOI 10.1128/JVI.74.2.652-660.2000; KIM CM, 1992, ONCOGENE, V7, P1525; Knowles DM, 1999, MODERN PATHOL, V12, P200; Kundu M, 1997, J BIOL CHEM, V272, P29468, DOI 10.1074/jbc.272.47.29468; Kundu M, 1998, J BIOL CHEM, V273, P8130, DOI 10.1074/jbc.273.14.8130; Kundu RK, 1999, BLOOD, V94, P275, DOI 10.1182/blood.V94.1.275.413a30_275_282; Lazzi S, 2002, HUM PATHOL, V33, P723, DOI 10.1053/hupa.2002.125372; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; Mahieux R, 2001, J VIROL, V75, P1736, DOI 10.1128/JVI.75.4.1736-1743.2001; Noonan D, 2000, Adv Pharmacol, V48, P229; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Rubartelli A, 1998, IMMUNOL TODAY, V19, P543, DOI 10.1016/S0167-5699(98)01351-6; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; STEIN GS, 1999, MOL BASIS CELL CYCLE; Stiegler P, 1998, J CELL BIOCHEM, P30; Sullivan CS, 2000, MOL CELL BIOL, V20, P6233, DOI 10.1128/MCB.20.17.6233-6243.2000; Vene R, 2001, CLIN EXP METASTAS, V18, P533, DOI 10.1023/A:1011991906685; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; Wu A, 1999, CANCER, V86, P2038, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2038::AID-CNCR22>3.0.CO;2-A; ZAULI G, 1995, BLOOD, V86, P3823, DOI 10.1182/blood.V86.10.3823.bloodjournal86103823	48	33	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6214	6219		10.1038/sj.onc.1206637	http://dx.doi.org/10.1038/sj.onc.1206637			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679860				2022-12-17	WOS:000185506200011
J	Yuan, ZQ; Kent, TS; Weber, TK				Yuan, ZQ; Kent, TS; Weber, TK			Differential expression of DOC-1 in microsatellite-unstable human colorectal cancer	ONCOGENE			English	Article						colorectal cancer; microsatellite instability; DOC-1; differential expression	MISMATCH REPAIR; INSTITUTE WORKSHOP; INSTABILITY; P12(DOC-1); GENES; CARCINOMAS; MUTATIONS; APOPTOSIS; PROFILES	The precise genetic mechanism of malignant transformation in DNA mismatch repair deficient, microsatellite-unstable colorectal cancer (CRC) has yet to be elucidated. We employed cDNA microarray to identify patterns of gene expression among CRC cell lines and to compare directly lines with and without microsatellite instability. This study was undertaken to test the hypothesis that microsatellite-unstable CRC cell lines demonstrate specific patterns of gene expression that differ significantly from those observed among microsatellite-stable CRC. Multiple differential expression patterns were identified. Genes demonstrating differential expression included deleted-in-oral-cancer-1 (DOC-1), a highly conserved growth suppressor. DOC-1 expression correlated with microsatellite status, with significantly decreased expression in microsatellite-unstable cell lines and constitutive expression in microsatellite-stable cell lines. We also observed alterations in the biologic behavior of p12(DOC-1)deficient cell lines, with increased S phase and decreased apoptosis compared to microsatellite-stable (DOC-1+) cell lines. Transfection of p12(DOC-1) into SW48, which lacks p12(DOC-1) expression, resulted in cell cycle and apoptosis profiles similar to other p12(DOC-1)+ cell lines. These results support the hypothesis that microsatellite-unstable CRC is characterized by novel patterns of gene expression different from those associated with microsatellite-stable CRC, and demonstrate that p12(DOC-1) has tumor suppressor potential in colon epithelial cells.	Yeshiva Univ Albert Einstein Coll Med, Dept Surg & Mol Genet, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Surg, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Weber, TK (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Surg & Mol Genet, 1300 Morris Pk Ave,Ullmann 1219, Bronx, NY 10461 USA.	tweber@aecom.yu.edu						Barnetson RA, 2000, INT J COLORECTAL DIS, V15, P83, DOI 10.1007/s003840050237; Boland CR, 1997, HOSP PRACT, V32, P79, DOI 10.1080/21548331.1997.11443598; Boland CR, 1998, CANCER RES, V58, P5248; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Cwikla SJ, 2000, J ORAL MAXIL SURG, V58, P406, DOI 10.1016/S0278-2391(00)90924-8; Fink D, 1997, BRIT J CANCER, V76, P890, DOI 10.1038/bjc.1997.480; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; Harris TM, 2000, NAT BIOTECHNOL, V18, P384, DOI 10.1038/74435; He YDD, 2001, NAT MED, V7, P658, DOI 10.1038/89022; Hegde P, 2001, CANCER RES, V61, P7792; Hu Miaofen, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P326; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kohno Y, 2002, ORAL ONCOL, V38, P274, DOI 10.1016/S1368-8375(01)00055-0; Kruschewski M, 2002, CLIN EXP METASTAS, V19, P71, DOI 10.1023/A:1013853224644; Loeb LA, 2001, CANCER RES, V61, P3230; Lynch HT, 1999, J MED GENET, V36, P801; Markowitz S, 2000, BBA-REV CANCER, V1470, pM13, DOI 10.1016/S0304-419X(99)00031-1; Martin L, 1999, EUR J CANCER PREV, V8, pS13; Matsuo K, 2000, FASEB J, V14, P1318, DOI 10.1096/fj.14.10.1318; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Notterman DA, 2001, CANCER RES, V61, P3124; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Sankila R, 1996, GASTROENTEROLOGY, V110, P682, DOI 10.1053/gast.1996.v110.pm8608876; Sepulveda AR, 1999, AM J GASTROENTEROL, V94, P3034, DOI 10.1016/S0002-9270(99)00509-2; Shintani S, 2001, CLIN CANCER RES, V7, P2776; Shintani S, 2000, MOL CELL BIOL, V20, P6300, DOI 10.1128/MCB.20.17.6300-6307.2000; Takemasa I, 2001, BIOCHEM BIOPH RES CO, V285, P1244, DOI 10.1006/bbrc.2001.5277; TODD R, 1995, FASEB J, V9, P1362, DOI 10.1096/fasebj.9.13.7557027; Tsuji T, 1998, J BIOL CHEM, V273, P6704, DOI 10.1074/jbc.273.12.6704	31	33	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6304	6310		10.1038/sj.onc.1206609	http://dx.doi.org/10.1038/sj.onc.1206609			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679870				2022-12-17	WOS:000185506200021
J	M'kacher, R; Bennaceur, A; Farace, F; Lauge, A; Plassa, LF; Wittmer, E; Dossou, J; Violot, D; Deutsch, E; Bourhis, J; Stoppa-Lyonnet, D; Ribrag, V; Carde, P; Parmentier, C; Bernheim, A; Turhan, AG				M'kacher, R; Bennaceur, A; Farace, F; Lauge, A; Plassa, LF; Wittmer, E; Dossou, J; Violot, D; Deutsch, E; Bourhis, J; Stoppa-Lyonnet, D; Ribrag, V; Carde, P; Parmentier, C; Bernheim, A; Turhan, AG			Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma	ONCOGENE			English	Article						DNA repair; ATM; P53; mantle cell lymphoma; irradiation	ATAXIA-TELANGIECTASIA GENE; IONIZING-RADIATION; MISSENSE MUTATIONS; C-ABL; ATM; PROTEIN; INACTIVATION; KINASE; PHOSPHORYLATION; P53	Mantle cell lymphomas (MCL) are characterized by their aggressive behavior and poor response to chemotherapy regimens. We report here evidence of increased in vitro radiation sensitivity in two cell lines that we have generated from two MCL patients (UPN1 and UPN2). However, despite their increased radiation sensitivity, UPN2 cells were totally resistant to apoptotic cell death, whereas UPN1 cells underwent massive apoptosis 6 h after irradiation. The frequency of induced chromosomal abnormalities was higher in UPN1 as compared to UPN2. Distinct mechanisms have been found to contribute to this phenotype: a major telomere shortening (UPN1 and UPN2), deletion of one ATM allele and a point mutation in the remaining allele in UPN2, mutation of p53 gene (UPN1 and UPN2) with absence of functional p53 as revealed by functional yeast assays. After irradiation, Ku70 levels in UPN1 increased and decreased in UPN2, whereas in the same conditions, DNA-PKcs protein levels decreased in UPN1 and remained unchanged in UPN2. Thus, irradiation-induced apoptotic cell death can occur despite the nonfunctional status of p53 (UPN1), suggesting activation of a unique pathway in MCL cells for the induction of this event. Overall, our study demonstrates that MCL cells show increased radiation sensitivity, which can be the result of distinct molecular events. These findings could clinically be exploited to increase the dismal response rates of MCL patients to the current chemotherapy regimens.	IGR, INSERM, U362, Translat Res Cell Therapy Lab, Villejuif, France; UPRES EA 27 10, Dept Med, Villejuif, France; UPRES EA 27 10, Dept Biol Clin, Villejuif, France; IGR, Cytogenet & Oncol Genet Lab, Villejuif, France; Inst Curie, Serv Genet Oncol, F-75231 Paris, France; Hop St Louis, Lab Biochim B, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Turhan, AG (corresponding author), IGR, INSERM, U362, Translat Res Cell Therapy Lab, Villejuif, France.	turali@igr.fr		deutsch, eric/0000-0002-8223-3697; Bourhis, Jean/0000-0001-5162-1171; bennaceur griscelli, annelise/0000-0002-3557-4499; TURHAN, Ali/0000-0002-4861-0137				Ahmed S, 2000, NATURE, V403, P159, DOI 10.1038/35003120; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Behr TM, 2002, CANCER-AM CANCER SOC, V94, P1363, DOI 10.1002/cncr.10307; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BOSCH F, 1994, BLOOD, V84, P2726; Brown KD, 1999, AM J HUM GENET, V64, P46, DOI 10.1086/302223; Camacho E, 2002, BLOOD, V99, P238, DOI 10.1182/blood.V99.1.238; Campo E, 1999, SEMIN HEMATOL, V36, P115; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; di Fagagna FD, 1999, NAT GENET, V23, P76; Dreyling MH, 1997, CANCER RES, V57, P4608; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Gatei M, 2000, CANCER RES, V60, P3299; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Gilley D, 2001, P NATL ACAD SCI USA, V98, P15084, DOI 10.1073/pnas.261574698; Gopal AK, 2002, BLOOD, V99, P3158, DOI 10.1182/blood.V99.9.3158; Hou M, 2001, CLIN CHEM, V47, P519; Iavarone A, 1997, NATURE, V387, P417; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; M'kacher R, 2003, CANCER GENET CYTOGEN, V143, P32, DOI 10.1016/S0165-4608(02)00823-3; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; Meyer KM, 1999, ONCOGENE, V18, P5795, DOI 10.1038/sj.onc.1202977; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Pandita TK, 1999, MOL CELL BIOL, V19, P5096; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Schaffner C, 2000, P NATL ACAD SCI USA, V97, P2773, DOI 10.1073/pnas.050400997; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Smilenov LB, 1999, MOL CELL BIOL, V19, P6963; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; TOLKSDORF G, 1980, BRIT J CANCER, V41, P168, DOI 10.1038/bjc.1980.27; VERPY E, 1994, P NATL ACAD SCI USA, V91, P1873, DOI 10.1073/pnas.91.5.1873; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Weisenburger DD, 1996, BLOOD, V87, P4483, DOI 10.1182/blood.V87.11.4483.bloodjournal87114483; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	38	33	35	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					7905	7912		10.1038/sj.onc.1206826	http://dx.doi.org/10.1038/sj.onc.1206826			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970738				2022-12-17	WOS:000185388200005
J	Elsasser, A; Franzen, M; Kohlmann, A; Weisser, M; Schnittger, S; Schoch, C; Reddy, VA; Burel, S; Zhang, DE; Ueffing, M; Tenen, DG; Hiddemann, W; Behre, G				Elsasser, A; Franzen, M; Kohlmann, A; Weisser, M; Schnittger, S; Schoch, C; Reddy, VA; Burel, S; Zhang, DE; Ueffing, M; Tenen, DG; Hiddemann, W; Behre, G			The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner	ONCOGENE			English	Article						AML1-ETO; c-jun; JNK1; AML; myeloid	COLONY-STIMULATING FACTOR; N-TERMINAL KINASE; HA-RAS GENE; TRANSCRIPTION FACTOR; C/EBP-ALPHA; GRANULOCYTIC DIFFERENTIATION; LINEAGE COMMITMENT; DOWN-REGULATION; DNA-BINDING; CELLS	Overexpression of proto-oncogene c-jun and constitutive activation of the Jun N-terminal kinase (JNK) signaling pathway have been implicated in the leukemic transformation process. However, c-jun expression and the role of the JNK signaling pathway have not been investigated in primary acute myeloid leukemia (AML) cells with frequently observed balanced rearrangements such as t(8;21). In the present study, we report elevated c-jun mRNA expression in AML patient bone marrow cells with t(8;21), t(15;17) or inv(16), and a high correlation in mRNA expression levels of AML1-ETO and c-jun within t(8;21)-positive AML patient cells. In myeloid U937 cells, c-jun mRNA and protein expression increase upon inducible expression of AML1-ETO. AML1-ETO transactivates the human c-jun promoter through the proximal activator protein (AP-1) site by activating the JNK pathway. Overexpression of JNK-inhibitor JIP-1 and chemical JNK inhibitors reduce the transactivation capacity of AML1-ETO on the c-jun promoter and the proapoptotic function of AML1-ETO in U937 cells. An autocrine mechanism involving granulocyte-colony stimulating factor (G-CSF) and G-CSF receptor (G-CSF-R) might participate in AML1-ETO mediated JNK-signaling, because AML1-ETO induces G-CSF and G-CSF-R expression, and G-CSF-R-neutralizing antibodies reduce AML1-ETO-induced JNK phosphorylation. These data suggest a model in which AML1-ETO induces protooncogene c-jun expression via the proximal AP-1 site of the c-jun promoter in a JNK-dependent manner.	Univ Munich, Univ Hosp Grosshadern, Dept Internal Med 3, Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, D-81377 Munich, Germany; Scripps Res Inst, La Jolla, CA USA; Tech Univ, Inst Human Genet, D-81377 Munich, Germany; Harvard Univ, Sch Med, Harvard Inst Med, Boston, MA 02115 USA	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Scripps Research Institute; Technical University of Munich; Harvard University; Harvard Medical School	Behre, G (corresponding author), Univ Munich, Dept Internal Med 3, Marchioninistr 15, D-81377 Munich, Germany.			Tenen, Daniel/0000-0002-6423-3888	NATIONAL CANCER INSTITUTE [R01CA041456] Funding Source: NIH RePORTER; NCI NIH HHS [CA41456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcalay M, 2001, ONCOGENE, V20, P5680, DOI 10.1038/sj.onc.1204642; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Baumann MA, 2001, AM J HEMATOL, V68, P99, DOI 10.1002/ajh.1160; Behre G, 1999, METHODS, V17, P231, DOI 10.1006/meth.1998.0733; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Bloomfield CD, 2002, GENE CHROMOSOME CANC, V33, P362, DOI 10.1002/gcc.10046; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; BRADBURY D, 1992, LEUKEMIA, V6, P562; Braess J, 2001, BRIT J HAEMATOL, V113, P975, DOI 10.1046/j.1365-2141.2001.02866.x; Brandstetter T, 1998, INT J CANCER, V75, P847, DOI 10.1002/(SICI)1097-0215(19980316)75:6<847::AID-IJC6>3.0.CO;2-V; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Burgess GS, 1998, BLOOD, V92, P2450, DOI 10.1182/blood.V92.7.2450.2450_2450_2460; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Emig M, 1999, LEUKEMIA, V13, P1825, DOI 10.1038/sj.leu.2401566; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Han ZN, 1999, J PHARMACOL EXP THER, V291, P124; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Katayama N, 1998, AM J HEMATOL, V58, P31, DOI 10.1002/(SICI)1096-8652(199805)58:1<31::AID-AJH6>3.0.CO;2-1; Kiaris H, 1999, ONCOGENE, V18, P7168, DOI 10.1038/sj.onc.1203213; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; KUROKAWA M, 1995, ONCOGENE, V11, P833; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rangatia J, 2002, MOL CELL BIOL, V22, P8681, DOI 10.1128/MCB.22.24.8681-8694.2002; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Shimizu K, 2000, BLOOD, V96, P288, DOI 10.1182/blood.V96.1.288.013k05_288_296; SPINNER DM, 1995, INT J CANCER, V63, P423, DOI 10.1002/ijc.2910630321; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; Sueoka E, 1998, BRIT J HAEMATOL, V101, P737, DOI 10.1046/j.1365-2141.1998.00757.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wei P, 1998, MOL ENDOCRINOL, V12, P1322, DOI 10.1210/me.12.9.1322; Wong C, 1999, MOL CELL BIOL, V19, P1821; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zada AAP, 2003, ONCOGENE, V22, P2296, DOI 10.1038/sj.onc.1206330	50	33	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5646	5657		10.1038/sj.onc.1206673	http://dx.doi.org/10.1038/sj.onc.1206673			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944913				2022-12-17	WOS:000184865900014
J	Ivanisevic, L; Banerjee, K; Saragovi, HU				Ivanisevic, L; Banerjee, K; Saragovi, HU			Differential cross-regulation of TrkA and TrkC tyrosine kinase receptors with p75	ONCOGENE			English	Article						receptor; neurotrophin; cross-regulation; ligand; Trk; signal transduction	NERVE GROWTH-FACTOR; NF-KAPPA-B; NEUROTROPHIN SIGNAL-TRANSDUCTION; CULTURED HIPPOCAMPAL-NEURONS; HIGH-AFFINITY; FUNCTIONAL INTERACTIONS; HUMAN NEUROBLASTOMAS; FACTOR-BINDING; P75(NTR); CELLS	The neurotrophins neurotrophin-3 (NT-3), brain-derived growth factor (BDNF) and nerve growth factor (NGF) bind to the p75 receptor, but each neurotrophin also binds a more selective Trk receptor (e.g. TrkA-NGF and TrkC-NT-3). The biochemical signals following engagement of either Trk or p75 with ligands are well understood, but long-term biological outcomes (trophic, proapoptotic or differentiative) remain unclear because they are cell/tissue specific. For example, Trk receptors are usually trophic but when overexpressed they can be proapoptotic in neuroblastomas and medulloblastomas. We hypothesized that coexpression of Trk and p75 receptors may lead to cross-regulation of signals and different biological outcomes; and used receptor-selective ligands to study cross-regulation by these receptors. We show that in the absence of Trk activation, expression of TrkC is permissive of p75 trophic and differentiation signals induced by p75 ligands, whereas expression of TrkA abolishes trophic and differentiation signals induced by p75 ligands. In contrast, in the presence of Trk activation, p75 ligands can regulate TrkA-mediated survival and TrkC-mediated differentiation. Therefore, a complex homeostasis of p75-selective and Trk-selective signals may determine the fate of cells expressing both receptors.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Oncol Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Saragovi, HU (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond St 1320, Montreal, PQ H3G 1Y6, Canada.	Uri@pharma.mcgill.ca						Atwal JK, 2000, NEURON, V27, P265, DOI 10.1016/S0896-6273(00)00035-0; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Barker PA, 1998, CELL DEATH DIFFER, V5, P346, DOI 10.1038/sj.cdd.4400375; Baskey JC, 2002, J NEUROCHEM, V80, P501, DOI 10.1046/j.0022-3042.2001.00730.x; Bhakar AL, 1999, J BIOL CHEM, V274, P21443, DOI 10.1074/jbc.274.30.21443; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; Bilderback TR, 2001, J NEUROCHEM, V76, P1540, DOI 10.1046/j.1471-4159.2001.00171.x; Brann AB, 2002, J BIOL CHEM, V277, P9812, DOI 10.1074/jbc.M109862200; Brann AB, 1999, J NEUROSCI, V19, P8199; Bredesen DE, 1997, TRENDS NEUROSCI, V20, P287, DOI 10.1016/S0166-2236(96)01049-1; Brodeur GM, 1997, J NEURO-ONCOL, V31, P49, DOI 10.1023/A:1005729329526; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Chao M, 1998, BRAIN RES REV, V26, P295, DOI 10.1016/S0165-0173(97)00036-2; Dechant G, 1997, J NEUROSCI, V17, P5281; Esposito D, 2001, J BIOL CHEM, V276, P32687, DOI 10.1074/jbc.M011674200; Frade JM, 1998, BIOESSAYS, V20, P137, DOI 10.1002/(SICI)1521-1878(199802)20:2<137::AID-BIES6>3.0.CO;2-Q; Gentry JJ, 2000, J BIOL CHEM, V275, P7558, DOI 10.1074/jbc.275.11.7558; Hapner SJ, 1998, DEV BIOL, V201, P90, DOI 10.1006/dbio.1998.8970; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; Hirata H, 2001, GLIA, V36, P245, DOI 10.1002/glia.1113; Ito H, 2003, J NEUROSCI RES, V72, P211, DOI 10.1002/jnr.10564; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; Kramer K, 1997, EUR J CANCER, V33, P2090, DOI 10.1016/S0959-8049(97)00210-4; Kuner P, 1998, J NEUROSCI RES, V54, P465, DOI 10.1002/(SICI)1097-4547(19981115)54:4<465::AID-JNR4>3.0.CO;2-T; Kuner P, 1998, J NEUROSCI RES, V54, P798, DOI 10.1002/(SICI)1097-4547(19981215)54:6<798::AID-JNR7>3.3.CO;2-K; Lachyankar MB, 2003, J NEUROSCI RES, V71, P157, DOI 10.1002/jnr.10480; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; MacDonald JIS, 1996, MOL CELL NEUROSCI, V7, P371, DOI 10.1006/mcne.1996.0027; MacPhee IJ, 1997, J BIOL CHEM, V272, P23547, DOI 10.1074/jbc.272.38.23547; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; Maliartchouk S, 1997, J NEUROSCI, V17, P6031; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Postigo A, 2002, GENE DEV, V16, P633, DOI 10.1101/gad.217902; Rabizadeh S, 1999, CELL DEATH DIFFER, V6, P1222, DOI 10.1038/sj.cdd.4400614; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Roux PP, 2001, J BIOL CHEM, V276, P23097, DOI 10.1074/jbc.M011520200; Saragovi HU, 1998, J BIOL CHEM, V273, P34933, DOI 10.1074/jbc.273.52.34933; Sarmiere PD, 2001, MOL CELL NEUROSCI, V18, P320, DOI 10.1006/mcne.2001.1021; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Urdiales JL, 1998, J NEUROSCI, V18, P6767; Vesa J, 2000, J BIOL CHEM, V275, P24414, DOI 10.1074/jbc.M001641200; Yamashiro DJ, 1996, ONCOGENE, V12, P37; Yamashita T, 2002, J CELL BIOL, V157, P565, DOI 10.1083/jcb.200202010; Yan CH, 2002, MOL PHARMACOL, V61, P710, DOI 10.1124/mol.61.4.710; Zaccaro MC, 2001, J BIOL CHEM, V276, P31023, DOI 10.1074/jbc.M104630200	46	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5677	5685		10.1038/sj.onc.1206864	http://dx.doi.org/10.1038/sj.onc.1206864			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944916				2022-12-17	WOS:000184865900017
J	Tashiro, E; Minato, Y; Maruki, H; Asagiri, M; Imoto, M				Tashiro, E; Minato, Y; Maruki, H; Asagiri, M; Imoto, M			Regulation of FGF receptor-2 expression by transcription factor E2F-1	ONCOGENE			English	Article						FGFR-2; cell cycle; promoter; transcription; E2F-1; pRB	FIBROBLAST GROWTH-FACTORS; CYCLIN-E GENE; RETINOBLASTOMA PROTEIN; PROMOTER; RECEPTOR; FAMILY; PRB; TRANSACTIVATION; BINDING; MOUSE	Fibroblast growth factors (FGF) and their receptors play an important role in cell proliferation, angiogenesis and embryonal development. In this study, we show that expression of the FGF receptor-2 (FGFR-2) protein is induced in the mid-to-late G1 phase of the cell cycle in serum-starved mouse NIH3T3 cells released from starvation. Transcription of mouse FGFR-2 was activated by E2F-1. Analysis of various mouse FGFR-2 promoter mutant constructs showed that a sequence located +57/+64 downstream of the transcriptional initiation site, related to the consensus E2F-responsive sequence, is necessary for the activation. The promoter activity of the mouse FGFR-2 gene is also positively regulated by E2F-2 and E2F-3, but not by E2F-4 and E2F-5. Moreover, the E2F-1-induced activation of mouse FGFR-2 gene transcription is suppressed by pRB. Taken together, the results demonstrate that FGFR-2 is a new class of targets for E2F, and expression of mouse FGFR-2 in mid-to-late G1 phase would be mediated, at least in part, by the activation of a pRB/E2F pathway.	Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Yokohama, Kanagawa 2238522, Japan	Keio University	Imoto, M (corresponding author), Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Yokohama, Kanagawa 2238522, Japan.			Tashiro, Etsu/0000-0003-4533-623X				AVIVI A, 1992, ONCOGENE, V7, P1957; Black AR, 1999, GENE, V237, P281, DOI 10.1016/S0378-1119(99)00305-4; Botz J, 1996, MOL CELL BIOL, V16, P3401; DEGREGORI J, 1997, P NATL ACAD SCI USA, V94, P2443; Geng Y, 1996, ONCOGENE, V12, P1173; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Ricol D, 1999, ONCOGENE, V18, P7234, DOI 10.1038/sj.onc.1203186; STARK KL, 1991, DEVELOPMENT, V113, P641; Takahashi Y, 2000, GENE DEV, V14, P804; Tashiro E, 2003, CANCER RES, V63, P424; Yamasaki L, 1998, Results Probl Cell Differ, V22, P199; ZHANG YH, 1995, ONCOGENE, V10, P2085	23	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5630	5635		10.1038/sj.onc.1206636	http://dx.doi.org/10.1038/sj.onc.1206636			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944911				2022-12-17	WOS:000184865900012
J	Hollander, MC; Poola-Kella, S; Fornace, AJ				Hollander, MC; Poola-Kella, S; Fornace, AJ			Gadd34 functional domains involved in growth suppression and apoptosis	ONCOGENE			English	Article						Gadd34; PEG-3; apoptosis	DAMAGE-INDUCIBLE GENE; DNA-DAMAGE; PROTEIN GADD34; ARREST; INTERACTS; SEQUENCE; SIGNALS; PEG-3; CELLS	Gadd34 (also known as MyD116) was originally described as a growth arrest and DNA damage-inducible gene. Increased expression of Gadd34 was subsequently found to correlate with apoptosis, and forced overexpression of the protein leads to apoptosis. Gadd34 protein modulates protein phosphatase type 1 activity through both direct binding to the protein, as well as through binding to other proteins that also modulate phosphatase activity. In addition, Gadd34 has a region of homology with the herpes simplex virus type 1 ICP34.5 protein that is involved in the prevention of apoptosis in infected cells. Recently it was reported that a novel rat Gadd34-related gene, PEG-3, was upregulated in transformed cells, and that forced expression of this gene led to increased tumorigenic potential of cells implanted into nude mice and increased angiogenesis of these tumors. We have found, however, that PEG-3 does not exist in normal rat cells, which have a single diploid complement of Gadd34. Sequence analysis of the rat Gadd34 gene and comparison with PEG-3 indicates that PEG-3 is most likely a mutant of Gadd34 that perhaps arose as a result of transformation. This finding suggests that truncated Gadd34 may interfere with normal Gadd34 function in transfected cells. However, human Gadd34 lacking the viral homology domain does not interfere with normal Gadd34-induced apoptosis in cultured cells. This suggests that viral similarity sequences may be required for Gadd34-mediated functions other than apoptosis.	NCI, Basic Res Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hollander, MC (corresponding author), NCI, Basic Res Lab, NIH, Bldg 37,Room 6144, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				Adler HT, 1999, MOL CELL BIOL, V19, P7050; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Grishin AV, 2001, P NATL ACAD SCI USA, V98, P10172, DOI 10.1073/pnas.191130798; Hasegawa T, 2000, J CELL BIOCHEM, V77, P596, DOI 10.1002/(SICI)1097-4644(20000615)77:4<596::AID-JCB7>3.0.CO;2-K; Hasegawa T, 1999, BIOCHEM BIOPH RES CO, V256, P249, DOI 10.1006/bbrc.1999.0275; Hasegawa T, 1999, BBA-GEN SUBJECTS, V1428, P161, DOI 10.1016/S0304-4165(99)00060-4; Hasegawa T, 2000, BIOCHEM BIOPH RES CO, V267, P593, DOI 10.1006/bbrc.1999.1991; Hasegawa T, 2000, BIOCHEM J, V352, P795, DOI 10.1042/0264-6021:3520795; He B, 1996, J VIROL, V70, P84, DOI 10.1128/JVI.70.1.84-90.1996; Hollander MC, 2001, CANCER RES, V61, P2487; Hollander MC, 2001, INT J CANCER, V96, P22, DOI 10.1002/1097-0215(20010220)96:1<22::AID-IJC3>3.0.CO;2-K; Hollander MC, 1997, J BIOL CHEM, V272, P13731, DOI 10.1074/jbc.272.21.13731; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Park JS, 2001, ONCOGENE, V20, P3266, DOI 10.1038/sj.onc.1204258; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; WU DY, 2002, J BIOL CHEM	20	33	39	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3827	3832		10.1038/sj.onc.1206567	http://dx.doi.org/10.1038/sj.onc.1206567			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813455				2022-12-17	WOS:000183612000001
J	Udtha, M; Lee, SJ; Alam, R; Coombes, K; Huff, V				Udtha, M; Lee, SJ; Alam, R; Coombes, K; Huff, V			Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors	ONCOGENE			English	Article						WT1; c-MYC; Wilms' tumor; cDNA microarray; smooth t-test	SUPPRESSOR GENE WT1; GROWTH-FACTOR; BETA-CATENIN; KIDNEY DEVELOPMENT; TRANSGENIC MICE; PRODUCT; REPRESSION; PROMOTER; RECEPTOR; PROTOONCOGENES	The Wilms' tumor suppressor gene, WT1, functions as a transcriptional regulator that represses or activates the expression of a variety of putative target genes. However, it is not clear which genes are the biological targets of WT1, nor which cellular pathway(s) is critically altered in tumors as a result of WT1 mutation. To investigate in Vivo the role of WT1 as a transcription factor in Wilms' tumors, we used cDNA microarrays to compare the expression of putative WT1 target genes in a set of 15 primary Wilmstumors carrying WT1-inactivating mutations versus a set of 16 tumors with no WT1 mutations. We hypothesized that the expression of direct downstream targets of WT1 that are relevant to tumor development would differ between these two genetically distinct sets of tumors. Using the Atlas Human Cancer 1.2 cDNA arrays to quantitate gene expression in the 31 tumors, we found that the expression of one WT1 putative target gene, c-MYC, statistically significantly differed between the two sets of tumors and was upregulated in WT1-mutant tumors. This increase of relative gene expression for c-MYC was confirmed using real-time reverse transcription-polymerase chain reaction. The differential expression of another putative target gene, EGR1, approached significance and was also upregulated in WT1-mutant tumors. These data, in addition to the coexpression of c-MYC and WT1 in embryonic renal mesenchyme, strongly suggest that c-MYC is a biologically relevant target of WT1 in Wilmstumors.	MD Anderson Canc Ctr, Dept Mol Genet Canc Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Huff, V (corresponding author), MD Anderson Canc Ctr, Dept Mol Genet Canc Genet, Box 11,1515 Holcombe Blvd, Houston, TX 77030 USA.			Coombes, Kevin/0000-0002-7630-2123	NCI NIH HHS [CA16672, CA78257, CA34936] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA034936, R01CA078257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baggerly KA, 2001, J COMPUT BIOL, V8, P639, DOI 10.1089/106652701753307539; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Coombes KR, 2002, J COMPUT BIOL, V9, P655, DOI 10.1089/106652702760277372; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; Englert C, 1997, CANCER RES, V57, P1429; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; Geick A, 2001, TRANSGENIC RES, V10, P501, DOI 10.1023/A:1013085228119; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1994, HUM MUTAT, V3, P212, DOI 10.1002/humu.1380030307; GOODYER P, 1995, ONCOGENE, V10, P1125; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEWITT SM, 1995, CANCER RES, V55, P5386; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; Huff V, 1998, AM J MED GENET, V79, P260, DOI 10.1002/(SICI)1096-8628(19981002)79:4<260::AID-AJMG6>3.0.CO;2-Q; Koesters R, 1999, CANCER RES, V59, P3880; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Maiti S, 2000, CANCER RES, V60, P6288; MCCANN S, 1995, J BIOL CHEM, V270, P23785, DOI 10.1074/jbc.270.40.23785; MUGRAUER G, 1991, J CELL BIOL, V112, P13, DOI 10.1083/jcb.112.1.13; NISEN PD, 1986, CANCER RES, V46, P6217; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Stanhope-Baker P, 2000, J BIOL CHEM, V275, P38139, DOI 10.1074/jbc.M004901200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TRUDEL M, 1991, KIDNEY INT, V39, P665, DOI 10.1038/ki.1991.80; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; WANG ZY, 1995, ONCOGENE, V10, P415; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Zhang XH, 1999, ANTICANCER RES, V19, P1641	36	33	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3821	3826		10.1038/sj.onc.1206597	http://dx.doi.org/10.1038/sj.onc.1206597			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802290				2022-12-17	WOS:000183551000017
J	Mikola, M; Kero, J; Nilson, JH; Keri, RA; Poutanen, M; Huhtaniemi, I				Mikola, M; Kero, J; Nilson, JH; Keri, RA; Poutanen, M; Huhtaniemi, I			High levels of luteinizing hormone analog stimulate gonadal and adrenal tumorigenesis in mice transgenic for the mouse inhibin-alpha-subunit promoter Simian virus 40 T-antigen fusion gene	ONCOGENE			English	Article						LH; adrenal and gonadal tumorigenesis; inhibin	IMMUNOREACTIVE INHIBIN; POSTMENOPAUSAL WOMEN; ACTIVATING MUTATION; OVARIAN-TUMORS; SERUM INHIBIN; CELL TUMORS; GONADOTROPIN; RECEPTOR; PROTEIN; CANCER	Transgenic (TG) mice expressing the Simian virus 40 T-antigen under the control of the murine inhibin-a promoter (Inhalpha/Tag) develop granulosa and Leydig cell tumors at the age of 5-6 months, with 100% penetrance. When these mice are gonadectomized, they develop adrenocortical tumors. Suppression of gonadotropin secretion inhibits the tumorigenesis in the gonads of intact animals and in the adrenals after gonadectomy. To study further the role of luteinizing hormone (LH) in gonadal and adrenal tumorigenesis, a double TG mouse model was generated by crossing the Inha/Tag mice with mice producing constitutively elevated levels of LH (bLHbeta-CTP mice). Our results show that in double TG mice (bLHbeta-CTP/Inhalpha/Tag), gonadal tumorigenesis starts earlier and progresses faster than in Inha/Tag mice. Both ovarian and testicular tumors were histologically comparable with the tumors found in Inhalpha/Tag mice. In addition, adrenal tumorigenesis was found in intact double TG females, but not in Inha/Tag females. Inhibin-a and LH receptor (LHR) were highly expressed in tumorigenic gonadal tissues, and the elevated LH levels were shown to be associated with ectopic LHR and high inhibin-a expression in the female adrenals. We conclude that in the Inhalpha/Tag tumor mouse model, elevated LH levels act as a tumor promoter, advancing gonadal and adrenal tumorigenesis.	Univ Turku, Dept Physiol, FIN-20520 Turku, Finland; Univ Turku, Dept Pediat, FIN-20520 Turku, Finland; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	University of Turku; University of Turku; Case Western Reserve University	Huhtaniemi, I (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Inst Reprod & Dev Biol, Du Cane Rd, London W12 0NN, England.	ilpo.huhtaniemi@ic.ac.uk	Keri, Ruth/ABF-2209-2021; kero, jukka/G-3448-2014; Poutanen, Matti/I-1700-2018	Keri, Ruth/0000-0002-1640-3088; kero, jukka/0000-0001-8767-7222; Poutanen, Matti/0000-0002-8953-1734; Ahtiainen, Maarit/0000-0002-3263-2307				ADELSON MD, 1993, CLIN OBSTET GYNECOL, V36, P690, DOI 10.1097/00003081-199309000-00025; Ala-Fossi SL, 2000, EUR J GYNAECOL ONCOL, V21, P187; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEJONG FH, 1990, J STEROID BIOCHEM, V37, P863, DOI 10.1016/0960-0760(90)90433-L; DING YQ, 1989, ACTA ENDOCRINOL-COP, V121, P46, DOI 10.1530/acta.0.1210046; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; GAYTAN F, 1994, J ENDOCRINOL, V142, P527, DOI 10.1677/joe.0.1420527; Gocze PM, 1997, GYNECOL ONCOL, V65, P143, DOI 10.1006/gyno.1997.4635; HEALY DL, 1993, NEW ENGL J MED, V329, P1539, DOI 10.1056/NEJM199311183292104; Herath CB, 2001, J ANDROL, V22, P838; HOGAN B, 1994, MANIPULATING MOUSE E; HUHTANIEMI I, 1994, EUR J ENDOCRINOL, V130, P25, DOI 10.1530/eje.0.1300025; HUHTANIEMI I, 1985, J CLIN ENDOCR METAB, V61, P698, DOI 10.1210/jcem-61-4-698; HUHTANIEMI IT, 1981, ENDOCRINOLOGY, V109, P588, DOI 10.1210/endo-109-2-588; Iczkowski KA, 1998, MODERN PATHOL, V11, P774; Illingworth PJ, 1996, J CLIN ENDOCR METAB, V81, P1321, DOI 10.1210/jc.81.4.1321; Kananen K, 1997, ENDOCRINOLOGY, V138, P3521, DOI 10.1210/en.138.8.3521; Kananen K, 1996, MOL CELL ENDOCRINOL, V119, P135, DOI 10.1016/0303-7207(96)03802-6; KANANEN K, 1995, MOL ENDOCRINOL, V9, P616, DOI 10.1210/me.9.5.616; Kananen K, 1996, MOL ENDOCRINOL, V10, P1667, DOI 10.1210/me.10.12.1667; Keri RA, 2000, P NATL ACAD SCI USA, V97, P383, DOI 10.1073/pnas.97.1.383; Kero J, 2000, J CLIN INVEST, V105, P633, DOI 10.1172/JCI7716; Kuhn B, 1999, BIOCHEMISTRY-US, V38, P12490, DOI 10.1021/bi990755m; Kumar TR, 1999, MOL ENDOCRINOL, V13, P851, DOI 10.1210/me.13.6.851; Kumar TR, 1996, ENDOCRINOLOGY, V137, P4210, DOI 10.1210/en.137.10.4210; LambertMesserlian GM, 1997, GYNECOL ONCOL, V65, P512, DOI 10.1006/gyno.1997.4719; LAPPOHN RE, 1989, NEW ENGL J MED, V321, P790, DOI 10.1056/NEJM198909213211204; Liu G, 1999, NEW ENGL J MED, V341, P1731, DOI 10.1056/NEJM199912023412304; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MATZUK MM, 1994, P NATL ACAD SCI USA, V91, P8817, DOI 10.1073/pnas.91.19.8817; Matzuk MM, 1996, RECENT PROG HORM RES, V51, P123; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; Mikola MK, 2001, J ENDOCRINOL, V170, P79, DOI 10.1677/joe.0.1700079; Mukherjee A, 1996, ENDOCRINOLOGY, V137, P3234, DOI 10.1210/en.137.8.3234; NEUMANN F, 1991, MUTAT RES, V248, P341, DOI 10.1016/0027-5107(91)90067-X; NISWENDER GD, 1968, P SOC EXP BIOL MED, V128, P807; Owens GE, 2002, MOL ENDOCRINOL, V16, P1230, DOI 10.1210/me.16.6.1230; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PEI L, 1991, MOL ENDOCRINOL, V5, P521, DOI 10.1210/mend-5-4-521; Rahman NA, 2001, BIOL REPROD, V64, P1122, DOI 10.1095/biolreprod64.4.1122; Rilianawati, 2000, J ENDOCRINOL, V166, P77, DOI 10.1677/joe.0.1660077; Rilianawati, 1998, MOL ENDOCRINOL, V12, P801, DOI 10.1210/me.12.6.801; RISMA KA, 1995, P NATL ACAD SCI USA, V92, P1322, DOI 10.1073/pnas.92.5.1322; Rulli SB, 2002, ENDOCRINOLOGY, V143, P4084, DOI 10.1210/en.2002-220490; SIMON WE, 1983, J NATL CANCER I, V70, P839; Toppari J, 1998, APMIS, V106, P101, DOI 10.1111/j.1699-0463.1998.tb01325.x; van Casteren JIJ, 2000, BIOL REPROD, V62, P886, DOI 10.1095/biolreprod62.4.886; VUORENTO T, 1989, SCAND J CLIN LAB INV, V49, P395, DOI 10.3109/00365518909089113; WILLEMSEN W, 1993, LANCET, V341, P986, DOI 10.1016/0140-6736(93)91071-S; WIMALASENA J, 1992, GYNECOL ONCOL, V46, P345, DOI 10.1016/0090-8258(92)90230-G; Wise PM, 1996, SCIENCE, V273, P67, DOI 10.1126/science.273.5271.67	52	33	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3269	3278		10.1038/sj.onc.1206518	http://dx.doi.org/10.1038/sj.onc.1206518			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761497				2022-12-17	WOS:000183040000009
J	Kinoshita, I; Leaner, V; Katabami, M; Manzano, RG; Dent, P; Sabichi, A; Birrer, MJ				Kinoshita, I; Leaner, V; Katabami, M; Manzano, RG; Dent, P; Sabichi, A; Birrer, MJ			Identification of cJun-responsive genes in Rat-1a cells using multiple techniques: increased expression of stathmin is necessary for cJun-mediated anchorage-independent growth	ONCOGENE			English	Article						c-jun; transformation; microarray; AP-1	LEUKOCYTE INTEGRIN GENE; V-JUN; C-JUN; TRANSCRIPTION FACTOR; TISSUE INHIBITOR; CANCER-CELLS; PHOSPHOPROTEIN STATHMIN; SIGNAL TRANSDUCTION; GALECTIN-3 GENE; DOWN-REGULATION	cJun is a major component of the transcription factor AP-1 and mediates a diverse set of biologic properties including proliferation, differentiation, and apoptosis. To identify cJun-responsive genes, we inducibly expressed cJun in Rat-1a cells and observed two distinct phenotypes: changes in cellular morphology with adherent growth and anchorage-independent growth. The biologic effects of cJun were entirely reversible demonstrating that they require the continued presence of cJun. To determine the genes, which mediate the biologic effects of cJun, we employed multiple methods including differential gene analysis, suppression subtractive hybridization, and cDNA microarrays. We identified 38 cJun-responsive genes including three uncharacterized genes under adherent and/or nonadherent conditions. Half of the known 36 genes were cytoskeleton- and adhesion-related genes, suggesting a major role of cJun in the regulation of the genes related to cell morphology. As proof of the principle that this approach could identify genes whose upregulation was necessary for nonadherent growth, we investigated one gene, stathmin whose upregulation by cJun was observed only under these conditions. Although overexpression of stathmin did not result in nonadherent growth, inhibition of stathmin protein expression by antisense oligonucleotides in cJun-induced Rat-1a cells prevented nonadherent growth. These results suggest that stathmin plays an essential role in anchorage-independent growth by cJun and may be a potential target for specific inhibitors for AP-1-dependent processes involved in carcinogenesis.	NCI, Cell & Canc Biol Dept, Ctr Canc Res, Rockville, MD 20850 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Virginia Commonwealth University	Birrer, MJ (corresponding author), NCI, Cell & Canc Biol Dept, Ctr Canc Res, Rockville, MD 20850 USA.	birrerm@bprb.nci.nih.gov		Gonzalez Manzano, Ramon/0000-0003-2266-6965				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Arthur JSC, 1998, BBA-PROTEIN STRUCT M, V1388, P247, DOI 10.1016/S0167-4838(98)00166-6; Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Bader AG, 2000, VIROLOGY, V270, P98, DOI 10.1006/viro.2000.0222; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Balogh A, 1996, EXP CELL RES, V224, P8, DOI 10.1006/excr.1996.0106; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERGERS G, 1994, EMBO J, V13, P1176, DOI 10.1002/j.1460-2075.1994.tb06367.x; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRASELMANN S, 1992, J CELL SCI, P97; BRATTSAND G, 1993, LEUKEMIA, V7, P569; BROWN PH, 1993, ONCOGENE, V8, P877; CERVELLA P, 1993, J BIOL CHEM, V268, P5148; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000; COOPER HL, 1991, J IMMUNOL, V146, P3689; COOPER HL, 1990, J IMMUNOL, V145, P1205; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DiPaolo G, 1996, J CELL BIOL, V133, P1383, DOI 10.1083/jcb.133.6.1383; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DOYE V, 1992, DIFFERENTIATION, V50, P89, DOI 10.1111/j.1432-0436.1992.tb00489.x; Fey MF, 1996, BBA-GENE STRUCT EXPR, V1306, P160, DOI 10.1016/0167-4781(95)00238-3; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; Gaudin JC, 1997, GLYCOBIOLOGY, V7, P1089, DOI 10.1093/glycob/7.8.1089; GHOSH PK, 1993, ONCOGENE, V8, P2869; Goller ME, 1998, ONCOGENE, V16, P2945, DOI 10.1038/sj.onc.1201819; GSCHWENDT M, 1989, FEBS LETT, V257, P357, DOI 10.1016/0014-5793(89)81571-6; Hadman M, 1998, ONCOGENE, V16, P655, DOI 10.1038/sj.onc.1201574; HAILAT N, 1990, ONCOGENE, V5, P1615; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Hosoya H, 1996, CELL STRUCT FUNCT, V21, P237, DOI 10.1247/csf.21.237; Howell B, 1999, J CELL SCI, V112, P3713; Jaworski J, 1999, J BIOL CHEM, V274, P28106, DOI 10.1074/jbc.274.40.28106; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; Kadrofske MM, 1998, ARCH BIOCHEM BIOPHYS, V349, P7, DOI 10.1006/abbi.1997.0447; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KATAI H, 1992, MOL CELL BIOCHEM, V118, P119; KOLCH W, 1993, ONCOGENE, V8, P361; KOPPEL J, 1993, FEBS LETT, V331, P65, DOI 10.1016/0014-5793(93)80298-9; Koski C, 1999, J BIOL CHEM, V274, P32619, DOI 10.1074/jbc.274.46.32619; Larsson N, 1999, J CELL BIOL, V146, P1289, DOI 10.1083/jcb.146.6.1289; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; LopezRodriguez C, 1996, J IMMUNOL, V156, P3780; Lorenzi MV, 1999, ONCOGENE, V18, P4742, DOI 10.1038/sj.onc.1202851; LUO XN, 1994, J BIOL CHEM, V269, P10312; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MAZZONE A, 1995, HAEMATOLOGICA, V80, P161; MELHEM RF, 1991, BIOCHEM BIOPH RES CO, V179, P1649, DOI 10.1016/0006-291X(91)91764-4; MELHEM RF, 1991, J BIOL CHEM, V266, P17747; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MISTRY S, 1995, CELL MOL BIOL RES, V41, P103; Mistry SJ, 1999, ANTICANCER RES, V19, P573; Morgan RO, 1995, J MOL EVOL, V41, P979; Noti JD, 1996, MOL IMMUNOL, V33, P115, DOI 10.1016/0161-5890(95)00140-9; NYLANDER K, 1995, HISTOCHEM J, V27, P155; OSEIFRIMPONG J, 1994, MOL CARCINOGEN, V10, P72, DOI 10.1002/mc.2940100204; PHILIPS N, 1995, J BIOL CHEM, V270, P9313, DOI 10.1074/jbc.270.16.9313; PRIETO J, 1994, CELL IMMUNOL, V156, P191, DOI 10.1006/cimm.1994.1164; RAPP UR, 1994, ONCOGENE, V9, P3493; Rodier A, 1999, EXP CELL RES, V249, P337, DOI 10.1006/excr.1999.4486; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Sabichi AL, 1998, J NATL CANCER I, V90, P597, DOI 10.1093/jnci/90.8.597; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SAWADA R, 1993, J BIOL CHEM, V268, P9014; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHUBART UK, 1992, DIFFERENTIATION, V51, P21, DOI 10.1111/j.1432-0436.1992.tb00676.x; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SOBEL A, 1989, J BIOL CHEM, V264, P3765; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Solito E, 1998, CELL GROWTH DIFFER, V9, P327; Spink BC, 1998, J CELL BIOCHEM, V70, P289, DOI 10.1002/(SICI)1097-4644(19980901)70:3<289::AID-JCB1>3.3.CO;2-H; Szabo E, 1998, CELL GROWTH DIFFER, V9, P475; Tang WM, 1996, J BIOL CHEM, V271, P28324, DOI 10.1074/jbc.271.45.28324; Tiwari B, 1998, DNA CELL BIOL, V17, P957, DOI 10.1089/dna.1998.17.957; Watsuji T, 1997, BIOCHEM BIOPH RES CO, V234, P769, DOI 10.1006/bbrc.1997.6705; Weinstein J, 1998, MOL GENET METAB, V64, P52, DOI 10.1006/mgme.1998.2698; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Xie JP, 1998, GENOMICS, V54, P338, DOI 10.1006/geno.1998.5583; Yet SF, 1998, J BIOL CHEM, V273, P10530, DOI 10.1074/jbc.273.17.10530	94	33	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2003	22	18					2710	2722		10.1038/sj.onc.1206371	http://dx.doi.org/10.1038/sj.onc.1206371			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743595				2022-12-17	WOS:000182569300002
J	van Golen, CM; Soules, ME; Grauman, AR; Feldman, EL				van Golen, CM; Soules, ME; Grauman, AR; Feldman, EL			N-Myc overexpression leads to decreased beta 1 integrin expression and increased apoptosis in human neuroblastoma cells	ONCOGENE			English	Article						Myc; neuroblastoma; apoptosis; integrin; adhesion	GROWTH-FACTOR-I; CHEMOTHERAPY-INDUCED APOPTOSIS; ADHESION CHARACTERISTICS; RECEPTOR ACTIVATION; MEDIATED SURVIVAL; GENE-EXPRESSION; C-MYC; BCL-2; AMPLIFICATION; DIFFERENTIATION	Neuroblastoma is a childhood tumor thought to arise through improper differentiation of neural crest cells. Increased N-Myc expression in neuroblastoma indicates highly malignant disease and poor patient prognosis. N-myc enhances cell growth, insulin-like growth factor type I receptor (IGF-IR) expression, and tumorigenicity in combination with Bcl-2. Despite these effects, N-Myc overexpression in SHEP neuroblastoma cells (SHEP/N-Myc cells) increases serum-withdrawal and mannitol-induced apoptosis. Although we have previously shown a protective effect of IGF-I in SHEP cells, in SHEP/N-Myc cells IGF-I rescue from mannitol-induced apoptosis is prevented. N-Myc overexpression has little effect on IGF-IR signaling pathways, but results in increased Akt phosphorylation when Bcl-2 is coexpressed. A loss of integrin-mediated adhesion promotes apoptosis in many systems. SHEP/N-Myc cells have dramatically less beta1 integrin expression than control cells, consistent with previous reports. beta1 integrin expression is decreased in more tumorigenic neuroblastoma cells lines, including IMR32 and SH-SY5Y cells. Reintroduction of beta1 integrin into the N-Myc-overexpressing cells prevents mannitol-mediated apoptosis. We speculate that N-Myc repression of beta1 integrin expression leads to a less differentiated phenotype, resulting in increased growth and tumorigenesis if properly supported or apoptosis if deprived of growth sustaining molecules.	Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Feldman, EL (corresponding author), Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA.	efeldman@umich.edu		Feldman, Eva/0000-0002-9162-2694	NCI NIH HHS [CA46592] Funding Source: Medline; NIAMS NIH HHS [AR20557] Funding Source: Medline; NINDS NIH HHS [R01 NS36778, T32 NS07222] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036778, T32NS007222] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amendola R, 1997, JNCI-J NATL CANCER I, V89, P1300, DOI 10.1093/jnci/89.17.1300; Amendola R, 2001, MED PEDIATR ONCOL, V36, P93, DOI 10.1002/1096-911X(20010101)36:1<93::AID-MPO1021>3.0.CO;2-3; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Bonfoco E, 2000, NEUROSCIENCE, V101, P1145, DOI 10.1016/S0306-4522(00)00429-2; Bordow SB, 1998, J CLIN ONCOL, V16, P3286, DOI 10.1200/JCO.1998.16.10.3286; Bozzo C, 1997, EXP CELL RES, V237, P326, DOI 10.1006/excr.1997.3777; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CASTLE VP, 1993, AM J PATHOL, V143, P1543; Castleberry RP, 1997, PEDIATR CLIN N AM, V44, P919, DOI 10.1016/S0031-3955(05)70537-X; Chambery D, 1999, CANCER RES, V59, P2898; Cheng HL, 2000, J BIOL CHEM, V275, P27197; Cianfarani S, 1997, EUR J PEDIATR, V156, P256, DOI 10.1007/s004310050595; Corvi R, 1997, J NEURO-ONCOL, V31, P25, DOI 10.1023/A:1005721027709; Dabrowska M, 2001, GYNECOL OBSTET INVES, V51, P248, DOI 10.1159/000058059; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; DOLE M, 1994, CANCER RES, V54, P3253; DOLE MG, 1995, CANCER RES, V55, P2576; FAVROT MC, 1991, INT J CANCER, V49, P347, DOI 10.1002/ijc.2910490306; FLICKINGER KS, 1994, EXP CELL RES, V213, P156, DOI 10.1006/excr.1994.1185; Fulda S, 2000, MED PEDIATR ONCOL, V35, P582, DOI 10.1002/1096-911X(20001201)35:6<582::AID-MPO19>3.0.CO;2-2; Galderisi U, 1999, J CELL BIOCHEM, V73, P97, DOI 10.1002/(SICI)1097-4644(19990401)73:1<97::AID-JCB11>3.0.CO;2-M; Gelbard HA, 1997, PEDIATR NEUROL, V16, P93, DOI 10.1016/S0887-8994(96)00258-5; George RE, 2001, MED PEDIATR ONCOL, V36, P169, DOI 10.1002/1096-911X(20010101)36:1<169::AID-MPO1041>3.0.CO;2-U; Gladson CL, 1996, AM J PATHOL, V148, P1423; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gross N, 2000, EXP CELL RES, V260, P396, DOI 10.1006/excr.2000.5007; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; HOEHNER JC, 1995, INT J CANCER, V62, P19, DOI 10.1002/ijc.2910620106; IKEDA H, 1995, J PEDIATR SURG, V30, P805, DOI 10.1016/0022-3468(95)90752-1; Jasty R, 2001, NEOPLASIA, V3, P304, DOI 10.1038/sj.neo.7900171; Judware R, 1997, ONCOGENE, V14, P1341, DOI 10.1038/sj.onc.1200955; Judware R, 1995, ONCOGENE, V11, P2599; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; KOIZUMI H, 1995, VIRCHOWS ARCH, V427, P167; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Leventhal Phillip S., 1999, V17, P425; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; LEVENTHAL PS, 1995, EXP CELL RES, V221, P179, DOI 10.1006/excr.1995.1365; Liu XD, 1998, CANCER RES, V58, P5432; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; MARTIN DM, 1992, MOL BRAIN RES, V15, P241, DOI 10.1016/0169-328X(92)90114-Q; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; Matthews CC, 1997, NEUROSCIENCE, V79, P525, DOI 10.1016/S0306-4522(96)00611-2; Mejia MC, 1998, ANTICANCER RES, V18, P801; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; Miller SE, 2001, CELL BIOL INT, V25, P61, DOI 10.1006/cbir.2000.0678; Mooney A, 1999, AM J PATHOL, V155, P599, DOI 10.1016/S0002-9440(10)65155-3; PHILIP T, 1992, AM J PEDIAT HEMATOL, V14, P97; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; REED JC, 1991, CANCER RES, V51, P6529; Rohn JL, 1998, ONCOGENE, V17, P2811, DOI 10.1038/sj.onc.1202393; ROSSINO P, 1991, CELL REGUL, V2, P1021, DOI 10.1091/mbc.2.12.1021; Rossler J, 2001, BIOCHEM BIOPH RES CO, V281, P272, DOI 10.1006/bbrc.2001.4342; Rozzo C, 1997, INT J CANCER, V70, P688, DOI 10.1002/(SICI)1097-0215(19970317)70:6<688::AID-IJC11>3.3.CO;2-V; ROZZO C, 1993, FEBS LETT, V332, P263, DOI 10.1016/0014-5793(93)80646-C; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; Shakibaei M, 1999, BIOCHEM J, V342, P615, DOI 10.1042/0264-6021:3420615; Singleton JR, 1996, CANCER RES, V56, P4522; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Stallmach A, 2001, EUR J IMMUNOL, V31, P1228, DOI 10.1002/1521-4141(200104)31:4<1228::AID-IMMU1228>3.0.CO;2-K; SULLIVAN KA, 1995, AM J PATHOL, V147, P1790; TANABE M, 1995, MED PEDIATR ONCOL, V24, P292, DOI 10.1002/mpo.2950240505; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; van Golen CM, 2001, CELL GROWTH DIFFER, V12, P371; van Golen CM, 2000, CELL DEATH DIFFER, V7, P654, DOI 10.1038/sj.cdd.4400693; Van Golen CM, 2000, J CELL PHYSIOL, V182, P24, DOI 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6; Wewer UM, 1997, AM J PATHOL, V151, P1191	69	33	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2003	22	17					2664	2673		10.1038/sj.onc.1206362	http://dx.doi.org/10.1038/sj.onc.1206362			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730680				2022-12-17	WOS:000182569000014
J	Leu, TH; Maa, MC				Leu, TH; Maa, MC			Tyr-863 phosphorylation enhances focal adhesion kinase autophosphorylation at Tyr-397	ONCOGENE			English	Article						Src; FAK; tyrosine kinase; tyrosol phosphorylation	PROTEIN-TYROSINE KINASE; ACTIVATION LOOP PHOSPHORYLATION; MAP KINASE; IN-VIVO; BINDING; SITE; SRC; REQUIREMENT; ASSOCIATION; FIBRONECTIN	Tyr-397 phosphorylation is important for focal adhesion kinase (FAK)-mediated signalling. In vitro FAK immunocomplex kinase experiments demonstrated that both FAK Tyr-576/577 and Tyr-863 phosphorylation regulated FAK Tyr-397 phosphorylation. While the former increased the intermolecular transphosphorylation activity of FAK, the latter was crucial for its cis-phosphorylation. This observation was further supported by the reduced complex formation between Src and 3F-FAK (576F/577F/863F-FAK) as compared to that between Src and 576F/577F-FAK or Src and 863F-FAK. Regulation of cis- and transphosphorylation activities of FAK by such a differential tyrosyl phosphorylation mechanism is unprecedented. Furthermore, in fibronectin-stimulated cells, both Tyr-576/577 and Tyr-863 phosphorylation could enhance FAK Tyr-397 phosphorylation. This observation implies that integrin-mediated FAK Tyr-397 phosphorylation was also regulated through both FAK cis- and transphosphorylation mechanisms.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan; Chung Shan Med Univ, Inst Biochem, Taichung, Taiwan	National Cheng Kung University; Chung Shan Medical University	Leu, TH (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan.							ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Maa MC, 1998, BIOCHEM BIOPH RES CO, V251, P344, DOI 10.1006/bbrc.1998.9464; Maa MC, 1999, BBA-MOL CELL RES, V1450, P341, DOI 10.1016/S0167-4889(99)00069-5; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786	25	33	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					6992	7000		10.1038/sj.onc.1205904	http://dx.doi.org/10.1038/sj.onc.1205904			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370821				2022-12-17	WOS:000178424900002
J	Kostyniuk, CL; Dehm, SM; Batten, D; Bonham, K				Kostyniuk, CL; Dehm, SM; Batten, D; Bonham, K			The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases	ONCOGENE			English	Article						Src; transcription; historic deacetylase; butyrate; Trichostatin A	LARGE-BOWEL CANCER; CHAIN FATTY-ACIDS; ADENOCARCINOMA CELL-LINE; COLON-CANCER; SODIUM-BUTYRATE; C-SRC; TRICHOSTATIN-A; TRANSCRIPTIONAL ACTIVATION; DIETARY FIBER; BREAST-CANCER	Histone deacetylase inhibitors have generated keen interest as potential chemopreventive and chemotherapeutic agents due to their ability to induce cell cycle arrest, differentiation, and apoptosis in a diverse group of cancer derived cell lines. Activation of the 60 kDa nonreceptor tyrosine kinase, c-Src, has been a consistent finding in many tumors and tumor derived cell lines, and has been implicated in these same cellular processes. We have shown that the histone deacetylase inhibitors, sodium butyrate and Trichostatin A, repressed c-Src mRNA and protein expression in a dose-dependent manner in cell lines derived from cancers of the colon, breast;and liver. Our group has previously identified two distinct promoters that are responsible for SRC transcription, separated by a distance of approximately 1 kb. Sodium butyrate and Trichostatin A strongly inhibited activity of each of these highly disparate SRC promoters, demonstrating histone deacetylase inhibitors directly repress SRC transcription. This repression did not require protein neosynthesis and was not associated with a decrease in binding of protein factors essential for either promoter's activity. Our finding that sodium butyrate and Trichostatin A inhibit both SRC promoters suggest this oncogene may be a major target of these agents, and may explain in part their anti-cancer activity.	Saskatchewan Canc Agcy, Canc Res Unit, Hlth Res Div, Saskatoon, SK S7N 4H4, Canada; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan; University of Saskatchewan	Bonham, K (corresponding author), Saskatchewan Canc Agcy, Canc Res Unit, Hlth Res Div, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada.							ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bonham K, 2000, J BIOL CHEM, V275, P37604, DOI 10.1074/jbc.M004882200; BONHAM K, 1993, ONCOGENE, V8, P1973; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cuisset L, 1997, J BIOL CHEM, V272, P24148, DOI 10.1074/jbc.272.39.24148; DArgenio G, 1996, GASTROENTEROLOGY, V110, P1727, DOI 10.1053/gast.1996.v110.pm8964397; Dehm S, 2001, FEBS LETT, V487, P367, DOI 10.1016/S0014-5793(00)02354-1; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Espinos E, 1999, MOL CELL BIOL, V19, P3474; FOSS FM, 1989, ONCOGENE RES, V5, P13; GAMET L, 1992, INT J CANCER, V52, P286, DOI 10.1002/ijc.2910520222; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200; Hass R, 1997, GASTROENTEROLOGY, V112, P875, DOI 10.1053/gast.1997.v112.pm9041249; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Iacomino G, 2001, BIOCHEM BIOPH RES CO, V285, P1280, DOI 10.1006/bbrc.2001.5323; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Luciano L, 1996, CELL TISSUE RES, V286, P81, DOI 10.1007/s004410050677; Mandal M, 1996, CELL GROWTH DIFFER, V7, P311; Mariadason JM, 2000, CANCER RES, V60, P4561; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Marks PA, 2001, CLIN CANCER RES, V7, P759; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; MARUTA H, 1986, J CELL BIOL, V103, P571, DOI 10.1083/jcb.103.2.571; MCINTYRE A, 1993, GUT, V34, P386, DOI 10.1136/gut.34.3.386; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Rajala RVS, 2000, BIOCHEM BIOPH RES CO, V273, P1116, DOI 10.1006/bbrc.2000.3066; REDDY BS, 1995, CRIT REV FOOD SCI, V35, P175, DOI 10.1080/10408399509527698; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Ritchie S, 2000, J BIOL CHEM, V275, P847, DOI 10.1074/jbc.275.2.847; Schwartz B, 1998, MOL CELL BIOCHEM, V188, P21, DOI 10.1023/A:1006831330340; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; Singh B, 1997, CARCINOGENESIS, V18, P1265, DOI 10.1093/carcin/18.6.1265; SOULEIMANI A, 1993, FEBS LETT, V326, P45, DOI 10.1016/0014-5793(93)81758-R; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; Sowa Y, 1999, CANCER RES, V59, P4266; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; Suzuki T, 2000, INT J CANCER, V88, P992, DOI 10.1002/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9; Topping DL, 2001, PHYSIOL REV, V81, P1031, DOI 10.1152/physrev.2001.81.3.1031; TOSCANI A, 1988, ONCOGENE RES, V3, P223; TROCK B, 1990, JNCI-J NATL CANCER I, V82, P650, DOI 10.1093/jnci/82.8.650; VanLint C, 1996, GENE EXPRESSION, V5, P245; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; Vigushin DM, 2001, CLIN CANCER RES, V7, P971; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	55	33	34	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6340	6347		10.1038/sj.onc.1205787	http://dx.doi.org/10.1038/sj.onc.1205787			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214274				2022-12-17	WOS:000177829000010
J	Risk, JM; Evans, KE; Jones, J; Langan, JE; Rowbottom, L; McRonald, FE; Mills, HS; Ellis, A; Shaw, JM; Leigh, IM; Kelsell, DP; Field, JK				Risk, JM; Evans, KE; Jones, J; Langan, JE; Rowbottom, L; McRonald, FE; Mills, HS; Ellis, A; Shaw, JM; Leigh, IM; Kelsell, DP; Field, JK			Characterization of a 500 kb region on 17q25 and the exclusion of candidate genes as the familial Tylosis Oesophageal Cancer (TOC) locus	ONCOGENE			English	Article						oesophageal cancer; transcript map; tylosis	PALMOPLANTAR KERATODERMA; CHROMOSOME 17Q; N-ACETYLTRANSFERASE; HUMAN GENOME; ALLELIC LOSS; EXPRESSION; CARCINOMA; TUMORS; MAP; IDENTIFICATION	The locus for a syndrome of focal palmoplantar keratoderma (Tylosis) associated with squamous cell oesophageal cancer (TOC) has been mapped to chromosome 17q25, a region frequently deleted in sporadic squamous cell oesophageal tumours. Further haplotype analysis described here, based on revised maps of marker order, has reduced the TOC minimal region to a genetic interval of 2 cM limited by the microsatellite markers D17S785 and D17S751. Partial sequence data and complete physical maps estimate the actual size of this region to be only 0.5 Mb. This analysis allowed the exclusion of proposed candidate tumour suppressor genes including MLL septin-like fusion (MSF), survivin, and deleted in multiple human cancer (DMC1). Computer analysis of sequence data from the minimal region identified 13 candidate genes and the presence of 50-70 other 'gene fragments' as ESTs and/or predicted exons and genes. Ten of the characterized genes were assayed for mutations but no disease-specific alterations were identified in the coding and promoter sequences. This region of chromosome 17q25 is, therefore, relatively gene-rich, containing 13 known and possibly as many as 50 predicted genes. Further mutation analysis of these predicted genes, and others possibly residing in the region, is required in order to identify the elusive TOC locus.	Univ Liverpool, Mol Genet & Oncol Grp, Dept Clin Dent Sci, Liverpool L69 3GN, Merseyside, England; Royal Liverpool Univ Hosp, Dept Gastroenterol, Liverpool L7 8XP, Merseyside, England; Univ London, Ctr Cutaneous Res, Barts & London Sch Med & Dent, London E1 2AT, England; Roy Castle Int Ctr Lung Canc Res, Liverpool L3 9TA, Merseyside, England	University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; University of London; Queen Mary University London	Risk, JM (corresponding author), Univ Liverpool, Mol Genet & Oncol Grp, Dept Clin Dent Sci, Edwards Bldg,Daulby St, Liverpool L69 3GN, Merseyside, England.	j.m.risk@liverpoool.ac.uk	Field, John K./AAD-5674-2020; McRonald, Fiona/B-4005-2009; Kelsell, David P/F-8767-2011	Field, John K./0000-0003-3951-6365; Kelsell, David/0000-0002-9910-7144; McRonald, Fiona/0000-0001-7226-9461				Blank V, 1997, GENOMICS, V44, P147, DOI 10.1006/geno.1997.4847; Brown LM, 2001, AM J EPIDEMIOL, V153, P114, DOI 10.1093/aje/153.2.114; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; Dunn J, 1999, ONCOGENE, V18, P987, DOI 10.1038/sj.onc.1202371; Ellis A, 1994, Eur J Cancer B Oral Oncol, V30B, P102, DOI 10.1016/0964-1955(94)90061-2; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; Franceschi S, 2000, INT J CANCER, V86, P626, DOI 10.1002/(SICI)1097-0215(20000601)86:5&lt;626::AID-IJC4&gt;3.0.CO;2-Y; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; Fukino K, 1999, GENE CHROMOSOME CANC, V24, P345, DOI 10.1002/(SICI)1098-2264(199904)24:4<345::AID-GCC8>3.0.CO;2-Q; Geylan YS, 2001, NEOPLASMA, V48, P108; GOTTLIEB M, 1987, ANAL BIOCHEM, V165, P33, DOI 10.1016/0003-2697(87)90197-7; Harada H, 2001, J HUM GENET, V46, P90, DOI 10.1007/s100380170115; HENNIES HC, 1995, GENOMICS, V29, P537, DOI 10.1006/geno.1995.9971; HOWELEVANS W, 1958, Q J MED, V27, P413; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Iwaya T, 1998, GASTROENTEROLOGY, V114, P1206, DOI 10.1016/S0016-5085(98)70426-3; Jones J, 2002, INT J ONCOL, V20, P697; Kalikin LM, 1999, GENOMICS, V57, P36, DOI 10.1006/geno.1998.5740; Kalikin LM, 1996, GENE CHROMOSOME CANC, V17, P64, DOI 10.1002/(SICI)1098-2264(199609)17:1<64::AID-GCC10>3.3.CO;2-1; Kelsell DP, 1996, HUM MOL GENET, V5, P857, DOI 10.1093/hmg/5.6.857; Kuhlenbaumer G, 1999, GENOMICS, V62, P242, DOI 10.1006/geno.1999.5991; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li FZ, 1999, CANCER RES, V59, P3143; Marty L, 1997, GENOMICS, V41, P453, DOI 10.1006/geno.1997.4691; MUNOZ N, 1994, EUR J GASTROEN HEPAT, V6, P649, DOI 10.1097/00042737-199408000-00002; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; PALLER AS, 1993, J INVEST DERMATOL, V100, P841, DOI 10.1111/1523-1747.ep12476755; Protopopov A, 2000, CYTOGENET CELL GENET, V88, P312, DOI 10.1159/000015516; RISK JM, 1994, NAT GENET, V8, P319, DOI 10.1038/ng1294-319; Risk JM, 1999, GENOMICS, V59, P234, DOI 10.1006/geno.1999.5857; RISK JM, 2002, IN PRESS BIOTECHNIQU; Robbins MJ, 2000, GENOMICS, V67, P8, DOI 10.1006/geno.2000.6226; Russell SEH, 2000, CANCER RES, V60, P4729; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; Shibuta K, 2001, AM J GASTROENTEROL, V96, P3419; Stevens HP, 1996, ARCH DERMATOL, V132, P640, DOI 10.1001/archderm.132.6.640; Sureau A, 1997, NUCLEIC ACIDS RES, V25, P4513, DOI 10.1093/nar/25.22.4513; Taniguchi A, 1998, BIOCHEM BIOPH RES CO, V243, P177, DOI 10.1006/bbrc.1998.8078; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; von Brevern M, 1998, ONCOGENE, V17, P2101, DOI 10.1038/sj.onc.1202139; WABINGA HR, 1993, INT J CANCER, V54, P26, DOI 10.1002/ijc.2910540106; Yokota T, 2001, GENE, V267, P95, DOI 10.1016/S0378-1119(01)00407-3; Zheng WP, 2001, CHEM BIOL, V8, P379, DOI 10.1016/S1074-5521(01)00020-5	45	33	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2002	21	41					6395	6402		10.1038/sj.onc.1205768	http://dx.doi.org/10.1038/sj.onc.1205768			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214281				2022-12-17	WOS:000177829000017
J	Johnson, KC; Kissil, JL; Fry, JL; Jacks, T				Johnson, KC; Kissil, JL; Fry, JL; Jacks, T			Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene	ONCOGENE			English	Article						Nf2; merlin; dominant-negative; transformation; contact inhibition	NEUROFIBROMATOSIS TYPE-2 GENE; MERLIN; PRODUCT; PROTEIN; GROWTH; ACTIN; EXPRESSION; COLOCALIZES; MEMBRANE; ADHESION	Mutations in the Nf2 tumor suppressor gene lead to tumor formation in humans and mice and cellular overproliferation phenotypes in Drosophila. The Nf2 encoded protein, merlin, shares close sequence similarity in its amino terminus to members of the band 4.1 family of membrane-cytoskeletal linkers. Similarities between merlin and this family suggest a role for merlin in regulating cytoskeletal function. However, the mechanism of the tumor suppressing activity of merlin is not yet understood. Mutational analysis of Nf2 in flies has led to the identification of a dominant-negative allele, which harbors mutations in the amino terminus of the protein. Here, we report that expression of a murine analog of this amino-terminal mutant of Nf2 leads to complete transformation of NIH3T3 fibroblasts in culture. Cells that express this Nf2 mutant allele display disruptions of the actin cytoskeleton, lack of contact inhibition of growth, and anchorage-independent growth. Finally, fibroblasts that express this mutant Nf2 allele form tumors when injected into nude mice.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Canc Res Ctr, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Jacks, T (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	tjacks@mit.edu		Fry, Jessica/0000-0003-2748-0334				FERNANDEZVALLE C, 1994, J NEUROBIOL, V25, P1207, DOI 10.1002/neu.480251004; FRANCK Z, 1993, J CELL SCI, V105, P219; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Giovannini M, 2000, GENE DEV, V14, P1617; Giovannini M, 1999, GENE DEV, V13, P978, DOI 10.1101/gad.13.8.978; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Gutmann DH, 1999, J NEUROSCI RES, V58, P706, DOI 10.1002/(SICI)1097-4547(19991201)58:5<706::AID-JNR12>3.3.CO;2-Q; Harwalkar JA, 1998, AM J OTOL, V19, P654; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Koga H, 1998, ONCOGENE, V17, P801, DOI 10.1038/sj.onc.1202010; LaJeunesse DR, 1998, J CELL BIOL, V141, P1589, DOI 10.1083/jcb.141.7.1589; LUTCHMAN M, 1995, CANCER RES, V55, P2270; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MCCLATCHEY AI, 2001, GENE DEV, V12, P1121; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; Obremski VJ, 1998, J NEUROBIOL, V37, P487, DOI 10.1002/(SICI)1097-4695(199812)37:4<487::AID-NEU1>3.3.CO;2-2; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; Rosenbaum C, 1998, NEUROBIOL DIS, V5, P55, DOI 10.1006/nbdi.1998.0179; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Ruttledge MH, 1996, AM J HUM GENET, V59, P331; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Sainio M, 1997, J CELL SCI, V110, P2249; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Stokowski RP, 2000, AM J HUM GENET, V66, P873, DOI 10.1086/302812; TIKOO A, 1994, J BIOL CHEM, V269, P23387; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	34	33	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					5990	5997		10.1038/sj.onc.1205693	http://dx.doi.org/10.1038/sj.onc.1205693			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203111	Bronze			2022-12-17	WOS:000177671300002
J	Merel, P; Prieur, A; Pfeiffer, P; Delattre, O				Merel, P; Prieur, A; Pfeiffer, P; Delattre, O			Absence of major defects in non-homologous DNA end joining in human breast cancer cell lines	ONCOGENE			English	Article						breast cancer; non-homologous end joining; DNA repair; chromosome instability	COMPARATIVE GENOMIC HYBRIDIZATION; REPAIR; MUTATIONS; STABILITY; BRCA1; PATHWAY; RECOMBINATION; MECHANISMS; GENE	Structural abnormalities of chromosomes, including translocations and deletions, are extremely frequent in human cancer cells and particularly in breast cancer cells. One hypothesis to account for these alterations is a deficiency in the repair of DNA double-strand breaks (DSB). This repair process relies on two distinct pathways, homologous recombination (HR) and non-homologous DNA end joining (NHEJ). To investigate this latter pathway, we have studied the ability of cell-free extracts from a variety of human cells to rejoin different types of DSBs. The end joining activity of eleven sporadic breast cancer cell lines (BCCLs) was compared with that of control cells including primary human fibroblasts and cells harbouring a limited number of chromosome abnormalities. In vitro rejoining activity was not detected in extracts from MO59J DNA-PKcs-deficient cells and was strongly inhibited by wortmannin in control extracts. In contrast, most sporadic BCCLs and BRCA1 or BRCA2 deficient cells demonstrated similar efficiencies and accuracies of in vitro NHEJ than control cells. Only two BCCLs, SKBR3 and MDA-MB-453 exhibited decreased in vitro NHEJ. This study therefore indicates that a major defect in the NHEJ pathway is unlikely to account for the high number of chromosomes abnormalities observed in sporadic and hereditary BCCLs.	INSERM, Inst Curie, Lab Pathol Mol Canc, U509, F-75248 Paris 05, France; Univ Essen Gesamthsch, Genet Univ, D-45117 Essen, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Duisburg Essen	Delattre, O (corresponding author), INSERM, Inst Curie, Lab Pathol Mol Canc, U509, 26 Rue Ulm, F-75248 Paris 05, France.			delattre, olivier/0000-0002-8730-2276				Bell DW, 1999, CANCER RES, V59, P3883; Davidson JM, 2000, BRIT J CANCER, V83, P1309, DOI 10.1054/bjoc.2000.1458; Daza P, 1996, BIOL CHEM, V377, P775, DOI 10.1515/bchm3.1996.377.12.775; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Feldmann E, 2000, NUCLEIC ACIDS RES, V28, P2585, DOI 10.1093/nar/28.13.2585; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Forozan F, 2000, CANCER RES, V60, P4519; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Hiramoto T, 1999, ONCOGENE, V18, P3422, DOI 10.1038/sj.onc.1202691; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kytola S, 2000, GENE CHROMOSOME CANC, V28, P308, DOI 10.1002/1098-2264(200007)28:3<308::AID-GCC9>3.0.CO;2-B; Loveday RL, 2000, INT J CANCER, V86, P494, DOI 10.1002/(SICI)1097-0215(20000515)86:4<494::AID-IJC8>3.3.CO;2-F; Matsuda M, 1999, ONCOGENE, V18, P3427, DOI 10.1038/sj.onc.1202692; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; PFEIFFER P, 1994, MOL CELL BIOL, V14, P888, DOI 10.1128/MCB.14.2.888; Rosenzweig KE, 1997, CLIN CANCER RES, V3, P1149; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; THODE S, 1990, CELL, V60, P921, DOI 10.1016/0092-8674(90)90340-K; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang HC, 2001, CANCER RES, V61, P270; Yu VPCC, 2000, GENE DEV, V14, P1400	28	33	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2002	21	36					5654	5659		10.1038/sj.onc.1205742	http://dx.doi.org/10.1038/sj.onc.1205742			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165865				2022-12-17	WOS:000177442000016
J	Bianco, NR; Montano, MM				Bianco, NR; Montano, MM			Regulation of prothymosin alpha by estrogen receptor alpha: molecular mechanisms and relevance in estrogen-mediated breast cell growth	ONCOGENE			English	Article						estrogen; estrogen receptor alpha; prothymosin alpha	QUINONE REDUCTASE GENE; TRANSCRIPTIONAL ACTIVATION; LINKER HISTONES; EXPRESSION; PROTEIN; PHOSPHORYLATION; IDENTIFICATION; PROLIFERATION; CLONING; REGION	Prothymosin alpha (PTalpha) is a small highly acidic protein found in the nuclei of virtually all mammalian tissues. Its high conservation in mammals and wide tissue distribution suggest an essential biological role. While the exact mechanism of action of PTalpha remains elusive, the one constant has been its relationship with the proliferative state of the cell and its requirement for cellular growth and survival. Recently PTalpha was found to promote transcriptional activity by sequestering the anticoactivator, REA from the Estrogen Receptor (ER) complex. We now report that Estradiol (E-2) upregulates PTa mRNA and protein expression. Further studies indicate that ERalpha regulates PTa gene transcriptional activity. We have also delimited the region of PTalpha gene promoter involved in ERalpha-mediated transcriptional regulation and identified a novel ERalpha-binding element. Increased intracellular PTalpha expression in the presence of estrogens is accompanied by increased nuclear/decreased cytoplasmic localization. Increased nuclear expression of PTalpha is correlated with increased proliferation as measured by expression of Ki67 nuclear antigen. Conversely, inhibition of nuclear PTalpha expression in breast cancer cells using antisense methodology resulted in the inhibition of E-2-induced breast cancer cell proliferation. Overall these studies underscore the importance of PTalpha in estrogen-induced breast cell proliferation.	Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44122 USA	Case Western Reserve University	Montano, MM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, HG Wood Bldg,W307,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@po.cwru.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008056] Funding Source: NIH RePORTER; NCI NIH HHS [CA80959] Funding Source: Medline; NIGMS NIH HHS [T32 GM08056] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; AUSUBEL FM, 1992, SHORT PROTOCALS MOL; Chen H, 1998, J BIOL CHEM, V273, P31352, DOI 10.1074/jbc.273.47.31352; CHO HS, 1991, MOL ENDOCRINOL, V5, P1323, DOI 10.1210/mend-5-9-1323; CLINTON M, 1991, P NATL ACAD SCI USA, V88, P6608, DOI 10.1073/pnas.88.15.6608; Crane-Robinson C, 1999, BIOESSAYS, V21, P367, DOI 10.1002/(SICI)1521-1878(199905)21:5<367::AID-BIES2>3.0.CO;2-4; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DiazJullien C, 1996, BBA-PROTEIN STRUCT M, V1296, P219, DOI 10.1016/0167-4838(96)00072-6; DUBIK D, 1988, J BIOL CHEM, V263, P12705; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Enkemann SA, 2000, J HISTOCHEM CYTOCHEM, V48, P1341, DOI 10.1177/002215540004801005; ESCHENFELDT WH, 1986, P NATL ACAD SCI USA, V83, P9403, DOI 10.1073/pnas.83.24.9403; Garnier M, 1997, J NEUROSCI, V17, P4591; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; Gomez-Marquez J, 1998, BIOCHEM J, V333, P1; GOMEZMARQUEZ J, 1989, J BIOL CHEM, V264, P8451; GOMEZMARQUEZ J, 1988, FEBS LETT, V226, P217, DOI 10.1016/0014-5793(88)81425-X; GOODALL GJ, 1986, P NATL ACAD SCI USA, V83, P8926, DOI 10.1073/pnas.83.23.8926; Iatropoulos MJ, 1996, EXP TOXICOL PATHOL, V48, P175, DOI 10.1016/S0940-2993(96)80039-X; Karetsou Z, 1998, NUCLEIC ACIDS RES, V26, P3111, DOI 10.1093/nar/26.13.3111; Klinge CM, 1997, J BIOL CHEM, V272, P31465, DOI 10.1074/jbc.272.50.31465; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; Loidi L, 1999, LIFE SCI, V64, P2125, DOI 10.1016/S0024-3205(99)00161-7; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; Magdalena C, 2000, BRIT J CANCER, V82, P584, DOI 10.1054/bjoc.1999.0968; MANROW RE, 1991, J BIOL CHEM, V266, P3916; Martini PGV, 2000, MOL CELL BIOL, V20, P6224, DOI 10.1128/MCB.20.17.6224-6232.2000; Martini PGV, 2001, ENDOCRINOLOGY, V142, P3493, DOI 10.1210/en.142.8.3493; MOL PC, 1995, MOL CELL BIOL, V15, P6999; Montano MM, 2000, J BIOL CHEM, V275, P34306, DOI 10.1074/jbc.M003880200; Montano MM, 1996, MOL ENDOCRINOL, V10, P230, DOI 10.1210/me.10.3.230; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; Orre RS, 2001, J BIOL CHEM, V276, P1794, DOI 10.1074/jbc.M008560200; PALVIMO J, 1990, FEBS LETT, V277, P257, DOI 10.1016/0014-5793(90)80860-L; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; PerezEstevez A, 1997, J BIOL CHEM, V272, P10506; Pineiro A, 2000, PEPTIDES, V21, P1433, DOI 10.1016/S0196-9781(00)00288-6; Rodriguez P, 1998, BIOCHEM J, V331, P753, DOI 10.1042/bj3310753; Russo IH, 1998, J MAMMARY GLAND BIOL, V3, P49, DOI 10.1023/A:1018770218022; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SBURLATI AR, 1991, P NATL ACAD SCI USA, V88, P253, DOI 10.1073/pnas.88.1.253; SBURLATI AR, 1993, BIOCHEMISTRY-US, V32, P4587, DOI 10.1021/bi00068a015; SZABO P, 1993, HUM GENET, V90, P629; Tsitsilonis OE, 1998, ANTICANCER RES, V18, P1501; WATTS JD, 1989, FEBS LETT, V245, P17, DOI 10.1016/0014-5793(89)80182-6; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Wu CL, 1997, LIFE SCI, V61, P2091, DOI 10.1016/S0024-3205(97)00882-5; ZALVIDE JB, 1992, J BIOL CHEM, V267, P8692; Zhao RB, 2000, GENE DEV, V14, P981	53	33	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5233	5244		10.1038/sj.onc.1205645	http://dx.doi.org/10.1038/sj.onc.1205645			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149645				2022-12-17	WOS:000177193900005
J	Shiraishi, M; Sekiguchi, A; Terry, MJ; Oates, AJ; Miyamoto, Y; Chuu, YH; Munakata, M; Sekiya, T				Shiraishi, M; Sekiguchi, A; Terry, MJ; Oates, AJ; Miyamoto, Y; Chuu, YH; Munakata, M; Sekiya, T			A comprehensive catalog of CpG islands methylated in human lung adenocarcinomas for the identification of tumor suppressor genes	ONCOGENE			English	Article						CpG island; DNA methylation; lung adenocarcinoma; methylated DNA binding domain column; chromatography; segregation of partly melted molecules	DE-NOVO METHYLATION; DNA METHYLATION; CHROMATIN-STRUCTURE; BINDING DOMAIN; FRAGMENTS; REPLICATION; EXPRESSION; RECEPTOR; REGIONS; COMPLEX	CpG island methylation is an important mechanism in gene silencing and is a key epigenetic event in cancer development. As yet, the number and identities of the genes that are inactivated in cancer cells has not been determined. In order to address this issue, we have performed a comprehensive isolation of CpG islands that are methylated in human lung adenocarcinomas. We have isolated approximately 200 CpG islands that are methylated in tumor DNA including those of known tumor-associated genes such as the HOXA5 gene. As the library contains the CpG islands of a number of known tumor suppressor genes it is highly likely that additional, previously unidentified tumor suppressor genes, will be present. On average, 1-2% of CpG islands were methylated specifically in tumors although this figure differed greatly between patients. This study provides an important resource in the search for genes inactivated in tumors and for the investigation of epigenetic dysregulation of gene expression by CpG island methylation.	Natl Canc Ctr, Res Inst, DNA Methylat & Genome Funct Project, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Shiraishi, M (corresponding author), Natl Canc Ctr, Res Inst, DNA Methylat & Genome Funct Project, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	mshirais@ncc.go.jp		Miyamoto, Yuji/0000-0003-3948-5044				Ahuja N, 1998, CANCER RES, V58, P5489; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Brock GJR, 1999, GENE, V240, P269, DOI 10.1016/S0378-1119(99)00442-4; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; CROSS SH, 1994, NAT GENET, V6, P126; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; Delgado S, 1998, EMBO J, V17, P2426, DOI 10.1093/emboj/17.8.2426; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; HASHIMOTOGOTOH T, 1993, GENE, V137, P211; Hughes J, 1999, HUM MOL GENET, V8, P543, DOI 10.1093/hmg/8.3.543; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; SCHMIDT M, 1990, P NATL ACAD SCI USA, V87, P3685, DOI 10.1073/pnas.87.10.3685; Shiraishi M, 1999, P NATL ACAD SCI USA, V96, P2913, DOI 10.1073/pnas.96.6.2913; SHIRAISHI M, 1995, P NATL ACAD SCI USA, V92, P4229, DOI 10.1073/pnas.92.10.4229; Shiraishi M, 1998, NUCLEIC ACIDS RES, V26, P5544, DOI 10.1093/nar/26.24.5544; Shiraishi M, 2001, P JPN ACAD B-PHYS, V77, P208, DOI 10.2183/pjab.77.208; Shiraishi M, 1999, BIOL CHEM, V380, P1127, DOI 10.1515/BC.1999.141; SHIRAISHI M, 1989, CANCER RES, V49, P6474; SHIRAISHI M, 2000, GENE THER MOL BIOL, V5, P35; SHIRAISHI M, 2002, IN PRESS BIOL CHEM; SHORT JM, 1992, METHOD ENZYMOL, V216, P495; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; Thibonnier M, 1996, GENOMICS, V31, P327, DOI 10.1006/geno.1996.0055; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	39	33	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3804	3813		10.1038/sj.onc.1205454	http://dx.doi.org/10.1038/sj.onc.1205454			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032849				2022-12-17	WOS:000175676000016
J	Joseph, T; Bryant, A; Frankel, P; Wooden, R; Kerkhoff, E; Rapp, UR; Foster, DA				Joseph, T; Bryant, A; Frankel, P; Wooden, R; Kerkhoff, E; Rapp, UR; Foster, DA			Phospholipase D overcomes cell cycle arrest induced by high-intensity Raf signaling	ONCOGENE			English	Article						phospholipase D; Raf; cell cycle; survival signals	PROTEIN-KINASE-C; PHOSPHATIDIC-ACID; ACTIVATION; RECEPTOR; RALA; FIBROBLASTS; INVOLVEMENT; APOPTOSIS; CANCER; PROLIFERATION	Low level expression of an active Raf kinase results in a transformed phenotype; however, high intensity Raf signals block cell cycle progression. Phospholipase D (PLD) has been implicated in regulating cell cycle progression and PLD activity is elevated in Raf transformed cells. We report here that high intensity Raf signals reduce PLD activity and that elevated expression of either PLD1 or PLD2 prevents cell cycle arrest induced by high intensity Raf signals. Overexpression of either PLD1 or PLD2 also reversed increases in p21(Cip1) and protein kinase C delta (PKC delta) cleavage seen with high intensity Raf signals. These data indicate that PLD signaling provides a novel survival signal that overcomes cell cycle arrest induced by high intensity Raf signaling.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany	City University of New York (CUNY) System; Hunter College (CUNY); University of Wurzburg	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edun			NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; ASKEW DS, 1991, ONCOGENE, V6, P1915; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; CRESSMAN CM, 1995, FEBS LETT, V367, P223, DOI 10.1016/0014-5793(95)00543-I; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; Frankel P, 1999, BIOCHEM BIOPH RES CO, V255, P502, DOI 10.1006/bbrc.1999.0234; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; Kerkhoff E, 1998, CANCER RES, V58, P1636; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Noh DY, 2000, CANCER LETT, V161, P207, DOI 10.1016/S0304-3835(00)00612-1; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; RAPP UR, 1987, ONCOGENES CANCER, P55; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Villalba M, 1998, NEUROREPORT, V9, P2381, DOI 10.1097/00001756-199807130-00042; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; ZHONG M, 2002, IN PRESS ONCOGENE, V21; Zhong MH, 2001, CELL GROWTH DIFFER, V12, P187; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	45	33	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3651	3658		10.1038/sj.onc.1205380	http://dx.doi.org/10.1038/sj.onc.1205380			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032867				2022-12-17	WOS:000175793700016
J	Caldwell, MC; Hough, C; Furer, S; Linehan, WM; Morin, PJ; Gorospe, M				Caldwell, MC; Hough, C; Furer, S; Linehan, WM; Morin, PJ; Gorospe, M			Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNF alpha cytotoxicity	ONCOGENE			English	Article						VHL; SAGE; renal cell carcinoma; gene expression; TNF alpha	ENDOTHELIAL GROWTH-FACTOR; HIPPEL-LINDAU PROTEIN; TUMOR-SUPPRESSOR PROTEIN; NECROSIS-FACTOR-ALPHA; APOPTOSIS; ELONGATION; PRODUCT; ARREST; DEATH	We have used serial analysis of gene expression (SAGE) to investigate the influence of the von Hippel-Lindau (VHL) gene on global gene expression profiles. SAGE libraries were prepared from renal cell carcinoma (RCC) lines that either lack (parental) or express wild-type VHL (wtVHL). Comparison of these libraries revealed some differentially expressed genes (Glut-1, for example) that were known to be influenced by VHL, but the majority of genes had not previously been reported to be affected by the cell's VHL status. The identification of several genes involved in TNFalpha-mediated events prompted us to compare the sensitivity of cells with different VHL status in TNFalpha cytotoxicity assays. Strikingly, VHL-deficient cells were much more resistant to the toxic influence of TNFalpha. We propose that VHL-dependent sensitization of RCC cells to TNFalpha-mediated killing may contribute to VHL's growth suppressive function.	NIA, GRC, IRP,NIH, Cellular & Mol Biol Lab, Baltimore, MD 21224 USA; NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gorospe, M (corresponding author), NIA, GRC, IRP,NIH, Cellular & Mol Biol Lab, Box 12,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.				NATIONAL INSTITUTE ON AGING [Z01AG000512] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FAJARDO LF, 1992, AM J PATHOL, V140, P539; Feng X, 2001, J BIOL CHEM, V276, P8341, DOI 10.1074/jbc.M007116200; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Gorospe M, 1996, CANCER RES, V56, P475; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; Hough CD, 2000, CANCER RES, V60, P6281; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Kroll SL, 1999, J BIOL CHEM, V274, P30109, DOI 10.1074/jbc.274.42.30109; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; Moutet M, 1998, FREE RADICAL BIO MED, V25, P270, DOI 10.1016/S0891-5849(98)00038-0; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; OHH M, 2000, J BIOL CHEM, V275, P25733; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; SATO K, 1994, TOHOKU J EXP MED, V173, P355, DOI 10.1620/tjem.173.355; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; Spyridopoulos I, 1997, J MOL CELL CARDIOL, V29, P1321, DOI 10.1006/jmcc.1996.0365; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012	26	33	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2002	21	6					929	936		10.1038/sj.onc.1205140	http://dx.doi.org/10.1038/sj.onc.1205140			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840338				2022-12-17	WOS:000173427100008
J	Aouacheria, A; Arnaud, E; Venet, S; Lalle, P; Gouy, M; Rigal, D; Gillet, G				Aouacheria, A; Arnaud, E; Venet, S; Lalle, P; Gouy, M; Rigal, D; Gillet, G			Nrh, a human homologue of Nr-13 associates with Bcl-Xs and is an inhibitor of apoptosis	ONCOGENE			English	Article						apoptosis; molecular cloning; Bcl-2 family; phylogeny	CYTOCHROME-C; BH3 DOMAIN; CELL-DEATH; BCL-2-RELATED GENE; ION-CHANNEL; BAX; FAMILY; EXPRESSION; PROTEINS; RELEASE	In search of human homologues of the anti-apoptotic protein Nr-13, we have characterized a human EST clone that potentially encodes a protein, which is the closest homologue of Nr-13 among the Bcl-2 family members, to date known, in humans. Phylogenetic analyses suggest Human nrh, Mouse diva/boo and Quail nr-13 to be orthologous genes. The nrh gene has the same overall organization as nr-13 and diva/boo with one single intron interrupting the ORF at the level of the Bcl-2-homology domain BH2. RT-PCR-based analysis of nrh expression indicated that this gene is preferentially expressed in the lungs, the liver and the kidneys. Interestingly, two in frame ATG codons can lead potentially to the synthesis of two products, one of them lacking 10 aminoacids at the N-terminal end. Sequence alignment with nr-13 and Diva/Boo in addition to secondary structure prediction of the nrh transcript suggested that the shortest protein will be preferentially synthetized. Immunohistochemical analyses have revealed that Nrh is associated with mitochondria and the nuclear envelope. Moreover, Nrh preferentially associates with the apoptosis accelerator Bcl-Xs and behaves as an inhibitor of apoptosis both in yeast and vertebrate cells.	Univ Lyon 1, CNRS, UMR 5086, Inst Biol & Chim Prot, F-69367 Lyon 07, France; Univ Lyon 1, CNRS, UMR 5558, F-67622 Villeurbanne, France; Etablissement Transfus Sanguine, F-69007 Lyon, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; VetAgro Sup	Gillet, G (corresponding author), Univ Lyon 1, CNRS, UMR 5086, Inst Biol & Chim Prot, 7 Passage Vercors, F-69367 Lyon 07, France.	g.gillet@ibcp.fr	gillet, germain/A-9095-2013; LALLE, Philippe/G-7734-2018	GILLET, Germain/0000-0002-1514-327X				Afonso CL, 2001, J VIROL, V75, P971, DOI 10.1128/JVI.75.2.971-978.2001; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Cotter T.G., 1996, TECHNIQUES APOPTOSIS; DONALDSON JG, 1998, CURRENT PROTOCOLS CE, V1; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Espanel X, 1998, ONCOGENE, V17, P585, DOI 10.1038/sj.onc.1201962; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GILLET G, 1993, ONCOGENE, V8, P565; GOLEMIS EA, 1999, CURRENT PROTOCOLS MO, V4; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hoetelmans RWM, 2000, CELL DEATH DIFFER, V7, P384, DOI 10.1038/sj.cdd.4400664; Hsu SY, 1998, J BIOL CHEM, V273, P30139, DOI 10.1074/jbc.273.46.30139; Inohara N, 1998, J BIOL CHEM, V273, P32479, DOI 10.1074/jbc.273.49.32479; JANIAK F, 1994, J BIOL CHEM, V269, P9842; Kasof GM, 1999, MOL CELL BIOL, V19, P4390; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Mangeney M, 1996, ONCOGENE, V13, P1441; Martinou JC, 1999, NATURE, V399, P411, DOI 10.1038/20804; Matsuyama S, 1998, J BIOL CHEM, V273, P30995, DOI 10.1074/jbc.273.47.30995; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Nouraini S, 2000, MOL CELL BIOL, V20, P1604, DOI 10.1128/MCB.20.5.1604-1615.2000; Otter I, 1998, J BIOL CHEM, V273, P6110, DOI 10.1074/jbc.273.11.6110; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; SAMBROOK J, 1989, MOL CLONING, V2, P9; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Simonen M, 1997, EUR J BIOCHEM, V249, P85, DOI 10.1111/j.1432-1033.1997.t01-1-00085.x; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Tao WK, 1997, J BIOL CHEM, V272, P15547, DOI 10.1074/jbc.272.24.15547; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Walczak H, 2000, CANCER RES, V60, P3051; WANG HG, 1994, ONCOGENE, V9, P2751; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang QF, 2000, BREAST CANCER RES TR, V61, P211, DOI 10.1023/A:1006474307180; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhang H, 2000, J BIOL CHEM, V275, P11092, DOI 10.1074/jbc.275.15.11092; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zhou M, 1998, J BIOL CHEM, V273, P11930, DOI 10.1074/jbc.273.19.11930	52	33	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2001	20	41					5846	5855		10.1038/sj.onc.1204740	http://dx.doi.org/10.1038/sj.onc.1204740			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593390				2022-12-17	WOS:000171037200008
J	Rabbitts, TH				Rabbitts, TH			Chromosomal translocation master genes, mouse models and experimental therapeutics	ONCOGENE			English	Article						cancer; therapy; chromosomal translocation; cytogenetics; leukaemia; sarcoma	T-CELL LEUKEMIA; LIM-PROTEIN RBTN2; C-MYC GENE; TRANSCRIPTION FACTORS; BURKITT-LYMPHOMA; HOMEOBOX GENE; CRE-LOXP; LMO2; FUSION; DOMAIN	Molecular biologists have elucidated general principles about chromosomal translocations by cloning oncogenes or fusion genes at chromosomal translocation junctions. These genes invariably encode intracellular proteins and in acute cancers, often involve transcription and developmental regulators, which are master regulators of cell fate (e.g. LMO2 which is involved in acute leukaemia). Chromosomal translocations are usually associated with specific cell types. The reason for this close association is under investigation using mouse models. We are trying to emulate the cell-specific consequences of chromosomal translocations in mice using homologous recombination in embryonic stem cells to generate de novo chromosomal translocations or to mimic the consequence of these translocations. In addition, chromosomal translocation genes and their products are important targets for therapy. We have designed new therapeutic strategies which include antigen-specific recruitment of endogenous cellular pathways to affect cellular viability and a novel structured form of antisense to ablate the function of fusion mRNAs. We will evaluate these procedures in the mouse models of chromosomal translocations and the long term aim is to perfect rapid procedures for characterizing patient-specific chromosomal translocations to tailor therapy to individual patients.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Rabbitts, TH (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	thr@mrc-lmb.cam.ac.uk	Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Bemark M, 2000, ONCOGENE, V19, P3404, DOI 10.1038/sj.onc.1203686; BENTLEY DL, 1981, CELL, V24, P613, DOI 10.1016/0092-8674(81)90088-X; BERNHEIM A, 1981, CANCER GENET CYTOGEN, V3, P307, DOI 10.1016/0165-4608(81)90039-X; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; Collins EC, 2000, EMBO REP, V1, P127, DOI 10.1093/embo-reports/kvd021; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; CROCE CM, 1979, P NATL ACAD SCI USA, V76, P3416, DOI 10.1073/pnas.76.7.3416; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; Delassus S, 1999, BLOOD, V94, P1495, DOI 10.1182/blood.V94.5.1495.417a08_1495_1503; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; DRYNAN LF, 2001, IN PRESS ONCOGENE; DUBE ID, 1991, BLOOD, V78, P2996; FISCH P, 1992, ONCOGENE, V7, P2389; Fischer A, 1998, SCIENCE, V280, P237, DOI 10.1126/science.280.5361.237; Grutz GG, 1998, EMBO J, V17, P4594, DOI 10.1093/emboj/17.16.4594; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; HOBART MJ, 1981, ANN HUM GENET, V45, P331, DOI 10.1111/j.1469-1809.1981.tb00346.x; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; Klein G, 1981, NATURE, V294, P313, DOI 10.1038/294313a0; KOVACS G, 1987, INT J CANCER, V40, P171, DOI 10.1002/ijc.2910400208; LARSON RC, 1995, ONCOGENE, V11, P853; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LARSON RC, 1994, ONCOGENE, V9, P3675; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; MALCOLM S, 1982, P NATL ACAD SCI-BIOL, V79, P4957, DOI 10.1073/pnas.79.16.4957; Martineau P, 1998, J MOL BIOL, V280, P117, DOI 10.1006/jmbi.1998.1840; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RABBITTS TH, 1983, BIOCHEM SOC T, V11, P119, DOI 10.1042/bst0110119; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; Rabbitts TH, 1999, CANCER RES, V59, p1794S; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RABBITTS TH, 1985, EMBO J, V4, P1461, DOI 10.1002/j.1460-2075.1985.tb03803.x; ROYERPOKORA B, 1995, ONCOGENE, V10, P1353; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; Sale JE, 1998, IMMUNITY, V9, P859, DOI 10.1016/S1074-7613(00)80651-2; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SANCHEZGARCIA I, 1991, ONCOGENE, V6, P577; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; Stocks MR, 2000, EMBO REP, V1, P59, DOI 10.1093/embo-reports/kvd003; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TAVLADORAKI P, 1993, NATURE, V366, P469, DOI 10.1038/366469a0; Tse E, 2000, P NATL ACAD SCI USA, V97, P12266, DOI 10.1073/pnas.97.22.12266; TSE E, 2001, IN PRESS METHDOS MOL; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VAN DJ, 1995, P NATL ACAD SCI USA, V92, P7376; Visintin M, 1999, P NATL ACAD SCI USA, V96, P11723, DOI 10.1073/pnas.96.21.11723; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wagner RW, 1997, MOL MED TODAY, V3, P31, DOI 10.1016/S1357-4310(96)10053-8; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yamada Y, 2000, P NATL ACAD SCI USA, V97, P320, DOI 10.1073/pnas.97.1.320; 2001, NATURE	73	33	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5763	5777		10.1038/sj.onc.1204597	http://dx.doi.org/10.1038/sj.onc.1204597			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607826				2022-12-17	WOS:000170887500017
J	Rounbehler, RJ; Schneider-Broussard, R; Conti, CJ; Johnson, DG				Rounbehler, RJ; Schneider-Broussard, R; Conti, CJ; Johnson, DG			Myc lacks E2F1's ability to suppress skin carcinogenesis	ONCOGENE			English	Article						Myc; E2F1; apoptosis; cell cycle; carcinogenesis	SQUAMOUS-CELL CARCINOMA; C-MYC; TRANSGENIC MICE; ORNITHINE DECARBOXYLASE; IN-VIVO; INDUCED APOPTOSIS; EXPRESSION; E2F-1; GENE; P53	Myc and E2F1 can each stimulate proliferation, induce apoptosis, and contribute to oncogenic transformation. However, only E2F1 has been shown to have a tumor suppressive activity under some conditions. To examine the potential of Myc to suppress tumorigenesis under one of the conditions in which E2F1 functions to suppress tumorigenesis, transgenic mice expressing Myc under the control of a keratin 5 (K5) promoter were generated. Like K5 E2F1 transgenic mice, K5 Myc transgenic mice have hyperplastic and hyperproliferative epidermis and develop spontaneous tumors in the skin and oral epithelium. In addition, K5 Myc and K5 E2F1 transgenic mice both display aberrant, p53-dependent apoptosis in the epidermis. It has been demonstrated that deregulated expression of E2F1 in the epidermis of transgenic mice inhibits tumorigenesis in a two-stage skin carcinogenesis assay. In sharp contrast to those results, deregulated expression of Myc in the epidermis of transgenic mice resulted in an enhanced response to two-stage skin carcinogenesis. We conclude that while Myc and E2F1 have similar proliferative, apoptotic and oncogenic properties in mouse epidermis, Myc lacks E2F1's tumor suppressive property. This suggests that E2F1's unique ability to inhibit skin carcinogenesis is not simply a consequence of promoting p53-dependent apoptosis.	Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Johnson, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, Park Rd 1C, Smithville, TX 78957 USA.			Johnson, David/0000-0002-6223-1790	NCI NIH HHS [CA42157, CA16672, CA79648] Funding Source: Medline; NIEHS NIH HHS [ES007784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079648, R01CA042157, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Conner EA, 2000, ONCOGENE, V19, P5054, DOI 10.1038/sj.onc.1203885; Conti C. J, 1994, HDB MOUSE MUTATIONS, P39; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DIGIOVANNI J, 1994, CARCINOGENESIS, P265; ELSON A, 1995, ONCOGENE, V11, P181; FIELD JK, 1989, ONCOGENE, V4, P1463; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; Hunt KK, 1997, CANCER RES, V57, P4722; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; Johnson DG, 2000, MOL CARCINOGEN, V27, P151, DOI 10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; MERRITT WD, 1990, ARCH OTOLARYNGOL, V116, P1394; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PENA A, 1993, J BIOL CHEM, V268, P27277; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Rodriguez-Puebla ML, 1998, CELL GROWTH DIFFER, V9, P31; Sakamuro D, 1995, ONCOGENE, V11, P2411; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Wang AJ, 1999, NUCLEIC ACIDS RES, V27, P4609, DOI 10.1093/nar/27.23.4609; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	41	33	34	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5341	5349		10.1038/sj.onc.1204691	http://dx.doi.org/10.1038/sj.onc.1204691			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536046				2022-12-17	WOS:000170575500009
J	Berquin, IM; Dziubinski, ML; Nolan, GP; Ethier, SP				Berquin, IM; Dziubinski, ML; Nolan, GP; Ethier, SP			A functional screen for genes inducing epidermal growth factor autonomy of human mammary epithelial cells confirms the role of amphiregulin	ONCOGENE			English	Article						EGF; EGFR; amphiregulin; breast cancer; autocrine growth factor	HUMAN-BREAST-CANCER; DIFFERENTIATION FACTOR HEREGULIN; FACTOR RECEPTOR; ESTROGEN-RECEPTOR; CARCINOMA CELLS; POOR RESPONSE; FACTOR-I; EXPRESSION; HORMONE; NEU	To gain better understanding of the molecular alterations responsible for the aggressive growth potential of epidermal growth factor receptor (EGFR)-positive breast cancers, we utilized an expression cloning strategy to seek gene products that mediate the EGF-independent growth of human breast cancer cells, A retroviral cDNA expression library was constructed from the EGFR-positive SUM-149PT cell line, and transduced into growth factor-dependent human mammary epithelial (HME) cells. Recipient cells were functionally selected for their ability to proliferate in serum-free, EGF-free medium. Library cDNAs were recovered from EGF-independent colonies by PCR amplification or by biological rescue. Clone H55a#1 contained a library insert encoding amphiregulin, This EGFR ligand,vas able to confer EGF independence when transduced into HME cells. SUM-149PT and H55a#1 cells overexpressed amphiregulin transcripts, and secreted moderate EGF-like activity in conditioned media, indicating a possible autocrine loop. EGFR membrane levels and constitutive phosphorylation were consistent with this hypothesis, as well as the sensitivity of the cells to an ErbB-specific kinase inhibitor. Expression of the WT1 Wilms' tumor suppressor gene, a transcriptional activator of amphiregulin, did not parallel amphiregulin transcript levels, suggesting that another factor regulates amphiregulin in SUM-149PT, Our data confirm the importance of amphiregulin in the etiology of breast cancer.	Univ Michigan, Dept Radiat Oncol, Div Radiat & Canc Biol, Ann Arbor, MI 48109 USA; Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA	University of Michigan System; University of Michigan; Stanford University	Ethier, SP (corresponding author), 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	spethier@umich.edu	Nolan, Garry/AAE-7903-2019	Nolan, Garry/0000-0002-8862-9043	NCI NIH HHS [R01 CA77416] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077416] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1990, CANCER RES, V50, P7351; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; BATTAGLIA F, 1988, EUR J CANCER CLIN ON, V24, P1685, DOI 10.1016/0277-5379(88)90068-5; Brown P, 2000, CONT ENDOCRINOL, P49; Clarke RB, 1997, CANCER RES, V57, P4987; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; ETHIER SP, 1991, CELL GROWTH DIFFER, V2, P593; ETHIER SP, 1987, J CELL PHYSIOL, V132, P161, DOI 10.1002/jcp.1041320123; Ethier SP, 1996, MOL CARCINOGEN, V15, P134; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; ETHIER SP, 1990, CANCER RES, V50, P5351; ETHIER SP, 1991, BREAST CANCER RES TR, V17, P221, DOI 10.1007/BF01806371; Forozan F, 1999, BRIT J CANCER, V81, P1328, DOI 10.1038/sj.bjc.6695007; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; HOLDAWAY IM, 1983, CANCER, V52, P479, DOI 10.1002/1097-0142(19830801)52:3<479::AID-CNCR2820520317>3.0.CO;2-O; Ignatoski KMW, 1999, BREAST CANCER RES TR, V54, P173, DOI 10.1023/A:1006135331912; Ignatoski KMW, 1999, ENDOCRINOLOGY, V140, P3615, DOI 10.1210/en.140.8.3615; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Kenney NJ, 1996, CELL GROWTH DIFFER, V7, P1769; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; LEJEUNE S, 1993, CANCER RES, V53, P3597; Ma L, 1999, ONCOGENE, V18, P6513, DOI 10.1038/sj.onc.1203042; MARTINEZLACACI I, 1995, ENDOCRINOLOGY, V136, P3983, DOI 10.1210/en.136.9.3983; NICHOLSON S, 1989, LANCET, V1, P182; NICHOLSON S, 1990, J STEROID BIOCHEM, V37, P811, DOI 10.1016/0960-0760(90)90424-J; NICHOLSON S, 1988, INT J CANCER, V42, P36, DOI 10.1002/ijc.2910420108; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; OSBORNE CK, 1985, SEMIN ONCOL, V12, P317; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pfeiffer JK, 1999, J VIROL, V73, P8441, DOI 10.1128/JVI.73.10.8441-8447.1999; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; RAM TG, 1995, J CELL PHYSIOL, V163, P589, DOI 10.1002/jcp.1041630320; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; Rao GS, 2000, INT J RADIAT ONCOL, V48, P1519, DOI 10.1016/S0360-3016(00)01358-4; Salomon DS, 2000, CONT ENDOCRINOL, P137; SCHRANK R, 1994, HARVARD BUS REV, V72, P77; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Smaill JB, 2000, J MED CHEM, V43, P1380, DOI 10.1021/jm990482t; SOULE HD, 1990, CANCER RES, V50, P6075; Tannheimer SL, 2000, BREAST CANCER RES, V2, P311, DOI 10.1186/bcr73; TOI M, 1989, INT J CANCER, V43, P220, DOI 10.1002/ijc.2910430208; Visscher DW, 1997, BREAST CANCER RES TR, V45, P75, DOI 10.1023/A:1005845512804; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	53	33	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					4019	4028		10.1038/sj.onc.1204537	http://dx.doi.org/10.1038/sj.onc.1204537			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494130				2022-12-17	WOS:000169681500010
J	Child, ES; Mann, DJ				Child, ES; Mann, DJ			Novel properties of the cyclin encoded by Human Herpesvirus 8 that facilitate exit from quiescence	ONCOGENE			English	Article						Human Herpesvirus 8; Kaposi's sarcoma; cyclin; cyclin-dependent kinase; retinoblastoma protein phosphorylation; quiescence	DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA PROTEIN; CATALYTIC SUBUNIT; STRUCTURAL BASIS; NUCLEAR IMPORT; S-PHASE; P27(KIP1); ACTIVATION; PHOSPHORYLATION; IDENTIFICATION	Viral DNA replication is generally dependent upon circumventing host cell cycle control to force S phase entry in an otherwise quiescent cell. Here we describe novel attributes of the cyclin encoded by Human Herpesvirus 8 (K cyclin) that enable it to subvert the quiescent state. K cyclin is most similar to the mammalian D-type cyclins in primary sequence but displays properties more akin to those of cyclin E. K cyclin (like cyclin E) can autonomously couple with its cognate cdk subunit and localize to the nucleus, D-type cyclins require mitogen stimulated accessory factors (such as p21(Cip1) and p27(Kip1)) to facilitate both of these processes. A striking difference between K cyclin and mammalian cyclins is that K cyclin binding to cdk6 can substantially activate the catalytic activity of the complex without the requirement for cyclin H/cdk7 phosphorylation of the cdk T-loop; this phosphorylation is obligatory for endogenous cyclin/cdk activity. However, K cyclin/cdk6 complexes are not totally immune from cell cycle control since CAK phosphorylation is necessary for complete activation, Thus, CAK phosphorylated K cyclin/cdk6 targets multiple sites in the retinoblastoma protein (pRb) whereas the unphosphorylated complex targets a single site. The restricted substrate specificity of the non-CAK phosphorylated K cyclin/cdk6 complex is insufficient to enable K cyclin-mediated S phase entry. Thus, the viral K cyclin is reliant upon endogenous CAK activity to subvert the quiescent state.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England	Imperial College London	Mann, DJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England.							Arooz T, 2000, BIOCHEMISTRY-US, V39, P9494, DOI 10.1021/bi0009643; BATES S, 1994, ONCOGENE, V9, P71; BRIDGER JM, 1993, J CELL SCI, V104, P297; BROWN AJ, 1994, MOL BIOL CELL, V5, P921, DOI 10.1091/mbc.5.8.921; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Card GL, 2000, EMBO J, V19, P2877, DOI 10.1093/emboj/19.12.2877; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ellis M, 1999, EMBO J, V18, P644, DOI 10.1093/emboj/18.3.644; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JUNG JU, 1994, MOL CELL BIOL, V14, P7235, DOI 10.1128/MCB.14.11.7235; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Kelly BL, 1998, P NATL ACAD SCI USA, V95, P2535, DOI 10.1073/pnas.95.5.2535; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee TA, 2000, ONCOGENE, V19, P2257, DOI 10.1038/sj.onc.1203556; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Li MT, 1997, J VIROL, V71, P1984, DOI 10.1128/JVI.71.3.1984-1991.1997; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; Mann DJ, 1997, ONCOGENE, V14, P1759, DOI 10.1038/sj.onc.1201134; Mann DJ, 1999, EMBO J, V18, P654, DOI 10.1093/emboj/18.3.654; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Yang J, 1999, TRENDS CELL BIOL, V9, P207, DOI 10.1016/S0962-8924(99)01577-9	51	33	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3311	3322		10.1038/sj.onc.1204447	http://dx.doi.org/10.1038/sj.onc.1204447			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423981				2022-12-17	WOS:000169248800001
J	Sutherland, LC; Lerman, M; Williams, GT; Miller, BA				Sutherland, LC; Lerman, M; Williams, GT; Miller, BA			LUCA-15 suppresses CD95-mediated apoptosis in Jurkat T cells	ONCOGENE			English	Article						LUCA-15; 3p21.3; apoptosis; CD95; staurosporine; Jurkat	CHEMOTHERAPY-INDUCED APOPTOSIS; MOLECULAR-GENETIC CHANGES; CYTOCHROME-C RELEASE; RNA-BINDING PROTEIN; LUNG-CANCER; HOMOZYGOUS DELETION; CHROMOSOME 3P21.3; TUMOR-GROWTH; EXPRESSION PATTERNS; MICROCELL HYBRIDS	The candidate tumour suppressor gene, LUCA-15, maps to the lung cancer tumour suppressor locus 3p21.3. Overexpression of an alternative RNA splice variant of LUCA-15 has been shown to retard human Jurkat T cell proliferation and to accelerate CD95-mediated apoptosis, An antisense cDNA to the 3'-UTR of this splice variant was able to suppress CD95-mediated apoptosis, Here, we report that overexpression of LUCA-15 itself suppresses CD95-mediated apoptosis in Jurkat cells. This suppression occurs Drier to the final execution stage of the CD95 signalling pathway, and is associated with upregulation of the apoptosis inhibitory protein Bcl-2, LUCA-15 overexpression is also able to inhibit apoptosis induced by the protein kinase inhibitor staurosporine, but is not able to significantly suppress apoptosis mediated by the topoisomerase II inhibitor etoposide, These findings suggest that LUCA-15 is a selective inhibitor of cell death, and confirm the importance of the LUCA-15 genetic locus in the control of apoptosis.	Sigfried & Janet Weis Ctr Res, Geisinger Clin, Henry Hood Res Program, Danville, PA 17822 USA; Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pediat,Div Hematol Oncol, Hershey, PA 17033 USA; NCI, Immunobiol Lab, FCRDC, Frederick, MD 21702 USA; Univ Keele, Sch Life Sci, Keele ST5 5BG, Staffs, England	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Keele University	Sutherland, LC (corresponding author), Sigfried & Janet Weis Ctr Res, Geisinger Clin, Henry Hood Res Program, 100 N Acad Ave, Danville, PA 17822 USA.		Williams, Gwyn/GQY-7555-2022	Williams, Gwyn/0000-0003-4556-9930	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR010732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046778, R56DK046778] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline; NCRR NIH HHS [M01RR10732] Funding Source: Medline; NIDDK NIH HHS [DK46778] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P342, DOI 10.1016/S0968-0004(99)01437-1; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chung GTY, 1995, ONCOGENE, V11, P2591; Daigo Y, 1999, CANCER RES, V59, P1966; DALY MC, 1993, ONCOGENE, V8, P1721; DOLE M, 1994, CANCER RES, V54, P3253; Drabkin HA, 1999, ONCOGENE, V18, P2589, DOI 10.1038/sj.onc.1202601; Frederick A, 1998, ONCOGENE, V16, P153, DOI 10.1038/sj.onc.1201537; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; GRAY DA, 1995, ONCOGENE, V10, P2179; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Imreh S, 1997, GENE CHROMOSOME CANC, V20, P224; Inoue A, 1996, NUCLEIC ACIDS RES, V24, P2990, DOI 10.1093/nar/24.15.2990; Jackers P, 1996, ONCOGENE, V13, P495; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Johnson DE, 2000, CANCER RES, V60, P1818; KAMESAKI S, 1993, CANCER RES, V53, P4251; KASHUBA VI, 1995, CANCER GENET CYTOGEN, V81, P144, DOI 10.1016/0165-4608(94)00215-W; Kashuba VI, 1997, FEBS LETT, V419, P181, DOI 10.1016/S0014-5793(97)01449-X; Kholodnyuk I, 1997, GENE CHROMOSOME CANC, V18, P200, DOI 10.1002/(SICI)1098-2264(199703)18:3<200::AID-GCC6>3.0.CO;2-5; KOK K, 1994, CANCER RES, V54, P4183; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Latif F, 1997, HUM GENET, V99, P334, DOI 10.1007/s004390050368; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lock RB, 1996, CANCER RES, V56, P4006; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MIYASHITA T, 1993, BLOOD, V81, P151; Oh JJ, 1999, NUCLEIC ACIDS RES, V27, P4008, DOI 10.1093/nar/27.20.4008; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shriver SP, 1998, MUTAT RES-GENOMICS, V406, P9, DOI 10.1016/S1383-5726(98)00006-5; Sithanandam G, 1996, MOL CELL BIOL, V16, P868; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Sutherland LC, 2000, ONCOGENE, V19, P3774, DOI 10.1038/sj.onc.1203720; Sutherland LC, 1997, J IMMUNOL METHODS, V207, P179, DOI 10.1016/S0022-1759(97)00118-X; Szeles A, 1997, GENE CHROMOSOME CANC, V20, P329; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Timmer T, 1999, EUR J HUM GENET, V7, P478, DOI 10.1038/sj.ejhg.5200334; Todd MC, 1996, ONCOGENE, V13, P2387; Uchida K, 1997, CYTOGENET CELL GENET, V78, P209, DOI 10.1159/000134658; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wei MH, 1996, CANCER RES, V56, P1487; Wyllie AH, 1997, EUR J CELL BIOL, V73, P189; YAMAKAWA K, 1993, ONCOGENE, V8, P327; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	50	33	34	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2713	2719		10.1038/sj.onc.1204371	http://dx.doi.org/10.1038/sj.onc.1204371			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420683				2022-12-17	WOS:000168652600012
J	El-Tanani, MK; Barraclough, R; Wilkinson, MC; Rudland, PS				El-Tanani, MK; Barraclough, R; Wilkinson, MC; Rudland, PS			Regulatory region of metastasis-inducing DNA is the binding site for T cell factor-4	ONCOGENE			English	Article						metastasis-inducing DNA; osteopontin promoter; Tcf-4; metastasis	BETA-CATENIN; TRANSCRIPTION FACTOR; EPITHELIAL-CELLS; HMG BOX; OSTEOPONTIN; CANCER; EXPRESSION; CARCINOMA; IDENTIFICATION; ACTIVATION	Small 1000 bp fragments of DNA derived from human malignant breast cancer cells have been isolated which, when transfected into a benign rat mammary cell line induce the production of osteopontin and thereby endow those cells with the capability to metastasize in syngeneic rats. Using transient transfections of an osteopontin promoter-reporter construct, we have now identified the active moiety in the metastasis-inducing DNA as the binding site for the T cell factor (Tcf) family of transcription factors and located Tcf-4, beta -catenin and E-cadherin in the relevant DNA complex in vitro. The regulatory effects of the metastasis-inducing DNAs are therefore exerted, at least in part, by a CAAAG sequence which can sequester Tcf-4, thereby promoting transcription of the direct effector for metastasis in this system, osteopontin.	Univ Liverpool, Canc & Polio Res Fund Labs, Mol Med Grp, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Rudland, PS (corresponding author), Univ Liverpool, Canc & Polio Res Fund Labs, Mol Med Grp, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England.		Barraclough, Roger/AAH-6516-2020	Wilkinson, Mark/0000-0003-3109-6888; Barraclough, Roger/0000-0002-7203-1194; El-Tanani, Mohamed/0000-0002-4735-5445				Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen DS, 1997, J BIOL CHEM, V272, P20283, DOI 10.1074/jbc.272.32.20283; Chen HJ, 1997, ONCOGENE, V14, P1581, DOI 10.1038/sj.onc.1200993; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; DAVIES BR, 1994, CANCER RES, V54, P2785; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; Hugh TJ, 1999, INT J CANCER, V82, P504, DOI 10.1002/(SICI)1097-0215(19990812)82:4<504::AID-IJC6>3.0.CO;2-6; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Oates AJ, 1996, ONCOGENE, V13, P97; RIDALL AL, 1995, ANN NY ACAD SCI, V760, P59, DOI 10.1111/j.1749-6632.1995.tb44620.x; RUDLAND PS, 1997, Patent No. 9725443; Schilham MW, 1998, SEMIN IMMUNOL, V10, P127, DOI 10.1006/smim.1998.0114; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x	19	33	34	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1793	1797		10.1038/sj.onc.1204358	http://dx.doi.org/10.1038/sj.onc.1204358			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313926				2022-12-17	WOS:000167750900012
J	Wolff, A; Technau, A; Ihling, C; Technau-Ihling, K; Erber, R; Bosch, FX; Brandner, G				Wolff, A; Technau, A; Ihling, C; Technau-Ihling, K; Erber, R; Bosch, FX; Brandner, G			Evidence that wild-type p53 in neuroblastoma cells is in a conformation refractory to integration into the transcriptional complex	ONCOGENE			English	Article						p53-localization; neuroblastoma; PAb1801; p53-conformation; TPEN; Cd2+; leptomycin B	TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; CYTOPLASMIC SEQUESTRATION; MONOCLONAL-ANTIBODIES; NUCLEAR-LOCALIZATION; BINDING; PHOSPHORYLATION; CYCLE; MDM2; TRANSACTIVATION	Neuroblastoma (NB) cells reportedly accumulate wildtype p53 exclusively in the cytoplasm, However, immunofluorescence assays with five different antibodies showed that p53 accumulates in the nucleus of up to 10% of NB cells. PAb1801 detected cytoplasmic 'punctate structures' which were also found in p53-null cells, rendering this antibody unsuitable for p53 detection, A comparison of DO-1 and PAb1801 staining in NB tissue sections confirmed the results obtained with NB cells. Nuclear accumulation of p53 was induced in NB cells using substances which disturb p53's tertiary structure at its zinc finger motif, or by treatment with mitomycin C, Constitutive nuclear accumulation was observed in an SK-N-SH variant, AW-1, which has a point mutation in p53 at Cys176>Ser, disturbing the same motif, Even though p53 showed DNA-binding capability after mitomycin C treatment of NB cells, the target gene products MDM2 and p21(WAF1.CIP1.SDI1) were not synthesized and no p53 transactivating activity measured in a reporter gene assay. Therefore we suggest that p53 in NB cells might be predominantly in a conformation refractory to integration into the transcriptional complex, resulting in at Least partial transcriptional inactivity, hyperactive nuclear export and resistance to degradation by exogenously expressed MDM2.	Univ Freiburg, Inst Med Microbiol & Hyg, Dept Virol, D-79104 Freiburg, Germany; Univ Freiburg, Inst Pathol, D-79104 Freiburg, Germany; Univ Heidelberg, ENT Univ Hosp, Mol Biol Lab, D-69120 Heidelberg, Germany	University of Freiburg; University of Freiburg; Ruprecht Karls University Heidelberg	Technau, A (corresponding author), Univ Freiburg, Inst Med Microbiol & Hyg, Dept Virol, Hermann Herder Str 11, D-79104 Freiburg, Germany.		Erber, Ralf/B-6790-2008; Erber, Ralf/AAF-3002-2020; Wolff, Antonio C./T-8796-2019	Wolff, Antonio C./0000-0003-3734-1063				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bonsing BA, 1997, CYTOMETRY, V28, P11, DOI 10.1002/(SICI)1097-0320(19970501)28:1<11::AID-CYTO2>3.3.CO;2-H; BOSARI S, 1995, AM J PATHOL, V147, P790; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Cohen PA, 1998, ONCOGENE, V17, P2445, DOI 10.1038/sj.onc.1202190; Craig AL, 1999, ONCOGENE, V18, P6305, DOI 10.1038/sj.onc.1203085; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Danks MK, 1998, CELL DEATH DIFFER, V5, P678, DOI 10.1038/sj.cdd.4400408; Drane P, 1997, ONCOGENE, V15, P3013, DOI 10.1038/sj.onc.1201492; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; GOLDER H, 1996, ARION, V4, P1; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HEBEL M, 1986, Z NATURFORSCH C, V41, P94; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KALTHOFF H, 1993, ONCOGENE, V8, P289; Kim E, 1999, ONCOGENE, V18, P7310, DOI 10.1038/sj.onc.1203139; Komarova EA, 1997, CANCER RES, V57, P5217; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Meplan C, 1999, J BIOL CHEM, V274, P31663, DOI 10.1074/jbc.274.44.31663; Merlin T, 1998, INT J ONCOL, V13, P1007; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Plaumann B, 1996, ONCOGENE, V13, P1605; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; Schwab M, 1999, NATURWISSENSCHAFTEN, V86, P71, DOI 10.1007/s001140050574; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SIEGEL J, 1995, ONCOGENE, V11, P1363; Smart P, 1999, ONCOGENE, V18, P7378, DOI 10.1038/sj.onc.1203260; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; TECHNAU A, 2001, IN PRESS INT J ONCOL, V18; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Wolff A, 1997, INT J ONCOL, V11, P123; WOLFF A, 1999, J CANC RES CLIN ON S, V125, P24; Zaika A, 1999, J BIOL CHEM, V274, P27474, DOI 10.1074/jbc.274.39.27474	53	33	33	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 15	2001	20	11					1307	1317		10.1038/sj.onc.1204251	http://dx.doi.org/10.1038/sj.onc.1204251			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313875				2022-12-17	WOS:000167495000005
J	Zvara, A; Fajardo, JE; Escalante, M; Cotton, G; Muir, T; Kirsch, KH; Birge, RB				Zvara, A; Fajardo, JE; Escalante, M; Cotton, G; Muir, T; Kirsch, KH; Birge, RB			Activation of the focal adhesion kinase signaling pathway by structural alterations in the carboxyl-terminal region of c-Crk II	ONCOGENE			English	Article						Crk; adaptor proteins; SH3 linker region; C-terminal SH3 domain; tyrosine phosphorylation; focal adhesion kinase	MEDIATED CELL-ADHESION; TYROSINE-PHOSPHORYLATION; ADAPTER PROTEIN; SH3 DOMAIN; PTP-PEST; V-CRK; SRC; P130(CAS); SUBSTRATE; RAS	The Crk II adaptor protein encodes an SH2/SH3-domain containing adaptor protein with an SH2-SH3-SH3 domain structure that transmits signals from tyrosine kinases, The two SH3 domains are separated by a 54 amino acid linker region, whose length is highly conserved in xenopus, chicken, and mamalian Crk II proteins. To gain a better understanding into the role of the C-terminal region of Crk, we generated a series of C-terminal SH3 domain and SH3 linker mutants and examined their role in tyrosine kinase pathways. Expression of point mutations in the C-terminal SH3 domain (W276K Crk), at the tyrosine phosphorylation site (Y222F Crk II), or truncation of the entire C-terminus (Crk I or Crk Delta 242), all increased c-Abl binding to the N-terminal SH3 domain of Crk and, where relevant, increased Tyr(222) phosphorylation, Deletion analysis of c-Crk II also revealed the presence of a C-terminal segment important for transactivation of FAK. Such mutants, Crk Delta 255 or Crk Delta 242 Extended Linker (Crk Delta 242([EL])), characterized by a disruption in the SH3 linker/C-terminal SH3 boundary, induced robust hyperphosphorylation of focal adhesion kinase (FAK) on Tyr(397), hyperphosphorylation of focal adhesion proteins p130(cas) and paxillin and increased focal adhesion formation in NIH3T3 cells. The effects of Crk Delta 242([EL]) could be abrogated by co-expression of dominant negative c-Src or the protein tyrosine phosphatase PTP - PEST, but not by dominant negative Abl. Our results suggest that the C-terminal region of Crk contains negative regulatory elements important for both Abl and FAK dependent signal pathways, and offers a paradigm for an autoinhibitory region in the SH3 linker/C-terminal SH3 domain.	Rockefeller Univ, Oncol Mol Lab, New York, NY 10021 USA; Rockefeller Univ, Lab Synthet Prot Chem, New York, NY 10021 USA	Rockefeller University; Rockefeller University	Birge, RB (corresponding author), Rockefeller Univ, Oncol Mol Lab, 1230 York Ave, New York, NY 10021 USA.		Muir, Tom/AHD-0860-2022	Muir, Tom/0000-0001-9635-0344; Kirsch, Kathrin/0000-0003-1532-1715	NIGMS NIH HHS [GM55760] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cote JF, 1999, J BIOL CHEM, V274, P20550, DOI 10.1074/jbc.274.29.20550; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Galletta BJ, 1999, GENE, V228, P243, DOI 10.1016/S0378-1119(99)00010-4; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Ling P, 1999, MOL CELL BIOL, V19, P1359; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OGAWA S, 1994, ONCOGENE, V9, P1669; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4	53	33	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2001	20	8					951	961		10.1038/sj.onc.1204173	http://dx.doi.org/10.1038/sj.onc.1204173			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314030				2022-12-17	WOS:000167097000006
J	Monni, R; Santos, SCR; Mauchauffe, M; Berger, R; Ghysdael, J; Gouilleux, F; Gisselbrecht, S; Bernard, O; Penard-Lacronique, V				Monni, R; Santos, SCR; Mauchauffe, M; Berger, R; Ghysdael, J; Gouilleux, F; Gisselbrecht, S; Bernard, O; Penard-Lacronique, V			The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells	ONCOGENE			English	Article						leukemogenesis; TEL-Jak2; Socs1; Ba/F3; interferon-gamma	GENE-EXPRESSION; IFN-GAMMA; PROTEINS; STAT5; MICE; FAMILY; ALPHA; JAK2; TEL; CIS	The leukemia-associated TEL-Jak2 fusion protein possesses a constitutive tyrosine kinase activity and transforming properties in hematopoietic cell lines and animal models, In the murine pro-B Ba/F3 cell line, this fusion constitutively activates the Signal Transducer and Activator of Transcription 5 (Stat5) factors and, as a consequence, induces the sustained expression of various Stat5-target genes including the Cytokine Inducible SH2-containing protein (Cis) gene, which codes for a member of the Suppressor of Cytokine Signaling (Socs) protein family, In TEL-Jak2-transformed Ba/F3 cells, me also observed the upregulation of the Socs1 gene, whose product has been reported to negatively regulate the Jak kinase activity. In transient transfection experiments, Socs1 physically interacts with TEL-Jak2 and interferes with the TEL-Jak2-induced phosphorylation and activation of Stat5 factors, probably through the Socs1-induced proteasome-mediated degradation of the fusion protein. Interestingly, TEL-Jak2-expressing Ba/F3 cells were found to be resistant to the antiproliferative activities of gamma interferon (IFN-gamma) seemingly as a consequence of Socs1 constitutive expression. These results indicate that the Socs1-dependent cytokine feedback loop, although active, is bypassed by the TEL-Jak2 fusion, but may play a role in the leukemogenic process by altering the cytokine responses of the leukemic cells. Our results also suggest that Socs1 plays a role in shutting down the signaling from the normally activated Jak2 kinase by inducing its proteasome-dependent degradation.	Ctr Etud Polymorphisme Humain, INSERM, U434, F-75010 Paris, France; Univ Paris 05, Inst Cochin Genet Mol, INSERM, U363, F-75014 Paris, France; Ctr Univ, Inst Curie, Sect Rech, CNRS,UMR 146, F-91405 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Penard-Lacronique, V (corresponding author), Ctr Etud Polymorphisme Humain, INSERM, U434, 27 Rue Juliette Dodu, F-75010 Paris, France.		GHYSDAEL, Jacques/F-3377-2013; Santos, Susana/AAM-8902-2021; Bernard, Olivier A./E-5721-2016; Penard-Lacronique, Virginie/E-5729-2016; Penard-Lacronique, Virginie/R-1938-2019	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; Bernard, Olivier/0000-0002-0463-9747; Constantino Rosa Santos, Susana/0000-0002-5711-1292; Gouilleux, Fabrice/0000-0001-6047-1718				Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Carron C, 2000, BLOOD, V95, P3891; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; De Sepulveda P, 1999, EMBO J, V18, P904; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Gisselbrecht S, 1999, EUR CYTOKINE NETW, V10, P463; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Metcalf D, 1999, LEUKEMIA, V13, P926, DOI 10.1038/sj.leu.2401440; Morita Y, 2000, P NATL ACAD SCI USA, V97, P5405, DOI 10.1073/pnas.090084797; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Nicholson SE, 1998, J LEUKOCYTE BIOL, V63, P665, DOI 10.1002/jlb.63.6.665; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; Schluter G, 2000, BIOCHEM BIOPH RES CO, V268, P255, DOI 10.1006/bbrc.2000.2109; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Tomic S, 1999, MOL CELL ENDOCRINOL, V158, P45, DOI 10.1016/S0303-7207(99)00180-X; Venkataraman C, 1999, J IMMUNOL, V162, P4053; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; Yamashita Y, 1998, BLOOD, V91, P1496, DOI 10.1182/blood.V91.5.1496.1496_1496_1507; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	38	33	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2001	20	7					849	858		10.1038/sj.onc.1204201	http://dx.doi.org/10.1038/sj.onc.1204201			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314018	Green Published			2022-12-17	WOS:000166924400008
J	Katich, SC; Zerfass-Thome, K; Hoffmann, I				Katich, SC; Zerfass-Thome, K; Hoffmann, I			Regulation of the Cdc25A gene by the human papillomavirus Type 16 E7 oncogene	ONCOGENE			English	Article						Cdc25; cell cycle; human papillomavirus type 16; E7 oncoprotein	CELL-CYCLE REGULATION; S-PHASE; G(1)/S TRANSITION; EXPRESSION; ACTIVATION; E2F; PHOSPHATASE; PHOSPHORYLATION; ONCOPROTEIN; REPRESSION	Cdc25A is a tyrosine phosphatase that is involved in the regulation of the G1/S phase transition by activating cyclin E/Cdk2 and cyclin A/Cdk2 complexes through removal of inhibitory phosphorylations. The E6 and E7 oncoproteins of the high-risk human papillomaviruses (HPV) interact with and functionally abrogate the p53 and pRB proteins, respectively. In the present study we have investigated the regulation of the Cdc25A promoter during G1 and S-phases of the cell cycle and by the HPV-16 E7 oncoprotein. Serum induction leads to a derepression of the Cdc25A promoter and can be mediated through two E2F binding sites, E2F-A and E2F-C, While E2F-A is by both E2F1 and E2F4, E2F-C is regulated only by E2F1, The Cdc25A promoter is transactivated by the E7 oncogene of HPV-16. Furthermore, Cdc25A levels art highly increased in E7-expressing cell lines, Inducible expression of E7 leads to an immediate increase in Cdc25A protein levels. These data suggest that Cdc25A may be a critical target of HPV-16 E7 in the disruption of the G1/S phase transition.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Hoffmann, I (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.							Arata Y, 2000, J BIOL CHEM, V275, P6337, DOI 10.1074/jbc.275.9.6337; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Botz J, 1996, MOL CELL BIOL, V16, P3401; Boyer SN, 1996, CANCER RES, V56, P4620; Chen X, 1999, MOL CELL BIOL, V19, P4695; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOPPESEYLER F, 1992, NUCLEIC ACIDS RES, V20, P6701, DOI 10.1093/nar/20.24.6701; Iavarone A, 1999, MOL CELL BIOL, V19, P916; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; Lammer C, 1998, J CELL SCI, V111, P2445; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Spitkovsky D, 1996, ONCOGENE, V12, P2549; Vigo E, 1999, MOL CELL BIOL, V19, P6379; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	32	33	38	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					543	550		10.1038/sj.onc.1204130	http://dx.doi.org/10.1038/sj.onc.1204130			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313986				2022-12-17	WOS:000166755000001
J	Droin, N; Rebe, C; Bichat, F; Hammann, A; Bertrand, R; Solary, E				Droin, N; Rebe, C; Bichat, F; Hammann, A; Bertrand, R; Solary, E			Modulation of apoptosis by procaspase-2 short isoform: selective inhibition of chromatin condensation, apoptotic body formation and phosphatidylserine externalization	ONCOGENE			English	Article						apoptosis; caspase-2 isoforms; nuclear changes	CELL-DEATH; DNA FRAGMENTATION; ADAPTER MOLECULE; MESSENGER-RNA; UP-REGULATION; CASPASE-2; ACTIVATION; EXPRESSION; PROTEIN; ANTIGEN	Procaspase-2 is one of the cysteine aspartate proteases involved in apoptotic cell death. Alternative splicing of CASP-2 messenger RNA generates a long isoform, procaspase-2L, whose overexpression induces cell death and a truncated isoform, procaspase-2S, whose function remains poorly defined. The present study explored the consequences of procaspase-2S overexpression in U937 human leukemic cells exposed to the topoisomerase If inhibitor etoposide as an apoptotic stimulus, Overexpression of procaspase-2S in U937 cells partially prevented nuclear changes associated with etoposide-induced cell death, as determined by Hoechst 33342 staining of nuclear chromatin and electron microscopy studies, Procaspase-2S also prevented the maturation of apoptotic bodies, delayed phosphatidylserine externalization on the plasma membrane and prevented the cleavage and activation of procaspase-2L, These effects were not observed when the cysteine 289 in the consensus QACRG motif was mutated into a serine. Wild-type procaspase-2S overexpression did not influence the cleavage of procaspase-3, procaspase-7 and poly(ADP-ribose)polymerase nor the fragmentation of nuclear DNA into nucleosome-sized fragments. Altogether, these results indicate that the short isoform of procaspase-2 negatively interferes with selective features of apoptosis, an activity that is suppressed by mutation of the cysteine 289.	Fac Med, INSERM U517, F-21033 Dijon, France; Fac Pharm, INSERM U517, F-21033 Dijon, France; Ctr Univ Montreal Hosp Ctr, Notre Dame Hosp, Montreal, PQ H2L 4M1, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Montreal	Solary, E (corresponding author), Fac Med, INSERM U517, 7 Blvd Jeanne Arc, F-21033 Dijon, France.		REBE, Cédric/AAD-4316-2019; Droin, Nathalie M/Y-5506-2018	REBE, Cédric/0000-0001-8831-145X; Droin, Nathalie M/0000-0002-6099-5324; Solary, Eric/0000-0002-8629-1341				Ahmad M, 1997, CANCER RES, V57, P615; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BERTRAND R, 1991, CANCER RES, V51, P6280; Bonnotte B, 1998, J IMMUNOL, V161, P1433; Bonnotte B, 2000, J IMMUNOL, V164, P1995, DOI 10.4049/jimmunol.164.4.1995; Buendia B, 1999, J CELL SCI, V112, P1743; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Droin N, 1998, ONCOGENE, V16, P2885, DOI 10.1038/sj.onc.1201821; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fujimura M, 1999, J CANCER RES CLIN, V125, P389, DOI 10.1007/s004320050291; Ito A, 2000, FEBS LETT, V470, P360, DOI 10.1016/S0014-5793(00)01351-X; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; Kojima M, 1998, NEUROSCI RES, V31, P211, DOI 10.1016/S0168-0102(98)00039-X; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Kumar S, 1997, CELL DEATH DIFFER, V4, P378, DOI 10.1038/sj.cdd.4400251; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; McCarthy JV, 1997, CELL DEATH DIFFER, V4, P756, DOI 10.1038/sj.cdd.4400296; McIlroy D, 2000, GENE DEV, V14, P549; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Pelassy C, 2000, BIOCHEM PHARMACOL, V59, P855, DOI 10.1016/S0006-2952(99)00383-4; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Ren Y, 1998, CELL DEATH DIFFER, V5, P563, DOI 10.1038/sj.cdd.4400407; Ronchetti A, 1999, J IMMUNOL, V163, P130; Rovere P, 1998, J IMMUNOL, V161, P4467; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Schmitt E, 1998, EXP CELL RES, V240, P107, DOI 10.1006/excr.1998.4003; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1999, CANCER RES, V59, P999; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Swanton E, 1999, ONCOGENE, V18, P1781, DOI 10.1038/sj.onc.1202490; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Verhoven B, 1999, CELL DEATH DIFFER, V6, P262, DOI 10.1038/sj.cdd.4400491; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zamzami N, 1999, NATURE, V401, P127, DOI 10.1038/43591; Zhang JD, 1999, J CELL BIOL, V145, P99, DOI 10.1083/jcb.145.1.99	56	33	33	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					260	269		10.1038/sj.onc.1204066	http://dx.doi.org/10.1038/sj.onc.1204066			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313953				2022-12-17	WOS:000166410900013
J	Remy, P; Baltzinger, M				Remy, P; Baltzinger, M			The Ets-transcription factor family in embryonic development: lessons from the amphibian and bird	ONCOGENE			English	Review						Xenopus; chicken; cell migration; epithelium/mesenchyme transition; adhesion; vascularization	NICOTINIC ACETYLCHOLINE-RECEPTOR; VASCULAR ENDOTHELIAL-CADHERIN; HEPATOCYTE GROWTH-FACTOR; TRANSGENIC MICE DEVELOP; TERNARY COMPLEX FACTORS; DEVELOPING AVIAN HEART; GA-BINDING-PROTEIN; NEURAL CREST CELLS; ONCOGENE C-ETS; XI-FLI GENE	This chapter reviews the expression and role of Ets-genes during embryogenesis of amphibians and birds. In addition to overlapping expression domains, some of them exhibit cell type-specific expression. Many of them are expressed in migratory cells: neural crest, endothelial and pronephric duct cells for instance. They are also transcribed in embryonic areas affected by epitheliomesenchymal transitions. Both processes involve modifications of cellular adhesion. Ets-family genes appear to coordinate changes in the expression of adhesion molecules and degradation of the extracellular matrix upon regulation of matrix metalloproteinases and their specific inhibitors. These functions are essential for physiological processes like tissue remodelling during embryogenesis or wound healing. Unfortunately they also play a harmful role in metastasis. Recent studies in the nervous system showed that Ets-genes contribute to the establishment of a cellular identity. This identity could rely on definite cell-surface determinants, among which cadherins could play an important role. In addition to cell-type specific expression, other factors contribute to the specificity of function of Ets-genes, These genes have a broad specificity of recognition of target sequences in gene promoters, insufficient for accurate control of gene expression. A fine tuning could arise from combinatorial interactions with other Ets- or accessory proteins.	IPCB, CNRS, FRE 2168, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Remy, P (corresponding author), IPCB, CNRS, FRE 2168, 21 Rue Rene Descartes, F-67084 Strasbourg, France.							ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; AMOUYEL P, 1988, BRAIN RES, V447, P149, DOI 10.1016/0006-8993(88)90976-6; Anderson MK, 1999, DEVELOPMENT, V126, P3131; Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Baltzinger M, 1999, DEV DYNAM, V216, P420, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<420::AID-DVDY10>3.0.CO;2-C; Barbeau B, 1996, BBA-GENE STRUCT EXPR, V1307, P220, DOI 10.1016/0167-4781(96)00060-7; Barnache S, 1998, ONCOGENE, V16, P2989, DOI 10.1038/sj.onc.1202095; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Begue A, 1997, GENE EXPRESSION, V6, P333; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BISCHOFF J, 1995, TRENDS CELL BIOL, V5, P69, DOI 10.1016/S0962-8924(00)88949-7; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURDETT LA, 1992, NUCLEIC ACIDS RES, V20, P371, DOI 10.1093/nar/20.2.371; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Buttice G, 1996, ONCOGENE, V13, P2297; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chang LF, 1996, J BIOL CHEM, V271, P6467, DOI 10.1074/jbc.271.11.6467; Charron G, 1995, J BIOL CHEM, V270, P30604, DOI 10.1074/jbc.270.51.30604; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JH, 1988, ONCOGENE RES, V2, P371; Chen YL, 1999, MECH DEVELOP, V80, P67, DOI 10.1016/S0925-4773(98)00194-4; Chen ZQ, 1997, CANCER RES, V57, P2013; CHEN ZQ, 1990, SCIENCE, V250, P1416, DOI 10.1126/science.2255913; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; COLLAZO A, 1993, DEVELOPMENT, V118, P363; CORNISH JA, 1993, DEV BIOL, V159, P338, DOI 10.1006/dbio.1993.1245; Crepieux Pascale, 1993, Gene Expression, V3, P215; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Dalgleish P, 2000, NUCLEIC ACIDS RES, V28, P560, DOI 10.1093/nar/28.2.560; Davies JA, 1996, ACTA ANAT, V156, P187; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; deLaunoit Y, 1997, BIOCHEM MOL MED, V61, P127, DOI 10.1006/bmme.1997.2605; DESBIENS X, 1991, DEVELOPMENT, V111, P699; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; Dhulipala PDK, 1998, ONCOGENE, V17, P1149, DOI 10.1038/sj.onc.1202030; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; DONAHUE JP, 1994, BBA-GENE STRUCT EXPR, V1219, P228, DOI 10.1016/0167-4781(94)90278-X; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; Edel MJ, 1999, ANTICANCER RES, V19, P2945; Edel MJ, 1998, ANTICANCER RES, V18, P4505; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; EKBLOM P, 1989, FASEB J, V3, P2142; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; FEENEY JF, 1946, J MORPHOL, V78, P231, DOI 10.1002/jmor.1050780205; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Gambarotta G, 1996, ONCOGENE, V13, P1911; Ghosh A, 1998, CELL, V95, P303, DOI 10.1016/S0092-8674(00)81762-6; GHYSDAEL J, 1986, EMBO J, V5, P2251, DOI 10.1002/j.1460-2075.1986.tb04492.x; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GHYSDAEL J, 1997, PROG GENE EXPRESS, P29; GOLTZENE F, 2000, IN PRESS EXP CELL RE; GORGONI B, 1995, BIOCHEM BIOPH RES CO, V215, P1088, DOI 10.1006/bbrc.1995.2575; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; Gory-Faure S, 1999, DEVELOPMENT, V126, P2093; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Habelhah H, 1999, ONCOGENE, V18, P1771, DOI 10.1038/sj.onc.1202465; Hagedorn L, 2000, DEV BIOL, V219, P44, DOI 10.1006/dbio.1999.9595; Hanzawa M, 2000, CARCINOGENESIS, V21, P1079, DOI 10.1093/carcin/21.6.1079; Hay ED, 1995, ACTA ANAT, V154, P8; Hendricks T, 1999, J NEUROSCI, V19, P10348; HENRY JJ, 1990, DEV BIOL, V141, P149, DOI 10.1016/0012-1606(90)90110-5; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; HROMAS R, 1994, INT J HEMATOL, V59, P257; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Inoue T, 1997, DEV BIOL, V183, P183, DOI 10.1006/dbio.1996.8501; Iwamoto M, 2000, J CELL BIOL, V150, P27, DOI 10.1083/jcb.150.1.27; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; JORCYK CL, 1991, ONCOGENE, V6, P523; Kamura T, 1997, J BIOL CHEM, V272, P11361; Kao HY, 2000, GENE DEV, V14, P55; Kas K, 2000, J BIOL CHEM, V275, P2986, DOI 10.1074/jbc.275.4.2986; Kherrouche Z, 1998, ONCOGENE, V16, P1357, DOI 10.1038/sj.onc.1201650; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kitange G, 1999, LAB INVEST, V79, P407; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Konishi Y, 1999, ONCOGENE, V18, P6795, DOI 10.1038/sj.onc.1203118; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Luton D, 1997, EARLY HUM DEV, V47, P147, DOI 10.1016/S0378-3782(96)01775-6; Macias D, 1998, ANAT EMBRYOL, V198, P307, DOI 10.1007/s004290050186; Mackie EJ, 1997, INT J BIOCHEM CELL B, V29, P1133, DOI 10.1016/S1357-2725(97)00031-9; Mager AM, 1998, INT J DEV BIOL, V42, P561; MagnaghiJaulin L, 1996, NUCLEIC ACIDS RES, V24, P1052, DOI 10.1093/nar/24.6.1052; Majka SM, 1997, MECH DEVELOP, V68, P127, DOI 10.1016/S0925-4773(97)00138-X; MARCHIONI M, 1993, MOL CELL BIOL, V13, P6479, DOI 10.1128/MCB.13.10.6479; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Mattot V, 2000, ONCOGENE, V19, P762, DOI 10.1038/sj.onc.1203248; McDonough J, 1997, J NEUROSCI, V17, P2273; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; MEDONOUGH J, 2000, IN PRESS J BIOL CHEM; Meyer D, 1997, INT J DEV BIOL, V41, P607; Meyer D, 1995, INT J DEV BIOL, V39, P909; MEYER D, 1993, MECH DEVELOP, V44, P109, DOI 10.1016/0925-4773(93)90061-2; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; Munchberg SR, 1999, MECH DEVELOP, V80, P53, DOI 10.1016/S0925-4773(98)00193-2; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NAKAGAWA S, 1995, DEVELOPMENT, V121, P1321; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Noti JD, 1996, MOL IMMUNOL, V33, P115, DOI 10.1016/0161-5890(95)00140-9; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; Pande P, 1999, J PATHOL, V189, P40, DOI 10.1002/(SICI)1096-9896(199909)189:1<40::AID-PATH405>3.0.CO;2-#; Papas Takis S., 1997, Leukemia (Basingstoke), V11, P557; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; Pardanaud L, 1996, DEVELOPMENT, V122, P1363; Pastorcic M, 1999, J BIOL CHEM, V274, P24297, DOI 10.1074/jbc.274.34.24297; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; PETERSOHN D, 1995, J BIOL CHEM, V270, P24361, DOI 10.1074/jbc.270.41.24361; PRASAD DDK, 1994, ONCOGENE, V9, P669; PRASAD DDK, 1992, CANCER RES, V52, P5833; Quaranta V, 2000, J CELL BIOL, V149, P1167, DOI 10.1083/jcb.149.6.1167; QUEVA C, 1993, ONCOGENE, V8, P2511; Rameil P, 2000, ONCOGENE, V19, P2086, DOI 10.1038/sj.onc.1203542; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Remy P, 1996, INT J DEV BIOL, V40, P577; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; SADAGHIANI B, 1987, DEV BIOL, V124, P91, DOI 10.1016/0012-1606(87)90463-5; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; Sarrazin S, 2000, MOL CELL BIOL, V20, P2959, DOI 10.1128/MCB.20.9.2959-2969.2000; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Shao NS, 1998, ONCOGENE, V17, P527, DOI 10.1038/sj.onc.1201931; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Sieweke Michael H., 1997, Leukemia (Basingstoke), V11, P486; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Starck J, 1999, MOL CELL BIOL, V19, P121; Starck J, 1999, EXP HEMATOL, V27, P630, DOI 10.1016/S0301-472X(99)00006-5; Stehelin Dominique, 1998, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V192, P217; STIEGLER P, 1990, NUCLEIC ACIDS RES, V18, P5298, DOI 10.1093/nar/18.17.5298; STIEGLER P, 1993, MECH DEVELOP, V41, P163, DOI 10.1016/0925-4773(93)90046-Z; STOCKER M, 1987, NATURE, V327, P239; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; Suzuki SC, 1997, MOL CELL NEUROSCI, V9, P433, DOI 10.1006/mcne.1997.0626; Tajima A, 2000, BBA-GENE STRUCT EXPR, V1492, P377, DOI 10.1016/S0167-4781(00)00121-4; Takaoka AS, 1998, J BIOL CHEM, V273, P33848, DOI 10.1074/jbc.273.50.33848; Tamir A, 1999, MOL CELL BIOL, V19, P4452; THIBAUDEAU G, 1993, DEV BIOL, V159, P657, DOI 10.1006/dbio.1993.1272; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Turque N, 1997, INT J DEV BIOL, V41, P103; Vallorosi CJ, 2000, J BIOL CHEM, V275, P3328, DOI 10.1074/jbc.275.5.3328; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; Vary CPH, 2000, EXP CELL RES, V257, P213, DOI 10.1006/excr.2000.4879; Vlaeminck-Guillem V, 2000, MECH DEVELOP, V91, P331, DOI 10.1016/S0925-4773(99)00272-5; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1997, TRANSCRIPTION FACTOR, P253; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WATSON DK, 1990, ONCOGENE, V5, P1521; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; WATSON DK, 1988, VIROLOGY, V167, P1, DOI 10.1016/0042-6822(88)90047-5; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WEN SC, 1995, EXP CELL RES, V217, P8, DOI 10.1006/excr.1995.1057; Wernert N, 1999, ANGEW CHEM INT EDIT, V38, P3228, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3228::AID-ANIE3228>3.0.CO;2-8; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Wheat W, 1999, MOL CELL BIOL, V19, P2231; WOLFF CM, 1991, CELL GROWTH DIFFER, V2, P447; WOLFF CM, 1990, NUCLEIC ACIDS RES, V18, P4603, DOI 10.1093/nar/18.15.4603; Yagi T, 2000, GENE DEV, V14, P1169; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; ZACKSON SL, 1986, DEV BIOL, V117, P342, DOI 10.1016/0012-1606(86)90304-0; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	206	33	34	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2000	19	55					6417	6431		10.1038/sj.onc.1204044	http://dx.doi.org/10.1038/sj.onc.1204044			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175358				2022-12-17	WOS:000166595000004
J	Lim, SJ; Lopez-Berestein, G; Hung, MC; Lupu, R; Tari, AM				Lim, SJ; Lopez-Berestein, G; Hung, MC; Lupu, R; Tari, AM			Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells	ONCOGENE			English	Article						Grb2; heregulin; ErbB2; Akt; breast cancer	PROTEIN-KINASE-B; RECEPTOR TYROSINE KINASES; MAMMARY EPITHELIAL-CELLS; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; TUMOR-CELLS; ACTIVATION; RAS	ErbB2 can be activated by its own overexpression or be transactivated by the heregulin polypeptide growth factor. Activation of ErbB2 leads to breast cancer cell proliferation, presumably by inducing the activation of extracellular signal-regulated kinases 1,2 (Erk1,2) and Akt. We have previously reported that the growth factor receptor bound protein-2 (Grb2) is required for the proliferation of ErbB2-overexpressing breast cancer cells. We investigated here whether Grb2 protein plays a role in heregulin-stimulated proliferation. Grb2 protein inhibition led to growth inhibition of heregulin-stimulated breast cancer cells, but not Erk1,2 inactivation. These findings are similar to our earlier observations in ErbB2-overexpressing cells. Since Akt can also be activated by heregulin, the effects of Grb2 inhibition on Akt were examined. Akt was inactivated following Grb2 downregulation in heregulin-stimulated breast cancer cells. We then examined the effects of Grb2 downregulation on Akt in ErbB2-overexpressing cells in the absence of heregulin, Similar to heregulin-stimulated cells, Grb2 inhibition also led to Akt inactivation in ErbB2-over-expressing breast cancer cells. Our results indicate that the activation of ErbB2 by heregulin or by its overexpression requires Grb2 to stimulate the Akt pathway to propagate mitogenic signals.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunobiol & Drug Carriers, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Tari, AM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunobiol & Drug Carriers, Box 60, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; ALIMANDI M, 1995, ONCOGENE, V10, P1813; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FIDDES RJ, 1995, CELL GROWTH DIFFER, V6, P1567; Filippa N, 1999, MOL CELL BIOL, V19, P4989; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; HOLMES WE, 1992, SCIENCE, V256, P1206; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Lewis GD, 1996, CANCER RES, V56, P1457; Li J, 1998, CANCER RES, V58, P5667; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Marais R, 1996, CANCER SURV, V27, P101; MARTE BM, 1995, ONCOGENE, V10, P167; MCCANN AH, 1991, CANCER RES, V51, P3296; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; PATERSON MC, 1991, CANCER RES, V51, P556; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIERCE JH, 1991, ONCOGENE, V6, P1189; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SEGATTO O, 1993, ONCOGENE, V8, P2105; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; TANG C, 1996, CANCER RES, P3350; TANG M, 1999, CANCER RES, V59, P1620; Tari AM, 1997, BIOCHEM BIOPH RES CO, V235, P383, DOI 10.1006/bbrc.1997.6791; Tari AM, 1999, ONCOGENE, V18, P1325, DOI 10.1038/sj.onc.1202422; Tari AM, 2000, INT J CANCER, V86, P295, DOI 10.1002/(SICI)1097-0215(20000415)86:2<295::AID-IJC22>3.0.CO;2-K; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717	54	33	37	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6271	6276		10.1038/sj.onc.1204014	http://dx.doi.org/10.1038/sj.onc.1204014			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175341				2022-12-17	WOS:000166210500010
J	Iwamoto, T; Senga, T; Naito, Y; Matsuda, S; Miyake, Y; Yoshimura, A; Hamaguchi, M				Iwamoto, T; Senga, T; Naito, Y; Matsuda, S; Miyake, Y; Yoshimura, A; Hamaguchi, M			The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation	ONCOGENE			English	Article						JAB; JAK; STAT; Src; cytokine	CONSTITUTIVE ACTIVATION; SIGNAL-TRANSDUCTION; CONFERS RESISTANCE; CELLS; PROTEIN; KINASE; GENE; TRANSFORMATION; ASSOCIATION; BINDING	Recently, constitutive activation of JAK kinases (JAKs) and/or signal transducers and activators of transcription (STATs) has been reported in growing numbers of human cancer cells as well as oncogene-transformed cells. JAB/SOCS-1 has been shown to be an intrinsic JAK tyrosine kinase inhibitor and to suppress the cytokine-dependent JAK - STAT pathway. In this report, we investigated the effect of ectopic expression of JAB on v-Src-induced JAK-STAT activation, Forced expression of JAB in v-Src-transformed NIH3T3 cells neither suppressed phosphorylation of STAT3 and JAK1/JAK2 nor blocked STAT3-reporter gene activation. Colony forming assay also showed that JAB did not suppress v-Src-induced transformation of NIH3T3 cells, while dominant negative STAT3 suppressed it. In contrast, JAB could downregulate phosphorylation of STAT1 and STAT3 induced by interferon gamma (IFN gamma,) and interleukin-6 (IL-6) plus soluble IL6 receptor (sIL-6R), respectively. Furthermore, in vitro kinase assay indicated that JAB suppressed hyperactivation of JAK1/JAK2 and JAK1 induced by INF, and IL-6 plus sIL-6R respectively, but not v-Src-induced basal JAK1/JAK2 activity. Nevertheless, both JAK1/JAK2 activated by v-Src and that activated by IL-6 plus sIL-6R could similarly bind JAB. These results clearly demonstrate that JAB distinguishes cytokine-induced JAK-STAT signaling from v-Src-induced one and can not suppress the transformation with v-Src.	Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Ophthalmol, Showa Ku, Nagoya, Aichi 4668550, Japan; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan	Nagoya University; Nagoya University; Kurume University	Hamaguchi, M (corresponding author), Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		Yoshimura, Akihiko/K-5515-2013					Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Niu GL, 1999, CANCER RES, V59, P5059; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	31	33	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4795	4801		10.1038/sj.onc.1203829	http://dx.doi.org/10.1038/sj.onc.1203829			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032030				2022-12-17	WOS:000089528800014
J	Maya, R; Oren, M				Maya, R; Oren, M			Unmasking of phosphorylation-sensitive epitopes on p53 and Mdm2 by a simple Western-phosphatase procedure	ONCOGENE			English	Article						p53; Mdm2; phosphatase; monoclonal antibodies; Western blot	PROTEIN-KINASE-C; DNA-BINDING FUNCTION; GROWTH ARREST; CELL-LINES; IN-VITRO; INDUCTION; DEPHOSPHORYLATION; SIGNALS	Monoclonal antibodies are widely used for the assessment of protein expression levels, protein-protein interactions and protein localization. Phosphorylation of one or more residues within an epitope recognized by a particular antibody may compromise the ability of that antibody to bind the target protein. Inhibition of immunoreactivity by phosphorylation has been reported for many antibody/protein pairs. Here me describe a simple convenient protocol for assessing the effect of phosphorylation on immunoreactivity? employing phosphatase treatment of Western blotted membranes. The efficacy of this protocol is demonstrated for p53 and for Mdm2. This method is useful for obtaining more uniform protein quantification, as well as for rapid assessment of changes in the extent of phosphorylation within a given epitope in response to defined signals.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, POB 26, IL-76100 Rehovot, Israel.			Oren, Moshe/0000-0003-4311-7172	NCI NIH HHS [R01 CA-40099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Bond JA, 1999, ONCOGENE, V18, P3788, DOI 10.1038/sj.onc.1202733; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Craig AL, 1999, ONCOGENE, V18, P6305, DOI 10.1038/sj.onc.1203085; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; Juven-Gershon T, 1998, MOL CELL BIOL, V18, P3974, DOI 10.1128/MCB.18.7.3974; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Milne DM, 1996, ONCOGENE, V13, P205; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pitkanen K, 1998, ONCOGENE, V16, P459, DOI 10.1038/sj.onc.1201528; RAYNAL S, 1994, GROWTH FACTORS, V11, P197, DOI 10.3109/08977199409046917; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39	23	33	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3213	3215		10.1038/sj.onc.1203658	http://dx.doi.org/10.1038/sj.onc.1203658			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918576				2022-12-17	WOS:000088019200010
J	Renard, CA; Fourel, G; Bralet, MP; Degott, C; De la Coste, A; Perret, C; Tiollais, P; Buendia, MA				Renard, CA; Fourel, G; Bralet, MP; Degott, C; De la Coste, A; Perret, C; Tiollais, P; Buendia, MA			Hepatocellular carcinoma in WHV/N-myc2 transgenic mice: oncogenic mutations of beta-catenin and synergistic effect of p53 null alleles	ONCOGENE			English	Article						woodchuck; hepatocellular carcinoma; hepatitis B virus; N-myc; p53; beta-catenin	WOODCHUCK HEPATITIS-VIRUS; GROWTH-FACTOR-II; C-MYC TRANSGENE; WILD-TYPE P53; LIVER-TUMORS; HEPADNAVIRUS INSERTION; INDUCED CARCINOGENESIS; NUCLEOTIDE-SEQUENCE; CELL-PROLIFERATION; N-MYC2 RETROPOSON	The intronless N-myc2 gene was originally identified as the major target of hepatitis virus insertion in woodchuck liver tumors. Here we report that transgenic mice carrying the N-myc2 gene controlled by woodchuck hepatitis virus (WHV) regulatory sequences are highly predisposed to fiver cancer. In a WHV/N-myc2 transgenic line, hepatocellular carcinomas or adenomas arose in over 70% of mice, despite barely detectable expression of the methylated transgene in liver cells, Furthermore, a transgenic founder carrying unmethylated transgene sequences succumbed to a large liver tumor by the age of two months, demonstrating the high oncogenicity of the woodchuck N-myc2 retroposon, Stabilizing mutations or deletions of beta-catenin were found in 25% of liver tumors and correlated with reduced tumor latency (P<0.05), confirming the important role of beta-catenin activation in MSc-induced tnmorigenesis, The ability of the tumor suppressor gene p53 to cooperate with N-myc2 in liver cell transformation was tested by introducing a p53-null allele into WHV/N-myc2 transgenic mice. The loss of one p53 allele in transgenic animals markedly accelerated the onset of liver cancer (P=0.0001), and most tumors of WHV/N-myc2 p53+/Delta mice harbored either a deletion of the wt p53 allele or a beta-catenin mutation. These findings provide direct evidence that activation of N-myc2 and reduction of p53 levels act synergistically during multistage carcinogenesis in vivo and suggest that different genetic pathways may underlie liver carcinogenesis initiated by a myc transgene.	Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75015 Paris, France; Hop Beaujon, Lab Anatomopathol, Clichy, France; Univ Paris 05, ICGM, INSERM, U129, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier	Buendia, MA (corresponding author), Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, 28 Rue Dr Roux, F-75015 Paris, France.		Perret-Mayeux, Christine/L-3297-2017	perret, christine/0000-0003-4710-7051				BLYTH K, 1995, ONCOGENE, V10, P1717; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Bruni R, 1999, VIROLOGY, V257, P483, DOI 10.1006/viro.1999.9678; BUENDIA MA, 1998, VIRAL HEPATITIS, P179; CARTIER N, 1992, ONCOGENE, V7, P1413; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; de la Coste A, 1999, CANCER RES, V59, P5017; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Devereux TR, 1999, ONCOGENE, V18, P4726, DOI 10.1038/sj.onc.1202858; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELSON A, 1995, ONCOGENE, V11, P181; ETIEMBLE J, 1994, ONCOGENE, V9, P727; Factor VM, 1997, HEPATOLOGY, V26, P1434; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; FOUREL G, 1992, MOL CELL BIOL, V12, P5336, DOI 10.1128/MCB.12.12.5336; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GALIBERT F, 1982, J VIROL, V41, P51, DOI 10.1128/JVI.41.1.51-65.1982; Ghebranious N, 1998, HEPATOLOGY, V27, P967, DOI 10.1002/hep.510270411; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANSEN LJ, 1993, MOL CELL BIOL, V13, P659, DOI 10.1128/MCB.13.1.659; HSU B, 1995, ONCOGENE, V11, P175; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Liu P, 1997, HEPATOLOGY, V25, P874, DOI 10.1002/hep.510250415; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MURAKAMI H, 1993, CANCER RES, V53, P1719; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Nagai H, 1998, HEPATITIS B VIRUS, P182; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; Quignon F, 1996, ONCOGENE, V12, P2011; Renard CA, 1998, RES VIROLOGY, V149, P133, DOI 10.1016/S0923-2516(98)80031-9; SANDGREN EP, 1989, ONCOGENE, V4, P715; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SantoniRugiu E, 1996, P NATL ACAD SCI USA, V93, P9577, DOI 10.1073/pnas.93.18.9577; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Tsujiuchi T, 1999, CANCER RES, V59, P3904; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; WEI Y, 1992, J VIROL, V66, P5265, DOI 10.1128/JVI.66.9.5265-5276.1992; Yang DY, 1996, J VIROL, V70, P6260, DOI 10.1128/JVI.70.9.6260-6268.1996	56	33	40	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	2000	19	22					2678	2686		10.1038/sj.onc.1203617	http://dx.doi.org/10.1038/sj.onc.1203617			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851067				2022-12-17	WOS:000087193000003
J	Chausovsky, A; Waterman, H; Elbaum, M; Yarden, Y; Geiger, B; Bershadsky, AD				Chausovsky, A; Waterman, H; Elbaum, M; Yarden, Y; Geiger, B; Bershadsky, AD			Molecular requirements for the effect of neuregulin on cell spreading, motility and colony organization	ONCOGENE			English	Article						neuregulin; ErbB-3/ErbB-2 heterodimers; cell spreading; PI3-kinase; MAPK kinase; microtubules	HEPATOCYTE GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; ACTIVATED PROTEIN-KINASE; RAT PC12 CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASE; SCATTER FACTOR; EPITHELIAL-CELLS; MAMMARY-GLAND	Neuregulin can trigger morphogenetic signals in cells both in vivo and in culture through the activation of receptors from the ErbB family. We have ectopically expressed various ErbB-receptors in 32D myeloid cells lacking endogenous ErbB-proteins, and in CHO cells, which express only ErbB-2. We show here that activation of ErbB-3/ErbB-2 heterodimeric receptors triggers PI3-kinase-dependent lamellipodia formation and spreading, while individual ErbB-receptor homodimers as well as ErbB-3/ErbB-1 heterodimers are much less effective. CHO cells expressing ErB3/ErbB-2 together with N-cadherin, an adhesion receptor, form epithelioid colonies. Neuregulin activates cell motility leading to transition of these colonies into ring-shaped multicellular arrays, similar to those induced by neuregulin in epithelial cells of different types (Chausovsky et al., 1998), This process requires both PI3-kinase and MAP kinase kinase activity and depends on coordinated changes in the actin- and microtubule-based cytoskeleton. Transactivation of ErbB-2 is not sufficient for the activation of cell motility and ring formation, and the C-terminal domain of ErbB-3 bearing the docking sites for the p85 subunit of PI3-kinase is essential for these morphogenetic effects. Thus, ErbB-3 in conjunction with ErbB-2 mediates, via its C-terminal domain, cytoskeletal and adhesion alterations which activate cell spreading and motility, leading to the formation of complex structures such as multicellular rings.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mat & Interfaces, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science	Bershadsky, AD (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, POB 26, IL-76100 Rehovot, Israel.		YARDEN, YOSEF/K-1467-2012	Bershadsky, Alexander/0000-0002-9571-7375				Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; BERSHADSKY AD, 1993, SYM SOC EXP BIOL, V47, P353; Birchmeier C, 1997, CIBA F SYMP, V212, P169; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bray D., 1992, CELL MOVEMENTS; Britsch S, 1998, GENE DEV, V12, P1825, DOI 10.1101/gad.12.12.1825; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Carpenter CL, 1997, ADV ENZYME REGUL, V37, P377, DOI 10.1016/S0065-2571(96)00005-2; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; Chausovsky A, 1998, MOL BIOL CELL, V9, P3195, DOI 10.1091/mbc.9.11.3195; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EDELMAN G, 1990, MORPHOREGLATORY MOL; Elbaum M, 1999, BIOCHEM SOC SYMP, V65, P147; Gabay L, 1997, DEVELOPMENT, V124, P3535; GHERARDI E, 1993, SYM SOC EXP BIOL, V47, P163; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hay ED, 1995, ACTA ANAT, V154, P8; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kim HH, 1998, BIOCHEM J, V334, P189, DOI 10.1042/bj3340189; Kita Y, 1998, J CELL SCI, V111, P907; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; Levenberg S, 1998, J CELL SCI, V111, P347; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; PELES E, 1992, J BIOL CHEM, V267, P12266; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Schaefer G, 1999, J BIOL CHEM, V274, P859, DOI 10.1074/jbc.274.2.859; Sierke SL, 1997, BIOCHEM J, V322, P757, DOI 10.1042/bj3220757; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SORIANO JV, 1995, J CELL SCI, V108, P413; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Trinkaus J. P., 1984, CELLS ORGANS FORCES; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215	55	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2000	19	7					878	888		10.1038/sj.onc.1203410	http://dx.doi.org/10.1038/sj.onc.1203410			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702796				2022-12-17	WOS:000085567700005
J	Schor, NF; Rudin, CM; Hartman, AR; Thompson, CB; Tyurina, YY; Kagan, VE				Schor, NF; Rudin, CM; Hartman, AR; Thompson, CB; Tyurina, YY; Kagan, VE			Cell line dependence of Bcl-2-induced alteration of glutathione handling	ONCOGENE			English	Article						oxidative stress; apoptosis; glutathione	NEOCARZINOSTATIN CYTO-TOXICITY; CHEMOTHERAPY-INDUCED APOPTOSIS; NEUROBLASTOMA-CELLS; NERVOUS-SYSTEM; FREE-RADICALS; CYTOCHROME-C; BCL-2; DEATH; DIFFERENTIATION; POTENTIATION	Bcl-2 has been associated with both oxidative and antioxidative effects in vivo. Moreover, despite evidence that Bcl-2 is antiapoptotic by virtue of its effect on reactive oxygen species and their scavengers, BcI-2 exerts its antiapoptotic effects even under anaerobic conditions. The reasons for the variable relationship between Bcl-2 and reactive oxygen species are not clear. The present studies demonstrate that the impact of Bcl-2 on glutathione (GSH) metabolism is cell line-dependent. Bcl-2 overproduction in PC12 cells is associated with increased functional thiol reserves, increased reductive activation of chemotherapeutic prodrugs, and GSH accumulation after treatment with N-acetlcysteine. In contrast, Bcl-2-overproducing MCF-7 breast cancer cells demonstrate neither altered GSH handling nor potentiation of chemotherapeutic prodrug reduction. These findings indicate that the effects of Bcl-2 on GSH handling are millieu-dependent. This could account for the variable effects of Bcl-2 in in vivo systems. Furthermore, since our previous studies have demonstrated that reduction-dependent prodrugs may be useful chemotherapeutic agents against tumors that demonstrate altered GSH handling, screening in vitro for alteration of GSH handling may predict responsiveness of such tumors to these reduction-dependent agents.	Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15213 USA; Dept Environm & Occupat Hlth, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Chicago	Schor, NF (corresponding author), Childrens Hosp Pittsburgh, Div Child Neurol, 3705 5th Ave, Pittsburgh, PA 15213 USA.		Rudin, Charles/R-2530-2019	Rudin, Charles/0000-0001-5204-3465; Tyurina, Yulia/0000-0003-0287-2091; Schor, Nina/0000-0002-3817-7376	NCI NIH HHS [CA74289] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074289, R55CA074289] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRECHT H, 1994, FEBS LETT, V351, P45, DOI 10.1016/0014-5793(94)00817-5; BEERMAN TA, 1977, BIOCHIM BIOPHYS ACTA, V475, P294, DOI 10.1016/0005-2787(77)90020-X; Beham A. W., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P224; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bonetti A., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P192; CAMPOS L, 1993, BLOOD, V81, P3091; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; CHIN DH, 1988, BIOCHEMISTRY-US, V27, P8106, DOI 10.1021/bi00421a020; Cortazzo M, 1996, CANCER RES, V56, P1199; DEGRAFF WG, 1985, CANCER RES, V45, P4760; DEGRAFF WG, 1985, J BIOL CHEM, V260, P8312; DOLE M, 1994, CANCER RES, V54, P3253; DOLE MG, 1995, CANCER RES, V55, P2576; Gelbard HA, 1997, PEDIATR NEUROL, V16, P93, DOI 10.1016/S0887-8994(96)00258-5; HALLIWELL B, 1985, TINS             JAN, P22; Hartsell TL, 1996, J PHARMACOL EXP THER, V277, P1158; HARTSELL TL, 1995, J PHARMACOL EXP THER, V275, P479; HUBEL CA, 1997, FREE RADICAL BIO MED, V23, P596; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Langmuir ME, 1996, FLUORESCENCE MICROSCOPY AND FLUORESCENT PROBES, P229; MAEDA H, 1994, ENEDIYNE ANTIBIOTICS, P363; Narayanan V, 1997, PEDIATR NEUROL, V16, P9, DOI 10.1016/S0887-8994(96)00257-3; Reber U, 1998, BIOCHEM PHARMACOL, V55, P349, DOI 10.1016/S0006-2952(97)00480-2; Schor NF, 1999, BRAIN RES, V831, P125, DOI 10.1016/S0006-8993(99)01414-6; SCHOR NF, 1992, J CLIN INVEST, V89, P774, DOI 10.1172/JCI115655; SEELIG GF, 1985, METHOD ENZYMOL, V113, P379; Smith TK, 1998, DEV BRAIN RES, V105, P175, DOI 10.1016/S0165-3806(97)00168-5; STEINMAN HM, 1995, J BIOL CHEM, V270, P3487; Stoyanovsky DA, 1996, ARCH BIOCHEM BIOPHYS, V330, P3, DOI 10.1006/abbi.1996.0219; TEIXEIRA C, 1995, CANCER RES, V55, P3902; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TYURINA YY, 1997, ARCH BIOCHEM BIOPHYS, V344, P412; WOOD KA, 1994, ANN NY ACAD SCI, V738, P400; WOOD KA, 1995, J NEUROSCI, V15, P5851; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	37	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					472	476		10.1038/sj.onc.1203324	http://dx.doi.org/10.1038/sj.onc.1203324			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656697				2022-12-17	WOS:000084873700020
J	Cleverley, SC; Costello, PS; Henning, SW; Cantrell, DA				Cleverley, SC; Costello, PS; Henning, SW; Cantrell, DA			Loss of Rho function in the thymus is accompanied by the development of thymic lymphoma	ONCOGENE			English	Article						Rho; lymphoma; thymus; transformation; C3-transferase	RAS TRANSFORMATION; TRANSGENIC MICE; GTPASES; COOPERATION; BOTULINUM; PROTEIN; TUMORS; MYB	In situ studies in model cell lines have implicated the GTPase Rho in the control of diverse cellular responses including the control of the actin cytoskeleton and the regulation of cell cycle progression. It is also reported that the transformation of fibroblasts via oncogenic Ras requires intact Rho signalling. An invaluable tool used to investigate Rho function is the bacterial toxin C3 transferase derived from Clostridium hotulinum. C3 transferase ribosylates Rho in its effector domain thereby abolishing interaction with downstream effecters. We have previously reported the use of C3 transferase under the control of the thymocyte specific Ick promoter to explore the role of Rho in T cell biology. Strikingly, Ick-C3 mice develop aggressive malignant thymic lymphoblastic lymphomas between 4 and 8 months of age. These studies reveal that loss of Rho function is associated with prediposition to lymphoid cell transformation. Inhibition of Rho function has been suggested as a therapeutic strategy for treatment of Ras-transformed tumours, The development of lymphomas in mice devoid of functional Rho in their T cell compartment shows that such a strategy would need to be used with caution.	Imperial Canc Res Fund, Lymphocyte Activat Lab, London WC2A 3PX, England	Cancer Research UK	Cantrell, DA (corresponding author), Imperial Canc Res Fund, Lymphocyte Activat Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.							ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Badiani PA, 1996, ONCOGENE, V13, P2205; Bronson R., 1990, GENETIC EFFECTS AGIN, VII, P279; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GALLANDRINI R, 1997, IMMUNITY, V7, P163; Henning SW, 1998, CURR OPIN IMMUNOL, V10, P322, DOI 10.1016/S0952-7915(98)80171-4; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; MA A, 1995, P NATL ACAD SCI USA, V92, P4763, DOI 10.1073/pnas.92.11.4763; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Owen MJ, 1996, CURR OPIN IMMUNOL, V8, P191, DOI 10.1016/S0952-7915(96)80057-4; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	23	33	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					13	20		10.1038/sj.onc.1203259	http://dx.doi.org/10.1038/sj.onc.1203259			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644975				2022-12-17	WOS:000084844300002
J	Shang, YF; Baumrucker, CR; Green, MH				Shang, YF; Baumrucker, CR; Green, MH			The induction and activation of STAT1 by all-trans-retinoic acid are mediated by RAR beta signaling pathways in breast cancer cells	ONCOGENE			English	Article						retinoic acid; RAR; STAT1; breast cancer; gene expression	PROMYELOCYTIC LEUKEMIA-CELLS; GROWTH-INHIBITION; RECEPTOR-BETA; INTERFERON-ALPHA; GENE-EXPRESSION; UP-REGULATION; LUNG-CANCER; APOPTOSIS; PROTEIN; ARREST	Retinoic acid receptor-beta (RAR beta) and signal transducer and activator of transcription 1 (STAT1) are important mediators of the antiproliferative and apoptotic actions of retinoids and cytokines/growth factors, respectively. Expression of both RAR beta and STAT1 is lost in most breast cancer cell lines but it can be induced by retinoids in estrogen receptor-positive cells, We investigated a possible functional connection between these two mediators and present evidence supporting RAR beta as a tumor suppressor. First, by using different receptor-selective retinoids, we demonstrated that RAR beta induction in MCF-7 cells by all-trans-retinoic acid (atRA) was associated with the activation of STAT1 gene transcription. The direct involvement of RAR beta in atRA-induced STAT1 gene activation was further demonstrated by showing that transfection with an anti-sense RAR beta construct blocked atRA-induced STAT1 expression in MCF-7 cells whereas introduction of a sense-RAR beta construct resulted in STAT1 induction by atRA in MDA-MB 231 cells. In addition, we showed that STAT1 was phosphorylated/activated under atRA treatment of MCF-7 cells; this process required the involvement of RAR beta and protein synthesis. STAT1 phosphorylation/ activation was accompanied by increased tyrosine kinase activity that was not due to the activation of JAK1, JAK2 or Tyk 2, suggesting the possible involvement of an unidentified tyrosine kinase.	Penn State Univ, Dept Nutr, University Pk, PA 16802 USA; Penn State Univ, Dept Dairy & Anim Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Green, MH (corresponding author), Penn State Univ, Dept Nutr, S-126 Henderson Bldg S, University Pk, PA 16802 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032500] Funding Source: NIH RePORTER; NICHD NIH HHS [R01-HD32500] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Fitzgerald P, 1997, CANCER RES, V57, P2642; GEIER A, 1992, IN VITRO CELL DEV-AN, V28A, P725; GERBERT JF, 1991, ONCOGENE, V6, P1859; GIANNI M, 1995, BIOCHEM BIOPH RES CO, V208, P846, DOI 10.1006/bbrc.1995.1413; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; HIGUCHI T, 1991, CANCER RES, V51, P3958; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; Kalvakolanu DV, 1996, CANCER INVEST, V14, P25, DOI 10.3109/07357909609018435; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; LANGENFELD J, 1997, P NATL ACAD SCI USA, V94, P12071; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Mangelsdorf David J., 1994, P319; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Shang YF, 1998, J BIOL CHEM, V273, P30608, DOI 10.1074/jbc.273.46.30608; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; Widschwendter M, 1997, CANCER RES, V57, P4158; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Zhang XK, 1996, MUTAT RES-FUND MOL M, V350, P267, DOI 10.1016/0027-5107(95)00102-6	28	33	33	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6725	6732		10.1038/sj.onc.1203084	http://dx.doi.org/10.1038/sj.onc.1203084			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597280				2022-12-17	WOS:000083792000014
J	Corre, I; Baumann, H; Hermouet, S				Corre, I; Baumann, H; Hermouet, S			Regulation by G(i2) proteins of v-fms-induced proliferation and transformation via Src-kinase and STAT3	ONCOGENE			English	Article						CSF-1R; receptor tyrosine-kinases; G(i2); Src-kinase; ERK-MAPK; STAT3	TYROSINE KINASES; COUPLED RECEPTORS; PERTUSSIS TOXIN; CELL-PROLIFERATION; MEDIATED ACTIVATION; DIRECT STIMULATION; BINDING-PROTEIN; GROWTH-FACTORS; ALPHA-SUBUNIT; TGF-BETA	We previously showed that G(i2) proteins interfere with the transduction of CSF-1 receptor (CSF-1R) proliferation signals (Corre and Hermouet, 1995). To identify CSF-1R pathways controlled by G(i2), we transfected nu-fms, the oncogenic equivalent of CSF-IR, in NIH3T3 cells in which G(i2) proteins were inactivated by stably expressing a dominant negative mutant form of the alpha subunit of G(i2) (alpha(i2)-G204A). Expression of alpha(i2)-G204A resulted in decreased Src-kinase activity, delayed activation of p42 ERK-MAPK, decreased cyclin D1 expression and reduced proliferation in response to serum. In alpha(i2)-G204A cells transfected with nu-fms, Src-kinase activity remained deficient but p42 MAPK activity and cyclin D1 expression were similar to those of vector/nu-fms cells, suggesting that nu-fms bypasses Src to activate the ERK-MAPK cascade. However, DNA synthesis and focus formation were inhibited by up to 80% in alpha(i2)-G204A/nu-fms cells compared to vector/nu-fms cells. We found that tyrosine phosphorylation of STAT3, also activated by CSP-1R/nu-fms, was inhibited in alpha(i2)-G204A/nu-fms cells; in addition, expression of an 85 kDa, C-terminal truncated form of STAT3 (STAT3 Delta) was constitutively increased. Both the inhibition of v-fms-induced STAT3 tyrosine phosphorylation and the increased expression of STAT3 Delta were reproduced by transfecting a dominant negative mutant of Src. Last, we show that expression of STAT3 Delta 55C, a mutant form of STAT3 lacking the last 55 C-terminal amino acids, is sufficient to inhibit DNA synthesis and nu-fms-induced transformation in NIH3T3 cells. In summary, adequate regulation by G(i2) proteins of the activity of both Src-kinase and STAT3 is required for optimal cell proliferation in response to CSF-1R/nu-fms.	Inst Biol, INSERM, U463, Grp Cytokines Recepteurs & Transduct Signal, F-44093 Nantes, France; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Roswell Park Cancer Institute	Hermouet, S (corresponding author), Inst Biol, INSERM, U463, Grp Cytokines Recepteurs & Transduct Signal, 9 Quai Moncousu, F-44093 Nantes, France.		Corre, Isabelle/L-2583-2015	CORRE, Isabelle/0000-0001-6444-1145				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BELKA C, 1995, LEUKEMIA, V9, P754; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; CHEN YH, 1994, J BIOL CHEM, V269, P27372; Corre I, 1999, EXP HEMATOL, V27, P28, DOI 10.1016/S0301-472X(98)00032-0; CORRE I, 1995, BLOOD, V86, P1776, DOI 10.1182/blood.V86.5.1776.bloodjournal8651776; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; HE YX, 1988, BLOOD, V71, P1187; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; IMAMURA K, 1988, J BIOL CHEM, V263, P14093; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; KOYASU S, 1989, CELL STRUCT FUNCT, V14, P459; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MAESTRONI GJM, 1994, EXP HEMATOL, V22, P313; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MAYANI H, 1995, EXP HEMATOL, V23, P422; MILLER BA, 1991, BLOOD, V77, P486; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROUSSEL MF, 1994, J CELL SCI, P105; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; WANG Y, IN PRESS HEPATOLOGY; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YEUNG YG, 1992, J BIOL CHEM, V267, P23447	41	33	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	1999	18	46					6335	6342		10.1038/sj.onc.1203010	http://dx.doi.org/10.1038/sj.onc.1203010			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597233				2022-12-17	WOS:000083934100018
J	Leblanc, V; Delumeau, I; Tocque, B				Leblanc, V; Delumeau, I; Tocque, B			Ras-GTPase activating protein inhibition specifically induces apoptosis of tumour cells	ONCOGENE			English	Article						Ras-GAP; apoptosis; RhoA; tumour cells	ACTIN STRESS FIBERS; BINDING PROTEIN; SIGNALING PATHWAY; ONCOGENIC RAS; RHO; EXPRESSION; TRANSFORMATION; GAP; ANTIBODIES; KINASES	Oncogenes and tumour suppressor genes control the balance between apoptotic death and anti-apoptotic survival signals determining whether a cell proliferates or dies. Through which effecters might oncoproteins generate sensitivity to apoptosis remains to be determined. Ras GTPase activating protein (Ras-GAP) is a key element in the Ras signalling pathway, being both a negative regulator and possibly an effector of Pas, Ras-GAP acts as a regulator of transcription, and possibly connects Ras to stress-activated protein kinases, A role for Ras-GAP in cell survival has been suspected from the study of knock-out mouse embryos. In search for selective killing of tumour cells, we asked whether Ras-GAP inhibition by other means would lead to apoptosis in established cell lines. We injected a monoclonal antibody directed against the SH3 domain of Ras-GAP (mAb200) that has been shown to block Res-GAP downstream signalling into various human normal and tumour cell lines. We show that inhibition of Res-GAP induces apoptosis specifically in tumour, but not in normal cells, therefore pointing at a specific role for Ras-GAP in tumour cell survival. MAb200-induced apoptosis is largely prevented by coinjection of activated RhoA or Cdc42 proteins, by injection of a constitutively activated mutant of phosphoinositide 3-OH kinase (PI3-K), but not by injection of v-Raf, These results show that targeting of Ras-GAP could represent a no, el anticancer approach.	ExonHit Therapeut, F-75013 Paris, France; Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, Cent Res, F-94403 Vitry, France	Sanofi-Aventis	Leblanc, V (corresponding author), ExonHit Therapeut, 65 Bld Massena, F-75013 Paris, France.							ALONSO T, 1990, MOL CELL BIOL, V10, P3117, DOI 10.1128/MCB.10.6.3117; Arceci R J, 1995, Curr Opin Hematol, V2, P268; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Cochet O, 1998, CANCER RES, V58, P1170; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fenton RG, 1998, CANCER RES, V58, P3391; Fiorentini C, 1998, EXP CELL RES, V242, P341, DOI 10.1006/excr.1998.4057; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Leblanc V, 1998, MOL CELL BIOL, V18, P5567, DOI 10.1128/MCB.18.9.5567; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOLLAT P, 1992, BIO-TECHNOL, V10, P1151, DOI 10.1038/nbt1092-1151; Moorman JP, 1996, J IMMUNOL, V156, P4146; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	33	33	38	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4884	4889		10.1038/sj.onc.1202855	http://dx.doi.org/10.1038/sj.onc.1202855			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490822				2022-12-17	WOS:000082184800013
J	Qin, XS; Liu, LL; Gerson, SL				Qin, XS; Liu, LL; Gerson, SL			Mice defective in the DNA mismatch gene PMS2 are hypersensitive to MNU induced thymic lymphoma and are partially protected by transgenic expression of human MGMT	ONCOGENE			English	Article						PMS2 deficiency; hMGMT; MNU; lymphoma	METHYL-N-NITROSOUREA; MAMMALIAN O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; CELL-CYCLE CHECKPOINT; ABERRANT CRYPT FOCI; REPAIR GENE; ADA GENE; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; INDUCED TUMORIGENESIS; ADDUCT FORMATION; RAS ONCOGENE	DNA mismatch repair (MMR) stabilizes the cellular genome, Mice defective in the MMR gene PMS2 are susceptible to spontaneous thymic lymphoma and sarcomas, To determine the sensitivity of PMS2 knockout mice to environmental carcinogens and the protective effect of O-6-methylguanine DIVA methyltransferase (MGMT), heterozygous PMS2 knockout mice and human MGMT (hMGMT) transgenic mice were mated and the PMS2(-/-) and PMS2(+/+) wit or without hMGMT offspring were treated at 5 weeks of age with 50 mg/kg N-methgl-N-nitrosourea (MNU), MNU produces carcinogenic O-6-methylguanine (O-6-meG) adducts, resulting in thymic lymphoma in mice, which can be prevented in normal mice by overexpression of hMGMT. A significantly higher incidence of thymic lymphomas,vas observed in MNU-treated PMS2(-/-) mice, compared to wildtype PMS2(+/+) mice (100 ra 52%; P < 0.001), The mean latency of lymphomas was also significantly shortened in PMS2(-/-) mice (81 vs 102 days, P<0.01), Transgenic expression of hMGMT significantly but incompletely blocked MNU lymphomagenesis in PMS2(-/-) mice. The incidence of lymphomas in PMS2(-/-)/hMGMT(+) mice was reduced to 80% (P<0.01) and mean latency increased to 91 days (P<0.05), Thy mic lymphomagenesis was efficiently blocked in PMS2(+/+)/hMGMT(+) mice with rapid repair of O-6-meG, Since O-6-meG:T mismatches in MMR+ cells may trigger mismatch repair resulting in abortive repair and cell death whereas in the absence of MMR, these mismatches are converted to A:T,,ve predicted that G to A point mutations in codon 12 of the K-ras gene would occur. In this study, we found G to A point mutations in codon 12 of the K-ras gene in many tumors. Thus, in MMR deficient tissues, methylating agents induce point mutations in cells with a higher rate of cell survival which together are potently carcinogenic in the thymus, These data suggest that PMS2 defective lymphomas may arise by the concerted action of environmental and perhaps endogenous methylation of DNA coupled to genomic instability.	Case Western Reserve Univ, Div Hematol Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Gerson, SL (corresponding author), Case Western Reserve Univ, Div Hematol Oncol, BRB-3 10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [R01CA063193, P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006288] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA63193, P30CA43703] Funding Source: Medline; NIEHS NIH HHS [R01ES06288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allay E, 1997, ONCOGENE, V15, P2127, DOI 10.1038/sj.onc.1201384; ALLAY E, 1999, IN PRESS ONCOGENE; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BELINSKY SA, 1989, CANCER RES, V49, P5305; Carethers JM, 1996, J CLIN INVEST, V98, P199, DOI 10.1172/JCI118767; COROMINAS M, 1991, CANCER RES, V51, P5129; Davis TW, 1998, CANCER RES, V58, P767; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; DUMENCO LL, 1991, CANCER RES, V51, P3391; EADIE JS, 1984, NATURE, V308, P201, DOI 10.1038/308201a0; ELLISON KS, 1989, P NATL ACAD SCI USA, V86, P8620, DOI 10.1073/pnas.86.22.8620; Fink D, 1998, CLIN CANCER RES, V4, P1; GALLOWAY SM, 1995, MUTAT RES LETT, V346, P231, DOI 10.1016/0165-7992(95)90040-3; GERSON SL, 1986, CARCINOGENESIS, V7, P745, DOI 10.1093/carcin/7.5.745; HAWN MT, 1995, CANCER RES, V55, P3721; Iwakuma T, 1997, CARCINOGENESIS, V18, P1631, DOI 10.1093/carcin/18.8.1631; LIM IK, 1990, CANCER RES, V50, P1701; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; Liu LL, 1996, CANCER RES, V56, P5375; LIU LL, 1994, CANCER RES, V54, P4648; Lowsky R, 1997, BLOOD, V89, P2276, DOI 10.1182/blood.V89.7.2276; MATSUKUMA S, 1989, MUTAT RES, V218, P197, DOI 10.1016/0921-8777(89)90004-9; Meikrantz W, 1998, CARCINOGENESIS, V19, P369, DOI 10.1093/carcin/19.2.369; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NAKATSURU Y, 1991, MUTAT RES, V254, P225, DOI 10.1016/0921-8777(91)90060-3; NAKATSURU Y, 1993, P NATL ACAD SCI USA, V90, P6468, DOI 10.1073/pnas.90.14.6468; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; NEWCOMB EW, 1990, AM J PATHOL, V136, P307; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; PEGG AE, 1990, CANCER RES, V50, P6119; PROLLA AT, 1998, NAT GENET, V18, P276; QIN XS, 1990, CARCINOGENESIS, V11, P235, DOI 10.1093/carcin/11.2.235; QIN XS, 1994, CARCINOGENESIS, V15, P851, DOI 10.1093/carcin/15.5.851; Reitmair AH, 1996, CANCER RES, V56, P3842; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; ROMACH E, 1994, CARCINOGENESIS, V15, P2275, DOI 10.1093/carcin/15.10.2275; RUDIGER HW, 1989, CANCER RES, V49, P5623; SAKUMAR S, 1983, NATURE, V306, P658; Sakumi K, 1997, CANCER RES, V57, P2415; STRIKE PW, 1991, STAT METHODS LAB MED, P53; THOMALE J, 1990, P NATL ACAD SCI USA, V87, P9883, DOI 10.1073/pnas.87.24.9883; TSZUKI T, 1996, CARCINOGENESIS, V17, P1215; WANG Y, 1990, CANCER RES, V50, P1591; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451	46	33	33	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4394	4400		10.1038/sj.onc.1202798	http://dx.doi.org/10.1038/sj.onc.1202798			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439048				2022-12-17	WOS:000081732700013
J	Kohzaki, H; Ito, K; Huang, G; Wee, HJ; Murakami, Y; Ito, Y				Kohzaki, H; Ito, K; Huang, G; Wee, HJ; Murakami, Y; Ito, Y			Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2	ONCOGENE			English	Article						AML1; AML1/ETO(MTG8); Bcl-2; 32Dcl3; granulocytic differentiation	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; STIMULATING FACTOR-RECEPTOR; FETAL LIVER HEMATOPOIESIS; MYOSIN HEAVY-CHAIN; FUSION PROTEIN; TRANSCRIPTION FACTOR; T(8-21) TRANSLOCATION; MYELOGENOUS LEUKEMIA; FOLLICULAR LYMPHOMA	The chimeric gene, AML1/ETO (MTG8), generated in t(8;21) acute myeloid leukemia enhances the expression of Bcl-2. To evaluate whether this enhancement is the primary role of AML1/ETO in leukemogenesis, effects of over-expression of Bcl-2 in the murine myeloid precursor cell line, 32Dc13, were examined. When 32Dc13 cells expressing exogenous Bcl-2 were induced to differentiate, the onset of morphological differentiation,vas delayed. However, even the cells expressing very high levels of exogenous Bcl-2 eventually underwent differentiation without a significant decrease in the synthesis of Bcl-2. On the contrary, 32Dc13 cells stably expressing AML1/ETO mere completely resistant to differentiation and continued to grow in the presence of G-CSF. These results are consistent with the interpretation that stimulation of Bcl-2 expression is not the primary target of AML1/ETO.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Ito, Y (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Shogoin, Kyoto 6068507, Japan.		Kohzaki, Hidetsugu/P-6151-2019; Kohzaki, Hidetsugu/D-2758-2018; Murakami, Yota/F-8850-2012	Kohzaki, Hidetsugu/0000-0003-0946-9676; 				Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; ASOU H, 1991, BLOOD, V77, P2031; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BAKHSHI A, 1985, CELL, V41, P889; Banker DE, 1998, CLIN CANCER RES, V4, P3051; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; ERICKSON P, 1992, BLOOD, V80, P1825; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Frank R, 1995, ONCOGENE, V11, P2667; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Ito K, 1996, EMBO J, V15, P5636, DOI 10.1002/j.1460-2075.1996.tb00948.x; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; ITO Y, 1997, CELL CYCLE REGULATOR, V2, P107; Kanno Y, 1998, MOL CELL BIOL, V18, P4252, DOI 10.1128/MCB.18.7.4252; KINASHI T, 1991, J EXP MED, V173, P1267, DOI 10.1084/jem.173.5.1267; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LU J, 1995, MOL CELL BIOL, V15, P1651; MATOZAKI S, 1995, BRIT J HAEMATOL, V89, P805; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYASHITA T, 1994, CANCER RES, V54, P3131; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; NUCIFORA G, 1995, BLOOD, V86, P1; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; OSATO M, 1999, IN PRESS BLOOD; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; Rodel JE, 1996, BLOOD, V87, P858, DOI 10.1182/blood.V87.3.858.bloodjournal873858; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Uchida H, 1997, J IMMUNOL, V158, P2251; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WARNER NL, 1969, J NATL CANCER I, V43, P963; YANAGISAWA K, 1991, BLOOD, V78, P451	59	33	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4055	4062		10.1038/sj.onc.1202735	http://dx.doi.org/10.1038/sj.onc.1202735			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435586				2022-12-17	WOS:000081431000002
J	Cereseto, A; Parks, RW; Rivadeneira, E; Franchini, G				Cereseto, A; Parks, RW; Rivadeneira, E; Franchini, G			Limiting amounts of p27(Kip1) correlates with constitutive activation of cyclin E-CDK2 complex in HTLV-I-transformed T-cells	ONCOGENE			English	Article						p27(Kip1); cyclin E; HTLV-I infection	DEPENDENT KINASE INHIBITOR; LEUKEMIA-LYMPHOMA VIRUS; P21(WAF1/CIP1) EXPRESSION; INTERLEUKIN-2 RECEPTOR; MOLECULAR MECHANISMS; POTENTIAL MEDIATOR; RESTRICTION POINT; BREAST-CANCER; MICE LACKING; PROTEIN	Human T-cells immortalized (interleukin-2 [IL-2] dependent) by the human T-cell lymphotropic/leukemia virus type I (HTLV-I), in time, become transformed (IL-2 independent). To understand the biochemical basis of this transition, we have used the sibling HTLV-I-infected T-cell lines, N1186 (IL-2 dependent) and N1186-94 (IL-2 independent), as models to assess the responses to antiproliferative signals. In N1186 cells arrested in G1 after serum/interleukin-2 (IL-2) deprivation, downregulation of the cyclin E-CDK2 kinase activity correlated with decreased phosphorylation of CDK2 and accumulation of p27(Kip1) bound to the cyclin E-CDK2 complex, as seen in normal activated PBMCs (peripheral blood mononuclear cells). In contrast, N1186-94 cells failed to arrest in G1 upon serum starvation, displayed constitutive cyclin E-associated kinase activity, and, although CDK2 was partially dephosphorylated, the amount of p27(Kip1) bound to the complex did not increase. This observation, extended to two other IL-2-dependent as well as to three IL-2-independent HTLV-I-infected T-cell lines, suggests that the lack of cyclin E-CDK2 kinase downregulation found in the late phase of HTLV-I transformation may correlate with insufficient amounts of p27(Kip1) associated with the cyclin E-CDK2 complex. Reconstitution experiments demonstrated that the addition of p27(Kip1) to lysates from N1186-94 starved cells resulted in the downregulation of cyclin E-associated kinase activity supporting the notion that the unresponsiveness of the cyclin E-CDK2 complex to growth inhibitory signals may be due to inadequate amounts of p27(Kip1) assembled with the complex in HTLV-I-transformed T-cells, In fact, the amount of p27(Kip1) protein was lower in most HTLV-I-transformed (IL-2-independent) than in the immortalized (IL-2-dependent) HTLV-I-infected T-cells, Furthermore, specific inhibitors of the phosphatidylinositol 3-kinase (PI3K) induced an increase of p27(Kip1) protein levels, which correlated,vith G1 arrest, in both IL-2-dependent and IL-2-independent HTLV-I-infected T-cells, Altogether, these results suggest that maintaining a low level of expression of p27(Kip1) is a key event in HTLV-I transformation.	NCI, Basic Res Lab, Div Basic Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cereseto, A (corresponding author), NCI, Basic Res Lab, Div Basic Sci, Bethesda, MD 20892 USA.			Cereseto, Anna/0000-0003-4453-2597	NATIONAL CANCER INSTITUTE [ZIABC005645, Z01BC005645] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1996, ONCOGENE, V12, P1645; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Cereseto A, 1997, LEUKEMIA, V11, P866, DOI 10.1038/sj.leu.2400665; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Dumont FJ, 1995, LIFE SCI, V58, P373, DOI 10.1016/0024-3205(95)02233-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; GONG JP, 1994, CANCER RES, V54, P4285; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARPER JW, 1993, CELL, V75, P805; Johnson D, 1998, ONCOGENE, V16, P2017, DOI 10.1038/sj.onc.1201727; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOFF A, 1992, SCIENCE, V257, P1959; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEACH FS, 1993, CANCER RES, V53, P1986; Liu Y, 1996, CANCER RES, V56, P31; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; MARKHAM PD, 1983, INT J CANCER, V31, P413, DOI 10.1002/ijc.2910310404; Migone TS, 1998, P NATL ACAD SCI USA, V95, P3845, DOI 10.1073/pnas.95.7.3845; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mulloy JC, 1998, J VIROL, V72, P4408, DOI 10.1128/JVI.72.5.4408-4412.1998; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POPOVIC M, 1983, P NATL ACAD SCI-BIOL, V80, P5402, DOI 10.1073/pnas.80.17.5402; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	42	33	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2441	2450		10.1038/sj.onc.1202567	http://dx.doi.org/10.1038/sj.onc.1202567			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229195				2022-12-17	WOS:000079703300004
J	Hurd, C; Dinda, S; Khattree, N; Moudgil, VK				Hurd, C; Dinda, S; Khattree, N; Moudgil, VK			Estrogen-dependent and independent activation of the P1 promoter of the p53 gene in transiently transfected breast cancer cells	ONCOGENE			English	Article						breast cancer; tumor suppressors; p53; estrogen; antiestrogens; tamoxifen	TUMOR-SUPPRESSOR P53; C-MYC; TRANSCRIPTIONAL REPRESSION; INDUCED APOPTOSIS; RETINOBLASTOMA; PROTEIN; EXPRESSION; PRODUCT; PHOSPHORYLATION; FIBROBLASTS	Loss of p53 function by mutational inactivation is the most common marker of the cancerous phenotype, Previous studies from our laboratory have demonstrated 17 beta estradiol (E-2) induction of p53 protein expression in breast cancer cells. Although direct effects of E-2 on the expression of p53 gene are not known, the steroid is a potent regulator of c-Myc transcription. In the present studies, we have examined the ability of E-2 and antiestrogens to regulate the P1 promoter of the p53 gene which contains a c-Myc responsive element, Estrogen receptor (ER)-positive T47D and MCF-7 cells were transiently transfected with the P1CAT reporter plasmid and levels of CAT activity in response to serum, E-2 and antiestrogens were monitored. Factors in serum were noted to be the dominant inducers of chloramphenicol acetyltransferase (CAT) expression in MCF-7 cells. The levels of CAT were drastically reduced when cells were maintained in serum free medium (SFM). However, a subtle ER-mediated induction of CAT expression was detectable when MCF-7 cells, cultured in SFM, were treated with E-2, In serum-stimulated T47D cells, the CAT expression was minimal. The full ER antagonist, ICI 182 780 (ICI) had no effect. Treatment with E-2 or 4-hydroxy tamoxifen (OHT) resulted in P1CAT induction; OHT was more effective than E-2. Consistent with c-Myc regulation of the P1 promoter, E-2 stimulated endogenous c-Myc in both cell lines. Two forms of c-Myc were expressed independent of E-2 stimuli. The expression of a third more rapidly migrating form was E-2-dependent and ER-mediated since it was blocked by the full ER antagonist, ICI, but not by the ER agonist/antagonist OHT, These data demonstrate both ER-mediated and ER-independent regulation of c-Myc and the P1 promoter of the p53 gene, and show differential effects of the two classes of antiestrogens in their ability to induce the P1 promoter of the p53 gene in breast cancer cells.	Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA; Oakland Univ, Ctr Biomed Res, Rochester, MI 48309 USA	Oakland University; Oakland University	Moudgil, VK (corresponding author), Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020893] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 20893] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altucci L, 1996, ONCOGENE, V12, P2315; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DUBIK D, 1988, J BIOL CHEM, V263, P12705; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HURD C, 1995, J BIOL CHEM, V270, P28507, DOI 10.1074/jbc.270.48.28507; Hurd C, 1997, ONCOGENE, V15, P991, DOI 10.1038/sj.onc.1201233; Hurd C, 1998, HANDBK PHYS, V1, P383; Kang Y, 1996, J NATL CANCER I, V88, P279, DOI 10.1093/jnci/88.5.279; KODALI S, 1994, BIOCHEM BIOPH RES CO, V202, P1413, DOI 10.1006/bbrc.1994.2088; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lukas J, 1996, MOL CELL BIOL, V16, P6917; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; REISMAN D, 1988, P NATL ACAD SCI USA, V85, P5146, DOI 10.1073/pnas.85.14.5146; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; WU HY, 1994, J BIOL CHEM, V269, P20067	26	33	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1067	1072		10.1038/sj.onc.1202398	http://dx.doi.org/10.1038/sj.onc.1202398			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023683				2022-12-17	WOS:000078510600024
J	Kato, M; Liu, W; Akhand, AA; Dai, Y; Ohbayashi, M; Tuzuki, T; Suzuki, H; Isobe, K; Takahashi, M; Nakashima, I				Kato, M; Liu, W; Akhand, AA; Dai, Y; Ohbayashi, M; Tuzuki, T; Suzuki, H; Isobe, K; Takahashi, M; Nakashima, I			Linkage between melanocytic tumor development and early burst of Ret protein expression for tolerance induction in metallothionein-I ret transgenic mouse lines	ONCOGENE			English	Article						metallothionein-I ret transgenic mouse lines; melanocytic tumor; Ret protein expression; immune surveillance; oncogene product-specific-tolerance	SV40 T-ANTIGEN; PROTOONCOGENE PRODUCTS; SAIKOSAPONIN-D; LYMPHOCYTES-T; CELLS; MICE; MECHANISM; RESPONSES; ONCOGENE; PEPTIDE	We examined the basis of the all or none difference in inducing melanocytic tumor development among three transgenic mouse lines (304, 192 and 242) to which the same promoter-enhancer (metallothionein-I) and oncogene (ret) were introduced. We initially demonstrated that both skin melanosis and Ret protein expression in skin, thymus and brain first became detectable before or immediately after birth in the mice of the tumor developing lines (304 and 192), whereas they became detectable a few days after birth in the mice of the nontumor developing line (242) by Western blotting and immunohistochemical analysis. Interestingly, the Ret protein expression in skin developed rapidly after birth as a burst with peak levels on 0.5-1.5 day newborns of lines 304 and 192 and on 7.0-7.5 day-old mice of line 242, The levels of autophosphorylation of Ret kinase in skin were, however, invariable among these three transgenic mouse lines. The mice of line 242, but not those of lines 192 and 304, responded to Ret protein immunization by increased antigen-dependent lymphocyte proliferation and T-cell-mediated tumor growth suppression in vitro. Furthermore, ret-transgenic mice of line 242, but not line 304, rejected the subcutaneously transplanted tumors that had originally developed in a mouse of line 304, These results suggest that whether oncogene product-specific-tolerance is established or not to antitumor immunity may be decided by the dynamics of rer oncogene expression before and after delivery and this is the primary factor determining development or non-development of melanoma.	Nagoya Univ, Sch Med, Dept Immunol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Chubu Natl Hosp, Inst Longev Sci, Dept Basic Gerontol, Aichi 4748511, Japan	Nagoya University; Nagoya University	Nakashima, I (corresponding author), Nagoya Univ, Sch Med, Dept Immunol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		isobe, ken-ichi/A-6685-2011; KATO, Masashi/I-7250-2014; Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	isobe, ken-ichi/0000-0002-8150-2496; Takahashi, Masahide/0000-0002-2803-2683; 				ASAI N, 1995, MOL CELL BIOL, V15, P1613; CAMPBELL AE, 1983, J IMMUNOL, V130, P490; CHEN LP, 1991, P NATL ACAD SCI USA, V88, P110, DOI 10.1073/pnas.88.1.110; CORRADIN G, 1977, J IMMUNOL, V119, P1048; DAI Y, 1994, INT J ONCOL, V5, P661; FAAS SJ, 1987, J EXP MED, V165, P417, DOI 10.1084/jem.165.2.417; ICHIHARA M, 1995, BRIT J CANCER, V71, P808, DOI 10.1038/bjc.1995.156; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; JUNG S, 1991, J EXP MED, V173, P273, DOI 10.1084/jem.173.1.273; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KATO M, 1994, CELL IMMUNOL, V159, P15, DOI 10.1006/cimm.1994.1291; KATO M, 1995, IMMUNOPHARMACOLOGY, V29, P207, DOI 10.1016/0162-3109(95)00059-3; MOSMANN TR, 1991, IMMUNOL REV, V123, P209, DOI 10.1111/j.1600-065X.1991.tb00612.x; NAKASHIMA I, 1982, EUR J IMMUNOL, V12, P713, DOI 10.1002/eji.1830120904; SCHRIMBECK R, 1992, EUR J IMMUNOL, V22, P759; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TANIGUCHI M, 1992, ONCOGENE, V7, P1491; TEVETHIA SS, 1980, VIROLOGY, V107, P13, DOI 10.1016/0042-6822(80)90268-8; TSUZUKI T, 1995, ONCOGENE, V10, P191; YANUCK M, 1993, CANCER RES, V53, P3257	21	33	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					837	842		10.1038/sj.onc.1202329	http://dx.doi.org/10.1038/sj.onc.1202329			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989837				2022-12-17	WOS:000078394400032
J	Rey, O; Baluda, MA; Park, NH				Rey, O; Baluda, MA; Park, NH			Differential gene expression in neoplastic and human papillomavirus-immortalized oral keratinocytes	ONCOGENE			English	Article						HPV; human oral keratinocytes; tumor development	PROMOTER-BINDING PROTEIN; HERPES-SIMPLEX VIRUS; SPLICING FACTOR; ADENOVIRUS E1A; CERVICAL-CARCINOMA; COMPLEMENTARY-DNA; NUCLEAR-BODIES; PML; ONCOPROTEIN; INFECTION	We have previously demonstrated that normal human oral keratinocytes immortalized by transfection with human papillomavirus type-16 Dna became tumorigenic after exposure to a chemical carcinogen, In an effort to detect differentially regulated genes associated with this transition from the immortal to the malignant phenotype, we employed representational differences analysis (a PCR-coupled subtractive hybridization technique). After analysing 50 colonies, 12 putative messages were identified. Northern analysis comparison using the identified cDNAs as probes was made between normal human oral keratinocyte, papillomavirus-immortalized human oral keratinocytes (HOK-16B), a neoplastic cell line derived from HOK-16B (HOK-16B-BaP-T) and the human oral cancer cell lines Hep-2, SCC-9 and Tu-177, We found that mRNAs encoding for cyclophilin A, c-myc binding protein 1, the heat shock protein 90 alpha and one unknown transcript were up-regulated in the oral cancer cell lines analysed as well as in HOK-16B cells. We also detected a downregulation of the mRNAs encoding the skin-derived antileukoproteinase SKALP/elafin, the translationally regulated p23 protein and one unknown transcript. Whether these messages are associated to the neoplastic conversion of human keratinocytes remains to be determined.	Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Dent Res, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Park, NH (corresponding author), Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA.			Rey, Osvaldo/0000-0003-1575-9864	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010598, R03DE011728, P20DE010598] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE10598, DE11728] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ahn JH, 1997, J VIROL, V71, P4599, DOI 10.1128/JVI.71.6.4599-4613.1997; ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; ALKEMADE HAC, 1993, AM J PATHOL, V143, P1679; ALKEMADE JAC, 1994, J CELL SCI, V107, P2335; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOHM H, 1989, BIOCHEM INT, V19, P277; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CHANG FJ, 1990, ARCH DERMATOL RES, V282, P493, DOI 10.1007/BF00371942; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; DEBLANDRE GA, 1995, J BIOL CHEM, V270, P23860, DOI 10.1074/jbc.270.40.23860; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DILUCA D, 1990, J DENT RES, V69, P51; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GISSMANN L, 1984, J INVEST DERMATOL, V86, pS26; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; LI WZ, 1994, J BIOL CHEM, V269, P18616; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LISITYSN N, 1993, SCIENCE, V259, P949; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; MEANWELL CA, 1988, CANCER SURV, V7, P481; MIN BM, 1994, ORAL ONCOL, V30B, P338, DOI 10.1016/0964-1955(94)90036-1; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; MOROZOV A, 1995, FEBS LETT, V371, P214, DOI 10.1016/0014-5793(95)00884-C; MULLEN MA, 1995, J VIROL, V69, P476, DOI 10.1128/JVI.69.1.476-491.1995; NOTHWANG HG, 1994, BBA-GENE STRUCT EXPR, V1219, P361, DOI 10.1016/0167-4781(94)90060-4; PARK NH, 1995, ONCOGENE, V10, P2145; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; RADICE P, 1995, GENOMICS, V26, P101, DOI 10.1016/0888-7543(95)80087-3; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; RAY RB, 1995, CELL GROWTH DIFFER, V6, P1089; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SHAFFER EL, 1980, J ORAL PATHOL MED, V9, P163, DOI 10.1111/j.1600-0714.1980.tb00373.x; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; SPITZ MR, 1988, CANCER, V61, P203, DOI 10.1002/1097-0142(19880101)61:1<203::AID-CNCR2820610134>3.0.CO;2-6; SUMMERS L, 1977, ORAL SURG, V38, P273; SUREAU A, 1992, P NATL ACAD SCI USA, V89, P11683, DOI 10.1073/pnas.89.24.11683; SYRJANEN KJ, 1983, BR J ORAL SURG, V21, P143; SYRJANEN S, 1992, SCAND J DENT RES, V100, P17; SYRJANEN SM, 1986, ORAL SURG ORAL MED O, V62, P660, DOI 10.1016/0030-4220(86)90262-8; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; YAMAZAKI M, 1989, NUCLEIC ACIDS RES, V17, P7108, DOI 10.1093/nar/17.17.7108; YEUDALL WA, 1992, ORAL ONCOL, V28B, P61, DOI 10.1016/0964-1955(92)90015-S; ZURHAUSEN H, 1977, CURR TOP MICROBIOL I, V778, P1	49	33	36	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					827	831		10.1038/sj.onc.1202328	http://dx.doi.org/10.1038/sj.onc.1202328			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989835				2022-12-17	WOS:000078394400030
J	Grand, RJA; Turnell, AS; Mason, GGF; Wang, WL; Milner, AE; Mymryk, JS; Rookes, SM; Rivett, AJ; Gallimore, PH				Grand, RJA; Turnell, AS; Mason, GGF; Wang, WL; Milner, AE; Mymryk, JS; Rookes, SM; Rivett, AJ; Gallimore, PH			Adenovirus early region 1A protein binds to mammalian SUG1-a regulatory component of the proteasome	ONCOGENE			English	Article						adenovirus; adenovirus 12; E1A; SUG1; proteasome; Trip 1	WILD-TYPE P53; E1A PROTEIN; TRANSCRIPTIONAL MEDIATOR; TUMOR-SUPPRESSOR; EPITHELIAL-CELLS; 26-S PROTEASOME; DNA-SYNTHESIS; ACTIVATION; APOPTOSIS; SUBUNIT	Adenovirus early region 1A (Ad E1A) is a multifunctional protein which is essential for adenovirus-mediated transformation and oncogenesis, Whilst E1A is generally considered to exert its influence on recipient cells through regulation of transcription it also increases the le, el of cellular p53 by increasing the protein half-life. With this in, view, we have investigated the relationship of Ad E1A to the proteasome, which is normally responsible for degradation of p53, Here we have shown that both Ad5 and Ad12 EIA 12S and 13S proteins can be co-immunoprecipitated with proteasomes and that the larger Ad12 E1A protein binds strongly to at least three components of the 26S but not 20S proteasome, One of these interacting species has been identified as mammalian SUG1, a proteasome regulatory component which also plays a role in the cell as a mediator of transcription, In vitro assays have demonstrated a direct interaction between Ad12 E1A 13S protein and mouse SUG1, Following infection of human cells with Ad5 wt and Ad5 mutants with lesions in the E1A gene it has been shown that human SUG1 can be co-immunoprecipitated with full-length E1A and with E1A carrying a deletion in conserved region 1 which is the region considered to be responsible for increased expression of p53, We have concluded therefore that Ad E1A binds strongly to SUG1 but that this interaction is not responsible for inhibition of proteasome activity, This is consistent with the observation that purified Ad12 E1A inhibits the activity of the purified 20S but not 26S proteasomes, We have also demonstrated that SUG1 can be co-immunoprecipitated with SV40 T and therefore,ve suggest that this may represent a common interaction of transforming proteins of DNA tumour viruses.	Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Western Ontario, Dept Oncol, London, ON N6A 4L6, Canada	University of Birmingham; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; University of Bristol; Western University (University of Western Ontario)	Grand, RJA (corresponding author), Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAYLEY ST, 1994, INT J ONCOL, V5, P425; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; BOULLATA IJ, 1991, MUSLIM WORLD, V81, P299; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fraser RA, 1997, J BIOL CHEM, V272, P7122, DOI 10.1074/jbc.272.11.7122; GALLIMORE PH, 1985, CANCER RES, V45, P2670; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; Grand RJA, 1998, VIROLOGY, V244, P330, DOI 10.1006/viro.1998.9102; Grand RJA, 1998, VIROLOGY, V244, P230, DOI 10.1006/viro.1998.9081; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Grand RJA, 1996, VIROLOGY, V218, P23, DOI 10.1006/viro.1996.0162; GRAND RJA, 1984, J GEN VIROL, V65, P2149, DOI 10.1099/0022-1317-65-12-2149; GRAND RJA, 1993, VIROLOGY, V193, P579, DOI 10.1006/viro.1993.1166; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; JONES N, 1995, CURR TOP MICROBIOL, V199, P59; KRISTENSEN P, 1994, BIOCHEM BIOPH RES CO, V205, P1785, DOI 10.1006/bbrc.1994.2876; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MARUYAMA K, 1987, ONCOGENE, V1, P361; MASON GGF, 1998, IN PRESS FEBS LETT; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MYMRYK JS, 1993, J GEN VIROL, V74, P2131, DOI 10.1099/0022-1317-74-10-2131; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; PARASKEVA C, 1982, J GEN VIROL, V58, P73, DOI 10.1099/0022-1317-58-1-73; PETERS JM, 1994, J BIOL CHEM, V269, P7709; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reidlinger J, 1997, J BIOL CHEM, V272, P24899, DOI 10.1074/jbc.272.40.24899; RIVETT AJ, 1994, METHOD ENZYMOL, V244, P331; RIVETT AJ, 1993, BIOCHEM J, V291, P1; RIVETT AJ, 1991, BIOCHEM J, V278, P171, DOI 10.1042/bj2780171; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Seeger M, 1997, J BIOL CHEM, V272, P8145, DOI 10.1074/jbc.272.13.8145; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; VOMBAUR E, 1995, EMBO J, V15, P110; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WILLIAMS J, 1995, CURR TOP MICROBIOL, V199, P149; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	53	33	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					449	458		10.1038/sj.onc.1202304	http://dx.doi.org/10.1038/sj.onc.1202304			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927201				2022-12-17	WOS:000078166500017
J	Pestov, DG; Grzeszkiewicz, TM; Lau, LF				Pestov, DG; Grzeszkiewicz, TM; Lau, LF			Isolation of growth suppressors from a cDNA expression library	ONCOGENE			English	Article						inducible vector; Rb; 3T3 cells	UBIQUITIN-CONJUGATING ENZYMES; G-PROTEIN; CRYSTAL-STRUCTURE; DEGRADATION; SYSTEM; CHECKPOINTS; REPRESSOR; IDENTIFICATION; PROTEOLYSIS; SEQUENCES	We describe an experimental procedure for the isolation of growth inhibitory sequences from a complex cDNA library, This approach first takes advantage of the SETGAP technique (selectable expression of transient growth arrest phenotype) to enrich for growth inhibitory sequences, followed by a screening procedure to identify individual cDNAs that inhibit cell proliferation. Here we provide a detailed description of the experimental protocol and report the characterization of two cDNA sequences isolated id our initial screen of a mouse cDNA Library. One of these cDNAs encodes the mouse ubiquitin-conjugation enzyme UbcM2, The other encodes a truncated form of a novel WD40 repeat protein, named Bop1, which is conserved from yeast to human. Together, these results demonstrate a new approach for the isolation of growth suppressors from cDNA libraries, and identify a previously unknown gene likely to be involved in growth control.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lau, LF (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.			Lau, Lester/0000-0002-4364-2914; Pestov, Dimitri/0000-0002-1425-9879	NATIONAL CANCER INSTITUTE [R01CA052220] Funding Source: NIH RePORTER; NCI NIH HHS [CA52220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; Bej Asim K., 1994, P219; Bonaldo MDF, 1996, GENOME RES, V6, P791, DOI 10.1101/gr.6.9.791; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; KALUZ S, 1992, NUCLEIC ACIDS RES, V20, P4369, DOI 10.1093/nar/20.16.4369; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LIU HP, 1992, GENETICS, V132, P665; LOO DT, 1989, CELL GROWTH CELL DIV, P17; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; Maki CG, 1996, CANCER RES, V56, P2649; Matuschewski K, 1996, J BIOL CHEM, V271, P2789, DOI 10.1074/jbc.271.5.2789; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; Nicholas KB., 1997, EMBNET NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PESTOV DG, 1994, P NATL ACAD SCI USA, V91, P12549, DOI 10.1073/pnas.91.26.12549; Pietrokovski S, 1996, NUCLEIC ACIDS RES, V24, P197, DOI 10.1093/nar/24.1.197; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shiyanov P, 1997, MOL BIOL CELL, V8, P1815, DOI 10.1091/mbc.8.9.1815; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TODARO GJ, 1965, J CELL COMPAR PHYSL, V66, P325, DOI 10.1002/jcp.1030660310; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1	42	33	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 17	1998	17	24					3187	3197		10.1038/sj.onc.1202260	http://dx.doi.org/10.1038/sj.onc.1202260			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872334				2022-12-17	WOS:000077517400012
J	Razavi, R; Ramos, JC; Yehia, G; Schlotter, F; Molina, CA				Razavi, R; Ramos, JC; Yehia, G; Schlotter, F; Molina, CA			ICER-II gamma is a tumor suppressor that mediates the antiproliferative activity of cAMP	ONCOGENE			English	Article						cAMP; ICER-II gamma; tumor suppressor; CREM	ELEMENT-BINDING-PROTEINS; TRANSCRIPTION FACTORS; GENE-EXPRESSION; CELL-CYCLE; KINASE; ACTIVATION; INHIBITION; PATHWAY; CREM; FIBROBLASTS	The second messenger cAMP inhibits the proliferation of most cell types. The nuclear response of cAMP is mediated by transcription factors like the cAMP-Responsive Element Modulator (CREM) gene. One of the products of the CREM gene, the transcriptional repressor Inducible cAMP Early Repressor-II gamma (ICER-II gamma), is induced by cAMP. ICER-II gamma blocks cells at the G2/M boundary of the cell cycle. Here we show that ICER-II gamma, dramatically inhibits the growth and DNA synthesis of mouse pituitary tumor cells and human choriocarcinoma cells. This alteration in cell growth is coupled with reduced ability of these cells to grow in an anchorage-independent manner and to form tumors in mice. These data demonstrate that ICER-II gamma is a tumor suppressor gene product mediating the antiproliferative activity of cAMP.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Obstet & Gynecol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Molina, CA (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Obstet & Gynecol, Newark, NJ 07103 USA.				NCI NIH HHS [R29 CA69316] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069316] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; Lamas M, 1997, MOL ENDOCRINOL, V11, P1425, DOI 10.1210/me.11.10.1425; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MOLINA CA, 1997, CELL DEATH REPROD PH, V15, P182; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; VALLEJO M, 1994, J NEUROENDOCRINOL, V6, P587, DOI 10.1111/j.1365-2826.1994.tb00623.x; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	17	33	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	1998	17	23					3015	3019		10.1038/sj.onc.1202225	http://dx.doi.org/10.1038/sj.onc.1202225			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881703				2022-12-17	WOS:000077427800008
J	Ayi, TC; Tsan, JT; Hwang, LY; Bowcock, AM; Baer, R				Ayi, TC; Tsan, JT; Hwang, LY; Bowcock, AM; Baer, R			Conservation of function and primary structure in the BRCA1-associated RING domain (BARD1) protein	ONCOGENE			English	Article						BRCA1; breast cancer; RING domain; BRCT domain; tumor suppressor	CANCER SUSCEPTIBILITY GENE; BREAST-CANCER; CELL-CYCLE; SUBCELLULAR-LOCALIZATION; EXPRESSION PATTERN; FAMILIAL BREAST; MESSENGER-RNA; MURINE BRCA1; DNA-DAMAGE; SEQUENCE	The BRCA1 gene encodes a tumor suppressor that has been implicated in hereditary forms of breast and ovarian cancer. During S phase of the cell cycle, BRCA1 polypeptides are found in discrete nuclear bodies ('BRCA1 nuclear dots') together with HsRad51, a human homolog of the E. coli recA protein, and BARD1, a protein that interacts with BRCA1 to form a stable heterodimer. BARD1 is structurally similar to BRCA1 in that both molecules harbor an amino-terminal RING domain and two carboxy-terminal BRCT domains. Here we describe the amino acid sequence and expression pattern of murine Bard1. A comparison of the mouse and human sequences reveals that the recognizable protein motifs of BARD1 are well conserved, including the RING domain, the three tandem ankyrin repeats, and, to a lesser extent, the two BRCT domains. However, the remaining sequences of BARD1 display a markedly lower degree of phylogenetic conservation, comparable to those reported for BRCA1 and BRCA2. Moreover, murine Bard1 retains the ability to associate in vivo with BRCA1, and its expression pattern in adult mice mirrors that of Brca1, with elevated levels of RNA transcripts found in the testes and spleen. These data suggest that BRCA1 and BARD1 have co-evolved to participate in a common pathway of tumor suppression.	Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Baer, R (corresponding author), Univ Texas, SW Med Ctr, Dept Microbiol, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.			Bowcock, Anne/0000-0001-8691-9090	NATIONAL CANCER INSTITUTE [R01CA076334, R01CA060650] Funding Source: NIH RePORTER; NCI NIH HHS [CA76334, CA60650] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; Bertwistle D, 1997, CANCER RES, V57, P5485; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Chen YM, 1996, SCIENCE, V272, P125, DOI 10.1126/science.272.5258.125; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Connor F, 1997, HUM MOL GENET, V6, P291, DOI 10.1093/hmg/6.2.291; Cox MM, 1997, P NATL ACAD SCI USA, V94, P11764, DOI 10.1073/pnas.94.22.11764; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Karlin S, 1996, J BACTERIOL, V178, P1881, DOI 10.1128/jb.178.7.1881-1894.1996; Katagiri T, 1998, GENE CHROMOSOME CANC, V21, P217, DOI 10.1002/(SICI)1098-2264(199803)21:3<217::AID-GCC5>3.0.CO;2-2; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; McAllister KA, 1997, CANCER RES, V57, P3121; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; SHARAN SK, 1995, HUM MOL GENET, V4, P2275, DOI 10.1093/hmg/4.12.2275; Sharan SK, 1997, GENOMICS, V40, P234, DOI 10.1006/geno.1996.4573; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Spillman MA, 1996, ONCOGENE, V13, P1639; Szabo CI, 1996, HUM MOL GENET, V5, P1289, DOI 10.1093/hmg/5.9.1289; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; Thomas JE, 1996, J BIOL CHEM, V271, P28630, DOI 10.1074/jbc.271.45.28630; TSAN JT, 1997, YEAST 2 HYBRID SYSTE, P217; Vaughn JP, 1996, CANCER RES, V56, P4590; Wang SC, 1997, BIOCHEM BIOPH RES CO, V234, P247, DOI 10.1006/bbrc.1997.6544; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zabludoff SD, 1996, ONCOGENE, V13, P649	48	33	38	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2143	2148		10.1038/sj.onc.1202123	http://dx.doi.org/10.1038/sj.onc.1202123			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798686				2022-12-17	WOS:000076540900014
J	Weinstein, EJ; Grimm, S; Leder, P				Weinstein, EJ; Grimm, S; Leder, P			The oncogene heregulin induces apoptosis in breast epithelial cells and tumors	ONCOGENE			English	Article						heregulin; apoptosis; Bcl-2; caspase; breast cancer	NEU DIFFERENTIATION FACTOR; GROWTH-FACTOR RECEPTOR; TRANSGENIC MICE; CANCER CELLS; C-MYC; PROTEIN; EXPRESSION; DEATH; INHIBITION; LIGAND	The products of a growing number of genes have been shown to display seemingly contradictory functions; namely, the induction of tumorigenesis and the induction of apoptosis, Heregulin's involvement in oncogenesis occurs through its interactions with members of the EGF receptor tyrosine kinase family, Recently one isoform of heregulin, beta 2b, was isolated in an in vitro screen for dominant, apoptosis-inducing genes in kidney epithelial cells. Here we show that heregulin is also capable of mediating apoptosis in human and murine mammary tumor cell lines and murine tumors. Furthermore, through transfection of the human breast cancer cell line MCF-7 with the truncated transmembrane/cytoplasmic segment of the heregulin gene, we show that the intracellular region of the heregulin precursor is sufficient for induction of apoptosis, Through the use of DNA fragmentation assays me also show that apoptosis occurs in cell lines established from heregulin-induced mammary gland tumors. TdT addition of digoxigenin labeled nucleotides to 3' OH ends of DNA breaks recapitulated these results in the actual tumors. Finally, over-expression of heregulin is shown to lead to the down-regulation of Bcl-2, an inhibitor of apoptosis. Conversely, the transfection of Bcl-2 into MCF-7 cells inhibits heregulin-mediated programmed cell death.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Leder, P (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.							ADAM L, 1995, CANCER RES, V55, P5156; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Amundadottir LT, 1996, ONCOGENE, V13, P757; Baulida J, 1996, J BIOL CHEM, V271, P5251; Benjamin CW, 1998, MOL PHARMACOL, V53, P446, DOI 10.1124/mol.53.3.446; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FOECKING MK, 1986, GENE, V45, P101, DOI 10.1016/0378-1119(86)90137-X; GOLD R, 1994, LAB INVEST, V71, P219; Grimm S, 1997, J EXP MED, V185, P1137, DOI 10.1084/jem.185.6.1137; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; GRIMM S, 1998, IN PRESS J EXP MED; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JAATTELA M, 1995, ONCOGENE, V10, P2297; Krane IM, 1996, ONCOGENE, V12, P1781; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; MAKAR AP, 1990, ACTA ONCOL, V29, P931, DOI 10.3109/02841869009096392; Mandal M, 1996, CELL GROWTH DIFFER, V7, P311; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Nickerson T, 1997, BIOCHEM BIOPH RES CO, V237, P690, DOI 10.1006/bbrc.1997.7089; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; Shimizu S, 1996, ONCOGENE, V12, P2251; SHUM L, 1994, J CELL BIOL, V125, P906; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; THIRY M, 1992, J HISTOCHEM CYTOCHEM, V40, P411, DOI 10.1177/40.3.1552179; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; ZEILLINGER R, 1989, ONCOGENE, V4, P109; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	45	33	34	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2107	2113		10.1038/sj.onc.1202428	http://dx.doi.org/10.1038/sj.onc.1202428			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798682				2022-12-17	WOS:000076540900010
J	Grundy, RG; Pritchard, J; Scambler, P; Cowell, JK				Grundy, RG; Pritchard, J; Scambler, P; Cowell, JK			Loss of heterozygosity for the short arm of chromosome 7 in sporadic Wilms tumour	ONCOGENE			English	Article						Wilms tumour; LOH 7p; WT tumour suppressor gene 7p 21-15	DENYS-DRASH SYNDROME; WT1 GENE; FAMILIAL PREDISPOSITION; DISTINCT REGIONS; POINT MUTATIONS; RENAL TUMORS; TRANSLOCATION; ABNORMALITIES; CHILDHOOD; LOCUS	Cytogenetic analysis of Wilms tumours (WT) have shown that abnormalities involving chromosome 7 occur in approximately 25% of tumours, In some cases, these abnormalities involve deletions of the short arm, and are seen as the sole cytogenetic change, strongly suggesting the presence of a tumour suppressor gene in this location. Since loss of heterozygosity (LOH) studies have been crucial in defining chromosomal regions involved in Wilms tumorigenesis, we have analysed 40 sporadic Wilms tumours using a panel of 10 microsatelite polymorphic markers distributed along the length of the chromosome arm. In our series, four tumours (10%) showed allelic loss for 7p markers which is twice the background rate of LOH in WT. The shortest common region of overlap of LOH was located between markers D7S517-D7S503 in band 7p21-15. In one tumour there was evidence for a homozygous, interstitial deletion at a locus within this region. These findings provide strong evidence for the existence of a tumour suppressor gene involved in Wilms tumorigenesis and defines the critical region of the chromosome involved.	Inst Child Hlth, Hematol Oncol Unit, London WC1N 1EH, England; Inst Child Hlth, Fetal Med Unit, London WC1N 1EH, England; Hosp Sick Children, Dept Hematol Oncol, London WC1, England	University of London; University College London; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Grundy, RG (corresponding author), Middlesex Hosp, Dept Pediat & Adolescent Oncol, Mortimer St, London W1N 8AA, England.		Scambler, Peter/AAZ-6026-2020; Scambler, Peter J/C-4998-2008	Scambler, Peter/0000-0002-1487-4628; Scambler, Peter J/0000-0002-1487-4628; Cowell, John/0000-0002-2079-5950				AUSTRUY E, 1995, GENE CHROMOSOME CANC, V14, P285, DOI 10.1002/gcc.2870140407; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BAIRD PN, 1992, ONCOGENE, V7, P2141; BARNARD JL, 1984, EUR J PEDS, V141, P175; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BRESLOW N, 1993, MED PEDIATR ONCOL, V21, P172, DOI 10.1002/mpo.2950210305; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; COPPES MJ, 1993, P NATL ACAD SCI USA, V90, P1416, DOI 10.1073/pnas.90.4.1416; COPPES MJ, 1992, GENE CHROMOSOME CANC, V5, P326, DOI 10.1002/gcc.2870050408; COPPES MJ, 1994, NEW ENGL J MED, V331, P586; DANGIO GJ, 1989, CANCER-AM CANCER SOC, V64, P349, DOI 10.1002/1097-0142(19890715)64:2<349::AID-CNCR2820640202>3.0.CO;2-Q; DEVILEE P, 1991, INT J CANCER, V47, P817, DOI 10.1002/ijc.2910470604; GREEN ED, 1994, HUM MOL GENET, V3, P489, DOI 10.1093/hmg/3.3.489; GRUNDY P, 1988, NATURE, V336, P375; GRUNDY PE, 1994, CANCER RES, V54, P2331; HEWITT M, 1991, J MED GENET, V28, P411, DOI 10.1136/jmg.28.6.411; HUFF V, 1992, CANCER RES, V52, P6117; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; HUFF V, 1991, AM J HUM GENET, V49, P44; KANEKO Y, 1991, CANCER RES, V51, P5937; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MANNENS M, 1990, CANCER RES, V50, P3279; MAW M, 1986, CANCER RES, V52, P3094; MELONI AM, 1992, J UROLOGY, V148, P253, DOI 10.1016/S0022-5347(17)36565-5; Miozzo M, 1996, GENOMICS, V37, P310, DOI 10.1006/geno.1996.0565; MITLEMAN F, 1991, CYTOGENET CELL GENET, V58, P152; PEIER AM, 1995, CANCER GENET CYTOGEN, V79, P92, DOI 10.1016/0165-4608(94)00110-W; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARD J, 1995, J CLIN ONCOL, V13, P124, DOI 10.1200/JCO.1995.13.1.124; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; Reynolds PA, 1996, GENE CHROMOSOME CANC, V17, P151, DOI 10.1002/(SICI)1098-2264(199611)17:3<151::AID-GCC2>3.0.CO;2-3; RIVERA H, 1985, ANN GENET-PARIS, V28, P52; RIVERA H, 1995, CANCER GENET CYTOGEN, V81, P97, DOI 10.1016/S0165-4608(94)00199-5; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; SAWYER JR, 1993, CANCER GENET CYTOGEN, V69, P57, DOI 10.1016/0165-4608(93)90114-2; SCHWARTZ CE, 1991, GENOMICS, V10, P927, DOI 10.1016/0888-7543(91)90181-D; SLATER RM, 1992, CANCER GENET CYTOGEN, V61, P111, DOI 10.1016/0165-4608(92)90071-F; SLATER RM, 1985, CANCER GENET CYTOGEN, V14, P95, DOI 10.1016/0165-4608(85)90220-1; SOLIS V, 1988, CANCER GENET CYTOGEN, V34, P223, DOI 10.1016/0165-4608(88)90264-6; Tsui L C, 1995, Cytogenet Cell Genet, V71, P2; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; WADEY RB, 1990, ONCOGENE, V5, P901; WANGWUU S, 1990, CANCER RES, V50, P2786; WILMORE HP, 1994, CANCER GENET CYTOGEN, V77, P93, DOI 10.1016/0165-4608(94)90221-6	46	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					395	400		10.1038/sj.onc.1201927	http://dx.doi.org/10.1038/sj.onc.1201927			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690521	Bronze			2022-12-17	WOS:000074947500014
J	Sharma, SV				Sharma, SV			Rapid recruitment of p120RasGAP and its associated protein, p190RhoGAP, to the cytoskeleton during integrin mediated cell-substrate interaction	ONCOGENE			English	Article						p120RasGAP; p190RhoGAP; cell-substrate interaction; integrins; cytoskeleton	FOCAL ADHESION KINASE; GTPASE-ACTIVATING PROTEIN; ACTIN STRESS FIBERS; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; RHO-FAMILY; DEPHOSPHORYLATION; INSULIN	The interaction of cells with their substrate triggers cascades of signal transduction that result in profound changes in cell morphology. The nature of these signals and how they are integrated to orchestrate changes in cell shape are beginning to be elucidated. In particular, adhesive interactions between cells and their substrate, mediated by cell-surface integrins and extracellular matrix (ECM) proteins, appear to result in massive rearrangement of the cell cytoskeleton via the small G-protein, Rho. Here we show that in mouse fibroblasts, the interaction between cells and their substrate results in the rapid recruitment to the cytoskeleton of RasGAP (p120RasGAP), its associated protein of 190 kilodaltons, the GTPase activating protein for RhoA (p190RhoGAP) and the focal adhesion kinase (p125FAK). Similar results were obtained when cells were plated on ECM proteins, such as fibronectin, suggesting that the phenomenon is integrin mediated. These studies suggest that in fibroblasts, cell-substrate interaction triggered by integrin engagement result in the recruitment to the cytoskeleton of signaling molecules such as p120RasGAP, p190RhoGAP and p125FAK and may be involved in the formation of membrane cytoskeleton-associated signaling complexes that are important in cytoarchitectural reorganization.	Univ Tennessee, Ctr Hlth Sci, Dept Microbiol & Immunol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Sharma, SV (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Microbiol & Immunol, Memphis, TN 38163 USA.				NCI NIH HHS [CA55983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BARRY ST, 1994, J CELL SCI, V107, P2033; BENZEEV A, 1979, CELL, V17, P859, DOI 10.1016/0092-8674(79)90326-X; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; Bottazzi ME, 1997, TRENDS CELL BIOL, V7, P348, DOI 10.1016/S0962-8924(97)01114-8; Burbelo PD, 1995, J BIOL CHEM, V270, P30919, DOI 10.1074/jbc.270.52.30919; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Bussey H, 1996, SCIENCE, V272, P224, DOI 10.1126/science.272.5259.224; Bussey H, 1996, SCIENCE, V273, P203, DOI 10.1126/science.273.5272.203; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CARRAWAY KL, 1995, BIOESSAYS, V17, P171, DOI 10.1002/bies.950170212; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CHANG JH, 1993, ONCOGENE, V8, P959; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; FELICE GR, 1990, EUR J CELL BIOL, V52, P47; FOSTER R, 1994, MOL CELL BIOL, V14, P7173, DOI 10.1128/MCB.14.11.7173; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gille J, 1996, ANN NY ACAD SCI, V797, P93, DOI 10.1111/j.1749-6632.1996.tb52952.x; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Hotchin NA, 1996, CANCER SURV, V27, P311; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Juliano Rudy, 1996, Bioessays, V18, P911, DOI 10.1002/bies.950181110; Konstantopoulos N, 1996, BIOCHEM J, V314, P387, DOI 10.1042/bj3140387; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ouwens DM, 1996, BIOCHEM J, V318, P609, DOI 10.1042/bj3180609; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PATCH LA, 1995, J CELL SCI, V108, P1371; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARTZ MA, 1989, P NATL ACAD SCI USA, V86, P4525, DOI 10.1073/pnas.86.12.4525; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Sharma SV, 1997, ONCOGENE, V14, P2641, DOI 10.1038/sj.onc.1201115; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tobe K, 1996, MOL CELL BIOL, V16, P4765; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wang DZM, 1997, CANCER RES, V57, P2478; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; ZHAO JF, 1995, ONCOGENE, V11, P161; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	75	33	34	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	1998	17	3					271	281		10.1038/sj.onc.1201921	http://dx.doi.org/10.1038/sj.onc.1201921			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690509				2022-12-17	WOS:000074947500002
J	Froeschle, A; Alric, S; Kitzmann, M; Carnac, G; Aurade, F; Rochette-Egly, C; Bonnieu, A				Froeschle, A; Alric, S; Kitzmann, M; Carnac, G; Aurade, F; Rochette-Egly, C; Bonnieu, A			Retinoic acid receptors and muscle b-HLH proteins: partners in retinoid-induced myogenesis	ONCOGENE			English	Article						retinoic acid receptors; muscle b-HLH proteins; protein-protein interaction; myogenesis	THYROID-HORMONE RECEPTOR; HELIX-LOOP-HELIX; BOX TRANSCRIPTION FACTORS; LIGAND-BINDING DOMAIN; CELL-LINE BA-HAN-1C; X RECEPTOR; NUCLEAR RECEPTORS; RXR-ALPHA; ALL-TRANS; IN-VITRO	The results reported here indicate that retinoic acid (RA) induces growth arrest and differentiation only in MyoD-expressing muscle cells. Transient transfection assays reveal a functional interaction between MyoD, a key myogenic regulator and RA-receptors, principal mediators of RA actions, Interestingly, we demonstrate that RXR-MyoD-containing complexes are recruited at specific MyoD DNA-binding sites in muscle cells, Furthermore, we also demonstrate that RA-receptors and the muscle basic helix-loop-helix (b-HLH) proteins interact physically. Mutational analysis suggests that this interaction occurs via the basic region of muscle b-HLH proteins and the DIVA-binding domain of RA-receptors and is important for functional interactions between these two families of transcription factors. In conclusion, these results highlight novel interactions between two distinct groups of regulatory proteins that influence cell growth and differentiation.	INRA, Lab Differenciat Cellulaire & Croissance, F-34060 Montpellier 1, France; CNRS, CRBM, Cell Biol Unit, F-34033 Montpellier, France; Inst Pasteur, Dept Biol Mol, URA 1148 CNRS, F-75724 Paris 15, France; CU Strasbourg, GBMC, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	INRAE; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Bonnieu, A (corresponding author), INRA, Lab Differenciat Cellulaire & Croissance, Pl Pierre Viala, F-34060 Montpellier 1, France.		Bonnieu, Anne/ABA-7182-2020; Carnac, Gilles/N-6744-2018	Carnac, Gilles/0000-0002-3518-8774				ALBAGLICURIEL O, 1993, DIFFERENTIATION, V52, P201, DOI 10.1111/j.1432-0436.1993.tb00632.x; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; ARNOLD HH, 1992, J CELL BIOL, V118, P877, DOI 10.1083/jcb.118.4.877; BENGAL E, 1994, P NATL ACAD SCI USA, V91, P6221, DOI 10.1073/pnas.91.13.6221; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DE LUCA LM, 1991, FASEB J, V5, P2924; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Froeschle A, 1996, ONCOGENE, V12, P411; GABBERT HE, 1988, CANCER RES, V48, P5264; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; Groisman R, 1996, J BIOL CHEM, V271, P5258; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Gudas L. J., 1994, RETINOIDS BIOL CHEM, P443; HALEVY O, 1993, J CELL PHYSIOL, V154, P566, DOI 10.1002/jcp.1041540315; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hofmann Clementine, 1994, P387; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE IJ, 1994, P NATL ACAD SCI USA, V91, P1647, DOI 10.1073/pnas.91.5.1647; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MOMOI T, 1992, BIOCHEM BIOPH RES CO, V187, P245, DOI 10.1016/S0006-291X(05)81484-6; Montarras D, 1996, J CELL SCI, V109, P551; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; REZNIKOFF CA, 1973, CANCER RES, V33, P3239; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TROUCHE D, 1993, NATURE, V363, P79, DOI 10.1038/363079a0; VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068; VANDROMME M, 1995, P NATL ACAD SCI USA, V92, P4646, DOI 10.1073/pnas.92.10.4646; VOMBAUR E, 1995, EMBO J, V15, P110; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	79	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	1998	16	26					3369	3378		10.1038/sj.onc.1201894	http://dx.doi.org/10.1038/sj.onc.1201894			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692544				2022-12-17	WOS:000074544100003
J	Blattner, C; Bender, K; Herrlich, P; Rahmsdorf, HJ				Blattner, C; Bender, K; Herrlich, P; Rahmsdorf, HJ			Photoproducts in transcriptionally active DNA induce signal transduction to the delayed U.V.-responsive genes for collagenase and metallothionein	ONCOGENE			English	Article						ultraviolet irradiation; p53 stabilization; collagenase 1; metallothionein; transcription-coupled repair; pyrimidine dimers	IMMUNODEFICIENCY VIRUS TYPE-1; CYCLOBUTANE PYRIMIDINE DIMERS; RECEPTOR TYROSINE KINASES; GROUP-C FIBROBLASTS; XERODERMA-PIGMENTOSUM; UV-LIGHT; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR FACTOR; NONIRRADIATED CELLS; ULTRAVIOLET-LIGHT	Mammalian cells in culture react to ultraviolet irradiation with the massive transcriptional activation of several genes and with the stabilization of the p53 protein. While U.V.-induced transcription of several immediate-response genes depends on U.V.-induced activation of signal transduction generated by non-nuclear mechanisms, stabilization of p53 and the transcription of several delayed-response genes are triggered by U.V.-induced DNA damage. By comparing dose responses for the activation by U.V. of delayed-responsive genes (collagenase 1, metallothionein IIA) in cells from patients with different DNA repair deficiencies (complementation groups of Xeroderma pigmentosum, Cockayne's syndrome and Trichothiodystrophy), we show here that U.V.-induced transcription of these genes does depend on pyrimidine dimers in transcribed regions of the genome (but not on damage in its silent part). Since all cells with defects in DNA repair that had been tested and which lack different enzymes, respond to U.V. with expression of these same genes, functional repair does not appear to be required for the induction of expression, and repair intermediates (which would not be identical in cells of different repair deficiency) cannot be responsible for signal generation.	Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology	Herrlich, P (corresponding author), Forschungszentrum Karlsruhe, Inst Genet, POB 3640, D-76021 Karlsruhe, Germany.		Blattner, Christine/ABI-2152-2020; Blattner, Christine/H-2105-2013	Blattner, Christine/0000-0002-7250-5273; Blattner, Christine/0000-0002-7250-5273				ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; [Anonymous], 1985, DNA REPAIR; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERNDER K, 1997, J PHOTOCH PHOTOBIO B, V37, P1; BLATTNER C, 1994, ENVIRON MOL MUTAGEN, V24, P3, DOI 10.1002/em.2850240103; BOOTSMA D, 1994, MUTAT RES, V307, P15, DOI 10.1016/0027-5107(94)90273-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROUGHTON BC, 1994, NAT GENET, V7, P189, DOI 10.1038/ng0694-189; BROUGHTON BC, 1990, MUTAT RES, V235, P33, DOI 10.1016/0921-8777(90)90020-6; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; EVENO E, 1995, CANCER RES, V55, P4325; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HANAWALT PC, 1995, MUTAT RES-DNA REPAIR, V336, P101, DOI 10.1016/0921-8777(94)00061-A; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERRLICH P, 1997, MOL BIOL TOXICOLOGY, pCH31; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; Huang CS, 1997, ONCOGENE, V14, P1945, DOI 10.1038/sj.onc.1201056; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Isaacs JS, 1997, ONCOGENE, V14, P1669, DOI 10.1038/sj.onc.1201001; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KRAMER M, 1993, J BIOL CHEM, V268, P6734; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEHMANN AR, 1988, CANCER RES, V48, P6090; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MISKIN R, 1981, P NATL ACAD SCI-BIOL, V78, P6236, DOI 10.1073/pnas.78.10.6236; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RENZING J, 1995, ONCOGENE, V10, P1865; ROTEM N, 1987, MOL CELL BIOL, V7, P622, DOI 10.1128/MCB.7.2.622; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; SIEGEL J, 1995, ONCOGENE, V11, P1363; STEFANINI M, 1993, CARCINOGENESIS, V14, P1101, DOI 10.1093/carcin/14.6.1101; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN B, 1989, J VIROL, V63, P4540, DOI 10.1128/JVI.63.11.4540-4544.1989; Tolmie J L, 1994, Clin Dysmorphol, V3, P1; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Weeda G, 1997, AM J HUM GENET, V60, P320; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YAROSH DB, 1993, J INVEST DERMATOL, V100, P790, DOI 10.1111/1523-1747.ep12476573	57	33	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2827	2834		10.1038/sj.onc.1201827	http://dx.doi.org/10.1038/sj.onc.1201827			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671403				2022-12-17	WOS:000073988200001
J	Hamazaki, Y; Kojima, H; Mano, H; Nagata, Y; Todokoro, K; Abe, T; Nagasawa, T				Hamazaki, Y; Kojima, H; Mano, H; Nagata, Y; Todokoro, K; Abe, T; Nagasawa, T			Tec is involved in G protein-coupled receptor- and integrin-mediated signalings in human blood platelets	ONCOGENE			English	Article						Tec; platelet; thrombin; integrin	BETA-GAMMA-SUBUNITS; TYROSINE KINASE GENE; THROMBIN-STIMULATED PLATELETS; X-LINKED AGAMMAGLOBULINEMIA; HETEROTRIMERIC G-PROTEINS; HEMATOPOIETIC-CELLS; RABBIT PLATELETS; ACTIVATION; PHOSPHORYLATION; FAMILY	Tec is a non-receptor type tyrosine kinase which is tyrosine phosphorylated and activated upon stimulation of hematopoietic cells with various cytokines. The role of Tec in G protein-coupled receptor-and integrin-mediated signalings has not been elucidated. We therefore investigated the regulation of Tec in human blood platelets. Tec was rapidly tyrosine phosphorylated in response to platelet agonists which activate G protein-coupled receptors such as thromboxane A, analog (U46619), thrombin, and thrombin receptor activating peptide (TRAP). TRAP-induced phosphorylation in Tec was significantly reduced under the conditions which abrogate fibrinogen binding to GP IIb-IIIa and subsequent platelet aggregation. However, TRAP induced significant levels of the phosphorylation even under these conditions and also in thrombasthenic platelets which lack functional GP IIb-IIIa molecules, suggesting that activation of G-protein-coupled receptor causes the phosphorylation. To clarify whether integrin engagement by itself causes the phosphorylation in Tee, we examined the state of the phosphorylation in platelets activated by integrin engagement. Platelet adhesion to immobilized fibrinogen or collagen induced significant levels of the phosphorylation. Furthermore, Tec was translocated to cytoskeleton in response to TRAP in a manner dependent on platelet aggregation, suggesting that Tec can be a component of integrin-mediated signalings. These results collectively indicate that Tec is involved in G protein-coupled receptor-and integrin-mediated signalings in human blood platelets.	Univ Tsukuba, Inst Clin Med, Div Hematol, Tsukuba, Ibaraki 305, Japan; Jichi Med Sch, Dept Biol Mol, Minami Kawachi, Tochigi 32904, Japan; RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 305, Japan	University of Tsukuba; Jichi Medical University; RIKEN	Kojima, H (corresponding author), Univ Tsukuba, Inst Clin Med, Div Hematol, Tsukuba, Ibaraki 305, Japan.		Hamazaki, Y*/Q-3076-2019	Hamazaki, Y*/0000-0001-5866-7340				AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; Cichowski K, 1996, J BIOL CHEM, V271, P7544, DOI 10.1074/jbc.271.13.7544; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; CLARK EA, 1994, J BIOL CHEM, V269, P28859; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DHAR A, 1990, MOL PHARMACOL, V37, P519; FAURE M, 1994, J BIOL CHEM, V269, P7851; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kojima H, 1995, THROMB HAEMOSTASIS, V74, P1541; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MACHIDE M, 1995, ONCOGENE, V11, P619; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1995, BLOOD, V85, P343; MANO H, 1993, ONCOGENE, V8, P417; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Miyazato A, 1996, CELL GROWTH DIFFER, V7, P1135; ODA A, 1992, J BIOL CHEM, V267, P20075; RASMUSSEN UB, 1993, J BIOL CHEM, V268, P14322; SALARI H, 1990, FEBS LETT, V263, P104, DOI 10.1016/0014-5793(90)80715-U; SCHOENWAELDER SM, 1994, J BIOL CHEM, V269, P32479; SHATTIL SJ, 1992, J BIOL CHEM, V267, P18424; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; TakahashiTezuka M, 1997, ONCOGENE, V14, P2273, DOI 10.1038/sj.onc.1201071; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; TOHYAMA Y, 1994, J BIOL CHEM, V269, P32796; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; Yamashita Y, 1997, EXP HEMATOL, V25, P211	45	33	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2773	2779		10.1038/sj.onc.1201799	http://dx.doi.org/10.1038/sj.onc.1201799			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652744				2022-12-17	WOS:000073812200009
J	Halaban, R; Cheng, E; Zhang, Y; Mandigo, CE; Miglarese, MR				Halaban, R; Cheng, E; Zhang, Y; Mandigo, CE; Miglarese, MR			Release of cell cycle constraints in mouse melanocytes by overexpressed mutant E2F1(E132), but not by deletion of p16(INK4A) or p21(WAF/CIP1)	ONCOGENE			English	Review						E2F1; cyclin D1; cyclin A; Rb; TPA; transcription	RETINOBLASTOMA GENE-PRODUCT; UBIQUITIN-PROTEASOME PATHWAY; TRANSCRIPTION FACTOR E2F1; ACTIVATED PROTEIN-KINASE; FAMILIAL MELANOMA; GROWTH-FACTOR; MURINE MELANOCYTES; MALIGNANT-MELANOMA; FIBROBLASTS LEADS; INHIBITOR P21	Compared to normal melanocytes, melanoma cell lines exhibit overexpression of hyperphosphorylated retinoblastoma tumor suppressor protein (Rb) or a marked decrease in, or lack of, expression of Rb. Hyperphosphorylation of Rb results in increased E2F-mediated transactivation of target genes and cell cycle progression. Using a combination of gene disruption and ectopic expression in growth factor-dependent mouse melanocytes, we studied the roles of E2F1 and the p16(INK4A) and p21(WAF1/CIP1) CKIs (cyclin dependent kinase inhibitors) in the acquisition of TPA (12-O-tetradecanoyl phorbol-13-acetate)-independent growth in culture, a hallmark of melanomas. Surprisingly, melanocytes from p16(INK4A)-or p21(WAF1/CIP1)-null mice remained TPA-dependent, and disruption of p21(WAF1/CIP1) accelerated cell death in the absence of this mitogen. Disruption of E2F1 had the most profound effect on melanocyte growth, resulting in a fourfold decrease in growth rate in the presence of TPA. Furthermore, enforced overexpression of the DNA-binding-defective E2F1(E132) mutant conferred TPA-independence upon melanocytes and was associated with sequestration of Rb and constitutive expression of E2F1 target genes, including p21(WAF1/CIP1). We conclude that neutralization of Rb by E2F1(E132), but not the disruption of pl6(INK4A) or p21(WAF1/CIP1), resulted in the accumulation of free E2F and cell cycle progression. Thus, mechanisms other than the loss of p16(INK4A) or p21(WAF1/CIP1) that activate E2F may play an important role in melanomas.	Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA	Yale University	Halaban, R (corresponding author), Yale Univ, Sch Med, Dept Dermatol, POB 208059, New Haven, CT 06520 USA.							Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; Bartkova J, 1996, CANCER RES, V56, P5475; BATAILLE V, 1995, BRIT J DERMATOL, V132, P134, DOI 10.1111/j.1365-2133.1995.tb08639.x; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CannonAlbright LA, 1996, SEMIN ONCOL, V23, P667; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1994, J CELL SCI, P81; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Flores JF, 1997, ONCOGENE, V15, P2999, DOI 10.1038/sj.onc.1201470; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; Geng Y, 1996, ONCOGENE, V12, P1173; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GRUIS NA, 1995, MELANOMA RES, V5, P169, DOI 10.1097/00008390-199506000-00005; Guldberg P, 1997, INT J CANCER, V72, P780, DOI 10.1002/(SICI)1097-0215(19970904)72:5<780::AID-IJC13>3.0.CO;2-D; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; Halaban R, 1996, SEMIN ONCOL, V23, P673; HALABAN R, 1998, IN PRESS INT J MOL M, V1; Haluska FG, 1995, CANCER SURV, V25, P277; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Healy E, 1996, J INVEST DERMATOL, V107, P318, DOI 10.1111/1523-1747.ep12363118; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; Jiang HP, 1996, MOL CELL DIFFER, V4, P67; JIANG HP, 1995, ONCOGENE, V10, P1855; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li JM, 1997, P NATL ACAD SCI USA, V94, P4948, DOI 10.1073/pnas.94.10.4948; LIU L, 1995, ONCOGENE, V11, P405; Liu Y, 1996, CANCER RES, V56, P31; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Lukas J, 1996, MOL CELL BIOL, V16, P6917; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maelandsmo GM, 1996, AM J PATHOL, V149, P1813; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Moll AC, 1997, OPHTHALMIC GENET, V18, P27, DOI 10.3109/13816819709057880; Moore DD, 1995, GLOB MOB SURV; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NEVINS JR, 1992, SCIENCE, V258, P424; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PEEPER DS, 1995, ONCOGENE, V10, P39; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; PUIG S, 1995, AM J HUM GENET, V57, P395; Puntoni F, 1997, BIOCHEM BIOPH RES CO, V235, P704, DOI 10.1006/bbrc.1997.6886; QUELLE DE, 1995, CELL, V83, P993; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REYMOND A, 1995, ONCOGENE, V11, P1173; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; TAMURA A, 1987, IN VITRO CELL DEV B, V23, P519; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Trotter MJ, 1997, J CUTAN PATHOL, V24, P265, DOI 10.1111/j.1600-0560.1997.tb00790.x; WAINWRIGHT B, 1994, NAT GENET, V8, P3, DOI 10.1038/ng0994-3; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; Wang HS, 1997, CANCER RES, V57, P1750; Wang YP, 1996, ONCOGENE, V12, P1069; Weinberg RA, 1996, CYTOKINES MOL THER, V2, P105; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yang XH, 1997, BIOCHEM BIOPH RES CO, V232, P336, DOI 10.1006/bbrc.1997.6284; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	104	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	1998	16	19					2489	2501		10.1038/sj.onc.1201773	http://dx.doi.org/10.1038/sj.onc.1201773			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627115				2022-12-17	WOS:000073672300007
J	Pyronnet, S; Gingras, AC; Bouisson, M; Kowalski-Chauvel, A; Seva, C; Vaysse, N; Sonenberg, N; Pradayrol, L				Pyronnet, S; Gingras, AC; Bouisson, M; Kowalski-Chauvel, A; Seva, C; Vaysse, N; Sonenberg, N; Pradayrol, L			Gastrin induces phosphorylation of eIF4E binding protein 1 and translation initiation of ornithine decarboxylase mRNA	ONCOGENE			English	Article							PANCREATIC-CELL LINE; MESSENGER-RNA; FACTOR 4E; TRANSFORMATION; 4E-BP1; KINASE; GROWTH; CHOLECYSTOKININ; ASSOCIATION; STIMULATION	Gastrin via its G-protein coupled specific receptor induces transcription of c-fos and c-jun genes through a ras-MAPK pathway. Ornithine Decarboxylase (ODC), a growth regulated proto-oncogene, was chosen to investigate gastrin effects on translation initiation of mRNAs exhibiting a 5'UnTranslated Region (5'UTR) responsible for translation repression in quiescent cells. In AR4-2J tumoral cells, we first demonstrated that gastrin increases ODC mRNA translation. Transient transfections with various CAT chimeric constructs suggested a direct involvement of the 5'UTR in this observation. Translation of this group of mRNAs is enhanced by the availability of the cap-binding protein (eIF4E) that is increased after phosphorylation of its specific binding protein eIF4E-BP1, We found that AR4-2J cells overexpressed eIF4E protein which was not modulated by gastrin treatment. Rapamycin which inhibits 4E-BP1 phosphorylation, completely prevents gastrin-mediated increase of ODC translation indicating that 4E-BP1 could be involved in regulating ODC translation. Implication of 4E-BP1 in mediating gastrin effects is corroborated by the capacity of the ligand to affect 4E-BP1 phosphorylation, These results indicate that gastrin enhances ornithine decarboxylase mRNA translation through a rapamycin sensitive pathway and provide the first evidence in the control of 4E-BP1 phosphorylation after occupancy of a G protein-coupled receptor.	CHU Rangueil, Inst Louis Bugnard, IFR 31, INSERM,U151, F-31403 Toulouse 4, France; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); McGill University	Pradayrol, L (corresponding author), CHU Rangueil, Inst Louis Bugnard, IFR 31, INSERM,U151, F-31403 Toulouse 4, France.		Gingras, Anne-Claude/E-9982-2010; Pyronnet, Stéphane/P-2419-2014; Kowalski-Chauvel, Aline/O-9212-2014; SEVA, Catherine/O-9166-2014; Gingras, Anne-Claude/ABA-8341-2020	Gingras, Anne-Claude/0000-0002-6090-4437; SEVA, Catherine/0000-0002-4265-7372; Gingras, Anne-Claude/0000-0002-6090-4437				AMSTERDA.A, 1974, J CELL BIOL, V63, P1037, DOI 10.1083/jcb.63.3.1037; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BARNEJI J, 1983, CELL, V33, P729; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BERTRAND V, 1994, INT J CANCER, V56, P427, DOI 10.1002/ijc.2910560324; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; GREENS A, 1990, J BIOL CHEM, V265, P11810; HAYASHI SI, 1995, BIOCHEM J, V306, P1; HICKOK NJ, 1986, P NATL ACAD SCI USA, V83, P594, DOI 10.1073/pnas.83.3.594; JOHNSON LR, 1977, ANNU REV PHYSIOL, V39, P135, DOI 10.1146/annurev.ph.39.030177.001031; KowalskiChauvel A, 1996, J BIOL CHEM, V271, P26356, DOI 10.1074/jbc.271.42.26356; KUZYK CJ, 1986, AM J PHYSIOL, V251, pG597; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEIJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Pyronnet S, 1996, CANCER RES, V56, P1742; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Sambrook J, 1989, MOL CLONING LAB MANU; SCEMAMA JL, 1989, AM J PHYSIOL, V256, pG846, DOI 10.1152/ajpgi.1989.256.5.G846; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SETHI T, 1992, CANCER RES, V52, P6031; SEVA C, 1994, REGUL PEPTIDES, V52, P31, DOI 10.1016/0167-0115(94)90018-3; SEVA C, 1990, CANCER RES, V50, P5829; SHANTZ LM, 1994, CANCER RES, V54, P2313; SINGH P, 1986, CANCER RES, V46, P1612; SOLOMON TE, 1987, GASTROENTEROLOGY, V92, P429, DOI 10.1016/0016-5085(87)90138-7; Sonenberg Nahum, 1993, Gene Expression, V3, P317; TAMORI A, 1995, CANCER RES, V55, P3500; TODISCO A, 1995, J BIOL CHEM, V270, P28337; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WALLON UM, 1990, FEBS LETT, V268, P161, DOI 10.1016/0014-5793(90)80998-X	36	33	33	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2219	2227		10.1038/sj.onc.1201748	http://dx.doi.org/10.1038/sj.onc.1201748			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619831				2022-12-17	WOS:000073298000007
J	Dehbi, M; Hiscott, J; Pelletier, J				Dehbi, M; Hiscott, J; Pelletier, J			Activation of the wt1 Wilms' tumor suppressor gene by NF-kappa B	ONCOGENE			English	Article						WT1; NF-kappa B; gene regulation; Wilms' tumor	TRANSCRIPTION FACTOR; NECROSIS-FACTOR; HL-60 CELLS; EXPRESSION; ENHANCER; ALPHA; PROMOTER; DIFFERENTIATION; INHIBITOR; MUTATIONS	The Wilm's tumor suppressor gene, wt1, is expressed in a very defined spatial-temporal fashion and plays a key role in development of the urogenital system, Transacting factors governing wt1 expression are poorly defined. The presence of putative kappa B binding sites within the wt1 gene prompted us to investigate whether members of the NF-kappa B/Rel family of transcription factors are involved in regulating wt1 expression. In transient transfection assays, ectopic expression of p50 and p65 subunits of NF-kappa B stimulated wt1 promoter activity 10-30-fold. Deletion mutagenesis revealed that NF-kappa B responsiveness is mediated by a short DNA fragment located within promoter proximal sequences of the major transcription start site. Two kappa B-binding sites are present in this region and form specific complexes with purified NF-kappa B proteins, as revealed by electrophoretic mobility gel shift assays. Ectopic expression of p50 and p65 resulted in increased transcription of the endogenous wt1 gene, as revealed by nuclear run-on experiments. Taken together, these results indicate that members of the NF-kappa B/Rel family are important for activating expression of wt1 and reside upstream of the regulatory cascade leading to wt1 activation.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	McGill University; McGill University; Lady Davis Institute; McGill University	Pelletier, J (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.							Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; Dehbi M, 1996, ONCOGENE, V13, P447; Dehbi M, 1996, EMBO J, V15, P4297, DOI 10.1002/j.1460-2075.1996.tb00804.x; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; HOFFMANN W, 1993, ONCOGENE, V8, P3123; HOHMANN HP, 1992, J BIOL CHEM, V267, P2065; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; MATSUNAGA E, 1981, HUM GENET, V57, P231; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PARK S, 1993, NAT GENET, V5, P363, DOI 10.1038/ng1293-363; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PHELAN SA, 1994, CELL GROWTH DIFFER, V5, P677; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKIYA M, 1994, BLOOD, V83, P1876; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WU YJ, 1995, J BIOL CHEM, V270, P5944, DOI 10.1074/jbc.270.11.5944	34	33	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2033	2039		10.1038/sj.onc.1201747	http://dx.doi.org/10.1038/sj.onc.1201747			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572484				2022-12-17	WOS:000073177200001
J	Veldhoen, N; Milner, J				Veldhoen, N; Milner, J			Isolation of canine p53 cDNA and detailed characterization of the full length canine p53 protein	ONCOGENE			English	Article						DNA binding; damaged DNA; full length canine p53	TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING; IN-VITRO; MUTATIONS; SEQUENCE; CANCER; OVEREXPRESSION; COMPLEXES; VARIANTS; CLEAVAGE	The p53 tumour suppressor protein plays a central role in the maintenance of genomic integrity. Mutations of the p53 gene are found in a number of canine cancers and many contribute to tumour formation, Here we describe isolation and expression of the complete wild type canine p53 cDNA. The encoded full length canine p53 protein displays strong sequence homology with p53 proteins from other higher vertebrates, Canine p53 protein produced in vitro was shown to recognize and bind to p53-specific DNA targets derived from the p21 and GADD45 promoters and to a consensus p53 binding site, We also show that canine p53 associates with oligonucleotides representing damaged DNA sites and undergoes proteolytic cleavage similar to that described for murine and human p53 proteins. Finally, we show that the canine p53 protein is able to transcriptionally activate a p53-dependent reporter gene in vivo, The results suggest that canine p53 is similar both in structure and function to human p53 and that canine cancer may provide a useful clinical model in the search for effective anti-cancer therapies based on p53.	Univ York, Dept Biol, YCRC P53 Res Grp, York YO1 5DD, N Yorkshire, England	University of York - UK	Veldhoen, N (corresponding author), Univ York, Dept Biol, YCRC P53 Res Grp, York YO1 5DD, N Yorkshire, England.							Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DEVILEE P, 1994, ANTICANCER RES, V14, P2039; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FREBOURG T, 1992, CANCER RES, V52, P6976; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; Gamblin RM, 1997, AM J VET RES, V58, P857; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HALL AR, 1995, ONCOGENE, V10, P561; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HARVEY M, 1993, ONCOGENE, V8, P2457; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; JUVEN T, 1993, ONCOGENE, V8, P341; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAEGEL SA, 1995, CANCER LETT, V92, P181, DOI 10.1016/0304-3835(95)03779-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN J, 1994, COLD SPRING HARB SYM, V59, P215, DOI 10.1101/SQB.1994.059.01.026; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MAYR B, 1994, BRIT VET J, V150, P81, DOI 10.1016/S0007-1935(05)80099-5; Mayr B, 1997, VET RES COMMUN, V21, P369, DOI 10.1023/A:1005820607258; Molinari M, 1996, ONCOGENE, V13, P2077; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sagartz JE, 1996, VET PATHOL, V33, P213, DOI 10.1177/030098589603300211; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Teifke JP, 1996, J COMP PATHOL, V114, P205, DOI 10.1016/S0021-9975(96)80010-7; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; vanLeeuwen IS, 1997, CANCER LETT, V111, P173, DOI 10.1016/S0304-3835(96)04529-6; vanLeeuwen IS, 1996, ANTICANCER RES, V16, P3737; Veldhoen N, 1998, ONCOGENE, V16, P249, DOI 10.1038/sj.onc.1201489; WADA H, 1994, LEUKEMIA, V8, P53; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wolf JC, 1997, VET PATHOL, V34, P394, DOI 10.1177/030098589703400503	40	33	35	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					1077	1084		10.1038/sj.onc.1201863	http://dx.doi.org/10.1038/sj.onc.1201863			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519881				2022-12-17	WOS:000072335900013
J	Wang, L; Darling, J; Zhang, JS; Qian, CP; Hartmann, L; Conover, C; Jenkins, R; Smith, DI				Wang, L; Darling, J; Zhang, JS; Qian, CP; Hartmann, L; Conover, C; Jenkins, R; Smith, DI			Frequent homozygous deletions in the FRA3B region in tumor cell lines still leave the FHIT exons intact	ONCOGENE			English	Article						deletions; tumor cell lines; FRA3B; FHIT	3P14.2 FRAGILE SITE; VIRAL INTEGRATION; TRANSLOCATION BREAKPOINT; CARCINOMA; CANCER; GENE; REPEAT; DNA; HETEROZYGOSITY; AMPLIFICATION	FRA3B at human chromosomal band 3p14.2 is the most active common fragile site in the human genome. The molecular mechanism of fragility at this region remains unknown but does not involve expansion of a trinucleotide or minisatellite repeat as has been observed for several of the cloned rare fragile sites. Deletions and rearrangements at FRA3B have been observed in a number of distinct tumors. The recently identified putative tumor suppressor gene FHIT spans FRA3B, and various groups have reported identifying deletions in this gene in different tumors. Using a high density of PCR amplifiable markers within FRA3B searching for deletions in the FRA3B region, we have analysed 21 tumor cell lines derived from renal cell, pancreatic, and ovarian carcinomas. We found a commonly deleted region in the renal cell and ovarian carcinoma cell lines located in the middle of an HPV16 viral integration site. Despite the presence of deletions in the FRA3B region in most of the cell lines, we did not detect alterations in FHIT exons in any of the cell lines examined. Thus, deletions of 3p14.2 in these carcinoma cell lines may simply reflect instability of the FRA3B region during tumor progression.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55902 USA; Mayo Clin & Mayo Fdn, Dept Med Oncol, Rochester, MN 55902 USA	Mayo Clinic; Mayo Clinic	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, 200 1st St SW, Rochester, MN 55902 USA.				NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; BOLDOG FL, 1993, P NATL ACAD SCI USA, V90, P8509, DOI 10.1073/pnas.90.18.8509; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Cohen S, 1997, ONCOGENE, V14, P977, DOI 10.1038/sj.onc.1200917; DRUCK T, 1995, CANCER RES, V55, P5348; Druck T, 1997, CANCER RES, V57, P504; EHLEN T, 1990, ONCOGENE, V5, P219; Fong KM, 1997, CANCER RES, V57, P2256; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Hendricks DT, 1997, CANCER RES, V57, P2112; JENKINS RB, 1993, CANCER GENET CYTOGEN, V71, P76, DOI 10.1016/0165-4608(93)90205-Z; JONES C, 1994, HUM MOL GENET, V3, P2123, DOI 10.1093/hmg/3.12.2123; KAMEL D, 1994, HISTOPATHOLOGY, V25, P339, DOI 10.1111/j.1365-2559.1994.tb01352.x; Kastury K, 1996, CANCER RES, V56, P978; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; Mao L, 1996, CANCER RES, V56, P5128; Mauillon JL, 1996, CANCER RES, V56, P5728; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Panagopoulos I, 1996, CANCER RES, V56, P4871; Paradee W, 1996, GENOMICS, V35, P87, DOI 10.1006/geno.1996.0326; PARADEE W, 1995, GENOMICS, V27, P358, DOI 10.1006/geno.1995.1057; PARRISH JE, 1994, NAT GENET, V8, P229, DOI 10.1038/ng1194-229; POPESCU NC, 1990, HUM GENET, V84, P383; Puget N, 1997, CANCER RES, V57, P828; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; Reiter LT, 1996, NAT GENET, V12, P288, DOI 10.1038/ng0396-288; Shridhar R, 1996, CANCER RES, V56, P4347; Shridhar V, 1997, ONCOGENE, V14, P1269, DOI 10.1038/sj.onc.1201100; SMEETS DFCM, 1986, HUM GENET, V72, P215, DOI 10.1007/BF00291880; SMITH PP, 1992, GENE CHROMOSOME CANC, V5, P150, DOI 10.1002/gcc.2870050209; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SUTHERLAND GR, 1985, OXFORD U MONOGRAPHS, V13; Todd S, 1997, CANCER RES, V57, P1344; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P59, DOI 10.1002/(SICI)1098-2264(199706)19:2<59::AID-GCC1>3.3.CO;2-O; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; WAGATSUMA M, 1990, J VIROL, V64, P813, DOI 10.1128/JVI.64.2.813-821.1990; Wang L, 1997, GENOMICS, V41, P485, DOI 10.1006/geno.1997.4690; Wang L, 1996, ONCOGENE, V12, P699; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; YAMAGISAWA K, 1996, CANCER RES, V56, P5579; Yu S, 1997, CELL, V88, P367, DOI 10.1016/S0092-8674(00)81875-9; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; Zimonjic DB, 1997, CANCER RES, V57, P1166	45	33	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					635	642		10.1038/sj.onc.1201576	http://dx.doi.org/10.1038/sj.onc.1201576			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482109				2022-12-17	WOS:000071816600008
J	Coffer, PJ; vanPuijenbroek, A; Burgering, BMT; KlopdeJonge, M; Koenderman, L; Bos, JL; Kruijer, W				Coffer, PJ; vanPuijenbroek, A; Burgering, BMT; KlopdeJonge, M; Koenderman, L; Bos, JL; Kruijer, W			Insulin activates Stat3 independently of p21ras-ERK and PI-3K signal transduction	ONCOGENE			English	Article						insulin; STAT; Ras; ERK; PI-3K	EPIDERMAL GROWTH-FACTOR; DNA-BINDING ACTIVITY; C-FOS EXPRESSION; PROTEIN-KINASE CASCADE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; SERINE PHOSPHORYLATION; TYROSINE PHOSPHORYLATION; CONSTITUTIVE ACTIVATION; CYTOKINE RECEPTORS	The binding of insulin to its receptor initiates multiple signal transduction pathways regulating such diverse processes as proliferation, differentiation, glucose transport, and glycogen metabolism, The STAT-family of transcription factors has been demonstrated to play a critical role in gene induction by a variety of hemopoietic cytokines and hormones, Furthermore, constitutive activation of STATs is observed in transformed cells, Here we describe activation of a transcriptional complex binding to a consensus STAT-transcriptional element in response to insulin challenge, This complex is induced rapidly after tyrosine autophosphorylation of the insulin receptor, and is sustained for several hours, Supershift analysis of the insulin-induced complex reveals that it specifically contains the transcription factor Stat3, DAN binding of this complex is inhibited by pre-incubation with tyrosine, but not serine/threonine protein kinase inhibitors, whereas transcriptional activation is inhibited by both, Utilising a dominant negative mutant of p21ras we demonstrate that both insulin-induced Stat3 DNA-binding and also transactivation do not require p21ras, Furthermore, although previous studies have suggested a role for MAP kinases (ERKs) and PI-3K in STAT activation, utilising the specific MEK inhibitor PD098059 and the PI-3K inhibitor wortmannin, we demonstrate that activation of ERKs or PI-3K are not required for insulin induced Stat3 phosphorylation or transactivation.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,NL-3584 CT UTRECHT,NETHERLANDS; UNIV UTRECHT,PHYSIOL CHEM LAB,NL-3584 CG UTRECHT,NETHERLANDS; UNIV GRONINGEN,CTR BIOL,DEPT GENET,NL-9750 AA HAREN,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; University of Groningen	Coffer, PJ (corresponding author), UNIV UTRECHT HOSP,DEPT PULM DIS,G03-550,HEIDELBERGLAAN 100,NL-3584 CX UTRECHT,NETHERLANDS.		Coffer, Paul J/A-5769-2009; Koenderman, Leo/AAE-7870-2020; Coffer, Paul/AAF-7970-2020	Koenderman, Leo/0000-0002-5636-6453; 				ALLESSI DR, 1995, J BIOL CHEM, V270, P27489; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BURGERING BMT, 1993, BIOCHEM SOC T, V21, P888, DOI 10.1042/bst0210888; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CAMPOS SP, 1992, MOL CELL BIOL, V12, P1789, DOI 10.1128/MCB.12.4.1789; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COFFER P, 1995, ONCOGENE, V10, P985; COFFER PJ, 1995, ONCOGENE, V11, P561; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; COFFER PJ, 1993, ONCOGENE, V9, P911; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; DERIJARD B, 1994, CELL, V76, P727; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DEVRIESSMITS AMM, 1995, METHOD ENZYMOL, V255, P221; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALANG CK, 1994, ONCOGENE, V9, P2913; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HEIDENREICH KA, 1993, J BIOL CHEM, V268, P14663; HILL CS, 1996, EMBO J, V15, P5037; HORN F, 1994, ANN NY ACAD SCI, V73, P308; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JHUN BH, 1995, BIOCHEMISTRY-US, V34, P7996, DOI 10.1021/bi00025a005; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LEE J, 1994, AM J PHYSIOL, V266, P319; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; Miller BS, 1996, BIOCHEMISTRY-US, V35, P8769, DOI 10.1021/bi952651r; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; OLSON AL, 1994, ENDOCRINOLOGY, V134, P271, DOI 10.1210/en.134.1.271; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1992, J BIOL CHEM, V267, P24058; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTH RA, 1992, J CELL BIOCHEM, V48, P12, DOI 10.1002/jcb.240480104; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SETH A, 1992, J BIOL CHEM, V267, P24796; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Shuai K, 1996, ONCOGENE, V13, P247; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WATLING D, 1993, NATURE, V366, P114; WeberNordt RM, 1996, BLOOD, V88, P809; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	83	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2529	2539		10.1038/sj.onc.1201429	http://dx.doi.org/10.1038/sj.onc.1201429			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399641				2022-12-17	WOS:A1997YG73200003
J	Mochizuki, T; Kitanaka, C; Noguchi, K; Sugiyama, A; Kagaya, S; Chi, SJ; Asai, A; Kuchino, Y				Mochizuki, T; Kitanaka, C; Noguchi, K; Sugiyama, A; Kagaya, S; Chi, SJ; Asai, A; Kuchino, Y			Pim-1 kinase stimulates c-Myc-mediated death signaling upstream of caspase-3 (CPP32)-like protease activation	ONCOGENE			English	Article						Pim-1; c-Myc; caspase; apoptosis; serine/threonine kinase; transformation	PROGRAMMED CELL-DEATH; BCL-2 HOMOLOG BAK; E-MU-MYC; TRANSGENIC MICE; INTERLEUKIN-1-BETA-CONVERTING ENZYME; INDUCED APOPTOSIS; GLIOMA-CELLS; CYCLE ARREST; GENE-PRODUCT; IN-VIVO	Pim-1 oncoprotein is a serine/threonine kinase that can closely cooperate with c-Myc in lymphomagenesis, as does Bcl-2. Although the molecular mechanism of this cooperative transformation remains unknown, it is speculated that, similar to Bcl-2, Pim-1 contributes to transformation by inhibiting apoptosis. In this study, therefore, we examined the effect of Pim-1 expression on c-Myc-mediated apoptosis of Rat-1 fibroblasts triggered by serum deprivation. Our results showed that, rather than inhibiting apoptosis, Pim-1 expression stimulated c-Myc-mediated apoptosis in Rat-1 fibroblasts. Pim-1 stimulated c-Myc-mediated apoptosis through an enhancement of the c-Myc-mediated activation of caspase-3 (CPP32)-like proteases, since the suppression of this activity by a specific caspase inhibitor abolished the apoptosis stimulation by Pim-1. A kinase-defective Pim-1 mutant failed to stimulate c-Myc-mediated apoptosis, and Pim-1 expression alone in the absence of c-Myc overexpression did not induce apoptosis of serum-deprived Rat-1 cells, indicating that the kinase activity of Pim-1 and the activated c-Myc signaling pathway mere required for apoptosis stimulation by Pim-1. Together, these results suggest that Pim-1 oncoprotein stimulates as a serine/threonine kinase the death signaling elicited by c-Myc at a step upstream of caspase-3-like protease activation in Rat-1 fibroblasts. Our results also suggest that Pim-1 kinase might function cooperatively with c-Myc through the phosphorylation of a factor(s) which regulates the common signaling pathway involved in c-Myc-mediated apoptosis and transformation.	NATL CANC CTR,RES INST,DIV BIOPHYS,CHUO KU,TOKYO 104,JAPAN; UNIV TOKYO,SCH MED,DEPT NEUROSURG,BUNKYO KU,TOKYO 113,JAPAN	National Cancer Center - Japan; University of Tokyo								Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ASAI A, 1994, CELL GROWTH DIFFER, V5, P1153; ASKEW DS, 1991, ONCOGENE, V6, P1915; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CROIX BS, 1996, NAT MED, V2, P1204; CUYPERS HT, 1984, CELL, V37, P141; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOOVER D, 1991, J BIOL CHEM, V266, P14018; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KITANAKA C, 1995, CELL DEATH DIFFER, V2, P123; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PADMA R, 1991, CANCER RES, V51, P2486; Poluha W, 1996, MOL CELL BIOL, V16, P1335; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TELERMAN A, 1988, MOL CELL BIOL, V8, P1498, DOI 10.1128/MCB.8.4.1498; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WINGETT D, 1992, NUCLEIC ACIDS RES, V20, P3183, DOI 10.1093/nar/20.12.3183; Zornig M, 1996, ONCOGENE, V12, P1789	51	33	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1471	1480		10.1038/sj.onc.1201326	http://dx.doi.org/10.1038/sj.onc.1201326			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333023				2022-12-17	WOS:A1997XW41100011
J	Packham, G; Cleveland, JL				Packham, G; Cleveland, JL			Induction of ornithine decarboxylase by IL-3 is mediated by sequential c-Myc-independent and c-Myc-dependent pathways	ONCOGENE			English	Article						c-Myc; ODC; IL-3	CELL-CYCLE ARREST; INDUCED APOPTOSIS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; SIGNALING PATHWAYS; PROTEIN COMPLEX; REPRESSOR SIN3; DNA-BINDING; IN-VIVO; MAX	Enforced c-Myc expression promotes continuous, growth factor-independent, cell cycle progression and activates expression of the ornithine decarboxylase (ODC) gene and its promoter. c-Myc-responsiveness of murine ODC is mediated by two conserved c-Myc:Max E-boxes in ODC intron 1. c-Myc and ODC are both required for cell growth and their expression is sequentially induced in G(0)/G(1) cells stimulated with mitogens, yet their expression is not modulated by the cell cycle in proliferating cells. Here we demonstrate that regulation of ODC and its promoter by Interleukin-3 (IL-3) in murine myeloid cells is mediated in part by c-Myc. c-Myc induced ODC through the same transcription start site as IL-3 and, in asynchronously growing cells, maximal activity of the ODC promoter required the intronic c-Myc binding sites. However, induction of ODC following IL-3 stimulation of quiescent cells is mediated by at least two pathways. The first phase of this response was independent of the intronic c-Myc:Max E-boxes and de novo protein synthesis. Sustained induction of the ODC promoter however required the c-Myc:Max binding sites and protein synthesis. Accumulation of c-Myc following stimulation of quiescent cells with IL-3 correlated with the delayed phase of the response. Consistent with a two pathway model of ODC regulation, inducible overexpression of dominant negative form of c-Myc (In373-Myc), which specifically inhibits the c-Myc-Max network, inhibited the delayed, but not immediate, induction of ODC promoter activity in response to IL-3. Dominant negative c-Myc protein also effectively suppressed induction of the endogenous ODC gene by IL-3. Therefore, c-Myc functions as a direct and required regulator of ODC. These results also suggest a model whereby c-Myc's role in regulating its targets may be to convert a transient, immediate-early, activation event into the persistent induction of gene expression.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, CTR HLTH SCI, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; ST MARYS HOSP, SCH MED, IMPERIAL COLL, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND; ST MARYS HOSP, SCH MED, IMPERIAL COLL, DEPT MED MICROBIOL, LONDON W2 1PG, ENGLAND	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Imperial College London; Ludwig Institute for Cancer Research; Imperial College London					NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER; NCI NIH HHS [P0 CA 21765] Funding Source: Medline; NIDDK NIH HHS [DK44158] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSEN MS, 1992, J BIOL CHEM, V267, P18866; ARMATI B, 1993, CELL, V72, P233; ARMATI B, 1994, CURR OPIN GENET DEV, V4, P102; ARMATI B, 1992, NATURE, V359, P423; ARMATI B, 1993, EMBO J, V12, P5083; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOWLIN TL, 1986, CELL IMMUNOL, V98, P341, DOI 10.1016/0008-8749(86)90294-7; BRABANT M, 1988, P NATL ACAD SCI USA, V85, P2200, DOI 10.1073/pnas.85.7.2200; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COLMAN MS, 1996, NUCLEIC ACIDS RES, V21, P5372; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DEAN M, 1987, ONCOGENE RES, V1, P279; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HO YS, 1987, NUCLEIC ACIDS RES, V15, P6746, DOI 10.1093/nar/15.16.6746; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATZ A, 1988, J BIOL CHEM, V263, P7604; KATZAV S, 1995, ONCOGENE, V11, P1079; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MANZELLA L, 1994, FEBS LETT, V348, P177, DOI 10.1016/0014-5793(94)00592-3; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MOSHIER JA, 1992, NUCLEIC ACIDS RES, V20, P2581, DOI 10.1093/nar/20.10.2581; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Packham G, 1996, ONCOGENE, V13, P461; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PACKHAM G, 1995, CELL MOL BIOL RES, V40, P699; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PENA A, 1993, J BIOL CHEM, V268, P27277; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6387; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHUETZ JD, 1995, CELL GROWTH DIFFER, V6, P1321; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SHOR J, 1995, ONCOGENE, V10, P587; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; TOBIAS KE, 1995, ONCOGENE, V11, P1721; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WATERS CM, 1991, ONCOGENE, V6, P797; WETTERS TV, 1989, NUCLEIC ACIDS RES, V17, P9843, DOI 10.1093/nar/17.23.9843; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; Wu SJ, 1996, ONCOGENE, V12, P621; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	73	33	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1219	1232		10.1038/sj.onc.1201273	http://dx.doi.org/10.1038/sj.onc.1201273			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294616	Bronze			2022-12-17	WOS:A1997XU99100012
J	Magae, J; Illenye, S; Tejima, T; Chang, YC; Mitsui, Y; Tanaka, K; Omura, S; Heintz, NH				Magae, J; Illenye, S; Tejima, T; Chang, YC; Mitsui, Y; Tanaka, K; Omura, S; Heintz, NH			Transcriptional squelching by ectopic expression of E2F-1 and p53 is alleviated by proteasome inhibitors MG-132 and lactacystin	ONCOGENE			English	Article						E2F/DP; transcription; p53	RETINOBLASTOMA GENE-PRODUCT; ADENOVIRUS E1A PROTEINS; TATA-BINDING PROTEIN; S-PHASE ENTRY; IN-VIVO; CELL-CYCLE; ACTIVATING MUTATIONS; APOPTOSIS; FAMILY; REPRESSION	The transcription factors p53 and E2F-1 play important roles in the control of cell cycle progression. In transient transfection experiments, expression of E2F-1, other E2F family members, or p53 squelched transcription from cotransfected plasmids in a dose-dependent manner, Although the proteasome inhibitors MG-132 and lactacystin markedly increased the level of expression of E2F-1 and p53, these inhibitors completely alleviated squelching by both proteins, Several observations indicate MG-132 alleviates squelching by influencing the conformation of newly synthesized p53 and E2F-1 MG-132 increased the fraction of wild type p53 bound by a monoclonal antibody which preferentially recognizes mutant conformers of p53, increased binding of hsp70 to p53 and inhibited nuclear accumulation of both p53 and E2F-1, but not the pocket protein p107, The protease inhibitors ALLN and ALLM did not influence expression of E2F-1 or p53, nor did they alleviate squelching by either transcription factor, Because MG-132 and lactacycstin are highly specific inhibitors of the proteasome protease, our results suggest that the proteasome influences post-translational processes involved in proper folding and cytoplasmic clearing of E2F-1 and p53.	UNIV VERMONT,DEPT PATHOL,BURLINGTON,VT 05405; NATL INST BIOSCI & HUMAN TECHNOL,TSUKUBA,IBARAKI 305,JAPAN; TOKYO METROPOLITAN INST MED SCI,BUNKYO KU,TOKYO 113,JAPAN; KITASATO INST,MINATO KU,TOKYO 108,JAPAN	University of Vermont; National Institute of Advanced Industrial Science & Technology (AIST); Tokyo Metropolitan Institute of Medical Science								ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EMILI A, 1995, J BIOL CHEM, V270, P13674, DOI 10.1074/jbc.270.23.13674; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOTTLIEB MT, 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATAOKA T, 1992, J ANTIBIOT, V45, P1618, DOI 10.7164/antibiotics.45.1618; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LIU X, 1995, MOL CELL BIOL, V15, P6474; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Magae J, 1996, J CELL SCI, V109, P1717; Maki CG, 1996, CANCER RES, V56, P2649; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MELILLO RM, 1994, MOL CELL BIOL, V14, P8241, DOI 10.1128/MCB.14.12.8241; MILBRANDT JD, 1981, P NATL ACAD SCI-BIOL, V78, P6043, DOI 10.1073/pnas.78.10.6043; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHULL S, 1991, J BIOL CHEM, V266, P24398; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOO JT, 1992, J ANTIBIOT, V45, P1108, DOI 10.7164/antibiotics.45.1108; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	70	33	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					759	769		10.1038/sj.onc.1201251	http://dx.doi.org/10.1038/sj.onc.1201251			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266962				2022-12-17	WOS:A1997XQ11700002
J	Moriyama, M; Yamochi, T; Semba, K; Akiyama, T; Mori, S				Moriyama, M; Yamochi, T; Semba, K; Akiyama, T; Mori, S			BCL-6 is phosphorylated at multiple sites in its serine- and proline-clustered region by mitogen-activated protein kinase (MAPK) in vivo	ONCOGENE			English	Article						BCL-6; MAP kinase; transcription factor; zinc finger; BTB/POZ; phosphorylation	NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; DNA-BINDING ACTIVITY; LARGE-CELL LYMPHOMA; C-FOS PROMOTER; CENTER B-CELLS; TRANSCRIPTION FACTOR; GROWTH-FACTOR; ZINC FINGERS; DOMAIN	BCL-6 gene alterations have been observed in 27-45% of diffuse large B-cell lymphomas (DLBs) with chromosomal translocations at 3q27. The deregulated expression of normal BCL-6 protein caused by this chromosomal translocation is believed to be responsible for lymphomagenesis. Recently, we demonstrated that BCL-6 is expressed at high levels in germinal center B-cells as a 92-98 kDa nuclear protein in a constitutively phosphorylated form. In this study, we show that BCL-6 is phosphorylated by mitogen-activated protein kinase (MAPK) in vitro at the sites phosphorylated in vivo. These numerous phosphorylation sites were found to be located in its serine- and proline-clustered (SPC) region (amino acids-250-483). BCL-6 phosphorylation significantly increased in Ramos cells following stimulation with 12-o-tetradecanoylphorbol-13-acetate (TPA) or BCL-6- and erk1-transfected COS-7 cells stimulated with epidermal growth factor (EGF), and the increase of phosphorylation was inhibited by MEK1 inhibitor, PD98059. Furthermore, we observed that BCL-6 was associated with MAPK in vivo and its SPC region was important for this association. These results suggest that the functions of BCL-6 are regulated by phosphorylation mediated by the MAPK signaling pathway.	UNIV TOKYO, INST MED SCI, DEPT CELLULAR & MOL BIOL, TOKYO 108, JAPAN; OSAKA UNIV, INST MICROBIAL DIS, DEPT ONCOGENE RES, OSAKA 565, JAPAN	University of Tokyo; Osaka University	Moriyama, M (corresponding author), UNIV TOKYO, INST MED SCI, DEPT PATHOL, 4-6-1 SHIROKANEDAI, TOKYO 108, JAPAN.							AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1995, GENE CHROMOSOME CANC, V13, P221, DOI 10.1002/gcc.2870130314; BASTARD C, 1994, BLOOD, V83, P2423; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHARDIN P, 1991, NUCLEIC ACIDS RES, V19, P1431, DOI 10.1093/nar/19.7.1431; CHAREST DL, 1993, MOL CELL BIOL, V13, P4679, DOI 10.1128/MCB.13.8.4679; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhordain P, 1995, ONCOGENE, V11, P2689; DIBELLO PR, 1991, GENETICS, V129, P385; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; LOCOCO F, 1994, BLOOD, V83, P1757, DOI 10.1182/blood.V83.7.1757.bloodjournal8371757; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MIKI T, 1994, BLOOD, V83, P26; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAO VN, 1994, ONCOGENE, V9, P1855; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SETH A, 1991, J BIOL CHEM, V266, P23521; Seyfert VL, 1996, ONCOGENE, V12, P2331; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; YAMOCHI T, IN PRESS LEUKEMIA; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	55	33	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	1997	14	20					2465	2474		10.1038/sj.onc.1201084	http://dx.doi.org/10.1038/sj.onc.1201084			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188861	Bronze			2022-12-17	WOS:A1997WZ68000010
J	Tsuneoka, M; Nakano, F; Ohgusu, H; Mekada, E				Tsuneoka, M; Nakano, F; Ohgusu, H; Mekada, E			c-myc activates RCC1 gene expression through E-box elements	ONCOGENE			English	Article						c-myc; RCC1; E box element; gene expression	PREMATURE CHROMOSOME CONDENSATION; ORNITHINE DECARBOXYLASE GENE; NUCLEAR-PROTEIN IMPORT; LOOP-HELIX PROTEIN; CELL-CYCLE; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; DEPENDENT TRANSFORMATION; BETA-GALACTOSIDASE; REPRESSOR SIN3	Proto-oncogene c-myc is implicated in proliferation of Although c-Myc protein has been function as a transcription factor recognizing an E-box (CACGTG) element, few c-myc-regulated genes have been identified and the specific role of c-myc is still unclear, RCC1 is necessary for mammalian cells to proliferate, Four CACGTG elements exist within 1.3 kb downstream of the major transcription start site for the human RCC1 gene in HeLa cells, Stimulation of HeLa cells with serum increased c-myc expression and RCC1 expression, Therefore the relationship between the expression of RCC1 and c-myc was investigated, Rat 3Y1 cells overexpressing c-myc contained about tw ice as much RCC1 mRNA as control cells, When a chimeric protein comprised of c-myc and the estrogen binding domain of estrogen receptor was activated by addition of 4-hydroxytamoxifen (OHT), expression of RCC1 mRNA increased twofold, To examine whether c-MSc functions through the CACGTG elements, a DNA fragment of RCC1 intron 4, exon 5 and part of intron 5 was joined to firefly luciferase cDNA to construct a reporter plasmid, In transient expression experiments using HeLa cells, co-transfection with c-myc stimulated the luciferase activity up to 2.5-fold in a dose-dependent manner, When the CACGTG elements in the reporter plasmid were destroyed, stimulation by c-myc was not observed, The four CACGTG elements did not contribute equally to the stimulation by c-myc. Gel retardation experiments suggest that c-Myc with Max binds to the CACGTG elements in the context of the RCC1 gene sequence in vitro. These results indicate that c-Myc can regulate expression of RCC1 through the E-box elements.			Tsuneoka, M (corresponding author), KURUME UNIV, INST LIFE SCI, 2432-3 AIKAWA MACHI, KURUME, FUKUOKA 839, JAPAN.			Mekada, Eisuke/0000-0001-8858-4781				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; DASSO M, 1992, MOL CELL BIOL, V12, P3337, DOI 10.1128/MCB.12.8.3337; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; ECKERT RL, 1982, CANCER RES, V42, P139; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; FURUNO N, 1991, GENOMICS, V11, P459, DOI 10.1016/0888-7543(91)90156-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KARN J, 1989, ONCOGENE, V4, P773; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; OKAZAKI K, 1992, EMBO J, V11, P2447, DOI 10.1002/j.1460-2075.1992.tb05309.x; PENA A, 1993, J BIOL CHEM, V268, P27277; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; TOBIAS KE, 1995, ONCOGENE, V11, P1721; TSUNEOKA M, 1992, J BIOL CHEM, V267, P9107; TSUNEOKA M, 1988, J BIOCHEM-TOKYO, V104, P560, DOI 10.1093/oxfordjournals.jbchem.a122510; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577; WEN L, 1989, J BIOL CHEM, V264, P9016; YAMASHITA T, 1980, INT J CANCER, V26, P435, DOI 10.1002/ijc.2910260408; YOSHIMORI T, 1988, CELL STRUCT FUNCT, V13, P311, DOI 10.1247/csf1975.13.311; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	65	33	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	1997	14	19					2301	2311		10.1038/sj.onc.1201067	http://dx.doi.org/10.1038/sj.onc.1201067			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178906				2022-12-17	WOS:A1997WY88300007
J	Puri, PL; Balsano, C; Burgio, VL; Chirillo, P; Natoli, G; Ricci, L; Mattei, E; Graessmann, A; Levrero, M				Puri, PL; Balsano, C; Burgio, VL; Chirillo, P; Natoli, G; Ricci, L; Mattei, E; Graessmann, A; Levrero, M			MyoD prevents cyclin A cdk2 containing E2F complexes formation in terminally differentiated myocytes	ONCOGENE			English	Article						MyoD; E2F; pRb2/p130; p21; cell cycle	TRANSCRIPTION FACTOR E2F; RETINOBLASTOMA GENE FAMILY; DNA-BINDING ACTIVITY; LARGE T-ANTIGEN; S-PHASE ENTRY; MYOGENIC DIFFERENTIATION; CELL-PROLIFERATION; IN-VIVO; MUSCLE DIFFERENTIATION; DEPENDENT KINASE	Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130, Downstream effecters of 'pocket' proteins are the components of the E2F family of transcription factors, which regulate the G(1)/S-phase transition, We analysed by EMSA the composition of E2F complexes in cycling, quiescent undifferentiated and differentiated C2C12 skeletal muscle cells, An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G(0)/G(1) complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G(1)/S complex), Serum stimulation reinduces DNA synthesis and the re-appearance of E2F-G(1)/S complexes in quiescent myoblasts but not in differentiated C2C12 myotubes, In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced, Thus, during myogenic differentiation, formation of E2F4 and pRb2/p130 containing complexes is an early event, but not enough on its own to prevent the reactivation of DNA synthesis, Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle, Our data indicate that, in differentiating myocytes, one mechanism through which MyoD induces permanent cell cycle arrest involves p21 upregulation and suppression of the proliferation-associated cdks-containing E2F complexes formation.	UNIV ROMA LA SAPIENZA,MED CLIN 1,I-00161 ROME,ITALY; UNIV AQUILA,DIPARTIMENTO MED INTERNA,I-67100 LAQUILA,ITALY; CNR,IST TECNOL BIOMED,ROME,ITALY; FREE UNIV BERLIN,INST MOL BIOL & BIOCHEM,D-1000 BERLIN,GERMANY	Sapienza University Rome; University of L'Aquila; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Free University of Berlin	Puri, PL (corresponding author), UNIV ROMA LA SAPIENZA,FDN A CESALPINO,VIALE POLICLIN 155,I-00161 ROME,ITALY.		Natoli, gioacchino/J-2100-2018; Natoli, gioacchino/ABB-8679-2020; Balsano, Clara/AAK-9870-2020; Levrero, Massimo/G-5680-2016	Balsano, Clara/0000-0002-9615-7031; Natoli, Gioacchino/0000-0003-0711-2411; Puri, Pier Lorenzo/0000-0003-4964-0095; Levrero, Massimo/0000-0002-4978-0875	Telethon [A.064] Funding Source: Medline	Telethon(Fondazione Telethon)		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CARUSO M, 1993, ONCOGENE, V8, P267; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORBEIL HB, 1995, ONCOGENE, V11, P909; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; CRESCENZI M, 1995, J CELL PHYSIOL, V162, P26, DOI 10.1002/jcp.1041620105; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOU QP, 1994, J BIOL CHEM, V269, P1306; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GRAESSMANN A, 1973, DEV BIOL, V35, P180, DOI 10.1016/0012-1606(73)90016-X; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HERTZINGER T, 1995, ONCOGENE, V10, P2079; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAIONE R, 1994, CELL GROWTH DIFFER, V5, P231; MAIONE R, 1992, ONCOGENE, V7, P85; MARTELLI F, 1994, ONCOGENE, V9, P3579; MAYOL X, 1993, ONCOGENE, V8, P2561; MAYOL X, 1995, ONCOGENE, V11, P801; Moberg K, 1996, MOL CELL BIOL, V16, P1436; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NATOLI G, 1994, ONCOGENE, V9, P2837; NEVINS JR, 1992, SCIENCE, V258, P424; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PHILPOTT A, 1994, MOL CELL BIOL, V14, P5000, DOI 10.1128/MCB.14.7.5000; PURI PL, 1995, J BIOL CHEM, V270, P22129, DOI 10.1074/jbc.270.38.22129; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SALA A, 1994, CANCER RES, V54, P1402; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; STOCKDALE F, 1961, EXP CELL RES, V24, P508, DOI 10.1016/0014-4827(61)90450-5; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WOLF DA, 1995, ONCOGENE, V10, P2067; YAFFE D, 1977, NATURE, V270, P225; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHANG YH, 1995, ONCOGENE, V10, P2085	84	33	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1171	1184		10.1038/sj.onc.1200941	http://dx.doi.org/10.1038/sj.onc.1200941			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121766				2022-12-17	WOS:A1997WM78200006
J	Arap, W; Knudsen, ES; Wang, JYJ; Cavenee, WK; Huang, HJS				Arap, W; Knudsen, ES; Wang, JYJ; Cavenee, WK; Huang, HJS			Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma	ONCOGENE			English	Article						tumor suppressor gene; CDKN2A; p16(INK4a); RB; mutation; glioma	CELL-CYCLE INHIBITION; HOMOZYGOUS DELETIONS; CDK4 AMPLIFICATION; HUMAN ASTROCYTOMAS; GENE-MUTATIONS; P16; RETINOBLASTOMA; P16(INK4); PROTEIN; LINES	Deletions of chromosomal region 9p21 are among the most common genetic alterations observed during the clonal evolution of high grade malignant gliomas. Structural and functional evidence has suggested that homozygous deletion involving CDKN2A (the genetic locus encoding the cyclin-dependent kinase inhibitor p16(INK4a)) is mechanism of inactivation of this gene and that it can be a growth suppressor in human gliomas. However, the presence of other potential suppressor genes in the 9p21 region and the relatively large sizes of the deletions has made it difficult to be certain that the CDKN2A gene is their actual target. Here, we tested this hypothesis by determining the growth suppressive effects, cell cycle inhibitions, and the activities of seven naturally occurring glioma-derived CDKN2A alleles carrying point mutations and found that two of them were functionally compromised. To resolve discrepancies among the different existing functional assays, we developed an assay for p16(INK4a) function that allowed us to demonstrate that the expression of wild-type CDKN2A, but not alleles with inactivating mutations, prevents pRB phosphorylation in vivo in human glioma cells. These data suggest that CDKN2A is a critical target for mutational inactivation in human malignant gliomas.	UNIV CALIF SAN DIEGO,LUDWIG INST CANC RES,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093; STANFORD UNIV,CAN BIOL PROGRAM,STANFORD,CA 94305	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Stanford University					NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA058320] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAP W, 1995, CANCER RES, V55, P1351; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Costello JF, 1996, CANCER RES, V56, P2405; DURO D, 1995, ONCOGENE, V11, P21; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; GIANI C, 1994, CANCER RES, V54, P6338; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GURNARI GB, 1995, CANCER SURV, V25, P233; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HE J, 1995, CANCER RES, V55, P4833; HE J, 1994, CANCER RES, V54, P5804; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; JAMES CD, 1993, CANCER RES, V53, P3674; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNUDSON AG, 1975, P NATL ACAD SCI USA, V72, P5116, DOI 10.1073/pnas.72.12.5116; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kyritsis A. P., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P582; Kyritsis AP, 1996, ONCOGENE, V12, P63; LI YJ, 1995, ONCOGENE, V11, P597; LIU Q, 1995, ONCOGENE, V10, P1061; LOUIS DN, 1995, BRAIN PATHOL, V5, P163, DOI 10.1111/j.1750-3639.1995.tb00590.x; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MOULTON T, 1995, AM J PATHOL, V146, P613; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OLOPADE OI, 1992, CANCER RES, V52, P2523; Parry D, 1996, MOL CELL BIOL, V16, P3844; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QUELLE DE, 1995, CELL, V83, P993; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; STONE S, 1995, CANCER RES, V55, P2988; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALKER DG, 1995, CANCER RES, V55, P20; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; YANG R, 1995, CANCER RES, V55, P2503	45	33	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					603	609		10.1038/sj.onc.1200870	http://dx.doi.org/10.1038/sj.onc.1200870			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053859				2022-12-17	WOS:A1997WF52400012
J	Soldi, R; Sanavio, F; Aglietta, M; Primo, L; Defilippi, P; Marchisio, PC; Bussolino, F				Soldi, R; Sanavio, F; Aglietta, M; Primo, L; Defilippi, P; Marchisio, PC; Bussolino, F			Platelet-activating factor (PAF) induces the early tyrosine phosphorylation of focal adhesion kinase (p125(FAK)) in human endothelial cells	ONCOGENE			English	Article						PAF; endothelial cells; FAK; cytoskeleton; cell motility	HEPATOCYTE GROWTH-FACTOR; IN-VIVO ANGIOGENESIS; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CYCLOOXYGENASE PRODUCTS; EXTRACELLULAR-MATRIX; CYTOKINE REGULATION; HUMAN NEUTROPHILS; CROSS-TALK; PP125(FAK)	Platelet-activating factor (PAF) is a potent activator of angiogenesis and controls the motility and the shape of vascular endothelium. The mechanism(s) whereby PAF exerts its action are in part known. Here we report that the biological active (R)PAF enantiomer administrated to cultured endothelial cells induces the early phosphorylation in tyrosine residues of focal (p125(FAK)) and paxillin, two molecules early signaling and cytoskeleton assembly in cells that undergo integrin-mediated adhesion or are challenged by neuropeptides or lysophosphatidic acid. The phenomenon is rapidly turned on, lasts for a few minutes and is adhesion-independent indicating that the chain of events induced by (R)PAF, including p125(FAK) activation, precedes adhesion. The inhibitory effect of WEB2086, a PAF receptor antagonist, and the lack of activity exerted by the (S)PAF enantiomer, indicate that (R)PAF-mediated p125(FAK) activation, is PAF receptor-dependent. Calphostin C, an inhibitor of protein kinase C blocks the effect of (R)PAF on p125(FAK); phosphorylation suggesting that protein kinase C activation is up-stream the activation of this tyrosine kinase. When endothelial cells are exposed to a substratum that allows adhesion and spreading. (R)PAF-stimulated cells, change their adhesive phenotype and start migrating. Inhibitors of tyrosine kinases, like 3-(1,4,-dihydroxytetralyl) methy-len-2-oxindole and herbimycin A, reduce the cells migration, the transendothelial flux of albumin and the enhancement of p125(FAK) activity induced by (R)PAF. The observation that increased tyrosine phosphorylation of p125(FAK) and its ensuing association with focal adhesion occurs rapidly upon (R)PAF challenge indicates that this signaling molecule has a primary and independent role also in the signaling cascade initiated by (R)PAF.	UNIV TURIN,DEPT GENET BIOL & MED CHEM,I-10126 TURIN,ITALY; UNIV TURIN,DEPT BIOMED SCI & HUMAN ONCOL,I-10126 TURIN,ITALY; IST SCI SAN RAFFAELE,DEPT BIOL & TECHNOL RES,I-20132 MILAN,ITALY	University of Turin; University of Turin; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele			DEFILIPPI, Paola/L-2232-2014; Bussolino, Federico/AES-3951-2022; Bussolino, Federico/K-2500-2016	Bussolino, Federico/0000-0002-5348-1341; PRIMO, Luca/0000-0002-1294-0441; Defilippi, Paola/0000-0001-6427-4906; AGLIETTA, Massimo/0000-0002-2255-7972				ANDRADE SP, 1994, J LIPID MEDIAT CELL, V9, P117; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BUSSOLINO F, 1994, J BIOL CHEM, V269, P2877; BUSSOLINO F, 1995, J CLIN INVEST, V96, P940, DOI 10.1172/JCI118142; BUSSOLINO F, 1995, EUR J BIOCHEM, V229, P327, DOI 10.1111/j.1432-1033.1995.tb20472.x; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CAMUSSI G, 1995, J IMMUNOL, V154, P6492; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DEFILIPPI P, 1995, EXP CELL RES, V221, P141, DOI 10.1006/excr.1995.1361; DERYCKX S, 1992, J IMMUNOL, V148, P1465; DHAR A, 1994, J BIOL CHEM, V269, P9123; DHAR A, 1991, J BIOL CHEM, V266, P18797; DHUMIERES S, 1986, EUR J PHARMACOL, V131, P13, DOI 10.1016/0014-2999(86)90510-8; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; GATES RE, 1994, CELL GROWTH DIFFER, V5, P891; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HANDLEY DA, 1984, IMMUNOPHARMACOLOGY, V8, P137, DOI 10.1016/0162-3109(84)90017-1; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HEUER HO, 1990, J PHARMACOL EXP THER, V255, P962; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HUMPHREY DM, 1982, LAB INVEST, V46, P422; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JUNCOS LA, 1993, J CLIN INVEST, V91, P1374, DOI 10.1172/JCI116339; KIM DY, 1995, AM J PHYSIOL-HEART C, V268, pH399, DOI 10.1152/ajpheart.1995.268.1.H399; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KUIJPERS TW, 1992, J CELL BIOL, V117, P565, DOI 10.1083/jcb.117.3.565; KURUVILLA A, 1994, J IMMUNOL, V153, P5433; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER R, 1988, BIOCHEM BIOPH RES CO, V153, P805, DOI 10.1016/S0006-291X(88)81167-7; LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; Mariani M., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P381; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MCMANUS LM, 1993, LAB INVEST, V69, P639; MONTRUCCHIO G, 1994, J EXP MED, V180, P377, DOI 10.1084/jem.180.1.377; NOURSHARGH S, 1995, BLOOD, V85, P2553, DOI 10.1182/blood.V85.9.2553.bloodjournal8592553; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; RANKIN S, 1994, J BIOL CHEM, V269, P704; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SCHWERTSCHLAG US, 1988, KIDNEY INT, V34, P779, DOI 10.1038/ki.1988.249; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SILVESTRO L, 1994, SEMIN THROMB HEMOST, V20, P214, DOI 10.1055/s-2007-1001905; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SMITH CS, 1994, J IMMUNOL, V153, P3997; STOSSEL TP, 1994, BLOOD, V84, P367; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VUORI K, 1993, J BIOL CHEM, V268, P21459; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	67	33	34	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					515	525						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760293				2022-12-17	WOS:A1996VB32800009
J	Lenahan, MK; Ozer, HL				Lenahan, MK; Ozer, HL			Induction of c-myc mediated apoptosis in SV40-transformed rat fibroblasts	ONCOGENE			English	Article						apoptosis; p53; T antigen; c-myc; fibroblasts; SV40	WILD-TYPE P53; LARGE-T-ANTIGEN; SIMIAN VIRUS-40; CELLULAR SENESCENCE; GENE; IMMORTALIZATION; TRANSFORMATION; TEMPERATURE; EXPRESSION; PROTEIN	The ability of SV40 T antigen to block apoptosis was investigated in Rat1-A fibroblasts expressing an estrogen-dependent c-myc construct, mycER (filers ed al., 1989). These RatmycER cells undergo apoptosis upon activation of c-myc by estradiol under conditions of serum deprivation. Under such conditions SV40-transfected derivatives of RatmycER undergo apoptosis as evidenced by rapid cell death, characteristic morphological changes and DNA fragmentation in a manner indistinguishable from the parental cell line, indicating that T antigen is not able to protect against myc-induced apoptosis. In as much as it had been reported that myc-mediated apoptosis involves wild-type p53 in other systems and T antigen is known to bind and inhibit p53 function, we examined these two polypeptides under different experimental conditions. In all cases, the great majority of the p53 in the SV40 transfectants was found to be in complexes with T antigen. Furthermore, the residual p53 in the uncomplexed state was not sufficient to transactivate an endogenous promoter, WAF1/p21. These data indicate that the failure of T antigen to block apoptosis cannot be attributed to defective function of T antigen and suggest that myc-mediated apoptosis may involve a p53-independent pathway in these cells.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MICROBIOL & MOLEC GENET,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY,GRAD SCH BIOMED SCI,DEPT MICROBIOL & MOLEC GENET,NEWARK,NJ 07103	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL INSTITUTE ON AGING [P01AG000378, R01AG004821] Funding Source: NIH RePORTER; NIA NIH HHS [AG00378, AG04821] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DHANARAJ SN, 1996, IN PRESS EXP CELL RE; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLIS RE, 1991, ANN REV CELL BIOL, V7, P633; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HAYASHI M, 1990, MUTAT RES, V245, P245, DOI 10.1016/0165-7992(90)90153-B; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HSU B, 1995, ONCOGENE, V11, P175; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; IMAI Y, 1994, INT J ONCOL, V5, P945; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; JIANG D, 1993, ONCOGENE, V8, P2805; LI QT, 1995, J BIOL CHEM, V270, P15777, DOI 10.1074/jbc.270.26.15777; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OZER HL, 1996, IN PRESS EXP GERONTO; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SEKIGUCHI T, 1995, EXP CELL RES, V218, P490, DOI 10.1006/excr.1995.1183; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SMALL MB, 1982, NATURE, V296, P671, DOI 10.1038/296671a0; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; TIEMANN F, 1994, J VIROL, V68, P2869, DOI 10.1128/JVI.68.5.2869-2878.1994; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANAI N, 1994, EXP CELL RES, V211, P296, DOI 10.1006/excr.1994.1090; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHENG DQ, 1994, ONCOGENE, V9, P3345	51	33	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1847	1854						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649844				2022-12-17	WOS:A1996UK49800002
J	Wang, BL; Mysliwiec, T; Krainc, D; Jensen, RA; Sonoda, G; Testa, JR; Golemis, EA; Kruh, GD				Wang, BL; Mysliwiec, T; Krainc, D; Jensen, RA; Sonoda, G; Testa, JR; Golemis, EA; Kruh, GD			Identification of ArgBP1, an Arg protein tyrosine kinase binding protein that is the human homologue of a CNS-specific Xenopus gene	ONCOGENE			English	Article						Arg; Xlan4; Abl; SH3 domain; proline-rich motif	MURINE LEUKEMIA-VIRUS; FLUORESCENCE INSITU HYBRIDIZATION; C-ABL; CELL-CYCLE; SIGNAL-TRANSDUCTION; DROSOPHILA-ABL; DOMAIN; DNA; LOCALIZATION; PHOSPHATASE	Arg and c-Abl represent the mammalian members of the Abelson family of nonreceptor protein-tyrosine kinases. To gain insight into the biological role of Arg we used the two-hybrid approach to identify interacting proteins. Using a C-terminal segment of Arg we identified a novel protein, ArgBP1 (Arg binding protein 1). ArgBP1 contains a C-terminal SH3 domain, several PEST sequences, a serine rich domain and an SH3 binding site. ArgBP1 is ubiquitously expressed as two transcripts of similar to 2.2 kb and similar to 8kb with highest levels in brain, heart and testis. The association of ArgBP1 with Arg in living cells was confirmed by coimmunoprecipitation in cotransfected COS cells. Analysis of the mechanism of association indicated that the ArgBP1 SH3 domain binds to a C-terminal Arg SH3-binding site, and that an N-terminal ArgBP1 proline-rich sequence binds to the Arg SH3 domain. Immunostaining indicated that the subcellular localization of ArgBP1 is cytoplasmic. The similarity of the ArgPB1 expression pattern and subcellular localization to those of Arg and the potential for a highly specific and potentially strong association mediated by two pairs of SH3 domain/proline-rich motif interactions, suggest that ArgBP1 is likely to be a regulator and/or effector of Arg function.	FOX CHASE CANC CTR, DEPT MED ONCOL, PHILADELPHIA, PA 19111 USA; UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA; FOX CHASE CANC CTR, DIV BASIC SCI, PHILADELPHIA, PA 19111 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; VANDERBILT UNIV, MED CTR, DEPT PATHOL, NASHVILLE, TN 37232 USA	Fox Chase Cancer Center; University of Pennsylvania; Fox Chase Cancer Center; Harvard University; Boston Children's Hospital; Harvard Medical School; Vanderbilt University				Golemis, Erica/0000-0003-3618-3673	NATIONAL CANCER INSTITUTE [P30CA006927, R29CA063366, R01CA057273, R55CA057273, R01CA063366] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927, CA57273, CA63366] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HOFFMANN FM, 1989, CURR TOP MICROBIOL, V147, P1; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LAEMMLI UK, 1968, MOL GEN GENET, V101, P333, DOI 10.1007/BF00436231; MATTIONI T, 1995, ONCOGENE, V10, P1325; MORRIS JF, 1991, ONCOGENE, V6, P2339; Mysliwiec T, 1996, ONCOGENE, V12, P631; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PEREGO R, 1991, ONCOGENE, V6, P1899; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; REDDY BA, 1992, MECH DEVELOP, V39, P143, DOI 10.1016/0925-4773(92)90041-H; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SHIELDS A, 1979, CELL, V18, P955, DOI 10.1016/0092-8674(79)90208-3; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TESTA JR, 1992, CYTOGENET CELL GENET, V60, P247, DOI 10.1159/000133350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E	46	33	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					1921	1929						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649853				2022-12-17	WOS:A1996UK49800011
J	Kretschmer, C; Murphy, C; Biesinger, B; Beckers, J; Fickenscher, H; Kirchner, T; Fleckenstein, B; Ruther, U				Kretschmer, C; Murphy, C; Biesinger, B; Beckers, J; Fickenscher, H; Kirchner, T; Fleckenstein, B; Ruther, U			A Herpes saimiri oncogene causing peripheral T-cell lymphoma in transgenic mice	ONCOGENE			English	Article						herpes virus; transgenic mice; T-cell lymphoma; tumor induction; oncogene	DELETION MUTANTS; U RNAS; REGION; VIRUS; GENE; TRANSFORMATION; CLASSIFICATION; MARMOSETS; SEQUENCES; STRAINS	Herpesvirus saimiri is an oncogenic virus causing rapid T-cell lymphomas in New World primates and rabbits, Deletion analysis of one strain of H saimiri has indicated an open reading frame, StpA, necessary for oncogenicity in monkeys, We have investigated the function of StpA in tumor induction by the generation of transgenic mice, Expression of two different constructs caused the development of peripheral lymphomas, The infiltrating cells were of T-cell origin, expressing mainly the CD4 phenotype and restricted sets of V beta chains, Thus, StpA is not only necessary for the oncogenicity of Herpesvirus saimiri, but is also sufficient for the induction of peripheral pleomorphic T-cell lymphomas.	HANNOVER MED SCH,INST MOL BIOL,D-30623 HANNOVER,GERMANY; UNIV ERLANGEN NURNBERG,INST PATHOL,D-91054 ERLANGEN,GERMANY; EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY; UNIV ERLANGEN NURNBERG,INST KLIN & MOLEK VIROL,D-91054 ERLANGEN,GERMANY	Hannover Medical School; University of Erlangen Nuremberg; European Molecular Biology Laboratory (EMBL); University of Erlangen Nuremberg			Beckers, Johannes/K-7237-2012; Murphy, Carol/ABE-4282-2021; Fickenscher, Helmut/A-3004-2010; Fickenscher, Helmut/J-9655-2019	Beckers, Johannes/0000-0001-7874-3822; Murphy, Carol/0000-0003-1353-8558; Fickenscher, Helmut/0000-0003-0043-1153				AHUJA SK, 1993, J BIOL CHEM, V268, P20691; ALBRECHT JC, 1992, J VIROL, V66, P3937, DOI 10.1128/JVI.66.6.3937-3940.1992; ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; BIEINGER B, 1995, J BIOL CHEM, V270, P4729; BIESINGER B, 1990, VIROLOGY, V176, P505, DOI 10.1016/0042-6822(90)90020-R; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; BODEMER W, 1986, J VIROL, V60, P114, DOI 10.1128/JVI.60.1.114-123.1986; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; COLE GA, 1994, INT IMMUNOL, V6, P1767, DOI 10.1093/intimm/6.11.1767; DESROSIERS RC, 1984, J VIROL, V49, P343, DOI 10.1128/JVI.49.2.343-348.1984; DESROSIERS RC, 1982, J VIROL, V43, P352, DOI 10.1128/JVI.43.1.352-356.1982; DESROSIERS RC, 1985, SCIENCE, V228, P184, DOI 10.1126/science.2983431; FALINI B, 1990, BLOOD, V75, P434; FLECKENSTEIN B, 1979, BIOCHIM BIOPHYS ACTA, V560, P301, DOI 10.1016/0304-419X(79)90007-6; FLECKENSTEIN B, 1982, HERPESVIRUSES, V1, P253; FODOR WL, 1995, J VIROL, V69, P3889, DOI 10.1128/JVI.69.6.3889-3892.1995; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; HARRIS NL, 1994, BLOOD, V84, P1361; HODGES E, 1994, LEUKEMIA, V8, P295; HOGAN B, 1986, MANIPULATING MOUSE E, P230; HUEGIN AW, 1991, SCIENCE, V252, P424; HUNT RD, 1970, J NATL CANCER I, V44, P447; JUNG JU, 1994, MOL CELL BIOL, V14, P7235, DOI 10.1128/MCB.14.11.7235; JUNG JU, 1991, P NATL ACAD SCI USA, V88, P7051, DOI 10.1073/pnas.88.16.7051; KOOMEY JM, 1984, J VIROL, V50, P662, DOI 10.1128/JVI.50.2.662-665.1984; KORBJUHN P, 1993, BLOOD, V82, P217, DOI 10.1182/blood.V82.1.217.bloodjournal821217; LEE SI, 1988, CELL, V54, P599, DOI 10.1016/S0092-8674(88)80004-7; LEE SI, 1990, J VIROL, V64, P3905, DOI 10.1128/JVI.64.8.3905-3915.1990; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MEDVECZKY P, 1984, J VIROL, V52, P938, DOI 10.1128/JVI.52.3.938-944.1984; MURPHY C, 1994, ONCOGENE, V9, P221; MURTHY S, 1986, EMBO J, V5, P1625, DOI 10.1002/j.1460-2075.1986.tb04405.x; MURTHY SCS, 1989, J VIROL, V63, P3307, DOI 10.1128/JVI.63.8.3307-3314.1989; MYER VE, 1992, P NATL ACAD SCI USA, V89, P1296, DOI 10.1073/pnas.89.4.1296; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; PALLESEN G, 1993, ADV CANCER RES, V62, P179, DOI 10.1016/S0065-230X(08)60319-X; ROTHER RP, 1994, J VIROL, V68, P730, DOI 10.1128/JVI.68.2.730-737.1994; ROUVIER E, 1993, J IMMUNOL, V150, P5445; SCHAFFER PA, 1975, J NATL CANCER I, V55, P1243, DOI 10.1093/jnci/55.5.1243; STANSFELD AG, 1988, LANCET, V1, P292; STANSFELD AG, 1988, LANCET, V1, P603; SZOMOLANYI E, 1987, J VIROL, V61, P3485, DOI 10.1128/JVI.61.11.3485-3490.1987; THOMSON BJ, 1991, NATURE, V351, P530, DOI 10.1038/351530a0; TRIMBLE JJ, 1988, SCIENCE, V239, P1145, DOI 10.1126/science.2830673; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587; YAO M, 1994, BRIT J HAEMATOL, V87, P535, DOI 10.1111/j.1365-2141.1994.tb08309.x; ZHOU XG, 1994, HISTOPATHOLOGY, V24, P115, DOI 10.1111/j.1365-2559.1994.tb01289.x	47	33	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1609	1616						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622880				2022-12-17	WOS:A1996UG45800002
J	Tulchinsky, EM; Georgiev, GP; Lukanidin, EM				Tulchinsky, EM; Georgiev, GP; Lukanidin, EM			Novel AP-1 binding site created by DNA-methylation	ONCOGENE			English	Article						AP-1; DNA-methylation; gene expression; mts1 gene	GLOBIN GENE-EXPRESSION; MESSENGER-RNA; MTS1 GENE; PROTEIN; CELLS; FOS; JUN; IDENTIFICATION; SEQUENCES; PROMOTER	DNA-methylation is known to repress transcription either by inactivation of positive regulatory cis-elements containing CpG dinucleotides or via the sequence-nonspecific and methylation-specific binding of inhibiting methyl-CpG binding protein 1 (MeCP1). In the present work we describe the novel way DNA-methylation can influence gene expression: a binding site for transcription factors AP-1 might be created by DNA-methylation. Such a DNA-methylation-dependent AP-1 binding site was found in the first intron of the metastasis-associated mts1 gene, The expression level of this gene correlates with the hypomethylation of the mts1 first intron sequence in mouse adenocarcinoma cells. The DNA methylation-dependent AP-1 binding site was found to be functionally active in the nucleotide context of the mts1 gene. When methylated, this site reproducibly repressed transcription of CAT-containing DNA that had been transiently transfected into mouse adenocarcinoma CSML100 cells.	INST GENE BIOL, MOSCOW 117334, RUSSIA	Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences	Tulchinsky, EM (corresponding author), DANISH CANC SOC, DEPT MOL CANC BIOL, STRANDBLVD 49 43, DK-2100 COPENHAGEN, DENMARK.		Tulchinsky, Eugene/ABD-7070-2021					ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Antequera F., 1993, Experientia Supplementum (Basel), V64, P169; Ausubel F.M., 1987, CURRENT PROTOCOLS MO; BAHLER DW, 1985, J IMMUNOL, V134, P2790; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAVIES BR, 1993, ONCOGENE, V8, P999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; Ehrlich M., 1993, Experientia Supplementum (Basel), V64, P145; FORD HL, 1995, ONCOGENE, V10, P1597; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; GIZANGGINSBERG E, 1994, MOL ENDOCRINOL, V8, P249, DOI 10.1210/me.8.2.249; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; GRIGORIAN M, 1994, ELECTROPHORESIS, V15, P463, DOI 10.1002/elps.1150150163; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; HEIZMANN CW, 1991, NOVEL CALCIUM BINDIN; HOWCROFT TK, 1993, EMBO J, V12, P3163, DOI 10.1002/j.1460-2075.1993.tb05985.x; HU JM, 1994, MOL CELL BIOL, V14, P1531, DOI 10.1128/MCB.14.3.1531; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; JOEL P, 1993, NUCLEIC ACIDS RES, V21, P5786, DOI 10.1093/nar/21.24.5786; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; OSTAPCHUK P, 1989, MOL CELL BIOL, V9, P2787, DOI 10.1128/MCB.9.7.2787; PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SINGERSAM J, 1993, DNA METHYLATION MOL, P359; SUETAKE I, 1993, NUCLEIC ACIDS RES, V21, P2125, DOI 10.1093/nar/21.9.2125; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; TULCHINSKY E, 1992, P NATL ACAD SCI USA, V89, P9146, DOI 10.1073/pnas.89.19.9146; TULCHINSKY E, 1993, ONCOGENE, V8, P79; YISRAELI J, 1988, P NATL ACAD SCI USA, V85, P4638, DOI 10.1073/pnas.85.13.4638; ZHANG XY, 1989, NUCLEIC ACIDS RES, V17, P1459, DOI 10.1093/nar/17.4.1459; ZHANG XY, 1990, NUCLEIC ACIDS RES, V18, P6253, DOI 10.1093/nar/18.21.6253	43	33	33	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1737	1745						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622894				2022-12-17	WOS:A1996UG45800016
J	ZORNIG, M; BUSCH, G; BENEKE, R; GULBINS, E; LANG, F; MA, A; KORSMEYER, S; MOROY, T				ZORNIG, M; BUSCH, G; BENEKE, R; GULBINS, E; LANG, F; MA, A; KORSMEYER, S; MOROY, T			SURVIVAL AND DEATH OF PRELYMPHOMATOUS B-CELLS FROM N-MYC/BCL-2 DOUBLE TRANSGENIC MICE CORRELATES WITH THE REGULATION OF INTRACELLULAR CA2+ FLUXES	ONCOGENE			English	Article						B-CELLS; N-MYC; BCL-2; TRANSGENIC MICE; APOPTOSIS; CALCIUM FLUX	HUMAN FOLLICULAR LYMPHOMA; C-MYC; PRE-B; BCL-2 GENE; N-MYC; FLOW-CYTOMETRY; APOPTOSIS; EXPRESSION; GENERATION; GROWTH	Coexpression of the proto-oncogenes c-myc and bcl-2 under the control of the immunoglobulin enhancer E mu provokes the rapid development of primitive lymphoid tumors in transgenic mice, In the present study we show that the myc family members N-myc and L-myc also cooperate with bcl-2 in oncogenesis and can provoke the development of more mature pre-B, B and T cell type lymphomas. The analysis of prelymphomatous B-cells from single E mu N-myc and bcl-2-Ig transgenic animals and from young, tumor free, double transgenic E mu N-myc/bcl-2-Ig mice revealed that E mu directed expression of N-myc leads to very rapid apoptosis after explantation and culturing compared to B-cells from normal mice. As expected, B-cells from bcl-2-Ig transgenics were protected to a certain degree from apoptosis, Strikingly however, B-cells from E mu N-myc/bcl-2-Ig double transgenic animals were found to be almost completely resistant towards a number of different apoptotic stimuli. Furthermore, after treatment with H2O2, which can trigger apoptosis, B-cells from E mu N-myc animals reach levels of intracellular free Ca2+ concentrations that are comparable to B-cells from normal mice, whereas B-cells from bcl-2-Ig or E mu N-myc/bcl-2-Ig double transgenic mice show no increase in intracellular Ca2+ concentrations after stimulation with H2O2. These findings suggest that the prevention of apoptosis conferred by bcl-2 correlates with the inhibition of intracellular Ca2+ fluxes whereas induction of apoptosis mediated by N-myc requires normal Ca2+ levels. We hypothesize therefore that the regulation of intracellular Ca2+ concentrations represent one important parameter in the oncogenic cooperation between bcl-2 and N-myc.	UNIV MARBURG,IMT,INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY; UNIV TUBINGEN,INST PHYSIOL 1,D-72076 TUBINGEN,GERMANY; HARVARD UNIV,CHILDRENS HOSP,SCH MED,CTR BLOOD RES,HOWARD HUGHES MED INST,BOSTON,MA 02115; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT PATHOL,ST LOUIS,MO 63110	Philipps University Marburg; Eberhard Karls University of Tubingen; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)			Moroy, Tarik/D-9923-2011; Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342				BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; CHEN U, 1992, IMMUNOBIOLOGY, V185, P366, DOI 10.1016/S0171-2985(11)80653-4; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; DOWD DR, 1992, MOL ENDOCRINOL, V6, P1843, DOI 10.1210/me.6.11.1843; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; GOUGH NM, 1981, P NATL ACAD SCI-BIOL, V78, P509, DOI 10.1073/pnas.78.1.509; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOGAN B, 1986, MANIPULATION MOUSE E; ISEKI R, 1993, J IMMUNOL, V151, P5198; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LANGDON WY, 1988, ONCOGENE RES, V3, P271; LEWIS S, 1982, CELL, V30, P807, DOI 10.1016/0092-8674(82)90285-9; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MOROY T, 1991, ONCOGENE, V6, P1941; NOWELL PC, 1987, DEV RECOGNITION TRAN; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; PERRY RP, 1980, P NATL ACAD SCI-BIOL, V77, P1937, DOI 10.1073/pnas.77.4.1937; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7202; Sambrook J., 1989, MOL CLONING LAB MANU; SENTMAN CL, 1992, CELL, V67, P879; SEYSCHAB H, 1989, EUR J IMMUNOL, V19, P1605, DOI 10.1002/eji.1830190913; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; YANCOPOULOS GD, 1984, NATURE, V311, P727, DOI 10.1038/311727a0; ZHING LT, 1993, P0 NATL ACAD SCI US, V90, P4533; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	45	33	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2165	2174						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478538				2022-12-17	WOS:A1995TF29700029
J	PELLEGATA, NS; CAJOT, JF; STANBRIDGE, EJ				PELLEGATA, NS; CAJOT, JF; STANBRIDGE, EJ			THE BASIC CARBOXY-TERMINAL DOMAIN OF HUMAN P53 IS DISPENSABLE FOR BOTH TRANSCRIPTIONAL REGULATION AND INHIBITION OF TUMOR-CELL GROWTH	ONCOGENE			English	Article						P53; C-TERMINAL DOMAINS	WILD-TYPE P53; DNA-BINDING; PROTEIN COMPLEXES; OLIGOMERIZATION; SUPPRESSION; MUTATIONS; TRANSFORMATION; WILD-TYPE-P53; LOCALIZATION; DETERMINANT	To investigate the relevance of the C-terminal domains of the human p53 tumor suppressor gene to its growth suppressive and transcriptional regulatory properties deletion mutants were generated which eliminated 30 (53 Delta 363), 60 (p53 Delta 333) and 87 (p53 Delta 306) amino acids from the C-terminus of the p53 protein. p53 Delta 363 has lost the highly basic tail of the protein (residues 360-386). p53 Delta 333 and p53 Delta 306 lack the oligomerization domain (residues 320-360); p53 Delta 306 has also lost the major nuclear localization signal of p53 (NLSI, residues 316-325). These mutants were assayed for transactivation from two p53 consensus binding sites and for transcriptional repression of two promoter systems in Calu6 lung cancer cells (p53 null). Moreover, their ability to inhibit cell growth in tumor cell lines with a defined p53 status was analysed. Deletion of the oligomerization domain correlated with significant loss of: (a) transactivation from a genomic sequence; (b) transcriptional repression; (c) the ability to inhibit colony formation. An intact NLSI was not a prerequisite for transactivation. p53 Delta 363 behaved similarly to wt p53 in all the assays. We established an inducible expression system for p53 Delta 363 in a human fibrosarcoma cell line known to be growth-suppressed by wt p53. The induction of p53 Delta 363 expression also inhibited cell proliferation albeit to a lesser extent than wt p53. However, p53 Delta 363 could upregulate WAF1/CIP1, GADD45 and MDM2 genes. Thus, the basis tail of p53 appears not to be required for the biological functions of the protein assayed.	UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine			Pellegata, Natalia S/I-1256-2012	Pellegata, Natalia S/0000-0002-8000-7784	NATIONAL CANCER INSTITUTE [P30CA062203, R01CA019401, R37CA019401] Funding Source: NIH RePORTER; NCI NIH HHS [CA-62203, CA 19401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON MJ, 1994, GENE CHROMOSOME CANC, V9, P266, DOI 10.1002/gcc.2870090407; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CAJOT JF, 1992, CANCER RES, V52, P6956; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DONEHOWER LA, 1992, NATURE, V56, P215; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V252, P49; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1707; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEHMAN TA, 1991, CANCER RES, V51, P4090; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TARUNINA M, 1993, ONCOGENE, V8, P3165; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	48	33	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					337	349						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624148				2022-12-17	WOS:A1995RK95700014
J	AHN, MJ; NASONBURCHENAL, K; MOASSER, MM; DMITROVSKY, E				AHN, MJ; NASONBURCHENAL, K; MOASSER, MM; DMITROVSKY, E			GROWTH SUPPRESSION OF ACUTE PROMYELOCYTIC LEUKEMIA-CELLS HAVING INCREASED EXPRESSION OF THE NONREARRANGED ALLELES - RAR-ALPHA OR PML	ONCOGENE			English	Article						RETINOIC ACID; ACUTE PROMYELOCYTIC LEUKEMIA; RAR-ALPHA; PML	TRANS-RETINOIC ACID; DIFFERENTIATION THERAPY; T(15-17) TRANSLOCATION; RIBONUCLEIC-ACID; THYROID-HORMONE; X-RECEPTOR; LINE; SEQUENCES; SURVIVAL; CLONING	The balanced t(15;17) rearrangement found in acute promyelocytic leukemia (APL) cells fuses PML on chromosome 15 to the retinoic acid receptor alpha (RAR alpha) on chromosome 17, PML/RAR alpha is expressed in APL cells with the non-rearranged alleles, PML and RAR alpha, Clinical remissions induced by all-trans-retinoic acid (RA) treatment of APL patients are linked to expression of PML/ RAR alpha, a transcription factor with reported dominant negative functions, The roles of PML and RAR alpha in the RA response of APL have not yet been fully explored, This study examines these roles by individually transfecting RAR alpha and PML into NB4 APL cells. NB4 is the sole APL cell Line containing the t(15;17), RA treatment represses NB4 cell growth and induces a myeloid phentoype, Full length cDNAs for RAR alpha and PML were individually cloned into a CMV-driven expression vector containing the neomycin resistance gene, Surprisingly, none of the obtained stable transfectants expressed exogenous RAR alpha or PML mRNAs even when reverse transcription polymerase chain reaction (RT-PCR) detection assays were used. All clones expressed the neomycin resistance gene and were similar to parental NB4 cells in their growth and differentiation properties, An explanation explored for this lack of gene expression was that increased levels of RAR alpha or PML might suppress APL cell growth, To examine this possibility, transfection experiments were repeated using an episomal vector-based expression system containing an SV40 driven RAR alpha or PML cDNA and the hygromycin B resistance gene, A new selection strategy augmented expression of the desired cDNAs, A control episomal vector lacked a cDNA insert, Following electroporation and selection, exogenous RAR alpha expression was obtained. Compared to controls, the growth of these transfectants was markedly inhibited before and after RA-treatment and these cells more prominently induced myeloid maturation markers, In contrast, exogenous PML expression was transient since these transfectants did not appear to propagate in culture, These findings indicate: (1) a growth disadvantage for NB4 cells having increased expression of RAR alpha or PML and (2) increased RAR alpha expression augmented RA-mediated maturation of NB4 cells, This implicates a role for RAR alpha or PML in regulating the growth or differentiation of APL cells, It is hypothesized this occurs through antagonism of PML/RAR alpha actions in these leukemic cells.	MEM HOSP,DEPT MED,GENITOURINARY ONCOL SERV,MOLEC MED LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,MOLEC PHARMACOL & THERAPEUT PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [K12CA001712, F32CA061646, R01CA062275] Funding Source: NIH RePORTER; NCI NIH HHS [1F32CA61646-01A1, 1R01 CA62275-01, CA01712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DALTON WT, 1988, BLOOD, V71, P242; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DMITROVSKY E, 1990, ONCOGENE, V5, P543; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KURIE JM, 1994, BBA-MOL CELL RES, V1222, P88, DOI 10.1016/0167-4889(94)90028-0; LANOTTE M, 1991, BLOOD, V77, P1080; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MILLER WH, 1990, ONCOGENE, V5, P511; MILLER WH, 1992, P NATL ACAD SCI USA, V89, P2694, DOI 10.1073/pnas.89.7.2694; MOASSER MM, 1995, ONCOGENE, V10, P1537; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; PACE U, 1994, CANCER RES, V54, P6365; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	31	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2307	2314						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784078				2022-12-17	WOS:A1995RE54300005
J	SETH, A; ROBINSON, L; PANAYIOTAKIS, A; THOMPSON, DM; HODGE, DR; ZHANG, XK; WATSON, DK; OZATO, K; PAPAS, TS				SETH, A; ROBINSON, L; PANAYIOTAKIS, A; THOMPSON, DM; HODGE, DR; ZHANG, XK; WATSON, DK; OZATO, K; PAPAS, TS			THE ENDOA ENHANCER CONTAINS MULTIPLE ETS BINDING-SITE REPEATS AND IS REGULATED BY ETS PROTEINS	ONCOGENE			English	Article							GENE FAMILY; C-FOS; TRANSCRIPTIONAL ACTIVATION; C-ETS-1 PROTOONCOGENE; ONCOGENIC ACTIVITY; EXPRESSION; MEMBER; MOUSE; PHOSPHORYLATION; IDENTIFICATION	EndoA is a type II keratin and with EndoB (type T keratin), constitutes intermediate filaments in various simple epithelial tissues. EndoA is developmentally regulated and has an enhancer that is located at the 3' - end of the gene. This enhancer contains two single and five dual Ets binding sites. Thus far, no other promoter or enhancer has been shown to contain as many potential clustered Ets binding sites. To study the transcriptional regulation of EndoA by the ETS family proteins, we amplified the EndoA enhancer fragment from mouse genomic DNA by PCR, and cloned it into the pBLCAT2 vector upstream from the CAT reporter gene. Several pBLCAT-ENDOA clones were squenced to verify the presence of all the ETS binding sites. Clones that did not show any point mutations in the ETS binding sites were chosen to study the transcription regulation by ETS1, ETS2 and ERGB/FLI-1 gene products. EMSA results indicated that the ETS1, ETS2 and ERGB/FLI-1 proteins bind to the enhancer sequence, and DNase I protection data demonstrated that the ETS proteins protect all seven EBS core sequences. Cotransfection of the COS cells with the pBLCAT-ENDOA construct, along with increasing amounts of different ETS expression vectors, resulted in a significant induction of CAT reporter gene expression. Previously, we have shown that the overexpression of the ETS1 gene transforms NIH3T3, and these transformed cells (7AQS2.1) produce high levels of ETS1 protein (Seth and Papas, 1990). In this report, we show that the undifferentiated P19 EC cells do not express detectable levels of ETS1; however, an elevated level of ETS1 is expressed in differentiated derivatives of these cells. We therefore used these two cell lines to examine the activity of the EndoA enhancer with the ETS1 product. Transfection of the pBLCAT-ENDOA construct alone in undifferentiated P19 EC cells results in very low CAT gene expression; however, upon differentiation with retinoic acid the level of CAT gene activity increases dramatically. Similarly, an increase in CAT expression from the same construct (pBLCAT-ENDOA) was also observed in 7AQS2.1 cells. Our results therefore indicate that the EndoA enhancer is regulated by ETS proteins via interaction with multiple ETS-binding site sequences.	PROGRAM RESOURCES INC,DYNCORP,FREDERICK,MD 21702									ASCIONE R, 1992, INT J ONCOL, V1, P631; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FISHER RJ, 1991, ONCOGENE, V6, P1001; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; HASHIDO K, 1991, EXP CELL RES, V192, P203, DOI 10.1016/0014-4827(91)90177-V; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HODGE DR, 1993, IN PRESS METHODS MOL; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; MCLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OSHIMA RG, 1985, CELL PROLIFERAT, V10, P51; PANAYIOTAKIS A, 1993, J VIRAL DISEASES, V1, P53; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; SAMBROOK J, 1989, MOL CLONING LABORATO, P542; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1989, ONCOGENE RES, V5, P61; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SETH A, 1993, INT J ONCOL, V2, P739; SETH A, 1993, CANCER PRINCIPLES PR, P23; TAKEMOTO Y, 1991, NUCLEIC ACIDS RES, V19, P2761, DOI 10.1093/nar/19.10.2761; TOPOL LZ, 1992, CANCER LETT, V67, P71, DOI 10.1016/0304-3835(92)90010-S; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	39	33	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					469	477						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	7507230				2022-12-17	WOS:A1994MW24800014
J	LI, CCH; CHEN, E; OCONNELL, CD; LONGO, DL				LI, CCH; CHEN, E; OCONNELL, CD; LONGO, DL			DETECTION OF C-MOS PROTOONCOGENE EXPRESSION IN HUMAN-CELLS	ONCOGENE			English	Note							MURINE SARCOMA-VIRUS; MATURATION-PROMOTING FACTOR; KINASE-ACTIVITY; MEIOTIC MATURATION; TRANSFORMING GENE; XENOPUS OOCYTES; CDC2 PROTEIN; DEVELOPMENTAL REGULATION; PROTOONCOGENE PRODUCT; HUMAN NEUROBLASTOMAS	Although the human c-mos proto-oncogene has been characterized for more than a decade, very little is known about its protein product and its expression in somatic cells. We generated three human c-mos-specific antisera and report here the detection of c-mos protein in a human neuroblastoma cell line, SK-N-BE2 (BE2). Both Western (immuno-) blot and immunoprecipitation analyses detected a p37 as the major form and p40 and p35 as minor forms of the c-mos protein. Using Northern blot analysis, 3.5- and 1.7-kb c-mos messages were detected. Using a highly sensitive method that combines reverse transcription and the polymerase chain reaction (RT-PCR), c-mos RNA was detected in all the human samples examined. With Western blot analysis, we further showed that c-mos proteins are expressed in cervical carcinoma-derived cell lines. This ubiquitous expression of low levels of c-mos suggests a fundamental role for the c-mos proto-oncogene.	NCI,FREDERICK CANC RES & DEV CTR,DIV CANC TREATMENT,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	LI, CCH (corresponding author), INC DYNCORP,PROGRAM RESOURCES,BIOL CARCINOGENESIS & DEV PROGRAM,POB B,BLDG 567,ROOM 202,FREDERICK,MD 21702, USA.		Longo, Dan L./F-6022-2011		NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BIEDLER JL, 1988, ADV NEUROBLASTOMA RE, V2, P265; BLAIR DG, 1986, CELL, V46, P785, DOI 10.1016/0092-8674(86)90354-5; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CHIN MT, 1989, J VIROL, V63, P2967, DOI 10.1128/JVI.63.7.2967-2976.1989; COFFIN JM, 1981, J VIROL, V40, P953, DOI 10.1128/JVI.40.3.953-957.1981; COHEN JB, 1983, NATURE, V306, P797, DOI 10.1038/306797a0; DANOS O, 1984, CANCER CELLS ONCOGEN, V2, P291; DIAMOND SL, 1990, J CELL PHYSL, V143, P3641; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FREEMAN RS, 1991, MOL CELL BIOL, V11, P1713, DOI 10.1128/MCB.11.3.1713; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1990, J VIROL, V64, P3093, DOI 10.1128/JVI.64.6.3093-3096.1990; KESHET E, 1988, ONCOGENE, V2, P235; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; LEIBOVITCH SA, 1991, ONCOGENE, V6, P1617; LI CCH, 1987, J VIROL, V61, P2684, DOI 10.1128/JVI.61.9.2684-2690.1987; LI CCH, 1990, PAPILLOMAVIRUSES, P119; LIU JX, 1990, ONCOGENE, V5, P171; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; OGISO Y, 1986, BIOCHEM BIOPH RES CO, V140, P477, DOI 10.1016/0006-291X(86)90757-6; OKAZAKI K, 1991, JPN J CANCER RES, V82, P250, DOI 10.1111/j.1349-7006.1991.tb01837.x; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PAPKOFF J, 1981, CELL, V27, P109, DOI 10.1016/0092-8674(81)90365-2; PARKAR MH, 1988, CANCER LETT, V43, P185, DOI 10.1016/0304-3835(88)90169-3; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PAULES RS, 1988, ONCOGENE, V3, P59; PROPST F, 1990, P NATL ACAD SCI USA, V87, P9703, DOI 10.1073/pnas.87.24.9703; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SETH A, 1987, P NATL ACAD SCI USA, V84, P3560, DOI 10.1073/pnas.84.11.3560; SETH A, 1988, ONCOGENE HDB, P195; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; SUNKARA PS, 1979, P NATL ACAD SCI USA, V76, P2799, DOI 10.1073/pnas.76.6.2799; VANBEVEREN C, 1981, NATURE, V289, P258, DOI 10.1038/289258a0; VANDERHOORN FA, 1991, ONCOGENE, V6, P929; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; YEE C, 1985, AM J PATHOL, V119, P361; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHAO X, 1991, ONCOGENE, V6, P43; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	65	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1685	1691						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502488				2022-12-17	WOS:A1993LE06400034
J	CHAN, AML; CHEDID, M; MCGOVERN, ES; POPESCU, NC; MIKI, T; AARONSON, SA				CHAN, AML; CHEDID, M; MCGOVERN, ES; POPESCU, NC; MIKI, T; AARONSON, SA			EXPRESSION CDNA CLONING OF A SERINE KINASE TRANSFORMING GENE	ONCOGENE			English	Article							ENDOCRINE NEOPLASIA TYPE-2A; DEPENDENT PROTEIN-KINASE; OKADAIC ACID; TUMOR PROMOTER; ONCOGENE; CELLS; CHROMOSOME-10; PHOSPHORYLATION; INTERLEUKIN-1; HYBRIDIZATION	By ectopic expression of cDNAs derived from a Ewing sarcoma cell line in NIH3T3 celts, we isolated a transforming gene (est). Sequence analysis revealed homology to the cot oncogene, which encodes a novel serine kinase. Whereas the cot product was truncated at its carboxy-terminal end as a result of gene rearrangement during transfection, est encodes the normal cot product. Thus, this gene can be activated as an oncogene by overexpression as well as by gene rearrangement. NIH3T3 cells transfected with est formed progressively growing colonies in soft agar and were tumorigenic in nude mice. The 3.2-kb est transcript was expressed at low level in both human fibroblasts and epithelial cells. Addition of the tumor promoter, okadaic acid (OA), or cytokine, interleukin 1 (IL-1), but not serum or platelet-derived growth factor (PDGF), induced increased expression of the est transcript. Using fluorescence in situ hybridization, we localized the est gene to the short arm of human chromosome 10 at band p11.2.	NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,1E24,BETHESDA,MD 20892; NCI,BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Chan, Andrew/AAC-1145-2020; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Chan, Andrew Man-Lok/0000-0001-9923-5464				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DINARELLO CA, 1991, BLOOD, V77, P1627; FERRARI S, 1985, FEBS LETT, V184, P72, DOI 10.1016/0014-5793(85)80656-6; GUY GR, 1991, J BIOL CHEM, V266, P14343; GUY GR, 1992, J BIOL CHEM, V267, P1846; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LAIRMORE TC, 1991, GENOMICS, V9, P181, DOI 10.1016/0888-7543(91)90237-9; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Maniatis T., 1982, MOL CLONING; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; NADINDAVIS SA, 1988, EMBO J, V7, P985, DOI 10.1002/j.1460-2075.1988.tb02905.x; NAROD SA, 1992, AM J HUM GENET, V51, P469; NORUM RA, 1990, GENOMICS, V8, P313, DOI 10.1016/0888-7543(90)90287-5; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P292; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; QWARNSTROM EE, 1991, P NATL ACAD SCI USA, V88, P1232, DOI 10.1073/pnas.88.4.1232; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1986, CELL, V46, P606; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SIMPSON NE, 1987, NATURE, V328, P528, DOI 10.1038/328528a0; SIMPSON NE, 1991, CYTOGENET CELL GENET, V58, P428, DOI 10.1159/000133170; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; VANBEVEREN C, 1981, NATURE, V289, P258, DOI 10.1038/289258a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	41	33	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1329	1333						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479752				2022-12-17	WOS:A1993KY32800026
J	KLEMPNAUER, KH				KLEMPNAUER, KH			METHYLATION-SENSITIVE DNA-BINDING BY V-MYB AND C-MYB PROTEINS	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; CELLULAR HOMOLOG; PROTO-ONCOGENE; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; TRANS-ACTIVATION; GENE; DIFFERENTIATION; EXPRESSION; PRODUCT	The retroviral oncogene v-myb and its cellular homolog c-myb encode nuclear DNA-binding phosphoproteins (v-MYB and c-MYB) that function as transcriptional regulators. v-MYB and c-MYB recognize a nucleotide sequence motif, PyAAC(G)/(T)G, that is present in the promoter region of the myb-inducible mim-1 gene and is required for regulation of mim-1 expression by v-MYB and c-MYB. Since the myb-binding motif contains a CpG dinucleotide that constitutes a potential target for methylation, we have investigated whether recognition of the binding site by myb proteins is sensitive to CpG methylation of the binding motif. The results presented here demonstrate that bacterially expressed v-MYB as well as authentic v-MYB and c-MYB bind to the myb binding site in a methylation-sensitive manner. Our observations raise the interesting possibility that myb function can be regulated by methylation of myb binding sites.			KLEMPNAUER, KH (corresponding author), MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,STUBEWEG 51,W-7800 FREIBURG,GERMANY.							BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CRAIG RW, 1984, CANCER RES, V44, P442; EVAN GI, 1984, MOL CELL BIOL, V4, P591; GARCIA A, 1991, ONCOGENE, V6, P265; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JACKSON D, 1991, PLANT CELL, V3, P115, DOI 10.1105/tpc.3.2.115; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PAZARES J, 1987, EMBO J, V6, P3552; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; STOBERGRASSER U, 1992, ONCOGENE, V7, P589; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	41	33	34	2	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					111	115						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423989				2022-12-17	WOS:A1993KN00500013
J	KOVAR, H; AUINGER, A; JUG, G; MULLER, T; PILLWEIN, K				KOVAR, H; AUINGER, A; JUG, G; MULLER, T; PILLWEIN, K			P53 MOSAICISM WITH AN EXON 8 GERMLINE MUTATION IN THE FOUNDER OF A CANCER-PRONE PEDIGREE	ONCOGENE			English	Article							TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; ACTIVATING MUTATIONS; TRANSFORMED-CELLS; GENE-MUTATIONS; BREAST-CANCER; LINE MUTATION; DNA; PROTEIN; CARCINOMAS	Changes in the tumor-suppressor gene p53 are frequently acquired during the course of malignant development of human tumors. Recently, constitutional heterozygous mutations in p53 exon 7 have been identified as the primary cause of cancer predisposition in cases of the familial Li-Fraumeni cancer syndrome. These findings underline the need for extensive mutation screening in families with high cancer incidence. This report describes the detection and follow-up by two-dimensional single-strand conformation polymorphism analysis (2DSSCP) of a new germline mutation of p53 exon 8 in a case of suspected Li-Fraumeni syndrome. Although a high cancer incidence had been reported in the family history of the father of siblings suffering from brain tumor and rhabdomyosarcoma, a constitutional heterozygous p53 mutation was identified only in the affected children. Retrospective analysis of archival tissue of a half-sister who died several years ago from a tumor of previously uncertain diagnosis revealed the same mutation. The mutation had therefore occurred in the germ cells of the mother, who thus appears to be a mosaic. The cancer predisposition of the paternal ancestors must have been due to other factors.	ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,VIENNA,AUSTRIA; UNIV VIENNA,DEPT PEDIAT,A-1010 VIENNA,AUSTRIA	Saint Anna Children's Hospital; University of Vienna				Kovar, Heinrich/0000-0001-6873-9109				BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUDOWLE B, 1991, AM J HUM GENET, V48, P137; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; CHIBA I, 1990, ONCOGENE, V5, P1603; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HELMUTH R, 1990, AM J HUM GENET, V47, P515; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JENKINS JR, 1988, ONCOGENE HDB, P403; KOVAR H, 1991, NUCLEIC ACIDS RES, V19, P3507, DOI 10.1093/nar/19.13.3507; KRESS M, 1979, J VIROL, V31, P472, DOI 10.1128/JVI.31.2.472-483.1979; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAW JC, 1991, CANCER RES, V51, P6385; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PROSSER J, 1990, ONCOGENE, V5, P1573; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P755; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRATTON MR, 1990, ONCOGENE, V5, P1297; STURZBECHER HW, 1990, ONCOGENE, V5, P795; VARLEY JM, 1991, ONCOGENE, V6, P413; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; WILLIAMS WR, 1985, FAM CANCER, P151; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; YOUNG JL, 1977, NATL CANCER I MONOGR, V57, P70	42	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2169	2173						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1359493				2022-12-17	WOS:A1992JW66500009
J	AVIVI, A; SKORECKI, K; YAYON, A; GIVOL, D				AVIVI, A; SKORECKI, K; YAYON, A; GIVOL, D			PROMOTER REGION OF THE MURINE FIBROBLAST GROWTH-FACTOR RECEPTOR-2 (BEK KGFR) GENE	ONCOGENE			English	Article							MAMMALIAN-CELLS; EXPRESSION; CLONING; FAMILY; PURIFICATION; MECHANISMS; PLASMIDS; BINDING; MEMBER; FGF	Fibroblast growth factors (FGFs) and their receptors play an important role in cell growth, angiogenesis and embryonal development. Four distinct genes encoding fibroblast growth factor receptors (FGFRs) were identified: flg, encoding FGFR1, bek encoding FGFR2, and the genes for FGFR3 and FGFR4. Both FGFR2 and keratinocyte growth factor receptor (KGFR) are encoded by the same gene, bek. To study the regulation of expression of the FGF receptors we analysed the DNA sequence flanking the 5' region of the cDNA of murine FGFR2 to seek elements that control its transcription. A 5-kbp fragment containing the 5' end of the cDNA was isolated from mouse genomic library and used to map the promoter region. We found that the sequence encoding the 5' non-translated region of the FGFR2/KGFR cDNA contains an intron located 210 bp upstream from the translation start site. Using RNAase protection and primer extension, we identified the mRNA start 37 bp upstream from the beginning of the bek cDNA. The promoter activity was found to reside in a 1.3-kbp fragment upstream from the cDNA, and deletion mapping further localized the promoter to a 0.7-kbp fragment. The sequence of this region shows high G + C content (62%), which is particularly emphasized in the 200 bp upstream from the mRNA start (80% G + C). This region contains the CCGCCC, GGGCGG AND GGAGG motifs also found in promoters of other growth factor receptors. Neither TATA nor CAAT boxes were found near the RNA start site. The characterization of this promoter will allow studies of the regulation of expression of the FGFR2 during development and in pathophysiological states. The differences between the promoter sequence of the gene for FGFR2 (bek) and FGFR1 (flg) may explain their differential expression during development.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AVIVI A, 1991, ONCOGENE, V6, P1089; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; Maniatis T., 1982, MOL CLONING; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERS KG, 1992, DEVELOPMENT, V114, P233; RAZ V, 1991, ONCOGENE, V6, P753; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SAITO H, 1992, BIOCHEM BIOPH RES CO, V183, P688, DOI 10.1016/0006-291X(92)90537-U; SANGER F, 1977, P NATL ACAD SCI USA, V83, P7137; SMITH JC, 1989, DEVELOPMENT, V105, P665; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	34	33	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1992	7	10					1957	1962						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408137				2022-12-17	WOS:A1992JP42400008
J	EYCHENE, A; BARNIER, JV; DEZELEE, P; MARX, M; LAUGIER, D; CALOGERAKI, I; CALOTHY, G				EYCHENE, A; BARNIER, JV; DEZELEE, P; MARX, M; LAUGIER, D; CALOGERAKI, I; CALOTHY, G			QUAIL NEURORETINA C-RMIL(B-RAF) PROTOONCOGENE CDNAS ENCODE 2 PROTEINS OF 93.5-KDA AND 95-KDA RESULTING FROM ALTERNATIVE SPLICING	ONCOGENE			English	Article							AVIAN LYMPHOMATOSIS VIRUS; COMPLETE CODING SEQUENCE; ROUS-SARCOMA VIRUS; C-MIL; KINASE-ACTIVITY; RAF ONCOGENE; TRANSFORMING ACTIVITY; CELL-PROLIFERATION; DNA FRAGMENTS; V-MIL	c-Rmil is the cellular allele of the v-Rmil oncogene transduced during in vitro passaging of Rous-associated virus type 1 in chicken embryonic neuroretina (NR) cells. The c-Rmil proto-oncogene is the avian homolog of the mammalian B-raf gene and belongs to the mil/raf oncogene family of serine/threonine protein kinases. The c-Rmil/B-raf gene is preferentially expressed in avian and mammalian neural tissues. Two c-Rmil cDNA species, resulting from an alternative splicing mechanism, were isolated from quail embryonic NR cDNA libraries. They encode two proteins of 767 and 807 amino acids that differ by the presence of an alternative exon, located upstream of the kinase domain. Expression of these cDNAs in COS-1 cells leads to the synthesis of two proteins with apparent molecular weights of 93.5 and 95 kDa, recognized by an Rmil-specific antiserum. Both proteins are phosphorylated in an immune complex kinase assay. A protein of 94 kDa is also immunoprecipitated in avian NR cells and is identical to the 93.5-kDa protein expressed in COS-1 cells, as shown by Staphylococcus aureus V8 protease mapping. The c-Rmil proteins contain the three conserved regions previously identified in mil/raf protein kinases. In addition, they contain amino-terminal sequences that are not present in the other mil/raf proteins identified to date. These additional sequences may define a novel functional domain for c-Rmil/B-raf and could play a role in signal transduction in neural cells.	CTR UNIV ORSAY,INST CURIE,CNRS,UNITE RECH 1443,F-91405 ORSAY,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay			Eychene, Alain/M-8838-2017	EYCHENE, Alain/0000-0002-6818-7225				AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P1213; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; DOZIER C, 1988, MOL CELL BIOL, V8, P1835, DOI 10.1128/MCB.8.4.1835; DOZIER C, 1991, ONCOGENE, V6, P1307; EYCHENE A, 1989, NUCLEIC ACIDS RES, V17, P1250, DOI 10.1093/nar/17.3.1250; EYCHENE A, 1990, J VIROL, V64, P231; FELDER MP, 1991, J VIROL, V65, P3633, DOI 10.1128/JVI.65.7.3633-3640.1991; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GUERMAH M, 1990, MOL CELL BIOL, V10, P3584, DOI 10.1128/MCB.10.7.3584; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; ISHIKAWA F, 1988, ONCOGENE, V3, P653; IZUMI T, 1991, J BIOL CHEM, V266, P7933; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KAN NC, 1983, P NATL ACAD SCI-BIOL, V80, P6566, DOI 10.1073/pnas.80.21.6566; KOENEN M, 1988, ONCOGENE, V2, P179; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; Maniatis T., 1982, MOL CLONING; MARK GE, 1986, P NATL ACAD SCI USA, V83, P6312, DOI 10.1073/pnas.83.17.6312; MARX M, 1988, J VIROL, V62, P4627, DOI 10.1128/JVI.62.12.4627-4633.1988; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PATCHINSKY T, 1986, MOL CELL BIOL, V6, P739; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; POIRIER F, 1982, J VIROL, V42, P780, DOI 10.1128/JVI.42.3.780-789.1982; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STORM SM, 1990, ONCOGENE, V5, P345; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	56	33	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1315	1323						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620546				2022-12-17	WOS:A1992HZ97100009
J	MORGAN, IM; RANSONE, LJ; BOS, TJ; VERMA, IM; VOGT, PK				MORGAN, IM; RANSONE, LJ; BOS, TJ; VERMA, IM; VOGT, PK			TRANSFORMATION BY JUN - REQUIREMENT FOR LEUCINE ZIPPER, BASIC REGION AND TRANSACTIVATION DOMAIN AND ENHANCEMENT BY FOS	ONCOGENE			English	Article							C-JUN; DNA-BINDING; GLUCOCORTICOID RECEPTOR; ONCOGENE JUN; FACTOR AP-1; V-JUN; PROTEINS; ACTIVATION; HETERODIMER; EXPRESSION	Mutants in the leucine zipper and basic regions of mouse c-jun were tested for transformation in chicken embryo fibroblast cultures. Reduction or elimination of the ability of Jun to dimerize or to bind to DNA severely decreased transformation. A chicken v-jun gene from which the major transactivation domain was deleted also failed to transform. We conclude that an intact leucine zipper, basic region and transactivation domain are required for Jun-induced oncogenic transformation. Coexpression of chicken c-Fos increased formation of transformed foci by Jun proteins of moderate to low oncogenic potency but had no effect on highly transforming Jun. Chicken c-Fos could also transform chicken embryo fibroblasts on its own, albeit after prolonged culture and at a low efficiency.	NORRIS CANC CTR, LOS ANGELES, CA 90033 USA; SALK INST BIOL STUDIES, MOLEC BIOL & VIRUS LAB, LA JOLLA, CA 92186 USA; EASTERN VIRGINIA MED SCH, DEPT MICROBIOL & IMMUNOL, NORFOLK, VA 23501 USA	Salk Institute; Eastern Virginia Medical School	MORGAN, IM (corresponding author), UNIV SO CALIF, SCH MED, DEPT MICROBIOL, LOS ANGELES, CA 90033 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; ANGEL P, 1989, New Biologist, V1, P35; BENBROOK DM, 1990, ONCOGENE, V5, P295; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BRUN G, 1989, NUCLEIC ACIDS RES, V17, P6393, DOI 10.1093/nar/17.15.6393; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; COHEN DR, 1990, ONCOGENE, V5, P929; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRAI S-I, 1989, New Biologist, V1, P181; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; NISHIMURA T, 1988, ONCOGENE, V3, P659; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; PERKINS KK, 1988, EMBO J, V7, P4265, DOI 10.1002/j.1460-2075.1988.tb03324.x; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SAKAI M, 1989, CANCER RES, V49, P5633; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	42	33	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1992	7	6					1119	1125						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594243				2022-12-17	WOS:A1992HU64200009
J	WICK, M; LUCIBELLO, FC; MULLER, R				WICK, M; LUCIBELLO, FC; MULLER, R			INHIBITION OF FOS-INDUCED AND RAS-INDUCED TRANSFORMATION BY MUTANT FOS PROTEINS WITH STRUCTURAL ALTERATIONS IN FUNCTIONALLY DIFFERENT DOMAINS	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; DNA-BINDING DOMAINS; PROTO-ONCOGENE FOS; C-FOS; GENE-EXPRESSION; LEUCINE ZIPPER; AUTO-REGULATION; JUN PROTEINS; ACTIVATION; COMPLEXES	We show that transformation-defective Fos proteins lacking either a functional leucine zipper (mutants L345 and J/R510s) or the 110 amino-terminal amino acids (mutant BR800) inhibit the induction of morphological transformation by v-Fos. Both types of mutants specifically repress transformation without any significant effect on cell proliferation. In contrast, several transformation-defective Fos mutants with structural alterations in the acidic region or the right half of the adjacent basic DNA contact site do not show any inhibition of transformation. This result, taken together with the repression of transformation by the leucine zipper-deficient mutants L345 and J/R510s, indicates that the interaction of Fos with proteins other than Jun is necessary for transformation. The leucine zipper-deficient mutants also inhibit Fos-mediated activation of AP-1-dependent transcription. This suggests that their inhibitory effect on transformation may at least in part be the result of the squelching of proteins other than Jun family members that are required for Fos-mediated transactivation. All three mutants were also found to inhibit transformation by the point-mutated H-ras oncogene from EJ carcinoma cells and to trigger a partial reversion of the transformed phenotype of Ras-transformed fibroblasts. These findings support the conclusion that Ras-induced transformation involves signal transduction pathways inducing the c-fos gene.	UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, EMIL MANNKOPFF STR 2, W-3550 MARBURG, GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ADAMKIEWICZ J, 1990, ONCOGENE, V5, P525; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LUCIBELLO F C, 1991, Critical Reviews in Oncogenesis, V2, P259; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUCIBELLO FC, 1991, NEW BIOL, V3, P671; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILLER AD, 1984, CELL, V36, P51; MORGAN JI, 1989, TRENDS NEUROSCI, V12, P459, DOI 10.1016/0166-2236(89)90096-9; MULLER R, 1985, BIOCHIM BIOPHYS ACTA, V823, P207; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUBERG M, 1991, ONCOGENE, V6, P1325; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	49	33	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					859	867						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570155				2022-12-17	WOS:A1992HP64200004
J	WAGNER, P; SIMANIS, V; MAIMETS, T; KEENAN, E; ADDISON, C; BRAIN, R; GRIMALDI, M; STURZBECHER, HW; JENKINS, J				WAGNER, P; SIMANIS, V; MAIMETS, T; KEENAN, E; ADDISON, C; BRAIN, R; GRIMALDI, M; STURZBECHER, HW; JENKINS, J			A HUMAN TUMOR-DERIVED MUTANT P53-PROTEIN INDUCES A P34CDC2 REVERSIBLE GROWTH ARREST IN FISSION YEAST	ONCOGENE			English	Article							SMALL-CELL CARCINOMA; P53 GENE; T-ANTIGEN; SCHIZOSACCHAROMYCES-POMBE; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; DNA-REPLICATION; CYCLE CONTROL; SHORT ARM; PROTEIN	We have expressed wild-type and human tumour-derived mutant p53 cDNA genes in the fission yeast Schizosaccharomyces pombe. In the case of one mutant this resulted in a growth arrest of recipient yeast cells. In contrast, wild-type p53 and three other mutant proteins tested did not block outgrowth of colonies. Human and yeast cdc2 acted as functionally equivalent extragenic suppressors of the mutant-induced growth arrest allowing the establishment of viable p53 expressor strains. In cotransformation assays the mutant allele was found to be dominant over wt p53. Our results provide the first evidence of a functional relationship between p53 and p34cdc2 in an in-vivo system and suggest that the wide variety of mutant proteins present in human tumours may fall into functionally distinct subclasses.	ESTONIAN BIOCENTER,TARTU 202400,ESTONIA,USSR; SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND	Swiss Institute Experimental Cancer Research	WAGNER, P (corresponding author), MARIE CURIE CANC RES INST,CELL PROLIFERAT LAB,THE CHART,OXTED RH8 0TL,SURREY,ENGLAND.		Maimets, Toivo/E-9268-2017	Maimets, Toivo/0000-0001-6461-3365				BENCHIMOL S, 1985, SOMAT CELL MOLEC GEN, V11, P505, DOI 10.1007/BF01534845; BENDAVID Y, 1988, ONCOGENE, V3, P179; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BROEKER M, 1987, Biotechniques, V5, P518; CARR AM, 1989, MOL GEN GENET, V218, P41, DOI 10.1007/BF00330563; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FANTES PA, 1989, MOL BIOL FISSION YEA; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; GOULD K, 1990, NATURE, V342, P39; GUSSOW D, 1989, NUCLEIC ACIDS RES, V17, P4000; Gutz H, 1974, HDB GENETICS, P395, DOI 10.1007/978-1-4899-1710-2_25; HENGST L, 1990, EMBO J, V9, P1949, DOI 10.1002/j.1460-2075.1990.tb08322.x; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LATHE RA, 1988, CYTOGENET CELL GENET, V41, P404; LAW DJ, 1988, SCIENCE, V241, P961, DOI 10.1126/science.2841761; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Maniatis T., 1982, MOL CLONING; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; Mitchison J. M., 1988, YEAST PRACTICAL APPR, P51; MONPEZAT JP, 1988, INT J CANCER, V41, P404, DOI 10.1002/ijc.2910410315; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MULERIS M, 1985, Annales de Genetique, V28, P206; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; ROVINSKI B, 1988, ONCOGENE, V2, P445; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STREIBLOVA E, 1988, YEAST PRACTICAL APPR, P9; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1988, ONCOGENE, V3, P405; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WAGNER P, 1987, EMBO J, V6, P2373, DOI 10.1002/j.1460-2075.1987.tb02514.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1988, ONCOGENE, V3, P471	53	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1539	1547						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923520				2022-12-17	WOS:A1991GX27400007
J	FEN, Z; DANIEL, TO				FEN, Z; DANIEL, TO			5' UNTRANSLATED SEQUENCES DETERMINE DEGRADATIVE PATHWAY FOR ALTERNATE PDGF B/C-SIS MESSENGER-RNAS	ONCOGENE			English	Article							SIMIAN SARCOMA-VIRUS; CARCINOMA CELL-LINES; FACTOR-B-CHAIN; GROWTH-FACTOR; C-SIS; PROTO-ONCOGENE; DIFFERENT ISOFORMS; ENDOTHELIAL-CELLS; MYC GENE; EXPRESSION	The 5' untranslated sequence (5' UTS) of the platelet-derived growth factor B (PDGF B/c-sis) mRNA is GC rich, includes AUGs upstream of the translation initiation site, and inhibits translation of downstream heterologous and autologous coding sequences. Its primary sequence has been remarkably conserved through evolution. In this study, we identified two additional PDGF B/c-sis mRNAs expressed in endothelial cells. These were shown by Northern, primer extension, and nuclease protection analyses to differ in extent of 5' untranslated first exon sequence. The predominant of these 5' truncated transcripts was 2.8 kb, extended 15nt upstream of the translation start site and was markedly stabilized by cycloheximide and anisomycin, but not puromycin or pactamycin. Cycloheximide increased the half-life of this mRNA approximately 7 fold, without affecting stability of the full length mRNA. Cycloheximide withdrawal caused its abrupt destabilization. The 2.8 kb PDGF B/c-sis mRNA lacks translation inhibitory 5' UTS, encodes the same PDGF B protein, appears initiated from within first exon genomic sequences, and is degraded through a process that is sensitive to translation arrest and distinct from that degrading the 3.8 kb PDGF B/c-sis mRNA.	VANDERBILT UNIV, DEPT MED, MCN 53223, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, DEPT CELL BIOL, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University	DANIEL, TO (corresponding author), VANDERBILT UNIV, DEPT MED, MCN 53223, NASHVILLE, TN 37232 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038517, P50DK039261] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38517, DK39261] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASSELIN C, 1989, ONCOGENE, V4, P549; BARRETT TB, 1987, P NATL ACAD SCI USA, V84, P1099, DOI 10.1073/pnas.84.4.1099; BERNARDS A, 1988, ONCOGENE, V2, P297; BESMER P, 1983, J VIROL, V46, P606, DOI 10.1128/JVI.46.2.606-613.1983; BETSHOLTZ C, 1989, MOL CHEM NEUROPATHOL, V10, P27, DOI 10.1007/BF02969484; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; BOWENPOPE DF, 1984, P NATL ACAD SCI-BIOL, V81, P2396, DOI 10.1073/pnas.81.8.2396; CHIU IM, 1984, CELL, V37, P123; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; COLLINS T, 1985, NATURE, V316, P748, DOI 10.1038/316748a0; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; DANIEL TO, 1987, J BIOL CHEM, V262, P11893; DANIEL TO, 1988, J BIOL CHEM, V263, P19815; DELLAFAVERA R, 1981, NATURE, V292, P31; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; FAN H, 1970, J MOL BIOL, V50, P655, DOI 10.1016/0022-2836(70)90091-4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOUSTIN AS, 1985, CELL, V41, P301, DOI 10.1016/0092-8674(85)90083-2; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1989, TRENDS GENET, V5, P108, DOI 10.1016/0168-9525(89)90040-1; HOGAN BLM, 1969, BIOCHIM BIOPHYS ACTA, V182, P264, DOI 10.1016/0005-2787(69)90546-2; IGARASHI H, 1987, ONCOGENE, V1, P79; KAPPEN LS, 1973, P NATL ACAD SCI USA, V70, P22, DOI 10.1073/pnas.70.1.22; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MEDCALF RL, 1986, EMBO J, V5, P2217, DOI 10.1002/j.1460-2075.1986.tb04487.x; PERES R, 1987, CANCER RES, V47, P3425; PRESS RD, 1988, BIOCHEMISTRY-US, V27, P5736, DOI 10.1021/bi00415a051; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; RATNER L, 1987, NUCLEIC ACIDS RES, V15, P6017, DOI 10.1093/nar/15.15.6017; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; Sambrook J., 1989, MOL CLONING LAB MANU; SEAL SN, 1972, BIOCHEM BIOPH RES CO, V46, P1895, DOI 10.1016/0006-291X(72)90067-8; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; STANLEY E, 1985, EMBO J, V4, P2569, DOI 10.1002/j.1460-2075.1985.tb03972.x; STANTON LW, 1987, MOL CELL BIOL, V7, P4266, DOI 10.1128/MCB.7.12.4266; STEWART TA, 1984, SCIENCE, V226, P707, DOI 10.1126/science.6494906; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; VANDENOUWELAND AMW, 1985, BIOCHIM BIOPHYS ACTA, V825, P140, DOI 10.1016/0167-4781(85)90097-1; VANDENOUWELAND MW, 1986, NUCLEIC ACIDS RES, V14, P765, DOI 10.1093/nar/14.2.765; VANZOELEN EJJ, 1985, MOL CELL BIOL, V5, P2289, DOI 10.1128/MCB.5.9.2289; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	49	33	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					953	959						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	2067847				2022-12-17	WOS:A1991GU62200009
J	GARCIA, IS; KANEKO, Y; GONZALEZSARMIENTO, R; CAMPBELL, K; WHITE, L; BOEHM, T; RABBITTS, TH				GARCIA, IS; KANEKO, Y; GONZALEZSARMIENTO, R; CAMPBELL, K; WHITE, L; BOEHM, T; RABBITTS, TH			A STUDY OF CHROMOSOME-11P13 TRANSLOCATIONS INVOLVING TCR-BETA AND TCR-DELTA IN HUMAN T-CELL LEUKEMIA	ONCOGENE			English	Article							BREAKPOINT CLUSTER REGION; CHAIN; LEUKEMIA; 11P13; LYMPHOMA; SEQUENCE; ORGANIZATION; INVERSION; DIVERSITY; TUMORS	A frequent site of translocation damage in human T-ALL has been localized to a specific region of chromosome band 11p13. Five new T-ALL cases are described which break in the major T-ALL(bcr) region of 11p13, two involving a novel translocation t(7;11)(q35;p13), with breakage at the T cell receptor (TCR) beta-gene from 7q35, and three involving TCR-delta from 14q11 in the more common t(11;14)(p13;q11). Analysis of the mechanism of one T-ALL(bcr)/TCR-beta translocation and a previously described t(11;14)(p13;q11) was conducted by genomic cloning of translocation breakpoints, using the polymerase chain reaction (PCR). Both seem to have occurred by recombinase error, but only the t(7;11) showed sequence-specific joining. Nonetheless recombinase mediation of the t(11;14) is implied by the presence of N-region addition (a hallmark of recombinase joins) on both derivative chromosomes. These observations reinforce the view that translocations in the T-ALL(bcr) region of chromosome 11p13 are a major lesion in human T-ALL. In addition, these can occur by mimicry of VDJ joining, but sequence specificity is not obligatory.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; SAITAMA CANC CTR,INA,SAITAMA 362,JAPAN; PRINCE WALES CHILDRENS HOSP,DIV HAEMATOL ONCOL,SYDNEY,NSW 2031,AUSTRALIA	MRC Laboratory Molecular Biology			Gonzalez-Sarmiento, Rogelio/V-5526-2019; Rabbitts, Terence/D-6262-2016	Gonzalez-Sarmiento, Rogelio/0000-0002-2726-6795; Rabbitts, Terence/0000-0002-4982-2609				BAER R, 1987, CELL, V50, P97, DOI 10.1016/0092-8674(87)90666-0; BAER R, 1985, CELL, V43, P705, DOI 10.1016/0092-8674(85)90243-0; BARKER PE, 1987, AM J HUM GENET, V39, P661; BOEHM T, 1990, NUCLEIC ACIDS RES, V18, P4298, DOI 10.1093/nar/18.14.4298; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; CHENG JT, 1990, J EXP MED, V171, P489, DOI 10.1084/jem.171.2.489; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; FORONI L, 1990, GENE CHROMOSOME CANC, V1, P301, DOI 10.1002/gcc.2870010407; KANEKO Y, 1989, LEUKEMIA, V3, P886; KANEKO Y, 1988, BLOOD, V72, P534; LOH EY, 1988, P NATL ACAD SCI USA, V85, P9714, DOI 10.1073/pnas.85.24.9714; RABBITTS TH, 1991, IN PRESS ADV IMMUNOL, V50; ROYERPOKORA B, 1989, HUM GENET, V82, P264, DOI 10.1007/BF00291167; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; STADEN R, 1990, COMPUT APPL BIOSCI, V6, P387; TOYONAGA B, 1985, P NATL ACAD SCI USA, V82, P8624, DOI 10.1073/pnas.82.24.8624; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; TUNNACLIFFE A, 1985, NUCLEIC ACIDS RES, V13, P6651, DOI 10.1093/nar/13.18.6651; TUNNACLIFFE A, 1985, P NATL ACAD SCI USA, V82, P5068, DOI 10.1073/pnas.82.15.5068; YOFFE G, 1989, BLOOD, V74, P374	21	33	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					577	582						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1827667				2022-12-17	WOS:A1991FR93900011
J	AHUJA, HG; TESTA, MP; CLINE, MJ				AHUJA, HG; TESTA, MP; CLINE, MJ			VARIATION IN THE PROTEIN CODING REGION OF THE HUMAN P53 GENE	ONCOGENE			English	Note											AHUJA, HG (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,JONSSON COMPREHENS CANC CTR,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024, USA.				PHS HHS [50275] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; ELIYAHU D, 1988, ONCOGENE, V3, P313; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402	13	33	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1409	1410						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	1977117				2022-12-17	WOS:A1990EC24100020
J	EICK, D; POLACK, A; KOFLER, E; LENOIR, GM; RICKINSON, AB; BORNKAMM, GW				EICK, D; POLACK, A; KOFLER, E; LENOIR, GM; RICKINSON, AB; BORNKAMM, GW			EXPRESSION OF P0- AND P3-RNA FROM THE NORMAL AND TRANSLOCATED C-MYC ALLELE IN BURKITTS-LYMPHOMA CELLS	ONCOGENE			English	Article									INST MED MIKROBIOL & HYG,VIROL ABT,W-7800 FREIBURG,GERMANY; CTR INT RECH CANC,F-69372 LYONS 08,FRANCE; UNIV BIRMINGHAM,CTR CANC STUDIES,CANC RES CAMPAIGN LABS,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND	World Health Organization; International Agency for Research on Cancer (IARC); University of Birmingham	EICK, D (corresponding author), GESELL STRAHLEN & UMWELTFORSCH MBH,INST KLIN MOLEK BIOL & TUMORGENET,MARCHIONINISTR 25,W-8000 MUNICH 70,GERMANY.							ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GAZIN C, 1986, EMBO J, V5, P2241, DOI 10.1002/j.1460-2075.1986.tb04491.x; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LENOIR GM, 1985, IARC SCI PUBL, V60, P309; Maniatis T., 1982, MOL CLONING; NISHIKURA K, 1987, J MOL BIOL, V193, P497, DOI 10.1016/0022-2836(87)90262-2; NISHIKURA K, 1983, P NATL ACAD SCI-BIOL, V80, P4822, DOI 10.1073/pnas.80.15.4822; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RAY D, 1987, MOL CELL BIOL, V7, P940, DOI 10.1128/MCB.7.2.940; RAY D, 1989, ONCOGENE RES, V5, P73; ROONEY CM, 1986, J NATL CANCER I, V77, P681, DOI 10.1093/jnci/77.3.681; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7	29	33	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1397	1402						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	2216463				2022-12-17	WOS:A1990EC24100018
J	HEIDARAN, MA; FLEMING, TP; BOTTARO, DP; BELL, GI; DIFIORE, PP; AARONSON, SA				HEIDARAN, MA; FLEMING, TP; BOTTARO, DP; BELL, GI; DIFIORE, PP; AARONSON, SA			TRANSFORMATION OF NIH3T3 FIBROBLASTS BY AN EXPRESSION VECTOR FOR THE HUMAN EPIDERMAL GROWTH-FACTOR PRECURSOR	ONCOGENE			English	Article									NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,ROOM 1E24,BETHESDA,MD 20892; UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute; University of Chicago			Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010; Di Fiore, Pier Paolo/K-2130-2012	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334; Di Fiore, Pier Paolo/0000-0002-2252-0950				BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DERYNCK R, 1987, CANCER RES, V47, P707; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIMARCO E, 1989, ONCOGENE, V4, P831; FINZI E, 1987, P NATL ACAD SCI USA, V84, P3733, DOI 10.1073/pnas.84.11.3733; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GENTRY LE, 1987, MOL CELL BIOL, V7, P1585, DOI 10.1128/MCB.7.5.1585; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KING CR, 1985, NUCLEIC ACIDS RES, V13, P8477, DOI 10.1093/nar/13.23.8477; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MROCZKOWSKI B, 1989, MOL CELL BIOL, V9, P2771, DOI 10.1128/MCB.9.7.2771; MROCZKOWSKI B, 1988, P NATL ACAD SCI USA, V85, P126, DOI 10.1073/pnas.85.1.126; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; XU YH, 1984, P NATL ACAD SCI-BIOL, V81, P7308, DOI 10.1073/pnas.81.23.7308	28	33	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1265	1270						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	2392327				2022-12-17	WOS:A1990DX36100022
J	AKIYAMA, T; TOYOSHIMA, K				AKIYAMA, T; TOYOSHIMA, K			MARKED ALTERATION IN PHOSPHORYLATION OF THE RB PROTEIN DURING DIFFERENTIATION OF HUMAN PROMYELOCYTIC HL60 CELLS	ONCOGENE			English	Article											AKIYAMA, T (corresponding author), UNIV TOKYO,INST MED SCI,DEPT ONCOL,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN.							AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BOOKSTEIN R, 1988, P NATL ACAD SCI USA, V85, P2210, DOI 10.1073/pnas.85.7.2210; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; SAKSELA K, 1989, EMBO J, V8, P149, DOI 10.1002/j.1460-2075.1989.tb03359.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SIMMONS DT, 1986, J VIROL, V60, P888, DOI 10.1128/JVI.60.3.888-894.1986; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOKOTA J, 1988, ONCOGENE, V3, P471	28	33	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1990	5	2					179	183						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU029	2320372				2022-12-17	WOS:A1990CU02900003
J	HERZOG, NK; RAMAGLI, LS; ARLINGHAUS, RB				HERZOG, NK; RAMAGLI, LS; ARLINGHAUS, RB			SOMATIC-CELL EXPRESSION OF THE C-MOS PROTEIN	ONCOGENE			English	Article									UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,TEXAS MED CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030	Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center					NCI NIH HHS [CA08570, CA16672, CA45125] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, F32CA008570, R01CA045125] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARLINGHAUS RB, 1985, J GEN VIROL, V66, P1845, DOI 10.1099/0022-1317-66-9-1845; BELLVE AR, 1977, J HISTOCHEM CYTOCHEM, V25, P480, DOI 10.1177/25.7.893996; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GATTONI S, 1982, MOL CELL BIOL, V2, P42, DOI 10.1128/MCB.2.1.42; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; Green M. C., 1981, Genetic variants and strains of the laboratory mouse., P8; HARLOW E, 1988, ANTIBODIES LABORATOR; HERZOG NK, 1988, ONCOGENE, V3, P225; HUNTER T, 1986, ENZYMES, V17, P192; JONES M, 1980, P NATL ACAD SCI-BIOL, V77, P2651, DOI 10.1073/pnas.77.5.2651; KECKWICK RA, 1940, BIOCHEM J, V149, P1248; KESHET E, 1988, ONCOGENE, V2, P235; KLOETZER WS, 1984, VIROLOGY, V138, P143, DOI 10.1016/0042-6822(84)90154-5; KLOETZER WS, 1983, P NATL ACAD SCI-BIOL, V80, P412, DOI 10.1073/pnas.80.2.412; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAQUIRE RT, 1983, P NATL ACAD SCI USA, V80, P1947; MAXWELL SA, 1985, J VIROL, V55, P874, DOI 10.1128/JVI.55.3.874-876.1985; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MINTZ B, 1955, ANAT REC, V122, P443; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; MUTTER GL, 1988, EMBO J, V7, P683, DOI 10.1002/j.1460-2075.1988.tb02863.x; OGISO Y, 1986, BIOCHEM BIOPH RES CO, V140, P477, DOI 10.1016/0006-291X(86)90757-6; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAULES RS, 1988, ONCOGENE, V3, P59; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; PROPST F, 1988, ONCOGENE, V2, P227; ROMRELL LJ, 1976, DEV BIOL, V49, P119, DOI 10.1016/0012-1606(76)90262-1; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SINGH B, 1986, VIROLOGY, V152, P502, DOI 10.1016/0042-6822(86)90156-X; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SWAN D, 1982, J VIROL, V44, P753; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; VANDERHOORN FA, 1984, NUCLEIC ACIDS RES, V12, P2147, DOI 10.1093/nar/12.4.2147; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817	43	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1307	1315						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2530484				2022-12-17	WOS:A1989AX65900006
J	TONIN, PN; YEGER, H; STALLINGS, RL; SRINIVASAN, PR; LEWIS, WH				TONIN, PN; YEGER, H; STALLINGS, RL; SRINIVASAN, PR; LEWIS, WH			AMPLIFICATION OF N-MYC AND ORNITHINE DECARBOXYLASE GENES IN HUMAN NEURO-BLASTOMA AND HYDROXYUREA-RESISTANT HAMSTER-CELL LINES	ONCOGENE			English	Article									HOSP SICK CHILDREN,DEPT PATHOL,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV CALIF LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545; COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); United States Department of Energy (DOE); Los Alamos National Laboratory; Columbia University	TONIN, PN (corresponding author), UNIV TORONTO,DEPT MICROBIOL,150 COLL ST,TORONTO M5S 1A8,ONTARIO,CANADA.		Stallings, Raymond/A-7213-2008					ADAIR GM, 1983, SOMAT CELL GENET, V9, P477, DOI 10.1007/BF01543048; ALT FW, 1985, UCLA S MOL CELLULAR, V20, P233; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CHAMPAGNE E, 1988, EUR J IMMUNOL, V18, P1033, DOI 10.1002/eji.1830180710; DEBATISSE M, 1986, MOL CELL BIOL, V6, P1776, DOI 10.1128/MCB.6.5.1776; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; HAMLIN JL, 1984, INT REV CYTOL, V90, P31, DOI 10.1016/S0074-7696(08)61487-4; KANDA N, 1987, CANCER RES, V47, P3291; KINZLER KW, 1986, P NATL ACAD SCI USA, V83, P1031, DOI 10.1073/pnas.83.4.1031; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; LEWIS WH, 1983, MOL CELL BIOL, V3, P1053, DOI 10.1128/MCB.3.6.1053; MICHALOPOULOS EE, 1985, HUM GENET, V70, P157, DOI 10.1007/BF00273074; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; RUSSELL DH, 1985, DRUG METAB REV, V16, P1, DOI 10.3109/03602538508991430; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P111; SHILOH Y, 1985, P NATL ACAD SCI USA, V82, P3761, DOI 10.1073/pnas.82.11.3761; SHILOH Y, 1986, CANCER RES, V46, P5297; SRINIVASAN PR, 1987, J BIOL CHEM, V262, P12871; STALLINGS RL, 1982, J HERED, V73, P399, DOI 10.1093/oxfordjournals.jhered.a109687; STALLINGS RL, 1981, SOMAT CELL GENET, V7, P683, DOI 10.1007/BF01538757; STARK GM, 1985, ANN REV BIOCH, V53, P447; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TONIN PN, 1987, CYTOGENET CELL GENET, V45, P102, DOI 10.1159/000132438; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; VANDERBLIEK AM, 1986, MOL CELL BIOL, V6, P1671, DOI 10.1128/MCB.6.5.1671; WAHL GM, 1983, MOL CELL BIOL, V3, P2066, DOI 10.1128/MCB.3.11.2066; WINQVIST R, 1986, CYTOGENET CELL GENET, V42, P133, DOI 10.1159/000132266; WRIGHT JA, 1987, SOMAT CELL MOLEC GEN, V13, P155, DOI 10.1007/BF01534695; YANG-FENG T L, 1987, Genomics, V1, P77, DOI 10.1016/0888-7543(87)90108-X	35	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1117	1121						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2780050				2022-12-17	WOS:A1989AM53100010
J	MAY, E; MOURIESSE, H; MAYLEVIN, F; CONTESSO, G; DELARUE, JC				MAY, E; MOURIESSE, H; MAYLEVIN, F; CONTESSO, G; DELARUE, JC			A NEW APPROACH ALLOWING AN EARLY PROGNOSIS IN BREAST-CANCER - THE RATIO OF ESTROGEN-RECEPTOR (ER) LIGAND-BINDING ACTIVITY TO THE ER-SPECIFIC MESSENGER-RNA LEVEL	ONCOGENE			English	Article									INST GUSTAVE ROUSSY,DEPT MED STAT,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT MED,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT ANAT PATHOL C,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,HORMONAL BIOCHEM LAB,F-94805 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	MAY, E (corresponding author), INST RECH SCI CANC,MOLEC ONCOL LAB,7 RUE GOY MOCQUET,F-94802 VILLEJUIF,FRANCE.							AAMDAL S, 1984, CANCER-AM CANCER SOC, V53, P2525, DOI 10.1002/1097-0142(19840601)53:11<2525::AID-CNCR2820531126>3.0.CO;2-8; ADAMI HO, 1985, BREAST CANCER RES TR, V5, P293, DOI 10.1007/BF01806024; ALLEGRA JC, 1979, CANCER TREAT REP, V63, P1271; BARRETTLEE PJ, 1987, CANCER RES, V47, P6653; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; CLARK GM, 1983, NEW ENGL J MED, V309, P1343, DOI 10.1056/NEJM198312013092240; CONTESSO G, 1987, J CLIN ONCOL, V5, P1378, DOI 10.1200/JCO.1987.5.9.1378; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; FISHER B, 1988, J CLIN ONCOL, V6, P1076, DOI 10.1200/JCO.1988.6.7.1076; GARCIA T, 1988, MOL ENDOCRINOL, V2, P785, DOI 10.1210/mend-2-9-785; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HAHNEL R, 1979, CANCER, V44, P671, DOI 10.1002/1097-0142(197908)44:2<671::AID-CNCR2820440238>3.0.CO;2-V; HENRY JA, 1988, BRIT J CANCER, V58, P600, DOI 10.1038/bjc.1988.267; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOWELL A, 1984, LANCET, V1, P588; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KHANDJIAN EW, 1986, MOL BIOL REP, V11, P107, DOI 10.1007/BF00364822; KNIGHT WA, 1977, CANCER RES, V37, P4669; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; MARTIN PM, 1981, EVALUATION MOYENS DI, P263; MCGUIRE WL, 1986, CANCER SURV, V5, P527; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PICHON MF, 1980, CANCER RES, V40, P3357; PIVA R, 1988, BIOCHEM BIOPH RES CO, V155, P943, DOI 10.1016/S0006-291X(88)80587-4; RIO MC, 1987, P NATL ACAD SCI USA, V84, P9243, DOI 10.1073/pnas.84.24.9243; SAMAAN NA, 1981, CANCER, V47, P554, DOI 10.1002/1097-0142(19810201)47:3<554::AID-CNCR2820470322>3.0.CO;2-W; STANFORD JL, 1986, EPIDEMIOL REV, V8, P42, DOI 10.1093/oxfordjournals.epirev.a036295; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889	29	33	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					1037	1042						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2761986				2022-12-17	WOS:A1989AJ29700014
J	TIMMONS, MS; WITTE, ON				TIMMONS, MS; WITTE, ON			STRUCTURAL CHARACTERIZATION OF THE BCR-GENE PRODUCT	ONCOGENE			English	Article									UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MICROBIOL,LOS ANGELES,CA 90024	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; CROCE CM, 1987, P NATL ACAD SCI USA, V84, P7174, DOI 10.1073/pnas.84.20.7174; DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9; FIALKOW PJ, 1981, BLOOD, V58, P158, DOI 10.1182/blood.V58.1.158.158; FROST E, 1978, VIROLOGY, V91, P39, DOI 10.1016/0042-6822(78)90353-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395; KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LIFSHITZ B, 1988, ONCOGENE, V2, P113; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; Maniatis T., 1982, MOL CLONING LABORATO, P86; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; PRIEST JR, 1980, BLOOD, V56, P15; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SANDBERG AA, 1980, CANCER GENET CYTOGEN, V2, P145, DOI 10.1016/0165-4608(80)90058-8; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0	42	33	35	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					559	567						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2657572				2022-12-17	WOS:A1989U768800005
J	STRANGE, R; AGUILARCORDOVA, E; YOUNG, LJT; BILLY, HT; DANDEKAR, S; CARDIFF, RD				STRANGE, R; AGUILARCORDOVA, E; YOUNG, LJT; BILLY, HT; DANDEKAR, S; CARDIFF, RD			HARVEY-RAS MEDIATED NEOPLASTIC DEVELOPMENT IN THE MOUSE MAMMARY-GLAND	ONCOGENE			English	Article											STRANGE, R (corresponding author), UNIV CALIF DAVIS,SCH MED,DEPT PATHOL,DAVIS,CA 95616, USA.							ASCH BB, 1981, P NATL ACAD SCI-BIOL, V78, P5643, DOI 10.1073/pnas.78.9.5643; ASHLEY RL, 1980, CANCER RES, V40, P4232; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1986, CARCINOGENESIS, V7, P1037, DOI 10.1093/carcin/7.7.1037; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CARDIFF RD, 1988, ONCOGENE, V3, P205; CARDIFF RD, 1984, ADV CANCER RES, V42, P167, DOI 10.1016/S0065-230X(08)60458-3; CHAN R, 1986, CANCER RES, V46, P6353; CLAIR T, 1987, CANCER RES, V47, P5290; COOPER GM, 1982, SCIENCE, V217, P801, DOI 10.1126/science.6285471; DANDEKAR S, 1986, MOL CELL BIOL, V6, P4104, DOI 10.1128/MCB.6.11.4104; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; EDWARDS PAW, 1988, ONCOGENE, V2, P402; EHMANN UK, 1987, JNCI-J NATL CANCER I, V78, P751; EHMANN UK, 1984, J CELL BIOL, V98, P1026, DOI 10.1083/jcb.98.3.1026; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; ETHIER SP, 1984, CANCER RES, V44, P4517; FOULDS L, 1969, NEOPLASTIC DEV, V1; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HAGER GL, 1979, J VIROL, V31, P795, DOI 10.1128/JVI.31.3.795-809.1979; HAND PH, 1987, J NATL CANCER I, V79, P59; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEDINA D, 1986, J NATL CANCER I, V76, P1143; Medina D., 1982, MOUSE BIOMEDICAL RES, VIV, P373; Morris D. W., 1987, ADV VIRAL ONCOL, V7, P123; ODONNELL PV, 1985, J VIROL, V55, P500, DOI 10.1128/JVI.55.2.500-503.1985; OWEN RD, 1987, MOL CELL BIOL, V7, P2512, DOI 10.1128/MCB.7.7.2512; PATHAK VK, 1987, J NATL CANCER I, V78, P327; POIRIER Y, 1988, J VIROL, V62, P3985, DOI 10.1128/JVI.62.11.3985-3992.1988; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REDMOND SMS, 1988, ONCOGENE, V2, P259; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SATO Y, 1986, AM J PATHOL, V125, P431; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; TANAKA T, 1986, CANCER RES, V46, P1465; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WONG G, 1986, CANCER RES, V46, P6029; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	45	33	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1989	4	3					309	315						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5676	2784851				2022-12-17	WOS:A1989U567600006
J	KUSHTAI, G; BARZILAY, J; FELDMAN, M; EISENBACH, L				KUSHTAI, G; BARZILAY, J; FELDMAN, M; EISENBACH, L			THE C-FOS PROTO-ONCOGENE IN MURINE 3LL CARCINOMA CLONES CONTROLS THE EXPRESSION OF MHC GENES	ONCOGENE			English	Article									WEIZMANN INST SCI, DEPT CELL BIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science				Eisenbach, Lea R/0000-0002-4816-1968	NATIONAL CANCER INSTITUTE [R01CA028139] Funding Source: NIH RePORTER; NCI NIH HHS [CA 28139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARZILAY J, 1987, LEUKEMIA, V1, P198; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BISHOP JM, 1985, TRENDS GENET, V1, P245, DOI 10.1016/0168-9525(85)90094-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; DANIEL F, 1983, EMBO J, V2, P1061, DOI 10.1002/j.1460-2075.1983.tb01546.x; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EISENBACH L, 1985, TRANSPLANT P, V17, P729; EISENBACH L, 1983, INT J CANCER, V32, P113, DOI 10.1002/ijc.2910320118; EISENBACH L, 1984, INT J CANCER, V34, P567, DOI 10.1002/ijc.2910340421; EISENBACH L, 1986, Cancer Reviews, V5, P1; EISENBACH L, 1986, BIOCH MOL GENETICS C, P167; EISENBACH L, 1986, EXPT MODALITIES CONT, P81; EISENBACH L, 1987, IN PRESS CANCER META; FELDMAN M, 1987, IN PRESS CANCER META; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; ISAKOV N, 1983, J NATL CANCER I, V71, P139; KNOWLES BB, 1980, NATURE, V288, P615, DOI 10.1038/288615a0; KRESS M, 1983, NATURE, V306, P602, DOI 10.1038/306602a0; KRESS M, 1983, J BIOL CHEM, V258, P3929; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LALANNE JL, 1983, NUCLEIC ACIDS RES, V11, P1567, DOI 10.1093/nar/11.5.1567; LEW AM, 1986, P NATL ACAD SCI USA, V83, P6084, DOI 10.1073/pnas.83.16.6084; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MASON I, 1985, DIFFERENTIATION, V30, P76, DOI 10.1111/j.1432-0436.1985.tb00516.x; MILBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789, DOI 10.1073/pnas.83.13.4789; MILLER AD, 1984, CELL, V36, P51; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MULLER R, 1986, EMBO J, V5, P311, DOI 10.1002/j.1460-2075.1986.tb04214.x; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; MULLER R, 1985, BIOCHIM BIOPHYS ACTA, V823, P207; MULLER R, 1984, EMBO J, V3, P1887, DOI 10.1002/j.1460-2075.1984.tb02063.x; MULLER R, 1983, EMBO J, V2, P679, DOI 10.1002/j.1460-2075.1983.tb01484.x; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OZATO K, 1981, J IMMUNOL, V126, P317; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINBERGER C, 1985, NATURE, V318, P670, DOI 10.1038/318670a0; WEISS EH, 1983, NATURE, V301, P671, DOI 10.1038/301671a0; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	62	33	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1988	2	2					119	127						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	2453011				2022-12-17	WOS:A1988M086000004
J	SCHULTZ, AM; COPELAND, T; OROSZLAN, S; RAPP, UR				SCHULTZ, AM; COPELAND, T; OROSZLAN, S; RAPP, UR			IDENTIFICATION AND CHARACTERIZATION OF C-RAF PHOSPHOPROTEINS IN TRANSFORMED MURINE CELLS	ONCOGENE			English	Article									NCI,FREDERICK CANC RES FACIL,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SCHULTZ, AM (corresponding author), NCI,FREDERICK CANC RES FACIL,MOLEC VIROL & CARCINOGENESIS LAB,BRI BASIC RES PROGRAM,FREDERICK,MD 21701, USA.				NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BONNER T, 1984, SCIENCE, V223, P71, DOI 10.1126/science.6691137; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FLORDELLIS CS, 1985, VIROLOGY, V141, P267, DOI 10.1016/0042-6822(85)90257-0; FUKUI M, 1985, P NATL ACAD SCI USA, V82, P5954, DOI 10.1073/pnas.82.17.5954; GRAZIANO SL, 1987, CANCER RES, V47, P2148; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; INOUE M, 1977, J BIOL CHEM, V252, P7610; ISHIKAWA F, 1986, JPN J CANCER RES, V77, P1183; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; KESKIOJA J, 1982, J CELL BIOCHEM, V20, P139, DOI 10.1002/jcb.240200206; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOLCH W, IN PRESS BIOCH BIOPH; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOLDERS H, 1985, EMBO J, V4, P693, DOI 10.1002/j.1460-2075.1985.tb03685.x; MUELLER R, 1984, EMBO (European Molecular Biology Organization) Journal, V3, P1121; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PATCHINSKY T, 1986, MOL CELL BIOL, V6, P739; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; PERINI F, 1979, ANAL BIOCHEM, V94, P431, DOI 10.1016/0003-2697(79)90386-5; RAPP UR, 1975, VIROLOGY, V65, P392, DOI 10.1016/0042-6822(75)90045-8; RAPP UR, 1985, RECENT RES CANCER, V99, P221; RAPP UR, 1980, P NATL ACAD SCI-BIOL, V77, P624, DOI 10.1073/pnas.77.1.624; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1983, J VIROL, V45, P914, DOI 10.1128/JVI.45.3.914-924.1983; RAPP UR, 1983, J VIROL, V45, P755, DOI 10.1128/JVI.45.2.755-765.1983; SARIBAN E, 1987, BLOOD, V69, P1437; SCHULTZ A, 1984, VIROLOGY, V133, P431, DOI 10.1016/0042-6822(84)90409-4; SCHULTZ AM, 1983, J VIROL, V46, P355, DOI 10.1128/JVI.46.2.355-361.1983; SCHULTZ AM, 1984, VIROLOGY, V135, P417, DOI 10.1016/0042-6822(84)90197-1; SCHULTZ AM, 1979, J VIROL, V30, P255, DOI 10.1128/JVI.30.1.255-266.1979; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; TAHIRA T, 1987, NUCLEIC ACIDS RES, V15, P4809, DOI 10.1093/nar/15.12.4809; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TEYSSIER JR, 1986, J NATL CANCER I, V77, P1187; YANG JC, 1982, ANAL BIOCHEM, V122, P360, DOI 10.1016/0003-2697(82)90295-0; YOSHIDA MA, 1986, CANCER RES, V46, P2139	47	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					187	193						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	3285297				2022-12-17	WOS:A1988M086000013
J	HINZPETER, M; DEPPERT, W				HINZPETER, M; DEPPERT, W			ANALYSIS OF BIOLOGICAL AND BIOCHEMICAL PARAMETERS FOR CHROMATIN AND NUCLEAR MATRIX ASSOCIATION OF SV40 LARGE T-ANTIGEN IN TRANSFORMED-CELLS	ONCOGENE			English	Article									UNIV ULM,DEPT BIOCHEM,POB 4066,D-7900 ULM,FED REP GER	Ulm University								BEREZNEY R, 1984, CHROMOSOMAL NONHISTO, V4, P119; BOURRE F, 1983, NATURE, V305, P68, DOI 10.1038/305068a0; BRADLEY MK, 1982, CELL, V28, P125, DOI 10.1016/0092-8674(82)90382-8; BURGER C, 1983, VIROLOGY, V126, P19, DOI 10.1016/0042-6822(83)90459-2; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUTEL JS, 1986, BIOCHIM BIOPHYS ACTA, V865, P171, DOI 10.1016/0304-419X(86)90027-2; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1979, NATURE, V277, P322, DOI 10.1038/277322a0; DEPPERT W, 1980, VIROLOGY, V104, P497, DOI 10.1016/0042-6822(80)90353-0; DEPPERT W, 1986, NUCLEOCYTOPLASMATIC, P199; DORN A, 1982, EUR J BIOCHEM, V128, P53; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; FANNING E, 1983, EMBO J, V1, P1023; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; GRUSS C, 1984, J VIROL, V50, P943, DOI 10.1128/JVI.50.3.943-946.1984; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; HINZPETER M, 1986, VIROLOGY, V148, P159, DOI 10.1016/0042-6822(86)90411-3; JONES KA, 1984, CELL, V36, P155, DOI 10.1016/0092-8674(84)90084-9; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KIT S, 1969, INT J CANCER, V4, P348; KLOCKMANN U, 1983, FEBS LETT, V151, P257, DOI 10.1016/0014-5793(83)80081-7; KLOCKMANN U, 1983, EMBO J, V2, P1151, DOI 10.1002/j.1460-2075.1983.tb01560.x; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1985, PROC R SOC SER B-BIO, V226, P25, DOI 10.1098/rspb.1985.0077; LANFORD RE, 1985, MOL CELL BIOL, V5, P1043, DOI 10.1128/MCB.5.5.1043; MARCHIONNI MA, 1981, CELL, V28, P245; MARTIN RG, 1977, CELL, V11, P859, DOI 10.1016/0092-8674(77)90297-5; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; OREN M, 1980, P NATL ACAD SCI-BIOL, V77, P220, DOI 10.1073/pnas.77.1.220; PAUCHA E, 1986, J VIROL, V57, P50, DOI 10.1128/JVI.57.1.50-64.1986; PINTEL D, 1981, J VIROL, V38, P518, DOI 10.1128/JVI.38.2.518-528.1981; POPE JH, 1964, J EXP MED, V120, P121, DOI 10.1084/jem.120.2.121; RAPP F, 1964, P SOC EXP BIOL MED, V116, P1131, DOI 10.3181/00379727-116-29472; Rigby P. W. J., 1983, ADV VIRAL ONCOL, V3, P31; RIGBY PWJ, 1985, PROC R SOC SER B-BIO, V226, P15, DOI 10.1098/rspb.1985.0076; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHEIDTMANN KH, 1984, J VIROL, V50, P1; SCHURMANN C, 1985, VIROLOGY, V146, P1, DOI 10.1016/0042-6822(85)90047-9; SCHUTZBANK T, 1982, CELL, V30, P481, DOI 10.1016/0092-8674(82)90245-8; SOPRANO KJ, 1981, VIROLOGY, V109, P27; SOULE HR, 1979, J VIROL, V30, P523, DOI 10.1128/JVI.30.2.523-532.1979; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STAUFENBIEL M, 1984, J CELL BIOL, V98, P1886, DOI 10.1083/jcb.98.5.1886; STRINGER JR, 1982, J VIROL, V42, P854, DOI 10.1128/JVI.42.3.854-864.1982; TEGTMEYE.P, 1971, J VIROL, V8, P516, DOI 10.1128/JVI.8.4.516-524.1971; TJIAN R, 1978, P NATL ACAD SCI USA, V75, P1279, DOI 10.1073/pnas.75.3.1279; TODARO GJ, 1966, SCIENCE, V153, P1252, DOI 10.1126/science.153.3741.1252; VOGT B, 1986, J VIROL, V58, P765, DOI 10.1128/JVI.58.3.765-772.1986; WEBER K, 1975, EXP CELL RES, V95, P111, DOI 10.1016/0014-4827(75)90615-1; WILSON VG, 1982, J VIROL, V44, P458, DOI 10.1128/JVI.44.2.458-466.1982	52	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1987	1	2					119	129						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6352	2830577				2022-12-17	WOS:A1987J635200004
J	Nimmakayala, RK; Leon, F; Rachagani, S; Rauth, S; Nallasamy, P; Marimuthu, S; Shailendra, GK; Chhonker, YS; Chugh, S; Chirravuri, R; Gupta, R; Mallya, K; Prajapati, DR; Lele, SM; Caffrey, TC; Grem, JL; Grandgenett, PM; Hollingsworth, MA; Murry, DJ; Batra, SK; Ponnusamy, MP				Nimmakayala, Rama Krishna; Leon, Frank; Rachagani, Satyanarayana; Rauth, Sanchita; Nallasamy, Palanisamy; Marimuthu, Saravanakumar; Shailendra, Gautam K.; Chhonker, Yashpal S.; Chugh, Seema; Chirravuri, Ramakanth; Gupta, Rohitesh; Mallya, Kavita; Prajapati, Dipakkumar R.; Lele, Subodh M.; C. Caffrey, Thomas; L. Grem, Jean; Grandgenett, Paul M.; Hollingsworth, Michael A.; Murry, Daryl J.; Batra, Surinder K.; Ponnusamy, Moorthy P.			Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							OXIDATIVE-PHOSPHORYLATION; MITOCHONDRIAL BIOGENESIS; TUMOR-GROWTH; IDENTIFICATION; GLIOBLASTOMA; GEMCITABINE; PLASTICITY; RESISTANCE; BIOMARKER	Pancreatic ductal adenocarcinoma (PDAC) metastasizes to distant organs, which is the primary cause of mortality; however, specific features mediating organ-specific metastasis remain unexplored. Emerging evidence demonstrates that cancer stem cells (CSCs) and cellular metabolism play a pivotal role in metastasis. Here we investigated the role of distinct subtypes of pancreatic CSCs and their metabolomic signatures in organ-specific metastatic colonization. We found that PDAC consists of ALDH+/CD133+ and drug-resistant (MDR1+) subtypes of CSCs with specific metabolic and stemness signatures. Human PDAC tissues with gemcitabine treatment, autochthonous mouse tumors from Kras(G12D); Pdx1-Cre (KC) and Kras(G12D); Trp53(R172H); Pdx-1 Cre (KPC) mice, and KPC- Liver/Lung metastatic cells were used to evaluate the CSC, EMT (epithelial-to-mesenchymal transition), and metabolic profiles. A strong association was observed between distinct CSC subtypes and organ-specific colonization. The liver metastasis showed drug-resistant CSC- and EMT-like phenotype with aerobic glycolysis and fatty acid beta-oxidation-mediated oxidative (glyco-oxidative) metabolism. On the contrary, lung metastasis displayed ALDH+/CD133+ and MET-like phenotype with oxidative metabolism. These results were obtained by evaluating FACS-based side population (SP), autofluorescence (AF+) and Alde-red assays for CSCs, and Seahorse-based oxygen consumption rate (OCR), extracellular acidification rate (ECAR), and fatty acid beta-oxidation (FAO)-mediated OCR assays for metabolic features along with specific gene signatures. Further, we developed in vitro human liver and lung PDAC metastasis models by using a combination of liver or lung decellularized scaffolds, a co-culture, and a sphere culture methods. PDAC cells grown in the liver-mimicking model showed the enrichment of MDR1+ and CPT1A+ populations, whereas the PDAC cells grown in the lung-mimicking environment showed the enrichment of ALDH+/CD133+ populations. In addition, we observed significantly elevated expression of ALDH1 in lung metastasis and MDR1/LDH-A expression in liver metastasis compared to human primary PDAC tumors. Our studies elucidate that distinct CSCs adapt unique metabolic signatures for organotropic metastasis, which will pave the way for the development of targeted therapy for PDAC metastasis.	[Nimmakayala, Rama Krishna; Leon, Frank; Rachagani, Satyanarayana; Rauth, Sanchita; Nallasamy, Palanisamy; Marimuthu, Saravanakumar; Shailendra, Gautam K.; Chugh, Seema; Chirravuri, Ramakanth; Gupta, Rohitesh; Mallya, Kavita; Batra, Surinder K.; Ponnusamy, Moorthy P.] Univ Nebraska, Med Ctr, Coll Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Chhonker, Yashpal S.; Murry, Daryl J.] Univ Nebraska, Med Ctr, Coll Pharm, Dept Pharm Practice & Sci, 986145 Nebraska Med Ctr, Omaha, NE 68198 USA; [Prajapati, Dipakkumar R.; Lele, Subodh M.] Univ Nebraska, Coll Med, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [C. Caffrey, Thomas; L. Grem, Jean; Grandgenett, Paul M.; Hollingsworth, Michael A.; Batra, Surinder K.; Ponnusamy, Moorthy P.] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Batra, SK; Ponnusamy, MP (corresponding author), Univ Nebraska, Med Ctr, Coll Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Batra, SK; Ponnusamy, MP (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA.	sbatra@unmc.edu; mpalanim@unmc.edu	Gautam, Shailendra/GLQ-9528-2022; Marimuthu, Saravanakumar/AAJ-2878-2021; Nallasamy, Palanisamy/AAH-7727-2021; Prajapati, Dipakkumar R/AAH-7578-2021; Gautam, Shailendra/ABD-2991-2021; Nimmakayala, Rama Krishna/CAG-5670-2022	Marimuthu, Saravanakumar/0000-0003-3640-5408; Nallasamy, Palanisamy/0000-0001-8962-2487; Prajapati, Dipakkumar R/0000-0001-8954-890X; Gautam, Shailendra/0000-0002-8959-1331; Nimmakayala, Rama Krishna/0000-0003-4637-4828; gupta, rohitesh/0000-0001-8515-5869	National Institutes of Health [P01 CA217798, R01 CA210637, R01 CA183459, R01 CA195586, R01 CA201444, R01 CA228524, U01 CA200466, R01 CA247471, R50CA211462, P50CA12729, U01 CA210240]; Nebraska Department of Health and Human Services [LB595]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nebraska Department of Health and Human Services	We thank Craig Semerad, Victoria B. Smith, and Samantha Wall of the Flow Cytometry Research Facility, University of Nebraska Medical Center, for assisting with flow cytometry. We thank Janice A. Taylor and James R. Talaska of the Advanced Microscopy Core Facility at the University of Nebraska Medical Center for assisting with confocal microscopy. Further, we thank Dr. Kelly Stauch, Seahorse Core director at the University of Nebraska Medical Center, for assisting with Seahorse experiments. We were supported primarily by the following grants from the National Institutes of Health P01 CA217798, R01 CA210637, R01 CA183459, R01 CA195586, R01 CA201444, R01 CA228524, U01 CA200466, R01 CA228524, R01 CA247471, R50CA211462, P50CA12729 and U01 CA210240, and the Nebraska Department of Health and Human Services LB595.	Akada M, 2005, CLIN CANCER RES, V11, P3094, DOI 10.1158/1078-0432.CCR-04-1785; Bhagwandin VJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148807; Celia-Terrassa T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08509-2; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Ciavardelli D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.285; De Luca A, 2015, ONCOTARGET, V6, P14777, DOI 10.18632/oncotarget.4401; Doege H, 2006, GASTROENTEROLOGY, V130, P1245, DOI 10.1053/j.gastro.2006.02.006; Gao WC, 2013, GASTROENTEROLOGY, V145, P636, DOI 10.1053/j.gastro.2013.05.049; Grillet F, 2017, GUT, V66, P1802, DOI 10.1136/gutjnl-2016-311447; Han SH, 2019, AUTOPHAGY, V15, P2076, DOI 10.1080/15548627.2019.1596492; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Duong HQ, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6030052; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Hu J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.72; Huang P, 2008, WORLD J GASTROENTERO, V14, P3903, DOI 10.3748/wjg.14.3903; Jiao L, 2018, AUTOPHAGY, V14, P671, DOI 10.1080/15548627.2017.1381804; Kim MP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020636; Klonisch T, 2008, TRENDS MOL MED, V14, P450, DOI 10.1016/j.molmed.2008.08.003; Lamb R, 2015, ONCOTARGET, V6, P30453, DOI 10.18632/oncotarget.5852; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; Lehuede C, 2016, CANCER RES, V76, P5201, DOI 10.1158/0008-5472.CAN-16-0266; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li CW, 2009, METHODS MOL BIOL, V568, P161, DOI 10.1007/978-1-59745-280-9_10; Liao JQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084941; Lin YH, 2018, HEPATOLOGY, V67, P188, DOI 10.1002/hep.29462; Liou GY, 2019, INT J BIOCHEM CELL B, V106, P1, DOI 10.1016/j.biocel.2018.10.013; Luo M, 2018, CELL METAB, V28, P69, DOI 10.1016/j.cmet.2018.06.006; Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563; Mashimo T, 2014, CELL, V159, P1603, DOI 10.1016/j.cell.2014.11.025; Menendez Javier A, 2014, Oncoscience, V1, P803; Menendez JA, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00262; Miranda-Lorenzo I, 2014, NAT METHODS, V11, P1161, DOI [10.1038/NMETH.3112, 10.1038/nmeth.3112]; Niess H, 2015, TARGET ONCOL, V10, P215, DOI 10.1007/s11523-014-0323-z; Nimmakayala RK, 2019, BBA-REV CANCER, V1871, P50, DOI 10.1016/j.bbcan.2018.10.006; Nimmakayala RK, 2018, GASTROENTEROLOGY, V155, P892, DOI 10.1053/j.gastro.2018.05.041; Pasto A, 2014, ONCOTARGET, V5, P4305, DOI 10.18632/oncotarget.2010; Poruk KE, 2017, CLIN CANCER RES, V23, P2681, DOI 10.1158/1078-0432.CCR-16-1467; Ramamoorthy P, 2019, CANCER RES, V79, P1681, DOI 10.1158/0008-5472.CAN-18-2602; Rasheed ZA, 2010, JNCI-J NATL CANCER I, V102, P340, DOI 10.1093/jnci/djp535; Rawla P, 2019, WORLD J ONCOL, V10, P10, DOI 10.14740/wjon1166; Richard V, 2013, J BIOMED RES INT, V2013, P8; Rubin MA, 2014, CANCER DISCOV, V4, P1262, DOI 10.1158/2159-8290.CD-14-1075; Sancho P, 2015, CELL METAB, V22, P590, DOI 10.1016/j.cmet.2015.08.015; Schild T, 2018, CANCER CELL, V33, P347, DOI 10.1016/j.ccell.2018.02.001; Shukla SK, 2017, CANCER CELL, V32, P71, DOI 10.1016/j.ccell.2017.06.004; Wang TY, 2018, CELL METAB, V27, P136, DOI 10.1016/j.cmet.2017.11.001; Wang YN, 2018, ONCOGENE, V37, P6025, DOI 10.1038/s41388-018-0384-z; Zhou YF, 2011, J BIOL CHEM, V286, P32843, DOI 10.1074/jbc.M111.260935	48	32	32	6	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					215	231		10.1038/s41388-020-01518-2	http://dx.doi.org/10.1038/s41388-020-01518-2		OCT 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33110235				2022-12-17	WOS:000582768100004
J	Li, LN; Liu, J; Xue, HS; Li, CX; Liu, Q; Zhou, YT; Wang, T; Wang, HJ; Qian, HL; Wen, T				Li, Lina; Liu, Jian; Xue, Hongsheng; Li, Chunxiao; Liu, Qun; Zhou, Yantong; Wang, Ting; Wang, Haijuan; Qian, Haili; Wen, Tao			A TGF-beta-MTA1-SOX4-EZH2 signaling axis drives epithelial-mesenchymal transition in tumor metastasis	ONCOGENE			English	Article							TGF-BETA; HEPATOCELLULAR-CARCINOMA; SOX4 EXPRESSION; POOR-PROGNOSIS; CANCER CELLS; MTA1; PROTEIN; EZH2; CONTRIBUTES; PROGRESSION	MTA1, SOX4, EZH2, and TGF-beta are all potent inducers of epithelial-mesenchymal transition (EMT) in cancer; however, the signaling relationship among these molecules in EMT is poorly understood. Here, we investigated the function of MTA1 in cancer cells and demonstrated that MTA1 overexpression efficiently activates EMT. This activation resulted in a significant increase in the migratory and invasive properties of three different cancer cell lines through a common mechanism involving SOX4 activation, screened from a gene expression profiling analysis. We showed that both SOX4 and MTA1 are induced by TGF-beta and both are indispensable for TGF-beta-mediated EMT. Further investigation identified that MTA1 acts upstream of SOX4 in the TGF-beta pathway, emphasizing a TGF-beta-MTA1-SOX4 signaling axis in EMT induction. The histone methyltransferase EZH2, a component of the polycomb (PcG) repressive complex 2 (PRC2), was identified as a critical responsive gene of the TGF-beta-MTA1-SOX4 signaling in three different epithelial cancer cell lines, suggesting that this signaling acts broadly in cancer cells in vitro. The MTA1-SOX4-EZH2 signaling cascade was further verified in TCGA pan-cancer patient samples and in a colon cancer cDNA microarray, and activation of genes in this signaling pathway predicted an unfavorable prognosis in colon cancer patients. Collectively, our data uncover a SOX4-dependent EMT-inducing mechanism underlying MTA1-driven cancer metastasis and suggest a widespread TGF-beta-MTA1-SOX4-EZH2 signaling axis that drives EMT in various cancers. We propose that this signaling may be used as a common therapeutic target to control epithelial cancer metastasis.	[Li, Lina; Liu, Jian; Wen, Tao] Capital Med Univ, Beijing Chao Yang Hosp, Med Res Ctr, Beijing 100020, Peoples R China; [Xue, Hongsheng] Dalian Univ, Dept Thorac Surg, Affiliated Zhongshan Hosp, Dalian 116001, Peoples R China; [Li, Chunxiao; Zhou, Yantong; Wang, Ting; Wang, Haijuan; Qian, Haili] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Mol Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China; [Liu, Qun] Capital Med Univ, Beijing Anzhen Hosp, Dept Obstet & Gynaecol, Beijing 100029, Peoples R China	Capital Medical University; Dalian University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Capital Medical University	Liu, J; Wen, T (corresponding author), Capital Med Univ, Beijing Chao Yang Hosp, Med Res Ctr, Beijing 100020, Peoples R China.; Qian, HL (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Mol Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China.	liujian2004811@126.com; qianhaili001@163.com; wentao5281@163.com	wang, tingting/AAK-2640-2020; Liu, Jian/GQZ-6995-2022	Liu, Jian/0000-0002-8969-8446; qian, haili/0000-0003-0652-4801	National Natural Science Foundation of China [81502384, 81572842, 81672459, 81872280, 81672338]; National Basic Research Program of China (973 Program) [2015CB553904]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-001, 2019-I2M-1-003]; Nonprofit Central Research Institute Fund of Chinese Academy of Medical Sciences [2017PT31029]; Open Issue of State Key Laboratory of Molecular Oncology [SKL-KF-2017-16]; Independent Issue of State Key Laboratory of Molecular Oncology [SKL-2017-16]; Dalian Science and Technology Project [2015E12SF117]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China (973 Program)(National Basic Research Program of China); CAMS Innovation Fund for Medical Sciences (CIFMS); Nonprofit Central Research Institute Fund of Chinese Academy of Medical Sciences; Open Issue of State Key Laboratory of Molecular Oncology; Independent Issue of State Key Laboratory of Molecular Oncology; Dalian Science and Technology Project	This work was financially supported by grants from the National Natural Science Foundation of China (Nos 81502384, 81572842, 81672459, 81872280, 81672338), the National Basic Research Program of China (973 Program) (No. 2015CB553904), the CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2016-I2M-1-001, 2019-I2M-1-003), the Nonprofit Central Research Institute Fund of Chinese Academy of Medical Sciences (No. 2017PT31029), the Open Issue of State Key Laboratory of Molecular Oncology (No. SKL-KF-2017-16), the Independent Issue of State Key Laboratory of Molecular Oncology (No. SKL-2017-16) and Dalian Science and Technology Project (No. 2015E12SF117).	Bin Cho K, 2010, CANCER LETT, V293, P230, DOI 10.1016/j.canlet.2010.01.013; David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009; De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174; Deng L, 2017, ONCOGENE, V36, P3976, DOI 10.1038/onc.2016.491; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Gan L, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-017-0547-3; Guan XM, 2015, ACTA PHARM SIN B, V5, P402, DOI 10.1016/j.apsb.2015.07.005; Hasegawa S, 2016, INT J ONCOL, V48, P145, DOI 10.3892/ijo.2015.3258; Jafarnejad SM, 2010, AM J PATHOL, V177, P2741, DOI 10.2353/ajpath.2010.100377; Jin YJ, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0903-5; Kim IK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42501-6; Koumangoye RB, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0284-y; Kuwahara M, 2012, NAT IMMUNOL, V13, P778, DOI 10.1038/ni.2362; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Li DQ, 2011, P NATL ACAD SCI USA, V108, P8791, DOI 10.1073/pnas.1018389108; Li ZW, 2017, CELL DEATH DIFFER, V24, P59, DOI 10.1038/cdd.2016.95; Lin L, 2016, TUMOR BIOL, V37, P15719, DOI 10.1007/s13277-016-5339-9; Liu J, 2014, CANCER METAST REV, V33, P843, DOI 10.1007/s10555-014-9511-7; Liu J, 2014, ONCOTARGET, V5, P5153, DOI 10.18632/oncotarget.2095; Ma JJ, 2016, TUMOR BIOL, V37, P9077, DOI 10.1007/s13277-015-4555-z; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Pakala SB, 2011, ONCOGENE, V30, P2230, DOI 10.1038/onc.2010.608; Parvani JG, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3466; Sen N, 2014, CANCER METAST REV, V33, P879, DOI 10.1007/s10555-014-9515-3; Shen H, 2015, INT J BIOL SCI, V11, P1363, DOI 10.7150/ijbs.13240; Shi S, 2015, DIS MARKERS, V2015, DOI 10.1155/2015/658141; Song QC, 2019, EXP CELL RES, V382, DOI 10.1016/j.yexcr.2019.05.031; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Theriault C, 2011, GYNECOL ONCOL, V121, P434, DOI 10.1016/j.ygyno.2011.02.020; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Toh Y, 2014, CANCER METAST REV, V33, P891, DOI 10.1007/s10555-014-9516-2; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Wang H, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0680-1; Wang L, 2013, PROSTATE CANCER P D, V16, P301, DOI 10.1038/pcan.2013.25; Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xue HS, 2015, ONCOL REP, V33, P885, DOI 10.3892/or.2014.3671; Yamaguchi H, 2014, CANCER RES TREAT, V46, P209, DOI 10.4143/crt.2014.46.3.209; Yoo YG, 2008, ONCOGENE, V27, P3405, DOI 10.1038/sj.onc.1211000; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Zhang JC, 2012, CANCER RES, V72, P4597, DOI 10.1158/0008-5472.CAN-12-1045; Zhang WC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116634; Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102; Zheng LS, 2017, CANCER RES, V77, P579, DOI 10.1158/0008-5472.CAN-16-1281	48	32	32	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2125	2139		10.1038/s41388-019-1132-8	http://dx.doi.org/10.1038/s41388-019-1132-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31811272				2022-12-17	WOS:000518584000008
J	Seifert, AM; Reiche, C; Heiduk, M; Tannert, A; Meinecke, AC; Baier, S; von Renesse, J; Kahlert, C; Distler, M; Welsch, T; Reissfelder, C; Aust, DE; Miller, G; Weitz, J; Seifert, L				Seifert, Adrian M.; Reiche, Charlotte; Heiduk, Max; Tannert, Anna; Meinecke, Ann-Christin; Baier, Stephanie; von Renesse, Janusz; Kahlert, Christoph; Distler, Marius; Welsch, Thilo; Reissfelder, Christoph; Aust, Daniela E.; Miller, George; Weitz, Juergen; Seifert, Lena			Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels	ONCOGENE			English	Article							T-CELLS; CANCER; EXPRESSION; ONCOGENESIS; SURVIVAL; IMMUNITY	Pancreatic ductal adenocarcinoma (PDAC) responds poorly to checkpoint blockade, such as anti-CTLA-4 and anti-PD-1. Galectin-9, a beta-galactoside-binding lectin, promotes immune suppression through T-cell inhibition, and programming of tolerogenic macrophages. Of all cancers tested, PDAC showed the highest expression of LGALS9 (galectin-9) mRNA. We analyzed formalin-fixed and paraffin-embedded specimens from 83 patients with PDAC stained for galectin-9. Using flow cytometry, we determined galectin-9 expression on immune cells from tumor and matched blood samples from 12 patients with resectable PDAC. Furthermore, we analyzed galectin-9 serum levels by enzyme-linked immunosorbent assay using serum samples from 70 patients with PDAC, from 36 individuals with benign pancreatic disease, and from 28 healthy controls. Galectin-9 was highly expressed in human PDAC compared with normal pancreas and present on both tumor and immune cells. Tumor-infiltrating immune cells, especially CD3(+) T cells, showed upregulation of galectin-9 compared with immune cells from matched blood. Blood gamma delta T cells from PDAC patients had higher galectin-9 expression than gamma delta T cells from healthy individuals. Galectin-9 polarized macrophages toward a protumoral M2 phenotype leading to suppressed T-cell cytokine secretion. Furthermore, serum concentration of galectin-9 was able to discriminate PDAC from benign pancreatic disease and healthy individuals, and was prognostic for stage IV patients. Galectin-9 is a new biomarker for the detection of PDAC.	[Seifert, Adrian M.; Reiche, Charlotte; Heiduk, Max; Tannert, Anna; Meinecke, Ann-Christin; Baier, Stephanie; von Renesse, Janusz; Kahlert, Christoph; Distler, Marius; Welsch, Thilo; Weitz, Juergen; Seifert, Lena] Univ Dresden, Fac Med, Univ Hosp Carl Gustav Carus, Dept Visceral Thorac & Vasc Surg, Dresden, Germany; [Seifert, Adrian M.; Heiduk, Max; Kahlert, Christoph; Welsch, Thilo; Weitz, Juergen; Seifert, Lena] German Canc Consortium DKTK, Partner Site Dresden, Heidelberg, Germany; [Seifert, Adrian M.; Heiduk, Max; Kahlert, Christoph; Welsch, Thilo; Weitz, Juergen; Seifert, Lena] German Canc Res Ctr, Heidelberg, Germany; [Heiduk, Max] Natl Ctr Tumor Dis NCT, Partner Site Dresden, Dresden, Germany; [Reissfelder, Christoph] Heidelberg Univ, Univ Med Mannheim, Med Fac Mannheim, Dept Surg, Mannheim, Germany; [Aust, Daniela E.] Univ Dresden, Univ Hosp Carl Gustav Carus, Fac Med, Dept Pathol, Dresden, Germany; [Aust, Daniela E.] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, NCT Biobank Dresden, Dresden, Germany; [Miller, George] NYU, Sch Med, Dept Surg, SA Localio Lab, New York, NY USA; [Miller, George] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Carl Gustav Carus University Hospital; New York University; New York University	Seifert, L (corresponding author), Univ Dresden, Fac Med, Univ Hosp Carl Gustav Carus, Dept Visceral Thorac & Vasc Surg, Dresden, Germany.; Seifert, L (corresponding author), German Canc Consortium DKTK, Partner Site Dresden, Heidelberg, Germany.; Seifert, L (corresponding author), German Canc Res Ctr, Heidelberg, Germany.	lena.seifert@ukdd.de	Seifert, Adrian M./AAL-3453-2021	Seifert, Adrian M./0000-0002-5329-3164; Reissfelder, Christoph/0000-0003-4591-1046; Seifert, Lena/0000-0003-4763-8127; Heiduk, Max/0000-0002-7907-4162	Ernst-Jung Stiftung; Monika Kutzner Stiftung; German Research Foundation (DFG); German Cancer Consortium (DKTK); Medical Faculty Carl Gustav Carus TU Dresden; CMCB Light Microscopy Facility of TU Dresden; Projekt DEAL	Ernst-Jung Stiftung; Monika Kutzner Stiftung; German Research Foundation (DFG)(German Research Foundation (DFG)); German Cancer Consortium (DKTK); Medical Faculty Carl Gustav Carus TU Dresden; CMCB Light Microscopy Facility of TU Dresden; Projekt DEAL	This work was supported by the Ernst-Jung Stiftung (LS), the Monika Kutzner Stiftung (LS), the German Research Foundation (DFG; LS), the German Cancer Consortium (DKTK; AMS) and the Medical Faculty Carl Gustav Carus TU Dresden (AMS, LS). We thank the CMCB Light Microscopy Facility of TU Dresden for their support. Open access funding provided by Projekt DEAL.	Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Balli D, 2017, CLIN CANCER RES, V23, P3129, DOI 10.1158/1078-0432.CCR-16-2128; Belo AI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065957; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan A, 2014, CLIN CANCER RES, V20, P5787, DOI 10.1158/1078-0432.CCR-14-0289; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Daley D, 2017, NAT MED, V23, P556, DOI 10.1038/nm.4314; Daley D, 2016, CELL, V166, P1485, DOI 10.1016/j.cell.2016.07.046; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Irie A, 2005, CLIN CANCER RES, V11, P2962, DOI 10.1158/1078-0432.CCR-04-0861; Jiang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081799; Kim J, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah5583; Li H, 2012, HEPATOLOGY, V56, P1342, DOI 10.1002/hep.25777; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Madireddi S, 2014, J EXP MED, V211, P1425, DOI 10.1084/jem.20132687; Maftouh M, 2014, ONCOTARGET, V5, P5335, DOI 10.18632/oncotarget.2104; Martinez-Bosch Neus, 2018, Oncotarget, V9, P32984, DOI 10.18632/oncotarget.26034; Nagahara K, 2008, J IMMUNOL, V181, P7660, DOI 10.4049/jimmunol.181.11.7660; Ohue Y, 2016, CANCER IMMUNOL RES, V4, P1049, DOI 10.1158/2326-6066.CIR-15-0266; Okura R, 2018, ONCOL LETT, V15, P407, DOI 10.3892/ol.2017.7316; Rabinovich GA, 2009, NAT REV IMMUNOL, V9, P338, DOI 10.1038/nri2536; Radon TP, 2015, CLIN CANCER RES, V21, P3512, DOI 10.1158/1078-0432.CCR-14-2467; Roda O, 2009, GASTROENTEROLOGY, V136, P1379, DOI 10.1053/j.gastro.2008.12.039; Royal RE, 2010, J IMMUNOTHER, V33, P828, DOI 10.1097/CJI.0b013e3181eec14c; Seifert AM, 2017, CLIN CANCER RES, V23, P454, DOI 10.1158/1078-0432.CCR-16-1163; Seifert L, 2016, NATURE, V532, P245, DOI 10.1038/nature17403; Shimamura T, 2002, CLIN CANCER RES, V8, P2570; Sideras K, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1273309; Song SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042699; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Wang Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152599; Wu C, 2014, IMMUNITY, V41, P270, DOI 10.1016/j.immuni.2014.06.011; Yadav D, 2013, GASTROENTEROLOGY, V144, P1252, DOI 10.1053/j.gastro.2013.01.068; Yang KS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3226; Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271	36	32	33	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3102	3113		10.1038/s41388-020-1186-7	http://dx.doi.org/10.1038/s41388-020-1186-7		FEB 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32055023	Green Published, hybrid			2022-12-17	WOS:000513314100001
J	Yang, R; Li, XX; Wu, YA; Zhang, GH; Liu, XR; Li, YP; Bao, YH; Yang, WC; Cui, HJ				Yang, Rui; Li, Xiuxiu; Wu, Yanan; Zhang, Guanghui; Liu, Xiaoran; Li, Yanping; Bao, Yonghua; Yang, Wancai; Cui, Hongjuan			EGFR activates GDH1 transcription to promote glutamine metabolism through MEK/ERK/ELK1 pathway in glioblastoma	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; SIGNAL-TRANSDUCTION; THERAPEUTIC TARGET; REDOX HOMEOSTASIS; CELL BIOLOGY; CANCER; ELK-1; RESISTANCE; PROTEIN; GLYCOLYSIS	Cancer metabolism research has recently been revived and its focus expanded from glucose and the Warburg's effects on other nutrients, such as glutamine. The underlying mechanism of oncogenic alterations of glutaminolysis remains unclear. Genetic alterations of EGFR are observed in similar to 50% of glioblastoma (GBM) patients, and have been found to play important roles in the metabolic abnormalities of GBM. In this study, we found that glutamine metabolism was upregulated after EGFR activation in a GDH1 (glutamate dehydrogenase 1)-dependent manner. Knockdown of GDH1 significantly reduced the cell proliferation, colony formation and tumorigenesis abilities of glioblastoma cells. Furthermore, we showed that GDH1-mediated glutaminolysis was involved in EGF-promoted cell proliferation. EGFR triggered the phosphorylation of ELK1 at Ser 383 through activating MEK/ERK signaling. Phosphorylated ELK1 enriched in the promoter of GDH1 to activate the transcription of GDH1, which then promoted glutamine metabolism. In addition, EGFR activation did not accelerate glutaminolysis in ELK1 knockdown or ELK1 Ser383-mutated cells. Collectively, our findings indicate that EGFR phosphorylates ELK1 to activate GDH1 transcription and glutaminolysis through MEK/ERK pathway, providing new insight into oncogenic alterations of glutamine metabolism.	[Yang, Rui; Liu, Xiaoran; Li, Yanping; Bao, Yonghua; Yang, Wancai] Jining Med Univ, Inst Precis Med, Key Lab Precis Oncol Shandong Higher Educ, Jining, Peoples R China; [Yang, Rui; Wu, Yanan; Zhang, Guanghui; Cui, Hongjuan] Southwest Univ, State Key Lab Silkworm Genome Biol, Chongqing, Peoples R China; [Li, Xiuxiu] Second Peoples Hosp Liaocheng, Dept Pharm, Liaocheng, Shandong, Peoples R China; [Zhang, Guanghui; Cui, Hongjuan] Southwest Univ, Engn Res Ctr Canc Biomed & Translat Med, Ctr Canc, Med Res Inst, Chongqing, Peoples R China; [Yang, Wancai] Univ Illinois, Dept Pathol, Chicago, IL USA	Jining Medical University; Southwest University - China; Southwest University - China; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Yang, R (corresponding author), Jining Med Univ, Inst Precis Med, Key Lab Precis Oncol Shandong Higher Educ, Jining, Peoples R China.; Yang, R; Cui, HJ (corresponding author), Southwest Univ, State Key Lab Silkworm Genome Biol, Chongqing, Peoples R China.; Cui, HJ (corresponding author), Southwest Univ, Engn Res Ctr Canc Biomed & Translat Med, Ctr Canc, Med Res Inst, Chongqing, Peoples R China.	simply_yang@126.com; hcui@swu.edu.cn		Yang, Wancai/0000-0001-7437-9197; Yang, Rui/0000-0002-0525-1728	National Natural Science Foundation of China [81672502, 81872071]; National Natural Science Foundation Cultivation Project of Jining Medical University [600788002]; Jining Medical University [600788001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation Cultivation Project of Jining Medical University; Jining Medical University	This research was supported by the National Natural Science Foundation of China (Nos. 81672502 and 81872071), the grant to the Key Laboratory of Higher Education Institutes of Shandong Province, the National Natural Science Foundation Cultivation Project of Jining Medical University (600788002) and Faculty Startup Fund for RY from Jining Medical University (600788001).	Agnihotri S, 2016, NEURO-ONCOLOGY, V18, P160, DOI 10.1093/neuonc/nov125; Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71; Babic I, 2013, CELL METAB, V17, P1000, DOI 10.1016/j.cmet.2013.04.013; Bhutia YD, 2015, CANCER RES, V75, P1782, DOI 10.1158/0008-5472.CAN-14-3745; Boros J, 2009, GENOME RES, V19, P1963, DOI 10.1101/gr.093047.109; Chai YL, 2001, ONCOGENE, V20, P1357, DOI 10.1038/sj.onc.1204256; Craze ML, 2019, BREAST CANCER RES TR, V174, P79, DOI 10.1007/s10549-018-5060-z; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Fan J, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.65; Felsberg J, 2017, CLIN CANCER RES, V23, P6846, DOI 10.1158/1078-0432.CCR-17-0890; Halatsch ME, 2006, CANCER TREAT REV, V32, P74, DOI 10.1016/j.ctrv.2006.01.003; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hatanpaa KJ, 2010, NEOPLASIA, V12, P675, DOI 10.1593/neo.10688; Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Jameson KL, 2013, NAT MED, V19, P626, DOI 10.1038/nm.3165; Ji HT, 2016, P NATL ACAD SCI USA, V113, P644, DOI 10.1073/pnas.1517112113; Jiang L, 2016, NATURE, V532, P255, DOI 10.1038/nature17393; Jin LT, 2018, MOL CELL, V69, P87, DOI 10.1016/j.molcel.2017.11.025; Jin LT, 2015, CANCER CELL, V27, P257, DOI 10.1016/j.ccell.2014.12.006; KOVACEVIC Z, 1971, BIOCHEM J, V125, P757, DOI 10.1042/bj1250757; Lee JH, 2018, MOL CELL, V70, P197, DOI 10.1016/j.molcel.2018.03.018; Liu F, 2015, MOL CELL, V60, P307, DOI 10.1016/j.molcel.2015.09.002; Ma JL, 2017, CANCER LETT, V411, P117, DOI [10.1016/j.canlet.2017.09.041, 10.1016/j.canlet.2017.10.026]; Mai WX, 2017, NAT MED, V23, P1342, DOI 10.1038/nm.4418; Maicas M, 2013, ONCOGENE, V32, P2069, DOI 10.1038/onc.2012.222; Mayers JR, 2015, TRENDS BIOCHEM SCI, V40, P130, DOI 10.1016/j.tibs.2015.01.004; Michalak KP, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/964321; Nwosu ZC, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0872-6; Ohguchi H, 2017, LEUKEMIA, V31, P2661, DOI 10.1038/leu.2017.141; Ostrom QT, 2018, NEURO-ONCOLOGY, V20, P1, DOI 10.1093/neuonc/noy131; Shao NS, 1998, ONCOGENE, V17, P527, DOI 10.1038/sj.onc.1201931; Stehle P, 2017, CLIN NUTR ESPEN, V17, P75, DOI 10.1016/j.clnesp.2016.09.007; Tanaka K, 2015, J CLIN INVEST, V125, P1591, DOI 10.1172/JCI78239; Tateishi K, 2016, CLIN CANCER RES, V22, P4452, DOI 10.1158/1078-0432.CCR-15-2274; Wang RN, 2011, IMMUNITY, V35, P871, DOI 10.1016/j.immuni.2011.09.021; Wang YQ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02951-4; Yang R, 2016, MOL CANCER THER, V15, P421, DOI 10.1158/1535-7163.MCT-15-0709; Yeh HY, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-70; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zhang XS, 2013, J BIOL CHEM, V288, P32742, DOI 10.1074/jbc.M113.478016	44	32	32	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2975	2986		10.1038/s41388-020-1199-2	http://dx.doi.org/10.1038/s41388-020-1199-2		FEB 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32034306				2022-12-17	WOS:000511752600006
J	Yang, R; Liu, N; Chen, L; Jiang, YQ; Shi, Y; Mao, C; Liu, YT; Wang, M; Lai, WW; Tang, HS; Gao, MH; Xiao, DS; Wang, X; Zhou, H; Tang, CE; Liu, WL; Yu, FL; Cao, Y; Yan, Q; Liu, S; Tao, YG				Yang, Rui; Liu, Na; Chen, Ling; Jiang, Yiqun; Shi, Ying; Mao, Chao; Liu, Yating; Wang, Min; Lai, Weiwei; Tang, Haosheng; Gao, Menghui; Xiao, Desheng; Wang, Xiang; Zhou, Hu; Tang, Can-e; Liu, Wenliang; Yu, Fenglei; Cao, Ya; Yan, Qin; Liu, Shuang; Tao, Yongguang			GIAT4RA functions as a tumor suppressor in non-small cell lung cancer by counteracting Uchl3-mediated deubiquitination of LSH	ONCOGENE			English	Article							LONG NONCODING RNA; LYMPHOID-SPECIFIC HELICASE; GENE-EXPRESSION; METHYLATION PATTERNS; DNA METHYLATION; BINDING-SITE; GINS COMPLEX; AXIS; PHOSPHORYLATION; PROLIFERATION	Elucidating mechanisms in tumor suppressors and epigenetic modifiers are needed to gain insights into the etiology and treatment of cancer, the interplay between long intergenic non-coding RNAs (lncRNAs) and chromatin remodeling remains unclear. Here, we showed that GIAT4RA, a poorly characterized lncRNA LOC102723729, was significantly decreased in lung cancer cells and tissues; while no association was observed with clinical risk factors, expression was linked with clinical stage and lymphatic metastasis. Higher expression of GIAT4RA was linked with overall survival in NSCLC. GIAT4RA inhibited many characteristics of tumorigenesis including cell growth, clonal formation, migration and invasion, epithelial-mesenchymal transition, tumor sphere and tumor growth in vivo. Mechanistically, GIAT4RA was essential for the degradation of chromatin modifier lymphoid-specific helicase (LSH) by counteracting the deubiquintination in proteasome pathway by binding to 227-589 AA of LSH. GIAT4RA interfered with ubiquitin hydrolase Uchl3-mediated interaction and stabilization of LSH. LSH knockdown rescued GIAT4RA-promoted features, and LSH overexpression prevented GIAT4RA-induced phenotypes. Taken together, lncRNA GIAT4RA plays a critical role in NSCLC adenocarcinoma as a ubiquitination regulator and tumor suppressor.	[Yang, Rui; Liu, Na; Chen, Ling; Jiang, Yiqun; Shi, Ying; Mao, Chao; Liu, Yating; Wang, Min; Lai, Weiwei; Tang, Haosheng; Gao, Menghui; Cao, Ya; Tao, Yongguang] Cent S Univ, Xiangya Hosp, Dept Pathol, Key Lab Carcinogenesis & Canc Invas,Minist Educ, Changsha 410078, Hunan, Peoples R China; [Yang, Rui; Liu, Na; Chen, Ling; Jiang, Yiqun; Shi, Ying; Mao, Chao; Liu, Yating; Wang, Min; Lai, Weiwei; Tang, Haosheng; Gao, Menghui; Cao, Ya; Tao, Yongguang] Cent S Univ, Sch Basic Med, Canc Res Inst, Key Lab Carcinogenesis,Minist Hlth, Changsha 410078, Hunan, Peoples R China; [Jiang, Yiqun; Xiao, Desheng] Cent S Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Hunan, Peoples R China; [Wang, Xiang; Liu, Wenliang; Yu, Fenglei; Tao, Yongguang] Cent S Univ, Xiangya Hosp 2, Dept Thorac Surg, Hunan Key Lab Tumor Models & Individualized Med, Changsha, Hunan, Peoples R China; [Zhou, Hu] Chinese Acad Sci, Shanghai Inst Mat Med, 555 Zu Chongzhi Rd,Zhangjiang Hitech Pk, Shanghai 201203, Peoples R China; [Tang, Can-e; Liu, Shuang] Cent S Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Dept Oncol,Inst Med Sci, Changsha 410008, Hunan, Peoples R China; [Yan, Qin] Yale Sch Med, Dept Pathol, New Haven, CT 06520 USA	Central South University; Central South University; Central South University; Central South University; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Central South University; Yale University	Tao, YG (corresponding author), Cent S Univ, Xiangya Hosp, Dept Pathol, Key Lab Carcinogenesis & Canc Invas,Minist Educ, Changsha 410078, Hunan, Peoples R China.; Tao, YG (corresponding author), Cent S Univ, Sch Basic Med, Canc Res Inst, Key Lab Carcinogenesis,Minist Hlth, Changsha 410078, Hunan, Peoples R China.; Tao, YG (corresponding author), Cent S Univ, Xiangya Hosp 2, Dept Thorac Surg, Hunan Key Lab Tumor Models & Individualized Med, Changsha, Hunan, Peoples R China.; Liu, S (corresponding author), Cent S Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Dept Oncol,Inst Med Sci, Changsha 410008, Hunan, Peoples R China.	shuangliu2016@csu.edu.cn; taoyong@csu.edu.cn	Mao, Chao/AAM-6358-2020	, chao/0000-0002-8685-8539; Jiang, Yiqun/0000-0003-3262-9498	National Natural Science Foundation of China [81672787, 81672991, 81874139, 81728014, 81672308]; National Basic Research Program of China [2015CB553903]; Fundamental Research Funds for the Central Universities [2017zzts828, 2017zzts206]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by the National Natural Science Foundation of China (81672787 [YT], 81672991 and 81874139 [SL], 81728014 [QY], 81672308 [XW]), the National Basic Research Program of China (2015CB553903 [YT]), and the Fundamental Research Funds for the Central Universities (2017zzts828 [RY] and 2017zzts206 [NL]).	Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Brunner AL, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-8-r75; Burrage J, 2012, J CELL SCI, V125, P5524, DOI 10.1242/jcs.111252; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Fan T, 2003, CANCER RES, V63, P4677; Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13; Forde PM, 2014, CLIN CANCER RES, V20, P2244, DOI 10.1158/1078-0432.CCR-13-2088; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; He XZ, 2016, CANCER RES, V76, P5743, DOI 10.1158/0008-5472.CAN-16-0268; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Jia JT, 2017, THERANOSTICS, V7, P3920, DOI 10.7150/thno.21389; Jiang Y, 2015, ONCOGENE, V34, P6079, DOI 10.1038/onc.2015.53; Jiang YQ, 2017, THERANOSTICS, V7, P3293, DOI 10.7150/thno.19988; Kamada K, 2007, NAT STRUCT MOL BIOL, V14, P388, DOI 10.1038/nsmb1231; Keren I, 2017, EPIGENETICS-US, V12, P584, DOI 10.1080/15592294.2017.1348446; Keyes WM, 2011, CELL STEM CELL, V8, P164, DOI 10.1016/j.stem.2010.12.009; Kim JY, 2011, FEBS LETT, V585, P1121, DOI 10.1016/j.febslet.2011.03.053; Kong LY, 2006, BIOCHEM BIOPH RES CO, V339, P1204, DOI 10.1016/j.bbrc.2005.11.136; Labib K, 2007, TRENDS CELL BIOL, V17, P271, DOI 10.1016/j.tcb.2007.04.002; Leveille N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7520; Liao CY, 2018, CELL REP, V23, P3352, DOI 10.1016/j.celrep.2018.05.033; Liu S, 2016, CHIN J CANCER, V35, DOI 10.1186/s40880-016-0138-7; Luo KT, 2016, GENE DEV, V30, P2581, DOI 10.1101/gad.289439.116; Mao C, 2018, CANCER RES, V78, P3484, DOI 10.1158/0008-5472.CAN-17-3454; Materne P, 2016, ELIFE, V5, DOI 10.7554/eLife.13500; Myant K, 2011, GENOME RES, V21, P83, DOI 10.1101/gr.108498.110; Reck M, 2013, LANCET, V382, P709, DOI 10.1016/S0140-6736(13)61502-0; Ren JK, 2015, NUCLEIC ACIDS RES, V43, P1444, DOI 10.1093/nar/gku1371; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shi Y, 2012, CARCINOGENESIS, V33, P1468, DOI 10.1093/carcin/bgs171; Shi Y, 2018, CANCER LETT, V422, P81, DOI 10.1016/j.canlet.2018.02.028; Taniue K, 2016, P NATL ACAD SCI USA, V113, P1273, DOI 10.1073/pnas.1500992113; Tao YG, 2011, NUCLEIC ACIDS RES, V39, P9508, DOI 10.1093/nar/gkr611; Tao YG, 2011, P NATL ACAD SCI USA, V108, P5626, DOI 10.1073/pnas.1017000108; Tao YG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009163; von Eyss B, 2012, EMBO J, V31, P972, DOI 10.1038/emboj.2011.451; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Xiao DS, 2017, THERANOSTICS, V7, P132, DOI 10.7150/thno.17032; Yan B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0542-9; Yoon JH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3939; Yu WS, 2014, GENOME RES, V24, P1613, DOI 10.1101/gr.172015.114; Yu WS, 2014, P NATL ACAD SCI USA, V111, P5890, DOI 10.1073/pnas.1320945111; Zemach A, 2013, CELL, V153, P193, DOI 10.1016/j.cell.2013.02.033; Zhang H, 2015, CANCER RES, V75, P2363, DOI 10.1158/0008-5472.CAN-14-2928; Zhang KC, 2017, THERANOSTICS, V7, P213, DOI 10.7150/thno.16044; Zhang PF, 2016, EMBO REP, V17, P1204, DOI 10.15252/embr.201642067; Zhao D, 2017, NATURE, V542, P484, DOI 10.1038/nature21357; Zheng J, 2016, NAT GENET, V48, P747, DOI 10.1038/ng.3568	51	32	34	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2019	38	46					7133	7145		10.1038/s41388-019-0909-0	http://dx.doi.org/10.1038/s41388-019-0909-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JN5HX	31417184				2022-12-17	WOS:000496930500002
J	Ramirez-Moya, J; Wert-Lamas, L; Riesco-Eizaguirre, G; Santisteban, P				Ramirez-Moya, Julia; Wert-Lamas, Leon; Riesco-Eizaguirre, Garcilaso; Santisteban, Pilar			Impaired microRNA processing by DICER1 downregulation endows thyroid cancer with increased aggressiveness	ONCOGENE			English	Article							MOLECULAR PATHOGENESIS; EXPRESSION; BIOGENESIS; MUTATIONS; METASTASIS; ONCOGENES; CELLS; RNAS	The global downregulation of microRNAs (miRNAs) is emerging as a common hallmark of cancer. However, the mechanisms underlying this phenomenon are not well known. We identified that the oncogenic miR-146b-5p attenuates miRNA biosynthesis by targeting DICER1 and reducing its expression. DICER1 overexpression inhibited all the miR-146b-induced aggressive phenotypes in thyroid cells. Systemic injection of an anti-miR-146b in mice with orthotopic thyroid tumors suppressed tumor growth and recovered DICER1 levels. Notably, DICER1 downregulation promoted proliferation, migration, invasion, and epithelial-mesenchymal transition through miRNA downregulation. Our analysis of The Cancer Genome Atlas revealed a general decrease in DICER1 expression in thyroid cancer that was associated with a worse clinical outcome. Administration of the small-molecule enoxacin to promote DICER1 complex activity reduced tumor aggressiveness both in vitro and in vivo. Overall, our data confirm DICER1 as a tumor suppressor and show that oncogenic miR-146b contributes to its downregulation. Moreover, our results highlight a potential therapeutic application of RNA-based therapies including miRNA inhibitors and restoration of the biogenesis machinery, which may provide treatments for thyroid and other cancers.	[Ramirez-Moya, Julia; Wert-Lamas, Leon; Riesco-Eizaguirre, Garcilaso; Santisteban, Pilar] UAM, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain; [Ramirez-Moya, Julia; Riesco-Eizaguirre, Garcilaso; Santisteban, Pilar] Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain; [Wert-Lamas, Leon; Riesco-Eizaguirre, Garcilaso] Hosp Univ Mostoles, Dept Endocrinol & Nutr, Madrid, Spain; [Riesco-Eizaguirre, Garcilaso] Univ Francisco de Vitoria, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Instituto de Salud Carlos III; Universidad Francisco de Vitoria	Santisteban, P (corresponding author), UAM, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain.; Santisteban, P (corresponding author), Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain.	psantisteban@iib.uam.es	Ramírez-Moya, Julia/B-9104-2018; Riesco-Eizaguirre, Garcilaso/O-8750-2015; Wert-Lamas, Leon/ABD-2880-2020	Ramírez-Moya, Julia/0000-0002-2458-2186; Riesco-Eizaguirre, Garcilaso/0000-0002-2608-6397; 	MINECO, Spain [SAF2016-75531-R]; ISCIII, Spain (FEDER) [PI14/01980]; CAM [B2017/BMD-3724]; F-AECC [GCB14142311CRES]; MECD (Spain)	MINECO, Spain; ISCIII, Spain (FEDER); CAM; F-AECC; MECD (Spain)	This work was supported by grants SAF2016-75531-R from MINECO, Spain and PI14/01980 from ISCIII, Spain (FEDER)); B2017/BMD-3724 from CAM and GCB14142311CRES from F-AECC. JR-M holds a FPU fellowship from MECD (Spain).	Adams BD, 2017, J CLIN INVEST, V127, P761, DOI 10.1172/JCI84424; Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Boufraqech M, 2015, CANCER RES, V75, P367, DOI 10.1158/0008-5472.CAN-14-2304; Braun J, 2010, ONCOGENE, V29, P4237, DOI 10.1038/onc.2010.169; Penha RCC, 2017, CELL CYCLE, V16, P2282, DOI 10.1080/15384101.2017.1380127; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Chou CK, 2013, J CLIN ENDOCR METAB, V98, pE196, DOI 10.1210/jc.2012-2666; de Kock L, 2014, J CLIN ENDOCR METAB, V99, pE1072, DOI 10.1210/jc.2013-4206; Emde A, 2015, EMBO J, V34, P2633, DOI 10.15252/embj.201490493; Erler P, 2014, SURGERY, V156, P1342, DOI 10.1016/j.surg.2014.08.007; Frezzetti D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027648; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Fuziwara CS, 2017, MOL CELL ENDOCRINOL, V456, P44, DOI 10.1016/j.mce.2016.12.017; Geraldo MV, 2012, ONCOGENE, V31, P1910, DOI 10.1038/onc.2011.381; Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298; Hammond SM, 2006, CURR OPIN GENET DEV, V16, P4, DOI 10.1016/j.gde.2005.12.005; Haugen BR, 2013, ENDOCR REV, V34, P439, DOI 10.1210/er.2012-1038; Hebrant A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103871; Khan NE, 2017, J CLIN ENDOCR METAB, V102, P1614, DOI 10.1210/jc.2016-2954; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Lim H, 2017, JAMA-J AM MED ASSOC, V317, p[1974, 1338]; Lima CR, 2017, MOL CELL ENDOCRINOL, V456, P62, DOI 10.1016/j.mce.2017.03.015; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Melo S, 2011, P NATL ACAD SCI USA, V108, P4394, DOI 10.1073/pnas.1014720108; Oue T, 2008, PEDIATR BLOOD CANCER, V50, P901, DOI 10.1002/pbc.21265; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Pacifico F, 2010, MOL CELL ENDOCRINOL, V321, P29, DOI 10.1016/j.mce.2009.10.010; Pallante P, 2014, NAT REV ENDOCRINOL, V10, P88, DOI 10.1038/nrendo.2013.223; Ramirez-Moya J, 2018, ONCOGENE, V37, P3369, DOI 10.1038/s41388-017-0088-9; Riesco-Eizaguirre G, 2016, EUR J ENDOCRINOL, V175, pR203, DOI 10.1530/EJE-16-0202; Riesco-Eizaguirre G, 2015, CANCER RES, V75, P4119, DOI 10.1158/0008-5472.CAN-14-3547; Rodriguez W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029929; Rome A, 2008, PEDIATR BLOOD CANCER, V50, P1081, DOI 10.1002/pbc.21431; Rutter MM, 2016, J CLIN ENDOCR METAB, V101, P1, DOI 10.1210/jc.2015-2169; Saiselet M, 2016, ONCOTARGET, V7, P52475, DOI 10.18632/oncotarget.9655; Sastre-Perona A, 2016, ONCOTARGET, V7, P49435, DOI 10.18632/oncotarget.10356; Shan G, 2008, NAT BIOTECHNOL, V26, P933, DOI 10.1038/nbt.1481; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Yan M, 2012, PATHOL ONCOL RES, V18, P343, DOI 10.1007/s12253-011-9450-3; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5	46	32	33	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5486	5499		10.1038/s41388-019-0804-8	http://dx.doi.org/10.1038/s41388-019-0804-8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30967628	Green Published, Green Submitted, hybrid			2022-12-17	WOS:000473842500011
J	Wang, TY; Song, P; Zhong, TT; Wang, XJ; Xiang, XP; Liu, Q; Chen, HY; Xia, T; Liu, H; Niu, YM; Hu, YS; Xu, L; Shao, YK; Zhu, LJ; Qi, HY; Shen, J; Hou, TJ; Fodde, RCRO; Shao, JM				Wang, Tingyang; Song, Ping; Zhong, Tingting; Wang, Xianjun; Xiang, Xueping; Liu, Qian; Chen, Haiyi; Xia, Tian; Liu, Hong; Niu, Yumiao; Hu, Yanshi; Xu, Lei; Shao, Yingkuan; Zhu, Lijun; Qi, Hongyan; Shen, Jing; Hou, Tingjun; Fodde, Riccardo; Shao, Jimin			The inflammatory cytokine IL-6 induces FRA1 deacetylation promoting colorectal cancer stem-like properties	ONCOGENE			English	Article							HISTONE DEACETYLASE; SELF-RENEWAL; C-JUN; CELLS; PROTEIN; NANOG; INTERLEUKIN-6; P53; ACCUMULATION; MACROPHAGES	Colorectal cancer (CRC) has long been known for its tight association with chronic inflammation, thought to play a key role in tumor onset and malignant progression through the modulation of cancer stemness. However, the underlying molecular and cellular mechanisms are still largely elusive. Here we show that the IL-6/STAT3 inflammatory signaling axis induces the deacetylation of FRA1 at the Lys-116 residue located within its DNA-binding domain. The HDAC6 deacetylase underlies this key modification leading to the increase of FRA1 transcriptional activity, the subsequent transactivation of NANOG expression, and the acquisition of stem-like cellular features. As validated in a large (n = 123) CRC cohort, IL-6 secretion was invariably accompanied by increased FRA1 deacetylation at K116 and an overall increase in its protein levels, coincident with malignant progression and poor prognosis. Of note, combined treatment with the conventional cytotoxic drug 5-FU together with Tubastatin A, a HDAC6-specific inhibitor, resulted in a significant in vivo synergistic inhibitory effect on tumor growth through suppression of CRC stemness. Our results reveal a novel transcriptional and posttranslational regulatory cross-talk between inflammation and stemness signaling pathways that underlie self-renewal and maintenance of CRC stem cells and promote their malignant behavior. Combinatorial treatment aimed at the core regulatory mechanisms downstream of IL-6 may offer a novel promising approach for CRC treatment.	[Wang, Tingyang; Song, Ping; Zhong, Tingting; Wang, Xianjun; Xiang, Xueping; Liu, Qian; Xia, Tian; Liu, Hong; Niu, Yumiao; Shao, Yingkuan; Qi, Hongyan; Shen, Jing; Shao, Jimin] Zhejiang Univ, Affiliated Hosp 2, Dept Pathol & Pathophysiol, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Wang, Tingyang; Song, Ping; Zhong, Tingting; Wang, Xianjun; Xiang, Xueping; Liu, Qian; Xia, Tian; Liu, Hong; Niu, Yumiao; Shao, Yingkuan; Qi, Hongyan; Shen, Jing; Shao, Jimin] Zhejiang Univ, Affiliated Hosp 2, Canc Inst, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Wang, Tingyang; Song, Ping; Xiang, Xueping; Shao, Yingkuan; Shao, Jimin] Zhejiang Univ, Sch Med, Key Lab Dis Prote Zhejiang Prov, Key Lab Canc Prevent & Intervent,China Natl Minis, Hangzhou, Zhejiang, Peoples R China; [Wang, Tingyang; Song, Ping; Xiang, Xueping; Shao, Yingkuan; Shao, Jimin] Zhejiang Univ, Sch Med, Res Ctr Air Pollut & Hlth, Hangzhou, Zhejiang, Peoples R China; [Chen, Haiyi; Hou, Tingjun] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou, Zhejiang, Peoples R China; [Hu, Yanshi] Zhejiang Univ, Coll Life Sci, Dept Bioinformat, Hangzhou, Zhejiang, Peoples R China; [Xu, Lei; Hou, Tingjun] Jiangsu Univ Technol, Sch Elect & Informat Engn, Inst Bioinformat & Med Engn, Changzhou, Peoples R China; [Zhu, Lijun] Zhejiang Univ, Affiliated Hosp 1, Key Lab Precis Diag & Treatment Hepatobiliary & P, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Fodde, Riccardo] Erasmus MC, Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands; [Zhong, Tingting] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Pathol, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Liu, Hong] Zhejiang Normal Univ Jinhua Peoples Hosp Joint Ct, Jinhua, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Jiangsu University of Technology; Zhejiang University; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Zhejiang University	Shao, JM (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Dept Pathol & Pathophysiol, Sch Med, Hangzhou, Zhejiang, Peoples R China.; Shao, JM (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Canc Inst, Sch Med, Hangzhou, Zhejiang, Peoples R China.; Shao, JM (corresponding author), Zhejiang Univ, Sch Med, Key Lab Dis Prote Zhejiang Prov, Key Lab Canc Prevent & Intervent,China Natl Minis, Hangzhou, Zhejiang, Peoples R China.; Shao, JM (corresponding author), Zhejiang Univ, Sch Med, Res Ctr Air Pollut & Hlth, Hangzhou, Zhejiang, Peoples R China.; Fodde, RCRO (corresponding author), Erasmus MC, Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands.	r.fodde@erasmusmc.nl; shaojimin@zju.edu.cn	Fodde, Riccardo/AAW-9394-2021; Hou, Tingjun/C-7492-2011; Hu, Yanshi/G-1650-2017; Shao, Yingkuan/AAO-9244-2020	Fodde, Riccardo/0000-0001-9839-4324; Hou, Tingjun/0000-0001-7227-2580; Hu, Yanshi/0000-0003-3219-3778; Shao, Yingkuan/0000-0001-9683-5691	National Natural Science Foundation of China [81572384, 81372138, 81702401, 81771518]; National Key R&D Program of China [2016YFC1303401]; National Science and Technology Major Project of China [2018ZX10302206-006-007]; ZJU funds; Dutch Digestive Foundation [FP 15-09]; Dutch Cancer Society; Erasmus MC [EMCR 2015-8090]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; National Science and Technology Major Project of China; ZJU funds; Dutch Digestive Foundation; Dutch Cancer Society(KWF Kankerbestrijding); Erasmus MC	The authors are grateful to the contribution of the specimen donors. We thank Professor Xin-Hua Feng from Life Sciences Institute and Innovation Center for Cell Signaling Network, Zhejiang University for providing HDAC6 overexpressing plasmids; Professor Qun-Ying Lei from Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University for providing HDAC1-6 overexpressing plasmids; Professor Cheng Qian from the Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University for providing Lv-NANOG, Lv-shNANOG, and Lv-scrambled plasmids; and Professor Chong Liu from the Department of Pathology & Pathophysiology, Zhejiang University School of Medicine for help with immunofluorescence technology. This work was supported by National Natural Science Foundation of China (81572384, 81372138, 81702401 and 81771518), National Key R&D Program of China (2016YFC1303401), and National Science and Technology Major Project of China (2018ZX10302206-006-007). RF is supported by ZJU funds and by the Dutch Digestive Foundation (FP 15-09), Dutch Cancer Society, and the Erasmus MC (EMCR 2015-8090).	Ali I, 2018, CHEM REV, V118, P340, DOI 10.1021/acs.chemrev.7b00181; Belguise K, 2012, ONCOGENE, V31, P4889, DOI 10.1038/onc.2011.659; Butler KV, 2010, J AM CHEM SOC, V132, P10842, DOI 10.1021/ja102758v; Canettieri G, 2010, NAT CELL BIOL, V12, P132, DOI 10.1038/ncb2013; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Grivennikov SI, 2011, ANN RHEUM DIS, V70, pI104, DOI 10.1136/ard.2010.140145; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He WZ, 2018, CANCER RES, V78, P3293, DOI 10.1158/0008-5472.CAN-17-3131; Hong A, 2018, CANCER DISCOV, V8, P74, DOI 10.1158/2159-8290.CD-17-0682; Hou T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089575; Hou TJ, 2012, J PROTEOME RES, V11, P2982, DOI 10.1021/pr3000688; Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a; Ibrahim EE, 2012, STEM CELLS, V30, P2076, DOI 10.1002/stem.1182; Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613; Kakumoto K, 2006, P NATL ACAD SCI USA, V103, P5490, DOI 10.1073/pnas.0601222103; Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j; Kryczek I, 2014, IMMUNITY, V40, P772, DOI 10.1016/j.immuni.2014.03.010; Lasry A, 2016, NAT IMMUNOL, V17, P230, DOI 10.1038/ni.3384; Lau EYT, 2016, CELL REP, V15, P1175, DOI 10.1016/j.celrep.2016.04.019; Lee TKW, 2011, CELL STEM CELL, V9, P50, DOI 10.1016/j.stem.2011.06.005; Liu H, 2015, CARCINOGENESIS, V36, P459, DOI 10.1093/carcin/bgv017; Liu YJ, 2012, J BIOL CHEM, V287, P29168, DOI 10.1074/jbc.M112.371120; Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255; Pakay JL, 2012, ONCOGENE, V31, P1817, DOI 10.1038/onc.2011.375; Qi J, 2015, CELL STEM CELL, V17, P597, DOI 10.1016/j.stem.2015.08.004; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Ryu HW, 2017, CANCER LETT, V391, P162, DOI 10.1016/j.canlet.2017.01.033; Salomon-Ferrer R, 2013, WIRES COMPUT MOL SCI, V3, P198, DOI 10.1002/wcms.1121; Sayan AE, 2012, ONCOGENE, V31, P1493, DOI 10.1038/onc.2011.336; Sun HY, 2014, PHYS CHEM CHEM PHYS, V16, P22035, DOI 10.1039/c4cp03179b; Sveen A, 2011, GENOME MED, V3, DOI 10.1186/gm248; Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005; van der Zee M, 2015, CANCER RES, V75, P3608, DOI 10.1158/0008-5472.CAN-14-2498; Vries RGJ, 2001, EMBO J, V20, P6095, DOI 10.1093/emboj/20.21.6095; Wan SS, 2014, GASTROENTEROLOGY, V147, P1393, DOI 10.1053/j.gastro.2014.08.039; Wang DZ, 2015, GASTROENTEROLOGY, V149, P1884, DOI 10.1053/j.gastro.2015.07.064; Wang DL, 2016, NATURE, V538, P118, DOI 10.1038/nature19759; Wang QS, 2010, CELL RES, V20, P701, DOI 10.1038/cr.2010.52; Xu L, 2013, J PHYS CHEM B, V117, P8408, DOI 10.1021/jp404160y; Xu RH, 2008, CELL STEM CELL, V3, P196, DOI 10.1016/j.stem.2008.07.001; Yang W, 2018, CANCER LETT, V415, P164, DOI 10.1016/j.canlet.2017.12.005; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Yao C, 2016, STEM CELLS, V34, P820, DOI 10.1002/stem.2320; Yoon DS, 2014, STEM CELLS, V32, P3219, DOI 10.1002/stem.1811; Zerbini LF, 2003, CANCER RES, V63, P2206; Zhang J, 2013, ONCOGENE, V32, P4397, DOI 10.1038/onc.2012.461	49	32	35	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					4932	4947		10.1038/s41388-019-0763-0	http://dx.doi.org/10.1038/s41388-019-0763-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30804456	Green Published, hybrid			2022-12-17	WOS:000472145900004
J	Bagati, A; Moparthy, S; Fink, EE; Bianchi-Smiraglia, A; Yun, DH; Kolesnikova, M; Udartseva, OO; Wolff, DW; Roll, MV; Lipchick, BC; Han, ZN; Kozlova, NI; Jowdy, P; Berman, AE; Box, NF; Rodriguez, C; Bshara, W; Kandel, ES; Soengas, MS; Paragh, G; Nikiforov, MA				Bagati, Archis; Moparthy, Sudha; Fink, Emily E.; Bianchi-Smiraglia, Anna; Yun, Dong Hyun; Kolesnikova, Masha; Udartseva, Olga O.; Wolff, David W.; Roll, Matthew V.; Lipchick, Brittany C.; Han, Zhannan; Kozlova, Nadezhda I.; Jowdy, Peter; Berman, Albert E.; Box, Neil F.; Rodriguez, Cesar; Bshara, Wiam; Kandel, Eugene S.; Soengas, Maria S.; Paragh, Gyorgy; Nikiforov, Mikhail A.			KLF9-dependent ROS regulate melanoma progression in stage-specific manner	ONCOGENE			English	Article							KRUPPEL-LIKE FACTORS; OXIDATIVE STRESS; MITOCHONDRIAL THIOREDOXIN; KEAP1-NRF2 PATHWAY; KINASE; SENESCENCE; BRAF; PHOTOPROTECTION; DYSREGULATION; ACTIVATION	Although antioxidants promote melanoma metastasis, the role of reactive oxygen species (ROS) in other stages of melanoma progression is controversial. Moreover, genes regulating ROS have not been functionally characterized throughout the entire tumor progression in mouse models of cancer. To address this question, we crossed mice-bearing knock-out of Klf9, an ubiquitous transcriptional regulator of oxidative stress, with two conditional melanocytic mouse models: Braf(CA) mice, where Braf(V600E) causes premalignant melanocytic hyperplasia, and Braf(CA)/Pten(-/-) mice, where Braf(V600E) and loss of Pten induce primary melanomas and metastases. Klf9 deficiency inhibited premalignant melanocytic hyperplasia in Braf(CA) mice but did not affect formation and growth of Braf(CA)/Pten(-/-) primary melanomas. It also, as expected, promoted Braf(CA)/Pten(-/-) metastasis. Treatment with antioxidant N-acetyl cysteine phenocopied loss of Klf9 including suppression of melanocytic hyperplasia. We were interested in a different role of Klf9 in regulation of cell proliferation in Braf(CA) and Braf(CA)/Pten(-/-) melanocytic cells. Mechanistically, we demonstrated that BRAF(V600E) signaling transcriptionally upregulated KLF9 and that KLF9-dependent ROS were required for full-scale activation of ERK1/2 and induction of cell proliferation by BRAF(V600E). PTEN depletion in BRAF(V600E)-melanocytes did not further activate ERK1/2 and cell proliferation, but rendered these phenotypes insensitive to KLF9 and ROS. Our data identified an essential role of KLF9-dependent ROS in BRAF(V600E) signaling in premalignant melanocytes, offered an explanation to variable role of ROS in premalignant and transformed melanocytic cells and suggested a novel mechanism for suppression of premalignant growth by topical antioxidants.	[Bagati, Archis; Moparthy, Sudha; Fink, Emily E.; Bianchi-Smiraglia, Anna; Yun, Dong Hyun; Kolesnikova, Masha; Udartseva, Olga O.; Wolff, David W.; Roll, Matthew V.; Lipchick, Brittany C.; Han, Zhannan; Jowdy, Peter; Kandel, Eugene S.; Nikiforov, Mikhail A.] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; [Wolff, David W.; Roll, Matthew V.; Lipchick, Brittany C.; Han, Zhannan; Rodriguez, Cesar; Nikiforov, Mikhail A.] Wake Forest Univ, Dept Canc Biol, Comprehens Canc Ctr, Winston Salem, NC 27109 USA; [Lipchick, Brittany C.] Wake Forest Univ, Dept Hematol & Oncol, Comprehens Canc Ctr, Winston Salem, NC 27109 USA; [Kozlova, Nadezhda I.; Berman, Albert E.] Orekhovich Inst Biomed Chem, Moscow 119121, Russia; [Box, Neil F.] Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO USA; [Bshara, Wiam] Roswell Pk Canc Inst, Dept Pathol Resource Network, Buffalo, NY 14263 USA; [Soengas, Maria S.] Spanish Natl Canc Res Ctr CNIO, Mol Oncol Programme, Melanoma Lab, Madrid 28029, Spain; [Paragh, Gyorgy] Roswell Pk Canc Inst, Dept Dermatol, Buffalo, NY 14263 USA; [Bagati, Archis] Dana Farber Canc Inst, Dept Canc Immunol & Virol, Smith Bldg,SM-0728,450 Brookline Ave, Boston, MA 02215 USA	Roswell Park Cancer Institute; Wake Forest University; Wake Forest University; Russian Academy of Medical Sciences; Institute of Biomedical Chemistry; University of Colorado System; University of Colorado Anschutz Medical Campus; Roswell Park Cancer Institute; Centro Nacional de Investigaciones Oncologicas (CNIO); Roswell Park Cancer Institute; Harvard University; Dana-Farber Cancer Institute	Nikiforov, MA (corresponding author), Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA.; Nikiforov, MA (corresponding author), Wake Forest Univ, Dept Canc Biol, Comprehens Canc Ctr, Winston Salem, NC 27109 USA.	mnikifor@wakehealth.edu	Udartseva, Olga/AAB-6216-2020; Soengas, Maria S/H-6455-2015; EBerman, Albert/F-5042-2017; Kozlova, Nadezda/ABD-7878-2020	Udartseva, Olga/0000-0003-2896-2300; Soengas, Maria S/0000-0003-0612-6299; Kolesnikova, Masha/0000-0001-7803-9632; Fink, Emily/0000-0003-2738-5732; Wolff, David/0000-0003-4201-3857	NCI [CA190533, CA193981, CA220096, CA224434, P30CA16056]; Program for Basic Research of Russian State Academies of Sciences; Russian Foundation for Basic Research [17-04-00716]; NATIONAL CANCER INSTITUTE [R01CA190533, P30CA016056, R01CA193981, R01CA224434, R21CA220096] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Program for Basic Research of Russian State Academies of Sciences; Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work has been supported by the following NCI grants to MAN: CA190533, CA193981, CA220096, CA224434, by NCI P30CA16056 to Roswell Park Cancer Institute and partially supported by the Program for Basic Research of Russian State Academies of Sciences for 2013-2020, and by the Russian Foundation for Basic Research (grant No. 17-04-00716).	Arner ESJ, 2009, BBA-GEN SUBJECTS, V1790, P495, DOI 10.1016/j.bbagen.2009.01.014; Bonett RM, 2009, ENDOCRINOLOGY, V150, P1757, DOI 10.1210/en.2008-1441; Bonham CA, 2009, J BIOL CHEM, V284, P22853, DOI 10.1074/jbc.M109.038612; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chen Y, 2006, FEBS LETT, V580, P6596, DOI 10.1016/j.febslet.2006.11.007; Chu JLY, 2016, CELL REP, V17, P374, DOI 10.1016/j.celrep.2016.09.006; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Cymerman RM, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw121; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Day CP, 2017, LAB INVEST, V97, P698, DOI 10.1038/labinvest.2016.155; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Denat L, 2014, J INVEST DERMATOL, V134, P1512, DOI 10.1038/jid.2014.65; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Ekwueme DU, 2011, J AM ACAD DERMATOL, V65, pS133, DOI 10.1016/j.jaad.2011.04.036; GAYNOR R, 1980, NATURE, V286, P400, DOI 10.1038/286400a0; Good KL, 2007, P NATL ACAD SCI USA, V104, P13420, DOI 10.1073/pnas.0703872104; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Jenkins NC, 2011, ONCOGENE, V30, P265, DOI 10.1038/onc.2010.419; Jiang K, 2000, NAT IMMUNOL, V1, P419, DOI 10.1038/80859; Kaneko T, 1996, MUTAT RES-DNAGING G, V316, P277, DOI 10.1016/S0921-8734(96)90010-7; Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001; Kidger AM, 2016, SEMIN CELL DEV BIOL, V50, P125, DOI 10.1016/j.semcdb.2016.01.009; Kirsch J, 2016, ARTERIOSCL THROM VAS, V36, P1891, DOI 10.1161/ATVBAHA.116.307843; Le Gal K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad3740; Leinonen HM, 2014, ADV CANCER RES, V122, P281, DOI 10.1016/B978-0-12-420117-0.00008-6; Lin JY, 2003, J AM ACAD DERMATOL, V48, P866, DOI 10.1067/mjd.2003.425; Linos E, 2009, J INVEST DERMATOL, V129, P1666, DOI 10.1038/jid.2008.423; Matsui MS, 2009, J INVEST DERM SYMP P, V14, P56, DOI 10.1038/jidsymp.2009.14; McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Morita M, 2003, MOL CELL BIOL, V23, P2489, DOI 10.1128/MCB.23.7.2489-2500.2003; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Qiao F, 2016, MOL CARCINOGEN, V55, P280, DOI 10.1002/mc.22277; Sander CS, 2003, BRIT J DERMATOL, V148, P913, DOI 10.1046/j.1365-2133.2003.05303.x; Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034; Simmen FA, 2007, AM J PHYSIOL-GASTR L, V292, pG1757, DOI 10.1152/ajpgi.00013.2007; Simon JD, 2009, PIGM CELL MELANOMA R, V22, P563, DOI 10.1111/j.1755-148X.2009.00610.x; Son Yong, 2011, J Signal Transduct, V2011, P792639, DOI 10.1155/2011/792639; Tetreault MP, 2013, NAT REV CANCER, V13, P701, DOI 10.1038/nrc3582; Tucker MA, 1997, JAMA-J AM MED ASSOC, V277, P1439, DOI 10.1001/jama.277.18.1439; Ying MY, 2011, STEM CELLS, V29, P20, DOI 10.1002/stem.561; Zhuang D, 2008, ONCOGENE, V27, P6623, DOI 10.1038/onc.2008.258; Zucker SN, 2014, MOL CELL, V53, P916, DOI 10.1016/j.molcel.2014.01.033; Zuo L, 2015, ACTA PHYSIOL, V214, P329, DOI 10.1111/apha.12515	46	32	33	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3585	3597		10.1038/s41388-019-0689-6	http://dx.doi.org/10.1038/s41388-019-0689-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30664687	Green Accepted			2022-12-17	WOS:000467379600003
J	White, SM; Murakami, S; Yi, CL				White, Shannon M.; Murakami, Shigekazu; Yi, Chunling			The complex entanglement of Hippo-Yap/Taz signaling in tumor immunity	ONCOGENE			English	Review							CANCER-ASSOCIATED FIBROBLASTS; INNATE IMMUNITY; YAP; MST1; PATHWAY; CELLS; PROLIFERATION; COMBINATION; ACTIVATION; EXPRESSION	The Hippo-Yap/Taz pathway, originally identified as a central developmental regulator of organ size, has been found perturbed in many types of human tumors, and linked to tumor growth, survival, evasion, metastasis, stemness, and drug resistance. Beside these tumor-cell-intrinsic functions, Hippo signaling also plays important immune-regulatory roles. In this review, we will summarize and discuss recent breakthroughs in our understanding of how various components of the HippoYap/Taz pathway influence the tumor immune microenvironment, including their effects on the tumor secretome and immune infiltrates, their roles in regulating crosstalk between tumor cells and T cells, and finally their intrinsic functions in various types of innate and adaptive immune cells. While further research is needed to integrate and reconcile existing findings and to discern the overall effects of Hippo signaling on tumor immunity, it is clear that Hippo signaling functions as a key bridge connecting tumor cells with both the adaptive and innate immune systems. Thus, all future therapeutic development against the Hippo-Yap/Taz pathway should take into account their multi-faceted roles in regulating tumor immunity in addition to their growth-regulatory functions. Given that immune therapies have become the mainstay of cancer treatment, it is also important to pursue how to manipulate Hippo signaling to boost response or overcome resistance to existing immune therapies.	[White, Shannon M.; Murakami, Shigekazu; Yi, Chunling] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA	Georgetown University	Yi, CL (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.	cy232@georgetown.edu		Morgan, Shannon/0000-0002-1351-943X	NIH [R01CA187090]; Toulmin Pilot Award; Cancer Center Support Grant [CA051008]; National Science Foundation Graduate Research Fellowship (NSFGRF) [2018265935]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Toulmin Pilot Award; Cancer Center Support Grant; National Science Foundation Graduate Research Fellowship (NSFGRF)(National Science Foundation (NSF))	Research in Yi lab is currently supported by NIH (R01CA187090), Toulmin Pilot Award, Sher Grant and Cancer Center Support Grant (CA051008). Shannon White is a current recipient of National Science Foundation Graduate Research Fellowship (NSFGRF#2018265935).	Abdollahpour H, 2012, BLOOD, V119, P3450, DOI 10.1182/blood-2011-09-378158; Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042; Bai XM, 2016, BLOOD ADV, V1, P219, DOI 10.1182/bloodadvances.2016000588; Boro M, 2016, SCI REP-UK, V6, DOI 10.1038/srep37695; Calvo F, 2013, NAT CELL BIOL, V15, P637, DOI 10.1038/ncb2756; Cen XH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00878; Choi J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008011; Cisowski J, 2016, ONCOGENE, V35, P1328, DOI 10.1038/onc.2015.186; Dong YL, 2009, J IMMUNOL, V183, P3865, DOI 10.4049/jimmunol.0900678; Du XR, 2018, NATURE, V558, P141, DOI 10.1038/s41586-018-0177-0; Du XR, 2014, J IMMUNOL, V192, P1525, DOI 10.4049/jimmunol.1301060; Dubey SK, 2018, MOL NEUROBIOL, V55, P1193, DOI 10.1007/s12035-017-0388-7; Ehmer U, 2014, CELL REP, V8, P370, DOI 10.1016/j.celrep.2014.06.025; Elosegui-Artola A, 2016, NAT CELL BIOL, V18, P540, DOI 10.1038/ncb3336; Foster CT, 2017, GENE DEV, V31, P2361, DOI 10.1101/gad.304501.117; Fu V, 2017, CURR OPIN CELL BIOL, V49, P99, DOI 10.1016/j.ceb.2017.12.012; Furth N, 2017, CELL DEATH DIFFER, V24, P1488, DOI 10.1038/cdd.2017.99; Furukawa KT, 2017, CELL REP, V20, P1435, DOI 10.1016/j.celrep.2017.07.032; Galan JA, 2016, BIOCHEMISTRY-US, V55, P5507, DOI 10.1021/acs.biochem.6b00763; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Geng J, 2017, NAT IMMUNOL, V18, P800, DOI 10.1038/ni.3748; Geng J, 2015, NAT IMMUNOL, V16, P1142, DOI 10.1038/ni.3268; Guo XC, 2017, GENE DEV, V31, P247, DOI 10.1101/gad.294348.116; Iurescia S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00711; Jiang H, 2016, NAT MED, V22, P851, DOI 10.1038/nm.4123; Jiao S, 2018, J EXP MED, V215, P699, DOI 10.1084/jem.20171116; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Katagiri K, 2006, NAT IMMUNOL, V7, P919, DOI 10.1038/ni1374; Katagiri K, 2009, EMBO J, V28, P1319, DOI 10.1038/emboj.2009.82; Kim J, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/8605471; Kim TW, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9769; Kim W, 2018, GUT, V67, P1692, DOI 10.1136/gutjnl-2017-314061; Knochelmann HM, 2018, CELL MOL IMMUNOL, V15, P458, DOI 10.1038/s41423-018-0004-4; Laklai H, 2016, NAT MED, V22, P497, DOI 10.1038/nm.4082; Lee BS, 2017, BIOCHEM BIOPH RES CO, V491, P493, DOI 10.1016/j.bbrc.2017.07.007; Lee DH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11961; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Li CX, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14275; Li J, 2015, J BIOL CHEM, V290, P30762, DOI 10.1074/jbc.M115.668442; Li WY, 2015, J CLIN INVEST, V125, P4239, DOI 10.1172/JCI81203; Liu B, 2016, CELL, V164, P406, DOI 10.1016/j.cell.2015.12.029; Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942; Liu F, 2015, AM J PHYSIOL-LUNG C, V308, pL344, DOI 10.1152/ajplung.00300.2014; Liu ZQ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14754; Lo B, 2017, CURR OPIN IMMUNOL, V49, P14, DOI 10.1016/j.coi.2017.07.014; Luecke S, 2017, CYTOKINE, V98, P4, DOI 10.1016/j.cyto.2016.10.003; Meng FS, 2016, GENE DEV, V30, P1086, DOI 10.1101/gad.277533.116; Meng ZP, 2018, NATURE, V560, P655, DOI 10.1038/s41586-018-0444-0; Miao J, 2017, ONCOTARGET, V8, P89802, DOI 10.18632/oncotarget.21155; Miyamura N, 2017, NAT COMMUN, V8, P1, DOI 10.1038/ncomms16017; Moon S, 2018, CELL MOL LIFE SCI, V75, P2303, DOI 10.1007/s00018-018-2804-1; Moroishi T, 2016, CELL, V167, P1525, DOI 10.1016/j.cell.2016.11.005; Mou F, 2012, J EXP MED, V209, P741, DOI 10.1084/jem.20111692; Moynihan KD, 2017, CANCER RES, V77, P5215, DOI 10.1158/0008-5472.CAN-17-1340; Murakami S, 2017, ONCOGENE, V36, P1232, DOI 10.1038/onc.2016.288; Murphy TL, 2016, ANNU REV IMMUNOL, V34, P93, DOI 10.1146/annurev-immunol-032713-120204; Nardone G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15321; Nehme NT, 2012, BLOOD, V119, P3458, DOI 10.1182/blood-2011-09-378364; Ni X., 2018, CANC DISCOV; Nishikimi A, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005199; Ramjee V, 2017, J CLIN INVEST, V127, P899, DOI 10.1172/JCI88759; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Samson A, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam7577; Sansores-Garcia L, 2011, EMBO J, V30, P2325, DOI 10.1038/emboj.2011.157; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Schupp J, 2019, CELL IMMUNOL, V343, DOI 10.1016/j.cellimm.2017.10.013; Sharma Padmanee, 2017, CELL REV, V168; Sica A, 2017, J AUTOIMMUN, V85, P117, DOI 10.1016/j.jaut.2017.07.010; Thaventhiran JED, 2012, P NATL ACAD SCI USA, V109, pE2223, DOI 10.1073/pnas.1209115109; Ueda Y, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2105; van Rensburg HJJ, 2018, CANCER RES, V78, P1457, DOI 10.1158/0008-5472.CAN-17-3139; von Ahrens D, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0448-5; Wang GC, 2016, CANCER DISCOV, V6, P80, DOI 10.1158/2159-8290.CD-15-0224; Wang S, 2017, NAT IMMUNOL, V18, P733, DOI 10.1038/ni.3744; Xu XL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105561; Yuan L, 2017, PALMITIC ACID DYSREG, DOI [10.1074/jbc.M117.804005, DOI 10.1074/JBC.M117.804005]; Zamarin D, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008095; Zappasodi R, 2018, CANCER CELL, V33, P581, DOI 10.1016/j.ccell.2018.03.005; Zhang Q, 2017, NAT CELL BIOL, V19, P362, DOI 10.1038/ncb3496; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhou DW, 2008, P NATL ACAD SCI USA, V105, P20321, DOI 10.1073/pnas.0810773105	84	32	36	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					2899	2909		10.1038/s41388-018-0649-6	http://dx.doi.org/10.1038/s41388-018-0649-6			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30617303	Green Accepted			2022-12-17	WOS:000465167600002
J	Liu, L; Yang, Y; Liu, SH; Tao, TY; Cai, JC; Wu, JH; Guan, HY; Zhu, X; He, ZJ; Li, J; Song, EW; Zeng, MS; Li, MF				Liu, Lei; Yang, Yi; Liu, Shihua; Tao, Tianyu; Cai, Junchao; Wu, Jueheng; Guan, Hongyu; Zhu, Xun; He, Zhenjian; Li, Jun; Song, Erwei; Zeng, Musheng; Li, Mengfeng			EGF-induced nuclear localization of SHCBP1 activates beta-catenin signaling and promotes cancer progression	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; CREB-BINDING PROTEIN; STEM-CELLS; DOWN-REGULATION; DRUG-RESISTANT; T790M MUTATION; COLON-CANCER; WNT; INHIBITOR	Aberrant activation of EGFR represents a common event in non-small cell lung carcinoma (NSCLC) and activates various downstream signaling pathways. While EGFR activation of beta-catenin signaling was previously reported, the mediating mechanism remains unclear. Our current study found that EGFR activation in NSCLC cells releases SHC-binging protein 1 (SHCBP1) from SHC adaptor protein 1 (SHC1), which subsequently translocates into the nucleus and directly promotes the transactivating activity of beta-catenin, consequently resulting in development of NSCLC cell stemness and malignant progression. Furthermore, SHCBP1 promotes beta-catenin activity through enhancing the CBP/beta-catenin interaction, and most interestingly, a candidate drug that blocks the CBP/beta-catenin binding effectively abrogates the aforementioned biological effects of SHCBP1. Clinically, SHCBP1 level in NSCLC tumors was found to inversely correlate with patient survival. Together, our study establishes a novel convergence between EGFR and beta-catenin pathways and highlights a potential significance of SHCBP1 as a prognostic biomarker and a therapeutic target.	[Liu, Lei; Yang, Yi; Liu, Shihua; Tao, Tianyu; Cai, Junchao; Wu, Jueheng; Zhu, Xun; He, Zhenjian; Li, Jun; Li, Mengfeng] Sun Yat Sen Univ, Minist Educ, Key Lab Trop Dis Control, Guangzhou, Guangdong, Peoples R China; [Liu, Lei; Liu, Shihua; Tao, Tianyu; Cai, Junchao; Wu, Jueheng; Li, Mengfeng] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou, Guangdong, Peoples R China; [Yang, Yi] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pharmacol, Guangzhou, Guangdong, Peoples R China; [Guan, Hongyu] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Endocrinol, Guangzhou, Guangdong, Peoples R China; [Guan, Hongyu] Sun Yat Sen Univ, Affiliated Hosp 1, Diabet Ctr, Guangzhou, Guangdong, Peoples R China; [Zhu, Xun] Guangdong Prov Key Lab Orthoped & Traumatol, Guangzhou, Guangdong, Peoples R China; [He, Zhenjian] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou, Guangdong, Peoples R China; [Li, Jun] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou, Guangdong, Peoples R China; [Song, Erwei] Sun Yat Sen Univ, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Med Res Ctr, Sun Yat Sen Mem Hosp, Guangzhou, Guangdong, Peoples R China; [Zeng, Musheng] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University	Yang, Y; Li, MF (corresponding author), Sun Yat Sen Univ, Minist Educ, Key Lab Trop Dis Control, Guangzhou, Guangdong, Peoples R China.; Li, MF (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou, Guangdong, Peoples R China.; Yang, Y (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pharmacol, Guangzhou, Guangdong, Peoples R China.	yangyi23@mail.sysu.edu.cn; limf@mail.sysu.edu.cn	LIU, LEI/AAY-2012-2020; LIU, LEI/AAL-7491-2021	LIU, LEI/0000-0003-4898-5665; zeng, musheng/0000-0003-3509-5591	National Key Research and Development Project of China [2017YFA0505600, 2017YFA0106300]; Foundation for Innovative Research Groups of the National Natural Science Foundation of China [81621004]; Guangzhou science and technology plan [201803010039, 201804010057]; National Natural Science Foundation of China [81572837, 81330058]; Guangdong Natural Science Foundation [2014A030313036]; Guangdong Natural Science Funds for Distinguished Young Scholar [2014A030306023]; Guangdong Te Zhi program youth science and technology talent of project [2015TQ01R281]; Fundamental Research Funds for the Central Universities [17ykpy06]	National Key Research and Development Project of China; Foundation for Innovative Research Groups of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou science and technology plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Guangdong Natural Science Funds for Distinguished Young Scholar; Guangdong Te Zhi program youth science and technology talent of project; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by The National Key Research and Development Project of China (No. 2017YFA0505600,2017YFA0106300); The Foundation for Innovative Research Groups of the National Natural Science Foundation of China (No. 81621004); Guangzhou science and technology plan (No. 201803010039, 201804010057); The National Natural Science Foundation of China (No. 81572837, 81330058); Guangdong Natural Science Foundation (No. 2014A030313036); Guangdong Natural Science Funds for Distinguished Young Scholar (No. 2014A030306023); Guangdong Te Zhi program youth science and technology talent of project (No. 2015TQ01R281); the Fundamental Research Funds for the Central Universities (No. 17ykpy06).SS	Akiri G, 2009, ONCOGENE, V28, P2163, DOI 10.1038/onc.2009.82; Arensman MD, 2014, MOL CANCER THER, V13, P2303, DOI 10.1158/1535-7163.MCT-13-1005; Berns A, 2005, CELL, V121, P811, DOI 10.1016/j.cell.2005.06.004; Brannon AR, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0454-7; Cai JC, 2013, CANCER RES, V73, P756, DOI 10.1158/0008-5472.CAN-12-2651; Casas-Selves M, 2012, CANCER RES, V72, P4154, DOI 10.1158/0008-5472.CAN-11-2848; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chen JF, 2012, GENE DEV, V26, P803, DOI 10.1101/gad.187641.112; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Faivre EJ, 2007, MOL CELL BIOL, V27, P466, DOI 10.1128/MCB.01539-06; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; FELD R, 1984, J CLIN ONCOL, V2, P1352, DOI 10.1200/JCO.1984.2.12.1352; Gang EJ, 2014, ONCOGENE, V33, P2169, DOI 10.1038/onc.2013.169; He KJ, 2014, INT J CANCER, V134, P43, DOI 10.1002/ijc.28341; Hwang KE, 2014, EXP CELL RES, V323, P288, DOI 10.1016/j.yexcr.2014.02.026; Ishizawa K, 2010, CELL STEM CELL, V7, P279, DOI 10.1016/j.stem.2010.08.009; Ji HT, 2009, MOL CELL, V36, P547, DOI 10.1016/j.molcel.2009.09.034; Krejci P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035826; Le Pechoux C, 2011, ONCOLOGIST, V16, P672, DOI 10.1634/theoncologist.2010-0150; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lian CJ, 2016, J PINEAL RES, V61, P317, DOI 10.1111/jpi.12349; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; Ma L, 2013, FEBS J, V280, P2027, DOI 10.1111/febs.12226; Mazieres J, 2005, CANCER LETT, V222, P1, DOI 10.1016/j.canlet.2004.08.040; Montembault E, 2010, J CELL BIOL, V191, P1351, DOI 10.1083/jcb.201007060; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nakayama S, 2014, CANCER RES, V74, P5891, DOI 10.1158/0008-5472.CAN-14-0184; Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030; Park M, 2015, J PROTEOME RES, V14, P3007, DOI 10.1021/acs.jproteome.5b00423; PASSLICK B, 1994, J CLIN ONCOL, V12, P1827, DOI 10.1200/JCO.1994.12.9.1827; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Roth JF, 2003, EMBO J, V22, P5186, DOI 10.1093/emboj/cdg473; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sato S, 2005, GASTROENTEROLOGY, V129, P1225, DOI 10.1053/j.gastro.2005.07.025; Schmandt R, 1999, ONCOGENE, V18, P1867, DOI 10.1038/sj.onc.1202507; Sequist LV, 2007, ONCOLOGIST, V12, P90, DOI 10.1634/theoncologist.12-1-90; Soeda A, 2008, J BIOL CHEM, V283, P10958, DOI 10.1074/jbc.M704205200; Sokol SY, 2011, DEVELOPMENT, V138, P4341, DOI 10.1242/dev.066209; Su KY, 2012, J CLIN ONCOL, V30, P433, DOI 10.1200/JCO.2011.38.3224; Su SC, 2017, CELL RES, V27, P461, DOI 10.1038/cr.2017.34; Suzuki M, 2007, CLIN CANCER RES, V13, P6087, DOI 10.1158/1078-0432.CCR-07-0591; Takahashi-Yanaga F, 2010, CLIN CANCER RES, V16, P3153, DOI 10.1158/1078-0432.CCR-09-2943; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tan XP, 2005, GASTROENTEROLOGY, V129, P285, DOI 10.1053/j.gastro.2005.04.013; To KKW, 2017, LUNG CANCER, V103, P58, DOI 10.1016/j.lungcan.2016.11.019; Togashi Y, 2015, J THORAC ONCOL, V10, P93, DOI 10.1097/JTO.0000000000000353; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wend P, 2013, EMBO J, V32, P1977, DOI 10.1038/emboj.2013.127; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yang Y, BIOCH BIOPHYS RES CO, V450, P899; Yang Y, 2014, INT J CANCER, V135, P1531, DOI 10.1002/ijc.28799; Zhang XR, 2013, J BIOL CHEM, V288, P32229, DOI 10.1074/jbc.M113.463554; Zheng Y, 2013, NATURE, V499, P166, DOI 10.1038/nature12308	60	32	34	5	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					747	764		10.1038/s41388-018-0473-z	http://dx.doi.org/10.1038/s41388-018-0473-z			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30177836	Green Published, hybrid			2022-12-17	WOS:000457300300010
J	Yu, XH; Liu, YH; Yin, LL; Peng, YB; Peng, YC; Gao, YX; Yuan, BW; Zhu, QL; Cao, TY; Xie, BW; Sun, LQ; Chen, Y; Gong, ZC; Qiu, YZ; Fan, XG; Li, X				Yu, Xiaohui; Liu, Youhong; Yin, Linglong; Peng, Yongbo; Peng, Yuchong; Gao, Yingxue; Yuan, Bowen; Zhu, Qianling; Cao, Tuoyu; Xie, Bowen; Sun, Lunquan; Chen, Yan; Gong, Zhicheng; Qiu, Yuanzheng; Fan, Xuegong; Li, Xiong			Radiation-promoted CDC6 protein stability contributes to radioresistance by regulating senescence and epithelial to mesenchymal transition	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; CELL-CYCLE; NASOPHARYNGEAL CARCINOMA; DNA-REPLICATION; MAMMALIAN CDC6; EXPRESSION; TRANSCRIPTION; ACTIVATION; APOPTOSIS; TARGETS	Ionizing radiation (IR) is a conventional cancer therapeutic, to which cancer cells develop radioresistance with exposure. The residual cancer cells after radiation treatment also have increased metastatic potential. The mechanisms by which cancer cells develop radioresistance and gain metastatic potential are still unknown. In this study acute IR exposure induced cancer cell senescence and apoptosis, but after long-term IR exposure, cancer cells exhibited radioresistance. The proliferation of radioresistant cells was retarded, and most cells were arrested in G0/G1 phase. The radioresistant cells simultaneously showed resistance to further IR-induced apoptosis, premature senescence, and epithelial to mesenchymal transformation (EMT). Acute IR exposure steadily elevated CDC6 protein levels due to the attenuation of ubiquitination, while CDC6 overexpression was observed in the radioresistant cells because the insufficiency of CDC6 phosphorylation blocked protein translocation from nucleus to cytoplasm, resulting in subcellular protein accumulation when the cells were arrested in G0/G1 phase. CDC6 ectopic overexpression in CNE2 cells resulted in apoptosis resistance, G0/G1 cell cycle arrest, premature senescence, and EMT, similar to the characteristics of radioresistant CNE2-R cells. Targeting CDC6 with siRNA promoted IR-induced senescence, sensitized cancer cells to IR-induced apoptosis, and reversed EMT. Furthermore, CDC6 depletion synergistically repressed the growth of CNE2-R xenografts when combined with IR. The study describes for the first time cell models for IR-induced senescence, apoptosis resistance, and EMT, three major mechanisms by which radioresistance develops. CDC6 is a novel radioresistance switch regulating senescence, apoptosis, and EMT. These studies suggest that CDC6(high)KI67(low) represents a new diagnostic marker of radiosensitivity, and CDC6 represents a new therapeutic target for cancer radiosensitization.	[Yu, Xiaohui; Liu, Youhong; Yin, Linglong; Peng, Yuchong; Gao, Yingxue; Yuan, Bowen; Zhu, Qianling; Cao, Tuoyu; Xie, Bowen; Sun, Lunquan; Li, Xiong] Cent South Univ, Xiangya Hosp, Ctr Mol Med, Changsha, Hunan, Peoples R China; [Yu, Xiaohui; Liu, Youhong; Yin, Linglong; Peng, Yuchong; Gao, Yingxue; Yuan, Bowen; Zhu, Qianling; Cao, Tuoyu; Xie, Bowen; Sun, Lunquan; Li, Xiong] Cent South Univ, Xiangya Hosp, Hunan Key Lab Mol Radiat Oncol, Changsha, Hunan, Peoples R China; [Peng, Yongbo] Hunan Univ, State Key Lab Chemo Biosensing & Chemometr, Changsha, Hunan, Peoples R China; [Chen, Yan] Cent South Univ, Xiangya Hosp 3, Dept Pathol, Changsha, Hunan, Peoples R China; [Gong, Zhicheng] Cent South Univ, Xiangya Hosp, Dept Pharm, Changsha, Hunan, Peoples R China; [Qiu, Yuanzheng] Cent South Univ, Xiangya Hosp, Dept Otorhinolaryngol, Changsha, Hunan, Peoples R China; [Fan, Xuegong] Cent South Univ, Xiangya Hosp, Hunan Key Lab Viral Hepatitis, Changsha, Hunan, Peoples R China	Central South University; Central South University; Hunan University; Central South University; Central South University; Central South University; Central South University	Li, X (corresponding author), Cent South Univ, Xiangya Hosp, Ctr Mol Med, Changsha, Hunan, Peoples R China.; Li, X (corresponding author), Cent South Univ, Xiangya Hosp, Hunan Key Lab Mol Radiat Oncol, Changsha, Hunan, Peoples R China.	lixiongxiangya@csu.edu.cn	Peng, Yong-bo/ADE-0574-2022	Peng, Yong-bo/0000-0003-4861-7184	National Natural Science Foundation of China (NSFC) [81572542]; Doctoral Fund of Ministry of Education of China (RFDP) [20130162110029]; Scientific Research Funds for Returned Overseas Chinese Scholars, Ministry of Education of China (SRF for ROCS, SEM) [2014-1685]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Doctoral Fund of Ministry of Education of China (RFDP); Scientific Research Funds for Returned Overseas Chinese Scholars, Ministry of Education of China (SRF for ROCS, SEM)	We thank Pro. Zhiqiang Xiao and the members of the Hunan Key Laboratory of Viral Hepatitis and Center of Molecular Medicine, Xiangya Hospital, Central South University for constructive discussion of this study. This work was supported by grants from the National Natural Science Foundation of China (NSFC, 81572542), the Doctoral Fund of Ministry of Education of China (RFDP, 20130162110029), and Scientific Research Funds for Returned Overseas Chinese Scholars, Ministry of Education of China (SRF for ROCS, SEM, 2014-1685).	Alexandrow MG, 2004, MOL CELL BIOL, V24, P1614, DOI 10.1128/MCB.24.4.1614-1627.2004; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Borlado LR, 2008, CARCINOGENESIS, V29, P237, DOI 10.1093/carcin/bgm268; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chang JC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004766; Chen W, 2015, CANCER BIOL MED, V12, P23, DOI 10.7497/j.issn.2095-3941.2014.0015; Clijsters L, 2013, J CELL BIOL, V201, P1013, DOI 10.1083/jcb.201211019; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Duursma A, 2005, MOL CELL BIOL, V25, P6937, DOI 10.1128/MCB.25.16.6937-6947.2005; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Feng DR, 2003, CANCER RES, V63, P7356; Gonzalez S, 2006, NATURE, V440, P702, DOI 10.1038/nature04585; Hampel B, 2004, EXP GERONTOL, V39, P1713, DOI 10.1016/j.exger.2004.05.010; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Lee AWM, 2005, INT J RADIAT ONCOL, V61, P1107, DOI 10.1016/j.ijrobp.2004.07.702; Lee M, 2014, BMB REP, V47, P51, DOI 10.5483/BMBRep.2014.47.2.005; Li G, 2013, EUR J CANCER, V49, P2596, DOI 10.1016/j.ejca.2013.03.001; Liu YH, 2014, BBA-GENE REGUL MECH, V1839, P297, DOI 10.1016/j.bbagrm.2014.02.016; Liu YH, 2014, MOL CARCINOGEN, V53, P380, DOI 10.1002/mc.21989; Liu YH, 2010, J CELL BIOCHEM, V111, P1546, DOI 10.1002/jcb.22886; Madani I, 2008, B CANCER, V95, P292, DOI 10.1684/bdc.2008.0598; Pawlik TM, 2004, INT J RADIAT ONCOL, V59, P928, DOI 10.1016/j.ijrobp.2004.03.005; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Raleigh DR, 2013, FUTURE ONCOL, V9, P219, DOI [10.2217/FON.12.185, 10.2217/fon.12.185]; Rufini A, 2013, ONCOGENE, V32, P5129, DOI 10.1038/onc.2012.640; Sideridou M, 2011, J CELL BIOL, V195, P1123, DOI 10.1083/jcb.201108121; Smit MA, 2010, AGING-US, V2, P735, DOI 10.18632/aging.100209; Su ZW, 2016, ONCOL REP, V36, P72, DOI 10.3892/or.2016.4768; Suarez C, 2010, EUR ARCH OTO-RHINO-L, V267, P1811, DOI 10.1007/s00405-010-1385-x; Walter D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10530; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Young A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-808	34	32	32	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2019	38	4					549	563		10.1038/s41388-018-0460-4	http://dx.doi.org/10.1038/s41388-018-0460-4			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HI6UB	30158672	Green Published, hybrid			2022-12-17	WOS:000456589800007
J	Bonetti, P; Climent, M; Panebianco, F; Tordonato, C; Santoro, A; Marzi, MJ; Pelicci, PG; Ventura, A; Nicassio, F				Bonetti, Paola; Climent, Montserrat; Panebianco, Fabiana; Tordonato, Chiara; Santoro, Angela; Marzi, Matteo Jacopo; Pelicci, Pier Giuseppe; Ventura, Andrea; Nicassio, Francesco			Dual role for miR-34a in the control of early progenitor proliferation and commitment in the mammary gland and in breast cancer	ONCOGENE			English	Article							STEM-CELLS; MOLECULAR PORTRAITS; MICRORNA; METASTASIS; MIRNAS; AXIS	The role of the tumour-suppressor miR-34 family in breast physiology and in mammary stem cells (MaSCs) is largely unknown. Here, we revealed that miR-34 family, and miR-34a in particular, is implicated in mammary epithelium homoeostasis. Expression of miR-34a occurs upon luminal commitment and differentiation and serves to inhibit the expansion of the pool of MaSCs and early progenitor cells, likely in a p53-independent fashion. Mutant mice (miR34-KO) and loss-of-function approaches revealed two separate functions of miR-34a, controlling both proliferation and fate commitment in mammary progenitors by modulating several pathways involved in epithelial cell plasticity and luminal-to-basal conversion. In particular, miR-34a acts as endogenous inhibitor of the Wnt/beta-catenin signalling pathway, targeting up to nine upstream regulators at the same time, thus modulating the expansion of the MaSCs/early progenitor pool. These multiple roles of miR-34a are maintained in a model of human breast cancer, in which chronic expression of miR-34a in triple-negative mesenchymal-like cells (enriched in cancer stem cells-CSCs) could promote a luminal-like differentiation programme, restrict the CSC pool, and inhibit tumour propagation. Hence, activation of miR-34a-dependent programmes could provide a therapeutic opportunity for the subset of breast cancers, which are rich in CSCs and respond poorly to conventional therapies.	[Bonetti, Paola; Climent, Montserrat; Panebianco, Fabiana; Marzi, Matteo Jacopo; Nicassio, Francesco] ITT, Ctr Genom Sci IIT SEMM, I-20139 Milan, Italy; [Tordonato, Chiara] IFOM, FIRC Inst Mol Oncol Fdn, I-20139 Milan, Italy; [Santoro, Angela; Pelicci, Pier Giuseppe] European Inst Oncol IE0, Dept Expt Oncol, I-20100 Milan, Italy; [Pelicci, Pier Giuseppe] Univ Milan, Dipartimento Sci Salute, I-20100 Milan, Italy; [Ventura, Andrea] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA	Istituto Italiano di Tecnologia - IIT; IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); University of Milan; Memorial Sloan Kettering Cancer Center	Bonetti, P; Nicassio, F (corresponding author), ITT, Ctr Genom Sci IIT SEMM, I-20139 Milan, Italy.	paola.bonetti@iit.it; francesco.nicassio@iit.it	Climent, Montserrat/K-6490-2019; Bonetti, Paola/Y-9182-2019; tordonato, chiara/AAQ-5819-2020; Pelicci, Pier Giuseppe/AAL-6572-2020; Marzi, Matteo Jacopo/AAB-9775-2019	Climent, Montserrat/0000-0002-9029-7914; Bonetti, Paola/0000-0002-8805-9837; tordonato, chiara/0000-0001-6556-1747; Marzi, Matteo Jacopo/0000-0002-5068-782X; nicassio, francesco/0000-0002-5954-5318	Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG14085, IG18774]; Cariplo [2015-0590]	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Cariplo(Fondazione Cariplo)	We thank the Genomic Unit and Imaging Unit, Federica Pisati for IHC, Thalia Vlachou for ChIP. Veronica Raker for manuscript editing. This work was supported by grants from the Associazione Italiana per la Ricerca sul Cancro (AIRC) to FN (IG14085 and IG18774), Cariplo (2015-0590) to FN.	Aranha MM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021396; Bader Andreas G., 2012, Frontiers in Genetics, V3, P120, DOI 10.3389/fgene.2012.00120; Boon RA, 2013, NATURE, V495, P107, DOI 10.1038/nature11919; Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569; Brisken C, 2000, GENE DEV, V14, P650; Brown BD, 2007, NAT BIOTECHNOL, V25, P1457, DOI 10.1038/nbt1372; Bu PC, 2013, CELL STEM CELL, V12, P602, DOI 10.1016/j.stem.2013.03.002; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Choi YJ, 2011, NAT CELL BIOL, V13, P1353, DOI 10.1038/ncb2366; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Concepcion CP, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002797; Deugnier MA, 2006, DEV BIOL, V293, P414, DOI 10.1016/j.ydbio.2006.02.007; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gonczy P, 2008, NAT REV MOL CELL BIO, V9, P355, DOI 10.1038/nrm2388; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Jafari N, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317701652; Kang L, 2015, CANCER SCI, V106, P700, DOI 10.1111/cas.12656; Kim NH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001744; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Lindvall C, 2006, J BIOL CHEM, V281, P35081, DOI 10.1074/jbc.M607571200; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu SL, 2010, J CLIN ONCOL, V28, P4006, DOI 10.1200/JCO.2009.27.5388; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Marzi MJ, 2012, J CELL BIOL, V199, P77, DOI 10.1083/jcb.201206033; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Park EY, 2014, CANCER RES, V74, P7573, DOI 10.1158/0008-5472.CAN-14-1140; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rokavec M, 2014, J MOL CELL BIOL, V6, P214, DOI 10.1093/jmcb/mju003; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Song R, 2014, NATURE, V510, P115, DOI 10.1038/nature13413; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Taube JH, 2013, SCI REP-UK, V3, DOI 10.1038/srep02687; van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054	47	32	32	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					360	374		10.1038/s41388-018-0445-3	http://dx.doi.org/10.1038/s41388-018-0445-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30093634	Green Published, hybrid			2022-12-17	WOS:000455851200005
J	Bhat, AA; Lu, H; Soutto, M; Capobianco, A; Rai, P; Zaika, A; El-Rifai, W				Bhat, Ajaz A.; Lu, Heng; Soutto, Mohammed; Capobianco, Anthony; Rai, Priyamvada; Zaika, Alexander; El-Rifai, Wael			Exposure of Barrett's and esophageal adenocarcinoma cells to bile acids activates EGFR-STAT3 signaling axis via induction of APE1	ONCOGENE			English	Article							GASTROESOPHAGEAL-REFLUX DISEASE; OXIDATIVE DNA-DAMAGE; KAPPA-B ACTIVATION; GENE-EXPRESSION; CONSTITUTIVE ACTIVATION; CONFERS RESISTANCE; NUCLEAR EGFR-STAT3; PROTEIN APE1/REF-1; UNITED-STATES; LOW PH	The development of Barrett's esophagus (BE) and its progression to esophageal adenocarcinoma (EAC) is highly linked to exposure to acidic bile salts due to chronic gastroesophageal reflux disease (GERD). In this study, we investigated the role of Apurinic/apyrimidinic endonuclease 1/redox effector factor-1 (APE1/REF-1) in STAT3 activation in response to acidic bile salts. Our results indicate that APE1 is constitutively overexpressed in EAC, whereas its expression is transiently induced in response to acidic bile salts in non-neoplastic BE. Using overexpression or shRNA knockdown of APE1, we found that APE1 is required for phosphorylation, nuclear localization, and transcriptional activation of STAT3. By using an APE1 redox-specific mutant (C65A) and APE1 redox inhibitor (E3330), we demonstrate that APE1 activates STAT3 in a redox-dependent manner. By using pharmacologic inhibitors and genetic knockdown systems, we found that EGFR is a required link between APE1 and STAT3. EGFR phosphorylation (Y1068) was directly associated with APE1 levels and redox function. Co-immunoprecipitation and proximity ligation assays indicated that APE1 coexists and interacts with the EGFR-STAT3 protein complex. Consistent with these findings, we demonstrated a significant induction in mRNA expression levels of STAT3 target genes (IL-6, IL-17A, BCL-xL, Survivin, and c-MYC) in BE and EAC cells, following acidic bile salts treatment. ChIP assays indicated that acidic bile salts treatment enhances binding of STAT3 to the promoter of its target genes, Survivin and BCL-xL. Inhibition of APE1/REF-1 redox activity using E3330 abrogated STAT3 DNA binding and transcriptional activity. The induction of APE1-STAT3 axis in acidic bile salts conditions provided a survival advantage and promoted cellular proliferation. In summary, our study provides multiple pieces of evidence supporting a critical role for APE1 induction in activating the EGFR-STAT3 signaling axis in response to acidic bile salts, the main risk factor for Barrett's carcinogenesis.	[Bhat, Ajaz A.; Lu, Heng; Soutto, Mohammed; Capobianco, Anthony; Zaika, Alexander; El-Rifai, Wael] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA; [Bhat, Ajaz A.] Sidra Med, Div Translat Med, Res Branch, Doha, Qatar; [Rai, Priyamvada] Univ Miami, Miller Sch Med, Div Med Oncol, Dept Med, Miami, FL 33136 USA; [Zaika, Alexander; El-Rifai, Wael] Miami Healthcare Syst, Dept Vet Affairs, Miami, FL 33125 USA	University of Miami; Sidra Medical & Research Center; University of Miami	El-Rifai, W (corresponding author), Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA.; El-Rifai, W (corresponding author), Miami Healthcare Syst, Dept Vet Affairs, Miami, FL 33125 USA.	welrifai@med.miami.edu	Bhat, Ajaz/V-3642-2019	Bhat, Ajaz/0000-0003-3640-6275; Rai, Priyamvada/0000-0001-7822-7553	U.S. National Institutes of Health [R01CA206563]; U.S. Department of Veterans affairs [1IK6BX003787, I01BX001179]; NATIONAL CANCER INSTITUTE [R01CA206564, R01CA206563] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002115, IK6BX003787, I01BX001179] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Veterans affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	This study was supported by grants from the U.S. National Institutes of Health (R01CA206563) and the U.S. Department of Veterans affairs (1IK6BX003787 and I01BX001179). The content of this work is solely the responsibility of the authors and do not necessarily represent the official views of the Department of Veterans Affairs, National Institutes of Health, or the University of Miami.	Abdel-Latif MMM, 2004, ANN SURG, V239, P491, DOI 10.1097/01.sla.0000118751.95179.c6; Bernstein H, 1999, TOXICOL LETT, V108, P37, DOI 10.1016/S0378-4274(99)00113-7; Bernstein H, 2009, WORLD J GASTROENTERO, V15, P3329, DOI 10.3748/wjg.15.3329; Bhakat KK, 2009, ANTIOXID REDOX SIGN, V11, P621, DOI [10.1089/ars.2008.2198, 10.1089/ARS.2008.2198]; Biswas A, 2015, AM J PHYSIOL-CELL PH, V309, pC296, DOI 10.1152/ajpcell.00022.2015; Bobola MS, 2005, CLIN CANCER RES, V11, P7405, DOI 10.1158/1078-0432.CCR-05-1068; Cardoso AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047462; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Chua CY, 2016, ONCOGENE, V35, P738, DOI 10.1038/onc.2015.131; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; Cook MB, 2009, BRIT J CANCER, V101, P855, DOI 10.1038/sj.bjc.6605246; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Di Maso V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143289; Dossa AY, 2016, AM J PHYSIOL-GASTR L, V310, pG81, DOI 10.1152/ajpgi.00065.2015; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Dvorak K, 2007, CLIN CANCER RES, V13, P5305, DOI 10.1158/1078-0432.CCR-07-0483; Dvorak K, 2007, GUT, V56, P763, DOI 10.1136/gut.2006.103697; Dvorakova K, 2004, CLIN CANCER RES, V10, P2020, DOI 10.1158/1078-0432.CCR-0437-03; Eloubeidi MA, 2003, AM J GASTROENTEROL, V98, P1627, DOI 10.1016/S0002-9270(03)00228-4; Farhadi A, 2002, AM J GASTROENTEROL, V97, P22; Fishel ML, 2007, MOL ASPECTS MED, V28, P375, DOI 10.1016/j.mam.2007.04.005; Fishel ML, 2011, MOL CANCER THER, V10, P1698, DOI 10.1158/1535-7163.MCT-11-0107; Fishel ML, 2010, EXP HEMATOL, V38, P1178, DOI 10.1016/j.exphem.2010.08.011; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Han W, 2012, CANCER LETT, V318, P124, DOI 10.1016/j.canlet.2012.01.011; Hong J, 2016, ONCOTARGET, V7, P16688, DOI 10.18632/oncotarget.7696; Hoshino M, 2007, PATHOBIOLOGY, V74, P15, DOI 10.1159/000101047; IFTIKHAR SY, 1993, ANN ROY COLL SURG, V75, P411; Inayama M, 2007, HEPATO-GASTROENTEROL, V54, P761; Izumi T, 2005, P NATL ACAD SCI USA, V102, P5739, DOI 10.1073/pnas.0500986102; Jaganathan S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019605; Jenkins GJS, 2008, MUTAGENESIS, V23, P399, DOI 10.1093/mutage/gen029; Jolly AJ, 2004, MUTAGENESIS, V19, P319, DOI 10.1093/mutage/geh035; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kauer WKH, 1997, SURGERY, V122, P874, DOI 10.1016/S0039-6060(97)90327-5; Kelley MR, 2011, ANTIOXID REDOX SIGN, V14, P1387, DOI 10.1089/ars.2010.3410; Kim JS, 2012, INT J RADIAT ONCOL, V82, P130, DOI 10.1016/j.ijrobp.2010.09.037; Lagergren J, 2005, GUT, V54, pI1, DOI 10.1136/gut.2004.041517; Le Bras GF, 2014, LAB INVEST, V94, P1134, DOI 10.1038/labinvest.2014.97; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Lechner S, 2002, CARCINOGENESIS, V23, P1281, DOI 10.1093/carcin/23.8.1281; Lee JS, 2001, MUTAT RES-FUND MOL M, V480, P189, DOI 10.1016/S0027-5107(01)00199-3; Li L, 2010, CANCER RES, V70, P8222, DOI 10.1158/0008-5472.CAN-10-0894; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Luo M, 2008, ANTIOXID REDOX SIGN, V10, P1853, DOI 10.1089/ars.2008.2120; Nehra D, 1999, GUT, V44, P598, DOI 10.1136/gut.44.5.598; Oda K, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100014; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; Peng DF, 2014, J CANCER, V5, P510, DOI 10.7150/jca.9215; Peng DF, 2012, GUT, V61, P1250, DOI 10.1136/gutjnl-2011-301078; Pera M, 2005, J SURG ONCOL, V92, P151, DOI 10.1002/jso.20357; Picardo SL, 2012, DIGEST SURG, V29, P251, DOI 10.1159/000341498; Poehlmann A, 2012, PATHOL RES PRACT, V208, P269, DOI 10.1016/j.prp.2012.03.007; Reid BJ, 2010, NAT REV CANCER, V10, P87, DOI 10.1038/nrc2773; Shao H, 2003, CANCER RES, V63, P3923; Sital RR, 2006, SCAND J GASTROENTERO, V41, P11, DOI 10.1080/00365520600664219; SOKOL RJ, 1995, GASTROENTEROLOGY, V109, P1249, DOI 10.1016/0016-5085(95)90585-5; Sommerfeld A, 2009, J BIOL CHEM, V284, P22173, DOI 10.1074/jbc.M109.005355; Tell G, 2010, CELL MOL LIFE SCI, V67, P3589, DOI 10.1007/s00018-010-0486-4; Tell G, 2009, ANTIOXID REDOX SIGN, V11, P601, DOI 10.1089/ars.2008.2194; Thakur S, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.42; Theisen J, 2000, J GASTROINTEST SURG, V4, P50, DOI 10.1016/S1091-255X(00)80032-3; Turkson J, 2004, EXPERT OPIN THER TAR, V8, P409, DOI 10.1517/14728222.8.5.409; Vigneron A, 2008, CANCER RES, V68, P815, DOI 10.1158/0008-5472.CAN-07-5115; Yang Z, 2014, INT J ONCOL, V45, P1820, DOI 10.3892/ijo.2014.2589; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Yu XT, 2007, J CANCER RES CLIN, V133, P145, DOI 10.1007/s00432-006-0139-z; Zhang F, 2015, J TOXICOL PATHOL, V28, P79, DOI 10.1293/tox.2014-0047; Zhang HY, 2009, CANCER RES, V69, P9083, DOI 10.1158/0008-5472.CAN-09-2518; Zhang R, 2005, WORLD J GASTROENTERO, V11, P6466, DOI 10.3748/wjg.v11.i41.6466	75	32	33	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2018	37	46					6011	6024		10.1038/s41388-018-0388-8	http://dx.doi.org/10.1038/s41388-018-0388-8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HA3SQ	29991802	Green Accepted			2022-12-17	WOS:000450175900001
J	Pavan, S; Meyer-Schaller, N; Diepenbruck, M; Kalathur, RKR; Saxena, M; Christofori, G				Pavan, Simona; Meyer-Schaller, Nathalie; Diepenbruck, Maren; Kalathur, Ravi Kiran Reddy; Saxena, Meera; Christofori, Gerhard			A kinome-wide high-content siRNA screen identifies MEK5-ERK5 signaling as critical for breast cancer cell EMT and metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TGF-BETA; TUMOR PROGRESSION; MASTER REGULATOR; MIR-200 FAMILY; MEK KINASE; PROTEIN; ACTIVATION; ERK5; PATHWAY	An epithelial to mesenchymal transition (EMT) has been correlated to malignant tumor progression and metastasis by promoting cancer cell migration and invasion and chemoresistance. Hence, finding druggable EMT effectors is critical to efficiently interfere with metastasis formation and to overcome therapy resistance. We have employed a high-content microscopy screen in combination with a kinome and phosphatome-wide siRNA library to identify signaling pathways underlying an EMT of murine mammary epithelial cells and breast cancer cells. This screen identified the MEK5-ERK5 axis as a critical player in TGF beta-mediated EMT. Suppression of MEK5-ERK5 signaling completely prevented the morphological and molecular changes occurring during a TGF beta-induced EMT and, conversely, forced highly metastatic breast cancer cells into a differentiated epithelial state. Inhibition of MEK5-ERK5 signaling also repressed breast cancer cell migration and invasion and substantially reduced lung metastasis without affecting primary tumor growth. The results suggest that the MEK5-ERK5 signaling axis via activation of MEF2B and other transcription factors plays an important role in the induction and maintenance of breast cancer cell migration and invasion and thus represents an exploitable target for the pharmacological inhibition of cancer cell metastasis.	[Pavan, Simona; Meyer-Schaller, Nathalie; Diepenbruck, Maren; Kalathur, Ravi Kiran Reddy; Saxena, Meera; Christofori, Gerhard] Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland	University of Basel	Pavan, S; Christofori, G (corresponding author), Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland.	simona.pavan@unibas.ch; gerhard.christofori@unibas.ch		Saxena, Meera/0000-0002-4060-4218	SystemsX.ch MTD project MetastasiX; Swiss National Science Foundation; Swiss Cancer League; Krebsliga Beider Basel; Marie-Heim Vogtlin grant from the Swiss National Foundation	SystemsX.ch MTD project MetastasiX; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League; Krebsliga Beider Basel; Marie-Heim Vogtlin grant from the Swiss National Foundation	This work was supported by the SystemsX.ch MTD project MetastasiX, the Swiss National Science Foundation, the Swiss Cancer League, and Krebsliga Beider Basel. N.M.-S. was supported by a Marie-Heim Vogtlin grant from the Swiss National Foundation.	Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810; Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Badshah II, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00071; Balwierz PJ, 2014, GENOME RES, V24, P869, DOI 10.1101/gr.169508.113; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5; Chaffer CL, 2016, CANCER METAST REV, V35, P645, DOI 10.1007/s10555-016-9648-7; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chen RQ, 2012, CANCER RES, V72, P1579, DOI 10.1158/0008-5472.CAN-11-2055; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; Diepenbruck M, 2016, CURR OPIN CELL BIOL, V43, P7, DOI 10.1016/j.ceb.2016.06.002; Diepenbruck M, 2014, J CELL SCI, V127, P1523, DOI 10.1242/jcs.139865; El-Deiry WS, 2016, CANCER RES, V76, P5189, DOI 10.1158/0008-5472.CAN-16-2055; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; Fabregat A, 2016, NUCLEIC ACIDS RES, V44, pD481, DOI 10.1093/nar/gkv1351; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gui Ting, 2012, J Signal Transduct, V2012, P289243, DOI 10.1155/2012/289243; Hodge RG, 2016, NAT REV MOL CELL BIO, V17, P496, DOI 10.1038/nrm.2016.67; Javaid S, 2015, MOL CANCER RES, V13, P934, DOI 10.1158/1541-7786.MCR-14-0604; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Klein AM, 2013, CURR OPIN CELL BIOL, V25, P272, DOI 10.1016/j.ceb.2013.01.002; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Kwon AT, 2012, G3-GENES GENOM GENET, V2, P987, DOI 10.1534/g3.112.003202; Laurent J, 2011, CANCER RES, V71, P3781, DOI 10.1158/0008-5472.CAN-10-3684; Lotz-Jenne C, 2016, ONCOTARGET, V7, P25983, DOI 10.18632/oncotarget.8418; Lou YM, 2008, DEV DYNAM, V237, P2755, DOI 10.1002/dvdy.21658; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marchetti A, 2008, CELL SIGNAL, V20, P2113, DOI 10.1016/j.cellsig.2008.08.002; Milacic Marija, 2012, Cancers (Basel), V4, P1180, DOI 10.3390/cancers4041180; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Mody N, 2003, BIOCHEM J, V372, P567, DOI 10.1042/BJ20030193; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Nakamura K, 2003, J BIOL CHEM, V278, P36989, DOI 10.1074/jbc.C300313200; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Sun WY, 2000, J BIOL CHEM, V275, P24421, DOI 10.1074/jbc.M003148200; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Tse JC, 2007, J CELL BIOCHEM, V101, P816, DOI 10.1002/jcb.21215; Turjanski AG, 2007, ONCOGENE, V26, P3240, DOI 10.1038/sj.onc.1210415; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; von Minckwitz G, 2007, EXPERT OPIN PHARMACO, V8, P485, DOI 10.1517/14656566.8.4.485; Whitmarsh AJ, 2007, ONCOGENE, V26, P3172, DOI 10.1038/sj.onc.1210410; Yan C, 2001, J BIOL CHEM, V276, P10870, DOI 10.1074/jbc.M009286200; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang QK, 2010, CANCER CELL, V18, P258, DOI 10.1016/j.ccr.2010.08.008; Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	66	32	35	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2018	37	31					4197	4213		10.1038/s41388-018-0270-8	http://dx.doi.org/10.1038/s41388-018-0270-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP1HN	29713055				2022-12-17	WOS:000440566100001
J	Ghannam-Shahbari, D; Jacob, E; Kakun, RR; Wasserman, T; Korsensky, L; Sternfeld, O; Kagan, J; Bublik, DR; Aviel-Ronen, S; Levanon, K; Sabo, E; Larisch, S; Oren, M; Hershkovitz, D; Perets, R				Ghannam-Shahbari, Dima; Jacob, Eyal; Kakun, Reli Rachel; Wasserman, Tanya; Korsensky, Lina; Sternfeld, Ofir; Kagan, Juliana; Bublik, Debora Rosa; Aviel-Ronen, Sarit; Levanon, Keren; Sabo, Edmond; Larisch, Sarit; Oren, Moshe; Hershkovitz, Dov; Perets, Ruth			PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma	ONCOGENE			English	Article							CELL-CYCLE ARREST; FALLOPIAN-TUBE; TUMOR SUPPRESSION; THYROID-HORMONE; CANCER; P53; EXPRESSION; P21; PROTEIN; MUTANT	High grade serous carcinoma (HGSC) is the most common subtype of ovarian cancer and it is now widely accepted that this disease often originates from the fallopian tube epithelium. PAX8 is a fallopian tube lineage marker with an essential role in embryonal female genital tract development. In the adult fallopian tube, PAX8 is expressed in the fallopian tube secretory epithelial cell (FTSEC) and its expression is maintained through the process of FTSEC transformation to HGSC. We now report that PAX8 has a pro-proliferative and anti-apoptotic role in HGSC. The tumor suppressor gene TP53 is mutated in close to 100% of HGSC; in the majority of cases, these are missense mutations that endow the mutant p53 protein with potential gain of function (GOF) oncogenic activities. We show that PAX8 positively regulates the expression of TP53 in HGSC and the pro-proliferative role of PAX8 is mediated by the GOF activity of mutant p53. Surprisingly, mutant p53 transcriptionally activates the expression of p21, which localizes to the cytoplasm of HGSC cells where it plays a noncanonical, pro-proliferative role. Together, our findings illustrate how TP53 mutations in HGSC subvert a normal regulatory pathway into a driver of tumor progression.	[Ghannam-Shahbari, Dima; Jacob, Eyal; Kakun, Reli Rachel; Wasserman, Tanya; Korsensky, Lina; Sternfeld, Ofir; Perets, Ruth] Technion Israel Inst Technol, Clin Res Inst Rambam, Div Oncol, Rambam Hlth Care Campus, Haifa, Israel; [Kagan, Juliana; Larisch, Sarit] Univ Haifa, Dept Biol, Cell Death Res Lab, Fac Sci, Haifa, Israel; [Bublik, Debora Rosa; Oren, Moshe] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel; [Aviel-Ronen, Sarit] Sheba Med Ctr, Dept Pathol, Talpiot Med Leadership Program, Ramat Gan, Israel; [Levanon, Keren] Sheba Med Ctr, Sheba Canc Res Ctr, Talpiot Med Leadership Program, Ramat Gan, Israel; [Levanon, Keren] Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel; [Sabo, Edmond] Technion Israel Inst Technol, Dept Pathol, Rambam Hlth Care Campus, Haifa, Israel; [Hershkovitz, Dov] Tel Aviv Univ, Dept Pathol, Tel Aviv Sourasky Med Ctr, Sackler Fac Med, Ramat Aviv, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; University of Haifa; Weizmann Institute of Science; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Rambam Health Care Campus; Technion Israel Institute of Technology; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Perets, R (corresponding author), Technion Israel Inst Technol, Clin Res Inst Rambam, Div Oncol, Rambam Hlth Care Campus, Haifa, Israel.	Ru_Perets@rambam.health.gov.il		Hershkovitz, Dov/0000-0002-7954-4486; Oren, Moshe/0000-0003-4311-7172; Levanon, Keren/0000-0002-5122-064X	The Israel Science Foundation [1901/13]; Israel Cancer Research Fund; The European Commission [PCIG13-GA-2013-618174]; Israel Cancer Association [20150894, 20170117]; The women's health grant at Rambam; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Israel Science Foundation [822/12]; Hymen Milgrom Trust	The Israel Science Foundation(Israel Science Foundation); Israel Cancer Research Fund; The European Commission(European CommissionEuropean Commission Joint Research Centre); Israel Cancer Association; The women's health grant at Rambam; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Israel Science Foundation(Israel Science Foundation); Hymen Milgrom Trust	The work presented here was funded by The Israel Science Foundation (1901/13), Israel Cancer Research Fund, The European Commission (PCIG13-GA-2013-618174), Israel Cancer Association (20150894, 20170117), The women's health grant at Rambam (all to R.P.), Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (to M.O.), Israel Science Foundation (822/12) (to S.L.), The Hymen Milgrom Trust (to S.L.). We would like to thank Prof. Ronny Drapkin (University of Pennsylvania) for FT237 immortalized FTSEC line and Prof. Reuven Agami (AVL, Nederland Cancer Institute) for retroviral p21 shRNA construct.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Ahmed AA, 2010, J PATHOL, V221, P49, DOI 10.1002/path.2696; Al-Hujaily EM, 2015, CANCER PREV RES, V8, P1163, DOI 10.1158/1940-6207.CAPR-15-0121-T; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Au AYM, 2006, ENDOCRINOLOGY, V147, P367, DOI 10.1210/en.2005-0147; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bieging KT, 2012, TRENDS CELL BIOL, V22, P97, DOI 10.1016/j.tcb.2011.10.006; Bijron JG, 2013, AM J SURG PATHOL, V37, P1123, DOI 10.1097/PAS.0b013e318282da7f; Blake JA, 2014, DEVELOPMENT, V141, P737, DOI 10.1242/dev.091785; Blecher-Gonen R, 2013, NAT PROTOC, V8, P539, DOI 10.1038/nprot.2013.023; Bowen NJ, 2007, GYNECOL ONCOL, V104, P331, DOI 10.1016/j.ygyno.2006.08.052; Brachova P, 2013, INT J MOL SCI, V14, P19257, DOI 10.3390/ijms140919257; Carcangiu ML, 2004, INT J GYNECOL PATHOL, V23, P35, DOI 10.1097/01.pgp.0000101082.35393.84; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chan DW, 2017, ONCOGENE, V36, P1404, DOI 10.1038/onc.2016.307; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; Chi N, 2002, TRENDS GENET, V18, P41, DOI 10.1016/S0168-9525(01)02594-X; Doberstein K, 2011, CARCINOGENESIS, V32, P262, DOI 10.1093/carcin/bgq249; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elias KM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87988; HARPER JW, 1993, CELL, V75, P805; Hua G, 2016, ONCOGENE, V35, P2247, DOI 10.1038/onc.2015.288; Iwanicki MP, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86829; Kar SP, 2017, BRIT J CANCER, V116, P524, DOI 10.1038/bjc.2016.426; Laury AR, 2011, AM J SURG PATHOL, V35, P816, DOI 10.1097/PAS.0b013e318216c112; Laury AR, 2010, AM J SURG PATHOL, V34, P627, DOI 10.1097/PAS.0b013e3181da7687; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091; Li CG, 2011, ONCOGENE, V30, P4824, DOI 10.1038/onc.2011.190; Li X, 2012, ONCOGENE, V31, P3419, DOI 10.1038/onc.2011.511; Liu WL, 2011, HEPATOLOGY, V53, P843, DOI 10.1002/hep.24124; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Medeiros F, 2006, AM J SURG PATHOL, V30, P230, DOI 10.1097/01.pas.0000180854.28831.77; Mhawech-Fauceglia P, 2012, GYNECOL ONCOL, V127, P198, DOI 10.1016/j.ygyno.2012.06.012; Mittag J, 2007, ENDOCRINOLOGY, V148, P719, DOI 10.1210/en.2006-1054; Nonaka D, 2008, AM J SURG PATHOL, V32, P1566, DOI 10.1097/PAS.0b013e31816d71ad; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Ordonez NG, 2012, ADV ANAT PATHOL, V19, P140, DOI 10.1097/PAP.0b013e318253465d; Oren O, 2017, STEM CELL REV REP, V13, P17, DOI 10.1007/s12015-016-9691-3; Perets R, 2016, CANCER RES, V76, P10, DOI 10.1158/0008-5472.CAN-15-1382; Perets R, 2013, CANCER CELL, V24, P751, DOI 10.1016/j.ccr.2013.10.013; Perets R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046467; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; Quartuccio SM, 2015, INT J CANCER, V137, P1528, DOI 10.1002/ijc.29528; Rodgers LH, 2016, ONCOTARGET, V7, P32785, DOI 10.18632/oncotarget.9051; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Satyanarayana A, 2008, MOL BIOL CELL, V19, P65, DOI 10.1091/mbc.E07-06-0525; Shah S, 2013, NAT GENET, V45, P1226, DOI 10.1038/ng.2754; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; Tong GX, 2011, DIAGN CYTOPATHOL, V39, P567, DOI 10.1002/dc.21426; Tung CS, 2009, MODERN PATHOL, V22, P1243, DOI 10.1038/modpathol.2009.92; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Wistuba J, 2007, J ENDOCRINOL, V192, P99, DOI 10.1677/JOE-06-0054; Xia X, 2015, EUR J GYNAECOL ONCOL, V36, P662; YAGINUMA Y, 1992, CANCER RES, V52, P4196; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	60	32	35	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2213	2224		10.1038/s41388-017-0040-z	http://dx.doi.org/10.1038/s41388-017-0040-z			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29379162				2022-12-17	WOS:000431100200001
J	Rajabi, H; Hiraki, M; Kufe, D				Rajabi, Hasan; Hiraki, Masayuki; Kufe, Donald			MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; GROUP PROTEIN EZH2; CARCINOMA-ASSOCIATED ANTIGEN; AGGRESSIVE BREAST-CANCER; LUNG-CANCER; PANCREATIC-CANCER; STEM-CELLS; MULTIPLE-MYELOMA; DNA METHYLATION; DRUG-RESISTANCE	The PRC2 and PRC1 complexes are aberrantly expressed in human cancers and have been linked to decreases in patient survival. MUC1-C is an oncoprotein that is also overexpressed in diverse human cancers and is associated with a poor prognosis. Recent studies have supported a previously unreported function for MUC1-C in activating PRC2 and PRC1 in cancer cells. In the regulation of PRC2, MUC1-C (i) drives transcription of the EZH2 gene, (ii) binds directly to EZH2, and (iii) enhances occupancy of EZH2 on target gene promoters with an increase in H3K27 trimethylation. Regarding PRC1, which is recruited to PRC2 sites in the hierarchical model, MUC1-C induces BMI1 transcription, forms a complex with BMI1, and promotes H2A ubiquitylation. MUC1-C thereby contributes to the integration of PRC2 and PRC1-mediated repression of tumor suppressor genes, such as CDH1, CDKN2A, PTEN and BRCA1. Like PRC2 and PRC1, MUC1-C is associated with the epithelial-mesenchymal transition (EMT) program, cancer stem cell (CSC) state, and acquisition of anticancer drug resistance. In concert with these observations, targeting MUC1-C downregulates EZH2 and BMI1, inhibits EMT and the CSC state, and reverses drug resistance. These findings emphasize the significance of MUC1-C as a therapeutic target for inhibiting aberrant PRC function and reprogramming the epigenome in human cancers.	[Rajabi, Hasan; Hiraki, Masayuki; Kufe, Donald] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA; [Hiraki, Masayuki] Osaka Univ, Grad Sch Med, Dept Gastrointestinal Surg, Suita, Osaka, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Osaka University	Kufe, D (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			US Department of Defense [BC151648]; National Cancer Institute of the National Institutes of Health [R01CA097098, R01CA166480, R21CA216553]; NATIONAL CANCER INSTITUTE [R01CA166480, R21CA216553, R01CA097098] Funding Source: NIH RePORTER	US Department of Defense(United States Department of Defense); National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This publication was supported by the US Department of Defense under award number BC151648 and the National Cancer Institute of the National Institutes of Health under award numbers R01CA097098, R01CA166480 and R21CA216553.	Agata N, 2008, CANCER RES, V68, P6136, DOI 10.1158/0008-5472.CAN-08-0464; Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0608-9; Ahmad R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001426; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Alam M, 2016, MOL CANCER RES, V14, P1266, DOI 10.1158/1541-7786.MCR-16-0233; Alam M, 2014, ONCOTARGET, V5, P2622, DOI 10.18632/oncotarget.1848; Alsuliman A, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0421-2; Behrens C, 2013, CLIN CANCER RES, V19, P6556, DOI 10.1158/1078-0432.CCR-12-3946; Blackledge NP, 2015, NAT REV MOL CELL BIO, V16, P643, DOI 10.1038/nrm4067; Bouillez A, 2017, ONCOGENE, V36, P4037, DOI 10.1038/onc.2017.47; Bouillez A, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1338998; Bouillez A, 2016, CANCER RES, V76, P1538, DOI 10.1158/0008-5472.CAN-15-1804; Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Butts C, 2014, LANCET ONCOL, V15, P59, DOI 10.1016/S1470-2045(13)70510-2; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; Chaika NV, 2012, P NATL ACAD SCI USA, V109, P13787, DOI 10.1073/pnas.1203339109; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Chen S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122577; Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533; Comet I, 2016, NAT REV CANCER, V16, P803, DOI 10.1038/nrc.2016.83; Crea F, 2012, CRIT REV ONCOL HEMAT, V83, P184, DOI 10.1016/j.critrevonc.2011.10.007; David JM, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1117738; Dongre A, 2017, CANCER RES, V77, P3982, DOI 10.1158/0008-5472.CAN-16-3292; Duraisamy S, 2007, INT J ONCOL, V31, P671; Dyson HJ, 2016, J BIOL CHEM, V291, P6714, DOI 10.1074/jbc.R115.692020; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Gong JL, 1998, P NATL ACAD SCI USA, V95, P6279, DOI 10.1073/pnas.95.11.6279; Gong Y, 2011, CANCER-AM CANCER SOC, V117, P5476, DOI 10.1002/cncr.26179; Goode G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176820; Gunda V, 2017, CLIN CANCER RES, V23, P5881, DOI 10.1158/1078-0432.CCR-17-1151; Hasegawa M, 2016, ONCOTARGET, V7, P11756, DOI 10.18632/oncotarget.7598; Hasegawa M, 2015, CLIN CANCER RES, V21, P2338, DOI 10.1158/1078-0432.CCR-14-3000; Hernandez-Munoz I, 2005, MOL CELL BIOL, V25, P11047, DOI 10.1128/MCB.25.24.11047-11058.2005; Hiraki M, 2017, ONCOGENE, V36, P2791, DOI 10.1038/onc.2016.439; Huang R, 2011, FASEB J, V25, P4138, DOI 10.1096/fj.11-185033; Inari H, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3154-3; Jang SH, 2016, J BREAST CANCER, V19, P53, DOI 10.4048/jbc.2016.19.1.53; Kharbanda A, 2014, CLIN CANCER RES, V20, P5423, DOI 10.1158/1078-0432.CCR-13-3168; Kharbanda A, 2013, MOL CANCER RES, V11, P714, DOI 10.1158/1541-7786.MCR-12-0668; Khodarev N, 2010, ONCOGENE, V29, P920, DOI 10.1038/onc.2009.391; Khodarev NN, 2009, CANCER RES, V69, P2833, DOI 10.1158/0008-5472.CAN-08-4513; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Koppens M, 2016, ONCOGENE, V35, P1341, DOI 10.1038/onc.2015.195; Kosugi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028234; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; KUFE D, 2009, CANCER BIOL THER, V8, P1201; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Leng YM, 2007, J BIOL CHEM, V282, P19321, DOI 10.1074/jbc.M703222200; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Lin XZ, 2015, BIOMOLECULES, V5, P3396, DOI 10.3390/biom5043396; Lou YY, 2016, CLIN CANCER RES, V22, P3630, DOI 10.1158/1078-0432.CCR-15-1434; MacDermed DM, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-16; Maeda T, 2018, CANCER RES, V78, P205, DOI 10.1158/0008-5472.CAN-17-1636; Mak MP, 2016, CLIN CANCER RES, V22, P609, DOI 10.1158/1078-0432.CCR-15-0876; Mills AA, 2010, NAT REV CANCER, V10, P669, DOI 10.1038/nrc2931; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Mody HR, 2016, MOL CANCER RES, V14, P1124, DOI 10.1158/1541-7786.MCR-16-0083; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nagarsheth N, 2016, CANCER RES, V76, P275, DOI 10.1158/0008-5472.CAN-15-1938; Nath S, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.16; Noman MZ, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1263412; Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800; Peng DJ, 2015, NATURE, V527, P249, DOI 10.1038/nature15520; Pitroda SP, 2009, P NATL ACAD SCI USA, V106, P5837, DOI 10.1073/pnas.0812029106; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Prakash R, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016600; Puppe J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2354; Quoix E, 2016, LANCET ONCOL, V17, P212, DOI 10.1016/S1470-2045(15)00483-0; Raina D, 2014, ONCOGENE, V33, P3422, DOI 10.1038/onc.2013.308; Raina D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135156; Rajabi H, 2016, ONCOGENE, V35, P6439, DOI 10.1038/onc.2016.180; Rajabi H, 2014, ONCOGENE, V33, P1680, DOI 10.1038/onc.2013.114; Rajabi H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07850-0; Rajabi H, 2017, BBA-REV CANCER, V1868, P117, DOI 10.1016/j.bbcan.2017.03.003; Rajabi H, 2012, J BIOL CHEM, V287, P10703, DOI 10.1074/jbc.M111.323311; Ramasamy S, 2007, MOL CELL, V27, P992, DOI 10.1016/j.molcel.2007.07.031; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Ren J, 2006, MOL CANCER RES, V4, P873, DOI 10.1158/1541-7786.MCR-06-0204; Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84; Riising EM, 2014, MOL CELL, V55, P347, DOI 10.1016/j.molcel.2014.06.005; Rosenblatt J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1298; Rosenblatt J, 2013, CLIN CANCER RES, V19, P3640, DOI 10.1158/1078-0432.CCR-13-0282; Sato T, 2013, SCI REP-UK, V3, DOI 10.1038/srep01911; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Shukla SK, 2017, CANCER CELL, V32, P71, DOI 10.1016/j.ccell.2017.06.004; Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Singh PK, 2008, J BIOL CHEM, V283, P26985, DOI 10.1074/jbc.M805036200; Singh PK, 2007, CANCER RES, V67, P5201, DOI 10.1158/0008-5472.CAN-06-4647; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Stroopinsky D, 2013, CANCER RES, V73, P5569, DOI 10.1158/0008-5472.CAN-13-0677; Tagde A, 2017, ONCOTARGET, V8, P69237, DOI 10.18632/oncotarget.20144; Tagde A, 2016, ONCOTARGET, V7, P38974, DOI 10.18632/oncotarget.9777; Tagde A, 2016, BLOOD, V127, P2587, DOI 10.1182/blood-2015-07-659151; Takahashi H, 2015, ONCOGENE, V34, P5187, DOI 10.1038/onc.2014.442; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Uchida Y, 2013, CANCER BIOL THER, V14, P127, DOI 10.4161/cbt.22634; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Vrzalikova K, 2008, J CANCER RES CLIN, V134, P1037, DOI 10.1007/s00432-008-0361-y; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang XH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19239; Wang YY, 2012, WORLD J SURG, V36, P1189, DOI 10.1007/s00268-012-1514-3; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Wen YP, 2017, ONCOTARGET, V8, P37974, DOI 10.18632/oncotarget.16467; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yan KS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061172; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yin L, 2012, BLOOD, V119, P810, DOI 10.1182/blood-2011-07-369686; Yong KJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6066	122	32	32	3	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	16					2079	2088		10.1038/s41388-017-0096-9	http://dx.doi.org/10.1038/s41388-017-0096-9			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GD5ZV	29379165	Green Accepted			2022-12-17	WOS:000430589000001
J	Saatci, O; Borgoni, S; Akbulut, O; Durmus, S; Raza, U; Eyupoglu, E; Alkan, C; Akyol, A; Kutuk, O; Wiemann, S; Sahin, O				Saatci, Ozge; Borgoni, Simone; Akbulut, Ozge; Durmus, Selvi; Raza, Umar; Eyupoglu, Erol; Alkan, Can; Akyol, Aytekin; Kutuk, Ozgur; Wiemann, Stefan; Sahin, Ozgur			Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer	ONCOGENE			English	Article							POLO-LIKE KINASE; SPINDLE-ASSEMBLY CHECKPOINT; ANTIBODY-DRUG CONJUGATE; LOW-DOSE CYTARABINE; TRASTUZUMAB EMTANSINE; TUMOR HETEROGENEITY; GENE-EXPRESSION; MITOTIC ARREST; CELLS; MECHANISMS	Trastuzumab-refractory, HER2 (human epidermal growth factor receptor 2)-positive breast cancer is commonly treated with trastuzumab emtansine (T-DM1), an antibody-drug conjugate of trastuzumab and the microtubule-targeting agent, DM1. However, drug response reduces greatly over time due to acquisition of resistance whose molecular mechanisms are mostly unknown. Here, we uncovered a novel mechanism of resistance against T-DM1 by combining whole transcriptome sequencing (RNA-Seq), proteomics and a targeted small interfering RNA (siRNA) sensitization screen for molecular level analysis of acquired and de novo T-DM1-resistant models of HER2-overexpressing breast cancer. We identified Polo-like kinase 1 (PLK1), a mitotic kinase, as a resistance mediator whose genomic as well as pharmacological inhibition restored drug sensitivity. Both acquired and de novo resistant models exhibited synergistic growth inhibition upon combination of T-DM1 with a selective PLK1 inhibitor, volasertib, at a wide concentration range of the two drugs. Mechanistically, T-DM1 sensitization upon PLK1 inhibition with volasertib was initiated by a spindle assembly checkpoint (SAC)-dependent mitotic arrest, leading to caspase activation, followed by DNA damage through CDK1-dependent phosphorylation and inactivation of Bcl-2/xL. Furthermore, we showed that Ser70 phosphorylation of Bcl-2 directly regulates apoptosis by disrupting the binding to and sequestration of the pro-apoptotic protein Bim. Importantly, T-DM1 resistance signature or PLK1 expression correlated with cell cycle progression and DNA repair, and predicted a lower sensitivity to taxane/trastuzumab combination in HER2-positive breast cancer patients. Finally, volasertib in combination with T-DM1 greatly synergized in models of T-DM1 resistance in terms of growth inhibition both in three dimensional (3D) cell culture and in vivo. Altogether, our results provide promising pre-clinical evidence for potential testing of T-DM1/volasertib combination in T-DM1 refractory HER2-positive breast cancer patients for whom there is currently no treatment available.	[Saatci, Ozge; Akbulut, Ozge; Durmus, Selvi; Raza, Umar; Eyupoglu, Erol; Sahin, Ozgur] Bilkent Univ, Dept Mol Biol & Genet, Fac Sci, TR-06800 Ankara, Turkey; [Borgoni, Simone; Wiemann, Stefan] German Canc Res Ctr, Div Mol Genome Anal, INF580, D-69120 Heidelberg, Germany; [Alkan, Can] Bilkent Univ, Dept Comp Engn, TR-06800 Ankara, Turkey; [Akyol, Aytekin] Hacettepe Univ, Dept Pathol, Sch Med, TR-06410 Ankara, Turkey; [Kutuk, Ozgur] Baskent Univ, Dept Med Genet, TR-01250 Adana, Turkey; [Saatci, Ozge; Sahin, Ozgur] Bilkent Univ, Natl Nanotechnol Res Ctr UNAM, TR-06800 Ankara, Turkey	Ihsan Dogramaci Bilkent University; Helmholtz Association; German Cancer Research Center (DKFZ); Ihsan Dogramaci Bilkent University; Hacettepe University; Baskent University; Ihsan Dogramaci Bilkent University	Saatci, O (corresponding author), Bilkent Univ, Dept Mol Biol & Genet, Fac Sci, TR-06800 Ankara, Turkey.; Saatci, O (corresponding author), Bilkent Univ, Natl Nanotechnol Res Ctr UNAM, TR-06800 Ankara, Turkey.	sahinozgur@gmail.com	Sahin, Özgür/F-4403-2014; Alkan, Can/D-2982-2009; Akyol, Aytekin/B-6384-2009; KUTUK, OZGUR/AAH-1671-2019; Durmus, Selvi/J-2075-2018; Akbulut Çalışkan, Özge/Q-8134-2018; Wiemann, Stefan/E-4424-2013	Sahin, Özgür/0000-0002-8033-7089; Alkan, Can/0000-0002-5443-0706; Akyol, Aytekin/0000-0002-4075-3475; KUTUK, OZGUR/0000-0001-9854-7220; Durmus, Selvi/0000-0003-3792-1607; Akbulut Çalışkan, Özge/0000-0002-3647-1969; Wiemann, Stefan/0000-0003-4683-3174; raza, umar/0000-0002-0081-6996; Borgoni, Simone/0000-0003-3833-0032	TUBITAK-BMBF Bilateral Grant [214Z130, 01DL16003]; EMBO Installation Grant [2791]; Genentech, USA Inc. [OR-213615]; Baskent University; The Science Academy	TUBITAK-BMBF Bilateral Grant; EMBO Installation Grant; Genentech, USA Inc.(Roche HoldingGenentech); Baskent University(Baskent University); The Science Academy	This project was supported by TUBITAK-BMBF Bilateral Grant numbers: TUBITAK, 214Z130 (to OS) and BMBF WTZ, 01DL16003 (to SW). OS further acknowledges the support from EMBO Installation Grant Number 2791. Special thanks to Genentech, USA Inc. for providing us with T-DM1 under Material Transfer Agreement with MTA number OR-213615. We thank the DKFZ Genomics and Proteomics Core Facility for providing sequencing excellent services. We also thank Deniz Atasoy and Pelin Dilsiz from Istanbul Medipol University for their help with confocal microscopy. OK acknowledges support from Baskent University and The Science Academy.	Akbani R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4887; Barok M, 2007, MOL CANCER THER, V6, P2065, DOI 10.1158/1535-7163.MCT-06-0766; Barok M, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3621; Barok M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2868; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Cheng L, 2015, CURR PHARM DESIGN, V21, P1347, DOI 10.2174/1381612820999141029162811; Daemen A, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r110; DeAngelo DJ, 2015, CL LYMPH MYELOM LEUK, V15, pS194, DOI 10.1016/j.clml.2015.04.046; Degenhardt Y, 2010, CLIN CANCER RES, V16, P384, DOI 10.1158/1078-0432.CCR-09-1380; Dohner H, 2014, BLOOD, V124, P1426, DOI 10.1182/blood-2014-03-560557; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Gagliato DD, 2016, ONCOTARGET, V7, P64431, DOI 10.18632/oncotarget.7043; Gajria D, 2011, EXPERT REV ANTICANC, V11, P263, DOI 10.1586/ERA.10.226; Gleixner KV, 2010, CANCER RES, V70, P1513, DOI 10.1158/0008-5472.CAN-09-2181; Gluck S, 2012, BREAST CANCER RES TR, V132, P781, DOI 10.1007/s10549-011-1412-7; Hain KO, 2016, SCI REP-UK, V6, DOI 10.1038/srep26766; Hayashi T, 2015, J UROLOGY, V194, P1120, DOI 10.1016/j.juro.2015.05.087; Henjes F, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.16; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Koninki K, 2010, CANCER LETT, V294, P211, DOI 10.1016/j.canlet.2010.02.002; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lee KS, 2008, CELL DIV, V3, DOI 10.1186/1747-1028-3-4; Leow CC, 2009, MOL CANCER THER, V8, P2131, DOI 10.1158/1535-7163.MCT-08-1038; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Liu XQ, 2015, TRANSL ONCOL, V8, P185, DOI 10.1016/j.tranon.2015.03.010; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LoRusso PM, 2011, CLIN CANCER RES, V17, P6437, DOI 10.1158/1078-0432.CCR-11-0762; MAGER PP, 1981, PHARMAZIE, V36, P382; Maire V, 2013, CANCER RES, V73, P813, DOI 10.1158/0008-5472.CAN-12-2633; Manchado E, 2012, CELL DEATH DIFFER, V19, P369, DOI 10.1038/cdd.2011.197; Marcotte R, 2016, CELL, V164, P293, DOI 10.1016/j.cell.2015.11.062; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Mutlu M, 2016, SCI REP-UK, V6, DOI 10.1038/srep32541; Nicoletti R, 2015, CLIN EXP METASTAS, V32, P29, DOI 10.1007/s10585-014-9688-8; Oroudjev E, 2010, MOL CANCER THER, V9, P2700, DOI 10.1158/1535-7163.MCT-10-0645; Orth JD, 2012, MOL BIOL CELL, V23, P567, DOI 10.1091/mbc.E11-09-0781; Pathan N, 2001, NEOPLASIA, V3, P70, DOI 10.1038/sj.neo.7900131; Phillips GDL, 2008, CANCER RES, V68, P9280, DOI 10.1158/0008-5472.CAN-08-1776; RAFFO AJ, 1995, CANCER RES, V55, P4438; Rantanen S, 2001, LEUKEMIA LYMPHOMA, V42, P1089, DOI 10.3109/10428190109097729; Raza U, 2016, ONCOTARGET, V7, P49859, DOI 10.18632/oncotarget.10489; Recondo G, 2016, CANCER MANAG RES, V8, P57, DOI 10.2147/CMAR.S104447; Roden DM, 2011, CIRCULATION, V123, P1661, DOI 10.1161/CIRCULATIONAHA.109.914820; Sahin O, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-1; Sahin O, 2007, P NATL ACAD SCI USA, V104, P6579, DOI 10.1073/pnas.0606827104; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sonntag J, 2014, EXPERT REV PROTEOMIC, V11, P757, DOI 10.1586/14789450.2014.971113; Spankuch B, 2007, ONCOGENE, V26, P5793, DOI 10.1038/sj.onc.1210355; Spector NL, 2009, J CLIN ONCOL, V27, P5838, DOI 10.1200/JCO.2009.22.1507; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Tanner M, 2004, MOL CANCER THER, V3, P1585; Vu T, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00062; Trakala M, 2015, BLOOD, V126, P1707, DOI 10.1182/blood-2015-03-634402; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Turpin J, 2016, ONCOGENE, V35, P6053, DOI 10.1038/onc.2016.129; van Vugt MATM, 2005, ONCOGENE, V24, P2844, DOI 10.1038/sj.onc.1208617; Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124; Vogel C, 2005, J BIOL CHEM, V280, P4025, DOI 10.1074/jbc.C400545200; Wang QF, 2012, CANCER RES, V72, P4417, DOI 10.1158/0008-5472.CAN-12-1339-T; Winkles JA, 2005, ONCOGENE, V24, P260, DOI 10.1038/sj.onc.1208219; Wright N, 2017, FRONT BIOSCI-LANDMRK, V22, P1549, DOI 10.2741/4558; Xiao DB, 2016, MOL CELL, V64, P493, DOI 10.1016/j.molcel.2016.09.016; Yamada HY, 2006, MOL CANCER THER, V5, P2963, DOI 10.1158/1535-7163.MCT-06-0319; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yim H, 2013, ANTI-CANCER DRUG, V24, P999, DOI 10.1097/CAD.0000000000000007; Yuan JP, 2011, AM J PATHOL, V179, P2091, DOI 10.1016/j.ajpath.2011.06.031; Zitouni S, 2014, NAT REV MOL CELL BIO, V15, P433, DOI 10.1038/nrm3819	75	32	35	0	37	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2251	2269		10.1038/s41388-017-0108-9	http://dx.doi.org/10.1038/s41388-017-0108-9			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29391599	Green Published			2022-12-17	WOS:000431100200004
J	Blomme, A; Van Simaeys, G; Doumont, G; Costanza, B; Bellier, J; Otaka, Y; Sherer, F; Lovinfosse, P; Boutry, S; Palacios, AP; De Pauw, E; Hirano, T; Yokobori, T; Hustinx, R; Bellahcene, A; Delvenne, P; Detry, O; Goldman, S; Nishiyama, M; Castronovo, V; Turtoi, A				Blomme, Arnaud; Van Simaeys, Gaetan; Doumont, Gilles; Costanza, Brunella; Bellier, Justine; Otaka, Yukihiro; Sherer, Felicie; Lovinfosse, Pierre; Boutry, Sebastien; Palacios, Ana Perez; De Pauw, Edwin; Hirano, Touko; Yokobori, Takehiko; Hustinx, Roland; Bellahcene, Akeila; Delvenne, Philippe; Detry, Olivier; Goldman, Serge; Nishiyama, Masahiko; Castronovo, Vincent; Turtoi, Andrei			Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases	ONCOGENE			English	Article							BREAST-CANCER; TUMOR XENOGRAFTS; MOUSE MODELS; F-18-FDG PET; THERAPY; MICE; DISEASE	Cancer research is increasingly dependent of patient-derived xenograft model (PDX). However, a major point of concern regarding the PDX model remains the replacement of the human stroma with murine counterpart. In the present work we aimed at clarifying the significance of the human-to-murine stromal replacement for the fidelity of colorectal cancer (CRC) and liver metastasis (CRC-LM) PDX model. We have conducted a comparative metabolic analysis between 6 patient tumors and corresponding PDX across 4 generations. Metabolic signatures of cancer cells and stroma were measured separately by MALDI-imaging, while metabolite changes in entire tumors were quantified using mass spectrometry approach. Measurement of glucose metabolism was also conducted in vivo using [F-18]-fluorodeoxyglucose (FDG) and positron emission tomography (PET). In CRC/CRC-LM PDX model, human stroma was entirely replaced at the second generation. Despite this change, MALDI-imaging demonstrated that the metabolic profiles of both stromal and cancer cells remained stable for at least four generations in comparison to the original patient material. On the tumor level, profiles of 86 water-soluble metabolites as well as 93 lipid mediators underlined the functional stability of the PDX model. In vivo PET measurement of glucose uptake (reflecting tumor glucose metabolism) supported the ex vivo observations. Our data show for the first time that CRC/CRC-LM PDX model maintains the functional stability at the metabolic level despite the early replacement of the human stroma by murine cells. The findings demonstrate that human cancer cells actively educate murine stromal cells during PDX development to adopt the human-like phenotype.	[Blomme, Arnaud; Costanza, Brunella; Bellier, Justine; Palacios, Ana Perez; Bellahcene, Akeila; Castronovo, Vincent; Turtoi, Andrei] GIGA Canc Univ Liege, Metastasis Res Lab, Liege, Belgium; [Van Simaeys, Gaetan; Sherer, Felicie; Goldman, Serge] Univ Libre Bruxelles, Hop Erasme, Brussels, Belgium; [Van Simaeys, Gaetan; Doumont, Gilles; Sherer, Felicie; Goldman, Serge] Univ Libre Bruxelles, Ctr Microscopy & Mol Imaging, Brussels, Belgium; [Otaka, Yukihiro; Yokobori, Takehiko; Nishiyama, Masahiko] Gunma Univ, Dept Mol Pharmacol & Oncol, Grad Sch Med, Gunma, Japan; [Lovinfosse, Pierre; Hustinx, Roland] Liege Univ Hosp, Med Phys Dept, Nucl Med & Oncol Imaging Div, Liege, Belgium; [Boutry, Sebastien] Univ Mons, Dept Gen Organ & Biomed Chem, NMR & Mol Imaging Lab, Mons, Belgium; [Boutry, Sebastien] Univ Mons UMONS, Ctr Microscopy & Mol Imaging, Charleroi, Gosselies, Belgium; [De Pauw, Edwin] Univ Liege, Mass Spectrometry Lab, Liege, Belgium; [Hirano, Touko] Gunma Univ, Lab Analyt Instruments, Grad Sch Med, Gunma, Japan; [Delvenne, Philippe] Univ Liege, Univ Hosp, Dept Pathol, Liege, Belgium; [Detry, Olivier] Univ Liege, Univ Hosp, Dept Abdominal Surg, Liege, Belgium; [Turtoi, Andrei] Inst Rech Cancerol Montpellier, Tumor Microenvironm & Resistance Treatment Lab, Montpellier, France; [Turtoi, Andrei] Inst Canc Montpellier, Montpellier, France; [Turtoi, Andrei] INSERM, U1194, Montpellier, France; [Turtoi, Andrei] Univ Montpellier, Montpellier, France	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Gunma University; University of Liege; University of Mons; University of Liege; Gunma University; University of Liege; University of Liege; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier	Turtoi, A (corresponding author), GIGA Canc Univ Liege, Metastasis Res Lab, Liege, Belgium.; Turtoi, A (corresponding author), Inst Rech Cancerol Montpellier, Tumor Microenvironm & Resistance Treatment Lab, Montpellier, France.; Turtoi, A (corresponding author), Inst Canc Montpellier, Montpellier, France.; Turtoi, A (corresponding author), INSERM, U1194, Montpellier, France.; Turtoi, A (corresponding author), Univ Montpellier, Montpellier, France.	andrei.turtoi@inserm.fr	Detry, Olivier/I-9333-2019; Turtoi, Andrei/ABD-1271-2021; Van Simaeys, Gaetan/AAR-8082-2020; Bonnemaison, Marc/AAD-9243-2021; Costanza, Brunella/AAB-6354-2022; Blomme, Arnaud/AAM-1440-2020; Blomme, Arnaud/AGO-7915-2022	Detry, Olivier/0000-0002-9436-6673; Turtoi, Andrei/0000-0003-3813-6635; Van Simaeys, Gaetan/0000-0002-2678-542X; Blomme, Arnaud/0000-0003-4183-8726; Otaka, Yukihiro/0000-0002-9162-7188; Costanza, Brunella/0000-0001-8279-805X	University of Fiege; National Fund for Scientific Research (FNRS); Gunma University (GIAR Research Program for Omics-Based Medical Science); European Regional Development Fund (ERDF); Walloon Region; Fondation ULB; Fonds Erasme; "Association Vingotte Nuclear" (AVN); ERDF; FabEx Mablmprove Starting Grant	University of Fiege; National Fund for Scientific Research (FNRS)(Fonds de la Recherche Scientifique - FNRS); Gunma University (GIAR Research Program for Omics-Based Medical Science); European Regional Development Fund (ERDF)(European Commission); Walloon Region; Fondation ULB; Fonds Erasme; "Association Vingotte Nuclear" (AVN); ERDF(European Commission); FabEx Mablmprove Starting Grant	The authors acknowledge the experimental support of Dr. Chantal Humblet, Mrs. Alice Marquet (GIGA-histology platform, ULg), Mr. Vincent Hennequiere, Mrs. Naima Maloujahmoum (Metastasis Research Laboratory), Mrs. Yezza Ben Salah (Tumor Microenvironment and Resistance to Treatment Lab, IRCM), Mr. Nicolas Passon (CMMI) and Mrs. Mari-Aline Laute (CMMI). The authors are thankful to Dr. Stephanie Gofflot (Biobank, University Hospital Liege) for providing patient material as well as the Cyclotron Unit of Erasme Hospital (Brussels, Belgium) for providing [18F]-FDG. Prof. Robert N. Muller (CMMI, Director of international partnerships) is thanked for his scientific input and support. Mr. Mathieu Roch (CMMI) is thanked for tumor volume measurements on MR images.This work was supported with grants from the University of Fiege, National Fund for Scientific Research (FNRS) and Gunma University (GIAR Research Program for Omics-Based Medical Science). The CMMI is supported by the European Regional Development Fund (ERDF), the Walloon Region, the Fondation ULB, the Fonds Erasme and the "Association Vingotte Nuclear" (AVN). GD is supported by the ERDF and the Walloon Region. Akeila Bellahcene is a Research Director at the FNRS. AT is a senior research fellow of the French National Institute of Health and Medical Research (INSERM) and is supported by FabEx Mablmprove Starting Grant. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams MC, 2010, AM J ROENTGENOL, V195, P310, DOI 10.2214/AJR.10.4923; Amos-Landgraf JM, 2014, P NATL ACAD SCI USA, V111, P16514, DOI 10.1073/pnas.1323064111; Blomme A, 2017, ONCOGENE, V36, P2116, DOI 10.1038/onc.2016.369; Boellaard R, 2010, EUR J NUCL MED MOL I, V37, P181, DOI 10.1007/s00259-009-1297-4; Cassidy JW, 2015, CANCER RES, V75, P2963, DOI 10.1158/0008-5472.CAN-15-0727; Chiavarina B, 2017, CURR MED CHEM, V24, P2846, DOI 10.2174/0929867324666170428104311; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; Fueger BJ, 2006, J NUCL MED, V47, P999; GIOVANELLA BC, 1989, SCIENCE, V246, P1046, DOI 10.1126/science.2555920; HOUGHTON JA, 1981, CANCER RES, V41, P144; Hylander BL, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-110; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kilkenny C, 2012, OSTEOARTHR CARTILAGE, V20, P256, DOI 10.1016/j.joca.2012.02.010; Kim MP, 2009, NAT PROTOC, V4, P1670, DOI 10.1038/nprot.2009.171; Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022; Lin D, 2017, ONCOTARGET, V8, P25928, DOI 10.18632/oncotarget.15237; Lou S, 2017, BBA-PROTEINS PROTEOM, V1865, P957, DOI 10.1016/j.bbapap.2016.09.020; McDonnell LA, 2014, J PROTEOME RES, V13, P1138, DOI 10.1021/pr400620y; Sanz L, 2009, LAB INVEST, V89, P91, DOI 10.1038/labinvest.2008.108; Sha W, 2013, EJNMMI RES, V3, DOI 10.1186/2191-219X-3-51; Siolas D, 2013, CANCER RES, V73, P5315, DOI 10.1158/0008-5472.CAN-13-1069; Tentler JJ, 2012, NAT REV CLIN ONCOL, V9, P338, DOI 10.1038/nrclinonc.2012.61; Valtorta S, 2017, J NUCL MED, V58, P42, DOI 10.2967/jnumed.116.176404; van Velden FHP, 2011, EUR J NUCL MED MOL I, V38, P1636, DOI 10.1007/s00259-011-1845-6; Wahl RL, 2009, J NUCL MED, V50, p122S, DOI 10.2967/jnumed.108.057307; Walsh NC, 2017, ANNU REV PATHOL-MECH, V12, P187, DOI 10.1146/annurev-pathol-052016-100332; Werner-Klein M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097860; Xu LA, 1999, HUM GENE THER, V10, P2941, DOI 10.1089/10430349950016357; Zhang XM, 2013, CANCER RES, V73, P4885, DOI 10.1158/0008-5472.CAN-12-4081	29	32	36	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	9					1237	1250		10.1038/s41388-017-0018-x	http://dx.doi.org/10.1038/s41388-017-0018-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FY0MK	29242606				2022-12-17	WOS:000426505400008
J	Jia, WZ; Zhao, XP; Zhao, L; Yan, H; Li, JJ; Yang, H; Huang, G; Liu, JJ				Jia, Wenzhi; Zhao, Xiaoping; Zhao, Li; Yan, Hui; Li, Jiajin; Yang, Hao; Huang, Gang; Liu, Jianjun			Non-canonical roles of PFKFB3 in regulation of cell cycle through binding to CDK4	ONCOGENE			English	Article							ADVANCED BREAST-CANCER; 6-PHOSPHOFRUCTO-2-KINASE PFKFB3; DEPENDENT KINASES; DOWN-REGULATION; GLYCOLYSIS; GROWTH; INHIBITORS; ARREST; EXPRESSION; CARCINOMA	There is growing interest in studying the molecular mechanisms of crosstalk between cancer metabolism and the cell cycle. 6-phosphate fructose-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) is a well-known glycolytic activator that plays an important role in tumorigenesis. We investigated whether PFKFB3 was directly involved in oncogenic signaling networks. Mass Spectrometry showed that PFKFB3 interacts with cyclin-dependent kinase (CDK) 4, which controls the transition from G1 phase to S phase of the cell cycle. Further analysis indicated that lysine 147 was a key site for the binding of PFKBFB3 to CDK4. PFKFB3 binding resulted in the accumulation of CDK4 protein by inhibiting ubiquitin proteasome degradation mediated by the heat shock protein 90-Cdc37-CDK4 complex. The proteasome-dependent degradation of CDK4 was accelerated by disrupting the interaction of PFKFB3 with CDK4 by mutating lysine (147) to alanine. Blocking PFKFB3-CDK4 interaction improved the therapeutic effect of FDA-approved CDK4 inhibitor palbociclib on breast cancer. These findings suggest that PFKFB3 is a hub for coordinating cell cycle and glucose metabolism. Combined targeting of PFKFB3 and CDK4 may be new strategy for breast cancer treatment.	[Jia, Wenzhi; Zhao, Xiaoping; Zhao, Li; Yan, Hui; Li, Jiajin; Yang, Hao; Huang, Gang; Liu, Jianjun] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Nucl Med, Shanghai, Peoples R China; [Huang, Gang] Shanghai Univ Med & Hlth Sci, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai University of Medicine & Health Sciences	Huang, G; Liu, JJ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Nucl Med, Shanghai, Peoples R China.; Huang, G (corresponding author), Shanghai Univ Med & Hlth Sci, Shanghai, Peoples R China.	huang2802@163.com; ljjsh@133sh.com		Li, Jiajin/0000-0003-1300-6025	National Natural Science Foundation of China [81471687, 81530053, 81372195, 81471685, 81572719, 81601520]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The study was supported by research grants from National Natural Science Foundation of China (No. 81471687, 81530053, 81372195, 81471685, 81572719, 81601520).	Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504; Atsumi T, 2002, CANCER RES, V62, P5881; Braden WA, 2008, ONCOGENE, V27, P7083, DOI 10.1038/onc.2008.319; Calvo MN, 2006, FEBS LETT, V580, P3308, DOI 10.1016/j.febslet.2006.04.093; Cavalier MC, 2012, PROTEINS, V80, P1143, DOI 10.1002/prot.24015; Cen L, 2012, NEURO-ONCOLOGY, V14, P870, DOI 10.1093/neuonc/nos114; Chesney J, 1999, P NATL ACAD SCI USA, V96, P3047, DOI 10.1073/pnas.96.6.3047; Cieslar-Pobuda A, 2015, ONCOTARGET, V6, P29753, DOI 10.18632/oncotarget.4995; Clem BF, 2013, MOL CANCER THER, V12, P1461, DOI 10.1158/1535-7163.MCT-13-0097; Dai MO, 2016, SCI REP-UK, V6, DOI 10.1038/srep35383; Dimco G, 2010, CELL CYCLE, V9, P4638, DOI 10.4161/cc.9.23.13955; Domenech E, 2015, NAT CELL BIOL, V17, P1304, DOI 10.1038/ncb3231; Enzo E, 2015, EMBO J, V34, P1349, DOI 10.15252/embj.201490379; Erez A, 2015, NAT REV CANCER, V15, P440, DOI 10.1038/nrc3949; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Finn RS, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-015-0661-5; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Gillam MP, 2015, ONCOGENE, V34, P932, DOI 10.1038/onc.2014.3; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Heilmann AM, 2014, CANCER RES, V74, P3947, DOI 10.1158/0008-5472.CAN-13-2923; Imbert-Fernandez Y, 2014, J BIOL CHEM, V289, P9440, DOI 10.1074/jbc.M113.529990; Jia Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097448; Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882; Katsumi Y, 2011, BIOCHEM BIOPH RES CO, V413, P62, DOI 10.1016/j.bbrc.2011.08.047; Klarer AC, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-2; Konecny GE, 2011, CLIN CANCER RES, V17, P1591, DOI 10.1158/1078-0432.CCR-10-2307; Li HM, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0481-1; Li TY, 2014, CELL PHYSIOL BIOCHEM, V34, P1351, DOI 10.1159/000366342; Lu J, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0194-5; Lu YZ, 2014, J CLIN INVEST, V124, P1672, DOI 10.1172/JCI63139; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Mao CQ, 2014, MOL THER, V22, P964, DOI 10.1038/mt.2014.18; McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; O'Leary B, 2016, NAT REV CLIN ONCOL, V13, P417, DOI 10.1038/nrclinonc.2016.26; Okar DO, 2001, TRENDS BIOCHEM SCI, V26, P30, DOI 10.1016/S0968-0004(00)01699-6; Perez M, 2015, ONCOTARGET, V6, P40557, DOI 10.18632/oncotarget.5829; Reid MA, 2016, GENE DEV, V30, P1837, DOI 10.1101/gad.287235.116; Rider MH, 2004, BIOCHEM J, V381, P561, DOI 10.1042/BJ20040752; Roberts PJ, 2012, JNCI-J NATL CANCER I, V104, P476, DOI 10.1093/jnci/djs002; Schoors S, 2014, CELL METAB, V19, P37, DOI 10.1016/j.cmet.2013.11.008; Shi H, 2009, CANCER SCI, V100, P1585, DOI 10.1111/j.1349-7006.2009.01223.x; Smith JR, 2009, ONCOGENE, V28, P157, DOI 10.1038/onc.2008.380; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Vaughan CK, 2008, MOL CELL, V31, P886, DOI 10.1016/j.molcel.2008.07.021; Vaughan CK, 2006, MOL CELL, V23, P697, DOI 10.1016/j.molcel.2006.07.016; Verba KA, 2016, SCIENCE, V352, P1542, DOI 10.1126/science.aaf5023; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wu AB, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-38; Yalcin A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.292; Yalcin A, 2009, J BIOL CHEM, V284, P24223, DOI 10.1074/jbc.M109.016816; Yamamoto T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4480; Yang C, 2017, ONCOGENE, V36, P2255, DOI 10.1038/onc.2016.379; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang Y, 2014, ONCOL REP, V31, P2759, DOI 10.3892/or.2014.3127; Young RJ, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12228; Zhong ZJ, 2010, CANCER RES, V70, P2105, DOI 10.1158/0008-5472.CAN-08-1108; Zhu Z, 2016, ONCOGENE, V35, P1399, DOI 10.1038/onc.2015.197	59	32	32	3	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	13					1685	1698		10.1038/s41388-017-0072-4	http://dx.doi.org/10.1038/s41388-017-0072-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA9AE	29335521				2022-12-17	WOS:000428632600001
J	Niu, Y; Jin, Y; Deng, SC; Deng, SJ; Zhu, S; Liu, Y; Li, X; He, C; Liu, ML; Zeng, Z; Chen, HY; Zhong, JX; Ye, Z; Wang, CY; Zhao, G				Niu, Yi; Jin, Yan; Deng, Shi-Chang; Deng, Shi-Jiang; Zhu, Shuai; Liu, Yang; Li, Xiang; He, Chi; Liu, Ming-Liang; Zeng, Zhu; Chen, Heng-Yu; Zhong, Jian-Xin; Ye, Zeng; Wang, Chun-You; Zhao, Gang			MiRNA-646-mediated reciprocal repression between HIF-1 alpha and MIIP contributes to tumorigenesis of pancreatic cancer	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; CELLULAR-RESPONSE; BREAST-CANCER; HYPOXIA; EXPRESSION; CELLS; MIGRATION; INVASION; TARGETS; GENE	Migration and invasion inhibitory protein (MIIP) is recently identified as an inhibitor in tumor development. However, the regulatory mechanism and biological contributions of MIIP in pancreatic cancer (PC) have been not elucidated. In this study, we demonstrated a negative feedback of MIIP and hypoxia-induced factor-1 alpha (HIF-1 alpha), which was mediated by a hypoxia-induced microRNA. Compared with paracarcinoma tissues, MIIP was downregulated in PC tissues. Overexpression of MIIP significantly impeded the proliferation and invasion of PC cells both in vitro and in mouse xenograft models. We further verified MIIP was downregulated under hypoxia in a HIF-1 alpha-mediated manner. Interestingly, although MIIP promoter containing two putative hypoxia response elements (HREs), the chromatin immunoprecipitation (ChIP) and luciferase reporter assays did not support an active interaction between HIF-1a and MIIP promoter. Meanwhile, microRNA array revealed a hypoxia-induced microRNA, miR-646, impaired stability of MIIP mRNA and consequently inhibited its expression by targeting the coding sequence (CDS). Coincidently, knockdown of miR-646 significantly repressed proliferation and invasion ability of PC cells both in vitro and in vivo by upregulating MIIP expression. Besides, ChIP and luciferase reporter assays further validated that HIF-1 alpha activated transcription of miR-646 in hypoxia condition. Therefore, these results suggested HIF-1 alpha indirectly regulated MIIP expression in post-transcriptional level through upregulating miR-646 transcription. Conversely, our results further revealed that MIIP suppressed deacetylase ability of histone deacetylase 6 (HDAC6) to promote the acetylation and degradation of HIF-1 alpha, by which impairing HIF-1 alpha accumulation. What is more, a specific relationship between downregulated MIIP and upregulated miR-646 expression was validated in PC samples. Moreover, the dysregulated miR-646 and MIIP expression was correlated with advanced tumor stage, lymphatic invasion, metastasis and shorter overall survival in PC patients. Together, our results highlight that the reciprocal loop of HIF-1 alpha/miR-646/MIIP might be implemented as an applicable target for pancreatic cancer therapy.	[Niu, Yi; Jin, Yan; Deng, Shi-Chang; Deng, Shi-Jiang; Zhu, Shuai; Liu, Yang; Li, Xiang; He, Chi; Liu, Ming-Liang; Zeng, Zhu; Chen, Heng-Yu; Zhong, Jian-Xin; Ye, Zeng; Wang, Chun-You; Zhao, Gang] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Pancreat Dis Inst,Dept Pancreat Surg, Wuhan, Hubei, Peoples R China	Huazhong University of Science & Technology	Zhao, G (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Pancreat Dis Inst,Dept Pancreat Surg, Wuhan, Hubei, Peoples R China.	gangzhao@aliyun.com	fuliyun_new, fuliyun_new/AAZ-4437-2020	Jin, Yan/0000-0001-5957-7443; Li, Xiang/0000-0002-5942-7282	National Natural Science Foundation of China [81672406, 81372666, 30972900, 81502076]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundation of China (no. 81672406, no. 81372666, no. 30972900, and no. 81502076).	Azam AT, 2016, TUMOR BIOL, V37, P5769, DOI 10.1007/s13277-015-3821-4; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Chen J, 2016, ONCOGENE, V35, P2506, DOI 10.1038/onc.2015.316; Chen Z, 2010, ONCOGENE, V29, P4362, DOI 10.1038/onc.2010.193; Deng SC, 2015, ONCOTARGET, V6, P39661, DOI 10.18632/oncotarget.5350; Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008; Fasanaro P, 2008, J BIOL CHEM, V283, P15878, DOI 10.1074/jbc.M800731200; Feldser D, 1999, CANCER RES, V59, P3915; Gomez-Roman N, 2016, ONCOTARGET, V7, P22650, DOI 10.18632/oncotarget.7998; Hausser J, 2013, GENOME RES, V23, P604, DOI 10.1101/gr.139758.112; Hui ABY, 2009, LAB INVEST, V89, P597, DOI 10.1038/labinvest.2009.12; Ji P, 2010, ONCOGENE, V29, P3501, DOI 10.1038/onc.2010.114; Jing W, 2011, ONCOTARGET, V7, P9118; Jones MF, 2015, P NATL ACAD SCI USA, V112, pE1550, DOI 10.1073/pnas.1503370112; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Krzywinski M, 2013, NAT METHODS, V10, P1139, DOI 10.1038/nmeth.2738; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Lee KJ, 2010, BBA-MOL CELL RES, V1803, P608, DOI 10.1016/j.bbamcr.2010.01.004; Li W., 2011, J NUCL ACIDS, V2011, P1, DOI DOI 10.4061/2011/870726; Li X, 2016, ONCOTARGET, V7, P6000, DOI 10.18632/oncotarget.6830; Liu GJ, 2015, MOL BIOL EVOL, V32, P623, DOI 10.1093/molbev/msu323; Liu Y, 2015, GENE THER, V22, P729, DOI 10.1038/gt.2015.39; Loscalzo J, 2010, J CLIN INVEST, V120, P3815, DOI 10.1172/JCI45105; Mace TA, 2013, J SURG RES, V184, P855, DOI 10.1016/j.jss.2013.04.061; Nallamshetty S, 2013, FREE RADICAL BIO MED, V64, P20, DOI 10.1016/j.freeradbiomed.2013.05.022; Pothula SP, 2015, CANC LETT, V24, P232; Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598; Reczko M, 2012, BIOINFORMATICS, V28, P771, DOI 10.1093/bioinformatics/bts043; Sermeus A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.48; Song FF, 2015, ONCOL REP, V33, P2771, DOI 10.3892/or.2015.3905; Sun Y, 2017, J PATHOL, V241, P67, DOI 10.1002/path.4823; Vaiman D, 2017, PLACENTA, V52, P127, DOI 10.1016/j.placenta.2016.12.026; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Wang R, 2014, SCI WORLD J, DOI 10.1155/2014/312704; Wang XC, 2016, ONCOTARGET, V7, P13717, DOI 10.18632/oncotarget.7263; Wang Y, 2011, CANCER RES, V70, P423; Wang YM, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0342-6; Wang YM, 2011, CURR PROTEIN PEPT SC, V12, P68; Wen W, 2010, CANCER RES, V70, P2010, DOI 10.1158/0008-5472.CAN-08-4910; Wu C, 2011, MOL CELL BIOL, V31, P4760, DOI 10.1128/MCB.05776-11; Wu Q, 2015, J BIOL CHEM, V290, P1170, DOI 10.1074/jbc.M114.601203; Wu Y, 2010, J BIOL CHEM, V285, P3554, DOI 10.1074/jbc.M109.063354; Ying Q, 2011, HEPATOLOGY, V54, P2064, DOI 10.1002/hep.24614; Zhang D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.240; Zhang DY, 2010, CANCER RES, V70, P813, DOI 10.1158/0008-5472.CAN-09-0448; Zhang Z, 2009, CELL CYCLE, V8, P2756, DOI 10.4161/cc.8.17.9387; Zhao G, 2013, MOL CANCER THER, V12, P83, DOI 10.1158/1535-7163.MCT-12-0534-T; Zhou HL, 2014, RNA, V20, P1431, DOI 10.1261/rna.045757.114; Zhu S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.189	49	32	34	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	13					1743	1758		10.1038/s41388-017-0082-2	http://dx.doi.org/10.1038/s41388-017-0082-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA9AE	29343850				2022-12-17	WOS:000428632600005
J	Xue, J; Zhu, W; Song, J; Jiao, Y; Luo, J; Yu, C; Zhou, J; Wu, J; Chen, M; Ding, WQ; Cao, J; Zhang, S				Xue, J.; Zhu, W.; Song, J.; Jiao, Y.; Luo, J.; Yu, C.; Zhou, J.; Wu, J.; Chen, M.; Ding, W-Q; Cao, J.; Zhang, S.			Activation of PPAR alpha by clofibrate sensitizes pancreatic cancer cells to radiation through the Wnt/beta-catenin pathway	ONCOGENE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; DOWN-REGULATION; WNT PATHWAY; EXPRESSION; FENOFIBRATE; CARCINOMA; GROWTH; RADIOSENSITIVITY; ADENOCARCINOMA; PROLIFERATION	Radiotherapy is emerging as an important modality for the local control of pancreatic cancer, but pancreatic cancer cell radioresistance remains a serious concern. Peroxisome proliferator-activated receptor a (PPAR alpha) is a member of the PPAR nuclear hormone receptor superfamily, which can be activated by fibrate ligands. The clinical relevance of PPAR alpha and its biological function in pancreatic cancer radiosensitivity have not been previously described. In this study, we examined PPAR alpha expression in tissue samples of pancreatic cancer patients. We found significantly higher expression of PPAR alpha in pancreatic cancer tissues than in tumor-adjacent tissues and that the PPAR alpha expression level is inversely associated with higher overall patient survival rate. We further observed that PPAR alpha activation by its agonist clofibrate sensitizes pancreatic cancer cells to radiation by modulating cell cycle progression and apoptosis in several pancreatic cancer cell lines. Small interfering RNA-mediated PPAR alpha silencing and PPAR alpha blockade by the antagonist GW6471 abolish the effect of clofibrate on radiosensitization. An in vivo study showed that PANC1 xenografts treated with clofibrate are more sensitive to radiation than untreated xenografts. mRNA profiling by microarray analysis revealed that the expression of PTPRZ1 and Wnt8a, two core components of the beta-catenin pathway, is downregulated by clofibrate. Chromatin immunoprecipitation analysis confirmed that clofibrate abrogates the binding of nuclear factor-kappa B to the PTPRZ1 and Wnt8a promoters, ultimately decreasing Wnt/beta-catenin signaling activity, which is associated with radiosensitivity. Overall, we demonstrate that PPARa is overexpressed in pancreatic cancer tissues and clofibrate-mediated PPARa activation sensitizes pancreatic cancer cells to radiation through the Wnt/beta-catenin pathway.	[Xue, J.; Zhu, W.; Song, J.; Jiao, Y.; Yu, C.; Cao, J.; Zhang, S.] Soochow Univ, Med Coll, Sch Radiat Med & Protect, 199 Renai Rd, Suzhou 215123, Peoples R China; [Xue, J.; Zhu, W.; Song, J.; Jiao, Y.; Yu, C.; Cao, J.; Zhang, S.] Soochow Univ, Jiangsu Higher Educ Inst, Collaborat Innovat Ctr Radiat Med, Suzhou, Peoples R China; [Xue, J.; Zhu, W.; Song, J.; Jiao, Y.; Yu, C.; Cao, J.; Zhang, S.] Soochow Univ, Jiangsu Prov Key Lab Radiat Med & Protect, Suzhou, Peoples R China; [Luo, J.] Nanjing Med Univ, Affiliated Hosp, Dept Oncol, Changzhou Peoples Hosp 2, Changzhou, Peoples R China; [Zhou, J.; Wu, J.] Nanjing Med Univ, Affiliated Suzhou Hosp, Core Lab, Suzhou Canc Ctr, Suzhou, Peoples R China; [Chen, M.; Zhang, S.] Zhejiang Canc Hosp, Zhejiang Key Lab Radiat Oncol, Hangzhou, Zhejiang, Peoples R China; [Ding, W-Q] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA	Soochow University - China; Soochow University - China; Soochow University - China; Nanjing Medical University; Nanjing Medical University; Zhejiang Cancer Hospital; University of Oklahoma System; University of Oklahoma Health Sciences Center	Cao, J; Zhang, S (corresponding author), Soochow Univ, Med Coll, Sch Radiat Med & Protect, 199 Renai Rd, Suzhou 215123, Peoples R China.	jpcao@suda.edu.cn; zhang.shuyu@hotmail.com	Chen, Ming/GYE-1379-2022	Chen, Ming/0000-0001-5041-9342	National Natural Science Foundation of China [81522039, 81573080, 81673100, 31670857]; Key Scientific Development Program of China [2016YFC0904700, 2016YFC0904702]; Suzhou Key Medical Center [SZZX201506]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Scientific Development Program of China; Suzhou Key Medical Center; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported by the National Natural Science Foundation of China (81522039, 81573080, 81673100 and 31670857), the Key Scientific Development Program of China (2016YFC0904700 and 2016YFC0904702), the Suzhou Key Medical Center (SZZX201506) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Afifi MM, 2014, BIOCONJUGATE CHEM, V25, P207, DOI 10.1021/bc400271x; [Anonymous], 2010, J MOL BIOL, V404, P172; [Anonymous], 2010, J MOL BIOL, V388, P225; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Chandran K, 2016, ONCOTARGET, V7, P15577, DOI 10.18632/oncotarget.6402; Changela K, 2016, CAN J GASTROENTEROL, V2016, DOI 10.1155/2016/4189358; Chen H, 2014, WORLD J GASTROENTERO, V20, P8681, DOI 10.3748/wjg.v20.i26.8681; Chen J, 2014, J NEUROSCI RES, V92, P1252, DOI 10.1002/jnr.23415; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cheng R, 2016, DIABETES, V65, P3730, DOI 10.2337/db16-0426; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; Cunningham TJ, 2015, DEV DYNAM, V244, P797, DOI 10.1002/dvdy.24275; Evans DB, 2008, J CLIN ONCOL, V26, P3496, DOI 10.1200/JCO.2007.15.8634; Gao JM, 2015, EUR J PHARMACOL, V765, P560, DOI 10.1016/j.ejphar.2015.09.027; Ge YY, 2014, TUMOR BIOL, V35, P10765, DOI 10.1007/s13277-014-2149-9; Goodman KA, 2016, CANCER J, V22, P290, DOI 10.1097/PPO.0000000000000206; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hajj C, 2015, REP PRACT ONCOL RADI, V20, P377, DOI 10.1016/j.rpor.2015.05.008; Han DF, 2015, ONCOTARGET, V6, P26119, DOI 10.18632/oncotarget.4444; Hoffe S, 2014, SEMIN RADIAT ONCOL, V24, P113, DOI 10.1016/j.semradonc.2013.11.002; Karim RZ, 2004, PATHOLOGY, V36, P120, DOI 10.1080/00313020410001671957; Kostapanos MS, 2013, WORLD J HEPATOL, V5, P470, DOI 10.4254/wjh.v5.i9.470; Li XQ, 2015, TUMORI, V101, P123, DOI 10.5301/tj.5000228; Lin H, 2010, AM J PATHOL, V177, P1697, DOI 10.2353/ajpath.2010.090789; Liu YT, 2007, AM J PATHOL, V171, P1978, DOI 10.2353/ajpath.2007.070741; Lucero OM, 2010, CURR ONCOL REP, V12, P314, DOI 10.1007/s11912-010-0114-3; Luo JD, 2013, CANCER SCI, V104, P1544, DOI 10.1111/cas.12248; Maggiora M, 2010, CELL BIOCHEM FUNCT, V28, P571, DOI 10.1002/cbf.1691; Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3; Midha S, 2016, CANCER LETT, V381, P269, DOI 10.1016/j.canlet.2016.07.022; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Misra P, 2014, BIOCHIMIE, V98, P63, DOI 10.1016/j.biochi.2013.11.011; Pisters PWT, 2002, J CLIN ONCOL, V20, P2537, DOI 10.1200/JCO.2002.11.064; Polireddy K, 2016, J CANCER, V7, P1497, DOI 10.7150/jca.14922; Saitoh T, 2002, INT J ONCOL, V20, P999; Segawa Y, 2002, PROSTATE, V51, P108, DOI 10.1002/pros.10058; Shang DH, 2013, WORLD J UROL, V31, P1547, DOI 10.1007/s00345-013-1077-4; Skrypnyk N, 2014, CANCER RES, V74, P621, DOI 10.1158/0008-5472.CAN-13-1928; Tang YT, 2015, SCI REP-UK, V5, DOI 10.1038/srep09476; Urbanska K, 2008, INT J CANCER, V123, P1015, DOI 10.1002/ijc.23588; Wright MB, 2014, MOL ENDOCRINOL, V28, P1756, DOI 10.1210/me.2013-1427; WYSOWSKI DK, 1990, JAMA-J AM MED ASSOC, V263, P2185, DOI 10.1001/jama.263.16.2185; Yamazaki K, 2007, GUT, V56, P1557, DOI 10.1136/gut.2007.129858; Yang W, 2016, ONCOTARGET, V7, P41505, DOI 10.18632/oncotarget.9214; Yin WH, 2013, ACTA CARDIOL SIN, V29, P251; Yokoyama Y, 2007, MOL CANCER THER, V6, P1379, DOI 10.1158/1535-7163.MCT-06-0722; Zhang QH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152407; Zhang SY, 2011, CARCINOGENESIS, V32, P1183, DOI 10.1093/carcin/bgr105; Zhao WL, 2007, RADIAT RES, V167, P581, DOI 10.1667/RR0814.1; Zhou JD, 2012, J BIOL CHEM, V287, P35161, DOI 10.1074/jbc.M112.367367	51	32	35	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					953	962		10.1038/onc.2017.401	http://dx.doi.org/10.1038/onc.2017.401			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059162				2022-12-17	WOS:000425281800012
J	Holmes, B; Benavides-Serrato, A; Freeman, RS; Landon, KA; Bashir, T; Nishimura, RN; Gera, J				Holmes, B.; Benavides-Serrato, A.; Freeman, R. S.; Landon, K. A.; Bashir, T.; Nishimura, R. N.; Gera, J.			mTORC2/AKT/HSF1/HuR constitute a feed-forward loop regulating Rictor expression and tumor growth in glioblastoma	ONCOGENE			English	Article							MTOR COMPLEX 2; HEAT-SHOCK; RICH ELEMENTS; CYCLIN D1; PTEN LOSS; AKT; CANCER; HSF1; TRANSLATION; PATHWAY	Overexpression of Rictor has been demonstrated to result in increased mechanistic target of rapamycin C2 (mTORC2) nucleation and activity leading to tumor growth and increased invasive characteristics in glioblastoma multiforme (GBM). However, the mechanisms regulating Rictor expression in these tumors is not clearly understood. In this report, we demonstrate that Rictor is regulated at the level of mRNA translation via heat-shock transcription factor 1 (HSF1)-induced HuR activity. HuR is shown to directly bind the 3' untranslated region of the Rictor transcript and enhance translational efficiency. Moreover, we demonstrate that mTORC2/AKT signaling activates HSF1 resulting in a feed-forward cascade in which continued mTORC2 activity is able to drive Rictor expression. RNAi-mediated blockade of AKT, HSF1 or HuR is sufficient to downregulate Rictor and inhibit GBM growth and invasive characteristics in vitro and suppress xenograft growth in mice. Modulation of AKT or HSF1 activity via the ectopic expression of mutant alleles support the ability of AKT to activate HSF1 and demonstrate continued HSF1/HuR/Rictor signaling in the context of AKT knockdown. We further show that constitutive overexpression of HuR is able to maintain Rictor expression under conditions of AKT or HSF1 loss. The expression of these components is also examined in patient GBM samples and correlative associations between the relative expression of these factors support the presence of these signaling relationships in GBM. These data support a role for a feed-forward loop mechanism by which mTORC2 activity stimulates Rictor translational efficiency via an AKT/HSF1/HuR signaling cascade resulting in enhanced mTORC2 activity in these tumors.	[Holmes, B.; Benavides-Serrato, A.; Gera, J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; [Holmes, B.; Benavides-Serrato, A.; Freeman, R. S.; Landon, K. A.; Bashir, T.; Nishimura, R. N.; Gera, J.] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Res & Dev, Los Angeles, CA USA; [Nishimura, R. N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Gera, J.] Univ Calif Los Angeles, Johnsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Gera, J.] Univ Calif Los Angeles, Mol Biol Inst, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Gera, J (corresponding author), Greater Los Angeles VA Healthcare Syst, Dept Hematol Oncol, 16111 Plummer St 151,Bldg 1,Room C111A, Los Angeles, CA 91343 USA.	gera@ucla.edu		Holmes, Brent/0000-0002-2768-2991; Gera, Joseph/0000-0002-2908-6894	VA MERIT grant [I01BX002665]; NIH grant [R01CA109312]; NATIONAL CANCER INSTITUTE [R01CA109312] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002665] Funding Source: NIH RePORTER	VA MERIT grant; NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	We thank Dr Eugene Kandel, Dr Jacob Fleischmann, Dr Norimoto Yanagawa, Dr Sanjai Sharma and Dr Paul Mischel for cell lines and reagents. We also thank Dr Alan Lichtenstein for comments on the manuscript and Jheralyn Martin and Janine Masri for technical assistance. This work was supported, in whole or in part, by VA MERIT I01BX002665 and NIH R01CA109312 grants.	Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012; Bashir T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047741; Bhattacharya K, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.34; Carpenter RL, 2015, ONCOGENE, V34, P546, DOI 10.1038/onc.2013.582; Chen CC, 2010, DEV CELL, V18, P592, DOI 10.1016/j.devcel.2010.03.008; Cheng HY, 2015, CANCER DISCOV, V5, P1262, DOI 10.1158/2159-8290.CD-14-0971; Chou SD, 2015, ONCOGENE, V34, P2178, DOI 10.1038/onc.2014.177; Cloninger C, 2011, MOL CANCER THER, V10, P2244, DOI 10.1158/1535-7163.MCT-11-0478; Cornu M, 2013, CURR OPIN GENET DEV, V23, P53, DOI 10.1016/j.gde.2012.12.005; Dai CK, 2012, J CLIN INVEST, V122, P3742, DOI 10.1172/JCI62727; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Driscoll DR, 2016, CANCER RES, V76, P6911, DOI 10.1158/0008-5472.CAN-16-0810; Gabai VL, 2012, MOL CELL BIOL, V32, P929, DOI 10.1128/MCB.05921-11; Gibault L, 2012, MODERN PATHOL, V25, P197, DOI 10.1038/modpathol.2011.163; Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017; Holmes B, 2016, J BIOL CHEM, V291, P14146, DOI 10.1074/jbc.M116.726927; Hsu JH, 2002, ONCOGENE, V21, P1391, DOI 10.1038/sj/onc/1205194; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Jo OD, 2008, J BIOL CHEM, V283, P23274, DOI 10.1074/jbc.M801185200; Koo J, 2015, J BIOL CHEM, V290, P14120, DOI 10.1074/jbc.M114.633057; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Leach MD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11704; Masri J, 2007, CANCER RES, V67, P11712, DOI 10.1158/0008-5472.CAN-07-2223; Masui K, 2016, BIOESSAYS, V38, P839, DOI 10.1002/bies.201600026; Mendillo ML, 2012, CELL, V150, P549, DOI 10.1016/j.cell.2012.06.031; Nabors LB, 2001, CANCER RES, V61, P2154; Oh WJ, 2011, CELL CYCLE, V10, P2305, DOI 10.4161/cc.10.14.16586; Oh WJ, 2010, EMBO J, V29, P3939, DOI 10.1038/emboj.2010.271; Read RD, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003253; Riemenschneider MJ, 2006, CANCER RES, V66, P5618, DOI 10.1158/0008-5472.CAN-06-0364; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Srikantan S, 2012, FRONT BIOSCI-LANDMRK, V17, P189, DOI 10.2741/3921; Tanaka K, 2011, CANCER DISCOV, V1, P524, DOI 10.1158/2159-8290.CD-11-0124; Tandon M, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3611; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Vartanian R, 2011, MOL CANCER RES, V9, P115, DOI 10.1158/1541-7786.MCR-10-0105; Wang B, 2017, NATURE, V545, P365, DOI 10.1038/nature22344; Wu Si-Han, 2014, Cancer Biology Medicine, V11, P255, DOI 10.7497/j.issn.2095-3941.2014.04.004; Yasuda K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142943; Zinzalla V, 2011, CELL, V144, P757, DOI 10.1016/j.cell.2011.02.014; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	42	32	35	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					732	743		10.1038/onc.2017.360	http://dx.doi.org/10.1038/onc.2017.360			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059166	Green Accepted, Green Submitted			2022-12-17	WOS:000424628100005
J	Chhabra, Y; Wong, HY; Nikolajsen, LF; Steinocher, H; Papadopulos, A; Tunny, KA; Meunier, FA; Smith, AG; Kragelund, BB; Brooks, AJ; Waters, MJ				Chhabra, Y.; Wong, H. Y.; Nikolajsen, L. F.; Steinocher, H.; Papadopulos, A.; Tunny, K. A.; Meunier, F. A.; Smith, A. G.; Kragelund, B. B.; Brooks, A. J.; Waters, M. J.			A growth hormone receptor SNP promotes lung cancer by impairment of SOCS2-mediated degradation	ONCOGENE			English	Article							SIGNALING PATHWAY; FACTOR-I; EXPRESSION; PROTEIN; PHOSPHORYLATION; MAMMARY; SOCS; IDENTIFICATION; SUPPRESSOR; STAT5	Both humans and mice lacking functional growth hormone (GH) receptors are known to be resistant to cancer. Further, autocrine GH has been reported to act as a cancer promoter. Here we present the first example of a variant of the GH receptor (GHR) associated with cancer promotion, in this case lung cancer. We show that the GHRP495T variant located in the receptor intracellular domain is able to prolong the GH signal in vitro using stably expressing mouse pro-B-cell and human lung cell lines. This is relevant because GH secretion is pulsatile, and extending the signal duration makes it resemble autocrine GH action. Signal duration for the activated GHR is primarily controlled by suppressor of cytokine signalling 2 (SOCS2), the substrate recognition component of the E3 protein ligase responsible for ubiquitinylation and degradation of the GHR. SOCS2 is induced by a GH pulse and we show that SOCS2 binding to the GHR is impaired by a threonine substitution at Pro 495. This results in decreased internalisation and degradation of the receptor evident in TIRF microscopy and by measurement of mature (surface) receptor expression. Mutational analysis showed that the residue at position 495 impairs SOCS2 binding only when a threonine is present, consistent with interference with the adjacent Thr494. The latter is key for SOCS2 binding, together with nearby Tyr487, which must be phosphorylated for SOCS2 binding. We also undertook nuclear magnetic resonance spectroscopy approach for structural comparison of the SOCS2 binding scaffold Ile455-Ser588, and concluded that this single substitution has altered the structure of the SOCS2 binding site. Importantly, we find that lung BEAS-2B cells expressing GHRP495T display increased expression of transcripts associated with tumour proliferation, epithelial-mesenchymal transition and metastases (TWIST1, SNAI2, EGFR, MYC and CCND1) at 2 h after a GH pulse. This is consistent with prolonged GH signalling acting to promote cancer progression in lung cancer.	[Chhabra, Y.; Tunny, K. A.; Brooks, A. J.; Waters, M. J.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia; [Chhabra, Y.; Tunny, K. A.; Brooks, A. J.] Univ Queensland, Translat Res Inst, Diamantina Inst, Woolloongabba, Qld 4102, Australia; [Wong, H. Y.] Univ Queensland, Ctr Clin Res, Herston, Qld, Australia; [Nikolajsen, L. F.; Steinocher, H.; Kragelund, B. B.] Univ Copenhagen, Dept Biol, Struct Biol & NMR Lab SBiNLab, Copenhagen, Denmark; [Papadopulos, A.; Meunier, F. A.] Univ Queensland, Queensland Brain Inst, Clem Jones Ctr Ageing Dementia Res, Brisbane, Qld, Australia; [Smith, A. G.] Queensland Univ Technol, Translat Res Inst, Sch Biomed Sci, Inst Hlth & Biomed Innovat, Woolloongabba, Qld, Australia	University of Queensland; University of Queensland; University of Queensland; University of Copenhagen; University of Queensland; Queensland University of Technology (QUT)	Brooks, AJ (corresponding author), Univ Queensland, Translat Res Inst, Diamantina Inst, Woolloongabba, Qld 4102, Australia.	abrooks@uq.edu.au	Meunier, Frederic A/C-8161-2009; Chhabra, Yash/C-8801-2018; Brooks, Andrew/A-9969-2011	Meunier, Frederic A/0000-0001-6400-1107; Chhabra, Yash/0000-0003-2883-4675; Brooks, Andrew/0000-0002-2691-1668; Wong, Ho Yi/0000-0002-1245-4056; Smith, Aaron/0000-0003-2937-1713; Nikolajsen, Louise Fletcher/0000-0002-7573-213X	National Health and Medical Research Council (NHMRC) of Australia [APP1084797, APP1002893, APP1025082]; Lundbeck Foundation; Novo Nordisk Foundation; Australian Research Council [LE0882864, DP170100125]; University of Queensland IPRS scholarship; Novo Nordisk Fonden [NNF15OC0016076, NNF15OC0016670, NNF14OC0010211] Funding Source: researchfish	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Lundbeck Foundation(Lundbeckfonden); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Australian Research Council(Australian Research Council); University of Queensland IPRS scholarship; Novo Nordisk Fonden(Novo Nordisk Foundation)	We thank Professor John J Kopchick (Ohio) for ghr-/- mice. We thank Queensland Brain Institute's (QBI) Advanced Microimaging and Analysis Facility for help with TIRF and the Translational Research Institute Microscopy Core Facility for help with imaging. This work was supported by project grants APP1084797, APP1002893 and APP1025082 from the National Health and Medical Research Council (NHMRC) of Australia grants to MJW and AJB, and by the Lundbeck Foundation and the Novo Nordisk Foundation to BBK. FAM is a NHMRC Senior Research Fellow (569596) and supported by Australian Research Council LIEF grant (LE0882864) and Discovery Project Grant (DP170100125). YC is supported by University of Queensland IPRS scholarship. This work is dedicated to Andrew Mitchell.	Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Brooks AJ, 2014, SCIENCE, V344, P710, DOI 10.1126/science.1249783; Bryksin AV, 2010, BIOTECHNIQUES, V48, P463, DOI 10.2144/000113418; Bullock AN, 2007, STRUCTURE, V15, P1493, DOI 10.1016/j.str.2007.09.016; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Cao GC, 2008, JPN J CLIN ONCOL, V38, P308, DOI 10.1093/jjco/hyn007; Chhabra Y, 2011, EXPERT REV ENDOCRINO, V6, P71, DOI [10.1586/eem.10.73, 10.1586/EEM.10.73]; Conway-Campbell BL, 2007, P NATL ACAD SCI USA, V104, P13331, DOI 10.1073/pnas.0600181104; Coschigano KT, 2003, ENDOCRINOLOGY, V144, P3799, DOI 10.1210/en.2003-0374; Dinkel H, 2016, NUCLEIC ACIDS RES, V44, pD294, DOI 10.1093/nar/gkv1291; Divisova J, 2006, BREAST CANCER RES TR, V98, P315, DOI 10.1007/s10549-006-9168-1; Du L, 2003, ENDOCRINOLOGY, V144, P868, DOI 10.1210/en.2002-220830; Flores-Morales A, 2006, MOL ENDOCRINOL, V20, P241, DOI 10.1210/me.2005-0170; Fujimoto M, 2003, TRENDS IMMUNOL, V24, P659, DOI 10.1016/j.it.2003.10.008; Greenhalgh CJ, 2002, MOL ENDOCRINOL, V16, P1394, DOI 10.1210/me.16.6.1394; Guevara-Aguirre J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001845; Gunnell D, 2001, EPIDEMIOL REV, V23, P313, DOI 10.1093/oxfordjournals.epirev.a000809; Hao B, 2007, MOL CELL, V26, P131, DOI 10.1016/j.molcel.2007.02.022; Haura EB, 2005, CLIN CANCER RES, V11, P8288, DOI 10.1158/1078-0432.CCR-05-0827; Haxholm GW, 2015, BIOCHEM J, V468, P495, DOI 10.1042/BJ20141243; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Huang HL, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0463-x; Hung JJ, 2009, THORAX, V64, P1082, DOI 10.1136/thx.2009.115691; Iavnilovitch E, 2004, INT J CANCER, V112, P607, DOI 10.1002/ijc.20484; Ikeno Y, 2009, J GERONTOL A-BIOL, V64, P522, DOI 10.1093/gerona/glp017; Jaffe CA, 1998, J CLIN INVEST, V102, P153, DOI 10.1172/JCI2908; Jiang RC, 2011, MOL DIAGN THER, V15, P347, DOI 10.2165/11599190-000000000-00000; Krebs DL, 2000, J CELL SCI, V113, P2813; Kuner R, 2009, LUNG CANCER, V63, P32, DOI 10.1016/j.lungcan.2008.03.033; Li Y, 2006, ONCOGENE, V25, P1896, DOI 10.1038/sj.onc.1209214; Lin XX, 2014, TOXICOL MECH METHOD, V24, P575, DOI 10.3109/15376516.2014.956909; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Lu TP, 2010, CANCER EPIDEM BIOMAR, V19, P2590, DOI 10.1158/1055-9965.EPI-10-0332; Malaney P, 2013, SCI REP-UK, V3, DOI 10.1038/srep02035; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Mukhina S, 2004, P NATL ACAD SCI USA, V101, P15166, DOI 10.1073/pnas.0405881101; Ocaranza P, 2012, J PEDIATR ENDOCR MET, V25, P273, DOI 10.1515/jpem-2011-0491; Papadopulos A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7297; Paul C, 2000, EUR J BIOCHEM, V267, P5849, DOI 10.1046/j.1432-1327.2000.01395.x; Plotnikov A, 2008, CANCER RES, V68, P1354, DOI 10.1158/0008-5472.CAN-07-6094; Rudd MF, 2006, GENOME RES, V16, P693, DOI 10.1101/gr.5120106; Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75; SOUZA SC, 1995, P NATL ACAD SCI USA, V92, P959, DOI 10.1073/pnas.92.4.959; Stajduhar E, 2014, TUMOR BIOL, V35, P6425, DOI 10.1007/s13277-014-1827-y; Su LJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-140; Tollet-Egnell P, 1999, ENDOCRINOLOGY, V140, P3693, DOI 10.1210/en.140.8.3693; Trengove MC, 2013, AM J CLIN EXP IMMUNO, V2, P1; Uyttendaele I, 2007, MOL ENDOCRINOL, V21, P2821, DOI 10.1210/me.2006-0541; Van Dyke AL, 2009, J CANCER EPIDEMIOL, V2009, DOI 10.1155/2009/242151; van Kerkhof P, 2007, J BIOL CHEM, V282, P20475, DOI 10.1074/jbc.M702610200; VANCE ML, 1985, J CLIN INVEST, V75, P1584, DOI 10.1172/JCI111864; Veldhuis JD, 1998, GROWTH HORM IGF RES, V8, P49, DOI 10.1016/S1096-6374(98)80024-5; Vesterlund M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025358; Vincent EE, 2011, BRIT J CANCER, V104, P1755, DOI 10.1038/bjc.2011.132; Wan Y, 2004, J BIOL CHEM, V279, P44775, DOI 10.1074/jbc.M406092200; Wang XZ, 1996, MOL ENDOCRINOL, V10, P1249, DOI 10.1210/me.10.10.1249; Wikman H, 2002, ONCOGENE, V21, P5804, DOI 10.1038/sj.onc.1205726; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200; Wu ZS, 2011, J CLIN ENDOCR METAB, V96, pE1619, DOI 10.1210/jc.2011-1245; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yang XXO, 2013, NAT IMMUNOL, V14, P732, DOI 10.1038/ni.2633; Yip PY, 2015, TRANSL LUNG CANCER R, V4, P165, DOI 10.3978/j.issn.2218-6751.2015.01.04; Yu H, 1999, JNCI-J NATL CANCER I, V91, P151, DOI 10.1093/jnci/91.2.151; Yu Y, 2015, CANCER CHEMOTH PHARM, V75, P917, DOI 10.1007/s00280-015-2710-2; Zhang HY, 2003, J BIOMOL NMR, V25, P173, DOI 10.1023/A:1022836027055	67	32	34	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					489	501		10.1038/onc.2017.352	http://dx.doi.org/10.1038/onc.2017.352			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28967904	Green Published, hybrid			2022-12-17	WOS:000423331600007
J	Diehl, K; Dinges, LA; Helm, O; Ammar, N; Plundrich, D; Arlt, A; Rocken, C; Sebens, S; Schafer, H				Diehl, K.; Dinges, L-A; Helm, O.; Ammar, N.; Plundrich, D.; Arlt, A.; Roecken, C.; Sebens, S.; Schaefer, H.			Nuclear factor E2-related factor-2 has a differential impact on MCT1 and MCT4 lactate carrier expression in colonic epithelial cells: a condition favoring metabolic symbiosis between colorectal cancer and stromal cells	ONCOGENE			English	Article							KEAP1-NRF2 PATHWAY; OXIDATIVE STRESS; PROTEASOME ACTIVITY; KEAP1/NRF2 PATHWAY; PROTEIN EXPRESSION; SIGNALING PATHWAY; BREAST CANCERS; NRF2; FIBROBLASTS; ACTIVATION	Malignant tumors, such as colorectal cancer (CRC), are heterogeneous diseases characterized by distinct metabolic phenotypes. These include Warburg-and reverse Warburg phenotypes depending on differential distribution of the lactate carrier proteins monocarboxylate transporter-4 and -1 (MCT4 and MCT1). Here, we elucidated the role of the antioxidant transcription factor nuclear factor E2-related factor-2 (Nrf2) as the key regulator of cellular adaptation to inflammatory/environmental stress in shaping the metabolism toward a reverse Warburg phenotype in malignant and premalignant colonic epithelial cells. Immunohistochemistry of human CRC tissues revealed reciprocal expression of MCT1 and MCT4 in carcinoma and stroma cells, respectively, accompanied by strong epithelial Nrf2 activation. In colorectal tissue from inflammatory bowel disease patients, MCT1 and Nrf2 were coexpressed as well, relating to CD68+inflammatory infiltrates. Indirect coculture of human NCM460 colonocytes with M1- but not M2 macrophages induces MCT1 as well as G6PD, LDHB and TALDO expression, whereas MCT4 expression was decreased. Nrf2 knockdown or reactive oxygen species (ROS) scavenging blocked these coculture effects in NCM460 cells. Likewise, Nrf2 knockdown inhibited similar effects of tBHQ-mediated Nrf2 activation on NCM460 and HCT15 CRC cells. M1 coculture or Nrf2 activation/overexpression greatly altered the lactate uptake but not glucose uptake and mitochondrial activities in these cells, reflecting the reverse Warburg phenotype. Depending on MCT1-mediated lactate uptake, Nrf2 conferred protection from TRAIL-induced apoptosis in NCM460 and HCT15 cells. Moreover, metabolism-dependent clonal growth of HCT15 cells was induced by Nrf2-dependent activation of MCT1-driven lactate exchange. These findings indicate that Nrf2 has an impact on the metabolism already in premalignant colonic epithelial cells exposed to inflammatory M1 macrophages, an effect accompanied by growth and survival alterations. Favoring the reverse Warburg effect, these Nrf2-dependent alterations add to malignant transformation of the colonic epithelium.	[Diehl, K.; Arlt, A.; Schaefer, H.] Lab Mol Gastroenterol, Dept Internal Med 1, UKSH Campus Kiel, Kiel, Germany; [Dinges, L-A; Helm, O.; Ammar, N.; Plundrich, D.; Sebens, S.; Schaefer, H.] Univ Kiel, Inst Expt Canc Res, UKSH Campus Kiel,Bldg 17,Arnold Heller Str 3, D-24105 Kiel, Germany; [Roecken, C.] Univ Kiel, Inst Pathol, UKSH Campus Kiel, Kiel, Germany; [Roecken, C.; Sebens, S.] Comprehens Canc Ctr Kiel, Biomat Bank, UKSH Campus Kiel, Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital	Schafer, H (corresponding author), Univ Kiel, Inst Expt Canc Res, UKSH Campus Kiel,Bldg 17,Arnold Heller Str 3, D-24105 Kiel, Germany.	hschaef@1med.uni-kiel.de	Schäfer, Heiner/C-1055-2011; Röcken, Christoph/A-9239-2010; Sebens, Susanne/C-1222-2010; Arlt, Alexander/G-7308-2019	Röcken, Christoph/0000-0002-6989-8002; Arlt, Alexander/0000-0002-6160-1059; Schafer, Heiner/0000-0001-6936-9090	Wilhelm-Sander-Stiftung [2015.011.01]; German-Cancer-Aid [111555]; Cluster of Excellence 'Inflammation at Interfaces'	Wilhelm-Sander-Stiftung; German-Cancer-Aid(Deutsche Krebshilfe); Cluster of Excellence 'Inflammation at Interfaces'	We thank Maike Witt-Ramdohr and Iris Kosmol (both from the Institute of Experimental Cancer Research), and Sandra Kruger and Deniza Hajzeri (both from the Institute of Pathology) for excellent technical assistance. We also thank Dr Jens Dischinger for supporting with radioactivity experiments. Financial support by the Wilhelm-Sander-Stiftung (2015.011.01 to HS), the German-Cancer-Aid (111555 to KD) and the Cluster of Excellence 'Inflammation at Interfaces' (to HS, AA and SS) is greatly acknowledged.	Alvarez Z, 2016, CEREB CORTEX, V26, P1046, DOI 10.1093/cercor/bhu281; Arlt A, 2009, ONCOGENE, V28, P3983, DOI 10.1038/onc.2009.264; Bolanos JP, 2016, J NEUROCHEM, V139, P115, DOI 10.1111/jnc.13486; Chartoumpekis DV, 2015, BIOCHEM SOC T, V43, P639, DOI 10.1042/BST20150049; Fang ZS, 2016, BBA-MOL CELL RES, V1863, P2245, DOI 10.1016/j.bbamcr.2016.05.016; Feron O, 2009, RADIOTHER ONCOL, V92, P329, DOI 10.1016/j.radonc.2009.06.025; Ferro S, 2016, ONCOTARGET, V7, P70639, DOI 10.18632/oncotarget.12156; Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949; Folmes CDL, 2016, SEMIN CELL DEV BIOL, V52, P68, DOI 10.1016/j.semcdb.2016.02.010; Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145; Ganan-Gomez I, 2013, FREE RADICAL BIO MED, V65, P750, DOI 10.1016/j.freeradbiomed.2013.06.041; Geismann C, 2014, ONCOTARGETS THER, V7, P1497, DOI 10.2147/OTT.S36624; Giudice A, 2006, BIOESSAYS, V28, P169, DOI 10.1002/bies.20359; Hadjiagapiou C, 2005, AM J PHYSIOL-GASTR L, V288, pG1118, DOI 10.1152/ajpgi.00312.2004; Hai T, 1999, GENE EXPRESSION, V7, P321; Halestrap AP, 2013, MOL ASPECTS MED, V34, P337, DOI 10.1016/j.mam.2012.05.003; Hashimoto Y, 2002, NUCLEIC ACIDS RES, V30, P2398, DOI 10.1093/nar/30.11.2398; Hawkins KE, 2016, CELL REP, V14, P1883, DOI 10.1016/j.celrep.2016.02.003; Hayes JD, 2014, TRENDS BIOCHEM SCI, V39, P199, DOI 10.1016/j.tibs.2014.02.002; Hayes JD, 2010, ANTIOXID REDOX SIGN, V13, P1713, DOI 10.1089/ars.2010.3221; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hu TH, 2013, J BIOMED RES, V27, P283, DOI 10.7555/JBR.27.20130069; Jaramillo MC, 2013, GENE DEV, V27, P2179, DOI 10.1101/gad.225680.113; Ji LL, 2014, INT J CLIN EXP PATHO, V7, P1124; Kensler TW, 2013, TOP CURR CHEM, V329, P163, DOI 10.1007/128_2012_339; Koukourakis MI, 2006, CANCER RES, V66, P632, DOI 10.1158/0008-5472.CAN-05-3260; Kruse ML, 2016, INFLAMM BOWEL DIS, V22, P2593, DOI 10.1097/MIB.0000000000000925; Kundu JK, 2012, FREE RADICAL BIO MED, V52, P2013, DOI 10.1016/j.freeradbiomed.2012.02.035; Lambert DW, 2002, BRIT J CANCER, V86, P1262, DOI 10.1038/sj.bjc.6600264; Lee Minjong, 2015, World J Biol Chem, V6, P148, DOI 10.4331/wjbc.v6.i3.148; Leinonen HM, 2015, BIOCHEM SOC T, V43, P645, DOI 10.1042/BST20150048; Leithner K, 2015, ONCOGENE, V34, P1044, DOI 10.1038/onc.2014.47; Li LN, 2015, PHARMACOL THERAPEUT, V150, P33, DOI 10.1016/j.pharmthera.2015.01.004; Martinez-Outschoorn UE, 2011, INT J BIOCHEM CELL B, V43, P1045, DOI 10.1016/j.biocel.2011.01.023; Martins SF, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2566-9; McCullagh KJA, 1996, AM J PHYSIOL-ENDOC M, V271, pE143, DOI 10.1152/ajpendo.1996.271.1.E143; Menendez JA, 2016, STEM CELL REP, V6, P273, DOI 10.1016/j.stemcr.2015.12.012; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Montal ED, 2015, MOL CELL, V60, P571, DOI 10.1016/j.molcel.2015.09.025; Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315; Nakajima EC, 2013, MOL CARCINOGEN, V52, P329, DOI 10.1002/mc.21863; Nakayama Y, 2012, EXP THER MED, V3, P25, DOI 10.3892/etm.2011.361; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; Pinheiro C, 2008, VIRCHOWS ARCH, V452, P139, DOI 10.1007/s00428-007-0558-5; Pinheiro C, 2012, J BIOENERG BIOMEMBR, V44, P127, DOI 10.1007/s10863-012-9428-1; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Sanita P, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-154; Schafer H, 2013, ONCOGENE, V32, P180, DOI 10.1038/onc.2012.44; Sebens S, 2011, J BIOL CHEM, V286, P40911, DOI 10.1074/jbc.M111.274902; Semenza GL, 2008, J CLIN INVEST, V118, P3835, DOI 10.1172/JCI37373; Shan T, 2017, ONCOL REP, V37, P1971, DOI 10.3892/or.2017.5479; Sivridis E, 2005, J CLIN PATHOL, V58, P1033, DOI 10.1136/jcp.2005.026260; Slocum SL, 2016, ARCH BIOCHEM BIOPHYS, V591, P57, DOI 10.1016/j.abb.2015.11.040; Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278; Suzuki T, 2013, TRENDS PHARMACOL SCI, V34, P340, DOI 10.1016/j.tips.2013.04.005; Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x; Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200; Upadhyay M, 2013, PHARMACOL THERAPEUT, V137, P318, DOI 10.1016/j.pharmthera.2012.11.003; Vincent EE, 2015, MOL CELL, V60, P195, DOI 10.1016/j.molcel.2015.08.013; Visconti R, 2009, IDRUGS, V12, P240; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Whitaker-Menezes D, 2011, CELL CYCLE, V10, P1772, DOI 10.4161/cc.10.11.15659; Winiarska K, 2003, METABOLISM, V52, P739, DOI 10.1016/S0026-0495(03)00035-0; Witkiewicz AK, 2012, CELL CYCLE, V11, P1108, DOI 10.4161/cc.11.6.19530; Witkiewicz AK, 2011, CELL CYCLE, V10, P1794, DOI 10.4161/cc.10.11.15675; Wong CC, 2017, ONCOGENE, V36, P3359, DOI 10.1038/onc.2016.485; Xu XD, 2015, ONCOL RES TREAT, V38, P117, DOI 10.1159/000375435; Yamamoto T, 2008, MOL CELL BIOL, V28, P2758, DOI 10.1128/MCB.01704-07; Yoshida GJ, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0221-y	70	32	36	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					39	51		10.1038/onc.2017.299	http://dx.doi.org/10.1038/onc.2017.299			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28846107				2022-12-17	WOS:000422625000005
J	Dokala, A; Thakur, SS				Dokala, A.; Thakur, S. S.			Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery	ONCOGENE			English	Review							ACQUIRED-RESISTANCE; LUNG-CANCER; GEFITINIB RESISTANCE; KINASE INHIBITORS; CRYSTAL-STRUCTURE; T790M MUTATION; FC-RECEPTORS; TUMOR-GROWTH; EXON 20; ACTIVATION	The epidermal growth factor receptor (EGFR) is a transmembrane receptor with tyrosine kinase activity involved in regulation of cellular multiplication, survival, differentiation and metastasis. Our knowledge about function and complex management of these receptors has driving the development of specific and targeted treatment modalities for human cancers in the last 20 years. EGFR is the first receptor target against which monoclonal antibodies (mAb) have been evolved for cancer treatment. Here we review the biology of ErbB receptors, including their architecture, signaling, regulation and therapeutic strategies and the mechanisms of resistances offered by the receptors against small-molecule tyrosine kinases and resistance overcome implications of mAbs. The efficacy of EGFR-specific mAb in cancer depends on site specific extracellular region of EGFR, which has crucial role in process of dimerization and activation. This review highlights evolution of various resistance mechanisms due to consequences of current small-molecule anti-EGFR therapies.	[Dokala, A.; Thakur, S. S.] CSIR Ctr Cellular & Mol Biol CSIR CCMB, Prote & Cell Signaling, Hyderabad, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Thakur, SS (corresponding author), Ctr Cellular & Mol Biol, Prote & Cell Signaling, Lab E409, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	sst@ccmb.res.in		Thakur, Suman/0000-0001-5928-8836	Department of Biotechnology [GAP0405]; Council of Scientific and Industrial Research [BSC0208]; AB SCIEX, India	Department of Biotechnology; Council of Scientific and Industrial Research(Council of Scientific & Industrial Research (CSIR) - India); AB SCIEX, India	We are thankful to the Department of Biotechnology (Grant Number GAP0405) and Council of Scientific and Industrial Research (Grant Number BSC0208) and AB SCIEX, India for funding and help. We are grateful to all the lab members for fruitful discussion.	AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Alexander S, 2010, CURR PROTOC CELL BIO, V67, P1236; Altomare DA, 2012, CURR MED CHEM, V19, P3748; Arena S, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad5640; Arteaga CL, 2003, CLIN CANCER RES, V9, P1579; Athale CA, 2006, J THEOR BIOL, V238, P771, DOI 10.1016/j.jtbi.2005.06.029; Bidkhori G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048004; Bonavia R, 2012, ONCOGENE, V31, P4054, DOI 10.1038/onc.2011.563; Brand TM, 2011, CANCER BIOL THER, V11, P777, DOI 10.4161/cbt.11.9.15050; CASTAGNINO P, 1995, ONCOGENE, V10, P723; Cohen MH, 2003, ONCOLOGIST, V8, P303, DOI 10.1634/theoncologist.8-4-303; COSTA S, 1988, LANCET, V2, P1258; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Dancey JE, 2003, LANCET, V362, P62, DOI 10.1016/S0140-6736(03)13810-X; Daoud MA, 2016, CANCER BIOL MED, V13, P136, DOI 10.28092/j.issn.2095-3941.2015.0009; Dawson JP, 2005, MOL CELL BIOL, V25, P7734, DOI 10.1128/MCB.25.17.7734-7742.2005; DELARCO JE, 1980, J BIOL CHEM, V255, P3685; Denduluri SK, 2015, GENES DIS, V2, P13, DOI 10.1016/j.gendis.2014.10.004; Deng QF, 2016, ONCOL LETT, V11, P535, DOI 10.3892/ol.2015.3945; DERYNCK R, 1987, CANCER RES, V47, P707; Dey N, 2015, AM J TRANSL RES, V7, P733; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; El-Obeid A, 2002, BIOCHEM BIOPH RES CO, V290, P349, DOI 10.1006/bbrc.2001.6210; El-Telbany Ahmed, 2012, Genes Cancer, V3, P467, DOI 10.1177/1947601912465177; Elleman TC, 2001, BIOCHEMISTRY-US, V40, P8930, DOI 10.1021/bi010037b; Emrah E, 2013, SCI SIGNAL, V11, P791; Eser S, 2014, BRIT J CANCER, V111, P817, DOI 10.1038/bjc.2014.215; Ferguson KM, 2000, EMBO J, V19, P4632, DOI 10.1093/emboj/19.17.4632; Forde PM, 2015, CLIN ADV HEMATOL ONC, V13, P528; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Grunwald Viktor, 2002, Current Problems in Cancer, V26, P109; Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588; Hong YS, 2014, ONCOL REP, V31, P2619, DOI 10.3892/or.2014.3161; Huang GC, 1998, BIOCHEM J, V331, P113, DOI 10.1042/bj3310113; Huang LH, 2015, ACTA PHARM SIN B, V5, P390, DOI 10.1016/j.apsb.2015.07.001; Ibrahim SO, 1997, ANTICANCER RES, V17, P4539; Johns TG, 2002, INT J CANCER, V98, P398, DOI 10.1002/ijc.10189; Ju L, 2013, CANCER CELL INT, V13, P1523; Khan NA, 2014, CASE REP ONCOL, V7, P491, DOI 10.1159/000365325; Khelwatty SA, 2015, BRIT J CANCER, V113, P1010, DOI 10.1038/bjc.2015.319; Kil SJ, 2000, J CELL PHYSIOL, V185, P47, DOI 10.1002/1097-4652(200010)185:1<47::AID-JCP4>3.3.CO;2-F; Kim S, 2012, IEEE INT SYMP INTELL, P1, DOI 10.1109/ISIC.2012.6398245; Klapper LN, 2000, ADV CANCER RES, V77, P25; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Li HB, 2002, BIOCHEM J, V362, P499, DOI 10.1042/bj3620499; Li L, 2015, ONCOGENE, V34, P129, DOI 10.1038/onc.2013.534; Li X, 2014, EXPERT OPIN THER TAR, V18, P1, DOI 10.1517/14728222.2014.859248; Lombardo CR, 1995, BIOCHEMISTRY-US, V34, P16456, DOI 10.1021/bi00050a029; Lu Y, 2007, CANCER RES, V67, P8240, DOI 10.1158/0008-5472.CAN-07-0589; Marschall ALJ, 2011, MABS-AUSTIN, V3, P3, DOI 10.4161/mabs.3.1.14110; Martinelli E, 2009, CLIN EXP IMMUNOL, V158, P1, DOI 10.1111/j.1365-2249.2009.03992.x; Martinelli E, 2007, CORE EVID, V2, P81; Mendelsohn J, 2001, ENDOCR-RELAT CANCER, V8, P3, DOI 10.1677/erc.0.0080003; MERLINO GT, 1985, J CLIN INVEST, V75, P1077, DOI 10.1172/JCI111770; Montano N, 2011, NEOPLASIA, V13, P1113, DOI 10.1593/neo.111338; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Pedersen MW, 2005, BRIT J CANCER, V93, P915, DOI 10.1038/sj.bjc.6602793; Peled N, 2013, CELL ONCOL, V36, P277, DOI 10.1007/s13402-013-0133-9; Qin BL, 2006, CANCER CHEMOTH PHARM, V58, P577, DOI 10.1007/s00280-006-0219-4; Reguart Noemi, 2010, Cancer Manag Res, V2, P143; Rubin MS, 2000, P AN M AM SOC CLIN, V19, P474; SAINSBURY JRC, 1988, BRIT J CANCER, V58, P458, DOI 10.1038/bjc.1988.240; Sanchez-Martin FJ, 2016, CLIN CANCER RES, V22, P3260, DOI 10.1158/1078-0432.CCR-15-2400; Scheid MP, 2005, MOL CELL BIOL, V25, P2347, DOI 10.1128/MCB.25.6.2347-2363.2005; SCHMITT DA, 1990, J INVEST DERMATOL, V94, pS15, DOI 10.1111/1523-1747.ep12874984; Seshacharyulu P, 2012, EXPERT OPIN THER TAR, V16, P15, DOI 10.1517/14728222.2011.648617; Shi J, 2015, ONCOL REP, V33, P2703, DOI 10.3892/or.2015.3916; Sos ML, 2009, CANCER RES, V69, P3256, DOI 10.1158/0008-5472.CAN-08-4055; Stewart EL, 2015, TRANSL LUNG CANCER R, V4, P67, DOI 10.3978/j.issn.2218-6751.2014.11.06; Suda K, 2014, LUNG CANCER, V85, P147, DOI 10.1016/j.lungcan.2014.05.018; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Tomas A, 2014, TRENDS CELL BIOL, V24, P26, DOI 10.1016/j.tcb.2013.11.002; TUIJNMAN WB, 1993, APMIS, V101, P319, DOI 10.1111/j.1699-0463.1993.tb00117.x; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Ultan MD, 2010, CANCER RES, V15, P1625; Valley CC, 2015, MOL BIOL CELL, V26, P4087, DOI 10.1091/mbc.E15-05-0269; Wang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088291; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97; Wieduwilt MJ, 2008, CELL MOL LIFE SCI, V65, P1566, DOI 10.1007/s00018-008-7440-8; Woo HS, 2014, INVEST NEW DRUG, V32, P1311, DOI 10.1007/s10637-014-0146-x; Wu K, 2013, ONCOTARGET, V4, P2430, DOI 10.18632/oncotarget.1431; Yamabhai M, 2002, J BIOL CHEM, V277, P24843, DOI 10.1074/jbc.C200277200; Yao Z, 2010, P NATL ACAD SCI USA, V107, P15535, DOI 10.1073/pnas.1009472107; Yokoyama H, 2006, BRIT J CANCER, V95, P1504, DOI 10.1038/sj.bjc.6603459; Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105; Yuriko I, 2013, FRONT CELL NEUROSCI, V7, P414; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	93	32	35	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2337	2344		10.1038/onc.2016.393	http://dx.doi.org/10.1038/onc.2016.393			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27775071				2022-12-17	WOS:000400268900001
J	Hu, L; Li, X; Liu, Q; Xu, J; Ge, H; Wang, Z; Wang, H; Wang, Z; Shi, C; Xu, X; Huang, J; Lin, Z; Pieper, RO; Weng, C				Hu, L.; Li, X.; Liu, Q.; Xu, J.; Ge, H.; Wang, Z.; Wang, H.; Wang, Z.; Shi, C.; Xu, X.; Huang, J.; Lin, Z.; Pieper, R. O.; Weng, C.			UBE2S, a novel substrate of Akt1, associates with Ku70 and regulates DNA repair and glioblastoma multiforme resistance to chemotherapy	ONCOGENE			English	Article							STRAND BREAK REPAIR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CONJUGATING ENZYME E2-EPF; UBIQUITIN CARRIER PROTEIN; TUMOR-GROWTH; CELL-CYCLE; LIGASE-IV; CANCER; INHIBITION; PHOSPHORYLATION	Glioblastoma multiforme (GBM) is the most common primary malignant brain cancer in adults. However, the molecular events underlying carcinogenesis and their interplay remain elusive. Here, we report that the stability of Ubiquitin-conjugating enzyme E2S (UBE2S) is regulated by the PTEN/Akt pathway and that its degradation depends on the ubiquitin-proteasome system. Mechanistically, Akt1 physically interacted with and phosphorylated UBE2S at Thr 152, enhancing its stability by inhibiting proteasomal degradation. Additionally, accumulated UBE2S was found to be associated with the components of the nonhomologous end-joining (NHEJ) complex and participated in the NHEJ-mediated DNA repair process. The association of Ku70 with UBE2S was enhanced, and the complex was recruited to double-stranded break (DSB) sites in response to etoposide treatment. Furthermore, knockdown of UBE2S expression inhibited NHEJ-mediated DSB repair and rendered glioblastoma cells more sensitive to chemotherapy. Overall, our findings provide a novel drug target that may serve as the rationale for the development of a new therapeutic approach.	[Hu, L.; Ge, H.; Lin, Z.] Harbin Med Univ, Affiliated Hosp 1, Dept Neurosurg, Harbin 150001, Heilongjiang Pr, Peoples R China; [Hu, L.; Liu, Q.; Weng, C.] Chinese Acad Agr Sci, Harbin Vet Res Inst, State Key Lab Vet Biotechnol, Harbin 150001, Heilongjiang Pe, Peoples R China; [Li, X.] Shandong Univ, Liaocheng Peoples Hosp, Dept Neurosurg, Liaocheng, Peoples R China; [Xu, J.] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin, Peoples R China; [Wang, Z.] Harbin Med Univ, Dept Epidemiol & Biostatist, Harbin, Peoples R China; [Wang, H.] Harbin Med Univ, Affiliated Hosp 1, Dept Pathol, Harbin, Peoples R China; [Wang, Z.] Univ Paris 06, St Antoine Res Ctr, CURIE, Paris, France; [Shi, C.] Univ Texas Dallas, Southwestern Med Ctr, Dept Neurosurg, Dallas, TX 75390 USA; [Xu, X.] Capital Normal Univ, DNA Damage Response & Coll Life Sci, Beijing Key Lab, Beijing, Peoples R China; [Huang, J.] Univ Florida, Dept Neurosurg, Gainesville, FL USA; [Pieper, R. O.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA	Harbin Medical University; Chinese Academy of Agricultural Sciences; Harbin Veterinary Research Institute, CAAS; Shandong University; Harbin Medical University; Harbin Medical University; Harbin Medical University; UDICE-French Research Universities; Sorbonne Universite; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Capital Normal University; State University System of Florida; University of Florida; University of California System; University of California San Francisco	Lin, Z (corresponding author), Harbin Med Univ, Affiliated Hosp 1, Dept Neurosurg, Harbin 150001, Heilongjiang Pr, Peoples R China.; Weng, C (corresponding author), Chinese Acad Agr Sci, Harbin Vet Res Inst, State Key Lab Vet Biotechnol, Harbin 150001, Heilongjiang Pe, Peoples R China.; Pieper, RO (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.	linzhgu@sina.com; rpieper@cc.ucsf.edu; wengchji@163.com	Liu, Qinfang/ABC-9159-2021	Liu, Qinfang/0000-0003-2930-3892	National Natural Science Foundation of China [81372721]; International Science & Technology Cooperation Program of China [2014DFA31630]; Specialized Research Fund for the Doctoral Program of Higher Education [20132307110029]; National Cancer Institute [R01 CA171610T]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); International Science & Technology Cooperation Program of China; Specialized Research Fund for the Doctoral Program of Higher Education(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Vera Gorbunova for providing the pEGFP-Pem1-Ad2 system. We thank Jane Gordon and Qimeng Tao for technical support. We thank Dr Lei Pan, Dr Changbin Shi for their critical review of the article. This work was supported by the National Natural Science Foundation of China (81372721); International Science & Technology Cooperation Program of China (2014DFA31630); Specialized Research Fund for the Doctoral Program of Higher Education (20132307110029) and National Cancer Institute (R01 CA171610T).	Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen MF, 2009, J MOL MED-JMM, V87, P307, DOI 10.1007/s00109-008-0430-3; Chen YC, 2008, J MOL MED, V86, P401, DOI 10.1007/s00109-008-0302-x; Dang DT, 2006, CANCER RES, V66, P1684, DOI 10.1158/0008-5472.CAN-05-2887; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davis AJ, 2014, DNA REPAIR, V17, P21, DOI 10.1016/j.dnarep.2014.02.020; Davis AJ, 2013, TRANSL CANCER RES, V2, P130, DOI 10.3978/j.issn.2218-676X.2013.04.02; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Fang LH, 2007, CELL RES, V17, P572, DOI 10.1038/cr.2007.50; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Gan WJ, 2015, NUCLEUS-PHILA, V6, P261, DOI 10.1080/19491034.2015.1074365; Gao DM, 2009, MOL BIOL CELL, V20, P3305, DOI 10.1091/mbc.E09-01-0092; Golding SE, 2009, CANCER BIOL THER, V8, P730, DOI 10.4161/cbt.8.8.7927; Hardee ME, 2012, CANCER RES, V72, P4119, DOI 10.1158/0008-5472.CAN-12-0546; Idogawa M, 2007, CANCER RES, V67, P911, DOI 10.1158/0008-5472.CAN-06-2360; Jung CR, 2006, NAT MED, V12, P809, DOI 10.1038/nm1440; Kao GD, 2007, J BIOL CHEM, V282, P21206, DOI 10.1074/jbc.M703042200; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Liang J, 2012, ONCOL REP, V28, P1519, DOI 10.3892/or.2012.1949; Liu PD, 2015, MOL CELL, V57, P648, DOI 10.1016/j.molcel.2015.01.005; Liu Z, 1996, J BIOL CHEM, V271, P2817, DOI 10.1074/jbc.271.5.2817; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Meerang M, 2011, NAT CELL BIOL, V13, P1376, DOI 10.1038/ncb2367; Plo I, 2008, CANCER RES, V68, P9404, DOI 10.1158/0008-5472.CAN-08-0861; Purow B, 2009, NAT REV NEUROL, V5, P419, DOI 10.1038/nrneurol.2009.96; Roos FC, 2011, AM J PATHOL, V178, P853, DOI 10.1016/j.ajpath.2010.10.033; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Seluanov A, 2004, P NATL ACAD SCI USA, V101, P7624, DOI 10.1073/pnas.0400726101; Smith JS, 2001, JNCI-J NATL CANCER I, V93, P1246, DOI 10.1093/jnci/93.16.1246; Squatrito M, 2011, CANCER RES, V71, P5945, DOI 10.1158/0008-5472.CAN-11-1245; Tedesco D, 2007, NEOPLASIA, V9, P601, DOI 10.1593/neo.07385; Tonic I, 2010, J BIOL CHEM, V285, P23790, DOI 10.1074/jbc.M110.104372; Toulany M, 2008, MOL CANCER THER, V7, P1772, DOI 10.1158/1535-7163.MCT-07-2200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; Williams GJ, 2014, DNA REPAIR, V17, P110, DOI 10.1016/j.dnarep.2014.02.009; Woodbine L, 2014, DNA REPAIR, V16, P84, DOI 10.1016/j.dnarep.2014.02.011; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W; Zhang H, 2002, J BIOL CHEM, V277, P39379, DOI 10.1074/jbc.M206399200	47	32	35	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1145	1156		10.1038/onc.2016.281	http://dx.doi.org/10.1038/onc.2016.281			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27593939				2022-12-17	WOS:000395371500012
J	Hwang, MH; Cho, KH; Jeong, KJ; Park, YY; Kim, JM; Yu, SL; Park, CG; Mills, GB; Lee, HY				Hwang, M. H.; Cho, K. H.; Jeong, K. J.; Park, Y-Y; Kim, J. M.; Yu, S-L; Park, C. G.; Mills, G. B.; Lee, H. Y.			RCP induces Slug expression and cancer cell invasion by stabilizing beta 1 integrin	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; INTEGRIN BETA-1; HUMAN BREAST; OVARIAN; SNAIL; OVEREXPRESSION; METASTASIS; MIGRATION; ADHESION; LEADS	Rab coupling protein (RCP)-induced tumor cell migration has been implicated in tumor pathophysiology and patient outcomes. In the present study, we demonstrate that RCP stabilizes beta 1 integrin leading to increased beta 1 integrin levels and activation of a signaling cascade culminating in Slug induction, epithelial-to-mesenchymal transition and increased invasion. Ectopic expression of RCP induced Slug expression. Silencing beta 1 integrin efficiently inhibited RCP-induced Slug expression and subsequent cancer cell invasion. Conversely, ectopic expression of beta 1 integrin was sufficient to induce Slug expression. Pharmacological inhibition of integrin linked kinase ( ILK), EGFR and NF-kappa B, as well as transfection of a dominant-negative mutant of Ras (RasN17), significantly inhibited RCP-induced Slug expression and cancer cell invasion. Strikingly, ectopic expression of RCP was sufficient to enhance metastasis of ovarian cancer cells to the lung. Collectively, we demonstrate a mechanism by which RCP promotes cancer cell aggressiveness through sequential beta 1 integrin stabilization, activation of an ILK/EGFR/Ras/NF-kappa B signaling cascade and subsequent Slug expression.	[Hwang, M. H.; Cho, K. H.; Yu, S-L; Park, C. G.; Lee, H. Y.] Konyang Univ, Coll Med, Dept Pharmacol, 821 Myunggok Med Bldg,158 Gwanjeodong Ro, Daejeon 35365, South Korea; [Hwang, M. H.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX USA; [Jeong, K. J.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX USA; [Park, Y-Y] Univ Ulsan, Coll Med, Asan Med Ctr, Asan Inst Life Sci,Dept Convergence Med, Seoul, South Korea; [Kim, J. M.] Chungnam Natl Univ, Reg Canc Ctr, Canc Res Inst, Sch Med, Daejeon, South Korea; [Kim, J. M.] Chungnam Natl Univ, Infect Signaling Network Res Ctr, Sch Med, Daejeon, South Korea	Konyang University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Ulsan; Asan Medical Center; Chungnam National University; Chungnam National University	Lee, HY (corresponding author), Konyang Univ, Coll Med, Dept Pharmacol, 821 Myunggok Med Bldg,158 Gwanjeodong Ro, Daejeon 35365, South Korea.	hoi@konyang.ac.kr	Jeong, Kangjin/HGT-9268-2022	Mills, Gordon/0000-0002-0144-9614; KIM, JIN MAN/0000-0003-0905-9730	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [NRF-2014R1A2A1A11051091]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology	This study was supported by a grant from Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2014R1A2A1A11051091).	Alves CC, 2009, FRONT BIOSCI-LANDMRK, V14, P3041, DOI 10.2741/3433; Arboleda MJ, 2003, CANCER RES, V63, P196; Azimifar SB, 2012, J CELL SCI, V125, P435, DOI 10.1242/jcs.091652; Braune S, 2015, CLIN HEMORHEOL MICRO, V61, P225, DOI 10.3233/CH-151995; Casas E, 2011, CANCER RES, V71, P245, DOI 10.1158/0008-5472.CAN-10-2330; Caswell PT, 2008, J CELL BIOL, V183, P143, DOI 10.1083/jcb.200804140; Choi MJ, 2015, ONCOGENE, V34, P3402, DOI 10.1038/onc.2014.270; Come C, 2006, CLIN CANCER RES, V12, P5395, DOI 10.1158/1078-0432.CCR-06-0478; Dong P, 2013, ONCOGENE, V32, P3286, DOI 10.1038/onc.2012.334; Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946; de Herreros AG, 2010, J MAMMARY GLAND BIOL, V15, P135, DOI 10.1007/s10911-010-9179-8; Jacquemet G, 2013, J CELL BIOL, V202, P917, DOI 10.1083/jcb.201302041; Jeong KJ, 2012, ONCOGENE, V31, P4279, DOI 10.1038/onc.2011.595; Ju LX, 2013, CANCER BIOMARK, V13, P329, DOI 10.3233/CBM-130362; Kenny HA, 2008, J CLIN INVEST, V118, P1367, DOI 10.1172/JCI33775; Krishnan M, 2013, MOL BIOL CELL, V24, P818, DOI 10.1091/mbc.E12-10-0745; Lambertini E, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-13; Lee MY, 2008, CLIN CANCER RES, V14, P4743, DOI 10.1158/1078-0432.CCR-08-0234; Lee M, 2010, INT J RADIAT ONCOL, V76, P1528, DOI 10.1016/j.ijrobp.2009.11.022; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Mills GB, 2009, J CLIN INVEST, V119, P2123, DOI 10.1172/JCI40256; Morello V, 2011, ONCOGENE, V30, P4087, DOI 10.1038/onc.2011.107; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Park SY, 2011, ONCOGENE, V30, P1351, DOI 10.1038/onc.2010.517; Rainero E, 2012, J CELL BIOL, V196, P277, DOI 10.1083/jcb.201109112; Rhee CM, 2016, NEPHROL DIAL TRANSPL, V31, P992, DOI 10.1093/ndt/gfv341; Sakai D, 2005, DEV GROWTH DIFFER, V47, P471, DOI 10.1111/j.1440-169X.2005.00821.x; Toguri JT, 2015, CLIN HEMORHEOL MICRO, V61, P237, DOI 10.3233/CH-151996; Tomaskovic-Crook E, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2416; Yao ES, 2007, CANCER RES, V67, P659, DOI 10.1158/0008-5472.CAN-06-2768; Zhang C, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000106; Zhang JQ, 2009, J CLIN INVEST, V119, P2171, DOI 10.1172/JCI37622	34	32	32	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1102	1111		10.1038/onc.2016.277	http://dx.doi.org/10.1038/onc.2016.277			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27524413				2022-12-17	WOS:000395371500008
J	Cai, G; Wu, D; Wang, Z; Xu, Z; Wong, KB; Ng, CF; Chan, FL; Yu, S				Cai, G.; Wu, D.; Wang, Z.; Xu, Z.; Wong, K-B; Ng, C-F; Chan, F. L.; Yu, S.			Collapsin response mediator protein-1 (CRMP1) acts as an invasion and metastasis suppressor of prostate cancer via its suppression of epithelial-mesenchymal transition and remodeling of actin cytoskeleton organization	ONCOGENE			English	Article							MOLECULAR CHARACTERIZATION; THERAPEUTIC TARGET; CELL INVASION; EXPRESSION; RECEPTOR; GROWTH; PROGRESSION; UNC-33; FAMILY; DIHYDROPYRIMIDINASE	The cancer cells can acquire migration and invasion capacities during the metastasis process through the developmental regulatory program epithelial-mesenchymal-transition (EMT), and through its reverse process mesenchymal-epithelial transition cancer cells can recolonize at distant metastatic sites. Among the multifaceted effects exerted by this program, reorganization of actin cytoskeleton is the key mechanical drive for the invasive properties gained by cancer cells. Collapsin response mediator protein-1 (CRMP1) is a cytosolic phosphoprotein and originally characterized as the mediator of semaphorin 3A signaling involved in axon differentiation during neural development. Here we report that CRMP1 can act as a suppressor of tumorigenicity and metastasis in prostate cancer cells. We demonstrated that CRMP1 exhibited a decreased expression pattern in high-grade prostate cancer tissues and many prostate cancer cell lines, and its downregulation in cancer cells was attributed to histone deacetylation and direct repression of its gene by the EMT regulator Snail. Functional analyses revealed that CRMP1 suppressed EMT in prostate cancer cells, as its knockdown could trigger EMT and enhance in vitro invasion capacity, whereas its overexpression could inhibit EMT and suppress both in vitro invasion and in vivo metastasis capacities of prostate cancer cells. Moreover, CRMP1 overexpression could significantly confer resistance to EMT induced by Snail or transforming growth factor-beta 1 in prostatic epithelial cells and prostate cancer cells. Finally, we demonstrated that CRMP1 could associate with actin and WAVE1, an activator of actin nucleation complex Arp2/3, and also its knockdown could stabilize F-actin and trigger the formation of stress fibers in prostate cancer cells. Together, our study shows that CRMP1 acts an EMT and metastasis suppressor in prostate cancer cells via its regulation of actin polymerization and also suggests that targeting the CRMP1-actin signaling in actin organization could be a potential strategy for management of prostate cancer metastasis.	[Cai, G.; Wu, D.; Wang, Z.; Xu, Z.; Chan, F. L.; Yu, S.] Chinese Univ Hong Kong, Sch Biomed Sci, Kwee Seong Integrated Biomed Sci Bldg, Shatin, Hong Kong, Peoples R China; [Wong, K-B] Chinese Univ Hong Kong, Sch Life Sci, Hong Kong, Hong Kong, Peoples R China; [Ng, C-F] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Chan, FL; Yu, S (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Kwee Seong Integrated Biomed Sci Bldg, Shatin, Hong Kong, Peoples R China.	franky-chan@cuhk.edu.hk; yushan771@hotmail.com	Chi-fai, NG/AAV-8270-2021; Wong, Kam-Bo/AAU-9364-2021; Ng, Chi-Fai/E-5134-2011; Wong, Kam-Bo/G-4258-2013; Chan, Franky L./M-1043-2018	Wong, Kam-Bo/0000-0002-6984-5373; Ng, Chi-Fai/0000-0002-1723-9646; Wong, Kam-Bo/0000-0002-6984-5373; Chan, Franky L./0000-0003-0567-2052; Wang, Zhu/0000-0002-5457-3731; Wu, Dinglan/0000-0002-5057-9626	earmarked research grant from the Research Grants Council of Hong Kong [CUHK4411-/06M]; research grant from the National Natural Science Foundation of China	earmarked research grant from the Research Grants Council of Hong Kong; research grant from the National Natural Science Foundation of China	We thank Dr Isaiah Fidler for providing the PC-3M and PC-3M-LN4 cell lines, Dr Andrew ML Chan for the A549 cell line, Dr Cheng-Chung Wu for the pGL3-CRMP1-Luc and Dr Alexander Staruschenko for the pcDNA3.1-His-WASF1. This work was supported by an earmarked research grant from the Research Grants Council of Hong Kong (project no. CUHK4411-/06M) and a research grant from the National Natural Science Foundation of China.	Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Byk T, 1996, J NEUROSCI, V16, P688; Charrier E, 2003, MOL NEUROBIOL, V28, P51, DOI 10.1385/MN:28:1:51; Cheung CP, 2005, J CLIN ENDOCR METAB, V90, P1830, DOI 10.1210/jc.2004-1421; Chu JH, 2009, PROSTATE, V69, P428, DOI 10.1002/pros.20897; Fukada M, 2000, J BIOL CHEM, V275, P37957, DOI 10.1074/jbc.M003277200; Gao M, 2008, BIOCHEM BIOPH RES CO, V376, P283, DOI 10.1016/j.bbrc.2008.08.144; Gao X, 2010, ONCOGENE, V29, P4555, DOI 10.1038/onc.2010.213; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555-012-9377-5; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; Hiroshima Y, 2013, ANN SURG ONCOL, V20, pS369, DOI 10.1245/s10434-012-2491-3; Hu Y, 2002, J BIOL CHEM, V277, P44462, DOI 10.1074/jbc.M205784200; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Kawano Y, 2005, MOL CELL BIOL, V25, P9920, DOI 10.1128/MCB.25.22.9920-9935.2005; Leung T, 2002, FEBS LETT, V532, P445, DOI 10.1016/S0014-5793(02)03736-5; Lui K, 2006, PROSTATE, V66, P1600, DOI 10.1002/pros.20429; Meyronet D, 2008, AM J SURG PATHOL, V32, P1699, DOI 10.1097/PAS.0b013e31817dc37c; MINTURN JE, 1995, J NEUROSCI, V15, P6757; Oliemuller E, 2013, INT J CANCER, V132, P1986, DOI 10.1002/ijc.27881; Pan SH, 2011, J CLIN INVEST, V121, P3189, DOI 10.1172/JCI42975; Pan SH, 2010, LUNG CANCER, V67, P93, DOI 10.1016/j.lungcan.2009.03.006; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Schmidt EF, 2007, ADV EXP MED BIOL, V600, P1; Shih JY, 2001, JNCI-J NATL CANCER I, V93, P1392, DOI 10.1093/jnci/93.18.1392; Smith BN, 2012, CELL ADHES MIGR, V6, P433, DOI 10.4161/cam.21687; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Wang LH, 1997, J NEUROCHEM, V69, P2261; Wu CC, 2008, MOL CANCER THER, V7, P1365, DOI 10.1158/1535-7163.MCT-08-0091; Wu DL, 2015, J PATHOL, V236, P103, DOI 10.1002/path.4505; Yamashita N, 2012, MOL NEUROBIOL, V45, P234, DOI 10.1007/s12035-012-8242-4; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yu S, 2008, ONCOGENE, V27, P3313, DOI 10.1038/sj.onc.1210986; Yu SA, 2007, CANCER RES, V67, P4904, DOI 10.1158/0008-5472.CAN-06-3855; Yu S, 2014, J PATHOL, V234, P514, DOI 10.1002/path.4413; Yu S, 2009, BIOCHEM BIOPH RES CO, V382, P756, DOI 10.1016/j.bbrc.2009.03.110	40	32	32	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					546	558		10.1038/onc.2016.227	http://dx.doi.org/10.1038/onc.2016.227			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27321179	Green Published, hybrid			2022-12-17	WOS:000394166700011
J	Cheng, Y; Ren, X; Yuan, Y; Shan, Y; Li, L; Chen, X; Zhang, L; Takahashi, Y; Yang, JW; Han, B; Liao, J; Li, Y; Harvey, H; Ryazanov, A; Robertson, GP; Wan, G; Liu, D; Chen, AF; Tao, Y; Yang, JM				Cheng, Y.; Ren, X.; Yuan, Y.; Shan, Y.; Li, L.; Chen, X.; Zhang, L.; Takahashi, Y.; Yang, J. W.; Han, B.; Liao, J.; Li, Y.; Harvey, H.; Ryazanov, A.; Robertson, G. P.; Wan, G.; Liu, D.; Chen, A. F.; Tao, Y.; Yang, J-M			eEF-2 kinase is a critical regulator of Warburg effect through controlling PP2A-A synthesis	ONCOGENE			English	Article							ELONGATION FACTOR-2 KINASE; CANCER-ASSOCIATED FIBROBLASTS; HISTONE DEACETYLASE SIRT6; PYRUVATE-KINASE; TUMOR-GROWTH; FACTOR-II; C-MYC; DEPENDENT PHOSPHORYLATION; CONFERS RESISTANCE; AEROBIC GLYCOLYSIS	Cancer cells predominantly metabolize glucose by glycolysis to produce energy in order to meet their metabolic requirement, a phenomenon known as Warburg effect. Although Warburg effect is considered a peculiarity critical for survival and proliferation of cancer cells, the regulatory mechanisms behind this phenomenon remain incompletely understood. We report here that eukaryotic elongation factor-2 kinase (eEF-2K), a negative regulator of protein synthesis, has a critical role in promoting glycolysis in cancer cells. We showed that deficiency in eEF-2K significantly reduced the uptake of glucose and decreased the productions of lactate and adenosine triphosphate in tumor cells and in the Ras-transformed mouse embryonic fibroblasts. We further demonstrated that the promotive effect of eEF-2K on glycolysis resulted from the kinase-mediated restriction of synthesis of the protein phosphatase 2A-A (PP2A-A), a key factor that facilitates the ubiquitin-proteasomal degradation of c-Myc protein, as knockdown of eEF-2K expression led to a significant increase in PP2A-A protein synthesis and remarkable downregulation of c-Myc and pyruvate kinase M2 isoform, the key glycolytic enzyme transcriptionally activated by c-Myc. In addition, depletion of eEF-2K reduced the ability of the transformed cells to proliferate and enhanced the sensitivity of tumor cells to chemotherapy both in vitro and in vivo. These results, which uncover a role of the eEF-2K-mediated control of PP2A-A in tumor cell glycolysis, provide new insights into the regulation of the Warburg effect.	[Cheng, Y.; Li, L.] Cent S Univ, Sch Pharmaceut Sci, Dept Pharmacol, 110 Xiangya Rd, Changsha 410008, Hunan, Peoples R China; [Cheng, Y.; Ren, X.; Shan, Y.; Zhang, L.; Takahashi, Y.; Yang, J. W.; Li, Y.; Robertson, G. P.; Wan, G.; Yang, J-M] Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Dept Pharmacol, Hershey, PA USA; [Cheng, Y.; Ren, X.; Shan, Y.; Zhang, L.; Takahashi, Y.; Yang, J. W.; Han, B.; Liao, J.; Li, Y.; Harvey, H.; Robertson, G. P.; Wan, G.; Yang, J-M] Milton S Hershey Med Ctr, Hershey, PA USA; [Yuan, Y.; Liu, D.] Washington State Univ, Coll Pharm, Dept Pharmaceut Sci, Spokane, WA USA; [Han, B.] Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Dept Pathol, Hershey, PA USA; [Liao, J.] Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Div Biostat & Bioinformat, Hershey, PA USA; [Liao, J.] Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Dept Med, Hershey, PA USA; [Harvey, H.] Rutgers State Univ, Robert Wood Jonson Med Sch, Dept Pharmacol, Piscataway, NJ USA; [Ryazanov, A.] Cent S Univ, Coll Pharm, Ctr Vasc & Translat Med, Changsha, Hunan, Peoples R China; [Ryazanov, A.] Cent S Univ, Xiangya Hosp 3, Changsha, Hunan, Peoples R China; [Chen, A. F.] Cent S Univ, Sch Basic Med, Canc Res Inst, Changsha, Hunan, Peoples R China; [Chen, A. F.] Cent S Univ, Key Lab Carcinogenesis & Canc Invas, Minist Educ, Changsha, Hunan, Peoples R China	Central South University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Washington State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Rutgers State University New Brunswick; Rutgers State University Medical Center; Central South University; Central South University; Central South University; Central South University	Cheng, Y (corresponding author), Cent S Univ, Sch Pharmaceut Sci, Dept Pharmacol, 110 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.; Yang, JM (corresponding author), Penn State Coll Med, Dept Pharmacol, 500 Univ Dr, Hershey, PA 17033 USA.; Yang, JM (corresponding author), Penn State Coll Med, Penn State Hershey Canc Inst, 500 Univ Dr, Hershey, PA 17033 USA.	chengyan0677@163.com; juy16@psu.edu	Wan, Guohui/G-3904-2011; ryazanov, alexey/J-8081-2017	Wan, Guohui/0000-0001-5170-7282; Takahashi, Yoshinori/0000-0002-8004-4817	National Basic Research Program of China (973 Program) [2015CB910700, 2014CB542400]; National Natural Science Foundation of China [81422051, 81472593, 31401208, 81372427]; National Basic Research Program of China [2015CB553903]; US Department of Defense [BC103654]; US Public Health Service [NIH/NCI R01CA135038]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China); US Department of Defense(United States Department of Defense); US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service)	We sincerely thank Dr Zhimin Lu (MD Anderson Cancer Center, USA) and Drs Jing Chen and Taro Hitosugi (Emory University School of Medicine) for PKM2 plasmids, Dr Christopher Proud (University of Southampton, UK) for eEF-2K plasmid and Dr Jayanta Debnath (University of California San Francisco, USA) for H-Ras<SUP>V12</SUP> retroviral plasmid. This work was supported by grants from the National Basic Research Program of China (973 Program) 2015CB910700 (to YC), 2014CB542400 (to AFC); the National Natural Science Foundation of China 81422051, 81472593 and 31401208 (to YC); the National Basic Research Program of China 2015CB553903 (to YT) and the National Natural Science Foundation of China 81372427 (to YT); the US Department of Defense BC103654 (to YC); and the US Public Health Service NIH/NCI R01CA135038 (to J-MY).	Arguelles S, 2014, FREE RADICAL BIO MED, V67, P131, DOI 10.1016/j.freeradbiomed.2013.10.015; BAGAGLIO DM, 1994, CELL GROWTH DIFFER, V5, P1403; BAGAGLIO DM, 1993, CANCER RES, V53, P2260; Ben Sahra I, 2010, CANCER RES, V70, P2465, DOI 10.1158/0008-5472.CAN-09-2782; Browne GJ, 2004, J BIOL CHEM, V279, P12220, DOI 10.1074/jbc.M309773200; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Capparelli C, 2012, CELL CYCLE, V11, P2272, DOI 10.4161/cc.20717; Capparelli C, 2012, CELL CYCLE, V11, P2285, DOI 10.4161/cc.20718; Cheng Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.254; Cheng Y, 2013, AUTOPHAGY, V9, P208, DOI 10.4161/auto.22801; Cheng Y, 2011, CANCER RES, V71, P2654, DOI 10.1158/0008-5472.CAN-10-2889; Cheng Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009715; Chu HP, 2014, DEV CELL, V28, P561, DOI 10.1016/j.devcel.2014.01.027; Connolly E, 2006, MOL CELL BIOL, V26, P3955, DOI 10.1128/MCB.26.10.3955-3965.2006; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Diggle TA, 2001, BIOCHEM J, V353, P621, DOI 10.1042/0264-6021:3530621; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Fu X, 2015, J BIOL CHEM, V290, P26445, DOI 10.1074/jbc.M115.665232; Gonzalez-Teran B, 2013, J CLIN INVEST, V123, P164, DOI 10.1172/JCI65124; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Gupta S, 2005, CANCER BIOL THER, V4, P87; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jorgensen R, 2003, NAT STRUCT BIOL, V10, P379, DOI 10.1038/nsb923; Kenney JW, 2016, J NEUROCHEM, V136, P276, DOI 10.1111/jnc.13407; Kenney Justin W., 2014, Advances in Biological Regulation, V55, P15, DOI 10.1016/j.jbior.2014.04.003; Leprivier G, 2013, CELL, V153, P1064, DOI 10.1016/j.cell.2013.04.055; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Maher JC, 2007, MOL CANCER THER, V6, P732, DOI 10.1158/1535-7163.MCT-06-0407; Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008; Moore CEJ, 2015, MOL CELL BIOL, V35, P1788, DOI 10.1128/MCB.01457-14; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; Parmer TG, 1999, BRIT J CANCER, V79, P59, DOI 10.1038/sj.bjc.6690012; Pavlides S, 2012, ANTIOXID REDOX SIGN, V16, P1264, DOI 10.1089/ars.2011.4243; Proud CG, 2015, BIOCHEM SOC T, V43, P328, DOI 10.1042/BST20140323; Ran C, 2013, CANCER RES, V73, P1831, DOI 10.1158/0008-5472.CAN-12-2460; REDPATH NT, 1993, BIOCHEM J, V293, P31, DOI 10.1042/bj2930031; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047; Simons AL, 2007, CANCER RES, V67, P3364, DOI 10.1158/0008-5472.CAN-06-3717; Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108; Tekedereli I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041171; Wang XM, 2015, BIOCHEM J, V467, P321, DOI 10.1042/BJ20150089; Wang XM, 2014, MOL CELL BIOL, V34, P4088, DOI 10.1128/MCB.01035-14; Wang YH, 2014, CELL, V158, P1309, DOI 10.1016/j.cell.2014.07.048; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wu H, 2006, CANCER RES, V66, P3015, DOI 10.1158/0008-5472.CAN-05-1554; Wu H, 2009, CANCER RES, V69, P2453, DOI 10.1158/0008-5472.CAN-08-2872; Xie JL, 2015, MOL CELL BIOL, V35, P1805, DOI 10.1128/MCB.00012-15; Yang WW, 2012, MOL CELL, V48, P771, DOI 10.1016/j.molcel.2012.09.028; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang Z, 2013, J EXP MED, V210, P2119, DOI 10.1084/jem.20130252; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041	55	32	33	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2016	35	49					6293	6308		10.1038/onc.2016.166	http://dx.doi.org/10.1038/onc.2016.166			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TJ	27181208				2022-12-17	WOS:000390247000003
J	Gan, L; Xiu, R; Ren, P; Yue, M; Su, H; Guo, G; Xiao, D; Yu, J; Jiang, H; Liu, H; Hu, G; Qing, G				Gan, L.; Xiu, R.; Ren, P.; Yue, M.; Su, H.; Guo, G.; Xiao, D.; Yu, J.; Jiang, H.; Liu, H.; Hu, G.; Qing, G.			Metabolic targeting of oncogene MYC by selective activation of the proton-coupled monocarboxylate family of transporters	ONCOGENE			English	Article							SLC16 GENE FAMILY; GLUTAMINE-METABOLISM; ANTITUMOR-ACTIVITY; N-MYC; INHIBITION; CANCER; NEUROBLASTOMA; CELLS; MCT1; 3-BROMOPYRUVATE	Deregulation of the MYC oncogene produces Myc protein that regulates multiple aspects of cancer cell metabolism, contributing to the acquisition of building blocks essential for cancer cell growth and proliferation. Therefore, disabling Myc function represents an attractive therapeutic option for cancer treatment. However, pharmacological strategies capable of directly targeting Myc remain elusive. Here, we identified that 3-bromopyruvate (3-BrPA), a drug candidate that primarily inhibits glycolysis, preferentially induced massive cell death in human cancer cells overexpressing the MYC oncogene, in vitro and in vivo, without appreciable effects on those exhibiting low MYC levels. Importantly, pharmacological inhibition of glutamine metabolism synergistically potentiated the synthetic lethal targeting of MYC by 3-BrPA due in part to the metabolic disturbance caused by this combination. Mechanistically, we identified that the proton-coupled monocarboxylate transporter 1 (MCT1) and MCT2, which enable efficient 3-BrPA uptake by cancer cells, were selectively activated by Myc. Two regulatory mechanisms were involved: first, Myc directly activated MCT1 and MCT2 transcription by binding to specific recognition sites of both genes; second, Myc transcriptionally repressed miR29a and miR29c, resulting in enhanced expression of their target protein MCT1. Of note, expressions of MCT1 and MCT2 were each significantly elevated in MYCN-amplified neuroblastomas and C-MYC-overexpressing lymphomas than in tumors without MYC overexpression, correlating with poor prognosis and unfavorable patient survival. These results identify a novel mechanism by which Myc sensitizes cells to metabolic inhibitors and validate 3-BrPA as potential Myc-selective cancer therapeutics.	[Gan, L.; Hu, G.] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Oncol, 1095 Jiefang Ave, Wuhan 430030, Peoples R China; [Gan, L.; Xiu, R.; Ren, P.; Yue, M.; Xiao, D.; Qing, G.] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Wuhan 430030, Peoples R China; [Su, H.; Guo, G.; Liu, H.] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Wuhan 430030, Peoples R China; [Yu, J.; Jiang, H.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Syst Biol, Shanghai, Peoples R China; [Qing, G.] Wuhan Univ, Med Res Inst, 185 Donghu Rd, Wuhan 430071, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Wuhan University	Hu, G (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Oncol, 1095 Jiefang Ave, Wuhan 430030, Peoples R China.; Qing, G (corresponding author), Wuhan Univ, Med Res Inst, 185 Donghu Rd, Wuhan 430071, Peoples R China.	gqhu@tjh.tjmu.edu.cn; qingguoliang@whu.edu.cn			National Natural Science Foundation of China [81171928, 81372205, 81272491, 81200381]; Huazhong University of Science and Technology [2014ZHYX002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Huazhong University of Science and Technology	We thank members of Qing and Liu laboratories for helpful suggestions. This study was supported by the National Natural Science Foundation of China (Grants 81171928 and 81372205 to GQ, 81272491 to GH and 81200381 to HL) and Huazhong University of Science and Technology (Grant 2014ZHYX002 to GQ).	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Birsoy K, 2013, NAT GENET, V45, P104, DOI 10.1038/ng.2471; Boidot R, 2012, CANCER RES, V72, P939, DOI 10.1158/0008-5472.CAN-11-2474; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Cardaci S, 2012, CANCER RES, V72, P4526, DOI 10.1158/0008-5472.CAN-12-1741; Cardaci S, 2012, J BIOENERG BIOMEMBR, V44, P17, DOI 10.1007/s10863-012-9422-7; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chapiro J, 2014, CLIN CANCER RES, V20, P6406, DOI 10.1158/1078-0432.CCR-14-1271; Chipumuro E, 2014, CELL, V159, P1126, DOI 10.1016/j.cell.2014.10.024; Dang CV, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014217; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Doherty JR, 2014, CANCER RES, V74, P908, DOI 10.1158/0008-5472.CAN-13-2034; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; GARCIA CK, 1995, J BIOL CHEM, V270, P1843, DOI 10.1074/jbc.270.4.1843; Geschwind Jean-Francois, 2004, Expert Rev Anticancer Ther, V4, P449, DOI 10.1586/14737140.4.3.449; Goga A, 2007, NAT MED, V13, P820, DOI 10.1038/nm1606; Green DR, 2014, SCIENCE, V345, P1466, DOI 10.1126/science.1250256; Halestrap AP, 2013, MOL ASPECTS MED, V34, P337, DOI 10.1016/j.mam.2012.05.003; Halestrap AP, 2012, IUBMB LIFE, V64, P109, DOI 10.1002/iub.572; Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600; Jiang H, 2009, GENE DEV, V23, P1895, DOI 10.1101/gad.1815309; Ko YH, 2012, J BIOENERG BIOMEMBR, V44, P163, DOI 10.1007/s10863-012-9417-4; Ko YH, 2001, CANCER LETT, V173, P83, DOI 10.1016/S0304-3835(01)00667-X; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009; Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107; Le Floch R, 2011, P NATL ACAD SCI USA, V108, P16663, DOI 10.1073/pnas.1106123108; Li B, 2013, CLIN CANCER RES, V19, P5835, DOI 10.1158/1078-0432.CCR-12-3629; Maher JC, 2004, CANCER CHEMOTH PHARM, V53, P116, DOI 10.1007/s00280-003-0724-7; Maschek G, 2004, CANCER RES, V64, P31, DOI 10.1158/0008-5472.CAN-03-3294; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Nilsson LM, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002573; Ota S, 2013, TARGET ONCOL, V8, P145, DOI 10.1007/s11523-013-0273-x; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Qing GL, 2012, CANCER CELL, V22, P631, DOI 10.1016/j.ccr.2012.09.021; Qing GL, 2010, CANCER RES, V70, P10351, DOI 10.1158/0008-5472.CAN-10-0740; Queiros O, 2012, J BIOENERG BIOMEMBR, V44, P141, DOI 10.1007/s10863-012-9418-3; Ren P, 2015, J PATHOL, V235, P90, DOI 10.1002/path.4429; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Thangaraju M, 2009, CANCER, V115, P4655, DOI 10.1002/cncr.24532; Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Wellen KE, 2012, NAT REV MOL CELL BIO, V13, P270, DOI 10.1038/nrm3305; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Xiang Y, 2015, J CLIN INVEST, V125, P2293, DOI 10.1172/JCI75836; Xu RH, 2005, CANCER RES, V65, P613; Yang D, 2010, P NATL ACAD SCI USA, V107, P13836, DOI 10.1073/pnas.1008366107; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003	56	32	36	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					3037	3048		10.1038/onc.2015.360	http://dx.doi.org/10.1038/onc.2015.360			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26434591				2022-12-17	WOS:000377474500009
J	Koch, A; Maia, A; Janssen, A; Medema, RH				Koch, A.; Maia, A.; Janssen, A.; Medema, R. H.			Molecular basis underlying resistance to Mps1/TTK inhibitors	ONCOGENE			English	Article							SPINDLE-ASSEMBLY CHECKPOINT; PROTEIN-KINASES; MITOTIC CHECKPOINT; MYELOID-LEUKEMIA; DRUG-RESISTANCE; AURORA KINASES; CANCER-THERAPY; BCR-ABL; CELLS; KINETOCHORES	Mps1/TTK is a dual-specificity kinase, with an essential role in mitotic checkpoint signaling, which has emerged as a potential target in cancer therapy. Several Mps1/TTK small-molecule inhibitors have been described that exhibit promising activity in cell culture and xenograft models. Here, we investigated whether cancer cells can develop resistance to these drugs. To this end, we treated various cancer cell lines with sublethal concentrations of a potent Mps1/TTK inhibitor in order to isolate inhibitor-resistant monoclonal cell lines. We identified four point mutations in the catalytic domain of Mps1/TTK that gave rise to inhibitor resistance but retained wildtype catalytic activity. Interestingly, cross-resistance of the identified mutations to other Mps1/TTK inhibitors is limited. Our studies predict that Mps1/TTK inhibitor-resistant tumor cells can arise through the acquisition of mutations in the adenosine triphosphate-binding pocket of the kinase that prevent stable binding of the inhibitors. In addition, our results suggest that combinations of inhibitors could be used to prevent acquisition of drug resistance. Interestingly, cross-resistance seems nonspecific for inhibitor scaffolds, a notion that can be exploited in future drug design to evict possible resistance mutations during clinical treatment.	[Koch, A.; Maia, A.; Janssen, A.; Medema, R. H.] Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands; [Janssen, A.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Dept Genome Dynam, Berkeley, CA 94720 USA	Netherlands Cancer Institute; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Medema, RH (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.medema@nki.nl		Janssen, Aniek/0000-0001-6731-6657; Medema, Rene/0000-0002-6754-0381; Koch, Andre/0000-0003-3502-382X; Maia, Ana/0000-0003-1261-7211	NWO Gravitation Program (Cancer Genomics Center, CGC.nl); EMBO long-term fellowship [ALTF-425-2013]	NWO Gravitation Program (Cancer Genomics Center, CGC.nl); EMBO long-term fellowship(European Molecular Biology Organization (EMBO))	We thank Geert Kops (UMC Utrecht, The Netherlands) Susanne Lens (UMC Utrecht, The Netherlands) and Anastassis Perrakis (NKI, Amsterdam, The Netherlands) for reagents. Roos Klop, Yoshitaka Hiruma and Mathijs Vleugel for technical help. Bram van den Broek (NKI, Amsterdam, The Netherlands) for providing the ImageJ analysis macro for mitotic index analysis. We thank our colleagues for support and helpful suggestions. The research was funded by the NWO Gravitation Program (Cancer Genomics Center, CGC.nl). AK was supported by an EMBO long-term fellowship (ALTF-425-2013).	Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Barouch-Bentov R, 2011, EXPERT OPIN INV DRUG, V20, P153, DOI 10.1517/13543784.2011.546344; Cho SW, 2013, NAT BIOTECHNOL, V31, P230, DOI 10.1038/nbt.2507; Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Chu MLH, 2010, BIOCHEMISTRY-US, V49, P1689, DOI 10.1021/bi901970c; Colombo R, 2010, CANCER RES, V70, P10255, DOI 10.1158/0008-5472.CAN-10-2101; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; D'Alise AM, 2008, MOL CANCER THER, V7, P1140, DOI 10.1158/1535-7163.MCT-07-2051; Daniel J, 2011, P NATL ACAD SCI USA, V108, P5384, DOI 10.1073/pnas.1007645108; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Eyers PA, 2005, CELL CYCLE, V4, P784, DOI 10.4161/cc.4.6.1693; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Girdler F, 2008, CHEM BIOL, V15, P552, DOI 10.1016/j.chembiol.2008.04.013; Glaab WE, 1997, CARCINOGENESIS, V18, P1, DOI 10.1093/carcin/18.1.1; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Hewitt L, 2010, J CELL BIOL, V190, P25, DOI 10.1083/jcb.201002133; Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106; Jemaa M, 2013, CELL DEATH DIFFER, V20, P1532, DOI 10.1038/cdd.2013.105; Kornev AP, 2008, P NATL ACAD SCI USA, V105, P14377, DOI 10.1073/pnas.0807988105; Kumar DV, 2012, BIOORG MED CHEM LETT, V22, P4377, DOI 10.1016/j.bmcl.2012.04.131; Kwiatkowski N, 2010, NAT CHEM BIOL, V6, P359, DOI 10.1038/nchembio.345; Lan WJ, 2010, J CELL BIOL, V190, P21, DOI 10.1083/jcb.201006080; Liu XD, 2012, ANNU REV BIOCHEM, V81, P561, DOI 10.1146/annurev-biochem-061611-090435; Liu Y, 2006, NAT CHEM BIOL, V2, P358, DOI 10.1038/nchembio799; London N, 2012, CURR BIOL, V22, P900, DOI 10.1016/j.cub.2012.03.052; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Marina Caldarelli MA, 2009, Pyrazolo-quinazolines, Patent No. [WO 2009156315 A1, 2009156315]; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Naud S, 2013, J MED CHEM, V56, P10045, DOI 10.1021/jm401395s; Nijenhuis W, 2014, NAT CELL BIOL, V16, P1257, DOI 10.1038/ncb3065; Santaguida S, 2010, J CELL BIOL, V190, P73, DOI 10.1083/jcb.201001036; Schmidt M, 2005, EMBO REP, V6, P866, DOI 10.1038/sj.embor.7400483; Scutt PJ, 2009, J BIOL CHEM, V284, P15880, DOI 10.1074/jbc.M109.005694; Shepperd LA, 2012, CURR BIOL, V22, P891, DOI 10.1016/j.cub.2012.03.051; Sloane DA, 2010, ACS CHEM BIOL, V5, P563, DOI 10.1021/cb100053q; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Tannous BA, 2013, JNCI-J NATL CANCER I, V105, P1322, DOI 10.1093/jnci/djt168; Tardif KD, 2011, MOL CANCER THER, V10, P2267, DOI 10.1158/1535-7163.MCT-11-0453; Vleugel M, 2013, J CELL BIOL, V203, P943, DOI 10.1083/jcb.201307016; Wacker SA, 2012, NAT CHEM BIOL, V8, P235, DOI [10.1038/NCHEMBIO.779, 10.1038/nchembio.779]; Weisberg E, 2007, NAT REV CANCER, V7, P345, DOI 10.1038/nrc2126; Yamagishi Y, 2012, NAT CELL BIOL, V14, P746, DOI 10.1038/ncb2515	43	32	33	4	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2518	2528		10.1038/onc.2015.319	http://dx.doi.org/10.1038/onc.2015.319			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26364596	Green Published, hybrid			2022-12-17	WOS:000376165500010
J	Giacobbe, A; Compagnone, M; Bongiorno-Borbone, L; Antonov, A; Markert, EK; Zhou, JH; Annicchiarico-Petruzzelli, M; Melino, G; Peschiaroli, A				Giacobbe, A.; Compagnone, M.; Bongiorno-Borbone, L.; Antonov, A.; Markert, E. K.; Zhou, J. H.; Annicchiarico-Petruzzelli, M.; Melino, G.; Peschiaroli, A.			p63 controls cell migration and invasion by transcriptional regulation of MTSS1	ONCOGENE			English	Article							BREAST-CANCER; P53 HOMOLOG; METASTASIS; CARCINOMA; SUPPRESSOR; TARGET; TUMORIGENESIS; DELTA-NP63; SURVIVAL; PATHWAY	Metastasis is a multistep cell-biological process, which is orchestrated by many factors, including metastasis activators and suppressors. Metastasis Suppressor 1 (MTSS1) was originally identified as a metastasis suppressor protein whose expression is lost in metastatic bladder and prostate carcinomas. However, recent findings indicate that MTSS1 acts as oncogene and pro-migratory factor in melanoma tumors. Here, we identify and characterized a molecular mechanism controlling MTSS1 expression, which impinges on a pro-tumorigenic role of MTSS1 in breast tumors. We found that in normal and in cancer cell lines Delta Np63 is able to drive the expression of MTSS1 by binding to a p63-binding responsive element localized in the MTSS1 locus. We reported that Delta Np63 is able to drive the migration of breast tumor cells by inducing the expression of MTSS1. Notably, in three human breast tumors data sets the MTSS1/p63 co-expression is a negative prognostic factor on patient survival, suggesting that the MTSS1/p63 axis might be functionally important to regulate breast tumor progression.	[Giacobbe, A.; Compagnone, M.; Bongiorno-Borbone, L.; Melino, G.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy; [Antonov, A.; Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England; [Markert, E. K.] Inst Adv Study, Simons Ctr Syst Biol, Olden Lane, Princeton, NJ 08540 USA; [Zhou, J. H.] Radboud Univ Nijmegen, Med Ctr Nijmegen, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands; [Annicchiarico-Petruzzelli, M.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Biochem Lab IDI IRCCS, Rome, Italy; [Peschiaroli, A.] CNR, IBCN, Rome, Italy	University of Rome Tor Vergata; University of Leicester; Institute for Advanced Study - USA; Radboud University Nijmegen; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia Cellulare e Neurobiologia (IBCN-CNR)	Melino, G (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy.; Peschiaroli, A (corresponding author), CNR, CNR IBCN Inst Cell Biol & Neurobiol, Viale E Ramarini 32, I-00015 Rome, Italy.	melino@uniroma2.it; angelo.peschiaroli@cnr.it	Annicchiarico-Petruzzelli, Margherita/AAG-7746-2020; Zhou, Huiqing/B-1721-2013; Zhou, Jo Huiqing/ADR-5134-2022	Annicchiarico-Petruzzelli, Margherita/0000-0002-4717-4740; Zhou, Huiqing/0000-0002-2434-3986; Zhou, Jo Huiqing/0000-0002-2434-3986; Giacobbe, Arianna/0000-0002-5874-1851; PESCHIAROLI, ANGELO/0000-0001-6311-2382	MFAG AIRC [15523]; Medical Research Council (UK); Ministry of Health [Rc1.1, Rc 1.3]; AIRC [IG-15653, 9979]; 'NCDs Fondazione Roma' grant; Medical Research Council [MC_U132670600] Funding Source: researchfish; MRC [MC_U132670600] Funding Source: UKRI	MFAG AIRC(Fondazione AIRC per la ricerca sul cancro); Medical Research Council (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Ministry of Health; AIRC(Fondazione AIRC per la ricerca sul cancro); 'NCDs Fondazione Roma' grant; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank the laboratory members for helpful discussion. This work has been supported by MFAG AIRC 15523 grant awarded to AP, and by Medical Research Council (UK), Ministry of Health 'Rc1.1' and 'Rc 1.3', AIRC Grant IG-15653, AIRC 5xmille (#9979), 'NCDs Fondazione Roma' grant awarded to GM.	Amelio I, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.9; Antonov AV, 2014, ONCOGENE, V33, P1621, DOI 10.1038/onc.2013.119; Barbareschi M, 2001, AM J SURG PATHOL, V25, P1054, DOI 10.1097/00000478-200108000-00010; Bergholz J, 2014, ONCOGENE, V33, P212, DOI 10.1038/onc.2012.564; Bompard G, 2005, J CELL SCI, V118, P5393, DOI 10.1242/jcs.02640; Candi E, 2007, CELL CYCLE, V6, P274, DOI 10.4161/cc.6.3.3797; Candi E, 2014, HUM MUTAT, V35, P702, DOI 10.1002/humu.22523; Celardo I, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.175; Chalcrabarti R, 2014, NAT CELL BIOL, V16, P1004, DOI 10.1038/ncb3040; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Cho MS, 2010, CELL CYCLE, V9, P2434, DOI 10.4161/cc.9.12.12051; Dawson JC, 2012, ONCOGENE, V31, P1781, DOI 10.1038/onc.2011.376; Du ZJ, 2010, CANCER SCI, V101, P2417, DOI 10.1111/j.1349-7006.2010.01700.x; Fan H, 2012, ONCOGENE, V31, P2298, DOI 10.1038/onc.2011.411; Flores ER, 2007, CELL CYCLE, V6, P300, DOI 10.4161/cc.6.3.3793; Fukushima H, 2009, CANCER RES, V69, P9263, DOI 10.1158/0008-5472.CAN-09-1188; Giacobbe A, 2013, CELL CYCLE, V12, P1395, DOI 10.4161/cc.24478; Graziano V, 2011, BBA-REV CANCER, V1816, P57, DOI 10.1016/j.bbcan.2011.04.002; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Kedmi M, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005866; Lee KB, 2014, CANCER LETT, V353, P124, DOI 10.1016/j.canlet.2014.07.016; Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231; Levine AJ, 2011, NAT REV MOL CELL BIO, V12, P259, DOI 10.1038/nrm3086; Machesky LM, 2007, J MOL MED-JMM, V85, P569, DOI 10.1007/s00109-007-0207-0; Malatesta M, 2013, ONCOGENE, V32, P4721, DOI 10.1038/onc.2012.463; Matin RN, 2013, J EXP MED, V210, P581, DOI 10.1084/jem.20121439; Mattila PK, 2007, J CELL BIOL, V176, P953, DOI 10.1083/jcb.200609176; Melino G, 2011, CELL DEATH DIFFER, V18, P1487, DOI 10.1038/cdd.2011.81; Memmi EM, 2015, P NATL ACAD SCI USA, V112, P3499, DOI 10.1073/pnas.1500762112; Mertz KD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4465; Missero C, 2014, EXP DERMATOL, V23, P143, DOI 10.1111/exd.12320; Parr C, 2009, EUR J CANCER, V45, P1673, DOI 10.1016/j.ejca.2009.02.019; Peschiaroli A, 2010, BIOCHEM BIOPH RES CO, V402, P425, DOI 10.1016/j.bbrc.2010.10.050; Ramsey MR, 2013, J CLIN INVEST, V123, P3525, DOI 10.1172/JCI68899; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Trink B, 2007, CELL CYCLE, V6, P240, DOI 10.4161/cc.6.3.3803; Truong AB, 2006, GENE DEV, V20, P3185, DOI 10.1101/gad.1463206; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; Velletri T, 2013, CELL CYCLE, V12, P3564, DOI 10.4161/cc.26771; Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148; Wang Xiaojuan, 2002, Breast Cancer, V9, P216, DOI 10.1007/BF02967592; Xie F, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-95; Xie Fei, 2011, Front Biosci (Schol Ed), V3, P621, DOI 10.2741/s175; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang XP, 2011, CANCER RES, V71, P3688, DOI 10.1158/0008-5472.CAN-10-3445	47	32	32	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1602	1608		10.1038/onc.2015.230	http://dx.doi.org/10.1038/onc.2015.230			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26119942				2022-12-17	WOS:000373063600013
J	Song, CL; Tang, H; Ran, LK; Ko, BCB; Zhang, ZZ; Chen, X; Ren, JH; Tao, NN; Li, WY; Huang, AL; Chen, J				Song, C-L; Tang, H.; Ran, L-K; Ko, B. C. B.; Zhang, Z-Z; Chen, X.; Ren, J-H; Tao, N-N; Li, W-Y; Huang, A-L; Chen, J.			Sirtuin 3 inhibits hepatocellular carcinoma growth through the glycogen synthase kinase-3 beta/BCL2-associated X protein-dependent apoptotic pathway	ONCOGENE			English	Article							PROMOTES DNA-REPAIR; OXIDATIVE STRESS; CELL-DEATH; MITOCHONDRIAL-DNA; BREAST-CANCER; EXPRESSION; METABOLISM; ACTIVATION; BAX; DEACETYLATION	SIRT3 is a class III histone deacetylase that has been implicated in a variety of cancers. The role of SIRT3 in hepatocellular carcinoma (HCC) remains elusive. In this study, we found that SIRT3 expression was frequently repressed in HCC and its downregulation was closely associated with tumor grade and size. Ectopic expression of SIRT3 inhibited cell growth and induced apoptosis in HCC cells, whereas depletion of SIRT3 in immortalized hepatocyte promoted cell growth and decreased epirubicin-induced apoptosis. Mechanistic studies revealed that SIRT3 deacetylated and activated glycogen synthase kinase-3 beta (GSK-3 beta), which subsequently induced expression and mitochondrial translocation of the pro-apoptotic protein BCL2-associated X protein (Bax) to promote apoptosis. GSK-3 beta inhibitor or gene silencing of BAX reversed SIRT3-induced growth inhibition and apoptosis. Furthermore, SIRT3 overexpression also suppressed tumor growth in vivo. Together, this study reveals a role of SIRT3/GSK-3 beta/Bax signaling pathway in the suppression of HCC growth, and also suggests that targeting this pathway may represent a potential therapeutic approach for HCC treatment.	[Song, C-L; Tang, H.; Ran, L-K; Chen, X.; Ren, J-H; Tao, N-N; Li, W-Y; Huang, A-L; Chen, J.] Chongqing Med Univ, Chinese Minist Educ, Affiliated Hosp 2, Chongqing 400016, Peoples R China; [Song, C-L; Tang, H.; Ran, L-K; Chen, X.; Ren, J-H; Tao, N-N; Li, W-Y; Huang, A-L; Chen, J.] Chongqing Med Univ, Chinese Minist Educ, Key Lab Mol Biol Infect Dis Designated, Chongqing 400016, Peoples R China; [Ko, B. C. B.] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Hong Kong, Peoples R China; [Ko, B. C. B.] Hong Kong Polytech Univ, State Key Lab Chirosci, Hong Kong, Hong Kong, Peoples R China; [Zhang, Z-Z] Chongqing Med Univ, Childrens Hosp, Dept Infect Dis, Chongqing, Peoples R China; [Huang, A-L] Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Zhejiang, Peoples R China	Chongqing Medical University; Chongqing Medical University; Hong Kong Polytechnic University; Hong Kong Polytechnic University; Chongqing Medical University; Collaborative Innovation Center for Diagnosis & Treatment of Infectious Diseases; Zhejiang University	Huang, AL; Chen, J (corresponding author), Chongqing Med Univ, Chinese Minist Educ, Affiliated Hosp 2, Chongqing 400016, Peoples R China.; Huang, AL; Chen, J (corresponding author), Chongqing Med Univ, Chinese Minist Educ, Key Lab Mol Biol Infect Dis Designated, Chongqing 400016, Peoples R China.	yixin_xinyuan@163.com; ahuang1964@163.com	Ko, Chi-bun/ACH-7514-2022	Ko, Ben Chi Bun/0000-0003-2027-5899	National Natural Science Foundation of China [81201282]; National Science and Technology Major Project [2013ZX10002002]; Chongqing Natural Science Foundation [cstc2012jjA10047]; Ministry of Education of China [20125503120004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Major Project; Chongqing Natural Science Foundation(Natural Science Foundation of Chongqing); Ministry of Education of China(Ministry of Education, China)	This study was supported by the National Natural Science Foundation of China (81201282), the National Science and Technology Major Project (2013ZX10002002), the Chongqing Natural Science Foundation (cstc2012jjA10047) and the PhD program through the Ministry of Education of China (Program 20125503120004).	Alhazzazi TY, 2011, BBA-REV CANCER, V1816, P80, DOI 10.1016/j.bbcan.2011.04.004; Alhazzazi TY, 2011, CANCER-AM CANCER SOC, V117, P1670, DOI 10.1002/cncr.25676; Allison SJ, 2007, CELL CYCLE, V6, P2669, DOI 10.4161/cc.6.21.4866; Ashraf N, 2006, BRIT J CANCER, V95, P1056, DOI 10.1038/sj.bjc.6603384; Bijur GN, 2003, NEUROREPORT, V14, P2415, DOI 10.1097/00001756-200312190-00025; Byun HO, 2012, EXP CELL RES, V318, P1808, DOI 10.1016/j.yexcr.2012.04.012; Chen J, 2013, HEPATOLOGY, V57, P2287, DOI 10.1002/hep.26278; Chen J, 2011, CANCER RES, V71, P4138, DOI 10.1158/0008-5472.CAN-10-4274; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Cheng Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.254; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; D'Aquila P, 2012, GENE, V497, P323, DOI 10.1016/j.gene.2012.01.042; Ding J, 2014, CANCER LETT, V346, P17, DOI 10.1016/j.canlet.2013.12.024; Elangovan S, 2011, CANCER RES, V71, P6654, DOI 10.1158/0008-5472.CAN-11-1446; Fabregat I, 2007, LIVER INT, V27, P155, DOI 10.1111/j.1478-3231.2006.01409.x; Fabregat I, 2009, WORLD J GASTROENTERO, V15, P513, DOI 10.3748/wjg.15.513; Giralt A, 2012, BIOCHEM J, V444, P1, DOI 10.1042/BJ20120030; Hall JA, 2013, J CLIN INVEST, V123, P973, DOI 10.1172/JCI64094; Hida Y, 2007, ARCH DERMATOL RES, V299, P103, DOI 10.1007/s00403-006-0725-6; Hori YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073875; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Jeong J, 2007, EXP MOL MED, V39, P8, DOI 10.1038/emm.2007.2; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Knight JRP, 2012, CURR OPIN ONCOL, V24, P68, DOI 10.1097/CCO.0b013e32834d813b; Lin ZH, 2012, MOL CELL, V46, P484, DOI 10.1016/j.molcel.2012.03.024; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Mao ZY, 2011, SCIENCE, V332, P1443, DOI 10.1126/science.1202723; Marfe G, 2009, J CELL BIOCHEM, V106, P643, DOI 10.1002/jcb.22044; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Monteserin-Garcia J, 2013, FASEB J, V27, P1561, DOI 10.1096/fj.12-220129; Qiu XL, 2010, CELL METAB, V12, P662, DOI 10.1016/j.cmet.2010.11.015; Sundaresan NR, 2008, MOL CELL BIOL, V28, P6384, DOI 10.1128/MCB.00426-08; Wang JX, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-297; Westphal D, 2011, BBA-MOL CELL RES, V1813, P521, DOI 10.1016/j.bbamcr.2010.12.019; Zhang CZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051703; Zhang LL, 2010, J CELL PHYSIOL, V224, P218, DOI 10.1002/jcp.22123; Zhao Y, 2013, ANN DIAGN PATHOL, V17, P483, DOI 10.1016/j.anndiagpath.2013.06.001	38	32	34	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					631	641		10.1038/onc.2015.121	http://dx.doi.org/10.1038/onc.2015.121			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25915842				2022-12-17	WOS:000369548800010
J	Wang, L; Song, G; Chang, X; Tan, W; Pan, J; Zhu, X; Liu, Z; Qi, M; Yu, J; Han, B				Wang, L.; Song, G.; Chang, X.; Tan, W.; Pan, J.; Zhu, X.; Liu, Z.; Qi, M.; Yu, J.; Han, B.			The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway	ONCOGENE			English	Article							THIOREDOXIN; PROTEIN; EXPRESSION; INHIBITORS; OVEREXPRESSION; TRANSITION; PROGNOSIS; BIOLOGY; DOMAIN; CELLS	Castration-resistant prostate cancer (CRPC) continues to be a major clinical problem and the mechanisms behind it remain unclear. Thioredoxin domain-containing protein 5 (TXNDC5) is involved in protein folding and chaperone activity, and its overexpression has been reported in multiple malignancies. In the current study, we demonstrated that TXNDC5 is up-regulated following long-term androgen-deprivation treatment (ADT) and is highly overexpressed in CRPC tumors compared with hormone-naive prostate cancer (PCa) cases. Functionally, in vitro and in vivo studies demonstrated that TXNDC5 overexpression promotes the growth of both androgen-dependent and castration-resistant PCa xenografts. Mechanistically, TXNDC5 directly interacts with the AR protein to increase its stability and thus enhances its transcriptional activity. TXDNC5-mediated CRPC growth can be fully abolished by AR inhibition, suggesting TXDNC5 up-regulation as an escape pathway for aberrant AR re-activation and CRPC growth in the milieu of low androgen. Indeed, we found that TXNDC5 is increased by ADT-induced hypoxia through HIF-1 alpha in an miR-200b-dependent manner. Overall, we defined an important role of TXNDC5 in CRPC and further investigations are needed to screen TXNDC5 antagonists as a novel therapeutic approaches to treat PCa patients with CRPC.	[Wang, L.; Tan, W.; Liu, Z.; Qi, M.; Han, B.] Shandong Univ, Sch Med, Dept Pathol, Jinan 250012, Shandong, Peoples R China; [Wang, L.; Pan, J.] Shandong Acad Med Sci, Key Lab Rare & Uncommon Dis Shandong Prov, Res Ctr Med Biotechnol, Jinan, Peoples R China; [Song, G.] Shandong Acad Med Sci, Inst Basic Med, Jinan, Peoples R China; [Chang, X.] Shandong Univ, Shandong Prov Qianfoshan Hosp, Med Res Ctr, Jinan 250012, Shandong, Peoples R China; [Zhu, X.] Shandong Inst Med & Hlth Informat, Jinan, Peoples R China; [Liu, Z.; Han, B.] Shandong Univ, Qilu Hosp, Dept Pathol, Jinan 250012, Shandong, Peoples R China; [Yu, J.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA	Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong University; Northwestern University; Feinberg School of Medicine	Han, B (corresponding author), Shandong Univ, Sch Med, Dept Pathol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.	boh@sdu.edu.cn			National Natural Science Foundation of China [81302239, 81300426]; Foundation for Scientific and Technological Achievements of Jinan [201302046]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation for Scientific and Technological Achievements of Jinan	We thank Professor Yaoqin Gong and Professor Huiqing Yuan from Shandong University Medical School for their critical reading of the manuscript. AR expression and PSA-Luc vectors were kindly provided by Professor Huiqing Yuan. This work was supported by the National Natural Science Foundation of China (Grant No. 81302239 and No. 81300426) and the Foundation for Scientific and Technological Achievements of Jinan (Grant No. 201302046).	Baumann C, 2012, ACTAS UROL ESP, V36, P1, DOI 10.1016/j.acuro.2011.07.017; Chan YC, 2011, J BIOL CHEM, V286, P2047, DOI 10.1074/jbc.M110.158790; Charlton HK, 2010, BIOCHEM BIOPH RES CO, V392, P234, DOI 10.1016/j.bbrc.2010.01.029; Dvorzhinski D, 2004, PROTEOMICS, V4, P3268, DOI 10.1002/pmic.200400847; Egan A, 2014, CANCER TREAT REV, V40, P426, DOI 10.1016/j.ctrv.2013.09.011; Fujino G, 2006, SEMIN CANCER BIOL, V16, P427, DOI 10.1016/j.semcancer.2006.09.003; Galluzzi L, 2009, MOL CELL, V36, P176, DOI 10.1016/j.molcel.2009.10.003; Gulerez IE, 2012, ACTA CRYSTALLOGR F, V68, P378, DOI 10.1107/S1744309112005866; Han B, 2009, MODERN PATHOL, V22, P1176, DOI 10.1038/modpathol.2009.79; Hsieh CL, 2008, J MOL ENDOCRINOL, V41, P13, DOI 10.1677/JME-07-0158; Hsu FN, 2011, AM J PHYSIOL-ENDOC M, V300, pE902, DOI 10.1152/ajpendo.00610.2010; Hu HL, 2012, CANCER CELL, V22, P781, DOI 10.1016/j.ccr.2012.10.024; Inoue T, 2011, PROSTATE CANCER, V2011, DOI 10.1155/2011/647987; Leo S, 2011, CHEMOTHERAPY, V57, P115, DOI 10.1159/000323581; Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25; Lin HK, 2003, J BIOL CHEM, V278, P50902, DOI 10.1074/jbc.M300676200; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; Messaoudi S, 2008, ANTI-CANCER AGENT ME, V8, P761, DOI 10.2174/187152008785914824; Mitani T, 2011, J STEROID BIOCHEM, V123, P58, DOI 10.1016/j.jsbmb.2010.10.009; Ni L, 2010, MOL CELL BIOL, V30, P1243, DOI 10.1128/MCB.01891-08; Pal SK, 2013, EXPERT OPIN PHARMACO, V14, P679, DOI 10.1517/14656566.2013.775251; Ramanathan RK, 2012, INVEST NEW DRUG, V30, P1591, DOI 10.1007/s10637-011-9739-9; Ranasinghe WKB, 2014, CANCER MED-US, V3, P245, DOI 10.1002/cam4.189; Ranasinghe WKB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054251; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Sharifi N, 2013, ENDOCRINOLOGY, V154, P4010, DOI 10.1210/en.2013-1466; Sullivan DC, 2003, J BIOL CHEM, V278, P47079, DOI 10.1074/jbc.M308124200; Thoenes L, 2010, J PROTEOMICS, V73, P1342, DOI 10.1016/j.jprot.2010.02.019; Tonissen KF, 2009, MOL NUTR FOOD RES, V53, P87, DOI 10.1002/mnfr.200700492; Vincent EE, 2011, ANTICANCER RES, V31, P1577; Wang L, 2014, PROSTATE, V74, P647, DOI 10.1002/pros.22783; Wang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053301; Wang L, 2010, INT J BIOL SCI, V6, P454; Wang YT, 2014, INT J NEUROPSYCHOPH, V17, P469, DOI 10.1017/S1461145713001429; Wang YH, 2007, EXP BIOL MED, V232, P1152, DOI 10.3181/0701-RM-8; Wei Q, 2007, PROSTATE CANCER P D, V10, P167, DOI 10.1038/sj.pcan.4500933; Zhang L, 2010, J CANCER RES CLIN, V136, P1497, DOI 10.1007/s00432-010-0807-x; Zhao LY, 2014, CANCER EPIDEM BIOMAR, V23, P1047, DOI 10.1158/1055-9965.EPI-13-0696; Zhu XJ, 2011, ORAL ONCOL, V47, P609, DOI 10.1016/j.oraloncology.2011.05.006	40	32	34	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4735	4745		10.1038/onc.2014.401	http://dx.doi.org/10.1038/onc.2014.401			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25500540				2022-12-17	WOS:000360931500007
J	Patsialou, A; Wang, Y; Pignatelli, J; Chen, X; Entenberg, D; Oktay, M; Condeelis, JS				Patsialou, A.; Wang, Y.; Pignatelli, J.; Chen, X.; Entenberg, D.; Oktay, M.; Condeelis, J. S.			Autocrine CSF1R signaling mediates switching between invasion and proliferation downstream of TGF beta in claudin-low breast tumor cells	ONCOGENE			English	Article							STIMULATING FACTOR-I; GENE-EXPRESSION; CIRCULATING LEVELS; MAMMARY-TUMORS; CANCER-CELLS; MOLECULAR PORTRAITS; METASTATIC BEHAVIOR; CSF-1 RECEPTOR; GROWTH; VIVO	Patient data suggest that colony-stimulating factor-1 (CSF1) and its receptor (CSF1R) have critical roles during breast cancer progression. We have previously shown that in human breast tumors expressing both CSF1 and CSF1R, invasion in vivo is dependent both on a paracrine interaction with tumor-associated macrophages and an autocrine regulation of CSF1R in the tumor cells themselves. Although the role of the paracrine interaction between tumor cells and macrophages has been extensively studied, very little is known about the mechanism by which the autocrine CSF1R signaling contributes to tumor progression. We show here that breast cancer patients of the claudin-low subtype have significantly increased expression of CSF1R. Using a panel of breast cancer cell lines, we confirm that CSF1R expression is elevated and regulated by TGF beta specifically in claudin-low cell lines. Abrogation of autocrine CSF1R signaling in MDA-MB-231 xenografts (a claudin-low cell line) leads to increased tumor size by enhanced proliferation, but significantly reduced invasion, dissemination and metastasis. Indeed, we show that proliferation and invasion are oppositely regulated by CSF1R downstream of TGF beta only in claudin-low cell lines. Intravital multiphoton imaging revealed that inhibition of CSF1R in the tumor cells leads to decreased in vivo motility and a more cohesive morphology. We show that, both in vitro and in vivo, CSF1R inhibition results in a reversal of claudin-low marker expression by significant upregulation of luminal keratins and tight-junction proteins such as claudins. Finally, we show that artificial overexpression of claudins in MDA-MB-231 cells is sufficient to tip the cells from an invasive state to a proliferative state. Our results suggest that autocrine CSF1R signaling is essential in maintaining low claudin expression and that it mediates a switch between the proliferative and the invasive state in claudin-low tumor cells downstream of TGF beta.	[Patsialou, A.; Wang, Y.; Pignatelli, J.; Chen, X.; Entenberg, D.; Condeelis, J. S.] Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10467 USA; [Wang, Y.; Entenberg, D.; Condeelis, J. S.] Albert Einstein Coll Med, Gruss Lipper Biophoton Ctr, Bronx, NY 10467 USA; [Oktay, M.] Montefiore Med Ctr, Dept Pathol, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Patsialou, A (corresponding author), UCL, UCL Canc Inst, Res Dept Canc Biol, 72 Huntley St, London WC1E 6DD, England.	a.patsialou@ucl.ac.uk; john.condeelis@einstein.yu.edu	Entenberg, David/AAT-2722-2020	Entenberg, David/0000-0003-0422-7264	NCI [P30 CA 013330, 5RO1CA164468, RO1CA170507]; NATIONAL CANCER INSTITUTE [R01CA170507, P30CA013330, P01CA100324, R01CA164468] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Paraic Kenny, Richard Stanley, Jeffrey Segall and members of the Condeelis lab for helpful discussions. The AFS98, total and phospho-Y559 CSF1R antibodies were a generous gift from Dr Richard Stanley. For technical help at Albert Einstein College of Medicine, we thank the Histotechnology and Comparative Pathology Facility, the shRNA Core Facility, the FACS Facility (supported by NCI P30 CA 013330) and the Genomics Facility. This work was supported by NCI grants 5RO1CA164468 (AP, YW, XC, DE and JSC) and RO1CA170507 (JP, MO and JSC).	Agarwal R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008002; Aharinejad S, 2004, CANCER RES, V64, P5378, DOI 10.1158/0008-5472.CAN-04-0961; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; ARTEAGA CL, 1988, CANCER RES, V48, P3898; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cross M, 2005, PROTEOMICS, V5, P4754, DOI 10.1002/pmic.200500058; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Entenberg D, 2011, NAT PROTOC, V6, P1500, DOI 10.1038/nprot.2011.376; Farina AR, 1998, INT J CANCER, V75, P721; FILDERMAN AE, 1992, CANCER RES, V52, P3661; Gil-Henn H, 2013, ONCOGENE, V32, P2622, DOI 10.1038/onc.2012.284; Gligorijevic B, 2012, J CELL SCI, V125, P724, DOI 10.1242/jcs.092726; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; KACINSKI BM, 1989, INT J RADIAT ONCOL, V17, P159, DOI 10.1016/0360-3016(89)90383-0; KACINSKI BM, 1988, INT J RADIAT ONCOL, V15, P823, DOI 10.1016/0360-3016(88)90113-7; KACINSKI BM, 1991, ONCOGENE, V6, P941; Kacinski BM, 1997, MOL REPROD DEV, V46, P71, DOI 10.1002/(SICI)1098-2795(199701)46:1<71::AID-MRD11>3.0.CO;2-6; KACINSKI BM, 1990, AM J PATHOL, V137, P135; Kedrin D, 2008, NAT METHODS, V5, P1019, DOI 10.1038/nmeth.1269; Lanigan F, 2009, INT J CANCER, V124, P2088, DOI 10.1002/ijc.24159; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Martinez-Estrada OM, 2006, BIOCHEM J, V394, P449, DOI 10.1042/BJ20050591; Morandi A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027450; Myal Y, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/956897; Patsialou Antonia, 2013, Intravital, V2, pe25294; Patsialou A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3344; Patsialou A, 2009, CANCER RES, V69, P9498, DOI 10.1158/0008-5472.CAN-09-1868; Paulus P, 2006, CANCER RES, V66, P4349, DOI 10.1158/0008-5472.CAN-05-3523; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pollard JW, 2008, J LEUKOCYTE BIOL, V84, P623, DOI 10.1189/jlb.1107762; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Resnick MB, 2005, HUM PATHOL, V36, P886, DOI 10.1016/j.humpath.2005.05.019; Roussos ET, 2011, J CELL SCI, V124, P2120, DOI 10.1242/jcs.086231; Ruffell B, 2012, TRENDS IMMUNOL, V33, P119, DOI 10.1016/j.it.2011.12.001; Sapi E, 1996, CANCER RES, V56, P5704; Scholl SM, 1996, BREAST CANCER RES TR, V39, P275, DOI 10.1007/BF01806155; SCHOLL SM, 1994, BRIT J CANCER, V69, P342, DOI 10.1038/bjc.1994.62; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; Sudo T, 1995, ONCOGENE, V11, P2469; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Weigelt B, 2012, NAT REV CLIN ONCOL, V9, P58, DOI 10.1038/nrclinonc.2011.125; Wrobel CN, 2004, J CELL BIOL, V165, P263, DOI 10.1083/jcb.200309102; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Wyckoff JB, 2000, CANCER RES, V60, P5401; Wyckoff JB, 2000, CANCER RES, V60, P2504; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	53	32	33	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2721	2731		10.1038/onc.2014.226	http://dx.doi.org/10.1038/onc.2014.226			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25088194	Green Accepted			2022-12-17	WOS:000354979500005
J	Wu, DW; Lee, MC; Hsu, NY; Wu, TC; Wu, JY; Wang, YC; Cheng, YW; Chen, CY; Lee, H				Wu, D-W; Lee, M-C; Hsu, N-Y; Wu, T-C; Wu, J-Y; Wang, Y-C; Cheng, Y-W; Chen, C-Y; Lee, H.			FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-kappa B/Slug-mediated PUMA reduction	ONCOGENE			English	Article							P53-MEDIATED APOPTOSIS; TUMOR SUPPRESSION; E6 ONCOPROTEIN; GENE; INACTIVATION; EXPRESSION; SURVIVAL; PATHWAY; GROWTH; TRANSACTIVATION	Fragile histidine triad (FHIT) loss by the two-hit mechanism of loss of heterozygosity and promoter hypermethylation commonly occurrs in non-small cell lung cancer (NSCLC) and may confer cisplatin resistance in NSCLC cells. However, the underlying mechanisms of FHIT loss in cisplatin resistance and the response to cisplatin-based chemotherapy in NSCLC patients have not yet been reported. In the present study, inhibition concentration of 50% cell viability induced by cisplatin (IC50) and soft agar growth and invasion capability were increased and decreased in FHIT-knockdown and -overexpressing cells, respectively. Mechanistically, Slug transcription is upregulated by AKT/NF-kappa B activation due to FHIT loss and, in turn, Slug suppresses PUMA expression; this decrease of PUMA by FHIT loss is responsible for cisplatin resistance. In addition, cisplatin resistance due to FHIT loss can be conquered by AKT inhibitor-perifosine in xenograft tumors. Among NSCLC patients, low FHIT, high p-AKT, high Slug and low PUMA were correlated with shorter overall survival, relapse-free survival and poorer response to cisplatin-based chemotherapy. Therefore, the AKT inhibitor perifosine might potentially overcome the resistance to cisplatin-based chemotherapy in NSCLC patients with low-FHIT tumors, and consequently improve the outcome.	[Wu, D-W; Hsu, N-Y; Cheng, Y-W; Lee, H.] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei, Taiwan; [Lee, M-C] Taichung Vet Gen Hosp, Dept Surg, Div Thorac Surg, Taichung, Taiwan; [Wu, T-C; Wang, Y-C] Chung Shan Med Univ Hosp, Div Chest Med, Taichung 40201, Taiwan; [Wu, T-C; Wang, Y-C] Chung Shan Med Univ, Sch Med, Taichung 40201, Taiwan; [Wu, J-Y] Buddhist Tzu Chi Gen Hosp, Taichung Branch, Div Thorac Surg, Taichung, Taiwan; [Wu, J-Y] Tzu Chi Univ, Dept Med, Hualien, Taiwan; [Chen, C-Y] China Med Univ Hosp, Dept Surg, Taichung, Taiwan	Taipei Medical University; Taichung Veterans General Hospital; Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University; Buddhist Tzu Chi General Hospital; Taichung Tzu Chi Hospital; Tzu Chi University; China Medical University Taiwan; China Medical University Hospital - Taiwan	Lee, H (corresponding author), Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Room 5,12F,3 Pk St, Taipei, Taiwan.	hl@tmu.edu.tw			National Health Research Institute [NHRI96-TD-G-111-006, NHRI97-TD-G-111-006]; National Science Council of Taiwan, ROC [100-2314-B-038-043-MY3]	National Health Research Institute(National Health Research Institutes - Taiwan); National Science Council of Taiwan, ROC(Ministry of Science and Technology, Taiwan)	This work was jointly supported by grants from the National Health Research Institute (NHRI96-TD-G-111-006; NHRI97-TD-G-111-006) and the National Science Council (100-2314-B-038-043-MY3) of Taiwan, ROC.	Andriani F, 2006, NEOPLASIA, V8, P9, DOI 10.1593/neo.05517; Andriani F, 2012, J THORAC ONCOL, V7, P631, DOI 10.1097/JTO.0b013e318244aed0; Bean GR, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003483; Cha HS, 2010, EXP MOL MED, V42, P428, DOI 10.3858/emm.2010.42.6.044; Chang TH, 2011, AM J RESP CRIT CARE, V183, P1071, DOI 10.1164/rccm.201009-1440OC; Cheng YW, 2007, CANCER RES, V67, P10686, DOI 10.1158/0008-5472.CAN-07-1461; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Jayachandran G, 2007, CANCER RES, V67, P10379, DOI 10.1158/0008-5472.CAN-07-0677; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Ji L, 1999, CANCER RES, V59, P3333; Joannes A, 2010, ONCOGENE, V29, P1203, DOI 10.1038/onc.2009.418; Kim CH, 2006, INT J CANCER, V118, P1692, DOI 10.1002/ijc.21573; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Maruyama R, 2004, CANCER-AM CANCER SOC, V100, P1472, DOI 10.1002/cncr.20144; Mimori K, 2006, CANCER RES, V66, P2683, DOI 10.1158/0008-5472.CAN-05-2509; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nishizaki M, 2004, CANCER RES, V64, P5745, DOI 10.1158/0008-5472.CAN-04-0195; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; Saegusa M, 2009, AM J PATHOL, V174, P2107, DOI 10.2353/ajpath.2009.081018; Semba S, 2006, ONCOGENE, V25, P2860, DOI 10.1038/sj.onc.1209323; Sozzi G, 1997, CANCER RES, V57, P2121; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Toledo G, 2004, MODERN PATHOL, V17, P440, DOI 10.1038/modpathol.3800081; Tseng JE, 1999, CANCER RES, V59, P4798; Urich D, 2009, FASEB J, V23, P2055, DOI 10.1096/fj.08-114546; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang J, 2006, CANCER LETT, V235, P18, DOI 10.1016/j.canlet.2005.03.058; Weiske J, 2007, P NATL ACAD SCI USA, V104, P20344, DOI 10.1073/pnas.0703664105; Wu DW, 2014, ONCOGENE, V33, P1515, DOI 10.1038/onc.2013.107; Wu DW, 2012, AM J PATHOL, V181, P1796, DOI 10.1016/j.ajpath.2012.07.032; Wu DW, 2011, CLIN CANCER RES, V17, P1895, DOI 10.1158/1078-0432.CCR-10-2316; Wu DW, 2010, CANCER RES, V70, P10392, DOI 10.1158/0008-5472.CAN-10-2341; Wu HH, 2010, CLIN CANCER RES, V16, P5200, DOI 10.1158/1078-0432.CCR-10-0020; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898; Zhang F, 2012, CELL REP, V2, P1272, DOI 10.1016/j.celrep.2012.09.023; Zienolddiny S, 2001, BRIT J CANCER, V84, P226, DOI 10.1054/bjoc.2000.1528	39	32	34	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2505	2515		10.1038/onc.2014.184	http://dx.doi.org/10.1038/onc.2014.184			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24998847				2022-12-17	WOS:000354190400009
J	Pasmant, E; Gilbert-Dussardier, B; Petit, A; de Laval, B; Luscan, A; Gruber, A; Lapillonne, H; Deswarte, C; Goussard, P; Laurendeau, I; Uzan, B; Pflumio, F; Brizard, F; Vabres, P; Naguibneva, I; Fasola, S; Millot, F; Porteu, F; Vidaud, D; Landman-Parker, J; Ballerini, P				Pasmant, E.; Gilbert-Dussardier, B.; Petit, A.; de Laval, B.; Luscan, A.; Gruber, A.; Lapillonne, H.; Deswarte, C.; Goussard, P.; Laurendeau, I.; Uzan, B.; Pflumio, F.; Brizard, F.; Vabres, P.; Naguibneva, I.; Fasola, S.; Millot, F.; Porteu, F.; Vidaud, D.; Landman-Parker, J.; Ballerini, P.			SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia	ONCOGENE			English	Article						SPRED1; tumour suppressor gene; childhood leukaemia; Legius syndrome; cafe-au-lait spots; neurofibromatosis type 1	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; SIGNAL-TRANSDUCTION; MUTATIONS; CANCER; PHENOTYPE; GENES; SPECTRUM; DISEASE; PROTEIN	Constitutional dominant loss-of-function mutations in the SPRED1 gene cause a rare phenotype referred as neurofibromatosis type 1 (NF1)-like syndrome or Legius syndrome, consisted of multiple cafe-au-lait macules, axillary freckling, learning disabilities and macrocephaly. SPRED1 is a negative regulator of the RAS MAPK pathway and can interact with neurofibromin, the NF1 gene product. Individuals with NF1 have a higher risk of haematological malignancies. SPRED1 is highly expressed in haematopoietic cells and negatively regulates haematopoiesis. SPRED1 seemed to be a good candidate for leukaemia predisposition or transformation. We performed SPRED1 mutation screening and expression status in 230 paediatric lymphoblastic and acute myeloblastic leukaemias (AMLs). We found a loss-of-function frameshift SPRED1 mutation in a patient with Legius syndrome. In this patient, the leukaemia blasts karyotype showed a SPRED1 loss of heterozygosity, confirming SPRED1 as a tumour suppressor. Our observation confirmed that acute leukaemias are rare complications of the Legius syndrome. Moreover, SPRED1 was significantly decreased at RNA and protein levels in the majority of AMLs at diagnosis compared with normal or paired complete remission bone marrows. SPRED1 decreased expression correlated with genetic features of AML. Our study reveals a new mechanism which contributes to deregulate RAS MAPK pathway in the vast majority of paediatric AMLs.	[Pasmant, E.; Luscan, A.; Gruber, A.; Laurendeau, I.; Vidaud, D.] Univ Paris 05, Sorbonne Paris Cite, Fac Sci Pharmaceut & Biol, UMR INSERM S745, F-75006 Paris, France; [Pasmant, E.; Luscan, A.; Goussard, P.; Vidaud, D.] Hop Cochin, AP HP, Serv Biochim & Genet Mol, F-75674 Paris, France; [Gilbert-Dussardier, B.] CHU Poitiers, Serv Genet, Poitiers, France; [Petit, A.; Deswarte, C.; Fasola, S.; Landman-Parker, J.] Hop A Trousseau, AP HP, Serv Hematol Oncol, Paris, France; [Petit, A.; Deswarte, C.; Fasola, S.; Landman-Parker, J.] Univ Paris 06, Paris, France; [Petit, A.; Lapillonne, H.; Deswarte, C.; Landman-Parker, J.] Univ Paris 06, UMR938, Paris, France; [de Laval, B.; Porteu, F.] Univ Paris 05, CNRS UMR8104, Inst Cochin, INSERM 1016, Paris, France; [Lapillonne, H.; Ballerini, P.] Hop Trousseau, AP HP, Serv Hematol Biol, F-75571 Paris, France; [Uzan, B.; Pflumio, F.; Naguibneva, I.] Univ Paris 07, CEA, UMR967, Fontenay Aux Roses, France; [Brizard, F.] CHU Poitiers, Lab Hematol Biol, Poitiers, France; [Vabres, P.] Univ Bourgogne, CHU Dijon, Serv Dermatol, Dijon, France; [Vabres, P.] Univ Bourgogne, EA 4271, Dijon, France; [Millot, F.] CHU Poitiers, Serv Pediat, Poitiers, France	UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Poitiers; Universite de Poitiers; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; CEA; UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; CHU Poitiers; Universite de Poitiers; CHU Dijon Bourgogne; Universite de Bourgogne; Institut Agro; AgroSup Dijon; Universite de Bourgogne; CHU Poitiers; Universite de Poitiers	Pasmant, E (corresponding author), Univ Paris 05, Sorbonne Paris Cite, Fac Sci Pharmaceut & Biol, UMR INSERM S745, F-75006 Paris, France.	eric.pasmant@gmail.com; paola.ballerini@trs.aphp.fr	Vabres, Pierre/V-3850-2019; Luscan, Armelle/O-8081-2017; Deswarte, Caroline/H-8018-2017; PORTEU, Françoise/I-8445-2016; Pasmant, Eric/O-7249-2017; Vabres, Pierre/D-3906-2011; A, Petit/H-1633-2011; Pflumio, Francoise/E-2074-2017; VIDAUD, Dominique/O-7357-2017	Vabres, Pierre/0000-0001-8693-3183; Deswarte, Caroline/0000-0002-8775-3368; PORTEU, Françoise/0000-0002-2403-4163; Pasmant, Eric/0000-0002-1881-8762; Vabres, Pierre/0000-0001-8693-3183; A, Petit/0000-0001-8363-1622; UZAN, Benjamin/0000-0001-6323-5737; Pflumio, Francoise/0000-0001-8995-596X; GILBERT-DUSSARDIER, Brigitte/0000-0001-7182-9914; de Laval, Berengere/0000-0002-5616-2338	l'Association pour la Recherche sur les Maladies Hematologiques de l'Enfant (A.R.M.H.E.)	l'Association pour la Recherche sur les Maladies Hematologiques de l'Enfant (A.R.M.H.E.)	This work was supported in part by grant from l'Association pour la Recherche sur les Maladies Hematologiques de l'Enfant (A.R.M.H.E.). We thank the patients and their parents for their participation. We are grateful to Pr. Akihiko Yoshimura for providing anti-Spred-1 antibody, Mrs. Frederique Siotto for expert technical assistance, and Dr. Audrey Sabbagh for her statistical expertise.	Bentires-Alj M, 2006, NAT MED, V12, P283, DOI 10.1038/nm0306-283; Braun BS, 2008, CLIN CANCER RES, V14, P2249, DOI 10.1158/1078-0432.CCR-07-1005; Brems H, 2007, NAT GENET, V39, P1120, DOI 10.1038/ng2113; Brems H, 2012, HUM MUTAT, V33, P1538, DOI 10.1002/humu.22152; Bundschu K, 2006, J BIOL CHEM, V281, P36477, DOI 10.1074/jbc.R600023200; Case M, 2008, CANCER RES, V68, P6803, DOI 10.1158/0008-5472.CAN-08-0101; Christiansen DH, 2005, LEUKEMIA, V19, P2232, DOI 10.1038/sj.leu.2404009; Cutts BA, 2009, BLOOD, V114, P3629, DOI 10.1182/blood-2009-02-205146; Gabert J, 2003, LEUKEMIA, V17, P2318, DOI 10.1038/sj.leu.2403135; Inoue H, 2005, J EXP MED, V201, P73, DOI 10.1084/jem.20040616; Ishizaki T, 2011, GENES CELLS, V16, P803, DOI 10.1111/j.1365-2443.2011.01529.x; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kindler T, 2010, BLOOD, V116, P5089, DOI 10.1182/blood-2010-04-261867; Lapillonne H, 2010, LEUKEMIA, V24, P205, DOI 10.1038/leu.2009.172; Lee W, 2010, NATURE, V465, P473, DOI 10.1038/nature09004; Letourneux C, 2006, EMBO J, V25, P727, DOI 10.1038/sj.emboj.7600980; Levine RL, 2009, NAT GENET, V41, P957, DOI 10.1038/ng0909-957; Messiaen L, 2009, JAMA-J AM MED ASSOC, V302, P2111, DOI 10.1001/jama.2009.1663; Miyoshi K, 2004, ONCOGENE, V23, P5567, DOI 10.1038/sj.onc.1207759; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Nonami A, 2004, J BIOL CHEM, V279, P52543, DOI 10.1074/jbc.M405189200; Papaemmanuil E, 2009, NAT GENET, V41, P1006, DOI 10.1038/ng.430; Pasmant E, 2009, J MED GENET, V46, P425, DOI 10.1136/jmg.2008.065243; Pasmant E, 2009, BLOOD, V114, P1131, DOI 10.1182/blood-2009-04-218503; Renneville A, 2008, LEUKEMIA, V22, P915, DOI 10.1038/leu.2008.19; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Stowe IB, 2012, GENE DEV, V26, P1421, DOI 10.1101/gad.190876.112; Tartaglia M, 2004, BLOOD, V104, P307, DOI 10.1182/blood-2003-11-3876; Trevino LR, 2009, NAT GENET, V41, P1001, DOI 10.1038/ng.432; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Walter RB, 2010, BLOOD, V116, P2420, DOI 10.1182/blood-2010-05-285387; Yoshida T, 2006, ONCOGENE, V25, P6056, DOI 10.1038/sj.onc.1209635	32	32	34	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					631	638		10.1038/onc.2013.587	http://dx.doi.org/10.1038/onc.2013.587			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24469042				2022-12-17	WOS:000348853500010
J	Smith, JR; de Billy, E; Hobbs, S; Powers, M; Prodromou, C; Pearl, L; Clarke, PA; Worknnan, P				Smith, J. R.; de Billy, E.; Hobbs, S.; Powers, M.; Prodromou, C.; Pearl, L.; Clarke, P. A.; Worknnan, P.			Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins	ONCOGENE			English	Article						CDC37; HSP90; client; kinase; chaperone	MOLECULAR CHAPERONE; CO-CHAPERONE; CYCLIN D1; PHOSPHORYLATION; P50(CDC37); COMPLEX; DEGRADATION; INHIBITORS; STABILITY; ONCOGENE	The HSP90 molecular chaperone plays a key role in the maturation, stability and activation of its clients, including many oncogenic proteins. Kinases are a substantial and important subset of clients requiring the key cochaperone CDC37. We sought an improved understanding of protein kinase chaperoning by CDC37 in cancer cells. CDC37 overexpression in human colon cancer cells increased CDK4 protein levels, which was negated upon CDC37 knockdown. Overexpressing CDC37 increased CDK4 protein half-life and enhanced binding of HSP90 to CDK4, consistent with CDC37 promoting kinase loading onto chaperone complexes. Against expectation, expression of C-terminus-truncated CDC37 (Delta C-CDC37) that lacks HSP90 binding capacity did not affect kinase client expression or activity; moreover, as with wild-type CDC37 overexpression, it augmented CDK4-HSP90 complex formation. However, although truncation blocked binding to HSP90 in cells, Delta C-CDC37 also showed diminished client protein binding and was relatively unstable. CDC37 mutants with single and double point mutations at residues M164 and L205 showed greatly reduced binding to HSP90, but retained association with client kinases. Surprisingly, these mutants phenocopied wild-type CDC37 overexpression by increasing CDK4-HSP90 association and CDK4 protein levels in cells. Furthermore, expression of the mutants was sufficient to protect kinase clients CDK4, CDK6, CRAF and ERBB2 from depletion induced by silencing endogenous CDC37, indicating that CDC37's client stabilising function cannot be inactivated by substantially reducing its direct interaction with HSP90. However, CDC37 could not compensate for loss of HSP90 function, showing that CDC37 and HSP90 have their own distinct and non-redundant roles in maintaining kinase clients. Our data substantiate the important function of CDC37 in chaperoning protein kinases. Furthermore, we demonstrate that CDC37 can stabilise kinase clients by a mechanism that is not dependent on a substantial direct interaction between CDC37 and HSP90, but nevertheless requires HSP90 activity. These results have significant implications for therapeutic targeting of CDC37.	[Smith, J. R.; de Billy, E.; Hobbs, S.; Powers, M.; Clarke, P. A.; Worknnan, P.] Haddow Labs, Inst Canc Res, Div Canc Therapeut, Canc Res UK Canc Therapeut Unit, Surrey SM2 5NG, England; [Prodromou, C.; Pearl, L.] Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, London SW3 6JB, England	Cancer Research UK; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Clarke, PA (corresponding author), Haddow Labs, Canc Res UK Ctr Canc Therapeut, Inst Canc Res, Div Canc Therapeut, 15 Cotswold Rd, Surrey SM2 5NG, England.	paul.clarke@icr.ac.uk; paul.workman@icr.ac.uk	Prodromou, Chrisostomos/ABA-9133-2021; de billy, emmanuel/AAA-6095-2020	Prodromou, Chrisostomos/0000-0003-4320-1147; de Crespin de Billy, emmanuel/0000-0002-3610-7083; Clarke, Paul/0000-0001-9342-1290; Pearl, Laurence/0000-0002-6910-1809	Cancer Research UK Programme [C3091A8274, C309/A11566]; Cancer Research UK [11566] Funding Source: researchfish	Cancer Research UK Programme(Cancer Research UK); Cancer Research UK(Cancer Research UK)	We thank our colleagues in the Signal Transduction and Molecular Pharmacology Team and Chaperone Project Team for helpful discussions and Craig McAndrew for valuable assistance with gel filtration. The authors' work is supported by Cancer Research UK Programme grant number C3091A8274 and C309/A11566. PW is a Cancer Research UK Life Fellow.	Arlander SJH, 2006, J BIOL CHEM, V281, P2989, DOI 10.1074/jbc.M508687200; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Dias SD, 2005, CANCER RES, V65, P10686, DOI 10.1158/0008-5472.CAN-05-2632; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Farrell A, 2000, MOL CELL BIOL, V20, P749, DOI 10.1128/MCB.20.3.749-754.2000; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; Ghatak S, 2005, J BIOL CHEM, V280, P8875, DOI 10.1074/jbc.M410882200; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Gray J, 2007, DANCING TIMES, V97, P67; Gray PJ, 2008, NAT REV CANCER, V8, P491, DOI 10.1038/nrc2420; Grbovic OM, 2006, P NATL ACAD SCI USA, V103, P57, DOI 10.1073/pnas.0609973103; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; Jiang YQ, 2010, J BIOL CHEM, V285, P21023, DOI 10.1074/jbc.M110.103390; Karnitz LM, 2007, SCI STKE, V2007, pe22; Katayama Y, 2004, INT J ONCOL, V25, P579; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; Lavictoire SJ, 2003, J BIOL CHEM, V278, P5292, DOI 10.1074/jbc.M209494200; Lee P, 2002, J CELL BIOL, V159, P1051, DOI 10.1083/jcb.200210121; MacLean M, 2003, CELL STRESS CHAPERON, V8, P114, DOI 10.1379/1466-1268(2003)008<0114:CGBHAK>2.0.CO;2; Mandal AK, 2007, J CELL BIOL, V176, P319, DOI 10.1083/jcb.200604106; Marino-Enriiquez A, 2014, ONCOGENE, V33, P1872, DOI 10.1038/onc.2013.127; Miyata Y, 2004, ANN NY ACAD SCI, V1030, P150, DOI 10.1196/annals.1329.019; Pascale RM, 2005, HEPATOLOGY, V42, P1310, DOI 10.1002/hep.20962; Pearl LH, 2008, BIOCHEM J, V410, P439, DOI 10.1042/BJ20071640; Pearl LH, 2005, CURR OPIN GENET DEV, V15, P55, DOI 10.1016/j.gde.2004.12.011; Polier S, 2013, NAT CHEM BIOL, V9, P307, DOI [10.1038/NCHEMBIO.1212, 10.1038/nchembio.1212]; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Rao J, 2001, J BIOL CHEM, V276, P5814, DOI 10.1074/jbc.M007385200; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; Salminen A, 2010, BIOCHEM BIOPH RES CO, V394, P439, DOI 10.1016/j.bbrc.2010.03.050; Scholz G, 2000, MOL CELL BIOL, V20, P6984, DOI 10.1128/MCB.20.18.6984-6995.2000; Schwarze SR, 2003, CANCER RES, V63, P4614; Shao JY, 2003, BIOCHEMISTRY-US, V42, P12577, DOI 10.1021/bi035138j; Shao JY, 2003, J BIOL CHEM, V278, P38117, DOI 10.1074/jbc.C300330200; Siligardi G, 2002, J BIOL CHEM, V277, P20151, DOI 10.1074/jbc.M201287200; Smith JR, 2009, ONCOGENE, V28, P157, DOI 10.1038/onc.2008.380; Smith JR, 2009, CELL CYCLE, V8, P362, DOI 10.4161/cc.8.3.7531; Sreeramulu S, 2009, J BIOL CHEM, V284, P3885, DOI 10.1074/jbc.M806715200; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Stepanova L, 2000, ONCOGENE, V19, P2186, DOI 10.1038/sj.onc.1203561; Stepanova L, 2000, MOL CELL BIOL, V20, P4462, DOI 10.1128/MCB.20.12.4462-4473.2000; Taipale M, 2012, CELL, V150, P987, DOI 10.1016/j.cell.2012.06.047; Taipale M, 2010, NAT REV MOL CELL BIO, V11, P515, DOI 10.1038/nrm2918; Terasawa K, 2005, FEBS J, V272, P4684, DOI 10.1111/j.1742-4658.2005.04884.x; Turnbull EL, 2005, FEBS J, V272, P4129, DOI 10.1111/j.1742-4658.2005.04825.x; Vaughan CK, 2008, MOL CELL, V31, P886, DOI 10.1016/j.molcel.2008.07.021; Vaughan CK, 2006, MOL CELL, V23, P697, DOI 10.1016/j.molcel.2006.07.016; Yu YK, 2010, BIOCHEM PHARMACOL, V79, P542, DOI 10.1016/j.bcp.2009.09.017; Zhang T, 2009, J BIOL CHEM, V284, P35381, DOI 10.1074/jbc.M109.051532; Zhang W, 2004, J MOL BIOL, V340, P891, DOI 10.1016/j.jmb.2004.05.007	50	32	32	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					15	26		10.1038/onc.2013.519	http://dx.doi.org/10.1038/onc.2013.519			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24292678	Green Accepted			2022-12-17	WOS:000349740100002
J	Chen, X; Makarewicz, JM; Knauf, JA; Johnson, LK; Fagin, JA				Chen, X.; Makarewicz, J. M.; Knauf, J. A.; Johnson, L. K.; Fagin, J. A.			Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition	ONCOGENE			English	Article						RAS; papilloma; farnesyl transferase inhibitor	WILD-TYPE RAS; H-RAS; PROTEIN TRANSFERASE; N-RAS; MOUSE SKIN; K-RAS; ACTIVATING MUTATIONS; GENE; CARCINOMAS; EXPRESSION	RAS-driven malignancies remain a major therapeutic challenge. The two-stage 7,12-dimethylbenz(a) anthracene (DMBA)/12-o-tetradecanoylphorbol-13-acetate (TPA) model of mouse skin carcinogenesis has been used to study mechanisms of epithelial tumor development by oncogenic Hras. We used mice with an Hras(G12V) knock-in allele to elucidate the early events after Hras activation, and to evaluate the therapeutic effectiveness of farnesyltransferase inhibition (FTI). Treatment of Caggs-Cre/FR-Hras(G12V) mice with TPA alone was sufficient to trigger papilloma development with a shorter latency and an similar to 10-fold greater tumor burden than DMBA/TPA-treated WT-controls. Hras(G12V) allele copy number was increased in all papillomas induced by TPA. DMBA/TPA treatment of Hras(G12V) knock-in mice induced an even greater incidence of papillomas, which either harbored Hras(G12V) amplification or developed an Hras(Q61L) mutation in the second allele. Laser-capture microdissection of normal skin, hyperplastic skin and papillomas showed that amplification occurred only at the papilloma stage. HRAS-mutant allelic imbalance was also observed in human cancer cell lines, consistent with a requirement for augmented oncogenic HRAS signaling for tumor development. The FTI SCH66336 blocks HRAS farnesylation and delocalizes it from the plasma membrane. NRAS and KRAS are not affected as they are alternatively prenylated. When tested in lines harboring HRAS, NRAS or KRAS mutations, SCH66336 delocalized, inhibited signaling and preferentially inhibited growth only of HRAS-mutant lines. Treatment with SCH66336 also induced near-complete regression of papillomas of TPA-treated Hras(G12V) knock-in mice. These data suggest that farnesyl transferase inhibitors should be reevaluated as targeted agents for human HRAS-driven cancers, such as those of bladder, thyroid and other epithelial lineages.	[Chen, X.; Makarewicz, J. M.; Knauf, J. A.; Fagin, J. A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY USA; [Knauf, J. A.; Fagin, J. A.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Johnson, L. K.] Sloan Kettering Inst, New York, NY USA; [Fagin, J. A.] Weill Cornell Med Coll, New York, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Fagin, JA (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave,Box 296,Zuckerman Bldg,ZRC 504, New York, NY 10065 USA.	Faginj@mskcc.org		chen, xu/0000-0003-2524-4979; Knauf, Jeffrey/0000-0003-4456-8792; Makarewicz, Jacek/0000-0003-2557-2817	NIH [RO1-CA72597, T32-DK07313]; Margot Rosenberg Pulitzer Foundation; Byrne Fund; Lefkofsky Family Foundation; NATIONAL CANCER INSTITUTE [R01CA050706, R01CA072597, P30CA008748, P50CA172012] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007313] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Margot Rosenberg Pulitzer Foundation; Byrne Fund; Lefkofsky Family Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH grants RO1-CA72597 and T32-DK07313, the Margot Rosenberg Pulitzer Foundation, the Byrne Fund and the Lefkofsky Family Foundation. We are indebted to the Molecular Cytology and Comparative Pathology Core facilities of Memorial Sloan Kettering Cancer Center. We are also grateful to Dr. Paul Kirschmeier and W Robert Bishop (formerly of Schering-Plough) for providing us with SCH 66336.	Ahearn IM, 2012, NAT REV MOL CELL BIO, V13, P39, DOI 10.1038/nrm3255; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Ashar HR, 2001, EXP CELL RES, V262, P17, DOI 10.1006/excr.2000.5076; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; Bastian BC, 2000, AM J PATHOL, V157, P967, DOI 10.1016/S0002-9440(10)64609-3; Bernhard EJ, 1998, CANCER RES, V58, P1754; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; Boichard A, 2012, J CLIN ENDOCR METAB, V97, pE2031, DOI 10.1210/jc.2012-2092; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BUCHMANN A, 1991, CANCER RES, V51, P4097; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Castellano Esther, 2011, Genes Cancer, V2, P216, DOI 10.1177/1947601911408081; Chen X, 2009, P NATL ACAD SCI USA, V106, P7979, DOI 10.1073/pnas.0900343106; Diaz R, 2005, INT J CANCER, V113, P241, DOI 10.1002/ijc.20563; Diaz R, 2002, CANCER RES, V62, P4514; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; Gordon LB, 2012, P NATL ACAD SCI USA, V109, P16666, DOI 10.1073/pnas.1202529109; Harousseau JL, 2009, BLOOD, V114, P1166, DOI 10.1182/blood-2009-01-198093; Hayes TK, 2013, CANCER DISCOV, V3, P24, DOI 10.1158/2159-8290.CD-12-0521; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Jeng HH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2173; Johnson BE, 2004, CLIN CANCER RES, V10, p4254S, DOI 10.1158/1078-0432.CCR-040016; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; Lim KH, 2008, NATURE, V452, P646, DOI 10.1038/nature06778; Modrek B, 2009, MOL CANCER RES, V7, P1244, DOI 10.1158/1541-7786.MCR-08-0532; Moura MM, 2011, J CLIN ENDOCR METAB, V96, pE863, DOI 10.1210/jc.2010-1921; NAMBA H, 1990, J CLIN ENDOCR METAB, V71, P223, DOI 10.1210/jcem-71-1-223; Plowman SJ, 2003, MOL CELL BIOL, V23, P9245, DOI 10.1128/MCB.23.24.9245-9250.2003; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Rao S, 2004, J CLIN ONCOL, V22, P3950, DOI 10.1200/JCO.2004.10.037; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Schuhmacher AJ, 2008, J CLIN INVEST, V118, P2169, DOI [10.1172/JCI3438S, 10.1172/JCI34385]; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Takano T, 2005, J CLIN ONCOL, V23, P6829, DOI 10.1200/JCO.2005.01.0793; To MD, 2013, ONCOGENE, V32, P4028, DOI 10.1038/onc.2012.404; Van Cutsem E, 2004, J CLIN ONCOL, V22, P1430, DOI 10.1200/JCO.2004.10.112; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Young A, 2013, CANCER DISCOV, V3, P112, DOI 10.1158/2159-8290.CD-12-0231; Zhang FL, 1997, J BIOL CHEM, V272, P10232; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721	46	32	37	3	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5442	5449		10.1038/onc.2013.489	http://dx.doi.org/10.1038/onc.2013.489			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24240680	Green Accepted			2022-12-17	WOS:000345120700006
J	Luis-Ravelo, D; Anton, I; Zandueta, C; Valencia, K; Ormazabal, C; Martinez-Canarias, S; Guruceaga, E; Perurena, N; Vicent, S; De Las Rivas, J; Lecanda, F				Luis-Ravelo, D.; Anton, I.; Zandueta, C.; Valencia, K.; Ormazabal, C.; Martinez-Canarias, S.; Guruceaga, E.; Perurena, N.; Vicent, S.; De Las Rivas, J.; Lecanda, F.			A gene signature of bone metastatic colonization sensitizes for tumor-induced osteolysis and predicts survival in lung cancer	ONCOGENE			English	Article						HDAC4; PITX1; ROBO1; microenvironment; osteoclastogenesis; MMP; outcome	HORMONE-RELATED PROTEIN; GROWTH-FACTOR-BETA; HISTONE DEACETYLASE-4; EXPRESSION; PITX1; RECEPTOR; ADENOCARCINOMA; ACTIVATION; KINASE; CELLS	Bone metastasis of lung adenocarcinoma (AC) is a frequent complication of advanced disease. The purpose of this study was to identify key mediators conferring robust prometastatic activity with clinical significance. We isolated highly metastatic subpopulations (HMS) using a previously described in vivo model of lung AC bone metastasis. We performed transcriptomic profiling of HMS and stringent bioinformatics filtering. Functional validation was assessed by overexpression and lentiviral silencing of single, double and triple combination in vivo and in vitro. We identified HDAC4, PITX1 and ROBO1 that decreased bone metastatic ability after their simultaneous abrogation. These effects were solely linked to defects in osseous colonization. The molecular mechanisms related to bone colonization were mediated by non-cell autonomous effects that include the following: (1) a marked decrease in osteoclastogenic activity in vitro and in vivo, an effect associated with reduced pro-osteoclastogenic cytokines IL-11 and PTHrP expression levels, as well as decreased in vitro expression of stromal rankl in conditions mimicking tumor-stromal interactions; (2) an abrogated response to TGF-beta signaling by decreased phosphorylation and levels of Smad2/3 in tumor cells and (3) an impaired metalloproteolytic activity in vitro. Interestingly, coexpression of HDAC4 and PITX1 conferred high prometastatic activity in vivo. Further, levels of both genes correlated with patients at higher risk of metastasis in a clinical lung AC data set and with a poorer clinical outcome. These findings provide functional and clinical evidence that this metastatic subset is an important determinant of osseous colonization. These data suggest novel therapeutic targets to effectively block lung AC bone metastasis.	[Luis-Ravelo, D.; Anton, I.; Zandueta, C.; Valencia, K.; Ormazabal, C.; Martinez-Canarias, S.; Perurena, N.; Vicent, S.; Lecanda, F.] Univ Navarra, Div Oncol, Adhes & Metastasis Lab, E-31080 Pamplona, Spain; [Guruceaga, E.] Univ Navarra, Ctr Appl Med Res CIMA, Bioinformat & Prote Unit, E-31080 Pamplona, Spain; [Vicent, S.] Univ Navarra, Sch Med, Dept Histol & Pathol, E-31080 Pamplona, Spain; [De Las Rivas, J.] Univ Salamanca CSIC USAL, Canc Res Ctr, Bioinformat & Funct Genom Res Grp, Salamanca, Spain	University of Navarra; University of Navarra; University of Navarra; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC)	Lecanda, F (corresponding author), Univ Navarra, Ctr Appl Med Res CIMA, E-31080 Pamplona, Spain.	flecanda@unav.es	Valencia, Karmele/I-8729-2017; De Las Rivas, Javier/G-5936-2014; Vicent, Silvestre/K-4261-2017; Guruceaga, Elizabeth/B-1796-2008	Valencia, Karmele/0000-0002-2882-7427; De Las Rivas, Javier/0000-0002-0984-9946; Vicent, Silvestre/0000-0002-9457-6881; Perurena, Naiara/0000-0003-0874-3389; Zandueta Pascual, Carolina/0000-0002-7931-8649; Luis-Ravelo, Diego/0000-0003-2876-9762; Guruceaga, Elizabeth/0000-0003-0547-681X	'UTE project FIMA' agreement, The Cancer Research Thematic Network of the Health Institute Carlos III [RTICC RD06/0020/0066, PI042282, SAF-2009-11280, SAF2012-40056]; Government of Navarra [67/2005, 09/2009]; La Caixa Foundation; FIMA; FPU; Basque Government; FIS-ISCIII grant [PI12/00624]; Ramon y Cajal Program (MICINN) [RYC-2011-09042]	'UTE project FIMA' agreement, The Cancer Research Thematic Network of the Health Institute Carlos III; Government of Navarra; La Caixa Foundation(La Caixa Foundation); FIMA; FPU(Spanish Government); Basque Government(Basque Government); FIS-ISCIII grant; Ramon y Cajal Program (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	We are grateful to the Core Histology Unit and Imaging Group facilities for their outstanding technical assistance. We also thank the Proteomics, Genomics and Bioinformatics Unit at the CIMA. This work was supported by 'UTE project FIMA' agreement, The Cancer Research Thematic Network of the Health Institute Carlos III (RTICC RD06/0020/0066), PI042282, SAF-2009-11280, SAF2012-40056, grants 67/2005 and 09/2009 from the Government of Navarra, and 'La Caixa Foundation' to FL. DL-R was supported by the FIMA and FPU. IA was funded by the Basque Government. JDLR was supported by FIS-ISCIII grant PI12/00624. SV is an investigator of the Ramon y Cajal Program (MICINN, RYC-2011-09042).	Anton I, 2012, AM J RESP CRIT CARE, V186, P96, DOI 10.1164/rccm.201110-1826OC; Backs J, 2006, J CLIN INVEST, V116, P1853, DOI 10.1172/JCI27438; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Catena R, 2011, CANCER RES, V71, P164, DOI 10.1158/0008-5472.CAN-10-1708; Chen Y, 2007, LUNG CANCER, V55, P287, DOI 10.1016/j.lungcan.2006.11.001; Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G; FELD R, 1984, J CLIN ONCOL, V2, P1352, DOI 10.1200/JCO.1984.2.12.1352; Fry WA, 1996, CANCER, V77, P1947, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1947::AID-CNCR27>3.0.CO;2-Z; Goldstraw P, 2011, LANCET, V378, P1727, DOI 10.1016/S0140-6736(10)62101-0; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; Hernandez I, 2010, ONCOGENE, V29, P3758, DOI 10.1038/onc.2010.130; Iguchi H, 2001, INT J CANCER, V94, P24, DOI 10.1002/ijc.1425; Justilien V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035040; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kolfschoten IGM, 2005, CELL, V121, P849, DOI 10.1016/j.cell.2005.04.017; Labbe E, 2007, CANCER RES, V67, P75, DOI 10.1158/0008-5472.CAN-06-2559; LECANDA F, 2011, DRUG DISCOV TODAY DI, V8, P87; Lord RVN, 2005, SURGERY, V138, P924, DOI 10.1016/j.surg.2005.05.007; Lu X, 2009, GENE DEV, V23, P1882, DOI 10.1101/gad.1824809; Luis-Ravelo D, 2011, CLIN EXP METASTAS, V28, P779, DOI 10.1007/s10585-011-9409-5; Marcil A, 2003, DEVELOPMENT, V130, P45, DOI 10.1242/dev.00192; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030; Reddy SDN, 2012, J BIOL CHEM, V287, P27843, DOI 10.1074/jbc.M112.348474; Rhee J, 2002, NAT CELL BIOL, V4, P798, DOI 10.1038/ncb858; Rhee J, 2007, NAT CELL BIOL, V9, P883, DOI 10.1038/ncb1614; Sapkota G, 2006, J BIOL CHEM, V281, P40412, DOI 10.1074/jbc.M610172200; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Stronach EA, 2011, CANCER RES, V71, P4412, DOI 10.1158/0008-5472.CAN-10-4111; Valencia K, 2012, CLIN CANCER RES, V18, P969, DOI 10.1158/1078-0432.CCR-11-1686; Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024; Vicent S, 2008, CANCER RES, V68, P2275, DOI 10.1158/0008-5472.CAN-07-6493; Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055; Wilson AJ, 2008, MOL BIOL CELL, V19, P4062, DOI 10.1091/mbc.E08-02-0139; Yang XM, 2010, BIOCHEM BIOPH RES CO, V396, P571, DOI 10.1016/j.bbrc.2010.04.152; Yasui T, 2011, J BONE MINER RES, V26, P1447, DOI 10.1002/jbmr.357; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523	38	32	32	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2014	33	43					5090	5099		10.1038/onc.2013.440	http://dx.doi.org/10.1038/onc.2013.440			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OF	24166494				2022-12-17	WOS:000343768400004
